[
  {
    "nctId": "NCT05117567",
    "endpoint": "measure - Symptomatic malaria diagnosed by RDT, description - Change in the number of symptomatic Plasmodium spp.\ninfections detected by RDT per week per village, timeFrame - Assessed weekly, longitudinally over 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05117567",
    "endpoint": "measure - Plasmodium spp. infection as determined by polymerase chain reaction (PCR) on RDT cassette samples, description - Change in the prevalence of Plasmodium spp.\ninfection as determined by polymerase chain reaction (PCR) from RDT cassette samples, timeFrame - Assessed weekly, longitudinally over 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05117567",
    "endpoint": "measure - Plasmodium spp. infection as determined by polymerase chain reaction (PCR) on dried blood spot samples, description - Change in the prevalence of Plasmodium spp.\ninfection as determined by polymerase chain reaction (PCR) from dried blood spot (DBS) samples, timeFrame - Assessed weekly, longitudinally over 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05117567",
    "endpoint": "measure - Plasmodium spp. infections with drug resistance mutations, description - Change in the prevalence of Plasmodium spp.\ninfection with drug resistance mutations., timeFrame - Assessed weekly, longitudinally over 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05117567",
    "endpoint": "measure - Prevalence of antibodies to Plasmodium spp., description - Prevalence of antibodies to Plasmodium spp.\ndetermined by Enzyme Linked Immunosorbent assay (ELISA) from RDT and DBS samples, timeFrame - Assessed weekly, longitudinally over 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05117567",
    "endpoint": "measure - Levels of antibodies to Plasmodium spp., description - Levels of antibodies to Plasmodium spp.\ndetermined by Enzyme Linked Immunosorbent assay (ELISA) from RDT and DBS samples, timeFrame - Assessed weekly, longitudinally over 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05117567",
    "endpoint": "measure - Prevalence of antibodies to vector salivary antigens, description - Levels of antibody biomarkers of vector exposure, timeFrame - Assessed weekly, longitudinally over 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05117567",
    "endpoint": "measure - Levels of antibodies to vector salivary antigens, description - Levels of antibody biomarkers of vector exposure, timeFrame - Assessed weekly, longitudinally over 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05117567",
    "endpoint": "measure - Levels of knowledge, attitude and practice regarding malaria prevention among MMPs, description - Focus group discussions, timeFrame - At approximately 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05117567",
    "endpoint": "measure - Proportion of survey respondents (MMPs) who accept and are willing to use&#x2F; did use the personal protection package according to the protocol, description - Questionnaire, timeFrame - At approximately 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07124156",
    "endpoint": "measure - Immunogenicity to MSP1-specific IgM antibody levels measured by ELISA, description - Humoral immunogenicity of SUM-101 in malaria-exposed adults assessed as MSP1-specific IgM antibody levels measured by serum ELISA in sera collected at Day 0 (pre-vaccination) and Day 84 (Pre-CHMI)., timeFrame - Day 0 (pre-vaccination) and Day 84 (Pre-CHMI).",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07124156",
    "endpoint": "measure - Immunogenicity assessed as antibody-mediated complement fixation activity., description - Humoral immunogenicity of SUM-101 in malaria-exposed adults assessed as antibody-mediated complement fixation activity., timeFrame - Day 0 (pre-vaccination) and Day 84 (Pre-CHMI)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07124156",
    "endpoint": "measure - Antibody-mediated complement fixation activity, description - Humoral immunogenicity of SUM-101 in malaria-exposed adults assessed as antibody-mediated complement fixation activity., timeFrame - Day 0 (pre-vaccination) and Day 84 (Pre-CHMI)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07124156",
    "endpoint": "measure - Antibody-dependent respiratory burst (ADRB) activity, description - Humoral immunogenicity of SUM-101 in malaria-exposed adults assessed as antibody-dependent respiratory burst (ADRB) activity., timeFrame - Day 0 (pre-vaccination) and Day 84 (Pre-CHMI)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04698980",
    "endpoint": "measure - Verification of the analysis method by the STANDARD G6PD test several times, description - Measurement of the G6PD activity will be done to assess the repeatability, accuracy or trueness of the STANDARD G6PD test according to the recommendations of standard NF EN ISO 15189: 2012 for accreditation., timeFrame - 3 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04698980",
    "endpoint": "measure - Verification of the analysis method by the STANDARD G6PD test by different operator, description - Measurement of the G6PD activity will be done to assess the inter-operator variability, of the STANDARD G6PD test according to the recommendations of standard NF EN ISO 15189: 2012 for accreditation., timeFrame - 3 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04698980",
    "endpoint": "measure - Verification of the analysis method by the STANDARD G6PD test in different conditions, description - Measurement of the G6PD activity will be done to assess the reproducibility, robustness and measurement interval of the STANDARD G6PD test according to the recommendations of standard NF EN ISO 15189: 2012 for accreditation., timeFrame - 3 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04698980",
    "endpoint": "measure - sequencing of the coding regions of the G6PD gene of 150 individuals, description - Analysis of the genotype of the G6PD gene and comparison to the phenotype, timeFrame - 3 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03384498",
    "endpoint": "measure - Allelic variations associated to drug resistance in P. falciparum at the locations surveyed, description - By using genotypes produced by high-throughput techniques (sequencing, PCR, mass spectrometry etc.)., timeFrame - up to 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03384498",
    "endpoint": "measure - Allelic variations associated to drug resistance in P. vivax at the locations surveyed, description - By using genotypes produced by high-throughput techniques (sequencing, PCR, mass spectrometry etc.)., timeFrame - up to 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03384498",
    "endpoint": "measure - Genetic differentiation between parasites populations at different locations in the Greater Mekong Subregion, description - By using population genetic measures such as FST and allele frequencies, timeFrame - up to 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03384498",
    "endpoint": "measure - Population structure of parasites, description - By using population genetics and clustering techniques, such as Principal Component Analysis and phylogeny, timeFrame - up to 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03384498",
    "endpoint": "measure - Gene flow patterns of P. falciparum malaria parasites in the Greater Mekong Subregion, description - , timeFrame - up to 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03384498",
    "endpoint": "measure - Likely geographic origin of P. falciparum malaria parasites in the Greater Mekong Subregion, description - , timeFrame - up to 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06923592",
    "endpoint": "measure - Proportion of individuals with PCR detectable P. vivax blood-stage infections 12 months after the second round of PvSeroTAT or 12 months after the second round of blood sampling in the control clusters., description - 12 months after the second round of PvSeroTAT, a blood sample will be collected from participants through fingerprick in the intervention clusters.\nIn the control clusters a blood sample to determine PCR prevalence will be collected 12 months after the second round of blood sampling in that control cluster., timeFrame - 12 months after the second round of PvSeroTAT or 12 months after the second round of blood sampling in the control clusters.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06923592",
    "endpoint": "measure - Proportion of individuals with PCR detectable P. vivax blood-stage infections 6 months after the first round of PvSeroTAT (before second round) or 6 months after the first round of blood sampling in the control clusters., description - 6 months after the first round of PvSeroTAT, a blood sample will be collected from participants through fingerprick in the intervention clusters.\nIn the control clusters a blood sample to determine PCR prevalence will be collected 6 months after the first round of blood sampling in that control cluster., timeFrame - 6 months after the first round of PvSeroTAT or 6 months after the first round of blood sampling in the control clusters.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06923592",
    "endpoint": "measure - Decrease of mean cluster prevalence of PCR detectable P. vivax blood-stage infections at month 6 after the first round of PvSeroTAT or 6 months after the first round of blood sampling in the control clusters, compared to baseline., description - , timeFrame - 6 months after the first round of PvSeroTAT or 6 months after the first round of blood sampling in the control clusters.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06923592",
    "endpoint": "measure - Decrease of mean cluster prevalence of PCR detectable P. vivax blood-stage infections at month 12 after the first round of PvSeroTAT or 12 months after the first round of blood sampling in the control clusters, compared to baseline., description - , timeFrame - 12 months after the first round of PvSeroTAT or 12 months after the first round of blood sampling in the control clusters.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06923592",
    "endpoint": "measure - Decrease of mean cluster prevalence of PCR detectable P. vivax blood-stage infections at month 18 after the first round of PvSeroTAT or 18 months after the first round of blood sampling in the control clusters, compared to baseline., description - , timeFrame - 18 months after the first round of PvSeroTAT or 18 months after the first round of blood sampling in the control clusters.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06923592",
    "endpoint": "measure - Incidence of clinical cases of P. vivax and P. falciparum malaria during the 6 months after the first round of PvSeroTAT or during the 6 months after the first round of blood sampling in the control clusters., description - , timeFrame - 6 months after the first round of PvSeroTAT or 6 months after the first round of blood sampling in the control clusters.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06923592",
    "endpoint": "measure - Incidence of clinical cases of P. vivax and P. falciparum malaria during the 12 months after the first round of PvSeroTAT or during the 12 months after the first round of blood sampling in the control clusters., description - , timeFrame - 12 months after the first round of PvSeroTAT or 12 months after the first round of blood sampling in the control clusters.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06923592",
    "endpoint": "measure - Incidence of clinical cases of P. vivax and P. falciparum malaria during the 18 months after the first round of PvSeroTAT or during the 18 months after the first round of blood sampling in the control clusters., description - , timeFrame - 18 months after the first round of PvSeroTAT or 18 months after the first round of blood sampling in the control clusters.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06923592",
    "endpoint": "measure - Hemoglobin level at day 3, description - , timeFrame - Day 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06923592",
    "endpoint": "measure - Hemoglobin level at day 7, description - , timeFrame - Day 7",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06923592",
    "endpoint": "measure - Decrease in Hemoglobin between baseline and day 3 (absolute and proportional), description - , timeFrame - Day 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06923592",
    "endpoint": "measure - Decrease in Hemoglobin between baseline and day 7 (absolute and proportional), description - , timeFrame - Day 7",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06923592",
    "endpoint": "measure - Incidence of potential signs of clinically relevant Haemolysis, description - 25% drop in hemoglobin or hemoglobin&lt;7gram&#x2F;dL or macroscopic haemoglobinuria or the need for a blood transfusion, timeFrame - 7 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06923592",
    "endpoint": "measure - Incidence of Serious Adverse Events, description - , timeFrame - 18 months after the first round of PvSeroTAT or 18 months after the first round of blood sampling in the control clusters.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06923592",
    "endpoint": "measure - Coverage of serological tests for P. vivax antibodies as proportion of number of individuals per cluster, description - , timeFrame - Day 0 of month 0 or month 6",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06923592",
    "endpoint": "measure - Proportion of eligible individuals that refuses participation in the study, description - , timeFrame - Day 0 of month 0 or month 6",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06923592",
    "endpoint": "measure - Proportion of participants with positive P. vivax serology that refuses P. vivax treatment, description - , timeFrame - Day 1 of drug administration",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06923592",
    "endpoint": "measure - Proportion of serological positive individuals that start primaquine treatment, description - , timeFrame - Day 1 of drug administration",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06923592",
    "endpoint": "measure - Proportion of study participants that complete the 7-day course of primaquine treatment., description - , timeFrame - Day of start of treatment until day 7 of treatment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06923592",
    "endpoint": "measure - Proportion of individuals that vomits at least once within 1 hour after treatment, description - , timeFrame - Day of start of treatment until day 7 of treatment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06923592",
    "endpoint": "measure - Proportion of individuals that vomits twice within 1 hour after treatment., description - , timeFrame - Day of start of treatment until day 7 of treatment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06064591",
    "endpoint": "measure - To investigate in malaria patients associations between host immune and metabolic factors and P. falciparum sexual conversion and infection potential, description - In patients with uncomplicated and severe malaria, the investigators will investigate associations between host inflammatory molecules, parasite-specific Ab and metabolic factors, with parasite SC rates.\nThe investigators hypothesize that SC rates will be higher in severe malaria patients and associated with specific molecules and metabolites., timeFrame - 2023-2025",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06064591",
    "endpoint": "measure - To validate associations between sexual conversion and host immune and metabolic factors in vitro, description - An in vitro assay, based on recently described gametocyte-reporter parasite lines 16 will be used to validate candidate associations identified in Objective 2. First, the effect of patient serum samples and specific metabolites and inflammatory factors via in vitro SC assays is tested.\nNext, in vitro cultures with significantly induced SC will be fed to Anopheles stephensi mosquitoes to assess infection potential via standard membrane feeding assays.\nIt is hypothesized that plasma&#x2F;factors identified in Objective 2, induce SC in vitro and increase mosquito infections., timeFrame - 2024-2026",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06064591",
    "endpoint": "measure - To explore transcriptional mechanisms driving parasite sexual conversion in the host environment during uncomplicated and severe malaria disease, description - Use of a single cell RNA-sequencing (scRNA-seq) approaches to generate the first in-depth characterization of gene expression patterns of very early sexual stages in the host circulation during natural infections in uncomplicated and severe clinical presentations (samples collected in Objective 2)., timeFrame - 2024-2026",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02721186",
    "endpoint": "measure - PCR determined community prevalence of Plasmodium infections in the MDA and control Shehias, description - PCR determined community prevalence of Plasmodium infections determined by cross-sectional screening in every other household in the study area at the time of the first round of MDA, and at six months after the second round of MDA., timeFrame - Baseline and 3 months after second round of MDA",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00330902",
    "endpoint": "measure - Presence of gametocytes detected by RT-PCR on days 3, 7 and 14., description - , timeFrame - 14 days from start of treatment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00330902",
    "endpoint": "measure - Packed Cell volume on days 7 and 14., description - , timeFrame - Over 14 days from start of treatment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05192265",
    "endpoint": "measure - Adequate clinical and parasitological response without correction for reinfection, description - <p>Adequate clinical and parasitological response (ACPR; absence of parasitaemia on day 28 without previously meeting criteria for ETF, LCF, or LPF).</p><p>Note:</p><p>ETF: Early treatment failure defined as danger signs or complicated malaria or failure to adequately respond to therapy on days 0-3.</p><p>LCF: Late clinical failure defined as danger signs or complicated malaria or fever and parasitaemia on days 4-28 without previously meeting criteria for ETF or LPF.</p><p>LPF: Late parasitological failure defined as asymptomatic parasitaemia on days 7-28 without previously meeting criteria for ETF or LCF.</p>, timeFrame - day 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05192265",
    "endpoint": "measure - Parasite clearance time, description - Time from first dose of ACT until first total and continued disappearance of asexual parasite forms., timeFrame - Treatment day 0 to 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05192265",
    "endpoint": "measure - Fever clearance time, description - Time from first dose until the first time the body temperature (for those with a raised temperature at enrolment) decrease to below 37.5 degree Celsius and remain so for at least 24 hours., timeFrame - Treatment day 0 to 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05192265",
    "endpoint": "measure - Gametocyte carriage, description - Proportions of patients with gametocyte at a given point in time., timeFrame - Treatment day 0 to 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05286359",
    "endpoint": "measure - Estimates of diagnostic accuracy characteristics with 95% confidence intervals of comparator tests (05FK50, 05FK80, 05FK120, LM), description - Estimates of diagnostic accuracy characteristics with 95% confidence intervals of comparator tests (05FK50, 05FK80, 05FK120, LM), using the reference test as standard of truth for the detection of P. falciparum and, when relevant, P.v.\ninfections in patients with symptoms suggestive of malaria, timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05286359",
    "endpoint": "measure - Estimates of diagnostic accuracy characteristics with 95% confidence intervals ofthe index tests for the detection of P.f.infections with hrp2 and&#x2F;or hrp3 deletions, description - Estimates of diagnostic accuracy characteristics with 95% confidence intervals of the index tests for the detection of P.f.\ninfections with hrp2 and&#x2F;or hrp3 deletions in patients with symptoms suggestive of malaria, timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06881732",
    "endpoint": "measure - To characterise the parasite growth profile of all blood stage parasites in participants following infection with NF54&#x2F;iGP3 using qPCR (parasites&#x2F;mL)., description - Measure the change in parasite count (parasites&#x2F;mL) of blood-stage NF54&#x2F;iGP3 parasites via qPCR, following inoculation until the administration of antimalarial treatment., timeFrame - From Inoculation (Day 1) until conditions for treatment are met (truncated at Day 22)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06881732",
    "endpoint": "measure - To characterise the post-treatment clearance profile of all blood stage parasites in participants following infection with NF54&#x2F;iGP3 using qPCR (parasites&#x2F;mL)., description - Measure the change in parasite count (parasites&#x2F;mL) of blood-stage NF54&#x2F;iGP3 parasites via qPCR, following administration of registered schizonticidal and gametocidal antimalarial treatments., timeFrame - From administration of antimalarial treatment until End of Study (Day 180)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06881732",
    "endpoint": "measure - Measure the parasite count (parasites&#x2F;mL) using qPCR in the participant&#x27;s blood at the time of large volume blood withdrawal., description - Measure the parasite count (parasites&#x2F;mL) via qPCR in collected blood samples from study participants infected with NF54&#x2F;iGP3, to determine the level of parasitemia., timeFrame - From Inoculation (Day 1) until parasitemia conditions are met, truncated at Day 22",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04661579",
    "endpoint": "measure - Time to First PCR-detectable Malaria Infection During the Active Detection of Infection Phase in Groups 2 and 5, description - <p>Participants were actively monitored for malarial infection starting 2 weeks after the third vaccination.\nBlood samples were assayed using a highly sensitive PCR (Plasmodium falciparum&#x2F; Pan-Plasmodium 18S rRNA LDT) that can detect sub-clinical parasitemia.\nA positive PCR result from blood samples collected during the ADI phase was recorded as a positive event for the presence of P. falciparum blood stage infection.</p><p>The time to first malaria infection is expressed in terms of rate of first malaria infection, that is, the number of malaria infection events reported over the time period elapsed until the event occurred (i.e.\nevents per Persons Year at Risk [PYAR]) for each group.</p>, timeFrame - The active detection of infection phase began 2 weeks after the third vaccination (approximately week 30) for up to 35 weeks. Participants provided blood samples every 21 days during the ADI phase for PCR assays.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04661579",
    "endpoint": "measure - Number of Participants With Serious Adverse Events (SAEs), description - <p>An adverse event is any untoward medical occurrence in a study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product, or temporally associated with a study procedure.</p><p>A serious adverse event is any adverse event that:</p><ul><li>Resulted in death,</li><li>Was life-threatening,</li><li>Resulted in disability&#x2F;incapacity,</li><li>Required hospitalization or prolongation of existing hospitalization,</li><li>Resulted in disability&#x2F;incapacity.</li><li>Resulted in a congenital anomaly and &#x2F; or birth defect.</li></ul>, timeFrame - From first dose to end of study, up to 65 weeks.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04661579",
    "endpoint": "measure - Number of Participants With Solicited Local and Systemic Adverse Events (AEs), description - <p>Solicited AEs are pre-specified local and systemic AEs that occur relatively more frequently or are known to be associated with immunization, which are monitored actively as potential indicators of vaccine reactogenicity.</p><p>Solicited local and general AEs were collected among RTS,S vaccinated groups in the first 50 participants enrolled in Groups 1 and 2 and all participants enrolled in Group 3 (Reactogenicity Cohort) for seven days (day of vaccination and six subsequent days) after each dose of vaccine.</p><p>Local (injection site) adverse events are defined as:</p><ul><li>Pain at injection site</li><li>Swelling at injection site</li></ul><p>Systemic adverse events are defined as:</p><ul><li>Fever (temperature ≥ 37.5°C)</li><li>Headache</li><li>Gastrointestinal problems</li><li>Fatigue</li><li>Muscle ache</li></ul>, timeFrame - Within 7 days after each vaccination.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04661579",
    "endpoint": "measure - Number of Participants With Unsolicited Adverse Events, description - <p>An adverse event is defined as any untoward medical occurrence in a study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product, or temporally associated with a study procedure.</p><p>Unsolicited AEs are any AEs reported spontaneously by the participant, observed by the study staff during study visits or those identified during review of medical records or source documents.\nSolicited AEs with an onset after the seven-day solicitation period were also considered unsolicited AEs.</p>, timeFrame - Within 28 days after each vaccination.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04661579",
    "endpoint": "measure - Geometric Mean Titer of Anti-Plasmodium Falciparum Circumsporozoite (CS) Antibodies in Groups 1, 2, and 3, description - <p>The RTS,S antigen consists of sequences of both the P. falciparum circumsporozoite protein and hepatitis B surface antigen.</p><p>Antibody levels against P. falciparum circumsporozoite (CS) protein central repeat region (NANP) were measured from blood samples of participants in Groups 1, 2 and 3 using standard enzyme-linked immunosorbent assays (ELISA) at Walter Reed Army Institute of Research (WRAIR), in Silver Spring, MD, United States.</p>, timeFrame - Baseline, Day 29 (28 days after first vaccination), Day 57 (28 days after second vaccination), Day 197 (24 weeks after second vaccination), and Day 225 (28 days after third vaccination)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04661579",
    "endpoint": "measure - Anti-Plasmodium Falciparum Circumsporozoite (CS) Antibody Avidity Index in Groups 1, 2, and 3, description - <p>Antibody levels against P. falciparum circumsporozoite (CS) protein central repeat region (NANP) measured by standard enzyme-linked immunosorbent assays (ELISA) for participants in Groups 1, 2 and 3. To measure antibody-antigen avidity (strength of binding) ELISA was performed with and without urea (to dissociate the antigen-antibody complex).</p><p>The avidity index is calculated by dividing the serum titer obtained in the presence of the urea by the serum titer without urea.</p>, timeFrame - Baseline, Day 29 (28 days after first vaccination), Day 57 (28 days after second vaccination), Day 197 (24 weeks after second vaccination), and Day 225 (28 days after third vaccination)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04661579",
    "endpoint": "measure - Geometric Mean Titer (GMT) of Anti-Hepatitis B Surface Antigen (HBsAg) Antibodies in Groups 1, 2, and 3, description - <p>The RTS,S vaccine antigen consists of sequences of both the P. falciparum circumsporozoite protein and hepatitis B surface antigen, hence anti-HBsAg antibodies were also measured.</p><p>Anti-hepatitis B surface antigen antibodies were assessed at the International AIDS Vaccine Initiative Human Immunology Laboratory (IAVI-HIL) at Imperial College, London, UK, using a commercially available ELISA kit.</p>, timeFrame - Baseline, Day 29 (28 days after first vaccination) and Day 225 (28 days after third vaccination)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04203186",
    "endpoint": "measure - Determine differences in pre-patent periods, description - Determine differences in prepatent periods in subjects infected with PfSPZ Challenge (NF54) vs PfSPZ Challenge (7G8) as detected by TBS, RDT, hsRDT and by PCR, timeFrame - 29 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04203186",
    "endpoint": "measure - Determine differences in the growth rate of parasites, description - Determine differences in the growth rate of parasites in the blood of subjects infected by PfSPZ Challenge (NF54) vs PfSPZ Challenge (7G8) as detected by PCR, timeFrame - 29 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07122232",
    "endpoint": "measure - Platelet count recovery over time, description - Change in mean platelet count at admission, day 3, and day 7, for each group., timeFrame - Day 0 to Day 7",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02895568",
    "endpoint": "measure - Percent prevalence of specimens with pfmdr1 copy number &gt;1 (marker of resistance to mefloquine), description - , timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02895568",
    "endpoint": "measure - Visualization and dissemination of molecular marker prevalence data to inform public health officials, researchers, policymakers and key stakeholders, description - , timeFrame - 2 yeas",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02610686",
    "endpoint": "measure - Ex vivo susceptibility of P. vivax isolates to QN, DHA , PPQ and CQ (Mean IC50 and IC90), description - Individual and mean IC50 and IC90 values will be computed for each drug using the IVART tool available online (http:&#x2F;&#x2F;www.wwarn.org&#x2F;tools-resources&#x2F;toolkit&#x2F;analyse&#x2F;ivart), timeFrame - At day0 and day of recurrence of P.vivax parasitemia after initial parasite clearance assessed up to day 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02143934",
    "endpoint": "measure - Time to first or only P. falciparum infection by light microscopy and PCR, description - , timeFrame - 8 months post-baseline",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02143934",
    "endpoint": "measure - Time to first or only P. ovale infection by light microscopy and PCR, description - , timeFrame - 8 months post-baseline",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02143934",
    "endpoint": "measure - Time to first or only P. malariae infection by light microscopy and PCR, description - , timeFrame - 8 months post-baseline",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05829187",
    "endpoint": "measure - Parasite clearence times, description - parasite reduction ratio, timeFrame - 28-days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05829187",
    "endpoint": "measure - Fever clearence time, description - time taken for the axilla temperature to fall below 37.5°C in patients who were febrile at inclusion, timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05829187",
    "endpoint": "measure - Number of adverse event, description - , timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01775592",
    "endpoint": "measure - efficacy of DHA-PPQ at day 42 post-treatment in Traleng Quangnam, Vietnam, description - treatment failure or success at day 42, timeFrame - Day 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01775592",
    "endpoint": "measure - in vitro susceptibility of P.falciparum isolates towards DHA and PPQ in Quang Nam Province, description - MarkIII in vitro test, timeFrame - Day 3-10",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02364583",
    "endpoint": "measure - Time to first or only Plasmodium vivax infection by light microscopy and polymerase chain reaction (PCR), description - Thick and thin blood films, along with PCR samples, will be collected at time of recruitment and then at any time the participant develops fever within the study period., timeFrame - 2 months from baseline",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02364583",
    "endpoint": "measure - Time to first or only clinical Plasmodium vivax episode, description - , timeFrame - 2 months from baseline",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02364583",
    "endpoint": "measure - Comparison of the rate of incidence of P. vivax relapses in 3.5 or 7 day treatment arm compared to standard 14 day regimen, description - , timeFrame - 2 months from baseline",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02364583",
    "endpoint": "measure - Pharmacokinetics - elimination half-life (t1&#x2F;2), description - , timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02364583",
    "endpoint": "measure - Pharmacokinetics - clearance (CL), description - , timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02364583",
    "endpoint": "measure - Pharmacokinetics - volume of distribution (Vd), description - , timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02364583",
    "endpoint": "measure - Pharmacokinetics - maximal concentration (Cmax), description - , timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02364583",
    "endpoint": "measure - Pharmacokinetics - area under the curve (AUC), description - , timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00392015",
    "endpoint": "measure - Part A Dose-Escalation: To Assess the Immunogenicity of NMRC-M3V-Ad-PfCA in Healthy Malaria-Naïve Adults Using ELISpot IFN-γ Responses, description - The NMRC-M3V-Ad-PfCA vaccine combines two adenovectors encoding circumsporozoite protein (CSP) and apical membrane antigen-1 (AMA1).\nIn Group 1 healthy volunteers received one intramuscular injection of 2x10^10 pu at Week 0 and in Group 2 a five-fold higher dose of 1 x 10^11 pu at Week 4. Immunogenicity was assessed by ELISpot IFN-γ responses against synthetic peptides derived from CSP and AMA1 as the range of spot forming cells&#x2F;million peripheral blood mononuclear cells [sfc&#x2F;m]., timeFrame - One month post immunization",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00392015",
    "endpoint": "measure - Part B Regimen-Comparison: To Assess the Immunogenicity of NMRC-M3V-Ad-PfCA in Healthy Malaria-Naïve Adults Using ELISpot IFN-γ Responses in Group 3, description - The NMRC-M3V-Ad-PfCA vaccine combines two adenovectors encoding circumsporozoite protein (CSP) and apical membrane antigen-1 (AMA1).\nGroup 3 healthy volunteers received 2 intramuscular injections of NMRC-M3V-Ad-PfCA (2 antigen combination) at a dose of 2x10^10 pu at Week 16 and Week 32.\nImmunogenicity was assessed by ELISpot IFN-γ responses against synthetic peptides derived from CSP and AMA1 using peripheral blood mononuclear cells during the study.\nIFN-γ ELISpot responses were measured as the range of spot forming cells&#x2F;million peripheral blood mononuclear cells [sfc&#x2F;m]., timeFrame - 22-23 days post immunization",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00392015",
    "endpoint": "measure - Part B Regimen-Comparison: To Assess the Immunogenicity of NMRC-MV-Ad-PfC in Healthy Malaria-Naïve Adults Using ELISpot IFN-γ Responses in Group 4, description - Group 4 healthy volunteers received 2 intramuscular injections of NMRC-MV-Ad-PfC (single antigen) at a dose of 1x10^10 pu at Week 16 and Week 32.\nImmunogenicity was assessed by ELISpot IFN-γ responses against synthetic peptides derived from circumsporozoite protein (CSP) using peripheral blood mononuclear cells during the study.\nIFN-γ ELISpot responses measured as the range of spot forming cells&#x2F;million peripheral blood mononuclear cells [sfc&#x2F;m]., timeFrame - 4 weeks post immunization",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00392015",
    "endpoint": "measure - Part A Dose-Escalation: To Assess the Immunogenicity of NMRC-M3V-Ad-PfCA in Healthy Malaria-Naïve Adults Using Intracellular Cytokine Staining of CD4+ and CD8+ T Cell IFN-γ Responses, description - The NMRC-M3V-Ad-PfCA vaccine combines two adenovectors encoding circumsporozoite protein (CSP) and apical membrane antigen-1 (AMA1).\nIn Group 1 healthy volunteers received one intramuscular injection of 2x10^10 pu at Week 0 and in Group 2 a five-fold higher dose of 1 x 10^11 pu at Week 4. Immunogenicity was assessed by Intracellular Cytokine Staining of CD4+ and CD8+ T cell IFN-γ responses to AMA1 and CSP using peripheral blood mononuclear cells during the study.\nCD4+ and CD8+ T cell IFN-γ responses were measured as percentage (%) range of positive responses., timeFrame - One month post immunization",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00392015",
    "endpoint": "measure - Part B Regimen-Comparison: To Assess the Immunogenicity of NMRC-M3V-Ad-PfCA in Healthy Malaria-Naïve Adults Using Intracellular Cytokine Staining CD4+ and CD8+ T Cell IFN-γ Responses in Group 3, description - The NMRC-M3V-Ad-PfCA vaccine combines two adenovectors encoding circumsporozoite protein (CSP) and apical membrane antigen-1 (AMA1).\nGroup 3 healthy volunteers received 2 intramuscular injections of NMRC-M3V-Ad-PfCA (2 antigen combination) at a dose of 2x10^10 pu at Week 16 and Week 32.\nImmunogenicity was assessed by Intracellular Cytokine Staining of CD4+ and CD8+ T cell IFN-γ responses to AMA1 and CSP measured using peripheral blood mononuclear cells during the study.\nCD4+ and CD8+ T cell IFN-γ responses were measured as percentage (%) range of positive responses., timeFrame - 22-23 days post immunization",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00392015",
    "endpoint": "measure - Part B Regimen-Comparison: To Assess the Immunogenicity of NMRC-MV-Ad-PfC in Healthy Malaria-Naïve Adults Using Intracellular Cytokine Staining of CD4+ and CD8+ T Cell IFN-γ Responses in Group 4, description - Group 4 healthy volunteers received 2 intramuscular injections of NMRC-MV-Ad-PfC (single antigen) at a dose of 1x10^10 pu at Week 16 and Week 32.\nImmunogenicity was assessed by Intracellular Cytokine Staining of CD4+ and CD8+ T cell IFN-γ responses to synthetic peptides derived from circumsporozoite protein (CSP) using peripheral blood mononuclear cells during the study.\nCD4+ and CD8+ T cell IFN-γ responses were measured as percentage (%) range of positive responses., timeFrame - 4 weeks post immunization",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01001650",
    "endpoint": "measure - To evaluate PfSPZ vaccine-mediated protection against P. falciparum challenge in the 4 groups., description - , timeFrame - October 2010",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01001650",
    "endpoint": "measure - To compare protective efficacy of the PfSPZ vaccine when given by SC versus ID administration in all groups., description - , timeFrame - October 2010",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05058885",
    "endpoint": "measure - Vector type, abundance, infectivity and anthropophily, description - This outcome will include a determination of the vector type and infectivity of the mosquitoes with Plasmodium as determined by published molecular methods., timeFrame - June 2022-December, 2023.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05058885",
    "endpoint": "measure - Entomological innoculation rate of vivax mosquitoes, description - Established methods will be used to determine the number of infective bites per person and per year., timeFrame - June 2022-December, 2023.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01002833",
    "endpoint": "measure - Immunological properties of different Plasmodium falciparum isolates, description - , timeFrame - 140 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01002833",
    "endpoint": "measure - Time to thick smear positivity between groups A, B and C, description - , timeFrame - 35 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01002833",
    "endpoint": "measure - Maximum parasitemia and duration of parasitemia as measured by PCR, description - , timeFrame - 35 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01002833",
    "endpoint": "measure - Frequency of signs and symptoms between groups A, B and C, description - , timeFrame - 140 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00197054",
    "endpoint": "measure - Safety: Occurrence of SAEs, description - Percentage of subjects experiencing SAEs classified by MedRA System Organ Class and Preferred Term (Month 6.5-12), timeFrame - months 6.5 thru 12",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00197054",
    "endpoint": "measure - Safety: Occurrence of SAEs, description - Percentage of subjects reporting SAEs classified by MedDRA System Organ Class and Preferred Term (Month 0-12), timeFrame - months 0 thru 12",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00197054",
    "endpoint": "measure - Occurrence of Hematology Parameters Below Normal Range, description - Occurrence of hematology parameters below normal range (Total Cohort), timeFrame - Days 0, 6, 66, and 90; Months 6 and 12",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00197054",
    "endpoint": "measure - Occurrence of Biochemistry Parameters Above Normal Ranges, description - Occurrence of parameters of biochemical monitoring above normal ranges (Total Cohort), timeFrame - Days 0, 6, and 90",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05788094",
    "endpoint": "measure - Characterise the safety and tolerability of three regimens, description - <p>Number of participants with drop in hemoglobin ≥2 g&#x2F;dL and&#x2F;or hematocrit by ≥10% from baseline</p><p>Number of participants with Non-serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs)</p>, timeFrame - Day3, Day7, Month1, Month2, Month3, Month4",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05788094",
    "endpoint": "measure - Characterise population pharmacokinetics of tafenoquine in three treatments, description - Area Under the Curve From Time-0 Extrapolated to Infinite Time (AUC0-infinite time) of Tafenoquine, timeFrame - Day3, Day7, Month1, Month2, Month3, Month4",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05788094",
    "endpoint": "measure - Met-Haemoglobin level a vivo pharmacodynamic proxy of oxidative antimalarial activity of tafenoquine, description - Percentage increase in Methaemoglobin level compared across three arms, timeFrame - Day3, Day7",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02353494",
    "endpoint": "measure - Proportion of patients aparasitaemic on days 1 and 2, description - , timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02353494",
    "endpoint": "measure - Haematological recovery, description - , timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02353494",
    "endpoint": "measure - Gametocyte carriage during follow up, description - , timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05400746",
    "endpoint": "measure - Humoral Immunogenicity of the Pfs48&#x2F;45 With Matrix-M Vaccine, When Administered to Healthy Adult Volunteers as Assessed by Humoral Responses to the Pfs48&#x2F;45 Protein, description - Antibody responses to the Pfs48&#x2F;45 protein will be assessed through total IgG isotypes and avidity, timeFrame - Days 1, 29, 57, 140 and 240",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05400746",
    "endpoint": "measure - Cellular Immunogenicity of the Pfs48&#x2F;45 With Matrix-M Vaccine, When Administered to Healthy Adult Volunteers as Assessed by Cellular Responses to the Pfs48&#x2F;45 Protein, description - T cell responses to Pfs48&#x2F;45 will be assessed by ex vivo enzyme-linked immunospot assays (ELISpot), timeFrame - Days 1, 29, 57, 140 and 240",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05400746",
    "endpoint": "measure - Ex Vivo Efficacy of the Pfs48&#x2F;45 With Matrix-M Vaccine, When Administered to Healthy Adult Volunteers Using Direct Membrane Feeding Assays as Assessed by Transmission-reducing Activity, description - Transmission-reducing activity, timeFrame - Days 1, 29, 57, 140 and 240",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05400746",
    "endpoint": "measure - Ex Vivo Efficacy of the Pfs48&#x2F;45 With Matrix-M Vaccine, When Administered to Healthy Adult Volunteers Using Direct Membrane Feeding Assays as Assessed by Transmission-blocking Activity, description - Transmission-blocking activity, timeFrame - Days 1, 29, 57, 140 and 240",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01728701",
    "endpoint": "measure - Presence of parasitemia after Pf CHMI as assessed by microscopy, description - <p>Thick smear samples will be taken from a 3 ml EDTA vacutainer tube.\nThick smears will be performed on all visits following immunizations and Pf CHMI until treatment is finished.</p><p>Thick smears will be performed according to a standard operating procedure, which is based on an internationally harmonized protocol for thick smears in CHMIs (Moorthy et al., WHO).\nIn short, 15μl of whole blood will be distributed on standardized 3-well slides, providing an equal slide thickness for all smears.\nSlides are dried and stained with Giemsa.\nPer slide, 200 fields will be read, which correlates to 0.5 µl of blood.\nSlides are considered positive if they contain 2 or more parasites per 200 fields.\nThick smears evaluation will take place at the RUNMC.</p>, timeFrame - Thick smears will be performed on all visits following immunizations and Pf CHMI until treatment is finished upto 53 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01728701",
    "endpoint": "measure - Time to parasitemia after Pf CHMI as assessed by microscopy, description - <p>Thick smear samples will be taken from a 3 ml EDTA vacutainer tube.\nThick smears will be performed on all visits following immunizations and Pf CHMI until treatment is finished.</p><p>Thick smears will be performed according to a standard operating procedure, which is based on an internationally harmonized protocol for thick smears in CHMIs (Moorthy et al., WHO).\nIn short, 15μl of whole blood will be distributed on standardized 3-well slides, providing an equal slide thickness for all smears.\nSlides are dried and stained with Giemsa.\nPer slide, 200 fields will be read, which correlates to 0.5 µl of blood.\nSlides are considered positive if they contain 2 or more parasites per 200 fields.\nThick smears evaluation will take place at the RUNMC.</p>, timeFrame - Thick smears will be performed on all visits following immunizations and Pf CHMI until treatment is finished upto 53 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01728701",
    "endpoint": "measure - Kinetics of parasitemia as assessed by qPCR, description - <p>Samples for qPCR will be collected from the same 3 ml EDTA vacutainer tubes as the thick smear sample.\nqPCR will be performed according to standard procedure described in Hermsen et al.\nMol, Biochem.\nParasitol.\n2001; 118: 247-251.\nIn short, qPCR will be performed on the multicopy 18S ribosomal RNA gene.\nAll samples are spiked with murine white blood cells and a murine albumin gene PCR is used to determine efficacy of DNA isolation.</p><p>Samples for quantitative measurement of parasitemia will be prepared and stored at RUNMC.\nMeasurement by qPCR will be performed retrospectively.</p>, timeFrame - Samples collected on all visits following immunizations and Pf CHMI until treatment is finished upto 53 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06607003",
    "endpoint": "measure - To establish an appropriate challenge agent dose for use in P. vivax IBSM studies., description - A suitable dose of challenge agent which generates parasitemia in a reliable and timely manner as determined by the investigator., timeFrame - From the time of inpatient admission to the time of discharge. Expected to be approximately 2 days after admission.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06607003",
    "endpoint": "measure - To evaluate transmission of P. vivax to vector mosquitoes in the IBSM model by mosquito feeding assays., description - Transmission of P. vivax to Anopheles spp.\nusing mosquito feeding assays including direct feeding assays and&#x2F;or membrane feeding assays as determined by the detection of oocysts following midgut dissection.\nAdditional optional measures may include salivary gland dissection or detection by molecular methods., timeFrame - From the time of inpatient admission to the time of discharge.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06607003",
    "endpoint": "measure - To establish a dataset that may be used as a historical control in future interventional IBSM studies., description - Demonstration of transmission in mosquito feeding assays among a requisite number of subjects., timeFrame - From the time of inpatient admission to the time of discharge.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03452475",
    "endpoint": "measure - Parasite clearance half-life, description - Parasite clearance half-life is assessed by entering the parasite counts (assessed by microscopy) in the WWARN PCE calculator, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03452475",
    "endpoint": "measure - Parasite reduction rates, description - Parasite reduction rates and ratios at 24 and 48 hours assessed by microscopy, timeFrame - 24 and 48 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03452475",
    "endpoint": "measure - Parasite count to fall 50%, description - Time for parasite count to fall 50% of initial parasite density, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03452475",
    "endpoint": "measure - Parasite count to fall 90%, description - Time for parasite count to fall 90% of initial parasite density, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03452475",
    "endpoint": "measure - Fever clearance time, description - The time taken for the tympanic temperature to fall below 37.5˚C and remain there for at least 24 hours, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03452475",
    "endpoint": "measure - Incidence of clinical adverse events and serious adverse events, description - , timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03452475",
    "endpoint": "measure - Incidence of adverse events concerning markers of hepatic or renal toxicity, description - Total bilirubin, Alanine transaminase, Aspartate transaminase, Alkaline phosphatase and creatinine will be measured, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03452475",
    "endpoint": "measure - Incidence of prolongation of the corrected QT interval, description - Incidence of the prolongation of the corrected QT interval above 500 ms or &gt; 60 ms above baseline values, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03452475",
    "endpoint": "measure - Prolongation of the corrected QT interval, description - Prolongation of the corrected QT interval compared at hour 4, hour 24, hour 28, hour 48 and hour 52 compared to baseline, timeFrame - Baseline, hour 4, hour 24, hour 28, hour 48 and hour 52",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03452475",
    "endpoint": "measure - Change in haematocrit, description - Change in haematocrit at hour 24, hour 48, hour 72, day 7, day 14, day 21, day 28, day 35 and day 42 according to geographical location and study arm, stratified for G6PD status, timeFrame - Baseline, hour 24, hour 48, hour 72, day 7, day 14, day 21, day 28, day 35 and day 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03452475",
    "endpoint": "measure - Proportion of patients that reports completing a full course of observed TACT or ACT, description - Proportion of patients that reports completing a full course of observed TACT or ACT without withdrawal of consent or exclusion from study because of drug related serious adverse event, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03452475",
    "endpoint": "measure - Prevalence of Kelch13 mutations of known significance, description - Prevalence of Kelch13 mutations of known significance, timeFrame - Baseline",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03452475",
    "endpoint": "measure - Prevalence&#x2F;incidence of other genetic markers of antimalarial drug resistance such as multidrug resistance gene 1 copy number and multidrug resistance gene 1 mutations, description - Prevalence&#x2F;incidence of other genetic markers of antimalarial drug resistance such as multidrug resistance gene 1 copy number and multidrug resistance gene 1 mutations, timeFrame - Baseline",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03452475",
    "endpoint": "measure - Genome wide association with in vivo&#x2F;in vitro sensitivity parasite phenotype, description - Genome wide association with in vivo&#x2F;in vitro sensitivity parasite phenotype, timeFrame - Baseline",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03452475",
    "endpoint": "measure - A comparison of transcriptomic patterns between sensitive and resistant parasites, description - Transcriptomic patterns measure at baseline and at specified time points after the start of treatment comparing sensitive and resistant parasites, timeFrame - Baseline and 6 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03452475",
    "endpoint": "measure - Proportion of patients with gametocytaemia before, during and after treatment, description - Proportion of patients with gametocytaemia before, during and after treatment, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03452475",
    "endpoint": "measure - Levels of RNA transcription coding for male or female gametocytes, description - Levels of RNA transcription coding for male or female gametocytes at admission, timeFrame - Baseline",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03452475",
    "endpoint": "measure - In vitro sensitivity of P. falciparum to artemisinins and partner drugs, description - , timeFrame - Baseline and day recurrent infection",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03452475",
    "endpoint": "measure - Pharmacokinetic profiles and interactions (Cmax) of arterolane and partner drugs, description - Pharmacokinetic profiles and interactions (Cmax) of arterolane and partner drugs, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03452475",
    "endpoint": "measure - Day 7 drug levels of partner drugs in association with treatment efficacy and treatment arm, description - Day 7 drug levels of partner drugs in association with treatment efficacy and treatment arm, timeFrame - 7 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03452475",
    "endpoint": "measure - Data on recent travel and current location of living, description - , timeFrame - Baseline",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03334747",
    "endpoint": "measure - Percentage of Participants With Polymerase Chain Reaction (PCR)-Corrected and Uncorrected Adequate Clinical and Parasitological Response (ACPR) at Day 15 and Day 29, description - PCR-corrected and PCR-uncorrected were evaluated at Days 15 and 29 (i.e., 14 and 28 days post-dose).\nThe presence of parasitaemia after 7 days due to reinfection was considered as PCR-corrected ACPR.\nMissing blood smear data at Day 15 visit and thereafter were not considered as responder for the visit unless there was a later blood smear test indicating no parasitaemia., timeFrame - Day 15, Day 29",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03334747",
    "endpoint": "measure - Parasite Clearance Time (PCT), description - Parasite Clearance Time (PCT) is defined as the time from the first dose until the first total and continued disappearance of asexual parasite forms which remained at least a further 48 hours.\nIn case a patient received rescue medication before (parasite) clearance, the time to event was censored at the first use of rescue medication., timeFrame - Day 29",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03334747",
    "endpoint": "measure - Fever Clearance Time (FCT), description - Fever Clearance Time (FCT) is defined as the time from the first dose until the first time the axillary body temperature decreased below and remained below 37.5°C axillary or 38.0°C oral&#x2F;tympanic&#x2F;rectal for at least a further 24 hours.\nIn case a patient received rescue medication before (fever) clearance, the time to event was censored at the first use of rescue medication., timeFrame - Day 29",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03334747",
    "endpoint": "measure - Time to Recrudescence and Reinfection at Study Day 29, description - Time to recrudescence is calculated from the date of first study medication to the date of first event.\nParticipants without recrudescence&#x2F;reinfection after Day 7 are censored at the time of treatment failure or at the time of last parasite assessment if no treatment failure occured., timeFrame - Day 29",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03334747",
    "endpoint": "measure - Maximum Peak Observed Concentration (Cmax), description - Maximum Peak Observed Concentration (Cmax), timeFrame - Day 1, Day 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03334747",
    "endpoint": "measure - Tmax, description - Tmax, timeFrame - Day 1, Day 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03334747",
    "endpoint": "measure - AUC0-24, description - AUC0-24, timeFrame - Day 1, Day 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03334747",
    "endpoint": "measure - Half-life (T^1&#x2F;2), description - Half-life (T^1&#x2F;2), timeFrame - Upto day 15 post dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02181088",
    "endpoint": "measure - To assess the cellular and humoral immunogenicity of ChAd63 RH5 when administered alone, and in heterologous prime-boost with MVA RH5 in healthy volunteers., description - P. falciparum RH5-specific immunogenicity will be assessed by a variety of immunological assays.\nThese may include ex vivo ELISpot assays for interferon gamma and flow cytometry assays, as well as antibody ELISAs, functional antibody assays and B cell analyses.\nOther exploratory immunological assays including cytokine analysis, other antibody assays, anti-adenovirus antibodies, DNA analysis of genetic polymorphisms potentially relevant to vaccine immunogenicity and gene expression studies amongst others may be performed at the discretion of the Investigators., timeFrame - 240 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01627951",
    "endpoint": "measure - Difference in time till thick smear positivity between groups infected with NF54, NF135 and NF166, description - Thick smears will be read twice daily from day 5 post-infection until day of thick smear positivity, or else until day 21 post-infection, timeFrame - between day 5 and day 21",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01627951",
    "endpoint": "measure - Difference in duration or peak height of parasitaemia between groups infected with NF54, NF135 and NF166, description - Parasitaemia will be measured retrospectively by QRT-PCR in twice daily drawn venous whole blood, from day 5 post-infection until day of thick smear positivity, or else until day 21 post-infection., timeFrame - between day 5 and day 21",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01627951",
    "endpoint": "measure - Difference in frequency of malaria-related symptoms and signs between groups infected with NF54, NF135 and NF166, description - Symptoms and signs will be assessed at twice daily check-up visits from day 5 post-infection until three days after thick smear positivity, or else until day 24 post-infection, and then again on day 35-post infection., timeFrame - between day 5 and day 35",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01627951",
    "endpoint": "measure - Difference in induced immunological responses between groups infection with NF54, NF135 and NF166, description - Peripheral venous whole blood will be drawn for assessment of serological and cellular immune responses on day 1-prior to infection, day 5 post-infection, day 9 post-infection and day 35 post-infection., timeFrame - between day -1 and day 35",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04788862",
    "endpoint": "measure - Cellular and Humoral Immune responses level at C-1, C+7, C+14, C+21, C+28, C+56, C+98 and diagnosis, description - P. falciparum specific immunogenicity following P. falciparum blood-stage infection, as assessed by antibody, B cell and T cell responses.\nDetermined by ELISA (concentration of antibodies), timeFrame - 98 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04788862",
    "endpoint": "measure - Cellular and Humoral Immune responses level at C-1, C+7, C+14, C+21, C+28, C+56, C+98 and diagnosis, description - P. falciparum specific immunogenicity following P. falciparum blood-stage infection, as assessed by antibody, B cell and T cell responses.\nDetermined by ELISpot (spots per 10^x PBMCs), timeFrame - 98 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04788862",
    "endpoint": "measure - Cellular and Humoral Immune responses level at C-1, C+7, C+14, C+21, C+28, C+56, C+98 and diagnosis, description - P. falciparum specific immunogenicity following P. falciparum blood-stage infection, as assessed by antibody, B cell and T cell responses.\nDetermined by flow cytometry (% of immune cell sub-population), timeFrame - 98 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04788862",
    "endpoint": "measure - To determine the effect of pre-exposure to malaria on parasite multiplication rates following controlled blood-stage P. falciparum infection., description - Comparison of PMRs between participants with low and high prior exposure to P. falciparum., timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04788862",
    "endpoint": "measure - To determine if malaria infection following inoculation of P. falciparum is caused by the inoculum parasite strain and not wild-type strains, description - Determine whole genome sequences (via whole genome analysis) following controlled blood-stage P. falciparum infection to confirm malaria infection is with inoculum strain and not wild-type parasite, timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01464125",
    "endpoint": "measure - Blood samples at 0,1,2,3,4,6,8,12,14,18,24, 26,30,36,38,42,48,50,54,60,62,66,72,78,84,90,96,108,120,144.168.240 hours, description - pharmacokinetic profile.\nFull profiles of pharmacokinetic parameters including Cmax, Tmax, peak, trough, Vd, AUC, T1&#x2F;2a, T1&#x2F;2t, renal and total Cl will be derived., timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01464125",
    "endpoint": "measure - PCR corrected cure rates, description - to differentiate between reinfections and recrudescence, timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02090036",
    "endpoint": "measure - Mean maximal fall in hemoglobin (g&#x2F;dl) from enrolment to day 28 of follow-up defined as mean greatest negative difference in hemoglobin per treatment arm., description - , timeFrame - 28 days.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03056391",
    "endpoint": "measure - Longitudinal change in creatinine, description - Longitudinal change in creatinine, as measured by the area under the creatinine-time curve, with creatinine measured 12 hourly from enrolment to 72 hours; and the effect of enrolment cell-free haemoglobin on longitudinal change in creatinine, timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03056391",
    "endpoint": "measure - Change in creatinine in severe malaria, description - Change in creatinine at 72 hours and longitudinal change in creatinine over 72 hours, including the effect of enrolment CFHb, in patients with severe knowlesi malaria., timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03056391",
    "endpoint": "measure - Development of AKI, description - Development of AKI over 72 hours: i) an absolute increase in serum creatinine of &gt;26.5 umol&#x2F;L from enrolment creatinine; ii) a percentage increase in serum creatinine of &gt;50% from enrolment; iii) post-enrolment onset of oliguria of less than 0.5ml&#x2F;kg&#x2F;hour for more than 6 hours; iv) 24 hour urine output of &lt;400ml after rehydration and urinary obstruction excluded.\nAKI on enrolment will also be described by the Kidney Disease Improving Global Outcomes (KDIGO) criteria (with baseline creatinine estimated using the MDRD equation)., timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03056391",
    "endpoint": "measure - Duration of AKI, description - Length of time elapsed until serum creatinine returns to normal (estimated using MDRD equation) in the absence of renal replacement therapy in those with AKI on enrolment and those that develop AKI after enrolment., timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03056391",
    "endpoint": "measure - Longitudinal changes in haemolysis: plasma cell-free haemoglobin, description - Longitudinal changes in plasma cell-free haemoglobin over 72 hours., timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03056391",
    "endpoint": "measure - Longitudinal changes in haemolysis: plasma cell-free haem, description - Longitudinal changes in plasma cell-free haem over 72 hours., timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03056391",
    "endpoint": "measure - Longitudinal changes in haemolysis: haem-to-protein cross-links, description - Longitudinal changes in haem-to-protein cross-links over 72 hours., timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03056391",
    "endpoint": "measure - Longitudinal changes in markers of oxidative stress: F2-IsoP, description - Longitudinal changes in plasma F2-isoprostanes [F2-IsoP] over 72 hours., timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03056391",
    "endpoint": "measure - Longitudinal changes in markers of oxidative stress: IsoF, description - Longitudinal changes in plasma isofurans [IsoF]) over 72 hours., timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03056391",
    "endpoint": "measure - Longitudinal changes in F2-IsoPs according to G6PD enzyme activity, description - Longitudinal changes in F2-IsoPs according to G6PD enzyme activity, assessed qualitatively by fluorescent spot test., timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03056391",
    "endpoint": "measure - Longitudinal changes in IsoFs according to G6PD enzyme activity, description - Longitudinal changes in IsoFs and CFHb according to G6PD enzyme activity, assessed qualitatively by fluorescent spot test., timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03056391",
    "endpoint": "measure - Longitudinal changes in CFHb according to G6PD enzyme activity, description - Longitudinal changes in CFHb according to G6PD enzyme activity, assessed qualitatively by fluorescent spot test., timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03056391",
    "endpoint": "measure - Longitudinal changes in F2-IsoPs according to G6PD genotype, description - Longitudinal changes in F2-IsoPs according to G6PD genotype, timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03056391",
    "endpoint": "measure - Longitudinal changes in IsoFs according to G6PD genotype, description - Longitudinal changes in IsoFs according to G6PD genotype, timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03056391",
    "endpoint": "measure - Longitudinal changes in CFHb according to G6PD genotype, description - Longitudinal changes in CFHb according to G6PD genotype, timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03056391",
    "endpoint": "measure - Population pharmacokinetics of paracetamol: Cmax, description - Peak plasma concentration (Cmax), timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03056391",
    "endpoint": "measure - Population pharmacokinetics of paracetamol: Tmax, description - Time to peak plasma concentration (Tmax), timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03056391",
    "endpoint": "measure - Population pharmacokinetics of paracetamol: AUC, description - Area under the plasma drug concentration-time curve (AUC), timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03056391",
    "endpoint": "measure - Population pharmacodynamics of paracetamol, description - Paracetamol dose-response curve, timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03056391",
    "endpoint": "measure - Fever clearance time, description - Defined as the time taken for the aural temperature to fall below 37.5°C, and the time taken for the temperature to fall below 37.5°C and remain there for at least 24hours, timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03056391",
    "endpoint": "measure - Fever duration, description - Defined as the duration in hours that an individual&#x27;s temperature is above 37.5°C, timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03056391",
    "endpoint": "measure - Area above the fever versus time curve (AUC-T°), description - Area above the 37.5°C temperature versus time curve (AUC-T°) within first 24 hours of treatment., timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03056391",
    "endpoint": "measure - Parasite clearance time (hours), description - Parasite clearance time, defined as (i) the time from commencement of antimalarial treatment to the first of 2 consecutive negative blood films, with blood films assessed by microscopy every 6 hours for the presence of asexual parasitaemia, and (ii) the linear portion of the slope of the log-parasitemia versus time relationship., timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03056391",
    "endpoint": "measure - Blood and urine biomarkers of pre-renal and renal injury, description - Neutrophil gelatinase-associated lipocalcin (NGAL), kidney injury molecule (KIM), urinalysis, urine microscopy, urine electrolytes, and urine creatinine., timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03056391",
    "endpoint": "measure - Longitudinal urine colour, description - Longitudinal urine colour (assessed by standardized urine colour charts).\nThe proportion of patients with enrolment urine pH less than 6 together with a urine color of 6 or greater who develop AKI will be compared between groups., timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03056391",
    "endpoint": "measure - Longitudinal urine pH, description - Longitudinal urinalysis dipstick test-strip: urine pH.\nThe proportion of patients with enrolment urine pH less than 6 together with a urine color of 6 or greater who develop AKI will be compared between groups., timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03056391",
    "endpoint": "measure - Longitudinal urine specific gravity, description - Longitudinal urinalysis dipstick test-strip: urine specific gravity, timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03056391",
    "endpoint": "measure - Longitudinal urine haemoglobin, description - Longitudinal urinalysis dipstick test-strip: urine haemoglobin, timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03056391",
    "endpoint": "measure - Change in creatinine (umol&#x2F;L) between therapeutic concentrations of paracetamol vs those with absent or low., description - Change in creatinine at 72 hours and longitudinal change in creatinine over 72 hours in patients with therapeutic concentrations of paracetamol, compared to patients with absent or low concentrations of paracetamol, timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03056391",
    "endpoint": "measure - Number of participants with treatment-related adverse events as assessed by CTCAE v4.0, description - Reporting of any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with paracetamol administration, timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03056391",
    "endpoint": "measure - Longitudinal red cell deformability, description - Longitudinal red cell deformability, as measured by laser-assisted optical rotational red cell analyser (LORCA) elongation index., timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03056391",
    "endpoint": "measure - Longitudinal changes in markers of endothelial dysfunction, description - Longitudinal changes in markers of weibel palade body exocytosis including angiopoietin-2, timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04862416",
    "endpoint": "measure - Number of Grade 1 and 2 Adverse Events, description - The number of solicited and unsolicited grade 1 and 2 adverse events possibly, probably or definitely related to the vaccine in the period from first R0.6C\nadministration up to 84 days after the last immunization., timeFrame - From first immunization up to 84 days after the last immunization",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04862416",
    "endpoint": "measure - Transmission Reducing Activity, description - The transmission reducing activity at other timepoint (I1+14, I2+14, I3+14, I3+111 [I4-1], and I4+84) compared to baseline (I1-1) in each of the four dose-adjuvant groups.\nThe TRA was calculated by dividing the total number of oocysts in mosquitoes fed with I1+14, I2+14, I3+14, I3+111 [I4-1], and I4+84 sera by total number of oocysts in mosquitoes fed with I1-1 sera., timeFrame - 14 days after immunization 1, 2 and 3. One day before immunization 4 and 84 days after immunization 4.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04862416",
    "endpoint": "measure - Anti-6C Antibody Quantities, description - The anti-6C antibody quantity in volunteer sera collected two weeks after fourth R0.6C immunization (I4+14) and at other time points (I1+14, I2+14, I3+14, I3+111 [I4-1], and I4+84) compared to baseline (I1-1) in each of the four dose-adjuvant combinations, as determined by ELISA., timeFrame - 14 days after each immunization. One day before immunization 4 and 84 days after immunization 4.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05357560",
    "endpoint": "measure - To assess the humoral and cellular immunogenicity of RH5.2-VLP with Matrix-M as assessed by magnitude assessment at various timepoint, description - RH5 serology (participants vaccinated with RH5.2-VLP only), blood samples taken at a number of key timepoints including baseline and post vaccination of V+7 (adults only), V+14, V+28 to allow for magnitude assessment, late timepoints used to assess longevity of response, timeFrame - From a number of key timepoints, baseline up to day 912 (dependant on group)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05357560",
    "endpoint": "measure - To assess the humoral and cellular immunogenicity of RH5.2-VLP with Matrix-M as assessed by antibody kinetics at various timepoints, description - RH5 serology (participants vaccinated with RH5.2-VLP only), blood samples taken at a number of key timepoints including baseline and post vaccination of V+7 (adults only), V+14, V+28 to allow for antibody kinetics, late timepoints used to assess longevity of response, timeFrame - From a number of key timepoints, baseline up to day 912 (dependant on group)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05357560",
    "endpoint": "measure - To assess the humoral and cellular immunogenicity of RH5.2-VLP with Matrix-M, performing ELISA at various timepoints, description - RH5 serology (participants vaccinated with RH5.2-VLP only), blood samples taken at a number of key timepoints performing ELISA at specified timepoints, timeFrame - From a number of key timepoints, baseline up to day 912 (dependant on group)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05357560",
    "endpoint": "measure - To assess the humoral and cellular immunogenicity of R21 with Matrix-M performing ELISA at various timepoints, description - R21 serology (participants vaccinated with R21 only), blood samples taken at a number of key timepoints performing ELISA at specified timepoints, timeFrame - From a number of key timepoints, baseline up to day 912 (dependant on group)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05357560",
    "endpoint": "measure - To assess the humoral and cellular immunogenicity of R21 with Matrix-M as assessed by antibody kinetics at various timepoints, description - R21 serology (participants vaccinated with R21 only), blood samples taken at a number of key timepoints including baseline and post vaccination of V+7 (adults only), V+14, V+28 to allow for antibody kinetics, late timepoints used to assess longevity of response, timeFrame - From a number of key timepoints, baseline up to day 912 (dependant on group)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05357560",
    "endpoint": "measure - To assess the humoral and cellular immunogenicity of R21 with Matrix-M as assessed by magnitude assessment at various timepoint, description - R21 serology (participants vaccinated with R21 only), blood samples taken at a number of key timepoints including baseline and post vaccination of V+7 (adults only), V+14, V+28 to allow for magnitude assessment, late timepoints used to assess longevity of response, timeFrame - From a number of key timepoints, baseline up to day 912 (dependant on group)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05357560",
    "endpoint": "measure - To assess the humoral and cellular immunogenicity of RH5.2-VLP and R21 with Matrix-M as assessed by antibody kinetics at various timepoints, description - Hepatitis B serology, blood samples taken at a number of key timepoints including baseline and post vaccination of V+7 (adults only), V+14, V+28 to allow for antibody kinetics, late timepoints used to assess longevity of response, timeFrame - From a number of key timepoints, baseline up to day 912 (dependant on group)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05357560",
    "endpoint": "measure - To assess the humoral and cellular immunogenicity of RH5.2-VLP and R21 with Matrix-M as assessed by magnitude assessment at various timepoints, description - Hepatitis B serology, blood samples taken at a number of key timepoints including baseline and post vaccination of V+7 (adults only), V+14, V+28 to allow for magnitude assessment, and late timepoints to assess longevity of response, timeFrame - From a number of key timepoints, baseline up to day 912 (dependant on group)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05357560",
    "endpoint": "measure - To assess the humoral and cellular immunogenicity of RH5.2-VLP and R21 with Matrix-M, performing ELISA at various timepoints, description - Hepatitis B serology, blood samples taken at a number of key timepoints performing ELISA at specified timepoints, timeFrame - From a number of key timepoints, baseline up to day 912 (dependant on group)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05357560",
    "endpoint": "measure - To assess the humoral and cellular immunogenicity of RH5.2-VLP with Matrix-M when administered to healthy volunteers at different doses and combinations and used in various regimens, description - Growth Inhibition Activity (GIA) (participants vaccinated with RH5.2-VLP only) performed at peak of response after the third vaccination, based on previous work this is likely to be at V3+14 or V3+28, timeFrame - Likely at V3+14 or V3+28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05357560",
    "endpoint": "measure - To assess the humoral and cellular immunogenicity of RH5.2-VLP and R21 with Matrix-M as assessed by antibody kinetics at various timepoints, description - Serum total IgG concentration determination, blood samples taken at a number of key timepoints including baseline and post vaccination of V+7 (adults only), V+14, V+28 to allow for antibody kinetics, late timepoints to assess longevity of response, timeFrame - From a number of key timepoints, baseline up to day 912 (dependant on group)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05357560",
    "endpoint": "measure - To assess the humoral and cellular immunogenicity of RH5.2-VLP and R21 with Matrix-M as assessed by magnitude assessment at various timepoints, description - Serum total IgG concentration determination, blood samples taken at a number of key timepoints including baseline and post vaccination of V+7 (adults only), V+14, V+28 to allow for magnitude assessment, late timepoints to assess longevity of response, timeFrame - From a number of key timepoints, baseline up to day 912 (dependant on group)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05357560",
    "endpoint": "measure - To assess the humoral and cellular immunogenicity of RH5.2-VLP and R21 with Matrix-M, performing ELISA at various timepoints, description - Serum total IgG concentration determination, blood samples taken at a number of key timepoints performing ELISA at specified timepoints, timeFrame - From a number of key timepoints, baseline up to day 912 (dependant on group)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05357560",
    "endpoint": "measure - To assess the humoral and cellular immunogenicity of R21 with Matrix-M when administered to healthy volunteers at different doses and combinations and used in various regimens, description - Inhibition of sporozoite invasion assay (ISI) (participants vaccinated with R21 only), blood samples taken at a number of key timepoints including baseline and post vaccination of V+7 (adults only), V+14, V+28 to allow for antibody kinetics and magnitude assessment, and late timepoints to assess longevity of response, performing ELISA at every timepoint where &#x27;immunology serum&#x27; is required, timeFrame - From a number of key timepoints, base line up to day 912 (dependant on group)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01540903",
    "endpoint": "measure - Time from inoculation until first positive parasitemia by thick smear in each volunteer in the two groups., description - , timeFrame - 5-28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01540903",
    "endpoint": "measure - Time from inoculation to until first positive parasitemia by qRT-PCR in each volunteer in the two groups., description - qRT-PCR will be performed according to standard procedure described in Hermsen et al.\nMol.\nBiochem.\nParasitol.\n2001; 118: 247-251.\nIn short, qRT-PCR will be performed on the multicopy 18S ribosomal RNA gene.\nCultured P. falciparum ring stage parasites are taken as a positive control.\nAll samples are spiked with murine white blood cells, and a murine albumin gene PCR is used to determine efficacy of DNA isolation., timeFrame - 5-28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01540903",
    "endpoint": "measure - Kinetics of parasitemia in positive volunteers in the two groups as measured by qRT-PCR., description - Thick smear, malaria rapid diagnostic test and qRT-PCR samples will be taken from the same 3 mL EDTA vacutainer tube.\nHistidine Rich Protein 2 based malaria rapid diagnostic tests will be used in parallel to thick smears., timeFrame - 5-28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01540903",
    "endpoint": "measure - Occurrence or intensity of signs or symptoms in the two groups of volunteers, description - Signs and symptoms will be recorded at all visits and whenever a trial volunteer reports signs or symptoms to the trial physician between visits.\nThe following signs and symptoms will be solicited: fever, headache, malaise, fatigue, myalgia, arthralgia, nausea, vomiting, chills, diarrhea, abdominal pain (Verhage, Telgt, Bousema, Hermsen, van Gemert, van der Meer, &amp; Sauerwein 2005), chest pain, palpitations and shortness of breath., timeFrame - 5 days to 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05567016",
    "endpoint": "measure - Prevalence of anemia, description - Proportion of routine Hb measurements that are low (&lt;11 g&#x2F;dL) or moderate-severe low (&lt;8 g&#x2F;dL), timeFrame - 24-30 months from enrollment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05567016",
    "endpoint": "measure - Prevalence of underweight status, description - Prevalence of underweight status will be defined as the percentage of participants with low weight for age z-scores of less than -2.\nThe World Health Organization (WHO) anthropometric indices will be utilized for standards., timeFrame - 24-30 months from enrollment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05567016",
    "endpoint": "measure - Prevalence of stunting, description - Prevalence of stunting will be defined as the percentage of participants with low height for age z-scores of less than -2.\nThe World Health Organization (WHO) anthropometric indices will be utilized for standards., timeFrame - 24-30 months from enrollment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05567016",
    "endpoint": "measure - Prevalence of wasting, description - Prevalence of wasting will be defined as the percentage of participants with low weight for height z-scores of less than -2.\nThe World Health Organization (WHO) anthropometric indices will be utilized for standards., timeFrame - 24-30 months from enrollment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05567016",
    "endpoint": "measure - Prevalence of malnutrition, description - Prevalence of malnutrition will be defined as the percentage of participants with a z-score of -3 to -2 indicating moderate malnutrition or a z-score of less than -3 indicating severe malnutrition in any of the following: weight for age, height for age, or weight for height., timeFrame - 24-30 months from enrollment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05567016",
    "endpoint": "measure - Prevalence of vomiting following administration of study drugs, description - Vomiting immediately or within 30minutes following administration of study drugs and measures of non-adherence., timeFrame - 24-30 months from enrollment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05567016",
    "endpoint": "measure - All-cause fever episodes, description - Number of fever episodes (reported fever in the past 48hrs and&#x2F;or axillary temperature of ≥37.5°C) per person time, timeFrame - 24-30 months from enrollment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05567016",
    "endpoint": "measure - Incidence of clinical symptoms, description - Number of days with overall symptoms reported as moderate (≥3 on a 5-point scale) per person time, timeFrame - 24-30 months from enrollment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05567016",
    "endpoint": "measure - Incidence of clinical malaria, description - New episodes of positive malaria test (with fever or other clinical symptoms) per person time, timeFrame - 24-30 months from enrollment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05567016",
    "endpoint": "measure - Proportion of fever episodes with clinical failure, description - Proportion of fever episodes that lead to clinical failure, defined as persistent or worsening symptoms assessed 7 and 28 days after initial evaluation., timeFrame - 24-30 months from enrollment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05567016",
    "endpoint": "measure - Prevalence of parasitemia, description - Proportion of routine samples with parasites detected by microscopy or quantitative polymerase chain reaction (qPCR)., timeFrame - 24-30 months from enrollment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05567016",
    "endpoint": "measure - Incidence in antibiotics prescribed, description - Number of antibiotic regimens prescribed per person time, timeFrame - 24-30 months from enrollment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05567016",
    "endpoint": "measure - Cognitive ability among children 0-3.4 years of age on the Global Scales of Early Development (GSED), description - GSED is a validated instrument that measures population-level early childhood development.\nThe tool measures children&#x27;s early skills and behaviors in four primary domains: motor, cognitive, language, and social-emotional development.Measures will be normalized within our sample to mean 0 and standard deviation 1, with higher scores indicating better test performance., timeFrame - 24-30 months from enrollment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05567016",
    "endpoint": "measure - Cognitive ability among children 3.5-5 years of age on the International Development and Early Learning Assessment (IDELA), description - The IDELA is a validated, global tool that uses direct child assessment to measure early learning and development across 4 core domains (Emergent Literacy, Emergent Numeracy, Motor, Social-emotional).\nScores range from 0-100% as a percentage of correct tasks averaged across the 4 domains.\nMeasures will be normalized within our sample to mean 0 and standard deviation 1, with higher scores indicating better test performance., timeFrame - 24-30 months from enrollment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05567016",
    "endpoint": "measure - Cognitive ability among children 6-12 years of age on the East Africa Neurodevelopment Assessment Tool, description - The East African Neurodevelopment Assessment Tool is a locally adapted modification of the Kaufman Brief Intelligence Test 2nd Ed.\nThe test assesses 3 core metrics including general intelligence, executive function, literacy skills - in addition to behavioral and emotional development.\nMeasures will be normalized within our sample to mean 0 and standard deviation 1, with higher scores indicating better test performance., timeFrame - 24-30 months from enrollment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05567016",
    "endpoint": "measure - Sustained attention among children 5-8 years of age on the Pencil Tapping Test, description - The pencil tapping test is one of the tasks in the Preschool Self-Regulation Assessment (PSRA) and is used to assess inhibitory control in younger children.\nThe child and an assessor have pencils, and child is instructed to tap one&#x2F;two times(s) depending on what assessor does, with the number of correct responses scored.\nMeasures will be normalized within our sample to mean 0 and standard deviation 1, with higher scores indicating better test performance., timeFrame - 24-30 months from enrollment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05567016",
    "endpoint": "measure - Sustained attention among children 9-12 years of age on the Code Transmission Test, a local adaptation of the Test of Everyday Attention for Children(TEA-Ch), description - Code transmission test is a sub-test of Test of Everyday Attention for Children (TEA-Ch) used for assessment of sustained attention in children.\nIn the test, the child must remember spoken digits, and remember the digit that comes before sequence of numbers.\nChild is scored on completed and correct answers.\nMeasures will be normalized within our sample to mean 0 and standard deviation 1, with higher scores indicating better test performance., timeFrame - 24-30 months from enrollment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05567016",
    "endpoint": "measure - Incidence of school absenteeism, description - The number of days of school absenteeism for any reason including illness., timeFrame - 24-30 months from enrollment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05567016",
    "endpoint": "measure - School performance, description - School performance will be defined as the incidence of school advancement to the next grade., timeFrame - 24-30 months from enrollment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05567016",
    "endpoint": "measure - Socioeconomic costs to participant, description - Estimated long-term income loss due to impaired early childhood development, timeFrame - 24-30 months from enrollment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05567016",
    "endpoint": "measure - Socioeconomic costs to family, description - Total caregiver-reported costs of sick visits and transport to sick visits plus estimated loss of income from number of days of caregiver work absenteeism., timeFrame - 24-30 months from enrollment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05567016",
    "endpoint": "measure - Socioeconomic costs to health system, description - Estimated costs of testing and treatment for caregiver-reported number of sick visits., timeFrame - 24-30 months from enrollment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05567016",
    "endpoint": "measure - Cost effectiveness, description - Cost per outcome averted (e.g., per sick visit averted, per disability adjusted life years (DALYs), and per economic dollar saved, etc.), timeFrame - 24-30 months from enrollment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05567016",
    "endpoint": "measure - Prevalence of systemic inflammation, description - Proportion of sick visits with elevated elevated C-reactive pep-tide (CRP), timeFrame - 24-30 months from enrollment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05567016",
    "endpoint": "measure - Proportion with antimalarial antibodies against P.falciparum, description - Percentage of patients with antimalarial antibodies, timeFrame - 24-30 months from enrollment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05567016",
    "endpoint": "measure - Proportion with biomarkers of inflammation, description - Percentage of patients with elevated cytokines, timeFrame - 24-30 months from enrollment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05567016",
    "endpoint": "measure - Proportion with general antibody responses to vaccines, description - Percentage of patients with vaccine antibodies, timeFrame - 24-30 months from enrollment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05567016",
    "endpoint": "measure - Proportion with general antibody responses to common pathogens, description - Percentage of patients with common pathogen antibodies, timeFrame - 24-30 months from enrollment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05567016",
    "endpoint": "measure - Incidence of adverse events (AEs), description - Number of AEs per person time.\nAEs will be considered as any grade 3-4 AE or serious adverse event (SAE); individual AEs; or AEs related to study drugs., timeFrame - 24-30 months from enrollment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05567016",
    "endpoint": "measure - Incidence of wasting, description - Incidence proportion of wasting will be defined for each age range of measurement.\nIt is defined as the proportion of children not wasted at the start of the period who became wasted during the age period (the proportion of children who had the onset of new episodes during the period).\nIncident wasting episodes are defined as a change in weight-for-length z-scores from above -2 Z in the prior measurement to below -2 Z in the current measurement.\nWe will define incident severe wasting analogously using a -3 Z cutoff.\nWe will assume a 60-day washout period before a new wasting episode could occur., timeFrame - 24-30 months from enrollment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05567016",
    "endpoint": "measure - Incidence of stunting, description - Incidence proportion of stunting will be defined for each age range of measurement.\nIt is defined as the proportion of children not stunted at the start of the period who became stunted during the age period.\nIncident stunting episodes will be defined as a change in length-for-age z-scores from above -2 Z in the prior measurement to below -2 Z in the current measurement.\nWe will define incident severe stunting analogously using a -3 Z cutoff., timeFrame - 24-30 months from enrollment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02251704",
    "endpoint": "measure - Number of Participants Infected With P. Falciparum by Center, Gender and Infection Status, description - The number of participants was summarized by: center number&#x2F; country [BF, SN, TZ, KE, GH, MA]&#x2F; city, gender (female, male) and infection status (infected, not infected)., timeFrame - At Day 1 (survey completion visit)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02251704",
    "endpoint": "measure - Number of Participants Infected With Plasmodium Species Other Than P. Falciparum, description - The infections with other Plasmodium species were determined using a blood smear slide and microscopy.\nThe number of participants infected with P. malaria, P. vivax and P. ovale was summarized., timeFrame - At Day 1 (survey completion visit)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02251704",
    "endpoint": "measure - Number of Participants Who Received Dose 3 of the Diphtheria, Tetanus, Pertussis&#x2F; Hepatitis B&#x2F; Haemophilus Influenzae Type b (DTP&#x2F;HepB&#x2F;Hib) Vaccine or Dose 1 of the Measles Vaccine, description - , timeFrame - At Day 1 (survey completion visit)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02251704",
    "endpoint": "measure - Number of Participants Who Received Anti-malarial Therapy or Any Other Medication Within 14 Days Prior to the Study Visit, description - The number of participants who received anti-malarial therapy out of those who reported malaria in the last 14 days prior to the study visit was summarized., timeFrame - Up to 14 days prior to the study visit at Day 1",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02251704",
    "endpoint": "measure - Number of Participants With Measured Fever at the Time of Their Study Visit, description - Fever was defined as an axillary temperature of 37.5°C or higher., timeFrame - At Day 1 (survey completion visit)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02251704",
    "endpoint": "measure - Number of Participants With Reported Fever in the 24 Hours Prior to Their Study Visit, description - Fever was defined as an axillary temperature of 37.5°C or higher., timeFrame - Up to 24 hours prior to their study visit at Day 1",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02251704",
    "endpoint": "measure - Number of Participants Demonstrating Care-seeking Behavior Following Reported Fever or Malaria up to 14 Days Prior to Their Study Visit, description - The number of participants demonstrating care-seeking behavior following reported fever or malaria was summarized by where the participant was taken for treatment (home, drug seller, pharmacy, private clinic, health center, hospital, other, not applicable [no treatment received]), by when the participant was taken for treatment (at onset, when the participant did not improve, when the participant got worse, other, not applicable [no treatment received], missing [participant was taken for treatment but did not answer the question regarding when]) and by what time the participant was taken for treatment (the same day, the next day, 2 days later, more than 2 days later, not applicable [no treatment received], missing [participant was taken for treatment but did not answer the question regarding the time])., timeFrame - Up to 14 days prior to their study visit at Day 1",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02251704",
    "endpoint": "measure - Number of Participants in Each Geo-referenced Segment, description - The number of participants was summarized by: center number&#x2F; country [BF, SN, TZ, KE, GH, MA]&#x2F; city followed by the segment ID. Positioning of the participant&#x27;s residence was attributed to a segment with a unique ID from the grid referencing study area map in which the participant resided; where necessary, grouping small geographically proximate villages so that each segment had at least 10 study participants to avoid personally identifiable information (PII), and proceeding as far as geographically appropriate., timeFrame - At Day 1 (survey completion visit)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02251704",
    "endpoint": "measure - Number of Participants Experiencing Malaria Risk Factors Categorized by the Number of Participants Living in the Same House (by Parasite Density), description - Participants were categorized by the number of people living in the same house relative to enrolled participants as follows: less than of equal to (&lt;=) 3 per 1 enrolled (LE 3&#x2F;1), 4-5 per 1 (4-5&#x2F;1), more than (&gt;) 5 per 1 (GT 5&#x2F;1); &lt;=3 per 2 enrolled (LE 3&#x2F;2), 4-5 per 2 (4-5&#x2F;2), &gt;5 per 2 (GT 5&#x2F;2); &lt;=3 per 3 enrolled (LE 3&#x2F;3), 4-5 per 3 (4-5&#x2F;3), &gt;5 per 3 (GT 5&#x2F;3); 4-5 per more than 3 enrolled (4-5&#x2F;GT 3), &gt;5 per more than 3 enrolled (GT 5&#x2F;GT 3).\nParticipants were also categorized by parasite density: low (&lt;2500 parasites&#x2F;μL), medium (2500-9999&#x2F;μL), high (10000-19999&#x2F;μL), very high (&gt;=20000&#x2F;μL), negative, and missing., timeFrame - At Day 1 (survey completion visit)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02251704",
    "endpoint": "measure - Number of Participants Experiencing Malaria Risk Categorized by Location (by Parasite Density), description - Participants were categorized by location as follows: situation area (rural, urban, semi-rural) and type of location (large city, small city, town, countryside).\nParticipants were also categorized by parasite density: low (&lt;2500 parasites&#x2F;μL), medium (2500-9999&#x2F;μL), high (10000-19999&#x2F;μL), very high (&gt;=20000&#x2F;μL), negative, and missing., timeFrame - At Day 1 (survey completion visit)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02251704",
    "endpoint": "measure - Number of Participants Experiencing Malaria Risk Factors Categorized by House Information (by Parasite Density), description - Participants were categorized by house characteristics as follows: wall material (mud, brick, cement&#x2F;plaster, clay, other), floor material (natural, rudimentary, vinyl&#x2F;asphalt strips, parquet&#x2F;polished wood, ceramic tiles, cement, carpet, clay, other), roof type (iron sheet, tiles, clay, other), window type (closed, open, no window, partially open, other), presence of nets (not present, present on all windows, present on some windows, other, missing), main drinking water source (closed, open), whether the open source was in the compound (yes, no, not available [NA]), and presence or absence of electricity.\nParticipants were also categorized by parasite density: low (&lt;2500 parasites&#x2F;μL), medium (2500-9999&#x2F;μL), high (10000-19999&#x2F;μL), very high (&gt;=20000&#x2F;μL), negative, and missing., timeFrame - At Day 1 (survey completion visit)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00740090",
    "endpoint": "measure - Antibody response determined by ELISA, to the AMA1-FVO and AMA1-3D7 proteins at selected time points. Inhibition of P. falciparum FVO and 3D7 parasite growth in vitro determined at selected time points., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02123290",
    "endpoint": "measure - Parasite Clearance kinetics, description - <ol><li>Parasite clearance time</li><li>PRR (Parasite reduction rate) and parasitemia half life</li><li><p>Times to microscopic clearance of asexual parasites</p><ol><li>Total reduction</li><li>99% reduction</li><li>90% reduction</li><li>50% reduction</li></ol></li><li>Percent reduction in asexual parasites from baseline (microscopically measured) at 24, 48 and 72 hours post-dose</li><li>Proportion of aparasitemic patients at 24, 48 and 72 hours post-dose</li></ol>, timeFrame - Day 0 to 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02123290",
    "endpoint": "measure - Endpoints concerning Safety and tolerability of DSM265 in patients, description - <p>For P. falciparum and for P. vivax:</p><ol><li>Incidence, severity, drug-relatedness, seriousness of adverse events</li><li>Laboratory values (biochemistry and haematology)</li><li>Vital signs</li><li>ECG findings, including heart rate, ECG intervals (PR, QTcB, QTcF), conduction changes or abnormalities</li></ol>, timeFrame - Day 0 to 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02123290",
    "endpoint": "measure - Endpoints concerning gametocytemia, description - <ol><li><p>Percent microscopic reduction in gametocytes (stratified by gametocyte status at inclusion) from baseline at</p><ol><li>24 hours after administration of study drug</li><li>72 hours after administration of study drug</li></ol></li><li>Proportion of subjects with gametocytes (stratified by gametocyte status at inclusion)</li><li>Area under the curve (AUC) over 14 and 28 days for gametocyte density (stratified by gametocyte status at inclusion)</li></ol>, timeFrame - Days 0 to 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02123290",
    "endpoint": "measure - The effect of DSM265 on signs and symptoms of malaria, description - <ol><li>28 day Adequate Clinical and Parasitological Response (for P. vivax and P. falciparum)</li><li>Kaplan Meier survival analysis for rate of recurrence, recrudescence and new infection over 28 days in comparison to historical controls</li></ol>, timeFrame - Day 0 to Day 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02123290",
    "endpoint": "measure - Antimalarial pharmacodynamics - minimum parasiticidal concentration, Minimum Inhibitory Concentration, Time and concentration of parasitemia nadir, description - <ol><li>Minimum Parasiticidal Concentration</li><li>Minimum Inhibitory Concentration</li><li>Time and concentration of parasitemia nadir (if observed)</li><li>A model based link between observed pharmacokinetics and observed parasite density over time</li></ol>, timeFrame - Day 0 to Day 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02802813",
    "endpoint": "measure - Time to P. vivax clearance, description - Detected by uPCR, timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02802813",
    "endpoint": "measure - The frequency of recurrent vivax infections (clinical and sub-clinical), description - , timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02802813",
    "endpoint": "measure - The follow-up period required to detect a statistically significant difference in the frequency of recurrent subclinical P. vivax infections between treated and untreated participants, description - measured by uPCR, timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02802813",
    "endpoint": "measure - Number of participants with treatment related Adverse event., description - , timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02802813",
    "endpoint": "measure - Number of participants with treatment related malaria episode, description - , timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02802813",
    "endpoint": "measure - Number of doses taken per participants, description - , timeFrame - 14 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02802813",
    "endpoint": "measure - Compare the percentage decrease in hemoglobin between those who receive primaquine and who those not receive primaquine, description - , timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02802813",
    "endpoint": "measure - Number of G6PD genotypes in participants with G6PD deficiency, description - , timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02802813",
    "endpoint": "measure - Number of P450 genotypes in participants with recurrent PV infection., description - , timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04327310",
    "endpoint": "measure - The area under the plasma drug concentration-time curve (AUC), description - Meplazumab serum concentration, timeFrame - 43±3 days (from first dose to end of study)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04327310",
    "endpoint": "measure - Maximum Plasma Concentration, description - , timeFrame - 43±3 days (from first dose to end of study)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04327310",
    "endpoint": "measure - Time to Maximum Plasma Concentration, description - , timeFrame - 43±3 days (from first dose to end of study)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04327310",
    "endpoint": "measure - Area under the serum concentration-time curve from time zero extrapolated to infinity, description - Calculated by linear up&#x2F;log down trapezoidal summation, timeFrame - 43±3 days (from first dose to end of study)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04327310",
    "endpoint": "measure - Area under the serum concentration-time curve from time zero to the time of the last quantifiable concentration, description - Calculated by linear up&#x2F;log down trapezoidal summation, timeFrame - 43±3 days (from first dose to end of study)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04327310",
    "endpoint": "measure - Terminal half-life, description - A minimum of 3 points will be used for estimation, timeFrame - 43±3 days (from first dose to end of study)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04327310",
    "endpoint": "measure - Systemic clearance, description - , timeFrame - 43±3 days (from first dose to end of study)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04327310",
    "endpoint": "measure - Volume of distribution, description - , timeFrame - 43±3 days (from first dose to end of study)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04327310",
    "endpoint": "measure - Volume of distribution at steady state, description - , timeFrame - 43±3 days (from first dose to end of study)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01190202",
    "endpoint": "measure - Number of Subjects With Plasmodium Falciparum (P. Falciparum) Parasitaemia (PFP), According to Annual Age for Children of 4 Years or Less, for Each Survey, description - The overall parasite prevalence (PP) data were collected across centers from subjects aged 4 years or less, for each Survey.\nThe number of subjects P. Falciparum parasitemia infected among the number of subjects with known result for P.falciparum parasitemia test was tabulated., timeFrame - At each Survey visit",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01190202",
    "endpoint": "measure - Number of Subjects With Anemia and Severe Anemia for Each Survey, description - The overall anemia and severe anemia data were collected across centers from subjects, aged between and including: 6M-4Y, 5-19 Y and 20Y+, for each survey.\nHemoglobin (Hgb) cut-offs used to define anemia and severe anemia in people living at sea level are: Anemia: children 6M to 5Y, Hgb lower than (&lt;) 11 gram per deciliter (g&#x2F;dL); children 5-11Y, Hgb &lt;11.5 g&#x2F;dL; children 12-13Y, Hgb &lt;12 g&#x2F;dL; non-pregnant females, Hgb &lt;12 g&#x2F;dL; pregnant females, Hgb &lt;11 g&#x2F;dL; males, Hgb &lt;13 g&#x2F;dL.\nSevere anemia: any age or gender, Hgb &lt;7 g&#x2F;dL.\nMissing&#x2F; Not applicable (NA) = if age or pregnancy status was not available.\nAmong each age category, results for both sub-categories &quot;Yes&quot; (subjects with anemia) and &quot;Missing&#x2F;NA&quot; are presented below, results for the category &quot;No&quot; can be deduced from the number of participants analyzed in the corresponding age category, minus (number of &quot;Yes&quot; + number of &quot;Missing&#x2F;NA&quot;).\nSimilar presentation is followed for &quot;severe anemia&quot; results., timeFrame - During the survey period (approximatively 1 year)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01190202",
    "endpoint": "measure - Number of Subjects With Anti-malarial Therapy in Survey 1, According to Parasite Density, description - The overall anti-malaria therapy data were collected across centers from subjects between and including: 6M-4Y, 5-19 Y and 20Y+, for Survey 1. Results were presented per the following P. falciparum parasite density status subgroups: Low, Medium, High, Very high, and Negative (Neg).\nResults include the following categories: Malaria treatment (MT) in past 14 days with sub-categories assessed: Yes, No; Exact days of malaria treatment (EDMT) with sub-categories assessed: Ongoing, 1-3 Days, ≥ 4 Days, Missing&#x2F;NA; Other medication (OM) in past 14 days with sub-categories assessed: Yes, No; Days of other medication (DOM) with sub-categories assessed: Ongoing, 1-7 Days, ≥ 8 Days, Missing&#x2F;NA; Malaria hospitalization (MH) in the last 3 months with sub-categories assessed: Yes, No. Missing&#x2F;NA = Missing or Not Applicable.*\nIn case of several medication (malaria treatment or other medication) taken per subject, the maximum duration was computed for this study., timeFrame - During the survey period (approximatively 1 year)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01190202",
    "endpoint": "measure - Number of Subjects With Anti-malarial Therapy in Survey 2, According to Parasite Density, description - The overall anti-malaria therapy data were collected across centers from subjects between and including: 6M-4Y, 5-19 Y and 20Y+, for Survey 2. Results were presented per the following P. falciparum parasite density status subgroups: Low, Medium, High, Very high, and Negative (Neg).\nResults include the following categories: Malaria treatment (MT) in past 14 days with sub-categories assessed: Yes, No; Exact days of malaria treatment (EDMT) with sub-categories assessed: Ongoing, 1-3 Days, ≥ 4 Days, Missing&#x2F;NA; Other medication (OM) in past 14 days with sub-categories assessed: Yes, No; Days of other medication (DOM) with sub-categories assessed: Ongoing, 1-7 Days, ≥ 8 Days, Missing&#x2F;NA; Malaria hospitalization (MH) in the last 3 months with sub-categories assessed: Yes, No. Missing&#x2F;NA = Missing or Not Applicable.*\nIn case of several medication (malaria treatment or other medication) taken per subject, the maximum duration was computed for this study., timeFrame - During the survey period (approximatively 1 year)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01190202",
    "endpoint": "measure - Number of Subjects With Anti-malarial Therapy in Survey 3, According to Parasite Density, description - The overall anti-malaria therapy data were collected across centers from subjects between and including: 6M-4Y, 5-19 Y and 20Y+, for Survey 3. Results were presented per the following P. falciparum parasite density status subgroups: Low, Medium, High, Very high, and Negative (Neg).\nResults include the following categories: Malaria treatment (MT) in past 14 days with sub-categories assessed: Yes, No; Exact days of malaria treatment (EDMT) with sub-categories assessed: Ongoing, 1-3 Days, ≥ 4 Days, Missing&#x2F;NA; Other medication (OM) in past 14 days with sub-categories assessed: Yes, No; Days of other medication (DOM) with sub-categories assessed: Ongoing, 1-7 Days, ≥ 8 Days, Missing&#x2F;NA; Malaria hospitalization (MH) in the last 3 months with sub-categories assessed: Yes, No. Missing&#x2F;NA = Missing or Not Applicable.*\nIn case of several medication (malaria treatment or other medication) taken per subject, the maximum duration was computed for this study., timeFrame - During the survey period (approximatively 1 year)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01190202",
    "endpoint": "measure - Number of Subjects With Anti-malarial Therapy in Survey 4, According to Parasite Density, description - The overall anti-malaria therapy data were collected across centers from subjects between and including: 6M-4Y, 5-19 Y and 20Y+, for Survey 4. Results were presented per the following P. falciparum parasite density status subgroups: Low, Medium, High, Very high, and Negative (Neg).\nResults include the following categories: Malaria treatment (MT) in past 14 days with sub-categories assessed: Yes, No; Exact days of malaria treatment (EDMT) with sub-categories assessed: Ongoing, 1-3 Days, ≥ 4 Days, Missing&#x2F;NA; Other medication (OM) in past 14 days with sub-categories assessed: Yes, No; Days of other medication (DOM) with sub-categories assessed: Ongoing, 1-7 Days, ≥ 8 Days, Missing&#x2F;NA; Malaria hospitalization (MH) in the last 3 months with sub-categories assessed: Yes, No. Missing&#x2F;NA = Missing or Not Applicable.*\nIn case of several medication (malaria treatment or other medication) taken per subject, the maximum duration was computed for this study., timeFrame - During the survey period (approximatively 1 year)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01190202",
    "endpoint": "measure - Mean Number of Days With Malaria Treatment at Survey 1, description - The mean and standard deviation of the number of days of malaria treatment (DMT) were calculated for the past 14 days period of treatment.\nThe malaria treatment data were collected across centers from subjects between and including: 6M-4Y, 5-19 Y and 20Y+, for Survey 1. Results were presented per the following P. falciparum parasite density status subgroups: Low, Medium, High, Very high, and Negative (Neg)., timeFrame - During the 14 day-period before the malaria treatment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01190202",
    "endpoint": "measure - Mean Number of Days With Malaria Treatment at Survey 2, description - The mean and standard deviation of the number of days of malaria treatment (DMT) were calculated for the past 14 days period of treatment.\nThe malaria treatment data were collected across centers from subjects between and including: 6M-4Y, 5-19 Y and 20Y+, for Survey 2. Results were presented per the following P. falciparum parasite density status subgroups: Low, Medium, High, Very high, and Negative (Neg)., timeFrame - During the 14 day-period before the malaria treatment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01190202",
    "endpoint": "measure - Mean Number of Days With Malaria Treatment at Survey 3, description - The mean and standard deviation of the number of days of malaria treatment (DMT) were calculated for the past 14 days period of treatment.\nThe malaria treatment data were collected across centers from subjects between and including: 6M-4Y, 5-19 Y and 20Y+, for Survey 3. Results were presented per the following P. falciparum parasite density status subgroups: Low, Medium, High, Very high, and Negative (Neg)., timeFrame - During the 14 day-period before the malaria treatment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01190202",
    "endpoint": "measure - Mean Number of Days With Malaria Treatment at Survey 4, description - The mean and standard deviation of the number of days of malaria treatment (DMT) were calculated for the past 14 days period of treatment.\nThe malaria treatment data were collected across centers from subjects between and including: 6M-4Y, 5-19 Y and 20Y+, for Survey 4. Results were presented per the following P. falciparum parasite density status subgroups: Low, Medium, High, Very high, and Negative (Neg)., timeFrame - During the 14 day-period before the malaria treatment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01190202",
    "endpoint": "measure - Number of Subjects With Fever in the Last 24 Hours or at Visit During Survey 1, description - Measured characteristics of fever were the following: Fever in the last 24 hours (F 24h) and Fever at visit (F at V). Note: Fever set to &quot;Yes&quot; if temperature recorded after axillary conversion was ≥ 37.5 degrees Celsius (°C).\nMissing&#x2F;NA = Missing or Not Applicable.\nFever data were collected across centers from subjects between and including: 6M-4Y, 5-19 Y and 20Y+, for Survey 1. Results were presented per the following P. falciparum parasite density status subgroups: Low, Medium, High, Very high, and Negative (Neg)., timeFrame - In the last 24 hours or at the survey visit",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01190202",
    "endpoint": "measure - Number of Subjects With Fever in the Last 24 Hours or at Visit During Survey 2, description - Measured characteristics of fever were the following: Fever in the last 24 hours (F 24h) and Fever at visit (F at V). Note: Fever set to &quot;Yes&quot; if temperature recorded after axillary conversion was ≥ 37.5 degrees Celsius (°C).\nMissing&#x2F;NA = Missing or Not Applicable.\nFever data were collected across centers from subjects between and including: 6M-4Y, 5-19 Y and 20Y+, for Survey 2. Results were presented per the following P. falciparum parasite density status subgroups: Low, Medium, High, Very high, and Negative (Neg)., timeFrame - In the last 24 hours or at the survey visit",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01190202",
    "endpoint": "measure - Number of Subjects With Fever in the Last 24 Hours or at Visit During Survey 3, description - Measured characteristics of fever were the following: Fever in the last 24 hours (F 24h) and Fever at visit (F at V). Note: Fever set to &quot;Yes&quot; if temperature recorded after axillary conversion was ≥ 37.5 degrees Celsius (°C).\nMissing&#x2F;NA = Missing or Not Applicable.\nFever data were collected across centers from subjects between and including: 6M-4Y, 5-19 Y and 20Y+, for Survey 3. Results were presented per the following P. falciparum parasite density status subgroups: Low, Medium, High, Very high, and Negative (Neg)., timeFrame - In the last 24 hours or at the survey visit",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01190202",
    "endpoint": "measure - Number of Subjects With Fever in the Last 24 Hours or at Visit During Survey 4, description - Measured characteristics of fever were the following: Fever in the last 24 hours (F 24h) and Fever at visit (F at V). Note: Fever set to &quot;Yes&quot; if temperature recorded after axillary conversion was ≥ 37.5 degrees Celsius (°C).\nMissing&#x2F;NA = Missing or Not Applicable.\nFever data were collected across centers from subjects between and including: 6M-4Y, 5-19 Y and 20Y+, for Survey 4. Results were presented per the following P. falciparum parasite density status subgroups: Low, Medium, High, Very high, and Negative (Neg)., timeFrame - In the last 24 hours or at the survey visit",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01190202",
    "endpoint": "measure - Mean Number of Days With Fever at Survey 1, description - The mean and standard deviation of the number of days ago with fever start (DaFs) were calculated for subjects having fever in the last 24 hours.\nFever data were collected across centers from subjects between and including: 6M-4Y, 5-19 Y and 20Y+, for Survey 1. Results were presented per the following P. falciparum parasite density status subgroups: Low, Medium, High, Very high, and Negative (Neg)., timeFrame - During the survey period (approximatively 1 year)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01190202",
    "endpoint": "measure - Mean Number of Days With Fever at Survey 2, description - The mean and standard deviation of the number of days ago with fever start (DaFs) were calculated for subjects having fever in the last 24 hours.\nFever data were collected across centers from subjects between and including: 6M-4Y, 5-19 Y and 20Y+, for Survey 2. Results were presented per the following P. falciparum parasite density status subgroups: Low, Medium, High, Very high, and Negative (Neg)., timeFrame - During the survey period (approximatively 1 year)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01190202",
    "endpoint": "measure - Mean Number of Days With Fever at Survey 3, description - The mean and standard deviation of the number of days ago with fever start (DaFs) were calculated for subjects having fever in the last 24 hours.\nFever data were collected across centers from subjects between and including: 6M-4Y, 5-19 Y and 20Y+, for Survey 3. Results were presented per the following P. falciparum parasite density status subgroups: Low, Medium, High, Very high, and Negative (Neg)., timeFrame - During the survey period (approximatively 1 year)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01190202",
    "endpoint": "measure - Mean Number of Days With Fever at Survey 4, description - The mean and standard deviation of the number of days ago with fever start (DaFs) were calculated for subjects having fever in the last 24 hours.\nFever data were collected across centers from subjects between and including: 6M-4Y, 5-19 Y and 20Y+, for Survey 4. Results were presented per the following P. falciparum parasite density status subgroups: Low, Medium, High, Very high, and Negative (Neg)., timeFrame - During the survey period (approximatively 1 year)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01190202",
    "endpoint": "measure - Axillary Temperature at Visit in Survey 1, description - The mean and standard deviation of the axillary temperature at visit (A temp.\nat V) were calculated.\nAxillary temperature data were collected across centers from subjects between and including: 6M-4Y, 5-19 Y and 20Y+, for Survey 1. Results were presented per the following P. falciparum parasite density status subgroups: Low, Medium, High, Very high, and Negative (Neg)., timeFrame - At Survey visit",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01190202",
    "endpoint": "measure - Axillary Temperature at Visit in Survey 2, description - The mean and standard deviation of axillary temperature at visit (A temp.\nat V) were calculated.\nAxillary temperature data were collected across centers from subjects between and including: 6M-4Y, 5-19 Y and 20Y+, for Survey 2. Results were presented per the following P. falciparum parasite density status subgroups: Low, Medium, High, Very high, and Negative (Neg)., timeFrame - At Survey visit",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01190202",
    "endpoint": "measure - Axillary Temperature at Visit in Survey 3, description - The mean and standard deviation of axillary temperature at visit (A temp.\nat V) were calculated.\nAxillary temperature data were collected across centers from subjects between and including: 6M-4Y, 5-19 Y and 20Y+, for Survey 3. Results were presented per the following P. falciparum parasite density status subgroups: Low, Medium, High, Very high, and Negative (Neg)., timeFrame - At Survey visit",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01190202",
    "endpoint": "measure - Axillary Temperature at Visit in Survey 4, description - The mean and standard deviation of axillary temperature at visit (A temp.\nat V) were calculated.\nAxillary temperature data were collected across centers from subjects between and including: 6M-4Y, 5-19 Y and 20Y+, for Survey 4. Results were presented per the following P. falciparum parasite density status subgroups: Low, Medium, High, Very high, and Negative (Neg)., timeFrame - At Survey visit",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01190202",
    "endpoint": "measure - Number of Subjects Living in the Same House at Survey 1, description - The malaria prevention and risk factors characteristics were: Number of persons living in the same part of the house (PLSPH) among persons enrolled in the study (PES), in the following combinations: &lt; y&#x2F;x (less than [&lt;] y PLSPH among x PES), y-z&#x2F;x (y to z PLSPH among x PES), &gt; z&#x2F;x (more than [&gt;] z PLSPH among x PES), y-z&#x2F;&gt; x (y to z PLSPH among more than [&gt;] x PES), &gt; z&#x2F;&gt; x (more than [&gt;] z PLSPH among more than [&gt;] x PES, or missing information).\nData were collected across centers from subjects between and including: 6M-4Y, 5-19 Y and 20Y+, for Survey 1. Results were presented per the following P. falciparum parasite density status subgroups: Low, Medium, High, Very high, and Negative (Neg)., timeFrame - At Survey visit",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01190202",
    "endpoint": "measure - Number of Subjects Living in the Same House at Survey 2, description - The malaria prevention and risk factors characteristics were: Number of persons living in the same part of the house (PLSPH) among persons enrolled in the study (PES), in the following combinations: &lt; y&#x2F;x (less than [&lt;] y PLSPH among x PES), y-z&#x2F;x (y to z PLSPH among x PES), &gt; z&#x2F;x (more than [&gt;] z PLSPH among x PES), y-z&#x2F;&gt; x (y to z PLSPH among more than [&gt;] x PES), &gt; z&#x2F;&gt; x (more than [&gt;] z PLSPH among more than [&gt;] x PES, or missing information).\nData were collected across centers from subjects between and including: 6M-4Y, 5-19 Y and 20Y+, for Survey 2. Results were presented per the following P. falciparum parasite density status subgroups: Low, Medium, High, Very high, and Negative (Neg)., timeFrame - At Survey visit",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01190202",
    "endpoint": "measure - Number of Subjects Living in the Same House at Survey 3, description - The malaria prevention and risk factors characteristics were: Number of persons living in the same part of the house (PLSPH) among persons enrolled in the study (PES), in the following combinations: &lt; y&#x2F;x (less than [&lt;] y PLSPH among x PES), y-z&#x2F;x (y to z PLSPH among x PES), &gt; z&#x2F;x (more than [&gt;] z PLSPH among x PES), y-z&#x2F;&gt; x (y to z PLSPH among more than [&gt;] x PES), &gt; z&#x2F;&gt; x (more than [&gt;] z PLSPH among more than [&gt;] x PES, or missing information).\nData were collected across centers from subjects between and including: 6M-4Y, 5-19 Y and 20Y+, for Survey 3. Results were presented per the following P. falciparum parasite density status subgroups: Low, Medium, High, Very high, and Negative (Neg)., timeFrame - At Survey visit",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01190202",
    "endpoint": "measure - Number of Subjects Living in the Same House at Survey 4, description - The malaria prevention and risk factors characteristics were: Number of persons living in the same part of the house (PLSPH) among persons enrolled in the study (PES), in the following combinations: &lt; y&#x2F;x (less than [&lt;] y PLSPH among x PES), y-z&#x2F;x (y to z PLSPH among x PES), &gt; z&#x2F;x (more than [&gt;] z PLSPH among x PES), y-z&#x2F;&gt; x (y to z PLSPH among more than [&gt;] x PES), &gt; z&#x2F;&gt; x (more than [&gt;] z PLSPH among more than [&gt;] x PES, or missing information).\nData were collected across centers from subjects between and including: 6M-4Y, 5-19 Y and 20Y+, for Survey 4. Results were presented per the following P. falciparum parasite density status subgroups: Low, Medium, High, Very high, and Negative (Neg)., timeFrame - At Survey visit",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01190202",
    "endpoint": "measure - Mean Number of Subjects Living in the Same House at Survey 1, description - The malaria prevention and risk factors characteristics were the following: the mean and standard deviation of the number of persons living in the same part of the house (PLSPH).\nData were collected across centers from subjects between and including: 6M-4Y, 5-19 Y and 20Y+, for Survey 1. Results were presented per the following P. falciparum parasite density status subgroups: Low, Medium, High, Very high, and Negative (Neg)., timeFrame - At Survey visit",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01190202",
    "endpoint": "measure - Mean Number of Subjects Living in the Same House at Survey 2, description - The malaria prevention and risk factors characteristics were the following: the mean and standard deviation of the number of persons living in the same part of the house (PLSPH).\nData were collected across centers from subjects between and including: 6M-4Y, 5-19 Y and 20Y+, for Survey 2. Results were presented per the following P. falciparum parasite density status subgroups: Low, Medium, High, Very high, and Negative (Neg)., timeFrame - At Survey visit",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01190202",
    "endpoint": "measure - Mean Number of Subjects Living in the Same House at Survey 3, description - The malaria prevention and risk factors characteristics were the following: the mean and standard deviation of the number of persons living in the same part of the house (PLSPH).\nData were collected across centers from subjects between and including: 6M-4Y, 5-19 Y and 20Y+, for Survey 3. Results were presented per the following P. falciparum parasite density status subgroups: Low, Medium, High, Very high, and Negative (Neg)., timeFrame - At Survey visit",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01190202",
    "endpoint": "measure - Mean Number of Subjects Living in the Same House at Survey 4, description - The malaria prevention and risk factors characteristics were the following: the mean and standard deviation of the number of persons living in the same part of the house (PLSPH).\nData were collected across centers from subjects between and including: 6M-4Y, 5-19 Y and 20Y+, for Survey 4. Results were presented per the following P. falciparum parasite density status subgroups: Low, Medium, High, Very high, and Negative (Neg)., timeFrame - At Survey visit",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01190202",
    "endpoint": "measure - Number of Subjects by Localisation and Type of Location at Survey 1, description - <p>The malaria prevention and risk factors characteristics were the following: localisation categories (i.e.: rural, urban, semi-rural or missing) and Type of Location (i.e.: Large city: &gt;1 million habitants; Small city: &gt;50000 &amp; &lt; 1 million habitants; Town: &gt; 10000 and &lt; 50000 habitants; Countryside: &lt; 10000 habitants or missing type of location).</p><p>Data were collected across centers from subjects between and including: 6M-4Y, 5-19 Y and 20Y+, for Survey 1. Results were presented per the following P. falciparum parasite density status subgroups: Low, Medium, High, Very high, and Negative (Neg).</p>, timeFrame - At Survey visit",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01190202",
    "endpoint": "measure - Number of Subjects by Localisation and Type of Location at Survey 2, description - <p>The malaria prevention and risk factors characteristics were the following: localisation categories (i.e.: rural, urban, semi-rural) and Type of Location (i.e.: Large city: &gt;1 million habitants; Small city: &gt;50000 &amp; &lt; 1 million habitants; Town: &gt; 10000 and &lt; 50000 habitants; Countryside: &lt; 10000 habitants).</p><p>Data were collected across centers from subjects between and including: 6M-4Y, 5-19 Y and 20Y+, for Survey 2. Results were presented per the following P. falciparum parasite density status subgroups: Low, Medium, High, Very high, and Negative (Neg).</p>, timeFrame - At Survey visit",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01190202",
    "endpoint": "measure - Number of Subjects by Localisation and Type of Location at Survey 3, description - <p>The malaria prevention and risk factors characteristics were the following: localisation categories (i.e.: rural, urban, semi-rural) and Type of Location (i.e.: Large city: &gt;1 million habitants; Small city: &gt;50000 &amp; &lt; 1 million habitants; Town: &gt; 10000 and &lt; 50000 habitants; Countryside: &lt; 10000 habitants).</p><p>Data were collected across centers from subjects between and including: 6M-4Y, 5-19 Y and 20Y+, for Survey 3. Results were presented per the following P. falciparum parasite density status subgroups: Low, Medium, High, Very high, and Negative (Neg).</p>, timeFrame - At Survey visit",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01190202",
    "endpoint": "measure - Number of Subjects by Localisation and Type of Location at Survey 4, description - <p>The malaria prevention and risk factors characteristics were the following: localisation categories (i.e.: rural, urban, semi-rural) and Type of Location (i.e.: Large city: &gt;1 million habitants; Small city: &gt;50000 &amp; &lt; 1 million habitants; Town: &gt; 10000 and &lt; 50000 habitants; Countryside: &lt; 10000 habitants).</p><p>Data were collected across centers from subjects between and including: 6M-4Y, 5-19 Y and 20Y+, for Survey 4. Results were presented per the following P. falciparum parasite density status subgroups: Low, Medium, High, Very high, and Negative (Neg).</p>, timeFrame - At Survey visit",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01190202",
    "endpoint": "measure - Number of Subjects by House Construction Material Regarding Walls and Floor at Survey 1, description - <p>The malaria prevention and risk factors characteristics were the following: Main house construction material (MHCM) walls and MHCM floor.\nMHCM walls data were assessed for the following sub-categories: mud, brick, cement&#x2F;plaster, cement&#x2F;paint, other and missing.\nMHCM floor data were assessed for the following sub-categories: natural floor, rudimentary floor, parquet polished wood, vinyl or asphalt strips, ceramic tiles, cement, carpet, missing.\nNote: Natural floor = earth, sand, dung; Rudimentary floor = wood planks, palm, bamboo.</p><p>Data were collected across centers from subjects between and including: 6M-4Y, 5-19 Y and 20Y+, for Survey 1. Results were presented per the following P. falciparum parasite density status subgroups: Low, Medium, High, Very high, and Negative (Neg).</p>, timeFrame - At Survey visit",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01190202",
    "endpoint": "measure - Number of Subjects by House Construction Material Regarding Walls and Floor at Survey 2, description - <p>The malaria prevention and risk factors characteristics were the following: Main house construction material (MHCM) walls and MHCM floor.\nMHCM walls data were assessed for the following sub-categories: mud, brick, cement&#x2F;plaster, cement&#x2F;paint, other.\nMHCM floor data were assessed for the following sub-categories: natural floor, rudimentary floor, parquet polished wood, vinyl or asphalt strips, ceramic tiles, cement, carpet.\nNote: Natural floor = earth, sand, dung; Rudimentary floor = wood planks, palm, bamboo.</p><p>Data were collected across centers from subjects between and including: 6M-4Y, 5-19 Y and 20Y+, for Survey 2. Results were presented per the following P. falciparum parasite density status subgroups: Low, Medium, High, Very high, and Negative (Neg).</p>, timeFrame - At Survey visit",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01190202",
    "endpoint": "measure - Number of Subjects by House Construction Material Regarding Walls and Floor at Survey 3, description - The malaria prevention and risk factors characteristics were the following: Main house construction material (MHCM) walls and MHCM floor.\nMHCM walls data were assessed for the following sub-categories: mud, brick, cement&#x2F;plaster, cement&#x2F;paint, other.\nMHCM floor data were assessed for the following sub-categories: natural floor, rudimentary floor, ceramic tiles, cement, carpet.\nNote: Natural floor = earth, sand, dung; Rudimentary floor = wood planks, palm, bamboo.\nData were collected across centers from subjects between and including: 6M-4Y, 5-19 Y and 20Y+, for Survey 3. Results were presented per the following P. falciparum parasite density status subgroups: Low, Medium, High, Very high, and Negative (Neg)., timeFrame - At Survey visit",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01190202",
    "endpoint": "measure - Number of Subjects by House Construction Material Regarding Walls and Floor at Survey 4, description - <p>The malaria prevention and risk factors characteristics were the following: Main house construction material (MHCM) walls and MHCM floor.\nMHCM walls data were assessed for the following sub-categories: mud, brick, cement&#x2F;plaster, cement&#x2F;paint, other.\nMHCM floor data were assessed for the following sub-categories: natural floor, rudimentary floor, vinyl or asphalt strips, ceramic tiles, cement, carpet.\nNote: Natural floor = earth, sand, dung; Rudimentary floor = wood planks, palm, bamboo.</p><p>Data were collected across centers from subjects between and including: 6M-4Y, 5-19 Y and 20Y+, for Survey 4. Results were presented per the following P. falciparum parasite density status subgroups: Low, Medium, High, Very high, and Negative (Neg).</p>, timeFrame - At Survey visit",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01190202",
    "endpoint": "measure - Number of Subjects Classified by House Construction Material Regarding Roof, Window&#x2F;Eaves and Nets at Survey 1, description - <p>The malaria prevention and risk factors characteristics were the following: main house construction material (MHCM) roof, windows&#x2F;eaves, nets.\nMHCM roof data were assessed for the following sub-categories: grass&#x2F;palm, iron sheet, tiles, other, missing.\nMHCM windows&#x2F;eaves data were assessed for the following sub-categories: closed, open, partially open, missing.\nMHCM nets data were assessed for the following sub-categories: nets not present, nets present on all windows, nets present on some windows, missing.</p><p>Data were collected across centers from subjects between and including: 6M-4Y, 5-19 Y and 20Y+, for Survey 1. Results were presented per the following P. falciparum parasite density status subgroups: Low, Medium, High, Very high, and Negative (Neg).</p>, timeFrame - At Survey visit",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01190202",
    "endpoint": "measure - Number of Subjects Classified by House Construction Material Regarding Roof, Window&#x2F;Eaves and Nets at Survey 2, description - <p>The malaria prevention and risk factors characteristics were the following: main house construction material (MHCM) roof, windows&#x2F;eaves, nets.\nMHCM roof data were assessed for the following sub-categories: grass&#x2F;palm, iron sheet, tiles, other.\nMHCM windows&#x2F;eaves data were assessed for the following sub-categories: closed, open, partially open.\nMHCM nets data were assessed for the following sub-categories: nets not present, nets present on all windows, nets present on some windows.</p><p>Data were collected across centers from subjects between and including: 6M-4Y, 5-19 Y and 20Y+, for Survey 2. Results were presented per the following P. falciparum parasite density status subgroups: Low, Medium, High, Very high, and Negative (Neg).</p>, timeFrame - At Survey visit",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01190202",
    "endpoint": "measure - Number of Subjects Classified by House Construction Material Regarding Roof, Window&#x2F;Eaves and Nets at Survey 3, description - <p>The malaria prevention and risk factors characteristics were the following: main house construction material (MHCM) roof, windows&#x2F;eaves, nets.\nMHCM roof data were assessed for the following sub-categories: grass&#x2F;palm, iron sheet, tiles, other.\nMHCM windows&#x2F;eaves data were assessed for the following sub-categories: closed, open, partially open.\nMHCM nets data were assessed for the following sub-categories: nets not present, nets present on all windows, nets present on some windows.</p><p>Data were collected across centers from subjects between and including: 6M-4Y, 5-19 Y and 20Y+, for Survey 3. Results were presented per the following P. falciparum parasite density status subgroups: Low, Medium, High, Very high, and Negative (Neg).</p>, timeFrame - At Survey visit",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01190202",
    "endpoint": "measure - Number of Subjects Classified by House Construction Material Regarding Roof, Window&#x2F;Eaves and Nets at Survey 4, description - <p>The malaria prevention and risk factors characteristics were the following: main house construction material (MHCM) roof, windows&#x2F;eaves, nets.\nMHCM roof data were assessed for the following sub-categories: grass&#x2F;palm, iron sheet, other.\nMHCM windows&#x2F;eaves data were assessed for the following sub-categories: closed, open, partially open.\nMHCM nets data were assessed for the following sub-categories: nets not present, nets present on all windows, nets present on some windows.</p><p>Data were collected across centers from subjects between and including: 6M-4Y, 5-19 Y and 20Y+, for Survey 4. Results were presented per the following P. falciparum parasite density status subgroups: Low, Medium, High, Very high, and Negative (Neg).</p>, timeFrame - At Survey visit",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01190202",
    "endpoint": "measure - Number of Subjects Classified by House Information Regarding Main Source of the Drinking Water and Presence of Electricity at Survey 1, description - <p>The malaria prevention and risk factors characteristics were the following: Main source of drinking water (MSDW): bottled water, closed water source (piped water, tube well, dug well, protected well), open water source (unprotected well, spring water, rainwater, tanker truck, surface water), missing; and Presence of electricity (PE): Yes, No, missing.</p><p>Data were collected across centers from subjects between and including: 6M-4Y, 5-19 Y and 20Y+, for Survey 1. Results were presented per the following P. falciparum parasite density status subgroups: Low, Medium, High, Very high, and Negative (Neg).</p>, timeFrame - At Survey visit",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01190202",
    "endpoint": "measure - Number of Subjects Classified by House Information Regarding Main Source of the Drinking Water and Presence of Electricity at Survey 2, description - <p>The malaria prevention and risk factors characteristics were the following: Main source of drinking water (MSDW): bottled water, closed water source (piped water, tube well, dug well, protected well), open water source (unprotected well, spring water, rainwater, tanker truck, surface water); and Presence of electricity (PE): Yes, No.</p><p>Data were collected across centers from subjects between and including: 6M-4Y, 5-19 Y and 20Y+, for Survey 2. Results were presented per the following P. falciparum parasite density status subgroups: Low, Medium, High, Very high, and Negative (Neg).</p>, timeFrame - At Survey visit",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01190202",
    "endpoint": "measure - Number of Subjects Classified by House Information Regarding Main Source of the Drinking Water and Presence of Electricity at Survey 3, description - <p>The malaria prevention and risk factors characteristics were the following: Main source of drinking water (MSDW): bottled water, closed water source (piped water, tube well, dug well, protected well), open water source (unprotected well, spring water, rainwater, tanker truck, surface water); and Presence of electricity (PE): Yes, No.</p><p>Data were collected across centers from subjects between and including: 6M-4Y, 5-19 Y and 20Y+, for Survey 3. Results were presented per the following P. falciparum parasite density status subgroups: Low, Medium, High, Very high, and Negative (Neg).</p>, timeFrame - At Survey visit",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01190202",
    "endpoint": "measure - Number of Subjects Classified by House Information Regarding Main Source of the Drinking Water and Presence of Electricity at Survey 4, description - <p>The malaria prevention and risk factors characteristics were the following: Main source of drinking water (MSDW): bottled water, closed water source (piped water, tube well, dug well, protected well), open water source (unprotected well, spring water, rainwater, tanker truck, surface water); and Presence of electricity (PE): Yes, No.</p><p>Data were collected across centers from subjects between and including: 6M-4Y, 5-19 Y and 20Y+, for Survey 4. Results were presented per the following P. falciparum parasite density status subgroups: Low, Medium, High, Very high, and Negative (Neg).</p>, timeFrame - At Survey visit",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01190202",
    "endpoint": "measure - Number of Subjects With Malaria Prevention Measures (MPM) at Each Survey, description - <p>The malaria prevention measures (MPM) data were collected across centers from subjects with age between and including: 6M-4Y, 5-19 Y and 20Y+, for each Survey.</p><p>The MPM results include the following categories: Use of Mosquito coils over 7 days (UMc &gt; 7D), Use of Insecticide spray over 7 days (UIs &gt; 7D), Use of Commercial Repellents over 7 days (UCR &gt; 7D), Use of Traditional Repellents over 7 days (UTR &gt; 7D), Use of none of above over 7 days (Una &gt;7D), Use of indoor residual spray in past 12 months to spray interior walls (Uirs past 12M), Use of indoor residual spray - number of months ago (Uirs-nM) or Use of indoor residual spray- no spray (Uirs-no spray): the number of months ago for each Uirs-nM sub-categories is defined using the following [x Months].\nNot all Uirs-nM sub-categories were analyzed in each survey.</p>, timeFrame - At each Survey visit",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01190202",
    "endpoint": "measure - Number of Subjects With Plasmodium Species Other Than P. Falciparum at Survey 1, description - <p>Data were collected across centers from subjects with age between and including: 6M-4Y, 5-19 Y and 20Y+, for Survey 1.</p><p>The other Plasmodium species assessed were: P. Malaria, P. Vivax, P. Ovale.\nInfection were determined using a blood smear slide, and categorized according positive (Pos) and negative (Neg) results.</p>, timeFrame - At Survey visit",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01190202",
    "endpoint": "measure - Number of Subjects With Plasmodium Species Other Than P. Falciparum at Survey 2, description - <p>Data were collected across centers from subjects with age between and including: 6M-4Y, 5-19 Y and 20Y+, for Survey 2.</p><p>The other Plasmodium species assessed were: P. Malaria, P. Vivax, P. Ovale.\nInfection were determined using a blood smear slide, and categorized according positive (Pos) and negative (Neg) results.</p>, timeFrame - At Survey visit",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01190202",
    "endpoint": "measure - Number of Subjects With Plasmodium Species Other Than P. Falciparum at Survey 3, description - <p>Data were collected across centers from subjects with age between and including: 6M-4Y, 5-19 Y and 20Y+, for Survey 3.</p><p>The other Plasmodium species assessed were: P. Malaria, P. Vivax, P. Ovale.\nInfection were determined using a blood smear slide, and categorized according positive (Pos) and negative (Neg) results.</p>, timeFrame - At Survey visit",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01190202",
    "endpoint": "measure - Number of Subjects With Plasmodium Species Other Than P. Falciparum at Survey 4, description - <p>Data were collected across centers from subjects with age between and including: 6M-4Y, 5-19 Y and 20Y+, for Survey 4.</p><p>The other Plasmodium species assessed were: P. Malaria, P. Vivax, P. Ovale.\nInfection were determined using a blood smear slide, and categorized according positive (Pos) and negative (Neg) results.</p>, timeFrame - At Survey visit",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01190202",
    "endpoint": "measure - Number of Subjects With Serious Adverse Events (SAEs) Related to Study Procedure for Each Survey, description - Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability&#x2F;incapacity.\nCapillary blood sampling was the only invasive procedure involved in this study.\nSAEs related to this procedure were recorded at the Survey visit., timeFrame - At each Survey visit",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06578572",
    "endpoint": "measure - Occurrence of Adverse Events (AEs) during follow up., description - <ol><li>Occurrence of solicited local and&#x2F;or systemic reactogenicity</li><li>Occurrence of unsolicited adverse events</li><li>Occurrence of abnormal hematology and biochemistry parameters ( clinically significant values)</li><li>Occurrence of serious adverse events ( throughout the trial)</li></ol>, timeFrame - Up to 28 days post vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06578572",
    "endpoint": "measure - Incidence of malaria infection in all age groups during the transmission season following mass vaccination with R21, description - Incidence of malaria infection will be determined by molecular analyses (PCR) in a cohort of 20 individuals per village in Burkina Faso and 30 individuals per villages in The Gambia through monthly home visits ( following mass vaccination with R21)., timeFrame - Up to 6 months post the third vaccination round",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06578572",
    "endpoint": "measure - Incidence of clinical malaria in all age groups following mass vaccination with R21., description - A passive case detection of clinical malaria throughout the study period, with special attention to the malaria transmission season (July-December), timeFrame - Up to 6 months post the third vaccination round",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06578572",
    "endpoint": "measure - Prevalence of malaria infection by PCR in all age groups at peak transmission following the booster dose., description - A cross-sectional survey will be conducted at peak transmission in October -November 2025 to determine prevalence of malaria infection., timeFrame - At 6 months ( October - November 2025) post booster dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06578572",
    "endpoint": "measure - Incidence of malaria infection in all age groups during the transmission season following the booster dose., description - Incidence of malaria infection will be determined by molecular analyses (PCR) in a cohort of 20 individuals per village in Burkina Faso and 30 individuals per villages in The Gambia through monthly home visits ( following the booster dose)., timeFrame - Up to 6 months post booster dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06578572",
    "endpoint": "measure - Incidence of clinical malaria in all age groups following the booster dose., description - Passive detection of clinical malaria both at the community and at health facility level, timeFrame - Up to 6 months post the third vaccination round",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06578572",
    "endpoint": "measure - Coverage of completed vaccination schedule (3 doses) during the mass vaccination with 3 doses., description - Coverage of completed vaccination schedule (3 doses) during the mass vaccination with 3 doses., timeFrame - Up to 4 weeks post the third vaccination round",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06578572",
    "endpoint": "measure - Coverage of at least one vaccine dose administered during the mass vaccination with 3 doses, description - Coverage of at least one vaccine dose, timeFrame - Up to 4 weeks post the third vaccination round",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06578572",
    "endpoint": "measure - Coverage of the booster dose, description - Coverage of the booster dose, timeFrame - Up to 4 weeks post booster dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06578572",
    "endpoint": "measure - Cost of vaccine administration and cost effectiveness, both for the mass vaccination campaign with 3 doses and the booster dose., description - A cross sectional survey will be carried out at the beginning of the project in both study arms to estimate the cost of seeking care among households and the costs supported by the health facility.\nCost of mass vaccination will be collected for each round., timeFrame - Up to 6 months post booster dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01157897",
    "endpoint": "measure - Time to Parasitemia for Immunogenicity Population, description - <p>Subjects were ranked according to time of onset of parasitemia and a non-parametric rankorder statistical test (eg, Log-Rank or Mann-Whitney) was performed to evaluate delays in parasitemia induced by vaccination.\nCox Proportional Hazards model was used to calculate days to parasitemia and Kaplan-Meier plots were used to display time to first positive malaria blood smear.</p><p>Hazard Ratio (HR).\nTime starts once subject has received t infectious bites.\nTime stops when subject has first positive blood smear.\nIf subject does not become parasitemic then time stops the day he&#x2F;she begins anti-malarial therapy.</p>, timeFrame - 280 day (during the study through 6 months aftr challenge)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01157897",
    "endpoint": "measure - Geometric Mean of Anti-VMP001 Antibody Titers in Serum Per Immunogenicity Population, description - Anti-VMP001 antibody concentrations were measured and summarized by geometric mean titers (GMT) with 95% confidence interval (CI).\nPeak responses were compared by performing Student&#x27;s t-test on data normalized by log transformation to ascertain the presence or absence of significant dose response differences.\nELISA Units (EU) were converted to log10 values for calculations and statistical comparison of geometric means.\nUnits that were reported as &#x27;&gt;50&#x27; were converted to &#x27;1&#x27;., timeFrame - study duration",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01157897",
    "endpoint": "measure - Geometric Mean of Anti-VMP001 Anti-body Titers in Serum Per Efficacy Population, description - Anti-VMP001 antibody concentrations were measured and summarized by geometric mean titers (GMT) with 95% confidence interval (CI).\nPeak responses were compared by performing Student&#x27;s t-test on data normalized by log transformation to ascertain the presence or absence of significant dose response differences.\nELISA Units (EU) were converted to log10 values for calculations and statistical comparison of geometric means.\nUnits that were reported as &#x27;&gt;50&#x27; were converted to &#x27;1&#x27;., timeFrame - study duration",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05052502",
    "endpoint": "measure - Population coverage of rfMDA interventions, description - This indicator will be measured in two ways.\nOperational program coverage will be defined as the proportion of individuals ≥18 months old and households visited and offered the rfMDA interventions within the target areas per time period.\nEffective program coverage is defined as the proportion of individuals (≥18 months old) that agreed to participate in the rfMDA intervention among all individuals ≥18 months old eligible to participate in the intervention in the target population per time period., timeFrame - 3 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05052502",
    "endpoint": "measure - Feasibility of conducting rfMDA at the community level, description - Feasibility will be determined based upon a combination of population coverage data, responses of provincial, district, and health staff, VMWs, and community members to interviews and focus groups at baseline and end line, village malaria workers (VMWs) competency checklists at baseline, midline, and end line, and cost data., timeFrame - 3 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05052502",
    "endpoint": "measure - Acceptability of rfMDA approach, description - Acceptability will be determined based upon refusal rates during interventions and responses of community members and VMWs to end line questionnaire, interviews, and focus groups., timeFrame - 3 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05052502",
    "endpoint": "measure - Adverse event rate, description - Safety measures will include the adverse event rate amongst treated individuals and hemoglobin measurement pre and post treatment for individuals receiving PQ., timeFrame - 3 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05052502",
    "endpoint": "measure - Operational feasibility of glucose-6-phosphate dehydrogenase (G6PD) testing and referral, description - Operational feasibility of G6PD testing and referral will be determined by responses of health staff and VMWs to interviews and focus groups at baseline and end line and competency checklists at baseline, midline, and end line, the proportion of P. vivax cases with a valid G6PD result, and proportion of referred cases presenting at a health facility for G6PD testing., timeFrame - 3 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05052502",
    "endpoint": "measure - Assessment of P. vivax treatment adherence, description - Treatment adherence will be determined by the proportion of P. vivax cases with physical evidence of adherence through pill count and the P. vivax relapse rate across study arms., timeFrame - 3 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02699099",
    "endpoint": "measure - Anti-CS Antibody Concentrations, Pre-vaccination and One Month Post Dose 3 of SB257049, description - Concentrations were expressed as Geometric Mean Concentrations (GMCs) with the following unit of measure: ELISA units per milliliter (EU&#x2F;mL).\nThe 95% CI for the GMC was obtained by exponential transformation (base 10) of the 95% CI for the mean of the log transformed concentrations.\nThe antibody response of anti-CS was assessed in the Coad Group and the RTS,S Group., timeFrame - At Day 0 and one month post Dose 3 of SB257049 (Month 4)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02699099",
    "endpoint": "measure - Number of Seropositive Subjects for Anti-CS Antibodies, Pre-vaccination and One Month Post Dose 3 of SB257049, description - A subject seropositive for anti-CS antibody was a subject whose antibody concentration was greater than or equal (≥) to the cut-off value (anti-CS ≥ 1.9 ELISA unit per milliliter [EU&#x2F;mL]).\nSeropositivity was assessed in the Coad Group and the RTS,S Group., timeFrame - At Day 0 and one month post Dose 3 of SB257049 (Month 4)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02699099",
    "endpoint": "measure - Anti-hepatitis B (Anti-HBs) Antibody Concentrations, Pre-vaccination and One Month Post-Dose 3 of SB257049, description - Concentrations were expressed as GMCs with the following unit of measure: milli-international unit per milliliter (mIU&#x2F;mL).\nThe antibody response of anti-HB was assessed in the Coad Group and the RTS,S Group., timeFrame - At Day 0 and one month post Dose 3 of SB257049 (Month 4)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02699099",
    "endpoint": "measure - Number of Seroprotected Subjects for Anti-HB Antibodies, Pre-vaccination and One Month Post-Dose 3 of SB257049, description - Seroprotection rate for anti-HBs antibody was defined as the percentage of subjects with antibody concentrations greater than or equal to an established cut-off value (anti-HBs ≥ 10 milli-international unit per milliliter [mIU&#x2F;mL]).\nSeroprotection was assessed in the Coad Group and the RTS,S Group., timeFrame - At Day 0 and one month post-Dose 3 of SB257049 (Month 4)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02699099",
    "endpoint": "measure - Number of Seroconverted Subjects for Anti-Measles (Anti-Me) Antibodies, One Month Post-vaccination With the Combined Measles and Rubella (MeRu) Vaccine, description - Seroconversion was defined as number of subjects with an anti-Measles antibodies pre-vaccination concentration below 150 mIU&#x2F;mL and a post-vaccination concentration ≥150 mIU&#x2F;mL.\nSeroconversion was assessed in the Coad group and the Control group., timeFrame - At one month post-vaccination with the combined measles and rubella (MeRu) vaccine (Month 4)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02699099",
    "endpoint": "measure - Anti-Me Antibody Concentrations, Pre-vaccination and One Month Post-vaccination With the Combined Measles and Rubella Vaccine, description - Concentrations were expressed in GMCs with the following unit of measure: milli-international unit per milliliter (mIU&#x2F;mL).\nThe antibody response of anti-Me was assessed in the Coad Group and the Control Group., timeFrame - At pre-vaccination (Month 3) and one month post-vaccination with combined measles and rubella vaccine (Month 4)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02699099",
    "endpoint": "measure - Number of Seropositive Subjects for Anti-Me Antibodies, Pre-vaccination and One Month Post-vaccination With the Combined Measles and Rubella Vaccine, description - A subject seropositive for anti-CS antibody was a subject whose antibody concentration was greater than or equal (≥) to the cut-off value (anti-Me ≥ 150 mIU&#x2F;mL).\nSeropositivity was assessed in the Coad Group and the Control Group., timeFrame - At pre-vaccination (Month 3) and one month post-vaccination with the combined measles and rubella vaccine (Month 4)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02699099",
    "endpoint": "measure - Number of Seroconverted Subjects for Anti-Rubella (Anti-Ru) Antibodies, One Month Post-vaccination With the Combined Measles and Rubella Vaccine, description - Seroconversion was defined as number of subjects with an anti-Ru pre-vaccination concentration less than (&lt;) 4 IU&#x2F;mL and a post-vaccination concentration ≥ 4 IU&#x2F;mL.\nSeroconversion was assessed in the Coad group and Control group., timeFrame - At one month post-vaccination with combined measles and rubella vaccine (Month 4)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02699099",
    "endpoint": "measure - Anti-Ru Antibody Concentrations, Pre-vaccination and One Month Post-vaccination With the Combined Measles and Rubella Vaccine, description - Concentrations were expressed as GMCs with the following unit of measure: International unit per milliliter (IU&#x2F;mL).\nThe antibody response of anti-Ru was assessed in the Coad Group and Control Group., timeFrame - At pre-vaccination (Month 3) and one month post-vaccination with combined measles and rubella vaccine (Month 4)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02699099",
    "endpoint": "measure - Number of Seropositive Subjects for Anti-Ru Antibodies, Pre-vaccination and One Month Post-vaccination With the Combined Measles and Rubella Vaccine, description - A subject seropositive for anti-Ru antibody was a subject whose antibody concentration was greater than or equal (≥) to the cut-off value (anti-Ru ≥ 4 IU&#x2F;mL).\nSeropositivity was assessed in the Coad Group and Control Group., timeFrame - At pre-vaccination (Month 3) and one month post-vaccination with combined measles and rubella vaccine (Month 4)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02699099",
    "endpoint": "measure - Number of Seropositive Subjects for Anti-Yellow Fever (Anti-YF) Antibodies, at One Month Post-vaccination With the YF Vaccine, description - Seropositivity was defined as number of subjects with anti-YF titers greater than or equal to (≥) 10 End point Dilution 50 (ED50).\nSeropositivity was assessed in the Coad group and Control group., timeFrame - At one month post-vaccination with the YF vaccine (Month 4)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02699099",
    "endpoint": "measure - Anti-YF Antibody Titers One Month Post-vaccination With the YF Vaccine, description - Titers were expressed as Geometric Mean Titres (GMTs).\nThe antibody response of anti-YF was assessed in the Coad Group and Control Group., timeFrame - At one month post-vaccination with the YF vaccine (Month 4)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02699099",
    "endpoint": "measure - Number of Subjects With Any and Grade 3 Solicited Local Symptoms for Coad Group and RTS,S Group After Administration of Vitamin A and Study Vaccines at 6 Months of Age, description - Assessed solicited local symptoms were pain, redness and swelling.\nAny = occurrence of the symptom regardless of intensity grade.\nGrade 3 pain = subject crying when limb was moved &#x2F;spontaneously painful.\nGrade 3 redness&#x2F;swelling = redness&#x2F;swelling spreading beyond 20 millimeters (mm) at injection site., timeFrame - During a 7-day follow-up period (day of administration and 6 subsequent days) after administration of Vitamin A and SB257049 dose 1 (Day 0)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02699099",
    "endpoint": "measure - Number of Subjects With Any, Grade 3, Related, Grade 3 and Related Solicited General Symptoms for the Coad Group and RTS,S Group After Administration of Vitamin A and Study Vaccines at 6 Months of Age, description - Assessed solicited general symptoms were drowsiness, irritability&#x2F;fussiness, loss of appetite, measles&#x2F;rubella-like rash and fever.\nAny = occurrence of the symptom regardless of intensity grade.\nAny Fever = temperature greater than or equal to (≥) 37.5° C (axillary route).\nGrade 3 drowsiness= symptom that prevented normal activity; Grade 3 Irritability&#x2F;Fussiness = Crying that couldn&#x27;t be comforted&#x2F;prevented normal activity; Grade 3 Loss of appetite = not eating at all; Grade 3 Measles &#x2F;rubella rash = &gt;150 lesions; Grade 3 fever= temperature grater than (&gt;) 39°C; Related = symptom assessed by the investigator as causally related to the vaccination., timeFrame - During a 7-day follow-up period (day of administration and 6 subsequent days) after administration of Vitamin A and SB257049 dose 1 (Day 0)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02699099",
    "endpoint": "measure - Number of Subjects With Any, Grade 3, Related, Grade 3 and Related Solicited General Symptoms for the Control Group After Administration of Vitamin A at 6 Months of Age, description - Assessed solicited general symptoms were drowsiness, irritability&#x2F;fussiness, loss of appetite, measles&#x2F;rubella-like rash and fever.\nAny = occurrence of the symptom regardless of intensity grade.\nAny Fever = temperature greater than or equal to (≥) 37.5° C (axillary route).\nGrade 3 drowsiness= symptom that prevented normal activity; Grade 3 Irritability&#x2F;Fussiness = Crying that couldn&#x27;t be comforted&#x2F;prevented normal activity; Grade 3 Loss of appetite = not eating at all; Grade 3 Measles &#x2F;rubella rash = &gt;150 lesions; Grade 3 fever= temperature grater than (&gt;) 39°C; Related = symptom assessed by the investigator as causally related to the vaccination., timeFrame - During a 7-day follow-up period (day of administration and 6 subsequent days) after administration of Vitamin A (Day 0)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02699099",
    "endpoint": "measure - Number of Subjects With Any and Grade 3 Solicited Local Symptoms for Coad Group and RTS,S Group After Dose of Study Vaccines Administered at 7.5 Months of Age, description - Assessed solicited local symptoms were pain, redness and swelling.\nAny = occurrence of the symptom regardless of intensity grade.\nGrade 3 pain = subject crying when limb was moved &#x2F;spontaneously painful.\nGrade 3 redness&#x2F;swelling = redness&#x2F;swelling spreading beyond 20 millimetres (mm) at injection site., timeFrame - During a 7-day follow-up period (day of administration and 6 subsequent days) after administration of SB257049 dose 2 (Month 1.5)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02699099",
    "endpoint": "measure - Number of Subjects With Any, Grade 3, Related, Grade 3 and Related Solicited General Symptoms for the Coad Group and RTS,S Group After Dose of Study Vaccines Administered at 7.5 Months of Age, description - Assessed solicited general symptoms were drowsiness, irritability&#x2F;fussiness, loss of appetite, measles&#x2F;rubella-like rash and fever.\nAny = occurrence of the symptom regardless of intensity grade.\nAny Fever = temperature greater than or equal to (≥) 37.5° C (axillary route).\nGrade 3 drowsiness= symptom that prevented normal activity; Grade 3 Irritability&#x2F;Fussiness = Crying that couldn&#x27;t be comforted&#x2F;prevented normal activity; Grade 3 Loss of appetite = not eating at all; Grade 3 Measles &#x2F;rubella rash = &gt;150 lesions; Grade 3 Fever= temperature grater than (&gt;) 39°C; Related = symptom assessed by the investigator as causally related to the vaccination., timeFrame - During a 7-day follow-up period (day of administration and 6 subsequent days) after administration of SB257049 dose 2 (Month 1.5)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02699099",
    "endpoint": "measure - Number of Subjects With Solicited General Symptoms for the Control Group, After Visit at 7.5 Months of Age, description - Solicited symptoms were not analyzed for the Control Group after visit at Month 1.5 because no vaccination was administered at that visit., timeFrame - After visit at Month 1.5",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02699099",
    "endpoint": "measure - Number of Subjects With Any and Grade 3 Solicited Local Symptoms for All Groups, After Dose of Study Vaccines Administered at 9 Months of Age, description - Assessed solicited local symptoms were pain, redness and swelling.\nAny = occurrence of the symptom regardless of intensity grade.\nGrade 3 pain = subject crying when limb was moved &#x2F;spontaneously painful.\nGrade 3 redness&#x2F;swelling = redness&#x2F;swelling spreading beyond 20 millimeters (mm) at injection site., timeFrame - During a 14-day follow-up period (day of administration and 13 subsequent days) after administration of SB257049 dose 3 in Coad (and MeRu+YF) and RTS,S Groups and after MeRu+YF vaccines in Control Group (Month 3)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02699099",
    "endpoint": "measure - Number of Subjects With Any, Grade 3, Related, Grade 3 and Related Solicited General Symptoms for All Groups, After Dose of Study Vaccines Administered at 9 Months of Age, description - Assessed solicited general symptoms were drowsiness, irritability&#x2F;fussiness, loss of appetite, measles&#x2F;rubella-like rash and fever.\nAny = occurrence of the symptom regardless of intensity grade.\nAny Fever = temperature greater than or equal to (≥) 37.5° C (axillary route).\nGrade 3 drowsiness= symptom that prevented normal activity; Grade 3 Irritability&#x2F;Fussiness = Crying that couldn&#x27;t be comforted&#x2F;prevented normal activity; Grade 3 Loss of appetite = not eating at all; Grade 3 Measles &#x2F;rubella rash = &gt;150 lesions; Grade 3 Fever= temperature grater than (&gt;) 39°C; Related = symptom assessed by the investigator as causally related to the vaccination., timeFrame - During a 14-day follow-up period (day of administration and 13 subsequent days) after administration of SB257049 dose 3 in Coad (and MeRu+YF) and RTS,S Groups and after MeRu+YF vaccines in Control Group (Month 3)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02699099",
    "endpoint": "measure - Number of Subjects With Unsolicited Adverse Events (AEs) for All Groups, After Administration of Vitamin A and Study Vaccines at 6 Months of Age, description - An unsolicited adverse event is any adverse event (i.e.\nany untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms., timeFrame - Within 30-day (Days 0-29) period after dose 1 of SB257049 and Vitamin A- Coad and RTS,S Groups, and 30-day period after Vitamin A administration - Control Group",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02699099",
    "endpoint": "measure - Number of Subjects With Unsolicited AEs for the Coad Group and RTS,S Group, After Dose of Study Vaccines at 7.5 Months of Age, description - An unsolicited adverse event is any adverse event (i.e.\nany untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms., timeFrame - Within 30-day (Day of vaccination and 29 subsequent days) period after dose 2 of SB257049 administered at Month 1.5 - Coad and RTS,S Groups",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02699099",
    "endpoint": "measure - Number of Subjects With Unsolicited AEs for the Control Group, at Visit at 7.5 Months of Age, description - An unsolicited adverse event is any adverse event (i.e.\nany untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms., timeFrame - During the 30-day period (Day of the visit and 29 subsequent days) after the visit at Month 1.5",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02699099",
    "endpoint": "measure - Number of Subjects With Unsolicited AEs for All Study Groups, After Dose of Study Vaccines Administered at 9 Months of Age, description - An unsolicited adverse event is any adverse event (i.e.\nany untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms., timeFrame - Within 42-day (vaccination day and 41 subsequent days) period after dose 3 of SB257049 in Coad (+MeRu+YF vaccines) and RTS,S groups, and 42-day period after MeRU+YF vaccination in Control group, administered at Month 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02699099",
    "endpoint": "measure - Number of Subjects With Serious Adverse Events (SAEs): All, Fatal and Related, for All Study Groups, Following Each Administration at Day 0, Month1.5 and Month 3, description - SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability&#x2F;incapacity., timeFrame - During 30-Days period (Day of vaccination and 29 subsequent days) following each administration at Day 0, Month1.5 and Month 3 for Coad and RTS,S groups and at Day 0 and Month 3 in the Control Group.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02699099",
    "endpoint": "measure - Number of Subjects With Any SAEs for All Study Groups, From Day 0 Until Month 4.5, description - SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability&#x2F;incapacity., timeFrame - From Day 0 up to Month 4.5",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02699099",
    "endpoint": "measure - Number of Subjects With Potential Immune-Mediated Disease (pIMDs) for All Study Groups From Day 0 Until Month 4.5, description - pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and&#x2F;or neurological disorders of interest which may or may not have an autoimmune etiology., timeFrame - From Day 0 up to Month 4.5",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02699099",
    "endpoint": "measure - Number of Subjects With Meningitis for All Study Groups From Day 0 Until Month 4.5, description - Meningitis is an adverse event of specific interest (AESI).\nAn AESI is defined as an AE including autoimmune diseases and other mediated inflammatory disorders.\nIt was assessed by the investigator as specific to the treatment administration., timeFrame - From Day 0 up to Month 4.5",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02699099",
    "endpoint": "measure - Number of Subjects With Seizures for All Groups, Post-vaccination for Vaccines Administered at 6, 7.5 or 9 Months of Age, description - Seizure is an adverse event of specific interest (AESI).\nAn AESI is defined as an AE including autoimmune diseases and other mediated inflammatory disorders.\nIt is assessed by the investigator as specific to the treatment administration., timeFrame - Within 30 days post-vaccination for vaccine doses administered at Day 0, Month 1.5 or 42 days post-vaccination (doses given at Month 3 [Coad &amp; Control Groups] or Month 4.5 [RTS,S Group]) vaccination period from Day 0 until Month 4.5",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02699099",
    "endpoint": "measure - Number of Subjects With Generalized Convulsive Seizure for All Study Groups, After Vaccines Administered at Day 0 and Month 1.5 (Coad and RTS,S Groups) and After Vaccines Administered at Month 3 (All Groups), description - Generalized convulsive seizure is an adverse event of specific interest (AESI).\nAn AESI is defined as an AE including autoimmune diseases and other mediated inflammatory disorders.\nIt is assessed by the investigator as specific to the treatment administration., timeFrame - Within 7 days after vaccines administered at Day 0 and Month 1.5 for the Coad and RTS,S groups and 14 days after vaccines administered at Month 3 for all groups",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02699099",
    "endpoint": "measure - Number of Subjects With Unsolicited AEs for the Coad Group and RTS,S Group, After the Booster Dose of Study Vaccine Administered at 27 Months of Age, description - An unsolicited adverse event is any adverse event (i.e.\nany untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms., timeFrame - During the 30-day period (Day of vaccination and 29 subsequent days) after booster dose administered at Month 21",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02699099",
    "endpoint": "measure - Number of Subjects With Unsolicited AEs for the Control Group, After Dose of Study Vaccine Administered at 10.5, 11.5, 12.5 and 30 Months of Age, description - An unsolicited adverse event is any adverse event (i.e.\nany untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms., timeFrame - During the 30-Day Period (Day of vaccination and 29 subsequent days) after primary doses of study vaccine administered at Month 4.5, Month 5.5, Month 6.5 (across primary doses), and after booster dose administered at Month 24",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02699099",
    "endpoint": "measure - Number of Subjects With SAEs for All Study Groups From Day 0 Until Study End, description - SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability&#x2F;incapacity., timeFrame - During the entire study period (From Day 0 until Month 33 for Coad and RTS,S Groups and Month 36 for the Control Group)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02699099",
    "endpoint": "measure - Number of Subjects With pIMDs for All Study Groups From Day 0 Until Study End, description - pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and&#x2F;or neurological disorders of interest which may or may not have an autoimmune etiology., timeFrame - During the entire study period (From Day 0 until Month 33 for Coad and RTS,S Groups and Month 36 for the Control Group)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02699099",
    "endpoint": "measure - Number of Subjects With Meningitis for All Study Groups From Day 0 Until Study End, description - Meningitis is an adverse event of specific interest (AESI).\nAn AESI is defined as an AE including autoimmune diseases and other mediated inflammatory disorders.\nIt is assessed by the investigator as specific to the treatment administration., timeFrame - During the entire study period (From Day 0 until Month 33 for Coad and RTS,S Groups and Month 36 for the Control Group)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02699099",
    "endpoint": "measure - Number of Subjects With Seizures for Vaccines Doses Administered at 6, 7.5, 27 Months of Age for Coad and RTS,S Groups; and at 9 Months of Age for Coad Group or 10.5 Months of Age for RTS,S Group, description - Seizure is an adverse event of specific interest (AESI).\nAn AESI is defined as an AE including autoimmune diseases and other mediated inflammatory disorders.\nIt was assessed by the investigator as specific to the treatment administration.\nResults are presented across all doses for Coad and RTS,S Groups., timeFrame - Within 30 days post-vaccination (doses given at Day 0, Month 1.5, Month 21) &amp; 42 days post-vaccination (dose given at Month 3 [Coad Group] or Month 4.5 [RTS,S Group])",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02699099",
    "endpoint": "measure - Number of Subjects With Seizures for Vaccines Doses Administered at 10.5, 11.5, 12.5, 30 and 9 Months of Age for Control Group, description - Seizure is an adverse event of specific interest (AESI).\nAn AESI is defined as an AE including autoimmune diseases and other mediated inflammatory disorders.\nIt was assessed by the investigator as specific to the treatment administration.\nResults are presented across all doses for the Control Group., timeFrame - Within 30 days post-vaccination (doses given at Month 4.5, Month 5.5, Month 6.5, Month 24) &amp; 42 days post-vaccination (dose given at Month 3)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02528279",
    "endpoint": "measure - Parasite clearance time, description - , timeFrame - 7 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02528279",
    "endpoint": "measure - Fever clearance time, description - , timeFrame - 7 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02528279",
    "endpoint": "measure - Reappearance of P. ovale parasitemia, description - Evidence and characterization of duration and frequency of relapses due to Plasmodium ovale after day 28.\nThis is a disctinct outcome measure from the primary outcome and will be presented seperately., timeFrame - from day 29 - 2 years of follow up",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06155448",
    "endpoint": "measure - Prevalence of malaria infection, description - Prevalence of reported malaria in eligible children aged 2-18 months visited in an endline cross-sectional survey after 18m of implementation., timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06155448",
    "endpoint": "measure - Prevalence of anaemia, description - Prevalence of anaemia (haemoglobin &lt;80g&#x2F;L) in eligible children aged 2-18 months visited in an endline cross-sectional survey after 18m of implementation., timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06155448",
    "endpoint": "measure - Incidence rate of all-cause hospitalisations, description - Incidence of all-cause hospitalisations in eligible children aged 2-18 months with an address in a study ward, collected from hospital registration records over 18 months* of implementation., timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06155448",
    "endpoint": "measure - Incidence rate of clinical malaria (rebound period), description - Incidence rate of parasitologically-confirmed clinical malaria cases in children aged 19-36 months presenting to selected sentinel facilities in the 12 months following the end of the implementation period, timeFrame - 12 months following implementation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06155448",
    "endpoint": "measure - Coverage of scheduled SP doses, description - For each of six scheduled doses of SP, the percentage of children who received the dose in question on time or within 4 weeks following the scheduled date will be estimated for children meeting age-eligibility criteria for each dose, in a cross sectional survey after 18 months* of implementation, timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06155448",
    "endpoint": "measure - Coverage of vaccine or vitamin A doses, description - For each EPI timepoint, the percentage of children who received the vaccine&#x2F;supplement in question in will be estimated for children meeting age-eligibility criteria for each dose, in a cross sectional survey after 18 months* of implementation, timeFrame - 18 months of implementation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06155448",
    "endpoint": "measure - Acceptability of PMC, description - Mean PMC acceptability score using an appropriate validated instrument (Acceptability of Intervention Measure - AIM), given by caregivers of eligible children in the intervention arm, measured during the endline cross-sectional survey after 18m of implementation.\n(intervention arms only) Mean PMC acceptability score using an appropriate validated instrument (Acceptability of Intervention Measure - AIM[Weiner et al 2017]&quot; The instrument is validated in short form to gauge respondent acceptance of a programme by answering 4 direct questions.\nMinimum and maximum values for this measure are 4 and 20., timeFrame - 18 month",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06155448",
    "endpoint": "measure - Integration of PMC into EPI delivery platform, description - Percentage of children visited in an endline cross-sectional survey who were eligible to receive SP and vaccines or vitamin A at a scheduled visit who received both an SP dose and the appropriate vaccine or Vitamin A on the same day.\n(intervention arms only), timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06155448",
    "endpoint": "measure - Appropriateness of PMC, description - <p>Mean appropriateness of PMC score using a suitable validated instrument (Intervention Appropriateness Measure - IAM27), given by policymakers at local (facility), state and national level interviewed at the end of follow-up.\nMean appropriateness of PMC score using a suitable validated instrument (Intervention Appropriateness Measure - IAM[Weiner et al 2017]&quot;).</p><p>The instrument is validated in short form to gauge degree of appropriateness (perspective of respondent) of a programme by answering 4 direct questions.\nMinimum and maximum values for this measure are 4 and 20.</p><p>No cut-off scores for these instruments have been validated so it is recommended that full or mean scores are compared.</p>, timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06155448",
    "endpoint": "measure - Fidelity of PMC delivery, description - <p>Mean health worker performance score based on a checklist-based survey of in-person observations of facility staff delivering PMC.\n(intervention arm only) Mean health worker performance score based on a checklist-based survey of in-person observations of facility[&#x2F;and CHW] staff delivering PMC&quot; using WHO health facility Survey manual.</p><p>Min=0 max=100</p>, timeFrame - 18months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06155448",
    "endpoint": "measure - . Adoption of PMC by facilities, description - Percentage of eligible intervention arm facilities surveyed that provided PMC services to children in the last 28 days.\n(intervention arms only), timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06069544",
    "endpoint": "measure - Descriptive statistics on antibody levels (including geometric means and 95% confidence interval) at assessed timepoints, description - For each cohort - Anti-CSP immunoglobulin G, timeFrame - Up to 365 days after last received IMP dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02329301",
    "endpoint": "measure - Total and confirmed outpatient (OPD) malaria case incidence and inpatient (IPD) malaria case incidence among all ages, description - Total and confirmed outpatient (OPD) malaria case incidence and inpatient (IPD) malaria case incidence among all ages, timeFrame - For up to 48 months (including retrospectively)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02329301",
    "endpoint": "measure - Malaria rapid diagnostic test test positivity rate from focal mass drug administration (fMDA) and mass drug administration (MDA) interventions (plus control group), description - Malaria rapid diagnostic test test positivity rate from focal mass drug administration (fMDA) and mass drug administration (MDA) interventions (plus control group), timeFrame - For up to 10 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02153996",
    "endpoint": "measure - Compare the P. falciparum-specific humoral and cellular immune response in na(SqrRoot) ve travelers and immigrants to age and sex matched individuals in malaria-endemic areas enrolled in ongoing LIG protocols in Mali., description - , timeFrame - 5 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00977899",
    "endpoint": "measure - Transmission-blocking activity, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03341754",
    "endpoint": "measure - Vaccine Efficacy Determined by Time to Development of Parasitemia, description - Vaccine Efficacy Determined by Time to Development of Parasitemia as measured by microscopic examination of thick smears and by Polymerase Chain Reaction (PCR) after CHMI and PCR analysis conducted retrospectively, timeFrame - after CHMI: Days 7 - 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03341754",
    "endpoint": "measure - Measurement of Antibody Titers Against Sporozoite and Erythrocyte Stage Parasites, description - Measurement of antibody titers against sporozoite and erythrocyte stage parasites by immunofluorescence assay (IFA) using sera&#x2F;plasma, timeFrame - Days 231 and 286",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03341754",
    "endpoint": "measure - Measure of correlation between pre-immunization HuAd5 neutralizing antibody titers and the protective efficacy against CHMI and humoral and cellular immune responses of the 2 prime-boost regimens, description - Assess the association between the subjects&#x27; pre-immunization neutralizing antibody titers to HuAd5 and the protective efficacy and humoral and cellular immunogenicity, of these prime-boost regimens to CSP, AMA1 and TRAP as measured by ELISA and FluoroSpot assays, timeFrame - HuAd5: Days -14 to -1; Cellular Immunity: Days -14 to -1, 84, 168 and 195; Humoral Immunity: Days -14 to -1, 14, 28, 42, 56, 70, 84, 168, 195",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03341754",
    "endpoint": "measure - Comparison of Immunogenicity of the 2 Vaccine Regimens, description - Comparison of immunogenicity,of the 2 heterologous prime-boost vaccine regimens (D&#x2F;ChAd63-CA vs. D&#x2F;ChAd63-CAT, timeFrame - Days 1 - 286",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02174978",
    "endpoint": "measure - Anti-FMP012 antibody titers in serum, description - , timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02174978",
    "endpoint": "measure - Time to parasitemia by blood smear after the P falciparum challenge, description - , timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05317117",
    "endpoint": "measure - Diagnostic accuracy of comparator tests for the detection of P. falciparum and, when relevant, P.vivax infections, description - 2.1 Estimates of diagnostic accuracy characteristics with 95% confidence intervals (sensitivity, specificity, NPV, PPV) of comparator tests for the detection of P. falciparum and, when relevant, P.vivax infections in patients with symptoms suggestive of malaria., timeFrame - 5 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05317117",
    "endpoint": "measure - Frequency of P. falciparum infections containing HRP2 and&#x2F;or HRP3 mutations., description - 2.2 Frequency of P. falciparum infections containing HRP2 and&#x2F;or HRP3 mutations., timeFrame - 5 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05317117",
    "endpoint": "measure - Diagnostic accuracy of the index tests for the detection of P. falciparum infections with HRP2 and&#x2F;or HRP3 deletions, description - 2.3 Estimates of diagnostic accuracy characteristics with 95% confidence intervals (sensitivity, specificity, NPV, PPV) of the index tests for the detection of P. falciparum infections with HRP2 and&#x2F;or HRP3 deletions in patients with symptoms suggestive of malaria., timeFrame - 5 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05317117",
    "endpoint": "measure - Usability: label comprehension, description - 2.4 Percent of end users who can accurately comprehend key messaging included in the investigational device packaging and labels., timeFrame - 1 week",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05317117",
    "endpoint": "measure - Usability: results interpretation, description - 2.5 Percent of end users who can accurately interpret the investigational device result output., timeFrame - 1 week",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01086917",
    "endpoint": "measure - Kinetics of infection, description - <p>To compare parasite kinetics between different doses of intradermal injection of PfSPZ Challenge as measured by:</p><ul><li>A significant difference in time of thick smear positivity between the groups of volunteers</li><li>A significant quantitative difference in parasitemia as measured by retrospective PCR between the groups of volunteers</li><li>A significant difference in kinetics of parasitemia between the groups of volunteers as measured by retrospective PCR</li><li>A difference in occurrence or intensity of signs or symptoms between the groups of volunteers</li></ul>, timeFrame - Upto 7 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00229775",
    "endpoint": "measure - Hemoglobin levels, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02149550",
    "endpoint": "measure - Time to patent parasitaemia in each group as assessed by QRT-PCR, description - Parasitaemia will be measured twice daily by QRT-PCR in venous whole blood, from day 5 post-infection until PCR-positive, or else until day 13 post-infection if subjects have not yet developed a positive PCR before then., timeFrame - between day 5 and day 13",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02149550",
    "endpoint": "measure - Magnitude of first peak of parasitaemia in each group as assessed by QRT-PCR, description - Parasitaemia will be measured twice daily by QRT-PCR in venous whole blood, from day 5 post-infection until PCR-positive, or else until day 13 post-infection if subjects have not yet developed a positive PCR before then., timeFrame - between day 5 and day 13",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02149550",
    "endpoint": "measure - Frequency of malaria-related symptoms and signs in each group, description - Symptoms and signs will be assessed at twice daily check-up visits from day 5 post-infection until three days after thick smear positivity, or else until day 16 post-infection, and then again on day 35-post infection., timeFrame - between day 0 and day 35",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01345240",
    "endpoint": "measure - Anti-Hepatitis B (HBs) Antibody Concentrations at Month 3, description - Concentrations, by enzyme-linked immunosorbent assay (ELISA), were presented as geometric mean concentrations (GMCs), and expressed in milli-international units per milliliter (mIU&#x2F;mL).\nThe assay cut-off was the seropositivity cut-off value of greater than or equal to (&gt;=) 10 mIU&#x2F;mL.\nA decrease in the specificity of the anti-HBs ELISA assay had been observed in some studies for low levels of antibody (10-100 mIU&#x2F;mL).\nThe table shows updated results following partial or complete retesting&#x2F;reanalysis. Results presented are for the study groups receiving the RTS,S vaccine, pooled by vaccine lot, that is, for the RTS,S Lot 1, RTS,S Lot 2, and RTS,S Lot 3 groups, as defined below., timeFrame - At Month 3, aka at one month post Dose 3 of RTS,S vaccine or Engerix-B",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01345240",
    "endpoint": "measure - Anti-Hepatitis B (HBs) Antibody Concentrations at Month 14 and 26, description - Concentrations, by enzyme-linked immunosorbent assay (ELISA), were presented as geometric mean concentrations (GMCs), and expressed in milli-international units per milliliter (mIU&#x2F;mL).\nThe assay cut-off was the seropositivity cut-off value of greater than or equal to (&gt;=) 10 mIU&#x2F;mL.\nA decrease in the specificity of the anti-HBs ELISA assay had been observed in some studies for low levels of antibody (10-100 mIU&#x2F;mL).\nThe table shows updated results following partial or complete retesting&#x2F;reanalysis. Results presented are for each RTS,S Regimen A, B &amp; C, and for each Engerix B Regimen A &amp; B study groups., timeFrame - At Months 14 and 26, aka at 12 and 24 months post Dose 3 of RTS,S vaccine or Engerix-B",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01345240",
    "endpoint": "measure - Anti-Hepatitis B (HBs) Antibody Concentrations at Month 38, 50 and 51, description - Concentrations, by enzyme-linked immunosorbent assay (ELISA), were presented as geometric mean concentrations (GMCs), and expressed in milli-international units per milliliter (mIU&#x2F;mL).\nThe assay cut-off was the seropositivity cut-off value of greater than or equal to (&gt;=) 10 mIU&#x2F;mL.\nA decrease in the specificity of the anti-HBs ELISA assay had been observed in some studies for low levels of antibody (10-100 mIU&#x2F;mL).\nThe table shows updated results following partial or complete retesting&#x2F;reanalysis. Results presented are for each RTS,S Regimen A, B &amp; C, and for each Engerix B Regimen A &amp; B study groups., timeFrame - At Months 38, 50 and 51, aka 36 and 48 months post Dose 3 of RTS,S vaccine or Engerix-B and one month post the Month 50 booster dose of Engerix-B",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01345240",
    "endpoint": "measure - Concentrations of Antibodies to the Hepatitis B RF1 Surface Antigen (Anti-HBs RF1) at Month 3, description - Anti-HBs RF1 antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and presented as geometric mean concentrations (GMCs) expressed in ELISA units per milliliter (EL.U&#x2F;mL).\nThe assay cut-off was the seropositivity cut-off value of greater than or equal to (&gt;=) 33 EL.U&#x2F;mL.\nThe table shows results for each RTS,S Regimen A, B &amp; C, and for each Engerix B Regimen A &amp; B study groups., timeFrame - At Month 3, aka at one month post Dose 3 of RTS,S vaccine or Engerix-B",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01345240",
    "endpoint": "measure - Concentrations of Antibodies to the Hepatitis B RF1 Surface Antigen (Anti-HBs RF1) at Month 51, description - Anti-HBs RF1 antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and presented as geometric mean concentrations (GMCs) expressed in ELISA units per milliliter (EL.U&#x2F;mL).\nThe assay cut-off was the seropositivity cut-off value of greater than or equal to (&gt;=) 33 EL.U&#x2F;mL.\nThe table shows results for each RTS,S Regimen A, B &amp; C, and for each Engerix B Regimen A &amp; B study groups., timeFrame - At Month 51, aka one month post the Month 50 booster dose of Engerix-B",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01345240",
    "endpoint": "measure - Anti-circumsporozoite Protein (Anti-CS) Antibody Concentrations at Month 3, description - Anti-CS antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and presented as geometric mean concentrations (GMCs) expressed in ELISA units per milliliter (EL.U&#x2F;mL).\nThe assay cut-off was the seropositivity cut-off value of greater than or equal to (&gt;=) 0.5 EL.U&#x2F;mL.\nThe table shows results for each RTS,S Regimen A, B &amp; C, and for each Engerix B Regimen A &amp; B study groups., timeFrame - At Month 3, aka at one month post Dose 3 of RTS,S vaccine or Engerix-B",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01345240",
    "endpoint": "measure - Anti-circumsporozoite Protein (Anti-CS) Antibody Concentrations at Month 14, description - Anti-CS antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and presented as geometric mean concentrations (GMCs) expressed in ELISA units per milliliter (EL.U&#x2F;mL).\nThe assay cut-off was the seropositivity cut-off value of greater than or equal to (&gt;=) 0.5 EL.U&#x2F;mL.\nThe table shows results for each RTS,S Regimen A, B &amp; C, and for each Engerix B Regimen A &amp; B study groups.\nNo anti-CS results are available for the time point 24 months post Dose 3 (Month 26) because the quantity of serum available for the anti-CS assay was insufficient for many samples., timeFrame - At Month 14, aka at 12 months post Dose 3 of RTS,S vaccine or Engerix-B",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01345240",
    "endpoint": "measure - Anti-circumsporozoite Protein (Anti-CS) Antibody Concentrations at Month 38 and 50, description - Anti-CS antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and presented as geometric mean concentrations (GMCs) expressed in ELISA units per milliliter (EL.U&#x2F;mL).\nThe assay cut-off was the seropositivity cut-off value of greater than or equal to (&gt;=) 1.9 EL.U&#x2F;mL.\nThe table shows results for each RTS,S Regimen A, B &amp; C, and for each Engerix B Regimen A &amp; B study groups., timeFrame - At Months 38 and 50, aka 36 and 48 months post Dose 3 of RTS,S vaccine or Engerix-B",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01345240",
    "endpoint": "measure - Pneumococcal Antibody Concentrations Against Synflorix Pneumococcal Vaccine Serotypes at Month 3, description - Antibody concentrations were measured by enzyme-linked immunosorbent assay (ELISA), and expressed as geometric mean concentrations (GMCs), in micrograms per milliliter (µg&#x2F;mL).\nThe pneumococcal vaccine serotypes assessed were the serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F.\nThe cut-off of the assay, by GSK assay, was greater than or equal to (&gt;=) 0.2 µg&#x2F;mL.\nThis corresponds to the standard ELISA value of 0.35 μg&#x2F;mL.\nThis outcome concerns the subjects who received the RTS,S or Engerix-B vaccine co-administered with Synflorix.\nResults presented are for the study groups pooled by co-administration, that is, for the RTS,S Regimen A and Engerix-B Regimen A groups., timeFrame - At Month 3, aka at one month post Dose 3 of Synflorix",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01345240",
    "endpoint": "measure - Pneumococcal Antibody Concentrations Against Synflorix Pneumococcal Vaccine Serotypes at Month 17, description - Antibody concentrations were measured by GSK assay, and expressed as geometric mean concentrations (GMCs), in micrograms per milliliter (µg&#x2F;mL).\nThe pneumococcal vaccine serotypes assessed were the serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F.\nThe cut-off of the assay, by GSK assay, was greater than or equal to (&gt;=) 0.2 μg&#x2F;mL.\nThis corresponds to the standard ELISA value of 0.35 μg&#x2F;mL.\nThis outcome concerns the subjects who received the RTS,S or Engerix -B vaccine co-administered with Synflorix.\nResults presented are for the study groups pooled by co-administration, that is, for the RTS,S Regimen A and Engerix -B Regimen A groups., timeFrame - At Month 17, aka one month post the Month 16 booster dose of Synflorix",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01345240",
    "endpoint": "measure - Titers for Opsonophagocytic Activity Against Synflorix Pneumococcal Vaccine Serotypes at Month 3, description - The pneumococcal vaccine serotypes assessed were the serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F.\nStreptococcus pneumoniae opsonophagocytic activity was presented as the dilution of serum (opsonic titer) able to sustain 50 % killing of live pneumococci under the assay conditions, expressed as geometric mean titers (GMTs).\nThe cut-off of the assay was an opsonic dilution &gt;= 8.\nThis outcome concerns the subjects who received the RTS,S or Engerix-B vaccine co-administered with Synflorix.\nResults presented are for the study groups pooled by co-administration, that is, for the RTS,S Regimen A and Engerix-B Regimen A groups., timeFrame - At Month 3, aka at one month (1M) post Dose 3 of Synflorix",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01345240",
    "endpoint": "measure - Titers for Opsonophagocytic Activity Against Synflorix Pneumococcal Vaccine Serotypes at Month 17, description - The pneumococcal vaccine serotypes assessed were the serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F.\nStreptococcus pneumoniae opsonophagocytic activity was presented as the dilution of serum (opsonic titer) able to sustain 50 % killing of live pneumococci under the assay conditions, expressed as geometric mean titers (GMTs).\nThe cut-off of the assay was an opsonic dilution &gt;= 8.\nThis outcome concerns the subjects who received the RTS,S or Engerix -B vaccine co-administered with Synflorix .\nResults presented are for the study groups pooled by co-administration, that is, for the RTS,S Regimen A and Engerix -B Regimen A groups., timeFrame - At Month 17, aka one month post the Month 16 booster dose of Synflorix",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01345240",
    "endpoint": "measure - Anti-protein D (PD) Antibody Concentrations at Month 3, description - Anti-PD antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and expressed as geometric mean concentrations (GMCs), in ELISA units per milliliter (EL.U&#x2F;mL).\nThe cut-off of the assay was the seropositivity cut-off value of greater than or equal to 100 EL.U&#x2F;mL.\nThis outcome concerns the subjects who received the RTS,S or Engerix-B vaccine co-administered with Synflorix.\nResults presented are for the study groups pooled by co-administration, that is, for the RTS,S Regimen A and Engerix-B Regimen A groups., timeFrame - At Month 3, aka at one month post Dose 3 of Synflorix",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01345240",
    "endpoint": "measure - Anti-protein D (PD) Antibody Concentrations at Month 17, description - Anti-PD antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and expressed as geometric mean concentrations (GMCs), in ELISA units per milliliter (EL.U&#x2F;mL).\nThe cut-off of the assay was the seropositivity cut-off value of greater than or equal to 100 EL.U&#x2F;mL.\nThis outcome concerns the subjects who received the RTS,S or Engerix -B vaccine co-administered with Synflorix.\nResults presented are for the study groups pooled by co-administration, that is, for the RTS,S Regimen A and Engerix -B Regimen A groups., timeFrame - At Month 17, aka one month post the Month 16 booster dose of Synflorix",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01345240",
    "endpoint": "measure - Concentrations of Antibodies Against Acellular B-pertussis (BPT) at Day 0 and at Month 3, description - The antibodies against BPT assessed were against pertussis toxoid (anti-PT), against filamentous haemagglutinin (anti-FHA), and against pertactin (anti-PRN).\nConcentrations were determined by enzyme-linked immunosorbent assay (ELISA) and expressed as geometric mean concentrations (GMCs), in ELISA units per milliliter (EL.U&#x2F;mL).\nThe cut-off of the assay was the seropositivity cut-off value of greater than or equal to (&gt;=) 5 EL.U&#x2F;mL.\nThe table shows results for study groups pooled by primary vaccine administered (RTS,S vs Engerix -B), timeFrame - At Day 0 and at Month 3 (one month post Dose 3 of Infanrix-Hib)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01345240",
    "endpoint": "measure - Anti-Rotavirus (Anti-RV) Antibody Concentrations, description - Anti-Rotavirus (anti-RV) antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and expressed as geometric mean concentrations (GMCs).\nThe cut-off of the assay was the seropositive cut-off value of greater than or equal to (&gt;=) 20 units per milliliter (U&#x2F;mL).\nThis outcome measure was assessed in subjects who were administered Rotarix as part of an EPI regimen, with and without RTS,S vaccine co-administration.\nThis outcome concerns the subjects who received the RTS,S or Engerix-B vaccine co-administered with Rotarix.\nResults presented are for the study groups pooled by RTS,S or Engerix-B vaccine co-administration, that is, for the RTS,S Regimen B and Engerix-B Regimen B groups., timeFrame - At Month 3, aka one month post Dose 2 of Rotarix",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01345240",
    "endpoint": "measure - Number of Subjects With Solicited Local Symptoms, description - Assessed solicited local symptoms were pain, redness and swelling at the site of injection.\nAll solicited local symptoms assessed were considered by the investigator as causally related to the study vaccination.\nAnalysis for this outcome was performed solely for the 7-days follow-up periods following the primary vaccination with RTS,S vaccine or Engerix-B (at Day 0, and Months 1 and 2).\nData presented are those for any occurrence of the assessed solicited local symptoms, that is, the occurrences of these symptoms regardless of their intensity grade., timeFrame - Within the 7-day follow-up period (Days 0-6) after administration of Dose (D) 1, 2 and 3, respectively, with RTS,S or Engerix-B vaccine",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01345240",
    "endpoint": "measure - Number of Subjects With Solicited General Symptoms, description - Assessed solicited general symptoms were fever, irritability&#x2F;fussiness, drowsiness, and loss of appetite.\nFever was defined as axillary temperature higher than (&gt;) 37.5 degrees Celsius (°C).\nAnalysis for this outcome was performed solely for the 7-days follow-up periods following the primary vaccination with RTS,S vaccine or Engerix-B (at Day 0, and Months 1 and 2).\nData presented are those for any occurrence of the assessed solicited general symptoms, that is, the occurrences of these symptoms regardless of their intensity grade or relationship to vaccination., timeFrame - Within the 7-day follow-up period (Days 0-6) after administration of Dose (D) 1, 2 and 3, respectively, with RTS,S or Engerix-B vaccine",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01345240",
    "endpoint": "measure - Number of Subjects With Potential Immune Mediated Disorders (pIMDs) From Day 0 to Month 8, description - A potential immune mediated disorder (pIMD) was defined as an event about which concerns arose that vaccination may have interfered with immunological self-tolerance of the subjects.\nIMDs assessed included among others neuroinflammatory disorders (such as optic neuritis, multiple sclerosis, or encephalitis), musculoskeletal disorders (such as cutaneous lupus, rheumatoid arthritis, juvenile arthritis, or psoriatic arthropathy), gastrointestinal disorders (ulcerative colitis and ulcerative proctitis, celiac disease), metabolic diseases (such as autoimmune thyroiditis, or diabetes Mellitus Type 1, Addison&#x27;s disease), skin disorders (such as psoriasis or vitiligo), and other disorders such as vasculitis, pernicious anemia, or, sarcoidosis., timeFrame - From Day 0 to Month 8",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01345240",
    "endpoint": "measure - Number of Subjects With Potential Immune Mediated Disorders (pIMDs) From Day 0 to Month 26, description - A potential immune mediated disorder (pIMD) was defined as an event about which concerns arose that vaccination may have interfered with immunological self-tolerance of the subjects.\nIMDs assessed included among others neuroinflammatory disorders (such as optic neuritis, multiple sclerosis, or encephalitis), musculoskeletal disorders (such as cutaneous lupus, rheumatoid arthritis, juvenile arthritis, or psoriatic arthropathy), gastrointestinal disorders (ulcerative colitis and ulcerative proctitis, celiac disease), metabolic diseases (such as autoimmune thyroiditis, or diabetes Mellitus Type 1, Addison&#x27;s disease), skin disorders (such as psoriasis or vitiligo), and other disorders such as vasculitis, pernicious anemia, or, sarcoidosis., timeFrame - From Day 0 to Month 26",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01345240",
    "endpoint": "measure - Number of Subjects With Potential Immune Mediated Disorders (pIMDs) From Day 0 up to Study End (Month 51), description - A potential immune mediated disorder (pIMD) was defined as an event about which concerns arose that vaccination may have interfered with immunological self-tolerance of the subjects.\nIMDs assessed included among others neuroinflammatory disorders (such as optic neuritis, multiple sclerosis, or encephalitis), musculoskeletal disorders (such as cutaneous lupus, rheumatoid arthritis, juvenile arthritis, or psoriatic arthropathy), gastrointestinal disorders (ulcerative colitis and ulcerative proctitis, celiac disease), metabolic diseases (such as autoimmune thyroiditis, or diabetes Mellitus Type 1, Addison&#x27;s disease), skin disorders (such as psoriasis or vitiligo), and other disorders such as vasculitis, pernicious anemia, or, sarcoidosis., timeFrame - From Day 0 up to Study End (Month 51)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01345240",
    "endpoint": "measure - Number of Subjects With Unsolicited Adverse Events (AEs), description - An unsolicited AE was defined as an untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms., timeFrame - Within the 30-day follow-up periods (Days 0-29) after vaccination with RTS,S vaccine or Engerix-B",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01345240",
    "endpoint": "measure - Number of Subjects With Any and Fatal Serious Adverse Events (SAEs) Within the 30-day Follow-up Periods (Days 0-29), description - A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability&#x2F;incapacity or a reported adverse event of specific interest such as seizures occurring within a 30-day period of vaccination, immune-mediated disorders, and specific autoimmune diseases.\nA fatal SAE was defined as a SAE resulting in the death of the study subject., timeFrame - Within the 30-day follow-up periods (Days 0-29) after vaccination with RTS,S vaccine or Engerix-B",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01345240",
    "endpoint": "measure - Number of Subjects With Any and Fatal Serious Adverse Events (SAEs) From Day 0 to Month 8, description - A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability&#x2F;incapacity or a reported adverse event of specific interest such as seizures occurring within a 30-day period of vaccination, immune-mediated disorders, and specific autoimmune diseases.\nA fatal SAE was defined as a SAE resulting in the death of the study subject., timeFrame - From Day 0 to Month 8",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01345240",
    "endpoint": "measure - Number of Subjects With Any and Fatal Serious Adverse Events (SAEs) From Day 0 to Month 26, description - A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability&#x2F;incapacity or a reported adverse event of specific interest such as seizures occurring within a 30-day period of vaccination, immune-mediated disorders, and specific autoimmune diseases.\nA fatal SAE was defined as a SAE resulting in the death of the study subject., timeFrame - From Day 0 to Month 26",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01345240",
    "endpoint": "measure - Number of Subjects With Any, Fatal and Related Serious Adverse Events (SAEs) From Day 0 up to Study End (Month 51), description - A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability&#x2F;incapacity or a reported adverse event of specific interest such as seizures occurring within a 30-day period of vaccination, immune-mediated disorders, and specific autoimmune diseases.\nA fatal SAE was defined as a SAE resulting in the death of the study subject.\nA related SAE was defined as a SAE assessed by the investigator as being causally related to vaccination., timeFrame - From Day 0 up to Study End (Month 51)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06153862",
    "endpoint": "measure - Anti-MSP1-19 malaria antibody, description - Number of participants with antiMSP1-19 malaria antibody as assessed by a lateral flow test kit., timeFrame - three years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04601714",
    "endpoint": "measure - Number of clinical malaria episodes per child-year at risk meeting the following secondary cases definition, description - Second Secondary case definition: Measured fever (Axillary temperature ≥37.5°C&#x2F;Tympanic ≥38°C or Forehead temperature ≥37.5°C using non-contact infrared thermometer) AND parasitemia of &gt;5,000 parasites (p) &#x2F; μl, timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04601714",
    "endpoint": "measure - Number of new P. falciparum clones acquired over time, description - , timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04601714",
    "endpoint": "measure - Immune responses to malaria candidate vaccines in the consortium portfolio, description - Panel of malaria vaccine candidate&#x27;s antigens such as PfSPZ CVAC, ME-TRAP, R21 (Pre erythrocytic stage antigens) and PfRH5, NPC-SE36 (Blood stage antigens) will be used to assess antibody responses at day 0 and 28 of confirmed episodes of clinical malaria., timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07036159",
    "endpoint": "measure - Area under the curve (AUC) of anti-NANP IgG antibodies, description - , timeFrame - At Month 7 and 19",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07036159",
    "endpoint": "measure - GMC of anti-NANP IgG antibodies, description - , timeFrame - At Month 0, 1, 2, 3, 7, 8, 14, and 19",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07036159",
    "endpoint": "measure - Number of participants with a greater than or equal to (&gt;=) 2-fold and a (&gt;=) 4-fold increase from pre-Dose 1 in IgG antibody concentration, description - , timeFrame - At Month 0, 1, 2, 3, 7, 8, 14, and 19",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07036159",
    "endpoint": "measure - Number of participants with solicited administration site events, description - Solicited administration site events include pain, redness, and swelling at administration site., timeFrame - Up to 7 days after each vaccine administration (vaccine administered on Day 1, Month 1, Month 2, and Month 7)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07036159",
    "endpoint": "measure - Number of participants with solicited systemic events, description - Solicited systemic events include fever, irritability&#x2F;fussiness, loss of appetite, sleepiness&#x2F;drowsiness, and vomiting., timeFrame - Up to 7 days after each vaccine administration (vaccine administered on Day 1, Month 1, Month 2, and Month 7)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07036159",
    "endpoint": "measure - Number of participants with unsolicited adverse events (AEs), description - An unsolicited AE is an AE that is either not included in the list of solicited events or could be included in the list of solicited events but with an onset outside the specified period of follow-up for solicited events., timeFrame - Within 30 days after each study vaccine administration (vaccine administered on Day 1, Month 1, Month 2, and Month 7)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07036159",
    "endpoint": "measure - Number of participants with serious adverse events (SAEs), description - An SAE is defined as any untoward medical occurrence that results in death, is life threatening, requires hospitalization or prolongs existing hospitalization, results in disability&#x2F;incapacity, or other medically significant events., timeFrame - From first study vaccine administration (Day 1) to the end of the study (Month 19)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07036159",
    "endpoint": "measure - Number of participants with SAEs, description - , timeFrame - From first study vaccine administration (Day 1) to 12 months after the last study vaccine administration (Month 14 for Groups 1 to 3 and Month 19 for Groups 4 and 5 and Groups 6 and 7)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07036159",
    "endpoint": "measure - Number of participants with adverse events of special interest (AESIs), description - AESIs include febrile convulsion that are defined as seizures that occur in febrile children between the ages of 6 and 60 months who do not have an intracranial infection, metabolic disturbance, or history of afebrile seizures., timeFrame - Up to 7 days after each vaccine administration (vaccine administered on Day 1, Month 1, Month 2, and Month 7)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07036159",
    "endpoint": "measure - Number of participants with AEs&#x2F;SAEs leading to withdrawal from the study and&#x2F;or discontinuation of study vaccine, description - , timeFrame - From first study vaccine administration (Day 1) to the end of the study (Month 19)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07036159",
    "endpoint": "measure - GMC of anti-hepatitis B surface antigens (HBs) antibody concentrations (IgG), description - , timeFrame - At Month 0, 1, 2, 3, 7, 8, 14, and 19",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07036159",
    "endpoint": "measure - Number of participants achieving anti-HBs IgG levels above 6.2 International Units per liter (IU&#x2F;L) and 10.0 IU&#x2F;L, description - , timeFrame - At Month 0, 1, 2, 3, 7, 8, 14, and 19",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07036159",
    "endpoint": "measure - Geometric mean fold increase over pre-Dose 1 for anti-HBs IgG, description - , timeFrame - At Month 0, 1, 2, 3, 7, 8, 14, and 19",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01465048",
    "endpoint": "measure - Frequency, Incidence and Nature of Adverse Events and Serious Adverse Events Arising., description - To assess the safety of PfSPZ Challenge administered in various regimens by analysing actively and passively collected data from clinical review of volunteers and laboratory measurements, including lab reports and adverse events., timeFrame - Participants will be followed for the duration of the study, an expected average of 3 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01465048",
    "endpoint": "measure - Dynamics of Plasmodium Falciparum Parasite Growth Following PfSPZ Challenge Administered in Various Regimens, description - To determine the parasite growth dynamics of PfSPZ Challenge administered in various regimens using highly sensitive PCR for Plasmodium falciparum DNA., timeFrame - 21 days post administration of PfSPZ Challenge",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07074665",
    "endpoint": "measure - Immunogenicity, description - Humoral immunogenicity by anti-CSP antibody concentrations after school age booster of R21&#x2F;Matrix-M at different doses., timeFrame - At baseline and one, six and twelve months after vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07074665",
    "endpoint": "measure - Safety - SAEs, description - Serious adverse events (SAEs) following school age booster vaccination., timeFrame - 1 year after vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07074665",
    "endpoint": "measure - Safety - deaths, description - Any deaths following school age booster vaccination, timeFrame - 1 year after vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04079621",
    "endpoint": "measure - The incidence risk of symptomatic P. vivax malaria at month 6 in patients enrolled with P. vivax, description - , timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04079621",
    "endpoint": "measure - The incidence risk of symptomatic P. vivax malaria at month 6 in patients enrolled with P. falciparum, description - , timeFrame - 6 month",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04079621",
    "endpoint": "measure - The incidence risk of symptomatic P. vivax malaria at day 28 in patients enrolled with P. falciparum and vivax malaria infection, description - , timeFrame - Day 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04079621",
    "endpoint": "measure - The incidence risk of all (symptomatic and asymptomatic) P. vivax malaria at day 28 in patients enrolled with P. falciparum and vivax malaria infection, description - , timeFrame - Day 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04079621",
    "endpoint": "measure - The incidence risk of asymptomatic P. vivax malaria at day 28 in patients enrolled with P. falciparum and vivax malaria infection, description - , timeFrame - Day 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03855995",
    "endpoint": "measure - Incidence rate of probable meningitis (final classification), description - <p>At the site level, a suspected probable meningitis case based on clinical symptoms and&#x2F;or signs is defined by the below characteristics:</p><p>CSF sample is available, no bacterial agent has been identified in the CSF, but some abnormalities in the CSF have been detected (such as turbid macroscopic aspect, positive Gram, positive antigen test, pleiocytosis, abnormal glucose or protein levels) or positive blood culture to a bacterial agent.</p><p>The incidence rate will be calculated by dividing the number of study participants reporting at least one event over the follow-up period by the total person-time.</p>, timeFrame - During the entire study period (From Day 0 up to Month 62)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03855995",
    "endpoint": "measure - Incidence rates of clinically suspected meningitis (final classification), description - <p>At the site level, a clinically suspected meningitis case based on clinical symptoms and&#x2F;or signs is defined by the below characteristics:</p><ul><li>If a CSF sample is available and all examinations are normal at first line laboratory level, or if no CSF sample is available and no alternative diagnosis.</li></ul><p>The incidence rate will be calculated by dividing the number of study participants reporting at least one event over the follow-up period by the total person-time.</p>, timeFrame - During the entire study period (From Day 0 up to Month 62)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03855995",
    "endpoint": "measure - Number of meningitis cases identified at site level (first line laboratory), description - <p>At the site level, a suspected meningitis case based on clinical symptoms and&#x2F;or signs is defined as:</p><ul><li>A child with sudden onset of fever (&gt; 38.0°C rectal or 37.5°C axillary) and one or more of the following signs: neck stiffness, altered consciousness with no other alternative diagnosis, or other meningeal sign such as bulging fontanelle in children under one year of age.</li></ul>, timeFrame - During the entire study period (From Day 0 up to Month 62)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03855995",
    "endpoint": "measure - Incidence rates of cerebral malaria (diagnosed by Rapid Diagnostic Test [RDT] and&#x2F;or microscopy), description - <p>Cerebral malaria is defined as:</p><ul><li>Severe Plasmodium falciparum malaria with impaired consciousness (Glasgow coma score &lt; 11 in children ≥ 2 years of age or Blantyre coma score &lt; 3 in children &lt; 2 years of age); And,</li><li>If malaria with seizure: coma persisting for &gt; 30 min after the seizure.</li><li>Other treatable causes of coma should be excluded before diagnosing cerebral malaria (e.g.\nhypoglycaemia, bacterial meningitis).</li></ul><p>Suspected malaria cases routinely tested using RDT will have a blood smear for reading by microscopy in parallel, in order to measure sensitivity and specificity.\nThis is done for all suspected cases presenting at primary health care facilities one day per month during the first year of the study.</p><p>The incidence rate will be calculated by dividing the number of study participants reporting at least one event over the follow-up period by the total person-time.</p>, timeFrame - During the entire study period (From Day 0 up to Month 62)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03855995",
    "endpoint": "measure - Incidence rates of malaria episodes diagnosed by RDT and&#x2F;or microscopy, description - Any malaria is uncomplicated malaria (i.e.\nPlasmodium parasitaemia &gt;0 detected by microscopy and&#x2F;or RDT, presence of fever (≥37.5°C) reported by parent(s)&#x2F;LARs or recorded at time of presentation and without severity signs or vital organ dysfunction) and severe malaria (SM) (i.e.\nP. falciparum parasitaemia &gt;0 detected by microscopy and&#x2F;or RDT, one&#x2F;more of the following: impaired consciousness, prostration, multiple convulsions, acidosis, hypoglycemia, severe malarial anemia, renal impairment, jaundice, pulmonary oedema, significant bleeding, shock, hyperparasitemia).\nSevere vivax malaria is SM but with no parasite density thresholds.\nCerebral malaria is SM with impaired consciousness with the exclusion of other treatable causes of coma.\nThe incidence rate will be calculated by dividing the number of subjects reporting at least one event over the follow-up period by the total person-time., timeFrame - During the entire study period (From Day 0 up to Month 62)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03855995",
    "endpoint": "measure - Incidence rates of anaemia cases at hospital entry among hospitalised children, description - <p>This outcome measure is assessed for children included only in active surveillance.</p><p>Anaemia is defined as:</p><ul><li>All anaemia: haemoglobin &lt;11 (grams per decilitre) g&#x2F;dL.</li><li>Severe anaemia: haemoglobin &lt;7g&#x2F;dL.\nThe incidence rate will be calculated by dividing the number of study participants reporting at least one event over the follow-up period by the total person-time.</li></ul>, timeFrame - During the entire study period (From Day 0 up to Month 62)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03855995",
    "endpoint": "measure - Incidence rates of hospitalisation cases, description - <p>Hospitalisation is defined as:</p><p>All causes and hospitalisations for any malaria (including P. falciparum malaria), severe malaria (including P. falciparum malaria) and cerebral malaria.</p><p>A hospitalised study participant with malaria (including P. falciparum malaria) and for whom malaria is the primary cause of hospitalisation.</p><p>This outcome measure is assessed for children included only in active surveillance.</p><p>The incidence rate will be calculated by dividing the number of study participants reporting at least one event over the follow-up period by the total person-time.</p>, timeFrame - During the entire study period (From Day 0 up to month 62)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03855995",
    "endpoint": "measure - Number of deaths, description - <p>Death is defined as:</p><ul><li>Malaria attributed death (including P. falciparum malaria) defined as a fatality for which malaria (including P. falciparum malaria) is listed as a contributing cause of death, based on either verbal autopsy using the INDEPTH Standard Verbal Autopsy Questionnaire for children, who died at home or medical judgment&#x2F;medical records for children who died at a primary health care facility or hospital.</li><li>Deaths attributed to an AE defined as a fatality for which an AE is listed as a contributing cause of death, based on either verbal autopsy using the INDEPTH Standard Verbal Autopsy Questionnaire for children, who died at home or medical judgment&#x2F;medical records for children who died at a primary health care facility or hospital.</li></ul><p>The incidence rate (mortality rate) will be calculated by dividing the number of study participants reporting at least one event over the follow-up period by the total person-time.</p>, timeFrame - During the entire study period (From Day 0 up to month 62)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01916954",
    "endpoint": "measure - Tolerability and safety measures, description - Detection and assessment of adverse events during the therapy and in the follow-up period., timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05644067",
    "endpoint": "measure - Evaluation of the opsonic phagocytosis activity of vaccine induced antibodies, description - In vitro immunological assay to evaluate immune responses by measuring opsonic phagocytosis activity in the sera or blood of all participants, at Day 0 pre-vaccination, Day 28 (Week 4), Day 56 (Week 8), Day 84 (Week 12), Day 112 (Week 16) and Day 140 (Week 20)., timeFrame - Changes assessed between Day 0 (pre-vaccination) up to Day 140 (last follow up visit)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05644067",
    "endpoint": "measure - Evaluation of complement fixation, activation and&#x2F;or membrane attack complex (MAC) formation of vaccine-induced antibodies, description - In vitro immunological assay to evaluate immune responses by assessing complement fixation, activation and&#x2F;or membrane attack complex (MAC) formation in the sera or blood of all participants, at Day 0 pre-vaccination, Day 28 (Week 4), Day 56 (Week 8), Day 84 (Week 12), Day 112 (Week 16) and Day 140 (Week 20)., timeFrame - Changes assessed between Day 0 (pre-vaccination) up to Day 140 (last follow up visit)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05644067",
    "endpoint": "measure - Evaluation of antibody-dependent respiratory burst (ADRB) activity of vaccine-induced antibodies, description - In vitro lab immunological assay to evaluate immune responses by assessing antibody-dependent respiratory burst (ADRB) activity measured in the sera or blood of all participants, at Day 0 pre-vaccination, Day 28 (Week 4), Day 56 (Week 8), Day 84 (Week 12), Day 112 (Week 16) and Day 140 (Week 20)., timeFrame - Changes assessed between Day 0 (pre-vaccination) up to Day 140 (last follow up visit)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05644067",
    "endpoint": "measure - Evaluation of antibody-dependent cellular cytotoxicity (ADCC-NK cells) activity of vaccine-induced antibodies, description - In vitro immunological assay to evaluate immune responses by assessing antibody-dependent cellular cytotoxicity (ADCC-NK cells) activity in the sera or blood of all participants, at Day 0 pre-vaccination, Day 28 (Week 4), Day 56 (Week 8), Day 84 (Week 12), Day 112 (Week 16) and Day 140 (Week 20)., timeFrame - Changes assessed between Day 0 (pre-vaccination) up to Day 140 (last follow up visit)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05644067",
    "endpoint": "measure - Evaluation of immune-mediated growth inhibition activity on Plasmodium falciparum asexual blood stage cell lines, description - In vitro functional assay to evaluate immune-mediated growth inhibition activity on a panel of Plasmodium falciparum asexual blood stage cell lines measured in the sera or blood of all participants, at Day 0 pre-vaccination, Day 28 (Week 4), Day 56 (Week 8), Day 84 (Week 12), Day 112 (Week 16) and Day 140 (Week 20)., timeFrame - Changes assessed between Day 0 (pre-vaccination) up to Day 140 (last follow up visit)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05644067",
    "endpoint": "measure - Comparison of MSP-1 IgG antibody concentrations by ELISA, description - Comparison of MSP-1 IgG antibody concentrations by ELISA between malaria pre-exposed participants in the current study and historical data obtained from malaria naïve participants of previous Phase Ia study conducted in Heidelberg that are assessed among SumayaVac-1 (SUM-101) participants only, timeFrame - Antibody concentrations compared between Day 0 (pre-vaccination) up to Day 84",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05149157",
    "endpoint": "measure - Genes for which expression (level of gene activity) correlates with rate of recovery for individual markers of tissue, organ, or organ system dysfunction, description - Genes for which expression correlates with the individual markers of tissue, organ, or organ system dysfunction will be identified by whole blood transcriptome analysis., timeFrame - Each study participant will be assessed over the 14 days following malaria diagnosis",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05149157",
    "endpoint": "measure - Rate of recovery for individual markers of tissue, organ, or organ system dysfunction, description - Rates of recovery will be calculated for individual markers of tissue, organ, or organ system dysfunction, timeFrame - Each study participant will be assessed over the 14 days following malaria diagnosis",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05149157",
    "endpoint": "measure - Sequences of clinical events predictive of recovery, as determined by Bayesian inference of dynamic pathways using the HyperTraPS statistical platform, description - Hypercubic transition path sampling (HyperTraPS) will be used to characterise patterns of recovery and identify predictors of fast vs slow recovery, timeFrame - Each study participant will be assessed over the 14 days following malaria diagnosis",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05878366",
    "endpoint": "measure - Parasite prevalence by microscopy at the end of the transmission season in all age groups, description - This endpoint will compare the parasite prevalence in all age groups between intervention arms., timeFrame - 4 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05878366",
    "endpoint": "measure - Parasite prevalence by qPCR at the end of the transmission season in all age groups, description - This endpoint will compare the parasite prevalence in all age groups between intervention arms., timeFrame - 4 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05878366",
    "endpoint": "measure - Parasite prevalence by microscopy prior to SMC rounds 2, 3 and 4 in SMC-targeted age groups, description - This endpoint will compare the prevalence by microscopy before SMC rounds (2, 3 and 4) between intervention arms., timeFrame - 8 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05878366",
    "endpoint": "measure - Rate of re-infection with P. falciparum at weeks 3, 4 and 5 after the last round of SMC, assessed in SMC-targeted age groups, description - This endpoint will assess the rate of malaria reinfection at different time points after the alst round of SMC between intervention arms, timeFrame - 10 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05878366",
    "endpoint": "measure - Gametocyte prevalence by qRT-PCR at weeks 3, 4 and 5 after the last round of SMC, assessed in SMC-targeted age groups, description - This endpoint will compare the gametocyte prevalence between intervention arms at different time points after the last round of SMC., timeFrame - 10 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05878366",
    "endpoint": "measure - Gametocyte prevalence by qRT-PCR at the end of the transmission season in all age groups, description - This endpoint will compare the gametocyte prevalence between intervention arms in all age groups, timeFrame - 8 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05878366",
    "endpoint": "measure - Plasma levels of AQ and DESAQ after the 4th round of SMC in children aged 3 months-9 years, description - This endpoint will compare the plasma levels of AQ and DESAQ between intervention arms., timeFrame - 6 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05878366",
    "endpoint": "measure - Clinical malaria incidence captured during passive-case detection (between arm comparison), description - This endpoint will compare the cases of malaria between intervention arms., timeFrame - Across study period (6 months)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05878366",
    "endpoint": "measure - Parasite prevalence by qPCR at the end of the transmission season compared between arms 1 and combined arms 2 + 3., description - This endpoint will assess the prevalence in targeted age groups in combined arms with similar treatment and population, timeFrame - 4 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05878366",
    "endpoint": "measure - Gametocyte prevalence by qRT-PCR at the end of the transmission season in age groups targeted by SMC (comparison between arm1 and 2 (in children aged 3-59 months) and arms 2 and arm 3 (in children aged 5 years-9 years)., description - This endpoint will assess the gametocyte prevalence and the end of the study between groups and combined similar groups., timeFrame - 4 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06735209",
    "endpoint": "measure - Median Net Optical Density (OD) 1.0 IgG antibodies to Plasmodium falciparum Circumsporozoite Protein (PfCSP), description - Measured by Enzyme-Linked Immunosorbent Assay (ELISA) on serum samples collected at baseline and post-vaccination prior to Controlled Human Malaria Infection (CHMI), timeFrame - Up to 16 weeks post-vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06735209",
    "endpoint": "measure - Percentage of malaria specific CD4+, CD8+, and gamma delta T cells expressing IFN-gamma and&#x2F;or IL-2, description - Measured by flow cytometry in PBMCs collected at baseline and post-vaccination prior to Controlled Human Malaria Infection (CHMI), timeFrame - Up to 16 weeks post-vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06735209",
    "endpoint": "measure - Proportion of participants with Malaria infection following Controlled Human Malaria Infection (CHMI), description - defined as a two positive qRT-PCR assays of any density taken &gt;&#x2F;= 6 hours apart, or a positive qRT-PCR assay with a parasite density of &gt;&#x2F;=250 estimated parasites&#x2F;mL, or a positive Thick Blood Smear (TBS), on a blood sample, timeFrame - Through 28 days following Controlled Human Malaria Infection (CHMI)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03689036",
    "endpoint": "measure - Genetic characterization of locally circulating malaria parasites over space and time, description - Determination of multilocus genotypes (using microsatellite markers) and complete genomes of Plasmodium vivax and Plasmodium falciparum isolates obtained from georeferenced households over the study period (5 years)., timeFrame - 2023",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03689036",
    "endpoint": "measure - Estimating the impact of interventions to control and eliminate malaria., description - Development and parametrization of mathematical models that incorporate risk heterogeneity in hosts to recapitulate major features of malaria transmission in the study site and estimate the impact of control measures (e.g., insecticide-treated bednet distribution, larviciding or improved antirelapse therapy for vivax malaria)., timeFrame - 2023",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03014258",
    "endpoint": "measure - Antibody reactivity against Circumsporozoite protein (CSP), description - Measured using plasma obtained during the surveillance period.\nAntibody reactivity is defined as the optical density at 410 nM of a 1&#x2F;300 dilution of the volunteers plasma sample minus the optical density at 410 nM of a 1&#x2F;300 dilution of the volunteer&#x27;s baseline sample., timeFrame - Up to Study Day 21",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03014258",
    "endpoint": "measure - Antibody reactivity against Glutamate-rich protein (GLURP), description - Measured using plasma obtained during the surveillance period.\nAntibody reactivity is defined as the optical density at 410 nM of a 1&#x2F;300 dilution of the volunteers plasma sample minus the optical density at 410 nM of a 1&#x2F;300 dilution of the volunteer&#x27;s baseline sample., timeFrame - Up to Study Day 21",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03014258",
    "endpoint": "measure - Antibody reactivity against Plasmodium Falciparum liver- and erythrocytic-stage antigen, description - Measured using plasma obtained during the surveillance period.\nAntibody reactivity is defined as the optical density at 410 nM of a 1&#x2F;300 dilution of the volunteers plasma sample minus the optical density at 410 nM of a 1&#x2F;300 dilution of the volunteer&#x27;s baseline sample., timeFrame - Up to Study Day 21",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03014258",
    "endpoint": "measure - Antibody reactivity against Plasmodium Falciparum pre-erythrocytic antigen, description - Measured using plasma obtained during the surveillance period.\nAntibody reactivity is defined as the optical density at 410 nM of a 1&#x2F;300 dilution of the volunteers plasma sample minus the optical density at 410 nM of a 1&#x2F;300 dilution of the volunteer&#x27;s baseline sample., timeFrame - Up to Study Day 21",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03014258",
    "endpoint": "measure - Percentage of subjects displaying signs and symptoms attributable to malaria, description - Such as malaise, chills&#x2F;rigors, nausea, vomiting, dizziness, arthralgia, abdominal pain, myalgia, and headache, timeFrame - Study Day 6 through Study Day 29",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03014258",
    "endpoint": "measure - Percentage of subjects with fever attributable to malaria, description - Fever as defined as &gt;38 degrees Celsius, timeFrame - Study Day 6 through Study Day 29",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04766879",
    "endpoint": "measure - Overall new malaria infections in core zones during intervention period., description - Measured by microscopy in children aged between 6 months to 10 years., timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04766879",
    "endpoint": "measure - Overall new malaria infections in buffer zones during intervention period., description - Measured by microscopy in children aged between 6 months to 10 years., timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04766879",
    "endpoint": "measure - Parasite-species-specific first-time malaria infections in the core zones., description - Measured by microscopy in children aged between 6 months to 10 years., timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04766879",
    "endpoint": "measure - Parasite-species-specific overall malaria infections in the core zones., description - Measured by microscopy in children aged between 6 months to 10 years., timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04766879",
    "endpoint": "measure - The first-time malaria infections in buffer zones during intervention period., description - Measured by microscopy in children aged between 6 months to 10 years., timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04766879",
    "endpoint": "measure - The first time malaria infections by two age groups (≤ 59 months old; 5 years to 10 years old)., description - Measured by microscopy in children aged between 6 months to 10 years., timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04766879",
    "endpoint": "measure - Overall malaria infections by two age groups (≤ 59 months old; 5 years to 10 years old)., description - Measured by microscopy in children aged between 6 months to 10 years., timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04766879",
    "endpoint": "measure - Anopheline-human contact (indoor and outdoor) using human biting rate (HBR) as an indicator for all anophelines and by anopheline species., description - Measured by human-landing catch (HLC) during 12-h intervals on a quarterly basis during intervention period., timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04766879",
    "endpoint": "measure - Anopheline parity rate as an indicator of population age structure for all anophelines and by anopheline species., description - Measured by mosquito ovarian dissections from a sub-sample of anophelines collected during HLC procedures during intervention period., timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04766879",
    "endpoint": "measure - Anopheline infectivity using sporozoite rate as an indicator for all anophelines and by anopheline species., description - Measured by laboratory detection of sporozoites in mosquito head-preps from a sub-sample of anophelines collected during HLC and&#x2F;or CDC-light trap procedures during intervention period., timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04766879",
    "endpoint": "measure - Anopheline infectivity using EIR as an indicator for all anophelines and by anopheline species., description - Measured by calculating the number of sporozoite-infected anopheline mosquitoes captured per person during intervention period from HLC and&#x2F;or CDC-light trap procedures., timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04766879",
    "endpoint": "measure - CDC-light trap indoor density for all anophelines and by anopheline species., description - Measured by CDC-light trap collections during 12-h intervals on a monthly basis during intervention period., timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04766879",
    "endpoint": "measure - Insecticide resistance., description - Measured by WHO filter paper test and CDC bottle assays during baseline and intervention period., timeFrame - 28 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04766879",
    "endpoint": "measure - Adverse Events and Serious Adverse Events., description - Measured by solicited and unsolicited reports during baseline and intervention period.\nMean, minimum and maximum frequency and percentage of AEs and SAEs across clusters among enrolled subjects will be summarized by treatment arm., timeFrame - 28 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04966871",
    "endpoint": "measure - Antibody responses to PfCSP post-immunization&#x2F;CHMI and correlation with protection in vaccinees vs controls, description - Antibody levels to PfCSP measured by ELISA comparing vaccinees to controls, timeFrame - 2 weeks post Vaccination 2 until 4 weeks post CHMI",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04966871",
    "endpoint": "measure - Antibody responses to PfCSP post-immunization&#x2F;CHMI and correlation with protection in protected vs unprotected vaccinees, description - Antibody levels to PfCSP measured by ELISA comparing protected (no parasitemia occurring post CHMI) and non-protected (parasitemia occurring post CHMI) vaccinees., timeFrame - 2 weeks post Vaccination 2 until 4 weeks post CHMI",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04966871",
    "endpoint": "measure - VE between different groups with CHMI at 14, 42 or 70 days after Vaccination 3, description - VE computed as one minus the estimated risk ratio for Pf infection (parasitemia) detected by qRT-PCR beginning 7 days after CHMI and censoring subjects at 28 days in the mITT population, timeFrame - Day of first immunization until 8 weeks post CHMI",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05340153",
    "endpoint": "measure - The proportion of patients with early treatment failure, late clinical failure, late parasitological failure or an adequate clinical and parasitological response as indicators of efficacy according to the WHO 2009 guidelines., description - <p>Eligible children for whom parent&#x2F;guardian informed consents are obtained will be randomized to receive either artemether-lumefantrine (group A) or dihydroartemisinin-piperaquine (group B) in the ratio of 1:1.</p><p>Recrudescence will be distinguished from re-infection by polymerase chain reaction (PCR) analysis.</p>, timeFrame - 10 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05340153",
    "endpoint": "measure - The number of participants with treatment-related adverse events as assessed by CTCAE v4.0., description - Eligible children for whom parent&#x2F;guardian informed consents are obtained will be randomized to receive either artemether-lumefantrine (group A) or dihydroartemisinin-piperaquine (group B) in the ratio of 1:1., timeFrame - 10 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05340153",
    "endpoint": "measure - The number of children with single nucleotide polymorphisms of P. falciparum genes responsible for resistance to AL and DHA-PPQ., description - Pre-treatment and recrudescence&#x2F;reinfection samples during follow-up shall be used to characterize the molecular markers of Plasmodium falciparum chloroquine resistant transporter(Pfcrt), Plasmodium falciparum multi-drug resistant 1 (Pfmdr1), and Plasmodium falciparum K13 (Pfk13) propeller domain conferring resistance to artemisinins or partner drugs., timeFrame - 10 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05340153",
    "endpoint": "measure - The number of children with single nucleotide polymorphisms of P. falciparum histidine-rich protein 2 and 3 genes., description - Pre-treatment shall be used to detect single nucleotide polymorphisms present in Plasmodium falciparum histidine-rich protein 2 and 3 genes., timeFrame - 10 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05796193",
    "endpoint": "measure - Malaria infection prevalence by malaria rapid diagnostic test HRP2&#x2F;pLDH [pf&#x2F;pan], description - Malaria infection prevalence (by RDT) in the study population of all ages, timeFrame - Baseline",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05796193",
    "endpoint": "measure - Malaria infection prevalence by malaria rapid diagnostic test HRP2&#x2F;pLDH [pf&#x2F;pan], description - Malaria infection prevalence (by RDT) in the study population of all ages, timeFrame - 6 months post intervention",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05796193",
    "endpoint": "measure - Malaria infection prevalence by malaria rapid diagnostic test HRP2&#x2F;pLDH [pf&#x2F;pan], description - Malaria infection prevalence (by RDT) in the study population of all ages, timeFrame - 12 months post intervention",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05796193",
    "endpoint": "measure - Vector Density per person per night using human indoor and outdoor landing catches, description - Indoor and outdoor Anopheles density per night per person, timeFrame - Over one year follow up",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05796193",
    "endpoint": "measure - Sporozoite rate in Anopheles detected using Enzyme Linked Immuno-Sorbent Assay (ELISA) circumsporozoite protein technique. landing catches, description - Proportion of Anopheles with malaria circumsporozoites in salivary gland, timeFrame - Over one year follow up",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05796193",
    "endpoint": "measure - Mean number of Plasmodium spp infective malaria vectors collected per person per night, description - Entomological inoculation rate measure as vector density x sporozoite rate, timeFrame - Over one year follow up",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01753323",
    "endpoint": "measure - Area Under the Curve (AUC)0-24h - Part 1, description - AUC0-24h was analyzed using parent drug in plasma samples.\nOn Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose.\nThe 24h sampling of first post dose was taken before the second dose.\nOn Day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose., timeFrame - Days 1 and 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01753323",
    "endpoint": "measure - Maximum Concentration (Cmax) - Part 1, description - Cmax was analyzed using parent drug in plasma samples.\nOn Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose.\nThe 24h sampling of first post dose should be taken before the second dose.\nOn Day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose., timeFrame - Days 1 and 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01753323",
    "endpoint": "measure - Time to Maximum Concentration (Tmax) - Part 1, description - Tmax was analyzed using parent drug in plasma samples.\nOn Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose.\nThe 24h sampling of first post dose should be taken before the second dose.\nOn Day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose., timeFrame - Days 1 and 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01753323",
    "endpoint": "measure - Area Under the Curve (AUC)Last - Part 1, description - AUClast was analyzed using parent drug in plasma samples.\nOn Day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose., timeFrame - Day 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01753323",
    "endpoint": "measure - Area Under the Curve (AUC)Inf - Part 1, description - AUCinf was analyzed using parent drug in plasma samples.\nOn Day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose., timeFrame - Day 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01753323",
    "endpoint": "measure - Half-life (T1&#x2F;2) - Part 1, description - T1&#x2F;2 was analyzed using parent drug in plasma samples.\nOn day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose., timeFrame - Day 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01753323",
    "endpoint": "measure - Clearance (CL&#x2F;F ) - Part 1, description - CL&#x2F;F was analyzed using parent drug in plasma samples.\nOn day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose., timeFrame - Day 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01753323",
    "endpoint": "measure - Apparent Volume of Distribution During the Terminal Elimination Phase Following Extravascular Administration (Vz&#x2F;F) - Part 1, description - Vz&#x2F;F was analyzed using parent drug in plasma samples.\nOn Day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose., timeFrame - Day 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01753323",
    "endpoint": "measure - Accumulation Ratio (Racc) (=AUC0-24h, day3&#x2F;AUC0-24h, day1) - Part 1, description - Racc was analyzed using parent drug in plasma samples.\nOn day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose., timeFrame - Day 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01753323",
    "endpoint": "measure - AUC0-24h - Part 2, description - AUC0-24h was analyzed using parent drug in plasma samples.\nOn Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose., timeFrame - Day 1",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01753323",
    "endpoint": "measure - AUC0-48h - Part 2, description - AUC0-48h was analyzed using parent drug in plasma samples.\nOn Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose., timeFrame - Day 1",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01753323",
    "endpoint": "measure - AUClast - Part 2, description - AUClast was analyzed using parent drug in plasma samples.\nOn Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose, timeFrame - Day 1",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01753323",
    "endpoint": "measure - AUCinf - Part 2, description - AUCinf was analyzed using parent drug in plasma samples.\nOn Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose, timeFrame - Day 1",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01753323",
    "endpoint": "measure - Cmax - Part 2, description - Cmax was analyzed using parent drug in plasma samples.\nOn Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose., timeFrame - Day 1",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01753323",
    "endpoint": "measure - Tmax - Part 2, description - Tmax was analyzed using parent drug in plasma samples.\nOn Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose., timeFrame - Day 1",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01753323",
    "endpoint": "measure - T1&#x2F;2 - Part 2, description - T1&#x2F;2 was analyzed using parent drug in plasma samples.\nOn Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose., timeFrame - Day 1",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01753323",
    "endpoint": "measure - CL&#x2F;F - Part 2, description - CL&#x2F;F was analyzed using parent drug in plasma samples.\nOn Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose., timeFrame - Day 1",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01753323",
    "endpoint": "measure - Vz&#x2F;F - Part 2, description - Vz&#x2F;F was analyzed using parent drug in plasma samples.\nOn Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose., timeFrame - Day 1",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01540474",
    "endpoint": "measure - Humoral Immune Response to FMP012&#x2F;GLA-SE, description - <p>Seroconversion was defined as a post-second vaccination titer (serum dilution of 1:100) that is 3 standard deviations higher than the average of the negative or pre-vaccination serum measured using enzyme-linked immunosorbent assay (ELISA).\nValues reported as &quot;below the detection limit&quot; were given a value of 50 units.\nThe safety population was used for immunogenicity analysis.\nOnly subjects who received vaccinations or were challenged were included in the analysis of immunogenicity.\nSubjects who withdrew from the study had data collected to the point of withdraw.</p><p>Geometric mean titers (GMT) were obtained by first calculating the mean and 95% confidence intervals for log-transformed values of the ELISA results, followed by exponentiation of the values.\nAmong those vaccinated, all values were below the detection limit until post-dose II.</p>, timeFrame - Up to 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01540474",
    "endpoint": "measure - Time to Onset of Parasitemia Following Sporozoite Challenge, description - Protective Efficacy of FMP012&#x2F;GLA-SE Measured against a P falciparum sporozoite challenge.\nVaccinated subjects were compared to infectivity controls to assess for delayed onset of parasitemia.\nTime of onset of parasitemia was based on the date of sporozoite challenge to the date of first positive blood smear detection., timeFrame - Up to 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02001428",
    "endpoint": "measure - Proportion of infant with recurrent parasitaemia due to any species at day 42 after treatment with DHP., description - Malaria parasitaemia is assessed by microscopy and PCR., timeFrame - Parasitaemia found at day 42 after treatment with DHP",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01816113",
    "endpoint": "measure - The humoral and cellular immunogenicity of ChAd63 PvDBP, when administered to healthy volunteers alone and with MVA PvDBP., description - <p>PvDBP_RII-specific immunogenicity will be assessed by a variety of immunological assays.\nThese may include ex vivo ELISpot assays for interferon gamma and flow cytometry assays, as well as antibody ELISAs.\nOther exploratory immunological assays including cytokine analysis, antibody assays, anti-adenovirus antibodies, DNA analysis of genetic polymorphisms potentially relevant to vaccine immunogenicity and gene expression studies amongst others may be performed at the discretion of the investigators.</p><p>Other exploratory immunology may be carried out in collaboration with other specialist labs, including labs outside of Europe.\nThis would involve transfer of serum&#x2F;plasma, but samples will be anonymised.\nVolunteers will be consented beforehand.</p>, timeFrame - U to 20 weeks post first vaccination.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06122142",
    "endpoint": "measure - Cost-effectiveness of SR distribution., description - Measure cost of SR implementation in relation to manufacturing, efficacy, and coverage to model projections of cost-effectiveness., timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06122142",
    "endpoint": "measure - Adverse Events and Serious Adverse Events., description - Measured by solicited and unsolicited reports during the intervention period.\nMean, minimum and maximum frequency and percentage of Adverse Events and Serious Adverse Eventss across clusters among enrolled subjects will be summarized by distribution channel arm., timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07235020",
    "endpoint": "measure - PCR-corrected and uncorrected ACPR, description - To assess the 28-day cure rate of an anti malarial agent administered orally as monotherapy in participants with uncomplicated P. falciparum malaria., timeFrame - Day 29",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07235020",
    "endpoint": "measure - Area under the concentration-time curve from time zero to the last measurable concentration sampling time (AUClast), description - To characterize the pharmacokinetics (PK) of the anti-malarial agent administered orally as monotherapy., timeFrame - Day 22",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07235020",
    "endpoint": "measure - Area under the concentration-time curve from time zero to infinity (AUCinf), description - To characterize PK of the anti-malarial agent administered orally as monotherapy., timeFrame - Day 22",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07235020",
    "endpoint": "measure - Maximum observed concentration (Cmax), description - To characterize PK of the anti-malarial agent administered orally as monotherapy., timeFrame - Day 22",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07235020",
    "endpoint": "measure - Time to reach maximum observed concentration (Tmax), description - To characterize PK of the anti-malarial agent administered orally as monotherapy., timeFrame - Day 22",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07235020",
    "endpoint": "measure - Elimination half-life (T1&#x2F;2), description - To characterize PK of the anti-malarial agent administered orally as monotherapy., timeFrame - Day 22",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07235020",
    "endpoint": "measure - Total body clearance (CL&#x2F;F), description - To characterize PK of the anti-malarial agent administered orally as monotherapy., timeFrame - Day 22",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07235020",
    "endpoint": "measure - Apparent volume of distribution (V&#x2F;F), description - To characterize PK of the anti-malarial agent administered orally as monotherapy., timeFrame - Day 22",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07235020",
    "endpoint": "measure - Area under the concentration-time curve (AUC0-t), description - To characterize PK of the anti-malarial agent administered orally as monotherapy., timeFrame - Day 22",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05041556",
    "endpoint": "measure - Number of children with a diagnosis of severe malaria in relation to the 4th dose of RTS,S, description - Hospital admissions with malaria which meet WHO criteria for a diagnosis of severe malaria, timeFrame - Through study completion, an average of 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05041556",
    "endpoint": "measure - Number of children with a diagnosis of cerebral malaria in relation to the 4th dose of RTS,S, description - Hospital admissions with malaria which meet WHO criteria for a diagnosis of cerebral malaria, timeFrame - Through study completion, an average of 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05041556",
    "endpoint": "measure - Number of deaths of any cause in relation to the 4th dose of RTS,S, description - Number of deaths of any cause in relation to the 4th dose of RTS,S among children aged 6-59 months., timeFrame - Through study completion, an average of 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05041556",
    "endpoint": "measure - Number of deaths among girls in relation to the 4th dose of RTS,S, description - Number of deaths in children stratified by gender in relation to the 4th dose of RTS,S among children aged 1-59 months, timeFrame - Through study completion, an average of 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06166498",
    "endpoint": "measure - Parasite clearance, description - Time to clearance of parasite genotypes among AS recipients positive at Day -7 by qPCR (presence&#x2F;absence of Pfdhps K540E) and measured to Day 0, timeFrame - 7 days (day -7 until day 0)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06166498",
    "endpoint": "measure - Protection from infection, description - (a) Mean duration of AS protection by qPCR (b) Mean duration of symptom-free status among AS recipients, timeFrame - Time Frame: 35 days (day 0 until day 35)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02098590",
    "endpoint": "measure - Antigen specificity of CPS-immunization induced antibodies against P. falciparum, description - Blood will be drawn to isolate plasmablast for further delineation of the antibody responses following CPS-immunization., timeFrame - 6-10 days after challenge infection",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02098590",
    "endpoint": "measure - Specificity of CPS-immunization induced T-cell responses against P. falciparum, description - Blood will be drawn to isolate monocytes and T cells, which will be used to determine the activity of T cells against specific target antigens of the pre-erythrocytic stages of Plasmodium falciparum., timeFrame - 14 days after each CPS-immunization",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05219565",
    "endpoint": "measure - Time to first malaria infection by PCR, description - The time to first malaria infection assessed by PCR in children aged 1-&lt;15 years enrolled in a cohort study, timeFrame - Two years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05219565",
    "endpoint": "measure - Malaria infection incidence by RDT (pLDH), description - The incidence rate of malaria infection detected by RDT (pLDH) in children aged 1-&lt;15 years enrolled in a cohort study, timeFrame - Two years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05219565",
    "endpoint": "measure - Malaria infection prevalence by RDT (pLDH), description - The prevalence of malaria infection detected by RDT (pLDH) in cross-sectional household surveys, timeFrame - Two years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05219565",
    "endpoint": "measure - Incidence of malaria illness (passive surveillance), description - The incidence rate of malaria illness (sick-visit with a positive malaria rapid diagnostic test or microscopy) assessed by health-facility and community-based surveillance, timeFrame - Two years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05219565",
    "endpoint": "measure - Incidence of non-malaria illness (cohort), description - The incidence rate of non-malaria illness in children aged 1-&lt;15 years enrolled in a cohort study, timeFrame - Two years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05219565",
    "endpoint": "measure - Incidence of non-malaria illness (passive surveillance), description - The incidence rate of non-malaria illness assessed by health-facility and community-based surveillance, timeFrame - Two years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05219565",
    "endpoint": "measure - Prevalence of non-malaria illness, description - The prevalence of non-malaria illness in cross-sectional household surveys, timeFrame - Two years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05219565",
    "endpoint": "measure - Malaria vector density, description - Entomological outcome: Malaria vector densities, timeFrame - Two years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05219565",
    "endpoint": "measure - Proportion of female anopheles mosquitoes older than three gonotrophic cycles,, description - Entomological outcome: The proportion of female anopheles mosquitoes older than three gonotrophic cycles., timeFrame - Two years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05219565",
    "endpoint": "measure - Sporozoite rate, description - Entomological outcomes: Sporozoite rate, timeFrame - Two years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05219565",
    "endpoint": "measure - Entomological Inoculation Rate (EIR), description - Entomological outcome: Entomological Inoculation Rate (EIR), timeFrame - Two years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05219565",
    "endpoint": "measure - Non-Target Organisms (NTOs) attracted to ATSBs, description - Entomological outcome: Proportion of monitoring visits where NTOs were observed on bait stations, timeFrame - Two years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05219565",
    "endpoint": "measure - Markers of insecticide resistance (dinotefuran), description - Entomological outcome: Proportion of mosquitoes with resistance to dinotefuran among total mosquitoes collected in 4 WHO mosquito tubes in the trial area, timeFrame - Two years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05219565",
    "endpoint": "measure - Markers of insecticide resistance (permethrin), description - Entomological outcome: Proportion of mosquitoes with resistance to permethrin among total mosquitoes collected in 4 WHO mosquito tubes in the trial area, timeFrame - Two years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05219565",
    "endpoint": "measure - Markers of insecticide resistance (deltamethrin), description - Entomological outcome: Proportion of mosquitoes with resistance to deltamethrin among total mosquitoes collected in 4 WHO mosquito tubes in the trial area, timeFrame - Two years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05219565",
    "endpoint": "measure - Antibody concentrations against malaria antigen MSP-1, description - Antibody concentration against merozoite surface protein-1 (MSP-1) among cohort participants, timeFrame - Two years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05219565",
    "endpoint": "measure - Antibody concentrations against malaria antigen CSP, description - Antibody concentration against circumsporozoite proteins (CSP) among cohort participants, timeFrame - Two years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05219565",
    "endpoint": "measure - Complexity of infection (COI), description - The complexity of (malaria) infection assessed by molecular markers, including, but not limited to, 24-single-nucleotide polymorphisms (24-SNP) barcodes, timeFrame - Two years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05219565",
    "endpoint": "measure - Mosquito salivary antigens, description - Presence of mosquito salivary antigens in human blood as a measure for mosquito biting rates among cohort participants, timeFrame - Two years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05219565",
    "endpoint": "measure - AEs, description - Number of adverse events associated with misuse of ATSBs., timeFrame - Two years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05219565",
    "endpoint": "measure - ATSB removal rate, description - The proportion of ATSBs that have been moved&#x2F;removed, timeFrame - Two years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05219565",
    "endpoint": "measure - Perceptions of ATSBs, description - The proportion of household heads who perceive ATSBs as safe and effective out of all household head who consented to ATSB deployment on their household structures., timeFrame - Two years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05219565",
    "endpoint": "measure - Household use of LLINs in the setting of ATSBs, description - The proportion of children aged 1-&lt;15 years enrolled in a cohort study who used an LLIN the night prior, timeFrame - Two years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05219565",
    "endpoint": "measure - Household care seeking behavior in the setting of ATSBs, description - The proportion of children aged 1-&lt;15 years enrolled in a cohort study who sought care for febrile illness, timeFrame - Two years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05219565",
    "endpoint": "measure - Cost-effectiveness, description - Incremental cost-effectiveness of ATSB above the standard of care measured through costing of intervention and efficacy outcomes, timeFrame - Two years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06173206",
    "endpoint": "measure - Parasite clearance, description - Time to clearance of parasite genotypes among SPAQ recipients positive at Day 0 by qPCR (presence&#x2F;absence of Pfdhps I431V) and measured to Day 63, timeFrame - 7 days (day 0 until day 7)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06173206",
    "endpoint": "measure - Protection from infection, description - (a) Mean duration of SPAQ protection by qPCR (b) Mean duration of symptom-free status among SPAQ recipients, timeFrame - 35 days (day 0 until day 38)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06173206",
    "endpoint": "measure - Therapeutic efficacy outcomes, description - For SP: (a)Acute clinical and parasitological response (ACPR) at Day 28 by presence&#x2F;absence of Pfdhps I431V (b) ACPR at Day 28 by presence&#x2F;absence of Pfdhps I431V + Pfdhps A581G For SPAQ: ACPR at Day 28, timeFrame - 28 days (day 0 until day 28)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05690841",
    "endpoint": "measure - Prevalence of Plasmodium vivax infection, description - Proportion of individuals with polymerase chain reaction (PCR)-confirmed infection in an endline survey, timeFrame - At endline survey in trial year 4, 3 years after enrollment in study in trial year 1",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05690841",
    "endpoint": "measure - Plasmodium vivax seroprevalence, description - Proportion of participants who are seropositive, rate at which seronegative individuals became seropositive estimated from age-specific seroprevalence from endline survey, adjusted by modeling longitudinal individual serological status and&#x2F;or antibody titers, timeFrame - At endline survey in trial year 4, 3 years after enrollment in study in trial year 1",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05690841",
    "endpoint": "measure - Genetic diversity of Plasmodium vivax, description - Diversity of locally acquired infections as defined by sequencing results, timeFrame - From enrollment through study completion, over 4 trial years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05690841",
    "endpoint": "measure - Tolerability of study drugs, description - Vomiting following administration of study drugs and non-adherence related to adverse effects, timeFrame - Over drug administration period, unique for each study drug (7 days for CQ&#x2F;PQ regimens and 3 days for CQ&#x2F;TQ regimens)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05690841",
    "endpoint": "measure - Adherence to study drugs, description - Number of missed doses, timeFrame - Unique for each patient based on drug regimen (7 days for CQ&#x2F;PQ regimens and 3 days for CQ&#x2F;TQ regimens)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05690841",
    "endpoint": "measure - Refusal rates, description - Number of refusals divided by number of individuals invited to participate, timeFrame - During each fMDA round, twice per year for 3 consecutive years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05690841",
    "endpoint": "measure - Program costs per unit fMDA round, description - Total costs divided by number of fMDA rounds, timeFrame - From enrollment through study completion, over 4 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05690841",
    "endpoint": "measure - Program costs per unit, description - Total costs divided by number of individuals receiving intervention, timeFrame - From enrollment through study completion, over 4 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05690841",
    "endpoint": "measure - Cost per incident case averted, description - Difference in cost between fMDA and control divided by the difference in the effect (incidence), timeFrame - From enrollment through study completion, over 4 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05690841",
    "endpoint": "measure - Cost per disability life year (DALY), description - Difference in cost between fMDA and control divided by the difference in the effect (DALYs), timeFrame - From enrollment through study completion, over 4 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05690841",
    "endpoint": "measure - Cost per economic dollar due to malaria saved, description - Difference in cost between fMDA and control divided by the difference in the effect (economic dollar due to malaria), timeFrame - From enrollment through study completion, over 4 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01361269",
    "endpoint": "measure - cure rate, description - The secondary endpoints will be the cure rate on Day 7 and the parasite and fever clearance times., timeFrame - day 7",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07235033",
    "endpoint": "measure - Parasite clearance time (PCT), description - To assess the parasite clearance time (PCT) of oral anti malarial agent versus the standard of care (SoC) in participants with uncomplicated P. falciparum malaria, timeFrame - up to Day 7",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07235033",
    "endpoint": "measure - PCR-uncorrected ACPR, description - To assess the 28-day cure rate of an anti malarial agent administered orally as combination therapy versus the SoC in participants with uncomplicated P. falciparum malaria., timeFrame - Day 29",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07235033",
    "endpoint": "measure - Area under the concentration-time curve from time zero to the last measurable concentration sampling time (AUClast), description - To characterize the pharmacokinetics (PK) of the anti-malarial agent administered orally as combination therapy., timeFrame - Day 8",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07235033",
    "endpoint": "measure - Maximum observed concentration (Cmax), description - To characterize the pharmacokinetics (PK) of the anti-malarial agent administered orally as combination therapy., timeFrame - Day 8",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07235033",
    "endpoint": "measure - Time to reach maximum observed concentration (Tmax), description - To characterize the pharmacokinetics (PK) of the anti-malarial agent administered orally as combination therapy., timeFrame - Day 8",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07235033",
    "endpoint": "measure - Elimination half-life (T1&#x2F;2), description - To characterize the pharmacokinetics (PK) of the anti-malarial agent administered orally as combination therapy., timeFrame - Day 8",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07235033",
    "endpoint": "measure - Total body clearance (CL&#x2F;F), description - To characterize the pharmacokinetics (PK) of the anti-malarial agent administered orally as combination therapy., timeFrame - Day 8",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07235033",
    "endpoint": "measure - Apparent volume of distribution (V&#x2F;F), description - To characterize the pharmacokinetics (PK) of the anti-malarial agent administered orally as combination therapy., timeFrame - Day 8",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07235033",
    "endpoint": "measure - Area under the concentration-time curve from time zero to infinity (AUCinf), description - To characterize the pharmacokinetics (PK) of the anti-malarial agent administered orally as combination therapy., timeFrame - Day 8",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07235033",
    "endpoint": "measure - Area under the concentration-time curve (AUC0-t), description - To characterize the pharmacokinetics (PK) of the anti-malarial agent administered orally as combination therapy., timeFrame - Day 8",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06300970",
    "endpoint": "measure - Number of Patients with Adverse Events, description - An adverse event is defined as any unfavorable, unintended sign, symptom, syndrome or disease that develops or worsens with the use of a medicinal product, regardless of whether it is related to the medicinal product during participation in the study, approximately 4 weeks., timeFrame - During participation in the study, approximately 4 weeks.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06575647",
    "endpoint": "measure - To compare the incidence by Rapid Diagnostic Test (RDT) of P. vivax before and 1-3-6 months after providing the single round of MDA with Tafenoquine radical cure treatment, description - Malaria Incidence by RDT reported from malaria post at month 1, 3 and 6, timeFrame - Month 1, 3 and 6",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06575647",
    "endpoint": "measure - To evaluate the adherence of healthcare workers to the SOP for implementing MDA of Tafenoquine., description - Proportion of village health workers adhere to the SOP for G6PD testing &amp; documentation, tafenoquine administration and adverse event recording &amp; reporting., timeFrame - Baseline survey and Month-1 survey",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06575647",
    "endpoint": "measure - To compare the prevalence by PCR of P. vivax before and a month after providing the single round of MDA., description - Difference in proportion positive to PCR positive before and a month after providing the single round of MDA., timeFrame - Baseline survey and Month-1 survey",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04724161",
    "endpoint": "measure - Correlation between cross-sectional and ANC population indicator values, description - District-level correlation between indicator values estimated from the ANC population and similar estimates from contemporary household cross-sectional surveys conducted by the New Nets Project., timeFrame - December 2020 to December 2022",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04094727",
    "endpoint": "measure - Odds of symptomatic malaria associated with receiving each intervention, description - The odds of clinical malaria associated with receiving each intervention will be measured by comparing the risk of exposure in cases (RDT-positive) to the risk in controls (RDT-negative) in HRPs within study areas., timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04094727",
    "endpoint": "measure - Total confirmed outpatient (OPD) malaria case incidence by health facility, stratified by HRP status, description - The total confirmed outpatient malaria case incidence will be estimated for each of the study health catchment areas and stratified by HRP status.\nRDTs used for routine malaria diagnosis will be collected and a short questionnaire affixed to the back to allow collection of key indicators to stratify incidence estimates.\nDenominators will be based on health catchment populations and population size estimates obtained through this study.\nA reduction in malaria incidence in HRPs and the overall catchment population will be evaluated using a difference-in-difference approach, comparing change (pre- versus post-intervention) between intervention and control groups., timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04094727",
    "endpoint": "measure - Malaria seroprevalence in HRPs, description - Malaria exposure in HRPs will be measured as the proportion of people with antimalarial antibodies present in their blood serum.\nELISA assays will be used to detect biomarkers of Pf exposure, using collected dried blood spots during baseline and endline cross-sectional surveys.\nThe reduction in malaria exposure will be assessed using a difference-in-difference approach, comparing change (pre- versus post-intervention) between intervention and control groups., timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04094727",
    "endpoint": "measure - Test positivity rates from RACD, description - Test positivity rates will be calculated as the proportion of individuals screened during routine RACD who test positive for malaria by RDT and PCR.\nRates will be stratified by HRP status and location of event (either within villages or at an HRP worksite).Differences in prevalence measures between HRP and non-HRP populations will be assessed using a χ2 test, as well as logistic regression models to account for potential confounding factors., timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04094727",
    "endpoint": "measure - Entomological Indicators, description - Entomological measurements including descriptions of vector occurrence, estimates of human biting rates, measures of indoor and outdoor densities, and insecticide susceptibility status and frequency.\nMeasures will be compared between intervention and control study areas, for each type of intervention., timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04094727",
    "endpoint": "measure - Intervention acceptability as evaluated by participation rate, description - The acceptability of a targeted delivery of presumptive treatment and vector control interventions to HRPs will be assessed as the proportion of targeted individuals refusing each intervention, among those eligible for inclusion.\nAcceptability of IRS will be assessed as the proportion of targeted farms refusing LLIN, among those with at least one sprayable structure missed during the spray campaign., timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04094727",
    "endpoint": "measure - Intervention acceptability as evaluated by qualitative assessment, description - Qualitative data collection methods such as focus groups and key informant interviews with HRPs, health extension workers, employers and other health sector staff will be implemented to assess intervention acceptability., timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04094727",
    "endpoint": "measure - Cost effectiveness, description - The costs and cost-effectiveness of the intervention package will be assessed as an incremental cost effectiveness ratio (ICER), as well as cost per population and case averted as measured through the difference in infections identified subsequent to the intervention.\nProgram data on costs&#x2F;expenditure for each intervention will be collected and combined with estimates of program effectiveness to estimate these measures., timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04094727",
    "endpoint": "measure - Adherence to presumptive treatment intervention as evaluated by pill count, description - Participant adherence to presumptive treatment will be assessed within a sub-sample of people distributed the drug and measured as the proportion of people who complete all pills in the pill pack after receiving the first dose of AL by DOT.\nChanges in proportions over time will be quantified between the two distribution rounds., timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04094727",
    "endpoint": "measure - Self-reported compliance to LLIN and topical repellents., description - Self-reported user compliance to LLINs and topical repellents will be assessed through the quantitative baseline and endline cross-sectional surveys, as well as through a use tracking log tracking compliance over a 30-day period (Appendix 16 and 17) in the cohort included in the pill count.\nLLIN use and condition will be empirically assessed during the endline cross-sectional survey and at 30 days, as well as repellent containers weighed after 30 in the cohort.\nQualitative information on use of these interventions will be collected during key informant interviews and focus group discussions., timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04094727",
    "endpoint": "measure - HRP population size, description - The population size of target HRPs will be estimated in intervention areas using a combination of multiplier and multiple capture-recapture (CR) methods.\nIn Ohangwena Region, the population is assumed fixed, although accessibility of cattle herders in Namibia may vary throughout the year.\nIn Zambezi Region, the population is estimated at two distinct time periods in order to capture turnover between agricultural seasons., timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04094727",
    "endpoint": "measure - HRP movement patterns, description - The proportion of individual&#x27;s time spent in different locations will be measured from aggregating GPS readings (located within pre-defined space-time windows) which are spatially located within a given type of area (farm, cattle post, grazing location, village etc).\nWhere possible, common locations will be tagged and classified by field workers to distinguish individual farms, fields and other points of interests (such as bars, homes, etc).\nAggregated GPS readings (located within pre-defined space-time windows) will be plotted to distinguish individual trips and measure specific characteristics of each trip, including distance of travel and frequency of trips., timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02115516",
    "endpoint": "measure - Time to microscopically detectable parasitemia (pre-patent period) in volunteers who become parasitemic within 21 days following CHMI after immunization using PfSPZ Challenge or placebo and an antimalarial., description - , timeFrame - Within 21 days following CHMI",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02115516",
    "endpoint": "measure - Occurrence of any related AE from time of first administration of an immunizing regimen (chemoprophylactic antimalarial and PfSPZ Challenge) until the end of the study., description - , timeFrame - 19 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05186363",
    "endpoint": "measure - Severe anemia, description - Severe anemia (as an indication of severe malaria) as a proportion of total malaria cases recorded in our study populations (internvetion and control) over the study period., timeFrame - Five months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05186363",
    "endpoint": "measure - Severe anemia levels, description - Severe anemia levels (as an indication of severe malaria) in our study populations (intervention and controls) at baseline and endline of our study period (as indicated through colour chart), timeFrame - Five months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05186363",
    "endpoint": "measure - Parestemia levels, description - Parestemia levels in our study populations (intervention and control) at baseline and endline of the study period., timeFrame - Five months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01290601",
    "endpoint": "measure - Number of Subjects Without Relapse of P. Vivax, description - <p>Number of subjects without relapse of P. vivax at 2, 3 and 4 months</p><p>- Blood smears were obtained at Days 28, 60, 90 and 120 to confirm the continued absence of P. vivax parasitemia</p>, timeFrame - Day 28, Months 2, 3 and 4",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01290601",
    "endpoint": "measure - Safety and Tolerability of Tafenoquine as Defined by Most Common Adverse Events (AEs), description - To evaluate the safety and tolerability of the tafenoquine dosing regimens as defined by the most common AE&#x27;s overall, occurring in &gt;10% of subjects in either treatment group, timeFrame - 90 Days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01290601",
    "endpoint": "measure - Parasite and Gametocyte Clearance Time (PCT and GCT), description - Serial blood smears to detect the presence of P. vivax parasites and gametocytes, conducted every 12 hours up to and including day 7, until blood smear became negative were utilized to determine the time to clearance.\nPCT and GCT were considered cleared if 2 consecutive blood smears were negative., timeFrame - up to day 7 after baseline smear",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03967054",
    "endpoint": "measure - Adverse Events, description - Number adverse events among the study population over the course of the intervention period.\nNote, this number includes all malaria cases that were part of the primary outcome that occurred in the cohort of children that were actively assessed for malaria on a weekly basis during the intervention., timeFrame - up to 8 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03967054",
    "endpoint": "measure - Survival Rate of Blood Fed Mosquitoes, description - Number of Blood Fed Mosquitoes Alive For 3 Days After Capture, timeFrame - up to 8 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05605925",
    "endpoint": "measure - Safety of ivermectin-artemether&#x2F;lumefantrine in malaria infected patients, description - Safety of the the use of ivermectin-artemether&#x2F;lumefantrine in malaria infected patients shall be assessed using the adverse events score scale of 1-mild, 2-moderate, 3-severe, 4-life threatening and 5-death, timeFrame - daily for 30 days while following up participant",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05323721",
    "endpoint": "measure - Anemia, description - Anemia as a sign of severe malaria, timeFrame - Four months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05323721",
    "endpoint": "measure - 28 day malaria incidence, description - Uncomplicated malaria within first 28 days, timeFrame - 1 month",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07246525",
    "endpoint": "measure - Number of cases of laboratory-confirmed malaria diagnosed among patients residing in the target area after the intervention is competed, description - malaria incidence: the number of cases of laboratory-confirmed malaria diagnosed at the MRC among patients residing in the target area, per unit time, divided by the total population of the target area in patients of all ages 12 months after intervention is completed, timeFrame - 12 months after intervention is completed",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07246525",
    "endpoint": "measure - Parasite prevalence among community residents 12 months after the intervention is implemented, description - Proportion of blood smears positive for parasites by microscopy at the time of community cross-sectional surveys, timeFrame - 12 months after the intervention is implemented",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07246525",
    "endpoint": "measure - Parasite prevalence among community residents 24 months after the intervention is implemented, description - Proportion of blood smears positive for parasites by microscopy at the time of community cross-sectional surveys, timeFrame - 24 months after the intervention is implemented",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07246525",
    "endpoint": "measure - Parasite prevalence among community residents 12 months after the intervention is completed, description - Proportion of blood smears positive for parasites by microscopy at the time of community cross-sectional surveys, timeFrame - 12 months after the intervention is completed",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07246525",
    "endpoint": "measure - Prevalence of molecular markers of DP resistance from parasite positive samples from community surveys 12 months after the intervention is implemented, description - Proportion of parasite positive samples with molecular markers of DP resistance detected, timeFrame - 12 months after the intervention is implemented",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07246525",
    "endpoint": "measure - Prevalence of molecular markers of DP resistance from parasite positive samples from community surveys 24 months after the intervention is implemented, description - Proportion of parasite positive samples with molecular markers of DP resistance detected, timeFrame - 24 months after the intervention is implemented",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07246525",
    "endpoint": "measure - Prevalence of molecular markers of DP resistance from parasite positive samples from community surveys 12 months after the intervention is completed, description - Proportion of parasite positive samples with molecular markers of DP resistance detected, timeFrame - 12 months after the intervention is completed",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07246525",
    "endpoint": "measure - Parasite prevalence among schoolchildren 12 months after the intervention is implemented, description - Proportion of blood smears positive for parasites by microscopy at the time of school surveys, timeFrame - 12 months after the intervention is implemented",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07246525",
    "endpoint": "measure - Parasite prevalence among schoolchildren 24 months after the intervention is implemented, description - Proportion of blood smears positive for parasites by microscopy at the time of school surveys, timeFrame - 24 months after the intervention is implemented",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07246525",
    "endpoint": "measure - Parasite prevalence among schoolchildren 12 months after the intervention is completed, description - Proportion of blood smears positive for parasites by microscopy at the time of school surveys, timeFrame - 12 months after the intervention is completed",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07246525",
    "endpoint": "measure - Anemia prevalence among schoolchildren 12 months after the intervention is implemented, description - <p>Proportion of children with anemia at the time of school surveys</p><p>Anemia defined based on WHO criteria as:</p><ol><li>hemoglobin less than 11.5g&#x2F;dl in children 5 - 11 years of age;</li><li>hemoglobin less than 12.0g&#x2F;dl in children 12 - 14 years of age and non-pregnant girls 15 years and above; and</li><li>hemoglobin less than 13.0g&#x2F;dl in boys 15 years and above) 12 and 24 months after the intervention is implemented and school attendance (defined as the number of days attending school &#x2F; number of days school in session) over the 24-month intervention period</li></ol>, timeFrame - 12 months after the intervention is implemented",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07246525",
    "endpoint": "measure - Anemia prevalence among schoolchildren 24 months after the intervention is implemented, description - <p>Proportion of children with anemia at the time of school surveys</p><p>Anemia defined based on WHO criteria as:</p><ol><li>hemoglobin less than 11.5g&#x2F;dl in children 5 - 11 years of age;</li><li>hemoglobin less than 12.0g&#x2F;dl in children 12 - 14 years of age and non-pregnant girls 15 years and above; and</li><li>hemoglobin less than 13.0g&#x2F;dl in boys 15 years and above) 12 and 24 months after the intervention is implemented and school attendance (defined as the number of days attending school &#x2F; number of days school in session) over the 24-month intervention period</li></ol>, timeFrame - 24 months after the intervention is implemented",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07246525",
    "endpoint": "measure - Anemia prevalence among schoolchildren 12 months after the intervention is completed, description - <p>Proportion of children with anemia at the time of school surveys</p><p>Anemia defined based on WHO criteria as:</p><ol><li>hemoglobin less than 11.5g&#x2F;dl in children 5 - 11 years of age;</li><li>hemoglobin less than 12.0g&#x2F;dl in children 12 - 14 years of age and non-pregnant girls 15 years and above; and</li><li>hemoglobin less than 13.0g&#x2F;dl in boys 15 years and above) 12 and 24 months after the intervention is implemented and school attendance (defined as the number of days attending school &#x2F; number of days school in session) over the 24-month intervention period</li></ol>, timeFrame - 12 months after the intervention is completed",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00889616",
    "endpoint": "measure - To determine the antibody response of the combination vaccine to the AMA1-1 and MSP1(42) proteins, as measured by antibody levels and growth inhibition., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06870344",
    "endpoint": "measure - A. Cluster-level Incidence of malaria among all residents, description - Acute febrile illness as previously defined AND positive RDT&#x2F;microscopy at catchment health facility among all residents will be collected., timeFrame - 1-, 3-, 6-, and 12-months post flooding.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06870344",
    "endpoint": "measure - Change in prevalence of anemia in children &lt;5 years of age, description - Hemoglobin concentration ≤7.0 g&#x2F;dL measured in children &lt;5 years of age using Hemocue device., timeFrame - baseline, 6-, and 12 months after the flooding",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06870344",
    "endpoint": "measure - Change in WHO Indicators of Acute Malnutrition in children &lt;5 years of age, description - Acute malnutrition will be assessed via mid-upper arm circumference (MUAC)., timeFrame - baseline, 6, and 12-months post flooding.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06870344",
    "endpoint": "measure - Change in WHO Indicators of Chronic Malnutrition in children &lt;5 years of age, description - <p>The WHO uses 3 indicators of chronic malnutrition (stunting, wasting, and underweight).\nThis will be assessed in children &lt;5 years as defined by any one of the following:</p><ul><li>stunting - height-for-age &lt;-2 SD of the WHO Child growth standards median;</li><li>wasting - weight-for-height &lt;-2 SD of the WHO Child growth standards median; and</li><li>underweight - weight-for-age &lt;-2 standard deviations (SD) of the WHO Child growth standards median</li></ul>, timeFrame - baseline, 6, and 12-months post flooding.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06870344",
    "endpoint": "measure - Prevalence of parasitemia in children, description - &gt;RDT performed in all children ≤12 years during household surveys., timeFrame - 1-, 3-, 6-, and 12-months post flooding.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06870344",
    "endpoint": "measure - Hospitalization for malaria, description - Self-reported history of hospitalization on bi-weekly questionnaire AND confirmation by study staff from hospital registers, timeFrame - 12 months after the flooding",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06870344",
    "endpoint": "measure - Cluster-level change in Anopheles density and species composition, description - Longitudinal surveillance of indoor and outdoor (i.e., peri-domestic) adult mosquitoes using Centers for Disease Control and Prevention (CDC) light traps, timeFrame - 12 months after the flooding",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06870344",
    "endpoint": "measure - Prevalence of juvenile Anopheles within peri-domestic space, description - Longitudinal surveys of 50 m radius around household with inspection of potential breeding sites, timeFrame - 12 months after the flooding",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06870344",
    "endpoint": "measure - Cluster-level change in blood-fed and parasite-carrying Anopheles, description - Polymerase Chain Reaction (PCR) of mosquitoes to estimate proportion with human blood and P. falciparum (i.e., sporozoite rate), timeFrame - 12 months after the flooding",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06870344",
    "endpoint": "measure - Cost-effectiveness of interventions (DP, DP+Bti) compared to control (LLINs), description - Incremental Disability Adjusted Life Year (DALY) averted., timeFrame - 12 months after the flooding",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06870344",
    "endpoint": "measure - Adherence to intervention components (LLIN, DP, and Bti), description - Self-reported bed net use the night prior to data collection; number of doses of DP administered per month over 3 month period; number of Bti applications over study period, timeFrame - 12 months after the flooding",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07257965",
    "endpoint": "measure - Prepatent period across different groups., description - Measurement of the prepatent period (time from challenge to first qPCR-positive result) in participants across different mosquito bite groups., timeFrame - Up to 21 days after the individual CHMI",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07257965",
    "endpoint": "measure - Humoral immune responses, description - Characterisation of humoral immune responses (antibody titress) to Plasmodium vivax infection, stratified by the number of mosquito bites received., timeFrame - Up to one year after antimalarial initiation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07257965",
    "endpoint": "measure - Humoral immune responses, description - Characterisation of humoral immune responses (Cytokine response) to Plasmodium vivax infection, stratified by the number of mosquito bites received., timeFrame - Up to one year after antimalarial initiation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07257965",
    "endpoint": "measure - Cellular immune responses, description - Characterisation of cellular immune responses (T-cell profiles) to Plasmodium vivax infection, stratified by the number of mosquito bites received., timeFrame - Up to one year after antimalarial initiation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07257965",
    "endpoint": "measure - Cellular immune responses, description - Characterisation of cellular immune responses (Neutrophil) to Plasmodium vivax infection, stratified by the number of mosquito bites received., timeFrame - Up to one year after antimalarial initiation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07257965",
    "endpoint": "measure - Gametocytaemia across different groups, description - Quantification of gametocytaemia measured by quantitative PCR (qPCR) across different groups, timeFrame - Up to 21 days after the individual CHMI",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07257965",
    "endpoint": "measure - AEs stratified by groups, description - Incidence, severity, and duration of AEs stratified by number of mosquito bites administered., timeFrame - Up to one year after antimalarial initiation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01524341",
    "endpoint": "measure - Number of participants with adverse events, description - Number of participants with adverse events determined by Vital sign(body temperature, blood pressure and pulse rate): pre dose, 4, 8, 12, 16, 20, 24 hours post dose on Day 1: then 6, 12, 18, 24 hours post dose on each day during domiciles period until at least two consecutive normal temperature readings are obtained, then it will measure daily until Day 6. ECG: 3-4 hours post dose on day1; pre dose, 3-4 hours post dose on Day 2; pre dose, 3-4 hours post dose on Day 3 and study completion.\nLab evaluation: Day 2, Day3 and Day5, study completion., timeFrame - vital signs: Days 1 through 6; ECG: Days1, 2, 3; Labs: Days 2, 3, 5, study completion",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01524341",
    "endpoint": "measure - Area under the curve (AUC)0-24h on Day 1 and Day 3, description - <p>The parent drug in plasma samples will be analyzed.\nOn Day 1: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose.\n*The 24h sampling of first post dose should be taken before the second dose.</p><p>On Day 3: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 144, and 192 hours post dose</p>, timeFrame - Day 1 and Day 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01524341",
    "endpoint": "measure - The accumulation ratio (Racc) (=AUC0-24h, day3&#x2F;AUC0-24h, day1), description - <p>The parent drug in plasma samples will be analyzed.\nOn Day 1: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose.\n*The 24h sampling of first post dose should be taken before the second dose.</p><p>On Day 3: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 144, and 192 hours post dose</p>, timeFrame - Day 1 and Day 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01524341",
    "endpoint": "measure - Maximum concentration (Cmax) on Day 1 and Day 3, description - <p>The parent drug in plasma samples will be analyzed.\nOn Day 1: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose.\n*The 24h sampling of first post dose should be taken before the second dose.</p><p>On Day 3: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 144, and 192 hours post dose</p>, timeFrame - Day 1 and Day 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01524341",
    "endpoint": "measure - Time to maximum concentration (Tmax) on Day 1 and Day 3, description - <p>The parent drug in plasma samples will be analyzed.\nOn Day 1: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose.\n*The 24h sampling of first post dose should be taken before the second dose.</p><p>On Day 3: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 144, and 192 hours post dose</p>, timeFrame - Day 1 and Day 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01524341",
    "endpoint": "measure - Half-life (T1&#x2F;2), description - The parent drug in plasma samples will be analyzed On Day 3: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 144, and 192 hours post dose, timeFrame - Day 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01524341",
    "endpoint": "measure - Clearance (CL&#x2F;F ), description - The parent drug in plasma samples will be analyzed On Day 3: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 144, and 192 hours post dose, timeFrame - Day 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01524341",
    "endpoint": "measure - The apparent volume of distribution during the terminal elimination phase following extravascular administration (Vz&#x2F;F), description - The parent drug in plasma samples will be analyzed.\nOn Day 3: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 144, and 192 hours post dose, timeFrame - Day 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04545905",
    "endpoint": "measure - Correlation between cross-sectional and ANC population indicator values, description - District-level correlation between indicator values estimated from the ANC population and similar estimates from contemporary household cross-sectional surveys conducted by the New Nets Project.\nThese indicators include: RDT confirmed malaria infection prevalence, net access, net use (household), net use (children under 5), prevalence of fever, malaria health care seeking (testing), malaria health care seeking (treatment)., timeFrame - August 2020 to December 2022",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02458092",
    "endpoint": "measure - Antibody Titers Per Subject by Enzyme Linked Immunosorbent Assay in 50 µg Dose Group, description - <p>Antibody concentrations will be presented by reporting the summarized Geometric Mean Titer (GMT) values with 95% Confidence Interval (CI) (not presented in results), at each time point at which blood samples are taken for serology.</p><p>Peak responses (Day 70) will be compared by Student&#x27;s T test on data normalized by log transformation to ascertain presence or absence of significant dose response difference.\nGMTs are presented without CI data.</p>, timeFrame - After each vaccination, blood draws performed on Days 0, 14, 28, 42, 56, 70 and 112",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02458092",
    "endpoint": "measure - Antibody Titers Per Subject by Enzyme Linked Immunosorbent Assay in Rabies Vaccine Group, description - <p>Antibody concentrations will be presented by reporting the summarized Geometric Mean Titer (GMT) values with 95% Confidence Interval (CI) at each time point at which blood samples are taken for serology.</p><p>Peak responses (Day 70) will be compared by Student&#x27;s T test on data normalized by log transformation to ascertain presence or absence of significant dose response difference.\nGMTs are presented without CI data.</p>, timeFrame - After each vaccination, blood draws performed on Days 0, 14, 28, 42, 56, 70 and 112",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01148459",
    "endpoint": "measure - Number of Subjects With Any and Grade 3 Solicited Local Symptoms, description - Assessed solicited local symptoms were pain, redness and swelling.\nAny = occurrence of the symptom regardless of intensity grade.\nGrade 3 pain = pain that prevented normal activity.\nGrade 3 redness&#x2F;swelling = redness&#x2F;swelling spreading beyond (&gt;) 20 millimeters (mm) of injection site., timeFrame - During the 7-day post-vaccination period following each dose and across doses: Day 1 through Day 7, Month 1 through Month 1 + 7 days (Day 37), Month 2 through Month 2 + 7 days (Day 67)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01148459",
    "endpoint": "measure - Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms, description - Assessed solicited general symptoms were drowsiness, irritability, loss of appetite and fever [defined as axillary temperature equal to or above (≥) 37.5 degrees Celsius (°C)].\nAny = occurrence of the symptom regardless of intensity grade.\nGrade 3 drowsiness = drowsiness that prevented normal activity.\nGrade 3 irritability&#x2F;fussiness = crying that could not be comforted&#x2F;prevented normal activity.\nGrade 3 loss of appetite = not eating at all.\nGrade 3 fever = fever &gt; 39.0 °C.\nRelated = symptom assessed by the investigator as causally related to the study vaccination., timeFrame - During the 7-day post-vaccination period following each dose and across doses: Day 1 through Day 7, Month 1 through Month 1 + 7 days (Day 37), Month 2 through Month 2 + 7 days (Day 67)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01148459",
    "endpoint": "measure - Number of Subjects With Any Unsolicited Adverse Events (AEs), description - An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.\nAny was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination., timeFrame - During the 30-day post-vaccination period (up to Day 90)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01148459",
    "endpoint": "measure - Number of Subjects With Non-malaria Related SAEs, description - SAEs (excluding malaria, cerebral malaria and P. falciparum parasitemia) assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability&#x2F;incapacity., timeFrame - During the entire study period (from 30 days before vaccine Dose 1 up to Month 14)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01148459",
    "endpoint": "measure - Anti-circumsporozoite Protein of P. Falciparum (Anti-CS) Antibody Concentrations, description - Anti-CS antibody concentrations are presented as geometric mean concentrations (GMCs), expressed in ELISA units per milliliter (EL.U&#x2F;mL).\nThe reference seropositivity cut-off value was equal to or above (≥) 0.5 EL.U&#x2F;mL., timeFrame - Prior to vaccination (PRE) and one month post Dose 3 (Month 3)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01148459",
    "endpoint": "measure - Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Titers, description - Anti-HBs antibody titers are presented as geometric mean titers (GMTs), expressed in milliinternational units per milliliter (mIU&#x2F;mL)., timeFrame - Prior to vaccination (PRE) and one month post Dose 3 (Month 3)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01148459",
    "endpoint": "measure - Anti-CS Antibody Concentrations, description - Anti-CS antibody concentrations are presented as geometric mean concentrations (GMCs), expressed in ELISA units per milliliter (EL.U&#x2F;mL).\nThe reference seropositivity cut-off value was equal to or above (≥) 0.5 EL.U&#x2F;mL., timeFrame - 12 months post Dose 3 (Month 14)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01148459",
    "endpoint": "measure - Anti-HBs Antibody Titers, description - Anti-HBs antibody titers are presented as geometric mean titers (GMTs), expressed in mIU&#x2F;mL., timeFrame - 12 months post Dose 3 (Month 14)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01148459",
    "endpoint": "measure - Number of Episodes With Clinical Malaria Disease According to Primary Case Definition, description - Primary case definition for clinical malaria: P. falciparum asexual parasitemia &gt; 2500 parasites&#x2F;μL and presence of fever (axillary temperature ≥ 37.5°C) at the time of presentation and occurring in a child who was unwell and brought for treatment to a healthcare facility., timeFrame - From Day 0 to Month 14",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01148459",
    "endpoint": "measure - Number of Episodes With Severe Malaria According to Primary Case Definition, description - The number of episodes of severe malaria of primary case definition within and outside risk period.\nPrimary case definition for severe malaria: P. falciparum &gt; 2500 parasites per μL and with one or more marker of disease severity and without a diagnosis of co-morbidity., timeFrame - From Day 0 to Month 14",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01148459",
    "endpoint": "measure - Number of Subjects Affected by Prevalent Parasitemia and Prevalent Moderate Anemia, description - The number of subjects affected by prevalent asexual P. falciparum parasitemia and prevalent moderate anemia.\nModerate anemia = hemoglobin &lt; 8 g&#x2F;dL., timeFrame - 12 months post Dose 3 (Month 14)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01148459",
    "endpoint": "measure - Asexual P. Falciparum Parasitemia Density, description - The number of subjects with a positive blood slide for asexual P. falciparum., timeFrame - 12 months post Dose 3 (Month 14)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01148459",
    "endpoint": "measure - Prevalent Hemoglobin Level, description - The prevalent hemoglobin level in subjects with a positive blood slide is reported as grams per deciliter (g&#x2F;dl)., timeFrame - 12 months post Dose 3 (Month 14)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01148459",
    "endpoint": "measure - HIV Viral Load, description - The HIV viral load is reported.\nDetectable HIV viral load: 400 or more copies&#x2F;mL., timeFrame - At baseline (PRE) and at one month (Month 3), 6 months (Month 8) and 12 months (Month 14) post Dose 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01148459",
    "endpoint": "measure - Percentage of CD4+ Cells, description - The percentage of CD4+ cells is reported., timeFrame - At baseline (PRE) and at one month (Month 3), 6 months (Month 8) and 12 months (Month 14) post Dose 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01148459",
    "endpoint": "measure - CD4+ Absolute Cell Counts, description - The CD4+ absolute cell counts are reported., timeFrame - At baseline (PRE) and at 1 month (Month 3), 6 months (Month 8) and 12 months (Month 14) post Dose 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01148459",
    "endpoint": "measure - World Health Organization (WHO) HIV Clinical Classification Progression, description - <p>Clinical staging was done at each time point according to the WHO HIV&#x2F;AIDS clinical staging system.\nClinical stages included:</p><ul><li>&quot;Stage 1&quot; (asymptomatic or have persistent generalized lymphadenopathy),</li><li>&quot;Stage 2&quot; (mildly symptomatic stage - presenting with unexplained weight loss of less than 10 percent of total body weight, recurrent respiratory infections or dermatological conditions),</li><li>&quot;Stage 3&quot; (moderately symptomatic stage - presenting with weight loss of greater than 10 percent of total body weight, prolonged unexplained diarrhea or pulmonary tuberculosis, severe systemic bacterial infections or mucocutaneous conditions),</li><li>&quot;Stage 4&quot; (severely symptomatic stage which includes all of the AIDS-defining illnesses) Additional categories included &quot;deceased&quot; and &quot;missing&quot;.</li></ul>, timeFrame - At baseline (PRE), at study months 1 (Month 1) and 2 (Month 2) and at 1 month (Month 3), 6 months (Month 8) and 12 months (Month 14) post Dose 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01148459",
    "endpoint": "measure - Growth Parameters: Weight, Age&#x2F;Length and Middle Upper Arm Circumference for Age Z-score, description - The following growth parameters: weight, age&#x2F;length and middle upper arm circumference for age z-score are reported., timeFrame - At baseline (PRE), at Month 3 and at study end (Month 14)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04966702",
    "endpoint": "measure - To assess the efficacy of the intervention using complementary methods (efficacy)., description - Time to first positive RDT in children in the cohort., timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04966702",
    "endpoint": "measure - To assess the efficacy of the intervention using complementary methods (efficacy)., description - Molecular force of infection in a subset of children in the cohort., timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04966702",
    "endpoint": "measure - To assess the efficacy of the intervention using complementary methods (efficacy)., description - Malaria case incidence in all ages presenting at health facility., timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04966702",
    "endpoint": "measure - To assess the efficacy of the intervention using complementary methods (efficacy)., description - Malaria prevalence in all ages one month after the last dose., timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04966702",
    "endpoint": "measure - To assess the efficacy of the intervention using complementary methods (efficacy)., description - Multiplicity of infection in all ages one month after the last dose., timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04966702",
    "endpoint": "measure - To assess the safety of the intervention with complementary methods (safety)., description - Observed tolerability of the dose., timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04966702",
    "endpoint": "measure - To assess the safety of the intervention with complementary methods (safety)., description - Rate of Suspected Unexpected Serious Adverse Reactions (SUSARs)., timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04966702",
    "endpoint": "measure - To assess the safety of the intervention with complementary methods (safety)., description - AEs and SAEs by organ system., timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04966702",
    "endpoint": "measure - To assess the PK of the proposed ivermectin dose&#x2F;regime in its relationship with efficacy and safety outcomes (efficacy and safety)., description - Whole blood concentrations of ivermectin in dried blood spots., timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04966702",
    "endpoint": "measure - To assess the impact of ivermectin MDA at the proposed regimen on the prevalence of selected ectoparasitic NTDs (efficacy on NTDs and acceptability)., description - <ul><li>Serial prevalence of scabies using a simplified version of the algorithm described by Mahe et al.</li><li>Serial prevalence of head lice by visual inspection.</li><li>Serial prevalence of Tunga penetrans via visual inspection of the skin in both feet and applying the Fortaleza scale.</li><li>Serial prevalence and severity of bed bug infestation by direct questions about bedbugs in the house.</li></ul>, timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04966702",
    "endpoint": "measure - To assess the relationship between malaria incidence in children (under 5 years in Mozambique and 5-15 years in Kenya) and community prevalence at the peak of the malaria season., description - <p>Prevalence - incidence correlation:</p><p>- Malaria infection incidence in children (under 5 years in Mozambique and 5-15 years in Kenya) in the pediatric active cohort at community and health facility levels.</p>, timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04966702",
    "endpoint": "measure - To assess the relationship between malaria incidence in children (under 5 years in Mozambique and 5-15 years in Kenya) and community prevalence at the peak of the malaria season., description - <p>Prevalence - incidence correlation:</p><p>- Malaria prevalence at all ages.</p>, timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04966702",
    "endpoint": "measure - To assess the relationship between active and passive surveillance for malaria at health facility (only Mozambique)., description - <ul><li>Infection incidence in children at community level (active surveillance)</li><li>Infection incidence in children at health facility level (passive surveillance)</li></ul>, timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04966702",
    "endpoint": "measure - To assess the accuracy for malaria diagnosis of two the different malaria rapid diagnostic tests (RDTs) used in comparison to Polymerase Chain Reaction (PCR) (Mozambique)., description - Results correlation between HRP2 and pLDH-based RDTs, timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04966702",
    "endpoint": "measure - To assess the accuracy for malaria diagnosis of two the different malaria rapid diagnostic tests (RDTs) used in comparison to PCR (Mozambique)., description - Results correlation between RDTs and PCR, timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04966702",
    "endpoint": "measure - To assess the accuracy for malaria diagnosis of two the different malaria rapid diagnostic tests (RDTs) used in comparison to PCR (Mozambique)., description - Proportion of RDT negative but PCR positive infections, timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01930331",
    "endpoint": "measure - 12-lead ECG recordings: Heart rate, PR interval, QRS duration, QT interval, QTc (Fridericia and Bazett corrections), any T wave or U-wave morphology., description - <p>For ARCO treatment arm (which will only receive a single dose of ARCO treatment), Holter recording will start 15 minutes before the dose of ARCO, and it will run continuously during 12 hours post dosing.</p><p>For Eurartesim treatment arm (which will receive three daily doses of Euratertesim treatment), Holter recording will run for 15 minutes before the first dose, and then it will start again 15 minutes before the third dose (last dose) running continuously for 12 hours post dosing.</p>, timeFrame - Holter recording will run continuously during 12 hours after the last dose of treatment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01464138",
    "endpoint": "measure - Day 7 cure rate of 100%, description - , timeFrame - Day 6",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01464138",
    "endpoint": "measure - Parasite Clearance Time, description - , timeFrame - 0-7 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01464138",
    "endpoint": "measure - Fever Clearance Time, description - , timeFrame - 0-7 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02080026",
    "endpoint": "measure - Functionality of CPS-immunization induced antibodies for protection against pre-erythrocytic stages of Plasmodium falciparum., description - On day 107 and day 142 of the study (14 days after the 3rd CPS-immunization and 14 days after the 4th immunization) blood will be drawn for IgG isolation, which will be used to determine the functionality of these antibodies against the pre-erythrocytic stages of Plasmodium falciparum., timeFrame - On day 107 and day 142 of the study (14 days after the 3rd CPS-immunization and 14 days after the 4th immunization)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02080026",
    "endpoint": "measure - The specificity of CPS-immunization induced T-cell responses against pre-erythrocytic stages of Plasmodium falciparum., description - Before the first immunization and six weeks after the malaria challenge infection leukapheresis will be performed to isolate T-cells, which will be used to determine the activity of T-cells against specific target antigens of the pre-erythrocytic stages of Plasmodium falciparum., timeFrame - On day 1-14 and on day 267-280 of the study (before the first immunization and after Controlled Human Malaria Infection (CHMI))",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01755559",
    "endpoint": "measure - Early treatment failure, description - <ul><li>General danger signs or signs of severe malaria on days 1, 2, or 3, in the presence of parasitaemia , or</li><li>Parasitaemia on day 2 higher than on day 0, irrespective of axillary temperature, or</li><li>Parasitaemia on day 3 with axillary temperature ≥ 37.5°C, or</li><li>Parasitaemia on day 3 ≥ 25% count on day 0 irrespective of axillary temperature.</li></ul>, timeFrame - 1 to 3 days after tratment start",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01755559",
    "endpoint": "measure - Late clinical failure, description - <ul><li>General danger signs or severe malaria in the presence of parasitaemia on any day between day 4 and day 42 in patients who did not previously meet any of the criteria of early treatment failure; or</li><li>Presence of parasitaemia on any day between day 4 and day 42 with axillary temperature ≥ 37.5 °C in patients who did not previously meet any of the criteria of early treatment failure.</li></ul>, timeFrame - from day 4 to day 42 after treatment start",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01755559",
    "endpoint": "measure - Late Parasitological Failure, description - - Presence of parasitaemia on any day between day 7 and day 42 with axillary temperature &lt; 37.5 °C in patients who did not previously meet any of the criteria of early treatment failure or late clinical failure., timeFrame - from day 7 to day 42 after treatment start",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00374998",
    "endpoint": "measure - T-cell immunogenicity (prime-boost groups), description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00374998",
    "endpoint": "measure - Humoral immunogenicity (prime-boost groups), description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00374998",
    "endpoint": "measure - Gene expression (prime-boost groups), description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05905432",
    "endpoint": "measure - anti-UF6b IgG concentration, description - Area under the curve of anti-UF6b immunoglobulin G (IgG) concentration, using a qualified and validated ELISA protocol., timeFrame - Day 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00289185",
    "endpoint": "measure - Concentrations of Anti-Circumsporozoite Protein (Anti-CS) Antibodies, description - Antibodies were measured by Enzyme-linked immunosorbent assay (ELISA).\nConcentrations are expressed as geometric mean concentrations (GMCs) in ELISA unit per milliliter (EL.U&#x2F;mL).\nThe cut-off of the assay was the seropositivity cut-off value of 0.5 EL.U&#x2F;mL., timeFrame - Prior to vaccination at Week 0 (PRE), at Month 2, at Month 3 and at Month 9.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00289185",
    "endpoint": "measure - Number of Subjects With Solicited Local Symptoms., description - Assessed solicited local symptoms were pain and swelling following vaccination with the RTS,S&#x2F;AS02D or Engerix-B vaccine., timeFrame - Within 7 days (Days 0-6) after vaccination with the RTS,S&#x2F;AS02D or Engerix-B vaccine.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00289185",
    "endpoint": "measure - Number of Subjects With Solicited Local Symptoms., description - Assessed solicited local symptoms were pain and swelling following vaccination with the TETRActHib vaccine.., timeFrame - Within 7 days (Days 0-6) after vaccination with the TETRActHib vaccine.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00289185",
    "endpoint": "measure - Number of Subjects With Solicited General Symptoms., description - Assessed solicited general symptoms were drowsiness, fever, irritability, and loss of appetite.\nFever was defined as axillary temperature above or equal to (&gt;=) 37.5 degrees Celsius (°C)., timeFrame - Within 7 days (Days 0-6) after vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00289185",
    "endpoint": "measure - Number of Subjects With Unsolicited Adverse Events (AEs)., description - An unsolicited adverse event is any adverse event (i.e.\nany untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms., timeFrame - Within 30 days (Days 0-29) after vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00289185",
    "endpoint": "measure - Number of Subjects With Serious Adverse Events (SAEs), description - SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability&#x2F;incapacity., timeFrame - Throughout the entire study, from Week 0 to Month 20.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00289185",
    "endpoint": "measure - Time to First Malaria Infection, description - Malaria infection by Plasmodium falciparum (P.\nfalciparum) was detected by active detection of infection (ADI) and passive case detection (PCD), and was defined as the presence of P. falciparum asexual parasitemia above 0 per microliter (µL) on Giemsa stained thick blood films.\nThe time to first malaria infection is expressed in terms of rate of first malaria infection, that is, the number of malaria infection events reported (n) over the period elapsed until the event occurred (i.e.\nevents per Persons Year at Risk [PYAR]) for each group., timeFrame - Over the period starting 14 days after Dose 3 of RTS,S or HBV vaccine and extending for 6 months thereafter (from Month 2.5 up to Month 9).",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00289185",
    "endpoint": "measure - Number of Subjects Prevalent for Parasitemia, description - Subjects prevalent for P. falciparum parasitemia were defined as subjects with the presence of P. falciparum asexual parasitemia above 0 per microliter (µL) on Giemsa stained thick blood films., timeFrame - At Month 9",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00289185",
    "endpoint": "measure - Plasmodium Falciparum (P. Falciparum) Parasite Density in Subjects Prevalent for Parasitemia, description - The parasite density in subjects prevalent for P. falciparum parasitemia (Subjects with the presence of P. falciparum asexual parasitemia above 0 per microliter (µL) on Giemsa stained thick blood films), was detected at a cross sectional time point 7 months after administration of Dose 3 of RTS,S or HBV vaccine (Month 9).\nParasite density is expressed as mean, minimum and maximum density in parasite per µL.\nThis outcome for solely assessed in the Engerix-B Group, as no subject in the RTS,S&#x2F;AS02D was assessed as prevalent for parasitemia., timeFrame - At Month 9",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04709692",
    "endpoint": "measure - Number of Participants With Signs and Symptoms of Uncomplicated Malaria, description - Number of participants with symptoms (including fever) or physical examination signs related to uncomplicated P. vivax or P. falciparum malaria, timeFrame - 42 days for each arm",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04709692",
    "endpoint": "measure - Parasite Clearance Time, description - Time to parasite clearance as measured by microscopy, timeFrame - 42 days for each arm",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04709692",
    "endpoint": "measure - Parasite Reduction Rate, description - The parasite reduction rate is calculated as the slope of the linear portion of the regression fit of natural log of average parasitemia (per microliter) versus time (in hours).\nReported slope is representative of all analyzed participants in each arm.\nSlope is analyzed during time frame in which there is active reduction of parasitemia by treatment (0-&gt;96 h)., timeFrame - 0-&gt;96 h, depending upon the time required to reach lower limit of detection",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04709692",
    "endpoint": "measure - Asexual Parasite Clearance Time, description - Time to clearance of asexual parasites as measured by microscopy including half life of clearance.\nClearance time represents the time at which the mean parasitemia has reached the given threshold for the arm&#x2F;cohort.\nFor PC100, the value represents the time at which all patients have undetectable parasitemia., timeFrame - 42 days for each arm",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04709692",
    "endpoint": "measure - Percent Change in Asexual Parasites From Baseline, description - Percentage change of asexual parasites as determined by microscopy, relative to baseline at the specified times.\nThe value represents the average parasitemia in the arm&#x2F;cohort at the given time (per microliter) versus time (in hours) compared to the average parasitemia at T0. Reported reduction is representative of all analyzed participants in each arm., timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04709692",
    "endpoint": "measure - Area Under the Plasma Concentration-time Curve (AUC), description - AUC of SJ733 and its metabolite SJ506 will be reported, timeFrame - 11 days for each arm",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04709692",
    "endpoint": "measure - Maximum Plasma Drug Concentration (Cmax), description - Cmax of SJ733 and its metabolite SJ506 will be reported, timeFrame - 11 days for each arm",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04709692",
    "endpoint": "measure - Time to Reach Maximum Plasma Concentration (Tmax), description - Time to reach maximum plasma concentration (Tmax) of SJ733 will be reported, timeFrame - 11 days for each arm",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04709692",
    "endpoint": "measure - Drug Clearance, description - Drug clearance of SJ733 and its metabolite SJ506 will be reported, timeFrame - 11 days for each arm",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04709692",
    "endpoint": "measure - Crude Adequate Clinical and Parasitological Response (ACPR) at Days 28, 35, and 42, description - Crude Adequate Clinical and Parasitological Response (ACPR) at Days 28, 35, and 42 as measured by microscopy., timeFrame - 42 days for each arm",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04709692",
    "endpoint": "measure - Time to Recurrence of Malaria Infection, description - Time to recurrence of either P. vivax or P. falciparum malaria as measured by signs and symptoms or malaria and microscopy, timeFrame - 42 days for each arm",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04709692",
    "endpoint": "measure - Fever Clearance Time, description - Time from baseline to the first of two consecutive post-dose auxiliary temperature measurements &lt; 37.5 C obtained within an interval of 4 to 24 hours of each other, timeFrame - 42 days for each arm",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03503058",
    "endpoint": "measure - The number of confirmed first infections* caused by Pf, description - <p>The number of confirmed first infections* caused by Pf among subjects receiving vaccine vs. placebo during the period from 10 days after arriving in eastern Indonesia through 10 days after leaving eastern Indonesia.</p><p>* thick blood smears from asymptomatic individuals will be read retrospectively, so there is no interference in ascertaining the number of clinical cases, which is the primary VE endpoint.</p>, timeFrame - 10 days after arriving in eastern Indonesia through 10 days after leaving eastern Indonesia",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03503058",
    "endpoint": "measure - The number of confirmed first clinical malaria cases caused by Pv, description - The number of confirmed first clinical malaria cases caused by Pv among subjects receiving vaccine vs. placebo during the period from 10 days after arriving in eastern Indonesia through 10 days after leaving eastern Indonesia., timeFrame - 10 days after arriving in eastern Indonesia through 10 days after leaving eastern Indonesia.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03503058",
    "endpoint": "measure - The number of confirmed first infections with Pv in eastern Indonesia, description - <p>The number of confirmed first infections* caused by Pv among subjects receiving vaccine vs. placebo during the period from 10 days after arriving in eastern Indonesia through 10 days after leaving eastern Indonesia.</p><p>* thick blood smears from asymptomatic individuals will be read retrospectively, so there is no interference in ascertaining the number of clinical cases, which is the primary VE endpoint.</p>, timeFrame - 10 days after arriving in eastern Indonesia through 10 days after leaving eastern Indonesia.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03503058",
    "endpoint": "measure - The number of confirmed relapsing infections from Pv, description - The number of confirmed relapsing infections from latent liver stages of Pv identified post-exposure in a malaria-free area., timeFrame - 10 days after arriving in eastern Indonesia through 10 days after leaving eastern Indonesia.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03503058",
    "endpoint": "measure - Humoral immune responses, description - <p>The humoral immune responses* induced by vaccination compared to those induced by placebo administration comparing vaccinees to controls; (b) the association between the immune responses and protection (no parasitemia or clinical malaria occurring during surveillance).</p><p>*(i) Levels of antibodies against Pf circumsporozoite protein (CSP) by ELISA 2 weeks after the third dose of vaccine; (ii) Optional: Levels of antibodies against PvCSP by ELISA 2 weeks after the third dose of vaccine; (iii) Optional: Levels of antibodies against other Pf and Pv proteins, PfSPZ, PvSPZ and Pf and Pv asexual erythrocytic stages (AES) 2 weeks after the third dose; (iv) Optional: inhibition of sporozoite invasion assay,</p>, timeFrame - 14 days after the third dose of vaccine",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02614404",
    "endpoint": "measure - Frequency of adverse events, description - <p>Adverse events (AEs) are defined as events possibly related to the study drug as judged by physician that occur within 1 week of beginning treatment with imatinib.</p><ol><li>Incidence, severity, drug-relatedness, seriousness of adverse events</li><li>Laboratory values (biochemistry and haematology)</li><li>Vital signs</li></ol>, timeFrame - Within 1 week of beginning treatment with imatinib",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03754322",
    "endpoint": "measure - Absolute birth weight, description - Birth weight in grams, timeFrame - At the head to toe assessment of the baby within 24 hours of delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03754322",
    "endpoint": "measure - Maternal hemoglobin, description - Maternal hemoglobin in g&#x2F;dL, timeFrame - During the pregnancy and at delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03754322",
    "endpoint": "measure - Neonatal hemoglobin at birth, description - Foetal hemoglobin in g&#x2F;dL, timeFrame - At the head to toe assessment of the baby within 24 hours of delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03754322",
    "endpoint": "measure - Proportion of fetal loss, description - Early stillbirth &lt; 20-27 completed weeks of pregnancy Late stillbirth 28 -36 weeks of pregnancy Term still birth &gt; 37 weeks of pregnancy, timeFrame - During the study time, for each inclusion until delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03754322",
    "endpoint": "measure - Prematurity, description - Baby born Extremely preterm &lt; 28 weeks of pregnancy Very preterm 28-32 weeks of pregnancy Moderate to late preterm 32-37 weeks of pregnancy, timeFrame - At delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02215707",
    "endpoint": "measure - Antibody titers to Pf proteins by ELISA, description - Assess the cellular and antibody responses induced by the PfSPZ Vaccine to determine whether any immune response(s) correlate with protection., timeFrame - Screening until week 52",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02215707",
    "endpoint": "measure - Antibody titers to Pf parasite stages by IFA, description - Assess the cellular and antibody responses induced by the PfSPZ Vaccine to determine whether any immune response(s) correlate with protection., timeFrame - Screening until week 52",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02215707",
    "endpoint": "measure - Capacity to inhibit sporozoite invasion of hepatocytes in vitro by ISI assay, description - Assess the cellular and antibody responses induced by the PfSPZ Vaccine to determine whether any immune response(s) correlate with protection., timeFrame - Screening until week 52",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02215707",
    "endpoint": "measure - Analysis of antibodies to any of the thousands of proteins in the Pf proteome using proteome array chips, description - Assess the cellular and antibody responses induced by the PfSPZ Vaccine to determine whether any immune response(s) correlate with protection., timeFrame - Screening until week 52",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02215707",
    "endpoint": "measure - Multi-channel intracellular staining (ICS) analysis by flow cytometry against PfSPZ and synthetic peptides and recombinant proteins from defined Pf proteins, description - Assess the cellular and antibody responses induced by the PfSPZ Vaccine to determine whether any immune response(s) correlate with protection., timeFrame - Screening until week 52",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02215707",
    "endpoint": "measure - Analysis of ELISpot responses in response to stimulation with PfSPZ and synthetic peptides and recombinant proteins from defined Pf proteins, description - Assess the cellular and antibody responses induced by the PfSPZ Vaccine to determine whether any immune response(s) correlate with protection., timeFrame - Screening until week 52",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02215707",
    "endpoint": "measure - Analysis of T cell receptor studies, description - Assess the cellular and antibody responses induced by the PfSPZ Vaccine to determine whether any immune response(s) correlate with protection., timeFrame - Screening until week 52",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02215707",
    "endpoint": "measure - B cell&#x2F;plasmablast studies, description - Assess the cellular and antibody responses induced by the PfSPZ Vaccine to determine whether any immune response(s) correlate with protection., timeFrame - Screening until week 52",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02215707",
    "endpoint": "measure - Human gene expression profiling focusing on immune response genes, description - Assess the cellular and antibody responses induced by the PfSPZ Vaccine to determine whether any immune response(s) correlate with protection., timeFrame - Screening until week 52",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02215707",
    "endpoint": "measure - Luminex or Luminex type studies to assess multiple cytokines and other host molecules, description - Assess the cellular and antibody responses induced by the PfSPZ Vaccine to determine whether any immune response(s) correlate with protection., timeFrame - Screening until week 52",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06555809",
    "endpoint": "measure - Safety, as measured by the number of participants with adverse events, description - Safety, as measured by the number of participants with adverse events, timeFrame - During standard of care treatment with intravenous artesunate",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06555809",
    "endpoint": "measure - Tolerability, as measured by the number of doses of artesunate administered to each participant, description - Tolerability of artesunate treatment, as measured by the number of doses of artesunate administered to each participant, timeFrame - During standard of care treatment with intravenous artesunate",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00870987",
    "endpoint": "measure - Number of sterile or partial protections, description - The DNA-Ad vaccine is considered efficacious if it offers any degree of sterile or partial protection that reaches statistical significance (p&lt;0.05).\nThe vaccine efficacy will be determined by two parameters: 1) sterile protection for 28 days after challenge, 2) partial protection as determined by delay to parasitemia by smears and PCR., timeFrame - 28 days after malaria challenge",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00870987",
    "endpoint": "measure - Number of humoral immunity expressions, description - The DNA-Ad vaccine is considered to confer humoral immunity if the increase of antibody response for CSP or AMA1 by ELISA post immunization is statistically significant (p&lt;0.05)\ncompared to the levels before immunization., timeFrame - 28 days after malaria challenge",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00870987",
    "endpoint": "measure - Number of cellular immunity expressions, description - The DNA-Ad vaccine is considered to confer cellular immunity if a positive ELISpot response is detected after immunization, timeFrame - 28 days after malaria challenge",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01378286",
    "endpoint": "measure - Assessment of clinical and parasitological efficacy based on temperature and parasitemia before and after PCR correction at D14 and D42 and before PCR correction at D28, description - , timeFrame - up to a maximum of 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01378286",
    "endpoint": "measure - Number of patients without parasite, description - , timeFrame - up to a maximum of 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01378286",
    "endpoint": "measure - Number of patients without fever, description - , timeFrame - up to a maximum of 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01378286",
    "endpoint": "measure - Number of patients with gametocytes, description - , timeFrame - up to a maximum of 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01378286",
    "endpoint": "measure - Change from baseline in Haemoglobin levels, description - , timeFrame - Day 7, Day 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01378286",
    "endpoint": "measure - Incidence and severity of adverse events collected, description - , timeFrame - up to a maximum of 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01378286",
    "endpoint": "measure - ECG (QTc) changes in patients group aged &gt;= 10 years from baseline, description - , timeFrame - Day 3, Day 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01378286",
    "endpoint": "measure - Assessment of biological tolerability (bilirubin, ALAT, Creatinine, Leukocytes, Neutrophils and platelets count) from baseline, description - , timeFrame - up to a maximum of 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04102592",
    "endpoint": "measure - Incidence of symptomatic malaria episodes among children, description - As defined by typical symptoms including fever, malaise, and convulsions., timeFrame - 12 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04102592",
    "endpoint": "measure - Incidence of P. falciparum malaria parasitemia among children, description - As determined by quantitative PCR, timeFrame - 12 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04102592",
    "endpoint": "measure - Change in mosquito salivary antigen response among children, description - , timeFrame - Baseline, 12 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04102592",
    "endpoint": "measure - Change in mosquito salivary antigen response among mothers, description - , timeFrame - Baseline, 12 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04102592",
    "endpoint": "measure - Changes in hemoglobin levels among children, description - , timeFrame - Baseline, 12 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04102592",
    "endpoint": "measure - Changes in hemoglobin levels among mothers, description - , timeFrame - Baseline, 12 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06225297",
    "endpoint": "measure - Difference in cumulative incidence of grade 3+ adverse events after drug administration between arms, description - Defined as the number of grade 3+ AEs divided by the participant population who received at least one dose of drug., timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06225297",
    "endpoint": "measure - Difference in the cumulative incidence of serious adverse events (SAE) after SMC administration between arms, description - Adverse events will be classified as serious or non-serious based on standardized AE grading scale, timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06225297",
    "endpoint": "measure - Difference in human behavior on net use before and after ITN&#x2F;meganet distribution, description - ITN use (e.g., sleeping under net in the previous night, sleeping indoors versus outdoors) will be assessed during cross-sectional surveys, timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06225297",
    "endpoint": "measure - Difference in indoor and outdoor adjusted human biting rates between arms, description - The human landing rate will be used as a proxy for the human biting rate (HBR).\nThe HBR data will be integrated with the human behavior observation (HBO) data on net use and sleep patterns data by calculating the hourly adjusted HBR., timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06225297",
    "endpoint": "measure - Difference in Anopheles biting trends between arms, description - Anopheles biting trends will be examined by measuring the Anopheles biting times (including peak biting time), biting locations (indoors and outdoors), and vector density (defined as mean number of bites received by one person in one night) during human landing catches, timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06225297",
    "endpoint": "measure - Acceptability of intervention package, description - Perceptions of intervention package and reasons for participation assessed through qualitative studies conducted throughout the study period, timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06225297",
    "endpoint": "measure - Difference in proportion of refusals between arms, description - Refusals will be defined as the number of those who refused a specific intervention divided by the number of participants who were targeted and eligible to receive the specific intervention (i.e., chemoprevention and meganets)., timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06225297",
    "endpoint": "measure - Difference in distribution coverage of chemoprevention strategies between arms, description - Distribution coverage will be defined as the number of persons who received intervention divided by number of those targeted and eligible, timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06225297",
    "endpoint": "measure - Difference in crude coverage of chemoprevention strategies between arms, description - Crude coverage will be defined using WHO criteria as number of persons who received the intervention divided by number of those who were targeted (regardless of eligibility), timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06225297",
    "endpoint": "measure - Cost per malaria case averted, description - Total intervention costs will be calculated in both arms and compared with efficacy measures of malaria incidence to generate the incremental cost effectiveness ratio., timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03963869",
    "endpoint": "measure - Malaria as detected by RDT, description - Malaria as detected by a rapid diagnostic test, timeFrame - 24 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03963869",
    "endpoint": "measure - Gametocyte density, description - Measured by quantifying the number of gametocyte infected erythrocytes and dividing by the number of leukocytes or by quantitative reverse transcriptase real time PCR.\nBoth results can be measured continuously and categorically (data will be transformed).\nTo account for a mixed-infection (either by species or by multiple strains) we will take the gametocyte to trophozoite ratio to reduce any apparent bias., timeFrame - 24 Months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03963869",
    "endpoint": "measure - Hemoglobin, description - Hemoglobin will be measured by POC testing which provides both continuous and categorical data (when analyzed by local standards) regarding anemia status., timeFrame - 24 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03963869",
    "endpoint": "measure - BMI, description - <p>Height in cm will be measured with a height measuring tape.\nWeight in kg will be measured with a scale.\nParticipants will be asked to remove shoes and shawls or cardigans, or other clothing that can be removed without ethical concerns.</p><p>BMI will be calculated as (kilograms&#x2F;meters squared).\nMeasures will be adjusted by age using the WHO Multicentre Growth Reference Study Group&#x27;s 2006 WHO Child Growth Standards: Length&#x2F;height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age: Methods and development.</p><p>Categorical BMI measurements will be based on standards for Asian Indians: Misra A, Chowbey P, Makkar BM, et al.\nConsensus Statement for Diagnosis of Obesity, Abdominal Obesity and the Metabolic Syndrome for Asian Indians and Recommendations for Physical Activity, Medical and Surgical Management.</p>, timeFrame - 24 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03963869",
    "endpoint": "measure - Body temperature, description - Body temperature will be measured with a digital thermometer placed under the participant&#x27;s tongue reported in degrees Fahrenheit., timeFrame - 24 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03963869",
    "endpoint": "measure - Mid-upper arm circumference, description - <p>Mid-Upper Arm Circumference (MUAC) Mid-Upper Arm Circumference (MUAC) is the circumference of the left upper arm, measured at the mid-point between the tip of the shoulder and the tip of the elbow (olecranon process and the acromium).\nParticipants will be asked to remove any clothes that may hinder the measurement (preferable directly on skin, but tight clothes can be accepted if they are difficult to remove).</p><p>MUAC will be measured in cm to one decimal using a Myotape&#x2F;tape measure.</p>, timeFrame - 24 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03963869",
    "endpoint": "measure - Plasmodium-specific serology, description - Measured by a high-throughput bead-based cytometric assay provides continuous and categorical (seropositive vs. seronegative) results., timeFrame - 24 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03963869",
    "endpoint": "measure - Plasmodium parasite genomic epidemiology, description - Plasmodium infections will be characterized for their mixed clonality, genetic diversity, and molecular force of infection by MinIon or Illumina NextGen sequencing., timeFrame - 24 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02511353",
    "endpoint": "measure - Mosquito survival, description - , timeFrame - Survival of mosquitoes at each day up to day 21 or 28 after each feeding experiments performed at 0, 2 day+4h, 10, 14, 21, 28 days after start of treatment.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02511353",
    "endpoint": "measure - Number of patients with malaria clinical and parasitological treatment response, description - , timeFrame - Up to day 28.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02511353",
    "endpoint": "measure - Area under the plasma concentration versus time curve (AUC) of ivermectin, description - , timeFrame - Up to day 28.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02511353",
    "endpoint": "measure - Area under the plasma concentration versus time curve (AUC) of piperaquine, description - Dihydroartemisinin-piperaquine is a combination drug.\nAs dihydroartemisinin has a very short elimination time, only the AUC for the longer acting piperaquine component will be determined., timeFrame - Up to day 28.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02511353",
    "endpoint": "measure - Peak plasma Concentration (Cmax) of ivermectin, description - , timeFrame - Up to day 28.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02511353",
    "endpoint": "measure - Peak plasma Concentration (Cmax) of piperaquine, description - Dihydroartemisinin-piperaquine is a combination drug.\nAs dihydroartemisinin has a very short elimination time, only the Cmax for the longer acting piperaquine component will be determined., timeFrame - Up to day 28.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02511353",
    "endpoint": "measure - Tolerability as assessed by adverse events reported in a general toxicity questionnaire, description - , timeFrame - Up to day 28.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02511353",
    "endpoint": "measure - CNS adverse events, description - , timeFrame - Up to day 28.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02511353",
    "endpoint": "measure - Serious adverse events, description - , timeFrame - Up to day 28.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02511353",
    "endpoint": "measure - Haemoglobin concentrations, description - , timeFrame - Up to day 28.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02511353",
    "endpoint": "measure - QTc interval, description - , timeFrame - At 52 hours.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02511353",
    "endpoint": "measure - Mydriasis quantitated by pupillometry, description - , timeFrame - Up to day 28.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03162614",
    "endpoint": "measure - Time to Onset of P. Falciparum Parasitemia After Sporozoite Challenge for Each Vaccination Schedule, description - For the analyses of time to onset of parasitemia, time at risk started on first day of challenge.\nTime at risk was censored on Day 315 (28 days post challenge), drop-out date, start date of antimalarial treatment or date meeting an endpoint, whichever occurs first., timeFrame - Following sporozoite challenge starting 3 months after the last vaccine dose (at Day 287) for up to 28 days post-challenge (at Day 315).",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03162614",
    "endpoint": "measure - Anti-Circumsporozoite (Anti-CS) Repeat Region Antibody Concentrations, description - Anti-CS antibody concentrations are presented as Geometric Mean Concentrations (GMCs), expressed in Enzyme-linked immunosorbent assay Unit per milliliter (EU&#x2F;mL).\nThe cut-off for the assay was 1.9 EU&#x2F;mL.\nThe GMC calculations were performed by taking the anti-log of the mean of the log transformations (base 10).\nAntibody concentrations below the cut-off of the assay were given an arbitrary value of half the cut-off (=1.0) for the purpose of GMC calculation., timeFrame - At Day 1, Day 59, Day 197, Day 227, Day 287, Day 315, and Day 377 for subjects from AduFx, 2PedFx, PedFx, and Adu2Fx Groups. At Day 1, Day 197, Day 227, Day 287, Day 315, and Day 377 for subjects from Adu1Fx Group",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03162614",
    "endpoint": "measure - Anti-Hepatitis B (Anti-HBs) Immunoglobulin G (IgG) Antibody Concentrations, description - Anti-HBs IgG antibody concentrations are presented as Geometric Mean Concentrations (GMCs), expressed in milli-International Unit per milliliter (mIU&#x2F;ml).\nThe cut-off for the assay was 6.2 mIU&#x2F;mL., timeFrame - At Day 1, Day 59, Day 197, Day 227, Day 287, Day 315, and Day 377 for subjects from AduFx, 2PedFx, PedFx, and Adu2Fx Groups. At Day 1, Day 197, Day 227, Day 287, Day 315, and Day 377 for subjects from Adu1Fx Group",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03162614",
    "endpoint": "measure - Number of Subjects With Any Solicited Local Symptoms, description - Solicited local symptoms assessed are pain, redness and swelling.\nAny occurrence of symptom regardless of intensity grade.\nAny Redness or any Swelling symptom = any symptom greater than (&gt;) 0 millimeter (mm)., timeFrame - Within the 7-day period (Days 1-7) after dose 1, dose 2 (except for Adu1Fx Group) and dose 3.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03162614",
    "endpoint": "measure - Number of Subjects With Any Solicited General Symptoms, description - Solicited general symptoms assessed are fatigue, gastrointestinal symptoms, headache and fever.\nAny occurrence of symptom regardless of intensity grade.\nFever was defined as temperature equal or greater than (≥) 37.5 degrees Celsius (°C) for oral route, axillary or tympanic route or 38.0°C for rectal route., timeFrame - Within the 7-day period (Days 1-7) after dose 1, dose 2 (except for Adu1Fx Group) and dose 3.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03162614",
    "endpoint": "measure - Number of Subjects With Any Unsolicited Adverse Events (AEs) After Any Vaccination, description - An unsolicited adverse event is any untoward medical occurrence in a clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product.\nAn unsolicited adverse event is any event reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms., timeFrame - Within the 30-day period (Days 1-30), after any vaccination (across doses)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03162614",
    "endpoint": "measure - Number of Subjects With Any Unsolicited AEs After Challenge, description - An adverse event is any untoward medical occurrence in a clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product., timeFrame - Within the 30-day (Days 1-30) period post-challenge",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03162614",
    "endpoint": "measure - Number of Subjects With Any, Fatal or Related Serious Adverse Events (SAEs) After Each Vaccination, description - SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability&#x2F;incapacity., timeFrame - Within the 30-day period (Days 1-30) after any vaccination (across doses)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03162614",
    "endpoint": "measure - Number of Subjects With Any, Fatal or Related SAEs During the Whole Study Period, description - SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability&#x2F;incapacity., timeFrame - From Day 1 up to study conclusion (Day 377)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03162614",
    "endpoint": "measure - Number of Subjects With Any AE and SAE Leading to Withdrawal From Further Vaccination, description - An adverse event is any untoward medical occurrence in a clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product.\nSAEs include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability&#x2F;incapacity., timeFrame - From Day 1 up to study conclusion (Day 377)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03162614",
    "endpoint": "measure - Number of Subjects With Potential Immune Mediated Diseases (pIMDs), description - Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and&#x2F;or neurologic disorders of interest which may or may not have an autoimmune etiology., timeFrame - From Day 1 up to study conclusion (Day 377)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03162614",
    "endpoint": "measure - Number of Subjects With Meningitis, description - Meningitis is to be reported as an adverse event of specific interest and tabulated per study group., timeFrame - From Day 1 up to study conclusion (Day 377)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03162614",
    "endpoint": "measure - Number of Subjects With Abnormal Laboratory Values Gradings, description - Biochemistry (Alanine Aminotransferase [ALT], Aspartate Aminotransferase [AST] and creatinine) and hematological (hemoglobin, platelets, White Blood Cells [WBC] decrease and WBC increase) laboratory values were presented according to toxicity grading scales (Grade 0 [GR0], Grade 1 [GR1], Grade 2 [GR2] Grade 3 [GR3]) and tabulated by group.\nGrading scale is taken from the [FDA guidance for industry: toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials (September 2007)]., timeFrame - At Visit 1 Screening (Day -89 to Day 1), Day 36, Day 59, Day 204, Day 227, between Day 292 &amp; Day 313, and Day 315 for each vaccinated subject.For Infectivity Control subjects at Visit 1b Screening (Day 231 to Day 287),between Day 292 &amp; Day 313,and Day 315",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03162614",
    "endpoint": "measure - Number of Subjects With Any, Fatal or Related SAE, After Challenge, description - SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability&#x2F;incapacity., timeFrame - From day of challenge (Day 287) to the end of the challenge phase (Day 315)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02694874",
    "endpoint": "measure - Time to clinical recovery, description - <p>Time to recovery including:</p><ol><li>Time to fever resolution for at least 24h.\nTemperature measurements will be taken at admission and every 4h for the first 4 days, and then every 12h until 2 normal results (&lt;37.5oC) are reported.</li><li>Time to sit unsupported</li><li>Time to hospital discharge</li></ol>, timeFrame - up to 96 hours after hospital admission",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02694874",
    "endpoint": "measure - Time to parasitological recovery, description - Time to parasitological recovery: Time (in hours) to clearance of parasitemia from the blood (both 50% and 90% decrease from admission baseline value).\nParasitemia will be quantified at admission and every 6h, for 4 days or until 2 negative readings are reported., timeFrame - up to 96 hours after hospital admission",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02694874",
    "endpoint": "measure - Mortality, description - Mortality in the first 48h post-hospital admission and at 14 days post-hospital admission, timeFrame - first 48h post-hospital admission and at 14 days post-hospital admission",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02694874",
    "endpoint": "measure - Blood lactate levels, assessed at admission, every 12h for 24 hours then daily for Blood lactate levels, description - Blood lactate levels, assessed at admission, every 12h for 24 hours then daily for 4 days, and once on day 14 and 6 month follow ups, timeFrame - Assessed at admission, every 12h for 24 hours then daily for 4 days, and once on day 14 and 6 month follow ups",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02694874",
    "endpoint": "measure - Change in levels of biomarkers of host response, description - Change in levels of biomarkers of host response at admission, every 12h for 24 hours then daily for 4 days, and once on day 14 and 6 month follow ups, timeFrame - at admission, every 12h for 24 hours then daily for 4 days, and once on day 14 and 6 month follow ups",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02694874",
    "endpoint": "measure - Blood glucose levels, description - Blood glucose levels assessed at admission and every 6h for the first 48h, and then every 24h for following 2 days, timeFrame - up to 96 hours after hospital admission",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02694874",
    "endpoint": "measure - Cardiac effects, description - Monitor for cardiac effects by conducting ECG at baseline, at 24h (immediately before third doses of rosiglitazone and artesunate treatment are administered) and at the end of rosiglitazone treatment (day 4).\nMain outcome of interest will be changes in QTc from baseline to the two different time points., timeFrame - from baseline to 24h, and day 4",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02694874",
    "endpoint": "measure - Biochemical and hematological parameters, description - Biochemical and hematological parameters including: AST, ALT, creatinine, complete blood count (e.g.\nhemoglobin, WBC and differential, hematocrit, platelet count) will be assessed at admission and every 24h until day 4, timeFrame - up to 96 hours after hospital admission",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02694874",
    "endpoint": "measure - AE&#x2F;SAE, description - AE&#x2F;SAE monitored using the pediatric toxicity tables modified from the US National Institutes of Allergy and Infectious Diseases, timeFrame - up to day 14 after hospital admission",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02694874",
    "endpoint": "measure - Neurocognitive outcomes, description - Participants with Adverse Events that Are Related and unrelated to Treatment by a variety of standard neurocognitive tests, timeFrame - From baseline to 6 months post discharge, and 18 months post discharge",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05535465",
    "endpoint": "measure - Difference of malaria prevalence between control and intervention arms, description - Prevalence will be calculated as the proportion of participants with malaria infection (i.e.\npositive blood smears) detected during the cross-sectionnal surveys, timeFrame - Day 0 (cross-sectional survey)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02692963",
    "endpoint": "measure - Changes in cellular (innate and adaptive) immune responses, description - , timeFrame - inclusion until day 120 after malaria challenge infection",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02692963",
    "endpoint": "measure - Changes in plasma cytokine levels, description - , timeFrame - inclusion until day 120 after malaria challenge infection",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02132299",
    "endpoint": "measure - Immune Responses after PfSPZ Vaccine, description - Cellular and humoral immune responses will be assessed in the vaccinated volunteers and controls (including central and effector memory responses and breadth and specificity of malaria antibodies)., timeFrame - 16 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02132299",
    "endpoint": "measure - Protective effect of the high dose PfSPZ Vaccine regimen, description - Number of volunteers negative in Group 3 and Group 4 compared to Group 2 through day 28 of follow up after homologous PfSPZ Challenge (NF54) IV inoculation., timeFrame - CHMI to day 28 after CHMI",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01397227",
    "endpoint": "measure - Immunogenicity, description - <ul><li>Anti-circumsporozoite antibodies will be assessed by enzyme-linked immunosorbent assay</li><li>T-cell responses against circumsporozoite protein will be assessed by ELISPOT assays and flow cytometry</li><li>Neutralizing antibodies to Ad26, and Ad35 will be assessed by neutralizing antibody assay</li></ul>, timeFrame - Blood samples drawn at baseline (screening) and Study Days 14, 28, 42, 55&#x2F;59, 69&#x2F;73, 86 and 115",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01397227",
    "endpoint": "measure - Efficacy - patent parasitemia, description - Development of patent parasitemia diagnosed on peripheral blood smear, timeFrame - Vaccine recipients are monitored for the development of parasitemia for 28 days post-malaria challenge",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00744133",
    "endpoint": "measure - Occurrence of a positive real-time quantitative polymerase chain reaction (PCR)., description - , timeFrame - After malaria challenge during a 56-day surveillance period (day of challenge and days 5-28, 35, 42, 49 and 56 after challenge).",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04864444",
    "endpoint": "measure - Difference in parasite prevalence by microscopy during high malaria transmission season, description - Parasite prevalence will be assessed via microscopy from samples obtained during cross-sectional survey conducted at the end of the transmission season., timeFrame - 3 months after last round of MDA",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04864444",
    "endpoint": "measure - Difference in parasite prevalence by polymerase chain reaction (PCR) during high malaria transmission season, description - Parasite prevalence will be assessed via polymerase chain reaction from samples obtained during cross-sectional survey conducted at the end of the transmission season., timeFrame - 3 months after last round of MDA",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04864444",
    "endpoint": "measure - Difference in serological markers of recent infection, description - Difference in seroprevalence from samples obtained during cross-sectional survey conducted at the end of the transmission season., timeFrame - 3 months after last round of MDA",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04864444",
    "endpoint": "measure - Difference in the change in prevalence of drug resistance markers, description - Prevalence of drug resistance markers (K13 and plasmepsin copy number) will be assessed from samples taken during the baseline and endline cross-sectional surveys., timeFrame - Change from baseline to endline; 1 year period",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04864444",
    "endpoint": "measure - Difference in the change in prevalence of parasite population dynamics, description - Prevalence of parasite population dynamics (multiplicity of infection) will be assessed from samples taken during the baseline and endline cross-sectional surveys., timeFrame - Change from baseline to endline; 1 year period",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03568344",
    "endpoint": "measure - Proportion of children &lt;5 years with severe febrile illness without parasites on day 28, description - Rapid diagnostic test for malaria, timeFrame - 28 days after RAS administration",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03568344",
    "endpoint": "measure - Proportion of children &lt;5 years with a recent history of fever (mild or severe) who attend CHW&#x2F;primary HF, description - Data obtained through Household surveys (semi-structured interviewer administered Treatment Seeking Questionnaire), timeFrame - Through study completion, an average of 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03568344",
    "endpoint": "measure - Proportion of children &lt;5 years with severe febrile illness seen by CHW&#x2F;primary HF who completed referral, description - Patient surveillance system (track patients from first point of contact at CHW or primary health facility until referral health facility), timeFrame - From RAS administration up to 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03568344",
    "endpoint": "measure - Number of children &lt;5 years with severe febrile illness who report directly to referral health facility, description - Patient surveillance system (patients with severe febrile illness reporting directly to referral health facility), timeFrame - Through study completion, an average of 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03568344",
    "endpoint": "measure - Proportion of children &lt;5 years with severe febrile illness managed pre-referral according to guidelines, description - Patient surveillance system (data collected at CHW &#x2F; primary HF), timeFrame - Through study completion, an average of 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03568344",
    "endpoint": "measure - Proportion of children &lt;5 years with severe febrile illness managed post-referral according to guidelines, description - Patient surveillance system (data collected at referral facility), timeFrame - Through study completion, an average of 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03568344",
    "endpoint": "measure - Frequency of passively reported adverse events after RAS administration, description - Continuous monitoring of patients medical records (referral facility) for adverse events, timeFrame - From RAS administration up to 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03568344",
    "endpoint": "measure - Frequency of delayed haemolytic anaemia within 28 days after RAS administration, description - Hemoglobin measurement, timeFrame - 28 days after RAS administration",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03568344",
    "endpoint": "measure - Proportion of trained and functional CHW and primary HF who provide QA RAS, description - Data obtained through routine monitoring of process indicators along the entire case management chain to continuously assess implementation progress of RAS (Programmatic records), timeFrame - Through study completion, an average of 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03568344",
    "endpoint": "measure - Proportion of CHW&#x2F;primary HF with RAS in stock, description - Data obtained through routine monitoring of process indicators (Programmatic records) and Health care provider surveys (structured checklist to assess the availability of essential medical supplies (incl.\nRAS) and equipment, human resource capacity, infrastructure and documentation), timeFrame - Through study completion, an average of 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03568344",
    "endpoint": "measure - Proportion of referral health facilities that have the capacity to manage severe malaria in children in line with global guidance, description - Data obtained through routine monitoring of process indicators (Programmatic records) and Health care provider surveys (structured checklist to assess the availability of essential medical supplies (incl.\nRAS) and equipment, human resource capacity, infrastructure and documentation and interviewer administered questionnaires to assess the health worker&#x27;s demographics, education and training, work experience and supervision, type and utility of any work-related training received, knowledge, attitudes and practices relevant to febrile case management (incl.\ndiagnostic algorithm and (RAS) treatment guidelines) and intermittent preventive treatment in infants and pregnancy (IPTi, IPTp), experiences implementing malaria&#x2F;febrile case management and prevention guidelines), timeFrame - Through study completion, an average of 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03568344",
    "endpoint": "measure - Proportion of CHW&#x2F;primary HF that received at least one supervisory visit in the past 3 months, description - Data obtained through routine monitoring of process indicators (Programmatic records), timeFrame - Through study completion, an average of 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03568344",
    "endpoint": "measure - Acceptability of pre-referral RAS among health workers, description - Qualitative data obtained through Health care provider surveys (interviewer administered questionnaires to assess the health worker&#x27;s demographics, education and training, work experience and supervision, type and utility of any work-related training received, knowledge, attitudes and practices relevant to febrile case management (incl.\ndiagnostic algorithm and (RAS) treatment guidelines) and intermittent preventive treatment in infants and pregnancy (IPTi, IPTp), experiences implementing malaria&#x2F;febrile case management and prevention guidelines), timeFrame - Through study completion, an average of 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03568344",
    "endpoint": "measure - Acceptability of pre-referral RAS among caretakers, description - Qualitative data obtained through Household surveys (semi-structured interviewer administered Treatment Seeking Questionnaire including attitude towards RAS use), timeFrame - Through study completion, an average of 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03568344",
    "endpoint": "measure - Total financial cost of managing severe case at community level. Marginal financial cost of adding RAS to the management, description - Costs extracted from the routine accounting documents of the iCCM projects in the three countries, Health care providers surveys and costs incurred by caretakers during referral (PSS Day 28 assessment), timeFrame - From RAS administration up to 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03568344",
    "endpoint": "measure - Financial cost of RAS interventions per death averted, description - Incremental cost-effectiveness of QA RAS introduction over current standard of care for management of severe malaria, timeFrame - Through study completion, an average of 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02043652",
    "endpoint": "measure - Number of Patients Reporting Relapses, description - Evaluate the relapse rate, that is reappearance of parasites, for up to 6 months after treatment., timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02237586",
    "endpoint": "measure - Dynamics of P. falciparum parasite growth, description - The dynamics of P. falciparum parasite growth following administration of PfSPZ Challenge is assessed by analyzing parasite multiplication rates using highly sensitive qPCR for P. falciparum DNA.\nMeasurements will be used to model parasite kinetics and to estimate the number of infected liver cells., timeFrame - From day 6 after injection until approximately day 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01624961",
    "endpoint": "measure - The time from parasite inoculation to first detection of blood stage parasitemia will be assessed by thick blood film microscopy., description - , timeFrame - Day 5 until day 21 or until treatment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01624961",
    "endpoint": "measure - The safety of PfSPZ Challenge administered ID or IV and the resultant P. falciparum infection will be assessed by analysing actively and passively collected data from clinical review of volunteers and laboratory measurements, description - These tests include full blood picture (complete blood count), liver enzymes and creatinine.\nAll of these will be performed once at screening, Day -1 (day before challenge), Day 21 when no parasitemia occurs until then and day of malaria diagnosis.\nLastly, these tests will also be performed during safety follow up at Days 28, 84 and 168., timeFrame - Screening to Day 168",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03824236",
    "endpoint": "measure - Time to Onset of P. Falciparum Parasitemia (Defined by a Positive Blood Slide) Following Sporozoite Challenge, description - For the analyses of time to onset of parasitemia (Kaplan-Meyer and log-rank), time at risk started on first day of challenge.\nTime at risk was censored on Day 50 (28 days post challenge), drop-out date, start date of anti-malarial treatment or date meeting an endpoint, whichever occured first.\nTime-at-risk was calculated as: censor date - date challenge + 1., timeFrame - During the sporozoite challenge period starting at Day 22 (after the vaccine dose administered at Day 1), up to Day 50",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03824236",
    "endpoint": "measure - Anti- Circumsporozoite (CS) Repeat Region Antibody Concentrations, description - Anti-CS antibody concentrations are presented as Geometric Mean Concentrations (GMCs), expressed in Enzyme-linked immunosorbent assay Unit per milliliter (EU&#x2F;mL).\nThe cut-off for the assay was equal to 1.9 EU&#x2F;mL.\nGMC calculations are performed by taking the inverse logarithm of the mean of the log concentration transformations.\nAntibody concentrations below the cut-off of the assay will be given an arbitrary value of half the cut-off of the assay for the purpose of GMC calculation., timeFrame - At Day 1, prior to challenge (Day 22), 28 days post-challenge (Day 50) and at study end (Day 190)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03824236",
    "endpoint": "measure - Anti-Hepatitis B (HBs) Immunoglobulin G (IgG) Antibody Concentrations, description - Anti-HBs IgG antibody concentrations are presented as Geometric Mean Concentrations (GMCs), expressed in milli-International Unit per milliliter (mIU&#x2F;mL).\nThe cut-off for the assay was equal to 6.2 mIU&#x2F;mL.\nGMC calculations are performed by taking the inverse logarithm of the mean of the log concentration transformations.\nAntibody concentrations below the cut-off of the assay will be given an arbitrary value of half the cut-off of the assay for the purpose of GMC calculation., timeFrame - At Day 1, prior to challenge (Day 22), 28 days post-challenge (Day 50) and at study end (Day 190)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03824236",
    "endpoint": "measure - Number of Subjects With Any Solicited Local Adverse Events (AEs) in the Booster Vaccination Groups, description - Solicited local AEs assessed are erythema, pain and swelling.\nAny occurrence of AE regardless of intensity grade are reported.\nAny Erythema or any Swelling symptom = any symptom recorded with a surface diameter greater than 0 millimeter., timeFrame - Within 7 days after vaccination (day of vaccination and 6 subsequent days) in the booster vaccination groups",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03824236",
    "endpoint": "measure - Number of Subjects With Any Solicited General AEs in the Booster Vaccination Groups, description - Solicited general AEs assessed are fatigue, gastrointestinal symptoms (nausea, vomiting, diarrhea and&#x2F;or abdominal pain), headache and fever.\nAny occurrence of symptom regardless of intensity grade and relationship to the vaccination.\nFever was defined as temperature equal or greater than 37.5 °C (preferably oral route measure)., timeFrame - Within 7 days after vaccination (day of vaccination and 6 subsequent days) in the booster vaccination groups",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03824236",
    "endpoint": "measure - Number of Subjects With Any Unsolicited AEs After Vaccination, in the Booster Vaccination Groups, description - An unsolicited adverse event is any untoward medical occurrence in a clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product.\nAn unsolicited adverse event is any event reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms., timeFrame - Up to 21 days after booster vaccination period (day of vaccination and 20 subsequent days), after booster vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03824236",
    "endpoint": "measure - Number of Subjects With Any Unsolicited AEs After Challenge, in All Study Groups, description - An adverse event is any untoward medical occurrence in a clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product., timeFrame - Within 29 days after challenge (day of challenge and 28 subsequent days)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03824236",
    "endpoint": "measure - Number of Subjects With AEs of Specific Interest (Potential Immune-mediated Diseases [pIMDs] and Meningitis), in All Study Groups, description - AEs of specific interest are potential immune-mediated diseases (pIMDs) and meningitis.\npIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and&#x2F;or neurologic disorders of interest which may or may not have an autoimmune etiology., timeFrame - From Day 1 up to study conclusion (Day 190)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03824236",
    "endpoint": "measure - Number of Subjects With Serious Adverse Events (SAEs) (Any, Fatal or Related to Investigational Vaccine) During the Whole Study Period, in All Study Groups, description - An SAE is any untoward medical occurrence that results in death, is life threatening, requires hospitalization or prolongation of hospitalization, results in disability&#x2F;incapacity or is a congenital anomaly&#x2F;birth defect in the offspring of a study subject., timeFrame - From Day 1 up to study conclusion (Day 190)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03824236",
    "endpoint": "measure - Number of Subjects With Abnormal Laboratory Values, description - Biochemistry (Alanine Aminotransferase [ALT], Aspartate Aminotransferase [AST] and Creatinine) and hematological (Hemoglobin, Platelets, White Blood Cells [WBC] decrease and WBC increase) laboratory values were presented according to toxicity grading scales and tabulated by group.\nGrading scale adapted from FDA guidance for industry: toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials (September 2007)., timeFrame - At screening, Day(D)1, D8, D22 (day of first parasitemia) and D50 (28 days post-challenge) for the booster vaccination groups; and at screening, D22 (day of first parasitemia) and D50 (28 days post-challenge) for the infectivity control subjects",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00349713",
    "endpoint": "measure - Antibody Response to FMP2.1 Over Time, description - Measurement of anti-AMA1 antibody titers over time, timeFrame - 90 Days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00349713",
    "endpoint": "measure - Anti-AMA1 Log Antibody Titers Over Time, description - Summary of Anti-AMA1 Log Antibody titers on days 0, 14, 30, 44, 60, 74 and 90, timeFrame - 90 Days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00349713",
    "endpoint": "measure - Geometric Mean Antibody Titers Over Time, description - Measurement of geometric mean antibody titers on days 0, 14, 30, 44, 60, 74 and 90, timeFrame - 90 Days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00349713",
    "endpoint": "measure - Subjects With 2- and 4-fold Increases in Anti-FMP2.1 Antibody Levels Over Time, description - Proportion of Subjects with 2- and 4-fold increases in Anti-FMP2.1 Antibody levels on days 14, 30, 44, 60, 74 and 90, timeFrame - 90 Days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01555255",
    "endpoint": "measure - association of placental malaria with infant birth weight, description - , timeFrame - at birth",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01555255",
    "endpoint": "measure - association of placental malaria with maternal hemoglobin, description - , timeFrame - twice during gestation and at delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01555255",
    "endpoint": "measure - accuracy of diagnostic tests at delivery, description - accuracy of malaria RDTs, peripheral blood smears and PCR performed on maternal peripheral blood to diagnose placental malaria at delivery, timeFrame - at delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02601716",
    "endpoint": "measure - Immunological outcomes, description - <ol><li>Antibody titers to other Pf proteins by ELISA</li><li>Antibody titers to Pf parasite stages by IFA</li><li>Capacity of sera from immunized volunteers to inhibit sporozoite invasion (ISI) of hepatocytes in vitro by ISI assay</li><li>Analysis of antibodies to any of the thousands of proteins in the Pf proteome using proteome array chips</li><li>Analysis of cellular immune responses against PfSPZ, Pf-infected erythrocytes and&#x2F;or synthetic peptides and&#x2F;or recombinant proteins from defined Pf proteins by multi-parameter intracellular staining (ICS) by flow cytometry</li><li>Analysis of cellular immune responses against PfSPZ, Pf-infected erythrocytes and&#x2F;or synthetic peptides and&#x2F;or recombinant proteins from defined Pf proteins by fluorospot assays</li><li>Human gene expression profiling focusing on immune response genes</li><li>Analysis of host cellular, cytokine and other host responses by Luminex or Luminex-type assays</li></ol>, timeFrame - Day of immunization till 28 days post-CHMI",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04419766",
    "endpoint": "measure - Mosquito breeding sites mapping, description - The mosquito breeding sites will be mapped using the &quot;participatory mapping&quot; approach (Dickin et al. 2014).\nCommunity generated maps will be digitized on a GIS to create a georeferenced map of community knowledge., timeFrame - continuous for the 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04419766",
    "endpoint": "measure - Prevalence of symptomatic malaria cases in the area covered by the Vinho health center, description - Malaria cases in the locality of Bebedo will be monitored through patients of all ages with suspected malaria, attending the Vinho Health Center.\nBlood will be collected, for blood-smears and PCR., timeFrame - continuous for the 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01575613",
    "endpoint": "measure - Parasite prevalence inside malaria hotspots, description - Parasite prevalence, determined by PCR, inside hotspot of malaria transmission in intervention and control clusters, timeFrame - 3 cross-sectional surveys in up to 210 days, the timing being: at enrolment; 45-75 days post enrolment (coinciding with the peak malaria transmission season) and 150-210 days post enrolment (coinciding with the end of the malaria transmission season)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01575613",
    "endpoint": "measure - Parasite prevalence in the evaluation zone as function of distance to the hotspot boundary, description - Parasite prevalence, determined by PCR, in relation to distance to the boundary of malaria hotspots in intervention and control clusters, timeFrame - 3 cross-sectional surveys in up to 210 days, the timing being: at enrolment; 45-75 days post enrolment (coinciding with the peak malaria transmission season) and 150-210 days post enrolment (coinciding with the end of the malaria transmission season)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01575613",
    "endpoint": "measure - Anopheles mosquito density, description - Indoor and outdoor anopheles mosquito density inside and outside hotspots of malaria transmission in intervention and control clusters, timeFrame - determined during fortnightly trapping, starting at enrolment and continuing until up to 210 days after enrolment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01575613",
    "endpoint": "measure - Passive case detection, description - Number of malaria cases reporting at health facilities, coming from intervention and control clusters, timeFrame - determined continuously for a period of up to 210 days after enrolment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01575613",
    "endpoint": "measure - Safety and acceptability of interventions, description - Side effects of FSAT, LLINs and IRS in targeted households, timeFrame - at a single cross-sectional survey 15-45 days after enrolment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01575613",
    "endpoint": "measure - Mosquito breeding site productivity, description - The presence and density of anopheles larvae in mosquito breeding sites in malaria hotspots in intervention and control clusters, timeFrame - determined on a weekly basis for a period of up to 210 days after enrolment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00217451",
    "endpoint": "measure - Parasite clearance time, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00217451",
    "endpoint": "measure - Fever clearance time, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00217451",
    "endpoint": "measure - PCR corrected day 28 cure rate, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01434381",
    "endpoint": "measure - To determine the antibody response to the Pfs25 protein vaccines as measured by ELISA and transmission blocking assays, and the effect on antibody responses of a third dose at four months, description - , timeFrame - ELISA testing will occur on vaccination days, 2 weeks after each vaccination, and periodically until study completion",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01624337",
    "endpoint": "measure - Cardiac safety of piperaquine as determined by QT interval prolongation, description - To document the effect on the electrocardiogram (EKG), particularly the QTc interval, in patients taking repeated monthly treatment courses of DHA-piperaquine., timeFrame - 4-5 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06294912",
    "endpoint": "measure - Number of Participants Who Experience an Adverse Event (AE), description - An AE is defined as any untoward medical occurrence associated with the use of a drug in a participant, whether or not considered drug related.\nAn AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product and does not imply any judgment about causality., timeFrame - Up to Day 45",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06294912",
    "endpoint": "measure - Number of Participants Who Discontinue Study Intervention Due to an AE, description - An AE is defined as any untoward medical occurrence associated with the use of a drug in a participant, whether or not considered drug related.\nAn AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product and does not imply any judgment about causality., timeFrame - Up to Day 13",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02532049",
    "endpoint": "measure - Immunogenicity of ChAd63 Pfs25-IMX313 when administered to healthy volunteers alone, and with MVA Pfs25-IMX313 in a prime-boost regime., description - , timeFrame - 8 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02532049",
    "endpoint": "measure - Ex-vivo efficacy of ChAd63 Pfs25-IMX313 when administered to healthy volunteers alone, and with MVA Pfs25-IMX313 in a prime-boost regime. The functional activity of the vaccine induced antibodies will be tested using membrane-feeding assays., description - , timeFrame - 8 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03278808",
    "endpoint": "measure - Safety: Solicited and unsolicited Adverse Events in each group, description - Groups will be analyzed by descriptive statistics and safety monitoring will be conducted throughout the study, timeFrame - Days 1 thru 56",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03278808",
    "endpoint": "measure - Electrocardiogram baseline vs peak concentration for AZ, description - QTcF will be analyzed for CQ&#x2F;AZ Group subjects at presumed field-effective time point (Day 11 post challenge) 6 hours after dosing, which will coincide with time to peak concentration for AZ.\nThis will be compared to baseline reading, timeFrame - Day 11 post challenge, 6 hours after dosing",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03278808",
    "endpoint": "measure - Pharmacokinetics: Cmax - comparison for CQ&#x2F;AZ-Group subjects, description - Cmax will be compared for CQ&#x2F;AZ-Group subjects who become symptomatic and parasitemic to CQ&#x2F;AZ-Group subjects who do not become parasitemic., timeFrame - Days 11 thru 15",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03278808",
    "endpoint": "measure - Pharmacokinetics: Tmax - comparison for CQ&#x2F;AZ-Group, description - Tmax will be compared for CQ&#x2F;AZ-Group subjects who become symptomatic and parasitemic to CQ&#x2F;AZ-Group subjects who do not become parasitemic., timeFrame - Days 11 thru 15",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03278808",
    "endpoint": "measure - Pharmacokentics: T½ - comparison for CQ&#x2F;AZ Group, description - T½ will be compared for CQ&#x2F;AZ-Group subjects who become symptomatic and parasitemic to CQ&#x2F;AZ-Group, timeFrame - Days 11 thru 15",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03278808",
    "endpoint": "measure - Pharmacokentics: AUC - comparison for CQ&#x2F;AZ Group, description - Area under the curve (AUC) will be compared for CQ&#x2F;AZ-Group subjects who become symptomatic and parasitemic to CQ&#x2F;AZ-Group subjects who do not become parasitemic., timeFrame - Days 11 thru 15",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00167739",
    "endpoint": "measure - Proportion of gametocytes carriers during the hospitalisation period and on days 7, 14, 21, and 28, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00167739",
    "endpoint": "measure - Parasite clearance time, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00167739",
    "endpoint": "measure - Fever clearance time, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00167739",
    "endpoint": "measure - Assessment of adverse events during the study period, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04050566",
    "endpoint": "measure - T cell repertoire, description - T cell repertoire as measured by FACS analysis, timeFrame - First 36 months of life",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02334462",
    "endpoint": "measure - Anti -Pfs25 and Anti-Pfs230 antibody levels elicited by as measured by ELISA in U.S. adults and in exposed Malian adults, description - , timeFrame - U.S. Study: D. 14,28,42,84,140,196 Mali (Safety Arm: Same as the U.S. Mali (Functional Arm): D. 14,28,42,84,140,168,182,196,210,240,300,360,420,480,540,554,568,582,610,670,730",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02793622",
    "endpoint": "measure - Prevalence of Placental Malaria by Histology, description - Any evidence of placental infection (parasites or pigment).\nNumber of participants with placental tissue positive for malaria parasites or pigment., timeFrame - Delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02793622",
    "endpoint": "measure - Prevalence of Placental Parasitemia, description - Proportion of placental blood samples positive for parasites by Loop-mediated isothermal amplification (LAMP) or microscopy, timeFrame - Delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02793622",
    "endpoint": "measure - Prevalence of Maternal Malaria, description - Maternal blood positive for malaria parasites by microscopy., timeFrame - Gestational age between 12-20 weeks (at study entry) up to delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02793622",
    "endpoint": "measure - Number of Participants With Adverse Events, description - All grade 3 and 4 adverse events, timeFrame - Starting at the time of their first study drug administration, approximately gestational age between 12-20 weeks, up to one month post-delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02793622",
    "endpoint": "measure - Prevalence of Anemia in Pregnant Women, description - hemoglobin &lt; 11 g&#x2F;dL, timeFrame - Starting at the time of their first study drug administration, approximately gestational age between 12-20 weeks, up to one month post-delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02793622",
    "endpoint": "measure - Prevalence of Anemia in Infants, description - <p>Defined as the proportion with hemoglobin &lt; 10 g&#x2F;dL measure routinely at 12, 28, and 52 weeks of age.\nNumber of cases per person year (PPY).</p><p>This is a prevalence measure but are repeated measures during infancy.\nIn other words we measured this outcome up to 3 times for each participant during infancy (at 12, 28 and 52 weeks of age).</p>, timeFrame - Birth up to 12 months of age or early termination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02793622",
    "endpoint": "measure - Prevalence of Asymptomatic Parasitemia in Pregnant Women, description - Proportion of routine monthly samples positive for parasites by microscopy and LAMP, timeFrame - Starting at the time of their first study drug administration, approximately gestational age between 12-20 weeks, up to one month post-delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02793622",
    "endpoint": "measure - Prevalence of Asymptomatic Parasitemia in Infants, description - Proportion of routine monthly samples positive for parasites by microscopy and LAMP, timeFrame - Birth up to 12 months of age or early termination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02793622",
    "endpoint": "measure - Incidence of Complicated Malaria in Infants, description - Complicated malaria defined as an episode of malaria with danger signs (any of the following: less than 3 convulsions over 24 h, inability to sit or stand, vomiting everything, unable to breastfeed or drink) or the meeting standardized criteria for severe malaria., timeFrame - Birth up to 12 months of age or early termination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02793622",
    "endpoint": "measure - Incidence of Hospital Admissions in Infants, description - Admission to the pediatric ward for any cause, timeFrame - Birth up to 12 months of age or early termination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02793622",
    "endpoint": "measure - Infant Mortality Rate, description - Any deaths occurring after birth, timeFrame - Birth up to 12 months of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01322581",
    "endpoint": "measure - serum cytokine profiles, description - Examine the relationship between age (surrogate for cumulative Pf exposure) and the gene-expression and serum cytokine profilesinduced by Pf infection., timeFrame - Triannual cross-sectional surveys and convalescence visits",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01322581",
    "endpoint": "measure - Pf-specific antibody profiles, description - Identify Pf-specific antibody profiles that are associated with malaria immunity by using a protein microarray representing 2000 Pf proteins (approx.\n40% of the Pf proteome), and determine how these profiles change with age.\nThe objective is to validate and extend findings from a preliminary study performed in the nearby village of Kambila, Mali, where a protein microarray containing approx.\n23% of the Pf proteome was used to profile Pf-specific antibody responses in children and adults before and after the 6-month malaria season, timeFrame - Triannual cross-sectional surveys and convalescence visits",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04072302",
    "endpoint": "measure - Number of subjects with adverse events, serious adverse events, and death, description - All information obtained on adverse events will be displayed by arm, treatment, and subject.\nThe number and percentage of subjects with adverse events will be tabulated by body system and preferred term with a breakdown by cohort and treatment., timeFrame - From screening to Day 43",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04072302",
    "endpoint": "measure - Pharmacokinetics of KAF156: Area under the plasma concentration-time curve from time zero to infinity (AUCinf), description - <p>KAF156 plasma concentration data will be listed by arm, subject, and sampling time point.</p><p>Descriptive summary statistics will be provided by arm and sampling time point.\nThese values will be used to calculate AUCinf</p>, timeFrame - Pre-dose, and Post-dose: 1 hour, 3 hours, 6 hours, 9 hours, 12 hours, 24 hours, 96 hours, 144 hours, 110 hours, 216 hours, 240 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04072302",
    "endpoint": "measure - Pharmacokinetics of KAF156: Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast), description - <p>KAF156 plasma concentration data will be listed by arm, subject, and sampling time point.</p><p>Descriptive summary statistics will be provided by arm and sampling time point.\nThese values will be used to calculate AUClast</p>, timeFrame - Pre-dose, and Post-dose: 1 hour, 3 hours, 6 hours, 9 hours, 12 hours, 24 hours, 96 hours, 144 hours, 110 hours, 216 hours, 240 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04072302",
    "endpoint": "measure - Pharmacokinetics of KAF156: Area under teh plasma concentration-time curve from time zero to time 24 h (AUC0-24), description - <p>KAF156 plasma concentration data will be listed by arm, subject, and sampling time point.</p><p>Descriptive summary statistics will be provided by arm and sampling time point.\nThese values will be used to calculate AUC0-24</p>, timeFrame - Pre-dose, and Post-dose: 1 hour, 3 hours, 6 hours, 9 hours, 12 hours, 24 hours, 96 hours, 144 hours, 110 hours, 216 hours, 240 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04072302",
    "endpoint": "measure - Pharmacokinetics of KAF156: Terminal elimination half life (T1&#x2F;2), description - <p>KAF156 plasma concentration data will be listed by arm, subject, and sampling time point.</p><p>Descriptive summary statistics will be provided by arm and sampling time point.\nThese values will be used to calculate T1&#x2F;2.</p>, timeFrame - Pre-dose, and Post-dose: 1 hour, 3 hours, 6 hours, 9 hours, 12 hours, 24 hours, 96 hours, 144 hours, 110 hours, 216 hours, 240 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04072302",
    "endpoint": "measure - Pharmacokinetics of KAF156: Apparent systemic clearance from plasma following oral administration (CL&#x2F;F), description - <p>KAF156 plasma concentration data will be listed by arm, subject, and sampling time point.</p><p>Descriptive summary statistics will be provided by arm and sampling time point.\nThese values will be used to calculate CL&#x2F;F</p>, timeFrame - Pre-dose, and Post-dose: 1 hour, 3 hours, 6 hours, 9 hours, 12 hours, 24 hours, 96 hours, 144 hours, 110 hours, 216 hours, 240 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04072302",
    "endpoint": "measure - Pharmacokinetics of KAF156: Apparent volume of distribution during the terminal phase following oral administration (Vz&#x2F;F), description - <p>KAF156 plasma concentration data will be listed by arm, subject, and sampling time point.</p><p>Descriptive summary statistics will be provided by arm and sampling time point.\nThese values will be used to calculate Vz&#x2F;F</p>, timeFrame - Pre-dose, and Post-dose: 1 hour, 3 hours, 6 hours, 9 hours, 12 hours, 24 hours, 96 hours, 144 hours, 110 hours, 216 hours, 240 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04072302",
    "endpoint": "measure - Pharmacokinetics of KAF156: Observed maximum plasma concentration (Cmax), description - <p>KAF156 plasma concentration data will be listed by arm, subject, and sampling time point.</p><p>Descriptive summary statistics will be provided by arm and sampling time point.\nThese values will be used to calculate Cmax</p>, timeFrame - Pre-dose, and Post-dose: 1 hour, 3 hours, 6 hours, 9 hours, 12 hours, 24 hours, 96 hours, 144 hours, 110 hours, 216 hours, 240 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04072302",
    "endpoint": "measure - Pharmacokinetics of KAF156: Time to reach the maximum concentration (Tmax), description - <p>KAF156 plasma concentration data will be listed by arm, subject, and sampling time point.</p><p>Descriptive summary statistics will be provided by arm and sampling time point.\nThese values will be used to calculate Tmax</p>, timeFrame - Pre-dose, and Post-dose: 1 hour, 3 hours, 6 hours, 9 hours, 12 hours, 24 hours, 96 hours, 144 hours, 110 hours, 216 hours, 240 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04072302",
    "endpoint": "measure - Parasite growth Kinetics by qRT-PCR, description - Parasitemia levels as measured by qRT-PCR will be summarized and displayed graphically over time., timeFrame - Pre-dose, days 7-23, Day 29, Day 43",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00453856",
    "endpoint": "measure - Determine the frequency of molecular markers for drug resistance, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05750459",
    "endpoint": "measure - Parasite (P. falciparum) density in thick blood smear., description - Parasite clearance as calculated from parasite density over time, as measured by thick blood smear such as parasite clearance half-life, total parasite clearance by Day 2, and time to 90% reduction in parasitemia., timeFrame - Day 1 through Day 5 minimum",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05750459",
    "endpoint": "measure - Time to hospital discharge., description - , timeFrame - Day 1 through 183",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02573857",
    "endpoint": "measure - Gametocytemia Clearance With DSM265, description - , timeFrame - From Drug administration up to day 28 (+&#x2F;-3 days) following inoculum",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02573857",
    "endpoint": "measure - P. Vivax Transmission, description - , timeFrame - From challenge inoculum (day 0) and up to day 28 (+&#x2F;-3 days)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02573857",
    "endpoint": "measure - Parasite Density (Parasite&#x2F;ml) Assessed by qPCR, description - , timeFrame - From From drug administration until Standard of Care administration, or up to day 28 (+&#x2F;-3 days)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02573857",
    "endpoint": "measure - Drug Concentration (PK) (ng&#x2F;ml), description - , timeFrame - From From drug administration until Standard of Care administration, or up to day 28 (+&#x2F;-3 days)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03483571",
    "endpoint": "measure - Incidence of falciparum malaria infection by RDT, description - Incidence of falciparum malaria infection by RDT, timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03483571",
    "endpoint": "measure - Incidence of vivax malaria infection by RDT, description - Incidence of vivax malaria infection by RDT, timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03483571",
    "endpoint": "measure - Incidence of mixed falciparum&#x2F;vivax malaria infection by RDT, description - Incidence of mixed falciparum&#x2F;vivax malaria infection by RDT, timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03483571",
    "endpoint": "measure - Incidence of falciparum malaria infection by usPCR, description - Incidence of falciparum malaria infection by usPCR, timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03483571",
    "endpoint": "measure - Incidence of vivax malaria infection by usPCR, description - Incidence of vivax malaria infection by usPCR, timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03483571",
    "endpoint": "measure - Incidence of mixed falciparum&#x2F;vivax malaria infection by usPCR, description - Incidence of mixed falciparum&#x2F;vivax malaria infection by usPCR, timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03483571",
    "endpoint": "measure - Seroreactivity to polymorphic malaria&#x2F;mosquito proteins, description - Seroreactivity to polymorphic malaria&#x2F;mosquito proteins, timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01921413",
    "endpoint": "measure - Monitoring the Effectiveness of Malaria Treatment by Rapid Urine Testing, description - <ul><li>Determine how quickly the cognate malaria antigens are cleared from patient urine after the prescribed three-day course of artemisinin-combination therapy (ACT);</li><li>Negative UMT results (as confirmed by microscopy during the study) will establish the effectiveness of malaria treatment and provide a means to rapidly monitor effective treatment;</li><li>Establish broader UMT utility for epidemiological monitoring in asymptomatic (afebrile) individuals.</li></ul>, timeFrame - From Day 3 of ACT administration, and followed up weekly for 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00158587",
    "endpoint": "measure - Secondary Efficacy Variables: Time to subsequent relapse episode, description - , timeFrame - 2004-March 2007",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00158587",
    "endpoint": "measure - Number of relapse episodes in 12 months, description - , timeFrame - 2004-March 2007",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00158587",
    "endpoint": "measure - Side effects &#x2F; adverse events, description - , timeFrame - 2004-March 2007",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04245033",
    "endpoint": "measure - Change in malaria incidence per 1000 population at local health facility level, description - Number of malaria episodes before and after intervention in a respective ward, timeFrame - from month 0 till month 12 of follow up",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04245033",
    "endpoint": "measure - Change from baseline in haemoglobin concentration, description - individual change in Haemoglobin before and after intervention, timeFrame - measured at month 12",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04245033",
    "endpoint": "measure - Number of participants with treatment-related adverse events, description - Number of participants with treatment-related adverse events encountered by subjects per study arm, timeFrame - through study completion, an average of 1 year&quot;",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04245033",
    "endpoint": "measure - Cardio safety profile by QTc prolongation from baseline, description - measured by ECG, timeFrame - Day 1, 2,3 and 7 after before and after dosing",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04245033",
    "endpoint": "measure - Acceptability of IPTsc in communities with high malaria endemicities, description - Through in depth interview in a guided questionnaire, timeFrame - At month 8 of implementation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01323972",
    "endpoint": "measure - Anti-hepatitis B (Anti-HB) Antibody Concentrations, description - Antibody concentrations are presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU&#x2F;mL)., timeFrame - One month post-dose 3 (Month 3)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01323972",
    "endpoint": "measure - Number of Subjects With Any and Grade 3 Solicited Local Symptoms, description - Assessed solicited local symptoms were pain, redness and swelling.\nAny = occurrence of the symptom regardless of intensity grade.\nGrade 3 pain = pain that prevented normal activity.\nGrade 3 redness&#x2F;swelling = redness&#x2F;swelling spreading beyond 20 millimeters (mm) of injection site., timeFrame - Over a 7-day (Days 0-6)post-vaccination period after each dose and across doses",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01323972",
    "endpoint": "measure - Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms, description - Assessed solicited general symptoms were drowsiness, irritability, loss of appetite, fever [defined as axillary temperature equal to or above (≥) 37.5 degrees Celsius (°C)].\nAny = occurrence of the symptom regardless of intensity grade or relationship to vaccination.\nGrade 3 loss of appetite = not eating at all.\nGrade 3 irritability = crying that could not be comforted&#x2F;prevented normal activity.\nGrade 3 drowsiness = drowsiness that prevented normal activity.\nGrade 3 fever = fever higher than (&gt;) 39.0 °C.\nRelated = symptom assessed by the investigator as related to the vaccination., timeFrame - Over a 7-day (Days 0-6) post-vaccination period after each dose and across doses",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01323972",
    "endpoint": "measure - Number of Subjects With Unsolicited Adverse Events, description - An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.\nAny was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination., timeFrame - Within the 30-day (Days 0-29) post-vaccination period",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01323972",
    "endpoint": "measure - Number of Subjects With Serious Adverse Events, description - Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability&#x2F;incapacity., timeFrame - Up to 8 months post-dose 1",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05478954",
    "endpoint": "measure - Prevalence over time of parasites with dhfr&#x2F;dhps&#x2F;pfcrt&#x2F;pfmdr1 mutations in symptomatic children with a positive diagnostic test residing in districts where SMC is implemented, description - The outcome measure to meet the secondary objective is the prevalence of molecular markers associated with SP (codons 108, 51 and 59 in dhfr and 437, 540 and 581 in dhps) and amodiaquine (codons 72-76 Pfcrt and 86, 184 and 1246 pfmdr1), as well as other markers of parasite genetic diversity, in blood samples collected from symptomatic children under five years with a positive RDT attending selected health facilities in areas with SMC., timeFrame - Five months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01280162",
    "endpoint": "measure - Number of Cambodian study subjects with reduced or null activity hepatic cytochrome P450 2D6 alleles, description - Using Polymerase Chain Reaction-based bead array assays, genotype the human hepatic CYP2D6 allele in study participants giving informed consent for genetic testing, timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01280162",
    "endpoint": "measure - Number of subjects with reduced or null hepatic CYP2D6 enzyme phenotype using activity-score A system, description - For each CYP2D6 genotype determined, use the AS-A system to assign predicted metabolism phenotype, timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00540410",
    "endpoint": "measure - PCR corrected and uncorrected clinical and parasitological cure rate, description - , timeFrame - at D28 and for the next attacks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00540410",
    "endpoint": "measure - Fever and parasitological clearance, description - , timeFrame - first attack",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00540410",
    "endpoint": "measure - Proportion of afebrile patients and proportion of patients without parasites, description - , timeFrame - at D3 for the following attacks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00540410",
    "endpoint": "measure - Clinical tolerability (incidence and intensity of recorded AE), description - , timeFrame - during the study period",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00540410",
    "endpoint": "measure - Biological tolerability (Hb, bilirubin, ALAT, Creatinine, Leukocytes, Neutrophils and platelets count), description - , timeFrame - during the study period",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00540410",
    "endpoint": "measure - Cardiac tolerability (QTc) for the first attack in patients group aged &gt;= 12 years), description - , timeFrame - at the time of the first attack",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00540410",
    "endpoint": "measure - Assessment and evolution of hearing function in patients groupe aged &gt;=12 years, description - , timeFrame - during the study period",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01231880",
    "endpoint": "measure - Risk of parasitemia, description - presence of asexual parasites on blood smear, timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01231880",
    "endpoint": "measure - Risk of hospital admissions, description - Admission of any cause, timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01231880",
    "endpoint": "measure - Risk of adverse events, description - Any untoward medical occurrence in a participant taking study medication, timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01231880",
    "endpoint": "measure - School performance, description - Average position in class as reported in the end of the year school report, timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01231880",
    "endpoint": "measure - Prevalence of anemia, description - Proportion of hemoglobin measurements &lt; 10 g&#x2F;dL., timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02658253",
    "endpoint": "measure - Proportion of volunteer with at least one Serious Adverse Event Following Immunization (SAEFI) for the entire duration of the study, description - clinical and biological SAEFI and SARI (Serious Adverse Reaction following Immunization (SARI) measured at any time during the volunteer follow-up, timeFrame - 14 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02658253",
    "endpoint": "measure - Proportion of volunteer with at least one of Adverse Event Following Immunization (AEFI) measured until 1 month post-dose 3, description - Immediate AEFI (within 1h following vaccination) as well as unrelated, Related or possibly related solicited and unsolicited AEFI, timeFrame - 3 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02658253",
    "endpoint": "measure - Proportion of volunteer with at least one Adverse Event Following Immunization (AEFI) measured between M3 and the end of the study (only phase Ia), description - Immediate AEFI (within 1h following vaccination) as well as unrelated, Related or possibly related solicited and unsolicited AEFI, timeFrame - 11 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02658253",
    "endpoint": "measure - Variation in humoral immune response to the vaccine antigen assessed by ELISA, description - The level of total IgG (g&#x2F;l): between D0 and the post-vaccination time points M1, M1+7D, M2, M2+7D, M3, M6 and M14, timeFrame - 14 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02658253",
    "endpoint": "measure - Variation in humoral immune response to the vaccine antigen assessed by ELISA, description - The level (g&#x2F;l) of the isotypic subtypes (IgG1, IgG2, IgG3, IgG4) between D0 and the post-vaccination time point M3, timeFrame - 3 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02658253",
    "endpoint": "measure - Cellular immune responses to the vaccine antigen by Elispot, description - The median number of spots by ELISpot assay, allowing the counting of IL5 and IFNg secreting cells following an ex-vivo stimulation of PBMC with the vaccine antigen at V0, and 7 days post-dose 1 and 3 (D0- D7 and M2+7D), timeFrame - 63 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02658253",
    "endpoint": "measure - Cellular immune responses to the vaccine antigen by FACS, description - CD19, IgD, CD27, CD38, CD24 and CD43 B lymphocytes subpopulations will be isolated from PBMC at D0 and M2+7D.\nThe data will be expressed for each phenotype as the median percentage of subpopulations among total CD19 B lymphocytes, timeFrame - 63 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00913146",
    "endpoint": "measure - malaria incidence in children with a positive Plasmodium falciparum PCR at baseline, description - , timeFrame - after 14 days of follow-up",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03496454",
    "endpoint": "measure - Time to Pf-NF54 parasitemia, description - Time to Pf-NF54 parasitemia after CHMI as assessed by qPCR, timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03496454",
    "endpoint": "measure - parasite growth, description - Dynamics of Pf-NF54 parasite growth from day 5 after CHMI until day 28 as assessed by qPCR, timeFrame - day 5 to day 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03496454",
    "endpoint": "measure - differences in immune responses, description - Intra and inter-group differences in cellular and humoral immune responses, timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02927145",
    "endpoint": "measure - the Humoral Immunogenicity of RH5.1&#x2F;AS01 Using Different Vaccine Doses and Vaccination Regimens., description - Antibody responses to the RH5.1 protein generated by vaccination, timeFrame - 2 weeks post final vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02927145",
    "endpoint": "measure - the Cellular Immunogenicity of RH5.1&#x2F;AS01 Using Different Vaccine Doses and Vaccination Regimens., description - T cell responses to the RH5.1 protein generated by vaccination, timeFrame - 2 weeks post final vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02927145",
    "endpoint": "measure - Immunological Readouts for Association With a Reduced Parasite Multiplication Rate., description - <p>Statistical correlation between anti-RH5 antibody responses induced by the RH5.1 vaccine and PMR.</p><p>A non-linear regression curve for all samples combined is available in the trial manuscript ; data is not presented here.</p>, timeFrame - 8 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01500980",
    "endpoint": "measure - ELISA, description - Humoral immune responses pre-&#x2F;post- ITV and subsequent challenge by binding ELISA for antibodies to P. falciparum liver stage, blood stage, and pre-erythrocytic antigens., timeFrame - up to 182 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01500980",
    "endpoint": "measure - IFN-y ELISPOT, description - Evaluation of cell-mediated immune responses to P. falciparum liver-stage and pre-erythrocytic antigens pre-&#x2F;post- ITV and subsequent challenge by (IFN-y) ELISPOT assay on peripheral blood mononuclear cells, timeFrame - up to 182 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01500980",
    "endpoint": "measure - ICS assay, description - Detection of cell-mediated immune responses pre-&#x2F;post- ITV and subsequent challenge by ICS assay for P. falciparum pre-erythrocytic antigens on peripheral blood mononuclear cells, timeFrame - up to 182 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01366534",
    "endpoint": "measure - Number of Days Until the Onset of P. Falciparum Parasitemia Following Sporozoite Challenge, description - The onset of P. falciparum parasitemia was defined by a positive blood slide., timeFrame - From day of challenge (Day 0) up to 159 days post-challenge",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01366534",
    "endpoint": "measure - Anti-circumsporozoite Protein (Anti-CS) Antibody Titers, description - Titers are presented as geometric mean titers (GMTs) and are measured in titers.\nVolunteers from Control Group did not receive any immunization, but were subjected to the sporozoite challenge, therefore GMTs for this group are presented as from Day 77., timeFrame - 28 days post-dose 1 (Day 28), 28 days post-dose 2 (Day 56), 21 days post-dose 3 (Day 77 = Day of challenge), 28 days post-challenge (Day 105), 63 days post-challenge (Day 140), 159 days post-challenge (Day 236)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01366534",
    "endpoint": "measure - Anti-hepatitis B (Anti-HBs) Antibody Titers, description - Titers are presented as geometric mean titers (GMTs) and are measured in titers.\nVolunteers from Control Group did not receive any immunization, but were subjected to the sporozoite challenge, therefore GMTs for this group are presented as from Day 77., timeFrame - 28 days post-dose 1 (Day 28), 28 days post-dose 2 (Day 56), 21 days post-dose 3 (Day 77 = Day of challenge), 28 days post-challenge (Day 105), 63 days post-challenge (Day 140), 159 days post-challenge (Day 236)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01366534",
    "endpoint": "measure - Anti-Adenovirus Type 35 (Ad35) Neutralizing Antibody Titers at Specified Time Points, description - Titers are presented as geometric mean titers (GMTs) and are measured in titers.\nVolunteers from Control Group did not receive any immunization, but were subjected to the sporozoite challenge, therefore GMTs for this group are presented as from Day 77., timeFrame - 28 days post-dose 1 (Day 28), 28 days post-dose 2 (Day 56), 21 days post-dose 3 (Day 77 = Day of challenge), 28 days post-challenge (Day 105), 63 days post-challenge (Day 140), 159 days post-challenge (Day 236)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01366534",
    "endpoint": "measure - Frequency of CS (Total CS or Repeat)-Specific CD4+ T-cells, description - CS-specific CD4+ T-cells expressing at least 2 cytokines&#x2F;activation markers between IL-2, IFN-γ, TNF-α and CD40-L are presented here.\nAnalysis was performed via intra-cellular staining (ICS) assays, data are presented as frequency of T-cells per million peripheral blood mononuclear cells (PBMCs).Volunteers from Control Group did not receive any immunization, but were subjected to the sporozoite challenge, therefore the frequency for this group is presented as from Day 77., timeFrame - 14 days post-dose 1 (Day 14), 14 days post-dose 2 (Day 42), 21 days post-dose 3 (Day 77 = Day of challenge), 28 days post-challenge (Day 105), 63 days post-challenge (Day 140), 159 days post-challenge (Day 236)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01366534",
    "endpoint": "measure - Frequency of CS (Total CS or Repeat)-Specific CD8+ T Cells, description - CS-specific CD8+ T-cells expressing at least 2 cytokines&#x2F;activation markers between IL-2, IFN-γ, TNF-α and CD40-L are presented here.\nAnalysis was performed via intra-cellular staining (ICS) assays, data are presented as frequency of T-cells per million peripheral blood mononuclear cells (PBMC).\nVolunteers from Control Group did not receive any immunization, but were subjected to the sporozoite challenge, therefore the frequency for this group is presented as from Day 77., timeFrame - 14 days post-dose 1 (Day 14), 14 days post-dose 2 (Day 42), 21 days post-dose 3 (Day 77 = Day of challenge), 28 days post-challenge (Day 105), 63 days post-challenge (Day 140), 159 days post-challenge (Day 236)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01366534",
    "endpoint": "measure - Frequency of HBs-specific CD4+ T-cells, description - HB-specific CD4+ T-cells expressing at least 2 cytokines&#x2F;activation markers between IL-2, IFN-γ, TNF-α and CD40-L are presented here.\nAnalysis was performed via intra-cellular staining (ICS) assays, data are presented as frequency of T-cells per million peripheral blood mononuclear cells (PBMCs).\nVolunteers from Control Group did not receive any immunization, but were subjected to the sporozoite challenge, therefore the frequency for this group is presented as from Day 77., timeFrame - 14 days post-dose 1 (Day 14), 14 days post-dose 2 (Day 42), 21 days post-dose 3 (Day 77 = Day of challenge), 28 days post-challenge (Day 105), 63 days post-challenge (Day 140), 159 days post-challenge (Day 236)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01366534",
    "endpoint": "measure - Frequency of CS-specific T-cells Producing IFN-γ, description - The analysis was performed via Enzyme-Linked Immunospot (ELISPOT) full length assay.\nData are presented as the number of spots per million peripheral blood mononuclear cells (PBMCs).\nVolunteers from Control Group did not receive any immunization, but were subjected to the sporozoite challenge, therefore the frequency for this group is presented as from Day 77., timeFrame - 14 days post-dose 1 (Day 14), 14 days post-dose 2 (Day 42), 21 days post-dose 3 (Day 77 = Day of challenge), 28 days post-challenge (Day 105), 63 days post-challenge (Day 140), 159 days post-challenge (Day 236)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01366534",
    "endpoint": "measure - Frequency of CS-specific T-cells Producing IFN-γ, description - The analysis was performed via Enzyme-Linked Immunospot (ELISPOT) N-terminal assay.\nData are presented as the number of spots per million peripheral blood mononuclear cells (PBMCs)., timeFrame - 14 days post-dose 1 (Day 14)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01422954",
    "endpoint": "measure - Development of parasitemia as measured by PCR, description - , timeFrame - 21 days after challenge (day 239 of study)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01422954",
    "endpoint": "measure - Frequency of signs or symptoms in study groups, description - , timeFrame - Day 0 - day 358 of study",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01422954",
    "endpoint": "measure - Cellular immune responses between study groups, description - , timeFrame - Day 0 -day 358 of study",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01422954",
    "endpoint": "measure - Humoral immune responses between study groups, description - , timeFrame - Day 0 - 358",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01857869",
    "endpoint": "measure - Time to Onset of P. Falciparum Parasitemia Infection Defined by a Positive Blood Slide, Following Sporozoite Challenge, description - The time to onset was expressed in days.\nThe definition of malaria infection for primary and secondary efficacy outcomes is the appearance of asexual blood stage P. falciparum parasites detected by blood slide at any time post challenge&#x2F;rechallenge up to 28 days., timeFrame - Up to 28 days post-challenge (Study Day 245)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01857869",
    "endpoint": "measure - Number of Subjects With Plasmodium Falciparum Parasitemia Defined by a Positive Blood Slide, Following Sporozoite Rechallenge, description - The definition of malaria infection for primary and secondary efficacy outcomes is the appearance of asexual blood stage P. falciparum parasites detected by blood slide at any time post challenge&#x2F;rechallenge up to 28 days., timeFrame - Up to 28 days post rechallenge (Booster Phase Day 49)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01857869",
    "endpoint": "measure - Time to Onset of P. Falciparum Parasitemia Infection Defined by a Positive Blood Slide, Following Sporozoite Rechallenge, description - The time to onset was expressed in days.\nThe definition of malaria infection for primary and secondary efficacy outcomes is the appearance of asexual blood stage P. falciparum parasites detected by blood slide at any time post challenge&#x2F;rechallenge up to 28 days., timeFrame - Up to 28 days post rechallenge (Booster Phase Day 49)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01857869",
    "endpoint": "measure - Anti-circumsporozoite (Anti-CS) Repeat Region Antibody Concentrations, description - Anti-CS antibody concentrations were determined by Enzyme Linked Immunosorbent Assay (ELISA) and expressed as EU&#x2F;mL., timeFrame - 7 days before vaccination (D-7), post-dose 1 at Day 28, post-dose 2 at Days 42, 56, 98, 196, at DoC Primary Phase (PP) (Day of CHMI = Day 217), at DoC PP (Day 217) + 7, 14, 28, 42, 56, 70, 84, 159 days (Days 224, 231, 245, 259, 273, 287, 301, 376).",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01857869",
    "endpoint": "measure - Anti-CS Repeat Region Antibody Concentrations for the Rechallenge Phase, description - Anti-CS antibody concentrations were determined by Enzyme Linked Immunosorbent Assay (ELISA) and expressed as EU&#x2F;mL., timeFrame - At Day 0 of rechallenge (pre-booster dose) and at DoC PP (Day 217 = Day of rechallenge)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01857869",
    "endpoint": "measure - Frequency of CS Repeat and T-cell Epitope (RT)-Specific Cluster of Differentiation 4 (CD4) T-cells, description - Frequency of Cluster of Differentiation 4 (CD4) polypositives T-cells with at least 2 cytokines&#x2F;activation markers between CD40-Ligand (CD40-L), interferon gamma (INF-g), interleukin-2 (IL-2) and tumor necrosis factor-alpha (TNF-a) was assessed for peripheral blood mononuclear cells (PBMC) with intracellular cytokine staining (ICS)., timeFrame - 7 days before vaccination (D-7), post-dose 1 at Day 14, post-dose 2 at Day 42, at DoC PP (Day of CHMI = Day 217), at DoC PP (Day 217) + 7, 28, 84, 159 days (Days 224, 245, 301, 376).",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01857869",
    "endpoint": "measure - Frequency of CS Repeat and T-cell Epitope (RT)-Specific CD8 T-cells, description - Frequency of CD8 polypositives T-cells with at least 2 cytokines&#x2F;activation markers between CD40-L, INF-g, IL-2 and TNF-a was assessed for PBMC with ICS., timeFrame - 7 days before vaccination (D-7), post-dose 1 at Day 14, post-dose 2 at Day 42, at DoC PP (Day of CHMI = Day 217), at DoC PP (Day 217) + 7, 28, 84, 159 days (Days 224, 245, 301, 376).",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01857869",
    "endpoint": "measure - Antibody Concentrations Against Hepatitis B Surface Antigen (Anti-HBs), description - Anti-HBs antibody concentrations were determined by Chemiluminometric Immunoassay (CLIA) and expressed as miliinternation units per mililier (mIU&#x2F;mL)., timeFrame - 7 days before vaccination (D-7), post-dose 1 at Day 28, post-dose 2 at Days 42, 56, 98, 196 after first dose, at DoC PP (Day of CHMI = Day 217), at DoC PP (Day 217)+ 7, 14, 28, 42, 56, 70, 84, 159 days (Days 224, 231, 245, 259, 273, 287, 301, 376).",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01857869",
    "endpoint": "measure - Anti-HBs Antibody Concentrations for Rechallenge Phase, description - Anti-HBs antibody concentrations were determined by Chemiluminometric Immunoassay (CLIA)., timeFrame - At Day 0 of rechallenge (pre-booster dose) and at DoC PP (Day 217 = Day of rechallenge)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01857869",
    "endpoint": "measure - Anti-CS Repeat Region Immunoglobulin G (IgG) Avidity Index for the Challenge Phase, description - The avidity index percentage was calculated by anti-CS repeat region concentration under chaotropic reagent&#x2F;anti-CS repeat region concentration without chaotropic reagent.\nThe median and inter-quartile (Q1 and Q3) range was reported at the prespecified time-points., timeFrame - Post-dose 1 at Day 28, post-dose 2 at Days 56, and 196, DoC PP (DoC = the day of CHMI, Day 217), DoC PP (Day 217) + 84 days (Day 301) and DoC PP (Day 217) +159 days (Day 376)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01857869",
    "endpoint": "measure - Anti-CS Repeat Region IgG Avidity Index for the Rechallenge Phase, description - The avidity index percentage was calculated by anti-CS repeat region titer under chaotropic reagent&#x2F;anti-CS repeat region titer without chaotropic reagent.\nThe median and inter-quartile (Q1 and Q3) range was reported at the prespecified time-points., timeFrame - Pre-booster dose (Booster phase Day 0) and at DoC Booster&#x2F;rechallenge phase (Day of Controlled Human Malaria Infection - Day 21)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01857869",
    "endpoint": "measure - Number of Subjects With Any and Grade 3 Solicited Local Symptoms, description - Assessed solicited local symptoms were pain, redness and swelling.\nAny = occurrence of the symptom regardless of intensity grade.\nGrade 3 pain = significant pain at rest, that prevented normal activity.\nGrade 3 redness&#x2F;swelling = redness&#x2F;swelling spreading beyond 100 millimeters (mm) of injection site., timeFrame - Within the 7-day (Days 0-6) post-vaccination period following each dose and across doses",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01857869",
    "endpoint": "measure - Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms, description - Assessed solicited general symptoms were fatigue, gastrointestinal symptoms (nausea, vomiting and&#x2F;or abdominal pain), headache and fever [defined as axillary temperature equal to or above (≥) 38.0 degrees Celsius (°C)].\nAny = occurrence of the symptom regardless of intensity grade.\nGrade 3 symptom = symptom that prevented normal activity.\nGrade 3 fever = fever ≥ 39.0 °C.\nRelated = symptom assessed by the investigator as related to the vaccination., timeFrame - Within the 7-day (Days 0-6) post-vaccination period following each dose and across doses",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01857869",
    "endpoint": "measure - Number of Subjects With Any and Grade 3 Solicited Local Symptoms, description - Assessed solicited local symptoms were pain, redness and swelling.\nAny = occurrence of the symptom regardless of intensity grade.\nGrade 3 pain = pain that prevented normal activity.\nGrade 3 redness&#x2F;swelling = redness&#x2F;swelling spreading beyond 100 millimeters (mm) of injection site., timeFrame - Within the 7-day (Days 0-6) post- booster vaccination period",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01857869",
    "endpoint": "measure - Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms, description - Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache and fever [defined as axillary temperature equal to or above (≥) 38.0 degrees Celsius (°C)].\nAny = occurrence of the symptom regardless of intensity grade.\nGrade 3 symptom = symptom that prevented normal activity.\nGrade 3 fever = fever ≥ 39.0 °C.\nRelated = symptom assessed by the investigator as related to the vaccination., timeFrame - Within the 7-day (Days 0-6) post- booster vaccination period",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01857869",
    "endpoint": "measure - Number of Subjects With Any Unsolicited Adverse Events (AEs), description - An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.\nAny was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination., timeFrame - Within 30-days (Days 0-29) post-primary vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01857869",
    "endpoint": "measure - Number of Subjects With Any Unsolicited Adverse Events (AEs), description - An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.\nAny was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination., timeFrame - Within 30-days (Days 0-29) post- booster vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01857869",
    "endpoint": "measure - Number of Subjects With Any Unsolicited Adverse Events (AEs), description - An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.\nAny was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination., timeFrame - Within 30-days (Days 0-29) post-first CHMI",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01857869",
    "endpoint": "measure - Number of Subjects With Any Unsolicited Adverse Events (AEs), description - An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.\nAny was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination., timeFrame - Within 30-days (Days 0-29) post- second CHMI",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01857869",
    "endpoint": "measure - Number of Subjects With Serious Adverse Events (SAEs), description - Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability&#x2F;incapacity., timeFrame - From study start to end of Primary Phase (Study Day 245)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01857869",
    "endpoint": "measure - Number of Subjects With Serious Adverse Events (SAEs), description - Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability&#x2F;incapacity., timeFrame - During the entire study period (Up to Day 105 of Booster Phase)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04445103",
    "endpoint": "measure - Endothelial dysfunction, description - Elevated markers of endothelial dysfunction, timeFrame - 2020-2023",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04445103",
    "endpoint": "measure - Inflammation, description - Elevated proinflammatory markers, timeFrame - 2020-2023",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01939886",
    "endpoint": "measure - the number of individuals with gametocytes after treatment with AL or MQ-AS, description - gametocyte carriage will be determined by microscopy and molecular QT-NASBA to generate gametocyte prevalence estimates on follow-up days and the mean duration of gametocyte carriage in days., timeFrame - 42 days follow-up",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06036030",
    "endpoint": "measure - Parasite clearence times, description - parasite reduction ratio, timeFrame - 0, 14, 28, and 42 days post-treatment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06036030",
    "endpoint": "measure - Fever clearance time, description - time taken for the axilla temperature to fall below 37.5°C in patients who were febrile at inclusion, timeFrame - 0, 14, 28, and 42 days post-treatment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00522132",
    "endpoint": "measure - Time to total clearance of asexual parasites (PC100), description - , timeFrame - after study drug administration",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00522132",
    "endpoint": "measure - Time to 99% reduction of asexual parasites (PC99), description - , timeFrame - after study drug administration",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00522132",
    "endpoint": "measure - Time to 90% reduction of asexual parasites (PC90), description - , timeFrame - after study drug administration",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00522132",
    "endpoint": "measure - PCR corrected Adequate Clinical and Parasitological Response on day 28, description - , timeFrame - on day 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00522132",
    "endpoint": "measure - plasma concentrations of artesunate following intravenous administration, description - , timeFrame - after study drug administration",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04716387",
    "endpoint": "measure - Vectors species composition, description - All Anopheles mosquitoes sampled during human landing collections (HLC) will be identified morphologically to species group, timeFrame - August 2020 to December 2022",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04716387",
    "endpoint": "measure - Species-specific population densities, description - Based on Anopheles mosquitoes sampled during HLCs., timeFrame - August 2020 to December 2022",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04716387",
    "endpoint": "measure - Biting behaviors, description - Based on Anopheles mosquitoes sampled during HLCs., timeFrame - August 2020 to December 2022",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04716387",
    "endpoint": "measure - Estimated entomological inoculation rates, description - Based on Anopheles mosquitoes sampled during HLCs., timeFrame - August 2020 to December 2022",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04716387",
    "endpoint": "measure - Insecticide resistance profile, description - Measurement of kdr and ace-1 mutation frequencies, WHO tube bioassays at minimum and CDC bottle bioassays to characterize insecticide resistance intensity, timeFrame - August 2020 to December 2022",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04716387",
    "endpoint": "measure - Parasite prevalence in children 6-59 months, description - Prevalence calculated from cross-sectional surveys conducted during the peak transmission season., timeFrame - August 2020, August 2021, August 2022",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04716387",
    "endpoint": "measure - Net use characteristics, description - Mapping the social determinants of intervention impact and transmission risk as the intersection of time at risk of mosquito blood feeding and human activities not under the protection of an ITN by gathering data on ITN uptake through structured observations, timeFrame - August 2020 to December 2022",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04716387",
    "endpoint": "measure - Cost-effectiveness measures, description - Estimated cost and cost-effectiveness through measurements of delivery and commodity costs collected through interviews and written questionnaires of New Nets Project stakeholders and representatives of the NMCP, implementing partners, procurement agencies, and manufacturing firms, in combination with effect estimates for interventions., timeFrame - August 2020 to December 2022",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04716387",
    "endpoint": "measure - Physical durability monitoring, description - Assess the physical durability of ITNs after two years of use., timeFrame - January 2021, July 2021, June 2022",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04716387",
    "endpoint": "measure - Insecticide durability monitoring, description - Assess the insecticidal effectiveness of ITNs after two years of use., timeFrame - January 2021, July 2021, June 2022",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04704830",
    "endpoint": "measure - Protective efficacy of R21&#x2F;Matrix-M against clinical malaria caused by P.falciparum, in 5-36 month old children living in a malaria endemic area, following the primary vaccination series across both vaccination regimes and following booster vaccinations., description - <ul><li>Efficacy against clinical malaria following the primary series, regardless of vaccination regime.</li><li>Efficacy against clinical malaria after each booster vaccination.\nThis will be assessed for the seasonal vaccination regime, standard vaccination regime and across both vaccination regimes together.</li></ul><p>Clinical malaria is defined (according to the primary case definition) as the presence of axillary temperature ≥37.5°C and&#x2F; or history of fever within the last 24 hours, and P. falciparum asexual parasitaemia &gt;5000 parasites&#x2F;μL.</p>, timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04704830",
    "endpoint": "measure - Efficacy of R21&#x2F;Matrix-M against asymptomatic P.falciparum malaria infection in either vaccination regime, following the primary vaccination series and following each booster vaccination., description - Asymptomatic malaria, defined by: Presence of axillary temperature &lt;37.5°C and absence history of fever within the last 24 hours AND P. falciparum asexual parasitaemia &gt; 0 parasites&#x2F;μL., timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04704830",
    "endpoint": "measure - Efficacy of R21&#x2F;Matrix-M against severe malaria disease in either vaccination regime, following the primary vaccination series and following each booster vaccination., description - <p>Severe malaria, defined by the primary case definition:</p><p>Presence of P. falciparum asexual parasitaemia &gt; 5000 parasites&#x2F;μL</p><p>AND one of more of the following criteria of disease severity:</p><ul><li>Prostration</li><li>Respiratory distress</li><li>Blantyre coma score ≤ 2</li><li>Seizures: 2 or more</li><li>Hypoglycaemia &lt; 2.2 mmol&#x2F;L</li><li>Acidosis BE ≤-10.0 mmol&#x2F;L</li><li>Lactate ≥ 5.0 mmol&#x2F;L</li><li>Anaemia &lt; 5.0 g&#x2F;dL AND without any of the following diagnosis of co-morbidity</li><li>Pneumonia (confirmed by X-ray)</li><li>Meningitis (confirmed by Cerebrospinal Fluid examination)</li><li>Sepsis (with Positive blood culture)</li><li>Gastroenteritis with dehydration</li></ul>, timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04704830",
    "endpoint": "measure - Efficacy of R21&#x2F;Matrix-M against clinical malaria according to different transmission settings (seasonal and standard vaccination regimes)., description - Clinical malaria is defined (according to the primary case definition) as the presence of axillary temperature ≥37.5°C and&#x2F; or history of fever within the last 24 hours, and P. falciparum asexual parasitaemia &gt;5000 parasites&#x2F;μL., timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04704830",
    "endpoint": "measure - Efficacy of R21&#x2F;Matrix-M against incident severe anaemia and the need for blood transfusion in both vaccination regimes following the primary vaccination series and each booster vaccination., description - <p>Incident severe anaemia according to the primary case definition: Documented Hb &lt;5.0 g&#x2F;dL identified at clinical presentation in association with P. falciparum asexual parasitaemia &gt; 5000 parasites&#x2F;μL.</p><p>Incident severe anaemia according to the secondary case definitions:</p><ul><li>Documented Hb &lt;5.0 g&#x2F;dL identified at clinical presentation in association with P. falciparum asexual parasitaemia &gt; 0 parasites&#x2F;μL</li><li>Documented Hb &lt;5.0 g&#x2F;dL identified at clinical presentation and requirement for a blood transfusion</li><li>Documented Hb &lt;5.0 g&#x2F;dL identified at clinical presentation</li></ul><p>Prevalent severe anaemia defined as: Documented Hb &lt;5.0 g&#x2F;dL</p><p>Prevalent moderate anaemia defined as: Documented Hb &lt;8.0 g&#x2F;dL</p><p>Prevalent mild anaemia defined as: Documented Hb &lt;10.0 g&#x2F;dl</p>, timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04704830",
    "endpoint": "measure - Efficacy of R21&#x2F;Matrix-M against malaria hospitalisation following the primary vaccination series and each booster vaccination., description - <p>Malaria hospitalisation defined by the primary case definition: Medical hospitalisation with confirmed P. falciparum asexual parasitaemia &gt; 5000 parasites&#x2F;μL.</p><p>Malaria hospitalisation defined by the secondary case definition: Medical hospitalisation which, in the judgement of the principal investigator, P. falciparum was the sole reason or major contributing factor.</p>, timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04704830",
    "endpoint": "measure - Safety, reactogenicity, humoral immunogenicity and efficacy of R21&#x2F;Matrix-M as a single-vial formulation, compared with the two-vial formulation., description - <p>Safety and reactogenicity of the single-vial formulation will be assessed as per the primary safety outcome (#2).</p><p>Efficacy of the single-vial formulation will be assessed as per the primary efficacy outcome (#1).</p><p>Immunogenicity will be assessed as per the secondary immunogenicity outcome (#11).</p>, timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04704830",
    "endpoint": "measure - Safety and reactogenicity (including Serious adverse events (SAEs) and any deaths) following each booster vaccination and for the duration of the study., description - Safety as per the primary outcome measures for safety but to be assessed post boost vaccinations., timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04704830",
    "endpoint": "measure - Humoral immunogenicity by anti-CSP antibody concentrations measured 12 months after completion of the primary series of 3 vaccinations and 12 months after each booster vaccination., description - <ul><li>Comparison of immunogenicity (antibody responses to CSP) in the R21&#x2F;Matrix-M vaccination groups with those in the control vaccine groups and the durability of responses</li><li>Serology to quantify antibodies to the vaccine components (regions of the CS antigen including the NANP repeat region and other elements of the protein as well as antibodies to HBsAg).</li></ul>, timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04704830",
    "endpoint": "measure - School age booster extension: Efficacy, description - <ul><li>Efficacy against clinical malaria at 6, 12 and 18 months after receiving a school age booster.</li><li>Efficacy against asymptomatic P. falciparum infection at 6, 12, 18 and 24 months after receiving a school age booster.</li><li>Efficacy against severe malaria disease at 12 and 24 months after receiving a school age booster.</li><li>Efficacy against severe anaemia at 12 and 24 months after receiving a school age booster.</li></ul>, timeFrame - 6, 12, 18 and 24 months after receiving a school age booster",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04704830",
    "endpoint": "measure - School age booster extension: Safety and reactogenicity, description - Safety and reactogenicity (including Serious adverse events (SAEs) and any deaths) following the school age booster vaccination and for the duration of the study., timeFrame - Two years after school age booster",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04704830",
    "endpoint": "measure - School age booster: Immunogenicity, description - <ul><li>To evaluate immunogenicity, magnitude, quality and functionality of induced antibodies to the circumsporozoite protein, antibodies to HBsAg and other exploratory immunological endpoints in all vaccination groups.</li><li>To assess vaccine-induced potential immune correlates of vaccine efficacy.</li></ul>, timeFrame - 28 days post school age booster, 1 year post school age booster and 2 years post school age booster",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04704830",
    "endpoint": "measure - School age booster extension: Impact, description - <ul><li>Assessment of impact of a school age booster of R21&#x2F;Matrix-M on school attendance.</li><li>Assessment of public health impact and cost-effectiveness of a school-age booster through modelling.</li></ul>, timeFrame - 2 years after school age booster",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00214643",
    "endpoint": "measure - Safety and tolerability of the two treatments during the entire study period, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00214643",
    "endpoint": "measure - Parasite clearance time, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00214643",
    "endpoint": "measure - Fever clearance time, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04944966",
    "endpoint": "measure - Number of participants of group 2 with Adequate Clinical and Parasitological Response (ACPR), description - Absence of parasitaemia on day 28 irrespective of axillary temperature without previously meeting any of the criteria of Early Treatment Failure or Late Clinical Failure or Late Parasitological Failure., timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01052584",
    "endpoint": "measure - Determine Early Treatment Failures, Late Clinical Failures, Late Parasitological Failures, or Adequate Clinical and Parasitological Response during 42 days of follow-up for P. falciparum. Measure the treatment failure of AL and CQ for P. vivax durin, description - , timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02298140",
    "endpoint": "measure - Number of fever patients who received diagnostic test, description - 1) Proportion of fever patients receiving a diagnostic test to rule out&#x2F;in malaria as per national guidelines., timeFrame - 10 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02298140",
    "endpoint": "measure - Number of confirmed malaria patients treated with recommended antimalaria, description - Proportion of malaria patients (fever with a positive test routine and gold standard) treated according to malaria treatment guidelines., timeFrame - 10months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02298140",
    "endpoint": "measure - Number of malaria patients who received correct dose of ACT, description - Proportion of patients who receive a correct dose of ACT based on age and&#x2F;or body weight for malaria treatment, timeFrame - 10 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02298140",
    "endpoint": "measure - Number of patients with a negative malaria test who did not receive antimalaria, description - Proportion of negative tested patients who did not receive antimalarials, timeFrame - 10 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02298140",
    "endpoint": "measure - Number of afebrile patients who are tested for malaria, description - Proportion of non-febrile (no fever or no history of fever within 48 hours) patients who are tested for malaria, timeFrame - 10 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02298140",
    "endpoint": "measure - Number of patients who received counselling messages, description - Proportion of patients who received recommended counseling messages, timeFrame - 10 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02298140",
    "endpoint": "measure - Number of patients who completed antimalaria doses as instructed, description - Proportion of complete and incomplete adherent patients, as prescribed by health worker., timeFrame - 10 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01743417",
    "endpoint": "measure - Working memory, description - Working memory will be measured by the Kaufman Assessment Battery for Children second edition, timeFrame - Measured at 12 months post-intervention",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04105855",
    "endpoint": "measure - Estimate of the frequency of parasitemia due to non-falciparum malaria, description - The frequency of parasitemia due to non-falciparum malaria and seroprevalence of parasitic infections due to organisms other than Plasmodium (e.g.\nfilarial spp., Schistosoma spp., soil-transmitted helminths) in these cohorts, timeFrame - 3 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01703884",
    "endpoint": "measure - The proportion of women with peripheral positive malaria infection at delivery, description - The proportion of women with peripheral positive malaria infection at delivery (defined via detection of asexual stages of P. f alciparum by microscopy), timeFrame - 9 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01265407",
    "endpoint": "measure - Malaria rates (episodes&#x2F;per year) in individuals and communities and by seasonality. Clinical episodes will be determined using RDT among febrile participants., description - to estimate the proportion of participants from the household surveillance that seek care for malaria in health facilities, timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01265407",
    "endpoint": "measure - Determine the rates of asymptomatic parasitemia among afebrileparticipants (determined by malaria smears and PCR)., description - to coordinate the community based surveillance with a facility based surveillance in health clinics servicing the selected communities, timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01265407",
    "endpoint": "measure - The prevalence of enlarged palpable spleen (splenomegaly) in children, description - to investigate the prevalence of sickle cell trait,glucose-6 phosphate dehydrogenase deficiency and hemoglobinopathies and their relationship to severe clinical malaria per year in children and adults., timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00290420",
    "endpoint": "measure - proportions of mothers with placental plasmodial infection, description - , timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00290420",
    "endpoint": "measure - proportions of mothers with moderate to severe anaemia (&lt;8g&#x2F;dl) at delivery, description - , timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00290420",
    "endpoint": "measure - maternal haemoglobin rate at delivery, description - , timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00290420",
    "endpoint": "measure - proportions of women with parasitaemia during pregnancy and at delivery, description - , timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00290420",
    "endpoint": "measure - mean parasites densities of women with parasitaemia during pregnancy and at delivery, description - , timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00290420",
    "endpoint": "measure - proportions of children with low birthweight (&lt;2,500 grams), description - , timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00290420",
    "endpoint": "measure - mean birthweight, description - , timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00290420",
    "endpoint": "measure - proportions of preterm deliveries, description - , timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03084289",
    "endpoint": "measure - Identify potential biomarkers of vaccine deposition in the liver (biomolecules measured will include: liver enzymes and plasma cytokine levels)., description - Changes in potential biomarkers before and after vaccination will be assessed to identify markers biologically consistent with hepatocyte perturbation and inflammation.\nSome of the methodology will include: clotting assays (e.g.\nD-dimer levels), peripheral blood gene transcriptional profiling and some exploratory proteomic analysis of urine and plasma., timeFrame - 3 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03084289",
    "endpoint": "measure - Assess changes in immune response before and after vaccination using exploratory immunological assays., description - Measures of immunogenicity generated in malaria naïve individuals of subcutaneous and intravenous administration of ChAd63 ME-TRAP, may include: ELISPOT (to enumerate IFN-γ producing T cells), flow cytometry and intracellular cytokine staining (to enumerate and functionally characterise immune cell populations such as T cells (e.g.\nCD4+ and CD8+) and B cells) and possibly gene expression profiling., timeFrame - 3 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06962319",
    "endpoint": "measure - Efficacy - ACPR Day 28, description - PCR-adjusted Adequate clinical and parasitological response by Day 28, timeFrame - Day 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05019729",
    "endpoint": "measure - Number of Participants Who Developed Plasmodium Falciparum (P. Falciparum) Parasitemia Following Controlled Human Malaria Infection (CHMI) Challenge, description - Parasitemia as determined by polymerase chain reaction (PCR) up to day 21 following CHMI to determine whether IV or SC administration of L9LS mediates protection against infectious P. falciparum following CHMI, timeFrame - Up to 21 days after CHMI",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05019729",
    "endpoint": "measure - Pharmacokinetic (PK) Parameters of L9LS: Maximum Observed Serum Concentration (Cmax), description - Serum concentrations of L9LS by dose group following a single administration.\nCmax is the peak serum concentration that L9LS achieves after it has been administered; it is determined as a maximum value on the summary pharmacokinetic (PK) curve for each study group., timeFrame - Baseline through 24 weeks after L9LS product administration",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05019729",
    "endpoint": "measure - Pharmacokinetic (PK) Parameters of L9LS: Time to Reach Maximum Observed Serum Concentration (Tmax), description - Tmax is the time it takes to reach Cmax of L9LS after it has been administered; it is determined based on the summary PK curve for each dose group., timeFrame - Baseline through 24 weeks after L9LS product administration",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05019729",
    "endpoint": "measure - Pharmacokinetic (PK) Parameters of L9LS: Beta Half-life (T1&#x2F;2b), description - Beta half-life (T1&#x2F;2b) is being reported for this study.\nBeta half-life (T1&#x2F;2b) is the time required for half of the L9LS product to be eliminated from the serum., timeFrame - Baseline through 24 weeks after L9LS product administration",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05019729",
    "endpoint": "measure - Pharmacokinetic (PK) Parameters of L9LS: Clearance (CL) Following IV Administration, description - Rate of L9LS elimination divided by the plasma L9LS concentration; determined based on the summary pharmacokinetic (PK) curve for each IV group., timeFrame - Baseline through 24 weeks after L9LS product administration",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05019729",
    "endpoint": "measure - Pharmacokinetic (PK) Parameters of L9LS: Clearance (CL&#x2F;F) Following SC or IM Administration, description - Rate of L9LS elimination divided by the plasma L9LS concentration; determined based on the summary pharmacokinetic (PK) curve for each SC and IM group.\nClearance following a SC or IM administration is calculated as Clearance (CL)&#x2F;Bioavailability (F)., timeFrame - Baseline through 24 weeks after L9LS product administration",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05019729",
    "endpoint": "measure - Pharmacokinetic (PK) Parameters of L9LS: Volume of Distribution at Steady-State (Vss) Following IV Administration, description - Theoretical volume that would be necessary to contain the total amount of administered drug at the same concentration as observed in plasma.\nIt represents the degree to which a drug is distributed in body tissue rather than the plasma and calculated based in the pharmacokinetic (PK) curve for each IV group., timeFrame - Baseline through 24 weeks after L9LS product administration",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05019729",
    "endpoint": "measure - Pharmacokinetic (PK) Parameters of L9LS: Volume of Distribution at Steady-State (Vss&#x2F;F) Following SC or IM Administration, description - Theoretical volume that would be necessary to contain the total amount of administered drug at the same concentration as observed in plasma.\nIt represents the degree to which a drug is distributed in body tissue rather than the plasma and calculated based in the PK curve for each SC and IM group.\nVolume of distribution at steady-state (Vss) following a SC or IM administration is calculated as Volume of distribution at steady-state (Vss)&#x2F;Bioavailability (F)., timeFrame - Baseline through 24 weeks after L9LS product administration",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01002183",
    "endpoint": "measure - To determine the viability and infectivity of gametocytes induced by the co-administration of fosmidomycin with clindamycin or with clindamycin plus artesunate to adult subjects with acute uncomplicated Plasmodium falciparum malaria., description - , timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00158561",
    "endpoint": "measure - Day 28 slide clearance rate defined as the number of treated patients with clearance of parasitaemia within 14 days of starting treatment, without subsequent recrudescence up to day 28., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00158561",
    "endpoint": "measure - Day 14 clinical failure rate (presence of symptoms of malaria in the presence of parasitaemia)., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00158561",
    "endpoint": "measure - Day 28 clinical failure rate., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00158561",
    "endpoint": "measure - Adverse events., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00158561",
    "endpoint": "measure - Haemoglobin level increased by at least 1g&#x2F;dl by day 14., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00158561",
    "endpoint": "measure - Clearance of gametocytaemia by day 3, 7, and 14., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00158561",
    "endpoint": "measure - Number of subsequent malaria episodes in next 6 months. It is assumed that the population of each treatment arm is equally likely to be re-infected in this time scale. Therefore any measurable difference in number of subsequent episodes between treatment, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00158561",
    "endpoint": "measure - In G6PD deficient patients the change in mean haemoglobin., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03512678",
    "endpoint": "measure - Reliability (comparison between 2 devices and repeat reads), description - , timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03512678",
    "endpoint": "measure - Cost-effectiveness as compared with routine methods, description - , timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03512678",
    "endpoint": "measure - Prevalence of parasite genetic markers of resistance to antimalarials by location and time period, description - , timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03512678",
    "endpoint": "measure - Prevalence of parasites carrying deletions of pfhrp2&#x2F;3 genes by location and time period, description - , timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02083068",
    "endpoint": "measure - Evolution of antibody titers, description - Follow up every 2 months (month 0, 2, 4 and 6) until the end of the trial will be done to assess the evolution of P. vivax antibody titers., timeFrame - At months 0, 2, 4 and 6 of the trial",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02083068",
    "endpoint": "measure - Specific cytokine induction, description - Specific cytokine induction will be measured by IFN- γ, TNF-α, IL-2; IL- 4, IL-6, IL-10, timeFrame - At months 0, 2, 4 and 6 of the trial",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02083068",
    "endpoint": "measure - Changes on vaccine biological security, description - Changes on vaccine biological security will be measured by renal, hepatic and hematologic function and pregnancy test., timeFrame - On the day next to immunization and 1 or 2 weeks before the next immunization",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02083068",
    "endpoint": "measure - Antibody functionality in vitro through inhibition of sporozoite invasion (ISI) to Hep-G2 cells., description - Antibody functionality will be tested in vitro through essays of inhibition of sporozoite invasion (ISI) to Hep-G2 cells., timeFrame - Every 2 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02083068",
    "endpoint": "measure - Vaccine-induced protection for P. vivax, description - Vaccine-induced protection for P. vivax will be assessed by pre-patent period onset after infected mosquito bites exposure, timeFrame - 28 days after mosquito bites",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03916003",
    "endpoint": "measure - Incidence risk of symptomatic P. vivax parasitaemia at day 63, description - incidence risk of symptomatic P. vivax parasitaemia at day 63, timeFrame - 63 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03916003",
    "endpoint": "measure - Incidence risk of all any P. vivax parasitaemia at day 28 and 42, description - Incidence risk of all any P. vivax parasitaemia at day 28 and 42, timeFrame - 28 and 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03916003",
    "endpoint": "measure - Incidence risk of any P. falciparum malaria at day 28, 42 and 63, description - incidence risk of any P. falciparum malaria at day 28, 42 and 63, timeFrame - 28&#x2F;42&#x2F;63 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03916003",
    "endpoint": "measure - proportion of patients vomiting their medication within 1 hour of administration, description - proportion of patients vomiting their medication on the day of enrollment within 1 hour of administration, timeFrame - 1 hour",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03916003",
    "endpoint": "measure - proportion of patients vomiting any of their PQ doses within 1 hour of administration, description - proportion of patients vomiting any of their PQ doses within 1 hour of administration, timeFrame - 7 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03916003",
    "endpoint": "measure - proportion of adverse events and serious adverse events, description - proportion of adverse events and serious adverse events, timeFrame - 63 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03916003",
    "endpoint": "measure - incidence risk of severe anaemia (Hb&lt;5g&#x2F;dl) and moderately severe anaemia (&lt;7g&#x2F;dl) and&#x2F;or the risk for blood transfusion between day 3 and 7, description - incidence risk of severe anaemia (Hb&lt;5g&#x2F;dl) and moderately severe anaemia (&lt;7g&#x2F;dl) and&#x2F;or the risk for blood transfusion between day 3 and 7, timeFrame - 7 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03916003",
    "endpoint": "measure - • The incidence risk of ≥25% fall in haemoglobin since baseline with and without hemoglobinuria at day 3 and day 7, description - • The incidence risk of ≥25% fall in haemoglobin since baseline with and without hemoglobinuria at day 3 and day 7, timeFrame - 7 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03916003",
    "endpoint": "measure - The incidence risk of ≥25% fall in haemoglobin to under 7g&#x2F;dl with and without hemoglobinuria at day 3 and day 7, description - The incidence risk of ≥25% fall in haemoglobin to under 7g&#x2F;dl with and without hemoglobinuria at day 3 and day 7, timeFrame - day 7",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03916003",
    "endpoint": "measure - Incidence risk of P. falciparum gametocytaemia between day 7 and 63, description - Incidence risk of P. falciparum gametocytaemia between day 7 and 63, timeFrame - 63 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03916003",
    "endpoint": "measure - Parasite clearance on day 1, 2 and 3, description - Parasite clearance on day 1, 2 and 3, timeFrame - 3 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03916003",
    "endpoint": "measure - Fever clearance on day 1, 2 and 3, description - Fever clearance on day 1, 2 and 3, timeFrame - 3 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04368910",
    "endpoint": "measure - Crude Cure Rate on Day 28, description - Percentage of subjects with crude cure rate at Day 28, defined as absence of parasitaemia on Day 28, irrespective of body temperature without previously meeting any of the criteria of treatment failure, timeFrame - Day 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04368910",
    "endpoint": "measure - Parasite Clearance Time (PCT), description - Parasite clearance time is defined as the time from first dosing to the time of first blood draw with parasite clearance.\nParasite clearance was defined as zero presence of asexual parasites for 2 consecutive negative readings taken between 7 and 25 hours apart, timeFrame - Days 0, 3, 7, 14, 21, 28, 35, and 42 (or on any other day if the subject spontaneously returned within the 42-day period)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04368910",
    "endpoint": "measure - Fever Clearance Time (FCT), description - Fever clearance time is defined as the time from first dosing to the first normal reading of temperature for 2 consecutive normal temperature readings taken between 7 and 25 hours apart, timeFrame - Day 0 and every 8 hours over ≥72 hours following first study drug administration or temperature normalization for ≥2 readings between 7 and 25 hours apart, then at each visit (Days 7, 14, 28 and 42)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04368910",
    "endpoint": "measure - Percentage of Patients Who Had Cleared Parasite on Days 1, 2, and 3, description - Parasite clearance is defined as at least 2 consecutive negative smears for asexual parasites obtained within an interval of 7 to 25 hours post-dosing, timeFrame - Days 1, 2, and 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04368910",
    "endpoint": "measure - Percentage of Patients Who Had Cleared Fever on Days 1, 2, and 3, description - Fever clearance is defined as at least 2 consecutive normal body temperature measurements (&lt;37.5 C axillary&#x2F;tympanic or &lt;38.0 C oral&#x2F;rectal) obtained within an interval of 7 to 25 hours postdosing, timeFrame - Days 1, 2, and 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04368910",
    "endpoint": "measure - Number of Participants With Adverse Events (AEs), description - Number of Participants with AEs, including clinically significant laboratory results, electrocardiogram (ECG), vital signs or physical examination abnormalities, timeFrame - Day 0 to 42. Subjects experiencing AEs at Day 42 were followed for up to 30 days after the end of study",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02836002",
    "endpoint": "measure - peak density gametocytes, description - Peak density and time-point of peak density of gametocytes by qRT-PCR., timeFrame - up to day 42 after challenge infection",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02836002",
    "endpoint": "measure - AUC gametocytes, description - The area under the curve of gametocyte density versus time., timeFrame - up to day 42 after challenge infection",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02836002",
    "endpoint": "measure - Gametocyte sex-ratio, description - ratio of male-female gametes, timeFrame - up to day 42 after challenge infection",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03304691",
    "endpoint": "measure - Determine the prevalence of P. vivax in Yirimadio in Duffy negative population, description - , timeFrame - Beginning, peak, and end of transmission season",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03304691",
    "endpoint": "measure - Identify the vector populations in and around the study area that may transmit malaria, including during the dry season, as well as the infection rates in these populations., description - , timeFrame - Monthly surveillance visits throughout length of the study",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03304691",
    "endpoint": "measure - Study the association between P. vivax parasitemia and anemia in Duffy-negative Africans., description - , timeFrame - Monthly surveillance visits throughout length of the study",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03304691",
    "endpoint": "measure - Determine by stool examinations the presence of hypnozoites in the liver that fail to cause blood infections., description - , timeFrame - Monthly surveillance visits throughout length of the study",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03304691",
    "endpoint": "measure - Determine the number of clones of P. vivax circulating in the community by DNA sequencing of polymorphic parasite proteins., description - , timeFrame - Monthly surveillance visits throughout length of the study",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05891236",
    "endpoint": "measure - Maximal observed concentration (Cmax) following single and repeat dosing of MAM01, description - Capillary blood samples via Volumetric Absorptive Microsampling Method (VAMS) or microtainers will be collected from participants in the Pharmacokinetic (PK) Population for measurement of MAM01 Cmax.\nBlood concentrations of MAM01 will be measured using a qualified immunoassay., timeFrame - Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours, Day 1: 24 hours, Day 2: 48 hours, Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140, 168, 224 and 280 post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05891236",
    "endpoint": "measure - Area under the curve (AUC) from Time=0 to the last measurable concentration (AUC0-t) of MAM01, description - Capillary blood samples via VAMS or microtainers will be collected from participants in the PK Population for measurement of MAM01 AUC 0-t.\nBlood concentrations of MAM01 will be measured using a qualified immunoassay., timeFrame - Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours, Day 1: 24 hours, Day 2: 48 hours, Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140, 168, 224 and 280 post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05891236",
    "endpoint": "measure - Partial AUC&#x27;s Time= 0 to the CHMI challenge (AUC0-CHMI) of MAM01, description - Capillary blood samples via VAMS or microtainers will be collected from participants in the PK Population for measurement of MAM01 AUC0-CHMI.\nBlood concentrations of MAM01 will be measured using a qualified immunoassay., timeFrame - Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours, Day 1: 24 hours, Day 2: 48 hours, Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140, 168, 224 and 280 post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05891236",
    "endpoint": "measure - Concentration at the time of CHMI (CCHMI) following single and repeat dosing of MAM01, description - Capillary blood samples via VAMS or microtainers will be collected from participants in the PK Population for measurement of MAM01 CCHMI.\nBlood concentrations of MAM01 will be measured using a qualified immunoassay., timeFrame - Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours, Day 1: 24 hours, Day 2: 48 hours, Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140, 168, 224 and 280 post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05891236",
    "endpoint": "measure - Blood terminal elimination rate constant (λz) following single and repeat dosing of MAM01, description - Capillary blood samples via VAMS or microtainers will be collected from participants in the PK Population for measurement of MAM01 λz.\nBlood concentrations of MAM01 will be measured using a qualified immunoassay., timeFrame - Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours, Day 1: 24 hours, Day 2: 48 hours, Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140, 168, 224 and 280 post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05891236",
    "endpoint": "measure - Terminal half life (t1&#x2F;2) of MAM01, description - Capillary blood samples via VAMS or microtainers will be collected from participants in the PK Population for measurement of MAM01 t1&#x2F;2.\nBlood concentrations of MAM01 will be measured using a qualified immunoassay., timeFrame - Time Frame: Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours, Day 1: 24 hours, Day 2: 48 hours, Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140, 168, 224 and 280 post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05891236",
    "endpoint": "measure - AUC from Time=0 extrapolated to infinity (AUC0-infinity) of MAM01, description - Capillary blood samples via VAMS or microtainers will be collected from participants in the PK Population for measurement of MAM01 AUC0-infinity.\nBlood concentrations of MAM01 will be measured using a qualified immunoassay., timeFrame - Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours, Day 1: 24 hours, Day 2: 48 hours, Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140, 168, 224 and 280 post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05891236",
    "endpoint": "measure - Percentage (%) AUC extrapolated (% AUCext) of MAM01, description - Capillary blood samples via VAMS or microtainers will be collected from participants in the PK Population for measurement of MAM01 (% AUCext.\nBlood concentrations of MAM01 will be measured using a qualified immunoassay., timeFrame - Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours, Day 1: 24 hours, Day 2: 48 hours, Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140, 168, 224 and 280 post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05891236",
    "endpoint": "measure - Bioavailability of SC formulation following single and repeat dosing of MAM01, description - Capillary blood samples via VAMS or microtainers will be collected from participants in the PK Population for measurement of MAM01 bioavailability.\nBlood concentrations of MAM01 will be measured using a qualified immunoassay., timeFrame - Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours, Day 1: 24 hours, Day 2: 48 hours, Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140, 168, 224 and 280 post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05891236",
    "endpoint": "measure - Part A: Cohorts 2 and 3: Accumulation ratio (AUC0-168) of MAM01, description - Capillary blood samples via VAMS or microtainers will be collected from participants in the PK Population for measurement of MAM01 AUC0-168.\nBlood concentrations of MAM01 will be measured using a qualified immunoassay., timeFrame - Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours, Day 1: 24 hours, Day 2: 48 hours, Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140 and 168 post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05891236",
    "endpoint": "measure - Part A: Cohorts 2 and 3: AUC (210-378) of MAM01, description - Capillary blood samples via VAMS or microtainers will be collected from participants in the PK Population for measurement of MAM01 AUC (210-378).\nBlood concentrations of MAM01 will be measured using a qualified immunoassay., timeFrame - Day 210 and up to Day 378",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05891236",
    "endpoint": "measure - Part A: Cohorts 2 and 3: Accumulation ratio AUC (210-378) of MAM01, description - Capillary blood samples via VAMS or microtainers will be collected from participants in the PK Population for measurement of MAM01 Accumulation ratio AUC (210-378).\nBlood concentrations of MAM01 will be measured using a qualified immunoassay., timeFrame - Day 210 and up to Day 378",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05891236",
    "endpoint": "measure - Number of participants with presence or absence of Pf infection assessed by quantitative polymerase chain reaction assay (qRT-PCR) after CHMI, description - A sensitive qRT-PCR will be used for the detection of Pf parasites in Efficacy Population., timeFrame - Through Day 27 post CHMI",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05891236",
    "endpoint": "measure - Time to parasitemia after CHMI in Efficacy Population, description - , timeFrame - Up to Day 378",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05891236",
    "endpoint": "measure - Part A: Cohorts 1, 4 and 5: Titers of anti-drug antibodies (ADAs) following administration of MAM01 in Immunogenicity Population, description - Percentage of participants with titers confirmed above the assay cut point will be summarized calculated by treatment group as appropriate., timeFrame - Up to Day 280",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05891236",
    "endpoint": "measure - Part A: Cohorts 2 and 3: Titers of ADAs following administration of MAM01 in Immunogenicity Population, description - , timeFrame - Up to Day 378",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05891236",
    "endpoint": "measure - Part B: Cohort 6: Titers of Number of participants with ADAs following administration of MAM01 in Immunogenicity Population, description - , timeFrame - Up to Day 84",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04230161",
    "endpoint": "measure - Vector species composition, description - All Anopheles mosquitoes sampled during Centers for Disease Control and Prevention light traps (CDCLT) and human landing collections (HLC) will be identified morphologically to species group, timeFrame - December 2019 to December 2022, monthly",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04230161",
    "endpoint": "measure - Species-specific population densities, description - Based on Anopheles mosquitoes sampled during CDCLT, timeFrame - December 2019 to December 2022, monthly",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04230161",
    "endpoint": "measure - Biting behaviors, description - Based on Anopheles mosquitoes sampled during CDCLT, timeFrame - December 2019 to December 2022, monthly",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04230161",
    "endpoint": "measure - Estimated entomological inoculation rates, description - Based on Anopheles mosquitoes sampled during CDCLT and HLC, timeFrame - December 2019 to December 2022, monthly",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04230161",
    "endpoint": "measure - Insecticide resistance profile, description - Measurement of kdr and ace-1 mutation frequencies, WHO tube bioassays at minimum and CDC bottle bioassays to characterize insecticide resistance intensity, timeFrame - December 2019 to December 2022, monthly",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04230161",
    "endpoint": "measure - Parasite prevalence in children 6 months or older, description - Prevalence calculated from cross-sectional surveys conducted during the peak transmission season, timeFrame - January 2020, January 2021, January 2022",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04695886",
    "endpoint": "measure - Plasmodium spp. infection detected by RDT, description - Change in the number of Plasmodium spp.\ninfections detected by RDT per week per village, timeFrame - Assessed weekly, longitudinally over 6-months.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04695886",
    "endpoint": "measure - Plasmodium spp. infections reported with 24 hours, description - Change in the number and percentage of Plasmodium spp.\ninfections reported within 24 hours of RDT per village, timeFrame - Assessed weekly, longitudinally over 6-months.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04695886",
    "endpoint": "measure - Plasmodium spp. infection detected by PCR, description - Change in the number of Plasmodium spp.\ninfections detected by polymerase chain reaction (PCR) (from RDT cassette) per week, timeFrame - Assessed weekly, longitudinally over 6-months.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04695886",
    "endpoint": "measure - Larval source management, description - Change in the number of larval sources managed by the volunteer per week, timeFrame - Assessed weekly, longitudinally over 6-months.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04695886",
    "endpoint": "measure - Dengue cases, description - Change in the number of suspected Dengue cases referred to the nearby clinic per week, timeFrame - Assessed weekly, longitudinally over 6-months.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04695886",
    "endpoint": "measure - Tuberculosis (TB) cases, description - Change in the number of suspected tuberculosis cases referred for diagnosis to national tuberculosis program per week, timeFrame - Assessed weekly, longitudinally over 6-months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04695886",
    "endpoint": "measure - TB DOTS, description - Number of TB patients monitored by volunteer for DOTS over the whole study period, timeFrame - 6-month",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04695886",
    "endpoint": "measure - Diarrheal cases diagnosed, treated and referred, description - Change in the number of diarrheal cases diagnosed, treated with ORS and zinc tablets and referred per week, timeFrame - Assessed weekly, longitudinally over 6-months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04695886",
    "endpoint": "measure - RDT-negative fever cases, description - Change in the number of RDT-negative fever cases referred per week, timeFrame - Assessed weekly, longitudinally over 6-months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04695886",
    "endpoint": "measure - Malaria treatment according to national policy, description - Change in the proportion of patients with confirmed malaria who received first-line antimalarial treatment according to national policy, timeFrame - Assessed weekly, longitudinally over 6-months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04695886",
    "endpoint": "measure - Data accuracy and completeness in reporting of malaria cases, description - Change in the number of accurately reported and complete malaria case records according the national malaria case-based reporting format, timeFrame - Assessed weekly, longitudinally over 6-months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04695886",
    "endpoint": "measure - Malaria drug resistance-associated mutations, description - Change in the proportion of Kelch13 and other resistance mutations detected by PCR from RDT cassettes, timeFrame - Assessed weekly, longitudinally over 6-months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04695886",
    "endpoint": "measure - Seroprevalence of malaria-associated antibodies, description - Change in the seroprevalence of anti-malarial antibodies detected by enzyme-linked immunosorbent assay (ELISA) from RDT cassette, timeFrame - Assessed weekly, longitudinally over 6-months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04695886",
    "endpoint": "measure - Levels of malaria-associated antibodies, description - Change in the levels of anti-malarial antibodies detected by enzyme-linked immunosorbent assay (ELISA) from RDT cassette, timeFrame - Assessed weekly, longitudinally over 6-months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04695886",
    "endpoint": "measure - Acceptability of the CIME model by villagers, description - Acceptability of the CIME model by villagers assessed by an investigator-developed questionnaire including component constructs such as affective attitude, burden, perceived effectiveness and self-efficacy., timeFrame - 6-month",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04695886",
    "endpoint": "measure - Acceptability of the CIME model by CIME volunteers, description - Acceptability of the CIME model by CIME volunteers assessed by an investigator-developed questionnaire including component constructs such as affective attitude, burden, perceived effectiveness and self-efficacy., timeFrame - 6-month",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04695886",
    "endpoint": "measure - Acceptability of the CIME model by stakeholders, description - Acceptability of the CIME model by stakeholders assessed by focus group discussions., timeFrame - 6-month",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04695886",
    "endpoint": "measure - Cost-effectiveness of the CIME model, description - Cost-effectiveness of the CIME model compared to ICMV model (Cost per unit detection, treatment and notification of a malaria case), timeFrame - 6-month",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02739763",
    "endpoint": "measure - Safety profile of PfSPZ challenge via direct venous injection, description - , timeFrame - day 0 to day 21",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02739763",
    "endpoint": "measure - Parasite growth rates with respect to antibody responses to over 100 falciparum antigens, description - , timeFrame - day 7 to day 21",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00375128",
    "endpoint": "measure - Immunogenicity, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02504918",
    "endpoint": "measure - To compare and describe levels of regulatory T cells in children who do or do not receive antimalarial treatment, in both rainy season and dry season. To compare and describe T cell stimulation responses in children who do or do not receive anti..., description - , timeFrame - Approximately 3-6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02504918",
    "endpoint": "measure - To determine and investigate phenotypic differences in T cell subsets in infected and uninfected subjects at baseline., description - , timeFrame - Approximately 3-6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02504918",
    "endpoint": "measure - To confirm that blood stage parasite burden is markedly reduced throughout the dry season by a single treatment with artemether-lumefantrine at enrollment; and to examine the association of parasite clearance during the dry season on malaria ris..., description - , timeFrame - Approximately 3-6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00316329",
    "endpoint": "measure - Clinical &amp; parasitological cure (after PCR correction) on D14 &amp; D28 in the global population &amp; in the two subpopulations-Time to clearance of parasitaemia &amp; fever-Changes in gametocytaemia &amp; anaemia during follow-up- Clinical &amp; laboratory safety, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02394197",
    "endpoint": "measure - Changes in the detection of parasite DNA in blood samples, description - Six punches of 5 mm of dried blood in filter paper were cut and used to extract DNA using the QIAamp® DNA Blood Mini Kit, following the manufacturer instructions.\nTo detect the P. vivax RNA ribosomal 18S subunit gene (18ssrRNA), we followed the methodology previously reported by Rubio et al. (1999)., timeFrame - at days 2, 3, 7, 14, 21, 28 and when antibody response were increased up to 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02394197",
    "endpoint": "measure - Changes in the antibodies against blood stages of P. vivax, description - Detect reduction, increases or seroconversión in the antibodies against blood stages of P. vivax per patients.\nFrom each patient, blood samples preserved in filter papers were eluted in PBS and tested in an indirect ELISA to detect IgG antibodies anti-P.\nvivax blood stages.\nThe reaction was revealed using goat anti-human IgG labeled with an enzyme, and as substrate and color was recorded in a spectrophotometer.\nCut off values were previously determined using unexposed individuals as the mean and 2 standard deviations; 0.25 value (95% confidence)., timeFrame - Monthly; from Day 28 to month 12 post-treatment administration",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02783833",
    "endpoint": "measure - PK Cmax, description - Estimation of the maximum plasma concentration over 28 days post administration of a single dose of MMV390048 using non-compartmental methods, timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02783833",
    "endpoint": "measure - PK Tmax, description - Estimation of the time to maximum plasma concentration over 28 days post administration of a single dose of MMV390048 using non-compartmental methods, timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02783833",
    "endpoint": "measure - PK Total exposure AUClast, description - Estimation of the last quantifiable concentration over 28 days post administration of a single dose of MMV390048 using non-compartmental methods, timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02783833",
    "endpoint": "measure - PK Total exposure AUCinf, description - Estimation of the area under the plasma concentration time curve over 28 days post administration of a single dose of MMV390048 using non-compartmental methods, timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02783833",
    "endpoint": "measure - PK distribution and clearance (CL&#x2F;F), description - Apparent oral clearance (CL&#x2F;F) over 28 days post administration of a single dose of MMV390048 using non-compartmental methods, timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02783833",
    "endpoint": "measure - PK distribution and clearance (Vz&#x2F;F), description - Apparent volume of distribution (Vz&#x2F;F) over 28 days post administration of a single dose of MMV390048 using non-compartmental methods, timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02783833",
    "endpoint": "measure - PK distribution and clearance (t½), description - Terminal half-life (t½) over 28 days post administration of a single dose of MMV390048 using non-compartmental methods, timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02783833",
    "endpoint": "measure - observed and self reported adverse events, description - The incidence, severity and relationship to the investigational product of observed and self-reported adverse events during 28 days post administration of a single oral dose of MMV390048 to healthy volunteers with induced blood stage malaria., timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01443130",
    "endpoint": "measure - Incidence of Placental Malaria by Placental Impression Smear, description - Maternal participants were followed to outcome of the pregnancy.\nThe outcome measure provides the incidence of malaria infection in the placenta based on diagnosis by positive placental impression smear results., timeFrame - At delivery: Approximately 12-36 weeks after enrollment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01443130",
    "endpoint": "measure - Incidence of Maternal Anemia (Hemoglobin &lt; 10 Grams&#x2F;Deciliter), description - Maternal participants were followed to outcome of the pregnancy.\nThe outcome measure provides the incidence of anemia among maternal participants during pregnancy .\nAnemia is defined as having a hemoglobin value less than 10 grams&#x2F;deciliter (gm&#x2F;dL)., timeFrame - From enrollment until delivery, approximately 12-36 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01443130",
    "endpoint": "measure - Incidence of Maternal Severe Anemia (Hemoglobin &lt; 7gm&#x2F;dl), description - Maternal participants were followed to outcome of the pregnancy.\nThe outcome measure provides the incidence of severe anemia among maternal participants during pregnancy.\nSevere anemia is defined as having a hemoglobin value less than 7 gm&#x2F;dl., timeFrame - From enrollment until delivery, approximately 12-36 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01443130",
    "endpoint": "measure - Incidence of Stillbirth, description - Maternal participants were followed to outcome of the pregnancy.\nThe outcome measure provides the incidence of participants&#x27; deliveries whose outcome was stillbirth, defined as an infant born without any signs of life at 28 weeks or greater of gestation., timeFrame - At delivery: Approximately 12-36 weeks after enrollment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01443130",
    "endpoint": "measure - Incidence of Miscarriage, description - Maternal participants were followed to outcome of the pregnancy.\nThe outcome measure provides the incidence of participants&#x27; deliveries whose outcome was miscarriage, defined as an infant delivered without any signs of life at less than 28 weeks of gestation., timeFrame - At delivery: Approximately 12-36 weeks after enrollment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01443130",
    "endpoint": "measure - Incidence of Preterm Delivery, description - Maternal participants were followed to outcome of the pregnancy.\nThe outcome measure provides the incidence of participants&#x27; deliveries whose outcome was preterm delivery, defined as delivery less than 37 weeks of gestation.\nThe outcome of the delivery was not considered, and could have been live birth, stillbirth, or miscarriage., timeFrame - At delivery: Approximately 12-36 weeks after enrollment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01443130",
    "endpoint": "measure - Infant Mortality Rate to 14 Weeks of Age, description - Infants were followed from the time of delivery until 14 weeks of age.\nThis outcome measure provides the incidence of infants who died within 14 weeks of delivery., timeFrame - For 14 weeks after delivery.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01443130",
    "endpoint": "measure - Incidence of Low Birth Weight (LBW) (Birthweight &lt; 2500 Grams), description - Maternal participants were followed to outcome of the pregnancy.\nThe outcome measure provides the incidence of infants whose birthweight was less than 2500 grams., timeFrame - At delivery: Approximately 12-36 weeks after enrollment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01443130",
    "endpoint": "measure - Incidence of Intrauterine Growth Restriction (IUGR), description - Infants were followed from the time of delivery until 14 weeks of age.\nThis outcome measure provides the incidence of infants with IUGR at delivery.\nIUGR is defined as weight below the 10th percentile for gestational age based on the World Health Organization (WHO) fetal growth curve.\nThis classification is supported by literature resulting from the INTERGROWTH-21st Project; José Villar., timeFrame - At delivery: Approximately 12-36 weeks after enrollment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01443130",
    "endpoint": "measure - Incidence of Active Placental Malaria Infection, description - Maternal participants were followed to outcome of the pregnancy.\nThis outcome measure provides the number of placental malaria infections in maternal subjects diagnosed by the presence of parasites and&#x2F;or pigment on histological section or molecular evidence of infection (PCR)., timeFrame - At delivery: Approximately 12-36 weeks after enrollment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01443130",
    "endpoint": "measure - Incidence of Malaria Infection, All Species., description - Maternal participants were followed to outcome of the pregnancy.\nThis outcome measure provides the number of malaria infection episodes measured by positive parasitemia in maternal subjects., timeFrame - Enrollment to delivery (approximately 12-36 weeks)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01443130",
    "endpoint": "measure - Incidence of Clinical Malaria, All Species, description - Maternal participants were followed to outcome of the pregnancy.\nClinical malaria is defined as malaria infection at any parasite density with associated symptoms including at least one of the following: objective fever measured at the clinic, history of fever in the past 48 hours or other symptoms in the last 48 hours including: headache, myalgia, vomiting, or weakness., timeFrame - Enrollment to delivery (approximately 12-36 weeks)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01443130",
    "endpoint": "measure - Incidence of Infection in the Fetal Circulation, description - Maternal participants were followed to outcome of the pregnancy.\nThis outcome measure provides the number of positive for malaria cord blood smear and cord PCR results in maternal subjects based on the results of the thick smear and PCR from the cord blood sample., timeFrame - At delivery: Approximately 12-36 weeks after enrollment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04157894",
    "endpoint": "measure - Vector species composition, description - All Anopheles mosquitoes sampled during Centers for Disease Control and Prevention light traps (CDCLT) and human landing collections (HLC) will be identified morphologically to species group, timeFrame - July 2019 to December 2022, monthly",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04157894",
    "endpoint": "measure - Species-specific population densities, description - Based on Anopheles mosquitoes sampled during CDCLT, timeFrame - July 2019 to December 2022, monthly",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04157894",
    "endpoint": "measure - Biting behaviors, description - Based on Anopheles mosquitoes sampled during CDCLT, timeFrame - July 2019 to December 2022, monthly",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04157894",
    "endpoint": "measure - Estimated entomological inoculation rates, description - Based on Anopheles mosquitoes sampled during CDCLT and HLC, timeFrame - July 2019 to December 2022, monthly",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04157894",
    "endpoint": "measure - Insecticide resistance profile, description - Measurement of kdr and ace-1 mutation frequencies, WHO tube bioassays at minimum and CDC bottle bioassays to characterize insecticide resistance intensity, timeFrame - July 2019 to December 2022, monthly",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04157894",
    "endpoint": "measure - Parasite prevalence in children 6-59 months, description - Prevalence calculated from cross-sectional surveys conducted during the peak transmission season., timeFrame - July 2019, July 2020, July 2021, July 2022",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01231503",
    "endpoint": "measure - Number of Subjects Reported With Unsolicited Adverse Events (AEs), description - An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.\n&quot;Any&quot; is defined an incidence of an unsolicited AE regardless of intensity or relationship to study vaccination.\nPlease note that, for this outcome measure, analysis was performed only on subjects with at least one administered dose of RTS,S&#x2F;AS01E and&#x2F;or DTPwHepB&#x2F;Hib for the Engerix-B Neo Group., timeFrame - During the 30-day (Days 0-29) post vaccination period following 3 doses of RTS,S&#x2F;AS01E versus DTPwHepB&#x2F;Hib for the Engerix-B Neo Group",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01231503",
    "endpoint": "measure - Number of Subjects Reported With Serious Adverse Events (SAEs), description - An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability&#x2F;incapacity, or may evolve into one of the outcomes listed above.\n&quot;Any&quot; is defined an incidence of a SAE regardless of intensity&#x2F;severity., timeFrame - From study start at Month 0 up to Month 18 (corresponding data lock point =23 March 2015)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01231503",
    "endpoint": "measure - Number of Subjects Reported With Biochemical Abnormalities, for the Alanine Aminotransferase (ALT) Parameter, description - This outcome measure concerns biochemical abnormalities, for the alanine aminotransferase (ALT) parameter.\nSubjects&#x27; levels were assessed as either normal, Grade 1, Grade 2, Grade 3, Grade 4 or Missing.\nNormal ALT level was defined as ALT&lt; 60 International units per milliliter (IU&#x2F;mL).\nGrade 1 ALT level was defined as 1.1 to 2.5 times the upper limit of normal (ULN).\nGrade 2 ALT level was defined as 2.6 to 5.0 times the ULN.\nGrade 3 ALT level was defined as 5.1 to 10.0 times the ULN.\nGrade 4 ALT level was defined as &gt; 10.0 times the ULN., timeFrame - At Day 7 post dose 1 (7D+W6) and at Day 30 post dose 3 (30D+W14).",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01231503",
    "endpoint": "measure - Number of Subjects Reported With Biochemical Abnormalities, for the Creatinine (CREA) Parameter, description - This outcome measure concerns biochemical abnormalities, for the creatinine (CREA) parameter.\nSubjects&#x27; levels were assessed as either normal, Grade 1, Grade 2, Grade 3, Grade 4 or Missing.\nNormal CREA level was defined as CREA ≤ 106, 88 and 71 micromoles per liter (µmol&#x2F;L) for subjects 1, 2 or ≥ 2 days of age, respectively.\nGrade 1 CREA level was defined as 1.1 to 1.3 times the upper limit of normal (ULN).\nGrade 2 CREA level was defined as 1.4 to 1.8 times the ULN.\nGrade 3 CREA level was defined as 1.9 to 3.4 times the ULN.\nGrade 4 CREA level was defined as ≥ 3.5 times the ULN., timeFrame - At Day 7 post dose 1 (7D+W6) and at Day 30 post dose 3 (30D+W14).",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01231503",
    "endpoint": "measure - Number of Subjects Reported With Haematological Abnormalities, for the Haemoglobin (HAE) Parameter, description - This outcome measure concerns haematological abnormalities, for the haemoglobin (HAE) parameter.\nSubjects&#x27; levels were assessed as either normal, Grade (G) 1, G 2, G 3, G 4 or Missing.\nNormal HAE level was defined as HAE &gt; 13.0 and 10.5 grams per deciliter (g&#x2F;dL) for subjects aged 1 to 21 and 22 to 35 days respectively.\nGrades were defined as follows: 1) In subjects aged 1 to 21 days: G1 = HAE as 12.0 to 13.0 g&#x2F;dL, G2 = HAE as 10.0 to 11.9 g&#x2F;dL, G3 = HAE as 9.0 to 9.9 g&#x2F;dL, G4 = HAE &lt; 9.0 g&#x2F;dL; 2) In subjects aged 22 to 35 days: G1 = HAE as 9.5 to 10.5 g&#x2F;dL, G2 = HAE as 8.0 to 9.4 g&#x2F;dL, G3 = HAE as 7.0 to 7.9 g&#x2F;dL, G4 = HAE &lt; 7.0 g&#x2F;dL; 3) In subjects aged 36 to 56 days: G1 = HAE as 8.5 to 9.4 g&#x2F;dL, G2 = HAE as 7.0 to 8.4 g&#x2F;dL, G3 = HAE as 6.0 to 6.9 g&#x2F;dL, G4 = HAE &lt; 6.0 g&#x2F;dL; 4) In subjects aged ≥ 57 days: G1 = HAE as 10.0 to 10.9 g&#x2F;dL, G2 = HAE as 9.0 to 9.9 g&#x2F;dL, G3 = HAE as 7.0 to 8.9 g&#x2F;dL, G4 = HAE &lt; 7.0 g&#x2F;dL., timeFrame - At Day 7 post dose 1 (7D+W6) and at Day 30 post dose 3 (30D+W14).",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01231503",
    "endpoint": "measure - Number of Subjects Reported With Haematological Abnormalities, for the Platelets (PLA) Parameter, description - This outcome measure concerns haematological abnormalities, for the platelets (PLA) parameter.\nSubjects&#x27; levels were assessed as either normal, Grade (G) 1, G2, G3, G4 or Missing.\nNormal PLA level was defined as &gt; 125 x 10 exp 9 PLA per liter (Billions PLA&#x2F;L).\nGrade 1 PLA level was defined as 100 to 125 Billions PLA&#x2F;L.\nGrade 2 PLA level was defined as 50 to 99 Billions PLA&#x2F;L.\nGrade 3 PLA level was defined as 25 to 49 Billions PLA&#x2F;L.\nGrade 4 PLA level was defined as &lt; 25 Billions PLA&#x2F;L., timeFrame - At Day 7 post dose 1 (7D+W6) and at Day 30 post dose 3 (30D+W14).",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01231503",
    "endpoint": "measure - Number of Subjects Reported With Haematological Abnormalities, for the White Blood Cells (WBC) Parameter, description - This outcome measure concerns haematological abnormalities, for the white blood cells (WBC) parameter.\nSubjects&#x27; levels were assessed as either normal, Grade 1, Grade 2, Grade 3, Grade 4 or Missing.\nNormal WBC level was defined as &gt; 2.5 x 10 exp 9 WBC per liter (Billions WBC&#x2F;L).\nGrade 1 WBC level was defined as 2.0 to 2.5 Billions WBC&#x2F;L.\nGrade 2 WBC level was defined as 1.5 to 1.999 Billions WBC&#x2F;L.\nGrade 3 WBC level was defined as 1.0 to 1.499 Billions WBC&#x2F;L.\nGrade 4 WBC level was defined as &lt; 1.0 Billions WBC&#x2F;L., timeFrame - At Day 7 post dose 1 (7D+W6) and at Day 30 post dose 3 (30D+W14).",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01231503",
    "endpoint": "measure - Concentrations of Antibodies Against Circumsporozoite Protein of Plasmodium Falciparum (Anti-CS Antibodies), description - Anti-CS antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and presented as geometric mean concentrations (GMCs) expressed in ELISA units per milliliter (EL.U&#x2F;mL).\nThe seropositivity cut-off value for the assay was greater than or equal to (≥) 0.5 EL.U&#x2F;mL., timeFrame - At Screening (SCR), at Month (M) 4, at M5, at M7 and&#x2F;or at M10, according to the vaccination scheduling for the specific group assessed concerned group",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01231503",
    "endpoint": "measure - Anti-Hepatitis B Surface Antibody (Anti-HBs) Concentrations., description - Concentrations, by enzyme-linked immunosorbent assay (ELISA), were presented as geometric mean concentrations (GMCs), and expressed in milli-international units per milliliter (mIU&#x2F;mL).\nThe seropositivity and seroprotection cut-off values for the assay were greater than or equal to (≥) 6.2 and 10 mIU&#x2F;mL, respectively., timeFrame - At Screening (SCR), at Month 5 (M5), at Month 7 (M7) and at Month 10 (M10), according to the vaccination scheduling",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01231503",
    "endpoint": "measure - Anti-diphtheria (Anti-D) and Anti-tetanus Toxoids (Anti-TT) Antibody Concentrations, description - Anti-D and anti-TT antibody concentrations were calculated, expressed as geometric mean concentrations (GMCs), in International units per milliliter (IU&#x2F;mL), and tabulated.\nThe seropositivity cut-off value for the assay was ≥ 0.1 IU&#x2F;mL., timeFrame - At Month 5",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01231503",
    "endpoint": "measure - Anti-polyribosyl Ribitol Phosphate (Anti-PRP) Antibody Concentrations, description - Anti-PRP antibody concentrations were calculated, expressed as geometric mean concentrations (GMCs), in microgram per milliliter (µg&#x2F;mL), and tabulated.\nThe seroprotection cut-off value for the assay was ≥ 0.15 µg&#x2F;mL., timeFrame - At Month 5",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01231503",
    "endpoint": "measure - Anti-polio Type 1, 2 and 3 (Anti-Polio 1, 2 and 3) Antibody Concentrations, description - Anti-Polio 1, 2 and 3 antibody concentrations were calculated, expressed as geometric mean concentrations (GMCs), in international units per mililiter (IU&#x2F;mL) and tabulated.\nThe seroprotection cut-off value for the assay was ≥ 8 IU&#x2F;mL., timeFrame - At Month 5",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01231503",
    "endpoint": "measure - Concentrations of Antibodies Against Acellular B-pertussis (BPT), description - Concentrations of anti-BPT antibodies were determined by enzyme-linked immunosorbent assay (ELISA) and expressed as geometric mean concentrations (GMCs), in ELISA units per milliliter (EL.U&#x2F;mL).\nThe seropositivity cut-off value for the assay was ≥ 15 EL.U&#x2F;mL., timeFrame - At Month 5",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01231503",
    "endpoint": "measure - Concentrations of Antibodies Against Measles Antigens, description - <p>Concentrations of anti measles antibodies were determined by ELISA and expressed as GMCs in milli-international units per millilitre (mIU&#x2F;mL).</p><p>The seropositivity cut-off value for the assay was ≥ 150 mIU&#x2F;mL.\nPlease note that this outcome measure was only assessed in subjects in the RTS,S 14-26-9M and Engerix-B Neo groups.</p>, timeFrame - At Month 10",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01231503",
    "endpoint": "measure - Number of Subjects Reported With Solicited Local Symptoms, description - Solicited local symptoms assessed include pain, redness and swelling.\n&quot;Any&quot; about a specific symptom is defined as incidence of this symptom, regardless of its intensity., timeFrame - Within 7 days (Days 0-6) after Week 0 vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01231503",
    "endpoint": "measure - Number of Subjects Reported With Solicited Local Symptoms, description - Solicited local symptoms assessed include pain, redness and swelling.\n&quot;Any&quot; about a specific symptom is defined as incidence of this symptom, regardless of its intensity., timeFrame - Within 7 days (Days 0-6) after Week 6 vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01231503",
    "endpoint": "measure - Number of Subjects Reported With Solicited Local Symptoms, description - Solicited local symptoms assessed include pain, redness and swelling.\n&quot;Any&quot; about a specific symptom is defined as incidence of this symptom, regardless of its intensity., timeFrame - Within 7 days (Days 0-6) after Week 10 vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01231503",
    "endpoint": "measure - Number of Subjects Reported With Solicited Local Symptoms, description - Solicited local symptoms assessed include pain, redness and swelling.\n&quot;Any&quot; about a specific symptom is defined as incidence of this symptom, regardless of its intensity., timeFrame - Within 7 days (Days 0-6) after Week 14 vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01231503",
    "endpoint": "measure - Number of Subjects Reported With Solicited Local Symptoms, description - Solicited local symptoms assessed include pain, redness and swelling.\n&quot;Any&quot; about a specific symptom is defined as incidence of this symptom, regardless of its intensity.\nRTS,S Neo-10-14 Group, RTS,S 6-10-14 Group and Engerix-B Neo Group didn&#x27;t receive vaccination at this time point., timeFrame - Within 7 days (Days 0-6) after Week 26 vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01231503",
    "endpoint": "measure - Number of Subjects Reported With Solicited Local Symptoms, description - Solicited local symptoms assessed include pain, redness and swelling.\n&quot;Any&quot; about a specific symptom is defined as incidence of this symptom, regardless of its intensity., timeFrame - Within 7 days (Days 0-6) after Month 9 vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01231503",
    "endpoint": "measure - Number of Subjects Reported With Solicited General Symptoms, description - Solicited general symptoms assessed include Drowsiness, Fever (temperature by axillary route ≥ 37.5°C), Irritability&#x2F;Fussiness and Loss of appetite.\n&quot;Any&quot; about a specific symptom is defined as incidence of this symptom, regardless of its intensity or relationship to vaccination., timeFrame - Within 7 days (Days 0-6) after Week 0 vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01231503",
    "endpoint": "measure - Number of Subjects Reported With Solicited General Symptoms, description - Solicited general symptoms assessed include Drowsiness, Fever (temperature by axillary route ≥ 37.5°C), Irritability&#x2F;Fussiness and Loss of appetite.\n&quot;Any&quot; about a specific symptom is defined as incidence of this symptom, regardless of its intensity or relationship to vaccination., timeFrame - Within 7 days (Days 0-6) after Week 6 vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01231503",
    "endpoint": "measure - Number of Subjects Reported With Solicited General Symptoms, description - Solicited general symptoms assessed include Drowsiness, Fever (temperature by axillary route ≥ 37.5°C), Irritability&#x2F;Fussiness and Loss of appetite.\n&quot;Any&quot; about a specific symptom is defined as incidence of this symptom, regardless of its intensity or relationship to vaccination., timeFrame - Within 7 days (Days 0-6) after Week 10 vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01231503",
    "endpoint": "measure - Number of Subjects Reported With Solicited General Symptoms, description - Solicited general symptoms assessed include Drowsiness, Fever (temperature by axillary route ≥ 37.5°C), Irritability&#x2F;Fussiness and Loss of appetite.\n&quot;Any&quot; about a specific symptom is defined as incidence of this symptom, regardless of its intensity or relationship to vaccination., timeFrame - Within 7 days (Days 0-6) after Week 14 vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01231503",
    "endpoint": "measure - Number of Subjects Reported With Solicited General Symptoms, description - Solicited general symptoms assessed include Drowsiness, Fever (temperature by axillary route ≥ 37.5°C), Irritability&#x2F;Fussiness and Loss of appetite.\n&quot;Any&quot; about a specific symptom is defined as incidence of this symptom, regardless of its intensity or relationship to vaccination.\nRTS,S Neo-10-14 Group, RTS,S 6-10-14 Group and Engerix-B Neo Group didn&#x27;t receive any vaccination at this time point, timeFrame - Within 7 days (Days 0-6) after Week 26 vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01231503",
    "endpoint": "measure - Number of Subjects Reported With Solicited General Symptoms, description - Solicited general symptoms assessed include Drowsiness, Fever (temperature by axillary route ≥ 37.5°C), Irritability&#x2F;Fussiness and Loss of appetite.\n&quot;Any&quot; about a specific symptom is defined as incidence of this symptom, regardless of its intensity or relationship to vaccination., timeFrame - Within 7 days (Days 0-6) after Month 9 vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00442403",
    "endpoint": "measure - Proportion of patients with positive blood smear during follow-u;, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00442403",
    "endpoint": "measure - Mean parasitemia during follow-up;, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00442403",
    "endpoint": "measure - Proportion of patients with clinical symptoms on day 3., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00984763",
    "endpoint": "measure - To detect differences in the multiplication rate responses between unvaccinated control subjects and volunteers vaccinated with AMA1-C1&#x2F;Alhydrogel® + CPG 7909, description - , timeFrame - Up to 16 days following blood stage parasite challenge",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04241705",
    "endpoint": "measure - Malaria burden, measured by antigen test, description - Testing for pan-Plasmodium antigens aldolase and LDH will determine active infection with malaria parasite, and, if the infecting species is Pf, by the presence of HRP2 antigen (Plucinski, Herman et al. 2018)., timeFrame - Two years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04241705",
    "endpoint": "measure - Malaria burden, measured by serology, description - Sero-prevalence will be determined using LUMINEX based multiplex assays.\nAge-specific sero-conversion and sero-reversion rates over the two years will be used to monitor changes in transmission and malaria exposure over time.\nAbsence of antimalarial antibodies, particularly in children, will show the success of tMDA or RCD interventions.\nAntigen selection will be informed by recent studies by EPHI and CDC and a panel of antibodies characterized to indicate recent change in transmission will be included (Kerkhof, Sluydts et al. 2016)., timeFrame - Two years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04241705",
    "endpoint": "measure - Malaria burden, measured by molecular testing, description - Real-time quantitative (qPCR) for parasite detection will be performed by targeting the 18S small rRNA gene for Pf and Pv using primer and probe sequences.\nPf parasites will be quantified using standard curves generated from a serial dilution of NF54 ring stage parasites.\nPv parasite quantification will be done using plasmid constructs to infer copy numbers as described before.\nBlood samples in RNA protect buffers will be used for extraction of RNA using the RNeasy Mini Kit (QIAGEN) for gametocyte quantification, gametocyte commitment and maturation assays, sex ratio estimation, asexual stage parasites detection, and expression level of regulators of the balance between reproduction and replication., timeFrame - Two years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04241705",
    "endpoint": "measure - Intervention coverage, description - To compare intervention coverage in RCD and tMDA arms.\nAfter RCD and tMDA interventions, coverage will be estimated by calculating the proportion of all enumerated household members reached in each index case event and the proportion of individuals tested and&#x2F;or on treatment., timeFrame - Two years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04241705",
    "endpoint": "measure - Acceptability, description - To compare acceptability of RCD and tMDA.\nDuring the baseline and endline cross-sectional surveys, the household head will be asked questions about the acceptability of the RCD and tMDA interventions (self-report)., timeFrame - Two years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04241705",
    "endpoint": "measure - Serious adverse events, description - To compare number of serious adverse events between the RCD and tMDA arms, timeFrame - Two years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04241705",
    "endpoint": "measure - Adherence, description - To compare the adherence to antimalarials between the RCD and tMDA arms.\nAdherence will be measured by self-report and pill count., timeFrame - Two years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04241705",
    "endpoint": "measure - Costs, description - To compare the costs of RCD and tMDA.\nCosts will be calculated using an ingredients approach that involves enumerating both the quantity of specific inputs (e.g., hours spent, cost of treatment, number of RDTs used, etc.) and the time spent during the intervention.\nQuantity and time will be converted to a common monetary cost measure.\nExisting infrastructure and recurrent inputs that would be present in the absence of the intervention will not be included in cost analysis.\nThe emphasis of the cost analysis is on determining the cost of RCD and tMDA alone., timeFrame - Two years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04241705",
    "endpoint": "measure - Cost-effectiveness, description - To assess the cost-effectiveness of RCD and tMDA relative to control.\nCost-effectiveness will be measured through incident malaria cases averted as measured through the difference in malaria incidence in RCD and tMDA kebeles., timeFrame - Two years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04241705",
    "endpoint": "measure - Sensitivity and specificity of polymerase chain reaction (PCR), description - To evaluate the sensitivity and specificity of PCR as compared to antigen- based multiplex testing, timeFrame - Two years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04241705",
    "endpoint": "measure - Ratio of imported to locally acquired incident cases, description - To assess the ratio of imported to locally acquired incident cases, timeFrame - Two years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02878265",
    "endpoint": "measure - Incidence of diarrhea attacks, description - While taking the supplement, diarrhea incidence will be measured, timeFrame - Every month up to six months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01976325",
    "endpoint": "measure - Decisional Conflict Score, description - The decisional conflict score will be measured based on responses in the questionnaire using specific questions from the Decisional Conflict Scale (O&#x27;Connor, 1993, revised 2005), the Medical Decision Making Scale (Adapted from Strull, 1984), the Values Scale (Adapted from O&#x27;Connor 1999), and the Decision Regret Scale (O&#x27;Connor, 1996).\nFor each scaled question, every possible response contains a predetermined scoring scheme.\nThe score is calculated by adding points from each question answered.\nThe sum of points forms the score., timeFrame - One year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01976325",
    "endpoint": "measure - Preparation for Decision-making Score, description - The preparation for decision making score will be measured based on responses in the questionnaire using specific questions from the Preparation for Decision Making Scale (Graham, O&#x27;Connor 1996, revised 2005), and the Choice Predisposition Scale (O&#x27;Connor 2000).\nFor each scaled question, every possible response contains a predetermined scoring scheme.\nThe score is calculated by adding points from each question answered.\nThe sum of points forms the score., timeFrame - One year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01976325",
    "endpoint": "measure - Medication Adherence Score, description - Medication adherence will be measured based on responses in the after-travel questionnaire using specific questions from the adapted ACTG Adherence questionnaire, and the Malaria Adherence Prophylactic Scale (MAPS).\nFor each multiple choice and scaled question, every possible response contains a predetermined scoring scheme.\nThe score is calculated by adding points from each question answered.\nThe sum of points forms the score., timeFrame - One year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05071079",
    "endpoint": "measure - Geometric mean and standard deviation&#x2F;error of Pvs25 gene transcript copy number&#x2F;microL at each time point, description - Measured by qPCR in experimental P. vivax infection through blood-stage challenge, timeFrame - Challenge day; day 1 to 5 or up to day of treatment and during subsequent days of follow-up through study completion, over one year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05071079",
    "endpoint": "measure - Transmissibility of gametocytes from the infected volunteer to Anopheles mosquito vector, description - Measured by gametocytes from the infected volunteer to Anopheles mosquito vector using Membrane feeding assay, timeFrame - Through study completion, over one year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05071079",
    "endpoint": "measure - Cellular Immune response to primary P. vivax infection (frequencies, percentages (%), and expression level of mononuclear cells), description - Immune cells including Innate and adaptive immune cells react and express during the PV infection (profile and frequency), timeFrame - Day-1, Day 2, Day 5, Day of blood donation, DayRx7, DayRx28, DayRx90, DayRx1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05071079",
    "endpoint": "measure - Level of antibodies and cytokines responses to primary P. vivax infection during different phase of infection, description - Immune cells defense PV antigen by determining the level of antibody response and inflammatory cytokine, timeFrame - Day-1, Day 2, Day 5, Day of blood donation, DayRx7, DayRx28, DayRx90, DayRx1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02392832",
    "endpoint": "measure - Changes in vector abundance, description - Malaria vector abundance is measured by the total density of An. gambiae, An. arabiensis, An. funestus and other Anopheles species capable of transmitting malaria, collected indoors and outdoors by the CO2-baited CDC light trap, 64 trap nights in each of indoor and outdoor environments per site per month.\nMalaria transmission intensity is measured by the sum of indoor and outdoor entomological inoculation rate (EIR)., timeFrame - baseline and 4 months following the interventions",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02392832",
    "endpoint": "measure - EIR, description - Malaria transmission intensity is measured by the sum of indoor and outdoor entomological inoculation rate (EIR)., timeFrame - baseline and 4 months following the interventions",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00761020",
    "endpoint": "measure - Subjects showing Anti- Pf MSP-1 IgG antibody response, description - The focus of the statistical analysis will be to characterize the antibody kinetics in subjects over that time, will be presented graphically in whole blood concentration vs. time plots.\nWe will identify individual Cmax, t 1&#x2F;2, and time to Cmax as well determined point estimates and confidence intervals for the cohorts.\nWe will also estimate the percentage cross-reactivity of the serum in each cohort by measuring the number of subjects who test Pf assay positive divided by the number of subjects Pf infected with in each cohort., timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00427167",
    "endpoint": "measure - Demonstrate that the immune responses to AMA1-C1 7909 in a saline buffer are not inferior to the immune responses to AMA-C1 + CPG 7909 in a phosphate buffer., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01341704",
    "endpoint": "measure - Number of subjects with solicited adverse events, description - <p>In this study, the following symptoms will directly be solicited for during 7 days immediately following each vaccination.</p><p>Solicited Local (injection site) adverse events</p><ul><li>Pain at injection site</li><li>Swelling at injection site</li><li>Induration at injection site</li><li>Erythema at injection site</li><li>Pruritus at injection</li></ul><p>Solicited systemic adverse events</p><ul><li>Fever (defined as axillary temperature ≥ 37.5°C)</li><li>Drowsiness</li><li>Loss of appetite</li><li>Irritability&#x2F;fussiness</li></ul>, timeFrame - 7 days following each vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01341704",
    "endpoint": "measure - Number of subjects with unsolicited adverse events, description - All the adverse events&#x2F;reactions, whether observed by the investigator or reported by the subject, will be documented.\nFor each event&#x2F;reaction the following details will be recorded: 1) description of the event(s)&#x2F;reaction(s), 2) date and time of occurrence, 3) duration, 4) intensity, 5)assessment of relationship to the vaccine, 6) action taken including treatment, 7) outcome., timeFrame - 30 days following each vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01341704",
    "endpoint": "measure - Number of subjects with serious adverse events, description - <p>A serious adverse event (experience) or reaction is any untoward medical occurrence that at any dose:</p><ul><li>results in death,</li><li>is life-threatening,</li><li>results in persistent or significant disability&#x2F;incapacity, or</li><li>is a congenital anomaly&#x2F;birth defect.</li></ul>, timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05348746",
    "endpoint": "measure - Prevalence of Plasmodium species resistant, description - <p>The investigators will evaluate the prevalence of resistance against SP derivatives in a population of malaria cases diagnosed in the study centers during the study period.</p><p>Parasite identification is based on nested PCR assay targeting the 18S rRNA gene.\nThe 18S rRNA gene is used as a target since it contains both highly conserved and variable regions for each Plasmodium species.\nThe genus-specific PCR will be followed by Plasmodium species-specific PCR amplification.\nAmplicons from the second PCR will be separated by electrophoresis on a 2% agarose gel and stained with ethidium bromide for visualization using ultraviolet trans-illumination.\nThe presence of parasitaemia will be confirmed when the expected band size corresponding to P. falciparum, P. vivax, P. malariae and or P. ovale will be identified.</p>, timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05348746",
    "endpoint": "measure - Incidence of maternal and fetal outcome, description - The researcher will evaluete in pregnant women with Malaria enrolled in the study the incidence of malaria-related adverse maternal and fetal outcomes (maternal anemia, maternal mortality, abortion, low birthweight, prematurity, perinatal mortality, placental malaria) in Oyam and Kole district for the period March 2022 to June 2023, timeFrame - 15 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05348746",
    "endpoint": "measure - Local spread of P. falciparum polymorphisms, description - <p>The investigators will evaluate the emergence and local spread of artemisinin resistance by means of the analysis of polymorphisms in the P. falciparum kelch 13 gene in the study cohort and in a population of patients diagnosed with malaria in Oyam and Kole district for the period June 2022 to May 2024.</p><p>The polymorphisms analysis of the propeller domain of the Pfk13 gene will be performed by PCR amplifications and subsequent sequencing.\nAnalysis of Pfdhfr gene at codons 51, 59, 108 and Pfdhps gene at codon positions 436, 437, 540, 581, 613 will be done by means of amplifications and subsequent Sanger sequencing.\nThe obtained sequences will be compiled and analyzed by Accelrys DS Gene software.\nPlasmoDB gene identification no.\nPF3D7_1343700 (P.\nfalciparum 3D7 strain) will be used as reference in the numbering of nucleotide and amino acid positions.</p>, timeFrame - 24 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00373607",
    "endpoint": "measure - Recrudescence, description - , timeFrame - Day 63",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00373607",
    "endpoint": "measure - Reinfections, description - , timeFrame - day 63",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00373607",
    "endpoint": "measure - SAE, description - , timeFrame - Day 63",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00373607",
    "endpoint": "measure - AE, description - , timeFrame - Day 63",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03432039",
    "endpoint": "measure - Maternal anxiety and depression, description - Anxiety and depression scores as measured by the Hopkins Symptom Checklist, timeFrame - 6 months post-discharge",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03432039",
    "endpoint": "measure - Behavioral problems in the child, description - Total Problems score of the Child Behavioral Checklist, timeFrame - 6 months post-discharge",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06805110",
    "endpoint": "measure - Ratio of TPR between health facility registers and RDT cassettes in intervention facilities over time., description - The change in ratio will be measured by using the TPR from the facility registers and the TPR from the cassettes entered into the HealthPulse app, timeFrame - 4 months (April - July 2025)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06805110",
    "endpoint": "measure - Total costs associated with monthly RDT validation exercises, description - Collection and analysis of cost data, including personnel costs, travel expenses, and other project-related expenses will be used to estimate the total costs associated with the validation meetings, timeFrame - 4 months (April - July 2025)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06805110",
    "endpoint": "measure - HCWs subjective norms, attitudes, perceptions and practices regarding RDT usage, description - A questionnaire will be administered to HCWs in the intervention and control group to compare differences in their subjective norms, attitudes, perceptions and practices regarding RDT, timeFrame - Immediately after intervention period (August 2025)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06805110",
    "endpoint": "measure - Acceptability and feasibility of implementing monthly RDT validation exercises, description - In-depth interviews will be conducted with HCWs, local government areas (LGAs) and state officials to understand their perceptions of the acceptability of the monthly validation processes, timeFrame - Immediately after intervention period (August 2025)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06805110",
    "endpoint": "measure - Acceptability and feasibility of using a digital smartphone application for monthly RDT validation exercises, description - In-depth interviews will be conducted with HCWs, LGA and state officials to understand their perceptions of the acceptability and feasibility of using the digital application during monthly validation, timeFrame - Immediately after intervention period (August 2025)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02938975",
    "endpoint": "measure - Incidence of clinical malaria through monthly measurement malaria positivity of SD Bioline Malaria Rapid Diagnostic Test to test for parasite antigen, description - Both active and passive malaria case detection will be taken by malaria RDT (SD Bioline Malaria Incidence of RDT positivity Participants will be tested for malaria every month using Rapid Diagnostic Test (RDT) SD Bioline Malaria Antigen Pf&#x2F;Pan (SD RDT) with RDT results interpreted by the Deki Reader device., timeFrame - Active and passive case detection for 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02938975",
    "endpoint": "measure - Compliance with intervention as measured through spot checking and weighing of repellent bottles, description - Each month bottles of repellent or placebo lotion will be weighed to measure application of repellent.\nCompliance with uniforms will be observed by spot checks once a month., timeFrame - Monthly assessment of intervention compliance with uniforms and lotions provided for 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02938975",
    "endpoint": "measure - Protective efficacy of uniforms measured by reduction in Anopheles arabiensis bites among those wearing uniforms for a sub-sample of uniforms tested under laboratory conditions with free flying mosquitoes, description - A random sample of 100 uniforms will be tested in the laboratory at the end of the study to measure their efficacy in preventing mosquito bites., timeFrame - After 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00440999",
    "endpoint": "measure - Crude Cure Rate on Days 21 and 28., description - Cure on Day 21 and 28 is defined as the absence of P. vivax parasitaemia on Day 21 and 28 irrespective of temperature (axillary, oral, tympanic, rectal) without previously meeting any of the criteria of treatment failure throughout the follow-up period., timeFrame - Day 21 and 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00440999",
    "endpoint": "measure - Parasite Clearance Time, description - Parasite clearance time is defined as the time from first dosing to the time of first blood draw with parasite clearance.\nParasite clearance is defined as zero presence of asexual parasites for 2 consecutive negative readings taken between 7 and 25 hours apart., timeFrame - Days 0 to 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00440999",
    "endpoint": "measure - Fever Clearance Time, description - Fever clearance time is defined as the time from first dosing to the first normal reading of temperature (&lt;37.5°C for axillary&#x2F;tympanic or &lt;38°C for oral&#x2F;rectal) for 2 consecutive normal temperature readings taken between 7 and 25 hours apart., timeFrame - Days 0 to 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00440999",
    "endpoint": "measure - Percentage of Subjects With Parasite Clearance on Days 1, 2, and 3, description - Percentage of subjects with parasite clearance on Day 1 (24 hours after first dose), Day 2 (48 hours after first dose), and Day 3 (72 hours after first dose)., timeFrame - Days 1, 2, and 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00440999",
    "endpoint": "measure - Percentage of Subjects With Fever Clearance on Days 1, 2, and 3, description - Percentage of subjects with fever clearance on Day 1 (24 hours after first dose), Day 2 (48 hours after first dose), and Day 3 (72 hours after first dose)., timeFrame - Day 1, 2, and 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00440999",
    "endpoint": "measure - Number of Participants With Adverse Events, description - Number of participants with adverse events, including clinically significant laboratory results, ECG, vital signs or physical examination abnormalities., timeFrame - Day 0 to 42. Subjects experiencing AEs at Day 42 were followed for up to 30 days after the end of study or resolution of the event, whichever was earlier",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06804902",
    "endpoint": "measure - Ratio of TPR between healthcare facility registers and RDT cassettes in intervention facilities over time., description - The TPR for RDT cassettes will be collected from each healthcare facility by the HealthPulse application during monthly RDT validation meetings.\nThe ratio will be calculated with these data, and the TPRs calculated from DHIS2., timeFrame - Four months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06804902",
    "endpoint": "measure - Proportion of suspected patients tested by RDT who receive an antimalarial prescription., description - For both the intervention and control arms, data on ACT prescription will be downloaded from the DHIS2 after the end of the study., timeFrame - Four months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06804902",
    "endpoint": "measure - The total number of antimalarials., description - For both arms, ACT prescription data will be downloaded from the DHIS2, and ACT consumption data from the integrated electronic logistics management system (e-SIGL) after the end of the study., timeFrame - Four months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06804902",
    "endpoint": "measure - The cost required to implement the monthly RDT validation meetings., description - This estimate will be made by recording the cost of training, the cost of smartphones and communication time, the number and categories of staff needed to plan and implement the monthly data validation meetings, as well as their travel expenses and per diems for attending the meeting.\nThe costs of any follow-up activities will be noted.\nThe time spent by different categories of staff will be tracked to provide an estimate of the level of effort required to implement the monthly validation meetings., timeFrame - Four months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06804902",
    "endpoint": "measure - Proportion of healthcare workers reporting compliance with negative RDT results when patients present with fever (i.e. recording the RDT result as negative, not recording the case as malaria and not prescribing antimalarial medication)., description - Subjective norms, attitudes and practices towards RDTs will be measured in a cross-sectional survey of healthcare workers in selected facilities at the end of the study., timeFrame - immediately after the intervention period",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06804902",
    "endpoint": "measure - Qualitative description of the acceptability and feasibility of conducting monthly RDT validations and using a digital tool (HealthPulse, Audere, Johannesburg, South Africa)., description - The acceptability and feasibility of the monthly RDT validation exercise, as well as perceptions of the digital tools used for RDT validation, will be measured through in-depth interviews with health facility staff, district epidemiological surveillance and monitoring and evaluation (CSE) officers and malaria focal points., timeFrame - immediately after the intervention period",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02118428",
    "endpoint": "measure - Bacterial Contamination of Fresh Whole Blood (FWB) Products, description - <p>Bacterial culture on blood products - products were collected within 7 days before transfusion to the study subject.</p><p>Control products were only sampled post-collection, so no results for post-Mirasol treatment.</p><p>All samples in Mirasol group that were positive post-collection became negative post-Mirasol treatment.</p><p>All samples in Mirasol group that were positive post-Mirasol treatment were negative post-collection.\nThese samples were likely contaminated in the clinical laboratory after Mirasol treatment during sampling for culture.</p>, timeFrame - immediately post-blood product collection &amp; within 7 days before transfusion, post-Mirasol treatment (within 24 hours post-blood product collection) &amp; within 7 days before transfusion",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02118428",
    "endpoint": "measure - Hematology Parameter in Fresh Whole Blood (FWB) Products - Hematocrit, description - Hematocrit measurement in FWB products.\nBlood products were collected independently from study enrollment and stored for maximum of 7 days before assignment&#x2F;transfusion to a study subject., timeFrame - Post-blood product collection (Day -7 to Day 0 per transfusion), prior to transfusion (Day 0 per transfusion)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02118428",
    "endpoint": "measure - Hematology Parameter in Fresh Whole Blood Products - Total Hemoglobin, description - Total hemoglobin measurement in Fresh Whole Blood products.\nBlood products were collected independently from study enrollment and stored for maximum of 7 days before assignment&#x2F;transfusion to a study subject., timeFrame - Post-blood product collection (Day -7 to Day 0 per transfusion), prior to transfusion (Day 0 per transfusion)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02118428",
    "endpoint": "measure - Hematology Parameter in Fresh Whole Blood Products - Red Blood Cell (RBC) Count, description - RBC count in Fresh Whole Blood products.\nBlood products were collected independently from study enrollment and stored for maximum of 7 days before assignment&#x2F;transfusion to a study subject., timeFrame - Post-blood product collection (Day -7 to Day 0 per transfusion), prior to transfusion (Day 0 per transfusion)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02118428",
    "endpoint": "measure - Hematology Parameter in Fresh Whole Blood Products - Platelet Count, description - Platelet count in Fresh Whole Blood products.\nBlood products were collected independently from study enrollment and stored for maximum of 7 days before assignment&#x2F;transfusion to a study subject., timeFrame - Post-blood product collection (Day -7 to Day 0 per transfusion), prior to transfusion (Day 0 per transfusion)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02118428",
    "endpoint": "measure - Hematology Parameter in Fresh Whole Blood Products - White Blood Cell (WBC) Count, description - WBC count in Fresh Whole Blood products.\nBlood products were collected independently from study enrollment and stored for maximum of 7 days before assignment&#x2F;transfusion to a study subject., timeFrame - Post-blood product collection (Day -7 to Day 0 per transfusion), prior to transfusion (Day 0 per transfusion)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02118428",
    "endpoint": "measure - Biochemistry Parameter in Fresh Whole Blood Products - Potassium, description - Potassium measurement in Fresh Whole Blood products.\nBlood products were collected independently from study enrollment and stored for maximum of 7 days before assignment&#x2F;transfusion to a study subject., timeFrame - Post-blood product collection (Day -7 to Day 0 per transfusion), prior to transfusion (Day 0 per transfusion)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02118428",
    "endpoint": "measure - Hematology Parameter in Patients - Hematocrit, description - Hematocrit measure in study participants.\nStudy participants may have received 1 or 2 blood product transfusions over 3 days while on study.\nThese measurements were taken relative to the first transfusion only, for consistency., timeFrame - Days 0, 1, 2, 3, 7, 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02118428",
    "endpoint": "measure - Hematology Parameter in Patients - Total Hemoglobin, description - Total hemoglobin measure in study participants.\nStudy participants may have received 1 or 2 blood product transfusions over 3 days while on study.\nThese measurements were taken relative to the first transfusion only, for consistency., timeFrame - Days 0, 1, 2, 3, 7, 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02118428",
    "endpoint": "measure - Hematology Parameter in Patients - Platelet Count, description - Platelet count in study participants.\nStudy participants may have received 1 or 2 blood product transfusions over 3 days while on study.\nThese measurements were taken relative to the first transfusion only, for consistency., timeFrame - Days 0, 1, 2, 3, 7, 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02118428",
    "endpoint": "measure - Hematology Parameter in Patients - Red Blood Cell (RBC) Count, description - RBC count in study participants.\nStudy participants may have received 1 or 2 blood product transfusions over 3 days while on study.\nThese measurements were taken relative to the first transfusion only, for consistency., timeFrame - Days 0, 1, 2, 3, 7, 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02118428",
    "endpoint": "measure - Hematology Parameter in Patients - White Blood Cell (WBC) Count, description - WBC count in study participants.\nStudy participants may have received 1 or 2 blood product transfusions over 3 days while on study.\nThese measurements were taken relative to the first transfusion only, for consistency., timeFrame - Days 0, 1, 2, 3, 7, 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02118428",
    "endpoint": "measure - Biochemistry Parameter in Patients - Potassium, description - Potassium measure in study participants.\nStudy participants may have received 1 or 2 blood product transfusions over 3 days while on study.\nThese measurements were taken relative to the first transfusion only, for consistency., timeFrame - Days 0, 1, 2, 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02118428",
    "endpoint": "measure - Coagulation Parameter in Patients - Prothrombin Time, description - Prothrombin time measure in study participants.\nStudy participants may have received 1 or 2 blood product transfusions over 3 days while on study.\nThese measurements were taken relative to the first transfusion only, for consistency., timeFrame - Days 0, 1, 2, 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02118428",
    "endpoint": "measure - Coagulation Parameter in Patients - Activated Partial Thromboplastin Time, description - Activated partial thromboplastin time measure in study participants.\nStudy participants may have received 1 or 2 blood product transfusions over 3 days while on study.\nThese measurements were taken relative to the first transfusion only, for consistency., timeFrame - Days 0, 1, 2, 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02118428",
    "endpoint": "measure - Coagulation Parameter in Patients - International Normalized Ratio (INR), description - INR measure in study participants.\nStudy participants may have received 1 or 2 blood product transfusions over 3 days while on study.\nThese measurements were taken relative to the first transfusion only, for consistency., timeFrame - Days 0, 1, 2, 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00699920",
    "endpoint": "measure - Fever and parasitological clearance evaluation by measuring the axillary temperature and monitoring paratesimia, description - , timeFrame - At the first attack",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00699920",
    "endpoint": "measure - Proportion of afebrile patients and proportion of patients without parasites, description - , timeFrame - At Day 3 (following attacks)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00699920",
    "endpoint": "measure - Evolution of baseline symptoms (Clinical efficacy measure), description - , timeFrame - During the study conduct",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00699920",
    "endpoint": "measure - Number of residual tablets in blisters (compliance), description - , timeFrame - At the end of the study treatment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00699920",
    "endpoint": "measure - Treatment incidence density: comparison of the number of malaria attacks between the 2 arms, description - , timeFrame - During the 2 years of follow-up",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00699920",
    "endpoint": "measure - Mean delay between 2 attacks, description - , timeFrame - during the 2 years of follow-up",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00699920",
    "endpoint": "measure - Incidence and intensity of recorded AE, description - , timeFrame - from the informed consent signed up to the end of the study",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00699920",
    "endpoint": "measure - Biological tolerability (Hb, Bilirubin, ALAT, Creatinine, Leucocytes, Neutrophils and Platelets count), description - , timeFrame - During the study conduct",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00699920",
    "endpoint": "measure - PCR corrected and uncorrected clinical and parasitological cure rate, description - , timeFrame - At Day 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05750628",
    "endpoint": "measure - Part A: PCR-corrected and uncorrected ACPR, description - Part A: To assess the 28-day cure rate of an anti malarial agent administered orally as monotherapy in patients with uncomplicated P. falciparum malaria, timeFrame - Day 29",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05750628",
    "endpoint": "measure - Parts B and C: PCT, description - Part B and C: To assess the parasite clearance time (PCT) of oral combinations of anti malarial agents versus the standard of care (SoC) in patients with uncomplicated P. falciparum malaria, timeFrame - up to Day 7",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05750628",
    "endpoint": "measure - Parts B and C: PCR-uncorrected ACPR, description - Part B and C: To assess the 28-day cure rate of an anti malarial agent administered orally as combination therapy versus the SoC in patients with uncomplicated P. falciparum malaria, timeFrame - Day 29",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05750628",
    "endpoint": "measure - Area under the concentration-time curve from time zero to the last measurable concentration sampling time (AUClast) of the anti-malarial agents (wherever possible), description - To characterize the pharmacokinetics (PK) of each anti-malarial agent administered orally as monotherapy [Part A] and&#x2F;or as combination therapy [Parts B and C] in patients with uncomplicated P. falciparum malaria.\nAUClast is the area under the curve (AUC) from time zero to the last measurable concentration sample time (tlast), timeFrame - Day 22",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05750628",
    "endpoint": "measure - Area under the concentration-time curve from time zero to infinity (AUCinf) of the anti-malarial agents (wherever possible), description - To characterize PK of each anti-malarial agent administered orally as monotherapy [Part A] and&#x2F;or as combination therapy [Parts B and C] in patients with uncomplicated P. falciparum malaria.\nAUCinf is the AUC from time zero to infinity., timeFrame - Day 22",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05750628",
    "endpoint": "measure - Maximum observed concentration (Cmax) of the anti-malarial agents, description - To characterize PK of each anti-malarial agent administered orally as monotherapy [Part A] and&#x2F;or as combination therapy [Parts B and C] in patients with uncomplicated P. falciparum malaria.\nCmax is the maximum (peak) observed plasma, blood, serum, or other blood fluid drug concentration after single dose administration., timeFrame - Day 22",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05750628",
    "endpoint": "measure - Time to reach maximum observed concentration (Tmax), description - To characterize PK of each anti-malarial agent administered orally as monotherapy [Part A] and&#x2F;or as combination therapy [Parts B and C] in patients with uncomplicated P. falciparum malaria.\nTmax is the time to reach maximum (peak) plasma, blood, serum, or other body fluid drug concentration after single dose administration., timeFrame - Day 22",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05750628",
    "endpoint": "measure - Elimination half-life (T1&#x2F;2) of the anti-malarial agents (wherever possible), description - To characterize PK of each anti-malarial agent administered orally as monotherapy [Part A] and&#x2F;or as combination therapy [Parts B and C] in patients with uncomplicated P. falciparum malaria.\nT1&#x2F;2 is the elimination half-life associated with the terminal slope of a semi-logarithmic concentration-time curve., timeFrame - Day 22",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05750628",
    "endpoint": "measure - Total body clearance (CL&#x2F;F) of the anti-malarial agents (wherever possible), description - To characterize PK of each anti-malarial agent administered orally as monotherapy [Part A] and&#x2F;or as combination therapy [Parts B and C] in patients with uncomplicated P. falciparum malaria.\nCl&#x2F;F is the total body clearance of drug from the plasma., timeFrame - Day 22",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05750628",
    "endpoint": "measure - Apparent volume of distribution (V&#x2F;F) of the anti-malarial agents (wherever possible), description - To characterize PK of each anti-malarial agent administered orally as monotherapy [Part A] and&#x2F;or as combination therapy [Parts B and C] in patients with uncomplicated P. falciparum malaria.\nV&#x2F;F is the apparent volume of distribution during terminal phase., timeFrame - Day 22",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05750628",
    "endpoint": "measure - Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs), description - Incidence and severity of AEs and SAEs by treatment group, including changes in vital signs, electrocardiograms (ECGs), and laboratory results qualifying and reported as AEs., timeFrame - Day 43",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02163447",
    "endpoint": "measure - Number of Participants With Blood Samples Positive for Parasites by Microscopy or LAMP, description - Prevalence of placental blood samples positive for parasites by microscopy or LAMP, timeFrame - Delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02163447",
    "endpoint": "measure - Number of Participants With Maternal Blood Samples Positive for Parasites by Microscopy and LAMP at Delivery, description - Prevalence of maternal parasitemia at delivery by microscopy and LAMP, timeFrame - At delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02163447",
    "endpoint": "measure - Number of Participants With One or More Birth Outcomes: Congenital Malformations, Spontaneous Abortion, LBW (&lt;2500g), Still Birth, Pre-term Delivery, description - Congenital malformations, spontaneous abortion, LBW (&lt;2500g), still birth, pre-term delivery, timeFrame - Delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02163447",
    "endpoint": "measure - Prevalence of Anemia in Pregnant Women, description - Prevalence of routine hemoglobin measurements &lt; 11 g&#x2F;dL, timeFrame - After first dose of study drugs up to delivery or early termination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02163447",
    "endpoint": "measure - Incidence of Complicated Malaria in Infants, description - Any treatment for malaria meeting criteria for severe malaria or danger signs, timeFrame - Birth up to 24 months of age or early study termination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02163447",
    "endpoint": "measure - Incidence of Hospital Admissions in Infants, description - Admission to a hospital for pediatric inpatient care for any reason, timeFrame - Birth up to 24 months of age or early study termination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02163447",
    "endpoint": "measure - Prevalence of Gametocytemia in Pregnant Women, description - Proportion of urgent blood smears positive for gametocytes, timeFrame - Gestational age between 12-20 weeks (at study entry) up to delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02163447",
    "endpoint": "measure - Prevalence of Parasitemia in Infants, description - Proportion of routine monthly samples positive for parasites by LAMP.\nProportion of routine samples (LAMP or blood smears) positive for asexual parasites., timeFrame - Birth up to 24 months of age or early study termination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02163447",
    "endpoint": "measure - Prevalence of Parasitemia at the Time of Monthly Routine Visits During Pregnancy, description - Detection of malaria parasites by LAMP during pregnancy, timeFrame - After first dose of study drug through delivery or early termination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02163447",
    "endpoint": "measure - Prevalence of Gametocytemia in Infants, description - Proportion of routine blood smears positive for gametocytes, timeFrame - Birth up to 24 months of age or early study termination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00320658",
    "endpoint": "measure - To demonstrate that the addition of CPG 7909 improves the specific immune responses to MSP142-FVO and MSP142-3D7, as compared to MSP142-C1&#x2F;Alhydrogel, description - , timeFrame - At Day 70",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00320658",
    "endpoint": "measure - To determine the dose of MSP142-C1&#x2F;Alhydrogel + CPG 7909 that generates the highest serum antibody levels of MSP142-FVO and MSP142-3D7, description - , timeFrame - At Day 70",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00121823",
    "endpoint": "measure - Prevention of malaria parasitaemia, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00384267",
    "endpoint": "measure - The rate of acquired malaria, description - , timeFrame - Immediately upon entry",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00384267",
    "endpoint": "measure - Prevalence of antimalarial antibodies in neonates, description - , timeFrame - Immediately upon entry",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00384267",
    "endpoint": "measure - The rate of congenital malaria, description - , timeFrame - Immediately upon entry",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00384267",
    "endpoint": "measure - Prevalence of specific hemoglobin types in study population, description - , timeFrame - Immediately upon entry",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01605786",
    "endpoint": "measure - Antibodies against synthetic PEBS, description - This will be measured by ELISA, timeFrame - Within one year following first vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01605786",
    "endpoint": "measure - Antibodies against parasite antigen, description - This will be measured by the following methods: whole parasite extract, ELISA, Western Blot, IFAT, timeFrame - Within one year following first vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01605786",
    "endpoint": "measure - PEBS Interferon-Gamma, description - This will be measured by ELISPOT, timeFrame - Within one year following first vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04336189",
    "endpoint": "measure - Number of Participants With Spontaneous Abortion, description - Spontaneous abortion defined as fetal loss at &lt; 28 weeks gestational age, timeFrame - Time of delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04336189",
    "endpoint": "measure - Incidence of Anemia Adverse Event Per Time at Risk, description - Grade 3-4 AEs as defined by the July 2017 NIH DAIDS Toxicity Tables, timeFrame - Day study drugs are first given until when study participants reach 28 days postpartum or early study termination, an average of 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04336189",
    "endpoint": "measure - Incidence of Grade 3-4 AEs Possibly Related to Study Drugs, description - Grade 3-4 AEs possibly or definitely related to study drug defined by the July 2017 NIH DAIDS Toxicity Tables, timeFrame - Day study drugs are first given until when study participants reach 28 days postpartum or early study termination, an average of 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04336189",
    "endpoint": "measure - Risk of Placental Malaria, description - Detection of malaria parasites or pigment by histopathology, timeFrame - At the time of delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04336189",
    "endpoint": "measure - Incidence of Malaria During Pregnancy, description - Episodes of symptomatic malaria (incidence per person year at risk following initiation of study drugs), timeFrame - Day study drugs first given until delivery, an average of 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04336189",
    "endpoint": "measure - Microscopic Parasitemia During Pregnancy, description - Proportion of routine samples with asexual parasites detected by microscopy, timeFrame - Day study drugs first given until delivery, an average of 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04336189",
    "endpoint": "measure - Prevalence of Anemia During Pregnancy, description - Proportion of routine hemoglobin measurements &lt; 11 g&#x2F;dL, timeFrame - Day study drugs are first given until delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04336189",
    "endpoint": "measure - Stillbirth, description - Stillbirth defined as infant born deceased at &gt; 28 weeks gestational age, timeFrame - Time of delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04336189",
    "endpoint": "measure - Low Birth Rate, description - Low birth weight defined as live birth with birth weight &lt; 2500 gm, timeFrame - Time of delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04336189",
    "endpoint": "measure - Preterm Delivery, description - Preterm delivery defined as live birth at &lt; 37 weeks gestational age, timeFrame - Time of delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04336189",
    "endpoint": "measure - Small-for-gestational Age, description - Small-for-gestational age defined as live birth with weight-for-gestational age &lt; 10th percentile of reference population, timeFrame - Time of delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04336189",
    "endpoint": "measure - Neonatal Death, description - Neonatal death defined as live birth with neonatal death within the first 28 days of life, timeFrame - Time of delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04336189",
    "endpoint": "measure - Microscopic or Sub-microscopic Parasitemia During Pregnancy, description - Proportion of routine samples with asexual parasites detected by microscopy or qPCR, timeFrame - Day study drugs first given until delivery, an average of 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04336189",
    "endpoint": "measure - Prevalence of Severe Anemia During Pregnancy, description - Proportion of routine hemoglobin measurements &lt; 8 g&#x2F;dL, timeFrame - Day study drugs are first given until delivery, an average of 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04336189",
    "endpoint": "measure - Incidence of Stillbirth Adverse Event Per Time at Risk, description - Grade 3-4 AEs as defined by the July 2017 NIH DAIDS Toxicity Tables, timeFrame - Day study drugs are first given until when study participants reach 28 days postpartum or early study termination, an average of 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04336189",
    "endpoint": "measure - Incidence of Congenital Anomaly Adverse Event Per Time at Risk, description - Grade 3-4 AEs as defined by the July 2017 NIH DAIDS Toxicity Tables, timeFrame - Day study drugs are first given until when study participants reach 28 days postpartum or early study termination, an average of 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04336189",
    "endpoint": "measure - Incidence of Neutropenia Adverse Event Per Time at Risk, description - Grade 3-4 AEs as defined by the July 2017 NIH DAIDS Toxicity Tables, timeFrame - Day study drugs are first given until when study participants reach 28 days postpartum or early study termination, an average of 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04336189",
    "endpoint": "measure - Incidence of Proteinuria Adverse Event Per Time at Risk, description - Grade 3-4 AEs as defined by the July 2017 NIH DAIDS Toxicity Tables, timeFrame - Day study drugs are first given until when study participants reach 28 days postpartum or early study termination, an average of 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04336189",
    "endpoint": "measure - Incidence of Thrombocytopenia Adverse Event Per Time at Risk, description - Grade 3-4 AEs as defined by the July 2017 NIH DAIDS Toxicity Tables, timeFrame - Day study drugs are first given until when study participants reach 28 days postpartum or early study termination, an average of 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04336189",
    "endpoint": "measure - Incidence of Postpartum Hemorrhage Adverse Event Per Time at Risk, description - Grade 3-4 AEs as defined by the July 2017 NIH DAIDS Toxicity Tables, timeFrame - Day study drugs are first given until when study participants reach 28 days postpartum or early study termination, an average of 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04336189",
    "endpoint": "measure - Incidence of Pre-eclampsia Adverse Event Per Time at Risk, description - Grade 3-4 AEs as defined by the July 2017 NIH DAIDS Toxicity Tables, timeFrame - Day study drugs are first given until when study participants reach 28 days postpartum or early study termination, an average of 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04336189",
    "endpoint": "measure - Incidence of Preterm Birth &lt;28 Gestational Age Adverse Event Per Time at Risk, description - Grade 3-4 AEs as defined by the July 2017 NIH DAIDS Toxicity Tables, timeFrame - Day study drugs are first given until when study participants reach 28 days postpartum or early study termination, an average of 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04336189",
    "endpoint": "measure - Incidence of Elevated Temperature Adverse Event Per Time at Risk, description - Grade 3-4 AEs as defined by the July 2017 NIH DAIDS Toxicity Tables, timeFrame - Day study drugs are first given until when study participants reach 28 days postpartum or early study termination, an average of 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01392014",
    "endpoint": "measure - Clearance of asexual stages P.falciparum, description - Finger prick blood samples are collected for malaria blood smear.\nThick and thin blood smears were stained with 3% Giemsa solution for 40 minutes and were read under binocular microscope with 1,000X magnification., timeFrame - 42 days post treatment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01838902",
    "endpoint": "measure - Prevalence of P.Falciparum gametocytes carriers, description - Prevalence of P. falciparum gametocyte carriers on days 3, 10, 14, 28 and 42, as determined by QT-NASBA, timeFrame - Days 3, 10, 14, 28 and 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01838902",
    "endpoint": "measure - Proportion of individuals infectious to mosquitoes (DMFA), description - % of individuals whose day 7 blood samples when fed to mosquitoes by direct membrane feeding assay, timeFrame - Day 7",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01838902",
    "endpoint": "measure - Haemoglobin change, description - Mean (±SD) difference in haemoglobin measured between baseline (day 0) and each follow up visit day by study arm, timeFrame - Day 0 and days 3, 7, 10, 14, 21, 28, 35 and 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01838902",
    "endpoint": "measure - Prevalence of infection (asexual stages), description - Proportion of participants carrying asexual forms of P. Falciparum on day 3, timeFrame - Day 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01838902",
    "endpoint": "measure - Proportion of participants with recurrent infection (PCR adjusted and unadjusted), description - % of participants previously negative for parasites with detectable parasite (by microscopy and PCR) in samples after day 7, timeFrame - Day 7 to Day 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01838902",
    "endpoint": "measure - Occurrence of adverse events (AEs) and serious adverse events (SAEs), description - Occurrence of adverse events (AEs) and serious adverse events (SAEs) during follow up, timeFrame - Day 3 to Day 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01708876",
    "endpoint": "measure - Rates of recurrent infection &#x2F; treatment failure at day 42., description - , timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01708876",
    "endpoint": "measure - Occurrence of anaemia at day 28 when using AS-MQ vs. CQ., description - , timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01708876",
    "endpoint": "measure - P. knowlesi and P. vivax gametocyte carriage throughout follow up when using AS-MQ vs. CQ., description - , timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01708876",
    "endpoint": "measure - Frequency of complications throughout follow up when using AS-MQ vs. CQ., description - , timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01708876",
    "endpoint": "measure - Utility of malaria rapid diagnostic tests in diagnosis of P. knowlesi infection., description - , timeFrame - 1 day",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01708876",
    "endpoint": "measure - Rates of P. knowlesi and P. vivax recurrence in a 1 year follow up period., description - , timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00425763",
    "endpoint": "measure - Side effects, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00425763",
    "endpoint": "measure - Molecular markers of drug resistance, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00312702",
    "endpoint": "measure - Anti-LSA-1 Antibody Response in Titer Units, description - Anti-LSA-1 Antibody Response in Titer Units on days 0, 28, 42 and 84, timeFrame - days 0, 28, 42 (challenge day) and 84",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03707041",
    "endpoint": "measure - Cohorts 2 and 3: Number of P218 TEAEs, description - Incidence, severity and relationship to the P218 treatment of observed or self-reported treatment emergent adverse events in non-immune healthy adult volunteers after two single doses of 1000 mg P218 administered 48 hours apart in a controlled human malaria infection (PfSPZ Challenge), timeFrame - 35 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03707041",
    "endpoint": "measure - Cohorts 2 and 3: Number of PfSPZ Challenge TEAEs, description - Incidence, severity and relationship to the PfSPZ Challenge of observed or self-reported treatment emergent adverse events in non-immune healthy adult volunteers before and after P218 administration, timeFrame - 35 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03707041",
    "endpoint": "measure - Cohorts 2 and 3: Malaria Clinical Score at the Time of Introduction of Rescue Therapy, description - <p>The malaria clinical score consists of 14 signs&#x2F;symptoms frequently associated with malaria and graded using a 4-point scale (absent: 0; mild: 1; moderate: 2; severe: 3) and summed to generate a total malaria clinical score (maximum score possible is 42): headache, myalgia (muscle ache), arthralgia (joint ache), fatigue&#x2F;lethargy, malaise (general discomfort&#x2F;uneasiness), chills&#x2F;shivering&#x2F;rigors, sweating&#x2F;hot spells, anorexia, nausea, vomiting, abdominal discomfort, fever, tachycardia and hypotension.</p><p>To determine severity of the 14 signs&#x2F;symptoms the CTCAE grading scale grade 1 - 5 was used.\nMild (1) equates to CTCAE grade 1, Moderate (2) equates to CTCAE grade 2 and Severe (3) equates to CTCAE grade 3 or above.\nIndividual scores for each symptom as well as the total score were recorded.</p>, timeFrame - On the day of positive parasitaemia or on Day 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03707041",
    "endpoint": "measure - Cohorts 1, 2 and 3: P218 AUC[0-48h] - Day 1, description - Area under the P218 plasma concentration-time curve from first administration to 48 hours after first administration, timeFrame - 9 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03707041",
    "endpoint": "measure - Cohort 1: P218-beta-acyl-glucuronide-OH AUC[48-96h], description - Area under the P218-beta-acyl-glucuronide-OH plasma concentration-time curve from 48 hours after first P218 administration to 96 hours after first P218 administration, timeFrame - 9 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03707041",
    "endpoint": "measure - Cohorts 1, 2 and 3: P218 Cmax - Day 1, description - Maximum observed P218 plasma concentration after each P218 administration, timeFrame - 9 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03707041",
    "endpoint": "measure - Cohorts 1, 2 and 3: P218 Tmax - Day 1, description - Time to P218 Cmax after each P218 administration, timeFrame - 9 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01867463",
    "endpoint": "measure - Antibody responses as measured by ELISA against recombinant Pfs25 and EPA, and B cell responses. Functional activity of the induced antibody will be assessed by direct transmission blocking assays, description - , timeFrame - 12 months following the last vaccination; and for 6 months following the fourth vaccination.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04041973",
    "endpoint": "measure - 28-day, 56-day, and 84-day PCR Plasmodium positivity rate for each species, description - , timeFrame - 28, 56 and, 84 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04041973",
    "endpoint": "measure - Proportion of participants with confirmed malaria reported between day 0 and day 28 for each species, description - , timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04041973",
    "endpoint": "measure - Incidence of confirmed clinical malaria cases as reported to government health facilities and village malaria workers.surveillance data., description - , timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04041973",
    "endpoint": "measure - Prevalence of Kelch13 mutations and other genetic markers of antimalarial drug resistance of known functional significance., description - , timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04041973",
    "endpoint": "measure - Incidence of adverse events and serious adverse events by study arms during the course of prophylaxis., description - , timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04041973",
    "endpoint": "measure - a. Number of people living in each village b. Number of people working in each reported location c. Number of people who have travelled to different locations within the preceding 2 months d. Number of people who have a mobile phone for their own use, description - , timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04041973",
    "endpoint": "measure - Latitude and longitude of the study participant over time in decimal degrees as recorded every 10-30 minutes by a GPS logging device., description - , timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04041973",
    "endpoint": "measure - Overall prevalence of Plasmodium at baseline, stratified by season and risk factors., description - , timeFrame - Day 0",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04041973",
    "endpoint": "measure - Day 0, 28, 56 and 84 capillary blood levels of lumefantrine., description - , timeFrame - 84 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04041973",
    "endpoint": "measure - Prevalence of serological diagnostic markers of other infectious diseases., description - , timeFrame - Day 0",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03168854",
    "endpoint": "measure - Documented malaria infection, defined as a positive qRT-PCR assays with parasite densities of &gt; &#x2F;= 20 estimated parasites&#x2F;mL, from blood samples obtained at least six hours apart or a positive TBS, description - , timeFrame - 28 days following CHMI",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03168854",
    "endpoint": "measure - Frequencies of PBMCs and PBMC subsets secreting specific cytokines on stimulation with whole sporozoites and potentially specific malaria antigens by intracellular cytokine staining (ICS) of cells, description - , timeFrame - Pre-vax visit, Pre-CHMI visit",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03168854",
    "endpoint": "measure - Levels of IgG antibodies to circumsporozoite protein (CSP) measured by ELISA on serum samples, description - , timeFrame - Pre-vax visit, Pre-CHMI visit",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01456858",
    "endpoint": "measure - Anaemia (From Haemoglobin levels), description - In each study cohort (ITPS V&#x27;s UPS arms in two camps) haemoglobin levels were monitored at 3 monthly intervals (three times during the 8 month monitoring period) using a HemoCue® photometer that was calibrated daily when used., timeFrame - 8 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01456858",
    "endpoint": "measure - Adverse Event to ITPS, description - Symptoms or conditions considered to be potential adverse events related to ITPS usage (dizziness, inflamed&#x2F;watery eyes, mucosal irritation, muscle cramps&#x2F;tremors, nausea, runny nose, skin burning, skin itching, skin paraesthesia, skin rash, skin redness, sneezing and tachycardia (pulse rate &gt;150)) were recorded during the monitoring period in both ITPS and UPS intervention arms in each camp.\nA symptom listed repeatedly within a seven day period for each child was considered to be the same adverse event as was any child having more than one of the symptoms present on a single day., timeFrame - 8 Months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01546389",
    "endpoint": "measure - T cell responses, effector&#x2F;central memory populations, and intracellular cytokine secretion (ICS) against the malaria antigens by Multiparameter Flow Cytometry, description - , timeFrame - Days 0, 5, 14 and 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01546389",
    "endpoint": "measure - Occurrence of a positive real-time quantitative polymerase chain reaction (PCR) after the malaria challenge during a 56-day surveillance period., description - , timeFrame - Days 0, 5-18, 20, 22, 24, 26, 28, 35, 42, and 56.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01546389",
    "endpoint": "measure - Antibody titers to the pre-erythrocytic stage antigens, and by indirect fluorescent antibody test for antibodies to P. falciparum sporozoites, late liver stage parasites, asexual and sexual erythrocytic stages., description - , timeFrame - Days 0, 5, 14 and 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07038837",
    "endpoint": "measure - Malaria incidence, description - Incidence of clinical malaria (biologically confirmed by RDT) in each study arm among children aged 6-59 months, irrespective of R21&#x2F;MM vaccination status, timeFrame - from enrolment to Month 17 (Aug 2025- Dec 2026)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07038837",
    "endpoint": "measure - R21&#x2F;MM vaccination coverage, description - Proportion of children having received the appropriate number of doses for their age, timeFrame - from enrolment to Month 17 (Aug 2025- Dec 2026)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07038837",
    "endpoint": "measure - Coverage of other malaria prevention measures, description - Proportion of children possessing, and proportion of children using, a long-lasting insecticidal net (LLIN) on the day before completing the coverage survey questionnaire, timeFrame - from enrolment to Month 17 (Aug 2025- Dec 2026)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07038837",
    "endpoint": "measure - Coverage of other EPI antigens, description - o Proportion of age-eligible children vaccinated against measles-1 and measles-2., timeFrame - from enrolment to Month 17 (Aug 2025- Dec 2026)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07038837",
    "endpoint": "measure - Protective efficacy against severe malaria, description - Protective efficacy of vaccination with R21&#x2F;MM will be measured at the individual level against severe malaria confirmed by RDT and microscopy.\nThe protective efficacy will be calculated from the relative risk (RR) of developing severe malaria in vaccinated and unvaccinated children., timeFrame - From enrollment to Month 17 (Aug 2025- december 2026)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07038837",
    "endpoint": "measure - Proportional morbidity, description - o Proportion of all-cause morbidity registered at health centres attributed to uncomplicated malaria, timeFrame - From enrollment to Month 17 (Aug 2025- december 2026)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07038837",
    "endpoint": "measure - R21&#x2F;MM safety, description - o Frequency of reported serious adverse events (SAEs), adverse events following immunization (AEFI), Serious AEFIs and reported adverse events of special interest (AESIs) following R21&#x2F;MM vaccination, timeFrame - From enrollment to Month 17 (Aug 2025- december 2026)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07038837",
    "endpoint": "measure - Coverage of other malaria prevention measures, description - SMC coverage: average number of doses received per child and proportion of children receiving 0 and 5 doses, timeFrame - From enrolment to month 17 (Aug 2025- Dec 2026)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00666380",
    "endpoint": "measure - Percent parasite growth inhibition, description - Functionality of antibodies elicited as measured by percent parasite growth inhibition in GIA against homologous (FVO) and heterologous (3D7) parasites, timeFrame - Up to 112 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00408668",
    "endpoint": "measure - Immunogenicity - Vaccine immunogenicity assessed by IFN-γ ELISPOT and ELISA for vaccine specific antibodies, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00408668",
    "endpoint": "measure - Safety - Vaccine safety assessed by collection of local and systemic adverse events., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01907672",
    "endpoint": "measure - Proportion of mRDT -ve clients who received an anti-malarial in the RDT arm, description - Out of all clients who test negative by RDT, number who receive an antimalarial, timeFrame - Until the estimated sample size is obtained or up to 2 years, whichever comes first",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01907672",
    "endpoint": "measure - Proportion of clients tested using a Rapid Diagnostic Test, description - The number of clients who agree to be tested with an RDT Out of all clients who meet inclusion criteria, timeFrame - Until the estimated sample size is obtained or up to 2 years, whichever comes first",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01907672",
    "endpoint": "measure - Proportion of clients in each arm receiving an antibiotic, description - The number of clients in the intervention and control arms who receive an antibiotic out of the total number of clients recruited into each arm, timeFrame - Until the estimated sample size is obtained or up to 2 years, whichever comes first",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01907672",
    "endpoint": "measure - Proportion of clients receiving addittional or alternative treatments to antimalarial and which these are, description - The number of clients who receive additional or alternative treatments in the intervention and control arms out of the total number recruited into both arms, timeFrame - Until the estimated sample size is obtained or up to 2 years, whichever comes first",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02389348",
    "endpoint": "measure - Incidence, relation to study drug and severity of AE, description - Assessment of tolerability and safety of OZ439 and DSM265 in the challenge model, timeFrame - From challenge inoculum and up to 42 days following inoculum",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02389348",
    "endpoint": "measure - Cmax, Tmax, AUC of DSM265 and OZ439, description - Appropriate PK parameters will be determined including non-compartmental and modeling characterisation, timeFrame - From Drug administration up to 42 days following inoculum",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05441410",
    "endpoint": "measure - Assessment of protective efficacy of PfSPZ-CVac&#x2F;Pyramax and of MVA ME-TRAP &#x2F;ChAd63 ME-TRAP in healthy, malaria-naïve adults against homologous CHMI with PfSPZ Challenge (NF54) by DVI, description - Assessment of the development of parasitemias following the controlled human malaria infection (CHMI), timeFrame - From administration of CHMI (Group 1:day 113, Group 2: 59) until the last follow-up visit (Group 1: day 136, Group 2: day 82)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00360230",
    "endpoint": "measure - Number of Subjects With Any and Grade 3 Solicited Local Symptoms, description - Assessed solicited local symptoms were pain and swelling.\nAny = occurrence of the symptom regardless of intensity grade.\nGrade 3 pain = pain that prevented normal activity.\nGrade 3 swelling = swelling spreading beyond 20 millimeters (mm) of injection site., timeFrame - During the 7-day (Days 0 - 6) post-vaccination period following each dose and across doses",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00360230",
    "endpoint": "measure - Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms, description - Assessed solicited general symptoms were drowsiness, fever [defined as axillary temperature equal to or above (≥) 37.5 degrees Celsius (°C)], irritability and loss of appetite.\nAny = occurrence of the symptom regardless of intensity grade.\nGrade 3 symptom = symptom that prevented normal activity.\nGrade 3 fever = fever higher than (&gt;) 39.0 °C.\nRelated = symptom assessed by the investigator as related to the vaccination., timeFrame - During the 7-day (Days 0 - 6) post-vaccination period following each dose and across doses",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00360230",
    "endpoint": "measure - Number of Subjects With Any Unsolicited Adverse Events (AEs), description - An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.\nAny was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination., timeFrame - During the 30-day (Days 0 - 29) post-vaccination period following each dose and across doses",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00360230",
    "endpoint": "measure - Titers for Anti-Circumsporozoite Protein of Plasmodium Falciparum (Anti-CS), description - Titers are presented as geometric mean titers (GMTs) and expressed in enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U&#x2F;mL)., timeFrame - At Day 0, at Month 2, at Month 7 and at Month 10",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00360230",
    "endpoint": "measure - Titers for Anti-Hepatitis B (Anti-HBs), description - Titers are presented as geometric mean titers (GMTs) and expressed in milli-international units per milliliter (mIU&#x2F;mL)., timeFrame - At Day 0 and at Month 2",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02672228",
    "endpoint": "measure - Safety profile of Malarisense technology for malaria diagnosis, description - Safety of the MalariSense Technology for malaria diagnosis over 3 days of observation, timeFrame - Day 1 - Day 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02672228",
    "endpoint": "measure - Correlation of incidence rate ratio of hemozoin-positive traces with level of parasite density as determined by microscopy, description - , timeFrame - Day1 - Day 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05343312",
    "endpoint": "measure - To evaluate the incidence of adverse events, description - Safety was assessed by administering a questionnaire about the nature and incidence of adverse events and serious adverse events.\nAn adverse event is defined as any unfavorable, unintended sign, symptom, syndrome or disease that develops or worsens with the use of a medicinal product, regardless of whether it is related to the medicinal product., timeFrame - 28&#x2F;42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05343312",
    "endpoint": "measure - To measure the Day PCR uncorrected cure rates of Artemether-Lumefantrine, Amodiaquine-Artesunate, Dihydroartemisinin-Piperaquine, and Pironaridine-Artesunate., description - This cure rate is defined as the proportion of patients with adequate clinical and parasitological response (ACPR) at Day 28&#x2F;42, without PCR correction to differentiate recrudescences from new infections and hence considering as treatment failures all parasite recurrences., timeFrame - 28&#x2F;42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05343312",
    "endpoint": "measure - Evaluate the presence of Molecular Markers associated with sub optimum responses to ACTs, description - The presence of molecular marks is defined as presence of mutations in pfk13 and pfmdr1 (at codons 86, 184 and 1246) genes identified by Sanger sequencing of pre-treatment samples., timeFrame - 28&#x2F;42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03576313",
    "endpoint": "measure - malaria prevalence, description - malaria prevalence at the peak of the first transmission season of number of participants with a positive varATS quantitative PCR divided by the total number of participants sampled, timeFrame - at 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03576313",
    "endpoint": "measure - incidence of clinical (laboratory confirmed) malaria cases, description - incidence of clinical (laboratory confirmed) malaria cases at health facilities of Number of clinical malaria cases observed divided by person-years of follow-up, timeFrame - after MDA over 6 months period",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03576313",
    "endpoint": "measure - serological markers of recent malaria, description - serological markers of recent malaria infection by Mean Fluorescent Intensity of the different antigens will be determined and presented as a geometric mean, timeFrame - after MDA over 6 months period",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03576313",
    "endpoint": "measure - serological markers of recent Anopheles exposure, description - serological markers of recent Anopheles exposure by Mean Fluorescent Intensity of the different antigens will be determined and presented as a geometric mean, timeFrame - after MDA over 6 months period",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03576313",
    "endpoint": "measure - mosquito density, description - Total number of mosquitoes collected during the study period across both intervention and control villages, timeFrame - over 24 months after MDA",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03576313",
    "endpoint": "measure - mosquito mortality, description - mosquito mortality after feeding on IVM treated individuals Number of mosquitoes that die after a blood meal 21 days post-treatment divided by total number of mosquitoes blood fed, timeFrame - 21 days post treatment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03576313",
    "endpoint": "measure - sporozoite rates in field-caught mosquitoes, description - Number of P. falciparum circumsporozoite antibody (CSP) positive mosquitoes divided by the total number of mosquitoes caught, timeFrame - over 24 months after MDA",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07060508",
    "endpoint": "measure - Pf blood-stage infection as detected by thick blood smear and RT-PCR, description - For 24 weeks after administration of study agent., timeFrame - Blood smear once every 2 weeks post injection through 24 weeks.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07060508",
    "endpoint": "measure - Concentration of L9LS in sera of recipients., description - , timeFrame - Through 24 weeks.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02533336",
    "endpoint": "measure - Effectiveness of DL on anemia, description - change in mean haemoglobin in the intervention arm compared to the control, timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00890760",
    "endpoint": "measure - Safety of vaccine, description - , timeFrame - Approxiamately 5-16 months following last intervention",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00984256",
    "endpoint": "measure - Measured Concentrations of Plasma Atovaquone With Determinations of T1&#x2F;2., description - Plasma concentrations (ng&#x2F;ml) were used to determine the elimination half life (t1&#x2F;2) of atovaquone (days)., timeFrame - 7, 6, 5, and 1 day prior to challenge; on the day of the challenge; 1, 4, 5, 6, 7, 8, 10and 14 days after the challenge; and on the day parasitemia develops.,",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00984256",
    "endpoint": "measure - Measured Concentrations of Plasma Atovaquone With Determinations of Area Under the Curve, description - Plasma concentrations were used to determine the pharmacokinetic curves with determinations of area under the curve (AUC).The smallest AUC Day 0-6.5 associated with protection from detectable parasitemia, and the highest AUC Day 0-6.5 observed in any cases of malaria (prophylactic failures) were to be reported., timeFrame - 7, 6, 5, and 1 day prior to challenge; on the day of the challenge; 1, 4, 5, 6, 7, 8, 10and 14 days after the challenge; and on the day parasitemia develops.,",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03906474",
    "endpoint": "measure - P. falciparum specific immunogenicity following primary, secondary and tertiary P. falciparum blood-stage infection, as assessed by antibody, B cell and T cell responses, description - , timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03906474",
    "endpoint": "measure - Gametocytaemia following primary, secondary and tertiary P. falciparum blood-stage infection., description - Gametocytaemia will be measured by PCR., timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01360112",
    "endpoint": "measure - a)Antibody levels to sexual P. falciparum antigens, and other antigens of interest., description - , timeFrame - 24 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01360112",
    "endpoint": "measure - b)Mosquito infectivity as measured by circumsporozoite protein (CSP) ELISA., description - , timeFrame - 24 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01360112",
    "endpoint": "measure - c)Hemoglobin level as measured by HemoCue., description - , timeFrame - 24 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01360112",
    "endpoint": "measure - d)Hemoglobin variants (hemoglobin S, C, alpha thalassemia), G6PD status, blood group&#x2F;Rh., description - , timeFrame - 24 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02207816",
    "endpoint": "measure - Incidence of Clinical Malaria Meeting Case Definition, description - Clinical malaria was defined as an episode of malaria with positive Plasmodium falciparum asexual parasitemia, accompanied by the presence of fever (axillary temperature ≥ 37.5°C ) at the time of presentation or history of fever within 24 hours of presentation and occurring in a child who was unwell and brought for treatment to a healthcare facility.\nThe incidence of clinical malaria for case definition 1 is expressed as a person year rate for each group (n&#x2F;T), representing the number of events (n) reported over the risk period, which was counted in days and expressed as person years a t risk (T).\nDue to late protocol approvals and retrospective data collection the sites did not collect the data according to protocol and as such the case definition cannot be applied.\nFor the final analysis, specific case definitions based on available data were developed., timeFrame - From Year 0 to Year 3 (Starting January 2014 and ending December 2016)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02207816",
    "endpoint": "measure - Number of Subjects With Malaria Hospitalization Meeting Case Definition 1., description - Malaria hospitalization, case definition 1, was defined as a medical hospitalization with confirmed positive Plasmodium falciparum asexual parasitemia (excludes planned admissions for medical investigation&#x2F;care or elective surgery and trauma)., timeFrame - From Year 0 to Year 3 (Starting January 2014 and ending December 2016)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02207816",
    "endpoint": "measure - Number of Subjects With Malaria Hospitalization Meeting Case Definition 2., description - Malaria hospitalization, case definition 2, was defined as a hospitalization for which, in the judgment of the principal investigator, Plasmodium falciparum infection was the sole or a major contributing factor to the presentation., timeFrame - From Year 0 to Year 3 (Starting January 2014 and ending December 2016)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02207816",
    "endpoint": "measure - Number of Subjects With Prevalent Parasitemia, description - Prevalent parasitemia (PP) was defined as a documented Plasmodium falciparum asexual parasite density greater than (&gt;) 0 parasites&#x2F;µL, identified at an annual visit., timeFrame - At Years 1, 2 and 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02207816",
    "endpoint": "measure - Number of Subjects With Prevalent Severe Anemia (Level of Hemoglobin &lt;5g&#x2F;dL), description - Prevalent severe anemia (PSA) was defined as a documented hemoglobin lower than (&lt;) 5.0 grams per deciliter (g&#x2F;dL), identified at an annual visit., timeFrame - At Years 1, 2 and 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02207816",
    "endpoint": "measure - Number of Subjects With Prevalent Moderate Anemia (Level of Hemoglobin &lt;8g&#x2F;dL), description - Prevalent moderate anemia (PMA) was defined as a documented hemoglobin &lt; 8.0 g&#x2F;dL, identified at an annual visit., timeFrame - At Years 1, 2 and 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02207816",
    "endpoint": "measure - Incidence of Severe Malaria Meeting Case Definition 1., description - Case definition 1 for severe malaria was defined as an episode of malaria with positive Plasmodium falciparum asexual parasitemia (within -1 to +3 days of admission) and with one or more marker of disease severity: Prostration, respiratory distress, Blantyre score equal to or less than (≤) 2, seizures 2 or more, hypoglycemia below (&lt;) 2.2 millimoles per liter (mmol&#x2F;L), acidosis BE ≤ -10.0 mmol&#x2F;L, lactate ≥ 5.0 mmol&#x2F;L or anemia &lt; 5.0 grams per deciliter (g&#x2F;dL).\nThe incidence of severe malaria for case definition 1 is expressed as a person year rate for each group (n&#x2F;T), representing the number of events (n) reported over the risk period, which was counted in days and expressed as person years at risk (T)., timeFrame - From Month 0 (study start of Malaria-055) to Year 3 (study end of Malaria-076)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02207816",
    "endpoint": "measure - Incidence of Severe Malaria Meeting Case Definition 2., description - Case definition 2 for severe malaria was defined as an episode of malaria with positive Plasmodium falciparum asexual parasitemia (within -1 to +3 days of admission) and with one or more marker of disease severity: Prostration, respiratory distress, Blantyre score equal to or less than (≤) 2, seizures 2 or more, hypoglycemia below (&lt;) 2.2 millimoles per liter (mmol&#x2F;L), acidosis BE ≤ -10.0 mmol&#x2F;L, lactate ≥ 5.0 mmol&#x2F;L or anemia &lt; 5.0 grams per deciliter (g&#x2F;dL) or SAE report including preferred terms (Malaria, Plasmodium falciparum infection or Cerebral malaria) within -1 to +3 days of admission.\nThe incidence of severe malaria for case definition 2 is expressed as a person year rate for each group (n&#x2F;T), representing the number of events (n) reported over the risk period, which was counted in days and expressed as person years at risk (T)., timeFrame - From Month 0 (study start of Malaria-055) to Year 3 (study end of Malaria-076)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02207816",
    "endpoint": "measure - Incidence of Clinical Malaria Meeting Case Definition, description - Clinical malaria was defined as an episode of malaria with positive Plasmodium falciparum asexual parasitemia, accompanied by the presence of fever (axillary temperature ≥ 37.5°C) at the time of presentation or history of fever within 24 hours of presentation and occurring in a child who was unwell and brought for treatment to a healthcare facility.\nThe incidence of clinical malaria for case definition 1 is expressed as a person year rate for each group (n&#x2F;T), representing the number of events (n) reported over the risk period, which was counted in days and expressed as person years at risk (T).\nDue to late protocol approvals and retrospective data collection the sites did not collect the data according to protocol and as such the case definition cannot be applied.\nFor the final analysis, specific case definitions based on available data were developed., timeFrame - From Month 0 (study start of Malaria-055) to Year 3 (study end of Malaria-076)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02207816",
    "endpoint": "measure - Number of Subjects With Malaria Hospitalization Meeting Case Definition 1., description - Malaria hospitalization, case definition 1, was defined as a medical hospitalization with confirmed positive Plasmodium falciparum asexual parasitemia (excludes planned admissions for medical investigation&#x2F;care or elective surgery and trauma)., timeFrame - From Month 0 (study start of Malaria-055) to Year 3 (study end of Malaria-076)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02207816",
    "endpoint": "measure - Number of Subjects With Malaria Hospitalization Meeting Case Definition 2., description - Malaria hospitalization, case definition 2, was defined as a hospitalization for which, in the judgment of the principal investigator, Plasmodium falciparum infection was the sole or a major contributing factor to the presentation., timeFrame - From Month 0 (study start of Malaria-055) to Year 3 (study end of Malaria-076).",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02207816",
    "endpoint": "measure - Number of Subjects With Cerebral Malaria Meeting Both Case Definitions., description - Cerebral malaria was defined as a positive P. falciparum asexual parasitemia (within -1 to +3 days of admission), accompanied either by the presence of a marker of disease severity (a Blantyre score ≤ 2) or a SAE report with &#x27;cerebral malaria&#x27; as preferred term., timeFrame - From Year 0 to Year 3 (Starting January 2014 and ending December 2016)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02207816",
    "endpoint": "measure - Number of Subjects With Fatal Malaria Meeting Case Definition 1., description - Fatal malaria, case definition 1, was defined as a SAE report with preferred terms &#x27;malaria&#x27;, &#x27;plasmodium falciparum infection&#x27;, &#x27;cerebral malaria&#x27; with confirmed positive Plasmodium falciparum asexual parasitemia associated with a fatal outcome (excludes planned admissions for medical investigation&#x2F;care or elective surgery and trauma)., timeFrame - From Year 0 to Year 3 (Starting January 2014 and ending December 2016)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02207816",
    "endpoint": "measure - Number of Subjects With Fatal Malaria Meeting Case Definition 2., description - Fatal malaria, case definition 2, was defined as a SAE report with preferred terms &#x27;malaria&#x27;, &#x27;plasmodium falciparum infection&#x27;, &#x27;cerebral malaria&#x27; associated with a fatal outcome., timeFrame - From Year 0 to Year 3 (Starting January 2014 and ending December 2016)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02207816",
    "endpoint": "measure - Number of Subjects With Cerebral Malaria, description - Cerebral malaria was defined as a positive P. falciparum asexual parasitemia (within -1 to +3 days of admission), accompanied either by the presence of a marker of disease severity (a Blantyre score ≤ 2) or a SAE report with &#x27;cerebral malaria&#x27; as preferred term., timeFrame - From Month 0 (study start of Malaria-055) to Year 3 (study end of Malaria-076).",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02207816",
    "endpoint": "measure - Number of Subjects With Fatal Malaria Meeting Case Definition 1., description - Fatal malaria, case definition 1, was defined as a SAE report with preferred terms &#x27;malaria&#x27;, &#x27;plasmodium falciparum infection&#x27;, &#x27;cerebral malaria&#x27; with confirmed positive Plasmodium falciparum asexual parasitemia associated with a fatal outcome (excludes planned admissions for medical investigation&#x2F;care or elective surgery and trauma)., timeFrame - From Month 0 (study start of Malaria-055) to Year 3 (study end of Malaria-076).",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02207816",
    "endpoint": "measure - Number of Subjects With Fatal Malaria Meeting Case Definition 2., description - Fatal malaria, case definition 2, was defined as a SAE report with preferred terms &#x27;malaria&#x27;, &#x27;plasmodium falciparum infection&#x27;, &#x27;cerebral malaria&#x27; associated with a fatal outcome., timeFrame - From Month 0 (study start of Malaria-055) to Year 3 (study end of Malaria-076).",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02207816",
    "endpoint": "measure - Number of Subjects Reporting Any, Related, Malaria and Fatal Serious Adverse Events (SAEs), description - Malaria SAEs were defined as SAEs coded by MedDRA preferred term level as &#x27;malaria&#x27;, &#x27;Plasmodium falciparum infection&#x27; or &#x27;cerebral malaria&quot;.\nA serious adverse event was any untoward medical occurrence that: resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization or resulted in disability&#x2F;incapacity.\nSAEs disclosed in this outcome are any SAEs , fatal SAEs, those that were related to vaccine administration in the primary study MALARIA-055 PRI (110021) and malaria hospitalization., timeFrame - From Year 0 to Year 3 (Starting January 2014 and ending December 2016)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02207816",
    "endpoint": "measure - Number of Subjects Reporting Any Potential Immune-mediated Disorders (pIMDs) SAEs, description - Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and&#x2F;or neurologic disorders of interest which may or may not have an autoimmune aetiology.\nRegardless of it being considered an AE or an SAE, it should have been reported per the SAE reporting rules., timeFrame - From Year 0 to Year 3 (Starting January 2014 and ending December 2016)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02207816",
    "endpoint": "measure - Number of Subjects With Meningitis SAEs, description - For the further evaluation of the safety signal of meningitis all the cases occurring during the study were reported as SAE.\nMeningitis is defined as an SAE coded at lowest level terms code, coded by MedDRA preferred term level as: &#x27;meningitis&#x27;, &#x27;meningitis haemophilus&#x27;, &#x27;meningitis meningococcal&#x27;, &#x27;meningitis salmonella&#x27;, &#x27;meningitis pneumococcal&#x27;, &#x27;meningitis staphylococcal&#x27;, &#x27;meningitis tuberculous&#x27;, &#x27;meningitis herpes&#x27;, &#x27;meningitis candida&#x27;, &#x27;meningitis enterococcal&#x27;, &#x27;meningitis enteroviral&#x27;, &#x27;meningitis neonatal&#x27;, &#x27;meningitis toxoplasmal&#x27;, &#x27;meningitis mumps&#x27;, &#x27;meningitis cryptococcal&#x27;, &#x27;meningitis histoplasma&#x27;, &#x27;meningitis trypanosomal&#x27;, &#x27;Neurosyphilis&#x27;, &#x27;meningitis leptospiral&#x27;, &#x27;meningitis listeria&#x27;, &#x27;meningitis in sarcoidosis&#x27; (code in preferred term &#x27;cerebral sarcoidosis&#x27;), &#x27;meningitis bacterial&#x27;, &#x27;meningitis viral&#x27;, &#x27;meningitis aseptic&#x27;, &#x27;meningitis fungal&#x27;., timeFrame - From Year 0 to Year 3 (Starting January 2014 and ending December 2016)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02207816",
    "endpoint": "measure - Antibody Concentrations Against Against Plasmodium Falciparum Circumsporozoite (Anti-CS), description - Antibody concentrations were assessed by enzyme-linked immunosorbent assay (ELISA) and presented as geometric mean titers (GMTs).\nSeropositivity anti-CS antibody cut-off was 0.5 EU&#x2F;mL for Malaria-055 time points and 1.9 EU&#x2F;mL for Malaria-076 time points., timeFrame - At screening, 1 month post Dose 3 (Month 3), 18 months post Dose 3 (Month 20), 1 month post Dose 4 (Month 21), 12 months post Dose 4 (Month 32) (of Malaria-055) and at Years 1, 2 and 3 (of Malaria-076)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03035305",
    "endpoint": "measure - Fever case, description - Fever case is defined by an axillary temperature greater than 37.5⁰C measured by electronic thermometer or notion fever within 48 hours.\nThis outcome will be defined as the occurrence of at least one fever case from the 2nd through the 4th round of SMC distribution., timeFrame - From the 2nd round of SMC distribution (4 weeks after the date of inclusion) to the 4th round of SMC distribution (12 weeks after the date of inclusion), assessed up to 8 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03035305",
    "endpoint": "measure - Global acute malnutrition case, description - Global acute malnutrition is defined by MUAC &lt;125mm (orange or red color MUAC) and&#x2F;or bilateral edema.\nThis outcome will be defined as the occurrence of at least one global acute malnutrition case from the 2nd through the 4th round of SMC distribution., timeFrame - From the 2nd round of SMC distribution (4 weeks after the date of inclusion) to the 4th round of SMC distribution (12 weeks after the date of inclusion), assessed up to 8 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03035305",
    "endpoint": "measure - Moderate acute malnutrition case, description - Moderate acute malnutrition is defined by MUAC between 115-124mm (orange color MUAC).\nThis outcome will be defined as the occurrence of at least one moderate acute malnutrition case from the 2nd through the 4th round of SMC distribution., timeFrame - From the 2nd round of SMC distribution (4 weeks after the date of inclusion) to the 4th round of SMC distribution (12 weeks after the date of inclusion), assessed up to 8 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03035305",
    "endpoint": "measure - Severe acute malnutrition case, description - Severe acute malnutrition is defined by MUAC &lt;115mm (red color MUAC) and&#x2F;or bilateral edema.\nThis outcome will be defined as the occurrence of at least one severe acute malnutrition case from the 2nd through the 4th round of SMC distribution., timeFrame - From the 2nd round of SMC distribution (4 weeks after the date of inclusion) to the 4th round of SMC distribution (12 weeks after the date of inclusion), assessed up to 8 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03035305",
    "endpoint": "measure - Medical referral case, description - This outcome will be defined as the occurrence of at least one illness of sufficient severity to warrant referral to the nearest medical structure for evaluation from the 2nd through the 4th round of SMC distribution., timeFrame - From the 2nd round of SMC distribution (4 weeks after the date of inclusion) to the 4th round of SMC distribution (12 weeks after the date of inclusion), assessed up to 8 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02932072",
    "endpoint": "measure - kappa statistic for parasite species detection, description - , timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02932072",
    "endpoint": "measure - Bland-Altman plots for parasite density estimation, description - , timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04618523",
    "endpoint": "measure - Proportion of adverse events and serious adverse events, description - Number of adverse events and serious adverse events that every participant will experience, timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04618523",
    "endpoint": "measure - Proportion of participants with positive blood smear at day 3, description - Number of participants who will still have parasites on day 3, timeFrame - 3 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02556242",
    "endpoint": "measure - Intervention costs per 1,000 households and cost-effectiveness of reactive, targeted indoor residual spraying (TIRS) compared to generalised IRS (GIRS), description - Cost of spray operations will be determined in each study arm, timeFrame - Up to 20 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02556242",
    "endpoint": "measure - Proportion of structures targeted for IRS unsprayed, description - , timeFrame - Up to 20 months whenever reactive spraying is triggered",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02556242",
    "endpoint": "measure - Household compliance (not painting, washing, re-plastering ), description - In a representative sample household survey in all clusters, a questionnaire will be used in which householders will be asked whether they painted, re-plastered or washed walls after spraying, timeFrame - By cross sectional household survey after 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02556242",
    "endpoint": "measure - Householder acceptability of IRS, description - In a representative sample household survey in all clusters, a questionnaire will be used in which householders will be asked whether they want their house sprayed with insecticide in future, timeFrame - By cross sectional household survey after 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02556242",
    "endpoint": "measure - If unsprayed, proportions due to refusals, spray teams not making contact and spray teams not calling back, description - In a representative sample household survey in all clusters, a questionnaire will be used in which householders whose houses remained unsprayed will be asked whether this was because they refused or because spray teams did not make contact or did not call back if they were away, timeFrame - By cross sectional household survey after 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02556242",
    "endpoint": "measure - Sero-prevalence of antibodies to malaria antigens AMA-1 and MSP-1-19, description - In a representative sample household survey in all clusters, a filter paper dried blood spot a will be taken from a sample of individuals of all ages, subject to informed written consent, timeFrame - By cross sectional household survey after 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00694694",
    "endpoint": "measure - Combined clinical and parasitological outcome by day 42, description - , timeFrame - 42 days after treatment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00694694",
    "endpoint": "measure - Adverse events other than parasitologial failure., description - , timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02940756",
    "endpoint": "measure - PCR-unadjusted efficacy, description - the proportion of children with treatment failure: all treatment failures detected during the follow-up, regardless of genotyping, timeFrame - day 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02940756",
    "endpoint": "measure - K-13 propeller polymorphisms, description - the proportion of mutations in portions of P. falciparum gene encoding kelch(K-13)-propeller domains (confering resistance to artemisinin), timeFrame - day 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02940756",
    "endpoint": "measure - incidence of adverse events, description - monitoring of all adverse events experienced by participants, timeFrame - day 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01228344",
    "endpoint": "measure - Adverse event, serious adverse event after artemether-lumefantrine treatment start, description - , timeFrame - 4 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01228344",
    "endpoint": "measure - Pregnancies after artemether-lumefantrine treatment start, description - , timeFrame - Up to delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05025761",
    "endpoint": "measure - Symptomatic malaria diagnosed by RDT, description - Change in the number of symptomatic Plasmodium spp.\ninfections detected by RDT per week per village, timeFrame - Assessed weekly, longitudinally over 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05025761",
    "endpoint": "measure - Plasmodium spp. infection as determined by polymerase chain reaction (PCR), description - Change in the number of Plasmodium spp.\ninfections as determined by PCR using from RDT cassettes and dried blood spots, timeFrame - Assessed weekly, longitudinally over 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05025761",
    "endpoint": "measure - Plasmodium spp. drug resistance mutations, description - Prevalence and change in the number of Plasmodium spp.\ndrug resistance mutations as determined by PCR from RDT cassettes and dried blood spots, timeFrame - Assessed weekly, longitudinally over 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05025761",
    "endpoint": "measure - Prevalence of antibodies to Plasmodium spp., description - Prevalence of antibodies to Plasmodium spp.\ndetermined by Enzyme Linked Immunosorbent assay (ELISA) from RDT and DBS samples, timeFrame - Assessed weekly, longitudinally over 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05025761",
    "endpoint": "measure - Levels of antibodies to Plasmodium spp., description - Levels of antibodies to Plasmodium spp.\ndetermined by Enzyme Linked Immunosorbent assay (ELISA) from RDT and DBS samples, timeFrame - Assessed weekly, longitudinally over 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05025761",
    "endpoint": "measure - Prevalence of antibodies to vector salivary antigens, description - Prevalence of antibody biomarkers of vector exposure determined by Enzyme Linked Immunosorbent assay (ELISA) from RDT and DBS samples, timeFrame - Assessed weekly, longitudinally over 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05025761",
    "endpoint": "measure - Levels of antibodies to vector salivary antigens, description - Levels of antibody biomarkers of vector exposure determined by Enzyme Linked Immunosorbent assay (ELISA) from RDT and DBS samples, timeFrame - Assessed weekly, longitudinally over 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05025761",
    "endpoint": "measure - Levels of knowledge, attitude and practice regarding malaria prevention among MMPs (qualitative research), description - Focus group discussions, timeFrame - At 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05025761",
    "endpoint": "measure - Proportion of survey respondents (MMPs) who accept and are willing to use&#x2F; did use the personal protection package according to the protocol, description - Focus group discussions; Questionnaire, timeFrame - At 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00164255",
    "endpoint": "measure - parasitemia at delivery (maternal peripheral, placental and cord), description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00164255",
    "endpoint": "measure - maternal illness, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00164255",
    "endpoint": "measure - birth weight, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00164255",
    "endpoint": "measure - gestational age, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00164255",
    "endpoint": "measure - fetal and infant health, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00164255",
    "endpoint": "measure - impact of maternal HIV infection on efficacy of malaria prevention during pregnancy, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01641289",
    "endpoint": "measure - Compare treatment arm with control arm with respect to duration of Acute Kidney Injury (AKI) and development of AKI., description - Duration of AKI will be defined as the length of time elapsed until serum creatinine returns to normal (&lt;1mg&#x2F;dL) in the absence of renal replacement therapy.\nDevelopment of AKI will be assessed using the Acute Kidney Injury Network (AKIN) criteria, and by a creatinine increase of &gt;= 0.5mg&#x2F;dl or 25%.\nPlasma paracetamol concentration will be measured daily by liquid chromatography-mass spectrometer (LC-MS&#x2F;MS)., timeFrame - 14 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01641289",
    "endpoint": "measure - Compare between groups correlations between oxidative stress, cell-free hemoglobin and renal function, description - Urine and plasma F2-isoprostanes and isofurans will be measured by gas chromatography-mass spectrometry.\nCell-free haemoglobin measured as plasma concentration by enzyme linked immunosorbent assay (ELISA) on admission then daily for 72hours.\nCell free haem measured in plasma using a chromogenic assay on admission then daily for 72hours.\nHaem-to-protein cross-links measured by high performance liquid chromatography (HPLC) on admission and daily for 72hours., timeFrame - 3 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01641289",
    "endpoint": "measure - Assessment of Blackwater fever and association with renal function, description - Blackwater fever assessed using a standardized urine colour chart and urine haemoglobin every 6 hours until clinical recovery between groups., timeFrame - 7 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01641289",
    "endpoint": "measure - Mortality and hemodialysis trends, description - To compare mortality and hemodialysis trends between groups and evaluate if they correlate with level of oxidative stress, cell free haemoglobin and renal function., timeFrame - 4 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01641289",
    "endpoint": "measure - Host factors of Intravascular Haemolysis, description - Intravascular haemolysis according to G6PD status., timeFrame - 4 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01641289",
    "endpoint": "measure - Fever clearance time, description - Compared fever clearance time defined as the time taken for the tympanic temperature to fall below 37.5°C and remain there for at least 24hours); Fever time defined as the duration in hours of an individuals temperature above 37.5°C; Area above the 37.5°C temperature versus time curve (AUC-T°) within first 24hours of treatment.\nAural temperature will be measured every 6 hours until fever clearance., timeFrame - 7 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01641289",
    "endpoint": "measure - Parasite clearance time, description - Parasite clearance time assessed by microscopy of peripheral blood films will be assessed every 6hours for the presence of asexual parasitaemia until negative on 2 consecutive blood films.\nParasite half lives and clearance time will be compared between groups.\nParasites will also be staged to assess if sequestration is inhibited due to temperature reduction., timeFrame - 7 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01641289",
    "endpoint": "measure - Parasite sequestration, description - Parasite sequestration assessed by capillary flow in the rectal microcirculation using Orthogonal Polarization Spectral (OPS) imaging will be compared between groups., timeFrame - 7 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01641289",
    "endpoint": "measure - Assessment of Acute Kidney Injury, description - Evaluation of pre-renal and acute tubular necrosis assessed by blood and urine biomarkers of pre-renal and renal injury including neutrophil gelatinase-associated lipocalcin (NGAL) and kidney injury molecule (KIM)., timeFrame - 7 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01641289",
    "endpoint": "measure - Urine scoring of dehydration and haemolysis, description - Urine colour will be assessed by standardized urine colour charts.\nUrine colour will be correlated with urine specific gravity, urine osmolality, urine haemoglobin and creatinine clearance., timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01641289",
    "endpoint": "measure - Safety assessment, description - Safety assessed by the number of patients with serious adverse events (SAEs) and by changes from baseline in vital signs and laboratory measurements., timeFrame - 6 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01641289",
    "endpoint": "measure - Assess the antimalarial drug sensitivity of patients treated with paracetamol, description - Preliminary in vitro studies suggest that paracetamol potentiates the anti-parasitic effect of artesunate as lower 50% inhibitory concentration of artesunate is observed when paracetamol is added to parasites in culture.\nWe will investigate whether this effect is dependent on the infecting P. falciparum parasite strain, timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01641289",
    "endpoint": "measure - Paracetamol pharmacokinetics, description - Pharmacokinetic modelling of oral paracetamol in severe and moderately severe malaria, timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01641289",
    "endpoint": "measure - Paracetamol pharmacodynamics, description - Pharmacodynamics on variables including temperature and parasitemia., timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01641289",
    "endpoint": "measure - Area under the plasma concentration versus time curve (AUC), description - for paracetamol, timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01641289",
    "endpoint": "measure - The maximum concentration (Cmax), description - for paracetamol, timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01449045",
    "endpoint": "measure - Number of children under 10 years of age presenting clinical Malaria with high parasite density, description - Malaria with parasite density at 3000 parasites&#x2F;uL or more in the presence of fever or history of fever in the previous 48hours in children under 10 years of age, timeFrame - up to 24 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02974608",
    "endpoint": "measure - Assess the prevalence rate of SP resistant parasites, description - Rate of SP resistant parasites (in vivo and molecular markers), timeFrame - Annual",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02974608",
    "endpoint": "measure - Assess the rate of pre-term and low birth weight deliveries, description - Number of pre-term deliveries, low birthweight deliveries, neonatal mortality, timeFrame - Annual",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03276962",
    "endpoint": "measure - Incidence of Clinical Malaria Meeting the Primary and Secondary Case Definitions of the Fx012-14-mFxD Group Versus the R012-20 Group, description - <p>The primary case definition is P. falciparum asexual parasitemia &gt; 5000 μl and presence of fever (axillary temperature ≥ 37.5°C) at the time of presentation and occurring in a child who is unwell and brought for treatment to a healthcare facility.</p><p>The secondary case definition is P. falciparum asexual parasitemia &gt; 0 and presence of fever (axillary temperature ≥ 37.5°C) at the time of presentation or history of fever within 24 hours of presentation and occurring in a child who is unwell and brought for treatment to a healthcare facility.\nThe incidence of clinical malaria for primary and secondary case definition is expressed as n&#x2F;T, representing the n reported over the risk period, which was counted in days and expressed as T.</p>, timeFrame - From Month 0 to Month 50",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03276962",
    "endpoint": "measure - Incidence of Clinical Malaria Meeting the Primary and Secondary Case Definitions of the Fx012-14-mFxD Group Versus the R012-14-mD Group, description - <p>The primary case definition is P. falciparum asexual parasitemia &gt; 5000 μl and presence of fever (axillary temperature ≥ 37.5°C) at the time of presentation and occurring in a child who is unwell and brought for treatment to a healthcare facility.</p><p>The secondary case definition is P. falciparum asexual parasitemia &gt; 0 and presence of fever (axillary temperature ≥ 37.5°C) at the time of presentation or history of fever within 24 hours of presentation and occurring in a child who is unwell and brought for treatment to a healthcare facility.\nThe incidence of clinical malaria for primary and secondary case definition is expressed as n&#x2F;T, representing the n reported over the risk period, which was counted in days and expressed as T.</p>, timeFrame - From Month 0 to Month 50",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03276962",
    "endpoint": "measure - The Prevalence of P. Falciparum Infections Defined by Positive Blood Slide at Each Cross-sectional Survey, description - Prevalence of P. falciparum infections of each RTS,S&#x2F;AS01E schedule at cross-sectional visits.\nAs specified in the statistical analysis plan, a graphical presentation of the prevalence over time was analyzed for this outcome measure and only the percentage values were reported to depict the prevalence of P. falciparum infections., timeFrame - Monthly from Month 0 to Month 20 and every 3 months thereafter until Study End (Month 50)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03276962",
    "endpoint": "measure - Incidence of P. Falciparum Infections Defined by Positive Blood Slide, description - <p>The incidence of P. falciparum infections is expressed as n&#x2F;T, representing the n reported over the risk period, which was counted in days and expressed as T.</p><p>Assessment of vaccine efficacy (VE) against first or only episodes of incident P. falciparum infections defined by positive blood slide over the entire study period (Month 0 to Month 50) was not done after the Month 21 Interim analysis since it was assumed that almost all children would have already contracted malaria at least once.</p>, timeFrame - Month 0 to Month 14",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03276962",
    "endpoint": "measure - Number of Seropositive Participants for Anti-circumsporozoite (Anti-CS) Antibodies, description - A seropositive participant is defined as a participant with antibody concentrations ≥ 0.5 ELISA units per milliliter (EU&#x2F;mL)., timeFrame - Before Dose 1, one month post-Dose 2, before and one month post-Dose 3, before and one month after Dose 4, before and one month after each yearly dose and at Study End (Month 50)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03276962",
    "endpoint": "measure - Number of Seropositive Participants for Anti-hepatitis B (Anti-HB) Antibodies, description - A seropositive participant is defined as a participant with antibody concentrations ≥ 10 milli-international units per milliliter (mIU&#x2F;mL)., timeFrame - Before Dose 1, one month post-Dose 2, before and one month post-Dose 3, before and one month after Dose 4, before and one month after each yearly dose and at Study End (Month 50)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03276962",
    "endpoint": "measure - Antibody Concentrations for Anti-CS, description - The antibody concentrations were calculated as geometric mean concentrations (GMCs) and expressed as EU&#x2F;mL., timeFrame - Before Dose 1, one month post-Dose 2, before and one month post-Dose 3, before and one month after Dose 4, before and one month after each yearly dose and at Study End (Month 50)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03276962",
    "endpoint": "measure - Antibody Concentrations for Anti-HB, description - The antibody concentrations were calculated as GMCs and expressed as mlU&#x2F;mL., timeFrame - Before Dose 1, one month post-Dose 2, before and one month post-Dose 3, before and one month after Dose 4, before and one month after each yearly dose and at Study End (Month 50)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03276962",
    "endpoint": "measure - Number of Participants With Any, Fatal and Related Serious Adverse Events (SAEs), description - SAEs assessed included any untoward medical occurrences that resulted in death, were life-threatening, required hospitalization or prolongation of hospitalization or resulted in disability&#x2F;incapacity.\nRelated SAEs= Any SAE related to investigational vaccine or related to study participation or to a GSK concomitant medication&#x2F;vaccine as assessed by the investigator.\nFatal SAEs= Any SAEs leading to death., timeFrame - From Day 0 to Month 50",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03276962",
    "endpoint": "measure - Number of Participants With Any Adverse Events (AEs) and SAEs Leading to Withdrawal From Further Vaccination, description - <p>An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product.</p><p>SAEs include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability&#x2F;incapacity.</p>, timeFrame - From Day 0 to Month 50",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03276962",
    "endpoint": "measure - Number of Participants With Cerebral Malaria and Severe Malaria, description - <p>Cerebral malaria is defined as Severe P. falciparum malaria with coma (Blantyre coma score less than [&lt;] 3); and if malaria with seizure: coma persisting for &gt; 30 min after the seizure.\nOther treatable causes of coma should be excluded before diagnosing cerebral malaria (e.g.\nhypoglycaemia, bacterial meningitis).</p><p>Severe malaria is defined as P. falciparum parasitemia &gt; 0 detected by microscopy and&#x2F;or rapid diagnostic test (RDT) and one or more of the following, occurring in the absence of an identified alternative cause: Impaired consciousness, Prostration, Multiple convulsions, Acidosis, Hypoglycemia, Severe malarial anemia, Renal impairment, Jaundice, Pulmonary edema, Significant bleeding: including recurrent or prolonged bleeding from the nose, gums or venipuncture sites, hematemesis or melaena, Shock, Hyperparasitemia.</p>, timeFrame - From Day 0 to Month 50",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03276962",
    "endpoint": "measure - Number of Participants With Potential Immune Mediated Diseases (pIMDs), description - Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and&#x2F;or neurologic disorders of interest which may or may not have an autoimmune etiology., timeFrame - From Day 0 to Month 50",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03276962",
    "endpoint": "measure - Number of Participants With Meningitis, description - Meningitis is an adverse event of specific interest (AESI).\nAn AESI is defined as an AE including autoimmune diseases and other mediated inflammatory disorders., timeFrame - From Day 0 to Month 50",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03276962",
    "endpoint": "measure - Number of Participants With Seizures, description - Seizure is an adverse event of specific interest (AESI).\nAn AESI is defined as an AE including autoimmune diseases and other mediated inflammatory disorders., timeFrame - During the 30-day (Day 0 to Day 29) follow-up period after any dose of study vaccine",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03276962",
    "endpoint": "measure - Number of Participants With Generalized Convulsive Seizures, description - Generalized convulsive seizure is an adverse event of specific interest (AESI).\nAn AESI is defined as an AE including autoimmune diseases and other mediated inflammatory disorders., timeFrame - During the 7-day (Day 0 to Day 6) follow-up period after any dose of study vaccine",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03276962",
    "endpoint": "measure - Number of Participants With Any Unsolicited AEs, description - An unsolicited AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product., timeFrame - During the 30-day (Day 0 to Day 29) follow-up period following the 1st 3 doses and post dose 4, 5 and 6 of study vaccine",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03276962",
    "endpoint": "measure - Number of Participants With Grade 4 Hematology and Biochemical Toxicities Before Dose 3, description - The assessed parameters (alanine aminotransferase [ALT], creatinine, haemoglobin, white blood cells [WBC], platelets) were summarized according to DAIDS, 2004 (Division of AIDS).\nGrade 1, mild; Grade 2, moderate; Grade 3, severe; Grade 4, life-threatening or disabling.\nData are presented for those participants who experienced Grade 4 toxicities.\nGrade 4 hematological toxicities included ALT: &gt; 10.0 x ULN (Upper limit of normal), creatine: &gt; 6.0 x ULN or requires dialysis, WBC: &lt; 1.0 x 103 per microliter, platelets: &lt; 25 x 103&#x2F;μl and clinical signs of bleeding, and hemoglobin: &lt; 5.0 grams&#x2F;deciliter and clinical signs of heart failure., timeFrame - Before Dose 3 (at Month 2)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03276962",
    "endpoint": "measure - Number of Participants With Grade 4 Hematology and Biochemical Toxicities at 7 Days Post-Dose 3, description - The assessed parameters (ALT, creatinine, haemoglobin, WBC, platelets) were summarized according to DAIDS, 2004 (Division of AIDS).\nGrade 1, mild; Grade 2, moderate; Grade 3, severe; Grade 4, life-threatening or disabling.\nData are presented for those participants who experienced Grade 4 toxicities.\nGrade 4 hematological toxicities included ALT: &gt; 10.0 x ULN, creatine: &gt; 6.0 x ULN or requires dialysis, WBC: &lt; 1.0 x 103 per microliter, platelets: &lt; 25 x 103&#x2F;μl and clinical signs of bleeding, and hemoglobin: &lt; 5.0 grams&#x2F;deciliter and clinical signs of heart failure., timeFrame - At 7 days post-Dose 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03276962",
    "endpoint": "measure - Number of Participants With Grade 4 Hematology and Biochemical Toxicities at 30 Days Post-Dose 3, description - The assessed parameters (ALT, creatinine, haemoglobin, WBC, platelets) were summarized according to DAIDS, 2004 (Division of AIDS).\nGrade 1, mild; Grade 2, moderate; Grade 3, severe; Grade 4, life-threatening or disabling.\nData are presented for those participants who experienced Grade 4 toxicities.\nGrade 4 hematological toxicities included ALT: &gt; 10.0 x ULN, creatine: &gt; 6.0 x ULN or requires dialysis, WBC: &lt; 1.0 x 103 per microliter, platelets: &lt; 25 x 103&#x2F;μl and clinical signs of bleeding, and hemoglobin: &lt; 5.0 grams&#x2F;deciliter and clinical signs of heart failure., timeFrame - At 30 days post-Dose 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03276962",
    "endpoint": "measure - Number of Participants With Any Solicited Local Symptoms, description - Assessed solicited local AEs are: redness, pain and swelling.\nAny = occurrence of the adverse event regardless of intensity grade.\nAny redness and swelling = adverse event reported with a surface diameter &gt; 0 millimeters., timeFrame - During the 4-day (Day 0 to Day 3) follow-up period after Dose 3, Dose 4, Dose 5 and Dose 6 of study vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03276962",
    "endpoint": "measure - Number of Participants With Any Solicited General Symptoms, description - Assessed solicited general AEs are: drowsiness, irritability&#x2F;fussiness and loss of appetite.\nAny = occurrence of the adverse event regardless of intensity grade or relation to study vaccination., timeFrame - During the 4-day (Day 0 to Day 3) follow-up period after Dose 3, Dose 4, Dose 5 and Dose 6 of study vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00541385",
    "endpoint": "measure - Percentage of Participants With PCR-Corrected ACPR on Day 14, description - Percentage of subjects with PCR-corrected adequate clinical and parasitological response (ACPR) on Day 14.\nThe PCR-corrected ACPR on Day 14 is defined as the absence of parasitaemia on Day 14 without the subject&#x27;s meeting any of the criteria of early treatment failure, late clinical failure, or late parasitological failure, timeFrame - Day 14",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00541385",
    "endpoint": "measure - Crude ACPR (Non-PCR Corrected ACPR) (Crude Cure Rate) on Day 14 and Day 28, description - Percentage of subjects with adequate clinical and parasitological response (ACPR) on Day 14 and 28, without correction by PCR.\nCrude ACPR on Day 14 and 28 is defined as the absence of parasitaemia on Day 14 and 28 without the subject&#x27;s meeting any of the criteria of early treatment failure, late clinical failure, or late parasitological failure, timeFrame - Days 14 and 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00541385",
    "endpoint": "measure - Parasite Clearance Time, description - Parasite clearance time is defined as the time from first dosing to the time of first blood draw with parasite clearance.\nParasite clearance was defined as zero presence of asexual parasites for 2 consecutive negative readings taken between 7 and 25 hours apart, timeFrame - Days 0, 3, 7, 14, 21, 28, 35, and 42 or on any other day if the subject spontaneously returned within the 42-day study period",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00541385",
    "endpoint": "measure - Fever Clearance Time, description - Fever clearance time is defined as the time from first dosing to the first normal reading of temperature for 2 consecutive normal temperature readings taken between 7 and 25 hours apart., timeFrame - Day 0 and every 8 hours over ≥72 hours following first study drug administration or temperature normalization for ≥2 readings between 7 and 25 hours apart, then at each visit and as clinically indicated (within the 42-day study period)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00541385",
    "endpoint": "measure - Proportion of Subjects With Cleared Parasites on Days 1, 2, and 3, description - Parasite clearance time is defined as the time from first dosing to the time of first blood draw with parasite clearance.\nParasite clearance was defined as zero presence of asexual parasites for 2 consecutive negative readings taken between 7 and 25 hours apart, timeFrame - Days 1, 2, and 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00541385",
    "endpoint": "measure - Proportion of Subjects With Fever Cleared on Days 1, 2, and 3, description - Fever clearance time is defined as the time from first dosing to the first normal reading of temperature for 2 consecutive normal temperature readings taken between 7 and 25 hours apart, timeFrame - Days 1, 2, and 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00541385",
    "endpoint": "measure - Number of Subjects With ≥1 Adverse Event, description - , timeFrame - Day 0 to 42. Subjects experiencing AEs at Day 42 were followed for up to 30 days after the end of study or resolution of the event, whichever was earlier",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02627456",
    "endpoint": "measure - Protective Efficacy (pilot phase), description - P. falciparum blood stage infection defined as detection of at least 2 P. falciparum parasites by microscopic examination of 0.5 (Micro)L starting immediately following PfSPZ CHMI(Arms lc, ld), timeFrame - Immediately following PfSPZ CHMI",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02627456",
    "endpoint": "measure - Protective Efficacy (main phase), description - P. falciparum blood stage infection defined as detection of at least 2 P. falciparum parasites by microscopic examination of 0.5 muL starting immediately following Vaccination #3 (Arms 2, 3), timeFrame - Immediately following 3rd vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04546633",
    "endpoint": "measure - Percentage of Participants with Polymerase Chain Reaction (PCR)-corrected and uncorrected Adequate Clinical and Parasitological Response (ACPR) at Day 15 and 43, description - A blood draw will be performed at each collection time point for parasitemia assessment., timeFrame - Day 15, Day 43",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04546633",
    "endpoint": "measure - Percentage of Participants with Polymerase Chain Reaction (PCR)-corrected and uncorrected Adequate Clinical and Parasitological Response (ACPR) at Day 29 (Run-in Cohort), description - A blood draw will be performed at Day 29 in the Run-in Cohort only for parasitemia assessment., timeFrame - Day 29",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04546633",
    "endpoint": "measure - Time to parasite clearance (PCT), description - Parasite Clearance Time (PCT) is defined as the time from the first dose until the first total and continued disappearance of asexual parasite forms which remained at least a further 48 hours., timeFrame - up to 43 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04546633",
    "endpoint": "measure - Time to fever clearance (FCT), description - Fever Clearance Time (FCT) is defined as the time from the first dose until the first time the axillary body temperature decreased below and remained below 37.5°C axillary or 38.0°C oral&#x2F;tympanic&#x2F;rectal for at least a further 24 hours., timeFrame - up to 43 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04546633",
    "endpoint": "measure - Proportion of patients with Early Treatment Failure (ETF), description - <p>ETF is defined as:</p><ul><li>Development of danger signs or severe malaria on Day 2, Day 3, Day 4 in the presence of parasitemia</li><li>Parasitemia on Day 3 higher than Day 1 count irrespective of axillary temperature</li><li>Parasitemia on Day 4 with axillary temperature ≥ 37.5°C</li><li>Parasitemia on Day 4 equals to or more than 25% of count on Day 1</li></ul>, timeFrame - Day 1 to Day 4",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04546633",
    "endpoint": "measure - Proportion of patients with Late Clinical Failure (LCF), description - <p>LCF is defined as:</p><ul><li>Development of danger signs or severe malaria on any day from Day 5 to Day 43 in the presence of parasitemia without previously meeting any of the criteria of ETF</li><li>Presence of parasitemia and axillary temperature ≥ 37.5oC on any day from Day 5 to Day 43 without previously meeting any of the criteria of ETF</li></ul>, timeFrame - Day 5 to Day 43",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04546633",
    "endpoint": "measure - Proportion of patients with Late Parasitological Failure (LPF), description - LPF is defined as the presence of parasitemia on any day from Day 8 to Day 43 and axillary temperature &lt; 37.5oC without previously meeting any of the criteria of ETF or LCF, timeFrame - Day 8 to Day 43",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04546633",
    "endpoint": "measure - Incidence rate of recrudescence and reinfection, description - <p>Time to event (recrudescence or reinfection) will be calculated from the time of first study medication to the date of first event if a patient experiences the event and be censored at the time of last parasite assessment if a patient does not experience the event due to whatever reason.</p><p>Reinfection is defined as appearance of asexual parasites after clearance of initial infection with a genotype different from those parasites present at baseline.</p><p>Recrudescence is defined as appearance of asexual parasites after clearance of initial infection with a genotype identical to that of parasites present at baseline.</p><p>Reinfection and Recrudescence must be confirmed by PCR analysis.</p>, timeFrame - Day 15, Day 29 and Day 43",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04546633",
    "endpoint": "measure - Number of Participants with On-Treatments Adverse Events, Serious Adverse Events, and Deaths, description - Analysis of absolute and relative frequencies for treatment emergent Adverse Event (AE), Serious Adverse Event (SAE) and Deaths by primary System Organ Class (SOC) to demonstrate that KAF156 and Lumefantrine-SDF combination, under fasted or fed conditions is safe through the monitoring of relevant clinical and laboratory safety parameters., timeFrame - Day 1 to Day 43",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04546633",
    "endpoint": "measure - Pharmacokinetics of KAF156 and LUM-SDF PK (Run-in Cohort, Cohort 1 and 2): Area Under the Plasma Concentration-time Curve (AUC), description - AUC is the area under the plasma concentration-time curve.\nPK parameters were calculated from plasma concentration-time data using non-compartmental methods., timeFrame - From Day 1 to Day 8",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04546633",
    "endpoint": "measure - Pharmacokinetic of KAF156 and LUM-SDF PK (Run-in Cohort, Cohort 1 and 2): Maximum Observed Plasma Concentration (Cmax), description - Cmax is the maximum observed plasma concentration following drug administration.\nPK parameters are calculated from plasma concentration-time data using non-compartmental methods., timeFrame - From Day 1 to Day 8",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04546633",
    "endpoint": "measure - Pharmacokinetic of KAF156 and LUM-SDF PK (Run-in Cohort, Cohort 1 and 2): Time to reach the maximum concentration after drug administration (Tmax), description - Tmax is the time to reach maximum plasma concentration following drug administration.\nPK parameters are calculated from plasma concentration-time data using non-compartmental methods., timeFrame - From Day 1 to Day 8",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04546633",
    "endpoint": "measure - Pharmacokinetics of KAF156 and LUM-SDF PK (Run-in Cohort, Cohort 1 and 2): Plasma drug concentration 168 hours post first dose administration (C168h), description - C168h is the plasma concentration at 168h post first dose administration., timeFrame - Day 8",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04546633",
    "endpoint": "measure - Pharmacokinetics of LUM from Coartem arm (Cohorts 1 and 2): Maximum Observed Plasma Concentration (Cmax), description - Cmax is the maximum observed plasma concentration following drug administration.\nPK parameters are calculated from plasma concentration-time data using non-compartmental methods., timeFrame - From Day 1 to Day 8",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04546633",
    "endpoint": "measure - Pharmacokinetics of LUM from Coartem arm (Cohorts 1 and 2): Plasma drug concentration 168 hours post first dose administration (C168h), description - C168h is the plasma concentration at 168h post first dose administration., timeFrame - Day 8",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00436007",
    "endpoint": "measure - Concentrations of Antibodies Against Hepatitis B (Anti-HB Antibodies)., description - Anti-HB antibody concentrations were expressed as geometric mean concentrations (GMCs) in milli-international unit per milliliter (mIU&#x2F;mL).\nThe seroprotection assay cut-off was 10 mIU&#x2F;mL.\nThis outcome only covers results for the GSK 257049 1 Group., timeFrame - At Months 0, 1, 3 and 7.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00436007",
    "endpoint": "measure - Concentrations of Antibodies Against Hepatitis B (Anti-HB Antibodies)., description - Anti-HB antibody concentrations were expressed as geometric mean concentrations (GMCs) in milli-international unit per milliliter (mIU&#x2F;mL).\nThe seroprotection assay cut-off was 10 mIU&#x2F;mL.\nThis outcome only covers results for the GSK 257049 2 Group., timeFrame - At Months 0, 3, 7 and 8.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00436007",
    "endpoint": "measure - Concentrations of Antibodies Against Hepatitis B (Anti-HB Antibodies)., description - Anti-HB antibody concentrations were expressed as geometric mean concentrations (GMCs) in milli-international unit per milliliter (mIU&#x2F;mL).\nThe seroprotection assay cut-off was 10 mIU&#x2F;mL.\nThis outcome only covers results for the Tritanrix™ HepB&#x2F;Hiberix™ Group., timeFrame - At Months 0, 3, 7 and 8.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00436007",
    "endpoint": "measure - Concentrations of Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T) Antibodies., description - Anti-D and Anti-T antibody concentrations were expressed as geometric mean concentrations (GMCs) in international unit per milliliter (IU&#x2F;mL).\nThe seroprotection assay cut-off was 0.1 IU&#x2F;mL., timeFrame - At Month 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00436007",
    "endpoint": "measure - Number of Subjects With Serious Adverse Events (SAEs)., description - SAEs were defined as medical occurrences that resulted in death, were life threatening, required hospitalization or prolongation of hospitalization or resulted in disability&#x2F;incapacity., timeFrame - From Month 8 to Month 19",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00436007",
    "endpoint": "measure - Concentrations of Anti-polyribosyl Ribitol Phosphate (Anti-PRP) Antibodies., description - Anti-PRP antibody concentrations were expressed as geometric mean concentrations (GMCs) in microgram per milliliter (µg&#x2F;mL).\nThe seroprotection assay cut-off was 0.15 µg&#x2F;mL., timeFrame - At Month 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00436007",
    "endpoint": "measure - Titers for Antibodies Against Poliomyelitis Types 1, 2 and 3 (Anti-Polio 1, 2 and 3 Antibodies)., description - Anti-Polio 1, 2 and 3 antibody titers were expressed as geometric mean titers (GMTs).\nThe seroprotection assay cut-off was 8., timeFrame - At Month 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00436007",
    "endpoint": "measure - Concentrations of Anti-Bordetella Pertussis Toxin (Anti-BPT) Antibodies., description - Anti-BPT antibodies were measured by enzyme-linked immunosorbent assay (ELISA).\nConcentrations were expressed as geometric mean concentrations (GMCs) in ELISA unit per milliliter (EL.U&#x2F;mL).\nThe seropositivity assay cut-off was 15 EL.U&#x2F;mL., timeFrame - At Month 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00436007",
    "endpoint": "measure - Concentrations of Anti-measles Antibodies., description - Anti-measles antibody concentrations were expressed as geometric mean concentrations (GMCs) in milli-international unit per milliliter (mIU&#x2F;mL).\nThe seropositivity assay cut-off was 150 mIU&#x2F;mL.\nThe analysis was only performed on subjects from the GSK 257049 2 and Tritanrix™ HepB&#x2F;Hiberix™ groups., timeFrame - At Months 7 and 8.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00436007",
    "endpoint": "measure - Titers for Anti-yellow Fever Antibodies., description - <p>Anti-yellow fever antibody titers were expressed as geometric mean titers (GMTs).\nThe seroprotection assay cut-off was 10.\nThe analysis was only performed on subjects from the GSK 257049 2 and Tritanrix™ HepB&#x2F;Hiberix™ groups.</p><p>The analysis was only performed on subjects from the GSK 257049 2 and Tritanrix™ HepB&#x2F;Hiberix™ groups.</p>, timeFrame - At Months 7 and 8.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00436007",
    "endpoint": "measure - Concentrations of Anti-circumsporozoite Protein (Anti-CS) Antibodies., description - Anti-CS antibody antibodies were measured by enzyme-linked immunosorbent assay (ELISA).\nConcentrations were expressed as geometric mean concentrations (GMCs) in ELISA unit per milliliter (EL.U&#x2F;mL).\nThe seropositivity assay cut-off was 0.5 EL.U&#x2F;mL.\nThis outcome only covers results for the GSK 257049 1 Group., timeFrame - At Months 0, 1, 3 and 7.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00436007",
    "endpoint": "measure - Concentrations of Anti-circumsporozoite Protein (Anti-CS) Antibodies., description - Anti-CS antiibodies were measured by enzyme-linked immunosorbent assay (ELISA).\nConcentrations were expressed as geometric mean concentrations (GMCs) in ELISA unit per milliliter (EL.U&#x2F;mL).\nThe seropositivity assay cut-off was 0.5 EL.U&#x2F;mL.\nThis outcome only covers results for the GSK 257049 2 Group., timeFrame - At Months 0, 3, 7 and 8.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00436007",
    "endpoint": "measure - Concentrations of Anti-circumsporozoite Protein (Anti-CS) Antibodies., description - Anti-CS antibodies were measured by Enzyme-linked immunosorbent assay (ELISA).\nConcentrations were expressed as geometric mean concentrations (GMCs) in ELISA unit per milliliter (EL.U&#x2F;mL).\nThe seropositivity assay cut-off was 0.5 EL.U&#x2F;mL.\nThis outcome only covers results for the Tritanrix™ HepB&#x2F;Hiberix™ Group., timeFrame - At Months 0, 3, 7 and 8.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00436007",
    "endpoint": "measure - Number of Subjects With Solicited Local Symptoms., description - Assessed solicited local symptoms were pain and swelling at injection site following vaccination with each of the following study vaccines administered intramuscularly, e. a. the Tritanrix™ HepB&#x2F;Hib, Rouvax™, GSK 257049 and Stamaril™ vaccines.\nThe numbers of subjects with each of the assessed solicited local symptoms reported were tabulated for each vaccine administered, separately., timeFrame - During the 7-day (Days 0-6) follow-up period after any vaccination with the Tritanrix™ HepB&#x2F;Hib, Rouvax™, GSK 257049 and Stamaril™ vaccines.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00436007",
    "endpoint": "measure - Number of Subjects With Solicited General Symptoms., description - Assessed solicited general symptoms were drowsiness, fever [axillary temperature equal or above (≥) 37.5 degrees Celsius (°C)], irritability and loss of appetite following any vaccination with any of the study vaccines, e. a. the Tritanrix™ HepB&#x2F;Hib, Rouvax™, GSK 257049, Stamaril™ and Polio Sabin™ vaccines., timeFrame - During the 7-day (Days 0-6) follow-up period after any vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00436007",
    "endpoint": "measure - Number of Subjects With Unsolicited Adverse Events (AEs), description - An unsolicited AE is any AE (i.e.\nany untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.\nUnsolicited AEs were assessed following vaccination with any of the study vaccines, e. a. the Tritanrix™ HepB&#x2F;Hib, Rouvax™, GSK 257049, Stamaril™ and Polio Sabin™ vaccines., timeFrame - During the 30-day (Days 0-29) follow-up period after any vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00436007",
    "endpoint": "measure - Number of Subjects With Serious Adverse Events (SAEs)., description - SAEs were defined as medical occurrences that resulted in death, were life threatening, required hospitalization or prolongation of hospitalization or resulted in disability&#x2F;incapacity., timeFrame - From Month 0 to Month 19",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06516042",
    "endpoint": "measure - Pf parasite prevalence in a subset of migrant farmworkers, description - Pf parasite prevalence measured in a subset of migrant farmworkers upon return to their home village in the western highlands, timeFrame - Up to 2 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06516042",
    "endpoint": "measure - Safety and tolerability of TDA, description - Safety and tolerability of TDA measured through the incidence of adverse events and survey responses, timeFrame - Up to 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06516042",
    "endpoint": "measure - Feasibility of enhanced case management through mobile clinics based on cost per case detected, description - A cost assessment of providing enhanced case management through mobile clinics, timeFrame - Up to 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06516042",
    "endpoint": "measure - Feasibility and acceptability of enhanced case management through mobile clinics based on endline survey responses, description - Feasibility and acceptability of providing enhanced case management among the study team based on endline survey responses, timeFrame - Up to 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06516042",
    "endpoint": "measure - Feasibility and acceptability of enhanced case management through mobile clinics based on qualitative interview data, description - Feasibility and acceptability of enhanced case management through mobile clinics based on information shared during qualitative interviews, timeFrame - Up to 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01902797",
    "endpoint": "measure - Determine the percentage of households with at least one long lasting insecticide treated nets (LLIN) or insecticide treated nets (ITNs, description - • percentage of households with at least one long lasting insecticide treated nets (LLIN) or insecticide treated nets (ITNs) per 2 persons, timeFrame - 1 day",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01902797",
    "endpoint": "measure - Determine the percentage of refugees sleeping under an ITN&#x2F;LLIN previous night, description - Percentage of refugees sleeping under an ITN&#x2F;LLIN previous night, timeFrame - 1 day",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01902797",
    "endpoint": "measure - Determine the percentage of refugees who can recall at least 1 key messages on malaria control and containment&#x2F;elimination, description - The percentage of refugees who can recall at least 1 key messages on malaria control and containment&#x2F;elimination, timeFrame - 1 day",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01902797",
    "endpoint": "measure - Determine percentage of refugees who stay overnight outside the camp, description - The percentage of refugees who stay overnight outside the camp, timeFrame - 1 day",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00414336",
    "endpoint": "measure - To determine the level and kinetics of the antibody response elicited by AMA1-C1&#x2F;Alhydrogel + CPG, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02315690",
    "endpoint": "measure - Seroprevalence, description - Prevalence of antibody response to markers of recent malaria exposure in target areas, timeFrame - during end line survey after intervention data collection completed",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02315690",
    "endpoint": "measure - Prevalence, description - Prevalence of infection by loop mediated isothermal amplification (LAMP) in target areas, timeFrame - during end line survey after intervention data collection completed",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02315690",
    "endpoint": "measure - Coverage, description - Proportion of persons residing within approximately 200 m of the index case who consented to participate in the study and who completed the initial procedures for their study arm (finger prick for RDT (rapid diagnostic test) in the RACD arm, initial dose of DHAp in the fMDA arm), timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02315690",
    "endpoint": "measure - Adherence, description - Proportion of persons who completed 3 days of therapy among all individuals initiated on fMDA as assessed by pill count in the first intervention per study locality, timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02315690",
    "endpoint": "measure - Safety related to DHAp, description - Number of participants experiencing serious adverse events (SAEs) deemed possibly, probably, or definitely related to DHAp, timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02315690",
    "endpoint": "measure - Acceptability, description - Qualitative assessment among individuals residing in target areas and with surveillance agents., timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02315690",
    "endpoint": "measure - Cost, description - Cost per index case-level intervention, cost per case averted, collected in 10 RACD and 10 fMDA events., timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02878200",
    "endpoint": "measure - prevalence of clinical (laboratory confirmed) malaria cases, description - the incidence of clinical (laboratory confirmed) malaria cases as detected through the health system; health facilities and village health worker, in both intervention and control clusters, timeFrame - 3-4 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02878200",
    "endpoint": "measure - the prevalence of antimalarial drug resistance molecular markers, description - the prevalence of antimalarial drug resistance molecular markers as determined among malaria infected individuals detected at cross-sectional surveys;, timeFrame - 4 months and 16 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02878200",
    "endpoint": "measure - treatment coverage, description - treatment coverage as determined by percentage of household members having received and taken at least 80% of the prescribed dose., timeFrame - 4 months and 16 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01397851",
    "endpoint": "measure - Contract Defaults, description - Defaults on input loans, as defined in the routine data collection system of the participating cotton outgrowing agribusiness.\nOdds ratios calculated in accordance with NIH guidance: http:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;articles&#x2F;PMC2938757&#x2F;, timeFrame - 2010-2011 season (up to 1 year)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01397851",
    "endpoint": "measure - Increase in Maize Productivity, description - Increase in self-reported maize productivity (yield on maize plots divided by size of maize plots), collected through validation survey; calculated as maize productivity 2010-11 minus maize productivity 2009-10, measured in bags (ordinarily 50kg bags; however, kg measure not specified), timeFrame - 2009-2010 and 2010-2011 seasons (up to 2 years)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01397851",
    "endpoint": "measure - Self-reported Malaria Prevalence, description - Over two weeks before interview, collected through validation survey.\nOdds ratio calculated in accordance with NIH guidance http:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;articles&#x2F;PMC2938757&#x2F;, timeFrame - 2010-2011 season (up to 1 year)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04206332",
    "endpoint": "measure - Pharmacokinetic (PK) Parameters of CIS43LS: Maximum Observed Serum Concentration (Cmax) - (Part A and Part B), description - Serum concentrations of CIS43LS by dose group following a single administration.\nCmax is the peak serum concentration that CIS43LS achieves after it has been administered; it is determined as a maximum value on the summary pharmacokinetic (PK) curve for each study group.\nAfter subcutaneous injection, Cmax could not be fully calculated because of COVID-19-related interruptions in sample collection., timeFrame - Baseline through 24 weeks after CIS43LS product administration",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04206332",
    "endpoint": "measure - Pharmacokinetic (PK) Parameters of CIS43LS: Maximum Observed Serum Concentration (Cmax) - (Part C), description - Serum concentrations of CIS43LS by dose group following a single administration.\nCmax is the peak serum concentration that CIS43LS achieves after it has been administered; it is determined as a maximum value on the summary pharmacokinetic (PK) curve for each study group., timeFrame - Baseline through 24 weeks after CIS43LS product administration",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04206332",
    "endpoint": "measure - Pharmacokinetic (PK) Parameters of CIS43LS: Time to Reach Maximum Observed Serum Concentration (Tmax) - (Part A and Part B), description - Tmax is the time it takes to reach Cmax of CIS43LS after it has been administered; it is determined based on the summary PK curve for each dose group., timeFrame - Baseline through 24 weeks after CIS43LS product administration",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04206332",
    "endpoint": "measure - Pharmacokinetic (PK) Parameters of CIS43LS: Time to Reach Maximum Observed Serum Concentration (Tmax) - (Part C), description - Tmax is the time it takes to reach Cmax of CIS43LS after it has been administered; it is determined based on the summary PK curve for each dose group., timeFrame - Baseline through 24 weeks after CIS43LS product administration",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04206332",
    "endpoint": "measure - Pharmacokinetic (PK) Parameters of CIS43LS: Beta Half-life (T1&#x2F;2b) - (Part A and Part B), description - Beta half-life (T1&#x2F;2b) is being reported for this study.\nBeta half-life (T1&#x2F;2b) is the time required for half of the CIS43LS product to be eliminated from the serum.\nA two-compartmental population pharmacokinetic model with first order SC absorption was used to estimate overall beta half-life and bootstrap 90% confidence intervals (CIs)., timeFrame - Baseline through 24 weeks after CIS43LS product administration",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04206332",
    "endpoint": "measure - Pharmacokinetic (PK) Parameters of CIS43LS: Beta Half-life (T1&#x2F;2b) - (Part C), description - Beta half-life (T1&#x2F;2b) is the time required for half of the CIS43LS product to be eliminated from the serum.\nA two-compartmental population pharmacokinetic model with first order SC absorption was used to estimate overall beta half-life and bootstrap 95% confidence intervals (CIs)., timeFrame - Baseline through 24 weeks after CIS43LS product administration",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04206332",
    "endpoint": "measure - Pharmacokinetic (PK) Parameters of CIS43LS: Clearance Rate - (Part A and Part B), description - Rate of CIS43LS elimination divided by the plasma CIS43LS concentration; determined based on the summary pharmacokinetic (PK) curve for each study group.\nA two-compartmental population pharmacokinetic model with first order SC absorption was used to estimate overall clearance and bootstrap 90% confidence intervals (CIs)., timeFrame - Baseline through 24 weeks after CIS43LS product administration",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04206332",
    "endpoint": "measure - Pharmacokinetic (PK) Parameters of CIS43LS: Clearance Rate - (Part C), description - Rate of CIS43LS elimination divided by the plasma CIS43LS concentration; determined based on the summary pharmacokinetic (PK) curve for each study group.\nA two-compartmental population pharmacokinetic model with first order SC absorption was used to estimate overall clearance and bootstrap 95% confidence intervals (CIs)., timeFrame - Baseline through 24 weeks after CIS43LS product administration",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04206332",
    "endpoint": "measure - Number of Participants Who Developed Plasmodium Falciparum (P. Falciparum) Parasitemia Following Controlled Human Malaria Infection (CHMI) Challenge (Part B), description - Parasitemia as determined by polymerase chain reaction (PCR) up to day 21 following CHMI to determine whether IV or SC administration of CIS43LS mediates protection against infectious P. falciparum following CHMI, timeFrame - Up to 21 days after CHMI",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04206332",
    "endpoint": "measure - Number of Participants Who Developed Plasmodium Falciparum (P. Falciparum) Parasitemia Following Controlled Human Malaria Infection (CHMI) Challenge (Part C), description - Parasitemia as determined by polymerase chain reaction (PCR) up to day 21 following CHMI to determine the lowest dose of CIS43LS administered IV and SC that confers protection against infectious P. falciparum following CHMI in Part C of the study, timeFrame - Up to 21 days after CHMI",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03199755",
    "endpoint": "measure - Reduced side effects by DLA vs. ACT among the 3 arms, description - Compare patient side effects observationally measured among the 3 treatment arms., timeFrame - Through 28 days for each patient.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00308061",
    "endpoint": "measure - Geometric Mean Titers for Anti-FMP1 Antibody, description - Immune response was measured by anti-FMP1 endpoint titers.\nData were obtained on day 0, 14, 30, 44, 60, 74, 90, 180, 272, and 364.\nSamples collected on vaccination days (days 0, 30, and 60) were collected immediately prior to vaccination., timeFrame - Days 0, 14, 30, 44, 60, 74, 90, 180, 272, and 364",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02536222",
    "endpoint": "measure - Prevalence of Plasmodium falciparum parasitaemia, description - Prevalence of infection by RDT&#x2F;polymerase chain reaction (PCR): will be measured during cross-sectional surveys at the beginning and at the end of the transmission season.\n16,000 participants are expected to take part in both cross sectional surveys.\nThe prevalence by PCR will only be available later when the laboratory results become available.\nA comparison before and after the intervention and between interventions and control villages will be done using a difference-in-difference analysis., timeFrame - At the begining (one month after the first rain) and the end (one month after the last rain) of the transmission season",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01771848",
    "endpoint": "measure - Safety of PfSPZ Challenge, description - The safety of PfSPZ Challenge and the resultant P. falciparum infection will be assessed by analysing actively and passively collected data from clinical review of volunteers and laboratory measurements., timeFrame - All study visits until day 90 post challenge",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01645254",
    "endpoint": "measure - Plasma concentration curves of the drug, description - The phramacokinetics measured will be performed depending on the treatment groups.\nThree different treatment groups have constituted, each group will be allocated a specific time point for PK assessment., timeFrame - 6 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01308112",
    "endpoint": "measure - Serum non-transferrin bound iron concentration, description - , timeFrame - 3 h after ingestion of first supplement with either iron or placebo",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01308112",
    "endpoint": "measure - Neonatal iron stores, description - Assessed by plasma ferritin concentration, restricted to infants without inflammation, timeFrame - At 1 month of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01308112",
    "endpoint": "measure - Maternal iron status, description - To be assessed by haemoglobin concentrations, prevalence of iron deficiency anaemia (plasma ferritin concentration &lt;12 µg&#x2F;L) and iron stores (ratio of ferritin:transferrin receptor concentrations); indicators based on ferritin and&#x2F;or transferrin receptor will be restricted to those without inflammation., timeFrame - At 1 month after delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01308112",
    "endpoint": "measure - Maternal intestinal pathogens, description - , timeFrame - At 1 month after delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00442442",
    "endpoint": "measure - Fever reports, description - , timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00442442",
    "endpoint": "measure - User acceptance, description - , timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00442442",
    "endpoint": "measure - entomological data, description - , timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01836458",
    "endpoint": "measure - Median Time to Parasite Clearance, description - Parasite clearance time will be estimated using thick&#x2F;thin blood films., timeFrame - pre-dose, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, 48, 54, 60, 66, 72 hours post dose of KAE609",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01836458",
    "endpoint": "measure - Median Time to Fever Clearance, description - Fever is monitored on participants every 4 hours for the first 24 hours, then every 6 hours until negative reading obtained., timeFrame - Day 1 to Day 5",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01836458",
    "endpoint": "measure - Percentage of Patients PCR-corrected Cure Rate by Day 28, Day 35 &amp; Day 42, description - PCR-corrected cure rate after a single dose of KAE609 by Day 28, Day 35 &amp; Day 42.\nPCR-corrected cure rate accounts for failures due to reappearance of parasites that were present in the blood before treatment (i.e.\nrecrudescent infection) but not for failures due to a post-treatment inoculation (i.e.\nnew infection)., timeFrame - Day 28, Day 35 &amp; Day 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03163121",
    "endpoint": "measure - Presence of parasitemia after CHMI in Stage B, description - Presence of parasitemia after CHMI with the wild-type NF54 strain, as detected by qPCR, timeFrame - From time of inoculation to till 28 days later",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00131794",
    "endpoint": "measure - Prevalence of malaria parasitemia., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02661373",
    "endpoint": "measure - Drug absorption in the fed cohort, description - Drug absorption of SJ733 and its metabolite in the fed cohort will be reported to assess the impact of food intake., timeFrame - From baseline through 7 days post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02661373",
    "endpoint": "measure - Drug clearance in the fed cohort, description - Drug clearance of SJ733 and its metabolite in the fed cohort will be reported to assess the impact of food intake., timeFrame - From baseline through 7 days post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02661373",
    "endpoint": "measure - Drug volume of distribution in the fed cohort, description - Drug volume of distribution of SJ733 and its metabolite in the fed cohort will be reported to assess the impact of food intake., timeFrame - From baseline through 7 days post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02661373",
    "endpoint": "measure - Area under the curve (AUC) in the fed cohort, description - AUC of SJ733 and its metabolite in the fed cohort will be reported to assess the impact of food intake., timeFrame - From baseline through 7 days post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02661373",
    "endpoint": "measure - Time above threshold concentration in the fed cohort, description - Time above threshold concentration SJ733 and its metabolite in the fed cohort will be reported to assess the impact of food intake., timeFrame - From baseline through 7 days post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02661373",
    "endpoint": "measure - Maximum drug concentration (Cmax) in the fed cohort, description - Drug absorption of SJ733 and its metabolite in the fed cohort will be reported to assess the impact of food intake., timeFrame - From baseline through 7 days post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02788864",
    "endpoint": "measure - The proportion of different anopheles species amongst all captured mosquito anopheles, description - The proportion of different anopheles species amongst all captured mosquito anopheles as identified by morphology, timeFrame - 1 month",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02788864",
    "endpoint": "measure - The proportion of sporozoite-carrying mosquitoes (any parasite, P.falciparum, mixed P.falciparum and P.vivax), description - The proportion of sporozoite-carrying mosquitoes (any parasite, P.falciparum, mixed P.falciparum and P.vivax) as assessed by PCR., timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01445938",
    "endpoint": "measure - Evolution of mean Parasitaemia over time (nb&#x2F;µL), description - , timeFrame - every 6 hours from baseline up to 72 hours (day 4)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01445938",
    "endpoint": "measure - Evolution of mean Gametocytes count over time (nb&#x2F;µL), description - , timeFrame - from baseline to end of study (day 28 ± 2)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01445938",
    "endpoint": "measure - Fever Clearance (time to reach Temperature &lt; 38°C), description - , timeFrame - every 6 hours from baseline up to 72 hours (day 4)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01445938",
    "endpoint": "measure - General conditions improvement: mean total symptom score over time, description - , timeFrame - every 6 hours from baseline up to 72 hours (day 4)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01445938",
    "endpoint": "measure - SAR97276 pharmacokinetic profile in plasma and blood, description - , timeFrame - from baseline up to 12 hours after the last study drug intake on (Day 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00385047",
    "endpoint": "measure - Anti-AMA-1 antibody titers during Immunization Phase, description - , timeFrame - Up to 70 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00385047",
    "endpoint": "measure - Anti-AMA-I antibody titers during Challenge Phase, description - , timeFrame - Up to 90 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00385047",
    "endpoint": "measure - Anti-AMA-I antibodies as percent parasite growth inhibition during Immunization Phase, description - , timeFrame - Up to 70 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00385047",
    "endpoint": "measure - Anti-AMA-I antibodies as percent parasite growth inhibition during Challenge Phase, description - , timeFrame - Up to 90 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00385047",
    "endpoint": "measure - Time to parasitemia development after primary challenge following administration of the FMP2.l&#x2F;ASOIB and FMP2.l &#x2F;AS02A, description - , timeFrame - Up to 1 Year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02458066",
    "endpoint": "measure - Prevalence of infection, adjusted for potential cofounders in 2-14 year olds, description - - RDT-based prevalence of infection in children between the ages of 2 and 14 of the participating localities, adjusted for potential confounders, such as bednet use, socio-economic status, age of subjects etc., timeFrame - 3-5 months post receiving IRS",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02458066",
    "endpoint": "measure - Severe anemia in children under 5, description - - Severe anaemia prevalence (haemoglobin&lt; 8 g&#x2F;dL) in children under 5 years of age of the participating localities., timeFrame - 3-5 months post receiving IRS",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00336388",
    "endpoint": "measure - Adherence to malaria case management guidelines by health care workers, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00336388",
    "endpoint": "measure - Cost effectiveness of malaria case management guidelines using malaria rapid diagnostic tests, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00336388",
    "endpoint": "measure - Acceptability of malaria rapid diagnostic tests to health care workers, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00336388",
    "endpoint": "measure - Acceptability of malaria rapid diagnostic tests to patients, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05946642",
    "endpoint": "measure - Prevalence of asymptomatic malaria, description - prevalence of asymptomatic parasitemia in the different study arms, timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05946642",
    "endpoint": "measure - Prevalence of anemia, description - prevalence of anemia in the different study arms, timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05946642",
    "endpoint": "measure - Prevalence of gametocytes determined by microscopy., description - prevalence of gametocytes in the different study arms, timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05946642",
    "endpoint": "measure - Prevalence of antimalarial drug resistance markers, description - prevalence of antimalarial drug resistance markers in the different study arms, timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05946642",
    "endpoint": "measure - Acceptability of the two IPTsc approaches, description - Acceptability of the two IPTsc approaches by the community., timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05946642",
    "endpoint": "measure - Cost-effectiveness analysis of IPTsc with SPAQ and DP plus IVM from a provider perspective, description - cost-effectiveness of the two IPTsc approaches, timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00380393",
    "endpoint": "measure - Frequency of First Case Malaria Meeting the Secondary Case Definition, description - The first case of malaria meeting the secondary case definition was defined as the first or only episodes with the presence of P.falciparum asexual parasitemia &gt; 0 per μL and the presence of fever ≥ 37.5°C by active case detection (ACD) or passive case detection (PCD).\nNumber of first case of malaria were assessed through estimate of vaccine efficacy (VE) adjusted or unadjusted for covariates, and are expressed in PYAR= number of episodes&#x2F;Person Years at Risk., timeFrame - Assessed over average of 7.8 months post Dose 3 (range 4.3 to 10.3 months)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00380393",
    "endpoint": "measure - Multiple Events of Malaria Meeting the Primary Case Definition, description - Multiple episodes of malaria meeting the primary case definition was defined as episodes with the presence of P.falciparum asexual parasitemia &gt; 25000 per μL and the presence of fever ≥ 37.5°C by active case detection (ACD) or passive case detection (PCD).\nNumber of primary case of malaria were assessed through estimate of vaccine efficacy (VE) adjusted or unadjusted for covariates, and are expressed in PYAR= number of episodes&#x2F;Person Years at Risk., timeFrame - Assessed over average of 7.8 months post Dose 3 (range 4.3 to 10.3 months)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00380393",
    "endpoint": "measure - Multiple Events of Malaria Meeting the Secondary Case Definition, description - Multiple episodes of malaria meeting the secondary case definition was defined as episodes with the presence of P.falciparum asexual parasitemia &gt; 0 per μL and the presence of fever ≥ 37.5°C by active case detection (ACD) or passive case detection (PCD).\nNumber of secondary case of malaria were assessed through estimate of vaccine efficacy (VE) adjusted or unadjusted for covariates, and are expressed in PYAR= number of episodes&#x2F;Person Years at Risk., timeFrame - Assessed over average of 7.8 months post Dose 3 (range 4.3 to 10.3 months)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00380393",
    "endpoint": "measure - Number of Subjects Positive for P. Falciparum Parasitaemia, description - , timeFrame - At the Cross-Sectional Visit that took place for each participant at on average 7.8 months post Dose 3 (range 4.3 to 10.3 months)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00380393",
    "endpoint": "measure - Geometric Mean Density of Asexual P. Falciparum Parasite, description - Estimates of asexual P. falciparum parasite density were made at the investigator&#x27;s sites according to laboratory standard operating procedures.\nParasite density was presented as a geometric mean (GMean), expressed in parasite per microliters (μL)., timeFrame - At the Cross-Sectional Visit that took place for each participant at on average 7.8 months post Dose 3 (range 4.3 to 10.3 months)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00380393",
    "endpoint": "measure - Haemoglobin Values at Cross-Sectional Visit, description - Haemoglobin values are expressed in grams per deciliter (g&#x2F;dL)., timeFrame - At the Cross-Sectional Visit that took place for each participant at on average 7.8 months post Dose 3 (range 4.3 to 10.3 months)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00380393",
    "endpoint": "measure - Number of Subjects With Any and Grade 3 Solicited Local Symptoms, description - Assessed solicited local symptoms were pain and swelling.\nAny = occurrence of the symptom regardless of intensity grade.\nGrade 3 pain = pain that prevented normal activity.\nGrade 3 swelling = swelling spreading beyond 20 millimeters (mm) of injection site., timeFrame - During the 7-day (Days 0-6) post-vaccination period following each dose and across doses",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00380393",
    "endpoint": "measure - Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms, description - Assessed solicited general symptoms were drowsiness, fever [defined as axillary temperature equal to or above (≥) 37.5 degrees Celsius (°C)], irritability and loss of appetite.\nAny = occurrence of the symptom regardless of intensity grade.\nGrade 3 symptom = symptom that prevented normal activity.\nGrade 3 fever = fever higher than (&gt;) 39.0 °C.\nRelated = symptom assessed by the investigator as related to the vaccination., timeFrame - During the 7-day (Days 0-6) post-vaccination period following each dose and across doses",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00380393",
    "endpoint": "measure - Number of Subjects With Any Unsolicited Adverse Events (AEs), description - An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.\nAny was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination., timeFrame - Within the 30-day (Days 0-29) post-vaccination follow-up period",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00380393",
    "endpoint": "measure - Number of Subjects With Serious Adverse Events (SAEs), description - Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability&#x2F;incapacity., timeFrame - Throughout the study period (Day 0 - Month 14)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00380393",
    "endpoint": "measure - Number of Subjects With Hemoglobin Values Outside Normal Ranges With Toxicity Grades, description - Definitions for toxicity grading for hemoglobin were: Normal Hemoglobin = equal to or above (≥) 8.0 g&#x2F;dL; Grade 1 Hemoglobin = under (&lt;) 8.0 g&#x2F;dL and above (&gt;) 6.0 g&#x2F;dL.; Grade 2 Hemoglobin = under (&lt;) 6.0 g&#x2F;dL., timeFrame - At Day 0, Month 3 and at Cross-sectional Visit (took place between 7 and 13 months post Dose 1, mean: 10 months, standard deviation: 1.29)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00380393",
    "endpoint": "measure - Number of Subjects With White Blood Cell (WBC) Values Outside Normal Ranges With Toxicity Grades, description - Definitions for toxicity grading for WBC were: Normal WBC = ≥ 4.0 x 10^3 cells per microliters (cells&#x2F;μL) or &lt; 17 x 10^3 cells &#x2F;μL; Grade 1 WBC = 2.5 to 4.0 x 10^3 cells&#x2F;μL., timeFrame - At Day 0, Month 3 and at Cross-sectional Visit (took place between 7 and 13 months post Dose 1, mean: 10 months, standard deviation: 1.29)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00380393",
    "endpoint": "measure - Number of Subjects With Platelet Values Outside Normal Ranges With Toxicity Grades, description - Definitions for toxicity grading for platelets were: Normal Platelets = ≥ 75 x 10^3 cells&#x2F;μL; Grade 1 Platelets = 50 to 74 x 10^3 &#x2F;μL; Grade 2 Platelets = 25 to 49 x 10^3 &#x2F;μL; Grade 3 Platelets = &lt; 25 x 10^3 &#x2F;μL., timeFrame - At Day 0, Month 3 and at Cross-sectional Visit (took place between 7 and 13 months post Dose 1, mean: 10 months, standard deviation: 1.29)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00380393",
    "endpoint": "measure - Number of Subjects With Alanine Aminotransferase (ALT) Values Outside Normal Ranges With Toxicity Grades, description - Definition for toxicity grading for ALT were: Normal ALT = ≤ 60 international units per liter (IU&#x2F;L); Grade 1 ALT = 1.1 to 2.5 x Upper Limit of Normal (ULN); Grade 2 ALT = 2.6 to 5.0 x ULN., timeFrame - At Day 0, Month 3 and at Cross-sectional Visit (took place between 7 and 13 months post Dose 1, mean: 10 months, standard deviation: 1.29)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00380393",
    "endpoint": "measure - Number of Subjects With Creatinine Values Outside Normal Ranges With Toxicity Grades, description - Definition for toxicity grading for creatinine were: Normal Creatinine = ≤ 60 micromols per liter (μmol&#x2F;L); Grade 1 Creatinine = 1.1 to 1.5 x ULN; Grade 2 Creatinine = 1.6 to 3.0 x ULN., timeFrame - At Day 0, Month 3 and at Cross-sectional Visit (took place between 7 and 13 months post Dose 1, mean: 10 months, standard deviation: 1.29)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00380393",
    "endpoint": "measure - Concentration of Antibodies Against the P. Falciparum Circumsporozoite (CS) Repeat Domain (Anti-CS), description - Concentrations are presented as geometric mean concentrations (GMCs), expressed in enzyme-linked immunosorbent assay (ELISA) units per milliliter (EU&#x2F;mL)., timeFrame - At Day 0, Month 3 and at Cross-sectional Visit (took place between 7 and 13 months post Dose 1, mean: 10 months, standard deviation: 1.29)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00380393",
    "endpoint": "measure - Concentration of Antibodies Against Hepatitis B Surface Antigen (Anti-HBs), description - Concentrations are presented as geometric mean concentrations (GMCs), expressed in enzyme-linked immunosorbent assay (ELISA) units per milliliter (EU&#x2F;mL)., timeFrame - At Day 0 and at Month 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00380393",
    "endpoint": "measure - Frequency of Cluster of Differentiation 4 (CD4+) CS-specific T-cells, description - T-cells expressing at least one of the following cytokines are presented here: interleukin-2 [IL-2], tumor-necrosis factor-alpha [TNF-α] and interferon-gamma [IFN-γ].\nFrequency is expressed in cells&#x2F;million, as assessed by Intracellular Cytokine Assay (ICA)., timeFrame - Prior to vaccination (Day 0)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00380393",
    "endpoint": "measure - Frequency of Cluster of Differentiation 8 (CD8+) CS-specific T-cells, description - T-cells expressing at least one of the following cytokines are presented here: interleukin-2 [IL-2], tumor-necrosis factor-alpha [TNF-α] and interferon-gamma [IFN-γ].\nFrequency is expressed in cells&#x2F;million, as assessed by Intracellular Cytokine Assay (ICA)., timeFrame - Prior to vaccination (Day 0)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00380393",
    "endpoint": "measure - Frequency of Cluster of Differentiation 4 (CD4+) CS-specific T-cells, description - T-cells expressing at least one of the following cytokines are presented here: interleukin-2 [IL-2], tumor-necrosis factor-alpha [TNF-α] and interferon-gamma [IFN-γ].\nFrequency is expressed in cells&#x2F;million, as assessed by Intracellular Cytokine Assay (ICA)., timeFrame - At Month 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00380393",
    "endpoint": "measure - Frequency of Cluster of Differentiation 8 (CD8+) CS-specific T-cells, description - T-cells expressing at least one of the following cytokines are presented here: interleukin-2 [IL-2], tumor-necrosis factor-alpha [TNF-α] and interferon-gamma [IFN-γ].\nFrequency is expressed in cells&#x2F;million, as assessed by Intracellular Cytokine Assay (ICA)., timeFrame - At Month 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00948896",
    "endpoint": "measure - Incidence of Any Adverse Events Defined as Severity Grade 3-4 That Are Possibly, Probably, or Definitely Related to Study Drugs, description - NIH Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events published December, 2004, timeFrame - Time from randomization until 24 months of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00948896",
    "endpoint": "measure - Rebound Incidence of Malaria Defined as the Number of Treatments for New Episodes of Malaria Per Time at Risk, description - , timeFrame - 24 months to 36 months of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02411994",
    "endpoint": "measure - PCR-corrected adequate clinical and parasitological response (ACPR), description - , timeFrame - day 42 after initial dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02411994",
    "endpoint": "measure - crude adequate clinical and parasitological response (ACPR), description - , timeFrame - day 28, day 42 after initial dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02411994",
    "endpoint": "measure - parasite clearance time, description - , timeFrame - up to 7 days after initial dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02411994",
    "endpoint": "measure - gametocyte clearance time, description - , timeFrame - up to 7 days after initial dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02411994",
    "endpoint": "measure - transmission potential to mosquitos, description - , timeFrame - day 7 after initial dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01666925",
    "endpoint": "measure - Vaccine immunogenicity, description - <p>Measures of immunogenicity will include:</p><p>Ex vivo ELISPOT responses to overlapping pools of ME - TRAP peptides.\nCultured ELISPOT responses to overlapping pools of ME - TRAP peptides.\nICS by flow cytometry for cell mediated immune responses ELISA for antibodies to malaria antigens</p>, timeFrame - 24 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01666925",
    "endpoint": "measure - Reactogenicity, description - All solicited and unsolicited local and systemic vaccine- linked adverse events (AEs) including clinically significant laboratory abnormalities., timeFrame - 24 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02535767",
    "endpoint": "measure - To measure the occurrence of adverse events, graded by severity, at each primaquine dose among G6PD deficient men, description - <p>Severity:</p><ol><li>= mild</li><li>= moderate</li><li>= severe</li><li>= life threatening</li></ol>, timeFrame - Days 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 14, and 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02535767",
    "endpoint": "measure - To measure the occurrence of absolute and fractional change in hemoglobin concentration (g&#x2F;dL) on day 7 vs. baseline at each primaquine dose among G6PD deficient men, in comparison with G6PD normal men, description - , timeFrame - Days 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 14, and 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02535767",
    "endpoint": "measure - To measure the occurrence of reticulocytosis (by microscopic quantification of reticulocytes stained with brilliant cresyl blue &#x2F; 1,000 RBCs) on each day of followup, at each primaquine dose, among G6PD deficient men, in comparison with G6PD normal men, description - , timeFrame - Days 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 14, and 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02535767",
    "endpoint": "measure - To monitor methemoglobin levels (%) on each day of followup, at each primaquine dose among G6PD deficient men, in comparison with G6PD normal men, description - Use of a Masimo Rad-57 pulse oximeter that measures methemoglobin levels non-invasively, based on absorption of light through the fingertip., timeFrame - Days 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 14, and 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02535767",
    "endpoint": "measure - To determine G6PD enzyme activity (semiquantitative testing, U&#x2F;g Hb), description - Semiquantitative testing will be performed on frozen blood samples to determine G6PD activity on day of enrolment, timeFrame - Day 0",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02535767",
    "endpoint": "measure - Area Under Curve (AUC) for primaquine, description - Pharmacokinetic analysis of plasma concentration of primaquine at all sampled timepoints, timeFrame - Hours 1, 2, 4, 6, 8, and 24 after primaquine administration",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02535767",
    "endpoint": "measure - Maximal concentration (Cmax) for primaquine, description - Pharmacokinetic analysis of plasma concentration of primaquine at all sampled timepoints, timeFrame - Hours 1, 2, 4, 6, 8, and 24 after primaquine administration",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02535767",
    "endpoint": "measure - Area Under Curve (AUC) for carboxyprimaquine, description - Pharmacokinetic analysis of plasma concentration of carboxyprimaquine, timeFrame - Hours 1, 2, 4, 6, 8, and 24 after primaquine administration",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02535767",
    "endpoint": "measure - Maximal concentration (Cmax) for carboxyprimaquine, description - Pharmacokinetic analysis of plasma concentration of carboxyprimaquine, timeFrame - Hours 1, 2, 4, 6, 8, and 24 after primaquine administration",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02535767",
    "endpoint": "measure - Area Under Curve (AUC) for select minor metabolites of primaquine, description - Pharmacokinetic analysis of plasma concentration of metabolites of primaquine, exact metabolites to be determined by ongoing in vivo studies (including 5-hydroxyprimaquine), timeFrame - Hours 1, 2, 4, 6, 8, and 24 after primaquine administration",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02535767",
    "endpoint": "measure - Maximal concentration (Cmax) for select minor metabolites of primaquine, description - Pharmacokinetic analysis of plasma concentration of metabolites of primaquine, exact metabolites to be determined by ongoing in vivo studies (including 5-hydroxyprimaquine), timeFrame - Hours 1, 2, 4, 6, 8, and 24 after primaquine administration",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02535767",
    "endpoint": "measure - Cytochrome P450 (CYP) 2D6 genotyping, description - To determine whether a correlation between CYP 2D6 metabolism (weak metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer) and hemolysis exists., timeFrame - Day 0",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00367653",
    "endpoint": "measure - A secondary objective is to assess the efficacy of azithromycin plus chloroquine., description - , timeFrame - duration of trial",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00367653",
    "endpoint": "measure - Additional secondary objectives include an assessment of the safety and tolerability of all treatment regimens., description - , timeFrame - duration of trial",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02914145",
    "endpoint": "measure - Population coverage of the MDA intervention, description - the proportion of individuals (≥6 months old) that agreed to participate in the MDA intervention and took under DOT the first dose of the 3-day long treatment of DHA-PQP among all individuals ≥6 months old eligible to participate in the intervention in the target population., timeFrame - 3 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01450293",
    "endpoint": "measure - Immunogenicity of heterologous prime-boost vaccination with AdCh63 ME-TRAP followed eight weeks later by MVA ME-TRAP, description - To assess the immunogenicity of heterologous prime-boost vaccination of healthy infants in a malaria-endemic area with AdCh63 ME-TRAP followed eight weeks later by MVA ME-TRAP by assessing induced antibody and T cell response to the vaccine insert, timeFrame - Participants will be followed for the duration of the study, an expected average of 16 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02453581",
    "endpoint": "measure - OZ439 Cmax, description - OZ439 Maximum concentration (Cmax), timeFrame - Pre-dose, and 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02453581",
    "endpoint": "measure - OZ439 AUC(0-144), description - OZ439 Area under the curve to 144 hours, timeFrame - Pre-dose, and 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01652365",
    "endpoint": "measure - Mean RDT Price Charged by Shops, description - , timeFrame - Up to One Year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01652365",
    "endpoint": "measure - Mean RDTs Purchased by Shops from Wholesaler, description - , timeFrame - Up To One Year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01652365",
    "endpoint": "measure - Fraction of Monitoring Checklist Items Performed Correctly by Shops, description - , timeFrame - Up To One Year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01652365",
    "endpoint": "measure - Fraction of Illnesses for which an Antimalarial&#x2F;ACT&#x2F;Antibiotic is Taken, description - <ul><li>Comparison of rate of antimalarial taking for illnesses in treatment vs. control</li><li>Comparison of rate of ACT taking for illnesses in treatment vs. control</li><li>Comparison of rate of antibiotic taking for illnesses in treatment vs. control</li></ul>, timeFrame - Up To One Year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00443131",
    "endpoint": "measure - Occurrence, intensity and relationship to vaccination of solicited local and general symptoms., description - , timeFrame - During the 7-day follow-up period following vaccination after each vaccine dose.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00443131",
    "endpoint": "measure - Occurrence, intensity and relationship to vaccination of unsolicited symptoms., description - , timeFrame - During the 30-day follow-up period following vaccination after each vaccine dose.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00443131",
    "endpoint": "measure - Occurrence of serious adverse events., description - , timeFrame - Up until 1 month post dose 3.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00443131",
    "endpoint": "measure - Antibody responses to the P. falciparum circumsporozoite (CS) antigen., description - , timeFrame - At Day 0, prior to dose 2, prior to dose 3 and 1 month post-dose 3.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00443131",
    "endpoint": "measure - Antibody responses to HBs antigen., description - , timeFrame - At Day 0, prior to dose 2, prior to dose 3 and 1 month post-dose 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00443131",
    "endpoint": "measure - Frequency of CS and Hepatitis B surface agent (HBs)-specific CD4+ and CD8+ T cells expressing Th1 specific activation markers and cytokines., description - , timeFrame - At Day 0, prior to dose 2, prior to dose 3 and 1 month post-dose 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00231452",
    "endpoint": "measure - (Clinical) Time to first or only episode of malaria (using other case definitions), anaemia and other clinical endpoints., description - Global comparison between the 3 study groups of the time to first or only episode of clinical malaria (according to the secondary case definitions) in the second year of follow up detected by passive case detection.\nOther endpoints include multiple episodes of malaria, time to first or only episode of anaemia, total hospital visits and prevalence of parasitaemia and anaemia at different time points.\nIn addition, pairwise comparisons of the 3 groups are also presented., timeFrame - 12 to 24 months of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00231452",
    "endpoint": "measure - Oxidative stress markers, description - Quantification of the antioxidant&#x2F;pro-oxidant status over the first two years of life in relation to age of first exposure to infection., timeFrame - multiple time points during the first two years of life (2.5, 5.5, 10.5, 15 and 24 months of age)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00231452",
    "endpoint": "measure - Humoral and cellular immune responses, description - Quantification of antibody and cytokine responses to P. falciparum protein antigens and toxins over the first two years of life in relation to age of first exposure to infection, timeFrame - multiple time points during the first two years of life (2.5, 5.5, 10.5, 15 and 24 months of age)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00231452",
    "endpoint": "measure - Host genetics, description - Analysis of haematological genetic factors, polymorphisms in genes involved in inflammatory or immunological responses to malaria and polymorphisms in genes involved in the Th1&#x2F;Th2 immunological pathway., timeFrame - 2.5 months of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00529620",
    "endpoint": "measure - Adverse events reported by the mother: vomiting, headache, fever, nausea, diarrhea, description - , timeFrame - within 4 days of the start treatment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00529620",
    "endpoint": "measure - Prevalence of P.falciparum parasitaemia, description - , timeFrame - Measured by microscopy 1 month after the last treatment, in December",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00529620",
    "endpoint": "measure - Haemoglobin concentration, description - , timeFrame - Measured 1 month after the last treatment, in December",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00529620",
    "endpoint": "measure - The proportion of children carrying P.falciparum genotypes associated with resistance to sulfadoxine and pyrimethamine, description - , timeFrame - Measured in December",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00529620",
    "endpoint": "measure - Compliance with the treatment regimen, description - , timeFrame - Recorded 4 days after the start of treatment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00978172",
    "endpoint": "measure - To determine further safety and effectiveness parameters of Artequin Paediatric, description - , timeFrame - Baseline (day1), day 4, day7, day 28, day 63",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02640495",
    "endpoint": "measure - Time needed until a plasma lactate concentration &lt;2 mmol&#x2F;L, description - , timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02640495",
    "endpoint": "measure - Change in Glasgow Coma Score (GCS) or Blantyre Coma Score (BCS), description - at 12 hours after initial treatment and coma recovery time defined as GCS&gt;10 or BCS&gt;3 and GCS=15 and BCS=5, timeFrame - 12 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02640495",
    "endpoint": "measure - Base excess clearance after 12 hours, description - Base excess clearance after 12 hours as proportion of the base excess at presentation, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02640495",
    "endpoint": "measure - Time until a base excess concentration ≥ minus 2 mmol&#x2F;L, description - , timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02640495",
    "endpoint": "measure - Time to resuming the ability to sit, eat, drink, stand unsupported and walk, description - , timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02640495",
    "endpoint": "measure - The parasite clearance half-life, description - , timeFrame - 48 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02640495",
    "endpoint": "measure - The parasite clearance ratios at H28 and H48 compared to parasite count on admission, description - , timeFrame - 48 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02640495",
    "endpoint": "measure - The parasite clearance time for parasite count to fall to 50%, 90% and 99% of initial parasite density, description - , timeFrame - 7 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02640495",
    "endpoint": "measure - Differences in transcriptome patterns between artemisinin resistant parasites and artemisinin sensitive parasites at baseline, description - , timeFrame - H0",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02640495",
    "endpoint": "measure - Differences in transcriptome patterns between artemisinin resistant parasites and artemisinin sensitive parasites at H6, description - , timeFrame - H6",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02640495",
    "endpoint": "measure - Differences in transcriptome patterns between artemisinin resistant parasites and artemisinin sensitive parasites at H12, description - , timeFrame - H12",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02640495",
    "endpoint": "measure - Differences in transcriptome patterns between artemisinin resistant parasites and artemisinin sensitive parasites at H48, description - , timeFrame - H48",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02640495",
    "endpoint": "measure - Time until resolution of fever, description - (time until tympanic temperature first &lt;37.5 Celsius and below 37.5C for 24 h), timeFrame - 14 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02640495",
    "endpoint": "measure - Proportion of patients developing new malaria, description - Proportion of patients developing new malaria severity signs as defined in the 2014 WHO severe malaria guidelines, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02640495",
    "endpoint": "measure - Proportion of patients developing new neurological signs assessed by neurological examination during hospitalization, description - , timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02640495",
    "endpoint": "measure - Prevalence of neurological sequelae assessed by neurological examination at discharge, description - , timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02640495",
    "endpoint": "measure - Prevalence of neurological sequelae assessed by neurological examination at day 7, description - , timeFrame - 7 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02640495",
    "endpoint": "measure - Prevalence of neurological sequelae assessed by neurologicalexamination at day 14, description - , timeFrame - 14 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02640495",
    "endpoint": "measure - Prevalence of neurological sequelae assessed by neurological examination at day 28 if day 14 is abnormal, description - , timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02640495",
    "endpoint": "measure - Prevalence of neurological sequelae assessed by neurological examination at day 42 if day 28 is abnormal, description - , timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02640495",
    "endpoint": "measure - Severity of neurological sequelae assessed by neurological examination at discharge, description - , timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02640495",
    "endpoint": "measure - Severity of neurological sequelae assessed by neurological examination at day 7, description - , timeFrame - 7 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02640495",
    "endpoint": "measure - Severity of neurological sequelae assessed by neurological examination at day 14, description - , timeFrame - 14 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02640495",
    "endpoint": "measure - Severity of neurological sequelae assessed by neurological examination at day 28 if day 14 is abnormal, description - , timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02640495",
    "endpoint": "measure - Severity of neurological sequelae assessed by neurological examination at day 42 if day 28 is abnormal, description - , timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02640495",
    "endpoint": "measure - Proportion treated with quinine, description - as a rescue treatment, antibiotics, blood products, anticonvulsants, renal replacement therapy, mechanical ventilation therapy, vasopressive drugs and oxygen therapy, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02640495",
    "endpoint": "measure - In hospital mortality, description - , timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02640495",
    "endpoint": "measure - Day 7, 14 hemoglobin or hematocrit levels, description - and in addition at day 28 and 42 if abnormal at day 14 or day 28 respectively, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02640495",
    "endpoint": "measure - Creatinine levels daily, description - during the first four days and thereafter on day 7 and 14 and in addition on day 28 and 42 if abnormal on day 14 or day 28 respectively, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02640495",
    "endpoint": "measure - Bilirubin, Alanine transaminase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase levels daily, description - during the first four days and thereafter on day 7, 14 and in addition on day 28 and 42 if abnormal on day 14 or 28 respectively, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02640495",
    "endpoint": "measure - Plasma biomarkers of severe (artemisinin resistant) malaria, description - , timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02640495",
    "endpoint": "measure - outcome of pregnancy during hospitalization, description - If pregnant, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02640495",
    "endpoint": "measure - Time until discharge, description - , timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01949909",
    "endpoint": "measure - Assessment of the humoral immune response to the vaccine antigen, description - The humoral response to the vaccine antigen will be assessed in all volunteers by ELISA to measure the level of total antigen specific IgG., timeFrame - 15 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01949909",
    "endpoint": "measure - Assessment of the cellular immune response to the vaccine antigen, description - The cellular immune response will be assessed in all volunteers by measuring the T cell proliferation and cytokine production following in vitro stimulation with the vaccine antigen (by Luminex on cell culture supernatant after in vitro stimulation of PBMC for 6 days with the P27A peptide).\nProliferation of carboxyfluorescein diacetate succinimidyl ester (CFSE) loaded CD3+ CD4+ and CD3+CD8+ T cells will be assayed by using polychromatic flow cytometry., timeFrame - 15 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04978272",
    "endpoint": "measure - Incidence of complicated malaria, description - Any incident episode of malaria meeting World Health Organization criteria for severe malaria or danger signs per time at risk, during the period after the intervention was given (2-4 years of age)., timeFrame - 2 years to 4 years of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04978272",
    "endpoint": "measure - Incidence of hospital admissions and&#x2F;or deaths, description - Admission to the pediatric ward for any cause, and deaths of any cause, timeFrame - 2 years to 4 years of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04978272",
    "endpoint": "measure - Prevalence of parasitemia, description - Proportion of routine visits with asexual parasites detected by blood smears or quantitative polymerase chain reaction (qPCR)., timeFrame - 2 years to 4 years of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04978272",
    "endpoint": "measure - Prevalence of anemia, description - Proportion of routine hemoglobin measurements &lt;11 grams&#x2F;dL, timeFrame - 2 years to 4 years of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01169077",
    "endpoint": "measure - Responses to tolerability questionnaire used to document subject feedback of electroporation mediated DNA vaccine delivery; proportion of subjects judging the procedure to be suitable for use in context of a prophylactic malaria vaccine., description - , timeFrame - Day 0, 28 and 56.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01169077",
    "endpoint": "measure - Antibody titers in serum measured against malaria circumsporozoite protein [Geometric Mean Titer and individual log Enzyme-Linked Immunosorbent Assay (ELISA) units] for subjects in groups II and III., description - , timeFrame - Day 0, 42, and 70.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01169077",
    "endpoint": "measure - Sample number showing positive falciparum-specific responses, Geometric Mean Titer spot-forming cells&#x2F;million peripheral blood mononuclear cell per cohort, subject frequency per cohort with at least 1 positive response., description - , timeFrame - Days 0, 42 and 70.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01169077",
    "endpoint": "measure - Interferon-gamma Enzyme-Linked Immunospot Assay (ELISPOT) assay., description - , timeFrame - Days 0, 42 and 70.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01658696",
    "endpoint": "measure - Vaccine immunogenicity, description - <p>Measures of immunogenicity will include:</p><p>Ex vivo ELISPOT responses to overlapping pools of ME - TRAP peptides.\n25 Cultured ELISPOT responses to overlapping pools of ME - TRAP peptides.\nICS by flow cytometry for cell mediated immune responses ELISA for antibodies to malaria antigens All solicited and unsolicited local and systemic vaccine- linked adverse events (AEs) including clinically significant laboratory abnormalities.</p>, timeFrame - 24 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01658696",
    "endpoint": "measure - Safety, description - All solicited and unsolicited local and systemic vaccine- linked adverse events (AEs) including clinically significant laboratory abnormalities., timeFrame - 24 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00866619",
    "endpoint": "measure - Rate of All Episodes of P. Falciparum Clinical Malaria Infection (CPFMI) of PCD and of Secondary Case Definitions (SCD) 1, SCD 2 and SCD 3, description - PCD=malaria episode with P. falciparum asexual parasitemia (PFAP) &gt; 5000 parasites&#x2F;µL accompanied by fever and occurring in a child unwell brought for treatment to a healthcare facility or a case of malaria meeting the PCD of severe malaria disease.\nSCD1=malaria episode with PFAP &gt; 0 and fever at time of presentation or history of fever within 24h of presentation in a subject unwell brought for treatment to a healthcare facility.\nSCD2=malaria episode with PFAP &gt; 500 parasites&#x2F;μL and fever at time of presentation in a subject unwell brought for treatment to a healthcare facility.\nSCD3=malaria episode with PFAP &gt; 20.000 parasites&#x2F;μL and fever at time of presentation in a subject unwell and brought for treatment to a healthcare facility.\nTime to all CPFMI episodes is expressed as person-year rate in each group (n&#x2F;T).\nResults are uncorrected for double enrollment of 1 subject receiving GSK257049 vaccine., timeFrame - From Month 2.5 to Month 14",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00866619",
    "endpoint": "measure - Rate of All Episodes of Clinical P. Falciparum Malaria Infection (CPFMI) of PCD, Overall and by Center, description - PCD = malaria episode with PFAP &gt; 5000 parasites&#x2F;µL accompanied by fever and occurring in a child unwell brought for treatment to a healthcare facility or a case of malaria meeting the PCD of severe malaria disease (see below endpoints on severe malaria for details).\nTime to all CPFMI episodes is expressed as person-year rate in each group (n&#x2F;T).\nResults are by center and across centers, and are uncorrected for double enrollment of 1 subject receiving GSK257049 vaccine., timeFrame - From Month 2.5 to Month 20",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00866619",
    "endpoint": "measure - Rate of All Episodes of Clinical P. Falciparum Malaria Infection (CPFMI) of SCD1, SCD2 and SCD3 (Overall), description - SCD1 = malaria episode with PFAP &gt; 0 and fever at time of presentation or history of fever within 24h of presentation in a subject unwell brought for treatment to a healthcare facility.\nSCD2 = malaria episode with PFAP &gt; 500 parasites&#x2F;μL and fever at time of presentation in a subject unwell brought for treatment to a healthcare facility.\nSCD3 = malaria episode with PFAP &gt; 20.000 parasites&#x2F;μL and fever at time of presentation in a subject unwell and brought for treatment to a healthcare facility.\nTime to all CPFMI episodes is expressed as person-year rate in each group (n&#x2F;T).\nResults are across centers, and are uncorrected for double enrollment of 1 subject receiving GSK257049 vaccine., timeFrame - From Month 2.5 to Month 20",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00866619",
    "endpoint": "measure - Rate of All Episodes of Clinical P. Falciparum Malaria Infection (CPFMI) of Primary Case Definition (PCD), by Centers and Across Centers, description - CPFMI of PCD = episode of malaria for which PFAP &gt; 5000 parasites&#x2F;µL accompanied by presence of fever (axillary temperature ≥ 37.5°C at time of presentation) AND occurring in a child unwell brought for treatment to a healthcare facility OR a case of malaria meeting the PCD of severe malaria disease.\nTime to all CPFMI episodes is expressed as person-year rate in each group (n&#x2F;T).\nResults are presented by center and across centers., timeFrame - From Month 2.5 up to study End (with a median follow-up time post-Dose 1 of 48 months for 5-17M groups and 38 months for 6-12W groups)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00866619",
    "endpoint": "measure - Rate of All Episodes of Clinical P. Falciparum Malaria Infection (CPFMI) of Secondary Case Definition 1 (SCD1), Across Centers, description - CPFMI of SCD1 = malaria episode with PFAP &gt;0 and fever at time of presentation or history of fever within 24h of presentation in a subject unwell brought for treatment to a healthcare facility.\nTime to all CPFMI episodes is expressed as person-year rate in each group (n&#x2F;T).\nResults are presented across centers., timeFrame - From Month 2.5 up to study end (with a median follow-up time post-Dose 1 of 48 months for 5-17M groups and 38 months for 6-12W groups)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00866619",
    "endpoint": "measure - Rate of All Episodes of Clinical P. Falciparum Malaria Infection (CPFMI) of Primary Case Definition (PCD) and Secondary Case Definition 1 (SCD1), Across Centers, description - CPFMI of PCD = episode of malaria for which PFAP &gt; 5000 parasites&#x2F;µL accompanied by the presence of fever (axillary temperature ≥ 37.5°C at time of presentation) AND occurring in a child unwell brought for treatment to a healthcare facility OR a case of malaria meeting the PCD of severe malaria disease.\nCPFMI of SCD1 = malaria episode with PFAP &gt;0 and fever at time of presentation or history of fever within 24h of presentation in a subject unwell brought for treatment to a healthcare facility.\nTime to all CPFMI episodes is expressed as person-year rate in each group (n&#x2F;T).\nResults are presented across centers., timeFrame - From Booster at Month 20 up to study end (with a median follow-up time post-Dose 1 of 48 months for 5-17M groups and 38 months for 6-12W groups)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00866619",
    "endpoint": "measure - Rate of All Episodes of Clinical P. Falciparum Malaria Infection (CPFMI) of PCD and SCD1, Across Centers, description - CPFMI of PCD = episode of malaria for which PFAP &gt; 5000 parasites&#x2F;µL accompanied by the presence of fever (axillary temperature ≥ 37.5°C at time of presentation) AND occurring in a child unwell brought for treatment to a healthcare facility OR a case of malaria meeting the PCD of severe malaria disease.\nCPFMI of SCD1 = malaria episode with PFAP &gt; 0 and fever at time of presentation or history of fever within 24h of presentation in a subject unwell brought for treatment to a healthcare facility.\nTime to all CPFMI episodes is expressed as person-year rate in each group (n&#x2F;T).\nResults are presented across centers., timeFrame - From Month 33 up to study end (with a median follow-up time post-Dose 1 of 48 months for 5-17M groups and 38 months for 6-12W groups)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00866619",
    "endpoint": "measure - Rate of All Episodes of Clinical P. Falciparum Malaria Infection (CPFMI) of PCD, by Center and Across Centers, description - CPFMI of PCD = episode of malaria for which PFAP &gt; 5000 parasites&#x2F;µL accompanied by the presence of fever (axillary temperature ≥ 37.5°C at time of presentation) AND occurring in a child unwell brought for treatment to a healthcare facility OR a case of malaria meeting the PCD of severe malaria disease.\nTime to all CPFMI episodes is expressed as person-year rate in each group (n&#x2F;T).\nResults are presented by center and across centers., timeFrame - From Month 2.5 to Month 32",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00866619",
    "endpoint": "measure - Rate of All Episodes of Clinical P. Falciparum Malaria Infection (CPFMI) of Secondary Case Definition 1 (SCD1), description - CPFMI of SCD1 = malaria episode with PFAP &gt; 0 and fever at time of presentation or history of fever within 24h of presentation in a subject unwell brought for treatment to a healthcare facility.\nTime to all episodes of CPFMI is expressed as a rate of all CPFMI (RaCPFMI), that is, person-year rate in each group (n&#x2F;T)., timeFrame - From Month 2.5 to Month 32",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00866619",
    "endpoint": "measure - Rate of All Episodes of Clinical P. Falciparum Malaria Infection (CPFMI) of Primary Case Definition (PCD) and Secondary Case Definition 1 (SCD1), description - CPFMI of PCD = episode of malaria for which PFAP &gt; 5000 parasites&#x2F;µL accompanied by the presence of fever (axillary temperature ≥ 37.5°C at time of presentation) AND occurring in a child unwell brought for treatment to a healthcare facility OR a case of malaria meeting the PCD of severe malaria disease.\nCPFMI of SCD1 = malaria episode with PFAP &gt; 0 and fever at time of presentation or history of fever within 24h of presentation in a subject unwell brought for treatment to a healthcare facility.\nTime to all episodes of CPFMI is expressed as a rate of all CPFMI (RaCPFMI), that is, person-year rate in each group (n&#x2F;T)., timeFrame - From Booster at Month 20 up to Month 32",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00866619",
    "endpoint": "measure - Percentage of Subjects With Severe PFMI (SPFMI) of PCD, SCD1, SCD2 and SCD3, Across Centers, description - SPFMI of PCD = PFMI &gt; 5000 parasites&#x2F;μL, at least one severity marker and no co-morbidity diagnosis.\nSPFMI of SCD1 = PFMI &gt;5000 parasites&#x2F;μL and with one or more severity marker.\nSPFMI of SCD2 = PFMI &gt;0 with one or more severity marker and without co-morbidity diagnosis.\nSPFMI of SCD3 = PFMI &gt;5000 parasites&#x2F;μL, with one or more severity marker, and without co-morbidity or HIV.\nSeverity markers = prostration; respiratory distress; Blantyre score ≤ 2; ≥ 2 seizures in 24 h prior to admission, emergency room and hospitalisation; hypoglycaemia &lt; 2.2 mmol&#x2F;L; acidosis BE ≤ -10.0 mmol&#x2F;L,l &lt; 5.0 mmol&#x2F;L; anaemia&lt;5.0\ng&#x2F;dL.\nComorbidities = radiographically proven pneumonia; meningitis; positive blood culture on a blood culture taken within 72 h of admission; gastroenteritis with dehydration.\nAnalysis was performed in a pooled manner across age categories.\nResults presented are uncorrected for double enrollment of one subject in 5-17 months age category receiving GSK257049 vaccine., timeFrame - From Month 2.5 up to the time when 250 subjects were diagnosed with severe malaria of PCD, SCD1, SCD2 and SCD3 (up to the Month 14 time point for each age category or date of booster dose, whichever occurred first)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00866619",
    "endpoint": "measure - Percentage of Subjects With Severe PFMI (SPFMI) of PCD and SCD1, description - SPFMI of PCD = PFMI&gt;5000 parasites&#x2F;μL, at least one severity marker and no co-morbidity diagnosis.\nSPFMI of SCD1 = PFMI&gt;5000 parasites&#x2F;μL and with one or more severity marker.\nSeverity markers = prostration; respiratory distress; Blantyre score ≤ 2; ≥ 2 seizures in 24h prior to admission, emergency room and hospitalisation; hypoglycaemia&lt;2.2\nmmol&#x2F;L; acidosis BE ≤ -10.0 mmol&#x2F;L,l ≥ 5.0 mmol&#x2F;L; anaemia&lt;5.0\ng&#x2F;dL.\nComorbidities = radiographically proven pneumonia; meningitis; positive blood culture on a blood culture taken within 72h of admission; gastroenteritis with dehydration.\nSPFMI of SCD1 = PFMI&gt;5000 parasites&#x2F;μL and with one or more severity marker.\nSeverity markers = prostration; respiratory distress; Blantyre score ≤ 2; ≥ 2 seizures in 24h prior to admission, emergency room and hospitalisation; hypoglycaemia&lt;2.2\nmmol&#x2F;L; acidosis BE ≤ -10.0 mmol&#x2F;L,l ≥ 5.0 mmol&#x2F;L; anaemia&lt;5.0\ng&#x2F;dL.\nResults presented are uncorrected for double enrollment of one subject in 5-17 months age category., timeFrame - From Month 2.5 to Month 14",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00866619",
    "endpoint": "measure - Percentage of Subjects With Severe PFMI (SPFMI) of PCD and SCD1, description - SPFMI of PCD = PFMI&gt;5000 parasites&#x2F;μL, at least one severity marker and no co-morbidity diagnosis.\nSPFMI of SCD1 = PFMI&gt;5000 parasites&#x2F;μL and with one or more severity marker.\nSeverity markers = prostration; respiratory distress; Blantyre score ≤ 2; ≥ 2 seizures in 24h prior to admission, emergency room and hospitalisation; hypoglycaemia&lt;2.2\nmmol&#x2F;L; acidosis BE ≤ -10.0 mmol&#x2F;L,l ≥ 5.0 mmol&#x2F;L; anaemia&lt;5.0\ng&#x2F;dL.\nComorbidities = radiographically proven pneumonia; meningitis; positive blood culture on a blood culture taken within 72h of admission; gastroenteritis with dehydration.\nSPFMI of SCD1 = PFMI&gt;5000 parasites&#x2F;μL and with one or more severity marker.\nSeverity markers = prostration; respiratory distress; Blantyre score ≤ 2; ≥ 2 seizures in 24h prior to admission, emergency room and hospitalisation; hypoglycaemia&lt;2.2\nmmol&#x2F;L; acidosis BE ≤ -10.0 mmol&#x2F;L,l ≥ 5.0 mmol&#x2F;L; anaemia&lt;5.0\ng&#x2F;dL.\nResults presented are uncorrected for double enrollment of one subject in 5-17 months age category., timeFrame - From Month 2.5 to Month 20 at Booster",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00866619",
    "endpoint": "measure - Percentage of Subjects With Severe PFMI (SPFMI) of PCD and SCD1, description - SPFMI of PCD = PFMI &gt;5000 parasites&#x2F;μL, at least one severity marker and no co-morbidity diagnosis.\nSPFMI of SCD1 = PFMI &gt;5000 parasites&#x2F;μL and with one or more severity marker.\nSeverity markers = prostration; respiratory distress; Blantyre score ≤ 2; ≥ 2 seizures in 24 h prior to admission, emergency room and hospitalisation; hypoglycaemia&lt;2.2\nmmol&#x2F;L; acidosis BE ≤ -10.0 mmol&#x2F;L,l ≥ 5.0 mmol&#x2F;L; anaemia&lt;5.0\ng&#x2F;dL.\nComorbidities = radiographically proven pneumonia; meningitis; positive blood culture on a blood culture taken within 72 h of admission; gastroenteritis with dehydration.\nSPFMI of SCD1 = PFMI &gt;5000 parasites&#x2F;μL and with one or more severity marker.\nSeverity markers = prostration; respiratory distress; Blantyre score ≤ 2; ≥ 2 seizures in 24 h prior to admission, emergency room and hospitalisation; hypoglycaemia&lt;2.2\nmmol&#x2F;L; acidosis BE ≤ -10.0 mmol&#x2F;L,l ≥ 5.0 mmol&#x2F;L; anaemia&lt;5.0\ng&#x2F;dL., timeFrame - From Month 2.5, from Month 20(booster), from Month 33 up to study end (median follow-up time of 48 months post-Dose 1 for 5-17M age category and of 38 months post-Dose 1 for 6-12W age category) and from Month 2.5 to Month 32 and from Month 20 to Month 32",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00866619",
    "endpoint": "measure - Percentage of Subjects With Incident Severe Anaemia (ISA) and Malaria Hospitalization (MH) for Case Definitions (CD) Considered, description - CD considered were CD1 for ISA and CD1 and CD2 for MH.\nISA of CD1 was defined as a documented hemoglobin &lt; 5.0 g&#x2F;dL identified at clinical presentation to morbidity surveillance system in association with a P. falciparum parasitemia &gt; 5000 parasites&#x2F;μL.\nMH of CD1 was defined as a medical hospitalization with confirmed P. falciparum &gt; 5000 parasites&#x2F;μL.\nMH of CD2 was defined as a hospitalization which, in the judgment of the principal investigator, P. falciparum infection was the sole or a major contributing factor to the presentation.\nResults presented are uncorrected for double enrollment of one subject in 5-17 months age category receiving GSK257049 vaccine., timeFrame - From Month 2.5 to Month 20",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00866619",
    "endpoint": "measure - Percentage of Subjects With Incident Severe Anaemia (ISA), Malaria Hospitalization (MH) and Fatal Malaria (FM) for Case Definitions (CD) Considered, description - ISA CD considered were CD1, CD2 and CD3 (definitions mentioned in the previous outcome measure).\nMH CD considered were CD1 and CD2 (definitions mentioned in the previous outcome measure).FM CD considered were primary CD (PCD) and sedondary CDs 1 and 4 (SCD1 and SCD4).\nFM of PCD was defined as a case of severe malaria meeting the primary case definition of severe malaria disease with a fatal outcome.\nFM of SCD1 was defined as a case of severe malaria meeting the secondary case definition 1 severe malaria disease with a fatal outcome.\nFM of SCD4 was defined as a fatal case associated with International Classification Disease (ICD10) codes B50, B53 and&#x2F;or B54.\nCode B50 corresponds to P. falciparum malaria including mixed infections of P. falciparum with any other Plasmodium species; Code B53 corresponds to other parasitologically confirmed malaria; Code B54 corresponds to unspecified malaria including clinically diagnosed malaria without parasitological confirmation., timeFrame - From Month 2.5 to up to study end (with a median follow-up time post-Dose 1 of 48 months for 5-17M groups and 38 months for 6-12W groups)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00866619",
    "endpoint": "measure - Percentage of Subjects With Incident Severe Anaemia (ISA), Malaria Hospitalization (MH) and Fatal Malaria (FM) for Case Definitions (CD) Considered, description - ISA CD considered were CD1, CD2 and CD3 (definitions mentioned in the previous outcome measure).\nMH CD considered were CD1 and CD2 (definitions mentioned in the previous outcome measure).FM CD considered were primary CD (PCD) and sedondary CDs 1 and 4 (SCD1 and SCD4).\nFM of PCD was defined as a case of severe malaria meeting the primary case definition of severe malaria disease with a fatal outcome.\nFM of SCD1 was defined as a case of severe malaria meeting the secondary case definition 1 severe malaria disease with a fatal outcome.\nFM of SCD4 was defined as a fatal case associated with International Classification Disease (ICD10) codes B50, B53 and&#x2F;or B54.\nCode B50 corresponds to P. falciparum malaria including mixed infections of P. falciparum with any other Plasmodium species; Code B53 corresponds to other parasitologically confirmed malaria; Code B54 corresponds to unspecified malaria including clinically diagnosed malaria without parasitological confirmation., timeFrame - From Month 2.5 to Month 32",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00866619",
    "endpoint": "measure - Percentage of Subjects With Prevalent Parasitemia, Prevalent Gametocytemia and Prevalent Severe and Moderate Anemia, description - Prevalent parasitemia (PP) was defined as a documented P. falciparum asexual parasite density &gt; 0 identified at timing of assessment.\nPrevalent gametocytemia (PG) was defined as a documented P. falciparum gametocyte density &gt; 0 identified at a cross sectional survey.\nPrevalent severe anemia (PSA) was defined as a documented hemoglobin &lt; 5.0 g&#x2F;dL identified at timing of assessment.\nPrevalent moderate anemia (PMA) was defined as a documented hemoglobin &lt; 8.0 g&#x2F;dL identified at at timing of assessment.\nResults presented are uncorrected for the double enrollment of one subject receiving RTS,S&#x2F;AS01., timeFrame - At Month 20 (Booster)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00866619",
    "endpoint": "measure - Percentage of Subjects With Prevalent Parasitemia and Prevalent Severe and Moderate Anemia, description - Prevalent parasitemia (PP) was defined as a documented P. falciparum asexual parasite density &gt; 0 identified at timing of assessment.\nPrevalent severe anemia (PSA) was defined as a documented hemoglobin &lt; 5.0 g&#x2F;dL identified at timing of assessment.\nPrevalent moderate anemia (PMA) was defined as a documented hemoglobin &lt; 8.0 g&#x2F;dL identified at timing of assessment.\nAnalysis was performed on subjects aged 5-17 months at enrollment.\nStudy End (Early) corresponds to children whose Month 32 visit took place after 30 June 2012 and who had one cross-sectional visit at study end.\nThese children&#x27;s last study visit was relatively earlier, with a median follow-up time of 14 months post Month 32.\nStudy End (Late) corresponds to children whose Month 32 visit took place before (and including) 30 June 2012, and who had 2 cross-sectional visits after Month 32.\nThese children&#x27;s last study visit was relatively later, with a median follow-up time of 17 months post Month 32)., timeFrame - At Months 32, 44, at study end (median follow-up time of 48 months post-Dose 1 for 5-17 months age category and of 38 months post-Dose 1 for 6-12 weeks age category) (early and late)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00866619",
    "endpoint": "measure - Percentage of Subjects With Pneumonia, All-cause Hospitalization and Sepsis, as Per Case Definitions Assessed, description - Pneumonia case definitions assessed are PCD and SCD 1, 2 and 3. Pneumonia of PCD was defined as cough or difficulty breathing AND tachypnea (≥ 50 breaths per minute &lt; 1 year, ≥ 40 breaths per minute ≥ 1year) AND lower chest wall indrawing.\nPneumonia of SCD1 was defined as pneumonia of PCD accompanied by chest X-ray (CXR) consolidation or pleural effusion on x-ray taken within 72 h of admission.\nPneumonia of SCD2 was defined as pneumonia of PCD accompanied by consolidation or pleural effusion or other infiltrates on a chest x-ray taken within 72 h of admission.\nPneumonia of SCD3 was defined as pneumonia of PCD accompanied by an oxygen saturation &lt; 90%.\nAll-cause hospitalization of PCD was defined as a medical hospitalization of any cause (excludes planned admissions for medical investigation&#x2F;care or elective surgery and trauma).\nSepsis cases were defined as a child with positive blood culture (CD1) or salmonella blood culture (CD2)., timeFrame - From Month 2.5 to Month 20",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00866619",
    "endpoint": "measure - Percentage of Subjects With Fatal Malaria (FM) and All-cause Mortality (ACM) as Per Case Definitions Assessed, description - Fatal malaria case definitions assessed were PCD and SCD1.\nFatal malaria of PCD was defined as a case of severe malaria meeting the primary case definition of severe malaria disease (defined in a previous outcome measure) with a fatal outcome.\nFatal malaria of SCD1 was defined as a case of severe malaria meeting the secondary case definition 1 severe malaria disease (defined previously) with a fatal outcome.\nAll-cause mortality case definitions assessed were the case definitions (CD) 1 and 2. All-cause mortality of CD1 was defined as a fatality (of any cause) (including mortality in the community and in hospital).\nAll-cause mortality of CD2 was defined as a fatality (medical cause) (including mortality in the community and in hospital), at the exclusion of trauma which may be diagnosed by verbal autopsy.\nResults presented are uncorrected for double enrollment of one subject in 5-17 months age category receiving GSK257049 vaccine., timeFrame - From Month 2.5 to Month 20",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00866619",
    "endpoint": "measure - Percentage of Subjects With Pneumonia, All-cause Hospitalization&#x2F;Mortality and Sepsis, as Per Case Definitions Assessed, description - Pneumonia of PCD was defined as cough or difficulty breathing (on history) AND tachypnea (&gt;= 50 breaths per minute &lt; 1 year, &gt;= 40 breaths per minute &gt;= 1year) AND lower chest wall indrawing,SCD1 was defined as pneumonia of PCD accompanied by chest X-ray (CXR) consolidation or pleural effusion on x-ray taken within 72 h of admission,SCD2 was defined as pneumonia of PCD accompanied by consolidation or pleural effusion or other infiltrates on a chest x-ray taken within 72 h of admission,SCD3 was defined as pneumonia of PCD accompanied by an oxygen saturation less than 90%.All-cause hospitalization of PCD was defined as a medical hospitalization of any cause (excluding planned admissions for medical investigation&#x2F;care or elective surgery and trauma).All-cause mortality of CD1 was defined as a fatality (of any cause),of CD2 defined as a fatality (medical cause).Sepsis of CD1 was defined as a child with positive blood culture;CD2 defined as a child with positive salmonella blood culture., timeFrame - From Month 2.5 up to study end (with a median follow-up time post-Dose 1 of 48 months for 5-17M groups and 38 months for 6-12W groups)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00866619",
    "endpoint": "measure - Percentage of Subjects With Blood Transfusion, as Per Case Definition Assessed, description - Blood transfusion case definition assessed was the case definition 1 (CD1).\nBlood transfusion of CD1 was defined as a child with inpatient admission with documented blood transfusion., timeFrame - From Month 2.5 up to study end (median follow-up time of 48 months post-Dose 1 for 5-17 months age category and of 38 months post-Dose 1 for 6-12 weeks age category)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00866619",
    "endpoint": "measure - Rate of All Episodes of Clinical P. Falciparum Malaria Infection (CPFMI) of Primary Case Definition (PCD), by Gender and Overall, description - CPFMI of PCD = episode of malaria for which PFAP &gt; 5000 parasites&#x2F;µL accompanied by the presence of fever (axillary temperature ≥ 37.5°C at time of presentation) AND occurring in a child unwell brought for treatment to a healthcare facility OR a case of malaria meeting the PCD of severe malaria disease.\nTime to all episodes of CPFMI is expressed as a rate of all CPFMI (RaCPFMI), that is, person-year rate in each group (n&#x2F;T).\nAnalysis was performed on subjects aged 5-17 months and 6-12 weeks at enrollment.\nResults were presented by gender and overall., timeFrame - From Month 2.5 to Month 32",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00866619",
    "endpoint": "measure - Height, Weight and Mid Upper Arm Circumference for Age Z-score (HAZ, WAZ and MUACZ), description - Anthropometry consisted of length&#x2F;height for age z-score [HAZ] (children &lt; 2 years length measure and children ≥ 2 years standing height measure), weight for age z-score [WAZ] and mid-upper arm circumference for age z-score [MUACZ] measurements, where a HAZ &lt; -1,5 z-score, indicates growth deficit, while a HAZ between -1,0 and ± 1,0 z-score, indicates normal height.\nA WAZ ≤ -3 z-score indicates a very low weight for age, a WAZ &gt; -3 and ≤ -2 z-score indicates a low weight for age, a WAZ &gt; - 2 z-score indicates normal weight.\nA MUACZ &lt; -2 z-score indicates children that are wasted, a MUACZ &lt; - 3 z-score indicates severely wasted children., timeFrame - At Month 20 (Booster)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00866619",
    "endpoint": "measure - Height, Weight and Mid Upper Arm Circumference for Age Z-score (HAZ, WAZ and MUACZ), description - Anthropometry consisted of length&#x2F;height for age z-score [HAZ] (children &lt; 2 years length measure and children ≥ 2 years standing height measure), weight for age z-score [WAZ] and mid-upper arm circumference for age z-score [MUACZ] measurements, where a HAZ &lt; -1,5 z-score, indicates growth deficit, while a HAZ between -1,0 and ± 1,0 z-score, indicates normal height.\nA WAZ ≤ -3 z-score indicates a very low weight for age, a WAZ &gt; -3 and ≤ -2 z-score indicates a low weight for age, a WAZ &gt; - 2 z-score indicates normal weight.\nA MUACZ &lt; -2 z-score indicates children that are wasted, a MUACZ &lt; - 3 z-score indicates severely wasted children.\nNote: The early study end refers to children whose last visit in the primary study phase (Month 32) was after 30 June 2012 and who by protocol had one cross-sectional study end and to late study end refers to children whose last visit in the primary study phase (Month 32) was after 30 June 2012 and who by protocol had one cross-sectional study end., timeFrame - At Months 32, 44, at study end (early and late) (median follow-up time of 48 months post-Dose 1 for 5-17 months age category and of 38 months post-Dose 1 for 6-12 weeks age category)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00866619",
    "endpoint": "measure - Antibody Concentrations Against Plasmodium Falciparum Circumsporozoite (Anti-CS), description - Anti-CS antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and presented as geometric mean concentrations (GMCs), expressed in ELISA units per milliliter (EL.U&#x2F;mL).\nThe seropositivity cut-off for the endpoint was a GMC value ≥ 0.5 EL.U&#x2F;mL.\nResults were assessed for the first 200 subjects enrolled in each study center., timeFrame - At Day 0 and at Month 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00866619",
    "endpoint": "measure - Antibody Concentrations Against P. Falciparum Circumsporozoite (Anti-CS), description - Anti-CS antibody concentrations were determined by ELISA and presented as geometric mean concentrations (GMCs), expressed in EL.U&#x2F;mL.\nThe seropositivity cut-off for the endpoint was a GMC value ≥ 0.5 EL.U&#x2F;mL.\nResults were assessed for the first 200 HIV-infected subjects enrolled in each study center.\nHIV infection was confirmed if present at screening or identified by morbidity surveillance, not infection confirmed by antibody testing after 18 months of age or by PCR, by the time of the analysis of results up to the Month 14 time point for the respective 5-17 months and 6-12 weeks age categories., timeFrame - At Day 0 and at Month 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00866619",
    "endpoint": "measure - Antibody Concentrations Against P. Falciparum Circumsporozoite (Anti-CS), description - Anti-CS antibody concentrations were determined by ELISA and presented as geometric mean concentrations (GMCs), expressed in EL.U&#x2F;mL.\nThe seropositivity cut-off for the endpoint was a GMC value ≥ 0.5 EL.U&#x2F;mL., timeFrame - At Months 20, 21 and 32",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00866619",
    "endpoint": "measure - Antibody Concentrations Against P. Falciparum Circumsporozoite (Anti-CS), description - Anti-CS antibody concentrations were determined by ELISA and presented as geometric mean concentrations (GMCs), expressed in EL.U&#x2F;mL.\nThe seropositivity cut-off for the endpoint was a GMC value ≥ 0.5 EL.U&#x2F;mL.\nResults for this endpoint were assessed for Agogo, Lilongwe and Siaya sites., timeFrame - At Month 44 and at study end (median follow-up time of 48 months post-Dose 1 for 5-17 months age category and of 38 months post-Dose 1 for 6-12 weeks age category)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00866619",
    "endpoint": "measure - Antibody Concentrations Against P. Falciparum Circumsporozoite (Anti-CS), by Tertile, description - Anti-CS antibody concentrations were determined by ELISA and presented as geometric mean concentrations (GMCs), expressed in EL.U&#x2F;mL.\nThe seropositivity cut-off for the endpoint was a GMC value ≥ 0.5 EL.U&#x2F;mL.\nResults were presented by tertiles of anti-CS responses in the first 200 participants per site, based on subjects assessed for vaccine efficacy results., timeFrame - At Month 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00866619",
    "endpoint": "measure - Rate of All Episodes of Clinical P. Falciparum Malaria Infection (CPFMI) of Primary Case Definition (PCD), by Tertile, description - CPFMI of PCD = episode of malaria for which PFAP &gt; 5000 parasites&#x2F;µL accompanied by presence of fever (axillary temperature ≥ 37.5°C at time of presentation) AND occurring in a child unwell brought for treatment to a healthcare facility OR a case of malaria meeting the PCD of severe malaria disease.\nTime to all episodes of CPFMI is expressed as a rate of all CPFMI (RaCPFMI), that is, person-year rate in each group (n&#x2F;T).\nRaCPFMI was calculated by tertile of anti-CS response post primary vaccination pooled across sites, on subjects in GSK257049-Menjugate Groups (5-17M; 6-12W) and Comparator Groups (5-17M; 6-12W), taking into account the first 200 participants per site., timeFrame - From Month 2.5 to Month 32",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00866619",
    "endpoint": "measure - Antibody Concentrations Against P. Falciparum Circumsporozoite (Anti-CS), by Tertile, description - Anti-CS antibody concentrations were determined by ELISA and presented as geometric mean concentrations (GMCs), expressed in EL.U&#x2F;mL.\nThe seropositivity cut-off for the endpoint was a GMC value ≥ 0.5 EL.U&#x2F;mL.\nResults were presented by tertiles of anti-CS responses in the first 200 participants per site, based on subjects assessed for vaccine efficacy results., timeFrame - At Month 21",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00866619",
    "endpoint": "measure - Rate of All Episodes of Clinical P. Falciparum Malaria Infection (CPFMI) of Primary Case Definition (PCD), by Tertile, description - CPFMI of PCD = episode of malaria for which PFAP &gt; 5000 parasites&#x2F;µL accompanied by presence of fever (axillary temperature ≥ 37.5°C at time of presentation) AND occurring in a child unwell brought for treatment to a healthcare facility OR a case of malaria meeting the PCD of severe malaria disease.\nTime to all episodes of CPFMI is expressed as a rate of all CPFMI (RaCPFMI), that is, person-year rate in each group (n&#x2F;T).\nRaCPFMI was calculated by tertile of anti-CS response post booster vaccination pooled across sites, on subjects in R3R (5-17M; 6-12W) (or R3R below) and C3C (5-17M; 6-12W) (or C3C below) groups taking into account the first 200 participants per site., timeFrame - From Booster at Month 20 to Month 32",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00866619",
    "endpoint": "measure - Antibody Concentrations Against Hepatitis B Surface Antigen (Anti-HBs), description - Antibody concentrations assessed by ELISA, were presented as geometric mean concentrations (GMCs), and expressed in milli-international units per milliliter (mIU&#x2F;mL).\nThe seropositivity and seroprotection cut-offs were ≥ 10 and 100 mIU&#x2F;mL, respectively.\nResults were assessed for the first 200 subjects in each center., timeFrame - At Day 0 and at Month 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00866619",
    "endpoint": "measure - Antibody Concentrations Against Hepatitis B Surface Antigen, description - Antibody concentrations as assessed by ELISA, were presented as geometric mean concentrations (GMCs), and expressed in mIU&#x2F;mL.\nThe seropositivity and seroprotection cut-offs were ≥ 10 and 100 mIU&#x2F;mL, respectively.\nResults were assessed for the first 200 HIV-infected subjects enrolled in each study center.\nHIV infection was confirmed if present at screening or identified by morbidity surveillance, not infection confirmed by antibody testing after 18 months of age or by PCR, by the time of the analysis of results up to the Month 14 time point for the respective 5-17 months and 6-12 weeks age categories., timeFrame - At Day 0 and at Month 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00866619",
    "endpoint": "measure - Antibody Concentrations Against Hepatitis B Surface Antigen (Anti-HBs), description - Antibody concentrations as assessed by ELISA, were presented as geometric mean concentrations (GMCs), and expressed in mIU&#x2F;mL.\nThe seropositivity and seroprotection cut-offs were ≥ 6.2 and 100 mIU&#x2F;mL, respectively.\nResults were assessed for the first 200 subjects in each center., timeFrame - At Months 20 and 21",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00866619",
    "endpoint": "measure - Antibody Titers Against Poliomyelitis (Anti-polio) Type 1, 2 and 3, description - Anti-Polio 1, 2 and 3 antibody titers were presented as geometric mean titers (GMTs).\nThe seroprotection cut-off for the assay was an antibody titer ≥ 1:8., timeFrame - At Day 0 and at Month 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00866619",
    "endpoint": "measure - Number of Subjects With Any and Grade 3 Solicited Local Symptoms, description - Assessed solicited local symptoms included pain, redness and swelling.\nAny = the incidence of a particular symptom, regardless of intensity grade.\nGrade 3 pain = cried when limb was moved, spontaneously painful.\nGrade 3 redness&#x2F;swelling = redness&#x2F;swelling spreading beyond 20 millimeters (mm) of injection site., timeFrame - During the 7-day (Days 0-6) post-primary vaccination period following each dose and across doses",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00866619",
    "endpoint": "measure - Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms, description - Assessed solicited general symptoms were drowsiness, irritability, loss of appetite, fever [defined as axillary temperature equal to or above (≥) 37.5 degrees Celsius (°C)].\nAny = occurrence of the symptom regardless of intensity grade or relationship to vaccination.\nGrade 3 symptom = symptom that prevented normal activity.\nGrade 3 fever = fever &gt; 39.0 °C.\nRelated = symptom assessed by the investigator as related to the vaccination., timeFrame - During the 7-day (Days 0-6) post-primary vaccination period following each dose and across doses",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00866619",
    "endpoint": "measure - Number of Subjects With Any and Grade 3 Solicited Local Symptoms, description - Assessed solicited local symptoms included pain, redness and swelling.\nAny = the incidence of a particular symptom, regardless of intensity grade.\nGrade 3 pain = cried when limb was moved, spontaneously painful.\nGrade 3 redness&#x2F;swelling = redness&#x2F;swelling spreading beyond 20 millimeters (mm) of injection site., timeFrame - During the 7-day (Days 0-6) post-booster vaccination period",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00866619",
    "endpoint": "measure - Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms, description - Assessed solicited general symptoms were drowsiness, irritability, loss of appetite, fever [defined as axillary temperature equal to or above (≥) 37.5 degrees Celsius (°C)].\nAny = occurrence of the symptom regardless of intensity grade or relationship to vaccination.\nGrade 3 symptom = symptom that prevented normal activity.\nGrade 3 fever = fever &gt; 39.0 °C.\nRelated = symptom assessed by the investigator as related to the vaccination., timeFrame - During the 7-day (Days 0-6) post-booster vaccination period",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00866619",
    "endpoint": "measure - Number of Doses With Seizures by Diagnostic Certainty Level, description - Diagnostic certainty levels included: Level 1- Witnessed sudden loss of consciousness and generalized, tonic, clonic, tonic-clonic, or atonic motor manifestations; Level 2- History of unconsciousness and generalized, tonic, clonic, tonic-clonic, or atonic motor manifestations; Level 3- History of unconsciousness and other generalized motor manifestations; Level 4- Reported generalized convulsive seizure with insufficient evidence to meet the case definition; Level 5- Not a case of generalized convulsive seizure., timeFrame - During the 7-day (Days 0-6) post-booster vaccination period, at Month 20 + 7 Day (Days 0-6)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00866619",
    "endpoint": "measure - Number of Subjects Reporting Mucocutaneous Changes (All Levels), description - Levels of mucocutaneous changes reported were: cutaneous and mucosal change; cutaneous only change; mucosal only change; cutaneous change focused on the nappy&#x2F;diaper area.\nMucocutaneous changes results calculated based on the first 200 subjects in the 6-12 weeks age category in each study center were enrolled, and with available data (i.e. who received a booster dose)., timeFrame - During the 30-day (Days 0-29) post-booster vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00866619",
    "endpoint": "measure - Number of Subjects Reporting Any Meningitis and Encephalitis Serious Adverse Events (SAEs), description - Meningitis and encephalitis SAEs included: meningitis&#x2F;encephalitis; meningitis&#x2F;encephalitis viral; meningism; meningitis haemophilus; meningitis meningococcal; meningitis pneumococcal; meningitis tuberculous; encephalomyelitis., timeFrame - At Month 0 until study end (median follow-up time of 48 months post-Dose 1 for 5-17 months age category and of 38 months post-Dose 1 for 6-12 weeks age category)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00866619",
    "endpoint": "measure - Number of Subjects Reporting Any Meningitis and Encephalitis SAEs, description - Meningitis and encephalitis SAEs included: meningitis&#x2F;encephalitis; meningitis haemophilus; meningitis meningococcal; meningitis tuberculous; encephalomyelitis., timeFrame - From Booster up to study end (median follow-up time of 48 months post-Dose 1 for 5-17 months age category and of 38 months post-Dose 1 for 6-12 weeks age category)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00866619",
    "endpoint": "measure - Number of Subjects Reporting Any Potential Immune-mediated Disorders (pIMDs), description - Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and&#x2F;or neurologic disorders of interest which may or may not have an autoimmune aetiology., timeFrame - From Month 0 up to study end (median follow-up time of 48 months post-Dose 1 for 5-17 months age category and of 38 months post-Dose 1 for 6-12 weeks age category)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00866619",
    "endpoint": "measure - Number of Subjects With Any Unsolicited Adverse Events (AEs), description - An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.\nAny was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.\nUnsolicited AEs were calculated based on the first 200 subjects enrolled in each study center., timeFrame - Within the 30-day (Days 0-29) post-primary vaccination period",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00866619",
    "endpoint": "measure - Number of Subjects With Unsolicited AEs Related to or Leading to Vaccination Withdrawal, description - An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.\nRelated = AE assessed by the investigator as related to the vaccination.\nUnsolicited AEs were calculated based on the first 200 subjects enrolled in each study center., timeFrame - Within the 30-day (Days 0-29) post-primary vaccination period",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00866619",
    "endpoint": "measure - Number of Subjects With Any Unsolicited AEs, description - An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.\nAny was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.\nUnsolicited AEs were calculated based on the first 200 subjects enrolled in each study center., timeFrame - Within the 30-day (days 0-29) post-booster vaccination period",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00866619",
    "endpoint": "measure - Number of Subjects With Unsolicited AEs Related to or Leading to Vaccination Withdrawal, description - An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.\nRelated = AE assessed by the investigator as related to the vaccination.\nUnsolicited AEs were calculated based on the subgroup of the first 200 subjects enrolled in each study center, who were reported with HIV infected status ((HIV status either as per general medical history taken at screening or as identified by morbidity surveillance)., timeFrame - Within the 30-day (Days 0-29) post-primary and post-booster vaccination period in HIV-infected children",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00866619",
    "endpoint": "measure - Number of Subjects With Unsolicited AEs Related to or Leading to Vaccination Withdrawal in the Low-weight (LW) and Very Low-weight (VLW) Category, description - An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.\nRelated = AE assessed by the investigator as related to the vaccination.\nUnsolicited AEs were calculated based on the subgroup of the first 200 subjects enrolled in each study center, who were reported with HIV infected status ((HIV status either as per general medical history taken at screening or as identified by morbidity surveillance).\nLow-weight subjects were defined as subjects whose weight for age z-score (WAZ) was &gt; -3 and ≤ -2.\nVery low-weight subjects were defined as subjects whose weight for age z-score (WAZ) was ≤ -3., timeFrame - Within the 30-day (Days 0-29) post-primary vaccination period in HIV-infected children",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00866619",
    "endpoint": "measure - Number of Subjects With Unsolicited AEs Related to Vaccination in the Low-weight (LW) and Very Low-weight (VLW) Category, description - An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.\nRelated = AE assessed by the investigator as related to the vaccination.\nUnsolicited AEs were calculated based on the subgroup of the first 200 subjects enrolled in each study center.\nLow-weight subjects were defined as subjects whose weight for age z-score (WAZ) was &gt; -3 and ≤ -2.\nVery low-weight subjects were defined as subjects whose weight for age z-score (WAZ) was ≤ -3., timeFrame - Within the 30-day (Days 0-29) post-booster vaccination period",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00866619",
    "endpoint": "measure - Number of Subjects With Serious Adverse Events (SAEs), description - Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability&#x2F;incapacity., timeFrame - From Month 0 up to Month 14",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00866619",
    "endpoint": "measure - Number of Subjects With Serious Adverse Events (SAEs), description - Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability&#x2F;incapacity., timeFrame - During the 30-day (Days 0-29) post-primary vaccination period",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00866619",
    "endpoint": "measure - Number of Subjects With Serious Adversee Events (SAEs), description - Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability&#x2F;incapacity., timeFrame - From Month 0 up to Month 20",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00866619",
    "endpoint": "measure - Number of Subjects With Serious Adverse Events (SAEs), description - Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability&#x2F;incapacity., timeFrame - From Booster (at Month 20) up to study end (median follow-up time of 48 months post-Dose 1 for 5-17 months age category and of 38 months post-Dose 1 for 6-12 weeks age category)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00866619",
    "endpoint": "measure - Number of Subjects With Serious Adverse Events (SAEs), description - Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability&#x2F;incapacity., timeFrame - From Month 0 up to study end (median follow-up time of 48 months post-Dose 1 for 5-17 months age category and of 38 months post-Dose 1 for 6-12 weeks age category)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00866619",
    "endpoint": "measure - Number of Subjects With Serious Adverse Events (SAEs), description - Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability&#x2F;incapacity., timeFrame - Within the 30-day (Days 0-29) post-booster vaccination period",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00866619",
    "endpoint": "measure - Number of Subjects With Serious Adverse Events (SAEs), description - Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability&#x2F;incapacity., timeFrame - From Month 0 up to Booster (Month 20), from Month 0 up to study end and from Month 20 up to study end",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00866619",
    "endpoint": "measure - Number of Low-weight (LW) Subjects With Serious Adverse Events (SAEs), description - Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability&#x2F;incapacity.\nLow-weight subjects were defined as subjects whose weight for age z-score (WAZ) was &gt; -3 and ≤ -2., timeFrame - From Month 0 up to Month 20",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00866619",
    "endpoint": "measure - Number of Low-weight (LW) Subjects With Serious Adverse Events (SAEs), description - Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability&#x2F;incapacity.\nLow-weight subjects were defined as subjects whose weight for age z-score (WAZ) was &gt; -3 and ≤ -2., timeFrame - From Booster (Month 20) up to study end (median follow-up time of 48 months post-Dose 1 for 5-17 months age category and of 38 months post-Dose 1 for 6-12 weeks age category)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00866619",
    "endpoint": "measure - Number of Very Low-weight (VLW) Subjects With Serious Adverse Events (SAEs), description - Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability&#x2F;incapacity.\nVery low-weight subjects were defined as subjects whose weight for age z-score (WAZ) was ≤ -3., timeFrame - From Month 0 up to Month 20",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00866619",
    "endpoint": "measure - Number of Very Low-weight Subjects With Serious Adverse Events (SAEs), description - Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability&#x2F;incapacity.\nVery low-weight subjects were defined as subjects whose weight for age z-score (WAZ) was ≤ -3., timeFrame - From Booster (Month 20) up to study end (median follow-up time of 48 months post-Dose 1 for 5-17 months age category and of 38 months post-Dose 1 for 6-12 weeks age category)]",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00866619",
    "endpoint": "measure - Number of Subjects With Fatal Outcomes, by Gender, description - Mortality was presented as overall mortality (up to Month 20 and up to study end), mortality due to severe malaria as per secondary case definition(SCD), cerebral malaria as per secondary case definition (SCD), meningitis, fatal all-cause traumas and fatal malaria.\nSCD= Plasmodium falciparum malaria &gt; 5000 parasites&#x2F;mcL and 1 or more markers of severe malaria (prostration, respiratory distress, Blantyre score ≤ 2, seizures 2 or more, hypoglycemia &lt; 2.2 mmol&#x2F;L, acidosis BE ≤ -10.0 mmol&#x2F;L,lactate ≥ 5.0 mmol&#x2F;L, anemia &lt; 5.0 g&#x2F;dL., timeFrame - From Month 0 up to study end (SE - median follow-up time of 48 months post-Dose 1 for 5-17 months age category and of 38 months post-Dose 1 for 6-12 weeks age category)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03352843",
    "endpoint": "measure - Sterilization of gametocytes, description - Proportion of participants with infected mosquitoes following membrane feeding experiment on day 7., timeFrame - 6 months after the start of recruitment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03352843",
    "endpoint": "measure - Gametocytes carriage on day 7, description - Proportion of participants with gametocytes carriage measured by QT-NASBA on day 7, timeFrame - 12 months after the start of recruitment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01023399",
    "endpoint": "measure - Number of patients without fever, description - , timeFrame - Day 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01023399",
    "endpoint": "measure - Number of patients without parasite, description - , timeFrame - Day 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01023399",
    "endpoint": "measure - Number of gametocytes, description - , timeFrame - Day 3, Day 7, Day 14, Day 21 and Day 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01023399",
    "endpoint": "measure - Evolution of in vitro resistance rate, description - , timeFrame - Day 3, Day 7, Day 14, Day 21 and Day 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01024686",
    "endpoint": "measure - Development of Parasitemia and Time to Parasitemia After Primary Malaria Challenge Following Administration of GAP, description - , timeFrame - From administration of study vaccine through the duration of the trial",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01024686",
    "endpoint": "measure - Development of Parasitemia and Time to Parasitemia After Re-challenge Following Administration of GAP, description - , timeFrame - From administration of study vaccine through the duration of the trial",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01024686",
    "endpoint": "measure - P. Falciparum Specific Cell-mediated Immune Responses, description - , timeFrame - From administration of study vaccine through the duration of the trial",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01374581",
    "endpoint": "measure - PCR unadjusted efficacy, description - Proportion of children without (PCR not adjusted) treatment failure (TF28U): all treatment failures detected during the active follow up, regardless of genotyping., timeFrame - Day 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01374581",
    "endpoint": "measure - Day 42 clinical efficacy, description - All clinical treatment failures detected during the 42 days follow up for the first line treatment, with and without PCR adjustment.\nAs no active monitoring of parasitaemia after day 3 is planned this includes ETF and LCF following WHO criteria., timeFrame - Day 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01374581",
    "endpoint": "measure - Change in Fever clearance time (FCT), description - The time (in days) from the time of randomization to the first two consecutive measurements on 2 different days of axillary temperature below 37.5°C., timeFrame - Day 0, Day 1, Day 2",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01374581",
    "endpoint": "measure - Change in Asexual parasite clearance time, description - <p>Asexual parasite clearance time is defined as the time (in days) from time of randomization to 2 consecutive negative blood slides (collected at different days).\nThe time to the event will be taken as the time to the first negative slide.</p><p>5. Gametocytaemia (prevalence and density) at day 7, 14, 21 and 28 after treatment.</p>, timeFrame - Day 0, Day 1, Day 2",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01374581",
    "endpoint": "measure - Hb changes, description - Variation in Hb level between two measurements., timeFrame - Day 0, Days 14 and Day 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01374581",
    "endpoint": "measure - Early Treatment Failure, description - Development of danger signs or severe malaria on Day 0, Day 1 Day 2 or Day 3, in the presence of parasitaemia Parasite density on Day 2 &gt; Day 0 count, irrespective of axillary temperature Presence of parasitaemia on Day 3 with fever (axillary temperature ≥ 37.5°C) Parasitaemia on Day 3 ≥ 25 % of count on Day 0., timeFrame - Day0-Day3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01374581",
    "endpoint": "measure - Late Clincial Failure, description - Development of danger signs or severe malaria after Day 3 in the presence of parasitaemia Presence of parasitaemia and fever on any day from Day 4 to Day 28, timeFrame - Day0-Day28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01373879",
    "endpoint": "measure - Immunogenicity of a heterologous prime-boost vaccine strategy with AdCh63 ME-TRAP and MVA ME-TRAP, description - To assess the immunogenicity of a heterologous prime-boost vaccine strategy with AdCh63 ME-TRAP and MVA ME-TRAP in healthy adults and children in The Gambia by assessing induced antibody and T cell response to the vaccine insert., timeFrame - Participants will be followed for the duration of the study, an expected average of 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03590340",
    "endpoint": "measure - Proportion of volunteers who become parasitemic will be recorded, detected by thick blood smear microscopy (TBS) and&#x2F; or quantitative real time polymerase chain reaction (qPCR), description - <ol><li>Development of Pf parasitemia by TBS following CHMI</li><li>Development of Pf parasitemia by qPCR following CHM</li></ol>, timeFrame - Post first immunization uptil 56 days post-CHMI",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03590340",
    "endpoint": "measure - Level of Antibodies against Pf proteins in volunteer sera, description - <ol><li>Antibody titres to pre-erythrocytic stage and erythrocytic stage antigens[PfCSP, PfLSA-1, PfEBA-175 , PfMSP-1, PfMSP-5, EXP-1] by ELISA</li><li>Antibody titres to Pf sporozoites, asexual and sexual erythrocytic stage parasites by IFA.</li><li>Analysis of antibodies to proteins in the Pf proteome array chip.</li></ol>, timeFrame - Post first immunization uptil 56 days post-CHMI",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03590340",
    "endpoint": "measure - Inhibitory Capacity of Volunteer Sera against in vitro Sporozoite Invasion of Hepatocytes, description - Capacity of sera from immunized volunteers to inhibit sporozoite invasion (ISI) of hepatocytes in vitro by ISI assay, timeFrame - Post first immunization uptil 56 days post-CHMI",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01054248",
    "endpoint": "measure - Number of adverse events, description - , timeFrame - Day 63",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01054248",
    "endpoint": "measure - Biochemical and haematological changes, description - , timeFrame - Day 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01054248",
    "endpoint": "measure - Kinetic parameters of artesunate, mefloquine, piperaquine and lumefantrine, description - , timeFrame - Day 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01054248",
    "endpoint": "measure - Anaemia, description - , timeFrame - Day 63",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01054248",
    "endpoint": "measure - Gametocyte carriage, description - , timeFrame - Day 63",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01054248",
    "endpoint": "measure - Changes in the Reticulocyte counts, description - , timeFrame - Day 63",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01054248",
    "endpoint": "measure - Malaria infection rate at delivery and placental parasitaemia, description - , timeFrame - Delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01054248",
    "endpoint": "measure - Pregnancy outcomes (abortions, low birth weight, premature birth, congenital abnormality, stillbirths, neonatal and infant mortality), description - , timeFrame - Delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01054248",
    "endpoint": "measure - Infant growth and development at 1 year of life, description - , timeFrame - 1 year after delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02015091",
    "endpoint": "measure - To determine if there is durability of PfSPZ Vaccine-mediatedprotection against infectious P. falciparum CHMI when the vaccine isadministered at 2.7 x 105 PfSPZ per injection by the IV route using amulti-dose schedule and the CHMI is ad..., description - , timeFrame - At 4 weeks after CHMI.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02015091",
    "endpoint": "measure - To determine if there is PfSPZ Vaccine-mediated protection againstinfectious P. falciparum CHMI when the vaccine is administered at 2.2x 106 PfSPZ per injection by the IM route using a multi-dose schedule and the CHMI is administered at 2-..., description - , timeFrame - At 4 weeks after CHMI.CHMI.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02015091",
    "endpoint": "measure - To determine if there is durability of PfSPZ Vaccine-mediatedprotection against infectious P. falciparum CHMI when the vaccine isadministered at 2.2 x 106 PfSPZ per injection by the IM route using a multi-dose schedule and the CHMI is admi..., description - , timeFrame - At 4 weeks after CHMI.CHMI.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01018459",
    "endpoint": "measure - Neutralizing antibody titers against Adenovirus type 35 by Adenovirus Neutralization Assay., description - , timeFrame - At days 0, 28, 56, 84, 112 and 140.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01018459",
    "endpoint": "measure - Antibody titers against the malaria circumsporozoite antigen [Geometric Mean Titer and individual log enzyme-linked immunosorbent assay (ELISA) units]., description - , timeFrame - At days 0, 28, 56, 84, 112 and 140.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00495508",
    "endpoint": "measure - Pharmacokinetic parameters, description - , timeFrame - 3.5 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00495508",
    "endpoint": "measure - Incidence of adverse events, description - , timeFrame - 3 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00495508",
    "endpoint": "measure - Pregnancy outcome, description - , timeFrame - 3.5 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00495508",
    "endpoint": "measure - Infant development during the first year of life, description - , timeFrame - 3 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00495508",
    "endpoint": "measure - Histopathological findings in the placenta, description - , timeFrame - 4 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03217851",
    "endpoint": "measure - Visualization and dissemination of molecular marker prevalence data to inform public health officials, researchers, policymakers and key stakeholders, description - , timeFrame - 3 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00298610",
    "endpoint": "measure - Percentage of Parasite Clearance, description - The target variable is detection (percentage) of asexual stage parasites of Plasmodium falciparum malaria in bloodstream by Giemsa - stained microscopy of thick and thin blood smears, timeFrame - 24 and 48 hours post dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00298610",
    "endpoint": "measure - Number of Subjects With Fever Clearance, description - Temperature is measured by oral digital thermometers, and fever clearance time is defined as the first time with resolution of fever (&lt;37.5C)\nsustained for 24 hours, timeFrame - Within 48 hours post dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00298610",
    "endpoint": "measure - Safety - Severity of Adverse Events, description - Determine the safety (defined as severity of AE&#x27;s using the Common Toxicity Criteria), timeFrame - up to 14 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00298610",
    "endpoint": "measure - Safety - Adverse Events Relationship to Study Drug, description - Determine the safety (defined as relationship to study drug of AE&#x27;s and SAE&#x27;s), timeFrame - up to 14 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00298610",
    "endpoint": "measure - Safety - Severity of Serious Adverse Events (SAE&#x27;s), description - Determine the safety (defined as severity of SAE&#x27;s using the Common Toxicity Criteria), timeFrame - up to 14 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00298610",
    "endpoint": "measure - Safety - Serious Adverse Event (SAE) Relationship to Study Drug, description - Determine the safety (defined as relationship to study drug of SAE&#x27;s), timeFrame - Up to 14 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00944840",
    "endpoint": "measure - prevalence of parasitaemia at the end of malaria transmission season in December 2008, description - , timeFrame - December 2008",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02592408",
    "endpoint": "measure - The proportion of patients with any parasitemia on day 1, 2 and 3 after treatment, description - Outcome measure is stratified for P. falciparum and P. vivax infections, timeFrame - on days 1,2,3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02592408",
    "endpoint": "measure - The proportion of patients with fever on day 1, 2 and 3 after treatment, description - Outcome measure is stratified for P. falciparum and P. vivax infections, timeFrame - on days 1, 2, 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02592408",
    "endpoint": "measure - The proportion of patients with gametocytemia on any of the follow up dates, description - Outcome measure is stratified for P. falciparum and P. vivax infections, timeFrame - In the first 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02592408",
    "endpoint": "measure - The proportion of patients with severe anaemia (Hb&lt;7g&#x2F;dl) or requiring blood transfusion within 42 days of enrolment, description - Outcome measure is stratified for P. falciparum and P. vivax infections, timeFrame - In the first 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02592408",
    "endpoint": "measure - The fractional change in Hb between baseline and day 7,14 and 16 (incl. proportion of patients with &gt;25% drop in Hb between the time points) in vivax &#x2F; mixed infection patients receiving PQ, description - Outcome measure is stratified for P. falciparum and P. vivax infections, timeFrame - on days 0, 7, 14 and 16",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02592408",
    "endpoint": "measure - The proportion of patients with adverse and serious adverse events, description - Outcome measure is stratified for P. falciparum and P. vivax infections, timeFrame - In the first 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02592408",
    "endpoint": "measure - The proportion of vivax patients adhering to 14 days of primaquine treatment in the vivax cohort as measured by pill count, description - , timeFrame - at the end of 14DPQ treatment (day 16)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02592408",
    "endpoint": "measure - The distribution of G6PD activity among the study population, description - , timeFrame - on day of enrolment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00203801",
    "endpoint": "measure - Association between study treatment and gametocyte carriage, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00203801",
    "endpoint": "measure - Pharmacokinetics by measurement of whole blood levels of Sulfadoxine and Pyrimethamine, and lumefantrine should a reliable assay become available, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00203801",
    "endpoint": "measure - Correlation of frequency of dihydropteroate synthase (DHFR) and dihydrofolate reductase (DHPS) mutations with parasitological outcome, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00203801",
    "endpoint": "measure - Tolerability by describing adverse events and changes in haematological parameters, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00203801",
    "endpoint": "measure - Capacity by describing the training and development of study teams and their subsequent skills attained, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02488902",
    "endpoint": "measure - Time to confirmation of parasitaemia, description - Time to confirmation of parasitaemia as documented by two consecutive positive smears and the incidence density of parasitaemia., timeFrame - 16 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00118807",
    "endpoint": "measure - Compliance with treatment regimen, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00118807",
    "endpoint": "measure - Parasitological failure by day 28, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00118807",
    "endpoint": "measure - Clinical failure by day 14, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00118807",
    "endpoint": "measure - Parasitological failure rate by day 14, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00118807",
    "endpoint": "measure - Mean PCV on day 28, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00118807",
    "endpoint": "measure - Gametocyte carriage rates, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00118807",
    "endpoint": "measure - Transmissibility after treatment, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01585077",
    "endpoint": "measure - Immune response, description - <p>Malaria signs and symptoms will be assessed to stablish severity and frequency of appearence in both groups: Pre-immune and naive.</p><p>Blood sample will be taken at the end of the study to determine the differences in celular and humoral immune responses in both study groups.</p>, timeFrame - Two months after the malaria challenge",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03511443",
    "endpoint": "measure - Diagnostic performance characteristics of hsRDT versus cRDT using PCR as gold standard, in the detection of P.falciparum infections, description - Outcomes measured between hsRDT and cRDT, timeFrame - Outcomes will be analyzed after 10 months of data collection",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03511443",
    "endpoint": "measure - Correlation of detection capability between cRDT and hsRDT, description - Outcomes measured by correlation of test positivity rates, timeFrame - PCR results will be analyzed during month 10",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03511443",
    "endpoint": "measure - Risk factors associated with malaria infection cases, description - Outcomes will be measured by relative risk of malaria in association with different risk factors identified, timeFrame - Outcome will be measured&#x2F;analyzed in month 10, after PCR results are released",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00941785",
    "endpoint": "measure - Pharmacokinetics of piperaquie: the oral clearance (CL&#x2F;F), AUC, steady state volume of distribution(s) (Vss&#x2F;F), inter-compartment clearance(s) (Q&#x2F;F) and absorption rate (ka) will be estimated., description - , timeFrame - during 30 days after start of treatment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05950191",
    "endpoint": "measure - Prevalence of parasitaemia, description - Proportion of blood smears positive for parasites by microscopy in individuals of all ages at the time of cross-sectional surveys, timeFrame - 24-months following LLIN distribution",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05950191",
    "endpoint": "measure - Prevalence of anemia, description - Proportion of children aged 2-4 years with haemoglobin &lt; 11 g&#x2F;dL at the time of cross-sectional surveys, timeFrame - 24-months following LLIN distribution",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05950191",
    "endpoint": "measure - Proportion of households that owned at least one LLIN, description - Proportion of households with at least one LLIN at the time of cross-sectional surveys, timeFrame - 24-months following LLIN distribution",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05950191",
    "endpoint": "measure - Proportion of households that owned at least one LLIN for every two occupants, description - Proportion of households with at least one LLIN per every two occupants at the time of cross-sectional surveys, timeFrame - 24-months following LLIN distribution",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05950191",
    "endpoint": "measure - Proportion of household residents who slept under an LLIN the previous night, description - Proportion of households residents who report sleeping under LLIN the previous night at the time of cross-sectional surveys, timeFrame - 24-months following LLIN distribution",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05950191",
    "endpoint": "measure - Number of female anopheles mosquitoes collected per household at the time of cross-sectional surveys, description - Vector density, timeFrame - 24-months following LLIN distribution",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02859350",
    "endpoint": "measure - Level of Antibodies against Pf proteins in volunteer sera, description - <ol><li>Antibody titres to pre-erythrocytic stage and erythrocytic stage antigens[PfCSP, PfLSA-1, PfEBA-175 , PfMSP-1, PfMSP-5, EXP-1] by ELISA</li><li>Antibody titres to Pf sporozoites, asexual and sexual erythrocytic stage parasites by IFA.</li><li>Analysis of antibodies to proteins in the Pf proteome array chip.</li></ol>, timeFrame - Post first immunization uptil 56 days post-CHMI or 56 days post-3rd immunization",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02859350",
    "endpoint": "measure - Inhibitory Capacity of Volunteer Sera against in vitro Sporozoite Invasion of Hepatocytes, description - Capacity of sera from immunized volunteers to inhibit sporozoite invasion (ISI) of hepatocytes in vitro by ISI assay, timeFrame - Post first immunization uptil 56 days post-CHMI or 56 days post-3rd immunization",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02859350",
    "endpoint": "measure - Quantitation of cellular immune responses against Pf proteins in volunteers, description - <ol><li>Identification of number of vaccine induced PBMCs following Intracellular cytokine staining by flow cytometry after stimulation with PfSPZ or Pf-infected erythrocytes, peptide pools and P. falciparum infected primary human hepatocyte cell lines.</li><li>Identification of numbers of vaccine induced CD4 and CD8 T cells following FluoroSpot assay after stimulation with PfSPZ or Pf-infected erythrocytes.</li></ol>, timeFrame - Post first immunization uptil 56 days post-CHMI or 56 days post-3rd immunization",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02859350",
    "endpoint": "measure - Whole genome expression profiles of volunteer, description - Human gene expression profiling focusing on immune response genes in volunteers, timeFrame - Post first immunization uptil 56 days post-CHMI or 56 days post-3rd immunization",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06652737",
    "endpoint": "measure - To further assess safety following vaccination by measuring incidence of mild to moderate solicited and unsolicited AEs in the 28 days after injection of PfSPZ-LARC2 Vaccine, description - Incidence of mild to moderate (a) solicited adverse events (AEs) in the 28 days after injection of PfSPZ-LARC2 Vaccine; and (b) unsolicited AEs in the 28 days after injection of PfSPZ-LARC2 Vaccine ., timeFrame - First 28 days following immunization with PfSPZ-LARC2 Vaccine",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06652737",
    "endpoint": "measure - To further assess safety following vaccination by measuring incidence of mild to moderate abnormal laboratory values one week after injection of PfSPZ-LARC2 Vaccine, description - Incidence of mild to moderate abnormal laboratory values one week after injection of PfSPZ-LARC2 Vaccine., timeFrame - 7 days after immunization with PfSPZ-LARC2 Vaccine",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06652737",
    "endpoint": "measure - To identify immune responses following vaccination and their association with age and sex by measuring Anti-P. falciparum circumsporozoite protein antibody levels two weeks after PfSPZ-LARC2 Vaccine administration., description - Anti-P.\nfalciparum circum-sporozoite protein antibody levels measured by ELISA two weeks after PfSPZ-LARC2 Vaccine administration., timeFrame - 14 days after immunization with PfSPZ-LARC2 Vaccine",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00144716",
    "endpoint": "measure - Reduction in all-cause fevers, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00243737",
    "endpoint": "measure - Efficacy: day 14v cure rate, parasite and fever clearance time, parasite reduction rate, gametocytemia, in relation to blood concentrations of Dihydroartemisinin and mefloquine, safety, tolerability, acceptability, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00243737",
    "endpoint": "measure - parasite and fever clearance time, parasite reduction rate, gametocytemia, in relation to blood concentrations of Dihydroartemisinin, description - Time to complete clearance of fever and parasitemia Assessment in relation to DHA and mefloquine blood levels, timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00243737",
    "endpoint": "measure - safety, tolerability, acceptability, description - Assessment of adverse events and reporting of tolerability, safety and acceptability, timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02704533",
    "endpoint": "measure - Number of adverse events following immunization (AEFI) for PfSPZ Vaccine, description - Number of adverse events following immunization (AEFI) from time of first administration of PfSPZ Vaccine to first administration of PfSPZ Challenge for CHMI consistent with a causal relationship., timeFrame - About 7 weeks (from day of first vaccination until 3 weeks after last vaccination)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02704533",
    "endpoint": "measure - Proportion of volunteers who become parasitemic will be recorded, detected by thick blood film microscopy or qPCR, description - Thick blood film microscopy and quantitative polymerase chain reaction (qPCR) assays will be performed during CHMI follow-up.\nThe proportion of volunteers who become parasitemic will be recorded, detected by thick blood film microscopy or qPCR, within 28 days following CHMI with 3,200 PfSPZ, given either as a single dose of 3,200 PfSPZ Challenge (NF54) (optimization phase) or as two subsequent injections of 3,200 PfSPZ Challenge (NF54) and PfSPZ Challenge (7G8), respectively in the verification phase., timeFrame - Up to 4 weeks (from day of CHMI until 28 days)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02704533",
    "endpoint": "measure - Proportion of volunteers who do not become parasitemic (protected) against homologous (NF54) and heterologous (7G8) CHMI, respectively., description - This endpoint can only be assessed during the verification phase of the trial., timeFrame - About 28 days (from day of first CHMI till 28 days)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06068530",
    "endpoint": "measure - The incidence of Deaths related to falciparum malaria among study groups, description - The number of Deaths related to falciparum malaria (confirmed by RDT or microscopy) will be recorded for two year following intervention.\nDeath rate among study groups will be compared, timeFrame - Data will be collected for two years following baseline intervention (Month 0 to Month 24)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06068530",
    "endpoint": "measure - The incidence of severe malaria disease among study groups, description - <p>The number of Severe malaria diseases (according to WHO criteria) will be recorded for two years following intervention and the incidences will be compared among study groups.</p><p>Primary case definition of severe malaria:</p><ul><li>Presence of P. falciparum (RDT positive or microscopy positive); AND one of more of the following criteria of disease severity:</li><li>Prostration</li><li>Respiratory distress</li><li>Blantyre coma score ≤ 3</li><li>Seizures: 2 or more</li><li>Hypoglycemia &lt; 2.2 mmol&#x2F;L</li><li>Acidosis BE ≤-8.0 mmol&#x2F;L</li><li>Lactate ≥ 5.0 mmol&#x2F;L</li><li>Anemia &lt; 5.0 g&#x2F;dL</li><li>Acute kidney injury</li><li>Pulmonary oedema</li><li>Significant bleeding</li><li>Shock (systolic BP &lt;70mm Hg); AND Without any of the following criteria of co- morbidity</li><li>Pneumonia (confirmed by X-ray)</li><li>Meningitis (confirmed by CSF examination)</li><li>Sepsis (with Positive blood culture)</li><li>Gastroenteritis with dehydration</li></ul>, timeFrame - Data will be collected for two years following baseline intervention (Month 0 to Month 24)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06068530",
    "endpoint": "measure - The incidence of severe anaemia among study groups, description - <p>The number of severe anemia cases will be recorded for two years following interventions among all participants and the proportions will be compared among study groups Severe anaemia due to severe malaria according to WHO criteria</p><ul><li>Anaemia &lt; 5.0 g&#x2F;dL</li><li>Requires blood transfusion according to National guidelines</li></ul>, timeFrame - Data will be collected for two years following baseline intervention (Month 0 to Month 24)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06068530",
    "endpoint": "measure - Vivax malaria incidence by study groups, description - <p>Vivax malaria incidence will be determined by the number of clinical vivax malaria cases confirmed by RDT or microscopy to determine the overall protective efficacy against clinical vivax malaria among study groups.</p><p>The investigators will look for the presence of axillary temperature ≥37.5°C\nAND P.vivax positive RDT or microscopy as a primary case definition of clinical vivax malaria.</p>, timeFrame - Data will be collected for two years following baseline intervention (Month 0 to Month 24)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06068530",
    "endpoint": "measure - Vivax malaria prevalence by study groups, description - <p>Vivax malaria prevalence will be determined by the number of positive vivax confirmed by dried blood spots PCR malaria detection method during cross-sectional surveys to determine the overall protective efficacy against subclinical P. vivax among study groups.</p><ul><li>The investigators will collect dried blood spots to detect malaria during cross-sectional surveys from the healthy participants.</li><li>Those who have axillary temperature ≥37.5°C\nAND P. vivax positive RDT or microscopy will receive treatment according to national treatment guideline.</li></ul>, timeFrame - PCR for malaria detection from DBS will be collected at 6th month intervals until two years following baseline intervention (Month 0, Month 6, Month 12, Month 18 and Month 24)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06068530",
    "endpoint": "measure - Overall percentage of vivax malaria positivity by study groups, description - <p>The percentage of vivax malaria positivity will be determined by the number of vivax positives detected by PCR, RDT or microscopy to determine overall protective efficacy against clinical and subclinical vivax malaria among study groups.\nDried blood spots to detect malaria from by PCR will be collected at baseline and every six months until two years.\nClinical malaria data detected by rapid diagnostic test or microscopy will be collected for two years following intervention.</p><ul><li>The investigators will look for the presence of axillary temperature ≥37.5°C\nAND P. vivax positive RDT or microscopy as a primary case definition of clinical malaria.</li><li>The investigators will collect dried blood spots to detect malaria during cross-sectional surveys from the healthy participants.</li></ul>, timeFrame - DBS: Month 0, Month 6, Month 12, Month 18 and Month 24 and Clinical malaria data for two year following intervention",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06068530",
    "endpoint": "measure - The incidence of adverse events, description - <p>The number of events will be assessed and graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 among all participants and compared among study groups to determine the safety and reactogenicity</p><ul><li>Occurrence of solicited local and&#x2F;or systemic reactogenicity signs and symptoms for 7 days following the intervention ((a) R21 adjuvanted with Matrix-M b) mass drug administration with DHA&#x2F;piperaquine plus SLDPQ c) vaccine and MDA combined)</li><li>Occurrence of unsolicited adverse events for 28 days following the intervention</li><li>Occurrence of serious adverse events for the duration of the trial</li></ul>, timeFrame - All adverse events which occur after administration of the first dose of the study drugs until one month after last dose of drugs or vaccine will be recorded. This data will be collected from Month 0 to month 24.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06068530",
    "endpoint": "measure - The concentration of antibodies against Plasmodium falciparum circumsporozoite (anti-NANP total IgG antibody) among subset of randomly selected participants from vaccinated and no intervention group., description - <ul><li>Comparison of immunogenicity (antibody responses to CSP) in the R21&#x2F;MM vaccination group with those in the a) combined group vaccine plus MDA b) control group (mass drug administration with DHA&#x2F;piperaquine plus SLDPQ)</li><li>ELISA to quantify antibodies to the vaccine components (regions of the CS antigen including the NANP repeat region and other elements of the protein as well as anti HBs)</li></ul>, timeFrame - One month after the completion of the third dose (at Study month 3), and one month after the booster dose (at Study Month 13)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06068530",
    "endpoint": "measure - Prevalence of molecular markers for drug resistant P. falciparum, description - The presence (Number) of molecular markers for drug resistant P. falciparum such as Kelch 13 mutations, plasmepsin 2 and mdr1 will be measured from DBS samples for all falciparum positive cases to determine the prevalence among test participants in each study group., timeFrame - Data will be collected for two years following baseline intervention (Month 0 to Month 24)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06068530",
    "endpoint": "measure - The acceptability of the intervention will be assessed by coverage (The number of residents participating in the interventions) reported as percentage of the target population participating in the intervention., description - , timeFrame - Month 3 and Month 13",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06068530",
    "endpoint": "measure - The acceptability of the intervention will be assessed by mixed social science methods, in depth interviews and Focus group discussions., description - , timeFrame - Data will be collected for two years following baseline intervention (Month 0 to Month 24)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06068530",
    "endpoint": "measure - The incidence of clinical falciparum malaria confirmed by RDT or microscopy among vaccinated and drug administered participants in compare to unvaccinated and no drug-administered participants living in standard-of-care villages., description - To determine the direct protective efficacy of the combined intervention MVDA against falciparum malaria infection.\nData on falciparum malaria infection confirmed by RDT or microscopy will be collected and measured., timeFrame - Data will be collected for two years following baseline intervention (Month 0 to Month 24)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06068530",
    "endpoint": "measure - The incidence of clinical falciparum malaria confirmed by RDT or microscopy among vaccinated participants in compare to unvaccinated participants living in standard-of-care villages., description - To determine direct protective efficacy of the vaccination alone against falciparum malaria infection.\nData on falciparum malaria infection confirmed by RDT or microscopy will be collected to measure incidence., timeFrame - Data will be collected for two years following baseline intervention (Month 0 to Month 24)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06068530",
    "endpoint": "measure - The incidence of clinical falciparum malaria confirmed by RDT or microscopy among drug administered participants in compare to no drug-administered participants living in standard-of-care villages., description - To determine direct protective efficacy of the mass drug administration alone against falciparum malaria infection.\nData on falciparum malaria infection confirmed by RDT or microscopy will be collected to measure incidence., timeFrame - Data will be collected for two years following baseline intervention (Month 0 to Month 24)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06068530",
    "endpoint": "measure - The incidence of clinical falciparum malaria confirmed by RDT or microscopy among unvaccinated and no drug-administered people living in intervention clusters relative to unvaccinated and no drug-administered people living in standard-of-care villages., description - To determine indirect protective efficacy of the combined intervention MVDA observed against falciparum malaria infection.\nData on falciparum malaria infection confirmed by RDT or microscopy will be collected and measured., timeFrame - Data will be collected for two years following baseline intervention (Month 0 to Month 24)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06068530",
    "endpoint": "measure - The incidence of clinical falciparum malaria confirmed by RDT or microscopy among unvaccinated people living in intervention clusters relative to unvaccinated people living in standard-of-care villages., description - To determine Indirect protective efficacy of the vaccination alone observed against falciparum malaria infection.\nData on falciparum malaria infection confirmed by RDT or microscopy will be collected and measured., timeFrame - Data will be collected for two years following baseline intervention (Month 0 to Month 24)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06068530",
    "endpoint": "measure - The incidence of clinical falciparum malaria confirmed by RDT or microscopy among no drug-administered people living in intervention clusters relative to no drug-administered people living in standard-of-care villages., description - To determine indirect protective efficacy of the mass drug administration alone observed against falciparum malaria infection.\nData on falciparum malaria infection confirmed by RDT or microscopy will be collected and measured., timeFrame - Data will be collected for two years following baseline intervention (Month 0 to Month 24)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02741024",
    "endpoint": "measure - The proportion of early therapeutic failures, late clinical failures and late parasitological failures in a period of 42 days after treatment initiation, description - , timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02741024",
    "endpoint": "measure - Recommendations to MoH on choice of antimalarial first line drugs, description - , timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03521973",
    "endpoint": "measure - The occurrence of all related solicited AE, description - The occurrence of all related solicited AE after vaccination, timeFrame - From the time of each PfSPZ Vaccine immunization until 7 days after each dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03521973",
    "endpoint": "measure - The occurrence of all related unsolicited AEs, description - The occurrence of all related unsolicited AE after vaccination, timeFrame - From the time of first PfSPZ Vaccine immunization until 28 days after the last dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01236612",
    "endpoint": "measure - Antibody production in groups 1, 2, 3 and 4, description - , timeFrame - 393 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01236612",
    "endpoint": "measure - Cellular immune response in groups 1, 2, 3 and 4, description - , timeFrame - 393 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01236612",
    "endpoint": "measure - Cytokine profile in groups 1, 2, 3 and 4, description - , timeFrame - 393 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00209794",
    "endpoint": "measure - Incidence of first or only malaria episodes by group up to 12 months of age as per protocol analysis., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00209794",
    "endpoint": "measure - Incidence of first or only malaria episodes by group up to 24 months of age., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00209794",
    "endpoint": "measure - Incidence of multiple malaria episodes up to 12 months of age., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00209794",
    "endpoint": "measure - Incidence of multiple malaria episodes up to 24 months of age., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00209794",
    "endpoint": "measure - Incidence of overall and severe anaemia up to 12 months of age., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00209794",
    "endpoint": "measure - Incidence of overall and severe anaemia up to 24 months of age., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00209794",
    "endpoint": "measure - Proportion of humoral and cellular immune responses against malaria at 12 months of age., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00209794",
    "endpoint": "measure - Total number of admissions and outpatient attendances up to 24 months of age., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00209794",
    "endpoint": "measure - Prevalence of P falciparum parasitaemia and overall and severe anaemia at 12 months of age., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00209794",
    "endpoint": "measure - Proportion of humoral responses and geometric mean antibody titres of polio, DTP and Hepatitis B at 5 months and of measles at 9 and 12 months, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00209794",
    "endpoint": "measure - Incidence of side effects in each group up to 12 months of age., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01190371",
    "endpoint": "measure - The proportion of patients with positive malaria smears, description - The number of patients still having parasites at these time points divided by the total treated will give an estimate of early cure rates or estimates of early treatment failure rates as a percentage., timeFrame - 24hr, 48hr, 72hr",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01190371",
    "endpoint": "measure - The percentage reduction of parasitaemia from baseline, description - These results will be used to compute the percentage of uncleared parasites so as to evaluate cases of early treatment failure according to the WHO criteria., timeFrame - 24hr, 48hr, 72hr",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01190371",
    "endpoint": "measure - The mean time to parasite clearance, description - Estimated by parametric survival analysis will give an estimate of how long the drug takes to clear parasites from the time of first dosing till the time of the first negative smear., timeFrame - Up to day 7",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01190371",
    "endpoint": "measure - The mean time to fever clearance, description - Estimated by parametric survival analysis mean time to fever clearance will be estimated to reflect the time it takes the the temperature to settle down consistently for at least 24 hours., timeFrame - Up to day 7",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01190371",
    "endpoint": "measure - To estimate the rates for late clinical and parasitological failure rates, description - We will estimate the cumulative incidence of success and failure rates at days 28 and 42, by both PCR-uncorrected and PCR-corrected for recrudescence, timeFrame - Days 28 and 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02698748",
    "endpoint": "measure - Early parasitologic failure, description - Detection of parasites once the initial parasitemia has been cleared in the time period from day 1 to day 3 after first day of drug intake, timeFrame - 1-3 days after first day of drug intake",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02698748",
    "endpoint": "measure - Late parasitologic failure, description - The detection of parasites in patients having cleared their initial parasitemia anytime from day 4 to day 28, timeFrame - 4-28 days after first day of drug intake",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02698748",
    "endpoint": "measure - Prevalence of chloroquine conferring pfcrt K76T mutation in pre-treatment infections, description - Proportion of the isolates detected with this specific mutation among isolates at baseline (before study drug initiation), timeFrame - 0 days after first day of drug intake",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02698748",
    "endpoint": "measure - Rates of pre treatment pfcrt K76T mutation in cases of chloroquine treatment failure, description - Proportion of the isolates detected with this specific mutation at baseline among cases with confirmed treatment failure those, timeFrame - 0 days after first day of drug intake",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02698748",
    "endpoint": "measure - Rates of post treatment pfcrt K76T mutation in cases of chloroquine treatment failure, description - Proportion of the isolates detected as new infections or recrudescent ones with this specific mutation, timeFrame - 28 days after first day of drug intake",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02698748",
    "endpoint": "measure - Clearance time of parasitaemia, description - time in hours until the clearance of parasitemia, timeFrame - 28 days after first day of drug intake",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05746819",
    "endpoint": "measure - Comparing specific abnormalities in the two groups by allocation: Brain atrophy, description - The Potchen volume score is 1-3 abnormal due to atrophy, 4-5 normal, 6-8 edema.\nAnd these are analyzed as three ordinal categories--atrophic, normal or edematous, timeFrame - at 1 month post recovery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05746819",
    "endpoint": "measure - Comparing specific abnormalities in the two groups by allocation: Brain atrophy, description - The Potchen volume score is 1-3 abnormal due to atrophy, 4-5 normal, 6-8 edema.\nAnd these are analyzed as three ordinal categories--atrophic, normal or edematous, timeFrame - at 12 months post recovery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05746819",
    "endpoint": "measure - Comparing specific abnormalities in the two groups by allocation: Gliosis by Fazekas score, description - Gliosis by Fazekas score, which assesses white matter lesions on brain MRI scans.\nThe scoring is from 0-3, with 0 = no lesion, 1 = mild, 2 = moderate and 3 = severe., timeFrame - 1 month post recovery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05746819",
    "endpoint": "measure - Comparing specific abnormalities in the two groups by allocation: Gliosis by Fazekas score, description - Gliosis by Fazekas score, which assesses white matter lesions on brain MRI scans.\nThe scoring is from 0-3, with 0 = no lesion, 1 = mild, 2 = moderate and 3 = severe., timeFrame - 12 month post recovery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05746819",
    "endpoint": "measure - Comparing specific abnormalities in the two groups by allocation:The presence or absence of regional gliosis or atrophy in cortical region, description - Comparing specific abnormalities in the two groups by allocation:The presence of regional gliosis or atrophy in cortical region, timeFrame - at 1 month post recovery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05746819",
    "endpoint": "measure - Comparing specific abnormalities in the two groups by allocation:The presence or absence of regional gliosis or atrophy in cortical region, description - Comparing specific abnormalities in the two groups by allocation:The presence of regional gliosis or atrophy in cortical region, timeFrame - at 12 month post recovery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05746819",
    "endpoint": "measure - Comparing specific abnormalities in the two groups by allocation:The presence or absence of regional gliosis or atrophy in deep gray, description - Comparing specific abnormalities in the two groups by allocation:The presence of regional gliosis or atrophy in deep gray, timeFrame - 1 month post recovery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05746819",
    "endpoint": "measure - Comparing specific abnormalities in the two groups by allocation:The presence or absence of regional gliosis or atrophy in deep gray, description - Comparing specific abnormalities in the two groups by allocation:The presence or absence of regional gliosis or atrophy in deep gray, timeFrame - 12 months post recovery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05746819",
    "endpoint": "measure - Comparing specific abnormalities in the two groups by allocation:The presence or absence of regional gliosis or atrophy in corpus callosum, description - Comparing specific abnormalities in the two groups by allocation:The presence of regional gliosis or atrophy in corpus callosum, timeFrame - 1 month post recovery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05746819",
    "endpoint": "measure - Comparing specific abnormalities in the two groups by allocation:The presence of or absence regional gliosis or atrophy in corpus callosum, description - Comparing specific abnormalities in the two groups by allocation:The presence of regional gliosis or atrophy in corpus callosum, timeFrame - 12 months post recovery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05746819",
    "endpoint": "measure - Comparing specific abnormalities in the two groups by allocation:The presence or absence of regional gliosis or atrophy in posterior fossa, description - Comparing specific abnormalities in the two groups by allocation:The presence of regional gliosis or atrophy in posterior fossa, timeFrame - 1 month post recovery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05746819",
    "endpoint": "measure - Comparing specific abnormalities in the two groups by allocation:The presence or absence of regional gliosis or atrophy in posterior fossa, description - Comparing specific abnormalities in the two groups by allocation:The presence or absence of regional gliosis or atrophy in posterior fossa, timeFrame - at 12 months post recovery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05746819",
    "endpoint": "measure - Safety assessment: bleeding, description - Where GRE imaging is available, we will compare presence&#x2F;absence of evidence of GRE positive findings, timeFrame - at 1-month",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05746819",
    "endpoint": "measure - Safety assessment: kidney, description - Compare incident chronic kidney disease based upon urine albumin:creatinine ratio with a cut off of ACR of 3, timeFrame - At least 6 months post malaria",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04265573",
    "endpoint": "measure - Proportion of community resources people with favourable opinions to the MFTs pilot program., description - Data will be collected at community level through qualitative surveys (FGDs; IDIs) from various profiles of informants., timeFrame - From the formative phase to the end of drugs deployment: 18 months duration.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04265573",
    "endpoint": "measure - Proportion of community resources people with unfavourable opinions to the MFTs pilot program., description - Data will be collected at community level through qualitative surveys (FGDs; IDIs) from various profiles of informants., timeFrame - From the formative phase to the end of drugs deployment: 18 months duration.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04265573",
    "endpoint": "measure - Average number of monitoring visits performed per annum, description - Data will be obtained though the health facility- based surveys., timeFrame - Through the MFTs deployment phase: 12 months of duration.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04265573",
    "endpoint": "measure - Average number of monitoring visits on which drugs stores have stock out of any dose of study ACTs per annum., description - Data will be obtained though the health facility- based surveys., timeFrame - Through the MFTs deployment phase: 12 months of duration.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04265573",
    "endpoint": "measure - Average number of monitoring visits on which health facilities have stock out of mRDTs per annum., description - Data will be obtained though the health facility- based surveys., timeFrame - Through the MFTs deployment phase: 12 months of duration.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04265573",
    "endpoint": "measure - Proportion of febrile episode seen at health facility level., description - Data will be obtained through health facility- based surveys using registers of Health Facilities (HF)., timeFrame - Through the MFTs deployment phase: 12 months of duration",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04265573",
    "endpoint": "measure - Proportion of febrile episode seen at health facility level (HFL) within 24 hours, description - Data will be obtained through health facility- based surveys using registers of HF., timeFrame - Through the MFTs deployment phase: 12 months of duration",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04265573",
    "endpoint": "measure - Proportion of febrile episode seen at HFL within 24 hours and tested for parasitemia., description - Malaria diagnosis will done using malaria rapid diagnosis test (mRDT).\nData will be obtained through health facility- based surveys using registers of HF., timeFrame - Through the MFTs deployment phase: 12 months of duration.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04265573",
    "endpoint": "measure - Proportion of febrile episode seen at HFL within 24 hours with positive diagnostic test who were given ACT according to the MFTs strategy, description - Malaria diagnosis will done using malaria rapid diagnosis test (mRDT).\nData will be obtained through health facility- based surveys using registers of HF., timeFrame - Through the MFTs deployment phase: 12 months of duration.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04265573",
    "endpoint": "measure - Proportion of febrile episode seen at HFL within 24 hours with negative diagnostic test who did not received any antimalarial., description - Malaria diagnosis will done using malaria rapid diagnosis test (mRDT).\nData will be obtained through health facility- based surveys using registers of HF., timeFrame - Through the MFTs deployment phase: 12 months of duration.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04265573",
    "endpoint": "measure - Proportion of febrile episode seen at HFL within 24 hours with negative diagnostic test who received an ACT., description - Malaria diagnosis will done using malaria rapid diagnosis test (mRDT).\nData will be obtained through health facility- based surveys using registers of HF., timeFrame - Through the MFTs deployment phase: 12 months of duration.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04265573",
    "endpoint": "measure - Proportion of febrile episodes treated with ACTs adhering to ACT treatment schedule (timing and doses) by HWs according to MFTs strategy, description - Household surveys (data will be collected in the community level through the KAP questionnaire)., timeFrame - During MFTs deployment phase at peak malaria season: 6 months of duration.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04265573",
    "endpoint": "measure - Cost per additional febrile episode receiving prompt treatment or confirmed negative diagnosis, description - Data will be obtained using the cost data collection forms through health facility- based surveys., timeFrame - Through the MFTs deployment phase: 12 months of duration.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04265573",
    "endpoint": "measure - Cost per additional inappropriate antimalarial treatment avoided., description - Data will be obtained using the cost data collection forms through health facility- based surveys., timeFrame - Through the MFTs deployment phase: 12 months of duration.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04265573",
    "endpoint": "measure - The cost per additional febrile episode appropriate managed for malaria with confirmed diagnosis, description - Data will be obtained using the cost data collection forms through health facility- based surveys., timeFrame - Through the MFTs deployment phase: 12 months of duration",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04265573",
    "endpoint": "measure - The total cost per capita of intervention (provider perspective), description - Data will be obtained using the cost data collection forms through health facility- based surveys., timeFrame - Through the MFTs deployment phase: 12 months of duration",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04265573",
    "endpoint": "measure - The total cost per capita of intervention (societal perspective), description - Data will be obtained using the cost data collection forms through household surveys (costing questionnaire administered at community level)., timeFrame - Through the MFTs deployment phase: 12 months of duration",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04265573",
    "endpoint": "measure - Cost to the HWs to participate to the MFTs strategy., description - Data will be obtained using the cost data collection forms through at health facilities level., timeFrame - Through the MFTs deployment phase: 12 months of duration.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04265573",
    "endpoint": "measure - Proportion of episode of uncomplicated fever seen by HWs tested for malaria parasitemia., description - Data will be obtained through the health facility- based surveys (data collected at health facilities level using the registers of HF)., timeFrame - From the formative phase to the end of drugs deployment: 18 months duration.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04265573",
    "endpoint": "measure - Proportion of uncomplicated fever episodes&#x2F;malaria seen by HW, tested positive and treated with correct dose of ACT according to MFTs pilot program, description - Data will be obtained through the health facility- based surveys (data collected at health facilities level using the registers of HF)., timeFrame - From the formative phase to the end of drugs deployment: 18 months duration.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04265573",
    "endpoint": "measure - Proportion of febrile episodes treated with ACTs according to MFTs pilot programme by HWs provided with appropriate dosing advice, description - Data will be obtained through the health facility- based surveys (data collected at health facilities level using the registers of HF)., timeFrame - From the formative phase to the end of drugs deployment: 18 months duration.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04265573",
    "endpoint": "measure - Proportion of uncomplicated febrile episodes&#x2F;malaria seen by HWs provided with advice on danger signs., description - Data will be obtained through the health facility- based surveys (data collected at health facilities level using the registers of HF)., timeFrame - From the formative phase to the end of drugs deployment: 18 months duration.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04265573",
    "endpoint": "measure - Incidence of uncomplicated febrile episode&#x2F;malaria within 4 weeks preceding the surveys, description - Household surveys before and during the MFTs deployment using KAP questionnaire administered at the community level., timeFrame - From the formative phase to the end of drugs deployment: 18 months duration.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04265573",
    "endpoint": "measure - Proportion of uncomplicated febrile episode&#x2F;malaria seen at health facility level before and during the MFTs deployment in the study area., description - Data will be obtained through the health facility- based surveys (data collected at the health facility level using the registers of HF)., timeFrame - Through the MFTs deployment phase: 12 months of duration.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04265573",
    "endpoint": "measure - Mortality rate related to febrile episode&#x2F;malaria before and during the pilot MFTs deployment., description - Data will be collected through the Health and demographic surveillance system mortality data and health facility- based surveys (data collected at the health facility level using the registers of HF)., timeFrame - From the formative phase to the end of drugs deployment: 18 months duration.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04265573",
    "endpoint": "measure - Proportion of individuals with fever in the last four weeks for whom advice or treatment was sought, description - Household surveys using KAP questionnaire administered at the community level, timeFrame - From the formative phase to the end of drugs deployment: 18 months duration.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04265573",
    "endpoint": "measure - Proportion of individuals with fever in the last four week who sought treatment at HFL within 24 hours, description - Household surveys using KAP questionnaire administered at the community level., timeFrame - From the formative phase to the end of drugs deployment: 18 months duration.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04265573",
    "endpoint": "measure - Source of advice or care for those suffering from fever in the last four weeks, description - Household survey using KAP questionnaire administered at the community level., timeFrame - From the formative phase to the end of drugs deployment: 18 months duration.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00261222",
    "endpoint": "measure - Total clinical failure rate on day 28., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00261222",
    "endpoint": "measure - Clinical failure rate on day 28 in rural study area., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00261222",
    "endpoint": "measure - Clinical failure rate on day 28 in urban study area., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00261222",
    "endpoint": "measure - Total early clinical failure rate., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00261222",
    "endpoint": "measure - Early clinical failure rate in rural study area., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00261222",
    "endpoint": "measure - Early clinical failure rate in urban study area., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00261222",
    "endpoint": "measure - Total late parasitological failure rate on day 14 and 28., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00261222",
    "endpoint": "measure - Late parasitological failure rate on day 14 and 28 in rural study area., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00261222",
    "endpoint": "measure - Late parasitological failure rate on day 14 and 28 in urban study area., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00261222",
    "endpoint": "measure - Incidence of observed and self-reported adverse events over the 28 days observation period, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00261222",
    "endpoint": "measure - Monitoring of concomitant drug intake, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00119132",
    "endpoint": "measure - Incidence of moderate (Hb&lt;8.0g&#x2F;dl&gt;5.0g&#x2F;dl) and severe anaemia (Hb&lt;5.0g&#x2F;dl) during the period of the intervention, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00119132",
    "endpoint": "measure - Incidence of severe and clinical malaria during the period of the intervention, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00119132",
    "endpoint": "measure - Prevalence of anaemia at the post intervention survey, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00119132",
    "endpoint": "measure - Prevalence of parasitaemia and gametocytemia at the post intervention survey, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00119132",
    "endpoint": "measure - Prevalence of molecular markers of resistance to SP among children who have malaria at the post intervention survey, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00121771",
    "endpoint": "measure - Comparison of immunogenicity with non-immune UK adults, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00739206",
    "endpoint": "measure - Parasite reduction, description - , timeFrame - 3 initial days (72h)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00739206",
    "endpoint": "measure - Safety assessment, description - , timeFrame - 28 days post 1st study drug administration",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02450578",
    "endpoint": "measure - Number of Participants With Adverse Events as a Measure of Safety &amp; Tolerability of DSM265, description - Safety &amp; tolerability of DSM265 for causal and suppressive chemoprophylaxis in non-immune healthy volunteers in a non-immune healthy volunteers in CHMI with PfSPZ challenge., timeFrame - From first dose (Day -1 in Cohort 1A and Day -7 in Cohort 2) to Day 60 post-inoculum",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02450578",
    "endpoint": "measure - Number of Participants With Treatment Emergent Adverse Events (TEAE) as a Measure of Safety &amp; Tolerability of Malarone, description - <p>Safety &amp; tolerability of Malarone for causal and suppressive chemoprophylaxis in non-immune healthy volunteers in a Plasmodium falciparum sporozoite challenge.\nMeasured by adverse events, laboratory data.</p><p>Malarone® was administered as a single daily dose over a period of 9 days from Day -1 to Day 7.</p>, timeFrame - From first dose (Day -1, Cohort 1b) to Day 60 post-inoculum",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02450578",
    "endpoint": "measure - Number of Participants With Adverse Events as a Measure of Safety and Tolerability of Plasmodium Falciparum Sporozoite Challenge Inoculum, description - Safety &amp; tolerability of Plasmodium falciparum sporozoite challenge inoculum during DSM265 administration, and Malarone administration.\nMeasured by adverse events, laboratory data, timeFrame - Day 0 to Day 60 post-inoculum",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02450578",
    "endpoint": "measure - DSM265 Pharmacokinetics Profile - T Max, description - Pre-dose and post-dose during the period including Day 28, timeFrame - From pre-dose of DSM265 (Day -1 in Cohort 1a and Day -7 in Cohort 2) to Day 28 post-inoculum",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02450578",
    "endpoint": "measure - DSM265 Pharmacokinetics Profile - T 1&#x2F;2, description - Pre-dose and post-dose during the period including Day 28, timeFrame - From pre-dose of DSM265 (Day -1 in Cohort 1a and Day -7 in Cohort 2) to Day 28 post-inoculum",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02450578",
    "endpoint": "measure - DSM265 Pharmacokinetics Profile - C Max, description - Pre-dose and post-dose during the period including Day 28, timeFrame - From pre-dose of DSM265 (Day -1 in Cohort 1a and Day -7 in Cohort 2) to Day 28 post-inoculum",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02450578",
    "endpoint": "measure - DSM265 Pharmacokinetics Profile - AUC 0-∞, AUC 0-168h, and AUC 0-480h, description - Pre-dose and post-dose during the period including Day 28 for AUC 0-∞, AUC 0-168h, and AUC 0-480h, timeFrame - From pre-dose of DSM265 (Day -1 in Cohort 1a and Day -7 in Cohort 2) to Day 28 post-inoculum",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02450578",
    "endpoint": "measure - DSM265 Pharmacokinetics Profile - CL&#x2F;F, description - Pre-dose and post-dose during the period including Day 28, timeFrame - From pre-dose of DSM265 (Day -1 in Cohort 1a and Day -7 in Cohort 2) to Day 28 post-inoculum",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02450578",
    "endpoint": "measure - DSM265 Pharmacokinetics Profile - Vz&#x2F;F, description - Pre-dose and post-dose during the period including Day 28, timeFrame - From pre-dose of DSM265 (Day -1 in Cohort 1a and Day -7 in Cohort 2) to Day 28 post-inoculum",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02450578",
    "endpoint": "measure - DSM450 Pharmacokinetics Profile - T Max, description - Pre-dose and post-dose during the period including Day 28, timeFrame - From pre-dose of DSM265 (Day -1 in Cohort 1a and Day -7 in Cohort 2) to Day 28 post-inoculum",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02450578",
    "endpoint": "measure - DSM450 Pharmacokinetics Profile - Cmax, description - Pre-dose and post-dose during the period including Day 28, timeFrame - From pre-dose of DSM265 (Day -1 in Cohort 1a and Day -7 in Cohort 2) to Day 28 post-inoculum",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02450578",
    "endpoint": "measure - DSM450 Pharmacokinetics Profile - AUC 0-t, AUC 0-168h, and AUC 0-480h, description - Pre-dose and post-dose during the period including Day 28 for AUC 0-t, AUC 0-168h, and AUC 0-480h, timeFrame - From pre-dose of DSM265 (Day -1 in Cohort 1a and Day -7 in Cohort 2) to Day 28 post-inoculum",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02450578",
    "endpoint": "measure - The Pharmacokinetic-pharmacodynamic Profile of Pre-administration of DSM265 on Clearance of Plasmodium Falciparum Parasites After Administration of the Sporozoite Challenge, description - The profile of plasma concentrations and pharmacokinetic parameters (AUC, Cmax, Tmax, T0-inf, AUC0-t, t1&#x2F;2) will be reviewed on a background of the safety profile (adverse events, laboratory and ECG data) and the clearance of Plasmodium falciparum parasites (efficacy) after administration of the sporozoite challenge, timeFrame - From first dose of DSM265 (Day -1 in Cohort 1a, Day -7 in Cohort 2 and Day -X in Cohort 3) to 480 hours post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02450578",
    "endpoint": "measure - Recrudescence of Parasite Kinetics Following DSM265 Administration., description - On any re-appearance of parasites, thick smears and PCR samples will be examined to determine whether the parasite is a different variant(recrudescence) or has the same genetic profile as the original infection (re-infection) post-dose, timeFrame - Day 6 post-inoculum to Day 60",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00853281",
    "endpoint": "measure - Reduction of malaria sero-prevalence, description - , timeFrame - 24 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01379430",
    "endpoint": "measure - Immunogenicity of vaccines, description - To evaluate the immunogenicity of AdCh63 ME-TRAP followed by MVA ME-TRAP in adults in Kenya by assessing induced antibody and T cell response to the vaccine insert., timeFrame - Participants will be followed for the duration of the study, an expected average of 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01379430",
    "endpoint": "measure - Immunogenicity of Vaccines, description - To compare the use of intra-muscular and intra-dermal MVA ME-TRAP, timeFrame - Participants will be followed for the duration of the study, an expected average of 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02389374",
    "endpoint": "measure - Proportion of Patients Receiving Blood Transfusion and With Severe Anaemia (Hb&lt;7g&#x2F;dl), description - , timeFrame - day 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02389374",
    "endpoint": "measure - Fractional Change in Hb Between Baseline and Day 9 and 16, description - , timeFrame - day 0 and 16",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02389374",
    "endpoint": "measure - Proportion of Patients With Anaemia Less Than 8g&#x2F;dl on Day 2, description - , timeFrame - on day 2",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02389374",
    "endpoint": "measure - Proportion of Patients With Any Parasitemia on Day 3 After Treatment, description - , timeFrame - day 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02389374",
    "endpoint": "measure - Proportion of Patients With Fever on Day 2 After Treatment, description - , timeFrame - day 2",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02389374",
    "endpoint": "measure - Recurrence of Parasitaemia Within 16 Days of Follow up, description - , timeFrame - day 16",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02389374",
    "endpoint": "measure - Proportion of Patients Adhering to 14 Days of Primaquine Treatment in the Vivax Cohort as Measured by Pill Count, description - , timeFrame - day 16",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02389374",
    "endpoint": "measure - The Distribution of G6PD Activity Measured in U&#x2F;gHb Among All Malaria Patients, description - , timeFrame - day 0",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02389374",
    "endpoint": "measure - Frequency and Type of Variants of the G6PD Gene Within the Study Population, description - Frequency and type of variants of the G6PD gene within the study population, timeFrame - day 0 or 1",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00487916",
    "endpoint": "measure - Assessment of the level, kinetics and the in-vitro biological activity of the antibody response to AMA1-FVO and AMA1-3D7., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05206201",
    "endpoint": "measure - Area under the curve from the time of dosing to the last measurable concentration (AUC0-t), description - Estimation of ZY-19489 and its metabolite ZY-20486, timeFrame - For Part 1 : Baseline to Day 28 and For Part 2 : Baseline to Day 30",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05206201",
    "endpoint": "measure - Cmax, description - Estimation of ZY-19489 and its metabolite ZY-20486, timeFrame - For Part 1 : Baseline to Day 28 and For Part 2 : Baseline to Day 30",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05206201",
    "endpoint": "measure - To assess the effect of ZY-19489&#x2F;ZY-20486on the QTc interval (concentration&#x2F;QTc modelling)., description - • Difference between baseline corrected QTc following placebo and baseline corrected QTc following ZY-19489, timeFrame - For Part 1 : Baseline to Day 28 and For Part 2 : Baseline to Day 30",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05206201",
    "endpoint": "measure - AUC0-∞, description - Estimation of ZY-19489 and its metabolite ZY-20486, timeFrame - For Part 1 : Baseline to Day 28 and For Part 2 : Baseline to Day 30",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05206201",
    "endpoint": "measure - Tmax, description - Estimation of ZY-19489 and its metabolite ZY-20486, timeFrame - For Part 1 : Baseline to Day 28 and For Part 2 : Baseline to Day 30",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05206201",
    "endpoint": "measure - T1&#x2F;2, description - Estimation of ZY-19489 and its metabolite ZY-20486, timeFrame - For Part 1 : Baseline to Day 28 and For Part 2 : Baseline to Day 30",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05206201",
    "endpoint": "measure - CL&#x2F;F, description - Estimation of ZY-19489 and its metabolite ZY-20486, timeFrame - For Part 1 : Baseline to Day 28 and For Part 2 : Baseline to Day 30",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05206201",
    "endpoint": "measure - VZ&#x2F;F, description - Estimation of ZY-19489 and its metabolite ZY-20486, timeFrame - For Part 1 : Baseline to Day 28 and For Part 2 : Baseline to Day 30",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05206201",
    "endpoint": "measure - λ, description - Estimation of ZY-19489 and its metabolite ZY-20486, timeFrame - For Part 1 : Baseline to Day 28 and For Part 2 : Baseline to Day 30",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05206201",
    "endpoint": "measure - AUC0-24, description - AUC0-24 after first dose on Day 0 will be calculated with PK samples on Day 01.\nAUC0-24 after third dose on Day 2 will be calculated with PK samples on Day 03, timeFrame - For Part 2 : Baseline to Day 30",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05206201",
    "endpoint": "measure - Accumulation Index, description - Estimation of ZY-19489 and its metabolite ZY-20486, timeFrame - For Part 2 : Baseline to Day 30",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05206201",
    "endpoint": "measure - Rac(AUC), description - Estimation of ZY-19489 and its metabolite ZY-20486, timeFrame - For Part 2 : Baseline to Day 30",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05206201",
    "endpoint": "measure - Rac(Cmax), description - Estimation of ZY-19489 and its metabolite ZY-20486, timeFrame - For Part 2 : Baseline to Day 30",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00832754",
    "endpoint": "measure - Incidence of severe anaemia (Hb &lt;8 g&#x2F;dl) in &lt; 48 month old children, description - , timeFrame - Three years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02013687",
    "endpoint": "measure - Assessment of Anti-Pfs25 IgG Following the Third Immunization., description - Serum anti-Pfs25 antibody IgG titers determined using an ELISA unit assay., timeFrame - 196 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02013687",
    "endpoint": "measure - Assessment of Transmission Reducing Activity (TRA) of Malaria Parasite, description - Assessment of TRA, as measured by the standard membrane feeding assay (SMFA), one month after the second vaccination (Study Day 84) in either the 30 μg or 100 μg dose groups., timeFrame - 84 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02013687",
    "endpoint": "measure - Assessment of Transmission Reducing Activity (TRA) of Malaria Parasite, description - Assessment of TRA, as measured by the standard membrane feeding assay (SMFA), showing ≥80% reduction of oocysts in Anopheles mosquito gut in ≥50% of the subjects with Study Day 196 sera (one month after the third vaccination) (Study Day 196) in either the 30 μg or 100 μg dose groups., timeFrame - 196 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05764746",
    "endpoint": "measure - PCR adjusted cure rates by day 28, 42 and 56., description - Assessment of cure rate as determined by parasitemia to distinguish recrudescence and reinfections, timeFrame - Through study completion, an average of 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02418962",
    "endpoint": "measure - Antibody titers to PfCSP, PfLSA-1, PfEXP-1 and PfMSP-5 by ELISA, description - Antibody titers to PfCSP, PfLSA-1, PfEXP-1 and PfMSP-5 by ELISA, and their functional activity to block invasion of hepatocytes at screening, before each vaccination, at 2 and 4 weeks after the first and second vaccinations (groups 2 and 3) and at 2, 4, 8, and 24 weeks after the last vaccination., timeFrame - Before each vaccination, at 2 and 4 weeks after 1st and 2nd vaccinations (groups 2 and 3) and at 2, 4, 8, and 24 weeks after the last vaccination.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02418962",
    "endpoint": "measure - Antibody titers to whole Pf sporozoite by Immunofluorescence (IFA), description - Antibody titers to whole Pf sporozoite by Immunofluorescence (IFA) and their functional activity to block invasion of hepatocytes at screening, before each vaccination, 2 and 4 weeks after each vaccination, and at 8, and 24 weeks after the last vaccination., timeFrame - Before each vaccination, 2 and 4 weeks after each vaccination, and at 8, and 24 weeks after the last vaccination.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02418962",
    "endpoint": "measure - Cellular immune responses, description - Cellular immune responses to the whole PfSPZ and synthetic peptides from selected Pf pre-erythrocytic antigens by ELISPOT and Intracellular Cytokine Staining (ICS) at screening and at 2 and 24 weeks after the last vaccination, timeFrame - Screening and at 2 and 24 weeks after the last vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02213211",
    "endpoint": "measure - Plasmodium falciparum parasitaemia, description - Presence of malaria parasites in blood sample using microscopy, timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02213211",
    "endpoint": "measure - Anaemia, description - Anaemia based on haemoglobin concentration assessed using Hemocue photometer, timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02213211",
    "endpoint": "measure - Child wellbeing, description - Child-recorded wellbeing charts completed by each child three days per week between May and July 2015, timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02213211",
    "endpoint": "measure - Cost effectiveness, description - Cost effectiveness analysis will consider reductions in absenteeism, timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02213211",
    "endpoint": "measure - Stakeholder perceptions of LTK intervention, description - Perceptions of intervention from teachers, school children and healthcare workers as well as key policy makers obtained through focus group discussions and in-depth interviews, timeFrame - End of intervention period",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00132548",
    "endpoint": "measure - Incidence of clinical malaria, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00132548",
    "endpoint": "measure - Side effects, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04666350",
    "endpoint": "measure - Oocyst Density, description - <p>Participants underwent feeding assays on two days, 24 hours apart (Day 1 and Day 2).\nAfter feeding, mosquitoes were maintained in locked environmental chambers for 9 days to allow oocyst development.</p><p>An oocyst is a structure that develops on the outer wall of the infected mosquito&#x27;s stomach that contains developing sporozoites.</p><p>Nine days after feeding mosquito midguts were dissected, stained with 1% mercurochrome and examined by optical microscopy.\nThe number of oocysts in each midgut were recorded.</p><p>Oocyst density is defined as the mean number of oocysts detected in infected mosquitoes that underwent feeding assays on the same participant.</p>, timeFrame - Feeding assays were performed on Day 1 and Day 2; Oocyst density in surviving mosquitos was assessed 9 days after feeding (Days 9 and 10).",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04666350",
    "endpoint": "measure - Sporozoite Prevalence, description - <p>Participants underwent feeding assays on two days, 24 hours apart (day 1 and Day 2).\nAfter feeding, mosquitoes were maintained in locked environmental chambers for 14 days to allow sporozoite development.</p><p>Sporozoites are the forms of the plasmodium that are liberated from the oocysts in the mosquito, accumulate in the salivary glands of the mosquito, and are transferred to humans when the mosquito feeds.</p><p>Fourteen days after feeding, salivary glands were dissected from live mosquitoes submerged in phosphate-buffered saline (PBS) in order to visualize motile sporozoites by microscopy.\nSporozoite prevalence was recorded.</p><p>Sporozoite prevalence is defined as the percentage of mosquitoes in a cup with at least one sporozoite detected in the salivary glands among the mosquitoes (in the same cup) that underwent feeding assays.</p>, timeFrame - Feeding assays were performed on Day 1 and Day 2; Sporozoite prevalence in surviving mosquitoes was assessed 14 days after feeding (Days 14 and 15).",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04666350",
    "endpoint": "measure - Sporozoite Density, description - <p>Sporozoite density is defined as the mean number of sporozoites detected in infected mosquitoes that underwent feeding assays.</p><p>Due to limitation on the state of the art, it was not possible to estimate the sporozoite density using the Optical Microscopy technique.</p>, timeFrame - Day 1 and Day 2",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00738946",
    "endpoint": "measure - Incidence of severe malaria, Incidence of anemia, Prevalence of anemia, Prevalence of parasitemia, Proportion of children with parasites carrying resistance markers to AQ and SP, Incidence of hospital admissions due to malaria., description - , timeFrame - 2008-2009",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02313376",
    "endpoint": "measure - CSP antibody titer, description - , timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02313376",
    "endpoint": "measure - Percent inhibition of in vitro sporozoite, description - , timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00424944",
    "endpoint": "measure - Humoral immune response to GLURP and MSP 3, description - , timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00424944",
    "endpoint": "measure - Cellural immune response, description - , timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02206451",
    "endpoint": "measure - Measurement of infection intensity for a given mosquito that was fed on a given subject, description - , timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00563914",
    "endpoint": "measure - Parasite clearance assessed by repeated measurements of parasitemia, description - , timeFrame - Sreening, days D1(T6 and T12),D2 (T0 and T6), D3( T0, T6 and T12) ,D4,D7,D14,D21and D28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00563914",
    "endpoint": "measure - Pharmacokinetics of ferroquine assessed by repeated measurement of blood concentration, description - , timeFrame - up to 28 days after last dosing",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02613520",
    "endpoint": "measure - Level of Antibodies against Pf proteins in volunteer sera, description - <ol><li>Antibody titres to pre-erythrocytic stage and erythrocytic stage antigens[PfCSP, PfLSA-1, PfEBA-175 , PfMSP-1, PfMSP-5, EXP-1] by ELISA</li><li>Antibody titres to Pf sporozoites, asexual and sexual erythrocytic stage parasites by IFA.</li><li>Analysis of antibodies to proteins in the Pf proteome array chip.</li></ol>, timeFrame - Post first immunization uptil 56 days post-CHMI or 56 days post-3rd immunization",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02613520",
    "endpoint": "measure - Inhibitory Capacity of Volunteer Sera against in vitro Sporozoite Invasion of Hepatocytes, description - Capacity of sera from immunized volunteers to inhibit sporozoite invasion (ISI) of hepatocytes in vitro by ISI assay, timeFrame - Post first immunization uptil 56 days post-CHMI or 56 days post-3rd immunization",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02613520",
    "endpoint": "measure - Quantitation of cellular immune responses against Pf proteins in volunteers, description - <ol><li>Identification of number of vaccine induced PBMCs following Intracellular cytokine staining by flow cytometry after stimulation with PfSPZ or Pf-infected erythrocytes, peptide pools and P. falciparum infected primary human hepatocyte cell lines.</li><li>Identification of numbers of vaccine induced CD4 and CD8 T cells following FluoroSpot assay after stimulation with PfSPZ or Pf-infected erythrocytes.</li></ol>, timeFrame - Post first immunization uptil 56 days post-CHMI or 56 days post-3rd immunization",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02613520",
    "endpoint": "measure - Whole genome expression profiles of volunteer, description - Human gene expression profiling focusing on immune response genes in volunteers, timeFrame - Post first immunization uptil 56 days post-CHMI or 56 days post-3rd immunization",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01062386",
    "endpoint": "measure - Proportion of families with knowledge, attitude and practice regarding malaria prevention, description - , timeFrame - January-February 2010",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01152931",
    "endpoint": "measure - 28-day cure rate., description - the number of patients with clinical and parasitological cure by day 28 divided by the total number of patients who could be evaluated (per protocol population)., timeFrame - 4 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07208760",
    "endpoint": "measure - Part 1a: Incidence and severity of local and systemic AEs, description - , timeFrame - Occurring within 7 days after the administration of L9LS and within 7 days after administration of each dose of R21&#x2F;Matrix-M™.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07208760",
    "endpoint": "measure - Part 1b: Incidence and severity of laboratory abnormalities, description - , timeFrame - Occurring within 7 days after the administration of study agent.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07208760",
    "endpoint": "measure - Part 2a: Incidence and severity of local and systemic AEs, description - , timeFrame - Occurring within 7 days after the administration of L9LS and within 7 days after administration of each dose of R21&#x2F;Matrix-M™.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07208760",
    "endpoint": "measure - Part 2b: Incidence and severity of laboratory abnormalities, description - , timeFrame - Occurring within 7 days after the administration of study agent.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07208760",
    "endpoint": "measure - Part 2c: Incidence and severity of hypersensitivity reactions, description - , timeFrame - Occurring within 7 days after the administration of each dose of R21&#x2F;Matrix-M™ vaccine.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07208760",
    "endpoint": "measure - Part 2d: Total IgG anti-NANP antibody titers, description - Measured by ECLIA, using the Meso Scale Discovery (MSD) LLC-based automation platform, timeFrame - 84 days after the third R21&#x2F;Matrix-M™ vaccination.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07208760",
    "endpoint": "measure - Part 2e: Detection of Anti-Drug Antibodies (ADAs) to L9LS, description - Measured by 3-tier MSD assay, timeFrame - Through study completion, an average of 2 years.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07208760",
    "endpoint": "measure - Part 2f: Serum concentrations of L9LS, description - Measured with an L9LS anti-idiotype antibody and a MSD LLC-based automation platform, timeFrame - Up to 18 months.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04083508",
    "endpoint": "measure - Cellular Immune response to primary P. vivax infection., description - immune cells including Innate and adaptive immune cells react and express during the PV infection (profile and frequency), timeFrame - up to 1 year after challenge",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04083508",
    "endpoint": "measure - Humoral Immune response to primary P. vivax infection., description - Immune cells defense PV antigen by determining the level of antibody response and inflammatory cytokine, timeFrame - up to 1 year after challenge",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04083508",
    "endpoint": "measure - Gametocytaemia following primary P. vivax infection delivered by the mosquito bite, description - Gametocyte qPCR following primary P. vivax infection delivered by the mosquito bite, timeFrame - up to 1 year after challenge",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01603251",
    "endpoint": "measure - Mosquitocidal activity, description - Daily mortality rates of (malaria-infected) Anopheles gambiae s.s. and An.\nfunestus mosquitoes after taking a blood meal 1, 3 or 7 days after initiation of treatment, timeFrame - feeding experiments performed up to 8 days after enrolment; survival of mosquitoes determined up to day 10 after feeding",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03138096",
    "endpoint": "measure - Immunogenicity of Pb(PfCS@UIS4) as Assessed by ELISA, description - Immunogenicity of repeated Pb(PfCS@UIS4) immunization as assessed by fold change in anti-P.\nfalciparum IgG from baseline to post-immunization (day prior to CHMI), as measured by ELISA., timeFrame - Group 3: from baseline until day prior to CHMI (approximately 15 weeks after first Pb(PfCS@UIS4) immunization)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04300309",
    "endpoint": "measure - Lumefantrine Day 8 Concentration (C168h), description - <p>Pharmacokinetic (PK) parameters were calculated by non-compartmental analysis based on lumefantrine plasma concentrations.</p><p>Dosing times were 0, 8, 24, 36, 48 and 60 hours.</p>, timeFrame - 168 hours after first dose (corresponding to 108 hours after last dose)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04300309",
    "endpoint": "measure - Lumefantrine Cmax After Last Dose, description - <p>Lumefantrine Cmax represents the highest concentration among four sampling time points after last dose.</p><p>Pharmacokinetic (PK) parameters were calculated by non-compartmental analysis based on lumefantrine plasma concentrations.</p><p>Dosing times were 0, 8, 24, 36, 48 and 60 hours.</p>, timeFrame - 62, 66, 68 and 84 hours after first dose (corresponding to 2, 6, 8 and 24 hours after last dose)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04300309",
    "endpoint": "measure - DHA Cmax After First Dose, description - <p>Dihydroartemisinin (DHA) is an active metabolite of artemether.\nDHA Cmax represents the highest concentration between the concentrations at 1 hour and 2 hours after first dose.</p><p>Pharmacokinetic (PK) parameters were calculated by non-compartmental analysis based on DHA plasma concentrations.</p>, timeFrame - 1 and 2 hours after first dose (Day 1)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04300309",
    "endpoint": "measure - Parasite Clearance Time (PCT), description - <p>PCT is defined as time from the first dose until the first total and continued disappearance of asexual parasite forms which remained at least a further 48 hours.\nPCT is based on uncorrected parasite counts.</p><p>Patients who received rescue medication before parasite clearance were censored at the first use of rescue medication.</p><p>Patients without parasite clearance were censored at the time of last parasite assessment.</p><p>PCT was calculated using the Kaplan-Meier method.</p>, timeFrame - Up to 48 hours after first dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04300309",
    "endpoint": "measure - Fever Clearance Times (FCT), description - <p>FCT is defined as time from the first dose until the first time the axillary body temperature decreased below and remained below 37.5°C axillary or 38.0°C oral&#x2F;tympanic&#x2F;rectal for at least a further 24 hours.</p><p>Patients who received rescue medication before fever clearance were censored at the first use of rescue medication.</p><p>Patients without fever clearance were censored at the time of last parasite assessment.</p><p>FCT was calculated using the Kaplan-Meier method.</p>, timeFrame - Up to 36 hours after first dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04300309",
    "endpoint": "measure - PCR-corrected Adequate Clinical and Parasitological Response (ACPR) - PPS Analysis, description - <p>PCR-corrected ACPR, defined as the absence of parasitemia, was evaluated on Days 15, 29 and 43.\nMicroscopic species identification was confirmed and determined by polymerase chain reaction (PCR) genotyping methods to establish malaria recrudescence&#x2F;reinfection.</p><p>A participant was considered as PCR-corrected ACPR if the participant did not meet any of the criteria of early treatment failure, late clinical failure or late parasitological failure and had absence of parasitemia on Days 15, 29 or 43 irrespective of axillary temperature unless the presence of parasitemia after 7 days was due to reinfection based on PCR.\nA presence of parasitemia after 7 days of treatment initiation was considered as a reinfection only if the parasitemia was clear before Day 8 and none of the parasite strain(s) detected on Day 8 or later matched with the parasite strain at baseline based on PCR.</p>, timeFrame - Days 15, 29 and 43",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04300309",
    "endpoint": "measure - PCR-corrected Adequate Clinical and Parasitological Response (ACPR) - FAS Analysis, description - <p>PCR-corrected ACPR, defined as the absence of parasitemia, was evaluated on Days 15, 29 and 43.\nMicroscopic species identification was confirmed and determined by polymerase chain reaction (PCR) genotyping methods to establish malaria recrudescence&#x2F;reinfection.</p><p>A participant was considered as PCR-corrected ACPR if the participant did not meet any of the criteria of early treatment failure, late clinical failure or late parasitological failure and had absence of parasitemia on Days 15, 29 or 43 irrespective of axillary temperature unless the presence of parasitemia after 7 days was due to reinfection based on PCR.\nA presence of parasitemia after 7 days of treatment initiation was considered as a reinfection only if the parasitemia was clear before Day 8 and none of the parasite strain(s) detected on Day 8 or later matched with the parasite strain at baseline based on PCR.</p>, timeFrame - Days 15, 29 and 43",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04300309",
    "endpoint": "measure - PCR-uncorrected Adequate Clinical and Parasitological Response (ACPR), description - <p>PCR-uncorrected ACPR, defined as the absence of parasitemia, was evaluated on Days 8, 15, 29 and 43.</p><p>A participant was considered as PCR-uncorrected ACPR if the participant did not meet any of the criteria of early treatment failure, late clinical failure or late parasitological failure and had absence of parasitemia on Days 8, 15, 29 or 43 irrespective of axillary temperature.</p>, timeFrame - Days 8, 15, 29 and 43",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04300309",
    "endpoint": "measure - Number of Participants With Recrudescence Events, description - Recrudescence is defined as appearance of asexual parasites after clearance of initial infection with a genotype identical to that of parasites present at baseline.\nRecrudescence had to be confirmed by PCR analysis., timeFrame - Days 15, 29 and 43",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04300309",
    "endpoint": "measure - Number of Participants With New Infections Events, description - New infection is defined as appearance of asexual parasites after clearance of initial infection with a genotype different from those parasites present at baseline.\nNew infection had to be confirmed by PCR analysis., timeFrame - Days 15, 29 and 43",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04300309",
    "endpoint": "measure - Number of Participants With Adverse Events (AEs), description - Number of participants with adverse events (any AEs regardless of seriousness), including changes in laboratory results qualifying and reported as adverse events., timeFrame - From first dose of study treatment until Day 43",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04300309",
    "endpoint": "measure - Number of Participants With Serious Adverse Events (SAEs), description - Number of participants with serious adverse events (SAEs), including changes in laboratory results qualifying and reported as serious adverse events., timeFrame - From first dose of study treatment until 12 months of age (assessed up to maximum 1 year)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02996695",
    "endpoint": "measure - Antibody titers against P. falciparum circumsporozoite protein (CSP) and other P. falciparum proteins at serology time points, description - , timeFrame - Days 3, 15, 31, 43,59, 71-77,87,245,and 413",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02996695",
    "endpoint": "measure - Markers of cell-mediated immunity as assessed by cells producing interferon gamma and&#x2F;or IL-2, description - , timeFrame - Days 3, 15, 31, 43,59, 71-77,87,245,and 413",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02996695",
    "endpoint": "measure - Time to P. falciparum parasitemia, detected by qPCR, description - , timeFrame - within six months after the last vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02996695",
    "endpoint": "measure - Time to P. falciparum parasitemia, detected by qPCR, description - , timeFrame - within twelve months after the last vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02996695",
    "endpoint": "measure - Time to P. falciparum parasitemia, detected by thick blood film microscopy, description - , timeFrame - within twelve months after the last vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02996695",
    "endpoint": "measure - Time to P. falciparum parasitemia, detected by thick blood smear microscopy, description - , timeFrame - Within six months after the last vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00461578",
    "endpoint": "measure - Parasite clearance, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00461578",
    "endpoint": "measure - Fever clearance, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00461578",
    "endpoint": "measure - Occurrence of adverse events, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03490162",
    "endpoint": "measure - Plasma levels of a single dose of DM1157 taken after food ingestion, description - , timeFrame - Day 1 through Day 14",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03490162",
    "endpoint": "measure - Plasma levels of multiple ascending dose (MAD) of DM1157, description - , timeFrame - Day 1 through Day 18",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03490162",
    "endpoint": "measure - Plasma levels of single ascending dose (SAD) of DM1157, description - , timeFrame - Day 1 through Day 14",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00422084",
    "endpoint": "measure - PCR-corrected Adequate Clinical and Parasitological Response (ACPR) on Day 14, description - Percentage of subjects with PCR-corrected adequate clinical and parasitological response (ACPR) on Day 14, defined as absence of parasitaemia on Day 14 without the subject&#x27;s meeting any of the criteria of early treatment failure, late clinical failure, or late parasitological failure., timeFrame - Day 14",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00422084",
    "endpoint": "measure - Crude ACPR (Non-PCR Corrected ACPR) on Day 14 and Day 28, description - Percentage of subjects with adequate clinical and parasitological response (ACPR) on Day 28, without correction by PCR, defined as absence of parasitaemia on Day 28 without the subject&#x27;s meeting any of the criteria of early treatment failure, late clinical failure, or late parasitological failure., timeFrame - Day 14 and 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00422084",
    "endpoint": "measure - Parasite Clearance Time, description - Parasite clearance time is defined as the time from first dosing to the time of first blood draw with parasite clearance.\nParasite clearance is defined as zero presence of asexual parasites for 2 consecutive negative readings taken between 7 and 25 hours apart., timeFrame - Days 0, 3, 7, 14, 21, 28, 35, and 42 (or on any other day if the subject spontaneously returned)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00422084",
    "endpoint": "measure - Fever Clearance Time, description - Fever clearance time is defined as the time from first dosing to first normal reading of temperature for 2 consecutive normal temperature readings taken between 7 and 25 hours apart, timeFrame - Day 0 and every 8 hours over ≥72 hours following first study drug administration or temperature normalization for ≥2 readings between 7 and 25 hours apart, then at each visit and as clinically indicated",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00422084",
    "endpoint": "measure - Percentage of Patients With Fever Clearance at Day 1, 2 and 3, description - Fever clearance time is defined as the time from first dosing to first normal reading of temperature for 2 consecutive normal temperature readings taken between 7 and 25 hours apart., timeFrame - Days 1, 2, 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00422084",
    "endpoint": "measure - Proportion of Patients With Parasite Clearance at Day 1, 2 and 3, description - Parasite clearance time is defined as the time from first dosing to the time of first blood draw with parasite clearance.\nParasite clearance was defined as zero presence of asexual parasites for 2 consecutive negative readings taken between 7 and 25 hours apart., timeFrame - Days 1, 2, 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00422084",
    "endpoint": "measure - Adverse Events and Clinically Significant Laboratory Results, description - Incidence of adverse events and of clinically significant laboratory results, ECG, vital signs or physical examination abnormalities., timeFrame - Day 0 to 42. Subjects experiencing AEs at Day 42 were followed for up to 30 days after the end of study or resolution of the event, whichever was earlier",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02431637",
    "endpoint": "measure - Safety: Number of AEs, description - Adverse events incidence, timeFrame - Blood stage Plasmodium falciparum Challenge Inoculum up to Day 31",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00379821",
    "endpoint": "measure - Number of Participants With Day 28 Adequate Clinical and Parasitologic Response in Each Treatment Arm, description - Adequate clinical and parasitologic response (ACPR) was defined as the absence of parasitemia at Day 28 and without previously meeting any of the criteria of early treatment or late clinical failure., timeFrame - Day 28 of initial malaria episode (Episode 0)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00379821",
    "endpoint": "measure - Number of Participants With Day 28 Adequate Clinical and Parasitologic Response in Each Treatment Arm, description - Adequate clinical and parasitologic response (ACPR) was defined as the absence of parasitemia at Day 28 and without previously meeting any of the criteria of early treatment or late clinical failure., timeFrame - Day 28 of first subsequent malaria episode (Episode 1)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00379821",
    "endpoint": "measure - Number of Participants With Day 28 Adequate Clinical and Parasitologic Response in Each Treatment Arm, description - Adequate clinical and parasitologic response (ACPR) was defined as the absence of parasitemia at Day 28 and without previously meeting any of the criteria of early treatment or late clinical failure., timeFrame - Day 28 of second subsequent malaria episode (Episode 2)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00379821",
    "endpoint": "measure - Number of Participants With Day 28 Adequate Clinical and Parasitologic Response in Each Treatment Arm, description - Adequate clinical and parasitologic response (ACPR) was defined as the absence of parasitemia at Day 28 and without previously meeting any of the criteria of early treatment or late clinical failure., timeFrame - Day 28 of third subsequent malaria episode (Episode 3)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00379821",
    "endpoint": "measure - Number of Participants With Day 28 Adequate Clinical and Parasitologic Response in Each Treatment Arm, description - Adequate clinical and parasitologic response (ACPR) was defined as the absence of parasitemia at Day 28 and without previously meeting any of the criteria of early treatment or late clinical failure., timeFrame - Day 28 of fourth subsequent malaria episode (Episode 4)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00379821",
    "endpoint": "measure - Number of Cases of Severe Malaria in Each Treatment Arm, description - A case of severe malaria included one or more of the following: Hemoglobin ≤5 g&#x2F;dL; prostration; respiratory distress; bleeding; recent seizures, coma or obtundation (Blantyre coma score &lt; 5); inability to drink, or persistent vomiting.\nAll cases were then adjudicated by a panel of investigators prior to analysis., timeFrame - 1 Year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00379821",
    "endpoint": "measure - Mean Hemoglobin at the Last Study Visit in Each Treatment Arm for the Age Group of Participants 3 Years of Age or Younger., description - Hemoglobin values were assessed from blood collected at the last study visit at one year after enrollment.\nGroup means are stratified by participants 3 years of age and under, and over 3 to 5 years of age., timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00379821",
    "endpoint": "measure - Mean Hemoglobin at the Last Study Visit in Each Treatment Arm for the Age Group of Participants Greater Than 3 Years to 5 Years of Age., description - Hemoglobin values were assessed from blood collected at the last study visit at one year after enrollment.\nGroup means are stratified by participants 3 years of age and under, and over 3 to 5 years of age., timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00379821",
    "endpoint": "measure - Mean Creatinine in Each Treatment Arm (Renal Function), description - Creatine values were assessed from blood draws at Day 0 and Day 14 of each malaria episode.\nSamples that were below the limit of detection were reported as 44.2 micromoles&#x2F;liter, equivalent to the lower limit of detection., timeFrame - Day 0 of initial malaria episode (Episode 0)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00379821",
    "endpoint": "measure - Mean Creatinine in Each Treatment Arm (Renal Function), description - Creatine values were assessed from blood draws at Day 0 and Day 14 of each malaria episode.\nSamples that were below the limit of detection were reported as 44.2 micromoles&#x2F;liter, equivalent to the lower limit of detection., timeFrame - Day 14 of initial malaria episode (Episode 0)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00379821",
    "endpoint": "measure - Mean Creatinine in Each Treatment Arm (Renal Function), description - Creatine values were assessed from blood draws at Day 0 and Day 14 of each malaria episode.\nSamples that were below the limit of detection were reported as 44.2 micromoles&#x2F;liter, equivalent to the lower limit of detection., timeFrame - Day 0 of first subsequent malaria episode (Episode 1)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00379821",
    "endpoint": "measure - Mean Creatinine in Each Treatment Arm (Renal Function), description - Creatine values were assessed from blood draws at Day 0 and Day 14 of each malaria episode.\nSamples that were below the limit of detection were reported as 44.2 micromoles&#x2F;liter, equivalent to the lower limit of detection., timeFrame - Day 14 of first subsequent malaria episode (Episode 1)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00379821",
    "endpoint": "measure - Mean Creatinine in Each Treatment Arm (Renal Function), description - Creatine values were assessed from blood draws at Day 0 and Day 14 of each malaria episode.\nSamples that were below the limit of detection were reported as 44.2 micromoles&#x2F;liter, equivalent to the lower limit of detection., timeFrame - Day 0 of second subsequent malaria episode (Episode 2)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00379821",
    "endpoint": "measure - Mean Creatinine in Each Treatment Arm (Renal Function), description - Creatine values were assessed from blood draws at Day 0 and Day 14 of each malaria episode.\nSamples that were below the limit of detection were reported as 44.2 micromoles&#x2F;liter, equivalent to the lower limit of detection., timeFrame - Day 14 of second subsequent malaria episode (Episode 2)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00379821",
    "endpoint": "measure - Mean Creatinine in Each Treatment Arm (Renal Function), description - Creatine values were assessed from blood draws at Day 0 and Day 14 of each malaria episode.\nSamples that were below the limit of detection were reported as 44.2 micromoles&#x2F;liter, equivalent to the lower limit of detection., timeFrame - Day 0 of third subsequent malaria episode (Episode 3)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00379821",
    "endpoint": "measure - Mean Creatinine in Each Treatment Arm (Renal Function), description - Creatine values were assessed from blood draws at Day 0 and Day 14 of each malaria episode.\nSamples that were below the limit of detection were reported as 44.2 micromoles&#x2F;liter, equivalent to the lower limit of detection., timeFrame - Day 14 of third subsequent malaria episode (Episode 3)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00379821",
    "endpoint": "measure - Mean Creatinine in Each Treatment Arm (Renal Function), description - Creatine values were assessed from blood draws at Day 0 and Day 14 of each malaria episode.\nSamples that were below the limit of detection were reported as 44.2 micromoles&#x2F;liter, equivalent to the lower limit of detection., timeFrame - Day 0 of fourth subsequent malaria episode (Episode 4)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00379821",
    "endpoint": "measure - Mean Creatinine in Each Treatment Arm (Renal Function), description - Creatine values were assessed from blood draws at Day 0 and Day 14 of each malaria episode.\nSamples that were below the limit of detection were reported as 44.2 micromoles&#x2F;liter, equivalent to the lower limit of detection., timeFrame - Day 14 of fourth subsequent malaria episode (Episode 4)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00379821",
    "endpoint": "measure - Mean Alanine Transaminase (ALT) in Each Treatment Arm (Hepatic Function), description - ALT values were assessed from blood draws at Day 0 and Day 14 of each malaria episode., timeFrame - Day 0 of initial malaria episode (Episode 0)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00379821",
    "endpoint": "measure - Mean Alanine Transaminase (ALT) in Each Treatment Arm (Hepatic Function), description - ALT values were assessed from blood draws at Day 0 and Day 14 of each malaria episode., timeFrame - Day 14 of initial malaria episode (Episode 0)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00379821",
    "endpoint": "measure - Mean Alanine Transaminase (ALT) in Each Treatment Arm (Hepatic Function), description - ALT values were assessed from blood draws at Day 0 and Day 14 of each malaria episode., timeFrame - Day 0 of first subsequent malaria episode (Episode 1)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00379821",
    "endpoint": "measure - Mean Alanine Transaminase (ALT) in Each Treatment Arm (Hepatic Function), description - ALT values were assessed from blood draws at Day 0 and Day 14 of each malaria episode., timeFrame - Day 14 of first subsequent malaria episode (Episode 1)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00379821",
    "endpoint": "measure - Mean Alanine Transaminase (ALT) in Each Treatment Arm (Hepatic Function), description - ALT values were assessed from blood draws at Day 0 and Day 14 of each malaria episode., timeFrame - Day 0 of second subsequent malaria episode (Episode 2)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00379821",
    "endpoint": "measure - Mean Alanine Transaminase (ALT) in Each Treatment Arm (Hepatic Function), description - ALT values were assessed from blood draws at Day 0 and Day 14 of each malaria episode., timeFrame - Day 14 of second subsequent malaria episode (Episode 2)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00379821",
    "endpoint": "measure - Mean Alanine Transaminase (ALT) in Each Treatment Arm (Hepatic Function), description - ALT values were assessed from blood draws at Day 0 and Day 14 of each malaria episode., timeFrame - Day 0 of third subsequent malaria episode (Episode 3)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00379821",
    "endpoint": "measure - Mean Alanine Transaminase (ALT) in Each Treatment Arm (Hepatic Function), description - ALT values were assessed from blood draws at Day 0 and Day 14 of each malaria episode., timeFrame - Day 14 of third subsequent malaria episode (Episode 3)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00379821",
    "endpoint": "measure - Mean Alanine Transaminase (ALT) in Each Treatment Arm (Hepatic Function), description - ALT values were assessed from blood draws at Day 0 and Day 14 of each malaria episode., timeFrame - Day 0 of fourth subsequent malaria episode (Episode 4)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00379821",
    "endpoint": "measure - Mean Alanine Transaminase (ALT) in Each Treatment Arm (Hepatic Function), description - ALT values were assessed from blood draws at Day 0 and Day 14 of each malaria episode., timeFrame - Day 14 of fourth subsequent malaria episode (Episode 4)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00379821",
    "endpoint": "measure - Number of Participants in Each Treatment Arm Who Change From &quot;Normal&quot; to &quot;Abnormal&quot; on Any Questions of the Neurological Examination, description - A basic age-appropriate neurological examination was conducted on Day 28 of each malaria illness episode and also at Days 112 and 224, and at 1 year.\nSubjects were were counted as a &quot;change from &#x27;normal&#x27; to &#x27;abnormal&#x27; &quot; if they had the &#x27;normal&#x27; (or not-applicable) response for the initial day 28 exam and an &#x27;abnormal&#x27; response at their last exam.\nIf a subject did not have an exam at 1 year then the last available exam that was not associated with an illness episode (either Day 112 or 224) was used., timeFrame - 1 Year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00379821",
    "endpoint": "measure - Number of Participants Infected With Parasites With the Mutation Pfcrt 76T on Day 0 of the Initial Episode of Malaria, description - The presence of parasites with the mutation pfCRT 76T was measured with filter paper specimens collected at the time of enrollment and with successful parasite DNA amplification using pyrosequencing., timeFrame - Day 0 of initial episode of malaria",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00379821",
    "endpoint": "measure - Number of Participants Infected With Parasites With the Mutation Pfcrt 76T at Recrudescent Episodes of Malaria, description - Participants were enrolled in the study at the time of the initial episode of malaria.\nIf the participant presented with a subsequent episode of malaria at any time during the one year of follow-up, the presence of parasites with the mutation pfCRT 76T was measured with filter paper specimens collected at the time of enrollment and with successful parasite DNA amplification using pyrosequencing., timeFrame - Recrudescent episodes of malaria within one year of enrollment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00379821",
    "endpoint": "measure - Number of Participants With New and Recrudescent Malaria Infections After Initial Treatment, description - Participants were enrolled at the time of initial malaria episode and treated.\nSubsequent to treatment, subjects were monitored for the occurrence of new and recrudescent malaria infections, which were distinguished by analysis of the infecting parasites using merozoite surface protein-2 polymorphic gene length variation., timeFrame - 28 days to 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00379821",
    "endpoint": "measure - Number of Participants With New and Recrudescent Infections After Subsequent New Episodes, description - Participants were enrolled at the time of initial malaria episode and treated.\nSubsequent to treatment, participants who subsequently suffered new malaria episodes were monitored for the additional occurrence of new and recrudescent malaria infections, which were distinguished by analysis of the infecting parasites using merozoite surface protein-2 polymorphic gene length variation., timeFrame - Day 28 to 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00379821",
    "endpoint": "measure - Time to First Malaria Episode in Participants Who Travelled and Slept Outside the City Versus Those Who Did Not Travel and Sleep Outside the City., description - The cumulative hazard of having a malaria attack within one year for those participants who travelled and slept in rural areas (outside the city) versus those who did not was calculated and is presented as a life table to display the number of subjects at risk, the number with first clinical episode and the number censored at each time point.\nParticipants are right-censored at the time of first malaria episode.\nParticipants who did not develop malaria during follow-up or were lost to follow-up were censored at the time of their last visit., timeFrame - Days 0 - 420",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00379821",
    "endpoint": "measure - Nearest Neighbor Index as a Measure of Spatial Pattern of the Distribution of Malaria Cases in Ndirande, description - The Global Positioning System (GPS) was used to establish the coordinates of participants&#x27; homes.\nThe distribution of these coordinates was analyzed for evidence of clustering, or occurring closer together than would be expected on the basis of chance.\nNearest Neighbor Index is a ratio of the observed mean distance over the expected mean distance.\nIf the index is less than 1, the pattern exhibits clustering.\nIf the index is greater than 1, the trend is toward dispersion., timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00379821",
    "endpoint": "measure - Pharmacokinetics of Chloroquine Represented by Time of Maximal Concentration (Tmax) and Chloroquine Half-life, description - 1727 non-zero concentration measurements from 479 participants were pooled and used for population pharmacokinetic modeling in Monolix413s.\nCompartmental population pharmacokinetic modeling was used due to highly sparse data.\nThe model was parameterized in terms of absorption rate constant for chloroquine (Ka), apparent clearance for chloroquine (CL&#x2F;F, with F as the unknown oral bioavailability), apparent volume of distribution of the central and peripheral compartments for chloroquine (Vd&#x2F;F), and the inter-compartmental clearance for chloroquine (Q&#x2F;F).\nOnly these primary population pharmacokinetic parameters could be estimated using the type of data collected.\nThe best-fit population PK model was then used to estimate individual parameter estimates to derive Tmax and half-life., timeFrame - Day 0 - Day 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00379821",
    "endpoint": "measure - Pharmacokinetics of Chloroquine Represented by Maximum Concentration (Cmax), description - 1727 non-zero concentration measurements from 479 participants were pooled and used for population pharmacokinetic modeling in Monolix413s.\nCompartmental population pharmacokinetic modeling was used due to highly sparse data.\nThe model was parameterized in terms of absorption rate constant for chloroquine (Ka), apparent clearance for chloroquine (CL&#x2F;F, with F as the unknown oral bioavailability), apparent volume of distribution of the central and peripheral compartments for chloroquine (Vd&#x2F;F), and the inter-compartmental clearance for chloroquine (Q&#x2F;F).\nOnly these primary population pharmacokinetic parameters could be estimated using the type of data collected.\nThe best-fit population PK model was then used to estimate individual parameter estimates to derive Cmax in nanograms per milliliter (ng&#x2F;mL)., timeFrame - Day 0 - Day 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02590627",
    "endpoint": "measure - parasite clearance after 72 hours., description - Microscope Blood slide for malaria reading 0 parasite., timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02590627",
    "endpoint": "measure - parasitological cure on day 14, description - Microscope Blood slide for malaria reading 0 parasite., timeFrame - 14 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02590627",
    "endpoint": "measure - extended parasitological cure on day 42 for ALu and 63 for DHA-PQ, description - PCR and Microscope Blood slide for malaria parasitemia reading 0., timeFrame - 63 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02590627",
    "endpoint": "measure - improvement in haemoglobin level at day 28 from the day 0 baseline, description - , timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02590627",
    "endpoint": "measure - reduction in gametocyte carriage at day 14 and day 28 from the day 0 baseline,, description - , timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02590627",
    "endpoint": "measure - occurrence and severity of adverse events and genomic profile of P.falciparum., description - , timeFrame - 63 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03988296",
    "endpoint": "measure - Statistical association between risk factors and diagnostic assays results., description - A brief enrollment questionnaire will be used to determine a statistical association between demographic and behavioral&#x2F;occupational risk factors and the assays results combined, timeFrame - 10 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02783820",
    "endpoint": "measure - PK Cmax, description - Estimation of the maximum plasma concentration over 28 days post administration of a single dose of MMV390048 using non-compartmental methods, timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02783820",
    "endpoint": "measure - PK Tmax, description - Estimation of the time to maximum plasma concentration over 28 days post administration of a single dose of MMV390048 using non-compartmental methods, timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02783820",
    "endpoint": "measure - PK Total Exposure AUClast, description - Estimation of the last quantifiable concentration over 28 days post administration of a single dose of MMV390048 using non-compartmental methods, timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02783820",
    "endpoint": "measure - PK Total Exposure AUCinf, description - Estimation of the area under the plasma concentration time curve over 28 days post administration of a single dose of MMV390048 using non-compartmental methods, timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02783820",
    "endpoint": "measure - PK Distribution and Clearance (CL&#x2F;F), description - Apparent oral clearance (CL&#x2F;F) over 28 days post administration of a single dose of MMV390048 using non-compartmental methods, timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02783820",
    "endpoint": "measure - PK Distribution and Clearance (Vz&#x2F;F), description - Apparent volume of distribution (Vz&#x2F;F) over 28 days post administration of a single dose of MMV390048 using non-compartmental methods, timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02783820",
    "endpoint": "measure - PK Distribution and Clearance (t½), description - Terminal half-life (t½) over 28 days post administration of a single dose of MMV390048 using non-compartmental methods, timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00203736",
    "endpoint": "measure - Association between study treatment and gametocyte carriage, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00203736",
    "endpoint": "measure - Pharmacokinetics by measurement of whole blood levels of Sulfadoxine and Pyrimethamine, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00203736",
    "endpoint": "measure - Correlation of frequency of DHFR and DHPS mutations with parasitological outcome, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00203736",
    "endpoint": "measure - Tolerability by describing adverse events and changes in haematological parameters, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00203736",
    "endpoint": "measure - Capacity by describing the training and development of study teams, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01837992",
    "endpoint": "measure - Safety and toxicity (1): Numbers with mild adverse events, description - Numbers in each treatment arm experiencing any documented adverse event defined as &quot;mild&quot; (not severe enough to interfere with daily activities)., timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01837992",
    "endpoint": "measure - Safety and toxicity (2) Numbers with moderate adverse events, description - Numbers in each treatment arm experiencing any documented adverse event defined as &quot;moderate&quot; (severe enough to interfere with daily activities but not severe enough to warrant admission to hospital)., timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01837992",
    "endpoint": "measure - Safety and toxicity (3) Numbers with severe adverse events, description - Numbers in each treatment arm experiencing any documented adverse event defined as &quot;severe&quot; (severe to warrant admission to hospital or to be considered a risk for death or disability arising from the event)., timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01837992",
    "endpoint": "measure - Safety and toxicity (4) Numbers with any adverse events, description - Numbers in each treatment arm experiencing any documented event (defined as either mild, moderate or severe as above)., timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01837992",
    "endpoint": "measure - Safety and toxicity (5) Numbers with assumed significant haemolysis, description - <p>Numbers in each treatment arm experiencing any of the following:</p><ol><li>Haemoglobinuria on dipstick examination</li><li>Scleral icterus</li><li>Haemoglobin concentration fall by more than 25% of baseline or absolute concentration &lt;5g&#x2F;dL</li></ol>, timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01837992",
    "endpoint": "measure - Safety and toxicity (6) Numbers with significant methaemoglobinaemia, description - <p>Numbers in each treatment arm experiencing any of the following:</p><ol><li>Cyanosis (blue tongue, lips and peripheries)</li><li>Measured methaemoglobin saturation (using Masimo Rad-57 plus oximeter) &gt;15%</li><li>Measured oxygen saturation &lt;85%</li></ol>, timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01150344",
    "endpoint": "measure - Parasitological cure rate, description - , timeFrame - At day 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01150344",
    "endpoint": "measure - Fever clearance, description - , timeFrame - At day 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01150344",
    "endpoint": "measure - Digestive tolerance, description - , timeFrame - At day 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01150344",
    "endpoint": "measure - Number of relapses, description - , timeFrame - At day 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04566510",
    "endpoint": "measure - Prevalence of Parasitaemia, description - Proportion of children aged 2-10 years at the time of cross-sectional surveys with blood smears positive for parasites by microscopy, timeFrame - 12 months following LLIN distribution",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04566510",
    "endpoint": "measure - Prevalence of Parasitaemia, description - Proportion children aged 2-10 years at the time of cross-sectional surveys with blood smears positive for parasites by microscopy, timeFrame - 24 months following LLIN distribution",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04566510",
    "endpoint": "measure - Prevalence of Anaemia, description - Proportion of children aged 2-4 years with haemoglobin &lt; 11 g&#x2F;dL at the time of cross-sectional surveys, timeFrame - 12 months following LLIN distribution",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04566510",
    "endpoint": "measure - Prevalence of Anaemia, description - Proportion of children aged 2-4 years with haemoglobin &lt; 11 g&#x2F;dL at the time of cross-sectional surveys, timeFrame - 24 months following LLIN distribution",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04566510",
    "endpoint": "measure - Proportion of Households That Owned at Least One LLIN, description - Proportion of households with at least one LLIN at the time of cross-sectional surveys, timeFrame - 12 months following LLIN distribution",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04566510",
    "endpoint": "measure - Proportion of Households That Owned at Least One LLIN, description - Proportion of households with at least one LLIN at the time of cross-sectional surveys, timeFrame - 24 months following LLIN distribution",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04566510",
    "endpoint": "measure - Proportion of Households That Owned at Least One LLIN for Every Two Occupants, description - Proportion of households with at least one LLIN per every two occupants at the time of cross-sectional surveys, timeFrame - 12 months following LLIN distribution",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04566510",
    "endpoint": "measure - Proportion of Households That Owned at Least One LLIN for Every Two Occupants, description - Proportion of households with at least one LLIN per every two occupants at the time of cross-sectional surveys, timeFrame - 24 months following LLIN distribution",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04566510",
    "endpoint": "measure - Proportion of Household Residents Who Slept Under an LLIN the Previous Night, description - Proportion of households residents who report sleeping under LLIN the previous night at the time of cross-sectional surveys, timeFrame - 12 months following LLIN distribution",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04566510",
    "endpoint": "measure - Proportion of Household Residents Who Slept Under an LLIN the Previous Night, description - Proportion of households residents who report sleeping under LLIN the previous night at the time of cross-sectional surveys, timeFrame - 24 months following LLIN distribution",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01450280",
    "endpoint": "measure - Assessment of immune response induced by vaccination, description - To assess the humoral and cellular immune responses generated by ChAd63 CS when administered to healthy volunteers alone and with MVA CS by assessing induced antibody and T cell response to the vaccine insert., timeFrame - Participants will be followed for the duration of the study, an expected average of 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00331708",
    "endpoint": "measure - Association of gametocyte carriage with pregnancy status, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00331708",
    "endpoint": "measure - Correlation of frequency of DHFR mutations at codons 108, 51, 59 (164) and DHPS mutations at codons 436, 437, 540 and 581 in maternal and placental samples with treatment outcome, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00331708",
    "endpoint": "measure - Birth outcomes in terms of congenital abnormalities, spontaneous abortions, still births and neonatal deaths, gestational age and birth weight, placental weight, newborn head circumference, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00331708",
    "endpoint": "measure - Risk of harm by describing adverse events and their causality assessments, neurodevelopmental assessment of infants and changes in full blood count (or haemoglobin), glucose, bilirubin, creatinine, urea and ALT, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00331708",
    "endpoint": "measure - Capacity building by describing the training and development of study teams and their subsequent skills attained., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05842954",
    "endpoint": "measure - Uncorrected ACPR, description - To further confirm the efficacy of KLU156 by demonstrating non-inferiority of KLU156 to Coartem (NI margin 7.5%) based on the uncorrected ACPR at Day 29, timeFrame - Day 29",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05842954",
    "endpoint": "measure - PCR-corrected and uncorrected ACPR, description - To confirm the efficacy of KLU156 by assessing uncorrected and PCR-corrected ACPR at additional time points, timeFrame - Days 22 and 43 (i.e., 21 and 42 days post-first dose administration)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05842954",
    "endpoint": "measure - Incidence rate of recrudescence and new infection, description - Proportion of patients with recrudescence and new infections between the two treatment arms, timeFrame - Days 22, 29 and 43",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05842954",
    "endpoint": "measure - Fever Clearance Time, description - To confirm the efficacy of KLU156 by assessing fever clearance between the two treatment arms, timeFrame - Up to Day 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05842954",
    "endpoint": "measure - Parasite Clearance Time, description - To assess parasite clearance time between the two treatment arms, timeFrame - Up to Day 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05842954",
    "endpoint": "measure - Gametocyte Clearance Time, description - To confirm the efficacy of KLU156 by assessing gametocyte clearance between the two treatment arms, timeFrame - Up to Day 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05842954",
    "endpoint": "measure - Proportion of patients with parasitemia, description - For the parasitemia assessment, blood sampling can be done by means of a finger prick except when the timing for parasitology assessments coincides with time for clinical laboratory tests, in which case, blood sample can be taken from the venous blood collected for clinical laboratory analyses., timeFrame - 12, 24, 48 and 72 hours after treatment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05842954",
    "endpoint": "measure - Gametocytemia, description - Disappearance or development of gametocytemia in patients with or without gametocytemia at baseline (pre-first dose administration), respectively, timeFrame - From baseline up to Day 43",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05842954",
    "endpoint": "measure - Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs), description - Incidence and severity of AEs and SAEs by treatment group, including changes in vital signs, electrocardiograms (ECGs), and laboratory results qualifying and reported as AEs., timeFrame - Day 43",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05842954",
    "endpoint": "measure - Extension phase: PCR-corrected and uncorrected ACPR, description - To evaluate efficacy over repeated treatment with KLU156 in adults and children ≥ 10 kg of body weight suffering from uncomplicated malaria caused by P. falciparum (with or without other Plasmodium spp.\nco-infection) for a maximum of 2 years, timeFrame - Day 29 of malaria episode",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05842954",
    "endpoint": "measure - Extension phase: KLU156-related AE&#x2F;SAE incidence and severity by malaria episode, description - To assess the safety and tolerability over repeated treatment with KLU156 in adults and children ≥ 10 kg of body weight suffering from uncomplicated malaria caused by P. falciparum (with or without other Plasmodium spp.\nco-infection) for a maximum of 2 years, timeFrame - Up to 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05842954",
    "endpoint": "measure - Extension phase: Gametocyte carriage over time, description - To assess gametocyte carriage over time by malaria episode in the extension phase, timeFrame - Up to 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01003314",
    "endpoint": "measure - Humoral and cellular immune responses generated by AdCh63 MSP1, when administered to healthy volunteers alone, with MVA MSP1, and following sporozoite challenge. Efficacy of AdCh63 MSP1 and MVA MSP1 against malaria sporozoite challenge, description - , timeFrame - Up to 6 months post enrollment into the study",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01994525",
    "endpoint": "measure - Identify and validate immunological PBMC biomarkers, description - Compare Peripheral Blood Mononuclear Cell(s) (PBMC) read-outs between protected and nonprotected subjects and between immunized and mock-immunized subjects., timeFrame - 52 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01994525",
    "endpoint": "measure - Identify and validate immunological serum biomarkers, description - Compare serum read-outs between protected and nonprotected subjects and between immunized and mock-immunized subjects., timeFrame - 52 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01994525",
    "endpoint": "measure - Identify and validate whole blood immunological biomarkers, description - Compare whole blood read-outs between protected and nonprotected subjects and between immunized and mock-immunized subjects., timeFrame - 52 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04370977",
    "endpoint": "measure - to evaluate the incidence of adverse events, description - Safety was assessed by administering a questionnaire about the nature and incidence of adverse events and serious adverse events.\nAn adverse event is defined as any unfavorable, unintended sign, symptom, syndrome or disease that develops or worsens with the use of a medicinal product, regardless of whether it is related to the medicinal product., timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04370977",
    "endpoint": "measure - To measure the Day PCR uncorrected cure rates of Artemether-Lumefantrine and Amodiaquine-Artesunate, description - This cure rate is defined as the proportion of patients with adequate clinical and parasitological response (ACPR) at Day 28, without PCR correction to differentiate recrudescences from new infections and hence considering as treatment failures all parasite recurrences., timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04370977",
    "endpoint": "measure - Evaluate the presence of Molecular Markers associated with sub optimum responses to ACTs, description - The presence of molecular marks is defined as presence of mutations in pfk13 and pfmdr1 (at codons 86, 184 and 1246) genes identified by Sanger sequencing of pre-treatment samples., timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02780154",
    "endpoint": "measure - Percent infectivity of each PfSPZ dose regimen, description - , timeFrame - Days 1-57",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02780154",
    "endpoint": "measure - Time to P. falciparum asexual parasitemia following experimental malaria challenge, description - , timeFrame - Days 1-57",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00203814",
    "endpoint": "measure - Association between study treatment and gametocyte carriage, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00203814",
    "endpoint": "measure - Pharmacokinetics by measurement of whole blood levels of Sulfadoxine and Pyrimethamine, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00203814",
    "endpoint": "measure - Correlation of the frequency of DHFR and DHPS mutations with parasitological outcome, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00203814",
    "endpoint": "measure - Tolerability by describing adverse events and changes in haematological parameters, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00203814",
    "endpoint": "measure - Capacity building by describing the training and development of study teams and their subsequent skills attained, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02654912",
    "endpoint": "measure - Incidence of malaria confirmed by RDT or microscopy as measured through passive case detection at health posts and health centers, description - Quality-improved incidence of malaria data confirmed by malaria rapid diagnostic test (RDT) or microscopy as measured through passive case detection at health posts and health centers in the study area., timeFrame - 24 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02654912",
    "endpoint": "measure - PCR parasite prevalence among individuals participating at 0, 30 and 90 days following a reactive research response for a period of 24 months, description - Polymerase Chain Reaction (PCR)-based testing for malaria parasite prevalence of individuals participating in each community at 0, 30 and 90 days following a reactive research response for a period of 24 months, timeFrame - 24 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00307021",
    "endpoint": "measure - Occurrence of solicited general and local reactions., description - , timeFrame - Over a 7-day follow-up period after each vaccination.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00307021",
    "endpoint": "measure - Occurrence of unsolicited symptoms., description - , timeFrame - After each vaccination over a 30-day follow-up",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00307021",
    "endpoint": "measure - Anti-CS antibody titers., description - , timeFrame - Prior to vaccination, one month post Dose 2",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00307021",
    "endpoint": "measure - Anti-Hepatitis B surface agent (anti-HBs) antibody titers., description - , timeFrame - Prior to vaccination, one month post Dose 2 and one month post Dose 3.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00158548",
    "endpoint": "measure - Day 14 gametocyte prevalence, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00158548",
    "endpoint": "measure - Fever clearance time, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00158548",
    "endpoint": "measure - cure rate (elimination of parasitaemia without recrudescence)., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00158548",
    "endpoint": "measure - Rate and time of parasite clearance., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00158548",
    "endpoint": "measure - Rate of resolution of fever., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00158548",
    "endpoint": "measure - Proportion of gametocyte carriers., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00158548",
    "endpoint": "measure - Transmissibility of gametocytes through mosquito feeding studies., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00158548",
    "endpoint": "measure - Tolerability., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00158548",
    "endpoint": "measure - Molecular characterisation of genetic diversity and resistance before and after treatment., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00167843",
    "endpoint": "measure - Proportion of children with at least one episode of severe anemia, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00167843",
    "endpoint": "measure - Proportion of hospitalized children with anemia, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00167843",
    "endpoint": "measure - Proportion of hospitalized children with malaria, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00167843",
    "endpoint": "measure - Proportion of hospitalized children with any disease, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00167843",
    "endpoint": "measure - Proportion of children with at least one episode of anemia from 3 to 12 months of life, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00167843",
    "endpoint": "measure - Proportion of children with at least one episode of malaria from 3 to 12 months of life., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00167843",
    "endpoint": "measure - Parasite drug resistance after intermittent sulfadoxine-pyrimethamine and placebo application, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00167843",
    "endpoint": "measure - Multiplicity of P. falciparum infections after the intermittent treatment, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00167843",
    "endpoint": "measure - Antibody responses against variable parasite genes after the intermittent treatment, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00167843",
    "endpoint": "measure - Specific responses to malaria vaccine candidates during the study period, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01954264",
    "endpoint": "measure - Number of Subjects With Other Medical History Characteristics, Overall, description - The medical history characteristics were as follows: -subject sleep under a mosquito net night before visit (Ssumnnbv), New net - less than 1 year (Nn &lt; 1Y), Impregnated Bednet (Ib), Pierced&#x2F;torn bednet (P&#x2F;tb), How many holes of that size (HS)., timeFrame - At Epoch 1 (Survey visit) (approximately 35 days)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01954264",
    "endpoint": "measure - Number of Subjects by Age, According to P. Falciparum Infection Status, description - The annual age extended over a 0 year-9 years range.\nThe age characteristics were summarized by P. falciparum infection status., timeFrame - At Epoch 1 (Survey visit) (approximately 35 days)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01954264",
    "endpoint": "measure - Number of Subjects by JTEG Age Group, According to P. Falciparum Infection Status, description - The JTEG categorisation referred to the distribution of subjects by different age groups: 6 months to 4 years of age inclusive (0.5Y-4Y category) and 5 to 9 years of age inclusive (5-9Y category), tabulated according to P. falciparum infection status., timeFrame - At Epoch 1 (Survey visit) (approximately 35 days)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01954264",
    "endpoint": "measure - Number of Subjects by Gender, According to P. Falciparum Infection Status, description - The gender characteristics were summarized by P. falciparum infection status., timeFrame - At Epoch 1 (Survey visit) (approximately 35 days)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01954264",
    "endpoint": "measure - Number of Subjects With Plasmodium Species Other Than P. Falciparum, by JTEG Age Group and Per Total Centers, description - Other Plasmodium species included: P. Malariae, P. Vivax, P. Ovale with Negative and Positive results.\nA subjects was defined as infected by a specified parasitemia if at least two of the subject&#x27;s blood slide readings were positive for the corresponding parasitemia.\nThe results were tabulated according to JTEG age categorisation., timeFrame - At Epoch 1 (Survey visit) (approximately 35 days)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01954264",
    "endpoint": "measure - Number of Subjects With Anti-malarial Therapy, Overall, description - Anti-malarial therapy included Malaria treatment (MT) in past 14 days, Other medication (OM) in past 14 days and Malaria hospitalization (MH) in the last 3 months., timeFrame - At Epoch 1 (Survey visit) (approximately 35 days)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01954264",
    "endpoint": "measure - Number of Days With Therapy, Overall, description - The duration of anti-malarial therapy referred to the exact number of days of malaria treatment (EDMT) and the number of days of other medication (DOM).\nNote: * In case of several medication (malaria treatment or other medication) taken per subject, the maximum duration was computed for this study., timeFrame - At Epoch 1 (Survey visit) (approximately 35 days)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01954264",
    "endpoint": "measure - Days of Malaria Treatment, Overall, description - This endpoint presents results per total centers and across all age categories., timeFrame - At Epoch 1 (Survey visit) (approximately 35 days)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01954264",
    "endpoint": "measure - Number of Subjects With Fever, Overall, description - Characteristics of fever were the following: Fever in the last 24 hours (F 24h) and Fever* at visit (F* at V). Note: *Fever set to Yes if temperature recorded at visit after axillary conversion was ≥ 37.5 ◦C., timeFrame - At Epoch 1 (Survey visit) (approximately 35 days)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01954264",
    "endpoint": "measure - Days With Fever, Overall, description - This endpoint presents results per total centers and across all age categories., timeFrame - At Epoch 1 (Survey visit) (approximately 35 days)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01954264",
    "endpoint": "measure - Number of Persons With P. Falciparum Living in the Same Part of the House of Persons Enrolled in the Study (PLSPH-PES), Overall, description - The malaria prevention and risk factor presented in this endpoint was: Number of persons living in the same part of the house - persons enrolled in the study (PLSPH-PES), in the following combinations: &lt; y&#x2F;x, where x are persons enrolled in the study among less than y persons living in the same part of the house, y-z&#x2F;x, where x are persons enrolled in the study among y to z persons living in the same part of the house, &gt; z&#x2F;x, where x persons are enrolled in the study among more than z persons living in the same part of the house, y-z&#x2F;&gt; x, where more than x persons enrolled in the study among y to z persons living in the same part of the house, &gt; z&#x2F;&gt; x, where more than x persons enrolled in the study among more than z persons living in the same part of the house., timeFrame - At Epoch 1 (Survey visit) (approximately 35 days)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01954264",
    "endpoint": "measure - Descriptive Statistics for Number of Persons With P. Falciparum Living in the Same Part of the House of Persons Enrolled in the Study (PLSPH-PES), Overall, description - The malaria prevention and risk factor presented in this endpoint was: Number of persons living in the same part of the house (PLSPH)., timeFrame - At Epoch 1 (Survey visit) (approximately 35 days)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01954264",
    "endpoint": "measure - Number of Subjects With Different P. Falciparum Parasite Densities, Living in the Same House, by Center, description - The malaria prevention and risk factor for this endpoint was: Number of subjects living in the same part of the house - persons enrolled in the study (PLSPH-PES), in the following combinations: &lt; y&#x2F;x, where x are persons enrolled in the study among less than y persons living in the same part of the house, y-z&#x2F;x, where x are persons enrolled in the study among y to z persons living in the same part of the house, &gt; z&#x2F;x, where x persons are enrolled in the study among more than z persons living in the same part of the house, y-z&#x2F;&gt; x, where more than x persons enrolled in the study among y to z persons living in the same part of the house, &gt; z&#x2F;&gt; x, where more than x persons enrolled in the study among more than z persons living in the same part of the house.\nResults are presented for the Nouna-Burkina Faso (NOU-BF), Ouagadougou-Burkina Faso (OUA-BF), Keur Soce [Dakar area)-Senegal (DA-1-SE) and Naikhar (Dakar area)-Senegal (DA-2-SE) centers., timeFrame - At Epoch 1 (Survey visit) (approximately 35 days)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01954264",
    "endpoint": "measure - Descriptive Statistics for Subjects With Different P. Falciparum Parasite Densities, Living in the Same House, by Center, description - The malaria prevention and risk factor for this endpoint was: Number of subjects living in the same part of the house (PLSPH).\nResults are presented for the Nouna-Burkina Faso (NOU-BF), Ouagadougou-Burkina Faso (OUA-BF), Keur Soce [Dakar area)-Senegal (DA-1-SE) and Naikhar (Dakar area)-Senegal (DA-2-SE) centers., timeFrame - At Epoch 1 (Survey visit) (approximately 35 days)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01954264",
    "endpoint": "measure - Number of Subjects With P. Falciparum by Situation Area, Overall, description - The malaria prevention and risk factor characteristics for this endpoint were the following: Situation area (rural, urban, semi-rural) and Type of Location*.\nNote: *Large city = &gt;1 million habitants; Small city = &gt;50000 &amp; &lt; 1 million habitants ; Town = &gt; 10000 and &lt; 50000 habitants; Countryside = &lt; 10000 habitants., timeFrame - At Epoch 1 (Survey visit) (approximately 35 days)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01954264",
    "endpoint": "measure - Number of Subjects With Different P. Falciparum Densities by Situation Area and Center, description - The malaria prevention and risk factor characteristics were the following: Situation area (urban, rural, semi-rural) and Type of Location*.\nNote: *Large city = &gt;1 million habitants; Small city = &gt;50000 &amp; &lt; 1 million habitants ; Town = &gt; 10000 and &lt; 50000 habitants; Countryside = &lt; 10000 habitants.\nResults are presented for the Nouna-Burkina Faso (NOU-BF), Ouagadougou-Burkina Faso (OUA-BF), Keur Soce [Dakar area)-Senegal (DA-1-SE) and Naikhar (Dakar area)-Senegal (DA-2-SE) centers., timeFrame - At Epoch 1 (Survey visit) (approximately 35 days)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01954264",
    "endpoint": "measure - Number of Subjects With P. Falciparum by House Construction Material and Other House Information, Overall, description - The malaria prevention and risk factor characteristics for this endpoint were the following: - Main house construction material (MHCM) walls, floor, roof, windows&#x2F;eaves, nets; - Main source of drinking water (MSDW); - Presence of electricity (PE).\nNote: *Natural floor = earth, sand, dung; Rudimentary floor = wood planks, palm, bamboo.\n% Closed water source (piper water, tube well, dug well, protected well); Open water source (unprotected well, spring water, rainwater, tanker truck, surface water)., timeFrame - At Epoch 1 (Survey visit) (approximately 35 days)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01954264",
    "endpoint": "measure - Number of Subjects With Different P. Falciparum Parasite Densities, by House Information and Center, description - The malaria prevention and risk factor characteristics for this endpoint were the following: - Main house construction material (MHCM) walls, floor, roof, windows&#x2F;eaves, nets; - Main source of drinking water (MSDW); - Presence of electricity (PE).\nNatural floor = earth, sand, dung; Rudimentary floor = wood planks, palm, bamboo.\nClosed water source = pipe water, tube well, dug well, protected well; Open water source = unprotected well, spring water, rainwater, tanker truck, surface water.\nResults are presented for the Nouna-Burkina Faso (NOU-BF), Ouagadougou-Burkina Faso (OUA-BF), Keur Soce [Dakar area)-Senegal (DA-1-SE) and Naikhar (Dakar area)-Senegal (DA-2-SE) centers., timeFrame - At Epoch 1 (Survey visit) (approximately 35 days)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01704508",
    "endpoint": "measure - the safety of AL and DP, description - Self-reported signs and symptoms, clinical evaluations during treatment, day 7 and then weekly until day 42.\nleucocytes day 0, 3, 7, 14 and 21., timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01697852",
    "endpoint": "measure - Moderate to severe anaemia in children under 5 years, description - , timeFrame - 9 months post randomisation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01697852",
    "endpoint": "measure - Post-spraying prevalence of infection with malarial parasites in children 6 months to 10 years, description - , timeFrame - 6 months post randomisation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00118794",
    "endpoint": "measure - Incidence of severe anaemia by day 28, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00118794",
    "endpoint": "measure - Compliance, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00118794",
    "endpoint": "measure - Incidence of adverse events, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00118794",
    "endpoint": "measure - Parasitological failure by day 28, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00118794",
    "endpoint": "measure - Clinical and parasitological failure rates by day 14, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00118794",
    "endpoint": "measure - Fall in Hb of 2g&#x2F;dl or more from screening value, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01364883",
    "endpoint": "measure - Vaccine immunogenicity, description - To assess the immunogenicity of vaccination of healthy adults with AdCh63 ME-TRAP and MVA ME-TRAP according to vaccination schedules 1 to 7, timeFrame - Participants will be followed for the duration of the study, an expected average of 21months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02174900",
    "endpoint": "measure - Gametocyte clearance time, description - Gametocyte clearance time, timeFrame - 14 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02687373",
    "endpoint": "measure - Part 2 - Ratio of Pf +BS in experimental arm to Pf +BS in placebo arm to determine efficacy of PfSPZ Vaccine during 12 months after last dose, description - Efficacy against malaria of PfSPZ Vaccine administered to infants 5-12 months of age in 3 doses by passive and active surveillance for naturally acquired Pf infection, measured by blood smear microscopy, during 12 months following the last vaccine dose will be performed and the prevalence ratio of the prevalence of malaria infection by blood smear between each dose study arm and placebo will be compared., timeFrame - 2 weeks to 12 months after the last vaccine dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02687373",
    "endpoint": "measure - Part 2 - Ratio of Pf positive PCR in experimental arm to Pf positive PCR in placebo arm to determine efficacy against submicroscopic malaria infection of PfSPZ Vaccine following 6 and 12 months after the last dose, description - Efficacy against submicroscopic malaria infection of PfSPZ Vaccine administered to infants 5-12 months of age in 3 doses by passive and active surveillance for naturally acquired Pf infection, measured by PCR, during 6 and 12 months following the last vaccine dose., timeFrame - 2 weeks to 6 and 12 months after the last vaccine dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02687373",
    "endpoint": "measure - Part 2 - Assessment of Pf-specific antibodies, parasite-specific T cell responses and RNA sequencing., description - Collection of blood samples for Anti PfSPZ antibodies and RNA sequencing at different time points.\nFollowing vaccination serum will be taken and an assessment of Plasmodium falciparum (Pf)f-specific antibodies against specific malaria proteins such as the circumsporozoite protein (CSP) PfCSP and whole Pf sporozoites (SPZ) will be determined by enzyme-linked immunosorbent assay (ELISA) and automated immunofluorescence assay (aIFA).\nFor assessment of parasite-specific T cell responses, PBMCs will be assessed by multi-parameter flow cytometry and &#x2F; or ELISPOT, and intracellular cytokine staining.\nRNA sequencing from whole blood will be performed by processing the RNA and performing deep sequencing.\nAnalysis of gene expression will be performed to develop biomarkers and predictors of protection., timeFrame - Before the first vaccination, 1 week after vaccination 1 and 2, 2 weeks after vaccination 3 and at 6 months and 12 months after the last vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02687373",
    "endpoint": "measure - Part 2 - Assessment of Pf-specific antibodies, parasite-specific T cell responses and RNA sequencing to determine correlation of immune response with efficacy, description - Comparison of the immune response at different time points and the protection against naturally acquired Pf infection.\nFollowing vaccination serum will be taken and an assessment of Plasmodium falciparum (Pf)f-specific antibodies against specific malaria proteins such as the circumsporozoite protein (CSP) PfCSP and whole Pf sporozoites (SPZ) will be determined by enzyme-linked immunosorbent assay (ELISA) and automated immunofluorescence assay (aIFA).\nFor assessment of parasite-specific T cell responses, PBMCs will be assessed by multi-parameter flow cytometry and &#x2F; or ELISPOT, and intracellular cytokine staining.\nRNA sequencing from whole blood will be performed by processing the RNA and performing deep sequencing.\nAnalysis of gene expression will be performed to develop biomarkers and predictors of protection., timeFrame - Entire study period",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04858087",
    "endpoint": "measure - Microscopic P. falciparum infection, description - Pf infection detected by microscopy, timeFrame - 6 weeks after screening",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04858087",
    "endpoint": "measure - Anemia, description - Hb measured by Hemocue and categorized using WHO age and gender specific values, timeFrame - 6 weeks after screening",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05085340",
    "endpoint": "measure - Malaria prevalence in under 2 year old children living in project districts, description - , timeFrame - Month 24",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05085340",
    "endpoint": "measure - Malaria incidence in under 2 year old children living in project districts, description - , timeFrame - Month 24",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05085340",
    "endpoint": "measure - Coverage of EPI routine vaccines in children living in project districts, description - , timeFrame - Month 24",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02052323",
    "endpoint": "measure - Number of patients with prolonged parasite clearance times, adequate drug levels and positive molecular markers of parasite resistance., description - <ul><li>Parasite clearance rate during the first 72 hours after artesunate administration as defined by the slope of the linear portion of the logarithm parasite clearance curve using qPCR</li><li>Parasite reduction ratios at 24 and 48 hours assessed by microscopy and qPCR</li><li>Time for parasite count to fall to 50%, 90%, 99% and 100% of initial parasite density</li><li>Fever clearance time</li><li>42-day PCR-adjusted treatment efficacy</li><li>Gametocyte carriage rates</li><li>Plasma levels of AS, DHA and MQ at selected time points</li><li>In vitro IC50, IC90, IC99 P. falciparum responses to a panel of antimalarial drugs, including dihydroartemisinin (DHA) and mefloquine</li><li>Parasite molecular markers of drug resistance as determined by GWAS, SNP analysis and other genotyping methodologies</li><li>A detailed characterization of drug-resistant malaria using integrated endpoints above, including clinical, in vitro and molecular</li></ul>, timeFrame - one year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06076213",
    "endpoint": "measure - Proportion of adverse events and serious adverse events, description - Number of adverse events and serious adverse events that every participant will experience, timeFrame - day 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06076213",
    "endpoint": "measure - Prevalence of HRP2 deletion, description - Proportion of positive samples that fail to be detected by malaria rapid diagnostic tests due to the deletion of the related antigen, timeFrame - Baseline",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06076213",
    "endpoint": "measure - Prevalence of resistance markers at baseline, description - Proportion of samples containing different markers of resistance to different antimalarial drugs, timeFrame - Baseline",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06076213",
    "endpoint": "measure - Quantification of Lumefantrine, description - Level of lumefantrine in the blood of children who will be randomized to the Artemether-lumefantrine arm, timeFrame - day 7",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06461026",
    "endpoint": "measure - Total IgG anti-NANP antibody titers measured by ELISA., description - , timeFrame - Measured 28 days and 84 days after the third R21&#x2F;Matrix-MTM vaccination.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06461026",
    "endpoint": "measure - Measurement of Anti-Drug Antibodies (ADA) to L9LS in sera of recipients., description - , timeFrame - Measured at day 28, 224 and 280",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05736679",
    "endpoint": "measure - Clinical malaria incidence, description - Measured in children between 6 months to 10 years old living in the study cohorts using passive case detection via the existing community health workers and health centers., timeFrame - 24 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05736679",
    "endpoint": "measure - Malaria parasitemia, description - Measured in children between 6 months to 10 years old in the cohorts of 55 children., timeFrame - 24 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05736679",
    "endpoint": "measure - Prevalence of moderate (defined as 7 - 9.9 g&#x2F;dL hemoglobin) to severe anemia (&lt;7 g&#x2F;dL hemoglobin), description - Measured in children under 5 years of age in the cohorts of 55 children four times: at the start and end of the rainy season (April and November respectively) of Year 1 and Year 2., timeFrame - 24 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05736679",
    "endpoint": "measure - Mean numbers of female malaria mosquitoes (An. gambiae s.l., An funestus s.l.) captured in study houses, description - Measured by CDC light traps in 20 clusters, 10 houses per cluster on a monthly basis., timeFrame - 24 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05736679",
    "endpoint": "measure - Malaria parasite sporozoite rate, description - Assessed in 10% of all anophelines captured by CDC light trap., timeFrame - 24 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05736679",
    "endpoint": "measure - Entomological Inoculation Rates, description - Measured in each study arm as the product of the anopheline vector density and sporozoite rate., timeFrame - 24 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03970993",
    "endpoint": "measure - To assess humoral immunogenicity generated in malaria-naïve individuals by adjuvanted R21 using different immunisation schedules in healthy malaria-naïve volunteers., description - To document immunogenicity measures, capturing humoral and cellular immune responses to R21 as follows: Anti-CS antibody titers, timeFrame - Blood samples will be taken to assess immune responses at specified time points over the duration of the study",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03970993",
    "endpoint": "measure - To assess the safety and tolerability of adjuvanted R21 using different immunisation schedules in healthy malaria-naïve volunteers following booster vaccination, description - Occurrence of solicited and unsolicited local and systemic adverse events, timeFrame - Solicited AEs will be collected for 7 days and Unsolicited AEs will be collected for 28 days. SAEs will be collected from enrolment until the end of the follow-up period",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03970993",
    "endpoint": "measure - To assess the efficacy of adjuvanted R21 against malaria sporozoite challenge in healthy malaria-naïve volunteers following a booster vaccination., description - To assess the efficacy (prevention of occurrence of P. falciparum parasitemia, assessed by PCR) of adjuvanted R21 against malaria sporozoite challenge, in healthy malaria-naïve volunteers following a booster vaccination., timeFrame - Week 2 following malaria infection",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03970993",
    "endpoint": "measure - To further assess the efficacy using different thresholds of adjuvanted R21 in two different vaccination regimes and compared to R21c against malaria sporozoite challenge, in healthy malaria-naïve volunteers., description - To further assess the efficacy using different thresholds, measured as time to P. falciparum parasitemia, assessed by PCR of adjuvanted R21 in two different vaccination regimes and compared to R21c against malaria sporozoite challenge, in healthy malaria-naïve volunteers., timeFrame - Weeks 2 &amp; 3 following malaria infection",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01165372",
    "endpoint": "measure - Clearance rate assessed from the fitted slope of the log-linear parasite curves, description - , timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01165372",
    "endpoint": "measure - Proportion of patients who have a parasite clearance time &gt;72 hours after initiation of each treatment, description - , timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01165372",
    "endpoint": "measure - Parasitological efficacy of the three treatment arms, description - , timeFrame - Over 72 hours and during follow-up treatment over a total follow-up period of 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01165372",
    "endpoint": "measure - Relative proportion of patients treated with artesunate 2mg&#x2F;kg&#x2F;day versus artesunate 4mg&#x2F;kg&#x2F;day versus dihydroartemisinin-piperaquine once daily, description - Patients who result as early treatment failures, late clinical failures, late parasitological failures or adequate clinical and parasitological response as indicators of efficacy, timeFrame - 03 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01165372",
    "endpoint": "measure - Recrudescence and new infection rate defined by polymerase chain reaction (PCR) analysis between treatment arms, description - , timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01165372",
    "endpoint": "measure - Number of adverse events in each treatment arm, description - , timeFrame - After initiation and during follow-up treatment over a total follow-up period of 42 days.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01165372",
    "endpoint": "measure - Assess the pharmacokinetic characteristics of artesunate and dihydroartemisinin-piperaquine by using population pharmacokinetic modeling, description - , timeFrame - 03 days and upon relapse",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01165372",
    "endpoint": "measure - Characterize different genetic patterns from different resistant strains, description - , timeFrame - 03 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01351948",
    "endpoint": "measure - Immunogenicity of vaccination, description - To assess the immunogenicity of vaccination of healthy adults with AdCh63 AMA1, MVA AMA1 &amp; AMA1-C1&#x2F;Alhydrogel® +&#x2F;- CPG 7909 administered in various schedules by measuring T cell responses (IFN-γ ELISPOT, flow cytometry), B cell responses and antibody responses to AMA1.\nFurther immunological assessments may be undertaken as necessary, timeFrame - Expected average of 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01845701",
    "endpoint": "measure - Safety by measure of changes in Physiologic, Blood, Liver and Kidney functions to define AE &amp; SAEs, description - <p>Prevalence of adverse events (AEs) and serious adverse events (SAEs): proportion of patients who experience AEs or SAEs during the follow up period of 42 days.</p><p>Changes in vital Physiologic parameters (blood pressure, pulse rate): proportion of patients who have significant changes in vital signs comparing to baseline during the follow up period of 42 days.</p><p>Prevalence of abnormal laboratory tests: proportion of patients who have abnormal values of laboratory tests (ALAT, ASAT, Bilirubin, Creatinine, Glucose, Urea etc), during the follow up period of 42 days.</p>, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00336375",
    "endpoint": "measure - Clearance kinetics of P. falciparum measured with PCR genotyping compared with blood slide reading, description - , timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02663700",
    "endpoint": "measure - Antibody titers against P. falciparum circumsporozoite protein (CSP) at serology time points, description - , timeFrame - Day 1 through Day 127",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00701961",
    "endpoint": "measure - The proportion of women in each treatment group with parasitological cure at 63 days, corrected by PCR for re-infection., description - , timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00371189",
    "endpoint": "measure - T cell responses against the malaria circumsporozoite antigen by enzyme-linked immunosorbent spot (ELISPOT) and flow cytometry., description - , timeFrame - Days 28, 56, 120, 180, 208.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00371189",
    "endpoint": "measure - Antibody titers against the malaria circumsporozoite antigen via enzyme-linked immunosorbent assay (ELISA)., description - , timeFrame - Days 28, 56, 120, 180, 208.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00371189",
    "endpoint": "measure - Neutralizing antibody titers against Adenovirus type 35 by Adenovirus Neutralization Assay., description - , timeFrame - Days 28, 56, 120, 180, 208.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00119145",
    "endpoint": "measure - Parasitological cure rate by day 14, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00119145",
    "endpoint": "measure - Parasitological cure rate by day 28, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00119145",
    "endpoint": "measure - Clinical cure rates by days 14 and 28, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00119145",
    "endpoint": "measure - Incidence rates of adverse events, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00119145",
    "endpoint": "measure - Gametocyte carriage at days 7, 14 and 28, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01065116",
    "endpoint": "measure - Parasitological cure rates, description - , timeFrame - Day 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01065116",
    "endpoint": "measure - Clinical cure rates, description - , timeFrame - Days 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04167566",
    "endpoint": "measure - The cost benefit analysis of the scaling up MTTT intervention in the area will be known., description - This outcome describes the benefit in terms of number of cases of malaria prevented or amount of income saved by the participants or resources saved by the health system as a result of implementing MTTT, timeFrame - 24 Months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03707353",
    "endpoint": "measure - To assess cell-mediated immunogenicity generated in malaria naïve individuals of vaccination schedules incorporating intramuscular prime dose(s) followed by intravenous booster with ChAd63 and MVA encoding ME-TRAP., description - The key measure of immunogenicity will be ELISPOT to enumerate IFN-γ producing T cells., timeFrame - Up to 11-13 months from initial vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02020330",
    "endpoint": "measure - Parasitaemia clearance time, description - Assessed by sensitive PCR on D3 in the 3 day arm and D5 in the 5 day arm, timeFrame - On day 3 and Day 5",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02020330",
    "endpoint": "measure - Gametocyte carriage rates, description - , timeFrame - Day 7",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02020330",
    "endpoint": "measure - artemether-lumefantrine tolerability, description - Tolerability of artemether-lumefantrine will be assessed by comparing the proportion of patients with anorexia, nausea, vomiting, abdominal pain and other symptoms of administration between the intervention arm and the control arm, timeFrame - 5 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02020330",
    "endpoint": "measure - Comparison of effectiveness, description - Comparison of effectiveness uncorrected and corrected will be assessed by PCR genotyping, timeFrame - Day 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02020330",
    "endpoint": "measure - concentrations of lumefantrine, description - , timeFrame - Day 7",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02020330",
    "endpoint": "measure - Haematological recovery rate, description - Assessed by comparing hemoglobin between baseline and after treatment at day 28, timeFrame - Day 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02020330",
    "endpoint": "measure - Incidence of vivax malaria relapses, description - Assessed by the microscopist find malaria smear positive within the follow up period, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02020330",
    "endpoint": "measure - Comparison of addition of food supplement (fish oil), description - Assessed by comparing lumefantrine concentration on day 7 and proportion of patients with detectable parasitaemia by qPCR, timeFrame - day 3 to day 21",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01878357",
    "endpoint": "measure - Anemia, description - Proportion of anemia in elementary school children (all arms), timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01328990",
    "endpoint": "measure - Tolerability, description - Adverse events will be recorded during home visits, timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00329134",
    "endpoint": "measure - Plasma concentration of quinine at day 4 between first and second administration, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01256658",
    "endpoint": "measure - Microscopy-confirmed Gametocyte Carriers at Community Screening Campaign 4 (CSC4) (Per Cluster), description - Data is presented &quot;per cluster&quot;.\nMicroscopy confirmed gametocyte carriers at Community Screening Campaign 4(CSC4) were assessed via microscopy at month 12 of period 1. Blood films were histologically treated and examined microscopically., timeFrame - Month 12 - period 1",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01256658",
    "endpoint": "measure - Microscopy Confirmed Asymptomatic Carriers of P. Falciparum at Community Screening Campaign 4 (CSC4) (Per Cluster), description - Data is presented &quot;per cluster&quot;.\nMicroscopy confirmation of asymptomatic carriers of P. falciparum at Community Screening Campaign 4 (CSC4) was conducted at month 12. Blood films were histologically treated and examined microscopically.\nWhen it was ascertained that P. falciparum was present, a count of the asexual forms against leukocytes was made using a tally counter., timeFrame - Month 12 - period 1",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01256658",
    "endpoint": "measure - Change in Hemoglobin Level (g&#x2F;dL) From Community Screening Campaign 1(CSC1)&#x2F;Day 1 to Community Screening Campaign 4 (CSC4)&#x2F;Day 1 (Per Cluster), description - Data is presented &quot;per cluster&quot;.\nComparison of hemoglobin level (g&#x2F;dL) from Community Screening Campaign 1 (CSC1)&#x2F;Day 1 to Community Screening Campaign 4 (CSC4)&#x2F;Day 1 in infants and children (&gt;6 months and &lt;5 years) by study arm was measured using the HemoCue® rapid test.\nThis test was performed using a drop of blood collected from the fingertip of each participant., timeFrame - Day 1 (CSC1&#x2F;day 1) and month 12 (CSC4&#x2F;day 1) - period 1",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01256658",
    "endpoint": "measure - Number of Symptomatic Malaria Episode, RDT-confirmed, With Parasitemia ≥5000&#x2F;μL (SMRC5000s) Per Person-year in Post Community Screening Campaign (CSC), description - <p>Number of Symptomatic malaria episode, RDT-confirmed, with parasitemia ≥5000&#x2F;μL (SMRC5000s) per person-year in post Community Screening Campaign (CSC), by study arm (individual level data) was detected by Rapid Diagnostic Test (RDT) (using a blood sample from each participant) and later confirmed to have a parasite density ≥5000&#x2F;uL by microscopy.</p><p>Number of SMRC5000: sum of all SMRC5000 for all subjects in post CSC.\nPerson-year observed: sum of duration (in days) in post CSC for all subjects present in study &#x2F;365.25.</p><p>Number of SMRC5000 per person-year = number of SMRC5000&#x2F;person-year observed.</p>, timeFrame - 12 months - period 1",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01256658",
    "endpoint": "measure - Number of Participants With Hospitalizations, Severe Malaria Episodes or Death Post Community Screening Campaign (CSC), description - Total number of participants (all ages) with hospitalizations, severe malaria episodes or death after Community Screening Campaign (CSC) was assessed., timeFrame - 12 months - period 1",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01256658",
    "endpoint": "measure - Number of Participants (Infants and Children (&gt; 6 Months and &lt; 5 Years)) With Hospitalizations, Severe Malaria Episodes or Death Post Community Screening Campaign (CSC), description - Total number of participants (infants and children (&gt; 6 months and &lt; 5 years)) with hospitalizations, severe malaria episodes or death after Community Screening Campaign (CSC) was assessed., timeFrame - 12 months - period 1",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01256658",
    "endpoint": "measure - Mean of Microscopy-confirmed Asymptomatic Carriers From Community Screening Campaigns 1, 2, 3 and 4 (CSC1, CSC2, CSC3 and CSC4) (Per Cluster), description - <p>Data is presented &quot;per cluster&quot;.\nMean number of asymptomatic carriers from Community Screening Campaigns 1, 2, 3 and 4 (CSC1, CSC2, CSC3 and CSC4) was measured by confirmed positive microscopy for P. falciparum asexual forms in participants with absence of clinical signs and symptoms of malaria.</p><p>Mean measured in this analysis is the mean percent indicting the mean of percentages of cluster frequencies under the study arm for that particular category.</p>, timeFrame - 12 months - period 1",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01256658",
    "endpoint": "measure - Mean Number of Microscopy-confirmed Gametocyte Carriers at Day 1 of Community Screening Campaign 1,2,3,4 (CSC1, CSC2, CSC3 and CSC4) (Per Cluster), description - <p>Data is presented &quot;per cluster&quot;.\nMean number of gametocyte carriers at Day 1 for Community Screening Campaign 1,2,3,4 (CSC1, CSC2, CSC3 and CSC4) was measured using gametocyte assessments (prevalence and density) via microscopy.</p><p>Mean measured in this analysis is the mean percent indicating the mean of percentages of cluster frequencies under the study arm for that particular category.</p>, timeFrame - 12 months - period 1",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01256658",
    "endpoint": "measure - Number of Microscopy and qRT-PCR-confirmed Gametocyte Carriers at Community Screening Campaign 4 (CSC4), description - Number of gametocyte carriers at Community Screening Campaign 4 (CSC4) was measured via microscopy and confirmed using Quantitative Reverse Transcription PCR (qRT-PCR) at day 1 of CSC4., timeFrame - Month 12 (CSC4&#x2F;day 1) - period 1",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01256658",
    "endpoint": "measure - Change in Hemoglobin Level (g&#x2F;dL) From Community Screening Campaign 1 (CSC1)&#x2F;Day 1 to CSC1&#x2F;Day 28 in Infants and Children (&gt;6 Months and &lt;5 Years) for Asymptomatic Carriers at CSC1, description - Change in hemoglobin level (g&#x2F;dL) from Community Screening Campaign 1 (CSC1)&#x2F;Day 1 to CSC1&#x2F;Day 28 in infants and children (&gt;6 Months and &lt;5 Years) for asymptomatic carriers at CSC1 was measured via hemoglobin levels using the HemoCue® rapid test.\nThis test was performed using a drop of blood collected from the fingertip of each participant.\nThe anemic status is defined as follows: hemoglobin (Hb) &lt;5 g&#x2F;dL = severe anemia, Hb 5 to &lt;8 g&#x2F;dL = moderate anemia, Hb 8 to &lt;11 g&#x2F;dL = mild anemia, Hb ≥11 g&#x2F;dL = no anemia)., timeFrame - Day 1 and day 28 - period 1",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01256658",
    "endpoint": "measure - Anemia Status Based on Community Screening Campaign 1 (CSC1)&#x2F;Day 1 in Infants and Children (&gt;6 Months and &lt;5 Years), description - Anemia status based on Community Screening Campaign 1 (CSC1)&#x2F;Day 1 in infants and children (&gt;6 months and &lt;5 years) was measured via hemoglobin levels using the HemoCue® rapid test.\nThis test was performed using a drop of blood collected from the fingertip of each participant.\nThe anemic status is defined as follows: hemoglobin (Hb) &lt;5 g&#x2F;dL = severe anemia, Hb 5 to &lt;8 g&#x2F;dL = moderate anemia, Hb 8 to &lt;11 g&#x2F;dL = mild anemia, Hb ≥11 g&#x2F;dL = no anemia)., timeFrame - Day 1 (CSC1&#x2F;day 1) - period 1",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01256658",
    "endpoint": "measure - Anemia Status Based on Community Screening Campaign 4 (CSC4)&#x2F;Day 1 in Infants and Children (&gt;6 Months and &lt;5 Years), description - Anemia status based on Community Screening Campaign 4 (CSC4&#x2F;Day 1) in infants and children (&gt;6 months and &lt;5 years) was measured via hemoglobin levels using the HemoCue® rapid test.\nThis test was performed using a drop of blood collected from the fingertip of each participant.\nThe anemic status is defined as follows: hemoglobin (Hb) &lt;5 g&#x2F;dL = severe anemia, Hb 5 to &lt;8 g&#x2F;dL = moderate anemia, Hb 8 to &lt;11 g&#x2F;dL = mild anemia, Hb ≥11 g&#x2F;dL = no anemia)., timeFrame - Month 12 (CSC4&#x2F;day 1) - period 1",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01256658",
    "endpoint": "measure - Hemoglobin Level (g&#x2F;dL) in Community Screening Campaign 1 (CSC1)&#x2F;Day 1 and CSC4&#x2F;Day 1 by Study Arm and Age Group (Per Cluster), description - Data is presented &quot;per cluster&quot;.\nHemoglobin levels at Community Screening Campaign 1 and 4 (CSC1 and CSC4) on day 1 per age group (5-9 years, 10-14 years, and ≥15 years) in the intervention versus the control arm was measured using the HemoCue® rapid test.\nThis test was performed using a drop of blood collected from the fingertip of each participant., timeFrame - Day 1 (CSC1&#x2F;day 1) and month 12 (CSC4&#x2F;day 1) - period 1",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01256658",
    "endpoint": "measure - Percentage of COA566-treated Microscopy-confirmed Asymptomatic Carriers at Community Screening Campaign 1, 2 and 3 (CSC1, CSC2 and CSC3) With Parasitological Cure Rate at Day 7, description - Percentage of participants with parasitological cure confirmed via microscopy at day 7 after treatment with COA566.\nThis assessment was done on asymptomatic carriers from Community Screening Campaigns 1, 2 and 3 (CSC1, CSC2 and CSC3) from the intervention group only., timeFrame - Day 7 of CSC1, CSC2 and CSC3 - period 1",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01256658",
    "endpoint": "measure - Percentage of Microscopy-confirmed Gametocyte Carriers Treated With COA566 for Asymptomatic Carriers, description - Percentage of microscopy-confirmed gametocyte asymptomatic carriers treated with COA566 for asymptomatic carriers in Community Screening Campaign 1, 2 and 3 (CSC1, CSC2 and CSC3)., timeFrame - Day 1, day 7 and day 28 - period 1",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01256658",
    "endpoint": "measure - Number of Asymptomatic Carriers With Increase in Hemoglobin Levels by at Least 0.5 g&#x2F;dL From Community Screening Campaign 1 (CSC1) Infants and Children (&gt;6 Months and &lt;5 Years)- Individual Data, description - Individual data of number of asymptomatic carriers with increase in hemoglobin levels by at least 0.5 g&#x2F;dL from Day 1 to Day 28 from Community Screening Campaign 1 (CSC1) infants and children (&gt;6 months and &lt;5 years).\nHemoglobin levels were measured using the HemoCue® rapid test.\nThis test was performed with a drop of blood collected from the fingertip at Day 1 and at Day 28., timeFrame - Day 1 to Day 28- period 1",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01256658",
    "endpoint": "measure - Number of Asymptomatic Carriers With Increase in Hemoglobin Levels by at Least 0.5 g&#x2F;dL From Day 1 to Day 28 of Community Screening Campaign 1 (CSC1) in Infants and Children (&gt;6 Months and &lt;5 Years)- Cluster Data, description - <p>Data is presented &quot;per cluster&quot;.\nCluster data of number of asymptomatic carriers with increase in hemoglobin levels by at least 0.5 g&#x2F;dL from Day 1 to Day 28 of Community Screening Campaign 1 (CSC1) in infants and children (&gt;6 months and &lt;5 years) was measured by Hemoglobin levels based on microscopy reading.</p><p>Mean and Standard Deviation (SD) percent were measured indicating the mean and SD of percentages of cluster frequencies under the study arm for that particular category.</p>, timeFrame - Day 1 to day 28 - period 1",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01256658",
    "endpoint": "measure - Number of Symptomatic Malaria Episode, RDT-confirmed, With Parasitemia ≥5000&#x2F;μL (SMRC5000) in Asymptomatic Carriers at Any Time of Diagnosis (Per Cluster), description - Data is presented &quot;per cluster&quot;.\nNumber of Symptomatic malaria episode, RDT-confirmed, with parasitemia ≥5000&#x2F;μL (SMRC5000) in asymptomatic carriers by study arm from all inhabitants diagnosed at any time for asymptomatic carriers.\nNumber of SMRC5000s is measured by Rapid diagnostic test (RDT) and later confirmed to have a parasite density ≥ 5000&#x2F;uL by microscopy., timeFrame - 12 months - period 1",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01256658",
    "endpoint": "measure - Number of Asymptomatic Carriers With Complicated and Uncomplicated Episodes Combined, description - Number of asymptomatic carriers diagnosed with 1 Symptomatic malaria episode, RDT-confirmed, with parasitemia ≥5000&#x2F;μL (SMRC5000), 2 SMRC5000, 3 SMRC5000 and &gt;3 SMRC5000 (complicated and uncomplicated episodes combined).\nNumber of SMRC5000s is measured by Rapid diagnostic test (RDT) and later confirmed to have a parasite density ≥ 5000&#x2F;uL by microscopy., timeFrame - 12 months - period 1",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01256658",
    "endpoint": "measure - Cumulative Number of Subjects With Symptomatic Malaria Episode, RDT-confirmed, With Parasitemia ≥5000&#x2F;μL From Week 1 to Week 50, description - <p>Cumulative number of asymptomatic carriers having Symptomatic malaria episode, RDT-confirmed, with parasitemia ≥5000&#x2F;μL (SMRC5000) from Week 1 to Week 50, was measured from group of participants diagnosed as asymptomatic carriers at Community Screening Campaign (CSC1)&#x2F;Day1.\nNumber of participants affected before and after diagnosed with ≥1 symptomatic malaria episode, RDT-confirmed, with parasitemia ≥5000&#x2F;μL (SMRC5000) (complicated and uncomplicated episodes combined).\nNumber of SMRC5000s was detected by Rapid Diagnostic Test (RDT) using a blood sample from each participant and later confirmed to have a parasite density &gt; or = 5000&#x2F;uL by microscopy.</p><p>Week (1-2) indicates day1 to day14, week (3-4) indicates day 15 to day 28, week (5-6) indicates day 29 to day 42, etc.\nAfter first diagnosis of asymptomatic carriers at CSC1&#x2F;Day1.</p>, timeFrame - Week 1 to Week 50",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03660839",
    "endpoint": "measure - Percentage of Participants With Crude Adequate Clinical and Parasitological Response at Day 28, description - ACPR: absence of parasitemia at Day 28, irrespective of AT, in participants not meeting any criteria of ETF: DS&#x2F;SoC&#x2F;SM at Day 1, 2 or 3 in presence of parasitemia, concomitant to at least 1 positive parasitemia; or parasitemia on Day 2 &gt; Day 0 irrespective of AT; or parasitemia on Day 3 with AT &gt;=37.5°C; or parasitemia count on Day 3 &gt;=25% on Day 0, or LCF: DS&#x2F;SM in presence of parasitemia between Day 4 and 28, concomitant to at least one positive parasitemia; or presence of parasitemia and AT&gt;=37.5°C on Day 4 to Day 28, or LPF: presence of parasitemia between Day 7 and 28 and AT&lt;37.5°C or having rescue therapy for malaria.\nPCR-corrected ACPR applied to recrudescence (appearance of asexual parasites after clearance of initial infection with genotype identical to that present at Baseline), excluding participants with re-infection, whereas crude ACPR does not distinguish reinfection (new clone of parasite) or recrudescence., timeFrame - Day 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03660839",
    "endpoint": "measure - Parasitemia: Change From Baseline in Number of Parasites Per Microliter of Blood at 6, 12, 18, 24, 30, 36, 48, 72, 96, 120, 144 and 168 Hours, description - Parasitemia (quantitative content of parasites present in the blood) at baseline until Day 7 (i.e.\n168 hours) was assessed by optical microscope., timeFrame - Baseline, 6, 12, 18, 24, 30, 36, 48, 72, 96, 120, 144 and 168 hours post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03660839",
    "endpoint": "measure - Observed Parasite Reduction Ratio (PRR) at 24 Hours, 48 Hours, and 72 Hours, description - The observed PRR was defined as the ratio of the number of parasites at time t=0 (baseline) divided by the parasite count at each specified time t (post-treatment).\nIf the post dose parasite count = 0 (due to a negative parasitemia) then a value of 1 parasite per microliter was imputed to allow a parasite reduction ratio calculation., timeFrame - Baseline, 24, 48 and 72 hours post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03660839",
    "endpoint": "measure - Time to 50% and 99% Parasite Reduction, description - Time to 50% and 99% parasite reduction was defined as time needed for the parasitemia (quantitative content of parasites present in blood) to be reduced to 50% and 99% of the initial value, respectively., timeFrame - Up to Day 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03660839",
    "endpoint": "measure - Parasite Clearance Time (PCT), description - PCT was defined as the time (in hours) from the start of study drug administration until the time of first negative blood film (no asexual parasites by microscopy).\nThis first negative film was confirmed by a second negative film which was taken &gt;=6 to &lt;=12 hours of the first film.\nIf the second film was performed &lt;6 hours or &gt;12 hours of the first film, then the parasite clearance was confirmed or invalidated by the third (thick) film following the second one, whatever the timing of this third film: If the third film was negative, then the clearance was considered confirmed and if the third film was positive, then the clearance was invalidated.\nKaplan-Meier method was used for the estimation., timeFrame - From the start of study drug administration up to the time of the first negative blood film (up to Day 28)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03660839",
    "endpoint": "measure - Parasite Clearance Rate, description - Parasite clearance rate (k) is the minus slope of the natural logarithm parasitemia versus time linear relationship, after exclusion of outliers, lag phase and Tail, using the worldwide antimalarial resistance network, Parasite Clearance Estimator., timeFrame - Up to Day 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03660839",
    "endpoint": "measure - Time to Re-emergence, description - Time to re-emergence (in days) was defined as the time to appearance of asexual parasites after clearance of initial infection irrespective of genotype.\nRe-emergence was confirmed by microscopy (positive blood smear).\nParticipants with confirmed parasite clearance were included in the analysis and Kaplan-Meier method was used for estimation., timeFrame - Up to Day 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03660839",
    "endpoint": "measure - Time to Recrudescence, description - Time to recrudescence (in days) was defined as the time to appearance of asexual parasites after clearance of initial infection with a genotype identical to that of parasites present at Baseline.\nRecrudescence was confirmed by PCR analysis.\nParticipants with confirmed parasite clearance were included in the analysis and Kaplan-Meier method was used for estimation., timeFrame - Up to Day 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03660839",
    "endpoint": "measure - Time to Re-infection, description - Time to re-infection (in days) was defined as the time to appearance of asexual parasites after clearance of initial infection with a genotype that differed from that of parasites present at Baseline.\nRe-infection was confirmed by PCR analysis.\nParticipants with confirmed parasite clearance were involved in the analysis and Kaplan-Maier method was used for estimation., timeFrame - Up to Day 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03660839",
    "endpoint": "measure - Time Elapsed Below the Limit of Quantification (LOQ) of Parasitemia, description - The time elapsed below LOQ (LOQ expressed in parasites&#x2F;microliter) of parasitemia (quantitative content of parasites present in the blood) was defined as the time (in days) for which no parasites were seen i.e., time corresponding to PCT, up to the time of occurrence of a new malaria infection or recrudescence.\nIf there was no occurrence of a new malaria infection or recrudescence, then this was the time corresponding to the first negative thick blood film, until the end of study.\nPCT (k) is the minus slope of the natural logarithm parasitemia versus time linear relationship, after exclusion of outliers, lag phase and Tail, using the worldwide antimalarial resistance network, Parasite clearance estimator.\nParticipants with confirmed parasite clearance were involved in the analysis and Kaplan-Meier method was used for estimation., timeFrame - Up to Day 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03660839",
    "endpoint": "measure - Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Adverse Event of Special Interest (AESI), description - An AE was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily had to have a causal relationship with the treatment.\nSAEs were any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability&#x2F;incapacity, congenital anomaly&#x2F;birth defect, or considered as medically important event.\nTEAEs were defined as AEs that developed or worsened or became serious during on-treatment phase that was defined as the time from the start of study drug up to the Day 28.\nAE of special interest (AESI) was an AE (serious or non-serious) of scientific and medical concern specific to the Sponsor&#x27;s product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor was required., timeFrame - From Baseline up to Day 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03660839",
    "endpoint": "measure - Pharmacokinetics (PK): Concentration of OZ439 in Plasma, description - Concentrations of OZ439 in plasma was analyzed by liquid chromatography tandem mass spectroscopy (LC-MS&#x2F;MS).\nThe lower limit of quantification (LLOQ) was 1 nanograms per milliliter for analysis of OZ439.\nData for this outcome measure was not planned to be collected and analyzed for &quot;Ferroquine 400 mg&quot; arm, since artefenomel was not administered., timeFrame - 1, 2, 4, 6, 12, 24, 48, 72, 120, 168 and 336 hours post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03660839",
    "endpoint": "measure - Pharmacokinetics: Concentration of FQ and Its Active Metabolite SSR97213 in Blood, description - Concentrations of FQ and SSR97213 in blood was analyzed by LC-MS&#x2F;MS.\nThe LLOQ was 5 nanograms per milliliter for analysis of FQ and SSR97213., timeFrame - 1, 4, 6, 8, 12, 24, 72, 168, 336 and 672 hours post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03660839",
    "endpoint": "measure - Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) of Artefenomel, description - Cmax is the maximum observed plasma concentration of Artefenomel.\nData for this outcome measure was not planned to be collected and analyzed for &quot;Ferroquine 400 mg&quot; arm, since artefenomel was not administered., timeFrame - Pre-dose, 1, 2, 4, 6, 12, 24, 48, 72, 120, 168 and 336 hours post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03660839",
    "endpoint": "measure - Pharmacokinetics: Time to Reach Maximum Plasma Concentration (Tmax) of Artefenomel, description - tmax is the time taken by the drug to reach the maximum plasma concentration.\nData for this outcome measure was not planned to be collected and analyzed for &quot;Ferroquine 400 mg&quot; arm, since artefenomel was not administered., timeFrame - Pre-dose, 1, 2, 4, 6, 12, 24, 48, 72, 120, 168 and 336 hours post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03660839",
    "endpoint": "measure - Pharmacokinetics: Plasma Concentration at 168 Hours Post-dose (C168h) of Artefenomel, description - The observed plasma concentration of artefenomel post 168 hours of drug administration.\nData for this outcome measure was not planned to be collected and analyzed for &quot;Ferroquine 400 mg&quot; arm, since artefenomel was not administered., timeFrame - At 168 hours post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03660839",
    "endpoint": "measure - Pharmacokinetics: Area Under the Concentration Curve (AUC) Form Time 0 to Infinity (AUC0-inf]) of Artefenomel, description - Area under the plasma concentration versus time curve from time 0 to infinity.\nData for this outcome measure was not planned to be collected and analyzed for &quot;Ferroquine 400 mg&quot; arm, since artefenomel was not administered., timeFrame - Pre-dose, 1, 2, 4, 6, 12, 24, 48, 72, 120, 168 and 336 hours post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03660839",
    "endpoint": "measure - Pharmacokinetics: Terminal Half-life (t1&#x2F;2) of Artefenomel, description - Terminal t1&#x2F;2 is defined as the time required for the plasma concentration of a drug to decrease by half of its initial concentration.\nData for this outcome measure was not planned to be collected and analyzed for &quot;Ferroquine 400 mg&quot; arm, since artefenomel was not administered., timeFrame - Pre-dose, 1, 2, 4, 6, 12, 24, 48, 72, 120, 168 and 336 hours post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03660839",
    "endpoint": "measure - Pharmacokinetics: Maximum Observed Plasma Concentration of Ferroquine and Its Active Metabolite SSR97213, description - Cmax is the maximum observed plasma concentration of Ferroquine., timeFrame - Pre-dose, 1, 4, 6, 8, 12, 24, 72, 168, 336 and 672 hours post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03660839",
    "endpoint": "measure - Pharmacokinetics: Time to Reach Maximum Plasma Concentration of Ferroquine and Its Active Metabolite SSR97213, description - tmax is the time taken by the drug to reach the maximum plasma concentration., timeFrame - Pre-dose, 1, 4, 6, 8, 12, 24, 72, 168, 336 and 672 hours post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03660839",
    "endpoint": "measure - Pharmacokinetics: Plasma Concentration at 168 Hours Post-dose of Ferroquine and Its Active Metabolite SSR97213, description - The observed plasma concentration of FQ and SSR97213 post 168 hours of FQ administration., timeFrame - At 168 hours post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03660839",
    "endpoint": "measure - Pharmacokinetics: Area Under the Concentration Curve Form Time 0 to Day 28 (AUC0-28) of Ferroquine and Its Active Metabolite SSR97213, description - Area under the plasma concentration versus time curve from time 0 to Day 28 (i.e.\n672 hours)., timeFrame - Pre-dose, 1, 4, 6, 8, 12, 24, 72, 168, 336 and 672 hours post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03660839",
    "endpoint": "measure - Pharmacokinetics: Area Under the Concentration Curve From Time 0 to Infinity of Ferroquine and Its Active Metabolite SSR97213, description - Area under the plasma concentration versus time curve from time 0 to infinity., timeFrame - Pre-dose, 1, 4, 6, 8, 12, 24, 72, 168, 336 and 672 hours post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03660839",
    "endpoint": "measure - Pharmacokinetics: Terminal Half-life of Ferroquine, description - Terminal t1&#x2F;2 is defined as the time required for the plasma concentration of a drug to decrease by half of its initial concentration., timeFrame - Pre-dose, 1, 4, 6, 8, 12, 24, 72, 168, 336 and 672 hours post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01038063",
    "endpoint": "measure - Incidence of clinical malaria during 18 months and 36 months of follow-up, description - , timeFrame - 18 and 36 months of follow up",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01635647",
    "endpoint": "measure - Duration of Protective efficacy against clinical malaria, description - To assess the protective efficacy against clinical malaria of ChAd63 ME-TRAP &#x2F; MVA ME-TRAP prime-boost immunisation, in 5-17 month old infants and children living in a malaria-endemic area, for 12 and 24* months after the last vaccination., timeFrame - 12 and 24 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01635647",
    "endpoint": "measure - Efficacy against asymptomatic P. falciparum infection, description - To assess the protective efficacy against asymptomatic P. falciparum infection of ChAd63 ME-TRAP &#x2F; MVA ME-TRAP prime-boost immunisation, in 5-17 month old infants and children living in a malaria-endemic area, 6, 12 and 24* months after the last vaccination, timeFrame - 6, 12 and 24 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01635647",
    "endpoint": "measure - Efficacy against secondary case definitions of clinical malaria, description - To assess the protective efficacy against secondary case definitions of clinical malaria of ChAd63 ME-TRAP &#x2F; MVA ME-TRAP prime-boost immunisation, in 5-17 month old infants and children living in a malaria-endemic area, for 6, 12 and 24 months after the last vaccination, timeFrame - 6, 12 and 24 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01635647",
    "endpoint": "measure - Safety Objective, description - To assess the safety and reactogenicity of ChAd63 ME-TRAP &#x2F; MVA ME-TRAP heterologous prime-boost immunisation, in 5-17 month old infants and children living in a malaria-endemic area, for 6, 12 and 24 months after the last vaccination., timeFrame - 6, 12 and 24 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01635647",
    "endpoint": "measure - Immunogenicity Objectives, description - <ul><li>To assess the immunogenicity of ChAd63 ME-TRAP &#x2F; MVA ME- TRAP heterologous prime-boost immunisation, in 5-17 month old infants and children living in a malaria-endemic area.</li><li>To explore the immunologic correlates of protective efficacy of ChAd63 ME-TRAP &#x2F; MVA ME-TRAP prime-boost immunisation, in 5-17 month old infants and children living in a malaria-endemic area.</li></ul>, timeFrame - 24 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00197028",
    "endpoint": "measure - Number of Subjects With Serious Adverse Events (SAEs)., description - SAEs were defined as medical occurrences that resulted in death, were life threatening, required hospitalization or prolongation of hospitalization or resulted in disability&#x2F;incapacity., timeFrame - Throughout the entire study period (from Month 0 to Month 14)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00197028",
    "endpoint": "measure - Concentrations of Antibodies Against Hepatitis B (Anti-HB), description - Concentrations were expressed as geometric mean concentrations (GMCs) in milli-international unit per milliliter (mIU&#x2F;mL).\nThe seroprotection cut-off of the assay was 10 mIU&#x2F;mL., timeFrame - Prior to vaccination at Month 0 (PRE) and 1 month post Dose 3 of Engerix-B® or RTS,S&#x2F;AS02D vaccine (Day 104).",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00197028",
    "endpoint": "measure - Concentrations of Anti-circumsporozoite Protein (Anti-CS) Antibodies., description - Antibodies were measured by Enzyme-linked immunosorbent assay (ELISA).\nConcentrations are expressed as geometric mean concentrations (GMCs) in ELISA unit per milliliter (EL.U&#x2F;mL).\nThe seropositivity cut-off of the assay was 0.5 EL.U&#x2F;mL., timeFrame - Prior to vaccination at Month 0 (PRE), 1 month post Dose 3 of Engerix-B® or RTS,S&#x2F;AS02D vaccine (Day 104) and 3½ months post Dose 3 of Engerix-B® or RTS,S&#x2F;AS02D vaccine (Day 180).",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00197028",
    "endpoint": "measure - Concentrations of Antibodies Against Anti-diphtheria (Anti-D), description - Antibodies were measured by Enzyme-linked immunosorbent assay (ELISA).\nConcentrations were expressed as geometric mean concentrations (GMCs) in international unit per milliliter (IU&#x2F;mL).\nThe seroprotection cut-off of the assay was 0.1 IU&#x2F;mL., timeFrame - At Day 90 (1 month post Dose 3 of TETRActHib™ vaccine)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00197028",
    "endpoint": "measure - Concentrations of Antibodies Against Tetanus (Anti-T), description - Antibodies were measured by Enzyme-linked immunosorbent assay (ELISA).\nConcentrations were expressed as geometric mean concentrations (GMCs) in international unit per milliliter (IU&#x2F;mL).\nThe seroprotection cut-off of the assay was 0.1 IU&#x2F;mL., timeFrame - At Day 90 (1 month post Dose 3 of TETRActHib™ vaccine)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00197028",
    "endpoint": "measure - Concentrations of Anti-Bordetella Pertussis Toxin Antibodies (Anti-BPT)., description - Antibodies were measured by Enzyme-linked immunosorbent assay (ELISA).\nConcentrations were expressed as geometric mean concentrations (GMCs) in ELISA unit per milliliter (EL.U&#x2F;mL).\nThe seropositivity cut-off of the assay was 15 EL.U&#x2F;mL., timeFrame - At Day 90 (1 month post Dose 3 of TETRActHib™ vaccine)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00197028",
    "endpoint": "measure - Concentrations of Anti-polyribosyl Ribitol Phosphate Antibodies (Anti-PRP)., description - Antibodies were measured by Enzyme-linked immunosorbent assay (ELISA).\nConcentrations were expressed as geometric mean concentrations (GMCs) in microgram per milliliter (µg&#x2F;mL).\nThe seroprotection cut-off of the assay was 0.15 µg&#x2F;mL., timeFrame - At Day 90 (1 month post Dose 3 of TETRActHib™ vaccine)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00197028",
    "endpoint": "measure - Time to First Malaria Infection, description - Malaria infection by Plasmodium falciparum (P.\nfalciparum) was detected by active detection of infection (ADI) and passive case detection (PCD), and was defined as the presence of P. falciparum asexual parasitemia above 0 per microliter (µL) on Giemsa stained thick blood films.\nThe time to first malaria infection is expressed in terms of rate of first malaria infection, that is, the number of malaria infection events reported (n) over the period elapsed until the event occurred (i.e.\nevents per Persons Year at Risk [PYAR]) for each group., timeFrame - Over the period starting 14 days after Dose 3 of RTS,S&#x2F;AS02D or Engerix-B® vaccine and extending for 12 weeks thereafter (from Month 2.5 to Month 6)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00197028",
    "endpoint": "measure - Number of Subjects Prevalent for Plasmodium Falciparum (P. Falciparum), description - Subjects prevalent for P. falciparum parasitemia were defined as subjects with the presence of P. falciparum asexual parasitemia above 0 per microliter (µL) on Giemsa stained thick blood films., timeFrame - At Month 6 (3½ months post Dose 3 of RTS,S&#x2F;AS02D or Engerix-B® vaccine)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00197028",
    "endpoint": "measure - Plasmodium Falciparum (P. Falciparum) Parasite Density in Subjects Prevalent for Parasitemia, description - The parasite density in subjects prevalent for P. falciparum parasitemia (subjects with the presence of P. falciparum asexual parasitemia above 0 per microliter (µL) on Giemsa stained thick blood films), was detected at a cross sectional time point 3 ½ months after administration of Dose 3 of RTS,S&#x2F;AS02D or Engerix-B® vaccine (Month 6).\nParasite density is expressed as mean, minimum and maximum density in parasite per µL., timeFrame - At Month 6 (3½ months post Dose 3 of RTS,S&#x2F;AS02D or Engerix-B® vaccine)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00197028",
    "endpoint": "measure - Number of Subjects With Solicited Local Symptoms., description - Assessed solicited local symptoms were pain and swelling at injection site., timeFrame - During the 7 day (Days 0-6) follow-up period after any vaccination with TETRActHib™ vaccine.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00197028",
    "endpoint": "measure - Number of Subjects With Solicited Local Symptoms., description - Assessed solicited local symptoms were pain and swelling at injection site., timeFrame - During the 7 day (Days 0-6) follow-up period after any vaccination with Engerix-B® or RTS,S&#x2F;AS02D vaccine.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00197028",
    "endpoint": "measure - Number of Subjects With Solicited General Symptoms., description - Assessed solicited general symptoms were drowsiness, fever, irritability and loss of appetite.\nFever was defined as axillary temperature equal or above (≥) to 37.5 degrees Celsius (C)., timeFrame - During the 7 day (Days 0-6) follow-up period after any vaccination with TETRActHib™ vaccine",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00197028",
    "endpoint": "measure - Number of Subjects With Solicited General Symptoms., description - Assessed solicited general symptoms were drowsiness, fever, irritability and loss of appetite.\nFever was defined as axillary temperature equal or above (≥) to 37.5 degrees Celsius (C)., timeFrame - During the 7 day (Days 0-6) follow-up period after any vaccination with Engerix-B® or RTS,S&#x2F;AS02D vaccine",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00197028",
    "endpoint": "measure - Number of Subjects With Unsolicited Adverse Events (AEs)., description - An unsolicited AE is any AE (i.e.\nany untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms., timeFrame - During the 14 day (Days 0-13) follow-up period after any vaccination with of TETRActHib™ vaccine",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00197028",
    "endpoint": "measure - Number of Subjects With Unsolicited Adverse Events (AEs)., description - An unsolicited AE is any AE (i.e.\nany untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms., timeFrame - During the 14 day (Days 0-13) follow-up period after vaccination with any among Doses 1 and 2 of Engerix-B® or RTS,S&#x2F;AS02D vaccine.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00197028",
    "endpoint": "measure - Number of Subjects With Unsolicited Adverse Events (AEs)., description - An unsolicited AE is any AE (i.e.\nany untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms., timeFrame - During the 30 day (Days 0-29) follow-up period after vaccination with Dose 3 of Engerix-B® or RTS,S&#x2F;AS02D vaccine.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00872963",
    "endpoint": "measure - To compare the age distribution of episodes of malaria following vaccination with RTS,S with the age distribution following control vaccination., description - , timeFrame - 4 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00872963",
    "endpoint": "measure - To compare the in vitro markers of naturally acquired immunity in vaccinated and unvaccinated children, and assess the associations of these markers with subsequent episodes of febrile malaria., description - , timeFrame - 4 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02009215",
    "endpoint": "measure - Entomologic inoculation rate (EIR) in the entomology survey, description - EIR will be defined as the number of infectious bites per person per year (the human biting rate multiplied by the sporozoite rate)., timeFrame - Over approximately 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02009215",
    "endpoint": "measure - Parasite prevalence measured by microscopy in the final school survey, description - Proportion of thick blood smears that are positive for asexual parasites, as measured by microscopy., timeFrame - During the final 1 month of the intervention",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00561899",
    "endpoint": "measure - The efficacy of the three drug regimens when used for seasonal IPT in children, description - , timeFrame - Onset of IPT to end of malaria season",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01210040",
    "endpoint": "measure - a) In the pregnant cohort: Prevalence of iron deficiency at first antenatal visit, description - Completed, timeFrame - Sept 2013",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01210040",
    "endpoint": "measure - a) In the pregnant cohort: Prevalence of anaemia at first antenatal clinic visit, description - Completed, timeFrame - Sept 2013",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01210040",
    "endpoint": "measure - a) In the pregnant cohort: Incidence of clinical malaria during the first and subsequent trimesters, description - Completed, timeFrame - Jan 2014",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01210040",
    "endpoint": "measure - a) In the pregnant cohort: Incidence of adverse pregnancy outcomes, description - Completed, timeFrame - Jan 2014",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01210040",
    "endpoint": "measure - a) In the pregnant cohort: Mean birth weight and prevalence of low birth weight (&lt;2500g), description - Completed, timeFrame - Jan 2014",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01210040",
    "endpoint": "measure - a) In the pregnant cohort: Mean gestational age at delivery, description - Completed, timeFrame - Jan 2014",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01210040",
    "endpoint": "measure - a) In the pregnant cohort: Prevalence of placental malaria, description - Completed, timeFrame - Jan 2014",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01210040",
    "endpoint": "measure - a) In the non-pregnant cohort: Prevalence of peripheral parasitaemia during the first rainy season after at least six months of supplementation, description - Completed, timeFrame - Nov 2012",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01210040",
    "endpoint": "measure - a) In the non-pregnant cohort: Incidence of clinical malaria, description - Completed, timeFrame - Nov 2013",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01210040",
    "endpoint": "measure - a) In the non-pregnant cohort: Incidence of gastrointestinal adverse events, description - Completed, timeFrame - Nov 2013",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01210040",
    "endpoint": "measure - a) In the non-pregnant cohort: Prevalence of iron deficiency after at least 18 months supplementation, description - Completed, timeFrame - Nov 2013",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01210040",
    "endpoint": "measure - a) In the non-pregnant cohort: Prevalence of anaemia after at least 18 months supplementation, description - Completed, timeFrame - Nov 2013",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01210040",
    "endpoint": "measure - a) In the non-pregnant cohort: Adherence to supplementation, description - Completed, timeFrame - Nov 2013",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01210040",
    "endpoint": "measure - a) In the non-pregnant cohort: Acceptability of weekly supplementation, description - Completed, timeFrame - June 2013",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01210040",
    "endpoint": "measure - In the non-pregnant cohort: Prevalence of bacterial vaginosis at end assessment, description - Completed, timeFrame - Nov 2013",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01210040",
    "endpoint": "measure - a) In the non-pregnant cohort: Prevalence of bacterial vaginosis at end assessment, description - Completed, timeFrame - Nov 2013",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01210040",
    "endpoint": "measure - a) In the non-pregnant cohort: Prevalence of bacterial vaginosis at first antenatal visit, description - Completed, timeFrame - Nov 2013",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01210040",
    "endpoint": "measure - a) In the non-pregnant cohort: Prevalence of iron deficiency at key study visits, description - Completed, timeFrame - Nov 2013",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01210040",
    "endpoint": "measure - a) In the non-pregnant cohort: Prevalence of peripheral parasitaemia at end assessment, description - Completed, timeFrame - Nov 2013",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01157689",
    "endpoint": "measure - ACPR day 28, description - , timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02898779",
    "endpoint": "measure - Area Under Curve (AUC) for primaquine up to 24 hours after the primaquine administration, description - This study would provide information on differential pharmacokinetics and metabolism of enantiomers of primaquine in normal human volunteers, timeFrame - between 0-24 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02898779",
    "endpoint": "measure - Maximum concentration (Cmax) for primaquine up to 24 hours after the primaquine administration, description - This study would provide information on differential pharmacokinetics and metabolism of enantiomers of primaquine in normal human volunteers, timeFrame - between 0-24 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02898779",
    "endpoint": "measure - Area Under Curve (AUC) for carboxyprimaquine, the major plasma metabolite of primaquine, up to 24 hours after primaquine administration, description - This study would provide information on differential pharmacokinetics and metabolism of enantiomers of primaquine in normal human volunteers, timeFrame - between 0-24 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02898779",
    "endpoint": "measure - Maximum concentration of carboxyprimaquine, the major plasma metabolite of primaquine, up to 24 hours after primaquine administration, description - This study would provide information on differential pharmacokinetics and metabolism of enantiomers of primaquine in normal human volunteers, timeFrame - between 0-24 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02898779",
    "endpoint": "measure - Maximum concentration of selected metabolites primaquine (other than carboxyprimaquine) up to 24 hours after primaquine administration, description - This study would provide information on differential pharmacokinetics and metabolism of enantiomers of primaquine in normal human volunteers.\nThe exact nature of these metabolites will be determined from previous animal and human studies, timeFrame - between 0-24 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02898779",
    "endpoint": "measure - hemoglobin and methemoglobin levels in the blood after administration of primaquine, description - To monitor hemoglobin and methemoglobin levels in normal human volunteers treated with single dose of primaquine not to exceed 45 mg, timeFrame - 0-72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02898779",
    "endpoint": "measure - Genotyping of Cytochrome P-450 (CYP), description - To determine correlation between metabolism of primaquine and CYP 2D6 genotype, timeFrame - day 0",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00197041",
    "endpoint": "measure - Occurrence of episodes of asymptomatic and symptomatic infections of Plasmodium falciparum malaria. Occurrence of solicited symptoms, unsolicited symptoms and SAEs., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01142765",
    "endpoint": "measure - Immunogenicity of vaccine, description - To assess immunogenicity of the vaccine regimes by measuring IFN-γ ELISPOT, flow cytometry and antibody responses to MSP1, AMA1 and ME-TRAP antigens before and after malaria infection.\nIf there is evidence of partial or complete protection, we will explore immunological correlates of protective immunity., timeFrame - Up to 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00126971",
    "endpoint": "measure - Proportion of pregnant women sleeping under ITNs who become re-infected with malaria before delivery following administration of a single dose of CD for P. falciparum parasitemia, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00126971",
    "endpoint": "measure - Proportion of treatment failures by day 28 following initial treatment, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00126971",
    "endpoint": "measure - Treatment failure will be defined according to standard WHO criteria for low to moderate transmission areas to account for fact that some pregnant women are asymptomatic, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00126971",
    "endpoint": "measure - Early treatment failure: development of danger signs or severe malaria on Day 1, Day 2 or Day 3 in the presence of parasitemia (severe malaria defined by altered sensorium convulsions, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00126971",
    "endpoint": "measure - persistent vomiting, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00126971",
    "endpoint": "measure - renal impairment, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00126971",
    "endpoint": "measure - respiratory distress), description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00126971",
    "endpoint": "measure - a fall in Hb below 5g&#x2F;dl anytime, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00126971",
    "endpoint": "measure - parasitemia on Day 2 higher than Day 0 count irrespective of axillary temperature, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00126971",
    "endpoint": "measure - parasitemia on Day 3 with axillary temperature &gt;= 37.5 °C, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00126971",
    "endpoint": "measure - parasitemia on Day 3 &gt;= 25% of count on Day 0, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00126971",
    "endpoint": "measure - Late clinical failure: development of danger signs of severe malaria after Day 3 in the presence of parasitemia, without previously meeting any of the criteria of early treatment failure, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00126971",
    "endpoint": "measure - presence of parasitemia and axillary temperature &gt;= 37.5 °C on any day from Day 4 (inclusive) to Day 28 (inclusive), without previously meeting any of the criteria of early treatment failure, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00126971",
    "endpoint": "measure - Late parasitological failure: parasitemia on any day between Day 7 (inclusive) and Day 28 (inclusive), description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00126971",
    "endpoint": "measure - axillary temperature &lt;37.5 °C without previously meeting any of the criteria of early treatment failure or late clinical failure, after exclusion of re-infection by PCR (days, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00126971",
    "endpoint": "measure - adequate clinical and parasitological response [ACPR] will be defined as: absence of parasitemia on Day 28 irrespective of axillary temperature without previously meeting any of the criteria of early treatment failure, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00126971",
    "endpoint": "measure - or late clinical failure, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00126971",
    "endpoint": "measure - or late parasitologic failure), description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00126971",
    "endpoint": "measure - Parasite clearance by Day 3, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00126971",
    "endpoint": "measure - Mean Hb concentrations by Day 28, and hematological recovery by day 28 (Hb &gt; 11 g&#x2F;dL), description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00126971",
    "endpoint": "measure - Gametocytemia, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00126971",
    "endpoint": "measure - Maternal parasitemia at delivery, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00126971",
    "endpoint": "measure - Placental malaria parasitemia, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00126971",
    "endpoint": "measure - Mean birth weight and gestational age of newborn, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00126971",
    "endpoint": "measure - Presence of congenital abnormalities, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00126971",
    "endpoint": "measure - Incidence of fetal loss, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00126971",
    "endpoint": "measure - Incidence of perinatal and neonatal mortality, assessed 4-6 weeks after due date of delivery, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00126971",
    "endpoint": "measure - Incidence of fetal death, defined as absence of fetal heartbeat, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00126971",
    "endpoint": "measure - Hypoglycemia requiring treatment, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00126971",
    "endpoint": "measure - Other adverse events during treatment period (up to 28 days), description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00550160",
    "endpoint": "measure - Prevalence of peripheral parasitaemia, description - , timeFrame - One year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00550160",
    "endpoint": "measure - Prevalence of anaemia, description - , timeFrame - One year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00550160",
    "endpoint": "measure - Parasite density (geometric means), description - , timeFrame - One year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00550160",
    "endpoint": "measure - Proportions adhering to strategies, description - , timeFrame - One year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00550160",
    "endpoint": "measure - Incidence of adverse drug effects within 7 days after intervention, description - , timeFrame - One year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02793414",
    "endpoint": "measure - Correlation of malaria parasite density with VOC concentrations, description - The correlation of malaria parasite density with VOC concentrations in patients with clinical and subpatent malaria and the recovery profile of VOC following acute malaria., timeFrame - 7 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02793414",
    "endpoint": "measure - G6PD variants, description - G6PD variants within the local population, timeFrame - 1 day",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02793414",
    "endpoint": "measure - G6PD activity in U&#x2F;gHb, description - The distribution of G6PD enzyme activity in the local population measured in U&#x2F;gHb., timeFrame - 1 day",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02793414",
    "endpoint": "measure - Performance characteristics of qualitative and quantitative G6PD test formats., description - Sensitivity and specificity of other G6PD diagnostic assays compared to the gold standard spectrophotometry, timeFrame - 1 day",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00157833",
    "endpoint": "measure - Day 42 P.falciparum cure rate corrected for reinfection by PCR genotyping, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00157833",
    "endpoint": "measure - Day 42 P.vivax cure rate, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00157833",
    "endpoint": "measure - Overall day 28 cure rate for P.falciparum, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00157833",
    "endpoint": "measure - Proportion of patients aparasitaemic on Days 1 and 2, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00157833",
    "endpoint": "measure - Haematological recovery, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00157833",
    "endpoint": "measure - Gametocyte Carriage during follow up, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02858817",
    "endpoint": "measure - Occurrence of any related AE, description - , timeFrame - from time of first administration of A&#x2F;P until the last follow up visit, 414 days after first administration",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02858817",
    "endpoint": "measure - Proportion of protected volunteers, description - . Protection is defined as the absence of parasites in the peripheral blood for 28 days following first and second CHMI with PfSPZ Challenge (NF54) and PfSPZ Challenge (7G8) in volunteers receiving PfSPZ-CVac with A&#x2F;P.\nParasitemia is defined as at least one qPCR result above 100 parasites per mL among three positive results at least 12 hours apart or as a positive thick blood smear.\nStatistical testing is hierarchical: 1) protection against first CHMI, 2) protection against second CHMI., timeFrame - From time of PfSPZ challenge administration until 28 days after PfSPZ challenge",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04321252",
    "endpoint": "measure - Part A - Pharmacokinetic of KAE609: Maximum Observed Plasma Concentration (Cmax), description - Venous whole blood samples were collected for activity-based pharmacokinetics characterization.\nCmax was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics., timeFrame - Day 1 (-1 hr, 2 min, 10 min, 30 min, 1 hr, 3 hr, 6 hr, 12 hr)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04321252",
    "endpoint": "measure - Part A - Pharmacokinetic of KAE609: Time to Reach the Maximum Concentration After Drug Administration (Tmax), description - Venous whole blood samples were collected for activity-based pharmacokinetics characterization.\nTmax was calculated from plasma concentration-time data using non-compartmental methods based on the actual time of sample collection and summarized using descriptive statistics., timeFrame - Day 1 (-1 hr, 2 min, 10 min, 30 min, 1 hr, 3 hr, 6 hr, 12 hr)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04321252",
    "endpoint": "measure - Part A - Pharmacokinetic of KAE609: Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUClast), description - Venous whole blood samples were collected for activity-based pharmacokinetics characterization.\nAUClast was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics., timeFrame - Day 1 (-1 hr, 2 min, 10 min, 30 min, 1 hr, 3 hr, 6 hr, 12 hr)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04321252",
    "endpoint": "measure - Part A - Pharmacokinetic of KAE609: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf), description - Venous whole blood samples were collected for activity-based pharmacokinetics characterization.\nAUCinf was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics., timeFrame - Day 1 (-1 hr, 2 min, 10 min, 30 min, 1 hr, 3 hr, 6 hr, 12 hr)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04321252",
    "endpoint": "measure - Part A - Pharmacokinetic of KAE609: Area Under the Plasma Concentration-time Curve From Time Zero to 24 Hours (AUC0-24hrs), description - Venous whole blood samples were collected for activity-based pharmacokinetics characterization.\nAUC0-24hrs was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics., timeFrame - Day 1 (-1 hr, 2 min, 10 min, 30 min, 1 hr, 3 hr, 6 hr, 12 hr)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04321252",
    "endpoint": "measure - Part A - Pharmacokinetic of KAE609: Terminal Elimination Half-life (T1&#x2F;2), description - Venous whole blood samples were collected for activity-based pharmacokinetics characterization.\nT1&#x2F;2 was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics., timeFrame - Day 1 (-1 hr, 2 min, 10 min, 30 min, 1 hr, 3 hr, 6 hr, 12 hr)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04321252",
    "endpoint": "measure - Part A - Pharmacokinetic of KAE609: Clearance From Plasma (CL) Following Drug Administration, description - Venous whole blood samples were collected for activity-based pharmacokinetics characterization.\nCL was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics., timeFrame - Day 1 (-1 hr, 2 min, 10 min, 30 min, 1 hr, 3 hr, 6 hr, 12 hr)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04321252",
    "endpoint": "measure - Part A - Pharmacokinetic of KAE609: Apparent Volume of Distribution During Terminal Phase (Vz), description - Venous whole blood samples were collected for activity-based pharmacokinetics characterization.\nVz was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics., timeFrame - Day 1 (-1 hr, 2 min, 10 min, 30 min, 1 hr, 3 hr, 6 hr, 12 hr)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04321252",
    "endpoint": "measure - Part B - Pharmacokinetic of KAE609: Maximum Observed Plasma Concentration (Cmax), description - Venous whole blood samples were collected for activity-based pharmacokinetics characterization.\nCmax was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics., timeFrame - Days 1 and 5 (-1 hr, 2 min, 10 min, 30 min, 1 hr, 3 hr, 6 hr, 12 hr)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04321252",
    "endpoint": "measure - Part B - Pharmacokinetic of KAE609: Time to Reach the Maximum Concentration After Drug Administration (Tmax), description - Venous whole blood samples were collected for activity-based pharmacokinetics characterization.\nTmax was calculated from plasma concentration-time data using non-compartmental methods based on the actual time of sample collection and summarized using descriptive statistics., timeFrame - Days 1 and 5 (-1 hr, 2 min, 10 min, 30 min, 1 hr, 3 hr, 6 hr, 12 hr)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04321252",
    "endpoint": "measure - Part B - Pharmacokinetic of KAE609: Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUClast), description - Venous whole blood samples were collected for activity-based pharmacokinetics characterization.\nAUClast was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics., timeFrame - Day 5 (-1 hr, 2 min, 10 min, 30 min, 1 hr, 3 hr, 6 hr, 12 hr)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04321252",
    "endpoint": "measure - Part B - Pharmacokinetic of KAE609: Area Under the Plasma Concentration-time Curve From Time Zero to 24 Hours (AUC0-24hrs), description - Venous whole blood samples were collected for activity-based pharmacokinetics characterization.\nAUC0-24hrs was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics., timeFrame - Days 1 and 5 (-1 hr, 2 min, 10 min, 30 min, 1 hr, 3 hr, 6 hr, 12 hr)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04321252",
    "endpoint": "measure - Part B - Pharmacokinetic of KAE609: Terminal Elimination Half-life (T1&#x2F;2), description - Venous whole blood samples were collected for activity-based pharmacokinetics characterization.\nT1&#x2F;2 was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics., timeFrame - Days 1 and 5 (-1 hr, 2 min, 10 min, 30 min, 1 hr, 3 hr, 6 hr, 12 hr)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04321252",
    "endpoint": "measure - Part B - Pharmacokinetic of KAE609: Clearance From Plasma (CL) Following Drug Administration, description - Venous whole blood samples were collected for activity-based pharmacokinetics characterization.\nCL was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics., timeFrame - Day 5 (-1 hr, 2 min, 10 min, 30 min, 1 hr, 3 hr, 6 hr, 12 hr)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04321252",
    "endpoint": "measure - Part B - Pharmacokinetic of KAE609: Apparent Volume of Distribution During Terminal Phase (Vz), description - Venous whole blood samples were collected for activity-based pharmacokinetics characterization.\nVz was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics., timeFrame - Day 5 (-1 hr, 2 min, 10 min, 30 min, 1 hr, 3 hr, 6 hr, 12 hr)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07281443",
    "endpoint": "measure - Clinical malaria burden, description - Cumulative P. falciparum clinical malaria incidence in study villages during the high transmission season (june to january) as recorded at community (CHW) and health-facility level.\nComparison between intervention and control periods will evaluate burden reduction associated with intervention status., timeFrame - year 1, year 2",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07281443",
    "endpoint": "measure - Spatio-temporal dynamics of clinical malaria incidence, description - Time-series of weekly cumulative incidence of clinical P. falciparum malaria recorded by CHW and health facilities in study villages during the high transmission season., timeFrame - year 1, year 2",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07281443",
    "endpoint": "measure - Mass drug administration safety (active), description - Frequency and severity of adverse events identified by active detection in a random sample of participants immediately after each MDA round., timeFrame - Day 4 after MDA start",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07281443",
    "endpoint": "measure - Mass drug administration safety (passive), description - Frequency and severity of adverse events recorded by passive detection at community (CHW) and health-facility level during each MDA (MDA1, 2, 3 and 4)., timeFrame - Day 0 to day 7 after MDA start",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07281443",
    "endpoint": "measure - Plasmodium falciparum carriage reservoir at the onset of the high transmission season (step 1), description - Number of participants with P. falciparum infection (measured by qPCR in cross sectional sample).\nSurvey conducted at step 1 (year 1, intervention in 50% of clusters).\nSurvey takes place immediately before SMC round 1 in control villages and immediately before MDA1 in intervention villages.\nThis period corresponds to the onset of the high transmission season (i.e. the end of the dry, low transmission season), timeFrame - immediately before MDA1&#x2F;SMC round 1, year 1",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07281443",
    "endpoint": "measure - Plasmodium falciparum carriage reservoir at the onset of the high transmission season (step 2), description - Number of participants with P. falciparum infection (measured by qPCR in cross sectional sample).\nSurveys conducted at step 2 (year 2, intervention in 100% of clusters), immediately before MDA3, at the onset of the high transmission season (i.e. at the end of the dry, low transmission season), timeFrame - immediately before MDA3, year 2",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07281443",
    "endpoint": "measure - Plasmodium falciparum infection prevalence in 10-14 and 15-24 years, description - Number of participants aged 10-14 and 15-24 years with P. falciparum infection (measured by qPCR in cross sectional sample).\nSurveys conducted at step 1 (year 1, intervention in 50% of clusters).\nSurvey takes place 4 months after SMC round 1 in control villages (i.e.\nimmediately before SMC round 5) and 4 months after MDA1 in intervention villages (i.e.\nimmediately before MDA2).\nThis subgroup analysis of secondary outcome 2 will enable comparison of prevalence and prevalence reduction between intervention and control periods by age-group to estimate potential effectiveness of the targeted control intervention., timeFrame - 4 months after SMC round 1 &#x2F; MDA1, year 1",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07281443",
    "endpoint": "measure - Plasmodium falciparum infection prevalence in 10-14 and 15-24 years, description - Number of participants aged 10-14 and 15-24 years with P. falciparum infection (measured by qPCR in cross sectional sample).\nSurveys conducted at step 2 (year 2, intervention in all clusters).\nSurvey takes place 4 months after MDA3 (i.e.\nimmediately before MDA4).\nThis subgroup analysis of secondary outcome 3 will enable comparison of prevalence and prevalence reduction between intervention and control periods by age-group to estimate potential effectiveness of the targeted control intervention., timeFrame - 4 months after MDA3, year 2",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07281443",
    "endpoint": "measure - Intervention cost-effectiveness, description - Intervention cost and cost-effectiveness ratio regarding prevalence reduction and clinical burden reduction, timeFrame - year 2 and year 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07281443",
    "endpoint": "measure - Participation to MDA intervention, description - Proportion of population participating to intervention relatively to total and eligible population, estimated for each MDA round (MDA1 to MDA4).\n3-dose complete participation measured at the end of each MDA round, as well as incomplete participation (only 1 or 2 doses taken)., timeFrame - Day 5 after MDA (MDA1 &amp; MDA2, year 1; MDA2 &amp; MDA3, year 2).",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07281443",
    "endpoint": "measure - Participation to targeted control intervention (15-24 years), description - Proportion of eligible 15-24 years old who completed at least one rapid diagnostic test during targeted control activities taking place from month 2 to month 3 after MDA1 during year 1 and from month 2 to month 3 after MDA3 during year 2., timeFrame - from month 2 to month 3 MDA1 (year 2) ; from month 2 to month 3 after MDA3 (year 2)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07281443",
    "endpoint": "measure - Intervention acceptability, description - Sekhon&#x27;s indicators of acceptability evaluated using mixed methods (quantitative during cross-sectional surveys and qualitative) evaluated prospectively before MDA and retrospectively after MDA.\nQuantitative evaluation will rely on a -7 to +7 scale established combining responses to close-ended questions on the 7 dimensions of acceptability., timeFrame - after MDA, year 1",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00132561",
    "endpoint": "measure - Side effects, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00132561",
    "endpoint": "measure - Change in the prevalence of drug resistance markers, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02491606",
    "endpoint": "measure - Prophylactic outcome after 7 weeks, description - <p>Thick blood films were stained with Giemsa stain and malaria parasite counts determined by counting the number of asexual parasites per 200 white blood cells.</p><p>A blood slide was not considered negative until an examination of 200 oil immersion fields showed no parasites.</p>, timeFrame - 7 Weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02491606",
    "endpoint": "measure - Prophylactic outcome after 10 weeks, description - <p>Thick blood films were stained with Giemsa stain and malaria parasite counts determined by counting the number of asexual parasites per 200 white blood cells.</p><p>A blood slide was not considered negative until an examination of 200 oil immersion fields showed no parasites.</p>, timeFrame - 10 Weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05652504",
    "endpoint": "measure - Safety and tolerability in pregnant women and their fetuses using solicited adverse events (AEs), unsolicited AEs, and laboratory abnormalities, description - Solicited local and systemic AEs through 7 days post injection (counts and proportions) -Clinical laboratory parameters through 14 days post injection (counts and proportions) -All unsolicited AEs, medically attended AEs (MAEs), and serious AEs (SAEs) through delivery and six months thereafter (counts and proportions), timeFrame - 7 and 14 days post injection; 6 months after delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03768908",
    "endpoint": "measure - The clinical and parasitological response outcome (i.e. cure rates) on days 14, day 28 and 42., description - Comparing proportion of response outcomes according to standard WHO classification i.e., cure rates on days 14, day 28 and 42.\nDefined as the absence of both re-parasitaemia and clinical symptoms suggestive of severe malaria during follow-up to the respective days., timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02605720",
    "endpoint": "measure - Change in QTcF interval after study drugs administration compared to baseline, description - , timeFrame - Day 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02605720",
    "endpoint": "measure - Change in QTcF interval after study drugs administration compared to baseline, description - , timeFrame - Day 31",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07172724",
    "endpoint": "measure - Levels of IgG antibodies, description - Mean levels of IgG antibodies, calculated by the geometric mean of the titers against vaccine and parasitic antigens on days 7, 14, 28, 35, 42, 56, 63, 70, 84, 120, 180, 270 and 360 in relation to time 0 and placebo, by ELISA., timeFrame - Day 7, 14, 28, 35, 42, 56, 63, 70, 84, 120, 180, 270 and 360 after immunization",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00075049",
    "endpoint": "measure - To assess the humoral immune response to the candidate vaccine, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00075049",
    "endpoint": "measure - To assess the efficacy of the candidate vaccine, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00545935",
    "endpoint": "measure - Incidence of serious adverse events (SAE) and the adequate clinical and parasitological response rate (ACPR), description - , timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00545935",
    "endpoint": "measure - Early treatment failure (ETF) rate, description - , timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00545935",
    "endpoint": "measure - Late clinical failure (LCF) rate at D14 and D28, description - , timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00545935",
    "endpoint": "measure - Late parasitological failure (LPF) rate at D14 and D28, description - , timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00545935",
    "endpoint": "measure - Fever clearance time, description - , timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00545935",
    "endpoint": "measure - Parasite clearance time, description - , timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00545935",
    "endpoint": "measure - Change in haematocrit after 2,14 and 28 days compared to baseline, description - , timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00545935",
    "endpoint": "measure - MB whole blood concentrations on D3,5 or 7 compared to concentrations after the first dose, description - , timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01814423",
    "endpoint": "measure - Parasitemia, description - Blood smear for microscopy will be performed in the morning and evening on the days of treatment, and for the 50 mg group on day 3.\nDuring follow-uo weekly until day 28., timeFrame - Twice a day dúring treatment and then weekly until day 28.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01663831",
    "endpoint": "measure - Malaria incidence, description - Through passive RDT case detection, timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05330273",
    "endpoint": "measure - Observed maximum plasma concentration (Cmax) for Ganaplacide metabolites (RHF218 and GOU089), description - Venous whole blood samples will be collected for activity-based pharmacokinetics characterization.\nCmax will be listed and summarized using descriptive statistics., timeFrame - 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 240, and 336 hours (post dose)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05330273",
    "endpoint": "measure - Area under the serum concentration-time curve from time zero to the time of last quantifiable concentration (AUClast) for Ganaplacide metabolites (RHF218 and GOU089), description - Venous whole blood samples will be collected for activity-based pharmacokinetics characterization.\nAUClast will be listed and summarized using descriptive statistics., timeFrame - 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 240, and 336 hours (post dose)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05330273",
    "endpoint": "measure - Area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time (AUCinf) for Ganaplacide metabolites (RHF218 and GOU089), description - Venous whole blood samples will be collected for activity-based pharmacokinetics characterization.\nAUCinf will be listed and summarized using descriptive statistics., timeFrame - 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 240, and 336 hours (post dose)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05330273",
    "endpoint": "measure - Area under the concentration-time curve from time zero (pre-dose) to the 24-hour time point (AUC0-24) for Ganaplacide metabolites (RHF218 and GOU089), description - Venous whole blood samples will be collected for activity-based pharmacokinetics characterization.\nAUC^0-24 will be listed and summarized using descriptive statistics., timeFrame - 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 240, and 336 hours (post dose)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05330273",
    "endpoint": "measure - Time of maximum observed drug concentration occurrence (Tmax) for Ganaplacide metabolites (RHF218 and GOU089), description - Venous whole blood samples will be collected for activity-based pharmacokinetics characterization.\nTmax will be listed and summarized using descriptive statistics., timeFrame - 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 240, and 336 hours (post dose)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05330273",
    "endpoint": "measure - Terminal elimination half-life (T^1&#x2F;2) for Ganaplacide metabolites (RHF218 and GOU089), description - Venous whole blood samples will be collected for activity-based pharmacokinetics characterization.\nT^1&#x2F;2 will be listed and summarized using descriptive statistics., timeFrame - 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 240, and 336 hours (post dose)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05330273",
    "endpoint": "measure - Metabolite to Parent Ratio (MR) for Ganaplacide metabolites (RHF218 and GOU089), description - Venous whole blood samples will be collected for activity-based pharmacokinetics characterization.\nMR will be listed and summarized using descriptive statistics., timeFrame - 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 240, and 336 hours (post dose)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05385510",
    "endpoint": "measure - Antibody responses to CSP and HBsAb, description - Antibody responses to CSP (total anti-IgG responses to NANP and C-term region of CSP) and HBsAb, timeFrame - 1 and 6 months following third dose, and 1 and 12 months following booster dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05385510",
    "endpoint": "measure - HIV viral load, description - Change in total HIV DNA copies per million CD4+ T cells, timeFrame - 7 days post doses 1 and 2, 30 days post dose 3, and 7, 30 and 365 days post booster",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05385510",
    "endpoint": "measure - CD4+ count, age at enrolment and vaccine immune response, description - CD4+ count, age at enrolment and vaccine immune response, timeFrame - 1 week after doses 1 and booster, 1 and 6 months after dose 3, and 1 and 12 months after the booster dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00873938",
    "endpoint": "measure - Reasons for non-compliance, description - , timeFrame - Within 28 days after diagnosis of malaria",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00873938",
    "endpoint": "measure - Participants&#x27; perception and acceptance of supervision, description - , timeFrame - Within 28 days after diagnosis of malaria",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00873938",
    "endpoint": "measure - Parasite clearance rates on day 14 and 28, description - , timeFrame - Within 28 days after diagnosis of malaria",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01205178",
    "endpoint": "measure - Maximum absolute decline in Hgb (or Hct) from baseline for TQ in G6PD-deficient healthy volunteers compared to G6PD-normal healthy volunteers., description - , timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00652275",
    "endpoint": "measure - Solicited adverse events measured from day 0 to day 7 after each dose, description - , timeFrame - 7 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00652275",
    "endpoint": "measure - Unsolicited adverse events measured up to one month after each dose, description - , timeFrame - Day 84",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00652275",
    "endpoint": "measure - Serious Adverse Events measured during the 12 months of study duration, description - , timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00652275",
    "endpoint": "measure - The humoral response to the vaccine antigen: assessed by measuring the level of IgG by ELISA, description - , timeFrame - Day 84",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00652275",
    "endpoint": "measure - IgG ability to recognize the native protein on Merozoite using Western Blot(WB) method, description - , timeFrame - Day 84",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00652275",
    "endpoint": "measure - Incidence of all clinical malaria episodes occurring through two transmission seasons subsequent to the 3 doses., description - , timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01024426",
    "endpoint": "measure - Prevalence of parasitemia in children under five in the cross-sectional surveys, description - Proportion of thick blood smears that are positive for asexual parasites, timeFrame - annually",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01024426",
    "endpoint": "measure - All-cause mortality, description - Probability of dying between birth and five years of age, expressed per 1,000 live births, timeFrame - Annually",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01024426",
    "endpoint": "measure - Incidence of hospitalizations in children under five in the cohort study, description - Overnight admission to a hospital or clinic, timeFrame - two years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01024426",
    "endpoint": "measure - Incidence of illness episodes in children under five in the cohort study, description - Episode of illness as reported by primary caregiver, timeFrame - Two years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01024426",
    "endpoint": "measure - Incidence of febrile episodes in children under five in the cohort study, description - Episode of illness associated with fever as reported by primary caregiver, timeFrame - Two years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01024426",
    "endpoint": "measure - Prompt effective treatment of fever in children under five in the cohort study, description - Proportion of children with fever treated within 24 hours of onset of symptoms with an ACT, timeFrame - Two years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01024426",
    "endpoint": "measure - Incidence of serious adverse events in children under five in the cohort study, description - Any experience that results in death, life-threatening experience, hospitalization, persistent or significant disability or incapacity, or specific medical or surgical intervention to prevent one of the other serious outcomes, timeFrame - Two years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01024426",
    "endpoint": "measure - Prompt effective treatment of malaria in children under five in the cohort study, description - Proportion of children with malaria (confirmed by a parasitological test) treated within 24 hours of onset of symptoms with an ACT, timeFrame - Two years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01024426",
    "endpoint": "measure - Appropriate treatment of malaria in children under five in the Patient Exit Interviews, description - Proportion of children under five with suspected malaria and a positive RDT result who are appropriately given an ACT + Proportion of children under five with suspected malaria and a negative RDT result who are not prescribed an ACT, timeFrame - Every six months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01024426",
    "endpoint": "measure - Inappropriate treatment of malaria in children under five in the Patient Exit Interviews, description - Proportion of children under five with suspected malaria and a positive RDT result who are inappropriately given a non-ACT regimen, timeFrame - Every six months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01024426",
    "endpoint": "measure - Patient satisfaction with health care in caregivers of children under five in the Patient Exit Interviews, description - Proportion of patients indicating they were satisfied with care provided at the health center in exit interviews, timeFrame - Every six months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01024426",
    "endpoint": "measure - Patient attendance in the Health facility surveillance, description - Total number of patients attending health facilities and their characteristics, including age, sex,village of residence, and diagnosis, timeFrame - Every two months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01024426",
    "endpoint": "measure - Stock-outs of ACTs in the Health facility surveillance, description - Days per month that AL supplied by NMS via the district is not available, timeFrame - Every two months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01024426",
    "endpoint": "measure - Knowledge questionnaire scores for Health workers, description - Proportion of questions answered correctly by clinicians following training in fever case management, timeFrame - Annually",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01024426",
    "endpoint": "measure - Prevalence of anemia in children aged 5-15years in the cross-sectional surveys, description - Proportion of hemoglobin measurements &lt; 11.0 g&#x2F;dL as measured in cross sectional surveys.\nAnemia will be classified according to severity: mild (Hb 8.0 - 10.9), moderate (Hb 5.0 - 7.9), severe (Hb &lt; 5.0)., timeFrame - annually",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00292942",
    "endpoint": "measure - Cardiovascular Responses: Number of Participants With Changes in Blood Pressure and Heart Rate After Infusion, description - Cardiovascular Responses: Number of participants with changes in blood pressure and heart rate after infusion to determine change from baseline, timeFrame - screening, on Day -1, on Days 1, 2, and 3, and at each follow-up visit",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00292942",
    "endpoint": "measure - Range of Pharmacokinetic Parameters for Artesunic Acid After Single 2.0, 4.0 and 8.0 mg&#x2F;kg Dose of Artesunate Daily for 3 Days (ng*hr&#x2F;mL), description - For artesunic acid, AUC0-last was determine for each dose; as well as the total area under the curve (AUClastTOTAL), calculated as the sum of AUClast for each of the doses (ng*hr&#x2F;mL), timeFrame - Pre-dose, 5, 20, 40 minutes after infusion and 1, 2, 4, 8, 24 and 72 hours after infusion",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00292942",
    "endpoint": "measure - Range of Pharmacokinetic Parameters for Artesunic Acid After Single 2.0, 4.0 and 8.0 mg&#x2F;kg Dose of Artesunate Daily for 3 Days (ng&#x2F;mL), description - For the predicted concentration at the time of dose administration (C0) was determine for each dose (ng&#x2F;mL), timeFrame - Pre-dose, 5, 20, 40 minutes after infusion and 1, 2, 4, 8, 24 and 72 hours after infusion",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00292942",
    "endpoint": "measure - Range of Pharmacokinetic Parameters for Dihydroartemisinin (DHA) After Single 2.0, 4.0 and 8.0 mg&#x2F;kg Dose of Artesunate Daily for 3 Days (ng*hr&#x2F;mL), description - For DHA, AUC24, and AUClast were calculated for each dose, as well as the total area under the curve extrapolated to infinite time (AUC∞TOTAL), calculated as the sum of AUC24 for each dose +C24&#x2F;λz., timeFrame - Pre-dose, 5, 20, 40 minutes after infution and 1, 2, 4, 8, 24 and 72 hours after infusion",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00292942",
    "endpoint": "measure - Cmax Assessment After Single 2.0, 4.0 and 8.0 mg&#x2F;kg Dose of Artesunate Daily for 3 Days (ng&#x2F;mL), description - Cmax was calculated after single 2.0, 4.0 and 8.0 mg&#x2F;kg dose of Artesunate daily for 3 days (ng&#x2F;mL), timeFrame - Pre-dose, 5, 20, 40 minutes after infution and 1, 2, 4, 8, 24 and 72 hours after infusion",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00292942",
    "endpoint": "measure - Tmax Assessment After Single 2.0, 4.0 and 8.0 mg&#x2F;kg Dose of Artesunate Daily for 3 Days (hr), description - Tmax was calculated after single 2.0, 4.0 and 8.0 mg&#x2F;kg dose of Artesunate daily for 3 days (hr), timeFrame - Pre-dose, 5, 20, 40 minutes after infution and 1, 2, 4, 8, 24 and 72 hours after infusion",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02497612",
    "endpoint": "measure - Percentage of Participants With Polymerase Chain Reaction-adjusted Adequate Clinical and Parasitological Response at Day 28: African &gt;5 Years Per Protocol Population at Day 28 (A5PP28), description - ACPR: negative parasitemia at Day 28, irrespective of AT, in participants not meeting any criteria of ETF: DS or SM at Day 1, 2 or 3 in presence of parasitemia; or Day 2 parasite count &gt; Day 0 irrespective of AT; or parasitemia at Day 3 with AT &gt;=37.5°C; or parasite count on Day 3 &gt;=25% on Day 0, or LCF: DS&#x2F; SM in presence of parasitemia between Day 4 and 28; or presence of parasitemia and AT &gt;=37.5°C between Day 4 and 28, or LPF: presence of parasitemia between Day 7 and 28 and AT &lt;37.5°C or having rescue therapy for malaria.\nPCR-adjusted ACPR was applied to recrudescence (appearance of asexual parasites after clearance of initial infection with a genotype identical to that of parasites present at Baseline), excluding participants with re-infection.\nHere, in the data table, &quot;overall number of participants analyzed&quot;=participants evaluable for this outcome measure., timeFrame - Day 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02497612",
    "endpoint": "measure - Percentage of Participants With Polymerase Chain Reaction-adjusted Adequate Clinical and Parasitological Response at Day 28: Asian PP Population at Day 28 (APP28), description - ACPR: negative parasitemia at Day 28, irrespective of AT, in participants not meeting any criteria of ETF: DS or SM at Day 1, 2 or 3 in presence of parasitemia; or Day 2 parasite count &gt; Day 0 irrespective of AT; or parasitemia at Day 3 with AT &gt;=37.5°C; or parasite count on Day 3 &gt;=25% on Day 0, or LCF: DS&#x2F; SM in presence of parasitemia between Day 4 and 28; or presence of parasitemia and AT &gt;=37.5°C between Day 4 and 28, or LPF: presence of parasitemia between Day 7 and 28 and AT &lt;37.5°C or having rescue therapy for malaria.\nPCR-adjusted ACPR was applied to recrudescence (appearance of asexual parasites after clearance of initial infection with a genotype identical to that of parasites present at Baseline), excluding participants with re-infection.\nHere, in the data table, &quot;overall number of participants analyzed&quot;=participants evaluable for this outcome measure., timeFrame - Day 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02497612",
    "endpoint": "measure - Percentage of Participants With Polymerase Chain Reaction-adjusted Adequate Clinical and Parasitological Response at Day 42: African &lt;=5 Years PP Population at Day 42 (PP42), description - ACPR: negative parasitemia at Day 42, irrespective of AT, in participants not meeting any criteria of ETF: DS or SM at Day 1, 2 or 3 in presence of parasitemia; or Day 2 parasite count &gt; Day 0 irrespective of AT; or parasitemia at Day 3 with AT &gt;=37.5°C; or parasite count on Day 3 &gt;=25% on Day 0, or LCF: DS&#x2F; SM in presence of parasitemia between Day 4 and 42; or presence of parasitemia and AT &gt;=37.5°C between Day 4 and 42, or LPF: presence of parasitemia between Day 7 and 42 and AT &lt;37.5°C or having rescue therapy for malaria.\nPCR-adjusted ACPR was applied to recrudescence (appearance of asexual parasites after clearance of initial infection with a genotype identical to that of parasites present at Baseline), excluding participants with re-infection.\nHere, in the data table, &quot;overall number of participants analyzed&quot;=participants evaluable for this outcome measure., timeFrame - Day 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02497612",
    "endpoint": "measure - Percentage of Participants With Polymerase Chain Reaction-adjusted Adequate Clinical and Parasitological Response at Day 63: African &lt;=5 Years PP Population at Day 63 (PP63), description - ACPR: negative parasitemia at Day 63, irrespective of AT, in participants not meeting any criteria of ETF: DS or SM at Day 1, 2 or 3 in presence of parasitemia; or Day 2 parasite count &gt; Day 0 irrespective of AT; or parasitemia at Day 3 with AT &gt;=37.5°C; or parasite count on Day 3 &gt;=25% on Day 0, or LCF: DS&#x2F; SM in presence of parasitemia between Day 4 and 63; or presence of parasitemia and AT &gt;=37.5°C between Day 4 and 63, or LPF: presence of parasitemia between Day 7 and 63 and AT &lt;37.5°C or having rescue therapy for malaria.\nPCR-adjusted ACPR was applied to recrudescence (appearance of asexual parasites after clearance of initial infection with a genotype identical to that of parasites present at Baseline), excluding participants with re-infection.\nHere, in the data table, &quot;overall number of participants analyzed&quot;=participants evaluable for this outcome measure., timeFrame - Day 63",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02497612",
    "endpoint": "measure - Percentage of Participants With Crude Adequate Clinical and Parasitological Response at Day 28: African &lt;=5 Years PP28 Population, description - ACPR was defined as negative parasitemia at Day 28, irrespective of AT, in participants not meeting any criteria of ETF: DS or SM at Day 1, 2 or 3 in presence of parasitemia; or Day 2 parasite count &gt; Day 0 irrespective of AT; or parasitemia at Day 3 with AT &gt;=37.5°C; or parasite count on Day 3 &gt;=25% on Day 0, or LCF: DS&#x2F; SM in presence of parasitemia between Day 4 and 28; or presence of parasitemia and AT &gt;=37.5°C between Day 4 and 28 or, LPF: presence of parasitemia between Day 7 and 28 and AT &lt;37.5°C or having rescue therapy for malaria.\nPCR-adjusted ACPR applied to recrudescence (appearance of asexual parasites after clearance of initial infection with a genotype identical to that of parasites present at Baseline), excluding participants with re-infection, whereas crude ACPR does not distinguish re-infection (new clone of parasite) or recrudescence., timeFrame - Day 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02497612",
    "endpoint": "measure - Percentage of Participants With Crude Adequate Clinical and Parasitological Response at Day 42: African &lt;=5 Years PP42 Population, description - ACPR was defined as negative parasitemia at Day 42, irrespective of AT, in participants not meeting any criteria of ETF: DS or SM at Day 1, 2 or 3 in presence of parasitemia; or Day 2 parasite count &gt; Day 0 irrespective of AT; or parasitemia at Day 3 with AT &gt;=37.5°C; or parasite count on Day 3 &gt;=25% on Day 0, or LCF: DS&#x2F; SM in presence of parasitemia between Day 4 and 42; or presence of parasitemia and AT &gt;=37.5°C between Day 4 and 42 or, LPF: presence of parasitemia between Day 7 and 42 and AT &lt;37.5°C or having rescue therapy for malaria PCR-adjusted ACPR applied to recrudescence (appearance of asexual parasites after clearance of initial infection with a genotype identical to that of parasites present at Baseline), excluding participants with re-infection, whereas crude ACPR did not distinguish re-infection (new clone of parasite) or recrudescence., timeFrame - Day 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02497612",
    "endpoint": "measure - Percentage of Participants With Crude Adequate Clinical and Parasitological Response at Day 63: African &lt;=5 Years PP63 Population, description - Crude ACPR was defined as negative parasitemia at Day 63, irrespective of AT, in participants not meeting any criteria of ETF: DS or SM at Day 1, 2 or 3 in presence of parasitemia; or Day 2 parasite count &gt; Day 0 irrespective of AT; or parasitemia at Day 3 with AT &gt;=37.5°C; or parasite count on Day 3 &gt;=25% on Day 0, or LCF: DS&#x2F; SM in presence of parasitemia between Day 4 and 63; or presence of parasitemia and AT &gt;=37.5°C between Day 4 and 63 or, LPF: presence of parasitemia between Day 7 and 63 and AT &lt;37.5°C or having rescue therapy for malaria.\nPCR-adjusted ACPR applied to recrudescence (appearance of asexual parasites after clearance of initial infection with a genotype identical to that of parasites present at Baseline), excluding participants with re-infection, whereas crude ACPR did not distinguish re-infection (new clone of parasite) or recrudescence., timeFrame - Day 63",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02497612",
    "endpoint": "measure - Time to Re-emergence, description - Time to re-emergence (in days) was defined as the time to appearance of asexual parasites after clearance of initial infection irrespective of genotype.\nParticipants with no event were censored at the time of study completion, premature study discontinuation, including switch to established anti-malarial treatment or start of any other treatment with anti-malarial activity, whichever was earliest.\nRe-emergence was confirmed by microscopy (positive blood smear).\nKaplan-Maier method was used for estimation.\nHere, &quot;overall number of participants analyzed&quot;=participants who were included in the analysis of below reported results which consisted of both, who had the event, plus those who were censored., timeFrame - Up to Day 63",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02497612",
    "endpoint": "measure - Time to Recrudescence, description - Time to recrudescence (in days) was defined as the time to appearance of asexual parasites after clearance of initial infection with a genotype identical to that of parasites present at Baseline.\nRecrudescence was confirmed by PCR analysis.\nKaplan-Maier method was used for estimation., timeFrame - Up to Day 63",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02497612",
    "endpoint": "measure - Time to Re-infection, description - Time to re-infection (in days) was defined as the time to appearance of asexual parasites after clearance of initial infection with a genotype that differs from that of parasites present at Baseline.\nRe-infection was confirmed by PCR analysis.\nKaplan-Maier method was used for estimation., timeFrame - Up to Day 63",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02497612",
    "endpoint": "measure - Parasite Clearance Time (PCT): African &lt;=5 Years PP Population, description - PCT was defined as the time (in hours) from the start of study drug administration until the time of first negative blood film (no asexual parasites).\nThis first negative film was confirmed by a second negative film which was taken &gt;=6 to &lt;=12 hours of the first film.\nKaplan-Meier method was used for the estimation.\nHere, in the data table &quot;overall number of participants analyzed&quot;=participants who were included in the analysis of below reported results which consisted of both, who had the event, plus those who were censored., timeFrame - From the start of study drug administration up to the time of the first negative film (up to Day 63)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02497612",
    "endpoint": "measure - Parasite Clearance Time: African &gt;5 Years PP Population, description - PCT was defined as the time (in hours) from the start of study drug administration until the time of first negative blood film (no asexual parasites).\nThis first negative film was confirmed by a second negative film which was taken &gt;=6 to &lt;=12 hours of the first film.\nKaplan-Meier method was used for the estimation.\nHere, &quot;overall number of participants analyzed&quot;=participants who were included in the analysis of below reported results which consisted of both, who had the event, plus those who were censored., timeFrame - From the start of study drug administration up to the time of the first negative film (up to Day 63)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02497612",
    "endpoint": "measure - Parasite Clearance Time: Asian PP Population, description - PCT was defined as the time (in hours) from the start of study drug administration until the time of first negative blood film (no asexual parasites).\nThis first negative film was confirmed by a second negative film which was taken &gt;=6 to &lt;=12 hours of the first film.\nKaplan-Meier method was used for the estimation.\nHere, &quot;overall number of participants analyzed&quot;=participants who were included in the analysis of below reported results which consisted of both, who had the event, plus those who were censored., timeFrame - From the start of study drug administration up to the time of the first negative film (up to Day 63)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02497612",
    "endpoint": "measure - Fever Clearance Time (FCT): African &lt;=5 Years PP Population, description - FCT was defined as the time (in hours) from start of study drug administration to the first assessment of adjusted body temperature &lt;37.5°C, confirmed by second assessment, taken within &gt;=6 to &lt;=12 hours of the first assessment.\nOnly participants with fever (adjusted body temperature &gt;=37.5°C\npresent at Baseline) and did not receive paracetamol on day of study drug administration until 96 hours after study drug administration were included in FCT analysis.\nParticipants with no event were censored at the time of study completion, premature study discontinuation, including switch to established anti-malarial treatment or start of any other treatment with anti-malarial activity, whichever was earliest.\nKaplan-Meier method was used for the estimation., timeFrame - From the start of study drug administration up to the time of the first temperature measurement &lt;37.5°C (up to Day 63)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02497612",
    "endpoint": "measure - Fever Clearance Time: African &gt;5 Years PP Population, description - FCT was defined as the time (in hours) from start of study drug administration to the first assessment of adjusted body temperature &lt;37.5°C, confirmed by second assessment, taken within &gt;=6 to &lt;=12 hours of the first.\nOnly participants with fever (adjusted body temperature &gt;=37.5°C\npresent at Baseline) and did not receive paracetamol on day of study drug administration until 96 hours after study drug administration were included in FCT analysis.\nParticipants with no event were censored at the time of study completion, premature study discontinuation, including switch to established anti-malarial treatment or start of any other treatment with anti-malarial activity, whichever was earliest.\nKaplan-Meier method was used for the estimation., timeFrame - From the start of study drug administration up to the time of the first temperature measurement &lt;37.5°C (up to Day 63)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02497612",
    "endpoint": "measure - Fever Clearance Time: Asian PP Population, description - FCT was defined as the time (in hours) from start of study drug administration to the first assessment of adjusted body temperature &lt;37.5°C, confirmed by second assessment, taken within &gt;=6 to &lt;=12 hours of the first.\nOnly participants with fever (adjusted body temperature &gt;=37.5°C\npresent at Baseline) and did not receive paracetamol on day of study drug administration until 96 hours after study drug administration were included in FCT analysis.\nParticipants with no event were censored at the time of study completion, premature study discontinuation, including switch to established anti-malarial treatment or start of any other treatment with anti-malarial activity, whichever was earliest.\nKaplan-Meier method was used for the estimation.\nHere, &quot;overall number of participants analyzed&quot;=participants who were included in the analysis of below reported results which consisted of both, who had the event, plus those who were censored., timeFrame - From the start of study drug administration up to the time of the first temperature measurement &lt;37.5°C (up to Day 63)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02497612",
    "endpoint": "measure - Parasite Reduction Ratio (PRRlog10) at 24 Hours and 48 Hours: African &lt;=5 Years PP Population, description - The PRR was calculated as the slope of the linear portion of the regression fit of logarithm parasitemia (per milliliter) versus time (in hours).\nThe PRR24 and PRR48 was the drop-in log units over 24 and 48 hours, respectively., timeFrame - 24 and 48 hours post dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02497612",
    "endpoint": "measure - Parasite Reduction Ratio at 24 Hours and 48 Hours: African &gt;5 Years PP Population, description - The PRR was calculated as the slope of the linear portion of the regression fit of logarithm parasitemia (per milliliter) versus time (in hours).\nThe PRR24 and PRR48 was the drop-in log units over 24 and 48 hours, respectively., timeFrame - 24 and 48 hours post dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02497612",
    "endpoint": "measure - Parasite Reduction Ratio at 24 Hours and 48 Hours: Asian PP Population, description - The PRR was calculated as the slope of the linear portion of the regression fit of logarithm parasitemia (per milliliter) versus time (in hours).\nThe PRR24 and PRR48 was the drop-in log units over 24 and 48 hours, respectively., timeFrame - 24 and 48 hours post dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02497612",
    "endpoint": "measure - Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Adverse Event of Special Interest (AESI), description - An AE was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily had to have a causal relationship with the treatment.\nSAEs were any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability&#x2F;incapacity, congenital anomaly&#x2F;birth defect, or considered as medically important event.\nTEAEs were defined as AEs that developed or worsened or became serious during on-treatment phase that was defined as the time from the start of the first dose of double-blind drug administration up to the Day 63.\nAE of special interest (AESI) was an AE (serious or non-serious) of scientific and medical concern specific to the Sponsor&#x27;s product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor was required., timeFrame - From Baseline up to Day 63",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02497612",
    "endpoint": "measure - Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) of Artefenomel, description - Cmax is the maximum observed plasma concentration of artefenomel., timeFrame - 2, 4, 6, 12, 24, 48, 72 and 672 hours post dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02497612",
    "endpoint": "measure - Pharmacokinetics: Area Under the Curve From Time 0 to Infinity (AUC0-inf) of Artefenomel, description - Area under the plasma concentration versus time curve from time zero to infinity., timeFrame - 2, 4, 6, 12, 24, 48, 72 and 672 hours post dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02497612",
    "endpoint": "measure - Pharmacokinetics (PK): Apparent Total Clearance of Artefenomel From Plasma After Oral Administration, description - Clearance is defined as a quantitative measure of the rate at which a drug substance is removed from the body., timeFrame - 2, 4, 6, 12, 24, 48, 72 and 672 hours post dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02497612",
    "endpoint": "measure - Pharmacokinetics: Apparent Volume of Distribution at Steady State After Non-intravenous Administration (Vss&#x2F;F) of Artefenomel, description - Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug., timeFrame - 2, 4, 6, 12, 24, 48, 72 and 672 hours post dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02497612",
    "endpoint": "measure - Pharmacokinetics: Maximum Observed Plasma Concentration of Ferroquine (Cmax), description - Cmax is the maximum observed plasma concentration of Ferroquine., timeFrame - 2, 4, 6, 12, 24, 48, 72 and 672 hours post dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02497612",
    "endpoint": "measure - Pharmacokinetics: Area Under the Curve From Time 0 to Day 28 (AUC0-day28) of Ferroquine, description - Area under the plasma concentration versus time curve from time 0 to Day 28 (i.e.\n672 hours)., timeFrame - 2, 4, 6, 8, 12, 24, 48, 168, 336 and 672 hours postdose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02497612",
    "endpoint": "measure - Pharmacokinetics: Apparent Total Clearance of Ferroquine From Plasma After Oral Administration, description - Clearance is defined as a quantitative measure of the rate at which a drug substance is removed from the body., timeFrame - 2, 4, 6, 12, 24, 48, 72 and 672 hours post dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02497612",
    "endpoint": "measure - Pharmacokinetics: Apparent Volume of Distribution at Steady State After Non-intravenous Administration of Ferroquine, description - Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug., timeFrame - 2, 4, 6, 12, 24, 48, 72 and 672 hours post dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02497612",
    "endpoint": "measure - Pharmacokinetics: Blood&#x2F;Plasma Ratio for Ferroquine and Its Active Metabolite SSR97213, description - , timeFrame - 2, 4, 6, 12, 24, 48, 72 and 672 hours post dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04795648",
    "endpoint": "measure - Number of overall new malaria infections during intervention period., description - Measured by microscopy in children aged between 6 months to 10 years., timeFrame - 24 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04795648",
    "endpoint": "measure - Parasite-species-specific first-time malaria infections., description - Measured by microscopy in children aged between 6 months to 10 years., timeFrame - 24 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04795648",
    "endpoint": "measure - Parasite-species-specific overall malaria infections., description - Measured by microscopy in children aged between 6 months to 10 years., timeFrame - 24 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04795648",
    "endpoint": "measure - Number of first-time malaria infections by two age groups (≤ 59 months old; 5 years old to 10 years old)., description - Measured by microscopy in children aged between 6 months to 10 years., timeFrame - 24 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04795648",
    "endpoint": "measure - Number of overall malaria infections by two age groups (≤ 59 months old; 5 years to 10 years old)., description - Measured by microscopy in children aged between 6 months to 10 years., timeFrame - 24 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04795648",
    "endpoint": "measure - Anopheline-human contact (indoor and outdoor) using human biting rate (HBR) as an indicator for all anophelines and by anopheline species., description - Measured by human-landing catch (HLC) during 12-h intervals on a quarterly basis during intervention period., timeFrame - 24 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04795648",
    "endpoint": "measure - Anopheline parity rate as an indicator of population age structure for all anophelines and by anopheline species., description - Measured by mosquito ovarian dissections from a sub-sample of anophelines collected during HLC procedures during intervention period., timeFrame - 24 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04795648",
    "endpoint": "measure - Anopheline infectivity using sporozoite rate as an indicator for all anophelines and by anopheline species., description - Measured by laboratory detection of sporozoites in mosquito head-preps from a sub-sample of anophelines collected during HLC and&#x2F;or CDC-light trap procedures during intervention period., timeFrame - 24 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04795648",
    "endpoint": "measure - Anopheline infectivity using entomological inoculation rate (EIR) as an indicator for all anophelines and by anopheline species., description - Measured by calculating the number of sporozoite-infected anopheline mosquitoes captured per person during intervention period from HLC and&#x2F;or CDC-light trap procedures., timeFrame - 24 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04795648",
    "endpoint": "measure - CDC-light trap indoor density for all anophelines and by anopheline species., description - Measured by CDC-light trap collections during 12-h intervals on a monthly basis during intervention period., timeFrame - 24 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04795648",
    "endpoint": "measure - Insecticide resistance., description - Measured by WHO filter paper test and CDC bottle assays during baseline and intervention period., timeFrame - 30 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04795648",
    "endpoint": "measure - Adverse Events and Serious Adverse Events., description - Measured by solicited and unsolicited reports during baseline and intervention period.\nMean, minimum and maximum frequency and percentage of Adverse Events(AEs) and Severe Adverse Events (SAEs) across clusters among enrolled subjects will be summarized by treatment arm., timeFrame - 30 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05155579",
    "endpoint": "measure - Safety of a delayed third dose, description - <p>Solicited adverse events:</p><ul><li>Occurrence of solicited local reactogenicity signs and symptoms for 7 days following the vaccination.</li><li>Occurrence of solicited systemic reactogenicity signs and symptoms for 7 days following the vaccination.</li></ul><p>Unsolicited adverse events</p><ul><li>Occurrence of unsolicited adverse events for 28 days following the vaccination.\nLaboratory adverse events</li><li>Change from baseline for safety laboratory measures thought to be clinically significant.</li></ul><p>Serious adverse events</p><p>• Occurrence of serious adverse events for the whole study duration.</p>, timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05155579",
    "endpoint": "measure - Immunogenicity of a delayed third dose, description - • To assess the humoral immunogenicity of a delayed third dose of R21&#x2F;Matrix-M in 5-36-month-old African children, at 30 and 180 days after administration of the second dose, and 0, 30, 180 and 360 days after the administration of the third dose of R21&#x2F;Matrix-M, timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00917202",
    "endpoint": "measure - Early treatment failure (ETF) rate, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00917202",
    "endpoint": "measure - Late clinical failure (LCF) rate at D14 and D28, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00917202",
    "endpoint": "measure - Late parasitological failure (LPF) rate at D14 and D28, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00917202",
    "endpoint": "measure - Fever clearance time, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00917202",
    "endpoint": "measure - Parasite clearance time, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00917202",
    "endpoint": "measure - Change in haematocrit after 2,3,7,14 and 28 days compared to baseline, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00917202",
    "endpoint": "measure - Incidence of observed and self-reported non-serious adverse events over the 28 days observation period, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00917202",
    "endpoint": "measure - Incidence of serious adverse events over the 28 days observation period, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00917202",
    "endpoint": "measure - MB whole blood concentrations (trough concentrations) on day 3,5 or 7 compared to trough concentrations after the first dose, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05084651",
    "endpoint": "measure - Observed maximum plasma concentration (Cmax) for Ganaplacide metabolites (RHF218 and GOU089), description - Venous whole blood samples will be collected for activity-based pharmacokinetics characterization.\nCmax will be listed and summarized using descriptive statistics., timeFrame - 0 (pre-dose), 0.5, 1, 3, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 240, and 336 hours (post dose)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05084651",
    "endpoint": "measure - Area under the serum concentration-time curve from time zero to the time of last quantifiable concentration (AUClast) for Ganaplacide metabolites (RHF218 and GOU089), description - Venous whole blood samples will be collected for activity-based pharmacokinetics characterization.\nAUClast will be listed and summarized using descriptive statistics., timeFrame - 0 (pre-dose), 0.5, 1, 3, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 240, and 336 hours (post dose)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05084651",
    "endpoint": "measure - Area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time (AUCinf) for Ganaplacide metabolites (RHF218 and GOU089), description - Venous whole blood samples will be collected for activity-based pharmacokinetics characterization.\nAUCinf will be listed and summarized using descriptive statistics., timeFrame - 0 (pre-dose), 0.5, 1, 3, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 240, and 336 hours (post dose)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05084651",
    "endpoint": "measure - Area under the concentration-time curve from time zero (pre-dose) to the 24-hour time point (AUC0-24) for Ganaplacide metabolites (RHF218 and GOU089), description - Venous whole blood samples will be collected for activity-based pharmacokinetics characterization.\nAUC^0-24 will be listed and summarized using descriptive statistics., timeFrame - 0 (pre-dose), 0.5, 1, 3, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 240, and 336 hours (post dose)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05084651",
    "endpoint": "measure - Time of maximum observed drug concentration occurrence (Tmax) for Ganaplacide metabolites (RHF218 and GOU089), description - Venous whole blood samples will be collected for activity-based pharmacokinetics characterization.\nTmax will be listed and summarized using descriptive statistics., timeFrame - 0 (pre-dose), 0.5, 1, 3, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 240, and 336 hours (post dose)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05084651",
    "endpoint": "measure - Terminal elimination half-life (T^1&#x2F;2) for Ganaplacide metabolites (RHF218 and GOU089), description - Venous whole blood samples will be collected for activity-based pharmacokinetics characterization.\nT^1&#x2F;2 will be listed and summarized using descriptive statistics., timeFrame - 0 (pre-dose), 0.5, 1, 3, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 240, and 336 hours (post dose)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05084651",
    "endpoint": "measure - Metabolite to Parent Ratio (MR) for Ganaplacide metabolites (RHF218 and GOU089), description - Venous whole blood samples will be collected for activity-based pharmacokinetics characterization.\nMR will be listed and summarized using descriptive statistics., timeFrame - 0 (pre-dose), 0.5, 1, 3, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 240, and 336 hours (post dose)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05072613",
    "endpoint": "measure - Evaluate the acceptability of the intervention, description - Acceptability will be measured as: 1) the number of women who agree to be tested for malaria, over the number of women who attend the ANC service and 2) via a specially designed questionnaire., timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05072613",
    "endpoint": "measure - Compare malaria prevalence in pregnant women with that of in children throughout the year., description - Malaria prevalence will be measured by Rapid Diagnostic Test and standard malaria microscopy in both populations (pregnant women and children) for a period of 12 months and results compared., timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00376155",
    "endpoint": "measure - Coverage of IPTC, description - , timeFrame - During the study period",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00376155",
    "endpoint": "measure - the proportion of children who received three IPT courses on schedule;, description - , timeFrame - during the study period",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00376155",
    "endpoint": "measure - the proportion of children who received partial or off-schedule IPT courses, description - , timeFrame - during the study period",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00376155",
    "endpoint": "measure - the proportion of children with no IPT., description - , timeFrame - during the study period",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00376155",
    "endpoint": "measure - Unit cost of delivery per fully adherent child., description - , timeFrame - during the study period",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00376155",
    "endpoint": "measure - Incremental cost-effectiveness ratio for each systems of delivery., description - , timeFrame - During the study period",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00376155",
    "endpoint": "measure - Mean Hb (g&#x2F;dl), description - , timeFrame - at the end of malaria transmission",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00376155",
    "endpoint": "measure - Prevalence of malaria parasitaemia, description - , timeFrame - At the end of the malaria transmission season",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02905019",
    "endpoint": "measure - Humoral immunogenicity generated in malaria naïve individuals with adjuvanted R21 at two different doses, description - Antibody response to the circumsporozoite protein generated by vaccination with adjuvanted R21., timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02905019",
    "endpoint": "measure - Cell-mediated immunogenicity generated in malaria naïve individuals with ChAd63 and MVA encoding ME-TRAP, description - T-cell responses to the TRAP antigen of the malaria parasite generated by vaccination with ChAd63 and MVA encoding ME-TRAP ., timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02905019",
    "endpoint": "measure - Efficacy measured as time to P. falciparum parasitemia assessed by PCR against malaria sporozoite challenge, in healthy malaria-naïve volunteers., description - Statistical analyses using blood stage infection as defined by 500 or more parasites&#x2F;ml in peripheral blood by quantitative PCR., timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02905019",
    "endpoint": "measure - Efficacy measured as time to P. falciparum parasitemia assessed by blood slide against malaria sporozoite challenge, in healthy malaria-naïve volunteers., description - Statistical analyses using blood stage infection defined by a composite of symptoms, blood film result and parasitaemia., timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02905019",
    "endpoint": "measure - Efficacy measured as time to P. falciparum parasitemia assessed by parasite density dynamics assessed by PCR against malaria sporozoite challenge, in healthy malaria-naïve volunteers., description - Statistical analyses using blood stage malaria infection as defined by 20 or more P. falciparum parasites&#x2F;ml in peripheral blood by quantitative PCR., timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00287300",
    "endpoint": "measure - Prevalence rate of abortions, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00287300",
    "endpoint": "measure - Prevalence rate of still births, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00287300",
    "endpoint": "measure - Prevalence rate of peripheral parasitemia at delivery, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00287300",
    "endpoint": "measure - Prevalence of placental malaria (thick blood film and histology), description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00287300",
    "endpoint": "measure - Prevalence rate of maternal anemia, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00687895",
    "endpoint": "measure - prescriptions of antibiotics, cost of drugs, description - , timeFrame - Day 0",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00687895",
    "endpoint": "measure - health outcome of the patients, description - , timeFrame - Day 1-6, day 7",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00519467",
    "endpoint": "measure - The key secondary efficacy endpoint is parasite viability (the proportion of ring-form parasites developing to schizonts) determined from rich adult data and confirmed with more sparse child data, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02297477",
    "endpoint": "measure - Efficacy at 28 days (with 95% confidence intervals) for atovaquone-proguanil and artesunate-atovaquone-proguanil for uncomplicated P. falciparum diagnosed by positive PCR-corrected malaria microscopy., description - , timeFrame - 4 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02297477",
    "endpoint": "measure - Rates of sexual stage infections at days 1, 4, week 1 and week 2 based on a combined endpoint of light microscopy and PCR analysis for detection of gametocyte maturity., description - , timeFrame - 2 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02297477",
    "endpoint": "measure - Comparative rates, duration and intensity of treatment-related adverse drug events, and total adverse events in each treatment group., description - , timeFrame - 6 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03773536",
    "endpoint": "measure - Safety of artesunate + amodiaquine and primaquine: Incidence of adverse events, description - Incidence of adverse events, particularly with regards to potential hematological adverse events of primaquine., timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04093765",
    "endpoint": "measure - Prevalence of P. falciparum infection measured in the village by URDT and by reference method (group 1), description - , timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04093765",
    "endpoint": "measure - Change in the incidence dynamics over the transmission season (group 2), description - , timeFrame - 3 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04093765",
    "endpoint": "measure - The percentage of participant among village resident tested by URDT., description - , timeFrame - 3 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04093765",
    "endpoint": "measure - % of P. falciparum positive samples by reference method which were positive by URDT and treated; % of P. falciparum negative samples by reference method which were positive by URDT and treated (group 1), description - , timeFrame - 3 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04704999",
    "endpoint": "measure - Sub-microscopic P. vivax recurrence after radical treatment between day 28 and month 4, description - , timeFrame - At Day 28; Month 4",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04704999",
    "endpoint": "measure - Sub-microscopic P. vivax recurrence with very low parasite density after radical cure treatment at days 14 and 21, description - , timeFrame - At Day 14 and 21",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04704999",
    "endpoint": "measure - Number of serious adverse events (e.g., hospitalization for symptomatic hemolysis or methemoglobinemia), description - , timeFrame - At Days 1, 2, 7, 14 and Months 1, 2, 3, 4",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04704999",
    "endpoint": "measure - Number of adverse events (e.g., gastrointestinal symptoms), description - , timeFrame - At Days 1, 2, 7, 14 and Months 1, 2, 3, 4",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04704999",
    "endpoint": "measure - Methemoglobin levels measured by pulse oximetry at day 7, description - , timeFrame - At Day 7",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04704999",
    "endpoint": "measure - Tafenoquine AUC and t1&#x2F;2 as estimated from plasma tafenoquine concentrations at days 0, 1, 2, and 7, and monthly visits until month 4, description - , timeFrame - At Day 0, 1, 2, and 7; Month 1, 2, 3, and 4",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04704999",
    "endpoint": "measure - Plasma tafenoquine concentrations at days 0, 1, 2, and 7, and at monthly visits until month 4, description - , timeFrame - At Day 0, 1, 2, and 7; Month 1, 2, 3, and 4",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04704999",
    "endpoint": "measure - Tafenoquine metabolites identification in red blood cell and urine at days 1, and 2 or 3, description - , timeFrame - At Day 1, 2, and 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04704999",
    "endpoint": "measure - The probability of treatment failure defined as by the probability of one or more of the observed recurrences within 4 months being a relapse, using time-to-event and estimated identity-by-descent of recurring parasite genotypes compared to enrolment, description - , timeFrame - At Day 0, 7, 14, 21, and 28; Month 2, 3, and 4",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00146731",
    "endpoint": "measure - Incidence of foetal death during treatment, defined as absence of foetal heartbeat assessed by Doppler, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00146731",
    "endpoint": "measure - Hypoglycaemia requiring treatment, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00146731",
    "endpoint": "measure - Parasite recrudescence or re-infection on day 28, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00146731",
    "endpoint": "measure - Parasite clearance on day 3, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00146731",
    "endpoint": "measure - Level of recovery of haemoglobin on day 14, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00146731",
    "endpoint": "measure - Fever clearance time, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00146731",
    "endpoint": "measure - Incidence of perinatal and neonatal mortality, assessed 4-6 weeks after due date of delivery, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00146731",
    "endpoint": "measure - Clinically apparent neonatal abnormality, assessed 4-6 weeks after due date of delivery, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00146731",
    "endpoint": "measure - Placental malaria, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00146731",
    "endpoint": "measure - Preterm delivery, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00146731",
    "endpoint": "measure - Other adverse events during treatment, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03589794",
    "endpoint": "measure - Antibody titer against the malaria circumsporozoite antigen, description - Measured by Enzyme-linked Immunosorbent Assay (ELISA), timeFrame - Day 1 through Day 574",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03589794",
    "endpoint": "measure - Presence of P. falciparum asexual parasitemia following experimental malaria challenge, description - , timeFrame - Day 118 to Day 141",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03589794",
    "endpoint": "measure - Time to P. falciparum asexual parasitemia following experimental malaria challenge, description - , timeFrame - Day 118 to Day 141",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02168569",
    "endpoint": "measure - to evaluate the incidence of adverse events, description - To evaluate the incidence of adverse events, including the variation of haemoglobin levels throughout follow-up, during the 28 days that each subject will be followed, timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02168569",
    "endpoint": "measure - PCR uncorrected Day 28 efficacy of AL and AQ-AS, description - , timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00238017",
    "endpoint": "measure - Incidence rate of haematological and biochemical evidence of drug-induced toxicity, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00238017",
    "endpoint": "measure - Primary endpoints in children with and without various genetic host factors, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00354380",
    "endpoint": "measure - Incidence of serious adverse events (definition: chapter 11) over the 28 days observation period, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00354380",
    "endpoint": "measure - ACPR rate until D28, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00354380",
    "endpoint": "measure - Early treatment failure (ETF) rate, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00354380",
    "endpoint": "measure - Late clinical failure (LCF) rate at D14 and D28, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00354380",
    "endpoint": "measure - Late parasitological failure (LPF) rate at D14 and D28, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00354380",
    "endpoint": "measure - Fever clearance time, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00354380",
    "endpoint": "measure - Parasite clearance time, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00354380",
    "endpoint": "measure - Change in haematocrit after 2, 3, 7, 14 and 28 days compared to baseline, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02610400",
    "endpoint": "measure - All-age infection prevalence, description - The investigators will determine all-age infection prevalence using loop-mediated isothermal amplification (LAMP) during the cross-sectional household survey.\nThis survey will be administered to a sample of residents of all intervention Enumeration Areas in the Study Area at study conclusion., timeFrame - Up to 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02610400",
    "endpoint": "measure - All-age seroprevalence, description - The investigators will determine all-age seroprevalence using ELISA during the cross-sectional household survey.\nThis survey will be administered to a sample of residents of all intervention EAs in the Study Area at study conclusion., timeFrame - Up to 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02610400",
    "endpoint": "measure - Feasibility of attaining coverage, description - The investigators will compare coverage of each intervention package and determine the feasibility of reaching 80% coverage for each intervention package.\nFor RACD intervention, this equates to the proportion of the population living in the Target Area that receives a finger prick to test for malaria.\nFor TPE intervention, coverage equates to the proportion that receive an initial dose of antimalarial drug (intention to treat analysis).\nFor RAVC intervention, coverage is defined as the proportion of houses in the Target Area that receive reactive Indoor Residual Spraying (IRS)., timeFrame - Up to 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02610400",
    "endpoint": "measure - Safety: Serious adverse events (SAEs), description - The investigators will compare the count of serious adverse events (SAEs) relative to the total number of participants receiving an Intervention, across interventions., timeFrame - Up to 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02610400",
    "endpoint": "measure - Acceptability, description - Using focus group discussions (FGDs), the investigators will ask two questions: &quot;Was this intervention acceptable to [participant]?&quot; and &quot;Would [participant] participate in this intervention again if given the opportunity?&quot;.\nThe investigators will compare the % of &quot;yes&quot; responses to each of these questions, in the TPE versus the RACD arms., timeFrame - Up to 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02610400",
    "endpoint": "measure - Refusal rates, description - Refusal rates for each intervention, timeFrame - Up to 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02610400",
    "endpoint": "measure - Cost of intervention, description - The investigators will collect detailed expenditure data on costs of delivery of the TPE and RACD interventions.\nCalculations will include costs for all consumables, as well as staff time, which will be prospectively collected every 10th TPE or RACD event.\nThe investigators will compare TPE versus RACD in terms of cost per intervention event as well as cost per population intervened upon., timeFrame - Up to 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02610400",
    "endpoint": "measure - Medication adherence, description - The investigators will measure medication adherence in both TPE and RACD by scheduled pill counts in a random subset of subjects receiving each of those interventions., timeFrame - Up to 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02511054",
    "endpoint": "measure - P. falciparum blood stage infection defined as detection of at least 2 P.falciparum parasites by microscopic examination of 0.5 L of blood or two consecutive positive diagnostic qRTPCR following homologous CHMI. (Protective Efficacy), description - , timeFrame - Approximately 1 month",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04456634",
    "endpoint": "measure - AUECt of pSTAT3 Inhibition, description - Area under the effect curve (AUECt) of pSTAT3 inhibition levels, timeFrame - up to 28 days after AL+Rux and AL+placebo administration",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01133314",
    "endpoint": "measure - Percentage of the parasites with mutations coding for resistance to antimalarials., description - , timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01350752",
    "endpoint": "measure - Health worker knowledge, description - Mean score (and standard deviation) in HW knowledge on malaria diagnosis and treatment, timeFrame - Two time points: (i) pre and post training evaluation and (ii) during the provider survey (3 months after implementation of interventions)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00469651",
    "endpoint": "measure - The humoral response to vaccine antigens will be assessed by measuring by ELISA, description - , timeFrame - ELISA on D0, D28, D56, D84, D168 and D365",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01031524",
    "endpoint": "measure - Incidence of adverse events, description - , timeFrame - 15 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04315272",
    "endpoint": "measure - Clinical Malaria, description - Clinical malaria will be defined by a positive rapid diagnostic test and fever., timeFrame - 2 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02230579",
    "endpoint": "measure - Determine ex Vivo Efficacy (IC50), description - Blood collection to determine efficacy of investigational drug against parasites using an ex vivo malaria assay - this was done only for cohort 3 The experimentally obtained bioassay IC50 values were determined and compared to IC50 obtained with reference serum sample spiked with a known amount of MMV390048 titrated into the P. falciparum assay., timeFrame - up to 144 hr post dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00808951",
    "endpoint": "measure - PCR adjusted treatment failure, description - , timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00808951",
    "endpoint": "measure - PCR unadjusted treatment failure, description - , timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00808951",
    "endpoint": "measure - PCR adjusted treatment failure, description - , timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00808951",
    "endpoint": "measure - Fever clearance time, description - , timeFrame - day 1, 2, 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00808951",
    "endpoint": "measure - Asexual parasite clearance time, description - , timeFrame - day 7, 14, 21, 28, 35, 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00808951",
    "endpoint": "measure - Gametocytaemia (prevalence and density), description - , timeFrame - Day 7, 14, 21, 28, 35 and 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00808951",
    "endpoint": "measure - Safety profiles of the two treatments, description - , timeFrame - 42 days overall",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00808951",
    "endpoint": "measure - Parasites in vitro sensitivity to the drugs tested and their relationship with the in vivo results, description - , timeFrame - before treatment and at the day of reccurrente parasitemia",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05689047",
    "endpoint": "measure - Cohort A and Cohort B0: Area Under Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of M5717 and Pyronaridine, description - The AUC from time zero (dosing time) extrapolated to infinity, based on the predicted value for the concentration at tlast, as estimated using the linear regression from lambda z determination.\nCalculated as AUC0-inf = AUC0-tlast + Clast pred&#x2F; lambda z., timeFrame - Predose and Post dose on Day 1, Post dose on Day 2, 3, 4, 8, 15, 22, 29 and Day 43",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05689047",
    "endpoint": "measure - Cohort A and Cohort B0: Area Under Plasma Concentration-Time Curve From Time Zero to 24 Hours (AUC0-24) of M5717 and Pyronaridine, description - The AUC from time zero (dosing time) to 24 hours post dose was calculated using the mixed log linear trapezoidal rule (linear up, log down) using the nominal dosing interval., timeFrame - Predose and Post dose on Day 1, Post dose on Day 2, 3, 4, 8, 15, 22, 29 and Day 43",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05689047",
    "endpoint": "measure - Cohort A and Cohort B0: Area Under Plasma Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC0-tlast) of M5717 and Pyronaridine, description - The AUC from time zero (= dosing time) to the time of the last quantifiable concentration (tlast), calculated using the mixed log linear trapezoidal rule (linear up, log down), timeFrame - Predose and Post dose on Day 1, Post dose on Day 2, 3, 4, 8, 15, 22, 29 and Day 43",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05689047",
    "endpoint": "measure - Cohort A and Cohort B0: Apparent Total Clearance (CL&#x2F;F) of M5717 and Pyronaridine, description - The apparent total body clearance of study intervention following extravascular administration.\nCL&#x2F; F was calculated by oral dose divided by Area under the plasma concentration curve 0- infinity., timeFrame - Predose and Post dose on Day 1, Post dose on Day 2, 3, 4, 8, 15, 22, 29 and Day 43",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05689047",
    "endpoint": "measure - Cohort A and Cohort B0: Maximum Plasma Concentration (Cmax) of M5717 and Pyronaridine, description - Cmax was taken directly from the observed concentration-time curve., timeFrame - Predose and Post dose on Day 1, Post dose on Day 2, 3, 4, 8, 15, 22, 29 and Day 43",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05689047",
    "endpoint": "measure - Cohort A and Cohort B0: Apparent Terminal Half-Life of M5717 and Pyronaridine, description - t1&#x2F;2 was the time measured for the concentration to decrease by one half.\nt1&#x2F;2 was calculated by natural log 2 divided by Lambda z., timeFrame - Predose and Post dose on Day 1, Post dose on Day 2, 3, 4, 8, 15, 22, 29 and Day 43",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05689047",
    "endpoint": "measure - Cohort A and Cohort B0: Time to Reach Maximum Plasma Concentration (Tmax) of M5717 and Pyronaridine, description - tmax was obtained directly from the concentration versus time curve., timeFrame - Predose and Post dose on Day 1, Post dose on Day 2, 3, 4, 8, 15, 22, 29 and Day 43",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05689047",
    "endpoint": "measure - Cohort A and Cohort B0: Apparent Volume of Distribution (Vz&#x2F;F) of M5717 and Pyronaridine, description - The apparent volume of distribution during the terminal phase following extravascular administration.\nVz&#x2F;F = Dose&#x2F;(AUC0-∞*λz) following single dose., timeFrame - Predose and Post dose on Day 1, Post dose on Day 2, 3, 4, 8, 15, 22, 29 and Day 43",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05689047",
    "endpoint": "measure - Cohort A and Cohort B0: Dose Normalized Area Under the Curve From Time Zero to 24 Hours Post Dose (AUC0-24h&#x2F;Dose) of M5717 and Pyronaridine, description - The dose normalized AUC from time zero to 24 hours post dose.\nNormalized using the dose, using the formula AUC0-24&#x2F;Dose., timeFrame - Predose and Post dose on Day 1, Post dose on Day 2, 3, 4, 8, 15, 22, 29 and Day 43",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05689047",
    "endpoint": "measure - Cohort A and Cohort B0: Dose Normalized Area Under the Curve From Time Zero to the Last Sampling Time (AUC0-tlast&#x2F;Dose) of M5717 and Pyronaridine, description - The dose normalized AUC from time zero to the last sampling time (tlast) at which the concentration is at or above the lower limit of quantification.\nNormalized using the dose, using the formula AUC0-tlast &#x2F;Dose., timeFrame - Predose and Post dose on Day 1, Post dose on Day 2, 3, 4, 8, 15, 22, 29 and Day 43",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05689047",
    "endpoint": "measure - Cohort A and Cohort B0: Dose Normalized Area Under the Curve From Time Zero Extrapolated to Infinity (AUC0-∞&#x2F;Dose) of M5717 and Pyronaridine, description - The dose normalized AUC from time zero extrapolated to infinity.\nNormalized using dose, using the formula AUC0-∞ &#x2F;Dose., timeFrame - Predose and Post dose on Day 1, Post dose on Day 2, 3, 4, 8, 15, 22, 29 and Day 43",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05689047",
    "endpoint": "measure - Cohort A and Cohort B0: Terminal Elimination Rate Constant (Lambda z) of M5717 and Pyronaridine, description - Lambda z was determined from the terminal slope of the log-transformed plasma concentration curve using linear regression method., timeFrame - Predose and Post dose on Day 1, Post dose on Day 2, 3, 4, 8, 15, 22, 29 and Day 43",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05689047",
    "endpoint": "measure - Cohort A and Cohort B0: Dose Normalized Maximum Concentration (Cmax&#x2F;Dose) of M5717 and Pyronaridine, description - The dose normalized maximum concentration.\nNormalized using the dose, and the formula Cmax &#x2F;Dose., timeFrame - Predose and Post dose on Day 1, Post dose on Day 2, 3, 4, 8, 15, 22, 29 and Day 43",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05689047",
    "endpoint": "measure - Cohort A and Cohort B0: Percentage of Participants With Early Treatment Failure (ETF), description - <p>Early treatment failure (ETF) was defined as meeting any of the following : 1. Danger signs or severe malaria 1, 2, or 3 days after treatment, in the presence of parasitemia2.\nParasitemia 2 days after treatment higher than on day of treatment, irrespective of axillary temperature</p><p>• Parasitemia 3 days after treatment with temperature ≥ 37.5°C 3. Parasitemia 3 days after treatment ≥ 25% of count on day of treatment.\nETF rate will be estimated with 95% confidence intervals.\nConfidence intervals was derived by use of Wilson&#x27;s score method.</p>, timeFrame - Up to Day 3 post treatment on Day 1",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05689047",
    "endpoint": "measure - Cohort A and Cohort B0: Percentage of Participants With Late Clinical Failure (LCF), description - Late clinical failure (LCF) was defined as:1.\nDanger signs or severe malaria in the presence of parasitemia on any day between 4 and 28 days after treatment (i.e., between Days 5 and 29) in participants who did not previously meet any of the criteria of ETF. 2. Presence of parasitemia on any day between 4 and 28 days after treatment with temperature ≥ 37.5°C in participants who did not previously meet any of the criteria of ETF.\nLCF was estimated with 95% confidence intervals.\nConfidence intervals will be derived by use of Wilson&#x27;s score method., timeFrame - Day 1 up to Day 29",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05689047",
    "endpoint": "measure - Cohort A and Cohort B0: Percentage of Participants With Late Parasitological Failure (LPF), description - Late parasitological failure (LPF) was defined as: Presence of parasitemia on any day between 7 and 28 days after treatment (i.e., between Days 8 and 29) with temperature &lt; 37.5°C in participants who did not previously meet any of the criteria of ETF or LCF.\nLPF was estimated with 95% confidence intervals.\nConfidence intervals will be derived by use of Wilson&#x27;s score method., timeFrame - From Day 8 to Day 29",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05689047",
    "endpoint": "measure - Cohort A: Percentage of Participants With Polymerase Chain Reaction (PCR)-Adjusted Adequate Clinical and Parasitological Response (ACPR), description - PCR-adjusted ACPR 28 and 42 days after treatment defined as absence of parasitemia (thick smear&#x2F;microscopy, after adjustment for parasitemia due to new infections as determined by genotyping using PCR techniques), irrespective of axillary temperature, in participants who did not previously meet any of the criteria of ETF, LCF, or LPF., timeFrame - Day 28 and 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05689047",
    "endpoint": "measure - Cohort A and B0: Percentage of Participants With Crude Adequate Clinical and Parasitological Response (ACPR), description - Crude ACPR 28 and 42 days after first dose is defined as absence of parasitemia (parasite count = 0) from thick smear&#x2F;microscopy, irrespective of axillary temperature, in participants who did not previously meet any of the criteria of ETF, LCF, or LPF., timeFrame - Day 28 and 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05689047",
    "endpoint": "measure - Cohort A and Cohort B0: Time to Fever Clearance as Estimated by Kaplan-Meier Method, description - Fever clearance time was defined as the time from first dosing to the first measurement of temperature &lt; 37.5°C for 2 consecutive temperature readings plus confirmed normal temperature 24 h after the first normal body temperature reading.\nThis analysis was done on participants with fever., timeFrame - Day 1 up to Day 29",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05689047",
    "endpoint": "measure - Cohort A and Cohort B0: Parasite Clearance Time as Estimated by Kaplan-Meier Method, description - Parasite clearance time defined as time from dosing to the first negative (no parasites) film, timeFrame - Day 1 up to Day 43",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05689047",
    "endpoint": "measure - Cohort B0: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs and Related TEAEs, description - An adverse event (AE) was defined as any untoward medical occurrence in a participant.\nTEAEs are defined as AEs which started at or after the administration of study intervention (study treatment) or which started prior to the first administration of study intervention but worsened after the dose intake, until the last scheduled assessment will be regarded as treatment-emergent, but before established rescue antimalarial treatment is administered, if required.\nA serious TEAE was an AE that resulted in any of the following outcomes: death; life threatening; persistent&#x2F;significant disability&#x2F;incapacity; initial or prolonged inpatient hospitalization; congenital anomaly&#x2F;birth defect or was otherwise considered medically important.\nA TEAE was considered to be &quot;related&quot; if a causal relationship between study treatment and the TEAE is at least reasonably possible., timeFrame - Day 1 up to Day 43",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02083406",
    "endpoint": "measure - Piperaquine (PQ) AUC(0-168h), description - PQ Area under the plasma concentration versus time curve, timeFrame - Up to 168h post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02083406",
    "endpoint": "measure - PQ Cmax, description - PQ Maximum observed concentration, timeFrame - Up to 168h post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02199951",
    "endpoint": "measure - Adverse events of special interest, description - <p>In case of an AESI confirmed by the study doctor, the sponsor shall be informed within 24 hours, even if the event does not satisfy any condition of seriousness.\nNotification will occur through the use of an ad hoc AESI form.\nAESIs can be related to:</p><ul><li>Cardio-toxicity i.e. prolonged QT</li><li>Neurotoxicity&#x2F;seizures</li><li>Cutaneous reactions&#x2F;phototoxicity</li></ul>, timeFrame - 28 Days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00935623",
    "endpoint": "measure - Parasitologic and clinical infections in challenge volunteers will be characterized by descriptive analysis of prepatent and patent periods, incubation period and time to resolution of signs and symptoms, and timing and number of relapses., description - , timeFrame - Cross-sectional",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01594931",
    "endpoint": "measure - PCR-Corrected ACPR at Day 14, description - Percentage of subjects with PCR-corrected adequate clinical and parasitological response (ACPR) on Day 14, defined as absence of parasitaemia on Day 14 without the subject&#x27;s meeting any of the criteria of early treatment failure, late clinical failure, or late parasitological failure, timeFrame - Day 14",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01594931",
    "endpoint": "measure - Parasite Clearance Time, description - Parasite clearance time was defined as the time (in hours) from first dosing to the time of first blood draw with parasite clearance.\nParasite clearance is defined as zero presence of parasites for two consecutive negative readings eight hours apart, with confirmed negative reading at 24 hours after the first negative slide, timeFrame - Thick blood slides were examined every 8 hours until at least 72 hours or until a negative smear was recorded",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01594931",
    "endpoint": "measure - Fever Clearance Time, description - Fever clearance time was defined as the time (in hours) from first dosing to the first normal reading with fever clearance (2 consecutive assessments without fever (&lt;37.5°C)).\nThe method of temperature measurement was the same (ie, axillary, tympanic, oral or rectal) for each subject.\nAny subjects with a documented history of fever at inclusion, but who did not subsequently have a documented temperature reading &gt;37.5°C during the 24 hours after initial dosing, were not included in this end point analysis., timeFrame - Every 8 hours for at least 72 hours after the first dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01594931",
    "endpoint": "measure - Parasite Clearance, description - Parasite clearance is defined as zero presence of parasites for 2 consecutive negative readings 8 hours apart, with confirmed negative reading at 24 hours after the first negative slide.\nThe proportion of subjects with parasite clearance was summarized at Days 1, 2, and 3., timeFrame - Days 1, 2, and 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01594931",
    "endpoint": "measure - Fever Clearance, description - Fever clearance was defined as a subject without fever for 2 consecutive assessments, plus confirmed normal temperature at 24 hours.\nThe proportion of subjects with fever clearance was summarized at Days 1, 2, and 3., timeFrame - Days 1, 2 and 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01594931",
    "endpoint": "measure - Adverse Events (AEs), description - An AE was defined as any unfavourable and unintended sign, symptom, syndrome, or illness that developed or worsened during the period of observation in the clinical study, timeFrame - Day 0 to 42. Subjects experiencing AEs at Day 42 were followed for up to 30 days after the end of study or resolution of the event, whichever was earlier",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00158574",
    "endpoint": "measure - 1.Mean Hb at 10-12 months of age (one month after the third course of IPTi), description - , timeFrame - 10-12 months of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00158574",
    "endpoint": "measure - 2.Incidence of severe anaemia (Hb &lt;7 g&#x2F;dl) during the period of 3-11 months of age, description - , timeFrame - 3-11 months of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00158574",
    "endpoint": "measure - 3.Prevalence of parasitaemia at 10-12 months of age (one month after the third course of IPTi), description - , timeFrame - 10-12 months of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00158574",
    "endpoint": "measure - 4.Incidence of clinical malaria [as defined above] during the period of 12-23 months of age., description - , timeFrame - 12-23 months of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00158574",
    "endpoint": "measure - 5.Level and repertoires of plasma antibodies to Plasmodium falciparum variant surface antigen (anti-VSA antibodies) at 10 and 18 months of age., description - , timeFrame - 10 and 18 months of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01697787",
    "endpoint": "measure - RDT performance Vs microscopy, description - The proportion of discrepancies between the RDT and the microscopy results, timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02083380",
    "endpoint": "measure - PCR - Adjusted ACPR at Day 42 in the PP Population, description - PCR - adjusted adequate clinical and parasitological response at Day 42, timeFrame - Days 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02083380",
    "endpoint": "measure - PCR-adjusted ACPR at Day 63 in the PP Population, description - PCR-adjusted adequate clinical and parasitological response at Day 63, timeFrame - Day 63",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02083380",
    "endpoint": "measure - Crude ACPR at Day 28 in the PP Population, description - Crude adequate clinical and parasitological response at Day 28, timeFrame - Day 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02083380",
    "endpoint": "measure - Crude ACPR at Day 42 in the PP Population, description - Crude adequate clinical and parasitological response at Day 42, timeFrame - Day 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02083380",
    "endpoint": "measure - Crude ACPR at Day 63 in the PP Population, description - Crude adequate clinical and parasitological response at Day 63, timeFrame - Day 63",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02083380",
    "endpoint": "measure - PCR-adjusted ACPR at Day 28 in the ITT Population, description - PCR-adjusted adequate clinical and parasitological response at Day 28.\nIntent to Treat ( ITT) population., timeFrame - Day 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02083380",
    "endpoint": "measure - PCR-adjusted ACPR at Day 42 in the ITT Population, description - PCR-adjusted adequate clinical and parasitological response at Day 42 in the ITT population, timeFrame - Day 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02083380",
    "endpoint": "measure - PCR-adjusted ACPR at Day 63 in the ITT Population, description - PCR-adjusted adequate clinical and parasitological response at Day 63 in the ITT population, timeFrame - Day 63",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02083380",
    "endpoint": "measure - Crude ACPR at Day 28 in the ITT Population, description - Crude adequate clinical and parasitological response at Day 28 in the ITT population, timeFrame - Day 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02083380",
    "endpoint": "measure - Crude ACPR at Day 42 in the ITT Population, description - Crude adequate clinical and parasitological response at Day 42 in the ITT population, timeFrame - Day 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02083380",
    "endpoint": "measure - Crude ACPR at Day 63 in the ITT Population, description - Crude adequate clinical and parasitological response at Day 63 in the ITT population, timeFrame - Day 63",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02083380",
    "endpoint": "measure - Kaplan-Meier Estimate of Recurrence, description - Kaplan-Meier estimate of number of recurrent infections (either recrudescence or new infection), timeFrame - Day 63",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02083380",
    "endpoint": "measure - Kaplan-Meier Estimate of Recrudescence, description - Kaplan-Meier estimate of number of patients with recrudescence, timeFrame - Day 63",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02083380",
    "endpoint": "measure - Kaplan-Meier Estimate of New Infection Rate, description - Kaplan-Meier estimate of number of patients with new infections, timeFrame - Day 63",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02083380",
    "endpoint": "measure - Parasite Clearance Time, description - Time post dose to parasite clearance, timeFrame - 0, 6, 12, 18, 24, 30, 36, 48 and 72 hours post dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02083380",
    "endpoint": "measure - Fever Clearance Time, description - Time to fever clearance (hours), timeFrame - Day 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02083380",
    "endpoint": "measure - PRR48, description - Parasite reduction ratio at 48 hours post dose, timeFrame - 0, 6, 12, 18, 24, 30, 36 and 48 hours post dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02083887",
    "endpoint": "measure - Immunogenicity of ChAd63 ME-TRAP &#x2F; MVA ME-TRAP prime boost immunisation co-administered with EPI vaccines., description - , timeFrame - Participants will be followed for the duration of the study, an expected average of 36 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04148690",
    "endpoint": "measure - Change in ANC coverage, description - Proportion of recently pregnant women completing the four, six, and eight ANC visits as measured by cross sectional household survey, timeFrame - Change between 0 and 18 months of implementation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04148690",
    "endpoint": "measure - Change in Gestational age at initiation of ANC, description - Mean gestational age at initiation of ANC measured by cross sectional household survey, timeFrame - Change between 0 and 18 months of implementation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04148690",
    "endpoint": "measure - Change in Proportion of women who recently gave birth who received blood pressure, urine test, blood test, tetanus, IFA, albendazole, ITN, and IPTp, description - Change in Proportion of women who recently gave birth who received blood pressure, urine test, blood test, tetanus, IFA, albendazole, ITN, and IPTp as measured by cross sectional household surveys, timeFrame - Change between 0 and 18 months of implementation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04148690",
    "endpoint": "measure - Change in Proportion of women who recently gave birth who had a facility-based delivery as measured by cross sectional household surveys, description - , timeFrame - Change between 0 and 18 months of implementation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04148690",
    "endpoint": "measure - Prevalence of malaria by RDT among pregnant women attending 1st ANC, description - , timeFrame - throughout study period; average of once per month",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04148690",
    "endpoint": "measure - Prevalence of malaria by RDT among among children under 5, description - , timeFrame - throughout study period; average of once per year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04148690",
    "endpoint": "measure - Difference in provider time required to deliver GANC versus individual ANC, description - , timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04002687",
    "endpoint": "measure - To measure the the maximum observed plasma concentration (Cmax) of atovaquone (ATV), proguanil (PG) and cycloguanil (CG), and amodiaquine (AQ) and desethyl-amodiaquine (DEAQ) following administration of ATV-PG and AQ alone and in combination., description - To measure the maximum observed plasma concentration (Cmax)., timeFrame - Day 1 to Day 22",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04002687",
    "endpoint": "measure - To measure the maximum plasma concentration (tmax) of atovaquone (ATV), proguanil (PG) and cycloguanil (CG), and amodiaquine (AQ) and desethyl-amodiaquine (DEAQ) following administration of ATV-PG and AQ alone and in combination., description - To measure time the maximum plasma concentration (tmax)., timeFrame - Day 1 to Day 22",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04002687",
    "endpoint": "measure - To measure the area under the plasma concentration-time curve from time zero to last detectable plasma concentration (AUC0-t) of atovaquone, proguanil and cycloguanil, and amodiaquine and desethyl-amodiaquine (DEAQ) following administration., description - To measure the area under the plasma concentration-time curve from time to zero to last detectable plasmaconcentration (AUC0-t)., timeFrame - Day 1 to Day 22",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04002687",
    "endpoint": "measure - To measure the area under the plasma concentration-time curve from time zero extrapolated to infinity (AUC0-inf) of atovaquone (ATV), proguanil (PG) and cycloguanil (CG), and amodiaquine (AQ) and desethyl-amodiaquine (DEAQ) following administr, description - To measure the area under the plasma concentration-time curve from time zero extrapolated to infinity (AUC0-inf), timeFrame - Day 1 to Day 22",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04002687",
    "endpoint": "measure - To measure the terminal elimination rate constant (λz) of atovaquone (ATV), proguanil (PG) and cycloguanil (CG), and amodiaquine (AQ) and desethyl-amodiaquine (DEAQ) following administr, description - To measure the terminal elimination rate constant (λz)., timeFrame - Day 1 to Day 22",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04002687",
    "endpoint": "measure - To measure the terminal elimination half-life (t1&#x2F;2) of atovaquone (ATV), proguanil (PG) and cycloguanil (CG), and amodiaquine (AQ) and desethyl-amodiaquine (DEAQ) following administr, description - To measure the terminal elimination half-life (t1&#x2F;2)., timeFrame - Day 1 to Day 22",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01680406",
    "endpoint": "measure - Number of episodes of P. vivax parasitemia over one year following initial effective therapy against P. vivax (i.e. parasite clearance), description - , timeFrame - 1 year after day 0 of enrollment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00988507",
    "endpoint": "measure - Cure rate at Day 28, description - , timeFrame - 4 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00988507",
    "endpoint": "measure - Parasite Clearance Time (Median)., description - , timeFrame - up to 63 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00988507",
    "endpoint": "measure - Fever Clearance Time (Median), description - , timeFrame - up to 63 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00988507",
    "endpoint": "measure - Recrudescent infections at Day 28 in the ferroquine group in monotherapy, description - , timeFrame - 4 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00988507",
    "endpoint": "measure - Recrudescent infections at Day 63, description - , timeFrame - 9 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00988507",
    "endpoint": "measure - Adequate Clinical and Parasitological Response (ACPR) at D28, description - , timeFrame - 4 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00157885",
    "endpoint": "measure - Day 42 P.falciparum cure rate corrected for reinfection by PCR genotyping, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00157885",
    "endpoint": "measure - Day 42 P.vivax cure rate, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00157885",
    "endpoint": "measure - Overall day 28 cure rate for P.falciparum, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00157885",
    "endpoint": "measure - Proportion of patients aparasitaemic on Days 1 and 2, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00157885",
    "endpoint": "measure - Haematological recovery, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00157885",
    "endpoint": "measure - Gametocyte Carriage during follow up, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01258049",
    "endpoint": "measure - Parasite Clearance Time (PCT) [MITT Population], description - Parasite clearance time (PCT).\nTime in hours from the initiation of therapy until the first of two successive parasite negative smears (zero parasite counts) are obtained, timeFrame - 28 days after start of treatment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01258049",
    "endpoint": "measure - PCT 90 [MITT Population], description - Time for parasite counts to fall by 90%, timeFrame - 28 days after start of treatment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01258049",
    "endpoint": "measure - PCT 50 [MITT Population], description - Time for parasite counts to fall by 50%, timeFrame - 28 days after start of treatment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01258049",
    "endpoint": "measure - PRR 24 [MITT Population], description - The percentage reduction in parasite counts 24 hours after first dose, timeFrame - 28 days after start of treatment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01258049",
    "endpoint": "measure - PRR 12 [MITT Population], description - The percentage reduction in parasite counts 12 hours after first dose, timeFrame - 28 days after start of treatment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01258049",
    "endpoint": "measure - Fever Clearance Time (FCT), description - Time in hours from the initiation of therapy until the disappearance of fever (tympanic temperature &lt; 38.0) that lasted at least 24 hours., timeFrame - 28 days after start of treatment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01258049",
    "endpoint": "measure - Complete Cure Rate, description - The complete resolution of clinical signs and symptoms, malaria-related laboratory abnormalities, and elimination of asexual parasites by Day 7, with no recurrence up to Day 28 (+&#x2F;- 2 days), and the 48h parasite count to be &lt; 25% of baseline with no clinical deterioration, timeFrame - 28 days after the start of treatment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01258049",
    "endpoint": "measure - Early Treatment Failure, description - <p>Early treatment failure is indicated by one or more of the following:</p><ul><li>Parasite count on Day 2 &gt; Day 0, irrespective of temperature</li><li>Parasite count on Day 3 &gt; 0 with tympanic temperature ≥ 38.0°C</li><li>Parasite count on Day 3 ≥ 25% of baseline</li><li>Administration of rescue antimalarial treatment</li></ul>, timeFrame - Three days after the start of treatment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01258049",
    "endpoint": "measure - Late Clinical Failure, description - <ul><li>Signs of severe malaria on any day between Day 4 and Day 28 in the presence of parasitaemia, without previously meeting any of the criteria of early treatment failure</li><li>Presence of parasitaemia and tympanic temperature ≥ 38.0°C (or history of fever), on any day between Day 4 and Day 28, without previously meeting any of the criteria of early treatment failure</li></ul>, timeFrame - 28 days after the start of treatment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01258049",
    "endpoint": "measure - Late Parasitological Failure, description - o Parasitaemia on any day from Day 7 to Day 28 and tympanic temperature ≤ 38.0°C, timeFrame - 28 days after the start of treatment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01258049",
    "endpoint": "measure - Time to Return to Full Consciousness, description - <p>Time in hours to return to full consciousness (Blantyre Coma Scale = 5), if level of consciousness is reduced (Blantyre Coma Scale &lt;5) prior to dosing or within 24hours of first dosing.</p><p>For the Blantyre Coma Scale</p><p>Total - maximum 5, eye movement - maximum 1, best motor response - maximum 2, best verbal response - maximum 2</p>, timeFrame - 28 days after start of treatment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01258049",
    "endpoint": "measure - Time to Return to Normal Per os Status, description - Time in hours to return to normal per os status.\nNormal per os was when the investigator considered the patient to be able to eat and drink normally., timeFrame - 28 days after start of treatment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01258049",
    "endpoint": "measure - Number of Participants With Treatment Emergent Adverse Events and Serious Adverse Events, of Possible, Probably and Definite Causalities, description - , timeFrame - 28 days after start of treatment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01258049",
    "endpoint": "measure - Number of Deaths or Neurological Sequelae at Day 28, description - , timeFrame - 28 days after start of treatment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00355225",
    "endpoint": "measure - Costs per malaria case and per DALY prevented, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00355225",
    "endpoint": "measure - Self-reported information on ANC visits, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00355225",
    "endpoint": "measure - Insecticide content on ITN and mortality of vector mosquitoes over time, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00355225",
    "endpoint": "measure - Acceptance of health staff and population, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00459615",
    "endpoint": "measure - Additional measures of parasite clearance will also be assessed., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00459615",
    "endpoint": "measure - A continuous variable of time to parasite reduction milestones:, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00459615",
    "endpoint": "measure - parasite clearance time (PCT90 and PCT100), and parasite reduction ratios (PRR12h and PRR24h) at defined time points , and, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00459615",
    "endpoint": "measure - A continuous variable of area under the curve (AUC) of quantifiable parasitemia, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00459615",
    "endpoint": "measure - Tolerability of the treatment regimens will also be assessed throughout the study through use of evaluation for adverse events and safety laboratories to include hematology and chemistry tests., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02431650",
    "endpoint": "measure - Safety: Number of AEs, description - Adverse events incidence, timeFrame - From Challenge inoculum on day 0 until end of study on day 31",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01095055",
    "endpoint": "measure - The level of immune response induced by vaccination with AdCh63 AMA1, when administered as a single vaccination and sequentially with MVA AMA1, description - To assess the level of immune response induced by vaccination with AdCh63 AMA1, when administered as a single vaccination and sequentially with MVA AMA1, timeFrame - Up to 6 moths following the last vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05801198",
    "endpoint": "measure - urea and creatinine, description - Kidney function test will be done on serum, to establish a baseline, and repeated at day 14 following completion of the treatment, timeFrame - 14 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05801198",
    "endpoint": "measure - Liver enzymes; ALT&#x2F; AST, description - Baseline test of the liver transaminases will be done on serum, and repeated at day 14, timeFrame - 14 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05801198",
    "endpoint": "measure - Urine dipstick, description - a urine dipstick will be done; PH, leucocytes, blood, nitrites, specific gravity, ketones, glucose, urobilinogen., timeFrame - 14 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06549257",
    "endpoint": "measure - To determine the Pfs25 and Pfs48&#x2F;45 humoral immune response, description - Pfs25 and Pfs48&#x2F;45 antibody levels elicited by Pfs25IMX313-Matrix-M and Pfs48&#x2F;45 in Matrix-M as measured by ELISA at Days 0, 14, 28, 42, 56, 72, 140, 236, timeFrame - Through study completion, an average of 8 months from enrolment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06549257",
    "endpoint": "measure - To determine the ex-vivo functional transmission blocking activity of Pfs25 and Pfs48&#x2F;45 administered alone and in combination, description - Standard membrane feeding assays (SMFA) and direct membrane feeding assays (DMFA) at Days 0, 14, 28, 42, 56, 72, 140, 236, reported as a percentage of transmission reducing activity compared to controls (% TRA)., timeFrame - Through study completion, an average of 8 months from enrolment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03599596",
    "endpoint": "measure - Prevalence of drug related adverse events associated with multiple doses of sulphadoxine pyrimethamine., description - Number of participants having drug related adverse events associated with multiple doses of sulphadoxine pyrimethamine will be noted., timeFrame - 4 Months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00811356",
    "endpoint": "measure - Plasma or blood concentrations of study drug, description - , timeFrame - Part A: 3-4 months; Part B: ~1 month",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04053907",
    "endpoint": "measure - Gametocyte prevalence by molecular methods at the end of study (cross-sectional survey)., description - Gametocyte prevalence in quantitative polymerase chain reaction (qPCR) detected infections is assessed by molecular methods and compared between arms., timeFrame - 16 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04053907",
    "endpoint": "measure - Gametocyte density by molecular methods at the end of study (cross-sectional survey)., description - Gametocyte density (gametocytes&#x2F;µL) in qPCR detected infections is assessed by molecular methods and compared between arms., timeFrame - 16 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04053907",
    "endpoint": "measure - Gametocyte prevalence of male and female gametocytes by molecular methods among P. falciparum infections at all study visits., description - Gametocyte prevalence of male and female gametocytes will be assessed by molecular methods and compared between study arms., timeFrame - Throughout study, an average of 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04053907",
    "endpoint": "measure - Gametocyte density of male and female gametocytes by molecular methods among P. falciparum infections at all study visits., description - Gametocyte density of male and female gametocytes will be assessed by molecular methods and compared between study arms., timeFrame - Throughout study, an average of 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04053907",
    "endpoint": "measure - Incidence of malaria infections, description - Regular visits by weekly active case detection and monthly screening will result in the identification of malaria infections that are not detected during CCM.\nNumber of infections detected in each arm will be quantified and compared between arms., timeFrame - Throughout study, an average of 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04053907",
    "endpoint": "measure - Infectivity of P. falciparum infections to mosquitoes, description - For a selection of infections, infectiousness to mosquitoes is assessed by membrane feeding assays., timeFrame - Throughout study, an average of 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00680732",
    "endpoint": "measure - To determine if the occurrence of malaria during pregnancy influences the incidence of clinical malaria in infants during their first year of life., description - , timeFrame - Up to one year after delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00680732",
    "endpoint": "measure - To determine the burden of clinical malaria during pregnancy and its consequences on maternal anaemia, new birth weight and foetal anaemia., description - , timeFrame - Up to delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00680732",
    "endpoint": "measure - Effect of standard antimalarial treatment on the selection of resistant parasites in pregnant women under weekly chemoprophylaxis or intermittent treatment., description - , timeFrame - Up to one year after delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00146692",
    "endpoint": "measure - • Mean haemoglobin count among the two groups at study end, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00146692",
    "endpoint": "measure - • Number of admissions to hospital with malaria among children under five years of age in both groups, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00146692",
    "endpoint": "measure - • Average number of visits to per child under five years to primary care facility among both groups, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00146692",
    "endpoint": "measure - • Anthropometric measurements of children in the two groups, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00146692",
    "endpoint": "measure - • All cause mortality in both groups, all ages, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02089841",
    "endpoint": "measure - Plasma lumefantrine concentration, description - Mean plasma lumefantrine concentration among patients on day 7 and day 14 following treatment with artemether&#x2F;lumefantrine as a predictor of cure rate., timeFrame - 7 days and 14 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03436160",
    "endpoint": "measure - Bioavailability of Carbon-14 radio labeled (14C) WR826647, WR909388, and WR909390, description - An analysis of variance (ANOVA) will be performed on the natural logarithm (ln) transformed dose-adjusted AUCinf to estimate the bioavailability., timeFrame - 0, 5 , 15 min, 0.5, 1, 2, 4, 6, 8, 12, and 24 hours, and then daily for 1 week, and weekly until 3 weeks following dosing.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01615822",
    "endpoint": "measure - OZ439 Cmax, description - Peak Plasma Concentration (Cmax) of OZ439, timeFrame - Up to 42 days post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01615822",
    "endpoint": "measure - MQ AUC0-t, description - Area under the plasma concentration versus time curve (AUC) of MQ, timeFrame - Up to 42 days post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01615822",
    "endpoint": "measure - MQ Cmax, description - Peak Plasma Concentration (Cmax) of MQ, timeFrame - Up to 42 days post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01976780",
    "endpoint": "measure - Parasitological clearance rates by quantitative Polymerase Chain Reaction (PCR), description - PCR adjusted clearance rates for the first 72 hours after first ACT dose in patients with uncomplicated P. falciparum malaria, timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01976780",
    "endpoint": "measure - PCR-adjusted treatment efficacy of AL and AS&#x2F;MQ, description - , timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01976780",
    "endpoint": "measure - Antimalarial drug sensitivity responses and molecular genotyping, description - Correlate clinical outcomes with results of above tests, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01976780",
    "endpoint": "measure - Identify common specific genetic determinants of artemisinin resistance derived from parasite populations, description - , timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01976780",
    "endpoint": "measure - Gametocyte carriage in patients with uncomplicated malaria after treatment, description - , timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01976780",
    "endpoint": "measure - Catalog parasite samples, description - Correlated to clinical datasets to longitudinally track resistance trends, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01976780",
    "endpoint": "measure - Pharmacokinetic parameters associated with ACT failure, description - , timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01713608",
    "endpoint": "measure - OZ439 Tmax, description - Time to reach maximum measured OZ439 plasma concentration, timeFrame - pre-dose, 2, 4, 6, 8, 12, and 18 hours post-dose Day 1and Day 3, pre dose Day 2 and 4 hours post dose Day 2, and 24, 48, 72, 96 and 168 hours post 3rd dose and at follow up.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01713608",
    "endpoint": "measure - OZ439 t½, description - OZ439 estimated terminal phase half life, timeFrame - pre-dose, 2, 4, 6, 8, 12, and 18 hours post-dose Day 1and Day 3, pre dose Day 2 and 4 hours post dose Day 2, and 24, 48, 72, 96 and 168 hours post 3rd dose and at follow up.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03705624",
    "endpoint": "measure - Parasite prevalence and density by molecular detection at the end of year 1 cross-sectional survey., description - Parasite prevalence and density in the cross-sectional survey conducted at the end of the transmission season of year 1.\nIf CCM and MSAT result in the early detection of infections, parasite prevalence will be lower in these arms compared to the control arm., timeFrame - Month 6 (end of first transmission season; January-February 2019)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03705624",
    "endpoint": "measure - Parasite prevalence and density by molecular detection at the end of dry season cross-sectional survey., description - Parasite prevalence and density in the cross-sectional survey conducted at the end of the dry season.\nIf CCM and MSAT result in the early detection of infections, parasite prevalence will be lower in these arms compared to the control arm., timeFrame - Month 12 (prior to second transmission season; June 2019)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03705624",
    "endpoint": "measure - Gametocyte prevalence and or density in P. falciparum infections at the end of study cross-sectional survey, description - Gametocyte prevalence in qPCR detected infections is assessed by molecular methods and compared between study arms., timeFrame - Month 18 (end of second transmission season; January-February 2020)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03705624",
    "endpoint": "measure - Gametocyte prevalence and or density in P. falciparum infections at the end of year 1 cross-sectional survey, description - Gametocyte density of male and female gametocytes will be assessed by molecular methods and compared between study arms., timeFrame - Month 6 (end of first transmission season; January-February 2019)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03705624",
    "endpoint": "measure - Gametocyte prevalence and or density in P. falciparum infections at the end of dry season cross-sectional survey, description - Gametocyte density of male and female gametocytes will be assessed by molecular methods and compared between study arms., timeFrame - Month 12 (prior to second transmission season; June 2019)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03705624",
    "endpoint": "measure - Gametocyte prevalence and or density in P. falciparum during all study visits, description - Gametocyte density of male and female gametocytes will be assessed by molecular methods and compared between study arms., timeFrame - Throughout study, an average of 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03705624",
    "endpoint": "measure - The number of incident infections., description - Regular visits by CCM and MSAT will result in the identification of malaria infections that are not detected during passive case detection.\nThe numbers of infections that are detected in each arm are quantified and compared between arms., timeFrame - Throughout study, an average of 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03705624",
    "endpoint": "measure - Infectivity to mosquitoes of P. falciparum infections, description - For a selection of infections, infectiousness to mosquitoes is assessed by membrane feeding assays., timeFrame - Throughout study, an average of 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00197067",
    "endpoint": "measure - To assess antibody levels for relevant immunological indicators at time points when blood sampling will be done., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00127998",
    "endpoint": "measure - Frequencies of dhfr, dhps, pfcrt and pfmdr1 P. falciparum genotypes and relationship with in vivo resistance to SP (dhfr and dhps), CQ, AQ, SP&#x2F;AQ, AQ&#x2F;AS, SP&#x2F;AS, and MQ, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00127998",
    "endpoint": "measure - Drug levels at 3 days and correlation with in vivo efficacy results, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01872702",
    "endpoint": "measure - Safety and acceptability of targeted malaria elimination (1017-13 and 1015-13), description - Safety and acceptability of targeted malaria elimination, evaluated by questionnaires filled out by participants or care givers., timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00890019",
    "endpoint": "measure - To assess the cellular immune response generated, and whether this is affected by immunity to human adenovirus, by AdCh63 ME-TRAP when administered individually and sequentially with MVA ME-TRAP in a prime-boost regime to healthy volunteers, description - , timeFrame - 24 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00317590",
    "endpoint": "measure - Clearance of major clinical symptoms&#x2F;signs, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00317590",
    "endpoint": "measure - Attributable fraction (AF) of fever episodes to malaria, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00317590",
    "endpoint": "measure - Performances of Paracheck® (sensitivity, specificity and predictive values) on malaria disease, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00317590",
    "endpoint": "measure - Cost-effectiveness of Paracheck® vs. presumptive (clinical) management of fever, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06879327",
    "endpoint": "measure - Geometric Mean Titers (GMTs) of Anti-CS IgG Before and 28 Days After 4th Vaccine Dose, description - , timeFrame - Month 15 predose and 28 days after vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06879327",
    "endpoint": "measure - Fold Increase in Anti-CS IgG Titer Post 4th Dose Compared to Pre-4th Dose, description - , timeFrame - Month 15 predose and 28 days after 4th dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06879327",
    "endpoint": "measure - Number of Clinical Malaria Episodes per Person-year Meeting the Primary Case Definition up to 27 Months, description - The primary case definition will be P. falciparum asexual parasitemia &gt; 5000 parasites&#x2F;µL detected by blood slide reading AND presence of fever (axillary temperature ≥ 37.5°C or tympanic temperature ≥ 38°C) or history of fever within 48 hours of presentation at the time of presentation AND occurring in an infant&#x2F;child who is unwell and brought for treatment to a healthcare facility., timeFrame - From 6 weeks of age to 27 months of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06879327",
    "endpoint": "measure - Number of Clinical Malaria Episodes per Person-year Meeting the Primary Case Definition up to 15 Months, description - The primary case definition will be P. falciparum asexual parasitemia &gt; 5000 parasites&#x2F;µL detected by blood slide reading AND presence of fever (axillary temperature ≥ 37.5°C or tympanic temperature ≥ 38°C) or history of fever within 48 hours of presentation at the time of presentation AND occurring in an infant&#x2F;child who is unwell and brought for treatment to a healthcare facility., timeFrame - From 6 weeks of age to 15 months of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06879327",
    "endpoint": "measure - Number of Clinical Malaria Episodes per Person-year Meeting the Primary Case Definition from 15.5 to 27 Months, description - The primary case definition will be P. falciparum asexual parasitemia &gt; 5000 parasites&#x2F;µL detected by blood slide reading AND presence of fever (axillary temperature ≥ 37.5°C or tympanic temperature ≥ 38°C) or history of fever within 48 hours of presentation at the time of presentation AND occurring in an infant&#x2F;child who is unwell and brought for treatment to a healthcare facility., timeFrame - From 15.5 months (2 weeks after the 4th vaccination) to 27 months of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06879327",
    "endpoint": "measure - Number of Clinical Malaria Episodes per Person-year Meeting the Secondary Case Definition up to 27 Months, description - The secondary case definition will be P. falciparum asexual parasitemia &gt; 0 parasites&#x2F;µL detected by blood slide reading and presence of fever (axillary temperature ≥ 37.5°C or tympanic temperature ≥ 38°C) or history of fever within 48 hours of presentation AND occurring in an infant&#x2F;child who is unwell and brought for treatment to a healthcare facility., timeFrame - From 6 weeks of age to 27 months of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06879327",
    "endpoint": "measure - Number of Clinical Malaria Episodes per Person-year Meeting the Secondary Case Definition up to 15 Months, description - The secondary case definition will be P. falciparum asexual parasitemia &gt; 0 parasites&#x2F;µL detected by blood slide reading and presence of fever (axillary temperature ≥ 37.5°C or tympanic temperature ≥ 38°C) or history of fever within 48 hours of presentation AND occurring in an infant&#x2F;child who is unwell and brought for treatment to a healthcare facility., timeFrame - From 6 weeks of age to 15 months of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06879327",
    "endpoint": "measure - Number of Clinical Malaria Episodes per Person-year Meeting the Secondary Case Definition from 15.5 to 27 Months, description - The secondary case definition will be P. falciparum asexual parasitemia &gt; 0 parasites&#x2F;µL detected by blood slide reading and presence of fever (axillary temperature ≥ 37.5°C or tympanic temperature ≥ 38°C) or history of fever within 48 hours of presentation AND occurring in an infant&#x2F;child who is unwell and brought for treatment to a healthcare facility., timeFrame - From 15.5 months (2 weeks after the 4th vaccination) to 27 months of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01614964",
    "endpoint": "measure - Number of Participants With Adverse Events, description - Adverse events (AEs) are defined as events possibly related to the study drug(s) as judged by blinded physician observers that occur within 4 weeks of beginning treatment with AQ-13 or Coartem.\nThe investigators asked participants to report the less serious adverse events (≤ grade 1) and the grade 2-4 adverse events and counted the number of participants who had those adverse events happen., timeFrame - Within 4 weeks of beginning treatment with either AQ-13 or Coartem",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01614964",
    "endpoint": "measure - Parasite Clearance Time, description - Blood smears are performed at the time of diagnosis and then (for persons who have been enrolled after providing their informed consent to participate) twice daily until two successive negative smears have been obtained., timeFrame - From the time of beginning treatment with either AQ-13 or Coartem to the first of 2 successive negative blood smears, assessed during the 1 week inpatient stay.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01614964",
    "endpoint": "measure - Number of Participants With Recrudescence of Infection, description - Recrudescence of infection with malaria is the reactivation of the disease after treatment due to incomplete eradication of the parasite, Plasmodium.\nThe parasites causing these recurrences had the same molecular markers as the original infections in these participants, they were considered recrudescences (late treatment failures) rather than new infections.\nThe investigators counted the number of participants who had recrudescence of infection., timeFrame - Within 42 days after beginning treatment with either AQ-13 or Coartem",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01614964",
    "endpoint": "measure - QTc Interval Response Following Antimalarial Treatment, description - Corrected QT (QTc) interval was measured at antimalarial dosing and at 4 hours after dosing using HolterCare (version 10.6.0)\nmonitors., timeFrame - Between dosing and 4 hours after dosing",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01614964",
    "endpoint": "measure - Mean Fever Clearance Time in Days, description - Body temperature was measured twice daily with an electronic (digital) thermometer during the 5-7 day inpatient stay.\nFever clearance time was defined as the first persistently normal temperature (&lt;37·5°C) during week 1 of inpatient stay., timeFrame - Days 1-7 after beginning treatment with either AQ-13 or Coartem",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01614964",
    "endpoint": "measure - Peak Cmax, description - One of the pharmacokinetic parameters for AQ-13 that was measured was Peak Cmax (Cmax=maximal concentration) which was calculated based on serial blood levels (35 blood level determinations of AQ-13 and its metabolites over the 42 day study period) and urine collections (24 hour collections for the first four days after beginning treatment)., timeFrame - 42 Days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01614964",
    "endpoint": "measure - Time to Peak Tmax, description - One of the pharmacokinetic parameters for AQ-13 that was measured was time to peak tmax (tmax is time from beginning treatment to the maximal concentration), which was calculated based on serial blood levels (35 blood level determinations of AQ-13 and its metabolites over the 42 day study period) and urine collections (24 hour collections for the first four days after beginning treatment)., timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01614964",
    "endpoint": "measure - 1-week AUC, description - One of the pharmacokinetic parameters for AQ-13 that was measured was 1-week area under the curve (AUC) for the first 7 days, which was calculated based on serial blood levels (35 blood level determinations of AQ-13 and its metabolites over the 42 day study period) and urine collections (24 hour collections for the first four days after beginning treatment)., timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01614964",
    "endpoint": "measure - Mean Residence Time, description - One of the pharmacokinetic parameters for AQ-13 that was measured was Mean Residence Time (MRT), which was calculated based on serial blood levels (35 blood level determinations of AQ-13 and its metabolites over the 42 day study period) and urine collections (24 hour collections for the first four days after beginning treatment)., timeFrame - 42 Days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01614964",
    "endpoint": "measure - Clearance, description - One of the pharmacokinetic parameters for AQ-13 that was measured was clearance (Cl&#x2F;f), which was calculated based on serial blood levels (35 blood level determinations of AQ-13 and its metabolites over the 42 day study period) and urine collections (24 hour collections for the first four days after beginning treatment)., timeFrame - 42 Days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01614964",
    "endpoint": "measure - Elimination t½, description - One of the pharmacokinetic parameters for AQ-13 that was measured was elimination t½ (t½=elimination half-life) which was calculated based on serial blood levels (35 blood level determinations of AQ-13 and its metabolites over the 42 day study period) and urine collections (24 hour collections for the first four days after beginning treatment)., timeFrame - 42 Days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03074435",
    "endpoint": "measure - Entomological Inoculation Rate, description - Number of infectious bites&#x2F;personn, timeFrame - Every 8 weeks during 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03074435",
    "endpoint": "measure - Malaria prevalence, description - % of positive blood smears among the 0-18 y&#x2F;o population as recorded during cross sectional surveys., timeFrame - Every 4 months during 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00791531",
    "endpoint": "measure - Pharmacokinetics of Methotrexate assessed by repeated measurement of blood concentrations, description - , timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02963324",
    "endpoint": "measure - Occurence of adverse events, description - adverse events (treatment-emergent and&#x2F;or leading to premature study drug discontinuation)., timeFrame - For 72 hours after dosing",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02963324",
    "endpoint": "measure - Laboratory changes, description - Change from baseline for clinical laboratory tests at the end of the study., timeFrame - For 72 hours after dosing",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02963324",
    "endpoint": "measure - Changes in electrocardiogram (ECG), description - Change from baseline in resting 12-channel electrocardiogram (ECG) at the end of the study., timeFrame - For 72 hours after dosing",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02910934",
    "endpoint": "measure - Entomological Indicators, description - Entomological measurements including descriptions of vector densities, estimates of human biting rates, sporozoite rates, measures of indoor and outdoor feeding behaviors, insecticide resistance patterns and estimates of entomological inoculation rates (EIR), timeFrame - 24 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02910934",
    "endpoint": "measure - Parasite prevalence, description - Changes in community-based parasitaemia measured through cross-sectional surveys, timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02910934",
    "endpoint": "measure - Health Behavior, description - Changes in malaria avoidance and health seeking behavior through cohort surveys and cross-sectional surveys, timeFrame - 24 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02910934",
    "endpoint": "measure - Cost per malaria case averted in children five years of age and under at the community, description - Derived from incidence in children five years of age and under at the community levels by active case detection along with implementation costing data using an ingredients approach, timeFrame - 24months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00709969",
    "endpoint": "measure - Proportion of patients free of parasites at 7, 14 and at 28 days, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00709969",
    "endpoint": "measure - Time to clearance from parasites (asexual forms), description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00709969",
    "endpoint": "measure - Time to clearance of fever, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00709969",
    "endpoint": "measure - Time to clearance of gametocytes (parasite sexual forms), description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02885506",
    "endpoint": "measure - Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Measurable Concentration (AUClast), description - Estimation of the following PK parameter (in fasted and fed cohorts) using non-compartmental methods: AUClast, timeFrame - During 11 days post administration of a single oral dose of P218 to healthy volunteers",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02885506",
    "endpoint": "measure - Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf), description - Estimation of the following PK parameter (in fasted and fed cohorts) using non-compartmental methods: AUCinf, timeFrame - During 11 days post administration of a single oral dose of P218 to healthy volunteers",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02885506",
    "endpoint": "measure - Maximum Plasma Drug Concentration (Cmax), description - Estimation of the following PK parameter (in fasted and fed cohorts) using non-compartmental methods: Cmax, timeFrame - During 11 days post administration of a single oral dose of P218 to healthy volunteers",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02885506",
    "endpoint": "measure - Time to Reach Maximum (Peak) Plasma Concentration Following Drug Administration (Tmax), description - Estimation of the following PK parameter (in fasted and fed cohorts) using non-compartmental methods: Tmax, timeFrame - During 11 days post administration of a single oral dose of P218 to healthy volunteers",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02885506",
    "endpoint": "measure - Elimination Half-life (t1&#x2F;2), description - Estimation of the following PK parameter (in fasted and fed cohorts) using non-compartmental methods: t1&#x2F;2, timeFrame - During 11 days post administration of a single oral dose of P218 to healthy volunteers",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02885506",
    "endpoint": "measure - Apparent Total Clearance of the Drug From Plasma After Oral Administration (CL&#x2F;F) (for Parent Only), description - Estimation of the following PK parameter (in fasted and fed cohorts) using non-compartmental methods: CL&#x2F;F (for parent only), timeFrame - During 11 days post administration of a single oral dose of P218 to healthy volunteers",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02885506",
    "endpoint": "measure - Apparent Volume of Distribution During Terminal Phase After Oral Administration (Vz&#x2F;F) (for Parent Only)., description - Estimation of the following PK parameter (in fasted and fed cohorts) using non-compartmental methods: Vz&#x2F;F (for parent only)., timeFrame - During 11 days post administration of a single oral dose of P218 to healthy volunteers",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02831023",
    "endpoint": "measure - Gametocyte prevalence, density, and sex ratio measured microscopically and by molecular methods., description - Outcome measured at baseline and days 1, 2, 3, 7, 14, 28, and 42 post first dose., timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02831023",
    "endpoint": "measure - Asexual parasite prevalence and density, description - Asexual parasitemia will be evaluated by blood smear microscopy and confirmed by more sensitive, molecular methods.\nOutcome measured at baseline and days 1, 2, 3, 7, 14, 28, and 42 post first dose., timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02831023",
    "endpoint": "measure - Safety measurements including hemoglobin and signs of hemolysis, description - The major safety endpoint is hemolysis.\nFor this reason, hemoglobin and methemoglobin values will be measured before treatment, at baseline and on days 1, 2, 3, 7, 14, 28, and 42 post first dose.\nIn addition, clinical review (including additional signs of hemolysis) will be assessed based on active and passive follow-up., timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02831023",
    "endpoint": "measure - Peak plasma concentration (Cmax) of primaquine, description - Outcome measured at hours 1, 2, 4, 6, 8, and 24 post first dose., timeFrame - 24 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02831023",
    "endpoint": "measure - Area under the concentration curve (AUC) of primaquine., description - Outcome measured at hours 1, 2, 4, 6, 8, and 24 post first dose., timeFrame - 24 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02831023",
    "endpoint": "measure - Elimination half life (t1&#x2F;2) of primaquine, description - Outcome measured at hours 1, 2, 4, 6, 8, and 24 post first dose., timeFrame - 24 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02831023",
    "endpoint": "measure - Peak plasma concentration (Cmax) of methylene blue, description - Outcome measured at hours 1, 2, 4, 6, 8, and 24 post first dose., timeFrame - 24 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02831023",
    "endpoint": "measure - Area under the concentration curve (AUC) of methylene blue, description - Outcome measured at hours 1, 2, 4, 6, 8, and 24 post first dose., timeFrame - 24 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02831023",
    "endpoint": "measure - Elimination half life (t1&#x2F;2) of methylene blue, description - Outcome measured at hours 1, 2, 4, 6, 8, and 24 post first dose., timeFrame - 24 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02831023",
    "endpoint": "measure - Peak plasma concentration (Cmax) of sulphadoxine-pyrimethamine, description - Outcome measured at hours 1, 2, 4, 6, 8, and 24 post first dose., timeFrame - 24 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02831023",
    "endpoint": "measure - Area under the concentration curve (AUC) of sulphadoxine-pyrimethamine, description - Outcome measured at hours 1, 2, 4, 6, 8, and 24 post first dose., timeFrame - 24 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02831023",
    "endpoint": "measure - Elimination half-life (t1&#x2F;2) of sulphadoxine-pyrimethamine, description - Outcome measured at hours 1, 2, 4, 6, 8, and 24 post first dose., timeFrame - 24 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02831023",
    "endpoint": "measure - Peak plasma concentration (Cmax) of dihydroartemisinin-piperaquine, description - Outcome measured at hours 1, 2, 4, 6, 8, and 24 post first dose., timeFrame - 24 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02831023",
    "endpoint": "measure - Area under the concentration curve (AUC) of dihydroartemisinin-piperaquine, description - Outcome measured at hours 1, 2, 4, 6, 8, and 24 post first dose., timeFrame - 24 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02831023",
    "endpoint": "measure - Elimination half-life (t1&#x2F;2) of dihydroartemisinin-piperaquine, description - Outcome measured at hours 1, 2, 4, 6, 8, and 24 post first dose., timeFrame - 24 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02831023",
    "endpoint": "measure - Identification of cytochrome P450 (CYP) 2D6 and G6PD polymorphisms, description - CYP2D6 and G6PD genotyping will be performed using Thermo Fisher Scientific OpenArray Technology and Copy Number Variation (CNV) assays on the QuantStudio™ 12K Flex Real-Time PCR System., timeFrame - 1 hour",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02817919",
    "endpoint": "measure - The proportion of adverse events following administration of injectable artemether (AR) or Injectable quinine (Q), description - , timeFrame - 28 days after administration of injectable artemether or injectable quinine",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02817919",
    "endpoint": "measure - The proportion of severe malaria cases that are treated with injectable. artesunate, artemether or quinine., description - , timeFrame - through study completion, an average of 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02817919",
    "endpoint": "measure - Availability and stock levels of injectable artesunate, artemether or quinine in participating health facilities., description - , timeFrame - through study completion, an average of 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02793336",
    "endpoint": "measure - symptomatic P. vivax, description - The incidence rate of symptomatic P. vivax over 1 year in all participants, timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02793336",
    "endpoint": "measure - severe anaemia (Hb&lt;7g&#x2F;dl) and&#x2F;or blood transfusion, description - The incidence risk of severe anaemia (Hb&lt;7g&#x2F;dl) and&#x2F;or the risk for blood transfusion, timeFrame - 4 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02793336",
    "endpoint": "measure - serious illnesses including hospitalization, description - The incidence risk and rate of serious illnesses including hospitalization, timeFrame - 4 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02793336",
    "endpoint": "measure - non-malarial febrile episodes and bacterial co-infections, description - The incidence risk and rate of non-malarial febrile episodes and bacterial co-infections, timeFrame - 4 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02793336",
    "endpoint": "measure - mortality, description - The incidence risk of mortality, timeFrame - 4 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02793336",
    "endpoint": "measure - growth retardation and neurodevelopment delay, description - The incidence risk of growth retardation and neurodevelopment delay, timeFrame - 4 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02793336",
    "endpoint": "measure - G6PD activity, description - The distribution of G6PD activity within the study population, timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02793336",
    "endpoint": "measure - Fluorescence spot test results (FST), description - The change in FST result performed during the baby cohort study compared to the FST result performed at 12 months age, timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02793388",
    "endpoint": "measure - The incidence risk of symptomatic P. vivax malaria over 4 months in patients enrolled with P. vivax malaria infection., description - , timeFrame - 4 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02793388",
    "endpoint": "measure - The incidence risk of symptomatic P. vivax malaria over 4 months in patients enrolled with P. falciparum malaria infection., description - , timeFrame - 4 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02793388",
    "endpoint": "measure - The incidence rate of symptomatic P. vivax malaria over 4 months in patients enrolled with malaria due to P. falciparum or P. vivax., description - , timeFrame - 4 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02793388",
    "endpoint": "measure - The incidence rate of symptomatic P. vivax malaria over 4 months in patients enrolled with P. vivax malaria., description - , timeFrame - 4 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02793388",
    "endpoint": "measure - The incidence rate of symptomatic P. vivax malaria over 4 months in patients enrolled with P. falciparum malaria., description - , timeFrame - 4 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02793388",
    "endpoint": "measure - The incidence risk of patent or sub-microscopic P. vivax malaria over 4 months in patients enrolled with malaria (sub-group analysis for patients recruited with P. vivax infection and P. falciparum infection), description - , timeFrame - 4 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02793388",
    "endpoint": "measure - The incidence risk of any patent or sub-microscopic parasitaemia due to P. vivax or P. falciparum over 4 months in patients, description - , timeFrame - 4 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02793388",
    "endpoint": "measure - The cost-effectiveness of supervised primaquine therapy in terms of cost per malaria episode averted, description - , timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02793388",
    "endpoint": "measure - Socio-economic factors for adherence to primaquine treatment, description - Factors are collected through a semi-standardized questionaire.\nFactors include indicators for economic status, as well as information on educational background., timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00587249",
    "endpoint": "measure - Immunogenicity of ICC-1132 plus alhydrogel in healthy human subjects., description - , timeFrame - Serum will be collected at the time of each immunization and at 14 and 28 days after each immunization. Day 84 following the 2nd immunization and at Day 56 after the 3rd vaccination and possibly at Day 168 after the 3rd vaccination.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05044637",
    "endpoint": "measure - Incidence rate (per person-year) of recurrent P. vivax, description - The overall incidence rate (per person-year) of any recurrent P. vivax parasitaemia detected by microscopy over 6 months of follow-up in the 3.5 mg&#x2F;Kg total dose group versus the 7.0 mg&#x2F;Kg total dose groups, timeFrame - 6 months after randomization",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05044637",
    "endpoint": "measure - Incidence risk of any recurrent symptomatic P. vivax malaria, description - The incidence rate (per person-year) of any recurrent symptomatic P. vivax parasitaemia over 6 months of follow-up in either the 7-day or the 14-day primaquine arms of 7.0 mg&#x2F;kg total dose compared with 7-day primaquine arm of 3.5 mg&#x2F;Kg total dose., timeFrame - 6 months after randomization",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05044637",
    "endpoint": "measure - The hematological recovery in patients with vivax malaria, description - Hematological recovery will be assessed as the incidence risk of severe anaemia (Hb&lt;7g&#x2F;dl) and&#x2F;or blood transfusion within the 6 month follow up period, and the mean fall in baseline Hb on day 7 and day 14.\nThese outcomes will be compared between the treatment arms, timeFrame - 6 months after randomization",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05044637",
    "endpoint": "measure - Proportion of patients with any adverse drug reactions, description - The proportion of patients with one or more adverse drug reactions within 42 days of their primary treatment and also at 6 months, timeFrame - 6 months after randomization",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05044637",
    "endpoint": "measure - Primaquine tolerability 1 hour, description - Tolerability of primaquine will be assessed by comparing the proportion of patients with nausea, vomiting, abdominal pain and vomiting of a dose within 1 hour of administration between the treatment arms, timeFrame - 7 to 14 days after randomization",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05044637",
    "endpoint": "measure - Primaquine tolerability, description - Drug tolerability between the treatment arms will also be assessed by comparing the proportion of patients completing a full course of primaquine therapy, timeFrame - 7 to 14 days after randomization",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05044637",
    "endpoint": "measure - Pharmacogenetics CYP2D6, description - Characterize hepatic cytochrome CYP2D6 enzyme phenotypes using Activity Score A (AS-A), timeFrame - 1 day after randomization",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05044637",
    "endpoint": "measure - Genotype CYP2D6, description - Genotype CYP2D6 alleles in this study population, timeFrame - 1 day after randomization",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05044637",
    "endpoint": "measure - Metabolomics, description - Describe the metabolic signatures present in patients with adverse events (AEs) and severe AEs (SAEs), timeFrame - 28 days after randomization",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03453840",
    "endpoint": "measure - Number of Participants With Serious Adverse Events, description - We recorded participants tolerance of AL using the NIH Division of AIDS Adult and Pediatric Toxicity Tables., timeFrame - study day 0-42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02742285",
    "endpoint": "measure - Concordance of concentrations of desbutyl-lumefantrine measured in DBS and in plasma, description - , timeFrame - Within the first two weeks after drug intake",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02742285",
    "endpoint": "measure - Concordance of lumefantrine and desbutyl-lumefantrine concentrations measured in dried venous blood spot samples and in plasma, description - , timeFrame - Within the first two weeks after drug intake",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02742285",
    "endpoint": "measure - Concordance of concentration of lumefantrine and desbutyl-lumefantrine measured in whole venous blood and in plasma, description - , timeFrame - Within the first two weeks after drug intake",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02742285",
    "endpoint": "measure - Determination of a ratio of intra-erythrocyte and plasma concentrations of lumefantrine and desbutyl-lumefantrine over time (corrected for hematocrit), description - , timeFrame - Within the first two weeks after drug intake",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02742285",
    "endpoint": "measure - Determination of a ratio of unbound plasma concentration and total plasma concentration of lumefantrine and desbutyl-lumefantrine over time, description - , timeFrame - Within the first two weeks after drug intake",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02742285",
    "endpoint": "measure - Determination of the limit of quantification of artemether and dihydroartemisinin in dried blood spots samples, using the standard method of a calibration curve, description - , timeFrame - Within the first 24 hours after drug intake",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02742285",
    "endpoint": "measure - Determination the relative precision of lumefantrine and desbutyl-lumefantrine concentrations in dried blood spots versus in plasma, using triplicate measurements and a hierarchical non-linear regression model, description - , timeFrame - Within the first two weeks after drug intake",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00169078",
    "endpoint": "measure - Proportion of children who cleared parasites carrying pfcrt-76T and pfmdr1-86Y alleles., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00169078",
    "endpoint": "measure - Prevalence of dhfr-51, 59, 108 and dhps-437, 540, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02654730",
    "endpoint": "measure - Haematology abnormalities during follow-up: haptoglobin concentration measured in venous blood samples by full blood count analysis, description - , timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02654730",
    "endpoint": "measure - Biochemistry abnormalities during follow-up: bilirubin concentration, description - , timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02654730",
    "endpoint": "measure - Biochemistry abnormalities during follow-up: lactate dehydrogenase, description - , timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02654730",
    "endpoint": "measure - Biochemistry abnormalities during follow-up: creatinine, description - , timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02654730",
    "endpoint": "measure - Biochemistry abnormalities during follow-up: potassium, description - , timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02654730",
    "endpoint": "measure - Number of participants with treatment-related adverse events graded and evaluated in terms of relatedness, description - grading and assessing relatedness will be done following according to criteria of the NIH&#x2F;NIAID division of microbiology and infectious diseases (DMID)https:&#x2F;&#x2F;www.niaid.nih.gov&#x2F;LabsAndResources&#x2F;resources&#x2F;DMIDClinRsrch&#x2F;Documents&#x2F;dmidadulttox.pdf, timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02654730",
    "endpoint": "measure - Haematology abnormalities during follow-up: mean corpuscular volume (MCV) measured in venous blood samples by full blood count analysis, description - , timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02654730",
    "endpoint": "measure - Haematology abnormalities during follow-up: red cell distribution width (RDW) measured in venous blood samples by full blood count analysis, description - , timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02654730",
    "endpoint": "measure - Haematology abnormalities during follow-up: leukocyte count measured in venous blood samples by full blood count analysis, description - , timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01156389",
    "endpoint": "measure - Summary of Treatment Emergent Adverse Events, description - Including all the treatment emergent adverse events, the number of subjects discontinued due to adverse events and the number of subjects with serious adverse events., timeFrame - Throughout the study",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00639873",
    "endpoint": "measure - Treatment response, description - Treatment response parameters: parasite, fever, and gametocyte clearance, timeFrame - 42 Days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06970600",
    "endpoint": "measure - To evaluate the incidence of adverse events, description - Safety was assessed by administering a questionnaire about the nature and incidence of adverse events and serious adverse events.\nAn adverse event is defined as any unfavorable, unintended sign, symptom, syndrome or disease that develops or worsens with the use of a medicinal product, regardless of whether it is related to the medicinal product., timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06970600",
    "endpoint": "measure - To evaluate the variation of the levels of haemoglobin during and after treatment, description - Haemoglobin levels were measured on Day 0, Day 14 and Day 28 using a haemoglobinometer and their levels were compared at these three points., timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06970600",
    "endpoint": "measure - Measuring the Day PCR uncorrected cure rates of Artemether-Lumefantrine., description - This cure rate is defined as the proportion of patients with adequate clinical and parasitological response (ACPR) at Day 28, without PCR correction to differentiate recrudescences from new infections and hence considering as treatment failures all parasite recurrences., timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06970600",
    "endpoint": "measure - Evaluate the presence of Molecular Markers associated with sub optimum responses to ACTs, description - The presence of molecular marks is defined as presence of mutations in pfk13 and pfmdr1 (at codons 86, 184 and 1246) genes identified by Sanger sequencing of pre-treatment samples., timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02374450",
    "endpoint": "measure - Number of Participants With at Least One Confirmed Meningitis Case From Month 0 to Month 79 (Final Classification), description - <p>Final classification refers to the definitive categorization of meningitis cases after further investigation, typically involving additional laboratory testing and review by an external panel of experts.\nThe criteria for final classification included:</p><p>Aetiology-Confirmed Meningitis, which was defined if any known aetiologic agent (bacterial or not) was identified in the CSF sample.</p><p>Probable Meningitis, which was defined if no aetiologic agent was identified in the CSF, but abnormalities were detected, or if there was a positive blood culture indicating bacterial infection.</p><p>Clinically Suspected Meningitis, which was defined if all laboratory results were normal after second line laboratory testing, or if no CSF sample was available but no alternative diagnosis was found based on clinical symptoms and signs.</p>, timeFrame - During the entire study period (From Month 0 up to Month 79)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02374450",
    "endpoint": "measure - Number of Participants With at Least One Confirmed Meningitis Case Identified at Site Level From Month 0 to Month 79 (First Line Laboratory), description - <p>First Line Laboratory refers to the initial laboratory testing conducted on cerebrospinal fluid (CSF) samples taken from patients suspected of having meningitis.\nThe purpose of first line laboratory testing was to identify any bacterial agents present in the CSF or detect abnormalities that may indicate meningitis.\nThe criteria for classifying cases at this stage included:</p><p>Bacterial Confirmed Meningitis which was defined if a bacterial agent was identified in the CSF sample.</p><p>Probable Meningitis which was defined if no bacterial agent was identified, but abnormalities were detected in the CSF or if there was a positive blood culture indicating bacterial infection.</p><p>Clinically Suspected Meningitis which was defined if no bacterial agent was identified and all laboratory results were normal at the first line level, or if no CSF sample was available but no alternative diagnosis was found based on clinical symptoms and signs.</p>, timeFrame - During the entire study period (From Month 0 up to Month 79)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02374450",
    "endpoint": "measure - Number of Participants With Risk Factors for AESI, Meningitis and Malaria Among Hospitalized Participants, description - As per Statistical analysis plan, Univariate and multivariate Poisson regression models for analysis of potential risk factors for AESI, aetiology-confirmed meningitis and cerebral malaria were only planned to be conducted if there were a minimum of 10 cases., timeFrame - During the entire study period (From Month 0 up to Month 79)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02374450",
    "endpoint": "measure - Incidence Rates of Death After the Virtual Secondary Schedule (Secondary Dose of DTP&#x2F;HepB&#x2F;Hib Administered at Day 31) for the Active Surveillance 6-12 Weeks and Active Surveillance 5-17 Weeks Groups, description - Incidence rate was calculated by dividing the number of participants reporting at least one event over the follow-up period by the total person-time.\nAnalysis of this outcome measure were reported only for the Active surveillance 6-12 weeks and Active surveillance 5-17 months groups, as the participants in the Enhanced hospitalization surveillance group were not administered with the DTP&#x2F;HepB&#x2F;Hib vaccine., timeFrame - Day 31 to approximately Month 13 (Within an at-risk period of 12 months after virtual secondary schedule)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02374450",
    "endpoint": "measure - Number of Participants Hospitalized With Causes (Including Those Attributed to an AESI, Other AE, Meningitis, or Malaria) From Month 0 to Month 79, description - Hospitalized cases attributed to an AESI, other AE, meningitis, or malaria were assessed in children &lt;5 years old, included in active or enhanced hospitalization surveillance, prior to implementation of RTS,S&#x2F;AS01E., timeFrame - During the entire study period (From Month 0 up to Month 79)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02374450",
    "endpoint": "measure - Number of Participants Reported Deaths From Month 0 to Month 79, description - Mortality events were assessed in children &lt;5 years old, included in active or enhanced hospitalization surveillance, prior to implementation of RTS,S&#x2F;AS01E., timeFrame - During the entire study period (From Month 0 up to Month 79)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02374450",
    "endpoint": "measure - Number of Participants With Malaria Cases Reported Using Rapid Diagnostic Test (RDT) and&#x2F;or Microscopy From Month 0 to Month 79, description - Any malaria includes uncomplicated and severe cases, including cerebral malaria.\nUncomplicated is defined as: Plasmodium parasitaemia greater than (&gt;) 0 detected by microscopy and&#x2F;or RDT, fever (temperature ≥ 37.5°C) and no signs of severity or evidence (clinical or laboratory) of vital organ dysfunction.\nSevere is defined as: P. falciparum parasitaemia &gt; 0 detected by microscopy and&#x2F;or RDT and one or more of the following: impaired consciousness, prostration, multiple convulsions, acidosis, hypoglycaemia, severe malarial anaemia, renal impairment, jaundice, pulmonary oedema, significant bleeding, shock, hyperparasitaemia.\nCerebral malaria is defined as severe P. falciparum malaria with impaired consciousness., timeFrame - During the entire study period (From Month 0 up to Month 79)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02374450",
    "endpoint": "measure - Number of Participants With All Anaemia and Severe Anaemia Cases Among Hospitalized Children From Month 0 to Month 79, description - Cases of anaemia were defined as follow: All anaemia: haemoglobin lower than 11grams per deciliter (g&#x2F;dL).\nSevere anaemia: haemoglobin lower than 7g&#x2F;dL ., timeFrame - During the entire study period (From Month 0 up to Month 79)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02374450",
    "endpoint": "measure - Number of Participants With All Cause Hospitalizations and Hospitalizations Attributed to Malaria (Including P. Falciparum) From Month 0 to Month 79, description - The hospitalization cases were assessed in children &lt;5 years old, included in active surveillance, prior to implementation of RTS,S&#x2F;AS01E.\nHospitalisation for malaria (including P. falciparum) was defined as a hospitalized participants with malaria (including P. falciparum malaria) and for whom malaria is the primary cause of hospitalization., timeFrame - During the entire study period (From Month 0 up to Month 79)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02374450",
    "endpoint": "measure - Number of Participants Reported All-cause Mortality and Deaths Attributed to Malaria (Overall and by Gender) From Month 0 to Month 79, description - All cause mortality and death attributed to malaria are summarized by overall and gender., timeFrame - During the entire study period (From Month 0 up to Month 79)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02450630",
    "endpoint": "measure - The proportion of sick children seeking care and receiving prompt treatment at private outlets within 24 hours of onset of symptoms;, description - Measured as the number of children seen at private facilities within 24 hours of the total number of sick children, timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02450630",
    "endpoint": "measure - The time between consultations at private outlets and uptake of referral at health facilities (referral facilities);, description - measure by time in hours, timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02450630",
    "endpoint": "measure - The cost-effectiveness of the intervention, description - The costs and effectiveness of the intervention per arm will be calculated as incremental cost per Disability Adjusted Life Years (DALY) averted of introducing a strengthened referral system (the cost-effectiveness), timeFrame - 2years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00703066",
    "endpoint": "measure - Humoral immune response to GLURP and MSP 3, description - , timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00703066",
    "endpoint": "measure - Cellular immune response, description - , timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00712374",
    "endpoint": "measure - Incidence of malaria by passive case detection, description - , timeFrame - 2008-2010",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05816330",
    "endpoint": "measure - Participants With Plasmodium Falciparum (Pf) Infection Detected by Real-Time Polymerase Chain Reaction (RT-PCR), description - Number of participants with Plasmodium falciparum (Pf) blood stage infection defined as blood sample positive for Pf was assessed by real-time polymerase chain reaction (RT-PCR) of blood sample collected from participants from day 7 through week 24 (168 days) after administration of L9LS or placebo.\nSample was collected every two weeks from day seven until week 24.\nAnalysis was done as number of participants who had at least one positive blood sample., timeFrame - Day 7 through week 24",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05816330",
    "endpoint": "measure - Maximum Total Plasma Concentration (Cmax) for L9LS, description - Maximum total plasma concentration (Cmax) following a 900 mg dose of L9LS.\nSerum collected on days 0, 1, 7, 14, 28, 56, 84, 112, 140, &amp; 168 after the administration of L9LS.\nCmax for L9LS was obtained directly by visual inspection of the plasma concentration versus time profiles postdose.\nAnalysis was done to determine each participant&#x27;s observed maximum concentration based on all available timepoints and cumulative output was calculated as the central tendency and dispersion metric based on the observed maximum concentrations., timeFrame - Measure through week 24",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05816330",
    "endpoint": "measure - Time to Maximum Plasma Concentration (TMax) for L9LS - Hours, description - Time to maximum total plasma concentration (Cmax) following a 900 mg dose of L9LS on day 7 post administration of drug.\nTmax for L9LS was obtained directly by visual inspection of the plasma concentration versus time profiles.\nAnalysis was done to determine the time (in hours) at which the maximum observed concentration was achieved for each participant and cumulative output was calculated as the central tendency and dispersion metric based on the observed time of maximum concentration., timeFrame - Day 7 post administration of drug",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05816330",
    "endpoint": "measure - Time to Maximum Plasma Concentration (TMax) for L9LS - Days, description - Time to maximum total plasma concentration (Cmax) following a 900 mg dose of L9LS.\nSerum collected on days 0, 1, 7, 14, 28, 56, 84, 112, 140, &amp; 168 after the administration of L9LS.\nTmax for L9LS was obtained directly by visual inspection of the plasma concentration versus time profiles.\nAnalysis was done to determine the time (in days) at which the maximum observed concentration was achieved for each participant and cumulative output was calculated as the central tendency and dispersion metric based on the observed time of maximum concentration., timeFrame - Measure through week 24",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00323622",
    "endpoint": "measure - Anti-circumsporozoite Protein (CS) Antibody Concentrations., description - Concentrations for anti-CS antibodies are presented as Geometric Mean Concentrations (GMCs), expressed in Enzyme-Linked Immunosorbent Assay (ELISA) units per milliliter (EL.U&#x2F;mL).\nThe cut-off of the assay was the seropositivity cut-off of 0.5 EL.U&#x2F;mL.\nSubjects were pooled across age ranges for this outcome measure., timeFrame - At Months 33 and 45 (Month 0 = administration of Dose 1 of RTS,S&#x2F;AS02A or comparator vaccine in the NCT00197041 study).",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00323622",
    "endpoint": "measure - Anti-hepatitis B (HBs) Antibody Concentrations., description - Concentrations are presented as geometric mean concentrations (GMCs), expressed in milli-international units per milliliter (mIU&#x2F;mL).\nAnti-HBs antibody concentration levels were measured in blood samples from Cohort 2 only., timeFrame - At Months 33 and 45 (Month 0 = administration of Dose 1 of RTS,S&#x2F;AS02A or comparator vaccine in the NCT00197041 study).",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00323622",
    "endpoint": "measure - Time to First or Only Clinical Episode of Symptomatic Plasmodium Falciparum Malaria Infection (PFMI) of Primary Case Definition, description - Malaria infection by Plasmodium falciparum was detected by passive case detection.\nA symptomatic PFMI episode of Primary Case Definition (PCD) was defined as the presence of P. falciparum asexual parasitaemia above 2500 per µL on Giemsa stained thick blood films accompanied by fever (axillary temperature equal or above 37.5 degrees Celsius at the time of presentation) occurring in an unwell child brought for treatment to a healthcare facility.\nThe time to first or only episode of symptomatic PFMI is expressed in terms of rate of first PFMI (RPFMI), that is, the number of PFMI events reported (n) over the period elapsed until the PFMI event occurred (i.e.\nevents per Persons Year at Risk [PYAR]) for each group.\nAnalysis for this outcome was solely performed on Cohort 1 subjects, with groups pooled across age ranges., timeFrame - From Month 21 to Month 33 (M21-33), and from Month 33 to Month 45 (M33-45). Month 0 = administration of Dose 1 of RTS,S&#x2F;AS02A or comparator vaccine in study NCT00197041",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00323622",
    "endpoint": "measure - Time to First or Only Episode of Symptomatic Plasmodium Falciparum Malaria Infection (PFMI) of Secondary Case Definition 1, description - PFMI was detected by passive case detection.\nSymptomatic PFMI of Secondary Case Definition (SCD) 1 was defined as the presence of P. falciparum asexual parasitaemia (any level if parasitemia) on Giemsa stained thick blood films accompanied by fever (axillary temperature equal or above 37.5 degrees Celsius) in an unwell child brought for treatment.\nThe time to first or only episode of symptomatic PFMI is expressed in terms of rate of first PFMI (RPFMI), that is, the number of PFMI events reported (n) over the period elapsed until the PFMI event occurred (i.e.\nevents per Persons Year at Risk [PYAR]) for each group.\nAnalysis for this outcome was solely performed on Cohort 1 subjects, with groups pooled across age ranges., timeFrame - From Month 21 to Month 33 (M21-33), and from Month 33 to Month 45 (M33-45). Month 0 = administration of Dose 1 of RTS,S&#x2F;AS02A or comparator vaccine in study NCT00197041",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00323622",
    "endpoint": "measure - Time to First or Only Episode of Symptomatic Plasmodium Falciparum Malaria Infection (PFMI) of Secondary Case Definition 2, description - PFMI was detected by passive case detection.\nSymptomatic PFMI of Secondary Case Definition (SCD) 2 was defined as the presence of P. falciparum asexual parasitaemia (any level if parasitemia) on Giemsa stained thick blood films in an unwell child brought for treatment with a history of fever (axillary temperature equal or above 37.5 degrees Celsius) within 24 hours or documented fever.\nThe time to first or only episode of symptomatic PFMI is expressed in terms of rate of first PFMI (RPFMI), that is, the number of PFMI events reported (n) over the period elapsed until the PFMI event occurred (i.e.\nevents per Persons Year at Risk [PYAR]) for each group.\nAnalysis for this outcome was performed on Cohort 1 subjects, with groups pooled across age ranges., timeFrame - From Month 21 to Month 33 (M21-33), and from Month 33 to Month 45 (M33-45). Month 0 = administration of Dose 1 of RTS,S&#x2F;AS02A or comparator vaccine in study NCT00197041",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00323622",
    "endpoint": "measure - Time to First or Only Episode of Symptomatic Plasmodium Falciparum Malaria Infection (PFMI) of Secondary Case Definition 3, description - PFMI was detected by passive case detection.\nSymptomatic PFMI of Secondary Case Definition (SCD) 3 was defined as the presence of P. falciparum asexual parasitaemia above 15000 per microliter (µL) on Giemsa stained thick blood films accompanied by fever (axillary temperature equal or above 37.5 degrees Celsius) in an unwell child brought for treatment to a healthcare facility.\nThe time to first or only episode of symptomatic PFMI is expressed in terms of rate of first PFMI (RPFMI), that is, the number of PFMI events reported (n) over the period elapsed until the PFMI event occurred (i.e.\nevents per Persons Year at Risk [PYAR]) for each group.\nAnalysis for this outcome was performed on Cohort 1 subjects solely, with groups pooled across age ranges., timeFrame - From Month 21 to Month 33 (M21-33), and from Month 33 to Month 45 (M33-45). Month 0 = administration of Dose 1 of RTS,S&#x2F;AS02A or comparator vaccine in study NCT00197041",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00323622",
    "endpoint": "measure - Number of Primary Case Definition Clinical Episodes of Symptomatic Plasmodium Falciparum Malaria Infection (PFMI), description - PFMI was detected by passive case detection.\nA symptomatic PFMI episode of Primary Case Definition (PCD) was defined as the presence of P. falciparum asexual parasitaemia above 2500 per µL on Giemsa stained thick blood films accompanied by fever (axillary temperature equal or above 37.5 degrees Celsius at the time of presentation) occurring in an unwell child brought for treatment to a healthcare facility.\nThe number of PFMI episodes (EPFMI) per person-year (pyr) was tabulated, using as unit EPFMI episode per pyr.\nAnalysis for this outcome was performed on Cohort 1 subjects solely, with groups pooled across age ranges., timeFrame - From Month 21 to Month 33 (M21-33), and from Month 33 to Month 45 (M33-45). Month 0 = administration of Dose 1 of RTS,S&#x2F;AS02A or comparator vaccine in study NCT00197041",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00323622",
    "endpoint": "measure - Number of Subjects With Anemia., description - Anemia was indicated by a hematocrit level (HL) below (&lt;) 25%.\nThe numbers of subjects with HL below (&lt;) and above or equal (≥) 25 %, and with missing HL results were tabulated.\nIn the tabulation below, the number of subjects falling into the &quot;HL ≥25%&quot; category corresponds to the number of subjects with anemia as asked per outcome.\nAnalysis for this outcome was performed on Cohort 1 subjects solely, with groups pooled across age ranges., timeFrame - At Months 33 and 45 (Month 0 = administration of Dose 1 of RTS,S&#x2F;AS02A or comparator vaccine in the NCT00197041 study).",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00323622",
    "endpoint": "measure - Number of Subjects Prevalent for Plasmodium Falciparum (P. Falciparum) Parasitemia, description - Subjects prevalent for P. falciparum parasitemia were defined as subjects with the presence of P. falciparum asexual parasitemia above 0 per microliter (µL) on Giemsa stained thick blood films.Analysis for this outcome was performed on Cohort 1 subjects solely, with groups pooled across age ranges., timeFrame - At Months 33 (M33) and 45 (M45) (Month 0 = administration of Dose 1 of RTS,S&#x2F;AS02A or comparator vaccine in the NCT00197041 study).",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06862453",
    "endpoint": "measure - Vaccine Efficacy (VE) (1 minus the risk ratio) against homologous CHMI with PfSPZ Challeng(NF54) conducted 12 weeks after 3rd immunization in the modified ITT (mITT) population, description - Proportion of protected volunteers following CHMI.\nProtection is defined as the absence of parasitemia in the peripheral blood for +21 days following CHMI with PfSPZ Challenge (NF54) in volunteers who received PfSPZ-LARC2 Vaccine., timeFrame - 21 days following CHMI",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06862453",
    "endpoint": "measure - Humoral immune responses to PfCSP and their relationship to VE., description - Antibody responses as measured by PfCSP ELISA., timeFrame - The day before immunization until 21 days post CHMI",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00362050",
    "endpoint": "measure - Median time to 50% parasite clearance, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00362050",
    "endpoint": "measure - Median parasite clearance time, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00362050",
    "endpoint": "measure - Fever clearance time, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00362050",
    "endpoint": "measure - Proportion of patients with Polymerase Chain Reaction (PCR)-corrected Adequate Clinical and Parasitological Response (ACPR) on Day 28. Proportion of patients with PCR-uncorrected ACPR on Day 28., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00362050",
    "endpoint": "measure - Proportion of patients with PCR-uncorrected ACPR on Day 14., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00362050",
    "endpoint": "measure - Relationship between RBx 11160 plasma concentrations at approximately 3 hours and 8 hours after study medication administration on Days 0 and 6 and PC90, PC50 and PCT., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00362050",
    "endpoint": "measure - Number of gametocytes at Days 0, 3, 6, 14, 21, and 28., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00362050",
    "endpoint": "measure - Safety endpoints:, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00362050",
    "endpoint": "measure - Incidence of adverse events or clinically significant changes in laboratory parameters, physical examination, ECG, or vital signs., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00707200",
    "endpoint": "measure - Laboratory indices of potential cytoadhesion (lactate, cell counts), description - , timeFrame - Presentation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00455494",
    "endpoint": "measure - Effect on heart repolarization (QTc interval change), description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00455494",
    "endpoint": "measure - Clearance, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00455494",
    "endpoint": "measure - Terminal elimination half-life, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00431808",
    "endpoint": "measure - *Immunogenicity evaluation through:, description - , timeFrame - 84 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00431808",
    "endpoint": "measure - The humoral response to the vaccine antigen: assessed by measuring the level of IgG by ELISA., description - , timeFrame - 84 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00431808",
    "endpoint": "measure - An IFA for at least two parasite strains will be used to verify that the antibodies elicited by the vaccine recognize the native protein on merozoites., description - , timeFrame - 84 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00878397",
    "endpoint": "measure - Household coverage and use of long lasting insecticide nets, description - , timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00323375",
    "endpoint": "measure - Pharmacokinetic Profile of AQ-13 and Chloroquine Metabolites, description - The metabolites of AQ-13 and CQ were monitored (measured) using the same HPLC assay used to measure AQ-13 and CQ because that assay also distinguishes the mono- and di-dealkylated metabolites of AQ-13 and CQ., timeFrame - These assays began before the time of dosing and continued for 4 weeks after the dosing of AQ-13 and CQ had been completed.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00323375",
    "endpoint": "measure - The incidence of pruritus in patients receiving Chloroquine Metabolites, description - Because pruritus has been reported in subjects receiving CQ, it was considered (discussed) with all patients who received either AQ-13 or CQ., timeFrame - This issue was reviewed with all subjects for the time from 1 to 28 days after beginning treatment with AQ-13 or CQ.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00146718",
    "endpoint": "measure - ACPR Day 14, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00146718",
    "endpoint": "measure - Early treatment failure, between days 1 and 3, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00146718",
    "endpoint": "measure - Late treatment failure, between days 4 and 14, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00538382",
    "endpoint": "measure - The levels of unbound DHA will be similar for parasitemic pregnant women (during the second and third trimesters) vs. parasitemic non-pregnant women., description - , timeFrame - 48 hours after drug administration",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00538382",
    "endpoint": "measure - The pharmacokinetics of ARTS and total DHA will be similar for parasitemic pregnant women (during the second and third trimesters) vs. the same women three months postpartum and parasitemic non-pregnant women., description - , timeFrame - 48 hours after drug administration",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00538382",
    "endpoint": "measure - The pharmacodynamics of therapy will be similar for parasitemic pregnant women (during the 2nd and 3rd trimesters) vs. parasitemic non-pregnant women. Pharmacodynamics will be determined by measuring the parasite clearance time (PCT), PC50, and PC90., description - , timeFrame - 48 hours after drug administration",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00538382",
    "endpoint": "measure - The pharmacodynamics and pharmacokinetic outcomes (as elaborated above) will be similar between the 2nd and 3rd trimester in parasitemic pregnant women., description - , timeFrame - 48 hours after drug administration",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00538382",
    "endpoint": "measure - Description of safety and tolerability of Artesunate in the target population (pregnant women in the 2nd and 3rd trimester)., description - , timeFrame - 0ne year postpartum",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05304611",
    "endpoint": "measure - Participants With Plasmodium Falciparum (Pf) Infection Detected by Real-Time Polymerase Chain Reaction (RT-PCR), description - Number of participants with Plasmodium falciparum (Pf) blood stage infection defined as blood sample positive for Pf was assessed by real-time polymerase chain reaction (RT-PCR) of blood sample collected from participants from day 0 through week 28 (196 days) after administration of L9LS or placebo.\nAnalysis was done as number of participants who had at least one positive blood sample., timeFrame - Measured through week 24 (dose escalation study) and week 28 (efficacy study)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05304611",
    "endpoint": "measure - Participants With Clinical Malaria - Pediatric Dose Escalation Study, description - Number of pediatric participants with clinical malaria during a single malaria season, defined by an illness accompanied by measured axillary fever ≥37.5°C, or history of fever (subjective or objective) in the previous 24 hours, and Plasmodium falciparum (Pf) asexual parasitemia &gt;5,000 parasites&#x2F;μL as detected from microscopic examination of thick blood smear.\nAssessment was done from day 0 through week 28 (196 days) after administration of L9LS or placebo.\nSubjective data, objective data and blood sample were collected from administration of intervention through week 28.\nAnalysis was done as number of participants who had at least one symptom and positive blood sample., timeFrame - Measured through Week 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05304611",
    "endpoint": "measure - Participants With Clinical Malaria - Pediatric Efficacy Study, description - Number of pediatric participants with clinical malaria during a single malaria season, defined by an illness accompanied by measured axillary fever ≥37.5°C, or history of fever (subjective or objective) in the previous 24 hours, and Plasmodium falciparum (Pf) asexual parasitemia &gt;5,000 parasites&#x2F;μL as detected from microscopic examination of thick blood smear.\nAssessment was done from day 0 through week 28 (196 days) after administration of L9LS or placebo.\nSubjective data, objective data and blood sample were collected from administration of intervention through week 28.\nAnalysis was done as number of participants who had at least one symptom and positive blood sample., timeFrame - Measured through Week 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05304611",
    "endpoint": "measure - Participants With Clinical Malaria Detected by Microscopic Examination of Thick Blood Smear - Pediatric Dose Escalation Study, description - Number of participants with clinical malaria during a single malaria season, defined by an illness accompanied by any level of Plasmodium Falciparum (Pf) asexual parasitemia as detected from microscopic examination of thick blood smear that results in the administration of anti-malarial treatment., timeFrame - Measured through Week 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05304611",
    "endpoint": "measure - Participants With Clinical Malaria Detected by Microscopic Examination of Thick Blood Smear - Pediatric Efficacy Study, description - Number of participants with clinical malaria during a single malaria season, defined by an illness accompanied by any level of Plasmodium Falciparum (Pf) asexual parasitemia as detected from microscopic examination of thick blood smear that results in the administration of anti-malarial treatment., timeFrame - Measured through Week 24",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05304611",
    "endpoint": "measure - Maximum Total Plasma Concentration (Cmax) for L9LS - Study Year One, description - Maximum total plasma concentration (Cmax) following a dose of 150 mg or 300 mg L9LS.\nSerum collected on days 0, 7, 28, 56, 84, 112, 140, 168, 196, 224, &amp; 252 after the administration of L9LS.\nCmax for L9LS was obtained directly by visual inspection of the plasma concentration versus time profiles post dose.\nAnalysis was done to determine each participant&#x27;s observed maximum concentration based on all available timepoints and cumulative output was calculated as the central tendency and dispersion metric based on the observed maximum concentrations., timeFrame - Measured through Week 36",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05304611",
    "endpoint": "measure - Time to Maximum Plasma Concentration (TMax) for L9LS - Study Year One, description - Time to maximum total plasma concentration (Cmax) following a dose of 150 mg or 300 mg L9LS.\nSerum was collected on days 0, 7, 28, 56, 84, 112, 140, 168, 196, 224, &amp; 252 after administration of L9LS.\nTmax for L9LS was obtained directly by visual inspection of the plasma concentration versus time profiles.\nAnalysis was done to determine the time (in days) at which the maximum observed concentration was achieved for each participant and cumulative output was calculated as the central tendency and dispersion metric based on the observed time of maximum concentration., timeFrame - Measured through Week 36",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02110784",
    "endpoint": "measure - Proportion of aparasitaemic patients, description - to evaluate efficacy of the treatment to clear blood from parasites, timeFrame - at day 1, 2, 3, 7, 21, 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02110784",
    "endpoint": "measure - Proportion of afebrile patients, description - to evaluate the efficacy of eurartesim in reducing fever caused by malaria, timeFrame - at day 1, 2, 3, 7, 21, 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02110784",
    "endpoint": "measure - uncorrected ACPR, description - , timeFrame - at day 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02110784",
    "endpoint": "measure - Number of Patients with Serious and Non-Serious Adverse Events, description - , timeFrame - up to 42 days from starting of treatment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01958619",
    "endpoint": "measure - Piperaquine Cmax, description - Piperaquine Observed maximum drug plasma concentration, timeFrame - Days 1 pre-dose and post-dose at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours (Day 2), and, 48 (Day 3), 72 (Day 4), 96 (Day 5) and 168 (Day 8) hours post-dose. Sampling will also be done on Day 11, 15, 29 and 43.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01958619",
    "endpoint": "measure - Piperaquine AUC0-∞, description - Piperaquine Area under plasma concentration time curve from time zero extrapolated to infinity., timeFrame - Days 1 pre-dose and post-dose at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours (Day 2), and, 48 (Day 3), 72 (Day 4), 96 (Day 5) and 168 (Day 8) hours post-dose. Sampling will also be done on Day 11, 15, 29 and 43.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00123552",
    "endpoint": "measure - Short term: clinical and parasitological outcome; rates of fever and parasite clearance; presence of gametocytes following treatment, description - , timeFrame - 14 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00123552",
    "endpoint": "measure - Short term: change in hemoglobin level from day 0-14; safety and tolerability of study medications, description - , timeFrame - 14 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00123552",
    "endpoint": "measure - Long term: risk of reinfection using Kaplan-Meier product limit estimates of risk at various time intervals, description - , timeFrame - Beyond 14 days to end of study",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00123552",
    "endpoint": "measure - Long term: risk of recrudescence; change in hemoglobin level; safety and tolerability of study medications, description - , timeFrame - Beyond 14 days to end of study",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00123552",
    "endpoint": "measure - Longitudinal: prevalence of asymptomatic parasitemia; mean hemoglobin, description - , timeFrame - 4 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01899820",
    "endpoint": "measure - Crude (PCR uncorrected) ACPR ratio at day 28 (PCR uncorrected ACPR), description - , timeFrame - Day 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01899820",
    "endpoint": "measure - Cure ratios at day 28, 42, (PCR corrected and PCR uncorrected). Change in this outcome measure will be assessed., description - , timeFrame - Day 28 and day 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01899820",
    "endpoint": "measure - Fever Clearance Time (FCT), description - This will be defined as the time (hrs) from the start of a patient&#x27;s treatment to the first consecutive axillary temp measurements below 37.5 for at least 48 hrs, timeFrame - 0 to 48 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01899820",
    "endpoint": "measure - Asexual parasite clearance time (PCT), description - PCT(proportion of patients remaining parasitaemic) defined as the time (in hours) from the start of a patient&#x27;s treatment to 2 consecutive negative blood slides (collected at different days), timeFrame - Day 0 to day 28, upto day 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01899820",
    "endpoint": "measure - Gametocyte carrier rates and geometric mean densities (excluding negatives) will be compared on days 7, 14, 28 and 42. Change in this outcome measure will be assessed., description - , timeFrame - Day 7, 14, 28 and 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01899820",
    "endpoint": "measure - Changes of haemoglobin (Hb) concentration from day 0 to days 28, and 42, description - , timeFrame - Day 0, day 28 and day 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01899820",
    "endpoint": "measure - Number of participants with adverse events, description - , timeFrame - Up to day 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01899820",
    "endpoint": "measure - Comparison between adverse events related to artemether lumefantrine and dihydroartemisinin piperaquine, description - , timeFrame - Up to day 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01899820",
    "endpoint": "measure - Temperature, description - , timeFrame - Up to day 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01899820",
    "endpoint": "measure - Oxygen saturation, description - , timeFrame - Up to day 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01899820",
    "endpoint": "measure - Heart rate, description - , timeFrame - Up to day 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01899820",
    "endpoint": "measure - Respiratory rate, description - , timeFrame - Up to day 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04577066",
    "endpoint": "measure - Humoral immune responses of volunteers exposed to the GA2 and GA1 parasite., description - Difference in concentration of anti-CSP antibodies between GA2 and GA1 immunised volunteers as assessed by ELISA prior to controlled human infection (study day 75)., timeFrame - From time of exposure to maximum 264 days later.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04577066",
    "endpoint": "measure - Cellular immune response of volunteers exposed to the GA2 and GA1 parasite., description - Difference in percentage of CD4+ and CD8+ T-cells producing IFN-γ between GA2 and GA1 immunised volunteers as assessed by flow cytometry prior tot controlled human infection (study day 75)., timeFrame - From time of exposure to maximum 264 days later.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01868438",
    "endpoint": "measure - Tmax and Terminal Half Life for Pyronaridine, Artesunate and DHA, description - Pharmacokinetic blood sampling for first or second intervention dose, timeFrame - First intervention: Day 1 pre-dose to Day 43 visit (D1, 2, 3, 4, 6, 8, 15, 22, 29, 36, 43) ; second intervention: Day 61 pre-dose to Day 103 visit (D61, 62, 63, 64, 66, 68, 75, 82, 89, 96, 103)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01868438",
    "endpoint": "measure - Safety Evaluation - Summary of Adverse Events, description - , timeFrame - End of study (Day 103)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01858831",
    "endpoint": "measure - Number of participants with adverse events, description - , timeFrame - up to 336h post dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01858831",
    "endpoint": "measure - Change in Systolic Blood Pressure, description - Change values at 4, 24, 72, 168 and 336 h post-dose from baseline (pre-dose), timeFrame - at pre-dose, 4, 24, 72, 168 and 336 h post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01858831",
    "endpoint": "measure - Change in ECG findings, description - Change at 4, 72, 168 and 336 h post-dose from baseline (pre-dose), timeFrame - at pre-dose, 4, 72, 168 and 336 h post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01858831",
    "endpoint": "measure - Laboratory, description - Change values at 72, 168 and 336 h post-dose from baseline (pre-dose), timeFrame - at pre-dose, 72, 168 and 336 h post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01858831",
    "endpoint": "measure - Change in Diastolic Blood Pressure, description - Change values at 4, 24, 72, 168 and 336 h post-dose from baseline (pre-dose), timeFrame - at pre-dose, 4, 24, 72, 168 and 336 h post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01858831",
    "endpoint": "measure - Change in Heart rate, description - Change values at 4, 24, 72, 168 and 336 h post-dose from baseline (pre-dose), timeFrame - at pre-dose, 4, 24, 72, 168 and 336 h post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01858831",
    "endpoint": "measure - Change in Hematology values, description - Change values at 72, 168 and 336 h post-dose from baseline (pre-dose), timeFrame - at pre-dose, 72, 168 and 336 h post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01858831",
    "endpoint": "measure - Change in Biochemistry values, description - Change values at 72, 168 and 336 h post-dose from baseline (pre-dose), timeFrame - at pre-dose, 72, 168 and 336 h post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01858831",
    "endpoint": "measure - Change in Urinalysis values, description - Change values at 72, 168 and 336 h post-dose from baseline (pre-dose), timeFrame - at pre-dose, 72, 168 and 336 h post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01853475",
    "endpoint": "measure - Piperaquine Cmax, description - Piperaquine maximum concentration observed, timeFrame - Day 1 pre-dose and post-dose at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours(Day 2), and, 48 (Day 3), 72 (Day 4), 96 (Day 5),168 (Day 8), Day 11, Day 15, Day 29 and Day 43",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01853475",
    "endpoint": "measure - Piperaquine AUC0-inf, description - Area under the Piperaquine plasma concentration time curve from time zero to time infinity using observed values., timeFrame - Day 1 pre-dose and post-dose at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours(Day 2), and, 48 (Day 3), 72 (Day 4), 96 (Day 5),168 (Day 8), Day 11, Day 15, Day 29 and Day 43",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01623557",
    "endpoint": "measure - The safety and immunogenicity of ChAd63-MVA CS and ChAd63-MVA ME-TRAP, description - <p>The safety of the vaccine regimens will be assessed by analysing actively and passively collected data from clinical review of volunteers and laboratory measurements.</p><p>The ability of the vaccines to induce malaria-specific immune responses (immunogenicity) will be assessed by the following laboratory tests;</p><p>(A) Interferon gamma ELISPOT.\n(B) Flow cytometry to measure T cell responses</p><p>Other laboratory investigations including microarray analysis may be performed.</p>, timeFrame - up to 7 months post first vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00146783",
    "endpoint": "measure - placental malaria, description - , timeFrame - on the day of delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00146783",
    "endpoint": "measure - maternal peripheral parasitaemia at delivery, description - , timeFrame - within seven days of dellivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00146783",
    "endpoint": "measure - tolerance and adverse events after taking study drugs, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00146783",
    "endpoint": "measure - molecular markers of drug resistance to SP and Amodiaquine, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00380146",
    "endpoint": "measure - Correlation of treatment outcome and gametocyte carriage with pharmacokinetic parameters and pregnancy status, description - , timeFrame - 0 hours (pre treatment) and repeated on day 0 or 1 at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours, and days 2, 3, 7, 14, 21, 28 and 42 , and time of birth outcome",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00380146",
    "endpoint": "measure - Correlation of frequency of DHFR mutations at codons 436, 437, 540 and 581 in maternal and placental samples with treatment outcomes, description - , timeFrame - Day 42 (or day of withdrawal)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00380146",
    "endpoint": "measure - Birth outcomes in terms of major congenital abnormalities, spontaneous abortions, still births and neonatal deaths, gestational age and birth weight, placental weight, newborn head circumference, arm circumference and neurological development, description - , timeFrame - Day of birth outcome",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00380146",
    "endpoint": "measure - Risk of harm by describing all adverse events and their causality assessments and changes in full blood count, glucose, bilirubin, creatinine, urea and ALT, description - , timeFrame - Days 3, 7, 14, 21, 28 and every 2 weeks thereafter until birth (for a minimum of 42 days) or withdrawal visit",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00380146",
    "endpoint": "measure - Capacity building by describing the training and development of study teams and their subsequent skills attained, description - , timeFrame - Duration of trial",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00120822",
    "endpoint": "measure - The prevalence of malaria parasitemia 14 days after administration of a dose of sulfadoxine-pyrimethamine to pregnant women., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00120822",
    "endpoint": "measure - The mean haemoglobin 14 days after administration of a single dose of sulfadoxine-pyrimethamine to pregnant women., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00130065",
    "endpoint": "measure - Effect of HIV serostatus on drug efficacy, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00386763",
    "endpoint": "measure - Proportion of patients free of parasites at 7 days and at 14 days, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00386763",
    "endpoint": "measure - Time to clearance from parasites, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00386763",
    "endpoint": "measure - Time to clearance of fever, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00386763",
    "endpoint": "measure - Hematology and biochemistry parameters, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00386763",
    "endpoint": "measure - Electrocardiogram, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02259426",
    "endpoint": "measure - Transmission to Anopheles gambiae mosquitoes, description - Mosquito membrane feeding assays will be used to determine the proportion of infected mosquitoes and the oocyst burden in infected mosquitoes., timeFrame - Day 3 and 7 during follow-up",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02259426",
    "endpoint": "measure - Haematological recovery, description - Haemoglobin concentration will be determined at enrolment and on days 2, 3, 7 and 14 during follow-up.\nHaemoglobin concentration will be presented as grams per decilitre and as concentration relative to enrollment value., timeFrame - 14 days during follow-up",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02259426",
    "endpoint": "measure - Gametocyte sex-ratio, description - The ratio of male:female gametocytes will be determined at enrolment and on days 2, 3, 7 and 14 during follow-up by qRT-PCR., timeFrame - 14 days of follow-up",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02259426",
    "endpoint": "measure - Gametocyte carriage during follow-up, description - Gametocyte prevalence at enrolment and on days 2, 3, 7 (primary outcome measure), and 14 during follow-up.\nThe duration of gametocyte carriage in days will be estimated., timeFrame - 14 days during follow-up",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00120809",
    "endpoint": "measure - Hemoglobin concentration six weeks after delivery., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01743820",
    "endpoint": "measure - gametocyte prevalence and density, description - Baseline, Hours 2, 6, 12, 24, Days 2, 3, 7, 14, 28, timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01743820",
    "endpoint": "measure - primaquine pharmacokinetics - area under the curve (AUC) of parent drug and metabolite, description - Hours 1, 2, 3, 4, 6, 8, 12, 24, timeFrame - 24 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01743820",
    "endpoint": "measure - asexual parasite prevalence and density, description - Baseline, Hours 2, 6, 12, 24, Days 2, 3, 7, 14, 28, timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01743820",
    "endpoint": "measure - safety measurements including hemoglobin and signs of hemolysis, description - Baseline, Days 1, 2, 3, 7, 14, 28, timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01659281",
    "endpoint": "measure - Parasitological cure rates, description - , timeFrame - Weekly to Day 56",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01659281",
    "endpoint": "measure - Occurence of treatment-emergent adverse events, description - , timeFrame - 3 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01659281",
    "endpoint": "measure - In vitro drug sensitivity profile for individual parasite isolates, description - , timeFrame - Baseline",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01659281",
    "endpoint": "measure - Mefloquine whole blood concentrations, description - , timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01887821",
    "endpoint": "measure - Proportion of patients classified as Early Treatment Failures, description - <p>One or more of the following:</p><ul><li>danger signs or severe malaria on day 1, 2 or 3 in the presence of parasitaemia;</li><li>parasitaemia on day 2 higher than on day 0, irrespective of temperature;</li><li>parasitaemia on day 3 with temperature ≥ 37.5 ºC;</li><li>parasitaemia on day 3 ≥ 25% of count on day 0.</li></ul>, timeFrame - Day 63",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01887821",
    "endpoint": "measure - The parasite clearance time, description - Defined as the time in hours from the first treatment dose to the first of two consecutive parasitemia counts of zero., timeFrame - Assessed every 6 hours until Day 3, or two consecutive parasite negative slides.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01887821",
    "endpoint": "measure - Fever clearance time, description - Defined as the time in hours from the first treatment dose to the start of the first sustained period of 24 hours without fever, timeFrame - Assessed every 6 hours until Day 3, or 24 hours without fever",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01887821",
    "endpoint": "measure - Frequency of adverse and serious adverse events, description - , timeFrame - Day 63",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01887821",
    "endpoint": "measure - Proportion of patients classified as Late Clinical Failures, description - <p>One or more of the following:</p><ul><li>danger signs or severe malaria in the presence of parasitaemia on any day between day 4 and day 63 in patients who did not previously meet any of the criteria of early treatment failure;</li><li>presence of parasitaemia on any day between day 4 and day 63 with temperature ≥ 37.5 ºC (or history of fever) in patients who did not previously meet any of the criteria of early treatment failure</li></ul>, timeFrame - Day 63",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01887821",
    "endpoint": "measure - Proportion of patients classified as Late Parasitological Failures, description - Presence of parasitaemia on any day between day 7 and day 63 with temperature &lt; 37.5 ºC in patients who did not previously meet any of the criteria of early treatment failure or late clinical failure, timeFrame - Day 63",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00452088",
    "endpoint": "measure - Humoral immune responses by ELISA before and four weeks after each vaccination, description - , timeFrame - 84 Days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00452088",
    "endpoint": "measure - Cellular immune response to the vaccine antigens by measuring the, description - , timeFrame - 84 Days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00452088",
    "endpoint": "measure - number of cells producing IFNγ&#x2F;106 cells by Elispot to MSP3-LSP and, description - , timeFrame - 84 Days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06860178",
    "endpoint": "measure - Malaria incidence among children aged 5-36 months over 24 and 36 months, description - Malaria incidence among children aged 5-36 months over 24 and 36 months post first dose using routine surveillance activities for clinical malaria detection and reporting;, timeFrame - From enrollment to 2 years after booster",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06860178",
    "endpoint": "measure - Malaria incidence among children aged 3-59 months over 24 and 36 months, description - Malaria incidence among children aged 3-59 months over 24 and 36 months post first dose using routine surveillance activities for clinical malaria detection and reporting, timeFrame - From enrollment to 2 years after booster",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06860178",
    "endpoint": "measure - Malaria prevalence at peak transmission, description - Malaria prevalence at peak transmission in November after SMC campaigns in 2025 and 2026, timeFrame - From enrollment to 2 years after booster dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06860178",
    "endpoint": "measure - Vaccine coverage, description - Pourcentage of children who has received 3 or 4 doses at 24 months post 1st vaccination, timeFrame - From enrollment to months 24",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06860178",
    "endpoint": "measure - Occurrence of adverse events (AEs) and serious adverse events (SAEs) following R21&#x2F;Matrix-M vaccination;, description - Occurrence of adverse events (AEs) and serious adverse events (SAEs) following R21&#x2F;Matrix-M vaccination, timeFrame - From enrollment to months 4",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06860178",
    "endpoint": "measure - Acceptability, description - Qualitative interviews and FGDs among policy makers, health managers, health providers and caregivers, timeFrame - From 12 months after study start to 36 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06860178",
    "endpoint": "measure - Stakeholder perceptions of the feasibility on the vaccine delivery strategy in each group, description - Acceptability and feasibility studies will use qualitative longitudinal study (QLS) research methods.\nWe will apply an ecological framework approach with emphasis on the interplay and inter-dependency between individual, interpersonal, organizational, and policy levels.\nQualitative data will be collected through ethnographic immersion, in-depth interviews, group interviews and focus group discussions.\nNo quantitative measurements will be made., timeFrame - From enrollment to months 36",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06860178",
    "endpoint": "measure - Contextual and behavioural factors impeding or facilitating R21&#x2F;Matrix-M vaccine uptake, description - Interviews and FGD - will be explained in a parallel protocol, timeFrame - From enrollment to months 24",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06860178",
    "endpoint": "measure - Stakeholders and caregivers perceptions of the factors that enhance and&#x2F;or constrain the succesful co,pletion of four doses of R21 and the key drivers of vaccination coverage, description - The study will cover a full, two-year R21&#x2F;Matrix-M delivery cycle with data collection at two time points in each arm: soon after the primary series is delivered, and soon after the booster dose is provided a year later.\nThis longitudinal approach will enable us to explore and chart dynamic processes as they occur, barriers and facilitators, and acceptability over time.\nIt is inherently suitable for studying R21&#x2F;Matrix-M introduction, requiring prolonged and repeated involvement by patients and providers.\nThis approach is also necessary to explore the drivers of vaccine hesitancy which is not a static state; vaccine decision-making changes over time as caregivers experience different influences and nudges along the way.\nQualitative data will be collected through ethnographic immersion, in-depth interviews, group interviews and focus group discussions to explore factors in the service delivery, household, and broader social environments that will lead to R21 adoption and adherence.\nA, timeFrame - From enrollment to months 24 and 36",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06860178",
    "endpoint": "measure - Incremental costs (per child vaccinated) and cost-effectiveness (per malaria case and separately, per DALY averted) of each vaccination strategy, calculated from a societal perspective, description - Costs associated with the different vaccination strategies will be estimated by collecting data on direct and indirect costs to health systems and opportunity costs to vaccinees and their caregivers (beneficiaries).\nBeneficiary costs will be collected during household surveys, via case report forms developed to collect data on direct costs (transport, food, medication) and indirect costs (time and income loss) incurred by their household related to each intervention arm.\nProvider costs will be collected using custom built spreadsheets structured to comprehensively capture the resources used for all intervention delivery related activities (excluding research activities) by cost category (person time, equipment, consumables including vaccines, storage, transport, overheads and other costs) by arm.\nMalaria incidence estimates (primary clinical outcome) will be used to calculate malaria cases and DALYs averted by arm, adjusted for intervention coverage (using the coverage survey data)., timeFrame - From enrollment to months 36",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00169117",
    "endpoint": "measure - Community acceptability, description - , timeFrame - November 2003",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00274235",
    "endpoint": "measure - mean birthweight, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00274235",
    "endpoint": "measure - proportion of mothers with placental plasmodial infection, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00274235",
    "endpoint": "measure - proportion of preterm deliveries, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00274235",
    "endpoint": "measure - proportion of mothers with anaemia (Haemoglobin level (Hb)&lt;11g&#x2F;dl) and severe anaemia (Hb&lt;8g&#x2F;dl) at delivery, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00274235",
    "endpoint": "measure - proportion of mothers with parasitaemia at delivery, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00274235",
    "endpoint": "measure - proportion of adverse events after taking study drugs, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00274235",
    "endpoint": "measure - proportion of congenital abnormalities, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00274235",
    "endpoint": "measure - proportion of stillbirths, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01026246",
    "endpoint": "measure - Number of subjects experiencing a 4-fold increase in Anti-EBA-175 RII-NG antibody level (ELISA)., description - , timeFrame - Days 14, 28, 42, 180 and 194 relative to baseline.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01026246",
    "endpoint": "measure - Relative binding inhibition of recombinant EBA-175 RII-NG to human red blood cells in vitro in the presence of serum from immunized individuals., description - , timeFrame - Days 0, 14, 28, 42, 180 and 194.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01026246",
    "endpoint": "measure - Anti-EBA-175 RII-NG antibody level by enzyme-linked immunosorbent assay (ELISA)., description - , timeFrame - Days 0, 14, 28, 42, 180 and 194.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01026246",
    "endpoint": "measure - Relative growth inhibition of Plasmodium falciparum in human red blood cells cultured in vitro in the presence of serum from immunized individuals., description - , timeFrame - Days 0, 14, 28, 42, 180 and 194.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01383109",
    "endpoint": "measure - Total Radioactivity in Blood: AUC0-t, AUC0-∞, description - <p>Pharmacokinetic Parameters:</p><p>AUC0-t: area under the plasma concentration-time curve from Hour 0 through the last quantifiable concentration time (LQCT), where LQCT is the time at which the last sample with a quantifiable concentration was collected AUC0-∞: area under the plasma concentration-time curve from Hour 0 to infinity</p><p>PK sampling performed at predose, 0.5, 1, 2, 4, 8, 12 and 24 hours, and 2, 4, 6, 7, 14, 21, 28, 35 and 42 days post-dose</p>, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01383109",
    "endpoint": "measure - Total Radioactivity in Blood: Cmax, description - <p>Pharmacokinetic Parameters:</p><p>Cmax: maximum observed peak observed concentration</p><p>PK sampling performed at predose, 0.5, 1, 2, 4, 8, 12 and 24 hours, and 2, 4, 6, 7, 14, 21, 28, 35 and 42 days post-dose</p>, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01383109",
    "endpoint": "measure - Total Radioactivity in Blood: Half-life, Tmax, description - <p>Pharmacokinetic Parameters:</p><p>Half-life: computed as ln (2) &#x2F; Kel Tmax: time to maximum concentration</p><p>PK sampling performed at predose, 0.5, 1, 2, 4, 8, 12 and 24 hours, and 2, 4, 6, 7, 14, 21, 28, 35 and 42 days post-dose</p>, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00386750",
    "endpoint": "measure - Rate of auditory changes following 3 days of treatment with artemether-lumefantrine at Days 7, 28, and 42 days assessed by pure tone thresholds assessments (a type of hearing test), description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00386750",
    "endpoint": "measure - Changes in auditory function with a non-ACT (artemisinin combined therapy) antimalarial (Malarone, atovaquone-proguanil) and another ACT combination (artesunate-mefloquine) assessed by pure tone thresholds (a type of hearing test), description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00386750",
    "endpoint": "measure - Relationship between changes in auditory function and drug exposure., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00623857",
    "endpoint": "measure - Haematologic and urinary indicators of micronutrient status, description - , timeFrame - 30 weeks after start of intervention",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00623857",
    "endpoint": "measure - Anthropometric indices, description - , timeFrame - 57 weeks after start of intervention",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00623857",
    "endpoint": "measure - T cell immune responses to in vitro stimulation with a crude Plasmodium falciparum lysate, description - , timeFrame - 30 weeks after start of intervention",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00623857",
    "endpoint": "measure - Plasma immunoglobulin concentrations, description - , timeFrame - 2 weeks after malaria episodes",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00347555",
    "endpoint": "measure - Relative binding inhibition of recombinant EBA-175 RII-NG to human RBCs in vitro in the presence of serum from immunized individuals., description - , timeFrame - Days 0, 14, 28, 42, 180, and 194.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00347555",
    "endpoint": "measure - Anti-parasite antibodies by indirect fluorescence antibody test (IFAT)., description - , timeFrame - Days 0, 14, 28, 42, 180, and 194.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00347555",
    "endpoint": "measure - Anti-EBA-175 RII-NG antibody level by ELISA., description - , timeFrame - Days 0, 14, 28, 42, 180, and 194.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00347555",
    "endpoint": "measure - Relative growth inhibition of Pf in human RBCs cultured in vitro in the presence of serum from immunized individuals., description - , timeFrame - Days 0, 14, 28, 42, 180, and 194.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00444106",
    "endpoint": "measure - Auditory Changes Following 3 Days of Treatment at Days 3, 7, 28, and 42 Days as Assessed by Pure Tone Thresholds Assessments (a Type of Hearing Test), description - Audiometric measurements such as pure-tone threshold (air conduction tested at 250 to 8000 HZ) day 3, 7, 28 and 42 following initiation of treatment, including changes from baseline.\nPure-tone average (PTA) calculated for each ear by averaging the pure-tone threshold values at 500, 1000, 2000 and 3000 HZ., timeFrame - Baseline (Day 1), 3, 7, 28 and Day 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00444106",
    "endpoint": "measure - Relationship Between Changes in Auditory Function and Treatment Groups, description - ABR Wave III latency (ms) changes from baseline to Day 7 in the three drug exposure groups., timeFrame - From Baseline to Day 7",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00444106",
    "endpoint": "measure - Efficacy of Polymerase Chain Reaction (PCR) Adjusted Malaria Cure Rates of the Three Treatment Regimens at Days 14, 28 and 42, description - Percentage of patients with clearance of asexual parasitemia (observed by optical microscopy) within 7 days of initiation of trial treatment without recrudescence within 14, 28 and 42 days respectively after initiation of treatment.\nPatients with recurrent parasitemia and paired PCR results were classified as either a new infection (different paired genotypes) or a recrudescence (matching paired genotypes).\nPatients without paired PCR results or ambiguous results were classified as treatment failures., timeFrame - Days 14, 28 and 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01218893",
    "endpoint": "measure - Cellular immune response between groups 1, 2, 3 and 4, description - , timeFrame - Day 0 - day 337 of study",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01218893",
    "endpoint": "measure - Antibody production between groups 1, 2, 3 and 4, description - , timeFrame - Day 0 - day 337 of study",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01218893",
    "endpoint": "measure - Cytokine profile in groups 1, 2, 3 and 4, description - , timeFrame - Day 0 - day 337 of study",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04201431",
    "endpoint": "measure - Assessment of the Humoral Immunogenicity of the PvDBPII-Matrix M1 Vaccine Candidate., description - Total IgG antibody response to the P. vivax Duffy-binding protein (PvDBPII) vaccine, timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04201431",
    "endpoint": "measure - Assessment of the Cellular Immunogenicity of the PvDBPII-Matrix M1 Vaccine Candidate., description - PvDBPII-specific CD4+ CD45RA- CCR7- effector memory T cells producing IFN-γ at 14 days after the third vaccination, timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04201431",
    "endpoint": "measure - Immunological Readouts for Association With a Reduced Parasite Multiplication Rate, description - Correlation between anti-PvDBP responses induced by the PvDBPII-Matrix M1 vaccine candidate and PMR., timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04201431",
    "endpoint": "measure - Assess the Durability of Any Reduction in PMR in Group 3 Volunteers Undergoing a Fourth Vaccination and Rechallenge, description - Assessed by quantitative PCR-derived parasite multiplication rate (PMR).\nComparison will be made between volunteers in Group 3 and two control groups: malaria-naive controls undergoing primary CHMI and volunteers undergoing their second CHMI in the parallel VAC069 study (NCT03797989)., timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03923725",
    "endpoint": "measure - 63-day PCR corrected and uncorrected efficacy, description - , timeFrame - 63 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03923725",
    "endpoint": "measure - 42-day PCR uncorrected efficacy, description - , timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03923725",
    "endpoint": "measure - Parasite clearance half-life, description - Assessed by microscopy as primary parameter to determine parasite clearance, timeFrame - 3 Days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03923725",
    "endpoint": "measure - Proportion of subjects with microscopically detectable P. falciparum parasitaemia, description - , timeFrame - Day 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03923725",
    "endpoint": "measure - Fever clearance time, description - fever clearance time (i.e. the time taken for the tympanic temperature to fall below 37.5 ºC), timeFrame - 63 Days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03923725",
    "endpoint": "measure - Proportion of subjects with gametocytaemia, description - proportion of subjects with gametocytaemia during and after treatment stratified by presence of gametocytes at enrolment, timeFrame - 63 Days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03923725",
    "endpoint": "measure - Incidence of adverse events, description - including markers of hepatic, renal or bone marrow toxicity; cardiotoxicity, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03923725",
    "endpoint": "measure - Incidence of serious adverse events, description - including markers of hepatic, renal or bone marrow toxicity; cardiotoxicity, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03923725",
    "endpoint": "measure - Number of cardiotoxicity events, description - In particular QT or QTc-interval above 500 ms at timepoint H4 and H52&#x2F;H64 and between these time points, timeFrame - 52 or 64 hours depends on treatment arm",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03923725",
    "endpoint": "measure - Change in haemoglobin stratified for G6PD status&#x2F;genotype, description - , timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03923725",
    "endpoint": "measure - Proportion of subjects requiring retreatment due to vomiting, description - Proportion of subjects requiring retreatment due to vomiting within 1 hour after administration of the study drugs, timeFrame - 1 hour",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03923725",
    "endpoint": "measure - Proportion of subjects that reports completing a full course of observed TACT, description - , timeFrame - 3 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03923725",
    "endpoint": "measure - Proportion of subjects that reports completing a full course of observed ACT, description - , timeFrame - 3 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03923725",
    "endpoint": "measure - proportion of subjects that reports completing a full course of observed TACT or ACT without withdrawal of consent or exclusion from study because of drug related serious adverse event., description - , timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03923725",
    "endpoint": "measure - Pharmacokinetic profiles, description - including Cmax and AUC) of artemisinin-derivatives and partner drugs in ACT and TACT treated subjects in correlation with pharmacodynamics measures of drug efficacy, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03923725",
    "endpoint": "measure - Pharmacokinetic interactions, description - including Cmax and AUC) of artemisinin-derivatives and partner drugs in ACT and TACT treated subjects in correlation with pharmacodynamics measures of drug efficacy, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03923725",
    "endpoint": "measure - Plasma levels of partner drugs, description - Plasma levels of partner drugs in correlation with treatment efficacy and treatment arm, timeFrame - 7 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05478720",
    "endpoint": "measure - PK measurement of DON in sera of recipients measured by half life, description - Measurement of half life, timeFrame - Measured through 18 hours post infusion",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05478720",
    "endpoint": "measure - PK measurement of DON in sera of recipients measured by volume of distribution, description - Measurement of Vd, timeFrame - Measured through 18 hours post infusion",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05478720",
    "endpoint": "measure - PK measurement of DON in sera of recipients measure by maximum concentration (Cmax), description - Measurement of Cmax, timeFrame - Measured through 18 hours post infusion",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05478720",
    "endpoint": "measure - PK measurement of DON in sera of recipients measure by time of maximal concentration (Tmax), description - Measurement of Tmax, timeFrame - Measured through 18 hours post infusion",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05478720",
    "endpoint": "measure - PK measurement of DON in sera of recipients measure by area under the concentrations vs. time curve (AUC), description - Measurement of AUC, timeFrame - Measured through 18 hours post infusion",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05478720",
    "endpoint": "measure - PK measurement of DON in sera of recipients measure by clearance, description - Clearance measured over time, timeFrame - Measured through 18 hours post infusion",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05478720",
    "endpoint": "measure - PK measurement of DON in sera of recipients measure by elimination rate, description - Elimination over time, timeFrame - Measured through 18 hours post infusion",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05478720",
    "endpoint": "measure - PK measurement of DON in sera of recipients measure by terminal T1&#x2F;2, description - Measurement of terminal T1&#x2F;2, timeFrame - Measured through 18 hours post infusion",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01082341",
    "endpoint": "measure - The number of subjects reporting any AEs, the occurrence of specifics AEs, and discontinuation due to AEs will be tabulated. Frequency of AEs will be cross-tabulated by group for each immunization session, description - , timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00844207",
    "endpoint": "measure - Tmax of azithromycin and chloroquine for each treatment cohort., description - , timeFrame - up to 96 hours post dose on Day 5",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00871156",
    "endpoint": "measure - QTcF, QT, QRS, RR and HR as assessed by 12-lead ECG, description - , timeFrame - 56 Days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00871156",
    "endpoint": "measure - Changes from baseline in QTcF, description - , timeFrame - 56 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01739036",
    "endpoint": "measure - Safety and immunogenicity of ChAd63-MVA ME-TRAP, ChAd63-MVA CS, ChAd63-MVA AMA1., description - <p>To assess the safety and immunogenicity of heterologous prime-boost immunisation of malaria-naïve individuals with ChAd63-MVA ME-TRAP combined with ChAd63-MVA CS or with ChAd63-MVA CS plus ChAd63-MVA AMA1.</p><p>The safety of the vaccine regimens will be assessed by analysing actively and passively collected data from clinical review of volunteers and laboratory measurements.\nThe ability of the vaccines to induce malaria-specific immune responses immunogenicity) will be assessed by the following laboratory tests; (A) Interferon gamma ELISPOT.\n(B) Flow cytometry to measure T cell responses.\nOther laboratory investigations including microarray analysis may be performed.</p>, timeFrame - Up to 7 months post first vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03939104",
    "endpoint": "measure - Efficacy defined as PCR corrected adequate clinical and parasitological response (ACPR), description - , timeFrame - 63-day",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03939104",
    "endpoint": "measure - Efficacy defined as adequate clinical and parasitological response (PCR), description - , timeFrame - 63-day",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03939104",
    "endpoint": "measure - Efficacy defined as adequate clinical and parasitological response (ACPR), description - , timeFrame - 42-day",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03939104",
    "endpoint": "measure - Parasite clearance half-life, description - , timeFrame - 7 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03939104",
    "endpoint": "measure - proportion of subjects with microscopically detectable P. falciparum parasitaemia, description - , timeFrame - 3 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03939104",
    "endpoint": "measure - Fever clearance time, description - Time taken for the tympanic temperature to fall below 37.5 ºC in patients who were febrile at inclusion, timeFrame - 7 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03939104",
    "endpoint": "measure - Proportion of subjects with gametocytemia during and after treatment stratified by presence of gametocytes at enrolment, description - , timeFrame - 63 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03939104",
    "endpoint": "measure - Number of adverse events, description - , timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03939104",
    "endpoint": "measure - Number of serious adverse events, description - Including markers of hepatic, renal or bone marrow toxicity, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03939104",
    "endpoint": "measure - Number of cardiotoxicity events, description - In particular QTc-interval above 500 ms or an increase &gt; 60 ms above baseline values at timepoint H4 and H52&#x2F;H64 and between these time points, timeFrame - 52 or 64 hours depends on treatment arm",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03939104",
    "endpoint": "measure - Change in haemoglobin stratified for G6PD status&#x2F;genotype, description - , timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03939104",
    "endpoint": "measure - Proportion of subjects requiring retreatment due to vomiting within 1 hour after administration of the study drugs, description - , timeFrame - 1 hour",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03939104",
    "endpoint": "measure - Proportion of subjects that reports completing a full course of observed TACT, description - , timeFrame - 3 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03939104",
    "endpoint": "measure - Proportion of subjects that reports completing a full course of observed ACT, description - , timeFrame - 3 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03939104",
    "endpoint": "measure - Pharmacokinetic profiles and interactions (including Cmax) of artemisinin-derivatives and partner drugs in ACT and TACT treated subjects in correlation with pharmacodynamics measures of drug efficacy, description - , timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03939104",
    "endpoint": "measure - Pharmacokinetic profiles and interactions (AUC) of artemisinin-derivatives and partner drugs in ACT and TACT treated subjects in correlation with pharmacodynamics measures of drug efficacy, description - , timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03939104",
    "endpoint": "measure - Plasma levels of partner drugs in correlation with treatment efficacy and treatment arm, description - , timeFrame - 7 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00675064",
    "endpoint": "measure - Pharmacokinetics, description - , timeFrame - Day 1 to Day 4",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00331136",
    "endpoint": "measure - Parasite Clearance Time, description - The time from first dosing to the time of first blood draw with parasite clearance.\nParasite clearance is defined as zero presence of parasites for 2 consecutive negative readings taken between 8 and 24 hours apart., timeFrame - Day 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00331136",
    "endpoint": "measure - Treatment Success or Failure, description - Treatment success for the ACPR analysis is defined as the clearance of asexual parasitaemia within 7 days of initiation of study medication without recrudescence within 28 days, without previously meeting any of the criteria for early treatment failure, late clinical failure, or late parasitological failure.\nEarly and late failures are classified according to the WHO Protocol 2005., timeFrame - Day 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00331136",
    "endpoint": "measure - Fever Clearance Time, description - <p>The time from first dosing to the first normal reading with fever clearance, defined as 2 consecutive assessments without fever (&lt;37.5°C)\ntaken between 8 and 24 hours apart.</p><p>NB: Time to fever clearance was only summarised for subjects who had fever at baseline or within the first 24 hours after the start of study treatment.\nSince only 12 subjects in total had fever during this time, the time to fever clearance estimates are not very meaningful.</p>, timeFrame - Day 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00331136",
    "endpoint": "measure - Number of Patients With PCR-corrected ACPR on Day 14, description - Clearance of asexual parasitaemia within 7 days of initiation of study medication without recrudescence within 14 days., timeFrame - Day 14",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00331136",
    "endpoint": "measure - Number of Patients With Parasite Clearance at Day 1, 2 and 3, description - Zero presence of parasites for 2 consecutive negative readings taken between 8 and 24 hours apart., timeFrame - Days 1, 2, 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00331136",
    "endpoint": "measure - Number of Subjects With P. Falciparum Gametocytes During the Trial, description - <p>The number of gametocytes per μl at Days 0, 3, 7, 14, 21, 28, 35, and 42 summarised from blood slides taken on the respective days.</p><p>P. falciparum gametocytes are responsible for transmission from host to vector.</p>, timeFrame - Day 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00331136",
    "endpoint": "measure - Percentage of Patients With Fever Clearance at Day 1, 2 and 3, description - <p>Patient without fever for 2 consecutive readings taken between 8 and 24 hours apart.</p><p>NB: Percentage of fever clearance was only summarised for subjects who had fever at baseline or within the first 24 hours after the start of study treatment.\nSince only 12 subjects in total had fever during this time, the time to fever clearance estimates are not very meaningful.</p>, timeFrame - Days 1, 2, 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00331136",
    "endpoint": "measure - Crude ACPR on Day 14, 28 and 42, description - The proportion of patients with crude (non-PCR corrected) ACPR., timeFrame - Days 14, 28, 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00331136",
    "endpoint": "measure - Number of Patients With PCR-corrected ACPR on Day 42, description - Clearance of asexual parasitaemia within 7 days of initiation of study medication without recrudescence within 42 days., timeFrame - Day 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04411836",
    "endpoint": "measure - Incidence risk any P vivax PQ7 &#x2F; TQ, description - The incidence risk (time to first event) of any P. vivax parasitaemia during the 6 months follow up period as determined by microscopy compared between PQ7 and TQ arms, timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04411836",
    "endpoint": "measure - Incidence risk symptomatic P vivax TQ &#x2F; PQ14, description - The incidence risk (time to first event) of symptomatic P. vivax parasitaemia during the 6 months follow up period as determined by microscopy compared between TQ and the control arm (PQ14)., timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04411836",
    "endpoint": "measure - Incidence risk any P vivax PQ7 &#x2F; PQ14, description - The incidence risk (time to first event) of symptomatic P. vivax parasitaemia during the 6-month follow up period as determined by microscopy compared between the PQ7 arm and the control arm (PQ14)., timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04411836",
    "endpoint": "measure - Incidence risk any P vivax PQ7 &#x2F; TQ, description - • The incidence risk (time to first event) of any P. vivax parasitaemia during the 6 months follow up period as determined by microscopy compared between PQ7 and TQ arms, timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04411836",
    "endpoint": "measure - Incidence risk any P vivax PQ14 &#x2F; TQ, description - The incidence risk (time to first event) of any P. vivax parasitaemia during the 6 months follow up period as determined by microscopy compared between PQ14 and TQ arms, timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00460525",
    "endpoint": "measure - Incidence Density of Clinical Malaria Episode, description - Clinical malaria episode was defined by significant parasitemia (2500&#x2F;mm^3) and temperature of greater than or equal to 37.5 degrees C. Event rate was determined by dividing the number of episodes (150 for the Rabies group and 121 for the FMP2.1&#x2F;ASO2A\ngroup) by the number of Person Years at Risk (PYAR) (126.341 for Rabies group and 127.411 for the FMP2.1&#x2F;ASO2A\ngroup)., timeFrame - Between randomization and 6 months after 3rd immunization.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00460525",
    "endpoint": "measure - Geometric Mean Titers of Anti-FMP2.1 Antibody Measured by Enzyme Linked ImmunoSorbent Assay (ELISA) at Day 0, description - Titers of Anti-FMP2.1 antibody were determined by ELISA from sera collected at Day 0 prior to the first vaccination., timeFrame - Day 0",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00460525",
    "endpoint": "measure - Geometric Mean Titers of Anti-FMP2.1 Antibody Measured by ELISA at Day 30., description - Titers of Anti-FMP2.1 antibody were determined by ELISA from sera collected at Day 30, prior to the second vaccination., timeFrame - Day 30 after initial vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00460525",
    "endpoint": "measure - Geometric Mean Titers of Anti-FMP2.1 Antibody Measured by ELISA at Day 60., description - Titers of Anti-FMP2.1 antibody were determined by ELISA from sera collected at Day 60, prior to the third vaccination., timeFrame - Day 60 after initial vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00460525",
    "endpoint": "measure - Geometric Mean Titers of Anti-FMP2.1 Antibody Measured by ELISA at Day 90., description - Titers of Anti-FMP2.1 antibody were determined by ELISA from sera collected at Day 90., timeFrame - Day 90 after initial vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00460525",
    "endpoint": "measure - Geometric Mean Titers of Anti-FMP2.1 Antibody Measured by ELISA at Day 150., description - Titers of Anti-FMP2.1 antibody were determined by ELISA from sera collected at Day 150., timeFrame - Day 150 after initial vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00460525",
    "endpoint": "measure - Geometric Mean Titers of Anti-FMP2.1 Antibody Measured by ELISA at Day 240., description - Titers of Anti-FMP2.1 antibody were determined by ELISA from sera collected at Day 240., timeFrame - Day 240 after initial vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00460525",
    "endpoint": "measure - Geometric Mean Titers of Anti-FMP2.1 Antibody Measured by ELISA at Day 364, description - Titers of Anti-FMP2.1 antibody were determined by ELISA from sera collected at Day 364., timeFrame - Day 364 after initial vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00460525",
    "endpoint": "measure - Geometric Mean Titers of Anti-FMP2.1 Antibody Measured by ELISA at Day 547, description - Titers of Anti-FMP2.1 antibody were determined by ELISA from sera collected at Day 547., timeFrame - Day 547 after initial vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00460525",
    "endpoint": "measure - Geometric Mean Titers of Anti-FMP2.1 Antibody Measured by ELISA at Day 730, description - Titers of Anti-FMP2.1 antibody were determined by ELISA from sera collected at Day 730., timeFrame - Day 730 after initial vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04329104",
    "endpoint": "measure - Participants With Plasmodium Falciparum (Pf) Infection Detected by Reverse Transcription Polymerase Chain Reaction (RT-PCR), description - Number of participants with Plasmodium falciparum (Pf) blood stage infection defined as blood smear-positive for Pf was assessed by reverse transcription polymerase chain reaction (RT-PCR) using dried blood spot specimen collected from participants from day 21 through week 24 (168 days) after administration of CIS43LS or placebo.\nSample was collected every two weeks until 24 weeks.\nPlasmodium 18S rRNA RT-PCR assay was applied to dried blood spots during analysis., timeFrame - Day 21 through week 24 (168 days) after administration of intervention",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04329104",
    "endpoint": "measure - Maximum Serum Concentration (Cmax) for CIS43LS, description - Maximum serum concentration (Cmax) of CIS43LS by dose group following a single intravenous administration to assess durability of CIS43LS and allow for correlation with Plasmodium falciparum (Pf) infection risk.\nCmax is the peak serum concentration that CIS43LS achieves after it has been administered.\nIt is determined as a maximum value on the summary pharmacokinetic (PK) curve for each study group and measured by a Meso Scale Discovery LLC-based automation platform., timeFrame - Measured through Week 24",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04329104",
    "endpoint": "measure - Time to Maximum Serum Concentration (Tmax) for CIS43LS, description - Time to maximum total serum concentration (Cmax) of CIS43LS by dose group following a single intravenous administration.\nTmax is the time it takes to reach Cmax of CIS43LS after it has been administered; it is determined based on the summary PK curve for each dose group.\nThis was calculated by subtracting the time the CIS43LS intravenous infusion was stopped from the time the blood was collected for the Cmax, at the post-one hour blood draw., timeFrame - One to 24 hours post-infusion",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00126217",
    "endpoint": "measure - Tuberculin reaction 2 months after intervention, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00126217",
    "endpoint": "measure - Scar reaction 2 months after intervention, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00126217",
    "endpoint": "measure - Malaria morbidity&#x2F;parasitaemia within 12 months after intervention, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00126217",
    "endpoint": "measure - Assessment of antibody and cellular immune responses 18 months after intervention, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00386503",
    "endpoint": "measure - Safety and tolerability&#x2F;Adverse events, physical examinations, vital signs including heart rate and blood pressure, ECG and laboratory parameters., description - , timeFrame - From the signature of the informed consent up to the end of the study",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02325180",
    "endpoint": "measure - Parasite clearance times, description - Parasite reduction ratio, parasite clearance half-life, timeFrame - 3 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02325180",
    "endpoint": "measure - Fever clearance times, description - , timeFrame - 3 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02325180",
    "endpoint": "measure - Prevalence of molecular markers and the impact on treatment outcomes, description - Pfcrt, Pfmdr1, Pfk13 and any other important molecular markers, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02325180",
    "endpoint": "measure - Prevalence of gametocyte, description - Proportion of patients with gametocyte, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02325180",
    "endpoint": "measure - Presence of other Plasmodium species, description - Plasmodium vivax, Plasmodium malariae, Plasmodium ovale spp, Plasmodium knowlesi, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02325180",
    "endpoint": "measure - Haematological recovery, description - Haemoglobin, timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02118090",
    "endpoint": "measure - Number of isolates characterized by whole genome sequencing and multiple Single Nucleotide Polymorphisms Bar Code, description - P. vivax Isolates will be characterize by SNPs barcode and whole genome sequencing.\nThe final objective is to defined correlations between SNPs detected by whole genome sequencing or bar coding and in vivo and in vitro phenotype, timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04280692",
    "endpoint": "measure - Use of sub-curative anti-malaria treatment for induction of gametocytes, description - Density of gametocytes as measured by qRT-PCR, timeFrame - Up to 42 days post infection with PfSPZ challenge",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04280692",
    "endpoint": "measure - Peak density and time point of gametocytaemia, description - Peak density and peak time point of gametocytes by drug-regimen and determine the area under the curve of density over time, timeFrame - Up to 42 days post infection with PfSPZ challenge",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02563496",
    "endpoint": "measure - Number of Participants With Gastrointestinal Adverse Events, description - Number of participants experiencing gastrointestinal adverse events including vomiting, abdominal pain, diarrhea, gastrointestinal disorder, epigastric discomfort and nausea were assessed.\nNumber of participants with gastrointestinal adverse events for each treatment group have been presented.\nSafety Population consisted of all participants who received at least one dose of study medication (tafenoquine)., timeFrame - Up to Day 120",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02563496",
    "endpoint": "measure - Number of Participants With Hemoglobin Decline From Baseline Over First 10 Days, description - Glucose-6-phosphate dehydrogenase (G6PD) deficiency is known to be a risk factor for hemolysis in participants treated with 8-aminoquinolines.\nBlood samples were collected for the evaluation of hemoglobin levels.\nHemoglobin decrease of &gt;=30 percent (%) of &gt;30 grams per liter (g&#x2F;L) from Baseline; or, an overall drop in hemoglobin below 60.0 g&#x2F;L in the first 15 days of the study were considered as protocol defined serious adverse events (SAEs).\nNumber of participants with hemoglobin decline from Baseline over first 10 days have been presented.\nBaseline was defined as the latest pre-tafenoquine dose assessment on Day 1., timeFrame - Baseline and up to Day 10",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02563496",
    "endpoint": "measure - Number of Participants With Non-serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs), description - An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporarily associated with the use of a medicinal product, whether or not considered related to the medicinal product.\nAn SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability&#x2F;incapacity, is a congenital anomaly&#x2F; birth defect, other situations and is associated with liver injury., timeFrame - Up to Day 120",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02563496",
    "endpoint": "measure - Number of Participants With Worst Case Hematology Results Relative to Potential Clinical Importance (PCI) Criteria Post-Baseline Relative to Baseline, description - Blood samples were collected for analysis of eosinophils, lymphocytes, platelets and reticulocytes.\nPCI ranges were &gt;1.5*10^9 (high) cells per liter (cells&#x2F;L) for eosinophils, &lt;0.5*10^9 cells&#x2F;L (low) or &gt;4*10^9 cells&#x2F;L (high) for lymphocytes, &lt;50*10^9 cells&#x2F;L (low) for platelet count and &gt;1*upper limit of normal (ULN) 10^12 cells&#x2F;L (high) for reticulocyte count.\nParticipants were counted in worst case category that their value changes to (low, within range or no change or high), unless there is no change in their category.\nParticipants whose laboratory value category was unchanged (e.g., High to High), or whose value became within range, were recorded in &quot;To within Range or No Change&quot; category.\nParticipants were counted twice if the participant has values that changed &#x27;To Low&#x27; and &#x27;To High&#x27;, so the percentages may not add to 100%.\nBaseline value is the latest pre-tafenoquine dose assessment on Day 1., timeFrame - Baseline (Day 1) and up to Day 8",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02563496",
    "endpoint": "measure - Number of Participants With Worst Case Clinical Chemistry Results Relative to PCI Criteria Post-Baseline Relative to Baseline, description - Blood samples were collected for analysis of clinical chemistry parameters.\nPCI ranges were &gt;3*ULN international units per liter (IU&#x2F;L) (alanine aminotransferase [ALT]), &gt;2.5*ULN IU&#x2F;L (alkaline phosphatase), &gt;3*ULN IU&#x2F;L (aspartate aminotransferase [AST]), &gt;1.5*ULN micromoles&#x2F;L (mcmol&#x2F;L) (bilirubin), &gt;5*ULN IU&#x2F;L (creatine kinase [CK]), 3*ULN mcmol&#x2F;L (creatinine), &gt;1.5*ULN mcmol&#x2F;L (indirect bilirubin), and &gt;11.067 millimoles&#x2F;L (urea).\nParticipants were counted in worst case category that their value changes to (low, within range or no change or high), unless there is no change in their category.\nParticipants whose laboratory value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the &quot;To within Range or No Change&quot; category.\nParticipants were counted twice if participant has values that changed &quot;To Low and To High&quot;, so the percentages may not add to 100%.\nBaseline value is the latest pre-Tafenoquine dose assessment on Day 1., timeFrame - Baseline (Day 1) and up to Day 8",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02563496",
    "endpoint": "measure - Number of Participants With Relapse-Free Efficacy at 4 Months, description - Relapse is defined as positive blood smear with or without vivax malaria symptoms.\nA participant was considered to have demonstrated relapse-free efficacy if: a) Participant is slide positive for Plasmodium vivax (P.\nvivax) at Baseline.\nb) Participant showed initial clearance of P. vivax parasitemia defined as a negative slide at or before the Day 29 visit.\nc) Participant is not slide-positive for P. vivax at any assessment.\nd) Participant did not take a concomitant medication with anti-malarial activity at any point between Study Day 1 and their last parasite assessment.\ne) Participant is parasite-free at 4 months defined as a negative asexual P. vivax parasite slide at the first parasite assessment performed during study.\nMicrobiologic-Intent-To-Treat (mITT) Population consisted of all participants who received a dose of study treatment (tafenoquine) and had microscopically-confirmed vivax parasitemia at Baseline., timeFrame - 4 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02563496",
    "endpoint": "measure - AUC(0-infinity) of Tafenoquine by Weight Band in Participants Aged &gt;=6 Months to &lt;2 Years (Weighing &gt;=5 kg), description - Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tafenoquine., timeFrame - Days 3, 15, 29 and 60 post dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00297882",
    "endpoint": "measure - Cure Rate Day 14, description - To evaluate antimalarial efficacy of AL and AQ-AS on day 14 post-treatment, timeFrame - Day 0-14",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02802501",
    "endpoint": "measure - Percentage of Participants With Relapse-free Efficacy at Six Months After Administration of Tafenoquine With DHA-PQP and Primaquine+DHA-PQP, description - A participant was considered to have demonstrated relapse-free efficacy at 6 months if: a) Participant had non-zero P. vivax asexual parasite count at Baseline (Day 1), b) Participant demonstrated initial clearance of P.vivax parasitemia, c) Participant had no positive asexual P.vivax parasite count at any assessment prior to or on study Day 180 following initial parasite clearance, d) Participants did not take a concomitant medication with anti-malarial activity (excluding study treatment) at any point between Study Day 1 and their last parasite assessment, e) Participant was parasite-free at 6 months.\nThe percentage of participants who were relapse-free at 6 months post dose has been presented., timeFrame - 6 months post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02802501",
    "endpoint": "measure - Percentage of Participants With Relapse-free Efficacy at Six Months After Administration of Primaquine With DHA-PQP and DHA-PQP Alone, description - A participant was considered to have demonstrated relapse-free efficacy at 6 months if: a) Participant had non-zero P. vivax asexual parasite count at Baseline (Day 1), b) Participant demonstrated initial clearance of P.vivax parasitemia, c) Participant had no positive asexual P.vivax parasite count at any assessment prior to or on study Day 180 following initial parasite clearance, d) Participants did not take a concomitant medication with anti-malarial activity (excluding study treatment) at any point between Study Day 1 and their last parasite assessment, e) Participant was parasite-free at 6 months.\nThe percentage of participants who were relapse-free at 6 months post dose has been presented., timeFrame - 6 months post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02802501",
    "endpoint": "measure - Percentage of Participants With Relapse-free Efficacy at Four Months After Administration of Tafenoquine With DHA-PQP and DHA-PQP Alone, description - A participant was considered to have demonstrated recurrence-free efficacy at 4 months if: a) Participant had non-zero P. vivax asexual parasite count at Baseline, b) Participant demonstrated initial clearance of P.vivax parasitemia, c) Participant had no positive asexual P.vivax parasite count at any assessment prior to or on Study Day 135 following initial parasite clearance, d) Participants did not take a concomitant medication with anti-malarial activity (excluding study treatment) at any point between Study Day 1 and their first parasite assessment after Study Day 105 (up to and including Study Day 135), e) Participant was parasite-free at 4 months.\nThe rate of relapse-free efficacy was estimated by Kaplan-Meier methodology.\nThe percentage of participants who were relapse-free at 4 months post dose has been presented., timeFrame - 4 months post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02802501",
    "endpoint": "measure - Time to Relapse of P. Vivax Malaria, description - Relapse is defined by a positive blood smear with or without vivax symptoms.\nRelapse is described as any recurrence of P. vivax malaria after clearance of the initial infection.\nThe time to relapse (number of days between the date of first positive count and date of Study Day 1) was analyzed by the Kaplan-Meier method.\nThe median number of days to relapse along with 95 percent (%) confidence interval (CI) has been presented for each treatment group., timeFrame - Up to Day 180",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02802501",
    "endpoint": "measure - Time to Fever Clearance, description - Time to fever clearance is defined as time from first dose of treatment to the time when body temperature falls to normal and remains normal for at least 48 hours up to the Day 7 visit.\nFever clearance is considered to have been achieved once an initial temperature of greater than 37.4 degree Celsius is reduced to a value less than or equal to 37.4 degree Celsius, in the absence of value greater than 37.4 degree Celsius in the following 48 hours up to Day 7 visit.\nThe time taken to achieve fever clearance was analyzed by Kaplan-Meier method., timeFrame - Up to Day 7",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02802501",
    "endpoint": "measure - Time to Parasite Clearance, description - Parasite clearance time is defined as time needed to clear asexual parasite from the blood that is, parasite numbers falling below the limit of detection in the thick blood smear and remaining undetectable after &gt;= 6 hours later.\nThe time to achieve parasite clearance was analyzed by Kaplan-Meier method., timeFrame - Up to Day 8",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02802501",
    "endpoint": "measure - Number of Participants With Recrudescence, description - Recrudescence was defined as blood stage treatment failure.\nA participant was considered to have had a recrudescence if both of the following were true: 1) if participant had a positive P. vivax asexual parasite count at Baseline and demonstrated clearance (i.e. two negative asexual P. vivax parasite counts, with at least 6 hours between the counts, and no positive counts in the interval); 2) Participant had a positive genetically homologous asexual P. vivax parasite count on or before Study Day 14, after their zero count in days 1 to 5., timeFrame - Up to Day 14",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02802501",
    "endpoint": "measure - Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs) During the Double-blind Treatment Phase, description - An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.\nA SAE is defined as as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability&#x2F;incapacity, is a congenital anomaly&#x2F;birth defect, is associated with liver injury and impaired liver function, other important medical events that may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed before., timeFrame - Up to Day 180",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02802501",
    "endpoint": "measure - Number of Participants With Chemistry Values Outside Clinical Concern Range, description - Blood samples were collected at indicated time points to analyze following chemistry parameters: alanine aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Bilirubin, Creatine Kinase, Creatinine, Indirect Bilirubin and Urea.\nClinical concern range for the parameters included ALT and AST (high: &gt;3 times Upper Limit of Normal [ULN]), ALP (high: &gt;2.5 times ULN), bilirubin and indirect bilirubin (high: &gt;1.5 times ULN), creatine kinase (high: &gt;5 times ULN), creatinine (high: &gt;3 times ULN) and urea (high: &gt;11.067 millimoles per Liter [mmol&#x2F;L].\nData for any time on treatment has been presented., timeFrame - Up to Day 120",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02802501",
    "endpoint": "measure - Number of Participants With Hematology Values Outside Clinical Concern Range, description - Blood samples were collected to analyze the following hematology parameters: Hemoglobin, lymphocytes and Platelet count.\nThe clinical concern ranges for the parameters included: hemoglobin (low: &lt;7 grams per deciliter), lymphocytes: (low: &lt;0.5x10^9 cells per liter and high: &gt;4x10^9 cells per liter),and platelets (low: &lt;50x10^9 cells per liter).\nData for any time on treatment has been presented., timeFrame - Up to Day 120",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02802501",
    "endpoint": "measure - Number of Participants With Electrocardiogram (ECG) Values Outside Clinical Concern Range-QT Interval Corrected Using Fredericia&#x27;s Formula (QTcF), description - 12-lead ECG was obtained at indicated time points using an automated ECG machine that measured QTcF.\nClinical concern range included:absolute QTcF interval (upper: &gt;480 milliseconds) and increase from Baseline in QTcF (upper: &gt;=60 milliseconds).\nData for maximum post-Baseline increase &gt;=60 and &gt;480 milliseconds has been presented., timeFrame - Up to Day 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02802501",
    "endpoint": "measure - Change From Baseline in QT Interval Corrected by Fridericia&#x27;s Formula (QTcF), description - 12-lead ECG was obtained at indicated time points using an automated ECG machine that measured QTcF interval.\nChange from Baseline is calculated as Post-Dose Visit Value minus Baseline value.\nDay 1 was considered as Baseline., timeFrame - Baseline (Day 1), Day 3: 4 hours post DHA-PQP dose, Days 7 and 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02802501",
    "endpoint": "measure - Number of Participants With Worst Case Body Temperature Results Relative to Normal Range Post-Baseline Relative to Baseline, description - Body temperature was measured with participants in semi-supine position after 5 minutes of rest.\nData was categorized as: body temperature &#x27;low: &lt;36.5 degrees celsius&#x27;, &#x27;high: &gt;37.3 degrees celsius&#x27; and &#x27;To Normal or No change&#x27;.\nParticipants were counted in the worst case category that their value changes to (low, normal or high), unless there was no change in their category.\nParticipants whose vital sign value category was unchanged (e.g.,High to High), or whose value became normal, are recorded in the &quot;To Normal or No Change&quot; category.\nParticipants were counted twice if the participant had values that changed &#x27;To Low&#x27; and &#x27;To High&#x27;, so the percentages may not add to 100%.\nDay 1 was considered as Baseline., timeFrame - Baseline (Day 1) and up to Day 180",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02802501",
    "endpoint": "measure - Number of Participants With Worst Case Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Results Relative to Normal Range Post-Baseline Relative to Baseline, description - SBP and DBP were measured with participants in semi-supine position after 5 minutes of rest.\nData was categorized as: systolic blood pressure (SBP) (low: &lt;90 and high: &gt;120 millimeters of mercury [mmHg]); diastolic blood pressure (DBP) (low: &lt;60 and high: &gt;80 mmHg); and &#x27;To Normal or No change&#x27;.\nParticipants were counted in the worst case category that their value changes to (low, normal or high), unless there was no change in their category.\nParticipants whose vital sign value category was unchanged (e.g.,High to High), or whose value became normal, are recorded in the &quot;To Normal or No Change&quot; category.\nParticipants were counted twice if the participant had values that changed &#x27;To Low&#x27; and &#x27;To High&#x27;, so the percentages may not add to 100%.\nDay 1 was considered as Baseline., timeFrame - Baseline (Day 1) and up to Day 180",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02802501",
    "endpoint": "measure - Number of Participants With Worst Case Pulse Rate Results Relative to Normal Range Post-Baseline Relative to Baseline, description - Pulse rate was measured with participants in semi-supine position after 5 minutes of rest.\nData was categorized as: pulse rate low: &lt;60 beats per minute [bpm], high: &gt;100 bpm and &#x27;To normal or No change&#x27;.\nParticipants were counted in the worst case category that their value changes to (low, normal or high), unless there was no change in their category.\nParticipants whose vital sign value category was unchanged (e.g.,High to High), or whose value became normal, are recorded in the &quot;To Normal or No Change&quot; category.\nParticipants were counted twice if the participant had values that changed &#x27;To Low&#x27; and &#x27;To High&#x27;, so the percentages may not add to 100%.\nDay 1 was considered as Baseline., timeFrame - Baseline (Day 1) and up to Day 180",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02802501",
    "endpoint": "measure - Number of Participants With Worst Case Respiratory Rate Results Relative to Normal Range Post-Baseline Relative to Baseline, description - Respiratory rate was measured with participants in semi-supine position after 5 minutes of rest.\nData was categorized as: respiratory rate low: &lt;12 breaths per minute&#x27;, high: &gt;18 breaths per minute and &#x27;To normal or No change&#x27;.\nParticipants were counted in the worst case category that their value changes to (low, normal or high), unless there was no change in their category.\nParticipants whose vital sign value category was unchanged (e.g.,High to High), or whose value became normal, are recorded in the &quot;To Normal or No Change&quot; category.\nParticipants were counted twice if the participant had values that changed &#x27;To Low&#x27; and &#x27;To High&#x27;, so the percentages may not add to 100%.Day 1 was considered as Baseline.\nDay 1 was considered as Baseline., timeFrame - Baseline (Day 1) and up to Day 180",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02802501",
    "endpoint": "measure - Number of Participants With Gastrointestinal AEs, description - The number of participants with gastrointestinal AEs: nausea, vomiting, diarrhea, dyspepsia, abdominal distension, abdominal discomfort and constipation has been presented., timeFrame - Up to Day 180",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02802501",
    "endpoint": "measure - Change From Baseline in Methemoglobin&#x2F; Total Hemoglobin, description - Blood samples were collected for the assessment of methemoglobin&#x2F;Total Hemoglobin (Hb).\nMethemoglobin is a type of Hb in the form of metalloprotein that cannot bind with oxygen, measured as percentage of methemoglobin in total hemoglobin.\nChange from Baseline is calculated as Post-Dose Visit Value minus Baseline value.\nDay 1 was considered as Baseline., timeFrame - Baseline (Day 1) and Days 2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,18,20,21,22,24,26,28 and 60",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02802501",
    "endpoint": "measure - Number of Participants With Protocol-defined SAE (Hemoglobin Drop), description - Blood samples were collected at indicated time points to analyze the hemoglobin level.\nHemoglobin drop is defined as any one of the following occurring in the first 15 days of the study: a relative hemoglobin decrease of &gt;=30% from Baseline, or an absolute hemoglobin decrease of &gt;3 grams per liter from Baseline, or a drop in absolute hemoglobin to &lt;7.0 grams per decilter (g&#x2F;dL).\nNumber of participants with a protocol-defined hemoglobin SAEs has been presented., timeFrame - Days 3, 5, 7, and 14",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02802501",
    "endpoint": "measure - Oral Clearance (CL&#x2F;F) of Tafenoquine When Co-administered With DHA-PQP, description - Blood samples were collected at the indicated time points for the determination of oral clearance following tefenoquine co-administered with DHA-PQP and was to be calculated by covariate analysis., timeFrame - Up to Day 60",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02802501",
    "endpoint": "measure - Volume of Distribution (V&#x2F;F) of Tafenoquine When Co-administered With DHA-PQP, description - Blood samples were collected at the indicated time points for the determination of volume of distribution following tefenoquine co-administered with DHA-PQP and was to be calculated by covariate analysis., timeFrame - Up to Day 60",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00484900",
    "endpoint": "measure - Parasitic clearance, description - , timeFrame - 28 day follow-up period",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00484900",
    "endpoint": "measure - Fever clearance, description - , timeFrame - 28 day follow-up period",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00484900",
    "endpoint": "measure - Parasitological re-infection, description - , timeFrame - 28 day follow-up period",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00484900",
    "endpoint": "measure - Gametocyte carriage, description - , timeFrame - 28 day follow-up period",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00484900",
    "endpoint": "measure - Safety - Adverse events, description - , timeFrame - 28 day follow-up period",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00484900",
    "endpoint": "measure - Haemoglobin levels, description - , timeFrame - 28 day follow-up period",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00484900",
    "endpoint": "measure - Clinical and biological tolerance (Haemogram + Lever tests), description - , timeFrame - 28 day follow-up period",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01144702",
    "endpoint": "measure - Description of adverse events, description - Any sign or symptom that is not present in the clinical evaluation of D0 and focusing on subsequent evaluations, will be defined as adverse effects of the treatment.\nFor this, a list of signs and symptoms should be questioned participants at all follow-up visits and adverse effects identified will be properly recorded.\nDepending on the intensity, these adverse effects should be treated according to medical advice.\nThe subject of the study with more severe adverse effects will be referenced to a secondary or tertiary health care for the Juruá Hospital., timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01288820",
    "endpoint": "measure - To assess the effects of drugs on parasite clearance and malaria associated symptoms, description - <p>Effect of drug trial on subsequent relapse of Plasmodium vivax.\nGametocyte carriage rates.\nGametocyte clearance time.\nProportion of subjects with fever, parasitemia clearance and increase methemoglobin level.</p><p>Hematological recovery.\nProportion of subjects with hemolysis.</p>, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04829695",
    "endpoint": "measure - Proportion of patients with early treatment failure, late clinical failure, late parasitological failure or an adequate clinical and parasitological response as indicators of efficacy according to the WHO 2009 guidelines, description - Eligible children for whom parent&#x2F;guardian informed consents are obtained will be randomized to receive either artesunate-amodiaquine (group A) or artemether-lumefantrine (group B) and follow-up will be done for a duration of 28 days.\nRecrudescence will be distinguished from re-infection by polymerase chain reaction (PCR) analysis., timeFrame - 10 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04829695",
    "endpoint": "measure - Number of participants with treatment-related adverse events as assessed by CTCAE v4.0, description - Eligible children for whom parent&#x2F;guardian informed consents are obtained will be randomized to receive either artesunate-amodiaquine (group A) or artemether-lumefantrine (group B) and follow-up will be done for a duration of 28 days., timeFrame - 10 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04829695",
    "endpoint": "measure - Number of children with single nucleotide polymorphisms of P. falciparum genes responsible for resistance to ASAQ and AL, description - Pre-treatment and recrudescence&#x2F;reinfection samples during follow-up shall be used to characterize the molecular markers of Plasmodium falciparum chloroquine resistant transporter(Pfcrt), Plasmodium falciparum multi-drug resistant 1 (Pfmdr1), and Plasmodium falciparum K13 (Pfk13) propellar domain conferring resistance to artemisinins or partner drugs., timeFrame - 10 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04829695",
    "endpoint": "measure - Number of children with single nucleotide polymorphisms of P. falciparum histidine-rich protein 2 and 3 genes, description - Pre-treatment shall be used to detect single nucleotide polymorphisms present in Plasmodium falciparum histidine-rich protein 2 and 3 genes., timeFrame - 10 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00317473",
    "endpoint": "measure - Anti-FMP1 Antibody Titer Responses, description - Antibody responses to FMP1 by ELISA following immunization with the study vaccine through 364 days following the first dose of study vaccine, timeFrame - 364 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03764527",
    "endpoint": "measure - Safety of treatment with Artesunate + Amodiaquine (AA) or Coartem® (CO): Proportion of subjects with adverse events, description - Proportion of subjects with adverse events, including early vomiting and mean values of white blood cells (WBC) and neutrophils, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03764527",
    "endpoint": "measure - Parasite clearance, description - Proportion of patients with microscopy detectable parasitaemia at each time point, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03764527",
    "endpoint": "measure - Gametocyte carriage, description - Proportion of patients with microscopy detectable gametocytes at each time point, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03764527",
    "endpoint": "measure - Fever clearance, description - Proportion of patients with fever at each time point, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03764527",
    "endpoint": "measure - Hemoglobin, description - Mean and individual hemoglobin values at different time points during follow up, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03764527",
    "endpoint": "measure - Selection of mutations in P. falciparum related to the resistance of the study drugs, description - Change in possible selections of mutations related to quinoline resistance.\nPercentage of pfcrt and pfmdr1 mutations on day 0 and day of recurrent infection., timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06044805",
    "endpoint": "measure - The secondary outcome of this study is determining parasite clearance rate based on parasite clearance time., description - This study&#x27;s secondary goal was to calculate the parasite clearance rate based on parasite clearance time.\nUsing hours, days, weeks, and months, parasite clearance time is calculated., timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06044805",
    "endpoint": "measure - The secondary outcome of this study is determining gametocyte clearance rate based on gametocyte clearance time., description - This study&#x27;s secondary goal was to calculate the gametocyte clearance rate based on gametocyte clearance time.\nUsing hours, days, weeks, and months, parasite clearance time is calculated., timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06044805",
    "endpoint": "measure - The secondary outcome of this study is determining fever clearance rate based on fever clearance time., description - Calculating the fever clearance rate based on fever clearance time was the secondary outcome of this clinical trial.\nFever clearance time is calculated using hours, days, weeks, and months.\nTemperatures less than 37.5 degrees celsius (T 37.5oC) are deemed to be fever-free(fever cleared) while temperatures greater than or equal to 37.5 degrees celsius (T&gt;37.5oC)\nare classified as having fever (fever not cleared)., timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06044805",
    "endpoint": "measure - The secondary outcome of this study is determining mean hemoglobin change overtime in the 42 days study period., description - Calculating the mean hemoglobin change overtime in the 42 study period based on hemoglobin concentration at D0, D14, D28 and D42 was the secondary outcome of this clinical trial.\nMilligrammes per deciliter are used to measure the concentration of haemoglobin., timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06044805",
    "endpoint": "measure - The secondary outcome of this study is evaluating the incidence of adverse events in 42 follow-up period., description - This study&#x27;s secondary goal was evaluating the incidence of adverse events in 42 follow-up period., timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01843764",
    "endpoint": "measure - Efficiency of P.falciparum specific rapid diagnostic tests, description - Efficiency of two rapid diagnostic tests based on two different antigens for diagnosis and treatment follow up among children &lt;5 years in a moderately high endemic area was determined.\nSpecificity and false positivity rate for HRP2 and LDH based rapid diagnostic tests are calculated against Giemsa stained microscopy and PCR., timeFrame - 2009 June to 2012 May (up to day 42)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07194668",
    "endpoint": "measure - Adverse event and severe adverse event reports for safety and tolerability assessment of the standard adult vaccine dose 10μg R21&#x2F;50μg Matrix-M and a half of the standard adult dose 5μg R21&#x2F;50μg Matrix-M, description - , timeFrame - At Month 1, Month 2, Month 3, Month 11 and Month 12",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07194668",
    "endpoint": "measure - Adverse event and severe adverse event reports for safety and tolerability assessment a half of the standard adult dose 5μg R21&#x2F;50μg Matrix-M with 2PE preservative vs, without 2PE preservative., description - , timeFrame - At Month 1, Month 2, Month 3, Month 11 and Month 12",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06413108",
    "endpoint": "measure - Within-group percent reduction in the proportion of mosquitoes infected in direct skin feeding assay (DSF), compared within groups between baseline and all feeding time points, and between groups at all feeding timepoints., description - , timeFrame - day 0 [baseline], 1, and 5",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06413108",
    "endpoint": "measure - Within-group percent reduction in the proportion of mosquitoes infected in direct membrane feeding assays (DMFA), compared within groups between baseline and all feeding time points, and between groups at all feeding timepoints., description - , timeFrame - day 0 [baseline], 1, 5, and 14",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06413108",
    "endpoint": "measure - Mosquito infection prevalence, assessed by direct skin feed and measured as the proportion dissected mosquitoes with any number of oocysts, compared within groups between baseline and all feeding time points, and between groups at all feeding timepoints., description - , timeFrame - day 0 [baseline], 1, and 5",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06413108",
    "endpoint": "measure - Mosquito infection prevalence, assessed by DMFA and measured as the proportion dissected with any number of oocysts, compared within groups between baseline and all feeding time points, and between groups at all feeding timepoints., description - , timeFrame - day 0 [baseline], 1, 5, and 14",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06413108",
    "endpoint": "measure - Mosquito infection intensity, assessed by direct skin feed and measured as the number of oocysts in dissected mosquitoes, compared within groups between baseline and all feeding time points, and between groups at all feeding timepoints., description - , timeFrame - day 0 [baseline], 1, and 5",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06413108",
    "endpoint": "measure - Mosquito infection intensity, assessed by DMFA and measured as the average number of oocysts in dissected mosquitoes, compared within groups between baseline and all feeding time points, and between groups at all feeding timepoints., description - , timeFrame - day 0 [baseline], 1, 5, and 14",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06413108",
    "endpoint": "measure - Participant infection prevalence, assessed by DSF as the proportion of individuals infectious to any number of mosquitoes, compared within groups between baseline and all feeding time points, and between groups at all feeding timepoints., description - , timeFrame - day 0 [baseline], 1, and 5",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06413108",
    "endpoint": "measure - Participant infection prevalence, assessed by DMFA as the proportion of individuals infectious to any number of mosquitoes, compared within groups between baseline and all feeding time points, and between groups at all feeding timepoints., description - , timeFrame - day 0 [baseline], 1, 5, and 14",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06413108",
    "endpoint": "measure - Transmission-reducing activity in school-age children and adults, measured as the percent reduction in mean oocyst intensity compared to experimental controls, compared within groups and between groups at all feeding timepoints., description - , timeFrame - day 0 [baseline], 5, 14, 28, 56, and 84",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04565184",
    "endpoint": "measure - Proportion of patients with early treatment failure, late clinical failure, late parasitological failure or an adequate clinical and parasitological response as indicators of efficacy according to the WHO 2009 guidelines, description - Eligible children for whom parent&#x2F;guardian informed consents are obtained will be randomized to receive either artesunate-amodiaquine (group A) or artemether-lumefantrine (group B) and follow-up will be done for a duration of 28 days.\nRecrudescence will be distinguished from re-infection by polymerase chain reaction (PCR) analysis, timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04565184",
    "endpoint": "measure - Number of participants with treatment-related adverse events as assessed by CTCAE v4.0, description - Eligible children for whom parent&#x2F;guardian informed consents are obtained will be randomized to receive either artesunate-amodiaquine (group A) or artemether-lumefantrine (group B) and follow-up will be done for a duration of 28 days., timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04565184",
    "endpoint": "measure - Number of children with single nucleotide polymorphisms of P. falciparum genes responsible for AS-AQ and AL resistance, description - Pre-treatment and recrudescence&#x2F;reinfection samples during follow-up shall be used to characterize the molecular markers of Plasmodium falciparum chloroquine resistant transporter(Pfcrt), Plasmodium falciparum multi-drug resistant 1 (Pfmdr1), and Plasmodium falciparum K13 (Pfk13) propellar domain conferring resistance to artemisinins or partner drugs., timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04565184",
    "endpoint": "measure - Number of children haboring single nucleotide polymorphisms in key genes involved in the metabolism of AS-AQ and AL, description - Pre-treatment samples shall be used to characterize the human pharmacogenomic biomarkers (N-acetyl transferase 2-NAT2 and cytochrome P450: CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and CYP3A5), timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02252640",
    "endpoint": "measure - Immunogenicity generated in malaria naïve individuals of two different dosing regimens of RTS,S&#x2F;AS01B given concomitantly with ChAd63&#x2F;MVA ME-TRAP, and of RTS,S&#x2F;AS01B alone at either full standard dose or with a reduced third dose., description - To document immunogenicity measures, capturing humoral and cellular immune responses to both ChAd63&#x2F;MVA ME-TRAP and RTS,S as follows: Anti-CS (RT, C-term, full-length), anti-HBs, and anti-ME-TRAP antibody titers; frequency of CS-specific, HBs-specific, and TRAP and ME specific T cells; ChAd63 neutralizing antibody titers; avidity index of anti-CS antibodies.\nTo undertake exploratory analysis of the correlation of these measures with vaccine efficacy.\nTo, furthermore, undertake an exploratory analysis of transcriptomic correlates of vaccine immunogenicity and efficacy.\nThis may be undertaken by microarray analysis or RNA sequencing or both techniques., timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00312663",
    "endpoint": "measure - Anti-LSA-1 Antibody Response in Titer Units on Days 0, 28, 42, and 84, description - Anti-LSA-1 Antibody Response in Titer Units on Days 0, 28, 42, and 84, timeFrame - Days 0, 28, 42, and 84",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05252845",
    "endpoint": "measure - Number of Participants With Seroconversions in C-Term, description - Number of Participants with Seroconversions in C-Term, timeFrame - at study Month 1",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05252845",
    "endpoint": "measure - Number of Participants With Seroconversions in C-Term, description - Number of Participants with Seroconversions in C-Term, timeFrame - at study Month 2",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05252845",
    "endpoint": "measure - Number of Participants With Seroconversions in C-Term, description - Number of Participants with Seroconversions in C-Term, timeFrame - at study Month 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05252845",
    "endpoint": "measure - Number of Participants With Seroconversions in C-Term, description - Number of Participants with Seroconversions in C-Term, timeFrame - at study Month 6",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05252845",
    "endpoint": "measure - Number of Participants With Seroconversions in NANP, description - Number of Participants with Seroconversions in NANP, timeFrame - at study Month 1",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05252845",
    "endpoint": "measure - Number of Participants With Seroconversions in NANP, description - Number of Participants with Seroconversions in NANP, timeFrame - at study Month2",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05252845",
    "endpoint": "measure - Number of Participants With Seroconversions in NANP, description - Number of Participants with Seroconversions in NANP, timeFrame - at study Month 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05252845",
    "endpoint": "measure - Number of Participants With Seroconversions in NANP, description - Number of Participants with Seroconversions in NANP, timeFrame - at study Month 6",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05252845",
    "endpoint": "measure - Number of Participants With Seroconversions in R21, description - Number of Participants with Seroconversions in R21, timeFrame - at study Month 1",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05252845",
    "endpoint": "measure - Number of Participants With Seroconversions in R21, description - Number of Participants with Seroconversions in R21, timeFrame - at study Month 2",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05252845",
    "endpoint": "measure - Number of Participants With Seroconversions in R21, description - Number of Participants with Seroconversions in R21, timeFrame - at study Month 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05252845",
    "endpoint": "measure - Number of Participants With Seroconversions in R21, description - Number of Participants With Seroconversions in R21, timeFrame - at study Month 6",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05252845",
    "endpoint": "measure - Number of Participants With Seroconversions in HBsAg, description - Number of Participants with Seroconversions in HBsAg, timeFrame - at study Month 1",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05252845",
    "endpoint": "measure - Number of Participants With Seroconversions in HBsAg, description - Number of Participants with Seroconversions in HBsAg, timeFrame - at study Month 2",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05252845",
    "endpoint": "measure - Number of Participants With Seroconversions in HBsAg, description - Number of Participants with Seroconversions in HBsAg, timeFrame - at study Month 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05252845",
    "endpoint": "measure - Number of Participants With Seroconversions in HBsAg, description - Number of Participants with Seroconversions in HBsAg, timeFrame - at study Month 6",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05252845",
    "endpoint": "measure - For Arms 1 and 3, Piperaquine Levels Following the Administration of the Antimalarials With or Without Vaccine, description - For Arms 1 and 3, Piperaquine levels (Cmax) following the administration of the antimalarials with or without vaccine, timeFrame - Study month 0",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05252845",
    "endpoint": "measure - For Arms 1 and 3, Piperaquine Levels Following the Administration of the Antimalarials With or Without Vaccine, description - For Arms 1 and 3, Piperaquine levels (AUC) following the administration of the antimalarials with or without vaccine, timeFrame - Study month 0",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05252845",
    "endpoint": "measure - For Arms 1 and 3, Piperaquine Levels Following the Administration of the Antimalarials With or Without Vaccine, description - For Arms 1 and 3, Piperaquine levels (Cmax) following the administration of the antimalarials with or without vaccine, timeFrame - Study month 1",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05252845",
    "endpoint": "measure - For Arms 1 and 3, Piperaquine Levels Following the Administration of the Antimalarials With or Without Vaccine, description - For Arms 1 and 3, Piperaquine levels (AUC) following the administration of the antimalarials with or without vaccine, timeFrame - Study month 1",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05252845",
    "endpoint": "measure - For Arms 1 and 3, Piperaquine Levels Following the Administration of the Antimalarials With or Without Vaccine, description - For Arms 1 and 3, Piperaquine levels (Cmax) following the administration of the antimalarials with or without vaccine, timeFrame - Study month 2",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05252845",
    "endpoint": "measure - For Arms 1 and 3, Piperaquine Levels Following the Administration of the Antimalarials With or Without Vaccine, description - For Arms 1 and 3, Piperaquine levels (AUC) following the administration of the antimalarials with or without vaccine, timeFrame - Study month 2",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03377296",
    "endpoint": "measure - Collection and freezing down of P. vivax-infected blood., description - Collection and freezing down of up to 250 mL P. vivax-infected blood from 2 volunteers., timeFrame - Collected between day 8 and day 14 post challenge, determined by symptoms and parasitaemia",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01883609",
    "endpoint": "measure - To assess immunogenicity generated in malaria naïve individuals of a malaria vaccine schedule containing RTS,S&#x2F;AS01B and ChAd63&#x2F;MVA ME-TRAP, and of RTS,S&#x2F;AS01B alone., description - Exploratory analysis of the correlation of the following humoral and cellular immune responses with vaccine efficacy: Anti-CS (RT, C-term, full-length), anti-HBs, and anti-ME-TRAP antibody titers; frequency of CS-specific, HBs-specific, and TRAP and ME specific T cells; ChAd63 neutralizing antibody titers.\nExploratory analysis of transcriptomic correlates of vaccine immunogenicity and efficacy (this may be undertaken by microarray analysis or RNA sequencing or both techniques)., timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01883609",
    "endpoint": "measure - To assess the efficacy of a combination immunization regimen with ChAd63&#x2F;MVA ME-TRAP and RTS,S&#x2F;AS01B, and of RTS,S&#x2F;AS01B alone, against malaria sporozoite challenge, in healthy malaria-naïve volunteers., description - Separate analyses on the following endpoints: (i) blood stage malaria infection as defined by 20 or more P. falciparum parasites&#x2F;ml in peripheral blood by quantitative PCR, (ii) blood stage infection as defined by 500 or more parasites&#x2F;ml in peripheral blood by quantitative PCR, and (iii) blood stage infection defined by a composite of symptoms, blood film result and parasitaemia.\nParasite density dynamics and parasite multiplication rates will also be compared., timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05974267",
    "endpoint": "measure - Percentage of Participants with Parasitemia (positive blood smear)., description - , timeFrame - From Study Start Day 1 up to End of Study (approximately 12 week)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05974267",
    "endpoint": "measure - Percentage of Participants with Polymerase Chain Reaction (PCR)-adjusted Parasitemia (Thick Smear&#x2F;Microscopy, after Adjustment for Parasitemia due to new Infections as determined by Genotyping using PCR Techniques), description - , timeFrame - From Study Start Day 1 up to End of Study (approximately 12 weeks)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05974267",
    "endpoint": "measure - Percentage of Participants with PCR-adjusted Parasitemia (Thick Smear&#x2F;Microscopy, after Adjustment for Parasitemia due to Recrudescence as determined by Genotyping using PCR Techniques), description - , timeFrame - From Study Start Day 1 up to End of Study (approximately 12 weeks)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05974267",
    "endpoint": "measure - Parasite Clearance Time, description - , timeFrame - Time from dosing to the first negative (no parasites) blood film (microscopy) , assessed up to 12 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05974267",
    "endpoint": "measure - Number of Participants With Treatment-Emergent Adverse Events (TEAE), Serious TEAEs and Related TEAEs, description - , timeFrame - From Study Start Day 1 up to End of Study (approximately 12 Weeks)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05974267",
    "endpoint": "measure - Pharmacokinetic (PK) Plasma Concentrations of M5717 and Pyronaridine, description - , timeFrame - Predose, 1, 2, 4, 6, 8, and 12 hours on Day 1 and (24 hours) on Day 2",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04675931",
    "endpoint": "measure - Percentage of participants achieving clinical success over time, description - <p>Clinical success is a composite endpoint based on following criterias:</p><ol><li>Is participant dead or alive</li><li>Presence of asexual parasites (yes&#x2F;no)</li><li>Presence of any of the key signs of severe malaria (yes&#x2F;no)</li></ol>, timeFrame - Day 3 (48 Hours), Day 4 to Day 29",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04675931",
    "endpoint": "measure - Percentage of participants with individual signs of severe malaria over time, description - <p>Individual signs of severe malaria over time will be monitored for the presence of the following signs of severe malaria during the entire study duration:</p><ol><li>Altered consciousness - Prostration or GCS &lt; 11 for participants &gt; 5 years &#x2F; BCS &lt; 3 for participants =&lt; 5 years of age</li><li>Renal Impairment - Serum creatinine &gt; 3xULN or &gt; 3 mg&#x2F;dL or need for renal replacement therapy</li><li>Acidosis - Serum lactate &gt; 4 mmol&#x2F;L</li><li>Respiratory distress - present or absent</li><li>Severe anemia - Hb &lt; 5 g&#x2F;dl or Hb &lt; 7g&#x2F;dl in pediatric and adults respectively or need of blood transfusion</li><li>Jaundice - Serum bilirubin &gt; 3 g&#x2F;dl</li><li>Hypoglycemia- plasma glucose &lt; 40 mg&#x2F;dL</li></ol>, timeFrame - Day 1 to Day 29",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04675931",
    "endpoint": "measure - Percentage of participants developing hemolysis (early and delayed) after treatment, description - <p>Development (early and delayed) of hemolysis after treatment are defined as follows:</p><p>Early Hemolytic anemia is defined as 10% or greater decrease in hemoglobin levels and an increase of LDH levels to &gt;390 U&#x2F;L, or an increase of &gt;= 10% above baseline occurring up to Day 8 of the study.</p><p>Delayed hemolytic anemia might occur &gt; 7 days after initiation of parenteral study drug (IV artesunate or IV cipargamin) during the study period.\nThe event is characterized by a 10% or greater decrease in hemoglobin levels accompanied by increase of LDH levels to &gt;390 U&#x2F;L, or an increase of &gt;= 10% compared to the values measured at Day 8 of the study.</p>, timeFrame - Day 8 and Day 29",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04675931",
    "endpoint": "measure - Percentage of participants with neurological sequelae at Day 29, description - <p>Detailed neurological examination will be conducted and relevant medical history collected under the following categories to assess the extent of neurological signs and symptoms at baseline and to monitor the extent of neurological sequelae in follow-up visits:</p><ol><li>Consciousness</li><li>Cranial Nerve Palsy</li><li>Motor system</li><li>Convulsions</li><li>Sense organs (Examination more useful at time of hospital discharge and in follow-up visits)</li></ol>, timeFrame - Day 29",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04675931",
    "endpoint": "measure - Percentage of participants achieving at least 90% reduction in Plasmodium falciparum (P. falciparum), description - A blood draw will be performed at each collection time point for parasitemia assessment, timeFrame - Day 2 (24 hours), Day 3 (48 hours)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04675931",
    "endpoint": "measure - Time to parasite clearance (PCT), description - Parasite Clearance Time (PCT) is defined as the time from the first dose until the first total and continued disappearance of asexual parasite forms which remained at least a further 24 hours, timeFrame - Day 1 (12 hours), Day 2 (24 hours), Day 3 (48 hours) and Day 4 (72 hours)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04675931",
    "endpoint": "measure - Time to fever clearance (FCT), description - Fever Clearance Time (FCT) is defined as the time from the first dose until the first time the axillary body temperature decreased below and remained below 37.5°C axillary or 38.0°C oral&#x2F;tympanic&#x2F;rectal for at least a further 24 hours., timeFrame - Day 1 (12 hours), Day 2 (24 hours), Day 3 (48 hours) and Day 4 (72 hours)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04675931",
    "endpoint": "measure - Percentage of participants achieving P. falciparum parasite reduction ratios (PRR) at 12, 24 and 48 hours, description - PRR is defined as the ratio of asexual parasite at baseline divided by asexual parasite at post-baseline.\nIf the asexual parasite count at post-baseline is 0, the half value of detection limit will be used to calculate the ratio., timeFrame - Day 1 (12 hours), Day 2 (24 hours) and Day 3 (48 hours)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04675931",
    "endpoint": "measure - Percentage of participants with recrudescence and reinfection, description - <p>Time to event (recrudescence or reinfection) will be calculated from the time of first study medication to the date of first event if a patient experiences the event and be censored at the time of last parasite assessment if a patient does not experience the event due to whatever reason.</p><p>Reinfection is defined as appearance of asexual parasites after clearance of initial infection with a genotype different from those parasites present at baseline.</p><p>Recrudescence is defined as appearance of asexual parasites after clearance of initial infection with a genotype identical to that of parasites present at baseline.</p><p>Reinfection and Recrudescence must be confirmed by PCR analysis.</p>, timeFrame - Day 29",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04675931",
    "endpoint": "measure - Time to recover from prostration, description - To assess recovery of participants as measured by time (days and hours) to discharge from hospital or recovery from prostration compared to baseline., timeFrame - Day 1 to Day 29",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04675931",
    "endpoint": "measure - Time to switch to oral therapy, description - Time to switch participants from IV therapy to Coartem (standard of drug for oral therapy) will be analyzed., timeFrame - Day 3 to Day 29",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04675931",
    "endpoint": "measure - Time to discharge from hospital, description - All participants will be hospitalized.\nTime (Days and Hours) to discharge from hospital will be analyzed., timeFrame - Day 3 to Day 29",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04675931",
    "endpoint": "measure - Number of Participants impacted on safety and tolerability assessments, description - Adverse events (AE), Serious Adverse events (SAEs) will be collected from first dosing, Death including whether in-hospital death and routine laboratory assessments will be done up to last follow-up visit or until the event has resolved to baseline grade or better or the event was assessed stable by the investigator or the participant was lost to follow-up or withdrew consent., timeFrame - Day 1 to Day 29",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04675931",
    "endpoint": "measure - Observed maximum plasma concentration (Cmax) of IV Cipargamin, description - Blood samples will be collected for activity-based pharmacokinetics characterization.\nCmax will be listed and summarized using descriptive statistics., timeFrame - Day 1 - Day 8",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04675931",
    "endpoint": "measure - Time of maximum observed drug concentration occurrence (Tmax) of IV Cipargamin, description - Blood samples will be collected for activity-based pharmacokinetics characterization.\nTmax will be listed and summarized using descriptive statistics., timeFrame - Day 1 - Day 8",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04675931",
    "endpoint": "measure - Area under the serum concentration-time curve from time zero to the time of last quantifiable concentration (AUClast) of IV Cipargamin, description - Blood samples will be collected for activity-based pharmacokinetics characterization.\nAUClast will be listed and summarized using descriptive statistics., timeFrame - Day 1 - Day 8",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04675931",
    "endpoint": "measure - Area under the concentration time curve from time zero (pre-dose) extrapolated to infinite time (AUCinf) of IV Cipargamin, description - Blood samples will be collected for activity-based pharmacokinetics characterization.\nAUC(0-inf) will be listed and summarized using descriptive statistics., timeFrame - Day 1 - Day 8",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04675931",
    "endpoint": "measure - Area Under the plasma concentration-time Curve from the time 0 to the last observed quantifiable concentration (AUC(0-t)) of IV Cipargamin, description - Blood samples will be collected for activity-based pharmacokinetics characterization.\nAUC(0-t) will be listed and summarized using descriptive statistics., timeFrame - Day 1 - Day 8",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04675931",
    "endpoint": "measure - AUC(0-t) divided by the dose administered (AUC(0- t)&#x2F;D) of IV Cipargamin, description - Blood samples will be collected for activity-based pharmacokinetics characterization.\nAUC(0-t)&#x2F;D will be listed and summarized using descriptive statistics., timeFrame - Day 1 - Day 8",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04675931",
    "endpoint": "measure - Terminal elimination half life (T^1&#x2F;2) of IV Cipargamin, description - Blood samples will be collected for activity-based pharmacokinetics characterization.\nThe half-live will be listed and summarized using descriptive statistics., timeFrame - Day 1 - Day 8",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04675931",
    "endpoint": "measure - Total systemic clearance for intravenous administration (CL) of IV Cipargamin, description - Blood samples will be collected for activity-based pharmacokinetics characterization.\nCL will be listed and summarized using descriptive statistics., timeFrame - Day 1 - Day 8",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04675931",
    "endpoint": "measure - volume of distribution during the terminal phase following intravenous elimination (Vz) of IV Cipargamin, description - Blood samples will be collected for activity-based pharmacokinetics characterization.\nVz will be listed and summarized using descriptive statistics., timeFrame - Day 1 - Day 8",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03882528",
    "endpoint": "measure - Diagnostic Efficacy; Time to Parasitemia by Blood Smear Method After the P Falciparum Challenge, description - Time to parasitemia by blood smear method after the P falciparum challenge.\nTime to parasitemia is defined as the time from CHMI to a first positive malaria parasite result.\nParasitemia was defined as the presence of 2 unambiguous malaria parasites on a single smear.\nBeginning on Day 1 after their challenge, subjects were seen and evaluated daily by a study investigator and blood was drawn for determination of parasitemia by qPCR.\nBeginning on Day 5 and through Day 19 after their challenge, blood from these daily draws was utilized to generate blood smears to evaluate the development of malaria infection.\nIn addition to smears, subjects were also evaluated for the presence of parasitemia via qPCR.\nIn addition to smears, subjects were also evaluated for the presence of parasitemia via qPCR.\nHowever, only blood smears were used for diagnosis during this trial and evaluation of treatment success., timeFrame - Within 2-3 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03882528",
    "endpoint": "measure - Diagnostic Efficacy; Time to Parasitemia (Days) by qPCR Method After the P Falciparum Challenge, description - Time to parasitemia by qPCR method after the P falciparum challenge.\nTime to parasitemia is defined as the time from CHMI to a first positive malaria parasite result.\nParasitemia was defined as the presence of 2 unambiguous malaria parasites on a single smear.\nOn Day 0, subjects were evaluated by qPCR once prior to challenge, to establish a baseline.\nBeginning on Day 1 through Day 19 after their challenge, subjects were seen and evaluated daily by a study investigator and blood was drawn for determination of parasitemia by qPCR.\nBeginning on Day 5 and going through Day 19 after their challenge, blood from these daily draws was utilized to generate blood smears to evaluate the development of malaria infection.\nIn addition to smears, subjects were also evaluated for the presence of parasitemia via qPCR.\nHowever, only blood smears were used for diagnosis during this trial and evaluation of treatment success., timeFrame - Within 2-3 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03882528",
    "endpoint": "measure - Diagnostic Efficacy; Quantification of Parasite Clearance Time (PCT) by Blood Smear and qPCR Methods After Initiation of Antimalarial Treatment, description - Time to Clearance was determined for all subjects for both smear and qPCR.\nTime to Clearance was defined as the time (in Days) from malaria diagnosis to confirmed clearance of parasitemia.\nConfirmed clearance of parasitemia by malaria smear was defined as the observation of 3 sequential negative (no parasites observed) daily smears.\nConfirmed clearance of parasitemia by qPCR was defined as 2 sequential daily (approximately 24 hours apart) negative qPCR assay results.\nFor clarity, the day of the final test in each sequence (smear, PCR) was used as the day of confirmed clearance for calculation purposes., timeFrame - Within 6 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06148792",
    "endpoint": "measure - The incidence risk of vivax parasitaemia, description - The incidence risk (time to first event) of any P. vivax parasitaemia during the 4-month follow up period as determined by microscopy compared between TQStandard and PQ7, timeFrame - 4 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06148792",
    "endpoint": "measure - The incidence risk of symptomatic vivax parasitaemia, description - The incidence risk (time to first event) of symptomatic P. vivax parasitaemia during the 4 months follow up period as determined by microscopy, timeFrame - 4 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06148792",
    "endpoint": "measure - The incidence risk of vivax parasitaemia, description - The incidence risk (time to first event) of any P. vivax parasitaemia at 6-month follow up as determined by microscopy, timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06148792",
    "endpoint": "measure - The incidence risk of symptomatic vivax parasitaemia, description - The incidence risk (time to first event) of symptomatic P. vivax parasitaemia at 6-month follow up as determined by microscopy, timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06148792",
    "endpoint": "measure - The incidence rate of vivax parasitaemia, description - The incidence rate (events per person-time) of any P. vivax parasitaemia during the 6 months follow up period as determined by microscopy, timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06148792",
    "endpoint": "measure - The incidence rate of symptomatic vivax parasitaemia, description - The incidence rate (events per person-time) of symptomatic P. vivax parasitaemia during the 6 months follow up period as determined by microscopy, timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06148792",
    "endpoint": "measure - The incidence risk of anaemia, description - The incidence risk of developing severe anaemia (Hb &lt; 5g&#x2F;dl) or moderate (5g&#x2F;dl and &lt;7g&#x2F;dl) anaemia within 7 and 14 days of starting treatment and&#x2F;or requiring blood transfusion within the 6 months follow up period, timeFrame - 7 and 14 days, 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06148792",
    "endpoint": "measure - The incidence risk of an acute drop in Hb, description - The incidence risk of an acute drop in Hb of &gt;25% to &lt;7g&#x2F;dl within 7 and 14 days of starting treatment, timeFrame - 7 and 14 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06148792",
    "endpoint": "measure - Adverse events, description - The number and proportion of adverse and serious adverse events in each arm within 42 days after start of treatment, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06148792",
    "endpoint": "measure - Meth Hb concentration, description - day 7 methaemoglobin concentration, timeFrame - day 7",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06524336",
    "endpoint": "measure - surrogate markers that predict risk of malaria, description - Number of individuals with surrogate markers that predict risk of malaria, timeFrame - one year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07021430",
    "endpoint": "measure - Percent of household members enrolled, description - Proportion of household members who consent to participate, timeFrame - At enrollment visit (Day 1)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07021430",
    "endpoint": "measure - Refusal to receive fMDA, description - Proportion of eligible household members who decline any fMDA intervention, timeFrame - Day 1 to study completion, generally 5 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07021430",
    "endpoint": "measure - fMDA Adherence, description - Proportion of DP blister packs returned with all medication taken (i.e., pill counts), timeFrame - Day 1 to study completion, generally 5 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07021430",
    "endpoint": "measure - P. falciparum parasitemia among household members, description - Prevalence of P. falciparum parasitemia among household members at three time points (enrollment, mid-point, delivery) as measured by malaria rapid diagnostic test, timeFrame - Day 1 to study completion, generally 5 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07021430",
    "endpoint": "measure - P. falciparum parasitemia among pregnant women, description - Prevalence of P. falciparum parasitemia as measured by RDT or PCR among women during any point in pregnancy, timeFrame - Day 1 to study completion, generally 5 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07021430",
    "endpoint": "measure - P. falciparum parasitemia in peripheral and placental blood at delivery, description - Prevalence of P. falciparum parasitemia in peripheral and placental blood at delivery as measured by PCR, timeFrame - At time of birth&#x2F;delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07021430",
    "endpoint": "measure - Clinical malaria incidence among pregnant women, description - Incidence of clinical malaria among pregnant women, defined as the presence of acute febrile illness and a positive malaria rapid diagnostic test (RDT), timeFrame - Day 1 to study completion, generally 5 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07021430",
    "endpoint": "measure - Maternal anemia, description - Change in prevalence of maternal anemia, defined as Hemoglobin &lt;11 g&#x2F;dL among participants, timeFrame - Day 1 to study completion, generally 5 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07021430",
    "endpoint": "measure - Adverse birth outcomes, description - Composite of adverse events including spontaneous abortion, premature delivery (&lt;37 weeks gestation), stillbirth, and low birthweight, timeFrame - Day 1 to study completion, generally 5 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07021430",
    "endpoint": "measure - Co-occurrence of malaria parasitemia in mother and household members, description - Proportion of RDT+ individuals in each household stratified by parasitemia status of pregnant women at enrollment visit, timeFrame - Day 1 to study completion, generally 5 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07021430",
    "endpoint": "measure - Number of adverse reactions to DP, description - Number of dihydroartemisinin-piperaquine administrations that result in vomiting or other known side effects, timeFrame - Day 1 to study completion, generally 5 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00157859",
    "endpoint": "measure - • Overall day 28 cure rate for P.falciparum. This will allow comparison with previous historical data at this time point., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00157859",
    "endpoint": "measure - • Parasite reduction. Parasite reduction will be calculated at Days 1, 2 and 3 after initiation of trial treatment as percentage of parasites&#x2F;uL compared to parasite density before the first dose of treatment., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00157859",
    "endpoint": "measure - • Proportion of patients with a negative slide at Days 1, 2 and 3, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00157859",
    "endpoint": "measure - • Gametocyte Carriage. Anti-gametocyte activity will be measured by the proportion of patients with a peripheral gametocytaemia between day 7 to day 28., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00157859",
    "endpoint": "measure - • Early Treatment Failure (ETF), description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00157859",
    "endpoint": "measure - • Late Treatment Failure (LTF), description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06958198",
    "endpoint": "measure - Immunogenicity: To assess the humoral immunogenicity of R21, RH5.1 and R78C in Matrix-M™ when used in different combinations in healthy adults and children living in a malaria-endemic area., description - <p>Immunogenicity will be assessed by a variety of immunological assays.\nThe following measures will be assessed:</p><ul><li><p>Serum response:</p><p>o Quantitative antigen-specific IgG antibody levels (µg&#x2F;mL readout) over time - analysis of peak responses and longevity;</p></li><li>In vitro GIA against 3D7 clone P. falciparum parasites using purified total IgG and a single-cycle pLDH readout assay</li></ul>, timeFrame - Immunology blood samples will be collected at screening, day of vaccination, at Days 42, 56, 182, 196, 210, 240, and 365.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02216123",
    "endpoint": "measure - Rate of Relapse-free Efficacy at Six Months Post Dose, description - A participant was considered to have demonstrated relapse-free efficacy at 6 months if: a) Participant had non-zero P. vivax asexual parasite count at Baseline.\nb) Participant showed initial clearance of P. vivax parasitemia defined as two negative asexual P. vivax parasite counts, with at least 6 hours between the counts, and no positive counts in the interval.\nc) Participant had no positive asexual P. vivax parasite count at any assessment prior to or on Study Day 201 following initial parasite clearance.\nd) Participant did not take a concomitant medication with anti-malarial activity at any point between Study Day 1 and their last parasite assessment.\ne) Participant is parasite-free at 6 months.\nThe rate of relapse-free efficacy was estimated by Kaplan-Meier methodology.\nThe percentage of participants who were relapse-free at 6 months post dose has been presented along with 95% confidence interval., timeFrame - 6 months post dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02216123",
    "endpoint": "measure - Rate of Relapse-free Efficacy at Four Months Post Dose, description - A participant was considered to have demonstrated recurrence-free efficacy at 4 months if: a) Participant had non-zero P. vivax asexual parasite count at Baseline.\nb) Participant showed initial clearance of P. vivax parasitemia.\nc) Participant had no positive asexual P. vivax parasite count at any assessment prior to or on Study Day 130 following initial parasite clearance.\nd) Participant did not take a concomitant medication with anti-malarial activity at any point between Study Day 1 and their last parasite assessment after Study Day 109 (up to and including Study Day 130).\ne) Participant is parasite-free at 4 months.\nThe rate of relapse-free efficacy was estimated by Kaplan-Meier methodology.\nThe percentage of participants who were relapse-free at 4 months post dose has been presented along with 95% confidence interval., timeFrame - 4 months post dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02216123",
    "endpoint": "measure - Time to Relapse of P. Vivax Malaria, description - Relapse is defined by a positive blood smear with or without vivax symptoms.\nRelapse is described as any recurrence of malaria that occurred after Day 32 of the study.\nThe time to relapse was analyzed by the Kaplan-Meier method.\nThe median number of days to relapse along with 95% confidence interval has been presented for each treatment group., timeFrame - Up to Day 180",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02216123",
    "endpoint": "measure - Time to Parasite Clearance, description - Parasite clearance time is defined as time needed to clear asexual parasite from the blood that is, parasite numbers falling below the limit of detection in the thick blood smear and remaining undetectable after 6 to 12 hours later.\nThe time to achieve parasite clearance was analyzed by Kaplan-Meier methodology.\nThe median parasite clearance time along with 95% confidence interval has been presented for each treatment group., timeFrame - Up to Day 180",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02216123",
    "endpoint": "measure - Time to Fever Clearance, description - Fever clearance time is defined as the time from first dose of treatment to the time when body temperature falls to normal within Study Days 1-4 and remains normal for at least 48 hours up to the Day 8 visit.\nFever clearance was considered to have been achieved once an initial temperature of more than 37.4 degree Celsius is reduced to a value less than or equal to 37.4 degree Celsius, in the absence of value more than 37.4 degree Celsius in the following 48 hours up to the Day 8 visit.\nThe time taken to achieve fever clearance was analyzed by Kaplan-Meier method., timeFrame - Up to Day 9",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02216123",
    "endpoint": "measure - Time to Gametocyte Clearance, description - Gametocyte clearance time is defined as time from first dose until the first slide that was gametocyte negative and remained so at the next slide reading.\nThe time taken to achieve gametocyte clearance was analyzed by Kaplan-Meier method., timeFrame - Up to Day 180",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02216123",
    "endpoint": "measure - Number of Participants With Recrudescence, description - Recrudescence is defined as any P. vivax parasitemia occurring on or before Day 32 (that is, blood stage treatment failure).\nA participant was considered to have had a recrudescence if both of the following were true: a) Participant had a positive P. vivax asexual parasite count at Baseline and demonstrated clearance (that is, did not have two negative asexual P. vivax parasite counts, with at least 6 hours between the counts, and no positive counts in the interval).\nb) Participant had a positive genetically homologous asexual P. vivax parasite count, after their zero count in Days 1 to 5, but on or before Study Day 32.\nThe number of participants with recrudescence before Study Day 33 has been presented., timeFrame - Up to Day 32",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02216123",
    "endpoint": "measure - Number of Participants With Genetically Homologous and Genetically Heterologous P. Vivax Infections, description - Two drops of peripheral blood were collected onto pre-printed filter paper for subsequent deoxyribonucleic acid (DNA) extraction and polymerase chain reaction (PCR) analysis of Plasmodium species on all participants at screening (Day 1; pre-dose) and; if necessary, at the time of the first recrudescence&#x2F;relapse or re-infection.\nPCR of the P. vivax genes, was used to distinguish between genetically homologous and genetically heterologous infection.\nThe number of participants with genetically homologous and genetically heterologous P. vivax infections has been summarized for each treatment group.\nOnly those participants with an infection occuring on or after Study Day 33 were analyzed., timeFrame - Up to Day 180",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02216123",
    "endpoint": "measure - Number of Participants With Clinical Chemistry Laboratory Data Outside the Reference Range, description - Plasma or serum samples were anlalyzed to evaluate clinical chemistry parameters such as alanine aminotransferase (ALT), alkaline phosphatase (ALP), aspartate aminotransferase (AST), bilirubin, creatine kinase, creatinine, glomerular filtration rate (GFR), indirect bilirubin and urea.\nThe number of participants with clinical chemistry laboratory values outside the extended normal range (F3) has been presented.\nThe upper and lower limits for F3 range were defined by multiplying the normal range limits by different factors.\nHigh and low indicated that the participants had values flagged as high and low respectively for the particular parameter any time on-treatment.\nSafety Population consisted of all randomized participants who received at least one dose of blinded study medication., timeFrame - Up to Day 120",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02216123",
    "endpoint": "measure - Number of Participants With Hematology Laboratory Data Outside the Reference Range, description - Blood samples were collected for the evaluation of hematology parameters including eosinophils, leukocytes, lymphocytes, neutrophils, platelets, reticulocytes and methemoglobin.\nThe number of participants with hematology laboratory data outside the extended normal range (F3) has been presented.\nThe upper and lower limits for F3 range were defined by multiplying the normal range limits by different factors.\nHigh and low indicated that the participants had values flagged as high and low respectively for the particular parameter any time on-treatment.\nParticipants having both High and Low values for Normal Ranges at any post-baseline visits for safety parameters were counted in both the High and Low categories., timeFrame - Up to Day 120",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02216123",
    "endpoint": "measure - Number of Participants With Abnormal Urinalysis Dipstick Results, description - Mid-stream urine was collected and analyzed for bilirubin, glucose, ketones, leukocyte esterase (LE), nitrites, occult blood, proteins and urobilinogen by dipstick method.\nThe number of participants with abnormal urinalysis results (Trace, +, ++, +++, ++++) has been presented.\nOnly those participants with data available at the specified data points were analyzed., timeFrame - Up to Day 120",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02216123",
    "endpoint": "measure - Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs, description - An adverse event (AE) is defined as any untoward medical occurrence in a participant under clinical investigation, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.\nSerious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability&#x2F;incapacity, is a congenital anomaly&#x2F; birth defect, other situations such as important medical events and events of possible drug induced liver injury with hyperbilirubinemia.\nTEAEs are defined as AEs with an onset date and time on or after that of the start of first dose of study medication (including CQ).\nNumber of participants with TEAEs and serious TEAEs have been presented., timeFrame - Up to Day 180",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02216123",
    "endpoint": "measure - Number of Participants With Electrocardiogram (ECG) Findings, description - 12 lead ECG was performed with the participant in a semi-supine position having rested in this position for at least 10 minutes.\nECG assessments were performed in triplicate at screening followed by single ECGs 12 hours after the first dose of study medication and at Day 29.\nThe number of participants with abnormal-clinically significant ECG findings have been presented.\nThe 12 Hour Post Randomized Treatment (11.5-12.5 Hours) timepoint included all readings taken between 11.5 and 12.5 hours post randomized treatment.\nThe 12 Hour Post Randomized Treatment (8-72 Hours) timepoint is a sensitivity analysis of the 12 Hour post randomized treatment timepoint, including all readings taken between 8 and 72 hours post randomized treatment.\nOnly those participants with data available at the specified data points were analyzed (represented by n=X in category title)., timeFrame - Up to Day 29",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02216123",
    "endpoint": "measure - Change From Baseline in Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP) and Mean Arterial Pressure (MAP), description - Vital signs were measured twice a day on Days 1 through 3, at least 4 hours apart, and immediately prior to pharmacokinetic (PK) measurements.\nMAP was calculated as the sum of SBP and two times DBP divided by 3. The mean and standard deviation of SBP, DBP and MAP has been presented.\nThe values presented does not include Day 3 assessments for participant number 570.\nBaseline value is defined as the latest pre-treatment assessment where treatment is their first dose of study medication (CQ&#x2F;PQ&#x2F;TQ&#x2F;Placebo).\nChange from Baseline is the value at post dose minus Baseline value.\nOnly those participants with data available at the specified data points were analyzed (represented by n=X in category title)., timeFrame - Baseline and up to Day 180",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02216123",
    "endpoint": "measure - Change From Baseline in Pulse Rate, description - Vital signs were measured twice a day on Days 1 through 3, at least 4 hours apart, and immediately prior to PK measurements.\nThe mean and standard deviation of pulse rate has been presented.\nThe values presented does not include Day 3 assessments for participant number 570.\nBaseline value is defined as the latest pre-treatment assessment where treatment is their first dose of study medication (CQ&#x2F;PQ&#x2F;TQ&#x2F;Placebo).\nChange from Baseline is the value at post dose minus Baseline value.\nOnly those participants with data available at the specified data points were analyzed (represented by n=X in category title)., timeFrame - Baseline and up to Day 180",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02216123",
    "endpoint": "measure - Change From Baseline in Temperature, description - Vital signs were performed twice a day on Days 1 through 3, at least 4 hours apart, and immediately prior to PK measurements.\nThe mean and standard deviation of pulse rate has been presented.\nThe values presented does not include Day 3 assessments for participant number 570.\nBaseline value is defined as the latest pre-treatment assessment where treatment is their first dose of study medication (CQ&#x2F;PQ&#x2F;TQ&#x2F;Placebo).\nChange from Baseline is the value at post dose minus Baseline value.\nOnly those participants with data available at the specified data points were analyzed (represented by n=X in category title)., timeFrame - Baseline and up to Day 180",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02216123",
    "endpoint": "measure - Number of Participants With P. Falciparum, description - Microscopic blood slides (two thick film and one thin film slide) were prepared and examined for asexual parasite count.\nThe number of participants with positive P. falciparum asexual parasite count post Baseline has been summarized for each treatment arm., timeFrame - Up to Day 180",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02216123",
    "endpoint": "measure - Number of Participants With Keratopathy, description - Ophthalmic assessments were carried out at pre-qualified sites prior to randomization and at Days 29 and 90 and at withdrawal follow-up visit.\nAssessments were carried out at Day 180 (and up to resolution) if the Day 90 assessments showed abnormalities.\nThe last assessment performed on the day of randomization or earlier was considered Baseline.\nThe number of participants displaying keratopathy in each eye has been summarized for each visit.\nThe number of participants with new keratopathy at any time post Baseline is also reported.\nOphthalmic Safety Population comprised of all participants in the Safety Population who have results from any eye assessments.\nOnly those participants with data available at the specified data points were analyzed (represented by n=X in category title)., timeFrame - Up to Day 180",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02216123",
    "endpoint": "measure - Number of Participants With Change in Best Corrected Visual Acuity Test Scores, description - Ophthalmic assessments were carried out at pre-qualified sites prior to randomization and at Days 29 and 90 and at withdrawal.\nAssessments were carried out at Day 180 if the Day 90 assessments showed abnormalities.\nThe last assessment performed on the day of randomization or earlier was considered Baseline.\nChange from Baseline is the value at post dose visit minus the Baseline value.\nBest corrected visual acuity was assessed individually for each eye.\nScores were recorded as a ratio.\nThe values were used to derive a logMAR score for statistical analysis where logMAR=-1x log10 (ratio score).\nThe number of participants with change in Best Corrected Visual Acuity Test Scores from Baseline has been presented where possible change is defined as a change from Baseline &gt;=0.12 to &lt;0.3 and definite change is defined as a change from Baseline &gt;=0.3 logMAR score.\nOnly those participants with data available at the specified data points were analyzed (represented by n=X in category title)., timeFrame - Baseline and up to Day 180",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02216123",
    "endpoint": "measure - Number of Participants With Retinal Changes From Baseline, description - Ophthalmic assessments were carried out at pre-qualified sites prior to randomization and at Days 29 and 90 and at withdrawal follow-up.\nAssessments were carried out at Day 180 (and up to resolution) if the Day 90 assessments showed abnormalities.\nThe last assessment performed on the day of randomization or earlier was considered Baseline.\nChange from Baseline was calculated as the value at post dose visit minus the Baseline value.\nThe number of participants with definite retinal change and questionable (ques) retinal change from Baseline has been presented.\nThe number of participants with maximum change post-Baseline (definite when absent or questionable at Baseline) has been presented for either eye.\nOnly those participants with data available at the specified data points were analyzed (represented by n=X in category title)., timeFrame - Baseline and up to Day 180",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02216123",
    "endpoint": "measure - Change From Baseline in Percent Methemoglobin, description - Methemoglbin is an oxidized and inactive form of hemoglobin.\nMethemoglobin assessment was made with the aid of a non-invasive signal extraction pulse CO-Oximeter handheld machine.\nThe change from Baseline in percent methemoglobin by treatment, time and sex has been summarized.\nThe latest pre-treatment assessment where treatment is their first dose of study medication (CQ&#x2F;PQ&#x2F;TQ&#x2F;Placebo) was considered as Baseline value.\nChange from Baseline is the value at post dose visit minus the Baseline value.\nOnly those participants with data available at the specified data points were analyzed (represented by n=X in category title)., timeFrame - Baseline and up to Day 120",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02216123",
    "endpoint": "measure - Cost Associated With Relapse Episode of P Vivax Malaria, description - Health outcomes were evaluated based on the total costs spent on treatment, transport, medication and tests.\nThe cost was summarized according to the place at which the participant went to for care (drug shop, trial clinic, other clinic, hospital emergency center, other).\nThe costs associated with a relapse episode of P. vivax malaria has been presented.\nParticipants may be represented in more than one category, so the total number of participants may be less than the number quoted.\nOnly those participants with data available at the specified data points were analyzed (represented by n=X in category title)., timeFrame - Up to Day 180",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02216123",
    "endpoint": "measure - Cost Associated With a Hemolysis Event, description - Health outcomes were evaluated based on cost incurred due to clinically relevant hemolysis.\nThe total cost was evaluated based on the amount spent on treatment, transport, medication and test.\nThe costs associated with hemolysis event has been presented.\nThe aim of this outcome measure was to determine the cost to a participant due to an event of hemolysis, regardless of treatment received in the study.\nIt was not expected there would be major cost differences with hemoglobin decrease between the treatment arms.\nThis was pre-specified in the statistical analysis plan., timeFrame - Up to Day 180",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02216123",
    "endpoint": "measure - Cost Incurred With Purchase of Medications Associated With Relapse Episode of P. Vivax Malaria, description - Health outcomes were evaluated based on the cost of medications purchased.\nThe total medication cost for paracetamol associated with relapse episode of P vivax malaria has been presented.\nMedications recorded as &quot;Other&quot; and medications without costs are excluded from the analysis.\nOnly those participants with data available at the specified data points were analyzed (represented by n=X in category title)., timeFrame - Up to Day 180",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02216123",
    "endpoint": "measure - Cost Incurred With Purchase of Medications Associated With Hemolysis Event, description - Health outcomes were evaluated based on the cost of medications purchased.\nThe total medication cost associated with hemolysis event has been presented.\nMedications recorded as &quot;Other&quot; and medications without costs are excluded from the analysis.\nThe aim of this outcome measure was to determine the cost to a participant due to an event of hemolysis, regardless of treatment received in the study.\nIt was not expected there would be major cost differences with hemoglobin decrease between the treatment arms.\nThis was pre-specified in the statistical analysis plan., timeFrame - Up to Day 180",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02216123",
    "endpoint": "measure - Number of Participants or Care Givers Who Had Taken Time Off From Normal Occupation Due to Relapse Episode of Malaria, description - Health outcomes were evaluated based on total time lost by participants or care givers due to an episode of malaria.\nThe number of participants or care givers who had taken off from their normal occupation due to relapse episode of P vivax malaria has been presented by country.\nParticipants may be represented in more than one category, so the total number of participants may be less than the number quoted.\nOnly those participants with data available at the specified data points were analyzed (represented by n=X in category title)., timeFrame - Up to Day 180",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02216123",
    "endpoint": "measure - Number of Participants or Care Givers Who Had Taken Time Off From Normal Occupation Due to a Hemolysis Event, description - Health outcomes were evaluated based on total time lost by participants or care givers due to a hemolysis event.\nThe number of participants or care givers who took days off from work due to a hemolysis event has been presented based on the normal occupation.\nThe aim of this outcome measure was to determine the time taken off by participants due to an event of hemolysis, regardless of treatment received in the study.\nIt was not expected there would be major differences in time taken off by participants with hemoglobin decrease between the treatment arms.\nThis was pre-specified in the statistical analysis plan., timeFrame - Up to Day 180",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02216123",
    "endpoint": "measure - Number of Participants With Action Taken to Treat Relapse Episode of P. Vivax Malaria, description - Health outcomes were evaluated based on the actions taken by the participants to treat relapse episode of P vivax malaria.\nThe number of participants with the type of action taken to treat relapse episode of P vivax malaria has been presented by country.\nParticipants may be represented in more than one category, so the total number of participants may be less than the number quoted.\nOnly those participants with data available at the specified data points were analyzed (represented by n=X in category title)., timeFrame - Up to Day 180",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02216123",
    "endpoint": "measure - Number of Participants With Action Taken to Treat a Hemolysis Event, description - Health outcomes were evaluated based on the actions taken by the participants to treat hemolysis events.\nThe number of participants in Brazil who attended the trial clinic to treat a hemolysis event has been presented.\nThe aim of this outcome measure was to determine the action taken by a participant due to an event of hemolysis, regardless of treatment received in the study.\nIt was not expected there would be major differences in action taken by the participants with hemoglobin decrease between the treatment arms.\nThis was pre-specified in the statistical analysis plan., timeFrame - Up to Day 180",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02216123",
    "endpoint": "measure - Oral Clearance (CL&#x2F;F) of TQ, description - Apparent population oral clearance of TQ, timeFrame - Day 2, Day 3, Day 8, Day 15, Day 29, Day 60 and Day 180",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02216123",
    "endpoint": "measure - Volume of Distribution (Vc&#x2F;F) of TQ, description - Apparent population central volume of distribution of TQ, timeFrame - Day 2, Day 3, Day 8, Day 15, Day 29, Day 60 and Day 180",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06928207",
    "endpoint": "measure - Case management of patients visiting the PMR suspected of having malaria, description - The proportion of patients suspected of malaria cases that are managed appropriately (tested for malaria in the PMR or elsewhere but with proof and purchase any ACT following a positive RDT test result or do not purchase an ACT after a negative RDT rest result), timeFrame - From enrollment exiting the PMR until the rapid test is conducted and the exit interview is concluded (approximately 30 min)]",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06928207",
    "endpoint": "measure - Out of pocket expenses incurred by patients suspected of having malaria, description - The out-of-pocket expenses incurred in the PMR by patients suspected of having malaria for ACTs and RDTs, timeFrame - From enrollment exiting the PMR until the rapid test is conducted and the exit interview is concluded (approximately 30 min)]",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06928207",
    "endpoint": "measure - Proportion of untested clients who purchase ACTs, description - Proportion of clients visiting the PMR that did not test in the drugshop and purchased ACTs, timeFrame - From enrollment exiting the PMR until the rapid test is conducted and the exit interview is concluded (approx 30 min)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05951595",
    "endpoint": "measure - 28-day PCR uncorrected efficacy, description - 28-day PCR uncorrected efficacy defined as the proportion of patients with absence up to Day 28 of P. falciparum parasitaemia, timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05951595",
    "endpoint": "measure - 42-day efficacy, description - 42-day efficacy defined as the proportion of patients with PCR-corrected adequate clinical and parasitological response (ACPR) at Day 42, i.e., absence up to Day 42 of P. falciparum parasitaemia (detected by microscopy) with parasites genetically identical to those detected at baseline (as determined by PCR product length polymorphisms), timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05951595",
    "endpoint": "measure - 42-day PCR-uncorrected efficacy, description - 42-day PCR-uncorrected efficacy defined as the proportion of patients with absence up to Day 42 of P. falciparum parasitaemia, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05951595",
    "endpoint": "measure - Parasite clearance half-life, description - Assessed by microscopy as primary parameter to determine parasite clearance half-life, timeFrame - 3 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05951595",
    "endpoint": "measure - Proportion of participants with microscopically detectable P. falciparum parasitaemia at Day 3, description - , timeFrame - 3 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05951595",
    "endpoint": "measure - Fever clearance time, description - Fever clearance time (i.e., the time taken for the tympanic temperature to fall below 37.5°C in participants who were febrile at inclusion), timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05951595",
    "endpoint": "measure - Proportion of participants with gametocytaemia, description - Proportion of participants with gametocytaemia during and after treatment stratified by presence of gametocytes at enrolment, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05951595",
    "endpoint": "measure - Incidence of adverse events (AEs), description - Incidence of AEs within the first 42 days including markers of hepatic, renal or bone marrow toxicity, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05951595",
    "endpoint": "measure - Incidence of serious adverse events (SAEs), description - Incidence of SAEs within the first 42 days including markers of hepatic, renal or bone marrow toxicity, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05951595",
    "endpoint": "measure - Number of cardiotoxicity events, description - Cardiotoxicity in particular QT or QTc-interval above 500 ms at timepoint H4, H52 or H64, D42, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05951595",
    "endpoint": "measure - Proportion of participants requiring retreatment due to vomiting, description - Proportion of participants requiring retreatment due to vomiting within 1 hour after administration of the study drugs, timeFrame - 1 hour after administration of each dose of the treatment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05951595",
    "endpoint": "measure - Proportion of participants who report completing a full course of observed TACT, description - Proportion of participants who report completing a full course of observed TACT without withdrawal of consent or exclusion from study because of drug related serious adverse event, timeFrame - 3 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05951595",
    "endpoint": "measure - Proportion of participants who report completing a full course of observed ACT, description - Proportion of participants who report completing a full course of observed ACT without withdrawal of consent or exclusion from study because of drug related serious adverse event, timeFrame - 2 or 3 days depending on the treatment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05951595",
    "endpoint": "measure - Peak plasma concentration, description - Peak plasma concentration (Cmax) of artemisinin-derivatives and partner drugs in ACT and TACT treated participants in correlation with pharmacodynamics measures of drug efficacy, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05951595",
    "endpoint": "measure - Area under curve, description - Area under the plasma concentration versus time curve (AUC) of artemisinin-derivatives and partner drugs in ACT and TACT treated participants in correlation with pharmacodynamic measures of drug efficacy, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05951595",
    "endpoint": "measure - Pharmacokinetic interactions - peak plasma concentration, description - Comparison of peak plasma concentration (Cmax) of artemisinin-derivatives and partner drugs in ACT and TACT treated participants in correlation with pharmacodynamics measures of drug efficacy, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05951595",
    "endpoint": "measure - Pharmacokinetic interactions - area under curve, description - Comparison of area under the plasma concentration versus time curve (AUC) of artemisinin-derivatives and partner drugs in ACT and TACT treated participants in correlation with pharmacodynamic measures of drug efficacy, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05951595",
    "endpoint": "measure - Plasma levels of partner drugs, description - Plasma levels of partner drugs in correlation with treatment efficacy and treatment arm on Day 7, timeFrame - 7 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05540470",
    "endpoint": "measure - prevalence reduction - Focus on effectiveness, description - To reduce the species-specific prevalence of P. vivax and P. falciparum among people involved in gold mining activities in the South of the Guiana Shield;, timeFrame - through study completion, an average of 3 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05540470",
    "endpoint": "measure - contact reduction - Focus on effectiveness, description - To reduce the proportion of garimpeiros with a high probability of recent P. vivax infection (and probably hypnozoite carriers);, timeFrame - through study completion, an average of 3 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05540470",
    "endpoint": "measure - malaria incidence reduction - Focus on effectiveness, description - To reduce the incidence of malaria cases associated with gold mining activity in the southern Guyanese Shield, as detected by the epidemiological surveillance systems of the countries involved;, timeFrame - through study completion, an average of 3 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05540470",
    "endpoint": "measure - Good use of antimalarial treatment - Focus on effectiveness, description - To increase the proportion of garimpeiros who adequately take anti-malarial treatment when they fall ill in illegal garimpos in French Guiana;, timeFrame - through study completion, an average of 3 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05540470",
    "endpoint": "measure - preventing P. vivax parasitaemia - Focus on effectiveness, description - level of P vivax parasietaemia (percentage of red blood cells which contains P. vivax) : estimate the individual-level effectiveness of module A intervention in preventing P. vivax parasitaemia, timeFrame - through study completion, an average of 3 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05540470",
    "endpoint": "measure - increase adherence in asymptomatic - Focus on implementation, description - Number of medication taken by the participants related to number of medication delivered to the participants: adherence to the primaquine posology among asymptomatic individuals;, timeFrame - through study completion, an average of 3 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05540470",
    "endpoint": "measure - safety - Focus on implementation, description - To assess the safety of medicines for Modules A and B on a community level;, timeFrame - through study completion, an average of 3 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05540470",
    "endpoint": "measure - increase health education with specific scales on level of disease comprehension by the participants - Focus on implementation, description - To evaluate the effectiveness of the health education activity carried out during the intervention with specifics scales on level of disease comprehension by the participants;, timeFrame - through study completion, an average of 3 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05540470",
    "endpoint": "measure - acceptability of digital tool - Focus on implementation, description - number of participants who regularly use the smartphone application To assess the acceptability of digital tools (smartphone app):, timeFrame - through study completion, an average of 3 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05540470",
    "endpoint": "measure - feasability of digital tool - Focus on implementation, description - number of participants who can regularly use the smartphone application:To assess the feasibility of digital tools (smartphone app);, timeFrame - through study completion, an average of 3 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05540470",
    "endpoint": "measure - effectiveness of training measured with specifics scales - Focus on implementation, description - Level of comprehension of the training measured with specifics scales: to evaluate the quality and effectiveness of the training received by facilitators;, timeFrame - through study completion, an average of 3 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05540470",
    "endpoint": "measure - increase inclusion process - Focus on implementation, description - To assess the fidelity of the inclusion and follow-up process;, timeFrame - through study completion, an average of 3 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05540470",
    "endpoint": "measure - quality of rapid serological test - Focus on implementation, description - To evaluate the sensitivity and specificity of the rapid serological test and to estimate the discriminatory capacity of this test to detect recent P. vivax infections in the epidemiological context of the study, timeFrame - through study completion, an average of 3 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05540470",
    "endpoint": "measure - intervention&#x27;s costs measured in euros - Focus on implementation, description - To estimate the programmatic cost of the intervention, timeFrame - through study completion, an average of 3 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05540470",
    "endpoint": "measure - needs identification - Focus on implementation, description - highlighting health risk factors by assessing the health situation of garimpeiros and additional health needs beyond malaria elimination, timeFrame - through study completion, an average of 3 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05540470",
    "endpoint": "measure - identify facilitating factors and barriers of the intervention - Focus on implementation, description - highlighting the obstacles and levers by assessing facilitating factors as well as barriers to delivering such an intervention in a pre-elimination setting and community involvement to be taken into account for further implementation, timeFrame - through study completion, an average of 3 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01625871",
    "endpoint": "measure - Fever clearance time, description - The time for fever clearance, timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01625871",
    "endpoint": "measure - Parasite clearance time, description - The time for the parasite to clear, timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06666491",
    "endpoint": "measure - Number of participants with clinically relevant hemolysis change from baseline, description - A decrease in hemoglobin of greater than or equal to (&gt;=) 30% or greater than (&gt;) 3g&#x2F;deciliter (dL) from baseline; or an overall drop in hemoglobin below 6.0 g&#x2F;dL or complications thereof (e.g., required transfusions, acute renal failure) are considered clinically relevant hemolysis changes., timeFrame - Up to Day 14",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06666491",
    "endpoint": "measure - Time to recurrence of P. vivax malaria, description - Recurrence is defined as a positive blood smear for P. vivax parasites within the 6-month follow-up period, after clearance of blood-stage parasitemia., timeFrame - Up to Month 6",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06666491",
    "endpoint": "measure - Number of participants with treatment emergent adverse events (TEAEs) up to Month 6, description - An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product., timeFrame - Up to Month 6",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06666491",
    "endpoint": "measure - Number of participants with TEAEs meeting &gt;= Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 criteria, description - Severity was graded according to DAIDS grading criteria, where Grade 1-mild, Grade 2-moderate, Grade 3-severe, Grade 4-potentially life-threatening, Grade 5-Death., timeFrame - Up to Month 6",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06666491",
    "endpoint": "measure - Number of participants with drug related TEAEs, description - An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product., timeFrame - Up to Month 6",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06666491",
    "endpoint": "measure - Number of participants with serious AEs (SAEs), description - A SAE is any untoward medical occurrence that results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization or result in disability&#x2F;incapacity, is a congenital anomaly&#x2F;birth defect in the offspring of a study participant., timeFrame - Up to Month 6",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06666491",
    "endpoint": "measure - Number of participants with AEs resulting in treatment discontinuation, description - An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product., timeFrame - Up to Month 6",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06666491",
    "endpoint": "measure - Number of participants with AEs leading to study withdrawal, description - An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product., timeFrame - Up to Month 6",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06666491",
    "endpoint": "measure - Number of participants with AEs considered to be hematologically related, description - An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product., timeFrame - Up to Month 6",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06666491",
    "endpoint": "measure - Number of deaths, description - , timeFrame - Up to Month 6",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06666491",
    "endpoint": "measure - Liver chemistry changes meeting Hy&#x27;s criteria, description - Hy&#x27;s criteria cases were defined as any elevated alanine aminotransferase (ALT) &gt;=3 times upper limit of normal (ULN) and total bilirubin &gt;=2 times ULN or ALT &gt;=3 times ULN and international normalized ratio (INR) &gt;1.5., timeFrame - Up to Month 6",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06666491",
    "endpoint": "measure - Laboratory parameters meeting &gt;= Division of AIDS (DAIDs) Grade 3 criteria, description - , timeFrame - Up to Month 6",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06666491",
    "endpoint": "measure - Vital sign parameters meeting &gt;=DAIDs Grade 3 criteria, description - , timeFrame - Up to Month 6",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06666491",
    "endpoint": "measure - Number of participants with TEAEs up to Week 4, description - An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product., timeFrame - Up to Week 4",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06666491",
    "endpoint": "measure - Change from baseline at each study visit for clinical chemistry parameters (ALT, AST, ALP), description - Data for alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP) is measured in international units&#x2F;liter (IU&#x2F;L)., timeFrame - At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06666491",
    "endpoint": "measure - Change from baseline at each study visit for clinical chemistry parameters (CPK), description - Data for creatine phosphokinase (CPK) is measured in units per liter (U&#x2F;L)., timeFrame - At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06666491",
    "endpoint": "measure - Change from baseline at each study visit for clinical chemistry parameters (total bilirubin, indirect bilirubin, blood urea nitrogen [BUN]&#x2F;Urea, and serum creatinine), description - Clinical chemistry parameters are measured in milligrams per decilitre (mg&#x2F;dL)., timeFrame - At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06666491",
    "endpoint": "measure - Change from baseline at each study visit for clinical chemistry parameters (serum electrolytes), description - Data for serum electrolytes is measured in millimoles per liter (mmol&#x2F;L)., timeFrame - At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06666491",
    "endpoint": "measure - Change from baseline at each study visit for haematology parameters (platelet count), description - Platelets are measured in number of platelets per microliter (µL)., timeFrame - At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06666491",
    "endpoint": "measure - Change from baseline at each study visit for haematology parameters (red blood cell [RBC] count), description - Data for RBC is measured in millions of cells per microliter (number of RBCs x10^6&#x2F;µL)., timeFrame - At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06666491",
    "endpoint": "measure - Change from baseline at each study visit for haematology parameters (mean corpuscular volume [MCV]), description - Data for MVC is measured in femtoliters (fL)., timeFrame - At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06666491",
    "endpoint": "measure - Change from baseline at each study visit for haematology parameters (mean corpuscular hemoglobin [MCH]), description - Data for MCH is measured in picograms (pg) per cell., timeFrame - At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06666491",
    "endpoint": "measure - Change from baseline at each study visit for haematology parameters (percentage of reticulocytes), description - , timeFrame - At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06666491",
    "endpoint": "measure - Change from baseline at each study visit for haematology parameters (white blood cell count [WBC] with differential), description - Data for neutrophils, lymphocytes, monocytes, eosinophils and basophils is presented as a count, which measures a percentage (%) of the WBC., timeFrame - At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06666491",
    "endpoint": "measure - Change from baseline at each study visit for haematology parameters (hemoglobin), description - Hemoglobin is measured in grams per deciliter (g&#x2F;dL)., timeFrame - At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06666491",
    "endpoint": "measure - Change from baseline at each study visit for haematology parameters (hematocrit), description - Hematocrit is measured in volume percentage (%) of RBC in blood., timeFrame - At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03307369",
    "endpoint": "measure - Compare the age of inpatient cases that meet or do not meet the 2015 WHO criteria for severe P. vivax, description - , timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03307369",
    "endpoint": "measure - Compare the sex of inpatient cases that meet or do not meet the 2015 WHO criteria for severe P. vivax, description - , timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03307369",
    "endpoint": "measure - Compare the medical history of inpatient cases that meet or do not meet the 2015 WHO criteria for severe P. vivax, description - , timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03307369",
    "endpoint": "measure - Compare the parasitaemia of inpatient cases that meet or do not meet the 2015 WHO criteria for severe P. vivax, description - , timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03307369",
    "endpoint": "measure - Compare the duration of hospital stay of inpatient cases that meet or do not meet the 2015 WHO criteria for severe P. vivax, description - , timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03307369",
    "endpoint": "measure - Compare the use of intravenous anti-malarial of inpatient cases that meet or do not meet the 2015 WHO criteria for severe P. vivax, description - , timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03307369",
    "endpoint": "measure - Compare the blood transfusion of inpatient cases that meet or do not meet the 2015 WHO criteria for severe P. vivax, description - , timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06424002",
    "endpoint": "measure - Proportion of enrolled school children who pass their examinations at the end of the year and proceed to the next class (Pupil&#x27;s passing fraction based on classroom records), description - Pass rate based on classroom records, timeFrame - During 18 months of follow up, classroom records will record children passing end of year examinations",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06424002",
    "endpoint": "measure - Proportion of enrolled school children with clinical malaria incident events throughout the study period (ACD), description - Based on symptoms of malaria plus a positive malaria rapid diagnostic test.\nA bood slide will also be collected for future assessment for malaria parasites, timeFrame - During 18 months of follow up, clinical malaria will be assessed during sick visits (PCD) and during active case detection",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06424002",
    "endpoint": "measure - Proportion of enrolled school children with P. falciparum infections during the study period (ACD)., description - Based dried blood spot (DBS) samples from index child, timeFrame - During 18 months of follow up, malaria infection will be assessed during the ACD visits",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06424002",
    "endpoint": "measure - Proportion of children with low levels of hemoglobin levels (hb&lt;11g&#x2F;dl) during the study period (ACD)., description - As measured by hemocue machines, timeFrame - At baseline, midline, endline and during ACD visits, hemoglobin levels will be measured during the 18 months follow up period",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06424002",
    "endpoint": "measure - Proportion of siblings of enrolled children with P. falciparum infections at the beginning and end of the study period (indirect or &quot;spill over&quot; effect) (ACD), description - Based DBS samples from siblings of index child, timeFrame - During 18 months of follow up, malaria infection will be assessed during the ACD visits",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06424002",
    "endpoint": "measure - Levels of antibodies against N-4-azido-2-nitrophenylpyridoxyl-5-phosphate (NANP) and CSP, description - Magnitude of immunoglobulin G (IgG) against NANP.\n2. Geometric mean of magnitude of antibodies against the two antigens, as well as avidity, and fractional catabolic rate (FcR) binding activity over time., timeFrame - At endline and during ACD visits, levels of antibodies will be measured during 18 months of follow up",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01567423",
    "endpoint": "measure - PCR-unadjusted clinical and parasitological cure rate up to day 42 of the follow-up period determined in the per-protocol population, description - , timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01567423",
    "endpoint": "measure - PCR-adjusted clinical and parasitological cure rate up to day 42 of the follow-up period determined by a survival analysis, description - A survival analysis was performed and patients with incomplete follow-up who did not reach the primary outcome interest were included in the analysis as non-failures, but censored on the last day of follow-up.\nThe risk of failure was calculated using the Kaplan-Meier product limit formula with data censored for patients who were not classified as failures and with interrupted follow-up.\nPatients wrongly included, who did not meet study inclusion criteria, were excluded from both analyses., timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01567423",
    "endpoint": "measure - PCR-unadjusted clinical and parasitological cure rate up to day 42 of the follow-up period determined by a survival analysis, description - , timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01567423",
    "endpoint": "measure - PCR-adjusted clinical and parasitological cure rate up to day 28 of the follow-up period determined in the per protocol population, description - , timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01567423",
    "endpoint": "measure - PCR-unadjusted clinical and parasitological cure rate up to day 28 of the follow-up period determined in the per protocol population, description - , timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02696928",
    "endpoint": "measure - Incidence of P. vivax, description - Passive and active surveillance, timeFrame - 180 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02696928",
    "endpoint": "measure - Adverse events (AE) during total follow-up period, description - Passive and active surveillance, timeFrame - 180 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02696928",
    "endpoint": "measure - Study costs, description - Costs per patient, timeFrame - 180 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06293339",
    "endpoint": "measure - Humoral immune responses after homologous CHMI rechallenge, description - Difference in concentration of anti-CSP antibodies between groups as assessed by ELISA., timeFrame - Moment of CHMI up to182 days post CHMI",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06293339",
    "endpoint": "measure - Cellular immune responses after homologous CHMI rechallenge, description - Difference in percentage of CD4+ and CD8+ T-cells producing IFN-γ between groups as assessed by flow cytometry, timeFrame - Moment of CHMI up to182 days post CHMI",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05440773",
    "endpoint": "measure - Decrease in gametocyte load in carriers with Artemisia afra tea by dose concentration, dose frequency, length of treatment, and formulation., description - , timeFrame - 4weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05440773",
    "endpoint": "measure - Acceptability (adherence and completion) of Artemisia afra treatment by dose concentration, dose frequency, length of treatment, and formulation (flavor)., description - , timeFrame - 4weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05440773",
    "endpoint": "measure - Safety (ASEs) of Artemisia afra treatment in participants by dose concentration, dose frequency length of treatment, and treatment formulation., description - , timeFrame - 4weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05440773",
    "endpoint": "measure - Likelihood and variability in the rate of reservoir elimination with treatment, compliance&#x2F; acceptability, and occurrence of side effects &#x2F;adverse events in different treatment arms., description - , timeFrame - 4weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05889052",
    "endpoint": "measure - Incidence of severe malaria, malaria deaths, anaemia and severe anaemia, description - Incidence of: (1) severe malaria, (2) malaria deaths, (3) anaemia, and (4) severe anaemia in children residing in areas designated to receive PMC (intervention) versus standard care (control)., timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05889052",
    "endpoint": "measure - Malaria and anaemia incidence by delivery platform, number of doses and dose schedule, description - Measure differences in incidence between children residing in areas designated to receive PMC (intervention) versus standard of care (control) based on differences in SP dose patterns by delivery platform, number of doses of SP, and the SP dose schedule., timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05889052",
    "endpoint": "measure - Dose-response effects of SP on malaria and anaemia, description - Measure the dose-response effects of SP on incidence of: (1) malaria infection, (2) clinical malaria, (3) severe malaria, (4) anaemia, (5) severe anaemia, and (6) malaria mortality throughout the period of observation., timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05889052",
    "endpoint": "measure - Effects of distance to health facility on malaria and anaemia, description - Measure the effects of distance to health facility on incidence of: (1) malaria infection, (2) clinical malaria, (3) severe malaria, (4) anaemia, (5) severe anaemia, and (6) malaria mortality throughout the period of observation., timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05889052",
    "endpoint": "measure - Incidence of moderate, severe and overall malnutrition, description - Incidence of: (1) moderate, (2) severe, and (3) overall malnutrition among children residing in areas designated to receive PMC (intervention) versus standard care (control)., timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05197751",
    "endpoint": "measure - To measure the frequency and grade of each solicited systemic and local reaction during the 7 days following each vaccination, for the combined active vaccination group, description - Frequency and grade of solicited systemic and local reaction during the 7 days following each vaccination, for the combined active vaccination group., timeFrame - 7 days following vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05197751",
    "endpoint": "measure - To measure the frequency and grade of each unsolicited systemic and local reaction during the 28 days for the combined active vaccination group of each dose levels (3 µg, 10 µg and 30 µg), administered on Day 1, 28 and 56, description - Frequency and grade of unsolicited systemic and local reaction during the 28 days following each vaccination, for the combined active vaccination group., timeFrame - 28 days following vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05197751",
    "endpoint": "measure - To measure the number of subjects with Adverse Events during the 28 days each vaccination, for the combined active vaccination group., description - the number of subjects with Adverse Events during the 28 days each vaccination, for the combined active vaccination group., timeFrame - 28 days after vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05197751",
    "endpoint": "measure - To measure the seroresponse rates (defined as the proportion with 2, 3, and 4-fold rise in titre of anti-MSP3 antibodies) determined 28 days after each vaccination as compared to baseline (Day 1), by treatment group., description - Seroresponse rates (defined as the proportion with 2, 3, and 4-fold rise in titre of anti-MSP3 antibodies) determined 28 days after each vaccination as compared to baseline (Day 1), by treatment group., timeFrame - 28 days after vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05197751",
    "endpoint": "measure - To measure the Geometric mean titres (GMT) of anti-MSP3 antibodies 28 days after each vaccination, by treatment group (total IgG and IgG sub classes).observed during the 28 days following each vaccination, for the combined active vaccination group., description - Geometric mean titres (GMT) of anti-MSP3 antibodies 28 days after each vaccination, by treatment group (total IgG and IgG sub classes)., timeFrame - 28 days after each vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05197751",
    "endpoint": "measure - To measure Geometric mean fold increase (GMFI) of anti-MSP3 antibodies determined 28 days after each vaccination as compared to baseline (total IgG and IgG sub classes)., description - Geometric mean fold increase (GMFI) of anti-MSP3 antibodies determined 28 days after each vaccination as compared to baseline (total IgG and IgG sub classes)., timeFrame - 28 days after each vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05197751",
    "endpoint": "measure - To measure the Proportion of participants with seroresponse across all time points, description - Proportion of participants with seroresponse across all time points, timeFrame - one month, 3 months, 6 months and 12 months after first vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05197751",
    "endpoint": "measure - To measure the Seroresponse rates, GMTs and GMFI of anti-MSP3 antibodies 3, 6 and 12 months after first vaccination (total IgG and IgG sub classes)., description - Seroresponse rates, GMTs and GMFI of anti-MSP3 antibodies 3, 6 and 12 months after first vaccination (total IgG and IgG sub classes)., timeFrame - 3, 6 and 12 month after first vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05197751",
    "endpoint": "measure - To measureIgG ability to recognize the native protein on merozoite by using Western Blot (WB) and IFAT methods, description - IgG ability to recognize the native protein on merozoite by using Western Blot (WB) and IFAT methods, timeFrame - one month after each vaccination and 3 months, 6 months and 12 months after first vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00964691",
    "endpoint": "measure - Low birth weight among primigravidae, description - , timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00964691",
    "endpoint": "measure - Maternal anaemia (Hb &lt;11 g&#x2F;dl) in the third trimester, description - , timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00964691",
    "endpoint": "measure - Maternal anaemia (Hb &lt;11 g&#x2F;dl) at delivery, description - , timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00964691",
    "endpoint": "measure - Malaria parasitemia at delivery, description - , timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06618885",
    "endpoint": "measure - IgG antibody titres against full-length MSP1, description - IgG antibody titters against the full-length MSP1 will be measured by ELISA., timeFrame - Changes assessed between Day 0 (pre-vaccination) up to Day 140 (last follow up visit).",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06618885",
    "endpoint": "measure - Identification of the dose of full-length MSP1&#x2F;GLA-SE (SUM-101) in young children and infants that give the safety profile., description - Comparison of local and systemic solicited adverse events (AEs) at least possibly related to the investigational medicinal product (IMP) SUM-101 will be recorded to evaluate safety and reactogenicity across different doses of full-length MSP1 and GLA-SE in infants and young children ., timeFrame - Recorded from after 1st vaccination (Day 0 post-vaccination) until the participant&#x27;s last visit (Day 140)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06618885",
    "endpoint": "measure - Identification of the dose of full-length MSP1&#x2F;GLA-SE (SUM-101) in young children and infants that give the strongest immune response., description - Comparison of IgG antibody titters against the full-length MSP1 will be measured by ELISA across different doses of full-length MSP1 and GLA-SE in infants and young children., timeFrame - Recorded from after 1st vaccination (Day 0 post-vaccination) until the participant&#x27;s last visit (Day 140)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06572644",
    "endpoint": "measure - Positive predictive value, description - Probability that P. falciparum infection is present when HS_RDT, Co_RDT, and microscopy are positive, timeFrame - At baseline",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06572644",
    "endpoint": "measure - Negative predictive value, description - Probability that P. falciparum infection is not present when HS_RDT, Co_RDT, and microscopy are negative, timeFrame - At baseline",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06572644",
    "endpoint": "measure - The prevalence of Pfhrp2 and Pfhrp3 genes deletions among the study participants, description - Proportion of pregnant women with malaria parasites carrying Pfhrp2&#x2F;Pfhrp3 deletions, timeFrame - At baseline",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06572644",
    "endpoint": "measure - Impact of intermittent preventive treatment in pregnancy with sulfadoxine-pyrimethamine (IPTp- SP) on falciparum parasitaemia, description - Proportion of pregnant women with falciparum parasitaemia 30 days after uptake of IPTp-SP, timeFrame - 30 days after uptake of IPTp-SP",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07183371",
    "endpoint": "measure - Immunogenicity:To assess the humoral immunogenicity of R78C with Matrix-M™, and the combination of RH5.1 with Matrix-M™ and R21 with Matrix-M™ in children living in a malaria-endemic area., description - Humoral immunogenicity will be assessed from blood samples taken at various timepoints.\nImmunogenicity will be determined following the quantification of antigen-specific IgG antibody levels (µg&#x2F;mL readout) over time, as well as by in vitro growth inhibition assays (GIA) against P. falciparum parasites using purified total IgG and a single-cycle pLDH readout assay., timeFrame - Blood samples for immunogenicity will be taken at Day -30 to 0, 0, 42, 56, 182, 196, 238, and 350.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07183371",
    "endpoint": "measure - Efficacy: To assess the protective efficacy against clinical malaria of R78C with Matrix-M™, in children living in a malaria-endemic area, for 3 months after the final vaccination, description - <p>The definition for clinical malaria is as follows:</p><ol><li><p>Presence of axillary temperature ≥37.5°C and&#x2F; or history of fever within the last 24 hours AND EITHER P. falciparum asexual parasitaemia &gt;0 parasites&#x2F;µL OR positive RDT</p><p>or</p></li><li>Presence of axillary temperature ≥37.5°C and&#x2F; or history of fever within the last 24 hours AND P. falciparum asexual parasitaemia &gt;20,000 parasites&#x2F;µL</li></ol><p>Efficacy will be determined following the comparison of mean parasite density in each study arm</p>, timeFrame - 3 months after the final vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07183371",
    "endpoint": "measure - Efficacy: To assess the protective efficacy against clinical malaria of the combination of RH5.1 with Matrix-M™ and R21 with Matrix-M™, in children living in a malaria-endemic area, for 3 months after the final vaccination, description - <p>The definition for clinical malaria is as follows:</p><ol><li><p>Presence of axillary temperature ≥37.5°C and&#x2F; or history of fever within the last 24 hours AND EITHER P. falciparum asexual parasitaemia &gt;0 parasites&#x2F;µL OR positive RDT</p><p>or</p></li><li>Presence of axillary temperature ≥37.5°C and&#x2F; or history of fever within the last 24 hours AND P. falciparum asexual parasitaemia &gt;20,000 parasites&#x2F;µL</li></ol><p>Efficacy will be determined following the comparison of mean parasite density in each study arm</p>, timeFrame - 3 months after the final vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07183371",
    "endpoint": "measure - Efficacy: To assess the protective efficacy against asymptomatic P. falciparum infection of R78C with Matrix-M™, and the combination of RH5.1 with Matrix-M™ and R21 with Matrix-M™, in children living in a malaria-endemic area., description - <p>This will be measured by looking at the following:</p><ul><li>Proportion of participants in each study arm that show presence of parasite density &gt;5000 asexual forms&#x2F;µL as measured by quantitative reverse-transcriptase PCR (qRT-PCR) from 14 days to 2 and 6 months after administration of the final study vaccination PLUS presence of axillary temperature &lt;37.5°C and absence of history of fever within the last 24 hours</li><li>Proportion of participants in each study arm that show presence of parasite density &gt;0 asexual forms&#x2F;µL as measured by qRT-PCR from 14 days to 2 and 6 months after administration of the final study vaccination PLUS presence of axillary temperature &lt;37.5°C and absence of history of fever within the last 24 hours</li><li>Parasite density in those with &gt;0 asexual forms&#x2F;µL as measured by qRT-PCR from 14 days to 2 and 6 after administration of the final study vaccination PLUS presence of axillary temperature &lt;37.5°C and absence of history of fever within the last 24 hours</li></ul>, timeFrame - 2 and 6 months after administration of the final dose of vaccine",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07183371",
    "endpoint": "measure - Efficacy: To assess the protective efficacy against gametocytaemia of R78C with Matrix-M™, and the combination of RH5.1 with Matrix-M™ and R21 with Matrix-M™, in children living in a malaria-endemic area, description - Protective efficacy against gametocytaemia will be assessed by measuring the proportion of participants in each study arm that show the presence of gametocytes &gt;0 gametocytes&#x2F;μL as measured by qRT-PCR from 14 days to 2 and 6 months after administration of the final study vaccination, timeFrame - 2 and 6 months after administration of the final dose of vaccine",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07183371",
    "endpoint": "measure - Efficacy: To assess the protective efficacy of R78C with Matrix-M™, and the combination of RH5.1 with Matrix-M™ and R21 with Matrix-M™, against prevalent moderate or severe anaemia at 6 months after administration of the final dose of vaccine, description - <p>Prevalent severe anaemia is defined as a documented haemoglobin (Hb) level &lt;5.0 g&#x2F;dL.</p><p>Prevalent moderate anaemia is defined as a documented Hb level &lt;8.0 g&#x2F;dL.</p>, timeFrame - 6 months after administration of the final dose of vaccine",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02014727",
    "endpoint": "measure - The humoral and cellular responses, description - <p>The humoral response to the vaccine antigens (DiCo1, DiCo2 and DiCo3) will be assessed by measuring the level of IgG by ELISA on samples obtained at screening visit Day 0, Week 4, 5, 8, 26, 27, 30 and 52.</p><p>The cellular immune response will be assessed by measuring the T cell cytokine IL-5, and IFNg production by ELISpot following in vitro stimulation with the vaccine antigens on samples obtained at Day 0, Week 26, 30 and 52.</p>, timeFrame - 6 months after the last vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05856357",
    "endpoint": "measure - Incidence of severe malaria, malaria deaths, anaemia and severe anaemia, description - Incidence of: (1) severe malaria, (2) malaria deaths, (3) anaemia, and (4) severe anaemia in children residing in areas designated to receive PMC (intervention) versus standard care (control)., timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05856357",
    "endpoint": "measure - Malaria and anaemia incidence by delivery platform, number of doses and dose schedule, description - Measure differences in incidence between children residing in areas designated to receive PMC (intervention) versus standard of care (control) based on differences in SP dose patterns by delivery platform, number of doses of SP, and the SP dose schedule., timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05856357",
    "endpoint": "measure - Dose-response effects of SP on malaria and anaemia, description - Measure the dose-response effects of SP on incidence of: (1) malaria infection, (2) clinical malaria, (3) severe malaria, (4) anaemia, (5) severe anaemia, and (6) malaria mortality throughout the period of observation., timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05856357",
    "endpoint": "measure - Effects of distance to health facility on malaria and anaemia, description - Measure the effects of distance to health facility on incidence of: (1) malaria infection, (2) clinical malaria, (3) severe malaria, (4) anaemia, (5) severe anaemia, and (6) malaria mortality throughout the period of observation., timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05856357",
    "endpoint": "measure - Incidence of moderate, severe and overall malnutrition, description - Incidence of: (1) moderate, (2) severe, and (3) overall malnutrition among children residing in areas designated to receive PMC (intervention) versus standard care (control)., timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01992900",
    "endpoint": "measure - Parasite clearance time, description - Blood film for parasite count will be read by two independent microscopists., timeFrame - At screening and then about every 12 hours until the time of the first negative result, then confirmed by a second negative result or up to three days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01992900",
    "endpoint": "measure - Fever clearance time, description - Body temperature will be recorded to collect information about the fever clearance time, timeFrame - At screening and then about every 12 hours until the time on which body temperature falls down below 37.5 °C, or up to three days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01992900",
    "endpoint": "measure - Change from baseline of electrocardiographic QT interval at 4-6 hours after the last study drug intake, description - <p>Triplicate ECGs will be undertaken on screening (before study drug administration)as well as 4-6 hours after the last drug administration.</p><p>The triplicate ECG values will be averaged in order to obtain one single value per patient and time point.\nThese averages will be used for the statistical analysis.</p><p>From the collected values the heart rate corrected QT intervals will be derived according to Fridericia&#x27;s correction (QTcF)</p>, timeFrame - Before randomization and then at 4-6 hours after the last dose of study drug.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01992900",
    "endpoint": "measure - Blood chemistry: proportion of patients with deterioration of parameters at day 7 respect to screening., description - The evaluated analytes are: Blood Urea Nitrogen, Creatinine, Glucose, Alanine aminotransferase, aspartate aminotransferase, Total Bilirubin, electrolytes (Na+, K+ and Cl-), timeFrame - screening and Day 7",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01992900",
    "endpoint": "measure - Hematology: proportion of patients with deterioration of parameters at day 7 respect to screening, description - the following parameters are evaluated: Hemoglobin, hematocrit and full blood counts including Red Blood Cell and differential White Blood Cells, Platelet Count, timeFrame - screening and day 7",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01992900",
    "endpoint": "measure - Adverse Events occurrence to calculate percentage of patients experiencing Adverse Events and Serious Adverse Events, description - , timeFrame - during all the study period from randomization and up to day 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04149106",
    "endpoint": "measure - Malaria infection prevalence at the start and the end of malaria transmission season, description - include changes in the prevalence of P. falciparum parasitemia and anemia measured during cross-sectional surveys before SMC provision (June&#x2F;July the beginning of transmission season) and after fourth round provision of SMC, timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04149106",
    "endpoint": "measure - Drug resistance marker prevalence in two 2 years period, description - prevalence of immunological markers for P. falciparum malaria, prevalence of molecular markers of drug resistance, timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04149106",
    "endpoint": "measure - SMC coverage and treatment compliance during malaria transmission season, description - total number of age eligible children sampled reporting to have received SMC and number of children who received SMC with drug metabolites in their blood divided by number of age eligible children in sample., timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00529867",
    "endpoint": "measure - To determine and compare Adequate Clinical and Parasitological Response (ACPR) at days 14 and 28, description - , timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00529867",
    "endpoint": "measure - To determine and compare proportion of children with gametocytes on days 0, 7, 14, and 28, description - , timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00529867",
    "endpoint": "measure - Monitor any possible adverse reactions following use of both drugs, description - , timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00282919",
    "endpoint": "measure - Percentage of Participants With Early Treatment Failures (ETF), description - ETF was defined as a participant meeting any of these criteria: development of signs of severe malaria (impaired consciousness [for example, obtundation, unarousable coma, delirium, stupor], respiratory distress [respiratory rate greater than or equal to {&gt;=} 30 breaths&#x2F;minute], seizures, hypoglycemia [glucose less than or equal to {&lt;=} 40 milligram&#x2F;deciliter], gross hematuria, increase in parasitemia to greater than 100,000 parasites&#x2F;microliter in 48 hours or later after the first treatment dose was administered) any day from Day 0 to 3 in the presence of P falciparum parasitemia; parasite count on Day 2 &gt; Day 0 (baseline), irrespective of axillary or oral temperature; parasite count on Day 3 &gt; 37.5 degrees Celsius (axillary temperature) and &gt;38 degrees Celsius (oral temperature) and parasite count on Day 3 &gt;=25 percent (%) of the first available parasite density on Day 0 (baseline)., timeFrame - Baseline up to Day 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00282919",
    "endpoint": "measure - Percentage of Participants With Late Treatment Failures (LTF), description - LTF included late clinical failure (LCF) and late parasitologic failure (LPF).\nLCF is defined as a participant meeting any of these criteria: development of signs or symptoms of severe malaria after Day 3 in the presence of P falciparum parasitemia, without previously meeting any of the criteria of ETF or presence of P falciparum parasitemia and fever or history of fever on any day from Day 4 to Day 28, without previously meeting any of the criteria of ETF.\nLPF is defined as presence of P falciparum parasitemia on any day from Day 7 to Day 28 and the absence of fever or history of fever without previously meeting any of the criteria of ETF or LCF., timeFrame - Baseline up to Day 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00282919",
    "endpoint": "measure - Percentage of Participants With Resistance to Treatment, description - Resistance is measured by clearance of asexual P falciparum parasitemia and categorized into 3 levels; resistance I (RI): clearance of asexual P. falciparum parasitemia before Day 7 followed by recurrence on or after Day 7, resistance II (RII): marked reduction (&lt;=25% of baseline) of asexual P. falciparum parasitemia but no clearance prior to and up to Day 7, and resistance III (RIII): no marked reduction (&gt;25% of baseline) of asexual P. falciparum parasitemia.\nRecurrence was defined as the reappearance of asexual P. falciparum parasitemia following a quiescent or latent period after the cessation of the primary attack.\nPercentage of participants with resistance as measured by RI, RII and RIII is reported., timeFrame - Days 7, 14, 21, 28, 35, 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00282919",
    "endpoint": "measure - Percentage of Participants With Clinical Cure, description - Clinical Cure is defined as resolution of the participant&#x27;s fever and other symptoms attributed to P falciparum malaria (for example, abdominal pain, malaise, and headache)., timeFrame - Day 3, 7, 28, and 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00282919",
    "endpoint": "measure - Percentage of Participants With Parasite Clearance at Day 7, 14, 21, 35, 42, description - Parasite clearance was defined as the clearance of asexual Plasmodium falciparum (P falciparum) parasitemia (defined as three consecutive 0 parasite counts) within 7 days of initiation of treatment, without subsequent recrudescence up to Day 28.\nFailure to achieve clearance of asexual P falciparum parasitemia was defined as parasitemia not cleared within 7 days of initiation of treatment, or subsequent recrudescence (confirmed by molecular testing) by Day 28 after achieving clearance.\nPercentage of participants with clearance is reported.\nHere &quot;N&quot; (Number of participants analyzed) signify participants who were evaluable (parasitological per protocol) at Day 28., timeFrame - Day 7, 14, 21, 35, 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00282919",
    "endpoint": "measure - Percentage of Participants With Gametocyte Clearance, description - Gametocyte clearance was defined as clearance of P falciparum gametocytemia (defined as attainment of 3 consecutive 0 gametocyte counts) without subsequent recurrence through the day of consideration.\nRecurrence was defined as the reappearance of asexual P. falciparum gametocytemia after achieving clearance.\nPercentage of participants with gametocyte clearance were reported., timeFrame - Day 7, 14, 21, 28, 35, 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00282919",
    "endpoint": "measure - Fever Clearance Time, description - Fever clearance time (FCT) was defined as the time from baseline to the first of 2 consecutive time points with temperature less than (&lt;) 37.5 degree Celsius (C) (axillary temperature) or &lt;38 degree C (oral temperature)., timeFrame - Baseline up to Day 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00282919",
    "endpoint": "measure - Parasite Clearance Time, description - Asexual P falciparum parasite clearance time was defined as the time from baseline to the first of the 3 consecutive 0 parasite counts., timeFrame - Baseline up to Day 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04516317",
    "endpoint": "measure - Mortality rates in the Group artesunate and Group quinine, description - Mortality reported as a mortality rate (%), timeFrame - At hospital discharge, an average of 1 month",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05790889",
    "endpoint": "measure - To assess the humoral immunogenicity of RH5.1 in Matrix-MTM and RH5.2-VLP in Matrix-MTM in 5-17 months old children living in a malaria-endemic area., description - <p>The following measures will be assessed</p><ul><li><p>Serum ELISA response:</p><p>1. Quantitative antigen-specific IgG antibody levels (µg&#x2F;mL readout) over time - analysis of peak responses and longevity; 2. Antigen-specific antibody subclass&#x2F;isotype measurement; 3. Antigen-specific antibody avidity measurement; In vitro GIA against 3D7 clone P. falciparum parasites using purified total IgG and a single-cycle pLDH readout assay</p></li><li>Purified IgG ELISA versus GIA titration &quot;Quality Analysis&quot;</li></ul>, timeFrame - Immunology blood samples will be collected at screening, day of vaccination (V) 1, 14 &amp; 28 days post V2, day of V3, 14 days post V3, 2, 6 and 12 months post V3.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05790889",
    "endpoint": "measure - To assess the protective efficacy against clinical malaria of RH5.1 in Matrix-MTM and RH5.2-VLP in Matrix-MTM in 5-17 months old children living in a malaria-endemic area for 3 months after the last vaccination., description - Time to first episode of clinical malaria (defined as the presence of axillary temperature ≥37.5°C and P. falciparum parasite density &gt;5000 asexual forms&#x2F;µL)., timeFrame - From 14 days after the third study vaccination until 3 months after the third study vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05790889",
    "endpoint": "measure - To assess the protective efficacy against clinical malaria of RH5.1 in Matrix-MTM and RH5.2-VLP in Matrix-MTM in 5-17 months old children living in a malaria-endemic area, description - Occurrence of solicited local reactogenicity signs and symptoms via clinic and home visits, timeFrame - For 12 months after the last vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05790889",
    "endpoint": "measure - To assess the protective efficacy against asymptomatic P. falciparum infection of RH5.1 in Matrix-MTM and RH5.2-VLP in Matrix-MTM in 5-17 months old children living in a malaria-endemic area, by qPCR., description - Efficacy tested by conducting qPCR analysis, timeFrame - At 6 and 12 months after administration of the final dose of vaccine.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05790889",
    "endpoint": "measure - To assess the protective efficacy against asymptomatic P. falciparum infection against gametocytaemia of RH5.1 in Matrix-MTM and RH5.2-VLP in Matrix-MTM in 5-17 months old children living in a malaria-endemic area, by qPCR., description - The proportion of participants in each study arm that show presence of parasite density &gt;5000 asexual forms&#x2F;µL as measured by quantitative reverse-transcriptase PCR PLUS presence of axillary temperature &lt;37.5°C and absence of history of fever within the last 24 hours.\nThe proportion of participants in each study arm that show presence of parasite density &gt;0 asexual forms&#x2F;µL as measured by quantitative reverse-transcriptase PCR PLUS presence of axillary temperature &lt;37.5°C and absence of history of fever within the last 24 hours., timeFrame - At 6 and 12 months post third study vaccination.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05790889",
    "endpoint": "measure - To assess the protective efficacy against clinical malaria of RH5.1 in Matrix-M and RH5.2-VLP in Matrix-M in 5-17 months old children living in a malaria-endemic area for 12 months after the last vaccination., description - Time to first episode of clinical malaria (defined as the presence of axillary temperature ≥37.5°C and P. falciparum parasite density &gt;5000 asexual forms&#x2F;µL)., timeFrame - From 14 days after the third study vaccination until 12 months after the third study vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05790889",
    "endpoint": "measure - To assess the protective efficacy against gametocytaemia of RH5.1 in Matrix-M and RH5.2-VLP in Matrix-M in 5-17 months old children living in a malaria-endemic area, by qPCR at 2 and 6 months after administration of the final dose of vaccine, description - The proportion of participants in each study arm that show presence of gametocytes &gt;0 gametocytes&#x2F;μL as measured by quantitative reverse-transcriptase PCR., timeFrame - At 2 and 6 months post third study vaccination.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05790889",
    "endpoint": "measure - Efficacy against incident severe anaemia and blood transfusion requirement, description - The proportion of participants in each study arm with documented Hb &lt;5.0 g&#x2F;dL identified at clinical presentation in association with P. falciparum asexual parasitaemia &gt; 5000 parasites&#x2F;µL.\nThe proportion of participants in each study arm with documented Hb &lt;5.0 g&#x2F;dL identified at clinical presentation and requirement for a blood transfusion., timeFrame - From 14 days after the third study vaccination until 6 months after the third study vaccination.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01081847",
    "endpoint": "measure - Immunogenicity assessment, description - Specific anti CS antibodies determination (B cell response) and specific induction of IFNγ production (T cell response).\nAll sera samples will be kept at -70° in Immunology Institute, FCVL or Asoclinic until use., timeFrame - 9 month",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01081847",
    "endpoint": "measure - Adverse Events, description - Each AE will be written on CRF forms and will be immediately be informed to the clinical monitor and IRB.\nAll volunteers will be followed until recovering it the initial condition.\nAdditional physical examination and laboratory tests will be performed in case any relation between the AE and the immunogen needs to be established., timeFrame - 9 month",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01081847",
    "endpoint": "measure - Safety Laboratories, description - Complete blood cell count, hepatic and renal function tests will be made on months 1, 2, 3, 6, 7 y 9 after the first immunization.\nEvery change in the laboratory results will be reported on the corresponding CRF´s; severity associated with vaccination will be established.\nSpecific studies will be made if it is necessary the AE end will be determined when these parameters will be normal., timeFrame - 8 month",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01081847",
    "endpoint": "measure - B-cell response, description - Specific antibody titers will be measured by ELISA technique using the corresponding peptide (N, R, C) as coating antigen and the recognition of the native protein will be assessed by Immunofluorescence technique (IFAT) using P vivax sporozoites obtained by dissection of experimentally infected Anopheles mosquitoes [91] Antibody titers will be considered as positive at 1:100 dilution by ELISA and 1:40 by IFAT., timeFrame - 8 month",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01081847",
    "endpoint": "measure - T-cell response evaluation, description - Cell mediated immune (CMI) responses will be evaluated will be made by the cytokines IFN-γ production using peripheral blood mononuclear cells (PBMC) using both ELIspot and ELISA techniques., timeFrame - 8 month",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01081847",
    "endpoint": "measure - Cytokine Production Evaluation by ELISA, description - PBMC will be stimulated with each of the three peptides (N, R or C) in a concentration of 10ug&#x2F;ml and cells cultures without the peptide will be used as negative control.\nPBMC stimulated with phyto-hemaglutinin (PHA) will be used as positive controls., timeFrame - 8 month",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01081847",
    "endpoint": "measure - Cytokine Production by ELIspot, description - This evaluation will be made in two phases: First the cytokine production in total PBMC, which will be stimulated with CS protein derived peptides of different length.\nSecond, positive samples for cytokine will be used to evaluate the production of cytokines by purified T lymphocytes subpopulations CD4+ or CD8+.\nThis will determine the subpopulation responsible for cytokine production.\nA positive selection of cell subpopulations will be performed using anti-CD4+ &#x2F; CD8+ coated pearls using MACS, and will be further used for ELIspot., timeFrame - 8 month",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03783299",
    "endpoint": "measure - Serology, description - Seropositivity to a panel of standard malaria parasite antigens for P. falciparum and P. vivax (including merozoite surface protein-1 (MSP-1) and apical membrane antigen-1 (AMA-1), will be used to examine both recent and medium-term exposures.\nThese data will also be mapped used captured global positioning system (GPS) coordinates to examine serological hotspots.\nFinally, novel antigens will also be used to further explore any differences in parasite exposure between study arms.\nVector exposure may also be explored using antigens to anopheline salivary proteins., timeFrame - 2 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03783299",
    "endpoint": "measure - Cost and cost effectiveness, description - For the costing portion of the study, the cost per case investigation conducted, cost per additional positive case identified using FTAT in village- and forest-based HRPs, and the cost per case actively detected per person screened during screen and treat.\nThe cost-effectiveness of screen and treat will also be compared between village-based activities and peer-navigator led testing., timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03783299",
    "endpoint": "measure - Sensitivity and specificity of HS-RDTs, description - The P. falciparum prevalence from all individuals tested with HS-RDTs will be compared with parallel results from standard RDTs (all field testing activities) and to subsequent PCR-based testing (cross-sectional survey, FTAT and MTAT subset).\nIn the latter case, the PCR-based result will serve as the gold standard for all comparisons.\nSensitivity and specificity and receiver operating curve (ROC) analyses will be conducted to assess the performance of the HS-RDTs in field situations, and in the presence of mixed-species infections.\nDBS will be collected for cross-sectional survey, FTAT and MTAT., timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00084227",
    "endpoint": "measure - tolerability and safety, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00137514",
    "endpoint": "measure - Genetic markers in parasites, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00137514",
    "endpoint": "measure - recrudescence rate, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00137514",
    "endpoint": "measure - re-infection rate, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02281344",
    "endpoint": "measure - Parasite Reduction Rate (PRR) Following MMV390048 Treatment, description - The clearance of malaria parasitemia by Polymerase Chain Reaction (PCR) measurement., timeFrame - From dosing up to Day 21 Post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02281344",
    "endpoint": "measure - MMV390048 Maximum Plasma Concentration (Cmax), description - Maximum Plasma Concentration (Cmax) of MMV390048, timeFrame - At pre-dose, and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, 24 (D1), 30, 36, 48 (D2), 72 (D3), and 144 hours (D6) and Days 8, 10, 14, 18 and D21.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02281344",
    "endpoint": "measure - MMV390048 Time to Maximum Plasma Concentration (Tmax), description - Time to Maximum Plasma Concentration (Tmax) of MMV390048, timeFrame - From dosing up to Day 21 Post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03867331",
    "endpoint": "measure - Anti-CSP IgG levels measured by ELISA, description - , timeFrame - day 113 after third dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03867331",
    "endpoint": "measure - Positive thick blood smear test for P. falciparum malaria following CHMI, description - , timeFrame - day 6 to day 20 post challenge",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03867331",
    "endpoint": "measure - Time to first positive thick blood smear test for P. falciparum following CHMI, description - Number of subjects with Plasmodium Falciparum parasitemia defined by a positive blood slide, following sporozoite challenge, timeFrame - day 6 to day 20 post challenge",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03867331",
    "endpoint": "measure - Percentage of participants with a minimum threshold of &gt;20 μg&#x2F;ml anti-CSP IgG after vaccination as measured by ELISA., description - , timeFrame - day 15 to post day 113 after third dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00344006",
    "endpoint": "measure - Parasitological cure rate, PCR-corrected, at day 14 and 42 ACPR, and ACPR PCR corrected at day 14, 28 and 42 Summary of asexual parasite densities on days 0, 1, 2, 3, 7, 14, 28 and 42 by treatment group., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02851108",
    "endpoint": "measure - Gametocyte Prevalence, description - measured microscopically at baseline and on day 1, 2, 3, 7, 14, and 28 of follow-up, timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02851108",
    "endpoint": "measure - Adverse Events (AE), description - Reports of observed or self-reported adverse event, timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02851108",
    "endpoint": "measure - Mothers&#x2F;Caretakers Questionnaire on Acceptance, description - Acceptance of the different treatment regimens by mothers&#x2F;caretakers, timeFrame - 14 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02851108",
    "endpoint": "measure - Gametocyte Density, description - measured microscopically at baseline and on day 1, 2, 3, 7, 14, and 28 of follow-up, timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05270265",
    "endpoint": "measure - Assessment of the humoral immunogenicity of the Pvs25-IMX313&#x2F;Matric-M1 vaccine, when administered to healthy adult volunteers as assessed by humoral responses to the Pvs25 protein, description - Antibody responses to the Pvs25 protein will be assessed through total IgG isotypes and avidity, timeFrame - Days 1, 29, 57, 140 and 240.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05270265",
    "endpoint": "measure - Assessment of the cellular immunogenicity of the Pvs25-IMX313&#x2F;Matrix-M1 vaccine, when administered to healthy adult volunteers as assessed by cellular responses to the Pvs25 protein., description - T cell responses to Pvs25 will be assessed by ex vivo enzyme-linked immunospot assays (ELISpot) and flow cytometry assays., timeFrame - Days 1, 29, 57, 140 and 240.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05270265",
    "endpoint": "measure - Assessment of ex vivo efficacy of the Pvs25-IMX313&#x2F;Matrix-M1 vaccine when administered to healthy adult volunteers using direct membrane feeding assays as assessed by transmission-reducing activity., description - Transmission-reducing activity, timeFrame - Days 1, 29, 57, 140 and 240.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05270265",
    "endpoint": "measure - Assessment of ex vivo efficacy of the Pvs25-IMX313&#x2F;Matrix-M1 vaccine when administered to healthy adult volunteers using direct membrane feeding assays as assessed by transmission-blocking activity., description - Transmission-blocking activity, timeFrame - Days 1, 29, 57, 140 and 240.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00677833",
    "endpoint": "measure - Percentage of Participants With PCR-corrected ACPR in the mITT Population, description - ACPR (PCR-corrected) was defined as asexual P.falciparum parasitologic clearance on Days 7, 14, 21, 35, 42 irrespective of axillary, oral, rectal, or tympanic temperature, without previously meeting the criteria of ETF (see measure description in secondary outcome measures 7 and 8) or PCR-corrected LTF (which includes PCR-Corrected LCF- see measure description in secondary outcome measure 9 and 10, and PCR-corrected LPF - see measure description in secondary outcome measure 11 and 12).\nPCR-corrected refers to the use of molecular testing to differentiate recrudescence from reinfection in the context of an efficacy evaluation., timeFrame - Days 7, 14, 21, 35, 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00677833",
    "endpoint": "measure - Percentage of Participants With PCR-corrected ACPR in PP Population, description - ACPR (PCR-corrected) was defined as asexual P.falciparum parasitologic clearance on Days 7, 14, 21, 35, 42 irrespective of axillary, oral, rectal, or tympanic temperature, without previously meeting the criteria of ETF (see measure description in secondary outcome measures 7 and 8) or PCR-corrected LTF (which includes PCR-corrected LCF - see measure description in secondary outcome measure 9 and 10, and PCR-corrected LPF - see measure description in secondary outcome measure 11 and 12).\nPCR-corrected refers to the use of molecular testing to differentiate recrudescence from reinfection in the context of an efficacy evaluation., timeFrame - Days 7, 14, 21, 35, 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00677833",
    "endpoint": "measure - Percentage of Participants With PCR-uncorrected ACPR in the mITT Population, description - ACPR (PCR-uncorrected) was defined as asexual P.falciparum parasitologic clearance on Days 7, 14, 21, 28, 35, 42 irrespective of axillary, oral, rectal, or tympanic temperature, without previously meeting the criteria of ETF (see measure description in secondary outcome measures 7 and 8) or PCR-uncorrected LTF (which includes PCR-uncorrected LCF - see measure description in secondary outcome measure 9 and 10, and PCR-uncorrected LPF - see measure description in secondary outcome measure 11 and 12).\nPCR-uncorrected: not adjusted for molecular testing which determined recrudescence or true failures from reinfection., timeFrame - Days 7, 14, 21, 28, 35, 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00677833",
    "endpoint": "measure - Percentage of Participants With PCR-uncorrected ACPR in PP Population, description - ACPR (PCR-uncorrected) was defined as asexual P.falciparum parasitologic clearance on Days 7, 14, 21, 28, 35, 42 irrespective of axillary, oral, rectal, or tympanic temperature, without previously meeting the criteria of ETF (see measure description in secondary outcome measures 7 and 8) or PCR-uncorrected LTF (which includes PCR-uncorrected LCF - see measure description in secondary outcome measure 9 and 10, and PCR-uncorrected LPF - see measure description in secondary outcome measure 11 and 12).\nPCR-uncorrected: not adjusted for molecular testing which determined recrudescence or true failures from reinfection., timeFrame - Days 7, 14, 21, 28, 35, 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00677833",
    "endpoint": "measure - Percentage of Participants With Early Treatment Failure (ETF) in the mITT Population (PCR-corrected), description - <p>ETF defined as participants who met the following criteria:</p><ol><li>Developed signs of severe malaria or clinical deterioration that required rescue medication on Days 0, 1, 2 or 3, in the presence of P. falciparum parasitemia</li><li>Last available asexual P. falciparum parasite count on Day 2 greater than the first available parasite count on Day 0 (Baseline), irrespective of axillary, oral or rectal temperature.</li><li>Parasitemia (P.\nfalciparum) on Day 3 with fever or</li><li>Last available P. falciparum parasite count on Day 3 &gt;=25% of the first available parasite count on Day 0 (Baseline).</li></ol><p>PCR-corrected refers to the use of molecular testing to differentiate recrudescence from reinfection in the context of an efficacy evaluation.</p>, timeFrame - Day 0 up to Day 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00677833",
    "endpoint": "measure - Percentage of Participants With ETF in PP Population (PCR-corrected), description - <p>ETF defined as participants who met the following criteria:</p><ol><li>Developed signs of severe malaria or clinical deterioration that required rescue medication on Days 0, 1, 2 or 3, in the presence of P.falciparum parasitemia</li><li>Last available asexual P.falciparum parasite count on Day 2 greater than the first available parasite count on Day 0 (Baseline), irrespective of axillary, oral or rectal temperature.</li><li>Parasitemia (P.falciparum) on Day 3 with fever or</li><li>Last available P.falciparum parasite count on Day 3 &gt;=25% of the first available parasite count on Day 0 (Baseline).</li></ol><p>PCR-corrected refers to the use of molecular testing to differentiate recrudescence from reinfection in the context of an efficacy evaluation.</p>, timeFrame - Day 0 up to Day 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00677833",
    "endpoint": "measure - Percentage of Participants With Late Clinical Failure (LCF) in the mITT Population (PCR-corrected), description - <p>LCF included participants who met any of the following criteria:</p><ol><li>Development of signs of severe malaria or clinical deterioration requiring rescue medication after Day 3 in the presence of P.falciparum parasitemia, without previously meeting any of the criteria of ETF (see measure description in secondary outcome measures 7 and 8)</li><li>Presence of P.falciparum parasitemia and fever on any day from Day 4 onward, without previously meeting any of the criteria of ETF (see measure description in secondary outcome measures 7 and 8).\nPCR-corrected refers to the use of molecular testing to differentiate recrudescence from reinfection in the context of an efficacy evaluation.</li></ol>, timeFrame - Days 7, 14, 21, 28, 35, 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00677833",
    "endpoint": "measure - Percentage of Participants With LCF in PP Population (PCR-corrected), description - <p>LCF included participants who met any of the following criteria:</p><ol><li>Development of signs of severe malaria or clinical deterioration requiring rescue medication after Day 3 in the presence of P.falciparum parasitemia, without previously meeting any of the criteria of ETF (see measure description in secondary outcome measures 7 and 8)</li><li>Presence of P.falciparum parasitemia and fever on any day from Day 4 onward, without previously meeting any of the criteria of ETF (see measure description in secondary outcome measures 7 and 8).\nPCR-corrected refers to the use of molecular testing to differentiate recrudescence from reinfection in the context of an efficacy evaluation.</li></ol>, timeFrame - Days 7, 14, 21, 28, 35, 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00677833",
    "endpoint": "measure - Percentage of Participants With Late Parasitologic Failure (LPF) in the mITT Population (PCR-corrected), description - LPF: Presence of P. falciparum parasitemia in the mITT population on any day from Day 7 onward and the absence of fever without previously meeting any of the criteria of ETF (see measure description in secondary outcome measures 7 and 8) or LCF (see measure description in secondary outcome measure 9 and 10).\nPCR-corrected refers to the use of molecular testing to differentiate recrudescence from reinfection in the context of an efficacy evaluation., timeFrame - Days 7, 14, 21, 28, 35, 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00677833",
    "endpoint": "measure - Percentage of Participants With LPF in PP Population (PCR-corrected), description - LPF: Presence of P.falciparum parasitemia in the PP population on any day from Day 7 onward and the absence of fever without previously meeting any of the criteria of ETF (see measure description in secondary outcome measures 7 and 8) or LCF (see measure description in secondary outcome measure 9 and 10).\nPCR-corrected refers to the use of molecular testing to differentiate recrudescence from reinfection in the context of an efficacy evaluation., timeFrame - Days 7, 14, 21, 28, 35, 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00677833",
    "endpoint": "measure - Percentage of Participants With Asexual Parasitologic Response (PCR-corrected), description - Percentage of participants who were cleared of asexual parasites.\nAsexual parasite clearance - clearance of asexual P.falciparum parasitemia within 7 days of initiation of treatment without subsequent recurrence (PCR-corrected) through the day of consideration.\nPCR-corrected refers to the use of molecular testing to differentiate recrudescence from reinfection in the context of an efficacy evaluation., timeFrame - Day 7, 14, 21, 28, 35, 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00677833",
    "endpoint": "measure - Percentage of Participants With Gametocytologic Response, description - Gametocyte response&#x2F;absence&#x2F;clearance: Clearance of P.falciparum gametocytemia (PCR-uncorrected) (attainment of 2 consecutive zero gametocyte counts) without subsequent recurrence through the day of consideration.\nPCR-uncorrected: not adjusted for molecular testing which determined recrudescence or true failures from reinfection., timeFrame - Days 7, 14, 21, 28, 35, 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00677833",
    "endpoint": "measure - Fever Clearance Time, description - Calculated as time of first occurrence of two consecutive time points with temperature less than (&lt;) 38.0 degrees C&#x2F;100.4 degrees Fahrenheit (F) (rectal), 37.2 degrees C&#x2F;99.0 degrees F (axillary), or &lt;37.5 degrees C&#x2F;99.5 degrees F (oral)., timeFrame - Baseline to Day 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00677833",
    "endpoint": "measure - Asexual Plasmodium Falciparum Parasite Clearance Time, description - Defined as time to first of two consecutive zero asexual P. falciparum parasite (PCR-corrected) counts, regardless of recurrence of parasitemia later.\nPCR-corrected refers to the use of molecular testing to differentiate recrudescence from reinfection in the context of an efficacy evaluation., timeFrame - Baseline to Day 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00677833",
    "endpoint": "measure - Nadir Hemoglobin Level, description - Nadir hemoglobin for each participant was defined as the minimum hemoglobin values obtained from Day 0 through Day 3., timeFrame - Day 0 through Day 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00677833",
    "endpoint": "measure - Change From Nadir Hemoglobin Level at Days 14, 28, and 42, description - Change from nadir = observation minus nadir.\nNadir defined as the minimum value for each participant on Days 0-3., timeFrame - Day 14, 28, 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00677833",
    "endpoint": "measure - Time to Recurrence of Parasitemia, description - Time from the day of clearance to the time of recurrence of asexual P.falciparum parasitemia (PCR-uncorrected)., timeFrame - Baseline (Day 0) to Day 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00677833",
    "endpoint": "measure - Number of Participants With Recurrent Parasitemia Versus Baseline Plasmodium Falciparum Chloroquine Resistance Transporter (PfCRT) Status, description - , timeFrame - Baseline to Day 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00677833",
    "endpoint": "measure - Percentage of Participants With PfCRT in True Failures, description - A genetic marker, P.falciparum chloroquine resistance transporter (PfCRT), indicative of P.falciparum chloroquine resistance was to be determined from blood blots obtained on Day 0 and at the time of treatment failure.\nTreatment failure was defined as any of the following events that a participant experienced from Day 0 through the Day 42 visit: ETF (see measure description in secondary outcome measures 7 and 8), LCF (PCR corrected) (see measure description in secondary outcome measure 9 and 10), or LPF (PCR corrected) (see measure description in secondary outcome measure 11 and 12).\nRecrudescence of asexual P.falciparum parasites was considered treatment failure., timeFrame - Baseline to Day 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04176029",
    "endpoint": "measure - Proportion of children that fulfill the criteria for a new pulmonary diagnosis &gt;6 hours from admission., description - Proportion of children without respiratory symptoms and a normal lung on lung ultrasound on admission that fulfil the criteria for a new pulmonary diagnosis &gt;6h from admission., timeFrame - From admission to discharge, aproximately 1 week",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04176029",
    "endpoint": "measure - Median lung ultrasound score, description - Median lung ultrasound score (range 0 to 36) on the first lung ultrasound performed after admission., timeFrame - On the day of hospital admission",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04176029",
    "endpoint": "measure - Percentage agreement between a positive lung auscultation (bilateral crepitations) and a lung ultrasound consistent with pulmonary oedema., description - Percentage agreement between a positive lung auscultation (bilateral crepitations) and a lung ultrasound consistent with pulmonary oedema., timeFrame - From hospital admission to discharge, aproximately 1 week",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04176029",
    "endpoint": "measure - Hospital mortality and 30 days mortality, description - Mortality rate in children with severe malaria suffering from a pulmonary complication at admission or during hospitalization and 30 day follow up., timeFrame - On hospital discharge, maximum 30 days after admission to hospital",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00371735",
    "endpoint": "measure - The proportion of subjects with parasites remaining at 24 hours post-first dose by treatment group. Parasitological cure rate, PCR-corrected, at day 14, by treatment group., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05125133",
    "endpoint": "measure - Prevalence of Plasmodium falciparum parasite., description - Prevalence of plasmodium falciparum parasite in households&#x27; residents of over 6 months old with ITENs &amp; ITWS compared to those without using qPCR analysis., timeFrame - Approximately 6 months post-installation, coinciding with the short rainy season.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05125133",
    "endpoint": "measure - Clinical malaria., description - The prevalence of clinical malaria cases defined by an axillary temperature of 37.5 degrees (fever) and positive mRDT in houses with ITENs and ITWS compared to the houses without., timeFrame - Approximately 6 months and 12 months post-installation, coinciding with the rainy seasons.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05125133",
    "endpoint": "measure - The density of malaria vectors and nuisance mosquitoes density., description - Indoor density of malaria vector and nuisance mosquitoes in houses with ITENs &amp; ITWS compared to houses without measured using Centres for Disease Control (CDC) light traps., timeFrame - Approximately 6 months and 12 months post-installation, coinciding with the rainy seasons.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05125133",
    "endpoint": "measure - ITENs &amp; ITWS fabric cost, description - The number of metres of material applied to houses., timeFrame - Baseline (During installation of ITENs &amp; ITWS)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05125133",
    "endpoint": "measure - ITENS &amp; ITWS time duration, description - Time in hours to install the intervention., timeFrame - Baseline (During installation of ITENs &amp; ITWS)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05125133",
    "endpoint": "measure - Adverse effects, description - The number of participants with perceived adverse effects from ITENs and ITWS., timeFrame - Approximately one month post installation.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05125133",
    "endpoint": "measure - Attrition, description - Determination of the physical presence of ITENs and ITWS in the field., timeFrame - Appriximately 6 months and 12 months post installation.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05125133",
    "endpoint": "measure - Fabric integrity, description - Determination of the number of holes in ITENs and ITWS in the field., timeFrame - Appriximately 6 months and 12 months post installation.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05125133",
    "endpoint": "measure - The induced mosquito mortality of ITENs and ITWs on the population of laboratory-reared mosquitoes., description - The bioefficacy (% induced mosquito mortality) of ITENs and ITWS after field use through WHO bioassays., timeFrame - Approximately 12 months post installation.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05125133",
    "endpoint": "measure - Insecticide retainment, description - The retention of deltamethrin and PBO in grams per kg will be assessed through high performance liquid chromatography., timeFrame - Appriximately 12 months post installation.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05125133",
    "endpoint": "measure - Use of ITENs and ITWS, description - Community opinions of ITENs and ITWS will be sought through questionnaires and Focus Group Discussions., timeFrame - Approximately 6 months and 12 months post installation.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04739917",
    "endpoint": "measure - Concentration of specific anti-PvCS IgG antibodies IgG (isotypes) against the different functional fragments of the Pv-CS protein., description - <p>Concentration of specific anti-PvCS IgG antibodies IgG (isotypes) against the different functional fragments of the Pv-CS protein (Amino, Central Repeat and Carboxilo terminal).\nExpressed both as antibody titers and Reactive Indices (RI) measured by in enzyme-linked immunosorbent assay (ELISA) and Immunofluorescence Test (IFAT).\nAntibody titers by IFAT are determine as the reciprocal of the end-points dilution showing a positive fluorescence.</p><p>Concentrations will be presented as geometric mean concentrations (GMCs).</p>, timeFrame - Days 0, 30, 60, 90, 120, 180, 210 and 240.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04739917",
    "endpoint": "measure - Specific cytokine induction, description - Specific cytokine induction will be measured by IFN- γ, TNF-α, IL-2; IL- 4, IL-6, IL-10, timeFrame - Days 0, 30, 60, 90, 120, 180, 210 and 240.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04739917",
    "endpoint": "measure - T-cell response measurement - Flow cytometry, description - In vitro proliferation of CD3+ T-cells (CD4+ and CD8+) and intracellular production of cytokines IFN-gamma, TNF-a, IL-12 by flow cytometry.\nResult will be expressed as percentages., timeFrame - Days 0, 30, 60, 90, 120, 180, 210 and 240.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04739917",
    "endpoint": "measure - T-cell response measurement - ELIspot, description - Production of IFN-gamma and IL-10 in total PBMC stimulated with the different antigens and &#x2F; or synthetic peptides by ELIspot assay.\nResults expressed as the mean number of IFN-γ spot-forming cells (sfc) per 106 Peripheral Blood Mononuclear Cells., timeFrame - Days 0, 30, 60, 90, 120, 180, 210 and 240.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04739917",
    "endpoint": "measure - T-cell response measurement - Bioplex, description - Multiplex cytokines profile (Th1&#x2F;Th2&#x2F;Treg) in sera by bioplex.\nCytokine concentrations were calculated from the standard curve using seven-parameter curve fitting software and the results were expressed in pg&#x2F;mL.\nThe limit of detection for the assay was 10 pg&#x2F;mL for all cytokines.\nResults will be expressed as percentages., timeFrame - Days 0, 30, 60, 90, 120, 180, 210 and 240.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04739917",
    "endpoint": "measure - Characterization of T lymphocytes, description - Phenotyping and profiles of memory T lymphocytes will be done in PBMCs using specific panels of markers by flow cytometry.\nThe frequency of cells as a biomarker post CHMI infection will be performed.\nCells will be stained by using different antibody cocktails targeting specific cell populations.\nCells acquisition will be done on a 4-laser BD flow cytometer and gating analysis with FlowJo software version 10.4.2.\nResults will be expressed as percentages., timeFrame - Days 0, 30, 60, 90, 120, 180, 210 and 240.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04739917",
    "endpoint": "measure - Characterization of B lymphocytes., description - Phenotyping and profiles of B lymphocytes will be done in PBMCs using specific panels of markers by flow cytometry.\nThe frequency of cells as a biomarker post CHMI infection will be performed.\nCells will be stained by using different antibody cocktails targeting specific cell populations.\nCells acquisition will be done on a 4-laser BD flow cytometer and gating analysis with FlowJo software version 10.4.2.\nResults will be expressed as percentages., timeFrame - Days 0, 30, 60, 90, 120, 180, 210 and 240",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04739917",
    "endpoint": "measure - Characterization of monocytes, description - Phenotyping and profiles of monocytes will be done in PBMCs using specific panels of markers by flow cytometry.\nThe frequency of cells as a biomarker post CHMI infection will be performed.\nCells will be stained by using different antibody cocktails targeting specific cell populations.\nCells acquisition will be done on a 4-laser BD flow cytometer and gating analysis with FlowJo software version 10.4.2.\nResults will be expressed as percentages., timeFrame - Days 0, 30, 60, 90, 120, 180, 210 and 240.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04739917",
    "endpoint": "measure - Antibody functionality in vitro through inhibition of sporozoite invasion (ISI) to Hep-G2 cells., description - Antibody functionality will be tested in vitro through essays of inhibition of sporozoite invasion (ISI) to Hep-G2 cells., timeFrame - Days 0, 30, 60, 90, 120, 180, 210 and 240.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04739917",
    "endpoint": "measure - Vaccine-induced protection for P. vivax, description - Vaccine-induced protection for P. vivax will be assessed by pre-patent period onset after infected mosquito bites exposure, timeFrame - Thirty days after mosquito bite challenge (Controlled Human Malaria Infection)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04739917",
    "endpoint": "measure - Multiomics testing (i.e., transcriptomics, genomics), description - <p>Tthe present study also seeks to evaluate host-related variables, especially those affected by the immune status prior to vaccination (naïve vs pre-immune participants).</p><p>To accomplish this, transcriptomics and genomics tests will be undertaken on days 0, 30, 195 and, 225.</p>, timeFrame - Days 0, 30, 90, 195 and 225.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04739917",
    "endpoint": "measure - Safety - Number of Subjects With Any and Grade 3 Solicited Local Symptoms, description - Assessed solicited local symptoms will be pain and swelling.\nAny = occurrence of the symptom regardless of intensity grade.\nGrade 3 pain = pain that prevented normal activity.\nGrade 3 swelling = swelling spreading beyond 20 millimeters (mm) of injection site., timeFrame - During the 7-day (Days 0-6) post-vaccination period following each dose and across doses",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04739917",
    "endpoint": "measure - Safety - Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms, description - <p>Assessed solicited general symptoms will be drowsiness, fever [defined as axillary temperature equal to or above (≥) 37.5 degrees Celsius (°C)], irritability and loss of appetite.</p><p>Any = occurrence of the symptom regardless of intensity grade.\nGrade 3 symptom = symptom that prevented normal activity.</p><p>Grade 3 fever = fever higher than (&gt;) 39.0 °C.\nRelated = symptom assessed by the investigator as related to the vaccination.</p>, timeFrame - During the 7-day (Days 0-6) post-vaccination period following each dose and across doses",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04739917",
    "endpoint": "measure - Safety - Number of Subjects With Any Unsolicited Adverse Events (AEs), description - <p>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</p><p>Any will be defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.</p>, timeFrame - Within the 30-day (Days 0-29) post-vaccination follow-up period",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04739917",
    "endpoint": "measure - Safety - Number of Subjects With Serious Adverse Events (SAEs), description - Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability&#x2F;incapacity., timeFrame - Throughout the study period (Day 0 - Month 14)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04739917",
    "endpoint": "measure - Safety - Number of Subjects With Hemoglobin Values Outside Normal Ranges With Toxicity Grades, description - Toxicity levels will be measured according to the Common Terminology Criteria for Adverse Events (CTCAE).\nVersion 5.0., timeFrame - Days 0, 30, 60, 90, 120, 180, 210 and 240.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04739917",
    "endpoint": "measure - Safety - Number of Subjects With White Blood Cell (WBC) Values Outside Normal Ranges With Toxicity Grades, description - Toxicity levels will be measured according to the Common Terminology Criteria for Adverse Events (CTCAE).\nVersion 5.0., timeFrame - Days 0, 30, 60, 90, 120, 180, 210 and 240.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04739917",
    "endpoint": "measure - Safety - Number of Subjects With Platelet Values Outside Normal Ranges With Toxicity Grades, description - Toxicity levels will be measured according to the Common Terminology Criteria for Adverse Events (CTCAE).\nVersion 5.0., timeFrame - Days 0, 30, 60, 90, 120, 180, 210 and 240.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04739917",
    "endpoint": "measure - Safety - Number of Subjects With Alanine Aminotransferase (ALT) Values Outside Normal Ranges With Toxicity Grades, description - Toxicity levels will be measured according to the Common Terminology Criteria for Adverse Events (CTCAE).\nVersion 5.0., timeFrame - Days 0, 30, 60, 90, 120, 180, 210 and 240.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04739917",
    "endpoint": "measure - Safety - Number of Subjects With Creatinine Values Outside Normal Ranges With Toxicity Grades, description - Toxicity levels will be measured according to the Common Terminology Criteria for Adverse Events (CTCAE).\nVersion 5.0., timeFrame - Days 0, 30, 60, 90, 120, 180, 210 and 240.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04739917",
    "endpoint": "measure - Safety - Number of Subjects With Bilirubin Values Outside Normal Ranges With Toxicity Grades, description - Toxicity levels will be measured according to the Common Terminology Criteria for Adverse Events (CTCAE).\nVersion 5.0., timeFrame - Days 0, 30, 60, 90, 120, 180, 210 and 240.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04739917",
    "endpoint": "measure - Safety - Number of Subjects With Alkaline phosphatase Values Outside Normal Ranges With Toxicity, description - Toxicity levels will be measured according to the Common Terminology Criteria for Adverse Events (CTCAE).\nVersion 5.0., timeFrame - Days 0, 30, 60, 90, 120, 180, 210 and 240.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04739917",
    "endpoint": "measure - Safety - Number of Subjects With Blood urea nitrogen (BUN) Values Outside Normal Ranges With Toxicity, description - Toxicity levels will be measured according to the Common Terminology Criteria for Adverse Events (CTCAE).\nVersion 5.0., timeFrame - Days 0, 30, 60, 90, 120, 180, 210 and 240.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04739917",
    "endpoint": "measure - Safety - Number of Subjects With Aspartate aminotransferase (AST) Values Outside Normal Ranges With Toxicity, description - Toxicity levels will be measured according to the Common Terminology Criteria for Adverse Events (CTCAE).\nVersion 5.0., timeFrame - Days 0, 30, 60, 90, 120, 180, 210 and 240.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04739917",
    "endpoint": "measure - Safety - Number of Subjects With Prothrombin time (PT)) Values Outside Normal Ranges With Toxicity, description - Toxicity levels will be measured according to the Common Terminology Criteria for Adverse Events (CTCAE).\nVersion 5.0., timeFrame - Days 0, 30, 60, 90, 120, 180, 210 and 240.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04739917",
    "endpoint": "measure - Safety - Number of Subjects With Partial thromboplastin time (PTT) Values Outside Normal Ranges With Toxicity, description - Toxicity levels will be measured according to the Common Terminology Criteria for Adverse Events (CTCAE).\nVersion 5.0., timeFrame - Days 0, 30, 60, 90, 120, 180, 210 and 240.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04739917",
    "endpoint": "measure - Safety - Number of participants with confirmed pregnancy, description - Number of participants with confirmed pregnancy during the study duration., timeFrame - Days 0, 30, 60, 90, 120, 180, 210 and 240.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04739917",
    "endpoint": "measure - Safety - Glucose-6-phosphate dehydrogenase deficiency, description - Glucose-6-phosphate dehydrogenase deficiency test will be done during baseline evaluation., timeFrame - Day 0.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02691910",
    "endpoint": "measure - Late clinical failure, description - danger signs or severe malaria in the presence of parasitaemia on any day between day 4 and day 28 OR parasitaemia on any day between day 4 and day 28 with axillary temperature ≥ 37.5 ºC (or history of fever) in patients who did not previously meet any of the criteria of early treatment failure, timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02691910",
    "endpoint": "measure - Late parasitological failure, description - presence of parasitaemia on any day between day 7 and day 28 with axillary temperature &lt; 37.5 ºC in patients who did not previously meet any of the criteria of early treatment failure or late clinical failure, timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06967519",
    "endpoint": "measure - Average change in glucose sensor readings, description - Change in average of continuous glucose monitor readings over the last 10 days.\n(Cohorts 1 vs 2), timeFrame - every 6 months up to 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06967519",
    "endpoint": "measure - Change in insulin resistance (HOMA-IR), description - Change in HOMA-IR in those living with and without HIV.\n(Cohorts 1+3 vs 2+4), timeFrame - baseline and 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06967519",
    "endpoint": "measure - Change in Body Mass Index (BMI), description - Change in BMI in children living with HIV from baseline and 2 years in kg&#x2F;m² (Cohort 1 vs 3), timeFrame - baseline and 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06967519",
    "endpoint": "measure - Pharmacokinetic parameters, description - AUC (0-8h) and AUC (last) for lumefantrine and DEAQ.\n(Cohorts 1 and 3), timeFrame - immediately post drug exposure (Day 1)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06967519",
    "endpoint": "measure - Change in HIV viral load, description - Change of HIV viral load suppression in those on DTG vs children not living with HIV.\n(Cohorts 1 vs 3), timeFrame - every 6 months up to 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06967519",
    "endpoint": "measure - Malaria treatment outcome, description - 28 and 42 day antimalarial treatment efficacy in those on DTG vs Children not living with HIV, as measured by peripheral blood smears, timeFrame - 28 days and 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06967519",
    "endpoint": "measure - HIV genotypic resistance to DTG, description - Resistance to DTG (binary measures as yes&#x2F;no) as measured by HIV molecular genotype (Cohort 1 and 3), timeFrame - baseline and 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06967519",
    "endpoint": "measure - Artemisinin PK concentration-time profile, description - Area under the plasma concentration versus time curve (AUC) in those receiving AL vs AS-AQ.\n(Cohorts 3 and 4), timeFrame - During treatment of malaria episodes over 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06967519",
    "endpoint": "measure - Rate of parasite clearance, description - Parasite clearance half-life in those treated with AL vs AS-AQ.\n(Cohorts 3 and 4), timeFrame - During treatment of malaria episodes over 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06967519",
    "endpoint": "measure - Rate of parasite clearance and HIV, description - Parasite clearance half-life in those living with HIV and those not living with HIV.\n(Cohorts 3 and 4), timeFrame - During treatment of malaria episodes over 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06967519",
    "endpoint": "measure - Gametocyte quantity, description - Quantity of gametocytes in the peripheral blood in those treated artemisinin sensitive vs resistant infections.\n(Cohorts 3 and 4), timeFrame - At the time of presentation with malaria up to 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02876549",
    "endpoint": "measure - Percentage of P. vivax patients receiving a correct primaquine prescription after G6PD testing compared to using phenotype as gold standard, description - , timeFrame - 3 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02876549",
    "endpoint": "measure - Level of primaquine metabolite in dried blood spots collected after treatment, description - Day 2, 7, 14, timeFrame - 2, 7 and 14 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02876549",
    "endpoint": "measure - Level of whole blood carboxyprimaquine at day 7, description - , timeFrame - 7 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02876549",
    "endpoint": "measure - Level of whole blood carboxyprimaquine at day 14, description - , timeFrame - 14 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02876549",
    "endpoint": "measure - The degree to which healthcare workers act appropriately on the results of G6PD testing in terms of primaquine prescription, description - , timeFrame - 3 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02876549",
    "endpoint": "measure - Barriers to long-term use of the approach based on a qualitative questionnaire-based survey, description - , timeFrame - 3 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00304980",
    "endpoint": "measure - Tolerability, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00304980",
    "endpoint": "measure - Clinical recovery, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00730782",
    "endpoint": "measure - Biological Safety, description - , timeFrame - 28 days after each vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00730782",
    "endpoint": "measure - Humoral and Cellular immunogenicity, description - , timeFrame - until 365 days after the first immunisation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02646410",
    "endpoint": "measure - malaria parasitemia, description - Parasite prevalence defined as the proportion of children with a positive malaria blood smear and parasite density, timeFrame - one week before the first round of SMC and 4-6 weeks after the last round of SMC",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02646410",
    "endpoint": "measure - moderate anemia, description - Prevalence of moderate anemia defined as hemoglobin concentration &lt; 8 g&#x2F;dL measured by hemoglobin analyzer, timeFrame - one week before the first round of SMC and 4-6 weeks after the last round of SMC",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02646410",
    "endpoint": "measure - immune response to malaria parasite, description - Cellular and humoral antimalarial immune responses to malaria parasites, timeFrame - one week before the first round of SMC and 4-6 weeks after the last round of SMC",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02646410",
    "endpoint": "measure - molecular markers of resistance to SP + AQ, description - Frequency of mutations at codons 51, 59, and 108 of the dhfr gene, 437 and 540 of the dhps gene, codon 76 in the P. falciparum chloroquine transporter gene (pfcrt), and codon 86 of the P. falciparum multidrug resistance gene one (pfmdr1)., timeFrame - one week before the first round of SMC and 4-6 weeks after the last round of SMC",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02646410",
    "endpoint": "measure - nutritional status, description - Prevalence of wasting stunting and underweight as defined by WHO Global database on Child Growth and Malnutrition, timeFrame - one week before the first round of SMC and 4-6 weeks after the last round of SMC",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02646410",
    "endpoint": "measure - Clinical malaria in Year 1, description - Clinical malaria defined as signs and symptoms suggestive of malaria with positive RDT and&#x2F;or positive blood smear., timeFrame - up to 4 weeks after the last round of SMC",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03797989",
    "endpoint": "measure - Safety of Secondary and Tertiary P. Vivax Controlled Blood-stage CHMI as Measured by (S)AE Occurrences, description - , timeFrame - 36 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03797989",
    "endpoint": "measure - Immune Response to Primary, Secondary and Tertiary P. Vivax Pre-treatment, description - As measured by antibody, B cell and T cell responses through experimental injection of P. vivax infected erythrocytes, timeFrame - 36 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03797989",
    "endpoint": "measure - Gametocytaemia, description - As measured by qPCR in primary, secondary and tertiary P. vivax blood-stage CHMI., timeFrame - 36 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03797989",
    "endpoint": "measure - Feasibility of Secondary and Tertiary P. Vivax Controlled Blood-stage CHMI as Measured by Successful Infection (Development of Detectable Persistent Parasitaemia by Thick Film and qPCR +&#x2F;- Clinical Symptoms), description - , timeFrame - 36 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03797989",
    "endpoint": "measure - Transmissibility of Gametocytes From the Infected Volunteer to Anopheline Mosquito Vector, Which Will be Assesed by Direct Membrane Feeding Assays (DMFA), description - , timeFrame - 36 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00682578",
    "endpoint": "measure - Crude or PCR uncorrected ACPR, description - , timeFrame - Day 56",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00682578",
    "endpoint": "measure - Early treatment failure (failure to clear parasitaemia), description - , timeFrame - 7 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00682578",
    "endpoint": "measure - fever clearance times, description - , timeFrame - Days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00682578",
    "endpoint": "measure - parasite clearance times with no recrudescence over the observation period, description - , timeFrame - days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00682578",
    "endpoint": "measure - gametocyte clearance times, description - , timeFrame - weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00682578",
    "endpoint": "measure - Haemoglobin levels on day 14 compared to admission, description - , timeFrame - day 14",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00682578",
    "endpoint": "measure - safety and tolerability (rate and severity of adverse events), description - , timeFrame - day 56",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01350856",
    "endpoint": "measure - Parasite clearance time, description - Assessed by microscopy, timeFrame - Day 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01350856",
    "endpoint": "measure - Parasite reduction rates and ratios, description - Assessed by microscopy and quantitative PCR., timeFrame - Day 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01350856",
    "endpoint": "measure - Time for parasite count to fall, description - Time for parasite count to fall to 50%, 90%, and 99% of initial parasite density, timeFrame - 50%, 90%, and 99%",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01350856",
    "endpoint": "measure - Fever clearance time, description - The time taken for tympanic temperature to fall below 37˚C and remain there for at least 24 hours, timeFrame - &gt; 24 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01350856",
    "endpoint": "measure - Gametocytemia in patients, description - Proportion of patients with gametocytemia before, during and after treatment with artesunate, assessed at admission, on days 3, 7 and 14, stratified by presence of gametocytes at enrolment, timeFrame - days 0, 3, 7 and 14",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01350856",
    "endpoint": "measure - Gametocyte carriage rates, description - , timeFrame - 14 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01350856",
    "endpoint": "measure - In vitro susceptibility of P.falciparum to artemisinins, description - Measure the inhibitory concentrations (IC) 50, IC90, IC99 of P. falciparum responses to artemisinins ex vivo, timeFrame - Day 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01350856",
    "endpoint": "measure - Pharmacokinetics relationships for artesunate and Dihydroartemisinin (DHA), description - Measure half-life, Cmax, AUC, Tmax of artesunate and DHA., timeFrame - Day 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01350856",
    "endpoint": "measure - Parasite molecular markers of drug resistance, description - To identify the parasite specific molecular marker which is correlated to artemisinin resistance, timeFrame - Day 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01350856",
    "endpoint": "measure - Identification of host factors that correlate with slow parasite clearance, description - To identify host factors influencing the clearance of P. falciparum, e.g.\nhaemoglobinopathies and G6PD deficiency, timeFrame - Day 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01350856",
    "endpoint": "measure - Efficacy at D42, description - The cure rate of artesunate plus ACT treatments at 42 day of follow up., timeFrame - Day 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01350856",
    "endpoint": "measure - Pharmacodynamics relationships for artesunate and Dihydroartemisinin (DHA), description - , timeFrame - Day 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05385471",
    "endpoint": "measure - To assess the humoral immunogenicity of R78C in Matrix-M™ and RH5.1 in Matrix-M when administered to healthy volunteers alone and in combination assessing antigen-specific IgG antibody levels, with comparison before and after vaccination, description - Serum ELISA response, quantitative antigen-specific IgG antibody levels (µg&#x2F;mL readout) over time - analysis of peak responses and longevity, with comparison before and after vaccination, timeFrame - From a number of key timepoints, baseline up to day 600 (dependant on group)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05385471",
    "endpoint": "measure - To assess the humoral immunogenicity of R78C in Matrix-M™ and RH5.1 in Matrix-M in healthy volunteers assessing antigen-specific antibody subclass&#x2F;isotype measurement, with comparison before and after vaccination, description - Serum ELISA response, antigen-specific antibody subclass&#x2F;isotype measurement, with comparison before and after vaccination, timeFrame - From a number of key timepoints, baseline up to day 600 (dependant on group)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05385471",
    "endpoint": "measure - To assess the humoral immunogenicity of R78C in Matrix-M™ and RH5.1 in Matrix-M in healthy volunteers assessing antigen-specific antibody avidity measurement, with comparison before and after vaccination, description - Serum ELISA response, antigen-specific antibody avidity measurement, with comparison before and after vaccination, timeFrame - From a number of key timepoints, baseline up to day 600 (dependant on group)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05385471",
    "endpoint": "measure - To assess the humoral immunogenicity of R78C in Matrix-M™ and RH5.1 in Matrix-M when administered to healthy volunteers alone and in combination assessing In vitro GIA, with comparison before and after vaccination, description - In vitro GIA against 3D7 clone P. falciparum parasites using purified total IgG and a single-cycle pLDH readout assay, with comparison before and after vaccination, timeFrame - From a number of key timepoints, baseline up to day 600 (dependant on group)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05385471",
    "endpoint": "measure - To assess the humoral immunogenicity of R78C in Matrix-M™ and RH5.1 in Matrix-M in healthy volunteers assessing Purified IgG ELISA versus GIA titration &quot;Quality Analysis&quot;, with comparison before and after vaccination, description - Purified IgG ELISA versus GIA titration &quot;Quality Analysis&quot;, timeFrame - From a number of key timepoints, baseline up to day 600 (dependant on group)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03300648",
    "endpoint": "measure - Neurodevelopmental Disability, description - Presence and severity of neurodevelopmental disability in survivors, timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03178643",
    "endpoint": "measure - Number of Participants With Severe Anemia, description - E.g., hemoglobin &lt;5.5 g&#x2F;dL, timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03178643",
    "endpoint": "measure - Number of Participants With Severe Malaria, description - Positive rapid diagnostic test (RDT)., timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03178643",
    "endpoint": "measure - Number of Participants With Hospitalization for Malaria, description - Patient admitted to hospital for malaria with confirmed positive RDT., timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03178643",
    "endpoint": "measure - Number of Participants With Light Microscopy (LM)-Positive Malaria, description - LM-positive malaria defined as the reported presence of P. falciparum parasites detected by LM irrespective of RDT or other detection results., timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03178643",
    "endpoint": "measure - Number of Participants With Unconfirmed Malaria, description - Defined as the receipt of antimalarials for suspected malaria episodes that were not confirmed by any objective diagnostic test., timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03178643",
    "endpoint": "measure - Number of Participants With Fatal Malaria, description - Defined as death during hospitalization for malaria with positive RDT., timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03178643",
    "endpoint": "measure - Number of Participants With Asymptomatic Parasitization, description - Defined as the presence of parasites during routine follow-up visits as detected by PCR in patients without fever or a history of recent fever., timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03178643",
    "endpoint": "measure - Number of Participants With Painful Events, description - Pain lasting two hours or more without obvious cause., timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03178643",
    "endpoint": "measure - Number of Participants With Dactylitis, description - Pain or tenderness with or without swelling of the hands or feet., timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03178643",
    "endpoint": "measure - Number of Participants With Transfusions, description - Receipt of RBCs (red blood cells) from any caregiver for any indication., timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03178643",
    "endpoint": "measure - Number of Participants With Acute Chest Syndrome, description - Defined as a new pulmonary infiltrate and at least 3 of the following findings: chest pain, temperature elevation &gt; 38.5°C, tachypnea, wheezing, or cough., timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03178643",
    "endpoint": "measure - Number of Participants With All-cause Hospitalization, description - Hospitalization at HBCH or any other inpatient facility with any admitting diagnosis., timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03178643",
    "endpoint": "measure - All-cause Deaths, description - Death by any cause., timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03178643",
    "endpoint": "measure - Molecular Markers of Malaria Parasite Drug Resistance, description - presence of SNPs in parasite genes that confer resistance to the study drugs, timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04009096",
    "endpoint": "measure - Safety of the ChAd63 and MVA PvDBP Vaccines Andidates, Administered in a Heterologous Prime-boost Regimen in a CHMI Study in Healthy Volunteers, description - No of participants reporting adverse event, timeFrame - Within 28 days following each vaccination. Vaccinations occurred at 0 and 2 months in Groups 1 and 3 (ChAd63, MVA PvDBP); and at 0, 17 and 19 months in Group 2 (ChAd63, ChAd63, MVA PvDBP).",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04009096",
    "endpoint": "measure - The Humoral Immunogenicity ChAd63 and MVA PvDBP Vaccine Candidates, Administered in a Heterologous Prime-boost Regimen, description - Total IgG antibody response to the P. vivax Duffy-binding protein (PvDBP), timeFrame - 14 days after the final vaccination. Final vaccinations (MVA PvDBP) occurred at 2 months in Groups 1 and 3; and at 19 months in Group 2.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04009096",
    "endpoint": "measure - The Cellular Immunogenicity ChAd63 and MVA PvDBP Vaccine Candidates, Administered in a Heterologous Prime-boost Regimen, description - PvDBPII-specific CD4+ CD45RA- CCR7- effector memory T cells producing IFN-γ, timeFrame - 14 days after the final vaccination. Final vaccinations (MVA PvDBP) occurred at 2 months in Groups 1 and 3 ; and at 19 months in Group 2.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04009096",
    "endpoint": "measure - Immunological Readouts for Association With a Reduced Parasite Multiplication Rate, description - Statistical correlation between anti-PvDBP antibody responses induced by the ChAd63 and MVA PvDBP vaccines and PMR., timeFrame - 3 months post CHMI",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00358332",
    "endpoint": "measure - Anti-FMP2.1 Antibody Titers Measured by ELISA, at Day 0, description - This outcome is the mean of the log anti-FMP2.1 antibody response measured by ELISA., timeFrame - Day 0",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00358332",
    "endpoint": "measure - Anti-FMP2.1 Antibody Titers Measured by ELISA, at Day 30, description - This outcome is the mean of the log anti-FMP2.1 antibody response measured by ELISA., timeFrame - Day 30 +&#x2F;- 7 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00358332",
    "endpoint": "measure - Anti-FMP2.1 Antibody Titers Measured by ELISA, at Day 60, description - This outcome is the mean of the log anti-FMP2.1 antibody response measured by ELISA., timeFrame - Day 60 +&#x2F;- 7 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00358332",
    "endpoint": "measure - Anti-FMP2.1 Antibody Titers Measured by ELISA, at Day 90, description - This outcome is the mean of the log anti-FMP2.1 antibody response measured by ELISA., timeFrame - Day 90 +&#x2F;- 10 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00358332",
    "endpoint": "measure - Anti-FMP2.1 Antibody Titers Measured by ELISA, at Day 180, description - This outcome is the mean of the log anti-FMP2.1 antibody response measured by ELISA., timeFrame - Day 180 +&#x2F;- 14 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00358332",
    "endpoint": "measure - Anti-FMP2.1 Antibody Titers Measured by ELISA, at Day 272., description - This outcome is the mean of the log anti-FMP2.1 antibody response measured by ELISA., timeFrame - Day 272 +&#x2F;- 14 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00358332",
    "endpoint": "measure - Anti-FMP2.1 Antibody Titers Measured by ELISA, at Day 364, description - This outcome is the mean of the log anti-FMP2.1 antibody response measured by ELISA., timeFrame - Day 364 +&#x2F;- 14 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04130282",
    "endpoint": "measure - Humoral and cellular immunogenicity of the Pfs25-IMX313&#x2F;Matrix-M1 vaccine, when administered to healthy adult volunteers, description - Pfs25-specific immunogenicity will be assessed by immunological assays, with comparison before and after vaccination.\nThe main outcome measures will be humoral and B cell responses to the Pfs25 protein - total IgG, isotypes and avidity; T cell responses to Pfs25 by ex vivo ELISpot and flow cytometry assays., timeFrame - 8 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04130282",
    "endpoint": "measure - Ex-vivo efficacy of the Pfs25-IMX313&#x2F;Matrix-M1 vaccine, when administered to healthy adult volunteers, description - Ex vivo functional blocking activity of purified IgG against the P. falciparum NF54 strain will be assessed by standard membrane feeding assay., timeFrame - 8 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04318002",
    "endpoint": "measure - Anti-RH5 antibody concentration by ELISA, description - Evaluation of the magnitude of antibody responses to RH5 in adults, children and infants residing in a malaria endemic country, as measured by ELISA, timeFrame - Through study completion (approx 2 years)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04318002",
    "endpoint": "measure - Growth inhibition activity of IgG from vaccinees on a panel of P. falciparum parasites, description - Evaluation of the quality of antibody responses to RH5 in adults, children and infants residing in a malaria endemic country, as measured by an assay of growth inhibition activity on the vaccinees&#x27; sera, timeFrame - Through study completion (approx 2 years)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04318002",
    "endpoint": "measure - Avidity of anti-RH5 antibodies by ELISA and&#x2F;or other assays (to be defined), description - Evaluation of the avidity of antibody responses to RH5 in adults, children and infants residing in a malaria endemic country, as measured by ELISA, timeFrame - Through study completion (approx 2 years)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04318002",
    "endpoint": "measure - Cellular immune responses to the RH5 by ELISpot assay and&#x2F;or Flow cytommetry, description - Evaluation of the magnitude and quality of cellular immune responses to PfRH5 in adults, children and infants residing in a malaria endemic country, by ELISpot assay and&#x2F;or Flow cytommetry, timeFrame - Through study completion (approx 2 years)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01935882",
    "endpoint": "measure - Transmission to Anopheles gambiae mosquitoes, description - Mosquito membrane feeding assays will be used to determine the proportion of infected mosquitoes and the oocyst burden in infected mosquitoes., timeFrame - day -1, day 3, day 7",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01935882",
    "endpoint": "measure - Haematological recovery, description - Haemoglobin concentration will be determined at enrolment and on days 2, 3, 7, 10 and 14 during follow-up.\nHaemoglobin concentration will be presented as grams per decilitre and as concentration relative to enrolment value., timeFrame - 14 days during follow-up",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01935882",
    "endpoint": "measure - Primaquine and lumefantrine pharmacokinetics, description - The pharmacokinetic sampling will measure primaquine, lumefantrine and metabolites.\nSampling involves 7 venous blood samples during the first 72 hours after treatment and a single later time point at day 7 post initiation of treatment.\nDrug plasma levels will be related to treatment arm and to the participant&#x27;s Cytochrome P450 2D6 metabolizer status.\nCYP2D6 is an enzyme involved in primaquine metabolism., timeFrame - 7 days during follow-up",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01325974",
    "endpoint": "measure - To measure the sensitivity and specificity of the malaria rapid tests compared to smear microscopy., description - , timeFrame - The day of patient&#x27;s enrollment only (day 0)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01325974",
    "endpoint": "measure - To estimate the median time to become negative for each of the rapid diagnostic test., description - , timeFrame - day 2, 3, 5, 7, 14, 21, 28, 35 and 42 after the start of antimalarial treatment intake",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01325974",
    "endpoint": "measure - To estimate the proportion of positive tests among smear negative results and the median time to become negative according to the initial parasitaemia and the presence of gametocytes., description - , timeFrame - day 2, 3, 5, 7, 14, 21, 28, 35 and 42 after the start of antimalarial treatment intake",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00442377",
    "endpoint": "measure - Significant differences in immune response between exposed and control volunteers (including NK-cell reactivity, TLR reactivity and regulatory T-cell reactivity), description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00442377",
    "endpoint": "measure - Significant differences in the outcome of in vitro functional malaria assays between exposed and control volunteers, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00442377",
    "endpoint": "measure - Significant differences in cellular reactivity against Pf antigens, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00442377",
    "endpoint": "measure - Significant differences in parasite VAR gene expression during infection, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00442377",
    "endpoint": "measure - The identification of immune mechanisms that correlate with protection, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00442377",
    "endpoint": "measure - 6. The identification of potential vaccine candidates that correlate with protection, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02894294",
    "endpoint": "measure - Confirmed malaria cases, description - clinical malaria cases confirmed by rapid diagnostic test or blood smear in the selected health facilities, timeFrame - six months (July to December)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02894294",
    "endpoint": "measure - Change in prevalence of anemia at baseline, description - hemoglobin &lt; 8 g&#x2F;dL, timeFrame - December 2014 (one month post last round of SMC)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02894294",
    "endpoint": "measure - Adverse events, description - frequency of adverse events, timeFrame - 7 days post SMC round in August, September, October and November in 2014",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02894294",
    "endpoint": "measure - Change from baseline in frequency of molecular markers of resistance to SP and AQ, description - mutations at codons 51, 59, and 108 of the dhfr gene, 437 and 540 of the dhps gene, mutations at codon 76 in the P. falciparum chloroquine transporter gene (pfcrt), and at codon 86 of the P. falciparum multidrug resistance gene one (pfmdr1), timeFrame - December 2014 (one month post last round of SMC)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01083095",
    "endpoint": "measure - Minimal number of infected mosquitoes required to infect all volunteers with a reproducible prepatent period, description - , timeFrame - 30 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02389439",
    "endpoint": "measure - hepatic biological values, description - the hepatic biological values will be measured which are AST,ALT,albumin and total bilirubin, timeFrame - at day 0, 3,7 and day 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02389439",
    "endpoint": "measure - eosinophil count, description - , timeFrame - at day 0, 3, 7 and day 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02389439",
    "endpoint": "measure - K13 and pfmdr1 of P falciparum resistance, description - , timeFrame - at day 0, 3, 7 and day 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02389439",
    "endpoint": "measure - numbers of patients with a positive malaria slide 72 hours after treatment initiation, description - , timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02389439",
    "endpoint": "measure - fever clearance time, description - the time taken for tympanic temperature to fall below 37.5˚C and remain there for at least 24 hours, timeFrame - 24 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02389439",
    "endpoint": "measure - Number of patient with reinfection and recrudescences, description - , timeFrame - over 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02389439",
    "endpoint": "measure - PCR uncorrected ACPR, description - PCR uncorrected ACPR at 28 days or 42 days for P. falciparum, P. falciparum and mixed infections in Pailin, timeFrame - at 28 days or 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02389439",
    "endpoint": "measure - PCR corrected ACPR, description - PCR corrected ACPR at 28 days or for P. falciparum, P. vivax and mixed infections and at 42 days for P. falciparum and mixed infections, timeFrame - at 28 days and 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02389439",
    "endpoint": "measure - Gametocyte carriage rates, description - , timeFrame - at day 0, 3, 7 day 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02389439",
    "endpoint": "measure - gametocyte clearance times, description - , timeFrame - at day 0, 3, 7 and day28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03947190",
    "endpoint": "measure - To measure cellular immunogenicity assessed by ELISPOT, description - Assessing cellular immunogenicity by ELISPOT to enumerate IFN-ƴ producing T cells, timeFrame - from vaccination day up to 90 days after malaria sporozoite challenge",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03947190",
    "endpoint": "measure - To measure humoral immunogenicity assessed by ELISA, description - Assessing humoral immunogenicity by ELISA to quantify antibodies to the vaccine components CS, NANP, TRAP and HBsAb., timeFrame - from vaccination day up to 90 days after malaria sporozoite challenge",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03947190",
    "endpoint": "measure - Parasite density dynamics assessed by qPCR, description - To assess any differences in efficacy estimates with ID versus DVI challenge in individuals receiving R21&#x2F;MM, timeFrame - up to 3 months after malaria sporozoite challenge",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05468606",
    "endpoint": "measure - Humoral immune responses of volunteers exposed to different intervention arms, description - Difference in concentration of anti-CSP antibodies between intervention arms as assessed by ELISA., timeFrame - Moment of immunization, pre-CHMI and up to 182 days post CHMI",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02543086",
    "endpoint": "measure - Plasma Pharmacokinetics (PK) of KAE609: Area Under the Plasma Concentration-time Curve (AUC), description - It will be measured by Area Under the Concentration-Time Curve (AUC) from the time of dosing to the last quantifiable concentration, timeFrame - Day 1: 0, 1, 2, 3, 4, 8, 12, 16 hours, then 24, 36, 48, 72, 96 and 120 hours post dose Days 2 to 6, Day 15 0, 12 hours post dose then 24, 48, 72, 96 and 120 hours post dose Day 16 to Day 20",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02543086",
    "endpoint": "measure - Safety and Tolerability as measured by adverse events (including serious) for incidence, KAE609 (and inoculum) relatedness and severity, description - Adverse events (including serious) will be recorded during the study and will be rated according to incidence, relation to study drug (inoculum) and severity, timeFrame - From day of screening until end of study (day 36)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00082576",
    "endpoint": "measure - tolerability, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03814616",
    "endpoint": "measure - PCR-adjusted APR, description - To assess the efficacy of each dosing regimen PCR-adjusted APR at Day 63, timeFrame - 63 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03814616",
    "endpoint": "measure - PCR-unadjusted APR, description - To assess the efficacy of each dosing regimen PCR-unadjusted APR at Day 63, timeFrame - 63 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03814616",
    "endpoint": "measure - Rate of recurrent infections, recrudescence and new infections, description - To assess the efficacy of each dosing regimen on rate of recurrent infections, recrudescence and new infections, timeFrame - 63 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03814616",
    "endpoint": "measure - Proportion of parasite free participants, description - Proportion of participants who are parasite free by 4-8 hours, Day 1, Day 2 and Day 3 post first dosing, timeFrame - 4 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03814616",
    "endpoint": "measure - Gametocyte incidence, description - The area under the curve (AUC) up to Day 14 (post first dose) of gametocytes in participants with gametocytes at baseline, and separately in participants without gametocytes at baseline, timeFrame - 14 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03814616",
    "endpoint": "measure - Adverse Events, description - <ul><li><p>Number (%) of patients and number of events with:</p><ul><li>TEAEs,</li><li>serious TEAEs,</li><li>study drug related TEAEs,</li><li>study drug related serious TEAEs,</li><li>malaria-related TEAEs,</li><li>malaria-related serious TEAEs</li></ul></li><li>Number (%) of patients with TEAEs and drug-related TEAEs by maximum severity, based on Grade 1 to Grade 5 (CTCAE V4.03) severity grading Adverse events will be coded by MedDRA primary system organ class and preferred term.</li><li>Hepatotoxicity related TEAEs o The number and percentage of patients with hepatotoxicity related TEAEs, based on the Standard MedDRA Query (SMQ) narrow search &quot;Drug-related hepatic disorders&quot; will be summarised and clinical biochemistry parameters</li></ul>, timeFrame - 63 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03814616",
    "endpoint": "measure - Clinical laboratory data - Haematology, description - Haemoglobin, haematocrit, erythrocytes, platelets, white blood cells, neutrophils, lymphocytes, monocytes, eosinophils, basophils will be summarised over time, as absolute values and changes from baseline with the number of observations, mean, standard deviation, median, quartiles, minimum and maximum.\nSI units will be used to summarise the data., timeFrame - 63 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03814616",
    "endpoint": "measure - Clinical laboratory data - Biochemistry, description - Total and conjugated bilirubin will be summarised over time, as absolute values and changes from baseline with the number of observations, mean, standard deviation, median, quartiles, minimum and maximum.\nSI units will be used to summarise the data., timeFrame - 63 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03814616",
    "endpoint": "measure - Clinical laboratory data - Liver Enzymes, description - Alanine aminotransaminase (ALT), Aspartate aminotransaminase (AST), Alkaline Phosphatase will be summarised over time, as absolute values and changes from baseline with the number of observations, mean, standard deviation, median, quartiles, minimum and maximum.\nIU&#x2F;L units will be used to summarise the data, timeFrame - 63 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03814616",
    "endpoint": "measure - Clinical laboratory data - Liver Enzyme Elevations, description - <p>The number (%) of participants with liver enzyme elevations after first drug administration as defined below will be summarised.</p><ul><li>ALT or AST &gt; 3 x Upper Limit of Normal (ULN)</li><li>ALT or AST &gt; 5 x ULN</li><li>ALT or AST &gt; 8 x ULN</li><li>ALT or AST &gt; 3 x ULN and bilirubin &gt; 2 x ULN at the same time point (when conjugated bilirubin fraction is missing)</li><li>ALT or AST &gt; 3 x ULN and bilirubin &gt; 2 x ULN, together with a conjugated bilirubin fraction &gt;35% (Potential Hy&#x27;s law cases), at the same time point</li></ul>, timeFrame - 63 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03814616",
    "endpoint": "measure - Vital signs - Blood pressure, description - Supine systolic and diastolic blood pressure (mm Hg) absolute values and changes from baseline will be summarised by time point with the number of observations, mean, standard deviation, median, minimum and maximum, and quartiles, timeFrame - 63 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03814616",
    "endpoint": "measure - Vital signs - Pulse rate, description - Pulse rate (bpm) absolute values and changes from baseline will be summarised by time point with the number of observations, mean, standard deviation, median, minimum and maximum, and quartiles, timeFrame - 63 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03814616",
    "endpoint": "measure - Vital signs - Temperature, description - Temperature (degrees Celsius) absolute values and changes from baseline will be summarised by time point with the number of observations, mean, standard deviation, median, minimum and maximum, and quartiles, timeFrame - 63 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00486694",
    "endpoint": "measure - Parasite and fever clearance times, the proportion of patients free of parasites at 42 days, and the proportion of patients with detectable gametocytes during follow-up., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03208179",
    "endpoint": "measure - Composite of foetal loss and neonatal mortality, description - Composite of foetal loss (spontaneous abortion or stillbirth) and neonatal mortality, timeFrame - 8 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03208179",
    "endpoint": "measure - SGA-LBW-PT composite, description - Composite of small for gestational age, low birth weight or preterm birth, timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03208179",
    "endpoint": "measure - SGA, description - Small for gestational age using the new INTERGROWTH population reference&#x27;s 10th percentile, timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03208179",
    "endpoint": "measure - LBW, description - Low birth weight defined as a corrected birth weight below 2.5 kg, timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03208179",
    "endpoint": "measure - PT, description - Preterm birth defined as birth at a gestational age above 28 weeks but less than 37 completed weeks, timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03208179",
    "endpoint": "measure - Neonatal length and stunting, description - Neonatal length and stunting, timeFrame - 8 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03208179",
    "endpoint": "measure - Clinical malaria during pregnancy, description - Incidence of clinical malaria during pregnancy, timeFrame - 6 months from randomisation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03208179",
    "endpoint": "measure - Malaria infection during pregnancy detected by microscopy and PCR, description - Prevalence and incidence of peripheral maternal (blood) malaria infection during pregnancy by microscopy and PCR, timeFrame - 6 months from randomisation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03208179",
    "endpoint": "measure - Composite placental malaria detected by microscopy, by molecular methods or by histology, description - Prevalence of placental malaria by microscopy, PCR and placental histology, timeFrame - 6 months from randomisation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03208179",
    "endpoint": "measure - Placental malaria detected by microscopy, description - Prevalence of placental malaria detected in maternal placental blood by microscopy, timeFrame - 6 months from randomisation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03208179",
    "endpoint": "measure - Placental malaria detected by molecular methods (PCR), description - Prevalence of placental malaria detected in maternal placental blood by PCR, timeFrame - 6 months from randomisation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03208179",
    "endpoint": "measure - Placental malaria detected by histology, description - Prevalence of placental malaria detected in full placental section by histology, timeFrame - 6 months from randomisation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03208179",
    "endpoint": "measure - Maternal nutritional status, description - Changes in maternal nutritional status by MUAC and BMI., timeFrame - 6 months from randomisation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03208179",
    "endpoint": "measure - Maternal anaemia during pregnancy and delivery, description - Prevalence and incidence of maternal anaemia (Hb &lt; 11g&#x2F;dl) at enrolment, last antenatal visit and delivery, timeFrame - 6 months from randomisation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03208179",
    "endpoint": "measure - Congenital anaemia, description - Prevalence of anaemia (Hb &lt; 13g&#x2F;dl) from newborn cord blood, timeFrame - 6 months from randomisation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03208179",
    "endpoint": "measure - Congenital malaria infection, description - Prevalence of malaria infection by microscopy or PCR from newborn cord blood, timeFrame - 6 months from randomisation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03208179",
    "endpoint": "measure - QTc-prolongation, description - QTcF-prolongation of more than 60ms between baseline DTcF prior to first dose of DP (+&#x2F;- AZ) on day 0 and repeat QTcF 4 - 6 hrs after administration of 3rd dose of DP(+&#x2F;- AZ) on day 2, or QTcF &gt; 480ms, 4 - 6 hours after on day 2 treatment administration.\nOnly on the DP containing arms., timeFrame - 6 months from randomisation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03208179",
    "endpoint": "measure - Congenital malformations, description - Any visible external congenital abnormality on surface examination, timeFrame - 6 months from randomisation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03208179",
    "endpoint": "measure - Maternal mortality, description - The death of a woman while pregnant or within 42 days of termination of pregnancy, irrespective of the duration and site of the pregnancy, from any cause related to or aggravated by the pregnancy or its management but not from accidental or incidental causes., timeFrame - 8 months from randomisation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03208179",
    "endpoint": "measure - Other SAEs and AEs, description - Incidence of AEs and SAEs, timeFrame - 8 months from randomisation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03208179",
    "endpoint": "measure - (History of) vomiting study drug, description - Prevalence and incidence of vomiting investigational product (IP) twice at the same IP administration visit, timeFrame - 6 months from randomisation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03208179",
    "endpoint": "measure - Dizziness, description - Prevalence of dizziness after a course of IP, timeFrame - 6 months from randomisation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03208179",
    "endpoint": "measure - Gastrointestinal complaints, description - Prevalence of gastrointestinal complaints after a course of IP, timeFrame - 6 months from randomisation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03208179",
    "endpoint": "measure - Molecular markers of drug resistance in Plasmodium falciparum infections during pregnancy and delivery, description - Prevalence and incidence of SP and artemisinin resistance markers from infection isolates after enrollment and at delivery, timeFrame - 6 months from randomisation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03208179",
    "endpoint": "measure - Presence of STIs&#x2F;RTIs prior to delivery (syphilis, gonorrhoea, Chlamydia trachomatis, Trichomonas vaginalis, and bacterial vaginosis), description - Prevalence and incidence of STIs&#x2F;RTIs (syphilis, gonorrhoea, Chlamydia trachomatis, Trichomonas vaginalis, and bacterial vaginosis) at randomization and last antenatal visit prior to delivery, timeFrame - 6 months from randomisation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03208179",
    "endpoint": "measure - Changes in macrolide resistance in Pneumococcus detected in maternal nasopharyngeal samples, description - Prevalence and incidence of carriage of macrolide resistant pneumococcus at randomization and delivery, timeFrame - 6 months from randomisation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03208179",
    "endpoint": "measure - Changes in the colony composition of maternal vaginal microbiota, and intestinal microbiota of mother and infant., description - Changes in maternal reproductive tract and gut microbiota from randomisation to last antenatal visit prior to delivery, and neonatal gut microbiota, timeFrame - 6 months from randomisation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05060198",
    "endpoint": "measure - Change in hemoglobin over time, description - Change in hemoglobin, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05060198",
    "endpoint": "measure - ACPR by baseline parasite density, description - Treatment efficacy stratified by baseline parasite density, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05060198",
    "endpoint": "measure - Reinfection incidence rates and rate ratios by study arm, preventable fraction (AL), description - Incidence rates calculated as number of reinfections per follow up period (28 days), by study arm; rate ratios by study arm, at 28 days; preventable fraction based on rate ratios, for 28 day follow up period., timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05060198",
    "endpoint": "measure - Reinfection incidence rates and rate ratios by study arm, preventable fraction (DP), description - Incidence rates calculated as number of reinfections per follow up period (42 days), by study arm; rate ratios by study arm, at 42 days; preventable fraction based on rate ratios, for 42 day follow up period., timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05060198",
    "endpoint": "measure - Evaluate duration of malaria HRP2&#x2F;pLDH RDT positivity after appropriate treatment with AL and DP, description - Using survival analysis, estimate median and end of follow up RDT positivity rate, by arm, baseline parasitemia, and in correlation with HRP2, LDH, and Aldolase lab values., timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05676645",
    "endpoint": "measure - AUC desbutyl-lumefantrine plasma, description - Plasma exposure of active metabolite, timeFrame - 0-24 hours after dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05676645",
    "endpoint": "measure - AUC desbutyl-lumefantrine breastmilk, description - Breastmilk exposure of active metabolite, timeFrame - 0-24 hours after dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05676645",
    "endpoint": "measure - Milk to plasma ratio of desbutyl-lumefantrine, description - Ratio of breastmilk to maternal plasma of active metabolite, timeFrame - 0-24 hours after dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05676645",
    "endpoint": "measure - Infant concentration lumefantrine, description - Infant lumefantrine exposure, timeFrame - 0-8 hours after maternal dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05676645",
    "endpoint": "measure - Infant concentration desbutyl-lumefantrine, description - Infant exposure to active metabolite, timeFrame - 0-8 hours after maternal dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05676645",
    "endpoint": "measure - Infant development, description - Infant assessment using Gross Motor Development Score (IGMDS), timeFrame - 0-1 year old",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05676645",
    "endpoint": "measure - Depression and anxiety in mothers, description - Patient Health Questionnaire (PHQ9), timeFrame - 0-1 year postpartum",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05676645",
    "endpoint": "measure - Depression and anxiety in mothers, description - General Anxiety Disorder (GAD7), timeFrame - 0-1 year postpartum",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05676645",
    "endpoint": "measure - Maternal beliefs about medicines, description - Beliefs about Medicines questionnaire (BMQ), timeFrame - 0-1 year postpartum",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01074905",
    "endpoint": "measure - Any recurrence of Plasmodium vivax parasitemia, description - Any recurrence of Plasmodium vivax parasitemia within the follow up period, timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01074905",
    "endpoint": "measure - Time to first recurrence, median time between episodes of vivax infections and total number of episodes, description - Time to first recurrence, median time between episodes of vivax infections and total number of episodes in the follow up period, timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01074905",
    "endpoint": "measure - Overall number of days of illness and haematocrit below 30%, description - Overall number of days of illness and haematocrit below 30% within the follow up period, timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01074905",
    "endpoint": "measure - Chloroquine level, description - Whole blood chloroquine level at day 7 and any day of recurrence of Plasmodium vivax malaria, timeFrame - Day 7",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01074905",
    "endpoint": "measure - Adverse events, description - Adverse event profiles of artesunate, chloroquine and primaquine, timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02903706",
    "endpoint": "measure - Microscopy: thick and thin smear, description - Each participant is screen for malaria using classic microscopy on thin and thick smears in order to obtain a prevalence of malaria positive individuals and to evaluate parasite quantities, and gametocyte carriage (transmission potential).\nIf either thin or thick smears are positive then the patient is estimated to have smear positive malaria., timeFrame - 1 month",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04897919",
    "endpoint": "measure - re-infection vs recrudescence, description - Cumulative re-infection and recrudescence rates, timeFrame - Day 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04897919",
    "endpoint": "measure - Haemoglobin level, description - Haemoglobin measured on day 42, timeFrame - Day 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01651416",
    "endpoint": "measure - Proportion of children with parasitaemia, description - Parasitaemia detected by rapid diagnostic test (RDT) and parasitologically confirmation of P. falciparum infection by blood slide.., timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01651416",
    "endpoint": "measure - Proportion of children with anaemia, description - Anaemia is defined as haemoglobin less than &lt;8 g&#x2F;dL, timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01651416",
    "endpoint": "measure - Number of referrals, description - Referrals to hospital and admissions due to malaria and other causes, timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01651416",
    "endpoint": "measure - Incidence of severe illness, description - , timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01651416",
    "endpoint": "measure - Incidence of adverse events, description - , timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01178021",
    "endpoint": "measure - secondary vivax attack, description - Completion of 6-months (± 1 month) follow-up without secondary vivax attack, timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01178021",
    "endpoint": "measure - G6PD prevalence, description - G6PD status of patients, timeFrame - Time of enrollment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01178021",
    "endpoint": "measure - Recurrence, description - Time to first recurrence, median time between episodes of vivax infections and total number of episodes in the follow up period, timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01178021",
    "endpoint": "measure - Days of illness, haematocrit, description - Overall number of days of illness and haematocrit below 30%, timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01178021",
    "endpoint": "measure - Chloroquine levels, description - Whole blood chloroquine level at day 7 and any day of recurrence of Plasmodium vivax malaria, timeFrame - Day 7",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01178021",
    "endpoint": "measure - Adverse events, description - Adverse event profiles of chloroquine and primaquine, timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00147368",
    "endpoint": "measure - safety, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00147368",
    "endpoint": "measure - pharmacokinetic (PK) parameters, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00147368",
    "endpoint": "measure - pharmacodynamic (PD) parameters, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00147368",
    "endpoint": "measure - oxidant stress, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00147368",
    "endpoint": "measure - gas transfer, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00147368",
    "endpoint": "measure - endothelial activation, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00147368",
    "endpoint": "measure - a priori subgroup analysis: endothelial function in those with baseline impairment of function, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01716260",
    "endpoint": "measure - To study the efficacy of Primaquine., description - In this study, Primaquine will be administered on day 28, and any relapse will be recorded to study relapse rates over a 12 month period., timeFrame - Patients with recurrence after day 28 will be recorded.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04767191",
    "endpoint": "measure - Number of patients (in the Artemether Lumefantrine arm arm) with treatment-related adverse events, description - , timeFrame - by day 28 post-treatment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04767191",
    "endpoint": "measure - Number of patients (in the Dihydroartemisinin-Piperaquine arm) with treatment-related adverse events, description - , timeFrame - by day 42 post-treatment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04767191",
    "endpoint": "measure - Number of patients (in the Artemether Lumefantrine arm) with molecular markers of drug resistance assessed via phenotype test, description - , timeFrame - by day 28 post-treatment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04767191",
    "endpoint": "measure - Number of patients (in the Dihydroartemisinin-Piperaquine arm) with molecular markers of drug resistance assessed via phenotype test, description - , timeFrame - by day 42 post-treatment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04422015",
    "endpoint": "measure - Proportion of individuals clearing the infection, description - Clearance of parasite infection as detected by qPCR, timeFrame - 1 month",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04422015",
    "endpoint": "measure - Proportion of individuals maintaining infections without fever, description - Confirmed P. falciparum ifection at day 28 by qPCR, timeFrame - 1 month",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00658450",
    "endpoint": "measure - Improvement in memory, reasoning, planning, behaviour and academic achievement, description - , timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00403260",
    "endpoint": "measure - PCR-corrected ACPR on Day 14, description - Percentage of subjects with PCR-corrected adequate clinical and parasitological response (ACPR) on Day 14, defined as absence of parasitaemia on Day 14 without the subject&#x27;s meeting any of the criteria of early treatment failure, late clinical failure, or late parasitological failure, timeFrame - Day 14",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00403260",
    "endpoint": "measure - Crude ACPR on Days 14 and 28, description - Percentage of subjects with adequate clinical and parasitological response (ACPR) on Days 14 and 28, without correction by PCR, defined as absence of parasitaemia on Days 14 and 28 without the subject&#x27;s meeting any of the criteria of early treatment failure, late clinical failure, or late parasitological failure, timeFrame - Days 14 and 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00403260",
    "endpoint": "measure - Parasite Clearance Time, description - Parasite clearance time was defined as the time from first dosing to time of first blood draw with parasite clearance.\nParasite clearance was defined as zero presence of asexual parasites for 2 consecutive negative readings taken between 7 and 25 hours apart., timeFrame - Thick blood films were examined every 8 hours until ≥72 hours or until 2 consecutive negative readings occurred 7 to 25 hours apart, and on Days 3, 7, 14, 21, 28, 35, and 42 (or any other day if the subject returned).",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00403260",
    "endpoint": "measure - Fever Clearance Time, description - Fever clearance time was defined as the time from first dosing to first normal reading of temperature (&lt;37.5°C\ntaken axillary or tympanic; &lt;38°C taken oral or rectal) for 2 consecutive normal temperature readings taken between 7 and 25 hours apart., timeFrame - Every 8 hours over ≥72 hours following first study drug administration or temperature normalisation for ≥2 readings between 7 and 25 hours apart, then at each visit.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00403260",
    "endpoint": "measure - Parasite Clearance at Day 1, 2 and 3, description - Parasite clearance time was defined as the time from first dosing to the time of first blood draw with parasite clearance.\nParasite clearance was defined as zero presence of asexual parasites for 2 consecutive negative readings taken between 7 and 25 hours apart., timeFrame - Days 1, 2 and 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00403260",
    "endpoint": "measure - Fever Clearance at Day 1, 2 and 3, description - Fever clearance time was defined as the time for at least 2 consecutive normal body temperature measurements (&lt;37.5°C\naxillary&#x2F;tympanic or &lt;38.0°C oral&#x2F;rectal) to be obtained within an interval of 7 to 25 hours post-dosing., timeFrame - Days 1, 2 and 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00403260",
    "endpoint": "measure - Adverse Events and Clinically Significant Laboratory Results, description - Cases and severity of adverse events and of clinically significant laboratory results, ECG, vital signs or physical examination abnormalities, timeFrame - Day 0 to 42. Subjects experiencing AEs at Day 42 were followed for up to 30 days after the end of study or resolution of the event, whichever was earlier",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03580824",
    "endpoint": "measure - To assess the cellular and humoral immunogenicity of R21 in humans with adjuvant Matrix- M in healthy adults, children and infants., description - <p>Comparison of immunogenicity (antibody responses) of the R21-Matrix-M1 - adjuvanted vaccination doses and the longevity of responses.</p><ul><li>ELISA to quantify antibodies to the vaccine components CS, NANP and HBsAb.</li><li>Flow cytometry assays with intracellular cytokine staining to enumerate and functionally characterise immune cell populations such as effector and memory T cells (e.g.\nCD4+ and CD8+), T follicular helper cells, regulatory T cells, B cells, plasma cells and dendritic cells</li><li>ELISPOT for enumeration of antibody-secreting cells (e.g.\nB and plasma cells)</li></ul>, timeFrame - up to 2 years following vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00497471",
    "endpoint": "measure - Clinical Malaria, description - , timeFrame - After first year of life",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00497471",
    "endpoint": "measure - Severe Anemia (PCV &lt; 25%), description - , timeFrame - After first year of life",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00497471",
    "endpoint": "measure - Outpatient visits, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00497471",
    "endpoint": "measure - Hospital Admissions, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00497471",
    "endpoint": "measure - Severe malaria, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05776017",
    "endpoint": "measure - Efficacy- different definitions of malaria fever and parasite thresholds on microscopy, description - <p>To compare efficacy against clinical malaria for different case definitions using</p><ul><li>Fever thresholds that are higher than 37.5ºC, such as 38.5ºC and 39.5ºC</li><li>History of fever instead of measured fever</li><li>Different parasitemia by microscopy thresholds [any parasitemia, 1000, 10,000 and 20,000&#x2F;µL]</li></ul><p>Efficacy outcomes</p><ul><li>clinical malaria episodes defined as a febrile episode with an axillary temperature of ≥ 38.5ºC with P. falciparum parasitemia ≥5000&#x2F;µL or ≥ 39.5ºC with P. falciparum parasitemia ≥5000&#x2F;µL or</li><li>clinical malaria episodes defined as history of fever with P. falciparum parasitemia of the following levels: any parasitemia, 1000, 10,000 and 20,000&#x2F;µL clinical malaria episodes defined as a febrile episode with an axillary temperature of ≥ 38.5ºC with or ≥ 39.5ºC with P. falciparum parasitemia of the following levels: any parasitemia, 1000, 10,000 and 20,000&#x2F;µL</li></ul>, timeFrame - For 12 months after first vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05776017",
    "endpoint": "measure - Efficacy duration, description - To assess the efficacy of MSP3-CRM-Vac4All&#x2F;Alhydrogel® in young children against clinical malaria occurring during the 12 months following dose 3., timeFrame - For 12 months following the first vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05776017",
    "endpoint": "measure - Efficacy against first malaria episodes, description - <p>To assess the efficacy of MSP3-CRM-Vac4All&#x2F;Alhydrogel® in young children against first clinical malaria episodes occurring from over the 6 month period 14 days after 2nd and 3rd vaccination and up to the end of study follow-up (12 months after first vaccination).</p><p>The efficacy outcome is first episode of clinical malaria, with the case definition of clinical malaria episodes defined as a febrile episode with an axillary temperature of ≥ 37.5ºC with P. falciparum parasitemia ≥5000&#x2F;µL</p>, timeFrame - From 14 days post 2nd or 3rd vaccination to 6 months following and up to the end of study follow-up (12 months after first vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05776017",
    "endpoint": "measure - Efficacy (conditional boost), description - To assess the efficacy of MSP3-CRM-Vac4All&#x2F;Alhydrogel® in young children against clinical malaria occurring The efficacy outcome is clinical malaria, with the primary case definition of clinical malaria episodes defined as a febrile episode with an axillary temperature of ≥ 37.5ºC with P. falciparum parasitemia ≥5000&#x2F;µL, timeFrame - For the 6 months following boost vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05776017",
    "endpoint": "measure - Efficacy (conditional boost), description - <p>To assess the efficacy of MSP3-CRM-Vac4All&#x2F;Alhydrogel® in young children against clinical malaria occurring.</p><p>The efficacy outcome is clinical malaria, with the primary case definition of clinical malaria episodes defined as a febrile episode with an axillary temperature of ≥ 37.5ºC with P. falciparum parasitemia ≥5000&#x2F;µL</p>, timeFrame - For the 12 months following boost vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05776017",
    "endpoint": "measure - Number of adverse events, description - To assess the safety and reactogenicity of 3 doses of 30 µg MSP3-CRM-Vac4All&#x2F;Alhydrogel® given at D0, D28 and D56 in healthy young children, timeFrame - During the month following each vaccination, and 6 months and 12 months after first vaccination.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05776017",
    "endpoint": "measure - Number of adverse events for conditional boost vaccination, description - Safety and reactogenicity of boost vaccination doses of MSP3-CRM-Vac4All&#x2F;Alhydrogel® in healthy young children, timeFrame - At one month, 6 month and 12 months following boost vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05776017",
    "endpoint": "measure - Immune response, description - To examine the duration of immune responses of a 3-dose regimen of during periods corresponding to that used for primary and other secondary efficacy endpoints as measured through a &gt; 5-fold decrease of MSP3-specific serum IgG antibody titers after each vaccination in comparison to baseline levels (14 days post last dose), timeFrame - From 14 days post last dose to up to a month after last dose, 6 months after last dose and 12 months after first dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05776017",
    "endpoint": "measure - Immune response, description - To determine immunogenicity in terms of the proportion with titres either more than 3SD above the median for negative controls (positive) or at least 50% of the positive controls (strongly positive) after dose 3., timeFrame - A month after dose 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05776017",
    "endpoint": "measure - Parasite densities, description - To measure effect on parasitemia by comparing parasite densities in malaria episodes occurring in vaccinees compared to control, timeFrame - From vaccination to up to 6 months after last dose and 12 months after first dose.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04695197",
    "endpoint": "measure - Median viral load of SARS-CoV-2, description - Median CT value as detected from mid-nasal swabs by PCR, timeFrame - by day 14",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04695197",
    "endpoint": "measure - Cumulative incidence of SARS-CoV-2 clearance, description - Defined as the proportion of participants with negative nasal swabs, timeFrame - by days 14, 21 and 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04695197",
    "endpoint": "measure - Time to clearance of nasal SARS-CoV-2, description - Defined as the number of days to a negative SARS-CoV-2 RNA PCR tests (swabs collected on days 1, 3, 7, 14, 21 and 28), timeFrame - by days 1, 3, 7, 14 and 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04695197",
    "endpoint": "measure - Cumulative seroconversion rates (IgG, IgM, IgA), description - proportion of antibody negative patients on enrolment who seroconvert, timeFrame - by days 7, 14, 21 and 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04695197",
    "endpoint": "measure - IgG, IgM, IgA antibody titres against SARS-CoV-2, description - Geometric mean, maximum, and change from baseline, timeFrame - by days 7, 14, 21 and 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04695197",
    "endpoint": "measure - IL-6, IL-7, IL-10, TNF-alpha and Interferon-Gamma, description - median, max and change from baseline, timeFrame - by days 3, 7, 14 and 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04695197",
    "endpoint": "measure - CRP and angiotensin-2, angiopoietin-1 and angiopoietin-2, description - median, max and change from baseline, timeFrame - by days 3, 7, 14 and 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04695197",
    "endpoint": "measure - Genomic responses to SARS-CoV-2 infection, description - Transcriptional profiling (gene expression) of whole blood and fixed whole blood for T and B cell markers, timeFrame - by day 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04695197",
    "endpoint": "measure - Cellular immune responses to SARS-CoV-2 infection, description - T cell responses, timeFrame - by day 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04695197",
    "endpoint": "measure - The clinical and parasitological antimalarial treatment response, description - Expressed as the proportion with early treatment failure, late clinical failure, late parasitological failure or an adequate clinical and parasitological response.\nRecrudescence will be differentiated from new infection by genotyping of malaria parasites, timeFrame - by day 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04695197",
    "endpoint": "measure - COVID-19 disease severity, description - Defined by a severity index score for COVID-19, timeFrame - by day 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04695197",
    "endpoint": "measure - COVID-19 disease duration, description - The proportion of days with symptoms after randomization, timeFrame - by day 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04695197",
    "endpoint": "measure - COVID-19 fever duration, description - The proportion of days with a fever after randomization, timeFrame - by day 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04695197",
    "endpoint": "measure - COVID-19 respiratory symptoms duration, description - The proportion of days with respiratory symptoms after randomization, timeFrame - by day 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04695197",
    "endpoint": "measure - COVID-19 disease duration in days, description - The number of days until symptom clearance, timeFrame - by day 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04695197",
    "endpoint": "measure - Treatment-related adverse events, serious adverse events, and adverse events resulting in treatment discontinuation, description - The cumulative proportion of patients with any of these events after the start of treatment, timeFrame - by day 7",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01936766",
    "endpoint": "measure - Association between the GEDVI,after conventional fluid resuscitation, and (1) serum creatinine level, (2) EVLWI, description - The association between the GEDVI at 6, 12, 18 or 24 hours after conventional fluid resuscitation and (1) serum creatinine level, (2) EVLWI, timeFrame - 24 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01936766",
    "endpoint": "measure - Correlation between GEDVI and changes over time in plasma lactate level, description - , timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01936766",
    "endpoint": "measure - Change in central venous oxygen saturation (ScvO2) in relation to GEDVI and its association with acid-base status, description - , timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01936766",
    "endpoint": "measure - Incidence of pulmonary edema and ALI&#x2F;ARDS, description - Incidence of pulmonary edema defined by increase of EVLWI (≥ 10 mL&#x2F;kg) and ALI&#x2F;ARDS in relation to proportion of blocked capillaries (observed by OPS), GEDVI and cumulative fluid administration, timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01936766",
    "endpoint": "measure - Incidence of AKI and induction rate of renal replacement therapy, description - Incidence of AKI defined by RIFLE or AKIN criteria and induction rate of renal replacement therapy in relation to proportion of blocked capillaries (observed by OPS), GEDVI and cumulative fluid balance, timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01936766",
    "endpoint": "measure - Time course of hemodynamic parameters in relation to fluid therapy, description - Time course of hemodynamic parameters, i.e.\nCardiac Index (CI), Global Ejection Fraction (GEF), Stroke Volume Variation (SVV) in relation to fluid therapy, timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01936766",
    "endpoint": "measure - Time course of respiratory parameters in relation to fluid therapy, description - Time course of respiratory parameters, i.e.\nPaO2&#x2F;FiO2 ratio, Pulmonary Vascular Permeability Index (PVPI) in relation to fluid therapy, timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01936766",
    "endpoint": "measure - Parasite burden in adults with severe malaria in relation to organ damage (renal, pulmonary), description - Parasite burden, i.e.\nPfHRP2, peripheral blood parasitemia, parasite staging at enrollment in adults with severe malaria in relation to organ damage (renal, pulmonary), timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01936766",
    "endpoint": "measure - Evaluation of Biomarkers for early detection of ARDS, description - Evaluation of Biomarkers for early detection of ARDS in both severe malaria and sepsis (plasma transferrin, albumin, others), timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01936766",
    "endpoint": "measure - Correlation between GEDVI and clinical variables, description - Correlation between GEDVI and clinical variables including the jugular venous pressure (JVP) as a measure of volume status or passive leg raising as an indicator of fluid responsiveness, timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01936766",
    "endpoint": "measure - Evaluation of the fluid requirements for resuscitation in patients with severe malaria or sepsis, description - Evaluation of the fluid requirements for resuscitation in patients with severe malaria or sepsis, based on the optimal GEDVI defined by primary outcome measures and secondary outcome measures No. 1, timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01082718",
    "endpoint": "measure - PCR correct cure rate on Day 63, description - , timeFrame - Day 63",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01783340",
    "endpoint": "measure - Duration of pre-patent period by thick smear, description - Duration of pre-patent period after challenge infection as measured by microscopy (thick smear), timeFrame - One year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01783340",
    "endpoint": "measure - Kinetics of parasitemia by PCR, description - Development of parasitemia as measured by PCR, timeFrame - One year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01783340",
    "endpoint": "measure - Adverse events, description - Frequency of adverse events in study groups, timeFrame - One year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01783340",
    "endpoint": "measure - Immune responses, description - Immune responses between study groups, timeFrame - One year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00426439",
    "endpoint": "measure - genetic markers of resistance, description - , timeFrame - 70 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00426439",
    "endpoint": "measure - recrudescence and re-infection rates, description - , timeFrame - 70 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00426439",
    "endpoint": "measure - Hospitalisation during follow-up, description - , timeFrame - 70 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00426439",
    "endpoint": "measure - Haemoglobin changes, description - , timeFrame - 70 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06347471",
    "endpoint": "measure - Mean within person percent change (presented as percent reduction) in mosquito infection rate from baseline, description - Mean within person percent change (presented as percent reduction) in mosquito infection rate from baseline to all feeding time-points.\nInfectivity is assessed by mosquito membrane feeding assays; comparisons are performed within treatment arms for ΔPfK13 vs wild type infections., timeFrame - days 0, 2, 7",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06347471",
    "endpoint": "measure - Mean oocyst intensity (in all&#x2F;all infected mosquitoes), description - Mean oocyst intensity (in all&#x2F;all infected mosquitoes) will be assessed at all feeding time-points; comparisons are performed within treatment arms for ΔPfK13 vs wild type infections, timeFrame - days 0, 2, 7",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06347471",
    "endpoint": "measure - Male and female gametocyte sex ratio (proportion male), description - Male and female gametocyte sex ratio (proportion male) at all time-points, determined by molecular assays; comparisons are performed within treatment arms for ΔPfK13 vs wild type infections., timeFrame - days 0, 1, 2, 3, 7",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06347471",
    "endpoint": "measure - Gametocyte circulation time, description - Gametocyte circulation time (cumulative), determined by microscopy or molecular assays, compared between treatment arms and between ΔPfK13 vs wild type infections, timeFrame - days 0, 1, 2, 3, 7",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06347471",
    "endpoint": "measure - Gametocyte area under the curve, description - Gametocyte area under the curve (cumulative), determined by microscopy or molecular assays, compared between treatment arms, and between ΔPfK13 vs wild type infections, timeFrame - days 0, 1, 2, 3, 7",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06347471",
    "endpoint": "measure - Asexual parasite prevalence, description - Asexual parasite prevalence at all time-points, determined by microscopy or molecular assays, with comparison within treatment arms, between arms, and between ΔPfK13 vs wild type infections, timeFrame - days 0, 1, 2, 3, 7",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06347471",
    "endpoint": "measure - Asexual parasite density, description - Asexual parasite density at all time-points, determined by microscopy or molecular assays, with comparison within treatment arms, between arms, and between ΔPfK13 vs wild type infections, timeFrame - days 0, 1, 2, 3, 7",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06347471",
    "endpoint": "measure - Total parasite prevalence, description - Total parasite prevalence at all time-points, determined by microscopy or molecular assays, with comparison within treatment arms, between arms, and between ΔPfK13 vs wild type infections, timeFrame - days 0, 1, 2, 3, 7",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06347471",
    "endpoint": "measure - Total parasite density, description - Total parasite density at all time-points, determined by microscopy or molecular assays, with comparison within treatment arms, between arms, and between ΔPfK13 vs wild type infections, timeFrame - days 0, 1, 2, 3, 7",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06347471",
    "endpoint": "measure - The density of ΔPfK13 vs wild type genotypes, description - The density of ΔPfK13 vs wild type genotypes in peripheral blood, the asexual parasite fraction and gametocyte fraction before and after initiation of treatment.\nThe relative abundance of ΔPfK13 genotypes will be compared between pre- and post-treatment timepoints, timeFrame - days 0, 1, 2, 3, 7",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06347471",
    "endpoint": "measure - The density of ΔPfK13 vs wild type genotypes in oocysts and sporozoites in mosquitoes that become infected before and after initiation of treatment, description - The density of ΔPfK13 vs wild type genotypes in oocysts and sporozoites in mosquitoes that become infected before and after initiation of treatment.\nThe relative abundance of ΔPfK13 genotypes will be compared between pre- and post-treatment timepoints, timeFrame - days 0, 2, 7",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06347471",
    "endpoint": "measure - Mean within person percent change (presented as percent reduction) in mosquito infection rate from baseline after gametocyte enrichment, description - Mean within person percent change (presented as percent reduction) in mosquito infection rate from baseline to all feeding time-points.\nInfectivity is assessed by mosquito membrane feeding assays after gametocyte enrichment; comparisons are performed within treatment arms for ΔPfK13 vs wild type infections., timeFrame - days 0, 2, 7",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01849640",
    "endpoint": "measure - Efficacy of Primaquine to treat sexual stage gametocyte infection and prevent transmission of P. falciparum gametocytes to mosquitoes., description - To detect efficacy of a onetime dose of primaquine after completion of therapy for blood stage infection on gametocytemia that may persist after DP treatment by using comparative rates of sexual stage infections between patients dosed with and without primaquine based on a composite endpoint of light microscopy and PCR detection and staging of gamteocytes with mosquito membrane feeding assay to detect oocysts in sterile lab-reared mosquitoes., timeFrame - 3 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00400101",
    "endpoint": "measure - Antibody concentration by IFAT and Western blot, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00400101",
    "endpoint": "measure - Cellular immunity, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00164359",
    "endpoint": "measure - Rate of adequate clinical and parasitological response at 14 days, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00164359",
    "endpoint": "measure - Rate of adequate clinical and parasitological response at 28 days, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00164359",
    "endpoint": "measure - Mean percent change in blood haemoglobin concentration between day 0 and day 28, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00164359",
    "endpoint": "measure - Incidence of adverse events other than abdominal pain during the period of observation, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00164359",
    "endpoint": "measure - Rate of Early Treatment Failure (per WHO definition), description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00164359",
    "endpoint": "measure - Rate of Late Clinical Failure (per WHO definition), description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00164359",
    "endpoint": "measure - Rate of Late Parasitological Failure (per WHO definition), description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00164359",
    "endpoint": "measure - Percent of patients with a decrease in haemoglobin concentration, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00164359",
    "endpoint": "measure - Percent of patients with a decrease in haemoglobin concentration of &gt;= 2g&#x2F;dl, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00164359",
    "endpoint": "measure - Prevalence of parasitemia on Day 2, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00164359",
    "endpoint": "measure - Prevalence of parasitemia on Day 3, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00164359",
    "endpoint": "measure - Gametocyte prevalence on Day 14, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00164359",
    "endpoint": "measure - Gametocyte prevalence on day 28, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02151578",
    "endpoint": "measure - - specific mortality preceded by acute febrile illness of children aged 6 to 59 months - severe malaria cases at community level, description - , timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03931473",
    "endpoint": "measure - Malaria Infection prevalence, description - Malaria infection prevalence measured in cross-sectional surveys 6 months and 18 months post- distribution, timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03931473",
    "endpoint": "measure - Entomological Inoculation Rate, description - EIR measured every quarter during entomological surveys, timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02647489",
    "endpoint": "measure - Area under the curve of anti-PAMVAC IgG concentration, description - , timeFrame - Before first administration, 1, 4, 5, 8, 9, 12, 24 and 36 weeks after first administration",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00811096",
    "endpoint": "measure - Recurrence (relapse, recrudescence or re-infection) of Plasmodium vivax between blood stage clearance and 90 days., description - , timeFrame - 90 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03201770",
    "endpoint": "measure - Overall safety, description - Evaluation of the adverse event reporting of Pyramax in the treatment of uncomplicated malaria under real life conditions., timeFrame - Assessment up to Day 28.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03201770",
    "endpoint": "measure - Evaluation of Efficacy, description - Evaluation of the efficacy based on crude Day 28 cure rate by species and PCR adjusted cure rate for Day 28 cure rate for P. falciparum of Pyramax in the treatment of uncomplicated malaria under real life conditions, timeFrame - Assessment up to Day 28.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01255215",
    "endpoint": "measure - Mortality, description - , timeFrame - 48 hours and 14 days after admission",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01255215",
    "endpoint": "measure - Time to hospital discharge, description - Recovery times (time to fever resolution, time to sit unsupported, and time to hospital discharge) are standard, clinically relevant outcomes in other therapeutic trials for malaria., timeFrame - From admission to approximately 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01255215",
    "endpoint": "measure - Time to parasite clearance., description - Parasitological efficacy outcome; quantitative assessment of parasite density by light microscopy of Giemsa-stained thin smears., timeFrame - From admission to approximately 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01255215",
    "endpoint": "measure - Biomarkers and genetic determinants of endothelial activation, inflammation and coagulopathy, to be determined., description - Biomarkers and genetic determinants of severe malaria pathogenesis may provide additional insight into the pathways and processes altered in cerebral malaria and affected by iNO delivery.\nWe plan to examine biomarkers of endothelial activation, inflammation including cytokines, and coagulopathy which are central to the pathophysiology of severe malaria.\nIn addition, genetic pathways involved in severe malaria and response to iNO will be investigated., timeFrame - From admission to approximately 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02987270",
    "endpoint": "measure - Prevalence of malaria infection, description - Prevalence of malaria infections diagnosed by blood smear microscopy were determined during three cross-sectional studies at baseline, after year 1, and after year 2., timeFrame - After year 1 and after year 2",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02987270",
    "endpoint": "measure - Incidence of clinical malaria, description - Incidence of clinical malaria as determined by passive surveillance in the ten study health facilities, after year 1 and after year 2., timeFrame - After year 1 and after year 2",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02987270",
    "endpoint": "measure - Entomological indices of transmission, description - Sporozoite and oocyst rates were compared in malaria vectors captured during pyrethrum spray catches and aspirations after year 1 and after year 2., timeFrame - After year 1 and after year 2",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02482116",
    "endpoint": "measure - Hospitalisation (yes&#x2F;no), description - This will be assessed for all study participants with either a malaria or pneumonia diagnosis as part of an epidemiological study, timeFrame - Within 30 days of first consultation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02482116",
    "endpoint": "measure - Death (yes&#x2F;no), description - This will be assessed for all study participants with either a malaria or pneumonia diagnosis as part of an epidemiological study, timeFrame - Within 30 days of first consultation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01019408",
    "endpoint": "measure - parasite clearance time, description - , timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01019408",
    "endpoint": "measure - fever clearance time, description - , timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01019408",
    "endpoint": "measure - gametocytaemia, description - , timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00473837",
    "endpoint": "measure - Curve of Hb Change Between Day 3 and Day 30 in the Two Placebo Arms; Changes in Markers of Iron Status, Measures of Inflammation, and Hb Response Between Day 3 and Day 30, and Between Day 3 and Day 90, description - , timeFrame - 90 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04223674",
    "endpoint": "measure - Time-to recur, description - Difference in the time-to recur of P. vivax by PCR in SSAT and control arms., timeFrame - 9 month",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04223674",
    "endpoint": "measure - Recurrence number, description - Difference in the number of recurrent P. vivax by PCR in SSAT vs. control arms, timeFrame - 9 month",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04223674",
    "endpoint": "measure - Recurrent symptomatic P. vivax, description - Difference in the incidence of recurrent symptomatic P. vivax by microscopy in SSAT vs control arms, timeFrame - 9 month",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04223674",
    "endpoint": "measure - Seroconversion rate, description - Seroconversion rate before and after intervention in SSAT and control arms., timeFrame - 9 month",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04223674",
    "endpoint": "measure - point-of-care assay performance, description - Sensitivity and specificity of point-of-care antibody detection test vs. gold standard Luminex assay, timeFrame - one month",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04223674",
    "endpoint": "measure - Adverse event and severe adverse event, description - Adverse event (AE) and Severe Adverse Event (SAE) of high dose PQ in schoolchildren., timeFrame - 9 month",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04223674",
    "endpoint": "measure - Sahli Hb, description - Hb level in Sahli&#x27;s method, Standard G6PD (SD Biosensor Inc., ROK) in comparison with (HemoCue AB, Angelholm, Sweden)., timeFrame - One month",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04223674",
    "endpoint": "measure - Skin gametocyte, description - Sensitivity and specificity of microscopic examination to detect parasitemia from the shallow skin vasculature of the ankle (light microscopy-skin&#x2F;LMS) compared to standard microscopic (light microscopy-finger&#x2F;LMF) and PCR., timeFrame - 9 month",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04223674",
    "endpoint": "measure - Gametocyte duration, description - Mean duration time of gametocyte in LMS and LMF, timeFrame - 9 month",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04223674",
    "endpoint": "measure - Hemozoin detection, description - Sensitivity and specificity of magneto-optical hemozoin detection (MOD) compared to standard malaria detection and PCR., timeFrame - One month",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01365598",
    "endpoint": "measure - Mean (+&#x2F;- SD) area under the curve of gametocyte density per day during 14 days of follow-up, description - An estimate of the area under the curve of gametocytes (measured by QT-NASBA) seen over time, averaged per day of follow up (days 0-14) and interpolated from measured data points, timeFrame - 14 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01365598",
    "endpoint": "measure - Requirement for blood transfusion, description - Percentage of children receiving blood transfusion per treatment arm during days 0-28, timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01365598",
    "endpoint": "measure - Follow-up day of Hb nadir, description - Mean day of follow up (day 0-28) per treatment arm of lowest Hb measurement (by Hemocue®), timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01365598",
    "endpoint": "measure - Incidence of serious adverse events by sign, symptom, laboratory parameter and relationship to taking study drug, description - Percentage (number) per treatment arm during days 0-28, timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01365598",
    "endpoint": "measure - Incidence of gastrointestinal symptoms after taking study drug, description - Percentage (number) of children with gastrointestinal symptoms per treatment arm during days 2-7, timeFrame - 6 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00082563",
    "endpoint": "measure - tolerability, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00513500",
    "endpoint": "measure - Number of Children Who do Not Respond to Treatment for Pneumonia, description - , timeFrame - one year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01669941",
    "endpoint": "measure - Decreased fetal morbidity, description - <p>Decreased fetal morbidity, defined as the composite of any of the following:</p><ul><li>Preterm birth (birth before 37 weeks gestation)</li><li>Low-birth-weight (birth weight under 2,500 grams)</li><li>Small for gestational age (SGA) defined as a binary outcome of &lt;10th percentile of fetal weight for attained gestational age using the Landis fetal weight nomogram from the Democratic Republic of Congo</li></ul>, timeFrame - Delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01669941",
    "endpoint": "measure - Frequency of fetal congenital malformations, description - , timeFrame - At delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01669941",
    "endpoint": "measure - Pharmacokinetics- piperaquine level, description - , timeFrame - At baseline, and day 2 and day 7 following dosing.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01669941",
    "endpoint": "measure - level of antibodies to variant surface antigens (VSAs), description - , timeFrame - At delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01669941",
    "endpoint": "measure - Frequency of maternal adverse events, description - , timeFrame - At each ANC visit and at delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01122134",
    "endpoint": "measure - Time to 50% parasite clearance (PCT50), description - Time to 50% parasite clearance (PCT50) parasite clearance rates and clinical recovery, timeFrame - 7 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00460369",
    "endpoint": "measure - effectiveness comparisons (PCR corrected), description - , timeFrame - day 14 and day 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00460369",
    "endpoint": "measure - incidence of adverse events, description - , timeFrame - day 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01546961",
    "endpoint": "measure - Relationship between pharmacokinetics and symptoms, description - Chloroquine pharmacokinetics versus symptomatology, timeFrame - 63 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01546961",
    "endpoint": "measure - Efficacy of Chloroquine, description - Chloroquine efficacy against P.vivax, timeFrame - 63 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01546961",
    "endpoint": "measure - Reticulocyte counts, description - Effect of chloroquine treatment on reticulocyte counts, timeFrame - 63 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01546961",
    "endpoint": "measure - Pregnancy outcomes, description - Pregnancy outcomes (abortions, low birth weight, premature birth, congenital abnormality, stillbirths, neonatal and infant mortality), timeFrame - 63 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00878007",
    "endpoint": "measure - Prevalence of malaria parasitemia, description - , timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00878007",
    "endpoint": "measure - Concentration as assessed by classroom-based tests of sustained attention, description - , timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00878007",
    "endpoint": "measure - School attendance as assessed by class attendance registers, description - , timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00878007",
    "endpoint": "measure - Examination results as assessed by government examination scores, description - , timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00878007",
    "endpoint": "measure - Cost-effectiveness, description - Cost-effectiveness analysis will consider improvements in educational achievement and reductions in anaemia, timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00878007",
    "endpoint": "measure - Community acceptability, description - A modified stakeholder analysis will assess key people&#x27;s views on the implementation and longer-term sustainability of the programme., timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00322907",
    "endpoint": "measure - Parasitological failure rate on day 14, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00322907",
    "endpoint": "measure - Fever clearance time, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00322907",
    "endpoint": "measure - Parasite clearance time, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00322907",
    "endpoint": "measure - Symptoms clearance time, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00322907",
    "endpoint": "measure - Occurrence of complications, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01047436",
    "endpoint": "measure - Parasite Clearance Time, description - Time in hours from the initiation of therapy until the first of two successive parasite-negative smears were obtained, timeFrame - 3h (hours), 6h, 12h, 18h, 24h, 30h, 36h, 48h, 54h, 60h",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01047436",
    "endpoint": "measure - Parasite Reduction Ratio (PRR) at 24 h (Hours) After the First Dose, description - Reduction in parasitaemia from baseline at 24 h after the first dose of study medication, timeFrame - 24 hours after first dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01047436",
    "endpoint": "measure - Parasite Reduction Ratio (PRR) at 12 Hours After the First Dose, description - Reduction in parasitaemia from baseline at 12 hours after the first dose of study medication, timeFrame - 12 h (hours) after first dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00223990",
    "endpoint": "measure - Time to First Clinical Episode of P Falciparum Malaria During the Efficacy Follow-up Period Adjusted for Time at Risk - According to Protocol (ATP) Population, description - <p>Days to first clinical episode of P falciparum malaria during the efficacy f&#x2F;u period for ATP population</p><p>Time at Risk adjusted for:</p><p>SA= study absence MT= malaria treatment SA MT= study absence and malaria treatment</p><p>Case Definitions:</p><p>Primary = &gt;37.5°C\nwith presence of a density of asexual stage P. falciparum &gt;50K parasites&#x2F;µL blood Secondary (200) = &gt;37.5°C\nwith presence of a density of asexual stage P. falciparum &gt;200K parasites&#x2F;µL blood Secondary (100) = &gt;37.5°C\nwith presence of a density of asexual stage P. falciparum &gt;100K parasites&#x2F;µL blood Secondary (10) = &gt;37.5°C\nwith presence of a density of asexual stage P. falciparum &gt;10K parasites&#x2F;µL blood Secondary (0) = &gt;37.5°C\nwith presence of a density of asexual stage P. falciparum &gt;0 parasites&#x2F;µL blood Secondary (0*) = &gt;37.5°C\nOR history of fever in the last 24 hrs with presence of a density of asexual stage P. falciparum &gt;0 parasites&#x2F;µL blood</p>, timeFrame - starting 14 days after the 3rd vaccination (day 71), every 28 days and ending on day 240",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00223990",
    "endpoint": "measure - Vaccine-Related Solicited Symptoms During 7-day Follow-up Period by Immunization - Intent to Treat (ITT) Population, description - <p>Each subject participated in the study approximately 14 months with 7-day follow-up for solicited adverse events (five visits: vaccination day plus post-vaccination days 1, 2, 3, and 6).</p><p>I1 = Immunization 1 I2 = Immunization 2 I3 = Immunization 3</p>, timeFrame - vaccination day plus post-vaccination days 1, 2, 3, and 6",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00223990",
    "endpoint": "measure - Vaccine-Related Solicited Symptoms During 7-day Follow-up Period by Immunization - According to Protocol (ATP) Population, description - <p>Each subject participated in the study approximately 14 months with 7-day follow-up for solicited adverse events (five visits: vaccination day plus post-vaccination days 1, 2, 3, and 6).</p><p>I1 = Immunization 1 I2 = Immunization 2 I3 = Immunization 3</p>, timeFrame - vaccination day plus post-vaccination days 1, 2, 3, and 6",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00223990",
    "endpoint": "measure - Vaccine-Related Unsolicited Adverse Events by Immunization - Intent to Treat (ITT) Population, description - <p>Each subject participated in the study approximately 14 months with 7-day follow-up for solicited adverse events (five visits: vaccination day plus post-vaccination days 1, 2, 3, and 6) and 30-day follow-up for unsolicited events (vaccination day plus 29 subsequent days).</p><p>I1 = Immunization 1 I2 = Immunization 2 I3 = Immunization 3</p>, timeFrame - vaccination day and 29 subsequent days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00223990",
    "endpoint": "measure - Vaccine-Related Unsolicited Adverse Events by Immunization - According to Protocol (ATP) Population, description - <p>Each subject participated in the study approximately 14 months with 7-day follow-up for solicited adverse events (five visits: vaccination day plus post-vaccination days 1, 2, 3, and 6) and 30-day follow-up for unsolicited events (vaccination day plus 29 subsequent days).</p><p>I1 = Immunization 1 I2 = Immunization 2 I3 = Immunization 3</p>, timeFrame - vaccination day and 29 subsequent days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00223990",
    "endpoint": "measure - Number of Patients Who Showed Symptoms, Unsolicited Adverse Events, and Serious Adverse Events by Immunization, description - Each subject participated in the study approximately 14 months with 7-day follow-up for solicited adverse events (five visits: vaccination day plus post-vaccination days 1, 2, 3, and 6) and 30-day follow-up for unsolicited events (vaccination day plus 29 subsequent days).\nFollow-up of SAEs continued for study duration (364 days), timeFrame - vaccination day plus post-vaccine days 1, 2, 3, and 6; 30 day follow-up for unsolicited events and follow-up for SAEs to continue for duration of study (364 days)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00223990",
    "endpoint": "measure - Vaccine-Related Local and Systemic Solicited Adverse Events by Immunization - According to Protocol (ATP), description - <p>Each subject participated in the study approximately 14 months with 7-day follow-up for solicited adverse events (five visits: vaccination day plus post-vaccination days 1, 2, 3, and 6) and 30-day follow-up for unsolicited events (vaccination day plus 29 subsequent days).</p><p>I1 = Immunization 1 I2 = Immunization 2 I3 = Immunization 3</p>, timeFrame - vaccination day plus 29 subsequent days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00223990",
    "endpoint": "measure - Vaccine-Related Local and Systemic Solicited Adverse Events by Immunization - Intent to Treat (ITT), description - <p>Each subject participated in the study approximately 14 months with 7-day follow-up for solicited adverse events (five visits: vaccination day plus post-vaccination days 1, 2, 3, and 6) and 30-day follow-up for unsolicited events (vaccination day plus 29 subsequent days).</p><p>I1 = Immunization 1 I2 = Immunization 2 I3 = Immunization 3</p>, timeFrame - vaccination day plus 29 subsequent days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01076868",
    "endpoint": "measure - Adverse events, description - Adverse event profile of primaquine, timeFrame - Up to 3 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04271306",
    "endpoint": "measure - Determine the Pfs25 specific antibody responses following immunization with different vaccination regimens in healthy Tanzanian adults and children., description - Pfs25 antibody levels elicited by Pfs25IMX313-Matrix-M as measured by ELISA at each time point where serology samples are analysed., timeFrame - Duration of the study (approx 2 years)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04271306",
    "endpoint": "measure - Determine the transmission blocking activity of Pfs25 specific antibodies elicited by the different vaccination regimens in healthy Tanzanian adults and children using Standard Membrane Feeding Assay (SMFA) and Direct Membrane feeding assay (DMFA)., description - Transmission blocking activity (TBA) of induced antibody as measured in standard membrane feeding assays (SMFA) and Direct Membrane feeding assays (DMFA)., timeFrame - Duration of the study (approx 2 years)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04271306",
    "endpoint": "measure - Determine the transmission blocking activity of Pfs25 specific antibodies elicited by the different vaccination regimens in healthy Tanzanian adults and children using Standard Membrane Feeding Assay (SMFA) and Direct Membrane feeding assay (DMFA)., description - Correlation of TBA with antibody levels at each time point where the membrane feeding assays are conducted., timeFrame - Duration of the study (approx 2 years)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04271306",
    "endpoint": "measure - Select the best vaccination regimen based on the peak Pfs25 specific antibodies after final immunization, their duration and transmission blocking activity by standard membrane feeding assay (SMFA) and direct membrane feeding assay (DMFA)., description - The vaccination schedule that lead to the highest peak and duration of anti-Pfs25 antibody response post vaccination, and the highest transmission blocking activity (TBA) as measured by standard membrane feeding assay (SMFA) and direct membrane feeding assay (DMFA)., timeFrame - Duration of the study (approx 2 years)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01376167",
    "endpoint": "measure - Number of Participants With Recurrence-free Efficacy at 4 Months Post Dose, description - A participant (par) was considered to have demonstrated recurrence-free efficacy at 4 months if: a) Par had non-zero P vivax asexual parasite count at Baseline.\nb) Par showed initial clearance of P vivax parasitemia.\nc) Par had no positive asexual P vivax parasite count at any assessment prior to or on Study Day 130 following initial parasite clearance.\nd) Par did not take a concomitant medication with anti-malarial activity at any point between Study Day 1 and their last parasite assessment after Study Day 109 (up to and including Study Day 130).\ne) Par is parasite-free at 4 months defined as a negative asexual P vivax parasite count at the first parasite assessment performed after Study Day 109 (up to and including Study Day 130).\nPar were censored if they did not have P.vivax at Baseline, or took a drug with anti-malarial action despite not having malaria parasites or did not have a 4 month assessment.\nThe number of par with recurrence-free efficacy at 4 months has been summarized., timeFrame - 4 months post dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01376167",
    "endpoint": "measure - Time to Recurrence of P Vivax Malaria, description - Recurrence was defined as the first confirmed presence of P vivax asexual stage parasites after clearance of initial parasitemia following CQ treatment.\nTime to recurrence was defined as the time (in days) from initial parasite clearance to recurrence.\nThe time to recurrence was analyzed by the Kaplan-Meier method.\nNA indicates data was not available due to insufficient number of participants with events during the follow up period in the study.\nThe median number of days to recurrence along with 95% confidence interval has been presented for each treatment group., timeFrame - Up to Day 180",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01376167",
    "endpoint": "measure - Time to Parasite Clearance, description - Parasite clearance time was defined as time needed to clear asexual parasite from the blood that is, parasite numbers falling below the limit of detection in the thick blood smear and remaining undetectable after 6 to 12 hours.\nThe time taken to achieve parasite clearance was analyzed using Kaplan Meier Methodology.\nThe median parasite clearance time along with 95% confidence interval has been presented for each treatment group., timeFrame - Up to Day 180",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01376167",
    "endpoint": "measure - Time to Fever Clearance, description - Fever clearance time was defined as time from first dose of treatment to the time when body temperature falls to normal within Study Days 1-4 and remains normal for at least 48 hours up to the Day 8 visit.\nFever clearance was considered to have been achieved once an initial temperature of more than 37.40 degree Celsius is reduced to a value less than or equal to 37.40 degree Celsius and in the absence of value more than 37.40 degree Celsius in the following 48 hours up to the Day 8 visit.\nThe time taken to achieve fever clearance was analyzed using Kaplan Meier Methodology.\nThe median fever clearance time along with 95% confidence interval has been presented for each treatment group., timeFrame - Up to Day 180",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01376167",
    "endpoint": "measure - Number of Participants With Hemoglobin Decline From Baseline Over First 29 Days, description - Glucose-6-phosphate dehydrogenase deficiency (G6PD) deficiency is known to be a risk factor for hemolysis in participants treated with 8-aminoquinolines.\nBlood samples were collected for the evaluation of hemoglobin levels.\nHemoglobin decreases of &gt;=30% or &gt;3 grams&#x2F;deciliter (g&#x2F;dL) from Baseline; or, an overall drop in hemoglobin below 6.0 g&#x2F;dL in the first 15 days of the study were considered as protocol defined serious adverse events (SAEs).\nNumber of participants with maximum hemoglobin decline from Baseline over first 29 days of study has been summarized.\nSafety Population consisted of all randomized participants who received at least one dose of study medication., timeFrame - Baseline and up to Day 29",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01376167",
    "endpoint": "measure - Number of Participants With Treatment Emergent Adverse Events (TEAEs) Potentially Related to Hemoglobin Decrease, description - TEAEs are defined as adverse events (AEs) with an onset date and time on or after that of the start of first dose of study medication (including CQ).\nThe number of participants with TEAEs potentially related to hemoglobin decrease has been presented., timeFrame - Up to Day 180",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01376167",
    "endpoint": "measure - Number of Participants Who Received Blood Transfusion, description - The number of participants who received blood transfusion as a result of hemoglobin decline has been summarized., timeFrame - Up to Day 180",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01376167",
    "endpoint": "measure - Number of Participants With Acute Renal Failure, description - There were no participants with acute renal failure in the study., timeFrame - Up to Day 180",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01376167",
    "endpoint": "measure - Change From Baseline in Percent Methemoglobin, description - Methemoglobin assessment was made with the aid of a non-invasive signal extraction pulse CO-Oximeter handheld machine (Masimo).\nThe change from Baseline in percent methemoglobin by treatment, time and sex has been summarized.\nThe last assessment performed prior to the first dose of study medication (CQ or randomized treatment) was considered as Baseline.\nChange from Baseline was calculated as the post baseline assessment minus the Baseline assessment for percent methemoglobin.\nOnly those participants with data available at the specified data points were analyzed., timeFrame - Baseline and up to Day 120",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01376167",
    "endpoint": "measure - Number of Participants With Gastrointestinal Disorders, description - Gastrointestinal tolerability was analyzed by the number of par experiencing gastrointestinal disorders such as abdominal pain, heartburn, diarrhea, constipation, nausea, and vomiting.\nThe number of participants with gastrointestinal disorders for each treatment group has been summarized., timeFrame - Up to Day 180",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01376167",
    "endpoint": "measure - Number of Participants With Keratopathy, description - Ophthalmic assessments were carried out at pre-qualified sites (Manaus) prior to randomization and at Days 29 and 90 and at withdrawal.\nAssessments were carried out at Day 180 if the Day 90 assessments showed abnormalities.\nThe last assessment performed on the day of randomization or earlier was considered Baseline.\nThe number of participants displaying keratopathy in each eye was summarized for each visit.\nThe number of participants with new keratopathy at any time post Baseline was also reported.\nOphthalmic Safety Population comprised of all participants in the Safety Population who have results from any eye assessments.\nOnly those participants with data available at the specified data points were analyzed., timeFrame - Up to Day 180",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01376167",
    "endpoint": "measure - Incidence of Visual Field Abnormalities Based on Best Corrected Visual Acuity Test Scores, description - Ophthalmic assessments were carried out at pre-qualified sites (Manaus) prior to randomization and at Days 29 and 90 and at withdrawal.\nAssessments were carried out at Day 180 if the Day 90 assessments showed abnormalities.\nThe last assessment performed on the day of randomization or earlier was considered Baseline.\nBest corrected visual acuity was assessed individually for each eye.\nScores were recorded as a ratio.\nThe values were used to derive a logMAR score for statistical analysis where logMAR=-1x log10 (ratio score).\nThe mean and standard deviation of logMAR score for each treatment group has been summarized.\nHigh scores were associated with worse vision, and low scores with better vision.\nOnly those participants with data available at the specified data points were analyzed., timeFrame - Up to Day 180",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01376167",
    "endpoint": "measure - Number of Participants With Retinal Changes From Baseline, description - Ophthalmic assessments were carried out at pre-qualified sites (Manaus) prior to randomization and at Days 29 and 90 and at withdrawal.\nAssessments were carried out at Day 180 if the Day 90 assessments showed abnormalities.\nThe last assessment performed on the day of randomization or earlier was considered Baseline.\nChange from Baseline was calculated as the post Baseline assessment minus the Baseline assessment.\nThe number of participants with definite retinal change and questionable (ques) retinal change from Baseline was presented.\nOnly those participants with data available at the specified data points were analyzed., timeFrame - Baseline and up to Day 180",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01376167",
    "endpoint": "measure - Number of Participants With TEAEs and Serious TEAEs, description - An AE is defined as any untoward medical occurrence in a participant under clinical investigation, temporarily associated with the use of a medicinal product, whether or not considered related to the medicinal product.\nSAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability&#x2F;incapacity, is a congenital anomaly&#x2F; birth defect, other situations and is associated with possible drug induced liver injury with hyperbilirubinemia.\nTEAEs is defined as AEs with an onset date and time on or after that of the start of first dose of study medication (including CQ).\nNumber of participants with TEAEs and serious TEAEs have been presented., timeFrame - Up to Day 180",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01376167",
    "endpoint": "measure - Number of Participants With TEAEs by Maximum Intensity, description - An AE is defined as any untoward medical occurrence in a participant under clinical investigation, temporarily associated with the use of a medicinal product, whether or not considered related to the medicinal product.\nTEAE is defined as AEs with an onset date and time on or after that of the start of first dose of study medication (including CQ).\nNumber of participants with AEs based on severity has been presented., timeFrame - Up to Day 180",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01376167",
    "endpoint": "measure - Number of Participants With Hematology Laboratory Data Outside the Reference Range, description - Blood samples were collected for the evaluation of hematology parameters including eosinophils, leukocytes, lymphocytes, neutrophils, platelets, reticulocytes and methemoglobin.\nThe number of participants with hematology laboratory data outside the extended normal range (F3) was presented.\nThe upper and lower limits for F3 range were defined by multiplying the normal range limits by different factors.\nHigh and low indicated that the participants had values flagged as high and low respectively for the particular parameter any time on-treatment.\nOnly those participants with data available at the specified data points were analyzed., timeFrame - Up to Day 120",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01376167",
    "endpoint": "measure - Number of Participants With Clinical Chemistry Laboratory Data Outside the Reference Range, description - Blood samples were collected for the evaluation of clinical chemistry parameters including Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.\nPhos), Aspartate Aminotransferase (AST), bilirubin, creatine kinase, creatinine, glomerular filtration rate (GFR), indirect bilirubin and urea.\nThe number of participants with clinical chemistry laboratory data outside the extended normal range (F3) was presented.\nThe upper and lower limits for F3 range were defined by multiplying the normal range limits by different factors.\nHigh and low indicated that the participants had values flagged as high and low respectively for the particular parameter any time on-treatment.\nOnly those participants with data available at the specified data points were analyzed., timeFrame - Up to Day 120",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01376167",
    "endpoint": "measure - Cost Associated With Recurrence Episode of P Vivax Malaria, description - Health outcomes were evaluated based on the total costs spent on treatment, transport, medication and tests.\nThe cost was summarized according to the place at which the participant went to for care (drug shop, trial clinic, other clinic, hospital (inpatient&#x2F;outpatient), traditional healer, other).\nThe reported costs by type and by site has been summarized.\nWhere costs have not been reported at a visit, the number of participants analyzed is given as 0. Only those participants with data available at the specified data points were analyzed., timeFrame - Up to Day 180",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01376167",
    "endpoint": "measure - Cost Incurred With Purchase of Medications Associated With Recurrence Episode of Malaria, description - Health outcomes were evaluated based on the cost of medications purchased.\nThe reported total medication cost for paracetamol associated with recurrence episode of P vivax malaria has been reported by site.\nWhere costs have not been reported at a visit, the number of participants analyzed is given as 0. Medications recorded as &quot;Other&quot; and medications without costs are excluded from the analysis.\nOnly those participants with data available at the specified data points were analyzed., timeFrame - Up to Day 180",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01376167",
    "endpoint": "measure - Time Lost by Participants or Care Givers From Normal Occupation, description - Health outcomes were evaluated based on total time lost by participants or care givers due to an episode of malaria.\nThe reported time lost due to recurrence episode of P vivax malaria has been summarized by category and by site.\nWhere categories by site have not been reported at a visit, the number of participants analyzed is given as 0. Only those participants with data available at the specified data points were analyzed., timeFrame - Up to Day 180",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01376167",
    "endpoint": "measure - Number of Participants With Action Taken to Treat Recurrence Episode of P Vivax Malaria, description - Health outcomes were evaluated based on the actions taken by the participants to treat recurrence episode of P vivax malaria.\nThe reported action taken by site is summarized.\nWhere no action by site have been reported at a visit, the number of participants analyzed is given as 0. Only those participants with data available at the specified data points were analyzed., timeFrame - Up to Day 180",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01376167",
    "endpoint": "measure - Oral Clearance (CL&#x2F;F) of TQ, description - Apparent population oral clearance of TQ, timeFrame - Day 2, Day 8, Day 15, Day 29 and Day 60",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01376167",
    "endpoint": "measure - Volume of Distribution (Vc&#x2F;F) of TQ, description - Apparent population central volume of distribution of TQ, timeFrame - Day 2, Day 8, Day 15, Day 29 and Day 60",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00565071",
    "endpoint": "measure - unit cost of non-malaria febrile treatment; therapeutic behaviour in light of pressure to prescribe antimalarials, description - , timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01388842",
    "endpoint": "measure - Mortality, description - Reduction in mortality at 48 hours, timeFrame - 48 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01388842",
    "endpoint": "measure - coma score, description - normalisation of coma score (Blantyre coma scale), timeFrame - 48 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01388842",
    "endpoint": "measure - retinopathy, description - Normalisation of malaria retinopathy measured by indirect fundoscopy, timeFrame - every 6 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01388842",
    "endpoint": "measure - tone, description - Improvement of posture and tone, timeFrame - 48 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01388842",
    "endpoint": "measure - Measure of occurrence of neurological sequelae in children, description - Reduction of incidence of neurological sequelae, including motor dysfunction, behavioral disorders, hearing, speech and sight disorders and seizure disorders., timeFrame - months 1, 3 and 6",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01388842",
    "endpoint": "measure - Vital signs, description - Improvement of vital signs: Systolic and diastolic blood pressure, pulse rate, temperature, timeFrame - every 6 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01388842",
    "endpoint": "measure - oxygen saturation, description - Both Hb Oxygen saturation (SpO2) and total MetHb levels continuously measured by pulse oximetry (Rascal Model 7, Massimo Corp.), timeFrame - every 6 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00113854",
    "endpoint": "measure - Time taken to sit un supported, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00113854",
    "endpoint": "measure - Time to begin oral intake, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00113854",
    "endpoint": "measure - Duration of hospitalisation, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00113854",
    "endpoint": "measure - Mortality, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00113854",
    "endpoint": "measure - Proportion of children recovering with neurological sequelae, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05911828",
    "endpoint": "measure - Area under the curve from the time of dosing to the last measurable concentration (AUC0-t)., description - Estimation of PK parameters of ZY19489, its major metabolite and FQ and its major metabolite using noncompartmental method.To characterize the PK of ZY19489-FQ combination in African asymptomatic adult carriers of Plasmodium falciparum mono-infections, timeFrame - Day 0 to Day 64",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05911828",
    "endpoint": "measure - Area under the curve from the time of dosing to the infinity (AUC0-∞), description - Estimation of PK parameters of ZY19489, its major metabolite and FQ and its major metabolite using noncompartmental method.To characterize the PK of ZY19489-FQ combination in African asymptomatic adult carriers of Plasmodium falciparum mono-infections, timeFrame - Day 0 to Day 64",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05911828",
    "endpoint": "measure - Maximum plasma concentration (Cmax), description - Estimation of PK parameters of ZY19489, its major metabolite and FQ and its major metabolite using noncompartmental method.To characterize the PK of ZY19489-FQ combination in African asymptomatic adult carriers of Plasmodium falciparum mono-infections, timeFrame - Day 0 to Day 64",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05911828",
    "endpoint": "measure - Time to reach maximum plasma concentration (Tmax), description - Estimation of PK parameters of ZY19489, its major metabolite and FQ and its major metabolite using noncompartmental method.To characterize the PK of ZY19489-FQ combination in African asymptomatic adult carriers of Plasmodium falciparum mono-infections, timeFrame - Day 0 to Day 64",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05911828",
    "endpoint": "measure - Terminal half life (t1&#x2F;2), description - Estimation of PK parameters of ZY19489, its major metabolite and FQ and its major metabolite using noncompartmental method.To characterize the PK of ZY19489-FQ combination in African asymptomatic adult carriers of Plasmodium falciparum mono-infections, timeFrame - Day 0 to Day 64",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05911828",
    "endpoint": "measure - Clearance (CL&#x2F;F), description - Estimation of PK parameters of ZY19489, its major metabolite and FQ and its major metabolite using noncompartmental method.To characterize the PK of ZY19489-FQ combination in African asymptomatic adult carriers of Plasmodium falciparum mono-infections, timeFrame - Day 0 to Day 64",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05911828",
    "endpoint": "measure - Volume of distribution (Vd&#x2F;F), description - Estimation of PK parameters of ZY19489, its major metabolite and FQ and its major metabolite using noncompartmental method.To characterize the PK of ZY19489-FQ combination in African asymptomatic adult carriers of Plasmodium falciparum mono-infections, timeFrame - Day 0 to Day 64",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05911828",
    "endpoint": "measure - Elimination rate constant (λ), description - Estimation of PK parameters of ZY19489, its major metabolite and FQ and its major metabolite using noncompartmental method.To characterize the PK of ZY19489-FQ combination in African asymptomatic adult carriers of Plasmodium falciparum mono-infections, timeFrame - Day 0 to Day 64",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03896724",
    "endpoint": "measure - Duration of Protective efficacy (number of cases) against clinical malaria, description - To assess the protective efficacy (number of cases) against clinical malaria of R21 adjuvanted with Matrix-M in 5-17 months old children living in a malaria-endemic area, timeFrame - for 12 months after administration of the third dose of vaccine, and for 6 and 12 months after each booster vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03896724",
    "endpoint": "measure - Efficacy (number of cases) against asymptomatic P. falciparum infection, description - Primary case definition of asymptomatic P. falciparum infection: Presence of axillary temperature &lt; 37.5°C and absence of history of fever within the last 24 hours; AND P. falciparum parasites density &gt; 0 asexual forms&#x2F;µL, timeFrame - at 6 and 12 months after administration of the third dose of vaccine, and for 12 months after each booster vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03896724",
    "endpoint": "measure - The safety and reactogenicity (number of adverse events) of R21 adjuvanted with Matrix-M in 5-17 month olds living in a malaria-endemic area in the month following each vaccination and at 12 months after administration of the final dose of vaccine, description - <ul><li>Occurrence of solicited local and&#x2F;or systemic reactogenicity signs and symptoms for 7 days following the vaccination</li><li>Occurrence of unsolicited adverse events for 28 days following the vaccination</li><li>Occurrence of serious adverse events for the duration of the trial</li></ul>, timeFrame - for 6 and 12 months after administration of the third dose of vaccine, and for 12 months after each booster vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03896724",
    "endpoint": "measure - The humoral immunogenicity (antibody response) of R21 adjuvanted with Matrix-M in 5-17 months old children living in a malaria-endemic area, description - <ul><li>Comparison of immunogenicity (antibody responses to CSP) in the R21&#x2F;MM vaccination group with those in the rabies vaccine group and the durability of responses</li><li>ELISA to quantify antibodies to the vaccine components (regions of the CS antigen including the NANP repeat region and other elements of the protein as well as anti HBs).</li></ul>, timeFrame - for 6 and 12 months after administration of the third dose of vaccine, and for 6 months after each booster vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02769013",
    "endpoint": "measure - Number of participants with positive serum antibodies specific to the asexual and gametocyte stages of Plasmodium falciparum., description - Number of participants with serum antibodies against P. falciparum gametocyte and&#x2F;or asexual blood stage antigens will be assessed., timeFrame - 15 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02769013",
    "endpoint": "measure - Percentage of mosquitoes attracted to Schistosoma-infected participants to non-infected individuals in a wind-tunnel assay., description - 100 mosquitoes will be released to Schistosoma infected and non-infected participants simultaneously lying in different tents in a two-way olfactometer., timeFrame - 15 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04238689",
    "endpoint": "measure - Serum Concentration of TB31F, description - The serum concentration of TB31F will be measured in all subjects throughout the study (until day 84) by Pfs48&#x2F;45 antigen ELISA., timeFrame - All groups: 6 hours, 24 hours, 48 hours, day 7, day 14, day 21, day 28, day 56, day 84. Groups 1-4 only: end of infusion, 1 hour, 3 hours. Group 5 only: day 4 and day 10.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04238689",
    "endpoint": "measure - Pharmacodynamics&#x2F;Functional Transmission-reducing Activity of TB31F, description - Transmission-reducing activity (TRA) of serum TB31F will be assessed in all subjects throughout the study (until day 84) by standard membrane feeding assays (SMFA).\nTRA is expressed as the percentage reduction in oocysts in mosquitoes fed on gametocytes in the presence of participants&#x27; serum, compared to oocysts in mosquitoes fed on gametocytes in the presence of pooled naïve serum (control).\nGiven the limited precision of low TRA estimates and the historical threshold value of &gt;80% TRA to support clinical development of transmission-blocking vaccines, TRA &gt;80% was pre-defined as the efficacy threshold of interest., timeFrame - Groups 1 to 4: throughout study until day 84 (baseline, end of infusion, day 7, day 28, day 56, day 84). Group 5: baseline, day 2, day 4, day 7. day 10, day 14, day 28, day 56, day 84.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03241901",
    "endpoint": "measure - Gametocyte Clearance, description - PCR determined gametocyte carriage&#x2F;clearance times, timeFrame - 42 Days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03241901",
    "endpoint": "measure - Cure Rate, description - Crude and PCR corrected cure rates by day 28, timeFrame - 28 Days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03241901",
    "endpoint": "measure - Genetic Markers of Drug Resistance, description - Selection of genetic drug resistance markers during the early treatment phase, timeFrame - 6 Days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03241901",
    "endpoint": "measure - Pharmacokinetics, description - Area under the plasma concentration versus time curve (AUC) of Artemether-lumefantrine, timeFrame - 7 Days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03241901",
    "endpoint": "measure - Peak Plasma Concentration (Cmax), description - Peak Plasma Concentration (Cmax) of Lumefantrine measured for 28 days, timeFrame - At hours, -1, 0 ,2 ,4 ,12, 24, 36, 40, 48, 52, 60, 72, 84, 88, 96, 100, 108,120, 132, 134, 136 ,144, 168, 192, 240, 336, 504 and 672",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03241901",
    "endpoint": "measure - Day 7 plasma lumefantrine, description - Day 7 plasma lumefantrine concentrations in the respective arms, timeFrame - 7 Days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04767217",
    "endpoint": "measure - Number of patients (in the artemether-lumefantrine arm) that developed molecular markers of drug (artemisinin) resistance (assessed via phenotype tests), description - , timeFrame - By day 28 post-treatment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04767217",
    "endpoint": "measure - Number of patients (in the dihydroartemisinin-piperaquine arm) that developed molecular markers of drug (artemisinin) resistance (assessed via phenotype tests), description - , timeFrame - By day 42 post-treatment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06171113",
    "endpoint": "measure - Part A: Area under the plasma drug concentration versus time curve from time zero (pre-dose) to last time of quantifiable concentration [AUC(0-t)] of GSK4024484C following single ascending doses in fasting conditions, description - , timeFrame - From study dose administration (Day 1) until the follow up contact (Day 29 +&#x2F;- 1 day post dose)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06171113",
    "endpoint": "measure - Part A: Area under the plasma drug concentration versus time curve from zero (pre-dose) extrapolated to infinite time [AUC(0-∞)] of GSK4024484C following single ascending doses in fasting conditions, description - , timeFrame - From study dose administration (Day 1) until the follow up contact (Day 29 +&#x2F;- 1 day post dose)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06171113",
    "endpoint": "measure - Part A: Maximum observed plasma drug concentration (Cmax) of GSK4024484C following single ascending doses in fasting conditions, description - , timeFrame - From study dose administration (Day 1) until the follow up contact (Day 29 +&#x2F;- 1 day post dose)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06171113",
    "endpoint": "measure - Part A: Time to maximum observed plasma drug concentration (Tmax) of GSK4024484C following single ascending doses in fasting conditions, description - , timeFrame - From study dose administration (Day 1) until the follow up contact (Day 29 +&#x2F;- 1 day post dose)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06171113",
    "endpoint": "measure - Part A: Apparent terminal half-life (t1&#x2F;2) of GSK4024484C following single ascending doses in fasting conditions, description - , timeFrame - From study dose administration (Day 1) until the follow up contact (Day 29 +&#x2F;- 1 day post dose)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06171113",
    "endpoint": "measure - Part B: AUC(0-t) of GSK4024484C following multiple ascending doses in fasting conditions, description - , timeFrame - From first study dose administration (Day 1) until the follow up contact (Day 33 +&#x2F;- 1 day post dose)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06171113",
    "endpoint": "measure - Part B: AUC(0-∞) of GSK4024484C following multiple ascending doses in fasting conditions, description - , timeFrame - From first study dose administration (Day 1) until the follow up contact (Day 33 +&#x2F;- 1 day post dose)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06171113",
    "endpoint": "measure - Part B: Cmax of GSK4024484C following multiple ascending doses in fasting conditions, description - , timeFrame - From first study dose administration (Day 1) until the follow up contact (Day 33 +&#x2F;- 1 day post dose)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06171113",
    "endpoint": "measure - Part B: Tmax of GSK4024484C following multiple ascending doses in fasting conditions, description - , timeFrame - From first study dose administration (Day 1) until the follow up contact (Day 33 +&#x2F;- 1 day post dose)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06171113",
    "endpoint": "measure - Part B: t1&#x2F;2 of GSK4024484C following multiple ascending doses in fasting conditions, description - , timeFrame - From first study dose administration (Day 1) until the follow up contact (Day 33 +&#x2F;- 1 day post dose)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06171113",
    "endpoint": "measure - Part B: Area under the plasma drug concentration versus time curve from zero to time of trough plasma concentration [AUC(0-tau)] of GSK4024484C following multiple ascending doses in fasting conditions, description - , timeFrame - Part B: From first study dose administration (Day 1) until the follow up contact (Day 33 +&#x2F;- 1 day post dose)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06171113",
    "endpoint": "measure - Part B: Trough plasma concentration (Ctau) of GSK4024484C following multiple ascending doses in fasting conditions, description - , timeFrame - From first study dose administration (Day 1) until the follow up contact (Day 33 +&#x2F;- 1 day post dose)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06171113",
    "endpoint": "measure - Part A: AUC(0-t) of GSK4024484C following single ascending doses in fed conditions, description - , timeFrame - From study dose administration (Day 1) until the follow up contact (Day 29 +&#x2F;- 1 day post dose)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06171113",
    "endpoint": "measure - Part A: AUC(0-∞) of GSK4024484C following single ascending doses in fed conditions, description - , timeFrame - From study dose administration (Day 1) until the follow up contact (Day 29 +&#x2F;- 1 day post dose)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06171113",
    "endpoint": "measure - Part A: Cmax of GSK4024484C following single ascending doses in fed conditions, description - , timeFrame - From study dose administration (Day 1) until the follow up contact (Day 29 +&#x2F;- 1 day post dose)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06171113",
    "endpoint": "measure - Part A: Tmax of GSK4024484C following single ascending doses in fed conditions, description - , timeFrame - From study dose administration (Day 1) until the follow up contact (Day 29 +&#x2F;- 1 day post dose)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06171113",
    "endpoint": "measure - Part A: t1&#x2F;2 of GSK4024484C following single ascending doses in fed conditions, description - , timeFrame - From study dose administration (Day 1) until the follow up contact (Day 29 +&#x2F;- 1 day post dose)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06171113",
    "endpoint": "measure - Part B: Observed accumulation ratio (R) of GSK4024484 based on AUC(Ro) following multiple ascending doses, description - , timeFrame - At Day 1 and at Day 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06171113",
    "endpoint": "measure - Part B: Observed accumulation ratio (R) of GSK4024484 based on Cmax(RCmax) following multiple ascending doses, description - , timeFrame - At Day 1 and at Day 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00374205",
    "endpoint": "measure - Clinical and PCR-controlled parasitological cure rate at day 14, description - , timeFrame - 14 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00374205",
    "endpoint": "measure - Effect on anaemia, description - , timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00374205",
    "endpoint": "measure - Molecular Drug Resistance Markers, description - , timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00374205",
    "endpoint": "measure - Recrudescence and Reinfection, description - , timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00374205",
    "endpoint": "measure - Effects on Gametocytemia, description - , timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00374205",
    "endpoint": "measure - Acceptance of Therapies, description - , timeFrame - 7 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00374205",
    "endpoint": "measure - Incidences of malaria episodes over a follow-up period of 1 year, description - , timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00509015",
    "endpoint": "measure - asexual parasite and gametocyte density by microscopy and molecular QT-NASBA, description - , timeFrame - monthly during the study period",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00509015",
    "endpoint": "measure - human immune responses to malaria antigens, description - , timeFrame - prior to the intervention and several months after the intervention",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00509015",
    "endpoint": "measure - the prevalence of drug resistant parasite strains, description - , timeFrame - prior to the intervention and several months after the intervention",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00509015",
    "endpoint": "measure - Possible side effects of intervention with primaquine, notably hemolysis, description - , timeFrame - one week after the intervention",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04622241",
    "endpoint": "measure - Parasite prevalence, description - Proportion of study participants with a thick blood smear positive for asexual parasites as measured by microscopy, timeFrame - 12 months following housing modification",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04622241",
    "endpoint": "measure - Prevalence of anaemia, description - Proportion of haemoglobin measurements categorised as anaemia as per WHO age-stratified guidelines, timeFrame - 12 months following housing modification",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04622241",
    "endpoint": "measure - Vector density, description - Number of female Anopheles mosquitoes captured&#x2F;room per night by CDC light traps, timeFrame - 12 months following housing modification",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04622241",
    "endpoint": "measure - Sporozoite rate, description - Proportion of captured female Anopheles mosquitoes that test positive for sporozoites, timeFrame - 12 months following housing modification",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04622241",
    "endpoint": "measure - Annual entomological inoculation rate, description - Number of infected bites per person per year (human biting rate x sporozoite rate x 365 days&#x2F;year), timeFrame - 12 months following housing modification",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04622241",
    "endpoint": "measure - Proportion of mosquitoes with insecticide resistance, description - Proportion of mosquitoes with phenotypic expression of insecticide resistance or containing genetic polymorphisms associated with resistance to insecticides of interest as identified by PCR, timeFrame - 12 months following housing modification",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04622241",
    "endpoint": "measure - Proportion of individuals satisfied with the interventions, description - Indicator of acceptability, timeFrame - 12 months following housing modification",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04622241",
    "endpoint": "measure - Proportion of households that require minimal maintenance of the implemented intervention over the period of the study, by study intervention, description - Indicator of durability, timeFrame - 12 months following housing modification",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04622241",
    "endpoint": "measure - Longer term cost of the maintenance and upkeep of the implemented intervention, by study intervention, description - Indicator of durability, timeFrame - 12 months following housing modification",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04622241",
    "endpoint": "measure - Costs of housing improvements, including maintenance, by improvement type, description - Indicator of feasibility, timeFrame - 12 months following housing modification",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04622241",
    "endpoint": "measure - Incremental cost-effectiveness ratios (ICER) of each package, description - Cost per malaria case averted, Cost per DALY averted, timeFrame - 12 months following housing modification",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04622241",
    "endpoint": "measure - Proportion of households that received the assigned housing modification, description - Indicator of fidelity, timeFrame - 12 months following housing modification",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04622241",
    "endpoint": "measure - Proportion of households that received 1 PBO LLIN for every 2 residents, description - Indicator of fidelity, timeFrame - 12 months following housing modification",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04622241",
    "endpoint": "measure - Proportion of households that received full&#x2F;partial&#x2F;no housing modifications, description - Dose delivered, timeFrame - 12 months following housing modification",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04622241",
    "endpoint": "measure - Proportion of households that received adequate&#x2F;inadequate&#x2F;no PBO LLINs, description - Dose delivered, timeFrame - 12 months following housing modification",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04622241",
    "endpoint": "measure - Proportion of households that utilized full&#x2F;partial&#x2F;no housing modifications, description - Dose received, timeFrame - 12 months following housing modification",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04622241",
    "endpoint": "measure - Proportion of household residents that slept under a PBO LLIN the previous night, description - Dose received, timeFrame - 12 months following housing modification",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04622241",
    "endpoint": "measure - Proportion of households that were fully covered by the assigned housing modification, description - Indicator of reach, timeFrame - 12 months following housing modification",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04622241",
    "endpoint": "measure - Proportion of household residents that were fully covered by the PBO LLINs, description - <p>Indicator of reach</p><p>Proportion of households fully covered by both the modifications &amp; PBO LLINs</p>, timeFrame - 12 months following housing modification",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04622241",
    "endpoint": "measure - Proportion of households fully covered by both the modifications &amp; PBO LLINs, description - Indicator of reach, timeFrame - 12 months following housing modification",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00142207",
    "endpoint": "measure - maternal anaemia - mean Hb at gestational age 36 weeks, prevalence of Hb&lt;100g&#x2F;L at gestational age 36 weeks, description - , timeFrame - Feb 2003 - Jan 2007",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00142207",
    "endpoint": "measure - spontaneous abortions, description - , timeFrame - Feb 2003 - Jan 2007",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00142207",
    "endpoint": "measure - stillbirths, description - , timeFrame - April 2003-Jan 2007",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01454752",
    "endpoint": "measure - Cognitive performance in tests of sustained attention, description - , timeFrame - 8 weeks after treatment (February 2012)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04478370",
    "endpoint": "measure - Comparison of the antibody titers determined in subgroups corresponding to different level of exposure., description - , timeFrame - Day 0, 7 (baseline), 14, 21, 28, 35, 42, 49, 56 (exposure period), 63, 70, 77, 84, 91, 98, 105 and 112 (post-exposure period).",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04478370",
    "endpoint": "measure - Comparison of the antibody titers determined in DBS and venous blood samples., description - , timeFrame - Day 0, 7 (baseline), 14, 21, 28, 35, 42, 49, 56 (exposure period), 63, 70, 77, 84, 91, 98, 105 and 112 (post-exposure period).",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00124267",
    "endpoint": "measure - Fever clearance time, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00124267",
    "endpoint": "measure - Coma recovery time, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00124267",
    "endpoint": "measure - Time to sit unsupported, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00124267",
    "endpoint": "measure - Time to begin oral intake, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00124267",
    "endpoint": "measure - Mortality, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00124267",
    "endpoint": "measure - Neurological sequelae, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00124267",
    "endpoint": "measure - Adverse drug events, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05550909",
    "endpoint": "measure - Change in mosquito infection rate assessed through membrane feeding assays (all timepoints), description - Within person percent change (presented as percent reduction) in mosquito infection rate from baseline to all feeding time-points, with comparison within and between arms., timeFrame - 6 days (day 0, day 2, day 7, day 14, day 21, day 28): 28 day span",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05550909",
    "endpoint": "measure - Mosquito infection rate assessed through membrane feeding assays, description - Mosquito infection rate at all feeding time-points, with comparison within treatment arms compared to baseline, and between arms., timeFrame - 6 days (day 0, day 2, day 7, day 14, day 21, day 28): 28 day span",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05550909",
    "endpoint": "measure - Human infectivity to locally reared mosquitoes assessed through membrane feeding assays, description - Infectivity to mosquitoes at all feeding time-points, with comparison within treatment arms compared to baseline, and between arms., timeFrame - 6 days (day 0, day 2, day 7, day 14, day 21, day 28): 28 day span",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05550909",
    "endpoint": "measure - Mosquito infection density assessed through membrane feeding assays, description - Oocyst intensity (in all&#x2F;all infected mosquitoes) at all feeding time-points, with comparison within treatment arms compared to baseline, and between arms., timeFrame - 6 days (day 0, day 2, day 7, day 14, day 21, day 28): 28 day span",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05550909",
    "endpoint": "measure - Gametocyte infectivity, description - Infectiousness to mosquitoes for a given gametocyte density (measured as mosquito infection rate&#x2F;gametocyte) at all feeding time-points, with comparison within treatment arms compared to baseline, and between arms., timeFrame - 6 days (day 0, day 2, day 7, day 14, day 21, day 28): 28 day span",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05550909",
    "endpoint": "measure - Asexual&#x2F;sexual stage parasite prevalence, description - <p>Male and female gametocyte prevalence at all time-points, determined by microscopy or molecular assays, with comparison within treatment arms compared to baseline, and between arms.</p><p>Asexual and total parasite prevalence at all time-points, determined by microscopy or molecular assays, with comparison within treatment arms compared to baseline, and between arms.</p>, timeFrame - 6 days (day 0, day 2, day 7, day 14, day 21, day 28): 28 day span",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05550909",
    "endpoint": "measure - Asexual&#x2F;sexual stage parasite density, description - <p>Male and female gametocyte density at all time-points, determined by microscopy or molecular assays, with comparison within treatment arms compared to baseline, and between arms.</p><p>Asexual and total parasite density at all time-points, determined by microscopy or molecular assays, with comparison within treatment arms compared to baseline, and between arms.</p>, timeFrame - 6 days (day 0, day 2, day 7, day 14, day 21, day 28): 28 day span",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05550909",
    "endpoint": "measure - Sexual stage parasite sex ratio, description - Male and female gametocyte sex ratio (proportion male) at all time-points, determined by microscopy or molecular assays, with comparison within treatment arms compared to baseline, and between arms., timeFrame - 6 days (day 0, day 2, day 7, day 14, day 21, day 28): 28 day span",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05550909",
    "endpoint": "measure - Sexual stage parasite circulation time, description - Gametocyte circulation time (cumulative), determined by microscopy or molecular assays, compared within and between treatment arms., timeFrame - 6 days (day 0, day 2, day 7, day 14, day 21, day 28): 28 day span",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05550909",
    "endpoint": "measure - Sexual stage parasite area under the curve (AUC), description - Gametocyte area under the curve (cumulative), determined by microscopy or molecular assays, compared within and between treatment arms., timeFrame - 6 days (day 0, day 2, day 7, day 14, day 21, day 28): 28 day span",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05550909",
    "endpoint": "measure - Haemoglobin density, description - Haemoglobin density (g&#x2F;dL) at all time-points, with comparison within treatment arms compared to baseline, and between arms., timeFrame - 7 days (day 0, day 1, day 2, day 7, day 14, day 21, day 28): 28 day span",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05550909",
    "endpoint": "measure - Change in haemoglobin density, description - Within person percent change (presented as percent reduction) in haemoglobin density (g&#x2F;dL) from baseline to all time-points, with comparison within and between arms., timeFrame - 7 days (day 0, day 1, day 2, day 7, day 14, day 21, day 28): 28 day span",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05550909",
    "endpoint": "measure - Incidence of adverse events, description - The frequency and prevalence of adverse events (all AE&#x27;s, treatment related AE&#x27;s, and haematological AE&#x27;s) observed up to and including day 2, 7, and 14 post-treatment, and at all timepoints., timeFrame - 7 days (day 0, day 1, day 2, day 7, day 14, day 21, day 28): 28 day span",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00137566",
    "endpoint": "measure - well-being of the child, description - , timeFrame - 35 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00084240",
    "endpoint": "measure - tolerability and safety, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00164710",
    "endpoint": "measure - • Rate of Adequate clinical and parasitological response 28 days, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00164710",
    "endpoint": "measure - • Mean percent change in blood haemoglobin concentration between day 0 and day 28, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00164710",
    "endpoint": "measure - • Incidence of adverse events during the period of observation, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00164710",
    "endpoint": "measure - • Rate of Early Treatment Failure (as defined by the WHO in their 2003 standardized protocol for assessing antimalarial drug efficacy), description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00164710",
    "endpoint": "measure - • Rate of Late Clinical Failure (as defined by the WHO), description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00164710",
    "endpoint": "measure - • Rate of Late Parasitologic Failure (as defined by the WHO), description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00164710",
    "endpoint": "measure - • Percent of patients with a decrease in haemoglobin concentration, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00164710",
    "endpoint": "measure - • Percent of patients with a decrease in haemoglobin concentration of ≥ 2g&#x2F;dl, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00164710",
    "endpoint": "measure - • Prevalence of parasitemia on Day 2, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00164710",
    "endpoint": "measure - • Prevalence of parasitemia on Day 3, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00164710",
    "endpoint": "measure - • Gametocyte prevalence on Day 14, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00164710",
    "endpoint": "measure - • Gametocyte prevalence on Day 28, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00285662",
    "endpoint": "measure - Incidence of moderate-to-severe (Hb &lt; 8 g&#x2F;dl) and severe anaemia (Hb&lt;5 g&#x2F;dl) from 3 - 15 months of age, description - , timeFrame - 15 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00285662",
    "endpoint": "measure - Mean haemoglobin concentration and prevalence of moderate-to-severe anaemia (Hb &lt; 8 g&#x2F;dl) at 15 months of age, description - , timeFrame - 15 months of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00285662",
    "endpoint": "measure - Prevalence and density of malaria parasitemia at 15 months of age, description - , timeFrame - 15 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00285662",
    "endpoint": "measure - Prevalence of splenomegaly at 15 months of age, description - , timeFrame - 15 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00285662",
    "endpoint": "measure - Incidence of symptomatic malaria from 15 - 27 months of age, description - , timeFrame - 27 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00285662",
    "endpoint": "measure - 9. Incidence of (symptomatic) moderate-to-severe (Hb &lt; 8 g&#x2F;dl) and severe anaemia (Hb&lt;5 g&#x2F;dl) from 15 - 27 months of age, description - , timeFrame - 27 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00285662",
    "endpoint": "measure - 10. Mean haemoglobin levels and prevalence of moderate-to-severe (Hb &lt; 8 g&#x2F;dl) or severe anaemia at 27 months of age, description - , timeFrame - 27 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00285662",
    "endpoint": "measure - 11. Prevalence and density of malaria parasitemia at 27 months of age, description - , timeFrame - 27 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00285662",
    "endpoint": "measure - 12. Prevalence of splenomegaly at 27 months of age., description - , timeFrame - 27 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00206739",
    "endpoint": "measure - • Rate and time points of hospitalizations with anemia, malaria or other diseases, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00206739",
    "endpoint": "measure - • Rate and time points of severe anemia episodes, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00206739",
    "endpoint": "measure - • Proportion and rates of children with one or more episodes of malaria or anemia in the age of 3 to 12 months of life, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00206739",
    "endpoint": "measure - • Antibody responses against parasite antigens, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00206739",
    "endpoint": "measure - • Multiplicity of P. falciparum infections, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00206739",
    "endpoint": "measure - • Proportion of P. falciparum isolates with SP resistance, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00206739",
    "endpoint": "measure - • Influence of host genetic variants on the rate of P. falciparum infections, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00716599",
    "endpoint": "measure - To compare changes in the proportion of patients with an inadequate response to initial therapy between health centers with and without an RDT training intervention., description - , timeFrame - 5 days after initial clinic visit",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00513669",
    "endpoint": "measure - Cell-mediated immunity, description - , timeFrame - 14 days post-injection",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05081089",
    "endpoint": "measure - Change in mosquito infection rate assessed through membrane feeding assays (all timepoints), description - Within person percent change (presented as percent reduction) in mosquito infection rate from baseline to all feeding time-points, with comparison within and between arms., timeFrame - 7 days (day 0, day 2, day 5, day 7, day 14, day 21, day 28): 28 day span",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05081089",
    "endpoint": "measure - Mosquito infection rate assessed through membrane feeding assays, description - Mosquito infection rate at all feeding time-points, with comparison within treatment arms compared to baseline, and between arms., timeFrame - 7 days (day 0, day 2, day 5, day 7, day 14, day 21, day 28): 28 day span",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05081089",
    "endpoint": "measure - Human infectivity to locally reared mosquitoes assessed through membrane feeding assays, description - Infectivity to mosquitoes at all feeding time-points, with comparison within treatment arms compared to baseline, and between arms., timeFrame - 7 days (day 0, day 2, day 5, day 7, day 14, day 21, day 28): 28 day span",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05081089",
    "endpoint": "measure - Mosquito infection density assessed through membrane feeding assays, description - Oocyst intensity (in all&#x2F;all infected mosquitoes) at all feeding time-points, with comparison within treatment arms compared to baseline, and between arms., timeFrame - 7 days (day 0, day 2, day 5, day 7, day 14, day 21, day 28): 28 day span",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05081089",
    "endpoint": "measure - Gametocyte infectivity, description - Infectiousness to mosquitoes for a given gametocyte density (measured as mosquito infection rate&#x2F;gametocyte) at all feeding time-points, with comparison within treatment arms compared to baseline, and between arms., timeFrame - 7 days (day 0, day 2, day 5, day 7, day 14, day 21, day 28): 28 day span",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05081089",
    "endpoint": "measure - Asexual&#x2F;sexual stage parasite prevalence, description - <p>Male and female gametocyte prevalence at all time-points, determined by microscopy or molecular assays, with comparison within treatment arms compared to baseline, and between arms.</p><p>Asexual and total parasite prevalence at all time-points, determined by microscopy or molecular assays, with comparison within treatment arms compared to baseline, and between arms.</p>, timeFrame - 7 days (day 0, day 2, day 5, day 7, day 14, day 21, day 28): 28 day span",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05081089",
    "endpoint": "measure - Asexual&#x2F;sexual stage parasite density, description - <p>Male and female gametocyte density at all time-points, determined by microscopy or molecular assays, with comparison within treatment arms compared to baseline, and between arms.</p><p>Asexual and total parasite density at all time-points, determined by microscopy or molecular assays, with comparison within treatment arms compared to baseline, and between arms.</p>, timeFrame - 7 days (day 0, day 2, day 5, day 7, day 14, day 21, day 28): 28 day span",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05081089",
    "endpoint": "measure - Sexual stage parasite sex ratio, description - Male and female gametocyte sex ratio (proportion male) at all time-points, determined by microscopy or molecular assays, with comparison within treatment arms compared to baseline, and between arms., timeFrame - 7 days (day 0, day 2, day 5, day 7, day 14, day 21, day 28): 28 day span",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05081089",
    "endpoint": "measure - Sexual stage parasite circulation time, description - Gametocyte circulation time (cumulative), determined by microscopy or molecular assays, compared within and between treatment arms., timeFrame - 7 days (day 0, day 2, day 5, day 7, day 14, day 21, day 28): 28 day span",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05081089",
    "endpoint": "measure - Sexual stage parasite area under the curve (AUC), description - Gametocyte area under the curve (cumulative), determined by microscopy or molecular assays, compared within and between treatment arms., timeFrame - 7 days (day 0, day 2, day 5, day 7, day 14, day 21, day 28): 28 day span",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05081089",
    "endpoint": "measure - Haemoglobin density, description - Haemoglobin density (g&#x2F;dL) at all time-points, with comparison within treatment arms compared to baseline, and between arms., timeFrame - 8 days (day 0, day 1, day 2, day 5, day 7, day 14, day 21, day 28): 28 day span",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05081089",
    "endpoint": "measure - Change in haemoglobin density, description - Within person percent change (presented as percent reduction) in haemoglobin density (g&#x2F;dL) from baseline to all time-points, with comparison within and between arms., timeFrame - 8 days (day 0, day 1, day 2, day 5, day 7, day 14, day 21, day 28): 28 day span",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05081089",
    "endpoint": "measure - Methaemoglobin density, description - Methaemoglobin density (g&#x2F;dL) at all time-points, with comparison within treatment arms compared to baseline, and between arms., timeFrame - 8 days (day 0, day 1, day 2, day 5, day 7, day 14, day 21, day 28)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05081089",
    "endpoint": "measure - Change in methaemoglobin density, description - Within person percent change (presented as percent reduction) in methaemoglobin density (g&#x2F;dL) from baseline to all time-points, with comparison within and between arms., timeFrame - 8 days (day 0, day 1, day 2, day 5, day 7, day 14, day 21, day 28): 28 day span",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05081089",
    "endpoint": "measure - Incidence of adverse events, description - The frequency and prevalence of adverse events (all AE&#x27;s, treatment related AE&#x27;s, and haematological AE&#x27;s) observed up to and including day 2, 7, and 14 post-treatment, and at all timepoints., timeFrame - 8 days (day 0, day 1, day 2, day 5, day 7, day 14, day 21, day 28): 28 day span",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01713517",
    "endpoint": "measure - Prevalence of P.falciparum Infection, description - Infection with plasmodial parasites (falciparum and&#x2F;or vivax) in randomly selected members of the study cohort in each study cluster during the peak of the malaria transmission season by rapid diagnostic test, timeFrame - 3 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01713517",
    "endpoint": "measure - Entomological Innoculation rate, description - Anopheles arabiensis mosquitoes collected in sentinel clusters by light trap, window trap, clay pot and pyrethrum sheet collection and determination of sporozoite, human blood index, feeding and resting behaviour., timeFrame - Average for months Sept, Oct, Nov for years 2011, 2012, 2013",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01713517",
    "endpoint": "measure - Frequency of insecticide resistance associated genotypes (kdr) in anopheles arabiensis, description - Molecular analysis of mosquito specimens caught in subset of clusters by pyrethrum spray collection., timeFrame - Yearly average 2011, 2012, 2013, 2014",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02084602",
    "endpoint": "measure - Parasite reduction rates and ratios, description - Parasite reduction rates and ratios assessed by microscopy and quantitative PCR, timeFrame - 24, 48 hours after the first administration of artesunate",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02084602",
    "endpoint": "measure - Time for parasite count to fall, description - Time for parasite count to fall to 50%, 90% and 99% of initial parasite density, timeFrame - at least 24 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02084602",
    "endpoint": "measure - Fever clearance time, description - Time taken for temperature to fall below 37˚C and remain there for at least 24 hours, timeFrame - at least 24 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02084602",
    "endpoint": "measure - Gametocyte carriage rates, description - Gametocyte carriage rates assessed in person weeks up to 14 days, timeFrame - up to 14 days since the first administration of artesunate",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05140278",
    "endpoint": "measure - Implementation perspective assessment of 1-step formulation of parenteral artesunate, description - Implementation perspective assessment of 1-step formulation of parenteral artesunate by interview study staff, health staff, and policymakers and stakeholders, timeFrame - 45 minutes",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05140278",
    "endpoint": "measure - Practicability assessment of 1-step formulation of parenteral artesunate, description - Practicability assessment of 1-step formulation of parenteral artesunate by interview study staff, health staff, and policymakers and stakeholders, timeFrame - 45 minutes",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05140278",
    "endpoint": "measure - Satisfaction assessment of 1-step formulation of parenteral artesunate, description - Satisfaction assessment of 1-step formulation of parenteral artesunate by interview study staff, health staff, and policymakers and stakeholders, timeFrame - 45 minutes",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00142246",
    "endpoint": "measure - Prevalence of Plasmodium falciparum parasitaemia, description - , timeFrame - March 2006",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00142246",
    "endpoint": "measure - Sustained attention, description - , timeFrame - March 2006",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00142246",
    "endpoint": "measure - Mean haemoglobin, description - , timeFrame - March 2006",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00857077",
    "endpoint": "measure - incidence of clinical malaria, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00857077",
    "endpoint": "measure - incidence of severe disease and mortality, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00857077",
    "endpoint": "measure - prevalence of anaemia and parasitaemia, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00857077",
    "endpoint": "measure - incidence of adverse events, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03554616",
    "endpoint": "measure - Incidence of malaria cases in children 6 months to 10 years, description - Malaria incidence cases will be assessed using Malaria Rapid Diagnostic test (CareStart), timeFrame - Two years post intervention follow up",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03554616",
    "endpoint": "measure - Prevalence of anaemia in children under 5 years old, description - Hemoglobin (Hb) concentration will be tested to assess anaemia (&lt;8 g&#x2F;dL) using HemoCue Hb 201+., timeFrame - 12, 18, 24, 30, 36 months post intervention",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03554616",
    "endpoint": "measure - Indoor Anopheles density, description - Anopheles density per house per night will be assess every quarter in 8 houses per cluster using light trap.\nAnopheles density and sporozoite rate will be used to estimate the entomological inoculation rate (EIR), timeFrame - Three years post intervention follow up",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03554616",
    "endpoint": "measure - Sporozoite rate, description - A sub-samples of Anopheles collected indoor will be tested for Plasmodium falciparum circumsporozoite protein using an ELISA test.\nSporozoite rate will be used to estimate the EIR with Anopheles density., timeFrame - Three years post intervention follow up",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03554616",
    "endpoint": "measure - Insecticide content in Long Lasting Insecticidal Net (LLIN), description - 30 LLINs will be collected at yearly interval and Insecticide content in g&#x2F;kg assessed with High-performance liquid chromatography (HPLC), timeFrame - at 0, 12, 24, 30, 36 months post intervention",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03554616",
    "endpoint": "measure - Mortality in Anopheles after one hour exposure to every study LLIN, description - 30 LLINs will be sampled every 6 months and tested in cone bio assay or tunnel test using resistant Anopheles and susceptible Kisumu Anopheles to assess for bio efficacy.\n24, 48 and 72 hours mortality post exposure will be recorded., timeFrame - at 0, 6, 12, 18, 24, 30, 36 months post intervention",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03554616",
    "endpoint": "measure - LLIN usage, description - The proportion of study participant declaring sleeping under a LLIN the previous night will be assessed during household survey every 6 months using a questionnaire., timeFrame - at 6, 12, 18, 24, 30, 36 months post intervention",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03554616",
    "endpoint": "measure - Malaria infection prevalence in children 6 months to 14 years, description - Malaria prevalence will be assessed using Malaria Rapid Diagnostic test (CareStart Malaria histidine-rich protein 2 (HRP2)&#x2F;plasmodium lactate dehydrogenase (pLDH) Combo, DiaSys, UK), timeFrame - 12 months post intervention",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03554616",
    "endpoint": "measure - Malaria infection prevalence in children 6 months to 14 years, description - Malaria prevalence will be assessed using Malaria Rapid Diagnostic test (CareStart Malaria histidine-rich protein 2 (HRP2)&#x2F;plasmodium lactate dehydrogenase (pLDH) Combo, DiaSys, UK), timeFrame - 18 months post intervention",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03554616",
    "endpoint": "measure - Malaria infection prevalence in children 6 months to 14 years, description - Malaria prevalence will be assessed using Malaria Rapid Diagnostic test (CareStart Malaria histidine-rich protein 2 (HRP2)&#x2F;plasmodium lactate dehydrogenase (pLDH) Combo, DiaSys, UK), timeFrame - 30 months post intervention",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03554616",
    "endpoint": "measure - Malaria infection prevalence in children 6 months to 14 years, description - Malaria prevalence will be assessed using Malaria Rapid Diagnostic test (CareStart Malaria histidine-rich protein 2 (HRP2)&#x2F;plasmodium lactate dehydrogenase (pLDH) Combo, DiaSys, UK), timeFrame - 36 months post intervention",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03554616",
    "endpoint": "measure - Cost &amp; DALYs of each type of bi-treated LLIN, description - Cost of each intervention will be gathered and used to calculate cost per malaria case averted and cost per DALY averted, timeFrame - Three years post intervention",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04706130",
    "endpoint": "measure - Genotypes of relapsing P. vivax parasites, description - Genotypes of relapsing P. vivax parasites, timeFrame - 3 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04327440",
    "endpoint": "measure - Gametocyte prevalence, description - Comparison of the prevalence of gametocytes (male and female) in cohorts exposed to RTS,S vs those not exposed, timeFrame - 6 months&#x2F;cohort, 4 cohorts",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04327440",
    "endpoint": "measure - Net usage, description - Comparison of nightly net usage in cohorts with PBO nets compared to cohorts with conventional nets, timeFrame - 6 months&#x2F;cohort, 4 cohorts",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04327440",
    "endpoint": "measure - Serological markers of immunity and exposure, description - Comparison of serological markers in cohorts exposed to RTS,S vs those not exposed to RTS,S, timeFrame - 6 months&#x2F;cohort, 4 cohorts",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04327440",
    "endpoint": "measure - Anopheles gravidity rates, description - Comparison of Anopheles gravidity rates in cohorts with PBO nets compared to cohorts with conventional nets, timeFrame - 6 months&#x2F;cohort, 4 cohorts",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04327440",
    "endpoint": "measure - Anopheles sporozoite rates, description - Comparison of Anopheles sporozoite rates in cohorts with PBO nets compared to cohorts with conventional nets, timeFrame - 6 months&#x2F;cohort, 4 cohorts",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02453308",
    "endpoint": "measure - Parasite clearance half-life, description - Parasite clearance half-life assessed by microscopy as primary parameter to de-termine parasite clearance, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02453308",
    "endpoint": "measure - Parasite reduction rates and ratios at 24 and 48 hours assessed by microscopy, description - , timeFrame - at 24 and 48 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02453308",
    "endpoint": "measure - Time for parasite count to fall to 50% of initial parasite density, description - , timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02453308",
    "endpoint": "measure - Time for parasite count to fall to 90% of initial parasite density, description - , timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02453308",
    "endpoint": "measure - Time for parasite count to fall to 99% of initial parasite density, description - , timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02453308",
    "endpoint": "measure - Fever clearance time, description - , timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02453308",
    "endpoint": "measure - Incidence of adverse events and serious adverse events, description - , timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02453308",
    "endpoint": "measure - Incidence of adverse events concerning markers of hepatic toxicity, description - Total billirubin, ALT, AST and Alkaline Phosphatase will be measured, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02453308",
    "endpoint": "measure - Incidence of adverse events concerning markersof renal toxicity, description - Creatinine will be measured, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02453308",
    "endpoint": "measure - Incidence of prolongation of the QTc-interval, description - Incidence of prolongation of the Qtc-interval above 500 ms or &gt; 60ms above baseline values, timeFrame - 3 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02453308",
    "endpoint": "measure - Change in hemoglobin&#x2F;hematocrit, description - Change in hemoglobin&#x2F;hematocrit on day 1 to 7, 14, 21, 28, 35 and 42 according to geographical location and study arm, stratified for G6PD status, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02453308",
    "endpoint": "measure - Proportion of patients that reports completing a full course of observed TACT or ACT without withdrawal of consent or exclusion from study, description - , timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02453308",
    "endpoint": "measure - Prevalence of Kelch13 mutations of known functional significance, description - , timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02453308",
    "endpoint": "measure - Prevalence&#x2F;incidence of other genetic markers of antimalarial drug resistance, description - , timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02453308",
    "endpoint": "measure - Genome wide association with in vivo&#x2F;in vitro sensitivity parasite phenotype, description - , timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02453308",
    "endpoint": "measure - Correlation between SNPs measured in dry blood spots and whole genome sequencing in leukocyte depleted blood samples, description - , timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02453308",
    "endpoint": "measure - Transcriptomic patterns at t=0 and t=6h comparing sensitive and resistant parasites, description - , timeFrame - 6hrs after start of treatment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02453308",
    "endpoint": "measure - Correlation between qPCR based versus microscopy based assessments of parasite clearance dynamics, description - , timeFrame - 14 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02453308",
    "endpoint": "measure - Proportion of patients with gametocytemia before,after treatment with Primaquine, description - , timeFrame - assessed at admission, up to day 14",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02453308",
    "endpoint": "measure - Levels of RNA transcription coding for male or female specific gametocytes, description - , timeFrame - at admission up to day 14",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02453308",
    "endpoint": "measure - In vitro sensitivity (expressed in IC50 values among others) of P. falciparum to artemisinins and partner drugs, description - , timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02453308",
    "endpoint": "measure - • Pharmacokinetic profiles and interactions of artemisinin-derivatives and partner drugs (half-life, Cmax, AUC, Tmax) in 20 ACT treated and 20 TACT treated patients of both study arms, description - , timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02453308",
    "endpoint": "measure - Day 7 drug levels of partner drugs in association with treatment efficacy and treatment arm, description - , timeFrame - Day 7",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04609098",
    "endpoint": "measure - Change in mosquito infectivity assessed through membrane feeding assays (days 2 and 14), description - The proportion of mosquitoes infected, assessed through membrane feeding and measured as oocyst prevalence in mosquitoes dissected on day 2 and 14 post feed, compared to baseline, timeFrame - 3 days (Days 0, 2, &amp; 14): 14 day span",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04609098",
    "endpoint": "measure - Mosquito infection density assessed through membrane feeding assays, description - Mosquito infection density, assessed through membrane feeding and measured as oocyst density in mosquitoes dissected on day 2, 7 and 14 post feed, compared within and between study arms, timeFrame - 4 days (Days 0, 2, 7 &amp; 14): 14 day span",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04609098",
    "endpoint": "measure - Mosquito infection prevalence assessed through membrane feeding assays, description - Mosquito infection prevalence and density, assessed through membrane feeding and measured as oocyst prevalence in mosquitoes dissected on day 2, 7 and 14 post feed, compared within and between study arms, timeFrame - 4 days (Days 0, 2, 7 &amp; 14): 14 day span",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04609098",
    "endpoint": "measure - Human infectivity assessed through membrane feeding assays, description - The proportion of individuals that infect any number of mosquitoes, assessed through membrane feeding and measured as oocyst prevalence&#x2F;density in mosquitoes dissected on day 2, 7 and 14 post feed, compared within and between study arms, timeFrame - 4 days (Days 0, 2, 7 &amp; 14): 14 day span",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04609098",
    "endpoint": "measure - Haemoglobin density, description - Haemolysis will be monitored by measuring haemoglobin levels (g&#x2F;dL) on days 0, 1, 2, 7, 14, 21, and 28 post treatment as part of the clinical assessment., timeFrame - 7 days (Days 0, 1, 2, 7, 14, 21 &amp; 28): 28 day span",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04609098",
    "endpoint": "measure - Methmoglobin density, description - Methmoglobin density (g&#x2F;dL) will be monitored on days 0, 1, 2, 7, 14, 21, and 28 post treatment as part of the clinical assessment., timeFrame - 7 days (Days 0, 1, 2, 7, 14, 21 &amp; 28): 28 day span",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04609098",
    "endpoint": "measure - Aspartate transaminase (AST)&#x2F;alanine transaminase (ALT) ratio, description - Aspartate transaminase (AST)&#x2F;alanine transaminase (ALT) ratio will be recorded on days 0, 1, 2, 7, 14, 21, and 28 post treatment as part of the clinical assessment., timeFrame - 7 days (Days 0, 1, 2, 7, 14, 21 &amp; 28): 28 day span",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04609098",
    "endpoint": "measure - Blood creatinine level, description - Blood creatine level will be recorded on days 0, 1, 2, 7, 14, 21, and 28 post treatment as part of the clinical assessment., timeFrame - 7 days (Days 0, 1, 2, 7, 14, 21 &amp; 28): 28 day span",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04609098",
    "endpoint": "measure - Asexual&#x2F;sexual stage parasite density, description - Asexual&#x2F;sexual stage parasite density (parasites&#x2F;microlitre) will be measured by microscopy and by molecular methods on days 0, 1, 2, 7, 14, 21, and 28 post treatment., timeFrame - 7 days (Days 0, 1, 2, 7, 14, 21 &amp; 28): 28 day span",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04609098",
    "endpoint": "measure - Asexual&#x2F;sexual stage parasite prevalence, description - Asexual&#x2F;sexual stage parasite prevalence will be measured by microscopy and by molecular methods on days 0, 1, 2, 7, 14, 21, and 28 post treatment., timeFrame - 7 days (Days 0, 1, 2, 7, 14, 21 &amp; 28): 28 day span",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04609098",
    "endpoint": "measure - Asexual&#x2F;sexual stage parasite circulation time, description - Asexual&#x2F;sexual stage parasite circulation time (days) will be determined from measures of density., timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04609098",
    "endpoint": "measure - Asexual&#x2F;sexual stage parasite area under the curve (AUC), description - Asexual&#x2F;sexual stage parasite area under the curve (AUC: Gametocytes per microlitre per day) will be determined from measures of density., timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04609098",
    "endpoint": "measure - Sexual stage parasite sex ratio, description - Gametocyte density will be determined by molecular methods for males and females separately, allowing analysis of sex ratio (proportion of total that is male) on days 0, 1, 2, 7, 14, 21 and 28 post treatment., timeFrame - 7 days (Days 0, 1, 2, 7, 14, 21 &amp; 28): 28 day span",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04609098",
    "endpoint": "measure - Incidence of adverse events, description - Incidence of adverse events will be monitored at each active (day 0,1,2,7,14,21,28) follow up visit.\nAE&#x27;s will also be recorded and acted upon if present at any other time during follow up., timeFrame - 7 days (Days 0, 1, 2, 7, 14, 21 &amp; 28): 28 day span",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02900079",
    "endpoint": "measure - Qualitative description of ease of self-&#x2F;peer- use of malaria RDT, measured by a self-reported questionnaire, description - , timeFrame - up to 12 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02900079",
    "endpoint": "measure - Time to treatment measured from time of obtaining test results by self-reporting, description - Use of study diary, timeFrame - up to 12 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02900079",
    "endpoint": "measure - Duration of symptoms by self-reporting, description - Use of study diary, timeFrame - up to 12 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02900079",
    "endpoint": "measure - Description of clinical symptoms and their frequencies by self-reporting, description - Use of study diary, timeFrame - up to 12 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02900079",
    "endpoint": "measure - self-reported management of illness in structured study diary, description - self-treatment, consultation, hospitalization, timeFrame - up to 12 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02900079",
    "endpoint": "measure - final clinical outcome of illness, description - change of travel plans, repatriation, hospitalization, death as a result of illness during travel, timeFrame - up to 12 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01640574",
    "endpoint": "measure - Adverse Events, description - Number of adverse events within 28 days of study medication, timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01640574",
    "endpoint": "measure - Recurrence of P. vivax, description - Recurrence with Plasmodium vivax malaria within 6 months of first treatment dose, timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01640574",
    "endpoint": "measure - Drug concentrations, description - Chloroquine, piperaquine and primaquine drug levels, timeFrame - 63 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00393679",
    "endpoint": "measure - PCR unadjusted treatment failure up to day 63 (TF63U): TF28U plus all cases of recurrent parasitaemia (symptomatic or asymptomatic) detected between day 29 and day 63 by passive follow up, regardless of genotyping, description - , timeFrame - Day 63",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00393679",
    "endpoint": "measure - PCR adjusted treatment failure for the whole period of passive surveillance (TFAPS): TF28A plus all episodes of recurrent parasitaemia identified as recrudescence by genotyping., description - , timeFrame - Day 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00393679",
    "endpoint": "measure - Fever clearance time., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00393679",
    "endpoint": "measure - Asexual parasite clearance time., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00393679",
    "endpoint": "measure - Gametocytaemia (prevalence and density) at day 7, 14, 21 and 28 after treatment (for both active follow-ups);, description - , timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00393679",
    "endpoint": "measure - Hb changes day 3, 7, 14 and 28 (first and second follow up);, description - , timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00393679",
    "endpoint": "measure - Clinical malaria after first active follow-up;, description - , timeFrame - 28 Days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00393679",
    "endpoint": "measure - Clinical malaria after second active follow-up;, description - , timeFrame - Up to seven months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00393679",
    "endpoint": "measure - TF second clinical episode (D28 and D63);, description - , timeFrame - 63 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00393679",
    "endpoint": "measure - Changes in the frequency of mutations in the dihydrofolate reductase (DHFR) gene at day 0 first follow-up and day re-appearance of parasitaemia (for patients treated with CDA - NOTE that CDA arm was discontinued on 17.02.2008)., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00393679",
    "endpoint": "measure - Safety profiles including significant changes in relevant laboratory values., description - , timeFrame - Up to seven months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04049916",
    "endpoint": "measure - Change in mosquito infectivity assessed through membrane feeding assays (day 7), description - The proportion of mosquitoes infected, assessed through membrane feeding and measured as oocyst prevalence in mosquitoes dissected on day 7 post feed, compared to baseline, timeFrame - 2 days (day 0 &amp; 7)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04049916",
    "endpoint": "measure - Mosquito infectivity assessed through membrane feeding assays - inter arm, description - Mosquito infection prevalence and density, assessed through membrane feeding and measured as oocyst prevalence&#x2F;density in mosquitoes dissected on day 2 and 7 post feed, compared between study arms, timeFrame - 3 days (day 0, 2 &amp; 7)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04049916",
    "endpoint": "measure - Duration of infectivity, description - Non PQ arms only: Duration of infectivity will be determined from measures of mosquito infection prevalence, assessed through membrane feeding and measured as oocyst prevalence in mosquitoes dissected on day 0, 2, 7, 10 and 14 post treatment, and then weekly until 2 sequential negative feeds or until day 49., timeFrame - 5-10 days (as described)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04049916",
    "endpoint": "measure - Area under the curve (AUC) of infectivity&#x2F;time, description - Non PQ arms only: AUC will be determined from measures of mosquito infection prevalence and density, assessed through membrane feeding and measured as oocyst prevalence&#x2F;density in mosquitoes dissected on day 0, 2, 7, 10 and 14 post treatment, and then weekly until 2 sequential negative feeds or until day 49., timeFrame - 5-10 days (as described)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04049916",
    "endpoint": "measure - Haemoglobin level, description - Haemolysis will be monitored by measuring haemoglobin levels (g&#x2F;dL) on days 0, 1, 2, 7, 10, 14, 21, 38, 35, 42 and 49 post treatment., timeFrame - 11 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04049916",
    "endpoint": "measure - Histidine rich protein 2 (HRP2) concentration, description - Histidine rich protein 2 (HRP2) protein concentration in plasma will be determined in subsequent lab analysis from samples collected on days 0, 1, 2, 7, 10, 14, 21, 38, 35, 42 and 49 post treatment., timeFrame - 11 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04049916",
    "endpoint": "measure - Histidine rich protein 2 (HRP2) circulation time, description - Histidine rich protein 2 (HRP2) protein circulation time will be compared between methods of detection, timeFrame - 11 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04049916",
    "endpoint": "measure - Histidine rich protein 2 (HRP2) area under the curve (AUC), description - Histidine rich protein 2 (HRP2) area under the curve (AUC) will be determined from measures of HRP2 concentration, timeFrame - 11 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04049916",
    "endpoint": "measure - Rapid diagnostic test result, description - Varied rapid diagnostic tests based on the detection of HRP2 will be used on days 0, 1, 2, 7, 10, 14, 21, 38, 35, 42 and 49 post treatment to determine infection prevalence, for comparison between study arms., timeFrame - 11 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04049916",
    "endpoint": "measure - Gametocyte density, description - Gametocyte density (parasites&#x2F;microlitre) will be measured by microscopy and by molecular methods on days 0, 1, 2, 7, 10, 14, 21, 38, 35, 42 and 49 post treatment., timeFrame - 11 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04049916",
    "endpoint": "measure - Gametocyte under the curve (AUC), description - Gametocyte area under the curve (AUC) will be determined from measures of density., timeFrame - 11 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04049916",
    "endpoint": "measure - Gametocyte prevalence, description - Gametocyte prevalence (parasites&#x2F;microlitre) will be measured by microscopy and by molecular methods on days 0, 1, 2, 7, 10, 14, 21, 38, 35, 42 and 49 post treatment., timeFrame - 11 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04049916",
    "endpoint": "measure - Gametocyte circulation time, description - Gametocyte circulation time (days) will be determined from measures of prevalence., timeFrame - 11 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04049916",
    "endpoint": "measure - Gametocyte sex ratio, description - Gametocyte density will be determined by molecular methods for males and females separately, allowing analysis of sex ratio (proportion of total that is male) on days 0, 1, 2, 7, 10, 14, 21, 38, 35, 42 and 49 post treatment., timeFrame - 11 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04049916",
    "endpoint": "measure - Asexual parasite density, description - Asexual parasite density (parasites&#x2F;microlitre) will be measured by microscopy and by molecular methods on days 0, 1, 2, 7, 10, 14, 21, 38, 35, 42 and 49 post treatment., timeFrame - 11 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04049916",
    "endpoint": "measure - Asexual parasite area under the curve (AUC), description - Asexual parasite area under the curve (AUC) will be determined from measures of density., timeFrame - 11 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04049916",
    "endpoint": "measure - Asexual parasite prevalence, description - Asexual parasite prevalence (parasites&#x2F;microlitre) will be measured by microscopy and by molecular methods on days 0, 1, 2, 7, 10, 14, 21, 38, 35, 42 and 49 post treatment., timeFrame - 11 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04049916",
    "endpoint": "measure - Asexual parasite circulation time, description - Asexual parasite circulation time (days) will be determined from measures of prevalence., timeFrame - 11 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04049916",
    "endpoint": "measure - Parasite genotype, description - Parasite merozoite surface protein 2 (MSP2) allelic diversity (presence of distinct alleles) will be determined in subsequent lab analysis from whole blood samples collected at baseline., timeFrame - 1 day",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04049916",
    "endpoint": "measure - Histidine rich protein gene deletion, description - Deletion (presence&#x2F;absence) of the HRP2&#x2F;3 genes will be determined from whole blood samples collected at baseline., timeFrame - 1 day",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01048801",
    "endpoint": "measure - Coverage of prompt effective treatment: % of &lt;5-year-old children with fever who received ACT treatment within 24 hours of onset of malaria, measured through household surveys., description - , timeFrame - 36 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00149383",
    "endpoint": "measure - Time to resolution of fever (in hours), description - , timeFrame - 5 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00149383",
    "endpoint": "measure - AST&#x2F;ALT levels (U&#x2F;L), description - , timeFrame - 2 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00149383",
    "endpoint": "measure - Capillary blood glucose (mmol&#x2F;L), description - , timeFrame - 2 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00149383",
    "endpoint": "measure - Need for ICU admission, description - , timeFrame - 5 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00149383",
    "endpoint": "measure - Tolerability of study drug&#x2F;placebo as assessed by patient log, description - , timeFrame - 5 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01780753",
    "endpoint": "measure - Pharmacokinetics Parameters of Primaquine and Carboxyprimaquine in blood. Area Under Curve (AUC)., description - Primaquine and carboxyprimaquine pharmacokinetic parameters to day 13 in the blood of lactating women and their breastfed infants, timeFrame - 13 Days. Time Frame: predose, 0,1,2,3,4,6,8,12,24,72 hours; Day 7, Day 13 post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01780753",
    "endpoint": "measure - Concentration of Primaquine in saliva and urine. Area Under Curve (AUC)., description - Primaquine concentration in saliva and urine., timeFrame - 13 Days. Time Frame: predose, 0,1,2,3,4,6,8,12,24,72 hours; Day 7, Day 13 post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01780753",
    "endpoint": "measure - Primaquine dosage in infant - the relative infant dose. Area Under Curve (AUC)., description - Relative infant dose of Primaquine., timeFrame - 13 Days. Time Frame: predose, 0,1,2,3,4,6,8,12,24,72 hours; Day 7, Day 13 post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01780753",
    "endpoint": "measure - Assessment of adverse events during primaquine administration, description - Adverse events in mothers and infants during treatment.\nNumber of Participants with Adverse Events as a Measure of Safety and Tolerability., timeFrame - 63 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01780753",
    "endpoint": "measure - Hematocrit levels in mother and child, description - Changes in maternal and infant hematocrit to day 63., timeFrame - 63 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02658435",
    "endpoint": "measure - Mean change from baseline in OCT parameter like central retinal thickness as a safety measure, description - SD-OCT images&#x2F;scan will be obtained.\nCentral retinal thickness is the thickness at the centre point of the macula, timeFrame - Baseline and Day 90(follow-up)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02658435",
    "endpoint": "measure - Mean change from baseline in OCT parameter like central subfield thickness as a safety measure., description - SD-OCT images&#x2F;scan will be obtained.\nCentral subfield thickness measures thickness from top of Internal limiting membrane (ILM) to bottom of Retinal pigment epithelium (RPE)., timeFrame - Baseline and Day 90(follow-up)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02658435",
    "endpoint": "measure - Mean change from baseline in OCT parameter like central retinal lesion thickness as a safety measure., description - SD-OCT images&#x2F;scan will be obtained.\nCentral retinal lesion thickness measures a greatest linear thickness from ILM to inner border of choriocapillaris, timeFrame - Baseline and Day 90(follow-up)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02658435",
    "endpoint": "measure - Mean change from baseline in OCT parameters;. Total macular volume as a safety measure., description - SD-OCT images&#x2F;scan will be obtained.\nTotal macular volume describes the overall thickness of retina from top of ILM to bottom of RPE as a volume measurement., timeFrame - Baseline and Day 90(follow-up)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02658435",
    "endpoint": "measure - Mean change from baseline in OCT parameters ;. Ellipsoid zone disruption as a safety measure., description - SD-OCT images&#x2F;scan will be obtained.\nEllipsoid zone disruption will measure zones of absent or irregular ellipsoid layer., timeFrame - Baseline and Day 90(follow-up)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02658435",
    "endpoint": "measure - Changes from baseline in the status of the outer retina&#x2F;photoreceptor complex as a safety measure., description - SD-OCT images&#x2F;scan will be obtained., timeFrame - Baseline and Day 90(follow-up)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02658435",
    "endpoint": "measure - Proportion of participants with abnormal changes from baseline observed on FAF as a safety measure., description - FAF images will be obtained.\nQualitative assessment will be done to check for any abnormal patterns of auto-fluorescence in the macular region that may be indicative of disease of the retinal pigment epithelium., timeFrame - Baseline and Day 90(follow-up)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02658435",
    "endpoint": "measure - Mean change from baseline in best corrected visual acuity (BCVA) as a safety measure of TQ in comparison to placebo., description - BCVA will be measured by a trained examiner, timeFrame - Baseline and Day 90(follow-up)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02658435",
    "endpoint": "measure - Proportion of participants with vortex keratopathy from the slit lamp examination as a safety measure of TQ in comparison to placebo., description - Vortex keratopathy (corneal deposits) will be confirmed by slit lamp examination.\nAnterior and posterior segment evaluation will be done., timeFrame - Baseline and Day 90(follow-up)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02658435",
    "endpoint": "measure - Number of participants with of adverse events as a safety measure, description - An AE is any untoward medical occurrence in a participant or clinical investigation temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product, timeFrame - 90 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02787070",
    "endpoint": "measure - The incidence risk of symptomatic P. vivax malaria over 6 months in patients enrolled with P. vivax malaria infection, description - , timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02787070",
    "endpoint": "measure - The incidence risk of symptomatic P. vivax malaria over 6 months in patients enrolled with P. falciparum malaria infection, description - , timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02787070",
    "endpoint": "measure - The incidence rate of symptomatic P. vivax malaria over 6 months in patients enrolled with malaria due to P. falciparum or P. vivax, description - , timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02787070",
    "endpoint": "measure - The incidence rate of symptomatic P. vivax malaria over 6 months in patients enrolled with P. vivax malaria, description - , timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02787070",
    "endpoint": "measure - The incidence rate of symptomatic P. vivax malaria over 6 months in patients enrolled with P. falciparum malaria, description - , timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02787070",
    "endpoint": "measure - The incidence risk of patent or sub-microscopic P. vivax malaria over six months in patients enrolled with a malaria (sub-group analysis for patients recruited with P. vivax infection and P. falciparum infection), description - , timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02787070",
    "endpoint": "measure - The incidence risk of any patent or sub-microscopic parasitaemia due to P. vivax or P. falciparum over six months in patients, description - , timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02787070",
    "endpoint": "measure - The proportion of patients vomiting their medication within 1 hour of administration, description - , timeFrame - 1 hour",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02787070",
    "endpoint": "measure - • The proportion of patients vomiting any of their primaquine doses during the 14 day supervised course, description - , timeFrame - 14 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02787070",
    "endpoint": "measure - • The proportion of adverse events and serious adverse events over 6 months in all patients, description - , timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02787070",
    "endpoint": "measure - • The incidence risk of severe anaemia (Hb&lt;7g&#x2F;dl) and&#x2F;or the risk for blood transfusion over 6 months, description - , timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02787070",
    "endpoint": "measure - • The incidence risk of an acute drop in Hb &gt;5g&#x2F;dl within 14 days of starting primaquine treatment, description - , timeFrame - 14 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02758353",
    "endpoint": "measure - Cost per Woman served with SP in Nigeria Naira, description - This will be obtained from costing data produced by the study and the total number of participants served as derived from the outcome forms., timeFrame - Up to 7 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02758353",
    "endpoint": "measure - Cost per SP dose delivered in Nigeria Naira, description - This will be obtained from costing data produced by the study and the total number of SP doses given as derived from the outcome forms., timeFrame - Up to 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02758353",
    "endpoint": "measure - Incidence of Stillbirths in stillbirths per 1000 term births, description - Stillbirth is a delivery that occurred after 7 months of gestation in which a baby was birthed without any signs of life (no breathing, no movement, and no sound) as reported by a participant or an informed family member., timeFrame - Up to 7 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02758353",
    "endpoint": "measure - Head circumference of Newborn in millimeters, description - Head circumference of live newborns was measured within 7 days postpartum by CBHV.\nThe information will be aggregated from individual outcome forms., timeFrame - Up to 7 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03355664",
    "endpoint": "measure - 42-day Polymerase Chain Reaction Corrected Efficacy According to Site&#x2F;Geographic Region, description - 42-day polymerase chain reaction corrected efficacy defined as adequate clinical and parasitological response (ACPR) according to site&#x2F;geographic region., timeFrame - 42 day",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03355664",
    "endpoint": "measure - Parasite Clearance Half-life, description - Parasite clearance half-life assessed by microscopy as primary parameter to determine parasite clearance, timeFrame - 42 day",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03355664",
    "endpoint": "measure - Fever Clearance Time, description - The time taken for the tympanic temperature to fall below 37.5˚C and remain there for at least 24 hours, timeFrame - 42 day",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03355664",
    "endpoint": "measure - Number of Severe Adverse Events by Study Arm, description - <p>All numerators in AE tables mean that the AE was reported as present according to the definitions defined in the US government DAIDS 2017 grading tables for reporting of adverse events.\nThe AEs are reported without grading in this table, but are graded in the paper reporting this clinical trial.</p><p>All Primary analyses are reported (also in the accepted manuscript) along with the secondary outcomes needed to support the primary analysis.\nSecondary outcomes not involving the randomised comparison will be updated when the analyses are available.\nPlease note that analyses of these Secondary outcomes will take time.</p>, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03355664",
    "endpoint": "measure - Incidence of Adverse Events Concerning Markers of Hepatic or Renal Toxicity, description - Total bilirubin, Alanine transaminase, Aspartate transaminase, Alkaline phosphatase and creatinine will be measured, timeFrame - 42 day",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03355664",
    "endpoint": "measure - Incidence of Prolongation of the Corrected QT Interval, description - We record the number of events where the QT interval exceeds 500ms or increases by 60ms or greater., timeFrame - 28 day",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03355664",
    "endpoint": "measure - Prolongation of the Corrected QT Interval, description - We record the number of events where the QT interval exceeds 500ms or increases by 60ms or greater.\nThere were zero events of this at any time point in either study arm.\nSo no further analyses are possible., timeFrame - Hour 4, Hour 24, Hour 28, Hour 48, Hour 52, Hour 60, Hour 64, Day 7 and Day 28 and between these time points",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03355664",
    "endpoint": "measure - Parasite Reduction Rates, description - <p>Parasite reduction rates and ratios at 24 and 48 hours assessed by microscopy</p><p>The data are collected, but this secondary outcome will come from analyses done by specialist researchers and the results will not affect the the presently reported primary outcomes of efficacy, safety and tolerability.\nThese fields will be updated once results become available.\nWe will also provide a link to the paper reporting the trial when it is published online as this will provide additional detail about the study.</p>, timeFrame - 24 and 48 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03355664",
    "endpoint": "measure - Parasite Count to Fall 50%, description - <p>Time for parasite count to fall 50% of initial parasite density</p><p>The data are collected, but this secondary outcome will come from analyses done by specialist researchers and the results will not affect the the presently reported primary outcomes of efficacy, safety and tolerability.\nThese fields will be updated once results become available.\nWe will also provide a link to the paper reporting the trial when it is published online as this will provide additional detail about the study.</p>, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03355664",
    "endpoint": "measure - Parasite Count to Fall 90%, description - <p>Time for parasite count to fall 90% of initial parasite density</p><p>The data are collected, but this secondary outcome will come from analyses done by specialist researchers and the results will not affect the the presently reported primary outcomes of efficacy, safety and tolerability.\nThese fields will be updated once results become available.\nWe will also provide a link to the paper reporting the trial when it is published online as this will provide additional detail about the study.</p>, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03355664",
    "endpoint": "measure - Parasite Count to Fall 99%, description - <p>Time for parasite count to fall 99% of initial parasite density</p><p>The data are collected, but this secondary outcome will come from analyses done by specialist researchers and the results will not affect the the presently reported primary outcomes of efficacy, safety and tolerability.\nThese fields will be updated once results become available.\nWe will also provide a link to the paper reporting the trial when it is published online as this will provide additional detail about the study.</p>, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03355664",
    "endpoint": "measure - Change in Haematocrit, description - <p>Change in haematocrit at specified time points according to geographical location and study arm, stratified for G6PD status</p><p>The data are collected, but this secondary outcome will come from analyses done by specialist researchers and the results will not affect the the presently reported primary outcomes of efficacy, safety and tolerability.\nThese fields will be updated once results become available.\nWe will also provide a link to the paper reporting the trial when it is published online as this will provide additional detail about the study.</p>, timeFrame - Day 1 to 7, 14, 21, 28, 35, 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03355664",
    "endpoint": "measure - Correlation Between the Host Genotype and the Pharmacokinetics and Pharmacodynamics of Antimalarials, description - <p>Correlation between the host genotype and the pharmacokinetics and pharmacodynamics of antimalarials</p><p>The data are collected, but this secondary outcome will come from analyses done by specialist researchers and the results will not affect the the presently reported primary outcomes of efficacy, safety and tolerability.\nThese fields will be updated once results become available.\nWe will also provide a link to the paper reporting the trial when it is published online as this will provide additional detail about the study.</p>, timeFrame - 42 day",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03355664",
    "endpoint": "measure - Proportion of Patients That Reports Completing a Full Course of Observed TACT or ACT, description - <p>Proportion of patients that reports completing a full course of observed TACT or ACT without withdrawal of consent or exclusion from study because of drug related serious adverse event</p><p>The data are collected, but this secondary outcome will come from analyses done by specialist researchers and the results will not affect the the presently reported primary outcomes of efficacy, safety and tolerability.\nThese fields will be updated once results become available.\nWe will also provide a link to the paper reporting the trial when it is published online as this will provide additional detail about the study.</p>, timeFrame - 42 day",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03355664",
    "endpoint": "measure - Prevalence of Kelch13 Mutations of Known Significance, description - <p>Prevalence of Kelch13 mutations of known significance</p><p>The data are collected, but this secondary outcome will come from analyses done by specialist researchers and the results will not affect the the presently reported primary outcomes of efficacy, safety and tolerability.\nThese fields will be updated once results become available.\nWe will also provide a link to the paper reporting the trial when it is published online as this will provide additional detail about the study.</p>, timeFrame - 42 day",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03355664",
    "endpoint": "measure - Prevalence&#x2F;Incidence of Other Genetic Markers of Antimalarial Drug Resistance Such as Multidrug Resistance Gene 1 Copy Number and Multidrug Resistance Gene 1 Mutations, description - <p>Prevalence&#x2F;incidence of other genetic markers of antimalarial drug resistance such as multidrug resistance gene 1 copy number and multidrug resistance gene 1 mutations</p><p>The data are collected, but this secondary outcome will come from analyses done by specialist researchers and the results will not affect the the presently reported primary outcomes of efficacy, safety and tolerability.\nThese fields will be updated once results become available.\nWe will also provide a link to the paper reporting the trial when it is published online as this will provide additional detail about the study.</p>, timeFrame - 48 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03355664",
    "endpoint": "measure - Genome Wide Association With in Vivo&#x2F;in Vitro Sensitivity Parasite Phenotype, description - <p>Genome wide association with in vivo&#x2F;in vitro sensitivity parasite phenotype</p><p>The data are collected, but this secondary outcome will come from analyses done by specialist researchers and the results will not affect the the presently reported primary outcomes of efficacy, safety and tolerability.\nThese fields will be updated once results become available.\nWe will also provide a link to the paper reporting the trial when it is published online as this will provide additional detail about the study.</p>, timeFrame - 42 day",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03355664",
    "endpoint": "measure - Correlation Between Single Nucleotide Polymorphisms and Whole Genome Sequencing, description - <p>Correlation between single nucleotide polymorphisms measured in dry blood spots and whole genome sequencing in leukocyte depleted blood samples</p><p>The data are collected, but this secondary outcome will come from analyses done by specialist researchers and the results will not affect the the presently reported primary outcomes of efficacy, safety and tolerability.\nThese fields will be updated once results become available.\nWe will also provide a link to the paper reporting the trial when it is published online as this will provide additional detail about the study.</p>, timeFrame - 42 day",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03355664",
    "endpoint": "measure - A Comparison of Transcriptomic Patterns Between Sensitive and Resistant Parasites, description - <p>Transcriptomic patterns measure at baseline and at specified time points after the start of treatment comparing sensitive and resistant parasites.</p><p>The data are collected, but this secondary outcome will come from analyses done by specialist researchers and the results will not affect the the presently reported primary outcomes of efficacy, safety and tolerability.\nThese fields will be updated once results become available.\nWe will also provide a link to the paper reporting the trial when it is published online as this will provide additional detail about the study.</p>, timeFrame - baseline and t = 6 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03355664",
    "endpoint": "measure - Correlation Between Quantitative Polymerase Chain Reaction Based Versus Microscopy Based Assessments of Parasite Clearance Dynamics, description - <p>Correlation between qPCR based versus microscopy based assessments of parasite clearance dynamics</p><p>The data are collected, but this secondary outcome will come from analyses done by specialist researchers and the results will not affect the the presently reported primary outcomes of efficacy, safety and tolerability.\nThese fields will be updated once results become available.\nWe will also provide a link to the paper reporting the trial when it is published online as this will provide additional detail about the study.</p>, timeFrame - 14 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03355664",
    "endpoint": "measure - Proportion of Patients With Gametocytaemia Before, During and After Treatment With TACT or ACT, description - <p>Proportion of patients with gametocytaemia before, during and after treatment with TACT or ACT stratified by the presence of gametocytes at enrolment</p><p>The data are collected, but this secondary outcome will come from analyses done by specialist researchers and the results will not affect the the presently reported primary outcomes of efficacy, safety and tolerability.\nThese fields will be updated once results become available.\nWe will also provide a link to the paper reporting the trial when it is published online as this will provide additional detail about the study.</p>, timeFrame - At admission and up to day 14",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03355664",
    "endpoint": "measure - Levels of RNA Transcription Coding for Male or Female Specific Gametocytes, description - <p>Levels of RNA transcription coding for male or female specific gametocytes at admission up to day 14, stratified by the presence of gametocytes at enrolment</p><p>The data are collected, but this secondary outcome will come from analyses done by specialist researchers and the results will not affect the the presently reported primary outcomes of efficacy, safety and tolerability.\nThese fields will be updated once results become available.\nWe will also provide a link to the paper reporting the trial when it is published online as this will provide additional detail about the study.</p>, timeFrame - 14 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03355664",
    "endpoint": "measure - In Vitro Sensitivity of P. Falciparum to Artemisinins and Partner Drugs, description - <p>In vitro sensitivity of P. falciparum to artemisinins and partner drugs according to study sites and genotype</p><p>The data are collected, but this secondary outcome will come from analyses done by specialist researchers and the results will not affect the the presently reported primary outcomes of efficacy, safety and tolerability.\nThese fields will be updated once results become available.\nWe will also provide a link to the paper reporting the trial when it is published online as this will provide additional detail about the study.</p>, timeFrame - At admission &amp; subjects with recurrent parasitaemia, up to 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03355664",
    "endpoint": "measure - Pharmacokinetic Profiles and Interactions (Cmax) of Artemisinin-derivatives and Partner Drugs, description - <p>Pharmacokinetic profiles and interactions (Cmax) of artemisinin-derivatives and partner drugs in 20 ACT treated and 20 TACT treated patients of both study arms in Vietnam</p><p>The data are collected, but this secondary outcome will come from analyses done by specialist researchers and the results will not affect the the presently reported primary outcomes of efficacy, safety and tolerability.\nThese fields will be updated once results become available.\nWe will also provide a link to the paper reporting the trial when it is published online as this will provide additional detail about the study.</p>, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03355664",
    "endpoint": "measure - Pharmacokinetic Profiles and Interactions (AUC) of Artemisinin-derivatives and Partner Drugs, description - <p>Pharmacokinetic profiles and interactions (AUC) of artemisinin-derivatives and partner drugs in 20 ACT treated and 20 TACT treated patients of both study arms in Vietnam</p><p>The data are collected, but this secondary outcome will come from analyses done by specialist researchers and the results will not affect the the presently reported primary outcomes of efficacy, safety and tolerability.\nThese fields will be updated once results become available.\nWe will also provide a link to the paper reporting the trial when it is published online as this will provide additional detail about the study.</p>, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03355664",
    "endpoint": "measure - Day 7 Drug Levels of Partner Drugs in Association With Treatment Efficacy and Treatment Arm, description - <p>Day 7 drug levels of partner drugs in association with treatment efficacy and treatment arm</p><p>The data are collected, but this secondary outcome will come from analyses done by specialist researchers and the results will not affect the the presently reported primary outcomes of efficacy, safety and tolerability.\nThese fields will be updated once results become available.\nWe will also provide a link to the paper reporting the trial when it is published online as this will provide additional detail about the study.</p>, timeFrame - 7 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03355664",
    "endpoint": "measure - Correlation Between Histidine-rich Protein 2 (HRP2) Based Versus Microscopy Based Assessments of Parasite Clearance Dynamics, description - <p>Correlation between histidine-rich protein 2 (HRP2) based versus microscopy based assessments of parasite clearance dynamics</p><p>The data are collected, but this secondary outcome will come from analyses done by specialist researchers and the results will not affect the the presently reported primary outcomes of efficacy, safety and tolerability.\nThese fields will be updated once results become available.\nWe will also provide a link to the paper reporting the trial when it is published online as this will provide additional detail about the study.</p>, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00111163",
    "endpoint": "measure - Moderate and severe anemia in the first year of life, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00111163",
    "endpoint": "measure - Serologic responses to Expanded Program on Immunization (EPI) vaccines (Polio, Diphtheria, Tetanus, Pertussis, Hepatitis B, Hemophilus Influenzae type B, and Measles), description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00111163",
    "endpoint": "measure - Nasal carriage rates of Haemophilus influenza type b, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00111163",
    "endpoint": "measure - All cause hospitalization in the first year of life, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03435874",
    "endpoint": "measure - Anti-RH5 antibody concentration by ELISA., description - Evaluation of the magnitude of antibody responses to PfRH5 in adults, children and infants residing in a malaria endemic country, as measured by ELISA, timeFrame - At baseline, and days 14 (adults only), 28, 56, 70, 84, 112, 140 and 168 after the first vaccination.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03435874",
    "endpoint": "measure - Growth inhibition activity of sera from vaccinees on a panel of P. falciparum parasites., description - Evaluation of the quality of antibody responses to RH5 in adults, children and infants residing in a malaria endemic country, as measured by an assay of growth inhibition activity on the vaccinees&#x27; sera, timeFrame - At baseline, and days 14 (adults only), 28, 56, 70, 84, 112, 140 and 168 after the first vaccination.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03435874",
    "endpoint": "measure - Avidity of anti-RH5 antibodies by ELISA and surface plasmon resonance (SPR) and&#x2F;or other assays (to be defined)., description - Evaluation of the longevity of antibody responses to PfRH5 in adults, children and infants residing in a malaria endemic country, as measured by ELISA, SPR +&#x2F;- other assays, timeFrame - At baseline, and days 14 (adults only), 28, 56, 70, 84, 112, 140 and 168 after the first vaccination.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03435874",
    "endpoint": "measure - Cellular immune responses to the RH5 by ELISpot assay and&#x2F;or Intracellular Cytokine Staining (ICS) and&#x2F;or other assays to be defined., description - Evaluation of the magnitude and quality of cellular immune responses to PfRH5 in adults, children and infants residing in a malaria endemic country, by ELISpot assay and&#x2F;or Intracellular Cytokine Staining (ICS) and&#x2F;or other assays to be defined., timeFrame - At baseline, and days 14 (adults only), 28, 56, 70, 84, 112, 140 and 168 after the first vaccination.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01660854",
    "endpoint": "measure - • Parasitemia and kinetics of parasitemia as measured by PCR, description - , timeFrame - 21 days after challenge",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01660854",
    "endpoint": "measure - Frequency of signs or symptoms in study groups, description - , timeFrame - 21 days after challenge",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01660854",
    "endpoint": "measure - • Immune responses between study groups, description - , timeFrame - 21 days after challenge",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07082205",
    "endpoint": "measure - Number of participants with adverse events following a dose of L9LS versus PDMC in children hospitalised with severe anaemia or severe malaria, description - Assess the safety and tolerability of a single dose of L9LS versus PDMC in children hospitalised with severe anaemia or severe malaria through number of participants with solicited and unsolicited adverse events following intervention product administration., timeFrame - From enrollment to12 months post-discharge",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07082205",
    "endpoint": "measure - Efficacy of a single dose of L9LS versus PDMC against the first or only microscopy or RDT-confirmed clinical malaria in children hospitalised with severe anaemia or severe malaria by 6 months post-discharge, description - To assess the efficacy of a single dose of L9LS versus PDMC against the first or only microscopy or RDT-confirmed clinical malaria in children hospitalised with severe anaemia or severe malaria by 6 months post-discharge.\nthe end point includes the first or only episode of clinical malaria from 3 to 26 weeks post-discharge, inclusive, by time-to-event analysis., timeFrame - 3-26 weeks post-discharge",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07082205",
    "endpoint": "measure - Efficacy of a single dose of L9LS versus PDMC against clinical malaria with parasite density &gt;5,000&#x2F;microlitre (3- 26 weeks post discharge), description - To assess the efficacy of a single dose of L9LS versus PDMC against clinical malaria with parasite density &gt;5,000&#x2F;microlitre (3-26 weeks post-discharge), timeFrame - 3-26 weeks post discharge (6 months)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07082205",
    "endpoint": "measure - Efficacy of a single dose of L9LS versus PDMC against readmission for any reason in children hospitalised with severe anaemia or severe malaria by 6 months post-discharge, description - To assess the efficacy of a single dose of L9LS versus PDMC against re-admission from any cause., timeFrame - 3-26 weeks post-discharge (6 months)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07082205",
    "endpoint": "measure - Efficacy of a single dose of L9LS versus PDMC on anaemia by 6 months post-discharge, description - To assess the efficacy of a single dose of L9LS versus PDMC on Hb and anaemia by 6 months post-discharge.\nThe end points include: Mean Hb at 6 months, Prevalence of any anaemia (Hb&lt;11 g&#x2F;dL), mild anaemia (Hb 10.0-10.99 g&#x2F;dl), moderate anaemia (Hb 7.0-9.99\ng&#x2F;dL) and moderate-severe anaemia (Hb&lt;7.0\ng&#x2F;dL) at 6 months, timeFrame - 6 months post discharge",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07082205",
    "endpoint": "measure - The incidence of clinical malaria from 27 to 52 weeks post-discharge, description - To assess the efficacy of L9LS vs PDMC on incidence of clinical malaria from 27-52 weeks post-discharge,, timeFrame - 27 - 52 weeks post discharge (post intervention)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07082205",
    "endpoint": "measure - The prevalence of malaria infection and parasite densities at 12 months, description - To assess whether protection by a single dose of L9LS versus PDMC in children hospitalised with severe anaemia or severe malaria results in delayed malaria after the effect of L9LS has waned.\nThe end-points is the prevalence of malaria infection and parasite densities at 12 months., timeFrame - 12 months post discharge",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07082205",
    "endpoint": "measure - Prevalence of mild (Z-score &lt;-2) and severe (Z-score &lt;-3) of low MUAC-for-age, low weight-for-age, low height-for-age, and low height-for-weight at 12 months, description - To assess the efficacy of a single dose of L9LS versus PDMC on physical growth by 12 months post-discharge, this involves mean Z scores and prevalence of mild (Z-score &lt;-2) and severe (Z-score &lt;-3) of low MUAC-for-age, low weight-for-age, low height-for-age, and low height-for-weight at 12 months (using the WHO child growth standards)., timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07082205",
    "endpoint": "measure - Efficacy of a single dose of L9LS versus PDMC against cause-specific readmissions (3-36 weeks post-discharge), description - To assess the efficacy of a single dose of L9LS versus PDMC against cause-specific readmissions (severe malaria, severe anaemia, severe malarial anaemia, severe non-malarial anaemia, readmissions for severe malaria or severe anaemia [composite], readmission for other reasons) (3-26 weeks post-discharge), timeFrame - 3-26 weeks post discharge",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07082205",
    "endpoint": "measure - Death from any cause (3-26 weeks post discharge), description - To assess the efficacy of a single dose of L9LS versus PDMC against death from any cause (by 6 months , 3-26 weeks post discharge), timeFrame - 3-26 weeks post discharge",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07082205",
    "endpoint": "measure - To assess the efficacy of a single dose of L9LS versus PDMC on growth by 6 months post discharge, description - Assess the mean Z-scores for mid-upper arm circumference (MUAC) for-age, weight-for-age, height-for-age, and height-for-weight (using the WHO child growth standards) in children who received L9LS versus PDMC at 6 months.\nWeight will be measured in Kilograms and height in centimeters.\nthese measurements will be converted to Z-scores., timeFrame - 6 months post discharge",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07082205",
    "endpoint": "measure - Prevalence of malaria infection detected by microscopy, RDT or PCR at 6 months, description - Prevalence of malaria infection detected by microscopy, RDT or PCR (composite, microscopy, RDT any band, PCR) at 6 months, timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07082205",
    "endpoint": "measure - Prevalence of malaria infection detected by microscopy, RDT or PCR at 12 months, description - Prevalence of malaria infection detected by microscopy, RDT or PCR (composite, microscopy, RDT any band, PCR) at 12 months, timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07082205",
    "endpoint": "measure - Sick-child clinic visits for any reason (all-cause) (3-26 weeks post-discharge), description - To assess the efficacy of a single dose of L9LS versus PDMC against sick-child clinic visits for any reason (all-cause) (3-26 weeks post-discharge), timeFrame - 3-26 weeks post discharge",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07082205",
    "endpoint": "measure - Sick-child clinic visits unrelated to malaria (all-cause minus primary outcome) (3-26 weeks post-discharge), description - To assess the efficacy of a single dose of L9LS versus PDMC against sick-child clinic visits unrelated to malaria in children hospitalised with severe anaemia or severe malaria by 6 months post-discharge, timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07082205",
    "endpoint": "measure - Efficacy of a single dose of L9LS versus PDMC against readmission or death from any cause (composite) (3-26 weeks post-discharge)., description - To assess the efficacy of a single dose of L9LS versus PDMC against readmission or death from any cause (composite) (3-26 weeks post-discharge)., timeFrame - 3-26 weeks post discharge",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07082205",
    "endpoint": "measure - Efficacy of a single dose of L9LS versus PDMC against sick-child clinic visits for any reason (all-cause) (27-52 weeks post-discharge), description - To assess the efficacy of a single dose of L9LS versus PDMC against sick-child clinic visits for any reason (all-cause) (27-52 weeks post-discharge), timeFrame - 27-52 weeks post-discharge",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07082205",
    "endpoint": "measure - Efficacy of a single dose of L9LS versus PDMC against sick-child clinic visits unrelated to malaria in children hospitalised with severe anaemia or severe malaria by 12 months post-discharge, description - To assess the efficacy of a single dose of L9LS versus PDMC against sick-child clinic visits unrelated to malaria in children hospitalised with severe anaemia or severe malaria by 12 months post-discharge, timeFrame - 27-52 weeks post-discharge",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07082205",
    "endpoint": "measure - Efficacy of a single dose of L9LS versus PDMC against readmission or death from any cause (composite) (27-52 weeks post-discharge), description - To assess the efficacy of a single dose of L9LS versus PDMC against readmission or death from any cause (composite) (27-52 weeks post-discharge), timeFrame - 27-52 weeks post-discharge",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07082205",
    "endpoint": "measure - Death from any cause (27-52 weeks post discharge), description - To assess the efficacy of a single dose of L9LS versus PDMC against death from any cause (by12months , 27-52 weeks post discharge), timeFrame - 27-52 weeks post-discharge",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07082205",
    "endpoint": "measure - Efficacy of a single dose of L9LS versus PDMC against cause-specific readmissions (27-52 weeks post-discharge), description - To assess the efficacy of a single dose of L9LS versus PDMC against cause-specific readmissions (severe malaria, severe anaemia, severe malarial anaemia, severe non-malarial anaemia, readmissions for severe malaria or severe anaemia [composite], readmission for other reasons) (27-52 weeks post-discharge), timeFrame - 27-52 weeks post-discharge",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01103830",
    "endpoint": "measure - Effect of Eurartesim™ administered in different food conditions, on ECG parameters, description - To evaluate the impact of a therapeutic dose of Eurartesim™ under different food intake conditions on the cardiac activity, as expressed by ECG parameters., timeFrame - before study drugs administration, during the 24 hrs post first and last dose and during follow-up",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01103830",
    "endpoint": "measure - Effect of food on bioavailability of Eurartesim™, description - To evaluate the impact of high-fat&#x2F;high-Kcal or high-fat&#x2F;low-Kcal meals on the overall relative bioavailability of Eurartesim™ in respect to no food., timeFrame - during the 24 hrs post first and last dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01103830",
    "endpoint": "measure - To evaluate differences in PK and ECG profiles according to posology scheme, description - To compare, within the Eurartesim™ groups, the PK profiles and the QT intervals of subjects with a body weight below or equal and above 75kg, timeFrame - during the 24 hrs post first and last dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01103830",
    "endpoint": "measure - relationship within the Pk parameters of active substances and ECG parameters, description - To evaluate the relationship between the PK parameters of Dihydroartemisinin and Piperaquine and the ECG parameters, timeFrame - during the 24 hrs post first and last dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01103830",
    "endpoint": "measure - to asses general safety and tolerability of Eurartesim™, description - To assess the safety and tolerability of Eurartesim™ under different food intake conditions in healthy subjects, timeFrame - during the treatment and follow-up period",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00465777",
    "endpoint": "measure - Cumulative post-discharge mortality on day 28 and length of hospitalisation, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00722150",
    "endpoint": "measure - Secondary outcome measures are time until parasite, fever, and gametocyte clearance (PCT, FCT, and GCT)., description - , timeFrame - Day 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02800109",
    "endpoint": "measure - The median neurocognitive scores by growth groups and malaria-exposed groups, description - , timeFrame - up to 2 years of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02800109",
    "endpoint": "measure - The median age of onset of anemia by growth groups and malaria-exposed Groups, description - , timeFrame - up to 2 years of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02800109",
    "endpoint": "measure - Characterize of molecular signatures (methylation profile of the DNA) by growth groups and malaria-exposed groups, description - , timeFrame - up to 2 years of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03167242",
    "endpoint": "measure - Part A and Part B: Number of Participants With Polymerase Chain Reaction (PCR)-Uncorrected Adequate Clinical and Parasitological Response (ACPR), description - <p>PCR-uncorrected ACPR defined as the absence of parasitaemia was evaluated at days 15, 29 and 43 (i.e., 14, 28 and 42 days post first dose).</p><p>A participant was considered as PCR-uncorrected ACPR at Days 15, 29 or 43 if the participant did not meet any of the criteria of early treatment failure, late clinical failure or late parasitological failure and was absence of parasitaemia on Days 15, 29 or 43 irrespective of axillary temperature.</p>, timeFrame - 14, 28 and 42 days post first dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03167242",
    "endpoint": "measure - Part A and Part B: Number of Participants With Polymerase Chain Reaction (PCR)-Corrected Adequate Clinical and Parasitological Response (ACPR), description - <p>PCR-corrected ACPR defined as the absence of parasitaemia was evaluated at days 15 and 43 (i.e., 14 and 42 days post first dose).\nMicroscopic species identification was confirmed and determined by PCR genotyping methods to establish malaria recrudescence&#x2F;reinfection.</p><p>A participant was considered as PCR-corrected ACPR at Day 15 or Day 43 if the participant did not meet any of the criteria of early treatment failure, late clinical failure or late parasitological failure and was absence of parasitaemia on Day 15 or Day 43 irrespective of axillary temperature unless the presence of parasitaemia after 7 days was due to reinfection based on PCR.\nA presence of parasitaemia after 7 days of treatment initiation was considered as a reinfection only if the parasitaemia was clear before Day 8 and none of the parasite strain(s) detected on Day 8 or later matched with the parasite strain at baseline based on PCR.</p>, timeFrame - 14 and 42 days post first dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03167242",
    "endpoint": "measure - Part A and Part B: Number of Participants With Recrudescence Events, description - Recrudescence is defined as appearance of asexual parasites after clearance of initial infection with a genotype identical to that of parasites present at baseline.\nRecrudescence must be confirmed by PCR analysis., timeFrame - 42 days post first dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03167242",
    "endpoint": "measure - Part A and Part B: Number of Participants With Reinfection Events, description - Reinfection is defined as appearance of asexual parasites after clearance of initial infection with a genotype different from those parasites present at baseline.\nReinfection must be confirmed by PCR analysis., timeFrame - 42 days post first dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03167242",
    "endpoint": "measure - Part A and Part B: Fever Clearance Time (FCT), description - Fever Clearance Time (FCT) is defined as the time from the first dose until the first time the axillary body temperature decreased below and remained below 37.5°C axillary or 38.0°C oral&#x2F;tympanic&#x2F;rectal for at least a further 24 hours.\nIn case a participant received rescue medication before (fever) clearance, the time to event was censored at the first use of rescue medication., timeFrame - 42 days post first dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03167242",
    "endpoint": "measure - PK Run-in, Part A and Part B: Parasite Clearance Time (PCT), description - Parasite Clearance Time (PCT) is defined as the time from the first dose until the first total and continued disappearance of asexual parasite forms which remained at least a further 48 hours.\nIn case a participant received rescue medication before (parasite) clearance, the time to event was censored at the first use of rescue medication., timeFrame - 42 days post first dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03167242",
    "endpoint": "measure - PK Run-in, Part A and Part B: Number of Participants With Parasitaemia, description - Parasitaemia is the quantitative content of parasites in the blood determined by microscopy examination validated methods.\nOnly Plasmodium Falciparum asexual form is used for parasitaemia assessments., timeFrame - 12, 24 and 48 hours post last dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03167242",
    "endpoint": "measure - Part A and Part B: Area Under the Blood Concentration-time Curve Over the Last 24 Hours After Last Treatment Dose (AUC0-24h) of KAF156, description - Pharmacokinetic (PK) parameters were calculated based on KAF156 blood concentrations determined by a validated liquid chromatography and tandem mass spectrometry (LC-MS&#x2F;MS) method.\nAUC0-24h was determined using non-compartmental methods., timeFrame - 3, 6, 18 and 24 hours post last dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03167242",
    "endpoint": "measure - Part A and Part B: Maximum Peak Observed Concentration (Cmax) of KAF156, description - Pharmacokinetic (PK) parameters were calculated based on KAF156 blood concentrations determined by a validated liquid chromatography and tandem mass spectrometry (LC-MS&#x2F;MS) method.\nCmax was determined using non-compartmental methods., timeFrame - 3, 6, 18, 24, 27, 30, 48, 51, 54, 68, 72 and 168 hours post last dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03167242",
    "endpoint": "measure - PK Run-in and Part A: Elimination Half-life (T½) of KAF156, description - Pharmacokinetic (PK) parameters were calculated based on KAF156 blood concentrations determined by a validated liquid chromatography and tandem mass spectrometry (LC-MS&#x2F;MS) method.\nT½ was determined using non-compartmental methods., timeFrame - 0, 1, 3, 6, 12, 18, 24, 27, 30, 36, 48, 72, 96 and 168 hours post last dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03167242",
    "endpoint": "measure - PK Run-in and Part A (Cohorts 1 and 2): Time to Reach Maximum Blood Concentrations (Tmax) of KAF156, description - Pharmacokinetic (PK) parameters were calculated based on KAF156 blood concentrations determined by a validated liquid chromatography and tandem mass spectrometry (LC-MS&#x2F;MS) method.\nTmax was determined using non-compartmental methods., timeFrame - 0, 1, 3, 6, 12, 18, 24, 30, 48, 96 and 168 hours post last dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06172686",
    "endpoint": "measure - Rate of Mosquito infections (proportion of infected mosquitoes), description - Rate of Mosquito infections (proportion of infected mosquitoes), timeFrame - 14, 21 and 28 days after infection challenge",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06172686",
    "endpoint": "measure - Infection burden (Oocysts density in infected mosquitoes), description - Infection burden (Oocysts density in infected mosquitoes), timeFrame - 14, 21 and 28 days after infection challenge",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06172686",
    "endpoint": "measure - Number of volunteers in each study arm that show prevalence of gametocytes as defined by quantitative reverse-transcriptase PCR (qRT-PCR) for CCp4 (female) and pfMGET (male) mRNA with a threshold of 5 gametocytes&#x2F;mL for positivity., description - Number of volunteers in each study arm that show prevalence of gametocytes as defined by quantitative reverse-transcriptase PCR (qRT-PCR) for CCp4 (female) and pfMGET (male) mRNA with a threshold of 5 gametocytes&#x2F;mL for positivity., timeFrame - Up to day 28 after blood infection challenge",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06172686",
    "endpoint": "measure - Time to peak density gametocytes from the time of challenge as measured by qRT-PCR., description - Time to peak density gametocytes from the time of challenge as measured by qRT-PCR., timeFrame - Up to day 28 after the blood infection challenge",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06172686",
    "endpoint": "measure - The area under the curve of gametocyte density versus time for both arms of the study, description - The area under the curve of gametocyte density versus time for both arms of the study, timeFrame - Up to day 28 after the blood infection challenge",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06172686",
    "endpoint": "measure - Gametocyte commitment after the blood infection challenge as estimated by dividing the peak gametocyte by the peak of asexual parasites, description - Gametocyte commitment after the blood infection challenge as estimated by dividing the peak gametocyte by the peak of asexual parasites, timeFrame - Up to day 28 after the blood infection challenge",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06172686",
    "endpoint": "measure - Gametocyte Sex-ratio after blood infection challenge as measured by the proportion of male gametocytes versus female gametocytes., description - Gametocyte Sex-ratio after blood infection challenge as measured by the proportion of male gametocytes versus female gametocytes., timeFrame - Up to day 28 after the blood infection challenge",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00493363",
    "endpoint": "measure - 56 day cure rates, in vitro sensitivity, molecular markers of drug resistance, description - 56 day cure rates, in vitro sensitivity, molecular markers of drug resistance, timeFrame - June 2008",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01906788",
    "endpoint": "measure - Haemoglobin level, description - We will compare the level of baseline haemoglobin on days 3, 7, 10 and 14 after the start of treatment between the two Primaquine arms, timeFrame - days 3, 7, 10 and 14",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00935688",
    "endpoint": "measure - % of PV patients not receiving CQ % of PF patients not receiving SP&#x2F;AS, description - , timeFrame - 2009-2010",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00935688",
    "endpoint": "measure - Diagnostic Accuracy of the different malaria tests, description - Sensitivity and specificity of mRDTs, Microscopy and clinical diagnosis., timeFrame - 2009-2010",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03195387",
    "endpoint": "measure - Incidence, severity and relationship to MMV390048 of the observed and self-reported treatment-emergent adverse events, description - Safety and tolerability assessments during 29 days after administration of a single oral dose of IMP., timeFrame - Until Day 29 after IMP administration (cohort-dependent)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03195387",
    "endpoint": "measure - Malaria clinical score and incidence, severity and relationship of the observed and self-reported adverse events after PfSPZ challenge, description - Safety and tolerability of the PfSPZ challenge in non-immune healthy volunteers., timeFrame - From PfSPZ challenge to the day of positive parasitaemia and to Day 28 and Day 60 (EOS visit)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03195387",
    "endpoint": "measure - Area under the plasma concentration-time curve from time zero to time of last measurable concentration (AUClast), description - Estimation of PK parameters using non-compartmental methods after a single oral dose of MMV390048., timeFrame - Duration of the PK study is up to 29 days after IMP administration",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03195387",
    "endpoint": "measure - Area under the plasma concentration-time curve from time zero to infinity (AUCinf), description - Estimation of PK parameters using non-compartmental methods after a single oral dose of MMV390048., timeFrame - Duration of the PK study is up to 29 days after IMP administration",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03195387",
    "endpoint": "measure - Maximum plasma drug concentration (Cmax), description - Estimation of PK parameters using non-compartmental methods after a single oral dose of MMV390048., timeFrame - Duration of the PK study is up to 29 days after IMP administration",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03195387",
    "endpoint": "measure - Time to reach maximum plasma drug concentration following administration (Tmax), description - Estimation of PK parameters using non-compartmental methods after a single oral dose of MMV390048., timeFrame - Duration of the PK study is up to 29 days after IMP administration",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03195387",
    "endpoint": "measure - Elimination half-life (t1&#x2F;2), description - Estimation of PK parameters using non-compartmental methods after a single oral dose of MMV390048., timeFrame - Duration of the PK study is up to 29 days after IMP administration",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03195387",
    "endpoint": "measure - Apparent total drug clearance from plasma after oral administration (CL&#x2F;F), description - Estimation of PK parameters using non-compartmental methods after a single oral dose of MMV390048., timeFrame - Duration of the PK study is up to 29 days after IMP administration",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03195387",
    "endpoint": "measure - Apparent volume of distribution during terminal phase (Vz&#x2F;F), description - Estimation of PK parameters using non-compartmental methods after a single oral dose of MMV390048., timeFrame - Duration of the PK study is up to 29 days after IMP administration",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03195387",
    "endpoint": "measure - MMV390048 plasma concentration upon PfSPZ challenge, description - Estimation of MMV390048 plasma concentration on the day of PfSPZ inoculation., timeFrame - One-off assessment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03195387",
    "endpoint": "measure - Time to installment of parasitaemia, description - Characterisation of the relationship between MMV390048 exposure and time of installment of P. falciparum parasitaemia assessed by qPCR after PfSPZ challenge., timeFrame - Up to 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00479206",
    "endpoint": "measure - Secondary outcome measures are time until parasite, fever, and gametocyte clearance (PCT, FCT, and GCT)., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02737007",
    "endpoint": "measure - Whole-Blood:Plasma ratio of Cmax of RDM following a single IV microdose of [14C]-GSK3191607, description - Cmax of RDM in whole blood will be compared with that of RDM in plasma., timeFrame - Pre-dose; and 0.25, 0.75, 1.5, 3, 6, 8, 12, 16, 24, 48, 72, 96, 120, 168, 216, 264, 312, and 336 hours following start of infusion",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02737007",
    "endpoint": "measure - Whole-Blood:Plasma ratio of tmax of RDM following a single IV microdose of [14C]-GSK3191607, description - Tmax of RDM in whole blood will be compared with that of RDM in plasma., timeFrame - Pre-dose; and 0.25, 0.75, 1.5, 3, 6, 8, 12, 16, 24, 48, 72, 96, 120, 168, 216, 264, 312, and 336 hours following start of infusion",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02737007",
    "endpoint": "measure - Whole-Blood:Plasma ratio of t1&#x2F;2 of RDM following a single IV microdose of [14C]-GSK3191607, description - T1&#x2F;2 of RDM in whole blood will be compared with that of RDM in plasma., timeFrame - Pre-dose; and 0.25, 0.75, 1.5, 3, 6, 8, 12, 16, 24, 48, 72, 96, 120, 168, 216, 264, 312, and 336 hours following start of infusion",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02737007",
    "endpoint": "measure - Whole-Blood:Plasma ratio of AUC(0-t) of RDM following a single IV microdose of [14C]-GSK3191607, description - AUC(0-t) of RDM in whole blood will be compared with that of RDM in plasma., timeFrame - Pre-dose; and 0.25, 0.75, 1.5, 3, 6, 8, 12, 16, 24, 48, 72, 96, 120, 168, 216, 264, 312, and 336 hours following start of infusion",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02737007",
    "endpoint": "measure - Whole-Blood:Plasma ratio of AUC(0-infinity) of RDM following a single IV microdose of [14C]-GSK3191607, description - AUC(0-infinity) of RDM in whole blood will be compared with that of RDM in plasma., timeFrame - Pre-dose; and 0.25, 0.75, 1.5, 3, 6, 8, 12, 16, 24, 48, 72, 96, 120, 168, 216, 264, 312, and 336 hours following start of infusion",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02737007",
    "endpoint": "measure - Number of subjects with adverse events, description - , timeFrame - Start of infusion until follow-up (up to Day 25)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02737007",
    "endpoint": "measure - Number of subjects with clinically significant abnormal laboratory parameters, description - Hematology, clinical chemistry, and urinalysis parameters will be evaluated., timeFrame - Day -1, Day 1, Day 2, and follow-up (up to Day 25)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02737007",
    "endpoint": "measure - Number of subjects with clinically significant abnormal 12-lead electrocardiogram (ECG) parameters, description - 12-lead ECGs will be obtained at each time point during the study using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QT duration corrected for heart rate by Bazett&#x27;s formula (QTcB) intervals., timeFrame - Pre-dose, Day 1, Day 2, and follow-up (up to Day 25)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02737007",
    "endpoint": "measure - Number of subjects with clinically significant abnormal vital signs parameters, description - Vital signs will be measured in a semi-supine position after 5 minutes rest and will include systolic and diastolic blood pressure and pulse rate., timeFrame - Pre-dose, Day 1, Day 2, Day 3, and follow-up (up to Day 25)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00540202",
    "endpoint": "measure - 1. Fever clearance time assessed by self report. 2. Hemoglobin changes on day 0, 7, 14 and 28. 3. Safety profiles. 4. Adherence: measured by patient report and pill count on day 3 for the artemether-Lumefantrine group and day 7 for the quinine group., description - , timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02751294",
    "endpoint": "measure - Safety as assessed by clinical monitoring of blood pressure, description - Systolic and diastolic blood pressure will be measured in semi-supine position after approximately 5 minutes rest.\nBlood pressure will be measured at pre-dose (at least 30 min.\nprior to dosing and at least 15 min.\nafter waking) and at 12 hours post dose., timeFrame - Up to 12 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02751294",
    "endpoint": "measure - Safety as assessed by clinical monitoring of pulse rate, description - Pulse rate will be measured in semi-supine position after approximately 5 minutes rest.\nPulse rate will be measured at pre-dose (at least 30 min.\nprior to dosing and at least 15 min.\nafter waking) and at 12 hours post dose., timeFrame - Up to 12 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02751294",
    "endpoint": "measure - Safety as assessed by clinical monitoring of electrocardiogram (ECGs), description - Single 12-lead ECGs will be obtained in the semi-supine position at screening using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QT interval corrected for heart rate according to Fridericia&#x27;s formula (QTcF) intervals, timeFrame - Day -1",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02751294",
    "endpoint": "measure - Safety as assessed by clinical monitoring of Haematology parameters, description - Haematology parameters include Platelet Count, red blood cell (RBC) Indices, white blood cell (WBC) count with differential, RBC Count, mean cell volume (MCV), neutrophils, hemoglobin, mean corpuscular hemoglobin (MCH), lymphocytes, hematocrit, monocytes, methemoglobin %, eosinophils and basophils.\nIt will be assessed on Day -1, Pre-dose and post-dose at Day 7 and Day 14., timeFrame - Up to Day 14",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02751294",
    "endpoint": "measure - Safety as assessed by clinical monitoring of Clinical Chemistry parameters, description - Clinical chemistry parameters includes blood urea nitrogen, potassium, aspartate aminotransferase (SGOT), total and direct bilirubin, creatinine, sodium, alanine aminotransferase (SGPT), total protein, glucose, calcium, alkaline phosphatase and albumin.\nIt will be assessed on Day -1, Pre-dose and post-dose at Day 7 and Day 14., timeFrame - Up to Day 14",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02751294",
    "endpoint": "measure - Safety as assessed by clinical monitoring of Urinalysis parameters, description - Urinalysis parameters include specific gravity, pH, glucose, protein, blood and ketones.\nIt will be assessed on Day -1, Pre-dose and post-dose at Day 7 and Day 14, timeFrame - Up to Day 14",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02751294",
    "endpoint": "measure - Number of participants with adverse events (AE), description - An AE is any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal., timeFrame - Up to Day 63",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02751294",
    "endpoint": "measure - Area under the plasma concentration-time curve from time 0 to last measurable concentration (AUC0-t) for Tafenoquine, description - PK samples will be obtained from venous blood and peripheral blood collection (via microsampling), timeFrame - Samples will be collected at Pre-dose and 1, 2, 6, 9, 12, 15, 20, 24, 36, 48, 60, and 72 hours post dose on Day 1 and single sample on Day 7, 14, 21, 28, and 56",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02751294",
    "endpoint": "measure - Maximum plasma concentration (Cmax) for Tafenoquine, description - PK samples will be obtained from venous blood and peripheral blood collection (via microsampling), timeFrame - Samples will be collected at Pre-dose and 1, 2, 6, 9, 12, 15, 20, 24, 36, 48, 60, and 72 hours post dose on Day 1 and single sample on Day 7, 14, 21, 28, and 56",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02751294",
    "endpoint": "measure - Time to Cmax (tmax) for Tafenoquine, description - PK samples will be obtained from venous blood and peripheral blood collection (via microsampling), timeFrame - Samples will be collected at Pre-dose and 1, 2, 6, 9, 12, 15, 20, 24, 36, 48, 60, and 72 hours post dose on Day 1 and single sample on Day 7, 14, 21, 28, and 56",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02751294",
    "endpoint": "measure - Terminal half-life (t1&#x2F;2) for Tafenoquine, description - PK samples will be obtained from venous blood and peripheral blood collection (via microsampling), timeFrame - Samples will be collected at Pre-dose and 1, 2, 6, 9, 12, 15, 20, 24, 36, 48, 60, and 72 hours post dose on Day 1 and single sample on Day 7, 14, 21, 28, and 56",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00284973",
    "endpoint": "measure - To assess the immunogenicity of the PfCP-2.9&#x2F;Montanide ISA 720 vaccine in healthy adult volunteers by evaluating and comparing antigen-specific antibody responses (anti-PfCP-2.9 ELISA) after each vaccination., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00284973",
    "endpoint": "measure - For exploratory analysis:, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00284973",
    "endpoint": "measure - To assess in vitro inhibition of parasite growth by vaccine-induced antibodies as measured by the GIA, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00284973",
    "endpoint": "measure - To assess the relationship between antibody levels as measured by ELISA with the corresponding degree of in vitro parasite growth inhibition as measured by GIA, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00284973",
    "endpoint": "measure - To assess antigen-specific antibody responses by IFA after each vaccination, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00284973",
    "endpoint": "measure - To assess the relationship between antibody levels as measured by ELISA with IFA titers that recognize the conformational antigens of the parasite., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01944189",
    "endpoint": "measure - Relative Oral Bioavailability of lumefantrine, description - <p>Nested Randomized Comparative Bioavailability study: Relative oral bioavailability between the two food arms will be assessed using lumefantrine pharmacokinetic exposure outcomes at 8 h after first dose.\nParameters to be considered will be attained peak concentrations (Cmax ) and area under concentration-time curve up to 8h after the first dose (AUC0-8h).</p><p>Peak concentrations (Cmax) and AUC0-8h will be used for relative bioavailability evaluations using confidence interval approach for average bioequivalence.</p>, timeFrame - 8 h after the first dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02288637",
    "endpoint": "measure - Difference in Anaemia in children, description - , timeFrame - up to 36 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02288637",
    "endpoint": "measure - Difference in Mosquito density for each vector species, description - , timeFrame - Up to 36 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02288637",
    "endpoint": "measure - Difference in Sporozoite rate for each mosquito vector species, description - , timeFrame - up to 36 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02288637",
    "endpoint": "measure - Prevalence of serological antibodies to malaria antigens, description - , timeFrame - at baseline",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02288637",
    "endpoint": "measure - Change in prevalence of insecticide resistance markers including kdr and metabolic mechanisms, description - , timeFrame - at baseline and up to 36 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01928914",
    "endpoint": "measure - Change from Baseline in QTcB, QTcI, QT, and HR for 1200mg dose of tafenoquine, description - electronic ECGs collected using holter monitors will be analysed to measure QTcF QTcB, QTcI, QT, and Heart Rate (HR), timeFrame - Day 1, Day 2, day 3, Day 4, Day 5 and Day 6",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01928914",
    "endpoint": "measure - Change from Baseline in QTcF QTcB, QTcI, QT, and HR for 300 mg single dose of tafenoquine, description - electronic ECGs collected using holter monitors will be analysed to measure QTcF QTcB, QTcI, QT, and Heart Rate (HR), timeFrame - Day 1, Day 2, day 3, Day 4, Day 5 and Day 6",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01928914",
    "endpoint": "measure - Change from Baseline in QTcF, QTcB, QTcI, QT, and HR for placebo, description - electronic ECGs collected using holter monitors will be analysed to measure QTcF QTcB, QTcI, QT, and Heart Rate (HR), timeFrame - Day 1, Day 2, day 3, Day 4, Day 5 and Day 6",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01928914",
    "endpoint": "measure - Change from Baseline in QTcF, QTcB, QTcI, QT, and HR for moxifloxacin, description - electronic ECGs collected using holter monitors will be analysed to measure QTcF QTcB, QTcI, QT, and Heart Rate (HR), timeFrame - Day 1, Day 2, day 3, Day 4, Day 5 and Day 6",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01928914",
    "endpoint": "measure - Plasma concentrations and derived pharmacokinetic parameters AUC(0-t), Cmax, and tmax of tafenoquine, description - Blood samples will be collected at pre-dose on Days 1 and 2, and Day 3: pre-dose, 1, 2, 3, 4, 5, 6, 9, 12, 15, 20, 24, 36, 48 and 72 hours post Day 3 dose, to measure plasma concentrations and derived pharmacokinetic parameters AUC(0-t), Cmax, and tmax of tafenoquine, timeFrame - Day 1, Day 2, day 3, Day 4, Day 5 and Day 6",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01928914",
    "endpoint": "measure - Safety and tolerability of tafenoquine as assessed by 12-lead ECGs, vital signs, adverse events, and clinical laboratory tests, description - Safety and tolerability of tafenoquine as assessed by 12-lead ECGs, vital signs, adverse events, and clinical laboratory tests, timeFrame - Day 1, Day 2 and Day 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01928914",
    "endpoint": "measure - Change from Baseline in QTcF QTcB, QTcI, QT, and HR for 600 mg single dose of tafenoquine, description - electronic ECGs collected using holter monitors will be analysed to measure QTcF QTcB, QTcI, QT, and Heart Rate (HR), timeFrame - Day 1, Day 2, day 3, Day 4, Day 5 and Day 6",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01928914",
    "endpoint": "measure - Plasma concentrations and derived pharmacokinetic parameters AUC(0-t), Cmax, and tmax of moxifloxacin, description - Blood samples will be collected at pre-dose on Days 1 and 2, and Day 3: pre-dose, 1, 2, 3, 4, 5, 6, 9, 12, 15, 20, 24, 36, 48 and 72 hours post Day 3 dose, to measure plasma concentrations and derived pharmacokinetic parameters AUC(0-t), Cmax, and tmax of moxifloxacin, timeFrame - Day 1, Day 2, day 3, Day 4, Day 5 and Day 6",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00168948",
    "endpoint": "measure - Interaction between erythrocyte polymorphisms and SP, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00168948",
    "endpoint": "measure - Influence on parasite multiplicity, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00168948",
    "endpoint": "measure - Impact on child development, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03009526",
    "endpoint": "measure - Electrocardiogram changes following the receipt of DP, description - QTc will be measured in a subset of women 4-6 hours after the 3rd dose of each course, timeFrame - 4-6 hours after the 3rd dose with each course",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03009526",
    "endpoint": "measure - Microbiome changes following receipt of DP or SP, description - We will measure the changes in the intestinal and vaginal microbiome induced by DP and SP, timeFrame - From date of randomization until the date of delivery or last date of follow-up, average of ~4-5 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03009526",
    "endpoint": "measure - Maternal hemoglobin at 3rd trimester, description - , timeFrame - 3rd trimester",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03009526",
    "endpoint": "measure - Maternal anemia at 3rd trimester, description - , timeFrame - 3rd trimester",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03009526",
    "endpoint": "measure - Fetal anemia, description - Anemia&#x2F; hemoglobin measured from cord blood, timeFrame - Delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03009526",
    "endpoint": "measure - Incidence of clinical malaria episodes, description - , timeFrame - From date of randomization until the date of delivery or last date of follow-up, average of ~4-5 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03009526",
    "endpoint": "measure - Incidence of all cause sick visits, description - , timeFrame - From date of randomization until the date of delivery or last date of follow-up, average of ~4-5 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03009526",
    "endpoint": "measure - Serious adverse events, description - , timeFrame - From date of randomization until the date of delivery or last date of follow-up, average of ~4-5 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01255605",
    "endpoint": "measure - Maternal anemia, congenital malaria,low birth weight, prematurity., description - <p>The investigators will check pregnant women haemoglobin level.A level&lt; 11g&#x2F;dl will be considered as anemia.</p><p>Congenital malaria will be assessed through cord blood smear.\nBirth weight &lt;2500g will be considered as low birth weight.\nPrematurity designs any birth before 37 gestation weeks.</p>, timeFrame - Maternal anemia: at antenatal clinics and at delivery. Congenital malaria: at delivery. Low birth weight: at delivery. Prematurity: at delivery.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00131703",
    "endpoint": "measure - Incidence of adverse drug events within seven days following treatment., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00131703",
    "endpoint": "measure - Proportions of pregnant women withdrawn from the study due to the occurrence of adverse drug events (clinical and laboratory) by day 7 following initiation of treatment., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00131703",
    "endpoint": "measure - Change in maternal haemoglobin concentrations at days 14 and 28 following treatment., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00131703",
    "endpoint": "measure - Prevalence of peripheral parasitaemia at delivery., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00131703",
    "endpoint": "measure - Prevalence of placental parasitaemia at delivery., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00131703",
    "endpoint": "measure - Proportions of abnormal biochemistry and white blood cell values on days 14 and 28 post treatment., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00131703",
    "endpoint": "measure - Sensitivity, specificity, positive and negative predictive values, likelihood ratios, and the area under receiver operating characteristic (ROC) curve for the OptiMAL antigen test., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00131703",
    "endpoint": "measure - Incidences of adverse pregnancy outcomes in the study group., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00131703",
    "endpoint": "measure - Prevalence of postpartum parasitaemia., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00131703",
    "endpoint": "measure - Prevalence of postpartum anaemia., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05426434",
    "endpoint": "measure - Adverse pregnancy outcome, description - <p>Composite adverse birth outcome is defined as the occurrence of any of the following:</p><ul><li>Spontaneous miscarriage: Fetal loss &lt;28 weeks of gestational age</li><li>Stillbirth: Infant born deceased at ≥28 weeks of gestational age</li><li>Low birth weight (LBW): Live birth with birth weight &lt;2,500 grams</li><li>Preterm birth (PTB): Live birth &lt;37 weeks gestational age</li><li>Small-for-gestational age (SGA): Live birth with birth weight-for-gestational-age &lt;10th percentile of the INTERGROWTH-21st reference</li><li>Neonatal death: Live birth with neonatal death within the first 28 days of life</li></ul><p>Prevalence of adverse pregnancy outcome</p>, timeFrame - Time of delivery up to 28 days postpartum",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05426434",
    "endpoint": "measure - Clinical malaria during pregnancy, description - Incidence of new episodes of fever or history of fever plus positive RDT confirmed by microscopy and&#x2F;or qPCR during pregnancy, timeFrame - Starting two weeks after initial dose until and including delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05426434",
    "endpoint": "measure - Parasitemia during pregnancy, description - Proportion of samples with parasites detected in maternal peripheral blood samples by microscopy or qPCR, timeFrame - Starting two weeks after initial dose until and including delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05426434",
    "endpoint": "measure - Composite placental malaria detected by microscopy, qPCR or by histology, description - Prevalence of placental parasites by microscopy, qPCR, or placental histology, timeFrame - At time of delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05426434",
    "endpoint": "measure - Placental malaria detected by microscopy, description - Prevalence of parasites in placental blood by microscopy, timeFrame - At time of delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05426434",
    "endpoint": "measure - Placental malaria detected by qPCR, description - Prevalence of parasites in placental blood by qPCR, timeFrame - At time of delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05426434",
    "endpoint": "measure - Active placental malaria detected by histology, description - Prevalence of active infection (presence of parasites) on histology, timeFrame - At time of delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05426434",
    "endpoint": "measure - Past placental malaria detected by histology, description - Prevalence of past infection (pigment only) on histology, timeFrame - At time of delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05426434",
    "endpoint": "measure - Placental malaria detected by histology, description - Prevalence of placental infection (active or past) on histology, timeFrame - At time of delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05426434",
    "endpoint": "measure - Composite fetal loss and neonatal death, description - Prevalence of fetal loss (spontaneous miscarriage or stillbirth) and neonatal death, timeFrame - Time of delivery up to 28 days postpartum",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05426434",
    "endpoint": "measure - Composite of SGA-LBW-PTB, description - Prevalence of small for gestational age, low birth weight, and preterm birth, timeFrame - At time of delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05426434",
    "endpoint": "measure - SGA, description - Prevalence of small for gestational age using the new Intergrowth-21st population reference&#x27;s 10th centile, timeFrame - At time of delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05426434",
    "endpoint": "measure - LBW, description - Prevalence of low birth weight, timeFrame - At time of delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05426434",
    "endpoint": "measure - PTB, description - Prevalence of preterm birth, timeFrame - At time of delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05426434",
    "endpoint": "measure - Birth weight, description - Mean birthweight, timeFrame - At time of delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05426434",
    "endpoint": "measure - Neonatal length, description - Neonatal length, timeFrame - At time of delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05426434",
    "endpoint": "measure - Maternal nutritional status, description - Changes in maternal body mass index (BMI), timeFrame - 8 months from randomisation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05426434",
    "endpoint": "measure - Maternal nutritional status, description - Changes in maternal mid-upper arm circumference (MUAC), timeFrame - 6 months from randomisation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05426434",
    "endpoint": "measure - Maternal anemia during pregnancy and at delivery, description - Proportion of routine haemoglobin measurements &lt;100 g&#x2F;L, timeFrame - 6 months from randomisation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05426434",
    "endpoint": "measure - Maternal hemoglobin levels during pregnancy and at delivery, description - Mean hemoglobin (g&#x2F;L) at the third trimester antenatal visit and at delivery, timeFrame - 6 months from randomisation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05426434",
    "endpoint": "measure - Congenital anemia, description - Prevalence of anaemia (Hb &lt;130 g&#x2F;L) from newborn cord blood, timeFrame - At delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05426434",
    "endpoint": "measure - Maternal gametocyte carriage during pregnancy and at delivery, description - Proportion of P. falciparum positive samples with gametocytes at the third trimester antenatal visit and at delivery, by light microscopy and RT-qPCR, timeFrame - 6 months from randomisation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05426434",
    "endpoint": "measure - Molecular markers of DP resistance, description - Proportion of parasite positive samples with molecular markers of DP resistance, timeFrame - 6 months from randomisation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05426434",
    "endpoint": "measure - Molecular markers of SP drug resistance, description - Proportion of parasite positive samples with molecular markers of SP resistance, timeFrame - 6 months from randomisation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05426434",
    "endpoint": "measure - Maternal mortality, description - he death of a woman while pregnant or within 42 days of the end of pregnancy, irrespective of the duration and site of the pregnancy, but not from accidental or incidental causes, timeFrame - 8 months from randomisation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05426434",
    "endpoint": "measure - Congenital malformations, description - Any visible external congenital abnormality on surface examination, timeFrame - 8 months from randomisation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05426434",
    "endpoint": "measure - Other SAEs and AEs, description - Incidence of AEs and SAEs, timeFrame - 8 months from randomisation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05426434",
    "endpoint": "measure - (History) of vomiting study drug, description - Prevalence of vomiting investigational product (IP) twice at the same IP administration visit, timeFrame - 6 months from randomisation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05426434",
    "endpoint": "measure - Dizziness, description - Prevalence of dizziness after a course of IP, timeFrame - 6 months from randomisation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05426434",
    "endpoint": "measure - Gastrointestinal complaints, description - Prevalence of gastrointestinal complaints after a course of IP, timeFrame - 6 months from randomisation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02184637",
    "endpoint": "measure - Pharmacokinetic endpoints including changes in time to Cmax (Tmax) and apparent terminal phase half-life (t½) for TQ, as data permit., description - , timeFrame - Up to Day 56",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02184637",
    "endpoint": "measure - Pharmacokinetic endpoints including changes in Tmax and t½ for each of the ACTs, as data permit., description - , timeFrame - Up to Day 56",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02184637",
    "endpoint": "measure - Changes in safety laboratory measures (including haemoglobin change from baseline [mean of pre-dose and Day-1 results]), description - Laboratory assessments will include haematology, clinical chemistry and urinalysis., timeFrame - Day -1 to Day 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02184637",
    "endpoint": "measure - Frequency of adverse events (AEs), description - An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product., timeFrame - Day -1 to Day 56",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02184637",
    "endpoint": "measure - Maximum change from baseline in QT interval corrected for heart rate by Fridericia&#x27;s formula (QTcF) for all cohorts, description - The baseline measurement will be the average of the triplicate measurements taken on pre-dose Day 1., timeFrame - Day 1 to Day 56",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02184637",
    "endpoint": "measure - Change from baseline in QTcF at 52-hours post-first dose for subjects who receive DHA+PQP (cohort 1 and 3), description - The baseline measurement will be the average of the triplicate measurements taken on pre-dose Day 1., timeFrame - Pre-dose (Day 1) and 52-hours post-dose ( Day 3)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02242799",
    "endpoint": "measure - Safety and tolerability of the drug combinations, description - Patients will be assessed clinically to identify safety concerns, panels of &#x27;safety bloods&#x27; will be performed at the time of rich PK sampling, and 12 lead ECGs will assess potential effects of the drugs&#x2F; combinations on the QT interval, timeFrame - Until 2 weeks after all medication has been discontinued at the end of study",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01843491",
    "endpoint": "measure - Safety, description - <p>Occurrence, severity, and duration of any solicited symptoms starting on the day of immunization through Day 7 after immunization</p><p>Occurrence of any unsolicited symptoms, abnormal physical findings, and laboratory values starting from the day of immunization through Day 28 after immunization.</p><p>Occurrence of any serious adverse events, as defined in 21 CFR 312.32, for the duration of the study</p>, timeFrame - 26 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01222962",
    "endpoint": "measure - Number of Treatment Emergent Adverse Events, description - Number of TEAEs and number of Subjects experiencing Adverse Events during all the study period, timeFrame - Day 0 and till Day 30 follow-up",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01222962",
    "endpoint": "measure - Hematology and blood chemistry changes respect to baseline values, description - Abnormalities in hematology (Haemoglobin, Hematocrit,RBC count, White cell count and differential count, Platelets) and clinical chemistry (Protein, Sodium, Potassium, Chloride ,Total Bilirubin, Conjugated Bilirubin, Alanine Aminotransferase, Aspartate Aminotransferase, Total Cholesterol, Glucose, Bicarbonate, Urea, Urate, Lactate Dehydrogenase, Albumin, Globulins, Triglycerides, Creatinine, Alkaline Phosphatase, Gamma glutamyltransferase, Total Calcium, Phosphate, C-reactive protein) will be recorded the day of the last study drug intake and after 30 days from the start of the drug treatment, timeFrame - Day 0, day 2, day 30",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01222962",
    "endpoint": "measure - QTc interval prolongation, description - ECG recordings will be obtained at baseline, after the last drug intake and 30 days follow-up to investigate changes in ECG parameters, and specifically QTc interval changes respect to baseline, timeFrame - Day 0, day 2, day 30",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01222949",
    "endpoint": "measure - Number of Treatment Emergent Adverse Events (TEAEs), description - Number of TEAEs and number of Subjects experiencing Adverse Events during all the study period, timeFrame - From Day 0 till Day 90",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01222949",
    "endpoint": "measure - Hematology and blood chemistry changes respect to baseline values, description - Abnormalities in hematology (Haemoglobin, Hematocrit,RBC count, White cell count and differential count, Platelets) and clinical chemistry (Protein, Sodium, Potassium, Chloride ,Total Bilirubin, Conjugated Bilirubin, Alanine Aminotransferase, Aspartate Aminotransferase, Total Cholesterol, Glucose, Bicarbonate, Urea, Urate, Lactate Dehydrogenase, Albumin, Globulins, Triglycerides, Creatinine, Alkaline Phosphatase, Gamma glutamyltransferase, Total Calcium, Phosphate, C-reactive protein) will be recorded the day of the last study drug intake and after 30 days from the start of the drug treatment, timeFrame - Day 0, Day 3, Day 28, Day 90",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01222949",
    "endpoint": "measure - QTc interval prolongation, description - ECG recordings will be obtained at baseline, after the last drug intake and 30 days follow-up to investigate changes in ECG parameters, and specifically QTc interval changes respect to baseline, timeFrame - Day 0, day 3, day 28, day 90",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04228315",
    "endpoint": "measure - Characterize the patterns of relapsing Southeast Asian P. vivax in infected subjects, description - Percentage of P. vivax relapse in subjects with uncomplicated P. vivax mono-infection in the 28 days following treatment with oral blood stage anti-malarial treatment with comparisons between those administered primaquine at enrollment and those who did not receive primaquine, timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04228315",
    "endpoint": "measure - Delineate relapse kinetics of P. vivax infection using molecular diagnostic methods,, description - At pre-determined time points starting at admission and prior to P. vivax relapse, compare limit of detection of recently emerged erythrocytic forms by blood smear, polymerase chain reaction (PCR) and ultra sensitive PCR, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04228315",
    "endpoint": "measure - Determine percentage of P. vivax isolates resistant to antimalarial drugs used for treatment, description - Parasite growth inhibition as measured by concentration at which 50% of growth is inhibited (IC50) to antimalarial drug panel using pLDH ELISA techniques, timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04228315",
    "endpoint": "measure - Establish rates of P. vivax relapse versus new infection with vivax using molecular methods, description - Perform genome sequencing to determine genetic signatures of the vivax parasite, comparing initial infection with recurrences to identify relapse versus a new infection, timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04228315",
    "endpoint": "measure - Characterize the rate glucose 6-phosphate dehydrogenase (G6PD) deficiency of study population, description - Incidence of G6PD deficiency (&lt;30% activity) using quantitative spectrophotometry diagnostics, timeFrame - 3 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04228315",
    "endpoint": "measure - Characterize hepatic cytochrome P450 (CYP450) 2D6 enzyme genotypes and predicted phenotypes in this study population, description - Genotype CYP450 2D6 alleles in this study population and resultant predicted metabolism phenotypes using Activity Score A (AS-A), timeFrame - 1 day",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04228315",
    "endpoint": "measure - Determine primaquine pharmacokinetics in this study population, description - Measure plasma concentrations of primaquine and its major metabolites at 0,2,4,8,10 and 24 hours after initial primaquine dose and calculate the area under the curve (AUC) for each subject, timeFrame - 56 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04228315",
    "endpoint": "measure - Determine primaquine pharmacokinetics in this study population, description - Measure urine concentrations of primaquine and its major metabolites at 0-4 hours, 4-10 hours and 10-24 hours after initial primaquine dose and calculate the area under the curve (AUC) for each subject, timeFrame - 56 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04228315",
    "endpoint": "measure - Assess impact of risk factors of travel and prior malaria history on P. vivax relapse kinetics, description - Determine number of days of travel to high malaria risk areas in 30 days prior to enrollment for each subject to compare with parasite genetic relatedness of initial and recurrent vivax infections, timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04228315",
    "endpoint": "measure - Measure rates of gametocyte carriage, description - Determine rate and duration of sexual stage infections based on light microscopy and molecular analyses (PCR) from samples drawn at enrollment and pre-determined time points over study period, timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04228315",
    "endpoint": "measure - Determine if humoral immunity contributes to protection against P. vivax recurrence, description - Measure antibody levels against vivax antigens merozoite surface protein-1 (MSP-1) and circumsporozoite protein (CSP) at Day 0,28,90 and 180 and compare to rate of P. vivax recurrence, timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01218932",
    "endpoint": "measure - Cmax, description - Primaquine and metabolites maximum concentrations, chloroquine and metabolites maximum concentration and AUC, timeFrame - 36 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01218932",
    "endpoint": "measure - Elimination rate, description - Primaquine and metabolites (mPQ) elimination rate constants (mPQ-λz), and elimination half life (mPQ-t1&#x2F;2),chloroquine metabolite(s) elimination rate constant (mCQ-λz), and elimination half life (mCQ-t1&#x2F;2), timeFrame - 36 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01218932",
    "endpoint": "measure - Adverse events, description - Safety and tolerability parameters, including adverse events, clinical laboratory, and vital signs assessments, timeFrame - 36 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01218932",
    "endpoint": "measure - Pharmacogenetics, description - Pharmacogenetic polymorphisms in the case of unusually high or low drug levels, timeFrame - 36 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02199977",
    "endpoint": "measure - Effect of malaria RDT subsidy on the uptake of testing (free versus paid RDT), description - , timeFrame - Within 2 days of group assignment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02199977",
    "endpoint": "measure - Effect of a conditional ACT subsidy on uptake of testing when the RDT is not free., description - , timeFrame - Within 2 days of group assignment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02461628",
    "endpoint": "measure - Number of Participants Using ACT Who Had a Positive Test, description - , timeFrame - 6 months, 12 months, 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02461628",
    "endpoint": "measure - Number of Participants Using an ACT Who Did Not Have a Test, description - , timeFrame - 6 months, 12 months, 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02461628",
    "endpoint": "measure - Number of Subjects Who Received a Correct Dose of AL (Artemether Lumefantrine), description - Denominator is all those who took AL.\nArtemether lumefantrine is one type of ACT., timeFrame - 6 months, 12 months, 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02461628",
    "endpoint": "measure - Number of Subjects With Fever That Received Correct Treatment, description - The number of people with fever that report receiving correct treatment with regards to malaria (i.e., received an RDT test and took ACTs if the result was positive, or did not take ACTs if the test result was negative)., timeFrame - 6 months, 12 months, 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00894660",
    "endpoint": "measure - Tolerability, description - , timeFrame - 1 month",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00894374",
    "endpoint": "measure - Tolerability, description - , timeFrame - 30-Aug-2009",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00859807",
    "endpoint": "measure - Cmax and AUC72 for DesethylAQ, description - , timeFrame - end of study",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05711485",
    "endpoint": "measure - Change in hemoglobin (Hb), description - The difference in Hb concentration between baseline (pre-transfusion) and post-transfusion, timeFrame - Pre- and post-transfusion, comparing baseline measurements to measurements taken 2 hours after transfusion completion and 24 hours later. For the Control arm, measurements will be made at baseline and Study Hour 6 ±2 and 24 hours later",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05711485",
    "endpoint": "measure - Change in platelet count, description - The difference in the platelet count between baseline (pre-transfusion) and post-transfusion, timeFrame - Pre- and post-transfusion, comparing baseline measurements to measurements taken 2 hours after transfusion completion and 24 hours later. For the Control arm, measurements will be made at baseline and Study Hour 6 ±2 and 24 hours later",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05711485",
    "endpoint": "measure - Change in white blood cell (WBC) count, description - The difference in the WBC count between baseline (pre-transfusion) and post-transfusion, timeFrame - Pre- and post-transfusion, comparing baseline measurements to measurements taken 2 hours after transfusion completion and 24 hours later. For the Control arm, measurements will be made at baseline and Study Hour 6 ±2 and 24 hours later",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05711485",
    "endpoint": "measure - Incidence of transfusion reaction, description - Transfusion reactions (e.g., hypersensitivity, TACO, TRALI) graded on severity and likeliness of being related to transfusion, timeFrame - During or after transfusion, up to the day of hospital discharge or in-hospital death, up to 28 days on average",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05711485",
    "endpoint": "measure - Length of hospitalization, description - Interval in days from date of admission to date of discharge&#x2F;death, timeFrame - Up to hospital discharge or in-hospital death, up to 28 days on average",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05711485",
    "endpoint": "measure - Parasite clearance, description - Time to microscopic conversion to negative, timeFrame - 0-72 hours, measured every 12±2 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06337253",
    "endpoint": "measure - Uncomplicated malaria within 28 days, description - A positive qPCR result for P. Falciparu, parasites within the first 28 days after SPAQ was administed, timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01782001",
    "endpoint": "measure - changes in weight and height&#x2F;length, description - Enrollment and end of supplementation, timeFrame - baseline and 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01782001",
    "endpoint": "measure - changes in vitamin A and zinc nutritional status within and between the groups, description - enrollment and end of supplementation, timeFrame - baseline and 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01782001",
    "endpoint": "measure - change in prevalence of anemia, description - enrollment and end of supplementation, timeFrame - baseline and 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01782001",
    "endpoint": "measure - the incidence of diarrhea and pneumonia, description - 1 time&#x2F;week, enrollment to end, total:24, timeFrame - 1 time per week up to 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01166815",
    "endpoint": "measure - Determine the time to diarrhea onset in both groups, description - Daily, field workers will visit each subject to dispense supplement and to record diarrhea morbidity data.\nThe time between day 0 and the first bout of diarrhea will be noted., timeFrame - Daily, for 104 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01166815",
    "endpoint": "measure - Determine the duration of each diarrhea episode in both groups, description - Daily, field workers will visit each subject to dispense supplement and to record diarrhea morbidity data.\nWith diarrhea defined as &gt;2 loose motions within a period of 24 hours, the duration (number of days) of the diarrhea will be recorded., timeFrame - Daily, for 104 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01166815",
    "endpoint": "measure - Determine the number of loose stools&#x2F;day&#x2F;episode of diarrhea in both groups, description - Daily, field workers will visit each subject to record diarrhea morbidity data.\nWith each bout of diarrhea, we will record the nuber of loose stools&#x2F;day., timeFrame - Daily, for 104 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03208907",
    "endpoint": "measure - Number of participants with negative parasitological test, description - Therapy efficacy will be assessed based on the presence or absence of Vivax Plasmodium parasites in blood, confirmed by the presence or absence of parasites in peripheral blood by microscopy., timeFrame - 6 months (for this analysis will not be considered the primary outcomes dates (Day42 and D180)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03208907",
    "endpoint": "measure - Number of participants with any biological intolerability, description - Evolution of haemoglobin levels until D28 will be monitored in all the scheduled visits and also on unscheduled visits., timeFrame - Until Day 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03208907",
    "endpoint": "measure - Number of participants with any treatment-related adverse event of clinical tolerability, description - The participants will be clinically monitored.\nIn all the scheduled visits a study physician will evaluate and register the clinical exam, and also obtain and update the clinical history to describe any adverse event.\nThe participants will have also a card with a 24h phone number to contact in case of clinical symptoms or others needing., timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03208907",
    "endpoint": "measure - Number of participants with treatment-related prolonged QT interval., description - Electrocardiogram evaluation will be assessed after completion of schizonticidal treatment, timeFrame - Day 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05391230",
    "endpoint": "measure - Change in child&#x27;s hemoglobin level, description - Change in child&#x27;s hemoglobin as measured by HemoCue® device, timeFrame - (Week 0), Week 12, and Week 24 visits",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05391230",
    "endpoint": "measure - Change in child&#x27;s growth parameters, description - Change in child&#x27;s height and weight (e.g., weight and height will be combined to report BMI in kg&#x2F;m^2)., timeFrame - (Week 0), Week 12, and Week 24 visits",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05391230",
    "endpoint": "measure - Change in child&#x27;s nutritional status, description - Change in child&#x27;s mid-upper arm circumference (MUAC), timeFrame - (Week 0), Week 12, and Week 24 visits using MUAC tape",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05391230",
    "endpoint": "measure - Prevalence of asymptomatic parasitemia, description - Presence of malaria parasites on bi-weekly dried blood spot (DBS) as determined by quantitative polymerase chain reaction(qPCR)., timeFrame - Every two weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05391230",
    "endpoint": "measure - Malaria hospitalization, description - Child admitted to inpatient ward for treatment of malaria, timeFrame - 14 days after onset of symptoms",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05391230",
    "endpoint": "measure - Incidence of clinical malaria in mother, description - The presence of typical symptoms (e.g., fever, lethargy) and a positive malaria RDT during observation, timeFrame - 7 days after onset of symptoms",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05391230",
    "endpoint": "measure - Change in mother&#x27;s hemoglobin level, description - Change in child&#x27;s hemoglobin as measured by HemoCue® device, timeFrame - (Week 0), Week 12, and Week 24 visits",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05391230",
    "endpoint": "measure - Adverse reaction to permethrin treatment, description - Self-reported history on bi-weekly questionnaire and confirmation by clinical staff., timeFrame - 7 days after onset",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04634695",
    "endpoint": "measure - Average maternal haematocrit, description - Maternal haematocrit will be carried out to confirm whether the mother is anaemic or not, timeFrame - May 2021",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04634695",
    "endpoint": "measure - Birth weight of babies, description - Birth weight of babies, timeFrame - May 2021",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04634695",
    "endpoint": "measure - Prevalence of placental malaria, description - Prevalence of placental malaria, timeFrame - May 2021",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05232227",
    "endpoint": "measure - relapse efficacy, description - <p>The incidence risk of symptomatic, microscopy-detectable P. vivax infection, The incidence risk of severe anemia (Hb &lt; 7g&#x2F;dl) and&#x2F;or requiring blood transfusion comparing PQdd14 to PQsd14.</p><ul><li>The incidence rate (events per person-time) of microscopy-detectable P. vivax infection, comparing PQdd14 to PQsd14.</li><li>The incidence rate (events per person-time) of symptomatic, microscopy-detectable P. vivax infection, comparing PQdd14 to PQsd14.</li></ul>, timeFrame - 6-month follow-up",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01119612",
    "endpoint": "measure - Low birth weight, description - Low birth weight will be defined as birth weight less than 2500 grams., timeFrame - Delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01119612",
    "endpoint": "measure - Maternal malaria infection, description - Maternal malaria will be defined as fever within the last 72 hours with any parasitemia on a peripheral blood smear., timeFrame - During pregnancy",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01119612",
    "endpoint": "measure - Maternal anemia, description - Anemia will be defined as hemoglobin less than 11 g&#x2F;dl.\nSevere anemia will be defined as less than 8.5 g&#x2F;dl., timeFrame - Delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01717885",
    "endpoint": "measure - Malaria reinfection (recrudescence or new infection), description - The association between PK exposure and malaria reinfection is the main secondary outcome., timeFrame - From Day 0 to 42 days of F&#x2F;U when using artemether-lumefantrine for uncomplicated malaria",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01717885",
    "endpoint": "measure - Parasite clearance rate, description - To assess the relationship between artemisinin exposure and parasite clearance, timeFrame - Days 0 to 42 of follow-up",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01717885",
    "endpoint": "measure - AL and ART toxicity, description - To assess the relationship between artemether, lumefantrine and antiretroviral exposure and toxicity, particularly neutropenia, timeFrame - Days 0 to 42 of follow-up",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00115921",
    "endpoint": "measure - Mean days of fever per participant, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00115921",
    "endpoint": "measure - Incidence of febrile episodes, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00115921",
    "endpoint": "measure - Mean haemoglobin at study end, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00115921",
    "endpoint": "measure - Change in mean haemoglobin between the start and end of the intervention, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00115921",
    "endpoint": "measure - Incidence of visits to health care facilities (drug shops, clinics, pharmacies, hospitals) and hospitalizations per participant, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00115921",
    "endpoint": "measure - Mortality rate, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00115921",
    "endpoint": "measure - Economic outcomes, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00928083",
    "endpoint": "measure - OZ439 AUC0-t, description - Area under the plasma concentration-time curve from zero to time t of the last measured concentration above the limit of quantification (AUC0-t)., timeFrame - Samples collected from Pre-dose up to 96h post dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00928083",
    "endpoint": "measure - OZ439 AUC0-∝, description - Area under the plasma concentration-time curve from zero to infinity (AUC0-∝)., timeFrame - Samples collected from Pre-dose up to 96h post dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00928083",
    "endpoint": "measure - OZ439 Cmax, description - Maximum observed plasma drug concentration (Cmax)., timeFrame - Samples collected from Pre-dose up to 96h post dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00928083",
    "endpoint": "measure - OZ439 Tmax, description - Time to maximum observed plasma drug concentration of OZ439, timeFrame - Samples collected from Pre-dose up to 96h post dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00928083",
    "endpoint": "measure - OZ439 t1&#x2F;2, description - Apparent terminal half-life (t1&#x2F;2), timeFrame - Samples collected from Pre-dose up to 96h post dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00928083",
    "endpoint": "measure - OZ439 Rac, description - <p>Accumulation index is the ratio of drug exposure observed during a dosing interval at steady-state divided by drug exposure after a single first dose, as described by the following equations:</p><p>Accumulation index (Rac) = AUC0-(Day 3)&#x2F; AUC0-(Day 1)</p>, timeFrame - Samples collected from Pre-dose up to 96h post dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00790881",
    "endpoint": "measure - Point estimates and 90% confidence intervals for the mean ratios of the lumefantrine, artemether and DHA log-transformed Cmax, AUC0-t, AUC0 ∞ , t½,z, tmax and MRT with&#x2F;without NVP, description - , timeFrame - 21 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01836731",
    "endpoint": "measure - Impact of CBEHPP on height-for-age in children under-5 years, description - Height-for-age data will be collected from all children under 5 years old.\nChanges in Z-scores for each of these measures between baseline and endline will be compared across the two study arms and the control group., timeFrame - 2.5 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01836731",
    "endpoint": "measure - Impact of CBEHPP on weight-for-age in children under-5 years, description - weight-for-age data will be collected from all children under 5 years old.\nChanges in Z-scores for each of these measures between baseline and endline will be compared across the two study arms and the control group., timeFrame - 2.5 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01836731",
    "endpoint": "measure - Impact of CBEHPP on drinking water quality, description - Water quality data will be collected at baseline and endline, and at an intermediate visit following implementation of the program.\nWater quality will be determined testing of drinking water; study households will provide a sample of drinking water for contamination tests., timeFrame - 2.5 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01836731",
    "endpoint": "measure - Impact of CBEHPP on incidence of malaria, description - Self-reported incidence of malaria, will be collected from households., timeFrame - 2.5 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01836731",
    "endpoint": "measure - Impact of CBEHPP on individual contribution to public goods game, description - A public goods game is played with a subset of community members.\nThe researchers examine the impact of the treatment on the level of contributions., timeFrame - 2.5 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01836731",
    "endpoint": "measure - Impact of CBEHPP on administratively verified cases of diarrhea, description - Total counts of child diarrhea cases recorded in catchment area clinics and community health worker records, timeFrame - 2.5 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01836731",
    "endpoint": "measure - Impact of CBEHPP on administratively verified cases of pneumonia and severe pneunomia, description - Total counts of child pneumonia cases recorded in catchment area clinics and community health worker records, timeFrame - 2.5 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00646126",
    "endpoint": "measure - 1. Malaria prevalence during the transmission season 2. Frequency of mutation in drug resistance genes, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00868465",
    "endpoint": "measure - To determine (sub-microscopic) gametocyte carriage after treatment with AL and DP, description - , timeFrame - during 42 day follow-up",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00868465",
    "endpoint": "measure - To determine malaria transmission to mosquitoes after treatment with AL or DP, description - , timeFrame - day 7 after initiation treatment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00868465",
    "endpoint": "measure - To determine molecular markers that are predictive of reduced susceptibility of parasite strains for AL and DP, description - , timeFrame - day 7 after initiation treatment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00868465",
    "endpoint": "measure - To determine molecular markers that are related to gametocytaemia or malaria transmission after treatment with AL and DP, description - , timeFrame - during 42 day follow-up",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00868465",
    "endpoint": "measure - To determine the relation between treatment success and the presence of anti-malaria antibodies, description - , timeFrame - during 42 day follow-up",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00868465",
    "endpoint": "measure - To explore the role of cellular oxidative stress in treatment with AL and DP, description - , timeFrame - during 42 day follow-up",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00868465",
    "endpoint": "measure - To determine the relation between transmission to mosquitoes and the presence of anti-malaria antibodies, description - , timeFrame - day 7 after initiation treatment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00720811",
    "endpoint": "measure - use of antimalarial and antibiotic drugs by community health workers, description - , timeFrame - After patient enrollment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00720811",
    "endpoint": "measure - Recovery rate from fever at Day 7, description - , timeFrame - Day 7",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01130155",
    "endpoint": "measure - Percent of patients receiving an ACT that adhered to full dose with correct dose timing, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01130155",
    "endpoint": "measure - Mean and median household cost per febrile episode, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01130155",
    "endpoint": "measure - The accuracy of RDTs performed by health workers, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01130155",
    "endpoint": "measure - Adequacy of health facility resources for diagnosis and treatment of malaria, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02792816",
    "endpoint": "measure - Proportion of the day-3 parasite positivity after ACT by microscopy, description - 72 hr after ACT is one of the indicator for delayed clearance of parasitaemia in falciparum malaria, timeFrame - 3rd day after initial dose of ACT",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02792816",
    "endpoint": "measure - Treatment failure rate, description - Early Treatment Failure (ETF), Late Clinical Failure (LCF), Late Parasitological Failure (LPF) based on the WHO standard protocol and definitions, timeFrame - anytime within observation period (28&#x2F;42 days after treatment with one of ACTs)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02792816",
    "endpoint": "measure - Mutant rate, description - Day-0 samples were used to amplify the artemisinin resistance molecular markers to know the mutant rate in each study sites, timeFrame - Day-0 samples",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00936767",
    "endpoint": "measure - Parasite clearance times (PCT, slope of the log clearance curve, PRR24, PRR48, PC50, PC90), description - , timeFrame - Variable",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00936767",
    "endpoint": "measure - Cure rate defined as clearance of asexual parasites without recrudescence within a 28 and 63-day period., description - , timeFrame - 63 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00936767",
    "endpoint": "measure - Number of adverse events, description - , timeFrame - 9 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00936767",
    "endpoint": "measure - Fever clearance time, description - , timeFrame - Variable",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00936767",
    "endpoint": "measure - In-vitro sensitivity to antimalarial drugs of P. falciparum from study patients, description - , timeFrame - Day 0",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00936767",
    "endpoint": "measure - Molecular determinants of antimalarial drug resistance., description - , timeFrame - Day 0",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00936767",
    "endpoint": "measure - Pharmacokinetic parameters, description - , timeFrame - Day 2",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00936767",
    "endpoint": "measure - Hematocrit levels, description - , timeFrame - Day 63",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00936767",
    "endpoint": "measure - Gametocyte clearance, description - , timeFrame - Variable",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03384472",
    "endpoint": "measure - Population structure of P.falciparum parasites, description - By using population genetics and clustering techniques, such as Principal Component Analysis and phylogeny, timeFrame - up to 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03384472",
    "endpoint": "measure - Gene flow patterns of P. falciparum malaria parasites in Cambodia, description - , timeFrame - up to 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03384472",
    "endpoint": "measure - Likely geographic origin of P. falciparum malaria parasites in Cambodia, description - , timeFrame - up to 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04778813",
    "endpoint": "measure - Adverse events frequency and type, description - Any unwanted sign&#x2F;symptom occurred in patients after consentement signature, timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04778813",
    "endpoint": "measure - Pharmacocinetic of Lumefantrin, description - Concentration of lumefantrin in blood at day 7 after IP administration, timeFrame - 7 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04708496",
    "endpoint": "measure - Change Maximum concentration [Cmax] of the antimalarials (Artemether, dihydroartemisinin [DHA], lumefantrin and desbutylumefantrine, description - Plots of plasma concentration versus time curves will be produced for artemether, dihydroartemisinin, lumefantrine and desbutyl-lumefantrine.\nPharmacokinetic parameter Cmax derived directly from the data.\nThe Cmax pharmacokinetic parameter will be presented using descriptive summary statistics including geometric means, geometric mean ratios (GMR) and confidence intervals (CI), or medians and interquartile ranges.\nThe CIs will be determined using logarithms of the individual geometric mean values; the calculated values will be then expressed as linear values., timeFrame - over 120hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04708496",
    "endpoint": "measure - Measuring level of Hemoglobin, description - Anemia is a common with Malaria.\nThe hemoglobin levels will be measured to assess for any reduction and also recovery of the hemoglobin level following treatment., timeFrame - Hemoglobin will be measured from on follow-up days; 7, 14, 21 and 28.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04708496",
    "endpoint": "measure - Change in Area under the time-concentration curve [AUC] of the antimalarials (Artemether, dihydroartemisinin [DHA], lumefantrin and desbutylumefantrine, description - Plots of plasma concentration versus time curves will be produced for artemether.\nAUC over 24 hours (AUC0-24) will be calculated using non-compartmental methods (WinNonlin® Version 6.2, Pharsight).\nThe pharmacokinetic parameter will be presented using descriptive summary statistics including geometric means, geometric mean ratios (GMR) and confidence intervals (CI), or medians and interquartile ranges.\nThe CIs will be determined using logarithms of the individual geometric mean values; the calculated values will be then expressed as linear values., timeFrame - over 120hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04708496",
    "endpoint": "measure - Change in Time to maximum concentration [Tmax] of the antimalarials (Artemether, dihydroartemisinin [DHA], lumefantrin and desbutylumefantrine), description - Plots of plasma concentration versus time curves will be produced for artemether, dihydroartemisinin, lumefantrine and desbutyl-lumefantrine.\nPharmacokinetic parameter time to maximal concentration (Tmax) will be derived directly from the data.\nThe pharmacokinetic parameter will be presented using descriptive summary statistics including geometric means, geometric mean ratios (GMR) and confidence intervals (CI), or medians and interquartile ranges.\nThe CIs will be determined using logarithms of the individual geometric mean values; the calculated values will be then expressed as linear values., timeFrame - over 120hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04708496",
    "endpoint": "measure - Change in Clearance [Cl&#x2F;F] of the antimalarials (Artemether, dihydroartemisinin [DHA], lumefantrin and desbutylumefantrine), description - Plots of plasma concentration versus time curves will be produced for artemether, dihydroartemisinin, lumefantrine and desbutyl-lumefantrine.\nThe apparent oral clearance will be calculated using non-compartmental methods (WinNonlin® Version 6.2, Pharsight).\nThis pharmacokinetic parameter will be presented using descriptive summary statistics including geometric means, geometric mean ratios (GMR) and confidence intervals (CI), or medians and interquartile ranges.\nThe CIs will be determined using logarithms of the individual geometric mean values; the calculated values will be then expressed as linear values., timeFrame - over 120hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04708496",
    "endpoint": "measure - Change in Trough concentration [Ctrough]) of the antimalarials (Artemether, dihydroartemisinin [DHA], lumefantrin and desbutylumefantrine), description - Plots of plasma concentration versus time curves will be produced for artemether, dihydroartemisinin, lumefantrine and desbutyl-lumefantrine.\nThe change in trough concentration will be presented using descriptive summary statistics including geometric means, geometric mean ratios (GMR) and confidence intervals (CI), or medians and interquartile ranges.\nThe CIs will be determined using logarithms of the individual geometric mean values; the calculated values will be then expressed as linear values., timeFrame - over 120hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04708496",
    "endpoint": "measure - Prolongation of the QT interval, description - ECG Monitoring A 12-lead ECG to monitor for QT prolongation will be performed.\nIf any prolongation of the QT interval is observed, the ECGs will be performed at every study visit until normalization., timeFrame - Over 35days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04708496",
    "endpoint": "measure - Change in the level on the liver enzymes ALT and ALP, description - Liver Function will be assessed at screening, and on days 7 and 35.\nShould any derangement in function be observed, the same will be performed at every study visit until normalization.\nAny participant with deranged liver function will be reported to have either adverse event or serious adverse event depending on the degree of severity and will be further assessed, treated appropriately and followed up till resolution, timeFrame - Over 35days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04708496",
    "endpoint": "measure - Change in creatinine and urea levels, description - Renal Function will be assessed at screening, and on days 7 and 35.\nShould any derangement in function be observed, the same will be performed at every study visit until normalization.\nAny participant with deranged renal function (Creatinine and urea levels) will be reported to have either adverse event or serious adverse event depending on the degree of severity and will be further assessed, treated appropriately and followed up till resolution&quot; Focus will be on monitoring change, timeFrame - Over 35days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00616304",
    "endpoint": "measure - Safety: Clinical and biochemical measures., description - , timeFrame - During and after infusion. In those receiving L-arginine, biochemical and hemodynamic measures at the completion of infusion will also be compared with measures at the start of infusion.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00616304",
    "endpoint": "measure - Change in endothelial function in each arginine infusion regimen vs saline placebo combined, description - , timeFrame - 1 hour response and end of infusion response",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00616304",
    "endpoint": "measure - Paired change in endothelial function, description - , timeFrame - paired comparison of post-vs pre-infusion values, overall, and in each arginine infusion regimen",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00616304",
    "endpoint": "measure - Lactate clearance for each infusion regimen, description - , timeFrame - Time for lactate to return to upper limit of normal",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00616304",
    "endpoint": "measure - Lactate:pyruvate ratio, description - , timeFrame - area under curve&#x2F;time to normal",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00616304",
    "endpoint": "measure - Fever clearance time, description - , timeFrame - Fever clearance time",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00616304",
    "endpoint": "measure - parasite clearance time, description - , timeFrame - parasite clearance time",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00616304",
    "endpoint": "measure - Change in L-arginine concentration, description - , timeFrame - at 1 and 8 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00616304",
    "endpoint": "measure - Improvement in microvascular obstruction (OPS), description - , timeFrame - at 1 and 8 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00616304",
    "endpoint": "measure - Tissue oxygen consumption and delivery (NIRS), description - , timeFrame - one and eight hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00616304",
    "endpoint": "measure - change in exhaled NO, description - , timeFrame - one and eight hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00616304",
    "endpoint": "measure - improvement in endothelial activation (decrease in angiopoietin-2 concentrations), description - , timeFrame - area under curve",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00616304",
    "endpoint": "measure - improvement in RHPAT among those with baseline dysfunction (RHPAT&lt;1.67), description - , timeFrame - 8 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01814683",
    "endpoint": "measure - The incidence rate (per person-year) of any recurrent P. vivax malaria., description - The incidence rate (per person-year) of any recurrent (i.e.\nsymptomatic and asymptomatic) P. vivax parasitaemia over 12 months of follow-up in the 7 and 14-day primaquine regimens for all sites combined and stratified by site., timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01814683",
    "endpoint": "measure - Incidence risk of any recurrent symptomatic of P. vivax malaria compared to control arm, description - The incidence rate (per person-year) of any recurrent symptomatic P. vivax parasitaemia over 12 months of follow-up in either the 7 or the 14-day primaquine regimens compared with the control arm, for all sites combined and stratified by site., timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01814683",
    "endpoint": "measure - The Haematological recovery in patients with vivax malaria, description - Haematological recovery will be assessed as the incidence risk of severe anaemia (Hb&lt;7g&#x2F;dl) and&#x2F;or blood transfusion within the 12 month follow up period, and the mean fall in baseline Hb at day 7 and day 14.\nThese outcomes will be compared between the intervention arms and also between each intervention arm and the controls., timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01814683",
    "endpoint": "measure - Proportion of patients with Serious Adverse Drug reactions, description - The proportion of patients with one or more serious adverse drug reactions within 42 days of their primary treatment and also at 6 and 12 months., timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01814683",
    "endpoint": "measure - Primaquine tolerability, description - Tolerability of primaquine will be assessed by comparing the proportion of patients with nausea, vomiting, abdominal pain and vomiting of a dose within 1 hour of administration between the intervention arms and also between each intervention arm and the controls., timeFrame - 14 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01814683",
    "endpoint": "measure - Primaquine tolerability comparison between patients in intervention arm and control arm, description - Drug tolerability will be assessed also by comparing the proportion of patients completing a full course of observed primaquine therapy between the intervention arms and also between each intervention arm and the controls., timeFrame - 14 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01814683",
    "endpoint": "measure - Incidence risk of severe anaemia in G6PD deficient arm, description - - The G6PD deficiency treatment arm will provide important data on the safety and tolerability of the WHO recommended weekly regimen.\nThe incidence risk of severe anaemia (Hb&lt;7g&#x2F;dl) and&#x2F;or requirement for blood transfusion within the 12 month follow up period and the mean fall in baseline Hb at day 7 and day 14 will be determined., timeFrame - 14 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01814683",
    "endpoint": "measure - Cost effective analysis in the management of P. vivax with respect to the use of G6PD tests, description - The cost of illness will be compared between the intervention arms and also between each intervention arm and the controls.\nA cost-effectiveness analysis for the management of P. vivax with respect to the use of G6PD tests, the dosing schedule and the epidemiological context will be conducted., timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00757887",
    "endpoint": "measure - Difference in immunological parameters between EHMI-8 and control volunteers., description - , timeFrame - 140 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04238845",
    "endpoint": "measure - The prevalence of mutant pfcrt allele, description - Difference between prevalence of mutant pfcrt in pre and post intervention months study period in malaria positive sample, timeFrame - One year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04238845",
    "endpoint": "measure - The prevalence of mutant pfmdr1 allele, description - Difference between prevalence of mutant pfmdr1 in pre and post intervention months study period in malaria positive sample, timeFrame - One year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04238845",
    "endpoint": "measure - The prevalence of mutant dhfr allele, description - Difference between prevalence of mutant dhfr in pre and post intervention months study period in malaria positive sample, timeFrame - One year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04238845",
    "endpoint": "measure - The prevalence of mutant dhps allele, description - Difference between prevalence of mutant dhps in pre and post intervention months study period in malaria positive sample, timeFrame - One year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04238845",
    "endpoint": "measure - SMC coverage, description - SMC coverage in the area will be determined as the ratio of children who actually received the intervention to the predetermined sample of eligible children from the HDSS dataset., timeFrame - Six months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04238845",
    "endpoint": "measure - SMC Compliance, description - proportion of full compliant individual over the total per arm the predetermined sample of eligible children from the HDSS dataset.\nCompliance will be determined by calculating, for each participant, the ratio between the number of tablets &#x2F; packets taken and the number of tablets &#x2F; packets that the patient should have taken.\nTwo groups of participants will be described: compliant = 100% treatment compliance and non-compliant = other cases, timeFrame - Six months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04238845",
    "endpoint": "measure - The incidence of adverse events in each study group will be considered, description - The number of adverse events in each arm, timeFrame - Six months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05086887",
    "endpoint": "measure - Immune responses to malaria and other parasites, description - Levels and breadth of P. falciparum specific antibody and memory B cell responses., timeFrame - A blood specimen will be collected from participants upon inclusion, and a subset of volunteers will be asked to contribute with a second blood sample after 6-12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04428385",
    "endpoint": "measure - Use of Malaria Rapid Diagnostic Test, description - Number of suspected malaria cases presenting to the retail outlet that are tested., timeFrame - Day of enrollment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04428385",
    "endpoint": "measure - Adherence to the RDT Result Among All Those Tested in the Shop, description - The number of tested participants who are adherent where adherence to the test result is defined as taking a quality-assured ACT if the RDT is positive or taking another drug (or no drug) if the test is negative, timeFrame - Day of enrollment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04428385",
    "endpoint": "measure - Appropriate Case Management, description - Number of all suspected malaria cases that are managed appropriately (tested for malaria, use ACT following a positive test, and do not purchase an ACT after a negative test)., timeFrame - Day of enrollment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04428385",
    "endpoint": "measure - ACT (Artemisinin Combination Therapy) Use Among Untested Participants, description - Number of participants who are not tested for malaria (did not test in the shop or have documentation of a test) and purchased an ACT., timeFrame - Day of enrollment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03640403",
    "endpoint": "measure - Prevalence of asymptomatic malaria infections at month 0, 12 and 20 of follow up, description - to be measured from microscopic detection of malaria parasite on blood slides, timeFrame - from month 0 till month12 and 20",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03640403",
    "endpoint": "measure - Prevalence of PCR confirmed sub-microscopic parasitaemia at months 0,12 and 20 of follow up, description - Polymerase chain reaction (PCR) confirmed from random subset of finger prick dry blood spots samples, timeFrame - at months 0, 12 and 20",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03640403",
    "endpoint": "measure - Prevalence of soil transmitted helminths and schistosomiasis, description - A stool sample will be used to determine prevalence (defined as adult or eggs) of STH and S. mansoni infection determined by duplicate Kato-Katz thick smears technique.\nUrine samples will be visually examined for the presence of blood (macrohaematuria) followed by laboratory examination for schistosomiasis infection (S.haematobium), timeFrame - at baseline, at month 12 and month 20.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03640403",
    "endpoint": "measure - Prevalence of schistosomiasis, description - Urine samples will be visually examined for the presence of blood (macrohaematuria) followed by laboratory examination for schistosomiasis infection (S.haematobium) for confirmation., timeFrame - at baseline, at month 12 and month 20.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03640403",
    "endpoint": "measure - Prevalence of validated common P. falciparum polymorphisms known to be associated with drug sensitivity at baseline, at months 12 and 20, description - from random subset of finger prick dry blood spots samples, timeFrame - at baseline, at month 12 and 20.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03640403",
    "endpoint": "measure - Proportion of children seropositive for Plasmodium falciparum AMA-1 and MSP-119 at baseline, at month 12 and 20, description - from random subset of finger prick dry blood spots samples, Antibody responses to P. falciparum blood-stages antigens, apical membrane antigen (AMA-1) and merozoite surface protein (MSP-119) will be determined., timeFrame - at baseline, at month 12 and 20.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03640403",
    "endpoint": "measure - Change in serum antibody responses to Plasmodium falciparum AMA-1 and MSP-119 at baseline, at month 12 and 20, description - From random subset of finger prick dry blood spots samples to be eluted for ELISA, timeFrame - at baseline, at month 12 and 20.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03640403",
    "endpoint": "measure - Percentages of school children with malnutrition through WHO&#x27;s BMI z-score, description - weight in kilograms and height in meters will be combined to report BMI in kg&#x2F;m^2, timeFrame - at month 0, 12, and 20",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03640403",
    "endpoint": "measure - Relative risk (RR), for all adverse events categorised to severity at month 12 and 20, description - Adverse events will be detected throughout the study, Each intervention arm will be compared to control arm to determine risk of an adverse event among the two arms.\nAlso events in two intervention arms will be compared to each other to assess risk in the two intervention arms., timeFrame - at month 12 and 20",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02612545",
    "endpoint": "measure - Compare parasite and fever clearance rates&#x2F;times following TACT versus ACT, description - , timeFrame - Days 0-6 post enrollment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02612545",
    "endpoint": "measure - Compare the safety and tolerability of TACT versus ACT, description - , timeFrame - Day 0-6 post enrollment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02612545",
    "endpoint": "measure - Compare ECG QTc prolongation following TACT versus ACT, description - , timeFrame - Days 0-2 post enrollment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04428307",
    "endpoint": "measure - Use of Malaria Rapid Diagnostic Test, description - Number of participants with suspected malaria cases presenting to the retail outlet that are tested., timeFrame - Day of enrollment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04428307",
    "endpoint": "measure - Adherence to the RDT (Rapid Diagnostic Test) Result Among All Those Tested in the Shop, description - The number of tested participants who are adherent where adherence to the test result is defined as taking a quality-assured ACT if the RDT is positive or taking another drug (or no drug) if the test is negative., timeFrame - Day of enrollment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04428307",
    "endpoint": "measure - Appropriate Case Management, description - Number of all participants with suspected malaria cases that are managed appropriately (tested for malaria, and use ACT following a positive test and do not purchase an ACT after a negative test), timeFrame - Day of enrollment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04428307",
    "endpoint": "measure - ACT (Artemisinin Combination Therapy) Use Among Untested Clients, description - Number of participants who are not tested for malaria and purchased an ACT, among those who did not test in the shop, do not have documentation of a test, and purchased any antimalarial at the shop., timeFrame - Day of enrollment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02348788",
    "endpoint": "measure - Parasite clearance time in hours, description - The difference in absolute time in hours post treatment to microscopic parasite clearance between treatment arms, timeFrame - Within 72 hours post treatment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02348788",
    "endpoint": "measure - Parasite clearance at day 1 and day 3, description - The difference in proportion of patients with negative microscopy for P. vivax asexual parasites at 24 and 72 hours between treatment arms, timeFrame - At 24 and 72 hours post treatment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02348788",
    "endpoint": "measure - Treatment outcome, description - Early treatment failure (ETF), late treatment failure (LTF), and adequate parasitological and clinical response (APCR) at day 28 and day 42, timeFrame - Day 28 and 42 post treatment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02348788",
    "endpoint": "measure - Risk of anaemia, description - Proportion with haemoglobin less than 12 g&#x2F;dL in women or less than 13 g&#x2F;dL in men between treatment arms, timeFrame - Day 28 post treatment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02348788",
    "endpoint": "measure - Fractional fall in haemoglobin at day 3, description - Difference in fractional fall in haemoglobin concentration between treatment arms 3 days post treatment, timeFrame - Day 3 post treatment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02348788",
    "endpoint": "measure - Haemoglobin nadir, description - Difference in risk of lowest recorded haemoglobin concentration between treatment arms during 42 day follow-up, timeFrame - 42 days post treatment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02348788",
    "endpoint": "measure - Risk of P. vivax gametocyte carriage during follow up, description - The difference in proportion of microscopic P. vivax gametocyte carriage between treatment arms during 42 day follow up, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02348788",
    "endpoint": "measure - Risk of adverse events, description - Risk of adverse events (AE) and serious adverse events (SAE) including relationship to study drugs throughout follow up, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02348788",
    "endpoint": "measure - Length of hospital inpatient stay, description - Number of days post enrolment requiring admission until treatment completed and 2 negative blood slides for malaria allowing discharge as per Malaysian Ministry of Health guidelines, timeFrame - From 2-9 days post enrolment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00356005",
    "endpoint": "measure - Secondary outcome measures are time until parasite, fever, and gametocyte clearance (PCT, FCT, and GCT)., description - , timeFrame - 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06257810",
    "endpoint": "measure - Consumption of hospital resources, description - Number of days in hospital., timeFrame - Day 7",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06257810",
    "endpoint": "measure - Consumption of hospital resources, description - Number of hospital visits within 7 days., timeFrame - Day 7",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06257810",
    "endpoint": "measure - Patient satisfaction, description - Patient satisfaction with the health care (measured on a scale of 1 (worse) to 5 (better))., timeFrame - Inclusion and Day 7",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06257810",
    "endpoint": "measure - Patient&#x27;s quality of life, description - Percentage on patient&#x27;s quality of life (1 (worse) to 100 (better)) + EQ-5D questionnaire., timeFrame - Inclusion and Day 7",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06257810",
    "endpoint": "measure - Patient&#x27;s loss of productivity, description - Questionnaire on number of working day lost., timeFrame - Inclusion and Day 7",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01100060",
    "endpoint": "measure - Tmax and Cmax of azithromycin and chloroquine., description - , timeFrame - Through Day 5",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01100060",
    "endpoint": "measure - AUClast, Tmax, and Cmax of desethylchloroquine., description - , timeFrame - Through Day 5",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03454048",
    "endpoint": "measure - Peak Density Gametocytes, description - Peak density of gametocytes by qRT-PCR., timeFrame - up to day 51 after challenge infection",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03454048",
    "endpoint": "measure - AUC Gametocytes, description - The area under the curve of gametocyte density versus time.\nThe median AUC was calculated for both cohorts.\nSince onset of gametocytaemia differs depending on method of infection a window of 15 days was used to calculate AUC, from the time-point where a minimum of 50% of participants within a cohort had detectable gametocytemia., timeFrame - up to day 51 after challenge infection",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03454048",
    "endpoint": "measure - Gametocyte Commitment, description - The gametocyte commitment rate is estimated by dividing the peak gametocyte by the peak of asexual parasites., timeFrame - up to day 51 after challenge infection",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03454048",
    "endpoint": "measure - Gametocyte Sex-ratio, description - Proportion of male gametocytes, timeFrame - up to day 51 after challenge infection",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03454048",
    "endpoint": "measure - Number of Participants Infectious for Mosquitoes Through DFA, description - Prevalence of gametocyte infectiousness for Anopheles mosquitoes through Direct Feeding Assays (Direct Skin Feeding Assay, DFA)., timeFrame - up to day 51 after challenge infection",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00840502",
    "endpoint": "measure - Examination of all newborns, description - , timeFrame - 6 months post natal",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05650502",
    "endpoint": "measure - Impact of Seasonal malaria chemoprevention, description - Hospital frequency rate of children, timeFrame - June 2023",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00146796",
    "endpoint": "measure - The proportion of slide negative cases given an antimalarial (overprescription of antimalarials) in the RDT arm compared to the standard care arm., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00146796",
    "endpoint": "measure - The proportion of slide positives not given an antimalarial who are slide positive (underprescription of antimalarials)., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00146796",
    "endpoint": "measure - Proportion of cases who are treated for malaria on clinical grounds alone, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00146796",
    "endpoint": "measure - Sensitivity and specificity of RDT and hospital malaria slide compared to double read research slide results., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00146796",
    "endpoint": "measure - The proportion of patients receiving additional or alternative treatments to antimalarials following a negative blood slide or RDT result. This will inform cost-effectiveness models, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04816461",
    "endpoint": "measure - The incidence of adverse events in each intervention arm versus SMC alone arm, description - Incidence of adverse events in each arm, timeFrame - 5 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01669512",
    "endpoint": "measure - Assess the effects of Matrix M™ on the immunogenicity of ChAd63 ME-TRAP &#x2F; MVA ME-TRAP heterologous prime boost vaccination, description - Comparison of immunogenicity of the Matrix M™ - adjuvanted vaccination regimens, versus the Control regimen., timeFrame - 24 weeks from first vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02653898",
    "endpoint": "measure - Overall rate of sexual stage infections at Months 1 through 6 in each arm based on a combined endpoint of light microscopy and PCR analysis for detection of gametocyte maturity., description - , timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02653898",
    "endpoint": "measure - Number of participants with abnormal lab values and&#x2F;or Adverse Events that are related to the treatments in each arm, description - , timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02653898",
    "endpoint": "measure - Kaplan-Meier survival analysis of asexual and sexual blood stage at 28-day intervals after treatment or prophylaxis up to 180 days, description - , timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02653898",
    "endpoint": "measure - Comparison of all-species and species-specific malaria incidence density in each arm over 180-day period, description - , timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02653898",
    "endpoint": "measure - Comparative incidence of malaria detected by RDT versus RT-PCR versus microscopy, description - , timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02653898",
    "endpoint": "measure - Comparative incidence of G6PD deficiency in the study population as determined by RDT, quantitative, and qualitative tests, description - , timeFrame - At the time of enrollment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02653898",
    "endpoint": "measure - Estimate of apparent rates of preexisting immunity to malaria based on medical history, days of fever prior to presentation, and preexisting parasitological parameters (gametocytemia, low asexual stage parasitemias), description - , timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02653898",
    "endpoint": "measure - Sensitivity and specificity assessment of the currently recommended rapid diagnostic test in Cambodia to detect moderate to severe G6PD deficiency using quantitative G6PD testing as the reference standard, description - , timeFrame - At the time of enrollment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02653898",
    "endpoint": "measure - Odds ratio for P.v recurrence for each CYP2D6 phenotype, description - , timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02653898",
    "endpoint": "measure - Rate of cytochrome P450 2D6 genotypes&#x2F;phenotypes in the population at risk, description - , timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02653898",
    "endpoint": "measure - Percent reduction in hemoglobin and HTC for each 2D6 haplotype in subjects with available CBC following PQ dosing, description - , timeFrame - Day 3 (and day 7 in those volunteers with Hgb or HCT drop of at least 10% from baseline on Day 3)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02653898",
    "endpoint": "measure - Percentage of subjects with malaria recurrence for each CYP2D6 phenotype, description - , timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03641534",
    "endpoint": "measure - Plasma creatinine levels, description - Measured in millimoles per liter., timeFrame - 48 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03641534",
    "endpoint": "measure - Positive chest X-ray for pulmonary edema (dichotomous variable), description - Other measures evaluating pulmonary congestion, timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03641534",
    "endpoint": "measure - The ratio between pulse oxymetry hemoglobin saturation and the fraction of inspired oxygen (SpO2&#x2F;FiO2 ratio)., description - Other measures evaluating pulmonary congestion, timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03641534",
    "endpoint": "measure - Proportion of fluid responsive patients, description - Fluid responsiveness is defined as a positive pulse pressure passive leg raise test (change in pulse pressure &gt;10% after leg raise manouver) or cardiac output-guided passive leg raise test (change in cardiac output &gt;10% after leg raise manouver).\nThe passive leg raise test is performed both a standard maneuver (bed tilting) and a modified maneuver (manual leg raise)., timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03641534",
    "endpoint": "measure - Prolonged capillary refill time (dichotomous variable, defined as ≥3 seconds), description - Other measures evaluating tissue perfusion, timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03641534",
    "endpoint": "measure - Skin mottling score (0-5), description - Other measures evaluating tissue perfusion, timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03641534",
    "endpoint": "measure - Cardiac index (in liters per minute per square meter of body surface area), description - Other measures evaluating tissue perfusion, timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03641534",
    "endpoint": "measure - Core-periphery temperature gradient(°C), description - Other measures evaluating tissue perfusion, timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03641534",
    "endpoint": "measure - Proportion of patients at enrolment and during admission with a low cardiac index and hypoperfusion state., description - , timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03641534",
    "endpoint": "measure - Proportion of patients with microvasculature obstruction or abnormalities, description - Microvasculature obstruction and abnormalities are detected with orthogonal polarization spectral imaging (OPS); red cell deformability is studied by laser assisted rotational cell analyser (LORCA)., timeFrame - 24 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03641534",
    "endpoint": "measure - Proportion of patients that develop pulmonary edema and acute respiratory distress syndrome (ARDS)., description - Pulmonary edema is defined as the presence of 2 or more positive lung zones per hemithorax on the lung ultrasound.\nAcute respiratory distress syndrome is defined according to the Berlin Definition criteria., timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03641534",
    "endpoint": "measure - Case fatality in first 30 days., description - , timeFrame - 30 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03641534",
    "endpoint": "measure - Acute kidney injury (AKI), description - Proportion of AKI as per Kidney Diseases Improving Global Outcomes definition: serum creatinine increase by ≥ 3 mg&#x2F;dl within 48 hours, or serum creatinine increase by ≥ 1.5 times baseline, or urine volume &lt;0.5 mg&#x2F;kg&#x2F;h for 6 hours.\nOutcome of AKI defined as renal recovery (time in days until creatinine returns to baseline)., timeFrame - At admission, up to day 14, and renal recovery by 30 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03641534",
    "endpoint": "measure - Proportion of patients that develop lower extremity deep venous thrombosis., description - Deep venous thrombosis is defined as a positive compressive ultrasonography on femoral or popliteal veins of lower limbs., timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03641534",
    "endpoint": "measure - Microbiological etiology of sepsis., description - Results of blood culture and organism identified in case of positive result, timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03641534",
    "endpoint": "measure - Number of patients with ARDS according to the Kigali Modification of the Berlin Definition of ARDS, description - , timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03641534",
    "endpoint": "measure - Diagnostic performance measures (sensitivity, specificity, positive predictive value, negative predictive value) of the digital microscope with expert microscopy as the gold standard, description - , timeFrame - 7 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04301531",
    "endpoint": "measure - Prevalence of anaemia in &lt;15 children, description - The difference in the prevalence of anaemia in children &lt;15 years in the intervention arm compared to the control arm, timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04301531",
    "endpoint": "measure - Prevalence of febrile illnesses, description - The difference in prevalence of febrile illnesses in children &lt;15 years in the intervention arm compared to the control arm, timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04301531",
    "endpoint": "measure - Prevalence of asymptomatic malaria parasitaemia among household members, description - The difference in asymptomatic malaria parasitaemia prevalence in household members in the intervention arm compared to the control arm., timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04301531",
    "endpoint": "measure - Difference in symptomatic malaria cases attending health facilities, description - The difference in symptomatic malaria cases attending health facilities from households in the intervention arm compared to the control arm., timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04301531",
    "endpoint": "measure - Cost benefit analaysis of implementing MTTT, description - The difference in cost benefit of MTTT between arm 1 and arm 2, timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03726593",
    "endpoint": "measure - Prevalence of molecular markers of drug resistance, description - , timeFrame - Day of enrollment and day of malaria recurrence up to 8 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03726593",
    "endpoint": "measure - Drug susceptibility testing of parasite isolates against standard antimalarial drugs, description - Ex vivo drug susceptibility testing, timeFrame - Day of enrollment and day of malaria recurrence up to 8 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03726593",
    "endpoint": "measure - Pharmakokinetics of each study drug - (Cmax), description - Peak plasma concentration (Cmax) for study drugs, timeFrame - multiple time points up to 8 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03726593",
    "endpoint": "measure - Pharmakokinetics of each study drug - (AUC), description - Area under the plasma concentration versus time curve (AUC), timeFrame - multiple time points up to 8 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03726593",
    "endpoint": "measure - Pharmakokinetics of each study drug - volume of distribution, description - volume of distribution for study drugs, timeFrame - multiple time points throughout 6 weeks of follow up",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03726593",
    "endpoint": "measure - Pharmakokinetics of each study drug - (T1&#x2F;2), description - elimination half-life (T1&#x2F;2) for study drugs, timeFrame - multiple time points up to 8 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03726593",
    "endpoint": "measure - Kaplan Meier survival analysis of asexual blood stage parasitemia and sexual stage gametocytes, description - , timeFrame - 6 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03726593",
    "endpoint": "measure - Gametocyte carriage rates on days 0, 1, 2, 3, and weeks 1 through 6 for each treatment arm, description - , timeFrame - Days 0, 1, 2, 3, and weekly, up to week 8",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03726593",
    "endpoint": "measure - The incidence of hepatotoxicity events for each treatment arm, description - Alanine aminotransferase (ALT)&gt;5 times the upper limit of normal (ULN) or percent of volunteers meeting the Hy&#x27;s law definition (ALT or aspartate aminotransferase [AST] &gt;3 x ULN and total bilirubin &gt;2 x ULN) at any post-dose time point within 6 weeks of follow up, timeFrame - Day 3 and week 6",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03726593",
    "endpoint": "measure - Rates of treatment-related adverse events, description - , timeFrame - 6 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03726593",
    "endpoint": "measure - Severity of treatment-related adverse events, description - Grade 1 - mild, Grade 2 - moderate, Grade 3 - severe, Grade 4- life threatening, timeFrame - 6 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03726593",
    "endpoint": "measure - Number of participants who say they are willing to take the same drug combination in the future, description - , timeFrame - day 2 and week 6",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03726593",
    "endpoint": "measure - Point efficacy with 95% Confidence Interval against blood stage malaria infection classified according to the WHO malaria treatment outcome classifications (ETF, LTF, LCTF, LPTF), description - , timeFrame - 4 weeks, 6 weeks, and 8 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03726593",
    "endpoint": "measure - Incidence of Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency, description - Comparative incidence of G6PD deficiency in the study population as determined by G6PD rapid-diagnostic tests (RDTs) and quantitative tests, to include sensitivity, specificity, negative predictive value (NPV) and positive predictive value (PPV) for each of the point-of-care tests against 10%, 30%, and 60% thresholds of normal G6PD activity, timeFrame - Enrollment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03726593",
    "endpoint": "measure - Number of infected mosquitos following membrane feeding, description - , timeFrame - Day 0, Day 3, Day 7, and on day of malaria recurrence up to 8 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05444790",
    "endpoint": "measure - Point estimates of comparator tests, description - Point estimates of diagnostic accuracy characteristics (sensitivity, specificity, NPV, PPV) with 95% confidence intervals of comparator tests using the reference test as standard of truth for the detection of P. falciparum and, P.vivax infections in patients with symptoms suggestive of malaria, timeFrame - 8 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05444790",
    "endpoint": "measure - Point estimates of index tests, description - Point estimates of diagnostic accuracy characteristics with 95% confidence intervals (sensitivity, specificity, NPV, PPV) of the index tests for the detection of P. falciparum infections with hrp2 and&#x2F;or hrp3 deletions in patients with symptoms suggestive of malaria., timeFrame - 8 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05444790",
    "endpoint": "measure - User ability to read and interpret test, description - 2.4 Percent of end users who can accurately interpret the investigational device result output., timeFrame - 8 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03695770",
    "endpoint": "measure - malaria prevalence, description - change PCR-Plasmodium prevalence amongst gold miners working illegally in French Guiana, timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03695770",
    "endpoint": "measure - KAP questionnaire, description - change the use of protection measures against mosquitoes, timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05085301",
    "endpoint": "measure - Point estimates of comparator tests, description - Point estimates of diagnostic accuracy characteristics (sensitivity, specificity, NPV, PPV) with 95% confidence intervals of comparator tests using the reference test as standard of truth for the detection of P. falciparum and, P.vivax infections in patients with symptoms suggestive of malaria, timeFrame - 2 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05085301",
    "endpoint": "measure - Frequencies of hrp2&#x2F;3 gene deletions, description - Frequencies of P. falciparum infections containing HRP2 and&#x2F;or HRP3 mutations and the impact of those on HRP2-based RDT diagnostic accuracy, timeFrame - 2 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02509481",
    "endpoint": "measure - Adverse Events, description - The number of adverse events.\nAdverse events data were collected via passive case detection from total population., timeFrame - Approximately 18 weeks, from the start of the first MDA to 3 weeks following the last MDA in the Experimental arm",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02509481",
    "endpoint": "measure - Entomological Indicator of Parasite Transmission, description - Change in human IgG reactivity (optical density; ∆OD) to an Anopheles salivary gland antigen (peptide gSG6-P1) over the trial period.\nA score of 0 indicates no change in seroreactivity from from immediately before to immediately after the trial, suggesting consistent mosquito biting throughout the trial.\nA positive score indicates increasing seroreactivity and thus increasing mosquito biting on participants from immediately before to immediately after the trial.\nA negative score indicates decreasing seroreactivity and thus decreasing mosquito biting on participants from immediately before to immediately after the trial., timeFrame - Approximately 20 weeks, from before the start of the first MDA to 4 weeks following the last MDA in the Experimental arm",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02509481",
    "endpoint": "measure - Molecular Force of P. Falciparum Infection, description - Examination of new P. falciparum clones acquired from the beginning to the end of the intervention (molecular force of infection; mFOI) per child.\nMolecular genotyping used capillary blood taken at the time of diagnosis of each positive malaria episode and consisted of nPCR of the msp2 gene.\nWe calculated the multiplicity of infection (MOI) per malaria episode, and then calculated the molecular force of infection (mFOI) associated with malaria episodes per child (over course of the trial), timeFrame - Approximately 18 weeks, from the start of the first MDA to 3 weeks following the last MDA in the Experimental arm",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02509481",
    "endpoint": "measure - Number of 6-10 Year Old Participants With Soil Transmitted Helminths (STH), description - Prevalence of soil transmitted helminth infections in children between 6-10 years old from the beginning to the end of the intervention, timeFrame - Approximately 20 weeks, from before the start of the first MDA to 4 weeks following the last MDA in the Experimental arm",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02509481",
    "endpoint": "measure - Entomological Inoculation Rate, description - The entomological inoculation rate (EIR per week per person) is the measure of the human biting rate per person per week, multiplied by the sporozoite rate (in biting mosquitoes) per week, an estimated from sampling mosquitoes from 8 households located in the center of each study village.\nThe EIR was calculated for each of the 6 sampling weeks of the treatment phase., timeFrame - 6 sampling periods over 18 weeks, starting in week 2 following the first MDA, and sampling every 3 weeks thereafter until week 17 of the treatment phase.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00711906",
    "endpoint": "measure - To evaluate efficacy of CTX prophylaxis in preventing malaria peripheral parasitaemia., description - , timeFrame - Pregnancy",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00711906",
    "endpoint": "measure - To evaluate efficacy of CTX prophylaxis in preventing perinatal mortality and in improving birth weight, description - , timeFrame - At birth",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00711906",
    "endpoint": "measure - To establish the safety of CTX prophylaxis on the offspring by measuring the gestational age at delivery and birth weight., description - , timeFrame - At birth",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00711906",
    "endpoint": "measure - To compare the efficacy profile of CTX prophylaxis to that of SP intermittent preventive treatment., description - , timeFrame - Pregnancy",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00711906",
    "endpoint": "measure - To compare the safety profile of CTX prophylaxis to that of SP intermittent preventive treatment., description - , timeFrame - Pregnancy",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00711906",
    "endpoint": "measure - Spontaneous abortion, description - , timeFrame - &lt;&#x2F;=28 weeks gestation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00711906",
    "endpoint": "measure - Pre-term delivery, description - , timeFrame - &lt;37 completed weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00711906",
    "endpoint": "measure - Neonatal mortality, description - , timeFrame - Within 28 days after birth",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00711906",
    "endpoint": "measure - Maternal mortality, description - , timeFrame - Up to 6 weeks following delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00711906",
    "endpoint": "measure - Major and minor birth defects, description - , timeFrame - At birth and up to 6 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03224052",
    "endpoint": "measure - Supportive care requirement, description - A requirement for supportive care as determined by the attending clinician.\nSupportive care is defined as a requirement renal replacement therapy (clinical symptoms of acute renal failure), vasopressor support (mean arterial blood pressure of less than 65mmHg despite fluid resuscitation), blood transfusion (haemoglobin &lt; 7 g&#x2F;dL) or mechanical ventilation (due to type 1 or type 2 respiratory failure), timeFrame - Within 30 days of enrolment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03810014",
    "endpoint": "measure - Number of Participants With a Positive mRDT That Purchased an ACT (Artemisinin-based Combination Therapy), description - , timeFrame - At the end of a participant&#x27;s visit to participating retail outlet, up to 1 hour",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03810014",
    "endpoint": "measure - Number of Participants With a Negative mRDT That Did Not Purchase an ACT, description - , timeFrame - At the end of a participant&#x27;s visit to participating retail outlet, up to 1 hour",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03810014",
    "endpoint": "measure - Number of Participants That Did Not Purchase an mRDT and Did Not Purchase an ACT, description - , timeFrame - At the end of a participant&#x27;s visit to participating retail outlet, up to 1 hour",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00692627",
    "endpoint": "measure - Acute renal failure, description - , timeFrame - By discharge",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00692627",
    "endpoint": "measure - Acute pulmonary oedema, description - , timeFrame - By discharge",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04251351",
    "endpoint": "measure - Number of patients with serious adverse events, description - Number of patients with serious adverse events (mortality and&#x2F;or hepatotoxicity, as defined by Hy&#x27;s Law)., timeFrame - AST&#x2F;ALT&#x2F;total bilirubin during the first 5 days from enrolment; mortality assessed Day 0 to 7.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04251351",
    "endpoint": "measure - Proportion of patients who develop Major Adverse Kidney Events (MAKE) composite, description - Major Adverse Kidney Events (MAKE) composite, defined as ≥ 1 efficacy renal endpoints: (i) death, (ii) need for renal replacement therapy, (iii)≥ 50% reduction in eGFR from baseline to 90 days., timeFrame - 90 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04251351",
    "endpoint": "measure - Fever clearance time, description - Time taken for aural temperature: (i) to fall &lt; 37.5°C (FCT-A), and (ii) to fall &lt; 37.5°C and remain there for &gt;24 h (FCT-B), timeFrame - 6-hourly temperature assessments during first 7 days from enrolment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04251351",
    "endpoint": "measure - Coma recovery, description - Time until Glasgow Coma Score (GCS) return to 15 (or Blantyre Coma Score (BCS) return to 5 in preverbal children), timeFrame - 6-hourly GCS&#x2F;BCS assessments during first 7 days from enrolment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04251351",
    "endpoint": "measure - Longitudinal change in renal function, description - As measured by creatinine concentration (umol&#x2F;L), timeFrame - During the first 7 days from enrolment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04251351",
    "endpoint": "measure - Longitudinal change in markers of hemolysis, description - As measured by cell-free haemoglobin (ug&#x2F;mL), haemopexin (ug&#x2F;mL), haptoglobin (ug&#x2F;mL), haem (uM), F2-isoprostane (pg&#x2F;mL) and isofurans (pg&#x2F;mL) concentrations, timeFrame - during the first 3 days from enrolment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04251351",
    "endpoint": "measure - Longitudinal change of endothelial activation, description - As measured by concentrations of angiopoietin-Tie2 pathway markers (i.e.\nAng-1, Ang-2, sTie2, sTie1), timeFrame - during the first 3 days from enrolment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04251351",
    "endpoint": "measure - Longitudinal change of immune activation, description - As measured by soluble triggering receptor expressed on myeloid cells concentration (sTREM-1; pg&#x2F;mL), timeFrame - during the first 3 days from enrolment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04251351",
    "endpoint": "measure - Longitudinal change of AKI biomarker, description - As measured by cystatin-C concentration (Cys-C; ug&#x2F;mL), timeFrame - during the first 3 days from enrolment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04251351",
    "endpoint": "measure - Parasite (parasites&#x2F;ul) clearance, description - as measured by time until two consecutive negative smears (hours), and by rate using the parasite clearance estimator to determine slope half-life (hours) from 12-hourly parasite counts., timeFrame - 12-hourly parasitemia assessments during first 7 days from enrolment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04251351",
    "endpoint": "measure - Exploratory analysis with sex, description - Primary efficacy analyses will be analysed using a logistic regression model to obtain odds ratios, comparing the odds of a combined endpoint of kidney function deterioration or death between treatment groups.\nA multivariable model including an interaction term (sex and treatment) will be assessed in the primary analyses to explore potential differences between males and females., timeFrame - During first 7 days from enrolment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04251351",
    "endpoint": "measure - Pharmacokinetic properties, description - Population pharmacokinetic model (relative bioavailability, mean transit absorption time (hours), apparent oral elimination clearance (L&#x2F;hours), apparent volume of distribution (L), timeFrame - during the first 24 hours from enrolment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04251351",
    "endpoint": "measure - Pharmacokinetic properties, description - Peak plasma concentration (Cmax; mg&#x2F;L), timeFrame - during the first 24 hours from enrolment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04251351",
    "endpoint": "measure - Pharmacokinetic properties, description - Time to peak plasma concentration (Tmax; hours), timeFrame - during the first 24 hours from enrolment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04251351",
    "endpoint": "measure - Pharmacokinetic properties, description - Terminal elimination (t1&#x2F;2; hours), timeFrame - during the first 24 hours from enrolment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04251351",
    "endpoint": "measure - Pharmacokinetic properties, description - Area under the plasma drug concentration-time curve (AUC0-24; mg×h×L-1), timeFrame - during the first 24 hours from enrolment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04251351",
    "endpoint": "measure - Pharmacodynamic relationships, description - Pharmacodynamic effects on creatinine concentration (mol&#x2F;L), timeFrame - during first 7 days from enrolment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04251351",
    "endpoint": "measure - Pharmacodynamic relationships, description - Pharmacodynamic effects on liver toxicity, as measured by AST and ALT (U&#x2F;L), timeFrame - during first 7 days from enrolment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04251351",
    "endpoint": "measure - Pharmacodynamic relationships, description - Pharmacodynamic effects on temperature (Celsius), timeFrame - during first 7 days from enrolment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04251351",
    "endpoint": "measure - Pharmacodynamic relationships, description - Pharmacodynamic effects on parasitemia, as measured by parasites&#x2F;ul and slope half-life, timeFrame - during first 7 days from enrolment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04251351",
    "endpoint": "measure - Pharmacodynamic relationships, description - Pharmacodynamic effects on GCS (or BCS in pre-verbal children), timeFrame - during first 7 days from enrolment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00527800",
    "endpoint": "measure - Prevalence of mutations known to confer resistance to antifolate drugs in pretreatment samples from patients diagnosed with malaria, description - , timeFrame - each time episode of malaria is diagnosed",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00527800",
    "endpoint": "measure - Risk of adverse events, description - , timeFrame - 28 days following each malaria treatment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00993031",
    "endpoint": "measure - Placental Malaria Defined as Positive Placental RDT, description - Number of participants with positive placental RDT for malaria.\nMalaria rapid diagnostic tests (RDTs) assist in the diagnosis of malaria by detecting evidence of malaria parasites (antigens) in human blood.\nRDTs permit a reliable detection of malaria infections particularly in remote areas with limited access to good quality microscopy services., timeFrame - Delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00993031",
    "endpoint": "measure - Maternal Malaria Defined as the Number of Treatments for New Episodes of Malaria Per Time at Risk During Pregnancy, description - , timeFrame - Number of treatments given for clinical malaria based on postive blood smear from time from randomization until 24 months after delivery or cessation of breastfeeding",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00993031",
    "endpoint": "measure - Prevalence of Composite Clinical Outcome Defined by LBW, Stillbirth(Intrauterine Fetal Demise &gt;20wks GA), Late Spontaneous Abortion(Miscarriage 12-20wks GA), Preterm Delivery(&lt;37wks Gestation), Neonatal Death(Death of Liveborn Infant Within First 28days), description - Percent of evaluated participants with composite clinical outcome defined by LBW, stillbirth (intrauterine fetal demise &gt;20wks GA), late spontaneous abortion(miscarriage 12-20wks GA), preterm delivery(&lt;37wks gestation), neonatal death(death of live-born infant within first 28 days), timeFrame - Time from randomization until 24 months postpartum or cessation of breastfeeding",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00993031",
    "endpoint": "measure - Placental Malaria Defined Placental Histopathologic Analysis, description - Number of participants with positive placental histopathology slide for malaria, timeFrame - Delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00993031",
    "endpoint": "measure - Maternal Malaria Defined as the Number of Treatments for New Episodes of Malaria Per Time at Risk After Pregnancy, description - , timeFrame - Number of treatments given for clinical malaria based on postive blood smear from time from delivery until 24 months after delivery or cessation of breastfeeding",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00993031",
    "endpoint": "measure - Number of Participants With Severe Maternal Anemia Defined by Hemoglobin &lt; 8g&#x2F;dl at Any Point During the Trial in Each Treatment Group, description - Proportion of women with severe maternal Anemia (hemoglobin &lt; 8g&#x2F;dl by hemacue or CBC) at any point during the trial in Each Treatment Group, timeFrame - Time from randomization until one year follow up",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00993031",
    "endpoint": "measure - Incidence of Pre-eclampsia Defined by Hypertension &gt; 140&#x2F;90 on Two Occasions Measured &gt; 6 Hours Apart With ≥1+ Proteinuria on Clean Catch Urine Dipstick, description - Pre-eclampsia Defined by Hypertension &gt; 140&#x2F;90 on Two Occasions Measured &gt; 6 Hours Apart With ≥1+ Proteinuria on Clean Catch Urine Dipstick, timeFrame - Time from randomization until delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00993031",
    "endpoint": "measure - Number of Participants With Maternal HIV RNA Suppression of &lt;400 Copies&#x2F;mL, description - Virologic suppression was defined as plasma HIV-1 RNA 400 copies&#x2F;ml or less based on the lower limit of detection of the available test., timeFrame - Time from randomization until delivery, an average of 20 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00993031",
    "endpoint": "measure - Change in Maternal CD4 Cell Counts, description - CD4 cell count recovery efavirenz at delivery, timeFrame - Time of randomization to delivery, an average of 20 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00993031",
    "endpoint": "measure - Number of Participants With Maternal to Child Transmission of HIV, Measured by Infant HIV DNA PCR, description - HIV tested by DNA PCR, timeFrame - Delivery to 48 weeks postpartum",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00993031",
    "endpoint": "measure - ART Levels in Hair Samples at Delivery, description - antiretroviral hair concentrations (per doubling), timeFrame - delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00993031",
    "endpoint": "measure - Number of Participants With Grade 3 or 4 Toxicity in the Two Treatment Groups in Women, description - , timeFrame - Randomization to one month postpartum",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01082705",
    "endpoint": "measure - Hematologic response to treatment measured as mean change in hemoglobin concentration from Day 0 to Day 42, description - , timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02671175",
    "endpoint": "measure - Readmission due to severe malaria (defined as any treatment with parenteral quinine or artesunate, or presence of severe anaemia and treatment with oral antimalarials) by 26 weeks from randomization, description - , timeFrame - 26 weeks from randomization",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02671175",
    "endpoint": "measure - All-cause readmission by 26 weeks from randomization, description - , timeFrame - 26 weeks from randomization",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02671175",
    "endpoint": "measure - Readmissions due to severe anaemia (defined as Haemoglobin (Hb) &lt;5g&#x2F;dL or packed-cell volume (PCV) &lt;15% or requirement for blood transfusion based on other clinical indication)by 26 weeks from randomization, description - , timeFrame - 26 weeks from randomization",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02671175",
    "endpoint": "measure - Readmission due to severe malarial anaemia (severe anaemia plus parenteral or oral antimalarial treatment)by 26 weeks from randomization, description - , timeFrame - 26 from randomization",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02671175",
    "endpoint": "measure - Readmission due to severe anaemia or severe malaria (composite outcome)by 26 weeks from randomization, description - , timeFrame - 26 weeks from randomization",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02671175",
    "endpoint": "measure - All-cause mortality by 26 weeks from randomization, description - , timeFrame - 26 weeks from randomization",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02671175",
    "endpoint": "measure - Clinic visits because of smear of rapid diagnostic test (RDT) confirmed non-severe malaria by 26 weeks from randomization, description - , timeFrame - 26 weeks from randomization",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02671175",
    "endpoint": "measure - Readmission due to severe malaria-specific anaemia (severe anaemia plus parenteral or oral antimalarial treatment and parasite density &gt;5000&#x2F;microlitre) by 26 weeks from randomization, description - , timeFrame - 26 weeks from randomization",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02671175",
    "endpoint": "measure - Readmission due to severe disease other than severe anaemia and severe malaria by 26 weeks from randomization, description - , timeFrame - 26 weeks from randomization",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02671175",
    "endpoint": "measure - Non-severe all-cause sick-child clinic visits by 26 weeks from randomization, description - , timeFrame - 26 weeks from randomization",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02671175",
    "endpoint": "measure - Non-malaria sick child clinic visits by 26 weeks from randomization, description - , timeFrame - 26 weeks from randomization",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02671175",
    "endpoint": "measure - Malaria infection at 6 month, description - , timeFrame - 6 month",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02671175",
    "endpoint": "measure - Hb at 6 months, description - , timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02671175",
    "endpoint": "measure - Any anaemia (Hb&lt;11 g&#x2F;dL), mild anaemia (Hb 8.0-10.99 g&#x2F;dl) moderate anaemia (Hb 5.0-7.99 g&#x2F;dL) and severe anaemia (Hb&lt;5 g&#x2F;dL) at 6 months, description - , timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02671175",
    "endpoint": "measure - Weight-for-age, height-for-age, and height-for-weight Z-scores, standard deviation (SD) scores of reference population) at 6 months, description - , timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02671175",
    "endpoint": "measure - Serious adverse events, excluding primary and secondary efficacy outcomes, by 26 weeks from randomization, description - , timeFrame - 26 weeks from randomization",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02671175",
    "endpoint": "measure - Serious adverse events within 7 days after the start of each course of PMC, excluding primary and secondary efficacy outcomes., description - , timeFrame - 26 weeks from randomization",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02671175",
    "endpoint": "measure - Adverse events by 26 weeks from randomization, description - , timeFrame - 26 weeks from randomization",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02671175",
    "endpoint": "measure - Adverse events within 7 days after start of each course of PMC., description - , timeFrame - 7 days post drug administration",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02671175",
    "endpoint": "measure - Corrected QT interval (QTc) prolongation measured by electro cardio gram (ECG)4-6 hours after 3rd dose of each course, description - , timeFrame - 4-6 hours after 3rd dose of each course",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02671175",
    "endpoint": "measure - Patients costs of receiving the intervention, description - , timeFrame - 26 weeks after randomization",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02671175",
    "endpoint": "measure - Patients costs related to treatment of the primary disease, readmission or death, description - , timeFrame - 26 weeks after randomization",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02671175",
    "endpoint": "measure - The costs of the health care system of providing the intervention, description - , timeFrame - 26 weeks after randomization",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02671175",
    "endpoint": "measure - The costs of the health system of treating the primary disease and anaemia, as well as treatment of readmissions or costs related to fatalities, description - , timeFrame - 26 weeks after randomization",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01084213",
    "endpoint": "measure - Prevalence of anaemia at the time of delivery or shortly afterwards., description - , timeFrame - 6 - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01084213",
    "endpoint": "measure - Prevalence of peripheral blood parasitaemia, description - , timeFrame - 6 - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01084213",
    "endpoint": "measure - Episodes of clinical malaria during the course of the pregnancy., description - , timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01084213",
    "endpoint": "measure - Serious adverse events in the mother., description - , timeFrame - 6 - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01084213",
    "endpoint": "measure - Adverse outcome of pregnancy - abortions, still births and neonatal deaths., description - , timeFrame - 6 - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01084213",
    "endpoint": "measure - Occurrence of congenital abnormalities., description - , timeFrame - 6 - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01084213",
    "endpoint": "measure - Feasibility and costs of each approach to the control of malaria in pregnancy., description - , timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01084213",
    "endpoint": "measure - Cost per cases of maternal anaemia (severe and non-severe) and peripheral malaria averted., description - , timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01084213",
    "endpoint": "measure - Acceptability of each approach by pregnant women and antenatal clinic staff., description - , timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02001012",
    "endpoint": "measure - Rates of recurrent infection &#x2F; treatment failure at day 42., description - , timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02001012",
    "endpoint": "measure - Occurrence of anaemia at day 28 when using AL vs. CQ., description - , timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02001012",
    "endpoint": "measure - P. knowlesi and gametocyte carriage throughout follow up when using AL vs. CQ., description - , timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02001012",
    "endpoint": "measure - Frequency of complications throughout follow up when using AL vs. CQ., description - , timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00978068",
    "endpoint": "measure - Percentage of Uncomplicated Malaria Episodes With Accompanying Adverse Events That Occurred in the 28 Days Following Antimalarial Therapy, description - The rates of adverse events, defined as severity grade 2 or higher that are possibly, probably or definitely related to study drugs over the course of the 28-day period after antimalarial therapy with artemether-lumefantrine (AL)., timeFrame - 28 days after antimalarial therapy",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00978068",
    "endpoint": "measure - Incidence-density of Malaria Defined as the Number of Incident Episodes of Complicated Malaria Per Time at Risk., description - , timeFrame - Time from randomization to at least 24 months of follow up or until end of the study",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00978068",
    "endpoint": "measure - Estimates of the 6-month Risk of a First Episode of Malaria, description - To assess the effect of ART independently of potential interactions with antimalarial therapy after treatment for malaria, we compared the two groups with respect to the time to the first episode of malaria.\nCumulative risk was estimated using the Kaplan-Meier product-limit formula., timeFrame - Enrollment to 6 months follow up",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00978068",
    "endpoint": "measure - 28-day Risk of Recurrent Parasitemia, description - To assess the effect of potential interactions between ART and artemether-lumefantrine, the risks of recurrent parasitemia at 28 days were compared between the two groups., timeFrame - 28 days after antimalarial therapy",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00978068",
    "endpoint": "measure - 63-day Risk of Recurrent Malaria, description - To assess the effect of potential interactions between ART and artemether-lumefantrine, the risks of recurrent malaria at 63 days were compared between the two groups., timeFrame - 28 days after antimalarial therapy",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02211729",
    "endpoint": "measure - macrolide resistant pneumococci carriage, description - , timeFrame - before administration of first dose of SMC and at the end of malaria transmission season in year 1, 2 and 3,",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02721420",
    "endpoint": "measure - Proportion of those with 60% uptake of PMC drugs during the 15 weeks of the study period., description - 60 % uptake is defined as administration of 6 or more [but less than 9] of the daily dosages out of the total of 9 during the 15 week study period., timeFrame - 15 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02721420",
    "endpoint": "measure - Proportion of those with 30 % uptake of PMC drugs during the 15 week trial period., description - 30 % PMC uptake is defined as administration of 3 or more [but less than 6] of the daily dosages out of the total of 9 during the 15 week trial period., timeFrame - 15 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02721420",
    "endpoint": "measure - Proportion of those with &lt;30% uptake of PMC drugs during the 15 week trial period., description - &lt;30 % PMC uptake is defined as administration of less than 3 of the daily dosages out of the total of 9 assessed during the 15 week trial period., timeFrame - 15 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02645513",
    "endpoint": "measure - Questionnaire measurement of diagnosis and treatment of pneumonia among outpatients, description - Patient exit interviews will be used to assess whether patients with surveyor-assessed pneumonia are prescribed the correct first-line antibiotic by health workers, timeFrame - 12 months after end of text messages",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02645513",
    "endpoint": "measure - Questionnaire measurement of diagnosis and treatment of diarrhea among outpatients, description - Patient exit interviews will be used to assess whether patients with surveyor-assessed diarrhea are prescribed the first-line diarrhea treatment by health workers., timeFrame - 12 months after end of text messages",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00499876",
    "endpoint": "measure - Measure the effect of malaria prophylaxis on malaria parasitaemia and haemoglobin levels in study patients, description - , timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00612547",
    "endpoint": "measure - To assess the Artesunate + Amodiaquine Fixed Dose Combination in term of effectiveness, tolerance, safety:; the reliability of the RDT; the real burden of the malaria in children under the age of five years in 2 different epidemiological strata., description - , timeFrame - one year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00432367",
    "endpoint": "measure - Prevalence of low birth weight (BW &lt; 2500g) at delivery or within 72 hours of delivery., description - , timeFrame - At delivery or within 72 hours of delivery.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00432367",
    "endpoint": "measure - Prevalence of maternal anaemia (Hb &lt; 11g&#x2F;dl) at 34 to 36 weeks of gestation., description - , timeFrame - At 34 to 36 weeks of gestation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00432367",
    "endpoint": "measure - Prevalence of placenta parasitaemia., description - , timeFrame - At delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00432367",
    "endpoint": "measure - Incidence of post-intervention malaria cases, description - , timeFrame - Anytime after enrolment and prior to delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00432367",
    "endpoint": "measure - Proportions of congenital anomalies in live births among the intervention groups stratified by gestation, gravidity, parity and age., description - , timeFrame - At delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00432367",
    "endpoint": "measure - Proportions of spontaneous abortions, intrauterine death, stillbirths, neonatal and maternal mortality and pre-term deliveries., description - , timeFrame - Anytime after enrolment and prior to delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00432367",
    "endpoint": "measure - Cost per severe maternal anaemia averted., description - , timeFrame - Anytime after enrolment and prior to delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00432367",
    "endpoint": "measure - Cost per (non-severe) maternal anaemia averted., description - , timeFrame - Anytime after enrolment and prior to delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00432367",
    "endpoint": "measure - Cost per peripheral malaria case averted., description - , timeFrame - Anytime after enrolment and prior to delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00432367",
    "endpoint": "measure - Cost per placental malaria averted., description - , timeFrame - At delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03697668",
    "endpoint": "measure - Frequency of residual parasitemia: % of patients with &gt;1000 parasites&#x2F; ul at day 3 and 28, description - Parasitemia is determined by assessing the parasite count in blood, using thin film, thick film and qPCR analysis., timeFrame - day 3 and day 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03697668",
    "endpoint": "measure - Frequency of fever and malaria symptoms, description - Percentage of patients with fever or malaria symptoms observed at Phisical Visit at day 3 and 28., timeFrame - day 3 and day 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03697668",
    "endpoint": "measure - Mean parasitemia in the control and investigational arms, description - Mean parasitemia by assessing the parasite count in blood, using thin film, thick film and qPCR analysis, expressed as parasites &#x2F; ul at day 2, 3 and 5 measured in the control and investigational arms, timeFrame - day 2 and day 5",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03697668",
    "endpoint": "measure - Parasite half-life measured at 12 and 24 hours, description - Mean parasite clearance half-life calculated using parasitemia measured at baseline, 12 and 24 hours post-treatment, timeFrame - from baseline to 24 hours post-treatment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05223933",
    "endpoint": "measure - percent of households visited every two weeks, description - percent of households visited every two weeks out of the number of the households registered in initial census, timeFrame - The event was assessed up to 30 weeks (15 biweekly visits).",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05223933",
    "endpoint": "measure - percent of households gave consent, description - percent of households that were visited every two weeks and gave consent for the screening during each visit, timeFrame - The event was assessed up to 30 weeks (15 biweekly visits).",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05223933",
    "endpoint": "measure - Fever incidence, description - percent of fever cases out of all individuals screened during each visit, timeFrame - The event was assessed up to 30 weeks (15 biweekly visits).",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05223933",
    "endpoint": "measure - Malaria incidence, description - percent of persons with positive RDT and fever cases out of all individuals screened during each visit, timeFrame - The event was assessed up to 30 weeks (15 biweekly visits).",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05223933",
    "endpoint": "measure - fever cases with RDT performed, description - percent of fever cases with RDT performed, timeFrame - The event was assessed up to 30 weeks (15 biweekly visits).",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05223933",
    "endpoint": "measure - RDT-positive persons treated with an ACT, description - percent of RDT-positive persons treated with an ACT during each visit, timeFrame - The event was assessed up to 30 weeks (15 biweekly visits).",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05223933",
    "endpoint": "measure - The change in the prevalence of anemia in women aged between 15 and 49 years old in the intervention versus control fokontany, description - Difference in differences (DiD) approach comparing baseline to endline is used to compare the prevalence of anemia in the 2 arms, timeFrame - an average of 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00902811",
    "endpoint": "measure - Early treatment failure, description - , timeFrame - Day 6",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00902811",
    "endpoint": "measure - Late treatment failure, description - , timeFrame - Day 63",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00902811",
    "endpoint": "measure - Adequate response, description - , timeFrame - Day 63",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03600844",
    "endpoint": "measure - IPTp1 Coverage, description - Proportion of women who have had a pregnancy that ended in the past 12 months and have received one or more doses of IPTp-SP, timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03600844",
    "endpoint": "measure - ANC 4 coverage, description - • Proportion of women who have had a pregnancy that ended in the past 12 months and have attended ANC clinics four times, timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03600844",
    "endpoint": "measure - ANC 1 Coverage, description - Proportion of women who have had a pregnancy that ended in the past 12 months and have attended ANC clinics at least once, timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03600844",
    "endpoint": "measure - Early ANC Coverage, description - Proportion of pregnant women attending the first ANC visit before or at week 14, timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03600844",
    "endpoint": "measure - C-IPTp Knowledge, description - Proportion of women who have had a pregnancy that ended in the past 12 months who know about the IPTp service provided by CHWs, timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07147400",
    "endpoint": "measure - To assess vaccine functional activity against transmission by DSF, description - Proportion reduction in proportion of infected mosquitoes (among those dissected), timeFrame - from 2 weeks to 24 weeks after completion of the primary vaccine course +&#x2F;- booster",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07147400",
    "endpoint": "measure - To assess vaccine functional activity against transmission by DSF, description - Proportion reduction in DSFs with at least one infected mosquito, timeFrame - from 2 weeks to 24 weeks after completion of the primary vaccine course +&#x2F;- booster",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07147400",
    "endpoint": "measure - humoral immunogenicity time trends and durability, description - Antibody responses to Pfs230D1, timeFrame - at baseline, 28 days after each dose and through study completion, at an average of 1 month",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07147400",
    "endpoint": "measure - humoral immunogenicity time trends and durability, description - Antibody responses to NANP, timeFrame - at baseline, 28 days after each dose and through study completion, at an average of 1 month",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07147400",
    "endpoint": "measure - To assess the protective efficacy against clinical malaria caused by Pf, description - Efficacy against clinical malaria as defined by: presence of asexual P. falciparum parasitemia &gt;0 parasites&#x2F;µL and&#x2F;or RDT positive with either an axillary temperature of ≥37.5 °C or one or more of the following symptoms: history of fever within the last 48 hours, headache, myalgia, arthralgia, malaise, nausea, dizziness, or abdominal pain, timeFrame - At 24 and 52 weeks after completion of the primary and booster vaccine course",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03508349",
    "endpoint": "measure - Prevalence of maternal anemia at delivery, description - comparison of prevalence of maternal anemia between women in intervention and control sites, timeFrame - at the time of delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03508349",
    "endpoint": "measure - Prevalence of low birth weight babies (&lt;37 weeks gestation), description - comparison of prevalence of LBW between women in intervention and control sites, timeFrame - at the time of delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03508349",
    "endpoint": "measure - Prevalence of preterm births, description - comparison of prevalence of preterm births between women in intervention and control sites, timeFrame - at the time of delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03508349",
    "endpoint": "measure - Episodes of clinical malaria during the course of the pregnancy, description - description of the number of episodes of malaria detected during antenatal care visits during pregnancy, timeFrame - assessed at the time of delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04158713",
    "endpoint": "measure - Efficacy of the intervention on the following listed secondary outcomes, description - <ol><li>Incidence of malaria infection</li><li>The individual components of the composite malaria infection endpoints</li><li>Incidence of clinical malaria.</li><li>Malaria infection at delivery</li><li>Placental malaria by histology (active, past, and active and past infections pooled)</li><li>Placental malaria by any measure</li><li>Maternal peripheral malaria infection at delivery by any measure</li><li>Placental inflammation or chorioamnionitis</li><li>Adverse pregnancy outcome: the composite of foetal loss (spontaneous abortion or stillbirth), or singleton live births born small-for-gestational-age (SGA), or with low birthweight (LBW), or preterm (PT) (SGA-LBW-PT), or subsequent neonatal death by day 28.</li><li>Composite of foetal loss and neonatal mortality.</li><li>SGA-LBW-PT composite.</li><li>The individual components of the above composites</li><li>Neonatal length and stunting.</li><li>Evidence of arboviral infections</li></ol>, timeFrame - The total duration of the trial is 24 months. Actual participant recruitment and follow up is expected to take up to 19 months (12 months recruitment plus 7 months of mother-infant follow-up until the child is 6 weeks old",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04158713",
    "endpoint": "measure - Safety: Cardiac safety, serious adverse events and MTCT of HIV, description - <ol><li>QTc-prolongation.</li><li>Congenital malformations.</li><li>Maternal mortality</li><li>Other SAEs and AEs.</li><li>Mother to child transmission of HIV</li></ol>, timeFrame - The total duration of the trial is 24 months. Actual participant recruitment and follow up is expected to take up to 19 months (12 months recruitment plus 7 months of mother-infant follow-up until the child is 6 weeks old",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04158713",
    "endpoint": "measure - Tolerance, description - <ol><li>History of vomiting study drug (&lt;30 min).</li><li>Dizziness.</li><li>Gastrointestinal complaints.</li></ol>, timeFrame - The total duration of the trial is 24 months. Actual participant recruitment and follow up is expected to take up to 19 months (12 months recruitment plus 7 months of mother-infant follow-up until the child is 6 weeks old",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04158713",
    "endpoint": "measure - Antimicrobial activity and resistance, description - Frequency of molecular markers of drug resistance in Plasmodium falciparum infections during pregnancy and delivery., timeFrame - The total duration of the trial is 24 months. Actual participant recruitment and follow up is expected to take up to 19 months (12 months recruitment plus 7 months of mother-infant follow-up until the child is 6 weeks old",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04158713",
    "endpoint": "measure - Pharmacokinetic parameters, description - Standard pharmacokinetic parameters for dolutegravir, piperaquine and CTX., timeFrame - The total duration of the trial is 24 months. Actual participant recruitment and follow up is expected to take up to 19 months (12 months recruitment plus 7 months of mother-infant follow-up until the child is 6 weeks old",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06468319",
    "endpoint": "measure - Number of neonatal deaths, description - Neonatal death as defined as early (≤7 days) or late (&gt;7 days ≤28 days) after delivery, timeFrame - Through study completion, an average of 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06468319",
    "endpoint": "measure - Incidence of low Birth Weight (LBW), description - LBW as defined as &lt;2.5 kg at birth, timeFrame - Through study completion, an average of 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06468319",
    "endpoint": "measure - Incidence of preterm birth, description - Preterm birth (≥28 to &lt;37 weeks), timeFrame - Through study completion, an average of 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06468319",
    "endpoint": "measure - Occurrence and description of malformations, description - Occurrence and description of malformations identified at delivery and within the first 6 months of life, timeFrame - Through study completion, an average of 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06468319",
    "endpoint": "measure - Occurrence of Small for Gestational Age (SGA), description - defined as newborns whose birth weight is &lt;10th percentile for gestational age as defined by INTERGROWTH-21st international standards, timeFrame - Through study completion, an average of 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06468319",
    "endpoint": "measure - Occurrence of malaria (symptomatic and asymptomatic) in neonates and infants, description - Detected by RDT and&#x2F;or blood smear and&#x2F;or PCR at birth and throughout first year of life defined as any parasitemia with or without malaria symptoms, timeFrame - Through study completion, an average of 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06468319",
    "endpoint": "measure - Occurrence of anemia during infancy at 6 and 12 months of age, description - Anemia during infancy as defined by age of testing, timeFrame - Through study completion, an average of 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06468319",
    "endpoint": "measure - Occurrence of neonatal&#x2F;infant&#x2F;pediatric adverse outcomes, description - Description and reporting of occurrence of neonatal&#x2F;infant&#x2F;pediatric adverse outcomes, timeFrame - Through study completion, an average of 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06468319",
    "endpoint": "measure - Timing of receipt of routine vaccinations, description - Reporting and timing of receipt of routine vaccinations, including malaria vaccines, and other standard of care anti-malarial treatment, timeFrame - Through study completion, an average of 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03431714",
    "endpoint": "measure - PCR corrected responses, description - Proportions of patients with 100% cure after PCR correction, timeFrame - one months after study completion",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07269314",
    "endpoint": "measure - Malaria PCR test, description - Secondary endpoint will be the comparison of the concentration of P. falciparum DNA in blood samples (measured by qPCR) according to parasitemia (&gt;5% vs &lt;5%)., timeFrame - From genuary 2025 to september 2026",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00852423",
    "endpoint": "measure - Time to failure, description - , timeFrame - Case by case",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00852423",
    "endpoint": "measure - PCR unadjusted treatment failure, description - , timeFrame - Day 63",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00852423",
    "endpoint": "measure - Gametocyte carriage (gametocyte-weeks), description - , timeFrame - Case by case",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00852423",
    "endpoint": "measure - Asexual parasite clearance time, description - , timeFrame - Days to 2 consecutive negative blood slides.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00852423",
    "endpoint": "measure - Gametocytaemia (prevalence and density), description - , timeFrame - Day 7, 14, 21, 28 and 63 after treatment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00852423",
    "endpoint": "measure - Haemoglobin changes, description - , timeFrame - Days 14, 28, 42 and 63",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00852423",
    "endpoint": "measure - The presence of acute, chronic or past infection of the placenta (prevalence), description - , timeFrame - Delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00852423",
    "endpoint": "measure - Mean birth weight and prevalence of low birth weight newborns, description - , timeFrame - Delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00852423",
    "endpoint": "measure - In vitro vitro and search of molecular markers related to drug resistance, description - , timeFrame - At the time of recurrent infection",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00852423",
    "endpoint": "measure - Determination of the PK profile of MQ, AQ and PQ (on 120 women&#x2F;treatment), description - , timeFrame - Case by case",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06507605",
    "endpoint": "measure - Anti-NANP IgG antibodies, description - Comparison of anti-NANP IgG antibodies, timeFrame - at 2 weeks post dose 3 in all treatment arms",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06507605",
    "endpoint": "measure - Anti-Pfs230D1 IgG antibodies, description - Comparison of Anti-Pfs230D1 IgG antibodies, timeFrame - at 2 weeks post dose 3 in all treatment arms",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00719602",
    "endpoint": "measure - Time of initiation of treatment for clinical malaria requiring conventional anti-malarial therapy, description - , timeFrame - Throughout study",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00719602",
    "endpoint": "measure - Severity of malarial disease, description - , timeFrame - Throughout study",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00719602",
    "endpoint": "measure - Measured anti-malaria IgG, protein in plasma, and mRNA transcripts in PBMC of chemokines, description - , timeFrame - Throughout study",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00719602",
    "endpoint": "measure - IL4-589C&#x2F;T genotypes, description - , timeFrame - Throughout study",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00440752",
    "endpoint": "measure - Parasitological failure occurring at day 3, 7, 14, 21, 28 or any other day during this period., description - , timeFrame - within 28 days of subject recruitment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00440752",
    "endpoint": "measure - Gametocyte development detected by reverse transcriptase PCR on day 0, 3, 14 and 28, description - , timeFrame - 2008 to 2009",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02909712",
    "endpoint": "measure - Proportion of pregnant women treated with DHA-PQP&#x2F;SP with and without asymptomatic parasitaemia who experienced clinical symptoms that could be related with a cardiac arrhythmia., description - Clinical assessment, timeFrame - Measured on day 28 post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02909712",
    "endpoint": "measure - Mean QTcF&#x2F;QTcB change from baseline and proportion of pregnant women treated with SP who experience changes in QT, QTcF and QTcB measurements from Day 0 pre-dose to Day 7, description - Electrocardiography, timeFrame - Measured on day 7 post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02909712",
    "endpoint": "measure - Comparative analysis of the QT changes from Day 0 pre-dose to Day 7 post first dosing in pregnant women given DHA-PQP versus SP, description - Electrocardiography, timeFrame - Measured on day 7 post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02909712",
    "endpoint": "measure - Analysis of values and changes from baseline for the other electrocardiogram (ECG) parameters (RR, HR, PR, QRS) in pregnant women given DHA-PQP or SP, description - Electrocardiography, timeFrame - Measured on day 7 post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02909712",
    "endpoint": "measure - Adequate Parasitological Responses (APR) at Days 7, 14, 21 and 28 post-dose, PCR-Corrected and uncorrected, description - Efficacy, timeFrame - Measured on day 28 post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02909712",
    "endpoint": "measure - Proportion of participants in Groups 1-4 with parasites at Days 0, 7, 14, 21 and 28 that carry the 581G and&#x2F;or K540E mutations associated with SP resistance, description - Parasite resistance, timeFrame - Measured on days 28 post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06915285",
    "endpoint": "measure - Positive Predictive Value (PPV) and Negative Predictive Value (NPV) of ASPIRE to Detect Malarial Retinopathy in Eyes of the Subjects Clinically Diagnosed With CM, description - Secondary endpoints include positive predictive value (PPV) and negative predictive value (NPV) of ASPIRE to detect malarial retinopathy in eyes of the subjects clinically diagnosed with CM, when compared against the reference standard., timeFrame - Through the study completion, an average of 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03376217",
    "endpoint": "measure - IPTp doses received, description - Proportion of women who received 1, 2, or 4 or more dose of IPT, timeFrame - through study completion, 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03376217",
    "endpoint": "measure - IPTp doses delivered by ANC, description - Proportion of doses delivered by the HSA vs at the ANC, timeFrame - through study completion, 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03376217",
    "endpoint": "measure - Total ANC visits, description - proportion of women who made 1, 2, 3, 4, or more ANC visits, timeFrame - through study completion, 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03376217",
    "endpoint": "measure - Gestational age at first IPTp, description - gestational age at the time of first ANC and at 1st dose of IPTp, timeFrame - through study completion, 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03813108",
    "endpoint": "measure - Time to Parasitemia, description - The effectiveness of CPS-immunization with NF135 sporozoites to protect against malaria challenge infection with homologous N135.C10 or heterologous NF54 sporozoites will be determined by the time to parasitemia in immunized versus non-immunized volunteers after the challenge infection., timeFrame - Day 1 - 28 after malaria challenge infection (28 days)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00421473",
    "endpoint": "measure - Blood will be taken for genotyping of CYP2C19 at study day 1., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00421473",
    "endpoint": "measure - HIV-1 RNA and CD4 determination will be done (HIV patients only) at inclusion screening, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01407887",
    "endpoint": "measure - P. falciparum gametocyte prevalence and density, description - P. falciparum gametocyte prevalence and density on day 1, 2, 3, 7, and 28 of follow-up (PCR determination) P. falciparum gametocyte prevalence and density on day 1, 2, 3, 7, and 28 of follow-up (microscopic determination), timeFrame - day 1, 2, 3, 7, and 28 of follow-up",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00259142",
    "endpoint": "measure - See detailed description, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00116766",
    "endpoint": "measure - Reduced human biting by mosquitoes, description - , timeFrame - per night over 45 nights",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02448745",
    "endpoint": "measure - Hemoglobin, description - Hemoglobin measured by Hemocue 301, timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02448745",
    "endpoint": "measure - Fever, description - Number of participants with Fever, defined as tympanic temperature above 37.5C, timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02448745",
    "endpoint": "measure - Mosquito biting rate., description - Mosquitoes trapped indoors and outdoors using light traps and exit traps., timeFrame - 2 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00673166",
    "endpoint": "measure - Parent&#x27;s perception of the quality of care received, description - , timeFrame - One year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06769815",
    "endpoint": "measure - Assess the impact of malaria co-infections on mortality, description - Number of deaths in children under 5 with malaria co-infection, timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06769815",
    "endpoint": "measure - Identify the underlying immunological mechanisms mediating malaria co-infections, description - Concentration of cytokines IL6, IL1β and TNFα and IL 10 in children under 5 years of age, timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06769815",
    "endpoint": "measure - Identify epigenetic and transcriptomic modifications in infant, maternal and placental blood cells mediating malaria co-infections, description - Expression level of transcripts according to the populations studied will be measured by RNA-seq, timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06769815",
    "endpoint": "measure - Identify molecules associated with epigenetic modifications (metabolome, proteome)., description - Expression level of proteins and metabolites according to the populations studied will be measured by RNA-seq, timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06769815",
    "endpoint": "measure - Identify determinants of malaria co-infections and severe bacterial infections., description - The number of malaria co-infection events associated with severe bacterial infection in febrile children under 5 years of age., timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02669823",
    "endpoint": "measure - • Diagnostic performance of the Sysmex XN analyser to diagnose malaria compared to malaria rapid diagnostic test, description - Malaria parasitemia is defined as the presence of one or more parasites in malaria microscopy or a malaria qPCR 18S result over 50 p&#x2F;ml, timeFrame - 1 year based on frozen specimens",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02669823",
    "endpoint": "measure - • Diagnostic sensitivity and specificity of Sysmex XN analyser to diagnose viral infections or non-bacteremic bacterial infections with or without malaria, description - <p>In participants of 5 years and older.\nPerformance will be tested before and after training the algorithm.</p><p>For description of case definitions, please see detailed description</p>, timeFrame - 1 year based on frozen specimens",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02669823",
    "endpoint": "measure - • Comparison of diagnostic performance of Sysmex XN analyser compared with C-reactive protein and procalcitonin in diagnosing malaria with or without co-infections, bacterial and viral infections., description - Performance will be tested before and after training the algorithm.\nFor description of case definitions, please see detailed description, timeFrame - 1 year based on frozen specimens",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02669823",
    "endpoint": "measure - • To develop and optimize an algorithm to diagnose viral and bacterial infection in children below 5 years of age., description - The data will be used to train an algorithm.\nFor description of case definitions, please see detailed description, timeFrame - 1 year based on frozen specimens",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05879224",
    "endpoint": "measure - The proportion of patients with any AESI during treatment, description - AESIs are collected during clinical review using a study-specific questionnaire, timeFrame - During treatment (up to 8 weeks)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05879224",
    "endpoint": "measure - The proportion of patients with a gastrointestinal (GI) AESI during treatment, description - AESIs are collected during clinical review using a study-specific questionnaire, timeFrame - During treatment (up to 8 weeks)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05879224",
    "endpoint": "measure - The proportion of patients with an AESI related to haemolysis during treatment, description - AESIs are collected during clinical review using a study-specific questionnaire, timeFrame - During treatment (up to 8 weeks) ]",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05879224",
    "endpoint": "measure - The proportion of patients an AESI related to methaemoglobinaemia, description - AESIs are collected during clinical review using a study-specific questionnaire, timeFrame - During treatment (up to 8 weeks)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05879224",
    "endpoint": "measure - Proportion of patients permanently stopping PQ before end of treatment, description - Discontinuation of PQ will be assessed using a study-specific questionnaire, timeFrame - During treatment (up to 8 weeks)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05879224",
    "endpoint": "measure - The proportion of patients receiving correct treatment based on G6PD activity, description - This will be assessed by linking patients G6PD activity results measured during study enrolment with primaquine dose prescribed on the same day, timeFrame - 1 day",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05879224",
    "endpoint": "measure - Proportion of patients who were reviewed on Day 3 and Day 7, description - This will be assessed by linking patients enrolment data with Day 3 and Day 7clinical review data, timeFrame - 1 week",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05879224",
    "endpoint": "measure - Perception of and experience with new radical cure tools among health care providers and community members, description - This will be assessed using stakeholder interviews, timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05879224",
    "endpoint": "measure - Proportion of health care practitioners who comply with the revised radical cure treatment algorithm, description - The outcome will be assessed from patients&#x27; enrolment data, timeFrame - 1 day",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05879224",
    "endpoint": "measure - Proportion of patients receiving a SD Biosensor G6PD test, description - The outcome will be assessed from patients&#x27; enrolment data, timeFrame - 1 day",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05879224",
    "endpoint": "measure - Proportion of eligible P. vivax malaria patients receiving the correct dose of primaquine based on the result of the G6PD test, description - The outcome will be assessed from patients&#x27; enrolment data, timeFrame - 1 day",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05879224",
    "endpoint": "measure - Proportion of P. vivax malaria patients who are ineligible for daily primaquine and are incorrectly given primaquine (including infants, pregnant females and G6PD deficient patients, description - The outcome will be assessed from patients&#x27; enrolment data, timeFrame - 1 day",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05879224",
    "endpoint": "measure - Proportion of P. vivax malaria patients that are reviewed on Day 3, description - This will be assessed by linking patients&#x27; enrolment data with clinical review data, timeFrame - 3 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05879224",
    "endpoint": "measure - Proportion of P. vivax malaria patients that adhere to their prescribed primaquine regimen, description - This will be assessed by linking patients&#x27; enrolment data with clinical review data, timeFrame - 3 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05879224",
    "endpoint": "measure - Factors influencing acceptability and feasibility of the new radical cure tools among health care providers are identified, description - This will be assessed using stakeholder interviews, observations and focus groups, timeFrame - 3 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05879224",
    "endpoint": "measure - Barriers and enablers of uptake and implementation at the sub-national levels are identified, description - This will be assessed using stakeholder interviews and focus groups, timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05879224",
    "endpoint": "measure - Factors influencing compliance with G6PD testing and perceptions of new drug regimens and serious adverse events among health care providers are identified, description - This will be assessed using stakeholder interviews and focus groups, timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05879224",
    "endpoint": "measure - Required knowledge, skills, and training to administer the revised case management and patient-counselling identified, description - This will be assessed using stakeholder interviews and focus groups, timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05879224",
    "endpoint": "measure - Factors influencing the barriers and facilitators to patient adherence to primaquine after the rollout of the revised case management identified, description - This will be assessed using stakeholder interviews and focus groups, timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05879224",
    "endpoint": "measure - Factors influencing the acceptability and feasibility of community-based clinical review at Day 3 of primaquine treatment identified, description - This will be assessed using stakeholder interviews and focus groups, timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05879224",
    "endpoint": "measure - Perceptions of the new radical cure tools and serious adverse events at the community level identified, description - This will be assessed using stakeholder interviews and focus groups, timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05879224",
    "endpoint": "measure - Local acceptability of the revised case management algorithms among patients, their families, and healthcare workers established, description - This will be assessed using stakeholder interviews and focus groups, timeFrame - Day 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05879224",
    "endpoint": "measure - The monthly incidence of confirmed symptomatic P. vivax malaria episodes (mono-infection or mixed) before implementation versus after implementation, description - This will be assessed by comparing facility surveillance data before implementation with facility surveillance data after implementation, timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05879224",
    "endpoint": "measure - The prevalence of P. vivax parasitaemia in patients presenting with fever before implementation versus after implementation, description - This will be assessed by comparing cross-sectional data on n=200 patients (per facility) collected before implementation to the prevalence collected in n=200patients (per facility) after implementation, timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05879224",
    "endpoint": "measure - Cumulative risk of representation to the same clinic with symptomatic P. vivax malaria within 6 months, description - This will be assessed by linking patients&#x27; enrolment data, timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05879224",
    "endpoint": "measure - Costs of implementing policy from a healthcare provider perspective, including health systems strengthening processes, description - This will be assessed from health system data collected throughout the study, timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05879224",
    "endpoint": "measure - Household costs per P. vivax episode, description - This will be assessed from a household cost survey on a subset of patients, timeFrame - 3 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05879224",
    "endpoint": "measure - Overall cost-effectiveness of changing policy if revised case management is effective, description - This will be assessed from health system data collected throughout the study, timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05879224",
    "endpoint": "measure - Cost per episode of P. vivax malaria from the healthcare provider and societal perspectives, description - This will be assessed from health system data collected throughout the study, timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05879224",
    "endpoint": "measure - Cost per component of the revised case management package, description - This will be assessed from health system data collected throughout the study, timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05879224",
    "endpoint": "measure - If revised case management package is effective (significantly reduces the incidence of malaria), then the cost-effectiveness of implementing the revised case management as compared with usual care, description - This will be assessed from health system data collected throughout the study, timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05879224",
    "endpoint": "measure - Proportion of CHWs who correctly act on early signs of haemolytic anaemia and GI events (i.e. refer patients for further medical review, instruct patient to discontinue treatment), description - This will be assessed from clinical review data and study-specific questionnaire, timeFrame - 3 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05879224",
    "endpoint": "measure - Number of patients with an SAE who are identified by community or clinic staff follow-up and referred to hospital for further management, description - This will be assessed by linking clinical review data, study specific questionnaire and SAE form, timeFrame - During treatment (up to 8 weeks)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05879224",
    "endpoint": "measure - The proportion of patients eligible to receive PQ who had a SAE during treatment, description - This will be assessed by linking enrolment data, clinical review, study specific questionnaire and SAE form, timeFrame - During treatment (up to 8 weeks)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05879224",
    "endpoint": "measure - Prevalence of severe anaemia in patients presenting with fever before and after implementation, description - This will be assessed by comparing the facility surveillance data before implementation with facility surveillance data after implementation, timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00152204",
    "endpoint": "measure - Prevalence of P falciparum parasitemia in children aged 2-11 months., description - , timeFrame - First year of life",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00152204",
    "endpoint": "measure - Prevalence of anaemia (Hb&lt;11 g&#x2F;dL) in children aged 2-11 months., description - , timeFrame - First year of life",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00152204",
    "endpoint": "measure - Period prevalence of fever without cough or diarrhoea (in preceding 2 weeks) in children aged 2-11 months., description - , timeFrame - First year of life",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06225700",
    "endpoint": "measure - Performance of LM, description - Point estimates of clinical performance characteristics with 95% confidence intervals (sensitivity, specificity, NPV, PPV, and DOR) of light microscopy using nPCR as reference for detecting malaria in patients with symptoms suggestive of malaria, timeFrame - 3 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06225700",
    "endpoint": "measure - Performance of comparator RDT, description - Point estimates of clinical performance characteristics with 95% confidence intervals (sensitivity, specificity, NPV, PPV, and DOR) of the comparator tests using nPCR as reference for detecting malaria in patients with symptoms suggestive of malaria, timeFrame - 3 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06225700",
    "endpoint": "measure - Comparison between nPOC [Truenat® Malaria Pv&#x2F;Pf; Truenat® Malaria Pv&#x2F;Pf Hi-Sens; Humasis Hs-Malaria P.f&#x2F;Pan test, Hemozoin Imager] and LM, description - Comparison between the clinical performance of nPOC and light microscopy, timeFrame - 3 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06225700",
    "endpoint": "measure - Comparison between Hemozoin Imager and comparator RDT, description - <p>Comparison between the clinical performance of between the clinical performance of Hemozoin Imager and comparator rapid diagnostic test [SD Bioline Combo&#x2F; First Response].</p><p>The percentage difference between the clinical performance characteristics of nPOC and comparator RDT with 95% confidence intervals using Tango&#x27;s score method.</p>, timeFrame - 3 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06225700",
    "endpoint": "measure - Comparison of Truenat Pv&#x2F;Pf and Truenat Pv&#x2F;Pf High-Sens, description - <p>Comparison between clinical performance of Truenat® Pv&#x2F;Pf and Truenat® Pv&#x2F;Pf Hi-Sens.</p><p>The percentage difference between the clinical performance characteristics of Truenat® Pv&#x2F;Pf and Truenat® Pv&#x2F;Pf Hi-Sens with 95% confidence intervals using Tango&#x27;s score method.</p>, timeFrame - 3 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06225700",
    "endpoint": "measure - Comparison between Truenat Pv&#x2F;Pf and Truenat Pv&#x2F;Pf High-Sens and Realstar, description - <p>Comparison between the clinical performance of Truenat® Pv&#x2F;Pf and Truenat® Pv&#x2F;Pf Hi-Sens with that of RealStar® Malaria Screen &amp; Type PCR Kit 1.0.</p><p>The percentage difference between the clinical performance characteristics of the Truenat® tests (Truenat® Pv&#x2F;Pf and Truenat® Pv&#x2F;Pf Hi-Sens) and RealStar® Malaria Screen &amp; Type PCR Kit 1.0 with 95% confidence intervals using Tango&#x27;s score method.</p>, timeFrame - 3 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06225700",
    "endpoint": "measure - Foot odour collection, description - The number of volatile organic compound (foot odour samples) from Plasmodium positive and negative febrile patients that have been collected., timeFrame - 3 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03610399",
    "endpoint": "measure - Participants With Adequate Clinical and Parasitologic Response Based on Microsatellite-corrected Analysis Per Protocol Day 168, description - Participants with microsatellite-corrected adequate clinical and parasitologic response among patients enrolled, meaning patients who did not fail treatment by day 168.\nThose are participants who at day 168 did not present clinical deterioration or presence of parasitemia with homologous (same genotype) parasites., timeFrame - 168 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04800055",
    "endpoint": "measure - Time to first infection, description - Time to first infection measured among the cohort and defined as the time to first PCR infection among participants aged ≥12 months and &lt;15 years of age., timeFrame - Seasonal (6 months)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04800055",
    "endpoint": "measure - Prevalence, detected by PCR, description - Prevalence of malaria infection measured by the cross-sectional household survey among participants aged ≥6 and older, detected by PCR., timeFrame - 6 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04800055",
    "endpoint": "measure - Prevalence, detected by RDT, description - Prevalence of malaria infection measured by the cross-sectional household survey among participants aged ≥6 and older, detected by RDT (patent infection)., timeFrame - 6 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04800055",
    "endpoint": "measure - Incidence rate of passively reported clinical malaria, description - Incidence rate of clinical malaria among participants of all ages, defined as the number of malaria confirmed cases (by RDT or microscopy) per 1,000 population per year, using routine data from health facilities linked to study clusters (i.e. by name of village of residence) and cluster population sizes for the denominator., timeFrame - Seasonal (6 months)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01640587",
    "endpoint": "measure - PCR adjusted adequate clinical and parasitological response, description - Day 42 PCR adjusted adequate clinical and parasitological response (ACPR) in both DP3 arm and MAS3 arm, timeFrame - Day 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01640587",
    "endpoint": "measure - Proportion of aparasitaemic, description - Proportion of aparasitaemic patients on day 3 in both DP3 arm and MAS3 arm, timeFrame - Day 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04319380",
    "endpoint": "measure - Clinical Episodes of Uncomplicated Febrile Illness, description - Passive and active surveillance to detect cases with temperature &gt; 37.5o C), or a history of fever within the past 48 hours, with a positive blood film (any level of asexual parasitaemia) or a positive rapid diagnostic test (RDT) for malaria, timeFrame - Passive surveillance in all health centers within the study area starting 1 April 2020 until 31 March 2022.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04319380",
    "endpoint": "measure - Hospital Admissions With Malaria, Including Severe Malaria, description - Hospital admissions with malaria, including cases of severe malaria which meet WHO criteria for a diagnosis of severe malaria., timeFrame - Through study completion, each child admitted in a study hospital will be treated and monitored until complete cure or death (a period of 2 years). Documentation of each hospital admission according to ICH-GCP",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04319380",
    "endpoint": "measure - Prevalence of Malaria Parasitaemia, Including Gametocytaemia and the Prevalence of Moderate and Severe Anemia and Malnutrition, description - The prevalence of malaria parasitaemia, including gametocytaemia, moderate and severe anaemia and malnutrition at the end of the malaria transmission season, timeFrame - Blood sample collection during 2-week cross sectional survey at the end of each malaria transmission season (November 2020&#x2F;21).).",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04319380",
    "endpoint": "measure - Serious Adverse Events (SAEs), description - Serious adverse events (SAEs), including any deaths, occurring at any time during the study with special reference to any cases of meningitis and cerebral malaria (WHO case definition), timeFrame - Through study completion (for 2 years), each SAE will be treated and documented according to ICH-GCP.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04319380",
    "endpoint": "measure - Immune Response to the Vaccine (Anti-CSP Antibody Concentrations), description - Anti-CSP antibody concentrations obtained before and after each booster dose, determined in a sub-sample of children., timeFrame - Blood sample collection 0-7 days before and one month after the booster doses (year 1 and 2).",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04319380",
    "endpoint": "measure - Prevalence of Malaria Parasitaemia in School Aged Children, description - The prevalence of malaria parasitaemia at the end of each malaria transmission season in school-age children resident in the study areas, to determine overall malaria transmission, timeFrame - Blood sample collection during the 2-week cross sectional survey at the end of each malaria transmission season (November 2020&#x2F;21).",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04319380",
    "endpoint": "measure - Polymorphisms in the P. Falciparum CSP, description - The prevalence of mutations in the Th2 or Th3 locus of the Plasmodium falciparum csp gene in isolates from children who have received RTS,S&#x2F;AS01 that differ from those of the isolate used in the preparation of the vaccine, timeFrame - Blood sample collection from children with clinical episodes of malaria and in children with parasitaemia at the 2-week cross-sectional survey (November 2020&#x2F;21)).",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04319380",
    "endpoint": "measure - Drug Resistance to SP and AQ, description - The presence of molecular markers of resistance to SP and AQ in parasite positive samples, timeFrame - Blood sample collection during the final 2-week cross sectional survey conducted at the end of malaria transmission season (November 2021)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04319380",
    "endpoint": "measure - SP+AQ Drug Sensitivity, description - The 28-day treatment outcome in children with asymptomatic malaria parasitaemia treated with SP+AQ., timeFrame - Children with asymptomatic malaria parasitaemia identified during the final cross-sectional survey (November 2021), treated with a full course of SP+AQ over 3 days and followed for 28 days.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00289250",
    "endpoint": "measure - Presence of gametocytes 56 days after treatment, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00289250",
    "endpoint": "measure - Asexual parasitaemia 14 days after treatment, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00730366",
    "endpoint": "measure - Anemia, description - , timeFrame - At 32 weeks gestation and at delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00730366",
    "endpoint": "measure - Peripheral and placental parasitaemia, description - , timeFrame - At 32 weeks gestation (peripheral) and at delivery (both)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00730366",
    "endpoint": "measure - Gestational age, description - , timeFrame - At first antenatal visit",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04009343",
    "endpoint": "measure - Elimination half-life of the gametocyte concentration-time curve, description - Alternative PD outcome of gametocyte dynamics, timeFrame - 72 hours up to 9 weeks for those with persistent gametocytemia",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04009343",
    "endpoint": "measure - Change over time of the gametocyte sex ratio (female:male), description - The ratio of female and male gametocytes over time during treatment is a hypothesized marker of transmissibility, timeFrame - 72 hours up to 9 weeks for those with persistent, emergent, or recurrent gametocytes",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04009343",
    "endpoint": "measure - Elimination half-life of the asexual parasite concentration-time curve, description - In addition to gametocyte dynamics, asexual parasite dynamics and how they relate to PK parameters and other covariates with also be examined, timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04009343",
    "endpoint": "measure - Allele frequency of genetic markers of parasite drug resistance in initial vs. recurrent parasites and fast vs. slow clearing parasites, description - Relative barriers to drug resistance of AL and DP will be tested using known and newly described parasite genetic markers of resistance and association with phenotypic susceptibility, timeFrame - 9 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04009343",
    "endpoint": "measure - Incidence of treatment-emergent adverse events (safety and tolerability), description - We will assess adverse events and serious adverse events associated with the study drugs in accordance with the WHO Toxicity Grading Scale for Determining the Severity of Adverse Events, timeFrame - 9 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03143218",
    "endpoint": "measure - Clinical Episodes of Uncomplicated Febrile Illness, description - Passive and active surveillance to detect cases with temperature &gt; 37.5o C), or a history of fever within the past 48 hours, with a positive blood film (any level of asexual parasitaemia) or a positive rapid diagnostic test (RDT) for malaria, timeFrame - Passive surveillance in all health centers within the study area, active surveillance in a sub set of study children starting July 2017 till April 2020.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03143218",
    "endpoint": "measure - Hospital Admissions With Malaria, Including Severe Malaria, description - Hospital admissions with malaria, including cases of severe malaria which meet WHO criteria for a diagnosis of severe malaria., timeFrame - Through study completion (30 months), each child admitted in a study hospital will be treated and monitored until complete cure or death (a period of 3 years). Documentation of each hospital admission according to ICH-GCP.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03143218",
    "endpoint": "measure - Prevalence of Malaria Infection Not Severe Enough to Warrant a Clinic Visit, description - Active surveillance of malaria at household level to assess the prevalence of malaria infection not severe enough to warrant a clinic visit detected in a subset of randomly selected children., timeFrame - Weekly home visits through study completion from July 2017 - April 2020 to screen study children for malaria.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03143218",
    "endpoint": "measure - Prevalence of Malaria Parasitaemia, Including Gametocytaemia and the Prevalence of Moderate and Severe Anemia and Malnutrition, description - The prevalence of malaria parasitaemia, including gametocytaemia, moderate and severe anaemia and malnutrition at the end of the malaria transmission season, timeFrame - Blood sample collection during 2-week cross sectional survey at the end of each malaria transmission season.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03143218",
    "endpoint": "measure - Serious Adverse Events (SAEs), description - Serious adverse events (SAEs), including any deaths, occurring at any time during the study with special reference to any cases of meningitis and cerebral malaria (WHO case definition), timeFrame - Through study completion (for 30 months), each SAE will be treated and documented according to ICH-GCP.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03143218",
    "endpoint": "measure - Immune Response to the Vaccine (Anti-CSP Antibody Concentrations), description - After priming and after each booster dose, determined in a sub-sample of children, timeFrame - Blood sample collection prior to 1st dose of vaccine and 1 month after 3rd dose of the primary series of vaccination. In years 2 and 3 blood will be collected before the booster dose and 1 month after administration of the 4th (and 5th) vaccine dose.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03143218",
    "endpoint": "measure - Drug Resistance to SP and AQ, description - The presence of molecular markers of resistance to SP and AQ in parasite positive samples, timeFrame - Blood sample collection during the 2-week cross sectional survey conducted at the end of malaria transmission season in 2019.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03143218",
    "endpoint": "measure - Prevalence of Malaria Parasitaemia in School Aged Children, description - The prevalence of malaria parasitaemia at the end of the malaria transmission season in school-age children resident in the study areas, to determine overall malaria transmission, timeFrame - Blood sample collection during the 2-week cross sectional survey at the end of the malaria transmission season in Year 2 and 3 (November 2018&#x2F;19).",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03143218",
    "endpoint": "measure - SP+AQ Drug Sensitivity, description - The 28-day treatment outcome in children with asymptomatic malaria parasitaemia treated with SP+AQ., timeFrame - Children with asymptomatic malaria parasitaemia identified during the final cross-sectional survey (November 2019), treated with a full course of SP+AQ over 3 days and followed for 28 days.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01728961",
    "endpoint": "measure - HIV-1 Viral Load, description - Dried Blood Spot (DBS) samples will be collected on all study subjects for HIV-1 viral load measurement., timeFrame - At study entry and study days 8, 14, and 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01728961",
    "endpoint": "measure - NVP resistance, description - Dried Blood Spot (DBS) samples will be collected on all subjects.\nDrug resistance testing will only be performed on subjects who show changes in viral load pattern between study entry and study day 42., timeFrame - At study entry and study day 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01619878",
    "endpoint": "measure - Polymerase Chain Reaction (PCR) Corrected Parasitological Cure Rate at Day 14 and 42, description - Number of participants with clearance of asexual parasites by day 7 after initiating study treatment without recrudescence at day 14 and day 42, corrected for re-infection by Polymerase Chain Reaction (PCR) assay., timeFrame - Day 14 and 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01619878",
    "endpoint": "measure - Number of Participants With Parasitological Uncorrected Cure Rate at Day 3, 7, 14, 28 and 42, description - Number of patients with clearance of asexual parasites at day 3, 7, 14, 28 and 42 after initiating study treatment., timeFrame - Day 3, 7, 14, 28 and 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01619878",
    "endpoint": "measure - Percent Change of Parasite Count From Baseline at 24 Hours, description - Percent change of parasite count from baseline at 24 hours, timeFrame - baseline, 24 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01619878",
    "endpoint": "measure - Number of Participants With Parasitaemia at 48 Hours After Treatment Initiation Greater Than at Baseline, description - Number of participants with parasite density at 48 hours after treatment initiation greater than parasite density at baseline., timeFrame - 48 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01619878",
    "endpoint": "measure - Number of Participants With Parasitaemia at 72 Hours After Treatment Initiation Greater Than or Equal to 25 Percent of Count at Baseline, description - Number of participants with parasite density at 72 hours after treatment initiation greater than or equal to 25 percent of parasite density at baseline., timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01619878",
    "endpoint": "measure - Time to Parasite Clearance (PCT), description - Time from first dose until first total and continued disappearance of asexual parasite forms which remains at least a further 48 hours., timeFrame - Up to 7 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01619878",
    "endpoint": "measure - Time to Fever Clearance (FCT), description - Time from first dose to the first time the axillary body temperature decreased below and remained below 37.5° C for at least 48 hours., timeFrame - Up to 7 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01619878",
    "endpoint": "measure - Time to Gametocyte Clearance (GCT), description - Time from first dose until first total and continued disappearance of gametocytes which remains at least a further 48 hours., timeFrame - Up to 7 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06601712",
    "endpoint": "measure - Number of children readmitted to hospital from all-cause and malaria-specific by the end of week 14 post-discharge, description - Incidence of all-cause and malaria-specific readmissions by the end of week 14 after discharge, i.e. the number of children readmitted for malaria by the end of week 14 after discharge out of the total sample size., timeFrame - 14 weeks post discharge",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06601712",
    "endpoint": "measure - Number of sick-child clinic visits from all-cause and malaria-specific by the end of week 14 post-discharge, description - Proportion of all-cause and malaria-specific sick-child clinic visits by the end of week 14 after discharge, i.e. the number of children who visit the hospital for any cause or due to malaria by the end of week 14 after discharge out of the total of sample size, timeFrame - 14 weeks post discharge",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06601712",
    "endpoint": "measure - Number of children who die within 14 weeks post-discharge, description - Incidence of all-cause mortality of children by the end of week 14 after discharge, i.e. the number of children who die within 14 weeks of discharge out of the total sample size, timeFrame - 14 weeks post discharge",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06601712",
    "endpoint": "measure - Number of serious adverse events following PDMC administration within 14 weeks post-discharge, description - Safety of PDMC strategy: Proportion of serious adverse events occurring after discharge to 14 weeks post-discharge, i.e. the number of children presenting serious adverse events by the end of week 14 after discharge out of the total sample size, timeFrame - 14 weeks post discharge",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06601712",
    "endpoint": "measure - Cost per Disability adjusted life years (DALY) averted for each intervention versus control arm, description - DALYs will be determined at the individual level and calculated based on the standard method used by the 2010 Global Burden of Disease Study (and using disability weights and life expectancies at age of death from the most recent WHO life tables).\nThe total number of DALYs will be calculated by adding the DALYs for each individual who receives the intervention&#x2F;s.\nThe cost per DALY averted for each intervention will be compared against published country-specific willingness-to-pay thresholds to assess cost-effectiveness, timeFrame - 14 weeks post discharge",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06601712",
    "endpoint": "measure - Stakeholder perceptions of the feasibility on the delivery strategy with adherence supports, description - Health providers, managers, health community workers, and policy stakeholders&amp;amp;#39; perceptions regarding the feasibility of the delivery strategy and adherence support by assessing barriers and constraints through focus group discussions and key in-depth interviews., timeFrame - Within 6 month following the benning of trial",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06601712",
    "endpoint": "measure - Stakeholder acceptability of the regimen of the PDMC strategy and perception of caregiver acceptability and adherence, description - Health providers, managers, health community workers, and policy stakeholders acceptability regarding the acceptability of the regimen and the perception of the caregivers acceptability and adherence.\nAcceptability theory will draw on Sekhon&#x27;s constructs of acceptability - - affective attitude (general feelings about the intervention), burden (perceptions of effort needed to take part), ethicality (fit with their value system), intervention coherence (understanding of the intervention and how it works), opportunity costs (what must be given up in order to participate), perceived effectiveness (perceptions of the intervention&#x27;s ability to achieve its aim), and self-efficacy (feeling that they can do what they need to do to take part) and unintended consequences., timeFrame - Within 6 month following the benning of trial",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02604966",
    "endpoint": "measure - Number of patients with Adequate Clinical and Parasitological Response (ACPR) to DHA-PPQ for the treatment for uncomplicated P falciparum malaria infections in central Vietnam., description - This outcome is measured at day 28 and 42 of follow-up.\nTreatment outcomes such as ACPR, early or late clinical failures are defined following WHO guidelines;, timeFrame - From day0 to day 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00725777",
    "endpoint": "measure - Frequency and severity of drug related adverse events, description - , timeFrame - D28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02866097",
    "endpoint": "measure - a) Medicine availability (artemether-lumefantrine), description - Defined as percentage of iCCM sites with artemether-lumefantrine in stock during the monthly assessments, timeFrame - Through study completion, up to six months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02866097",
    "endpoint": "measure - b) Clinical supervision coverage, description - Defined as proportion of CHWs who received at least one supervisory contact (in person) every 3 months during which a sick child visit or scenario was assessed and coaching provided., timeFrame - Through study completion, up to six months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02866097",
    "endpoint": "measure - c) Virtual supervision coverage (via mobile technology), description - Defined as proportion of CHWs who received at least SMS per month from their supervisor reinforcing the appropriate use of the iCCM algorithm for classification and treatment., timeFrame - Through study completion, up to six months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02866097",
    "endpoint": "measure - d) Average cost per iCCM contact, description - Defined as average expenditure per iCCM contact by type of condition, timeFrame - Through study completion, up to six months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02866097",
    "endpoint": "measure - e) Diagnostic availability, description - Defined as percentage of iCCM sites with all iCCM diagnostics (malaria rapid diagnostic tests) in stock during the monthly assessments, timeFrame - Through study completion, up to six months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02866097",
    "endpoint": "measure - f) Medicine availability (amoxicillin), description - Defined as percentage of iCCM sites with amoxicillin in stock during the monthly assessments, timeFrame - Through study completion, up to six months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02866097",
    "endpoint": "measure - g) Medicine availability (ORS), description - Defined as percentage of iCCM sites with ORS in stock during the monthly assessments, timeFrame - Through study completion, up to six months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02866097",
    "endpoint": "measure - h) Medicine availability (Zinc), description - Defined as percentage of iCCM sites with Zinc in stock during the monthly assessments, timeFrame - Through study completion, up to six months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05978037",
    "endpoint": "measure - To assess the humoral immunogenicity of RH5.2-VLP with Matrix-MTM and RH5.1 soluble protein with Matrix-M when administered to healthy volunteers at different doses and used in various regimens, with comparison before and after vaccination, description - Serum ELISA response, antigen-specific antibody avidity measurement, antigen-specific antibody subclass&#x2F;isotype measurement, quantitative antigen-specific IgG antibody levels (µg&#x2F;mL readout) over time - analysis of peak responses and longevity, with comparison before and after vaccination, timeFrame - From a number of key timepoints (Baseline up to day 790 (dependant on group))",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05978037",
    "endpoint": "measure - To compare the anti-RH5 serum IgG functional immunogenicity between the RH5.2-VLP and soluble RH5.1 protein when used at different doses and in various regimens, description - In vitro GIA against 3D7 clone P. falciparum parasites using purified total IgG and a single-cycle pLDH readout assay, with comparison before and after vaccination., timeFrame - From a number of key timepoints (Baseline up to day 790 (dependant on group))",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05978037",
    "endpoint": "measure - To determine the phenotype of vaccine specific immune cells in axillary lymph nodes, description - BCR sequencing with vaccine-specific B cells obtained from axillary lymph nodes to characterise the B cell repertoire (Group 1 &amp; 3 only), timeFrame - Day 140 (group 1) and Day 266 (group 3)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05978037",
    "endpoint": "measure - To determine the frequency of vaccine specific immune cells in axillary lymph nodes, description - BCR sequencing with vaccine-specific B cells obtained from axillary lymph nodes to characterise the B cell repertoire (Group 1 &amp; 3 only), timeFrame - Day 140 (group 1) and Day 266 (group 3)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02374580",
    "endpoint": "measure - Predicted longevity of minimum 10 years if current support does not increase, description - This outcome will be measured by asking the VHTs if they predict being able to continue in their positions for at least 10 more years if their current support does not increase., timeFrame - Up to 5 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05753150",
    "endpoint": "measure - Appropriate use of PQ based on G6PD activity, description - Percentage of P. vivax patients aged ≥16 years treated or not with daily PQ in accordance with the appropriate level of G6PD enzyme activity, timeFrame - 8 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05753150",
    "endpoint": "measure - Appropriate application of treatment algorithm, description - Percentage of P. vivax patients who receive TQ or PQ based on the correct application of the treatment algorithm, timeFrame - 8 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05753150",
    "endpoint": "measure - Reported drug-induced AHA., description - Frequency of reported drug-induced AHA., timeFrame - 8 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01204411",
    "endpoint": "measure - To assess the incidence of adverse events during the follow-up period, description - , timeFrame - 42 day follow-up",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00493922",
    "endpoint": "measure - Proportion of RDT test-positive patients who were not prescribed an antimalarial in both settings, description - , timeFrame - Two years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00493922",
    "endpoint": "measure - Proportion of clinic microscopy slide-negative patients who were prescribed an anti-malarial in the setting with microscopy available, description - , timeFrame - Two years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00493922",
    "endpoint": "measure - Proportion of patients receiving additional or alternative treatments to antimalarials following a negative RDT result and which treatments these are., description - , timeFrame - Two years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01972321",
    "endpoint": "measure - Community health workers with medicine stock-out &lt;1 week each quarter, description - The proportion of community health workers with medicine stock-out &lt;1 week each quarter, timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05874869",
    "endpoint": "measure - Incidence of severe malaria, description - Defined according to the WHO criteria, timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05874869",
    "endpoint": "measure - Prevalence of malaria infection, description - Defined as the presence of asexual parasitemia.\nIndividuals do not show any signs or symptoms related to malaria infection but they have asexual P. falciparum parasites confirmed by mRDT or microscopy., timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05874869",
    "endpoint": "measure - Prevalence of anaemia, description - Prevalence of mild, moderate, or severe anaemia defined as an hemoglobin concentration of 11 g&#x2F;dL, 8 g&#x2F;dL, or 5 g&#x2F;dL, respectively., timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05874869",
    "endpoint": "measure - Prevalence of hospital admissions, description - Prevalence of individuals admitted to the health facility due to malaria infection during the SMC will be assessed.\nHospital admission will be defined as a stay of at least 24 hours in hospital for treatment., timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05874869",
    "endpoint": "measure - Prevalence of participants with any anthropometric indices., description - The prevalence of children with anthropometric indices including wasting, stunting, or underweight as defined by WHO will be assessed before and after the three rounds of SMC and then compared., timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05874869",
    "endpoint": "measure - Prevalence of household heads with positive health seeking behavior, description - Initiatives to seek treatment once feels sick.\nA questionnainne will be used to gather information from the household heads of the children involved in the study on what initiatives do they take when they or their children become sick., timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05874869",
    "endpoint": "measure - Prevalence of molecular markers, description - Molecular markers of artemisinin and partner drugs resistance., timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04473768",
    "endpoint": "measure - Contribution of handheld diagnostics and point-of-care tests to bloodstream infection diagnosis, description - Assess the contribution of handheld diagnostic instruments and point-of-care tests to the detection of danger signs associated with all pathogen bloodstream infection (NTS and other-pathogen bloodstream infections combined), timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04473768",
    "endpoint": "measure - Clinical decision support model for bloodstream infection, description - Develop a clinical decision support model for diagnosis of bloodstream infection caused by all pathogens (NTS and other pathogens combined), timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04473768",
    "endpoint": "measure - Case fatality, description - Determine the clinical signs and symptoms associated with case fatality in NTS bloodstream infection and all pathogen bloodstream infections (NTS and other pathogen combined), timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04473768",
    "endpoint": "measure - Geographical clustering, description - Assess the geographical clustering of cases with NTS bloodstream infection, timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05874271",
    "endpoint": "measure - The proportion of patients with any AESI during treatment, description - AESIs are collected during clinical review using a study-specific questionnaire, timeFrame - During treatment (up to 8 weeks)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05874271",
    "endpoint": "measure - The proportion of patients with a gastrointestinal (GI) AESI during treatment, description - AESIs are collected during clinical review using a study-specific questionnaire, timeFrame - During treatment (up to 8 weeks)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05874271",
    "endpoint": "measure - The proportion of patients with an AESI related to haemolysis during treatment, description - AESIs are collected during clinical review using a study-specific questionnaire, timeFrame - During treatment (up to 8 weeks)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05874271",
    "endpoint": "measure - The proportion of patients an AESI related to methaemoglobinaemia, description - AESIs are collected during clinical review using a study-specific questionnaire, timeFrame - During treatment (up to 8 weeks)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05874271",
    "endpoint": "measure - Proportion of patients permanently stopping PQ before end of treatment, description - Discontinuation of PQ will be assessed using a study-specific questionnaire, timeFrame - During treatment (up to 8 weeks)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05874271",
    "endpoint": "measure - The proportion of patients receiving correct treatment based on G6PD activity, description - This will be assessed by linking patients G6PD activity results measured during study enrolment with primaquine dose prescribed on the same day, timeFrame - 1 day",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05874271",
    "endpoint": "measure - Proportion of patients who were reviewed on Day 3 and Day 7, description - This will be assessed by linking patients enrolment data with Day 3 and Day 7 clinical review data, timeFrame - 1 week",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05874271",
    "endpoint": "measure - Perception of and experience with new radical cure tools among health care providers and community members, description - This will be assessed using stakeholder interviews, timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05874271",
    "endpoint": "measure - Proportion of health care practitioners who comply with the revised radical cure treatment algorithm, description - The outcome will be assessed from patients&#x27; enrolment data, timeFrame - 1 day",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05874271",
    "endpoint": "measure - Proportion of patients receiving a SD Biosensor G6PD test, description - The outcome will be assessed from patients&#x27; enrolment data, timeFrame - 1 day",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05874271",
    "endpoint": "measure - Proportion of eligible P. vivax malaria patients receiving the correct dose of primaquine based on the result of the G6PD test, description - The outcome will be assessed from patients&#x27; enrolment data, timeFrame - 1 day",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05874271",
    "endpoint": "measure - Proportion of P. vivax malaria patients who are ineligible for daily primaquine and are incorrectly given primaquine (including infants, pregnant females and G6PD deficient patients), description - The outcome will be assessed from patients&#x27; enrolment data, timeFrame - 1 day",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05874271",
    "endpoint": "measure - Proportion of P. vivax malaria patients that are reviewed on Day 3, description - This will be assessed by linking patients&#x27; enrolment data with clinical review data, timeFrame - 3 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05874271",
    "endpoint": "measure - Proportion of P. vivax malaria patients that adhere to their prescribed primaquine regimen, description - This will be assessed by linking patients&#x27; enrolment data with clinical review data, timeFrame - 3 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05874271",
    "endpoint": "measure - Factors influencing acceptability and feasibility of the new radical cure tools among health care providers are identified, description - This will be assessed using stakeholder interviews, observations and focus groups, timeFrame - 3 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05874271",
    "endpoint": "measure - Barriers and enablers of uptake and implementation at the sub-national levels are identified, description - This will be assessed using stakeholder interviews and focus groups, timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05874271",
    "endpoint": "measure - Factors influencing compliance with G6PD testing and perceptions of new drug regimens and serious adverse events among health care providers are identified, description - This will be assessed using stakeholder interviews and focus groups, timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05874271",
    "endpoint": "measure - Required knowledge, skills, and training to administer the revised case management and patient-counselling identified, description - This will be assessed using stakeholder interviews and focus groups, timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05874271",
    "endpoint": "measure - Factors influencing the barriers and facilitators to patient adherence to primaquine after the rollout of the revised case management identified, description - This will be assessed using stakeholder interviews and focus groups, timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05874271",
    "endpoint": "measure - Factors influencing the acceptability and feasibility of community-based clinical review at Day 3 of primaquine treatment identified., description - This will be assessed using stakeholder interviews and focus groups, timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05874271",
    "endpoint": "measure - Perceptions of the new radical cure tools and serious adverse events at the community level identified, description - This will be assessed using stakeholder interviews and focus groups, timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05874271",
    "endpoint": "measure - Local acceptability of the revised case management algorithms among patients, their families, and healthcare workers established, description - This will be assessed using stakeholder interviews and focus groups, timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05874271",
    "endpoint": "measure - The monthly incidence of confirmed symptomatic P. vivax malaria episodes (mono-infection or mixed) before implementation versus after implementation, description - This will be assessed by comparing facility surveillance data before implementation with facility surveillance data after implementation, timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05874271",
    "endpoint": "measure - The prevalence of P. vivax parasitaemia in patients presenting with fever before implementation versus after implementation, description - This will be assessed by comparing cross-sectional data on n=200 patients (per facility) collected before implementation to the prevalence collected in n=200 patients (per facility) after implementation, timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05874271",
    "endpoint": "measure - Cumulative risk of representation to the same clinic with symptomatic P. vivax malaria within 6 months, description - This will be assessed by linking patients&#x27; enrolment data, timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05874271",
    "endpoint": "measure - Costs of implementing policy from a healthcare provider perspective, including health systems strengthening processes, description - This will be assessed from health system data collected throughout the study, timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05874271",
    "endpoint": "measure - Household costs per P. vivax episode, description - This will be assessed from a household cost survey on a subset of patients, timeFrame - 3 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05874271",
    "endpoint": "measure - Overall cost-effectiveness of changing policy if revised case management is effective, description - This will be assessed from health system data collected throughout the study, timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05874271",
    "endpoint": "measure - Cost per episode of P. vivax malaria from the healthcare provider and societal perspectives, description - This will be assessed from health system data collected throughout the study, timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05874271",
    "endpoint": "measure - Cost per component of the revised case management package, description - This will be assessed from health system data collected throughout the study, timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05874271",
    "endpoint": "measure - If revised case management package is effective (significantly reduces the incidence of malaria), then the cost-effectiveness of implementing the revised case management as compared with usual care, description - This will be assessed from health system data collected throughout the study, timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05874271",
    "endpoint": "measure - Proportion of CHWs who correctly act on early signs of haemolytic anaemia and GI events (i.e. refer patients for further medical review, instruct patient to discontinue treatment), description - This will be assessed from clinical review data and study-specific questionnaire, timeFrame - 3 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05874271",
    "endpoint": "measure - Number of patients with an SAE who are identified by community or clinic staff follow-up and referred to hospital for further management, description - This will be assessed by linking clinical review data, study specific questionnaire and SAE form, timeFrame - During treatment (up to 8 weeks)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05874271",
    "endpoint": "measure - The proportion of patients eligible to receive PQ who had a SAE during treatment, description - This will be assessed by linking enrolment data, clinical review, study specific questionnaire and SAE form, timeFrame - During treatment (up to 8 weeks)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05874271",
    "endpoint": "measure - Prevalence of severe anaemia in patients presenting with fever before and after implementation, description - This will be assessed by comparing the facility surveillance data before implementation with facility surveillance data after implementation, timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06232954",
    "endpoint": "measure - Assessment of the diversionary effect of spatial repellent in the buffer zone using RDT and microscopy, description - Clusters are defined as discrete villages with a core and buffer zone.\nBuffer zones will be approximately 2km from the outer perimeter of the core zone and will not receive the intervention.\nThis buffer zone will mitigate against the diversionary impact in the instance where villages are split into multiple clusters.\nThe diversionary impact of the intervention on mosquitoes to locally unprotected individuals will be evaluated by measuring the malaria prevalence among children ≤ 5 years of age as determined by Rapid Diagnostic Test (RDT) positivity and confirmed by microscopy in a subset of households in the buffer zones.\nMosquito population density and human biting rate will also be measured in the buffer zones., timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06232954",
    "endpoint": "measure - Entomological correlates of transmission, description - Mosquito species composition and population density in mosquitoes caught using indoor CDC-light traps and Anopheline-human contact (indoor and outdoor) using human biting rate (HBR) as an indicator for all anophelines.\nMeasured by human-landing catch (HLC)., timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06232954",
    "endpoint": "measure - Household surveys, description - Household surveys to collect information on subject behaviour related to exposure to malaria and use of existing control tools, timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06232954",
    "endpoint": "measure - Air sampling, description - Quantification of the temporal changes in concentration of transfluthrin present in the air over the duration of its use and the impact of indoor temperature on the concentration, timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06232954",
    "endpoint": "measure - Safety of intervention, description - Safety of intervention through monitoring of adverse events (AEs) and serious adverse events (SAEs), timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06232954",
    "endpoint": "measure - Acceptability survey, description - Acceptability of Mossie-GO in these communities, timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05096702",
    "endpoint": "measure - Percentage of patients with P. vivax ≥6 months treated or not with PQ according to the appropriate level of G6PD enzyme activity, description - , timeFrame - 15 months after study start",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05096702",
    "endpoint": "measure - Description of the characteristics of patients treated with TQ or PQ, description - , timeFrame - 15 months after study start",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05096702",
    "endpoint": "measure - Frequency of drug-induced acute hemolytic anemia (AHA), description - Proportion of participants that reported signs and symptoms of hemolysis after P. vivax treatment on malaria notification forms, timeFrame - 15 months after study start",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05096702",
    "endpoint": "measure - Hospitalization due to confirmed drug-induced AHA, description - Proportion of participants hospitalized due drug-induced AHA after malaria treatment, screened in electronic medical records at local reference units and the national hospitalization database., timeFrame - 15 months after study start",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00959517",
    "endpoint": "measure - Asexual parasite clearance by day 7, description - , timeFrame - 7 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00959517",
    "endpoint": "measure - Gametocyte carriage on or after day 7, description - , timeFrame - 7 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03529396",
    "endpoint": "measure - Regimen efficacy, description - Relapse rate over follow-up period after treatment, timeFrame - 6 months post treatment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03529396",
    "endpoint": "measure - Adverse effects, description - Presence of adverse reactions as a result of intervention, measured by clinical and laboratory tests, timeFrame - From date of randomization until the date of first documented event, assessed up to 12 weeks.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03529396",
    "endpoint": "measure - Change in hemoglobin values over treatment, description - Absolute variation of hemoglobin levels before and during intervention., timeFrame - through study completion: before intervention and up to 12 weeks during intervention.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00811421",
    "endpoint": "measure - Trial 1: Prevalence of placental P. falciparum infection. Prevalence of moderate maternal anaemia at delivery., description - , timeFrame - day 0, delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00811421",
    "endpoint": "measure - Trial 2: Prevalence of placental P. falciparum infection. Prevalence of low birth weight babies (&lt; 2500 g)., description - , timeFrame - day 0, birth",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02974348",
    "endpoint": "measure - Hemoglobin level, description - The ability of the drug to restore hemoglobin level back to normal, timeFrame - 42 days follow-up",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02974348",
    "endpoint": "measure - parasite clearance rate assessment, description - The ability of the drug to completely eliminate plasmodium in the blood stream including participant without symptoms of fever, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02974348",
    "endpoint": "measure - PCR-correction, description - blood sample from patients with parasitaemia at any day of follow-up are analysed by PCR to evaluated the genetic profile of the MSP1 and MSP2, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02198807",
    "endpoint": "measure - Per protocol, PCR-corrected cure rates on Day 7 and Day 63, description - Weekly smears on days 35 +&#x2F;- 3 days, 42 +&#x2F;- 3 days and 63 +&#x2F;- 3 days, timeFrame - 63 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02198807",
    "endpoint": "measure - Derived parasite reduction ratio at 48 hours, description - Six-hourly asexual counts until negative on three successive occasions, timeFrame - 2 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02198807",
    "endpoint": "measure - Parasite clearance time, description - Six-hourly asexual counts until negative on three successive occasions, timeFrame - 96 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02198807",
    "endpoint": "measure - Fever clearance time, description - Six hourly temperature recordings until normal on three successisve occasions, timeFrame - 96 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02198807",
    "endpoint": "measure - Proportion of subjects with gametocytes on Day 7, description - Smear on Day 7, timeFrame - 7 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02198807",
    "endpoint": "measure - Adverse event recording, description - <p>Recording of vital signs and ECG monitoring</p><p>Recording of incidence, severity, drug-relatedness and seriousness of AEs and laboratory abnormalites</p>, timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01660672",
    "endpoint": "measure - Toxicity Related to LVT, description - Toxicity including vomiting, aspiration, complications related to the NGT, laboratory parameters at 24 hours and 1 week post LVT administration, and an overall acute case fatality rate significantly above the consistent historical ward average for CM.\nPk studies to evaluate LVT absorption and elimination in pediatric CM., timeFrame - 1 week",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01660672",
    "endpoint": "measure - Range of Plasma Concentration of LVT Across All Individuals, description - Range of plasma LVT concentrations will be determined through HPLC method at eight timepoints post administration to evaluate LVT absorption and elimination in pediatric CM., timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06624631",
    "endpoint": "measure - Proportion of children who are readmitted with malaria, description - All-cause and malaria-specific sick-child clinic visits by the end of week 14 after discharge, timeFrame - 0-14 weeks post discharge",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06624631",
    "endpoint": "measure - Proportion of children who are readmitted with any cause, description - All-cause and cause-specific readmissions by the end of week 14 after discharge, timeFrame - 0-14 weeks post discharge",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06624631",
    "endpoint": "measure - Proportion of children who die within 14 weeks of discharge, description - All-cause mortality by the end of week 14 after discharge, timeFrame - 0-14 weeks post discharge",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06624631",
    "endpoint": "measure - Incidence of serious adverse events, description - Incidence of serious adverse events, timeFrame - 0-14 weeks post discharge",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06624631",
    "endpoint": "measure - Cost-effectiveness, description - Incremental cost per DALY averted of alternative PDMC adherence support strategies (adherence support option A [Aa], adherence support option B [Ab]) with no adherence support (Ac), and with each other, timeFrame - 0-14 weeks post discharge",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06624631",
    "endpoint": "measure - User and provider perceptions of acceptability and feasibility, description - Acceptability and feasibility of PDMC delivery strategies, timeFrame - Trial month 6+",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02282293",
    "endpoint": "measure - Maternal Parasitemia at Delivery by Microscopy and LAMP, description - Proportion of women with parasitemia detected by microscopy or LAMP at delivery, timeFrame - At delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02282293",
    "endpoint": "measure - Placental Parasitemia (Number of Women With Placental Blood Samples Positive for Malaria by Microscopy or PCR), description - Proportion of placental blood samples positive for malaria by microscopy or PCR, timeFrame - At delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02282293",
    "endpoint": "measure - Number of Monthly Routine Visits With Positive Blood Samples for Parasites, description - Proportion of monthly routine blood samples positive by LAMP for parasites, timeFrame - Following administration of first dose of study drug to delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02282293",
    "endpoint": "measure - Composite Adverse Birth Outcome (Proportion With Low Birth Weight (&lt;2500 gm), Spontaneous Abortion (&lt;28 Weeks), Stillbirth (Fetal Demise ≥28 Weeks), Congenital Anomaly, or Preterm Delivery (&lt;37 Weeks), description - Proportion with low birth weight (&lt;2500 gm), spontaneous abortion (&lt;28 weeks), stillbirth (fetal demise ≥28 weeks), congenital anomaly, or preterm delivery (&lt;37 weeks), timeFrame - At delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02282293",
    "endpoint": "measure - Number of Routine Visits Measured Every 8 Weeks During Pregnancy for Which the Participants Had Anemia, description - Anemia (hemoglobin less than 11g&#x2F;dL) measured every 8 weeks during pregnancy, timeFrame - Following administration of first dose of study drugs to delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00885287",
    "endpoint": "measure - Changes in pharmacokinetic profiles of nevirapine-based and other used antiretrovirals;, description - , timeFrame - 42 days of post-treatment follow-up",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01214876",
    "endpoint": "measure - Geographical patterns in malaria morbidity, description - Households are geo-located by GPS and hotspots of malaria transmission will be determined and related to serological profiles., timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01214876",
    "endpoint": "measure - Asymptomatic parasite carriage and immune responses in different age-groups exposed to intense malaria transmission, description - ASYMPTOMATIC PARASITE CARRIAGE will be confirmed by microscopy and PCR., timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00399074",
    "endpoint": "measure - Malaria related admissions, description - , timeFrame - 1 month",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00399074",
    "endpoint": "measure - Adverse drug effects, description - , timeFrame - 4 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01319448",
    "endpoint": "measure - Efficacy against malaria, description - , timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06599593",
    "endpoint": "measure - Alternative malaria Indicators, description - For children enrolled in active surveillance across both arms, the team will assess the cumulative incidence of malaria parasitemia by RDT with or without fever, timeFrame - 5 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06599593",
    "endpoint": "measure - Severe malaria, description - Severe malaria will be diagnosed at participating healthcare facilities and defined as vital organ dysfunction and&#x2F;or hyperparasitemia.\nData on severe malaria cases will be collected by passive surveillance., timeFrame - 5 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06599593",
    "endpoint": "measure - All-cause clinic visits., description - Primary healthcare data collected via passive surveillance will include all sick child visits during the study period and will include information related to diagnoses and treatments., timeFrame - 5 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06083688",
    "endpoint": "measure - Mean hemoglobin concentration, description - g&#x2F;dL (continuous), timeFrame - 6-8 weeks after the last intervention",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06083688",
    "endpoint": "measure - Literacy skills, description - Early grade reading assessment, timeFrame - 6-8 weeks after the last intervention",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06083688",
    "endpoint": "measure - Math skills, description - Early grade math assessment, timeFrame - 6-8 weeks after the last intervention",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06083688",
    "endpoint": "measure - Rate of school absenteeism among participants, description - Proportion of days absent among days where attendance is assessed, timeFrame - through study completion (approximately 6 months)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06083688",
    "endpoint": "measure - P. falciparum prevalence among children less than 5 years old living in households with study participants, description - detected by PCR, timeFrame - 6-8 weeks after the last intervention",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06083688",
    "endpoint": "measure - Rate of clinical malaria among children less than 5 years old living in households with study participants, description - cumulative incidence, timeFrame - through study completion (approximately 6 months)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02427360",
    "endpoint": "measure - Proportion of aparasitaemic patients, description - , timeFrame - day 3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02427360",
    "endpoint": "measure - gametocytaemia, description - gametocytaemia will be measured on pre and post treatment, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02427360",
    "endpoint": "measure - haematocrit change, description - Haematocrit changes will be measured on pre and post treatment, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02427360",
    "endpoint": "measure - Prevalence and temporal trend of resistance molecular markers, description - the following molecular markers will be measured; SNP on Kelch&#x2F;K13 gene and Pfmdr1 copy number, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00852371",
    "endpoint": "measure - Risk of Recrudescence (Adjusted by Genotyping) in Participants Who Were Parasitaemic at Enrollment, description - Proportion of participants whose thick blood smears that are positive with the same asexual parasites at baseline and on the day of failure at genotyping, timeFrame - after 42 days of follow-up",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00852371",
    "endpoint": "measure - Risk of New Infection (Adjusted by Genotyping) in All Participants, description - Proportion of participants whose thick blood smears that are positive for new asexual parasites on day of failure at genotyping, timeFrame - after 42 days of follow-up",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00852371",
    "endpoint": "measure - Risk of Clinical Failure Due to Recrudescence (Adjusted by Genotyping) in Children Who Were Parasitaemic at Enrollment, description - Proportion of children who were parasitaemia at enrollment, with subsequent fever and a positive thick blood smear for asexual parasites on the day of failure during follow-up, timeFrame - Over 42 days of follow-up",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00852371",
    "endpoint": "measure - Mean Change in Haemoglobin, description - Haemoglobin measured in g&#x2F;dL; Mean change in haemoglobin calculated as the difference in mean haemoglobin (g&#x2F;dL) on Day 42 - Day 0, in children treated with the different antimalarial regimens, timeFrame - Between day 0 to day 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00852371",
    "endpoint": "measure - Risk of Serious Adverse Events, description - Any untoward medical occurrence in a participant taking study medication after 14 and 42 days of follow up leading to death, disability, hospitalization or extended hospitalization, timeFrame - over 42 days of follow-up",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00852371",
    "endpoint": "measure - Acceptability of IPT Regimens, description - Perceived willingness to take study medication as routine preventive treatment, timeFrame - on day 7",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00852371",
    "endpoint": "measure - Risk of Clinical Failure Due to Recrudescence (Adjusted by Genotyping) in Children Who Were Parasitaemic at Enrollment, description - Proportion of children who were parasitaemia at enrollment, with subsequent fever and a positive thick blood smear for asexual parasites on the day of failure during follow-up, timeFrame - after 42 days of follow-up",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00126906",
    "endpoint": "measure - Proportion of newborns with low birth weight, stratified by HIV status, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00126906",
    "endpoint": "measure - Proportion of women with third trimester anemia, stratified by HIV status, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00126906",
    "endpoint": "measure - Proportion of pregnancies that suffer fetal loss, stratified by HIV status, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03944317",
    "endpoint": "measure - malaria parasitaemia at the point of delivery, description - number of pregnant women with maternal peripheral blood and placental parasitaemia, number of new born with cord blood parasitaemia at birth among pregnant women who use sulfadoxine pyrimethamine and azithromycin for malaria prevention in pregnancy, timeFrame - at the time of delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01982812",
    "endpoint": "measure - Required Additional AED, description - Additional AEDs required (including for breakthrough seizures in LVT group) during admission for seizure control (yes&#x2F;no), timeFrame - 7 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01982812",
    "endpoint": "measure - Mean Time From Admission to BCS &gt;&#x2F;= 4, description - <p>The mean time in hours from admission until the subject reaches Blantyre Coma Scale of greater than or equal to 4. Participants who died are excluded from this analysis.</p><p>The Blantyre Coma Score has ranges from 0-5 based upon the a sum of the following 3 domains- Eye movement</p><p>1 - Watches or follows 0 - Fails to watch or follow</p><p>Best motor response 2 - Localizes painful stimulus 1 - Withdraws limb from painful stimulus 0 - No response or inappropriate response</p><p>Best verbal response 2 - Cries appropriately with pain, or, if verbal, speaks</p><p>1 - Moan or abnormal cry with pain 0 - No vocal response to pain</p>, timeFrame - 7 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01982812",
    "endpoint": "measure - Sequelae, description - <p>Neurologic outcome in 3 categories--</p><ol><li>Neurologically intact at discharge</li><li>Neurologic sequelae at discharge--specifically new sensory or motor deficits, ongoing seizures, or behavioral abnormalities based upon a physician examination at discharge</li><li>Died during admission, never discharged</li></ol>, timeFrame - 7 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00408369",
    "endpoint": "measure - To distinguish the mechanism of prophylaxis: causal vs suppressive, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00408369",
    "endpoint": "measure - To evaluate the pharmacokinetics of DB289 and DB75, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00408369",
    "endpoint": "measure - To assess the safety of DB289, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00938379",
    "endpoint": "measure - Reduction in Japanese Encephalitis and &#x2F; or Dengue infections, description - , timeFrame - After 7 months intervention",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01707199",
    "endpoint": "measure - Adverse events, description - The incidence of any adverse event will be documented.\nAll patients will be asked routinely about previous symptoms and about symptoms that have emerged since the previous follow-up visit., timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01707199",
    "endpoint": "measure - Molecular markers for antimalarial drug resistance, description - To study polymorphisms in PfDHFR, PfDHPS and copy number of PfGCH1 which are considered as markers of resistance to Sulphadoxine-pyrimethamine (SP) components., timeFrame - Baseline",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02434952",
    "endpoint": "measure - Determine G6PD enzyme activity, description - Quantitative G6PD testing among all participants using the G6PD enzyme assay from Trinity Biologicals, USA, yielding G6PD enzyme results in U&#x2F;g Hb., timeFrame - Day 0",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02434952",
    "endpoint": "measure - Assess usefulness of field adapted WHO haemoglobin colour card vs. Hemocue, description - Comparison of quantitative (HemoCue, g&#x2F;dL HB) and qualitative (WHO haemolglobin colour card) estimates of haemoglobin concentration, timeFrame - Day 0",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02434952",
    "endpoint": "measure - Assess usefulness of rapid test for G6PDd in predicting acute intravascular haemolysis, description - Comparison of rapid G6PD test (AccessBio, USA) qualitative result against quantitative G6PD assay to determine predictive value for clinically significant haemolysis, timeFrame - Day 0",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02434952",
    "endpoint": "measure - Proportion patients with ≥25% change in haemoglobin as a marker of intravascular haemolysis, description - Comparing across all 4 arms: proportion of all patients with fractional change in haemoglobin ≥25% from day 0 to day 7, timeFrame - Change from Day 0 to Day 7",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02434952",
    "endpoint": "measure - Plasma haemoglobin concentration as a marker of intravascular haemolysis, description - Comparing across all 4 arms: plasma haemoglobin concentration at day 7, timeFrame - Day 7",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02434952",
    "endpoint": "measure - Urine colour change as a marker of intravascular haemolysis, description - Change in urine colour grade from day 0 to day 7 (Hillmen, Hall et al. 2004), timeFrame - Change from Day 0 to Day 7",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02434952",
    "endpoint": "measure - Fractional change in haemoglobin as a marker of intravascular haemolysis, description - Comparing across all 4 arms: fractional change in haemoglobin on day 7 vs. day 0, timeFrame - Change from Day 0 to Day 7",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02434952",
    "endpoint": "measure - Clearance rate of primaquine, description - Primaquine elimination clearance rate, modelled from population pharmacokinetic data from all patients receiving at least one dose of DHA PP + PQ, timeFrame - Day 0-7",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02434952",
    "endpoint": "measure - Half life of primaquine, description - Primaquine terminal elimination half life, modelled from population pharmacokinetic data from all patients receiving at least one dose of DHA PP + PQ, timeFrame - Day 0-7",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02434952",
    "endpoint": "measure - Primaquine volume of distribution, description - Primaquine apparent volume of distribution (Vd), modelled from population pharmacokinetic data from all patients receiving at least one dose of DHA PP + PQ, timeFrame - Day 0-7",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02434952",
    "endpoint": "measure - Clearance rate of piperaquine, description - Piperaquine elimination clearance rate, modelled from population pharmacokinetic data from all patients receiving at least one dose of DHA PP +&#x2F;- PQ, timeFrame - Day 0-28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02434952",
    "endpoint": "measure - Half life of piperaquine, description - Piperaquine terminal elimination half life, modelled from population pharmacokinetic data from all patients receiving at least one dose of DHA PP +&#x2F;- PQ, timeFrame - Day 0-28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02434952",
    "endpoint": "measure - Piperaquine volume of distribution, description - Piperaquine apparent volume of distribution (Vd), modelled from population pharmacokinetic data from all patients receiving at least one dose of DHA PP +&#x2F;- PQ, timeFrame - Day 0-28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02434952",
    "endpoint": "measure - Peak plasma concentration (Cmax) of primaquine, description - Cmax taken directly from population pharmacokinetic data from all patients receiving at least one dose of DHA PP + PQ, timeFrame - Day 0-7",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02434952",
    "endpoint": "measure - Peak plasma concentration (Cmax) of piperaquine, description - Cmax taken directly from population pharmacokinetic data from all patients receiving at least one dose of DHA PP +&#x2F;- PQ, timeFrame - Day 0-28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02434952",
    "endpoint": "measure - Time to primquine peak plasma concentration (Tmax), description - Tmax taken directly from population pharmacokinetic data from all patients receiving at least one dose of DHA PP + PQ, timeFrame - Day 0-7",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02434952",
    "endpoint": "measure - Time to piperaquine peak plasma concentration (Tmax), description - Tmax taken directly from population pharmacokinetic data from all patients receiving at least one dose of DHA PP +&#x2F;- PQ, timeFrame - Day 0-28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02434952",
    "endpoint": "measure - Area under the plasma concentration versus time curve - primaquine, description - Modelled from population pharmacokinetic data from all patients receiving at least one dose of DHA PP + PQ, timeFrame - Day 0-7",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02434952",
    "endpoint": "measure - Area under the plasma concentration versus time curve - piperaquine, description - Modelled from population pharmacokinetic data from all patients receiving at least one dose of DHA PP +&#x2F;- PQ, timeFrame - Day 0-28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05980156",
    "endpoint": "measure - Number of participants with anemia, description - World Health Organization age-sex definitions (binary), timeFrame - 6-8 weeks after the last intervention",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05980156",
    "endpoint": "measure - Mean hemoglobin concentration, description - g&#x2F;dL (continuous), timeFrame - 6-8 weeks after the last intervention",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05980156",
    "endpoint": "measure - Total parasite density, description - log transformed (continuous), timeFrame - 6-8 weeks after the last intervention",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05980156",
    "endpoint": "measure - Rate of clinical malaria, description - cumulative incidence, timeFrame - through study completions, approximately 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05980156",
    "endpoint": "measure - P. falciparum prevalence among children less than 5 years old living in households with study participants, description - detected by PCR, timeFrame - 6-8 weeks after the last intervention",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05980156",
    "endpoint": "measure - sustained attention, description - code transmission test score (continuous), timeFrame - 6-8 weeks after the last intervention",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05980156",
    "endpoint": "measure - selective attention, description - selective attention test score (continuous), timeFrame - 6-8 weeks after the last intervention",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05980156",
    "endpoint": "measure - Literacy skills, description - onetest reading test score (continuous), timeFrame - 6-8 weeks after the last intervention",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05980156",
    "endpoint": "measure - Math skills, description - onetest math score (continuous), timeFrame - 6-8 weeks after the last intervention",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03806465",
    "endpoint": "measure - Number of deaths in children by gender, description - Number of deaths in children stratified by gender in children aged 1-59 months, timeFrame - From 0 to 46 months after vaccination starts",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03806465",
    "endpoint": "measure - Number of deaths in hospitalised children by gender, description - Number of deaths in hospitalized children stratified by gender in children aged 1-59 months., timeFrame - From 0 to 46 months after vaccination starts",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03806465",
    "endpoint": "measure - Number of malaria associated deaths in hospitalised children by gender, description - Number of malaria specific deaths stratified by gender in hospitalized children aged 1-59 months., timeFrame - From 0 to 46 months after vaccination starts",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03806465",
    "endpoint": "measure - Number of children with a diagnosis of severe malaria, description - Hospital admissions with malaria which meet WHO criteria for a diagnosis of severe malaria., timeFrame - From 0 to 30 months after vaccination starts",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03806465",
    "endpoint": "measure - Number of deaths excluding those attributed to trauma, poisoning and drowning, description - Number of non traumatic deaths in children aged 1-59 months., timeFrame - From 0 to 46 months after vaccination starts",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03806465",
    "endpoint": "measure - Number of children with a diagnosis of aetiology confirmed meningitis, description - Number of hospital admissions which meet WHO criteria for a diagnosis of aetiologically confirmed meningitis admitted to sentinel hospitals, timeFrame - 30 months after vaccination starts",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03806465",
    "endpoint": "measure - Number of children with a diagnosis of suspected meningitis, description - Number of hospital admissions which meet WHO criteria for a diagnosis of suspected meningitis admitted to sentinel hospitals, timeFrame - From 0 to 30 months after vaccination starts",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03806465",
    "endpoint": "measure - Number of children with a diagnosis of probable meningitis, description - Number of hospital admissions which meet WHO criteria for a diagnosis of probable meningitis admitted to sentinel hospitals, timeFrame - From 0 to 30 months after vaccination starts",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03806465",
    "endpoint": "measure - Number of children with a diagnosis of malaria, description - Number of hospital admissions which meet WHO criteria for a diagnosis of malaria admitted to sentinel hospitals, timeFrame - From 0 to 30 months after vaccination starts",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03806465",
    "endpoint": "measure - Number of children with a non-malaria diagnosis, description - Number of hospital admissions which do not meet WHO criteria for a diagnosis of malaria admitted to sentinel hospitals, timeFrame - From 0 to 30 months after vaccination starts",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03806465",
    "endpoint": "measure - Number of children with a diagnosis of anaemia, description - Number of hospital admissions which meet WHO criteria for a diagnosis of anaemia admitted to sentinel hospitals .\nAnaemia is haemoglobin less than 11g&#x2F;dL., timeFrame - From 0 to 30 months after vaccination starts",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03806465",
    "endpoint": "measure - Number of children who have received all their routine EPI vaccines as recommended by their national immunization schedule, description - Routine EPI vaccines include all doses of OPV, pentavalent, rotavirus, pneumococcal and measles vaccines, timeFrame - At 18 and 30 months after vaccination starts",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03806465",
    "endpoint": "measure - Number of children who have received all the recommended malaria prevention and control measures, description - Recommended malaria prevention and control measures include insecticide treated bed nets, IPTi and indoor residual spraying., timeFrame - At 18 and 30 months after vaccination starts",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03806465",
    "endpoint": "measure - Number of children who have received all of the other key childhood interventions, description - Other key childhood interventions include anti-helminth administration (deworming) and Vitamin A supplementation, timeFrame - At 18 and 30 months after vaccination starts",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05685875",
    "endpoint": "measure - Malaria requiring in-patient care, description - Patients with confirmed malaria admitted to hospital, timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05685875",
    "endpoint": "measure - Cerebral malaria, description - Confirmed malaria and Glasgow Coma Scale &lt;11, timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05685875",
    "endpoint": "measure - Severe malaria with kidney failure, description - Confirmed malaria and Creatinine &gt;265, timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05244954",
    "endpoint": "measure - Number of participant with anemia, description - World Health Organization age-sex definitions (binary), timeFrame - 6-8 weeks after the last intervention",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05244954",
    "endpoint": "measure - Mean hemoglobin concentration, description - g&#x2F;dL (continuous), timeFrame - 6-8 weeks after the last intervention",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05244954",
    "endpoint": "measure - Total parasite density, description - log transformed (continuous), timeFrame - 6-8 weeks after the last intervention",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05244954",
    "endpoint": "measure - Gametocyte density, description - log transformed (continuous), timeFrame - 6-8 weeks after the last intervention",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05244954",
    "endpoint": "measure - Rate of clinical malaria, description - cumulative incidence, timeFrame - from the first intervention to 6-8 weeks after the last intervention",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05244954",
    "endpoint": "measure - P. falciparum prevalence among household members, description - detected by PCR, timeFrame - 6-8 weeks after the last intervention",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06141057",
    "endpoint": "measure - To assess the humoral immunogenicity of RH5.1 soluble protein with Matrix-M when administered to healthy volunteers at different doses., description - Serum ELISA response, quantitative antigen-specific IgG antibody levels (µg&#x2F;mL readout) over time - analysis of peak responses and longevity, with comparison before and after vaccination, timeFrame - From a number of key timepoints (Baseline up to day 547)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06141057",
    "endpoint": "measure - To compare the anti-RH5 serum IgG functional immunogenicity between the two groups receiving soluble RH5.1 at different doses by assessing purified IgG versus GIA titration (quality analysis), description - Immunogenicity will be assessed to characterise quantity, quality and longevity of serum anti-RH5 IgG responses as measured by standardised ELISA.\nThe growth inhibition activity will be used to determine functionality of these responses and allow quality analysis.\nComparisons between two groups receiving soluble RH5.1 protein at different doses will be made post vaccination to determine how differing doses affect these responses., timeFrame - After each vaccinations (D0, D28 and D182)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06141057",
    "endpoint": "measure - To compare differences in the innate immune responses following the first and third vaccinations and correlated these with adverse event data and adaptive immune responses, description - Innate immune cell analyses will include flow cytometry analyses and quantitative measurements of pro-inflammatory cytokines to phenotype innate immune cell populations primarily in the first 7 days following vaccination., timeFrame - 7, 28 days following first and third vaccinations",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03337152",
    "endpoint": "measure - Significance of CYP2D6, description - relevance of Dextromethorphan assay results to risk of haemolysis models, timeFrame - 28 days after enrollment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03337152",
    "endpoint": "measure - Association of Drug Levels, description - Association of chloroquine and primaquine drug levels at the time of sampling for haematological and G6PD profiles., timeFrame - Days 1,2,3,5,7,9,11,14,17,21",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03337152",
    "endpoint": "measure - Serious Adverse Events, description - frequency of serious adverse events in women heterozygous for G6PD, timeFrame - 28 days after enrollment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03337152",
    "endpoint": "measure - Significance of Reticulocyte Count, description - relevance of reticulocyte count to risk of haemolysis models, timeFrame - Days 1,2,3,5,7,9,11,14,17,21",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03337152",
    "endpoint": "measure - Significance of Urobilinogen Levels, description - relevance of urobilinogen tests to risk of haemolysis models, timeFrame - Days 1,2,3,5,7,9,11,14,17,21",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00944359",
    "endpoint": "measure - Incidence of stunting, underweight, and wasting, description - , timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00944359",
    "endpoint": "measure - Change in hemoglobin and iron status, description - , timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03671109",
    "endpoint": "measure - Incidence of clinical malaria, description - , timeFrame - On average six months follow up during pregnancy",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03671109",
    "endpoint": "measure - Incidence of all-cause admissions, description - , timeFrame - On average six months follow up during pregnancy",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03671109",
    "endpoint": "measure - Incidence of all-cause outpatient attendances, description - , timeFrame - On average six months follow up during pregnancy",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03671109",
    "endpoint": "measure - Frequency and severity of adverse events, description - , timeFrame - On average six months follow up during pregnancy",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03671109",
    "endpoint": "measure - Mean haemoglobin concentration, description - , timeFrame - At delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03671109",
    "endpoint": "measure - Prevalence of submicroscopic P. falciparum peripheral parasitaemia, description - , timeFrame - At delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03671109",
    "endpoint": "measure - Prevalence of anaemia (Hb&lt;11 g&#x2F;dL), description - , timeFrame - At delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03671109",
    "endpoint": "measure - Prevalence of severe anaemia (Hb&lt;7 g&#x2F;dL), description - , timeFrame - At delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03671109",
    "endpoint": "measure - Mean CD4+ T cell counts levels, description - , timeFrame - At delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03671109",
    "endpoint": "measure - Proportion of women with detectable HIV viral load, description - , timeFrame - At delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03671109",
    "endpoint": "measure - Prevalence of placental P. falciparum infection, description - , timeFrame - At delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03671109",
    "endpoint": "measure - Prevalence of P. falciparum peripheral parasitaemia at the post-partum visit, description - , timeFrame - On average 42 days after end of pregnancy (post-partum visit)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03671109",
    "endpoint": "measure - Maternal mortality rate, description - , timeFrame - On average six months follow up during pregnancy and 42 days after end of pregnancy (post-partum visit)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03671109",
    "endpoint": "measure - Prevalence of P. falciparum parasitaemia in cord blood, description - , timeFrame - At birth",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03671109",
    "endpoint": "measure - Prevalence of neonatal anaemia, description - , timeFrame - Neonatal period ( in first 28 days of life)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03671109",
    "endpoint": "measure - Mean birth weight, description - , timeFrame - At birth",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03671109",
    "endpoint": "measure - Prevalence of low birth weight (&lt;2500 g), description - , timeFrame - At birth",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03671109",
    "endpoint": "measure - Mean gestational age at birth, description - , timeFrame - At birth",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03671109",
    "endpoint": "measure - Prevalence of prematurity, description - , timeFrame - At birth",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03671109",
    "endpoint": "measure - Prevalence of embryo and foetal losses, description - , timeFrame - On average six months follow up during pregnancy",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03671109",
    "endpoint": "measure - Prevalence of small for gestational age, description - , timeFrame - At birth",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03671109",
    "endpoint": "measure - Frequency of congenital malformations, description - , timeFrame - At birth",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03671109",
    "endpoint": "measure - Incidence of clinical malaria, description - , timeFrame - During first year of life",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03671109",
    "endpoint": "measure - Neonatal mortality rate, description - , timeFrame - During neonatal period (during first 28 days of life)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03671109",
    "endpoint": "measure - Frequency of mother to child transmission of HIV at one and at 12 months of age, description - , timeFrame - During first year of life",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03671109",
    "endpoint": "measure - Infant mortality rate, description - , timeFrame - During first year of life",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03671109",
    "endpoint": "measure - Composite malaria outcome: proportion of participants with malaria infection diagnosed, description - Any malaria confirmed infection during follow up, delivery and post-partum period (blood smear, malaria PCR, placental infection), timeFrame - From enrolment until one month after end of pregnancy (on average seven months of study follow up of women, depending on gestational age at inclusion)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03671109",
    "endpoint": "measure - Composite maternal malaria and anemia: proportion of particiapnts diganosed either with malaria or anemia, description - , timeFrame - At delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03671109",
    "endpoint": "measure - Composite adverse pregnancy outcome, description - LBW, miscarriage, stillbirth, prematurity, timeFrame - Birth",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01958905",
    "endpoint": "measure - Percentage of adequate clinical and parasitological response corrected by PCR, description - same as primary outcome but after 42 days of follow-up, timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01958905",
    "endpoint": "measure - Proportion of treatment failures by types (Early Treatment Failure, Late Clinical Failure, Late Parasitological Failure), description - Endpoints defined by the standardised WHO protocol, timeFrame - 28 and 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01958905",
    "endpoint": "measure - Proportion of reinfection and recrudescence, description - , timeFrame - 28 and 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01958905",
    "endpoint": "measure - Bio-availability of lumefantrine, description - Area under curve, Cmax, Tmax of lumefantrine (estimated through population based approach, 5 samples collected per subject), timeFrame - 21 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01958905",
    "endpoint": "measure - Type and frequency of adverse events, description - , timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01194557",
    "endpoint": "measure - Appropriateness of referral of complicated malaria cases, description - , timeFrame - 36 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01043744",
    "endpoint": "measure - Etiologic agent of non-malarial febrile illness, description - , timeFrame - Day 0",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00970879",
    "endpoint": "measure - placental malaria mean parasite density at delivery, description - , timeFrame - delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00970879",
    "endpoint": "measure - proportion of low birth weight infants (&lt;2500 g) and mean birth weight, description - , timeFrame - delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00970879",
    "endpoint": "measure - proportion of maternal anaemia (&lt;11g&#x2F;dl) and severe maternal anaemia (&lt;8g&#x2F;dl) at delivery and during pregnancy, description - , timeFrame - course of pregnancy and delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00970879",
    "endpoint": "measure - cord blood malaria infection at delivery (infant parasitemia), description - , timeFrame - delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00970879",
    "endpoint": "measure - pre-term deliveries (&lt; 37 weeks), description - , timeFrame - delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00970879",
    "endpoint": "measure - spontaneous abortions (early:&lt;28 weeks, late: ≥28 weeks) and still births, description - , timeFrame - course of pregnancy",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00970879",
    "endpoint": "measure - congenital anomalies, description - , timeFrame - first 6 months of life",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00970879",
    "endpoint": "measure - safety profile of the two treatments: proportion and detailed description of adverse effects in each treatment arm, description - , timeFrame - course of pregnancy (mother) anf first 6 months of life (infant)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00970879",
    "endpoint": "measure - Mother-to-child HIV transmission rate in each treatment arm, description - , timeFrame - 2 months after breastfeeding cessation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00970879",
    "endpoint": "measure - To document the effect of cotrimoxazole in reducing infections in HIV-infected women, we will measure the incidence of bacterial and parasitic infections (other than malaria) during pregnancy, description - , timeFrame - course of pregnancy",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01053325",
    "endpoint": "measure - To evaluate the effectiveness of co-trimoxazole prophylaxis and SP IPT in reducing placenta malaria in HIV+ pregnant women with CD4 ≥ 350&#x2F;µl and in the combined group of HIV- and HIV+ pregnant women with CD4 ≥ 350&#x2F;µl, description - , timeFrame - Up to the end of pregnancy",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01053325",
    "endpoint": "measure - To evaluate the effectiveness of CTX and SP IPT in reducing malaria peripheral infection, in HIV negative, and in HIV positive pregnant women with a CD4 cell count ≥ 350&#x2F;µl, description - , timeFrame - Up to the end of pregnancy",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01053325",
    "endpoint": "measure - To evaluate the effect of CTX and SP IPT on the offspring by measuring the gestational age at delivery, perinatal mortality and birth weight, in HIV negative pregnant women and in HIV positive pregnant women with a CD4 cell count ≥ 350&#x2F;µl, description - , timeFrame - At delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01053325",
    "endpoint": "measure - To compare the effectiveness and safety profiles of CTX prophylaxis to that of SP IPT, in HIV negative pregnant women and in HIV positive pregnant women with a CD4 cell count ≥ 350&#x2F;µl, description - , timeFrame - Up to the end of pregancy",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02504593",
    "endpoint": "measure - Percent of RDTs with a false negative reading by CHVs compared across the first and tenth tests, description - Percent of RDTs with a false negative reading by CHVs compared across the first and tenth tests read with the Deki Reader for each CHV., timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02504593",
    "endpoint": "measure - Percent of RDTs with a false positive reading by CHVs compared across the first and tenth tests, description - Percent of RDTs with a false positive reading by CHVs compared across the first and tenth tests read with the Deki Reader for each CHV., timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02504593",
    "endpoint": "measure - Percent of invalid RDTs not properly identified by CHVs compared across the first and tenth tests, description - Percent of invalid RDTs not properly identified by CHVs compared across the first and tenth tests read with the Deki Reader for each CHV., timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02504593",
    "endpoint": "measure - Percent of RDTs that CHVs performed with an improper test procedure compared across the first and tenth tests., description - Percent of RDTs that CHVs performed with an improper test procedure compared across the first and tenth tests read with the Deki Reader for each CHV., timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02504593",
    "endpoint": "measure - Overall sensitivity (measured as the proportion of positive tests as determined by the DR which the CHVs correctly identify)., description - Overall sensitivity of RDTs performed by CHVs compared to the Deki Reader results.\nSensitivity will be measured as the proportion of positive tests as determined by the DR which the CHVs correctly identify., timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02504593",
    "endpoint": "measure - Overall specificity (measured as the proportion of negative tests as determined by the DR which the CHVs correctly identify)., description - Overall specificity of RDTs performed by CHVs compared to the Deki Reader results.\nSpecificity will be measured as the proportion of negative tests as determined by the DR which the CHVs correctly identify., timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01746199",
    "endpoint": "measure - observance CTM prophylaxis, description - , timeFrame - until the end of pregnancy",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01746199",
    "endpoint": "measure - occurrence of specific events related to the effectiveness of CTM prophylaxis and IPT-SP, description - <p>considered events :</p><ul><li>maternal anemia (hemoglobinemia &lt; 10g&#x2F;dl)</li><li>incidence of malaria episodes during pregnancy</li><li>abortions, stillbirth, premature (birth &lt;37 weeks of amenorrhea) and low birth weight (&lt; 2500g)</li><li>placenta malaria and umbilical malaria transmission</li></ul>, timeFrame - until the end of pregnancy",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01746199",
    "endpoint": "measure - occurence of adverse events, description - , timeFrame - until the end of pregnancy",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02708199",
    "endpoint": "measure - Number of the cases that showed drug resistance molecular markers in asymptomatic malaria infection, description - K13, Pffd, Pfmdr2 and Pfcrt markers for falciparum and Pvcrt-O, Pvdhps, Pvdhfr and Pvmdr1 for vivax asymptomatic infections.The target sequences will be analysed to detect the specific single nucleotide polymorphism (SNPs).\nMolecular marker analysis will be done as soon as after asymptomatic infection have been confirmed.\nIt will be finished in 2016 April.\n(up to 6 months after last sample collection), timeFrame - 2016 April",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02708199",
    "endpoint": "measure - Prevalence of the different Malaria Antibody in local resident in Myanmar, description - Malaria antibody that against the malaria parasites will be assessed by using high sensitive protein microarray.\nTotal overall prevalence will be assessed and time to time change of the antibody status will be observed.\nIt will be started in April until December 2016.(Up to 14 months after last sample collection), timeFrame - 2016 December",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02461186",
    "endpoint": "measure - 42 day PCR corrected adequate clinical and parasitological response (ACPR), description - , timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01658774",
    "endpoint": "measure - Prevalence and density of Plasmodium spp. infection., description - , timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01658774",
    "endpoint": "measure - Antibody isotype response to Plasmodium antigens., description - ELISA analysis will be carried out to determine IgG1and IgG3 antibody response to Plasmodium antigens (schizont extract and Merozoite Surface Proteins (MSP), timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01658774",
    "endpoint": "measure - Antibody isotype response to helminth antigens., description - ELISA analysis will be carried out to determine and IgE, IgG2, IgG4 and IgM responses to hookworm and Ascaris lumbricoides., timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02996513",
    "endpoint": "measure - Prevalence of malaria (plasmodium falciparum), description - Percentage of children with malaria (Plasmodium falciparum) as determined by a rapid test (CareStart Malaria HRP2) and confirmed by PCR., timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02996513",
    "endpoint": "measure - Prevalence of inflammation, description - Percentage of children with C-reactive protein (CRP) &gt;5 mg&#x2F;L and&#x2F;or alpha-glycoprotein (AGP) &gt;1 g&#x2F;L, timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02996513",
    "endpoint": "measure - Serum retinol, description - Serum concentration of retinol (HPLC), timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02996513",
    "endpoint": "measure - Blood haemoglobin concentration, description - Haemoglobin concentration (Quikread), timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02996513",
    "endpoint": "measure - Ferritin concentration, description - Serum concentration of ferritin (ELISA), timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02996513",
    "endpoint": "measure - Soluble transferrin receptor concentration, description - Serum concentration of soluble transferrin receptor concentration (ELISA), timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02996513",
    "endpoint": "measure - Retinol binding protein, description - Serum concentration of retinol binding protein (ELISA), timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00233337",
    "endpoint": "measure - Proportion of patients free of parasites in the blood after 7 days, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00233337",
    "endpoint": "measure - Time to clearance of fever, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00233337",
    "endpoint": "measure - Time to clearance of parasites in the blood, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00233337",
    "endpoint": "measure - Proportion of patients with presence of sexual forms of the parasite in the blood (gametocytes);, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00233337",
    "endpoint": "measure - Hematology and biochemistry, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04412005",
    "endpoint": "measure - Number of pregnant women with maternal anemia, description - Hemoglobin levels (Hemocue), timeFrame - 3 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04412005",
    "endpoint": "measure - Number of pregnant women delivering a newborn with low birthweight, description - grams in a digital scale, timeFrame - 3 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03996967",
    "endpoint": "measure - Probable bacterial pneumonia (versus viral pneumonia or severe malaria), description - Based on the review of data by an expert panel, patients will be assigned to either: a) the probable bacterial group (BA) or the b) non bacterial group.\nData to be reviewed by the panel will include chest X-ray, complete blood cell counts, other laboratory results, the clinical course during admission and following discharge.\nChildren will be assigned to the non bacterial group (i.e, VI or MA) if they have X-ray without endpoint pneumonia, pleural effusion or infiltrates, do not have bacterial infection as per the algorithm for definitive diagnosis and are not classified as bacterial infection by the expert panel., timeFrame - At admission",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03996967",
    "endpoint": "measure - Oxygen saturation curve, description - Area under the first five days of the oxygen saturation curve.\nOxygen saturation will be recorded daily in the morning in a follow-up form, timeFrame - Within the first 5 days of admission",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03996967",
    "endpoint": "measure - Need to switch antibiotic therapy, description - All patients will be classified as either needing or not needing to switch within the first three days of hospitalization their antibiotic therapy prescribed at admission based on a follow-up form, timeFrame - Within the first 3 days of admission",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03996967",
    "endpoint": "measure - Duration of hospital admission, description - The total length of hospital admission will be calculated in days for each patient based on the difference between the dates of discharge and admission., timeFrame - Within 3 days of hospital discharge",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03996967",
    "endpoint": "measure - Time to start feeding well, description - Time to feed well will be defined based on the child examination in the morning within the first 5 days of follow-up that will be recorded in a follow-up form, timeFrame - Within the first 5 days of admission",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05757167",
    "endpoint": "measure - Birthweight, description - Birthweight in grams, timeFrame - Delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05757167",
    "endpoint": "measure - Number of infants with low birthweight, description - &lt; 2500 grams, livebirth, timeFrame - Delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05757167",
    "endpoint": "measure - Gestational age (GA), description - GA at delivery in weeks&#x2F;days, livebirth, timeFrame - Delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05757167",
    "endpoint": "measure - Preterm, description - &lt; 37 0&#x2F;7 weeks, livebirth, timeFrame - Delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05757167",
    "endpoint": "measure - Number of infants that are small for gestational age, description - Weight for gestational age &lt; 10th percentile, livebirth, timeFrame - Delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05757167",
    "endpoint": "measure - Number of adverse newborn outcomes, description - low birthweight OR preterm OR small for gestational age, timeFrame - Delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05757167",
    "endpoint": "measure - Number of spontaneous abortions, description - Pregnancy loss &lt; 22 0&#x2F;7 weeks gestation, timeFrame - Delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05757167",
    "endpoint": "measure - Number of stillbirths, description - Pregnancy loss ≥ 22 0&#x2F;7 weeks gestation, timeFrame - Delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05757167",
    "endpoint": "measure - Number of early fetal deaths, description - Pregnancy loss 22 0&#x2F;7 - 27 6&#x2F;7 weeks gestation, timeFrame - Delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05757167",
    "endpoint": "measure - Number of late fetal deaths, description - Pregnancy loss ≥ 28 0&#x2F;7 weeks gestation, timeFrame - Delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05757167",
    "endpoint": "measure - Number of pregnancy losses, description - Spontaneous abortion OR stillbirth, timeFrame - Delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05757167",
    "endpoint": "measure - Number of neonatal deaths, description - Before the 28th day of life, livebirth, timeFrame - Delivery to 28 days Post-delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05757167",
    "endpoint": "measure - Number of perinatal deaths, description - Late fetal death OR Neonatal death, timeFrame - Delivery to 28 days Post-delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05757167",
    "endpoint": "measure - Incidence of clinical malaria during pregnancy, description - Maternal symptoms with peripheral malaria parasitemia detected by light microscopy or rapid diagnostic test, timeFrame - Enrollment to Delivery (including each antenatal care visit)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05757167",
    "endpoint": "measure - Number of mothers with peripheral parasitemia at delivery, description - Maternal peripheral parasitemia at delivery by PCR, timeFrame - Delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05757167",
    "endpoint": "measure - Mean maternal hemoglobin concentration, description - Maternal hemoglobin (g&#x2F;dL), timeFrame - Enrollment and Delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05757167",
    "endpoint": "measure - Number of mothers with anemia at delivery, description - Maternal Hb concentration ≤ 11 g&#x2F;dL, timeFrame - Delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05757167",
    "endpoint": "measure - Number of mothers with severe anemia at delivery, description - Maternal Hb concentration ≤ 7 g&#x2F;dL, timeFrame - Delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04844099",
    "endpoint": "measure - All cause sick visits, description - The incidence of all cause sick visits, timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04844099",
    "endpoint": "measure - Incidence of malaria parasitaemia, description - The incidence of malaria parasitaemia, timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04844099",
    "endpoint": "measure - Malaria specific sick visits, description - The incidence of malaria-specific sick visits, timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04844099",
    "endpoint": "measure - All-cause and malaria-specific hospitalisation, description - The incidence of all-cause and malaria-specific hospitalisation, timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04844099",
    "endpoint": "measure - Sickle Cell Anaemia-related vaso-occlusive events, description - The incidence of SCA-related vaso-occlusive events (including severe pain events and dactylitis); acute chest syndrome, stroke and need for blood transfusion, timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04844099",
    "endpoint": "measure - Death, description - The incidence of death., timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04844099",
    "endpoint": "measure - QTc prolongation, description - Change in Corrected QT interval (QTc) length and QTc-prolongation on four-monthly ECG recordings., timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04844099",
    "endpoint": "measure - Serious cardiac adverse events, description - Incidence of serious cardiac adverse events (e.g., convulsions or syncope within 48 hours after drug intake), timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04844099",
    "endpoint": "measure - Serious adverse events, description - Incidence of serious adverse events, timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04844099",
    "endpoint": "measure - Tolerance - vomiting, description - <ol><li>Vomiting the study drug within 30 min of administration;</li><li>Incidence of gastrointestinal complaints.</li></ol>, timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04844099",
    "endpoint": "measure - Other gastro-intestinal complaints, description - Incidence of gastrointestinal complaints., timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04844099",
    "endpoint": "measure - Level of adherence, description - Level of adherence to study drugs, timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04844099",
    "endpoint": "measure - Provider costs, description - Provider costs of delivering the interventions and provider costs of managing malaria in SCA children., timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04844099",
    "endpoint": "measure - Direct and indirect costs, description - Direct and indirect costs of patients receiving the interventions and managing cases of malaria., timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04844099",
    "endpoint": "measure - Incremental cost-effectiveness, description - Incremental cost-effectiveness of replacing current standards of care (SP) with DP or DP+SP from the perspectives of the health care provider and the society., timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01662700",
    "endpoint": "measure - Parasite clearance time, description - Parasite clearance time assessed by microscopy, timeFrame - 7 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01662700",
    "endpoint": "measure - Parasite density time, description - Time of parasite count to fall to 50%, 90% and 99% of initial parasite density, timeFrame - 7 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01662700",
    "endpoint": "measure - Fever clearance time, description - Fever clearance time (i.e. the time taken for temperature to fall below 37 degrees celsius and remain there for at least 24 hrs), timeFrame - 7 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01662700",
    "endpoint": "measure - Proportion of patients with gametocytemia, description - Proportion of patients with gametocytemia before, during and after treatment, assessed at admission, on day 3 stratified by presence of gametocytes at enrolment, timeFrame - 7 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01662700",
    "endpoint": "measure - In vitro antimalarial drug susceptibility, description - IC0, IC90, IC99 of Plasmodium vivax responses to antimalarial drugs ( ex vivo), timeFrame - 7 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00140517",
    "endpoint": "measure - see detailed description, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04268420",
    "endpoint": "measure - Determine the Protective Efficacy of FMP013&#x2F;ALFQ against a Plasmodium falciparum controlled human malaria infection., description - Proportion of vaccinated subjects without P.falciparum parasitemia (defined as one positive qRT-PCR test.\nTime to onset of P. falciparum parasitemia (defined as one positive qRT-PCR test) following CHMI., timeFrame - 505 Days (+&#x2F;-14)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04268420",
    "endpoint": "measure - Measure Immune Responses to CSP, induced by FMP013&#x2F;ALFQ using various immunoassays., description - The Quantitative Anti-CSP IgG antibody titers, isotypes, and avidity measured by ELISA, ELISpot, and multiplex-based detection systems.\nAssess cellular immune responses to CSP by multicolor flow cytometry, ELISpot, and stimulation assays., timeFrame - 505 Days (+&#x2F;-14)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04268420",
    "endpoint": "measure - Measure Immune Responses to CSP, induced by FMP013&#x2F;ALFQ using various immunoassays., description - The Qualitative Anti-CSP IgG antibody titers, isotypes, and avidity measured by ELISA, ELISpot, and multiplex-based detection systems.\nAssess cellular immune responses to CSP by multicolor flow cytometry, ELISpot, and stimulation assays., timeFrame - 505 Days (+&#x2F;-14)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03780712",
    "endpoint": "measure - Evaluate Procalcitonin (PCT) for late onset neonatal sepsis diagnostic, description - To measure in peripheral blood the association and performance of PCT and the diagnosis of late onset neonatal sepsis for infants at risk to develop infection, timeFrame - At one week after birth",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03780712",
    "endpoint": "measure - To draw Procalcitonin (PCT) expression profile during 12 weeks after birth, description - To measure PCT concentration during 12 weeks (sampling at birth, week 1, week 4, week 8 and week 12) and explore the relevance of host biomarker-driven antibiotherapy in a low-income country, timeFrame - Twelve weeks follow-up after birth",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03780712",
    "endpoint": "measure - Evaluate 2 host biomarkers mRNA expression (CD74 and CX3CR1) to prognostic neonatal sepsis, description - To measure CD74 and CX3CR1 mRNA expression in order to evaluate their performance on the early prognostic of neonatal sepsis for infants at risk to develop infections (occurrence of secondary infections and mortality rate), timeFrame - Twelve weeks follow-up after birth",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03780712",
    "endpoint": "measure - FilmArray panels for early diagnosis of neonatal sepsis, description - To test commercial FilmArray panels in order to evaluate the role of novel diagnostic techniques as part of the diagnostic algorithm on the early diagnosis of neonatal sepsis over a period of 12 weeks for infants at risk to develop infection, timeFrame - Twelve weeks follow-up after birth",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04160026",
    "endpoint": "measure - Effectiveness of service delivery, description - Proportion of pregnant women attending ANC for their first and second visit in their second or third trimester who receive the drug course correctly on exit from ANC.\nFor IPTp-SP the full dose should be given by DOT., timeFrame - Assessed 6-10 months after implementation commences",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06278181",
    "endpoint": "measure - symptomatic malaria, description - any symptomatic malaria detected during the study period , defined as symptoms such as fever, headache, body ache and positive microscopy and&#x2F;or RDT, timeFrame - 1 year follow up",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00914225",
    "endpoint": "measure - To determine the effect of LLIN and a simple microbiological water purification system on the incidence of malaria and reported diarrheal disease when added to the standard regimen of TMP&#x2F;SMX among antiretroviral naïve, HIV infected adults in Kenya., description - Aim 2: To determine the effect of the intervention on the incidence of diarrheal disease and malaria parasitemia, we will compare the frequency of reported diarrheal illness and documented parasitemia between the intervention and comparison groups using poisson regression or generalized estimating equation model., timeFrame - Same as primary outcome.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00914225",
    "endpoint": "measure - To determine the durability of provision of an LLIN and a simple microbiological water purification system on markers of disease progression up to 24 months among antiretroviral naïve, HIV infected adults in Kenya., description - Aim 3: To determine the durability of the intervention, we will evaluate the effect of the provision of LLIN and water filters on markers of disease progression up to 24 months.\nWe will compare the time to eligibility for ART between the groups and the time to CD4 counts of less than 200 and 350 respectively using Cox regression analysis models.\nIn addition, we will compare changes in mean CD4 counts overtime between the groups using linear mixed effects models controlling for baseline values., timeFrame - Same as primary outcome",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05045547",
    "endpoint": "measure - The number of VMWs that can correctly perform RDTS following a directly observed practical assessment and questionnaire., description - The number of VMWs that can correctly perform RDTS following a directly observed practical assessment and questionnaire., timeFrame - Approximately 18-24 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05045547",
    "endpoint": "measure - The number of VMWs who correctly follow the treatment algorithms following a directly observed practical assessment and questionnaire., description - The number of VMWs who correctly follow the treatment algorithms following a directly observed practical assessment and questionnaire., timeFrame - Approximately 18-24 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05045547",
    "endpoint": "measure - The overall consensus of stakeholders regarding the new roles of VMWs following stakeholder interviews, description - The overall consensus of stakeholders regarding the new roles of VMWs following stakeholder interviews, timeFrame - 0 months, mid-point of the study (12 months) and at study completion (24 months)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05045547",
    "endpoint": "measure - The overall consensus of stakeholders of the impact on non-malarial febrile illness management following stakeholder interviews, description - The overall consensus of stakeholders of the impact on non-malarial febrile illness management following stakeholder interviews, timeFrame - 0 months, mid-point of the study (12 months) and at study completion (24 months)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05045547",
    "endpoint": "measure - The number of VMWs that can correctly deliver one of four health intervention packages following a directly observed practical assessment and questionnaire., description - The number of VMWs that can correctly deliver one of four health intervention packages following a directly observed practical assessment and questionnaire., timeFrame - 0 months, mid-point of the study (12 months) and at study completion (24 months)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05045547",
    "endpoint": "measure - The number of health centre staff that can correctly perform RDTs following a directly observed practical assessment and questionnaire, description - The number of health centre staff that can correctly perform RDTs following a directly observed practical assessment and questionnaire, timeFrame - Approximately 18-24 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05045547",
    "endpoint": "measure - The overall consensus of stakeholders on the use of novel RDTs following stakeholder interviews and focus group discussions., description - The overall consensus of stakeholders on the use of novel RDTs following stakeholder interviews and focus group discussions., timeFrame - Approximately 18-24 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05045547",
    "endpoint": "measure - The overall consensus of stakeholders regarding these new roles following stakeholder interviews, description - The overall consensus of stakeholders regarding these new roles following stakeholder interviews, timeFrame - At study completion (24 months)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06182176",
    "endpoint": "measure - Incidence of clinical malaria, defined as fever of &gt;37.5C, description - History of fever in the preceding 48 hours, and a positive malaria blood film with a parasite density of &gt;0 per µl, timeFrame - Detected by passive case detection during the surveillance period, an average of 5 months after co-administration of the study medications",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06182176",
    "endpoint": "measure - Change in prevalence of anaemia on the day of inclusion, and post-intervention at the end of malaria transmission season; anaemia will be defined as Hb less than 11 g&#x2F;dL, description - Comparison of the pre- and post-intervention values of Hb concentration of study children, timeFrame - On the day of inclusion, and post-intervention at the end of malaria transmission season i.e. one month after the last SMC cycle.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06182176",
    "endpoint": "measure - Incidence of solicited adverse events and adverse drug reactions, description - Safety assessment to be related to the study medications, timeFrame - During a period of six consecutive days after co-administration of study medications",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06182176",
    "endpoint": "measure - Prevalence of P.falciparum and helminth co-infection, description - Prevalence of malaria-helminth co-infection, timeFrame - On the day of inclusion, and post-intervention at the end of malaria transmission season i.e. one month after the last SMC cycle.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06182176",
    "endpoint": "measure - Density of P.falciparum and helminth co-infection, description - Density of malaria-helminth co-infection, timeFrame - On the day of inclusion, and post-intervention at the end of malaria transmission season i.e. one month after the last SMC cycle.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01163877",
    "endpoint": "measure - Isotope incorporation into erythrocytes, description - , timeFrame - Day 15",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01163877",
    "endpoint": "measure - Biochemical parameters of iron status and infection, description - , timeFrame - Day 1",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01163877",
    "endpoint": "measure - Biochemical parameters of iron status and infection, description - , timeFrame - Day 15",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01163877",
    "endpoint": "measure - Biochemical parameters of iron status and infection, description - , timeFrame - Day 29",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01163877",
    "endpoint": "measure - Biochemical parameters of iron status and infection, description - , timeFrame - Day 43",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01163877",
    "endpoint": "measure - Isotope incorporation into erythrocytes, description - , timeFrame - Day 43",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01403350",
    "endpoint": "measure - Proportion of falciparum patients treated with artesunate combination therapy, description - Measured against the PCR result from the blood sample, timeFrame - Outcomes measured during consultation - approximately 30-40 minutes",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01403350",
    "endpoint": "measure - Accuracy of the RDT, description - Sensitivity and specificity measured against the PCR blood sample, timeFrame - Outcomes measured during consultation - approximately 30-40 minutes",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01403350",
    "endpoint": "measure - Accuracy of treatment given by the CHW in response to the RDT result, description - Proportion of patients with a positive RDT not given and appropriate antimalarial Proportion of patient with a negative RDT who are given any antimalarial, timeFrame - Outcomes measured during consultation - approximately 30-40 minutes",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01403350",
    "endpoint": "measure - Cost effectiveness of the intervention(s), description - Comparative cost-effectiveness between the arms, timeFrame - Outcomes measured during consultation - approximately 30-40 minutes",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04494854",
    "endpoint": "measure - Identification of dialogue tools allowing a better relationship of trust between doctor and patient within the framework of a prevention consultation, and better delivery of key information, description - The main themes identified through thematic coding will be used to develop the basis for a medical speech expected by patients and adapted to their needs, timeFrame - Through study completion, an average of 30 minutes",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03399318",
    "endpoint": "measure - Parasite Clearance, description - Parasite clearance was based upon AUC for plasma HRP2 concentration every six hours, timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03399318",
    "endpoint": "measure - Area-under-the-curve (AUC) of Fever ≥ 38.5°C (Best), description - AUC fever for temperatures above 37.5 degrees Celsius based upon continuous temperature monitoring A secondary efficacy measure included fever exposure as measured by the area under the temperature × time curve for T≥38.5°C during the 72-hour follow-up period, categorized as 0, &gt; 0 and &lt; 2, and ≥ 2 degree-hours.\nAn ordinal logistic regression model assuming proportional odds with terms for treatment group, country, and disease severity as covariates was used to derive the estimated adjusted treatment group odds ratio and associated 95% confidence interval.\nSensitivity analyses with best-case and worst-case imputation were performed to accommodate missing data for the 12 participants with insufficient temperature data to determine the proper outcome category, timeFrame - 72 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01441167",
    "endpoint": "measure - The secondary objectives are related to PfSPZ vaccine-mediated protection against Plasmodium falciparum (Pf) challenge at the 3 higher dosage levels., description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01754701",
    "endpoint": "measure - Hematological recovery in the immediate vs. delayed groups on Day 56, description - All children will receive iron stable isotope 57Fe on Day 0 and iron stable isotope 58Fe on Day 28.\nChildren in the immediate group will begin 27 days of daily iron syrup at home on Day 1. Children in the delayed group will begin 27 days of daily iron syrup at home on Day 29.\nAll children will be assessed at the hospital at Day 28 and Day 56., timeFrame - 56 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00510679",
    "endpoint": "measure - Proportion of children with pneumonia who received recommended treatment, according to Integrated Management of Childhood Illness guidelines., description - , timeFrame - 3 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00510679",
    "endpoint": "measure - Proportion of children with malaria who received recommended treatment, according to Integrated Management of Childhood Illness guidelines., description - , timeFrame - 3 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00819858",
    "endpoint": "measure - weight gain, description - , timeFrame - 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04189744",
    "endpoint": "measure - Individual components of the primary outcome- adverse pregnancy outcomes, description - Prevalence of individual components of primary outcome, timeFrame - 8 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04189744",
    "endpoint": "measure - Foetal loss, description - Spontaneous abortion or stillbirth (binary), timeFrame - 8 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04189744",
    "endpoint": "measure - Neonatal mortality, description - Death in the first 28 days of life (binary), timeFrame - 8 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04189744",
    "endpoint": "measure - Low birthweight, description - Birthweight &lt;2.5 kg (binary), timeFrame - 8 months from randomisation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04189744",
    "endpoint": "measure - Preterm birth, description - Birth at &lt;37 gestational weeks, timeFrame - 8 months from randomisation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04189744",
    "endpoint": "measure - Birth weight (continuous), description - Weight at birth (g), timeFrame - 8 months from randomisation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04189744",
    "endpoint": "measure - Gestational age at delivery (continuous), description - Based on gestational age measured by ultrasound at enrolment (days), timeFrame - 8 months from randomisation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04189744",
    "endpoint": "measure - Z-score for birthweight (continuous), description - Z-score for birthweight (g) from regional population reference, timeFrame - 8 months from randomisation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04189744",
    "endpoint": "measure - Small for gestational age (binary), description - Estimated as a stand-alone secondary outcome using the 10th percentile of regional reference charts on the corrected birthweight, timeFrame - 8 months from randomisation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04189744",
    "endpoint": "measure - Clinical malaria during pregnancy (binary), description - <p>Clinical malaria at any point from enrolment including delivery and 28 day postpartum, both:</p><ul><li>Documented fever (≥37.5°C), or recent history of fever in the past 24 hours, or other symptoms of acute illness that resulted in a woman seeking care with an unscheduled visit</li><li>Maternal malaria patent infection detectable by Rapid Diagnostic Test (RDT) for women with malaria symptoms only</li></ul>, timeFrame - 8 months from randomisation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04189744",
    "endpoint": "measure - Maternal malaria infection (binary), description - Malaria infection detected by PCR during pregnancy in the peripheral blood at any point during pregnancy (scheduled and unscheduled visits) from study registration, including delivery., timeFrame - 8 months from randomisation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04189744",
    "endpoint": "measure - Any malaria at delivery (binary), description - Malaria infection at delivery detected in peripheral blood by PCR or placental blood by microscopy, PCR or histology (active infection), timeFrame - 8 months from randomisation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04189744",
    "endpoint": "measure - Placental malaria infection (binary), description - <p>Placental malaria detected by microscopy, PCR , or histology (active and past infection) including any Plasmodium species detected in the placental blood or biopsy tissue by either:</p><ul><li>Placental incision smear microscopy (standard microscopy)</li><li>PCR placental blood (maternal)</li><li>Placental malaria by histology (active and past infection)</li></ul>, timeFrame - 8 months from randomisation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04189744",
    "endpoint": "measure - Congenital malaria infection (binary), description - Malaria infection detected in foetal cord blood of the new born at birth by standard microscopy, timeFrame - 8 months from randomisation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04189744",
    "endpoint": "measure - Placental malaria by histology (binary), description - <ul><li><p>Active Infection:</p><ol><li>Chronic: pigment present and asexual parasites present</li><li>Acute: pigment absent and asexual parasites present</li></ol></li><li>Past Infection: Pigment in fibrin detected in the absence of asexual parasites.</li><li><p>Placental histology categories</p><ol><li>Any</li><li>Active</li><li>Active acute</li><li>Active chronic</li><li>Past</li></ol></li></ul>, timeFrame - 8 months from randomisation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04189744",
    "endpoint": "measure - Placental Inflammation or chorioamnionitis (binary), description - Any inflammation in the placenta or chorioamnionitis detected by placental histology, timeFrame - 8 months from randomisation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04189744",
    "endpoint": "measure - Maternal anaemia (binary) and haemoglobin concentration (continuous (g&#x2F;dL) at enrolment and delivery, description - <p>Definition:</p><ul><li>No anaemia (Hb &gt;11 g&#x2F;dL)</li><li>Mild (Hb &gt;10 to &lt;11 g&#x2F;dL)</li><li>Moderate (Hb &gt;7 to &lt;10 g&#x2F;dL</li><li>Severe (Hb &lt;7 g&#x2F;dL)</li></ul>, timeFrame - 8 months from randomisation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04189744",
    "endpoint": "measure - Congenital anaemia in umbilical cord blood at delivery, description - Hb&lt;12.5 g&#x2F;dL in umbilical cord blood at birth, which is 2 standard deviations below the mean cord Hb in developed countries, timeFrame - 8 months from randomisation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04189744",
    "endpoint": "measure - Congenital malformations (binary), description - Physical abnormality of live born baby detected at delivery or newly noted abnormality during the infant visits (7 days or 2-6 weeks post-natal), timeFrame - 8 months from randomisation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04189744",
    "endpoint": "measure - Maternal mortality (binary), description - Maternal mortality from registration until 28 days after delivery, timeFrame - 8 months from randomisation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04189744",
    "endpoint": "measure - SAEs and AEs defined by MedDRA (listings), description - <p>AEs and SAEs will be defined according to the Medical Dictionary for Regulatory Activities (MedDRA) and reported by study arm:</p><ul><li>Overall</li><li>By system organ class and preferred term</li></ul>, timeFrame - 8 months from randomisation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04189744",
    "endpoint": "measure - History of vomiting study drug - Prevalence at each cycle of treatment (binary), description - Vomited within 30 minutes of taking study drug at any scheduled administration, timeFrame - 8 months from randomisation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04189744",
    "endpoint": "measure - Dizziness - Prevalence at each cycle of treatment, description - Dizziness at any point within 30 minutes of first drug administered during a treatment cycle, reported as Mothers adverse event, timeFrame - 8 months from randomisation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04189744",
    "endpoint": "measure - Gastrointestinal complaints - Prevalence at each cycle of treatment (binary), description - Nausea or vomiting within 30 minutes of first drug administered during a treatment cycle, timeFrame - 8 months from randomisation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04189744",
    "endpoint": "measure - Presence of any one or more STIs&#x2F;RTIs - Prevalence at enrolment (binary), description - Any or more infection of syphilis, gonorrhoea, chlamydia, trichomoniasis, and bacterial vaginosis, timeFrame - 8 months from randomisation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03431168",
    "endpoint": "measure - Low Birthweight (&lt;2500 Grams), description - Neonatal weight measured with digital scale, timeFrame - at birth",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03431168",
    "endpoint": "measure - Proportion With Adverse Birth Outcomes, description - Composite measure: low infant birthweight (&lt;2500 grams), miscarriage (&lt;28 weeks), preterm delivery (&lt;37 weeks), small for gestational age (SGA), congenital anomaly detected on surface examination, early neonatal mortality (within 7 days of birth), timeFrame - Birth outcomes will be measured at birth for all outcomes except early neonatal mortality defined as within 7 days of birth. Early neonatal mortality will be assessed at a six week follow up phone call.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03431168",
    "endpoint": "measure - Maternal Adherence to the Prophylactic Regimen, description - Directly observed therapy (DOT) in clinic for the 1st dose of study medication.\nSelf-report and pill count will be used to assess adherence and maternal tolerability for study medications taken at home from the time of enrollment until delivery.\nAt each follow up visit and at delivery, participants will complete a medication adherence survey.\nThey will self-report adherence to the 3 day study regimen (AZ or placebo)., timeFrame - Adherence of study medication taken at home will be documented from the date of randomization until the time of delivery, assessed up to 42 weeks.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03431168",
    "endpoint": "measure - Proportion of Participants With Symptomatic Malaria, description - Fever and positive malaria test (rapid diagnostic test) at routine visits or sick call visits or maternal report of malaria diagnosis., timeFrame - From the date of randomization until the time of delivery, assessed up to 42 weeks.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03431168",
    "endpoint": "measure - Proportion With Placental Malaria, description - Placentas will be collected on a subset of women and impression smear will be used to assess for malaria infection, timeFrame - At delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03431168",
    "endpoint": "measure - Proportion With Maternal Anemia and Severe Maternal Anemia, description - anemia defined as hemoglobin &lt;11 g&#x2F;dL, severe anemia defined as hemoglobin &lt;7 g&#x2F;dL., timeFrame - At the end of pregnancy (&gt;35 weeks) or at delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03431168",
    "endpoint": "measure - Composite STI Measure (Including All STI Tests), description - Proportion of women with GC&#x2F;CT (by NAAT), syphilis (by serology), Mycoplasma genitalium (NAAT)., timeFrame - After 35 weeks GA or at delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03431168",
    "endpoint": "measure - GBS Colonization, description - anogenital GBS colonization detected by NAAT (PCR), timeFrame - at or near term or at delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05924776",
    "endpoint": "measure - Incidence of adverse events (AE) and serious adverse events (SAE), description - Any adverse medical event occurred in the subjects who participated in the clinical study and received Plasmodium immunotherapy., timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05924776",
    "endpoint": "measure - Pain score, description - Patients are regularly evaluated with Visual Analog Scale for Pain.\nThe minimum value is 0, and the maximum value is 10.\nThe higher scores mean a worse outcome., timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01017770",
    "endpoint": "measure - Treatment failure up to day 42 (PCR adjusted and unadjusted), description - , timeFrame - Day 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01017770",
    "endpoint": "measure - Gametocytes (prevalence and density), description - , timeFrame - At day 7, 14, 21, 28, 35 and 42 days after treatment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01017770",
    "endpoint": "measure - Hb changes, description - , timeFrame - Day 35",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01941264",
    "endpoint": "measure - Birth weight, description - Babies of mothers included in the study will be weighed after delivery., timeFrame - After delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06588790",
    "endpoint": "measure - Number of participants who self-report testing for Malaria and HIV when indicated, description - <ul><li>Malaria: Self-report of malaria test for each testing indication event after baseline (presence of a fever after the baseline enrollment visit)</li><li>HIV: Self-report of HIV test for each testing indication event after baseline (possible HIV exposure as defined by screening indication)</li><li>Composite: Proportion of testing indication events after baseline that received appropriate screening&#x2F;testing for malaria and HIV.</li></ul>, timeFrame - Over a period of 6 months.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06588790",
    "endpoint": "measure - Time from testing to treatment initiation or linkage to care among participants who tested positive for malaria or HIV, description - Time from testing to treatment initiation or linkage to care if&#x2F;when indicated, for malaria and HIV, among those participants who had an indication for screening or testing., timeFrame - Over a period of 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06588790",
    "endpoint": "measure - Prevalence and incidence of positive malaria test results among participants asymptomatic and symptomatic for malaria among study populations in Zambia and Kenya, description - , timeFrame - Over a period of 6 months.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06588790",
    "endpoint": "measure - Diagnostic accuracy of a research use only malaria test for asymptomatic or symptomatic infection, as compared to rt-PCR testing from dried blood spots, description - , timeFrame - Over a period of 6 months.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06179732",
    "endpoint": "measure - feasibility, acceptance and uptake of Mesh, description - To measure community and household acceptance and uptake of Mesh, a questionnaire will be conducted with the Mesh-receiving households., timeFrame - 7 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02786589",
    "endpoint": "measure - Progression free survival(PFS), description - Progression free survival(PFS):Starting from treatment until the disease is first found or the time of any cause of death(disease progression refers to tumor growth, or metastasis of primary tumor, or discovery of new lesions)., timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02786589",
    "endpoint": "measure - Overall survival(OS), description - The time starting from the treatment to death of whatever causes (when subjects have lost to follow-up before death , the last follow-up time will be calculated as the time of death)., timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02786589",
    "endpoint": "measure - Tumor marker level, description - The patient&#x27;s sensitive tumor markers will be reviewed periodically from the time they are enrolled into the study., timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02786589",
    "endpoint": "measure - Objective response rate(ORR), description - The proportion of patients whose tumor is reduced to a certain amount and maintain a certain period of time., timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02786589",
    "endpoint": "measure - Quality of life score, description - Patients are regularly with QLQ-C30(cancer patient quality of life scale)to assess the quality of life of the patients., timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02786589",
    "endpoint": "measure - Time to progression(TTP), description - The time starting from the research to tumor progression., timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02786589",
    "endpoint": "measure - 1 year of survival rate, description - The number of cancer cases remaining after 1 year of treatment&#x2F;the total number of cancer cases treated*100%., timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02786589",
    "endpoint": "measure - 2 year of survival rate, description - The number of cancer cases remaining after 2 year of treatment&#x2F;the total number of cancer cases treated*100%., timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02786589",
    "endpoint": "measure - Immunological index, description - Detection of absolute number of immune cells(such as CD3+CD4+、CD3+CD8+ and so on) in peripheral blood by cytometry., timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01115478",
    "endpoint": "measure - Maternal anemia, description - Anemia is defined as hemoglobin less than 11 g&#x2F;dl.\nSevere anemia is less than 8.5 g&#x2F;dl., timeFrame - Delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01115478",
    "endpoint": "measure - Perinatal death, description - , timeFrame - at or after 28 weeks of gestation and in the first 7 days of life",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01115478",
    "endpoint": "measure - Maternal malaria, description - Maternal malaria will be defined as fever within the last 72 hours with any parasitemia on a peripheral blood smear., timeFrame - During pregnancy",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00137657",
    "endpoint": "measure - To measure CTX-resistance among Salmonella and other enteric bacterial pathogens in patients with diarrhea in the study area, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00137657",
    "endpoint": "measure - To assess the efficacy of sulfadoxine-pyrimethamine (SP) treatment of breakthrough P. falciparum parasitemia and clinical malaria among HIV-infected persons taking daily CTX prophylaxis, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00137657",
    "endpoint": "measure - To measure sulfa metabolite levels in HIV-infected persons receiving daily CTX who develop a drug reaction, to determine if differing rates of metabolism contribute to the development of adverse reactions, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00137657",
    "endpoint": "measure - To assess the effect of daily CTX prophylaxis on the etiology of diarrheal diseases in HIV-infected persons, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00137657",
    "endpoint": "measure - To evaluate the serotype distribution of and immune response to colonizing pneumococci, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00137657",
    "endpoint": "measure - To assess the cause of diarrheal diseases among HIV-infected persons, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00137657",
    "endpoint": "measure - To measure the change in quality of life indicators among clients receiving daily CTX, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01231113",
    "endpoint": "measure - prevalence of birth defects, description - birth defects obvious on inspection, timeFrame - assessment made 24-72 hours post-partum",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01231113",
    "endpoint": "measure - Comparative prevalence of adverse and serious adverse events, description - the data monitoring committee will assess adverse events data quarterly and advice accordingly.\nWhere there is no justification to stop the study before completion, the final assessments will done on study completion, timeFrame - three-monthly and at end of study",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01231113",
    "endpoint": "measure - pregnancy outcomes (spontaneous abortions, still births, preterm delivery, etc), description - data monitoring committee will assess generated data on the above and advice accordingly, timeFrame - quaterly from first recorded delivery and on completion",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01160809",
    "endpoint": "measure - Household ownership and utilization of LLINs, description - Owneship and utilization of LLINs by household members during the night before the baseline survey, timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01810731",
    "endpoint": "measure - Vaccine efficacy of standard dose (15 µg) QIV and double dose (30 µg) QIV in mothers and infants compared to control mothers and infants., description - Incidence of influenza infection will be measured in all participants by surveillance for influenza-like illness (ILI) throughout the study period.\nWomen with fever and cough will be tested for influenza via rRT-PCR of NP&#x2F;OP swabs.\nInfants with fever, hypothermia, apnea or any respiratory symptom will also be tested for influenza via rRT-PCR of NP&#x2F;OP swabs., timeFrame - Entire follow-up period, approx. 9 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01810731",
    "endpoint": "measure - HIV infection and placental antibody transfer, description - Compare geometric mean HI titers and geometric mean tetanus antibody titers at delivery in HIV-infected and HIV-uninfected mothers with titers in cord blood., timeFrame - Delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01810731",
    "endpoint": "measure - Birth weight, description - Compare birth weight adjusted for gestational age among standard dose (15 µg) QIV and double dose (30 µg) QIV recipients compared to controls., timeFrame - Delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01810731",
    "endpoint": "measure - Peripheral and placental parasitemia impact on vaccination, description - Compare change in geometric mean HI titers from day 0 to day 28 in women with and without peripheral parasitemia at the time of vaccination.\nCompare amount of passive antibody transfer to infants in cord blood in mothers with and without placental parasitemia, timeFrame - Day 0 and delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01810731",
    "endpoint": "measure - baseline polio immunity and polio antibody transfer, description - Assess baseline immunity to polio types 1, 2, 3 among all study participants.\nAssess polio antibody transfer to infants from mothers who did and did not receive IPV., timeFrame - day 0 and delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03934450",
    "endpoint": "measure - Primaquine Plasma concentration, ng&#x2F;mL, description - Plasma concentrations of parent drug, timeFrame - Days 0, 3, 5, 7",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03934450",
    "endpoint": "measure - Carboxy- Primaquine Plasma concentration, ng&#x2F;mL, description - Plasma concentrations of carboxy-primaquine metabolite, timeFrame - Days 0, 3, 5, 7",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03934450",
    "endpoint": "measure - Primaquine N-carbamoyl-glucuronide Plasma concentration, ng&#x2F;mL, description - Plasma concentrations of Primaquine N-carbamoyl-glucuronide metabolite, timeFrame - Days 0, 3, 5, 7",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03934450",
    "endpoint": "measure - Primaquine Orthoquinone Plasma concentration, ng&#x2F;mL, description - Plasma concentrations of Primaquine Orthoquinone metabolite, timeFrame - Days 0, 3, 5, 7",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03934450",
    "endpoint": "measure - Change in Hematocrit (%) Compared to baseline, description - Change in Hematocrit (%) Compared to baseline, timeFrame - Days 0, 3, 5, 7",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03934450",
    "endpoint": "measure - Change in Hemoglobin (g&#x2F;dL) Compared to baseline, description - Change in Hemoglobin (g&#x2F;dL) Compared to baseline, timeFrame - Days 0, 3, 5, 7",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03934450",
    "endpoint": "measure - Change in AST (U&#x2F;L) Compared to baseline, description - Change in Aspartate aminotransferase (U&#x2F;L) Compared to baseline; used to monitor liver function, timeFrame - Days 0, 3, 5, 7",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03934450",
    "endpoint": "measure - Change in ALT (U&#x2F;L) Compared to baseline, description - Change in Alanine aminotransferase (U&#x2F;L) Compared to baseline; used to monitor liver function, timeFrame - Days 0, 3, 5, 7",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03934450",
    "endpoint": "measure - Change in Total Bilirubin (mg&#x2F;dL) Compared to baseline, description - Change in Total Bilirubin (mg&#x2F;dL) Compared to baseline; used to monitor liver function and red cell integrity, timeFrame - Days 0, 3, 5, 7",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03375983",
    "endpoint": "measure - Progression free survival, description - Progression free survival (PFS): Starting from treatment until the disease progression is first found or the time of any cause of death (disease progression refers to tumor growth, or metastasis of primary tumor, or discovery of new lesions)., timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03375983",
    "endpoint": "measure - Overall survival, description - The time starting from the treatment to death of whatever causes (when subjects have lost for follow-up before death, the last follow-up time will be calculated as the time of death)., timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03375983",
    "endpoint": "measure - Tumor marker level, description - The patient&#x27;s sensitive tumor markers will be reviewed periodically from the time they are enrolled into the study., timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03375983",
    "endpoint": "measure - Objective response rate (ORR), description - The proportion of patients whose tumor is reduced to a certain amount and maintain a certain period of time., timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03375983",
    "endpoint": "measure - the Score of Quality of life, description - Patients are regularly filled with QLQ-C30 (cancer patient quality of life scale) to assess the quality of life of the patients., timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03375983",
    "endpoint": "measure - 1 year of survival rate, description - The number of cancer cases remaining after 1 year of treatment &#x2F; the total number of cancer cases treated * 100%., timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03375983",
    "endpoint": "measure - 2 year of survival rate, description - The number of cancer cases remaining after 2 years of treatment &#x2F; the total number of cancer cases treated * 100%., timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03375983",
    "endpoint": "measure - Immunological index, description - Detection of absolute number of immune cells（such as CD3+CD4+、CD3+CD8+ and so on ）in peripheral blood by flow cytometry., timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03128515",
    "endpoint": "measure - Clinical malaria incidence, description - Clinical malaria is defined as a history of fever or measured axillary temperature ≥37.5 degrees, plus Plasmodium species on blood smear., timeFrame - Over 24 month period on study drug",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03128515",
    "endpoint": "measure - Vaso-occlusive crises, description - <p>SCA-related adverse events defined as:</p><ul><li>Pain event</li><li>Dactylitis</li><li>Acute chest syndrome</li></ul>, timeFrame - Over 24 month period on study drug",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03128515",
    "endpoint": "measure - Incidence of severe adverse events (SAE), description - Death, hospitalization &gt;7 days, life-threatening event, timeFrame - Over 24 month period on study drug",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03128515",
    "endpoint": "measure - Incidence of hematologic toxicities, description - <p>Hematologic toxicities are defined as:</p><ul><li>Hemoglobin (Hb) &lt;4.0g&#x2F;dL</li><li>Hb &lt;6.0g&#x2F;dL AND absolute reticulocyte count (ARC) &lt;100 x 10E9&#x2F;L</li><li>Hb &lt;7.0g&#x2F;dL AND ARC &lt;80 x 10E9&#x2F;L</li><li>Platelets &lt;80 x 10E9&#x2F;L</li><li>Absolute neutrophil count (ANC) &lt;1.0 x 10E9&#x2F;L</li></ul>, timeFrame - Over 24 month period on study drug",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03128515",
    "endpoint": "measure - Cerebrovascular function, description - Transcranial Doppler blood vessel velocity to determine cerebrovascular function, timeFrame - At study treatment initiation then at 12 months and 24 months after study initiation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03128515",
    "endpoint": "measure - Change in creatinine levels, description - Changes in creatinine level as a measure of renal function, timeFrame - Over 24 month period on study drug",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03128515",
    "endpoint": "measure - Change in cystatin C, description - Changes in cystatin C level as a measure of renal function, timeFrame - Over 24 month period on study drug",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03128515",
    "endpoint": "measure - Change in splenic function, description - Quantitative micronuclei [Howell Jolly bodies] measured by flow cytometry, timeFrame - Over 24 month period on study drug",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03128515",
    "endpoint": "measure - Change in height-for-age z-score, description - Change in height-for-age z-score, timeFrame - Over 24 month period on study drug",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03128515",
    "endpoint": "measure - Change in weight-for-age z-score, description - Change in weight-for-age z-score, timeFrame - Over 24 month period on study drug",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03128515",
    "endpoint": "measure - Change in weight-for-height z-score, description - Change in weight-for-height z-score, timeFrame - Over 24 month period on study drug",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04296279",
    "endpoint": "measure - Determine the number of days before Plasmodium falciparum infection in controlled humans vaccinated with FMP014&#x2F;ALFQ, description - Proportion of vaccinated subjects without P.falciparum parasitemia (defined as one positive qRT-PCR test.\nTime to onset of P. falciparum parasitemia (defined as one positive qRT-PCR test) following CHMI., timeFrame - 505 Days (+&#x2F;- 14)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04296279",
    "endpoint": "measure - Measure (Quantitative) Immune Responses to CSP, induced by FMP014&#x2F;ALFQ using various immunoassays., description - Measuring the number of T-cells using peripheral blood mononuclear cells that appear in individuals each day post exposure to FPM014&#x2F;ALFQ, timeFrame - 505 Days (+&#x2F;- 14)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04296279",
    "endpoint": "measure - Measure (Qualitative) Immune Responses to CSP, induced by FMP014&#x2F;ALFQ using various immunoassays., description - Measuring quality of life by the Physicians Global Assessment that appear in individuals each day post exposure to FPM014&#x2F;ALFQ, timeFrame - 505 Days (+&#x2F;- 14)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00414479",
    "endpoint": "measure - Schistosomiasis infection, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00414479",
    "endpoint": "measure - malaria infection, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00414479",
    "endpoint": "measure - iron deficiency, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01283165",
    "endpoint": "measure - Impact of school based parasite treatment and health education intervention., description - To determine the impact of combined school based deworming and prompt malaria treatment on prevalence of helminths-Plasmodium co-infections, anaemia and severity of anaemia among primary schoolchildren in rural and commercial farming areas in Zimbabwe.\nCombined school based parasite treatment were performed at baseline and at each follow up survey.\nSustained prompt malaria treatment was performed throughout the study period., timeFrame - 3 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01785979",
    "endpoint": "measure - 3 months intermediate clinical cure, description - Reduction in spleen size of at least 40% at the 3 month follow up examination, timeFrame - 3 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01785979",
    "endpoint": "measure - 6 months intermediate clinical cure, description - Reduction in spleen size of at least 40% at the 3 month follow up examination, timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01785979",
    "endpoint": "measure - Anaemia, description - Incidence of HMS related-anemia defined by hemoglobin levels below 10 g&#x2F;L at 12 months, timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01785979",
    "endpoint": "measure - Malaria episode, description - occurrence of an acute episode of malaria identified by passive-case detection in the hospital facilities during the follow up period., timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01785979",
    "endpoint": "measure - Bacterial infection, description - occurrence of an acute bacterial infection identified by passive-case detection in the hospital facilities during the follow up period., timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04844905",
    "endpoint": "measure - Vector parous rate, description - Vector parous rate will be determined by assessment of mosquitoes trapped 7-14 days following MDA.\nVector parity will be used to determine Anopheles gambiae age structure to estimate vector survival between arms., timeFrame - 7-14 days post-MDA",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04844905",
    "endpoint": "measure - Prevalence of infection with Plasmodium falciparum, description - Prevalence of infection with Plasmodium falciparum in all age groups estimated using a cross-sectional survey sample conducted after the first year of intervention, timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04844905",
    "endpoint": "measure - Incidence of clinical malaria (Passive Case Detection), description - Incidence of clinical malaria diagnosed at health facilities confirmed by malaria Rapid Diagnostic Test, timeFrame - For six months during the malaria transmission season",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04844905",
    "endpoint": "measure - Incidence of clinical malaria (Active Case Detection), description - Incidence of clinical malaria confirmed by malaria Rapid Diagnostic Test in a cohort of 50 children per cluster aged 5-14 years, timeFrame - For six months during the malaria transmission season",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04844905",
    "endpoint": "measure - Age-adjusted prevalence of recent exposure to Plasmodium falciparum, description - Mean Median Fluorescence Intensity of serological markers associated with recent exposure to Plasmodium falciparum in all age groups estimated using a cross-sectional survey sample during peak transmission season after each year of intervention, timeFrame - Peak transmission season at 1 year and 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04844905",
    "endpoint": "measure - Vector density, description - Total number of trapped mosquitoes per cluster, timeFrame - For six months during the malaria transmission season",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04844905",
    "endpoint": "measure - Vector species composition, description - Species characterisation using nucleic acid amplification tests as a proportion of total mosquitoes caught in traps, timeFrame - For six months during the malaria transmission season",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04844905",
    "endpoint": "measure - Prevalence of exposure to Anopheles exposure, description - Mean Median Fluorescence Intensity of serological markers associated with exposure to Anopheles salivary antigen in all age groups estimated using a cross-sectional survey sample, timeFrame - Peak transmission season at 1 year and 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04844905",
    "endpoint": "measure - Vector sporozoite rates, description - Proportion of Plasmodium falciparum circumsporozoite antibody (CSP) positive mosquitoes caught in traps, timeFrame - For six months during the malaria transmission season",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04844905",
    "endpoint": "measure - Prevalence of Ivermectin-susceptible Neglected Tropical Diseases (NTDs), description - Prevalence of IVM-susceptible NTDs (scabies, strongyloides, other soil-transmitted helminths and lymphatic filariasis) and head lice using clinical and serological parameters estimated using a cross-sectional survey sample during the dry season after two years of intervention., timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04844905",
    "endpoint": "measure - MDA coverage estimates, description - Cluster level coverage estimates calculated from MDA distribution and denominator census, timeFrame - During MDA in year 1 and year 2",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04844905",
    "endpoint": "measure - Prevalence of resistance to artemisinin and partner drugs in humans, description - Prevalence of resistance to artemisinin and partner drugs in humans using molecular markers of resistance in all age groups estimated using a cross-sectional survey sample, timeFrame - Peak transmission season at 1 year and at 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02557425",
    "endpoint": "measure - Z scores for Behavioral Rating Scale, description - , timeFrame - 24, 36, and 60 months of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02557425",
    "endpoint": "measure - Z scores for Behavior Related Inventory of Executive Function (BRIEF), description - , timeFrame - 24, 36, and 60 months of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02557425",
    "endpoint": "measure - Z scores for Child Behavior Checklist (CBCL), description - , timeFrame - 24, 36, and 60 months of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01517230",
    "endpoint": "measure - Under-5 child all cause mortality, description - , timeFrame - 1year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01517230",
    "endpoint": "measure - Preventive behaviours for main causes of under-five children mortality, description - <ol><li>Antenatal consultations during the last pregnancy which lasts more than 6 months and place of delivery</li><li>Breastfeeding practices for the youngest under-five child</li><li>Behaviours to prevent cases of diarrhoea and malaria in the youngest under-five child</li></ol>, timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01517230",
    "endpoint": "measure - Knowledge, description - <ol><li>Knowledge about danger signs during pregnancy, delivery and in young ill children</li><li>Knowledge about preventive measure against malaria during pregnancy</li><li>Knowledge about recommended breastfeeding behaviours</li><li>Knowledge about transmission of malaria and diarrhoea</li><li>Knowledge about health care seeking behaviours in young children suffering from diarrhoea, bad cough</li></ol>, timeFrame - 30-36 months after the start of the intervention",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01517230",
    "endpoint": "measure - Cost-effectiveness of mass media campaigns in terms of dollars per disability-adjusted life year (DALY) averted, description - , timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01517230",
    "endpoint": "measure - Curative behaviours for main causes of under-five children mortality, description - Health care behaviours to treat cases of diarrhoea, fever, cough and respiratory difficulties in the youngest under-five child during the 15 previous days, timeFrame - 15 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05354258",
    "endpoint": "measure - Prevalence of helminth co-infection, description - Faecal egg counts for soil transmitted helminths, timeFrame - On the day of randomisation (pre-intervention) and up to 4 months post-intervention",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05354258",
    "endpoint": "measure - Prevalence of Schistosoma co-infection, description - Urine egg counts for Schistosoma haematobium, timeFrame - On the day of randomisation (pre-intervention) and up to 4 months post-intervention",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05354258",
    "endpoint": "measure - Prevalence of intensity of helminth infection, description - Arithmetic mean intensity of helminth infection, timeFrame - On the day of randomisation (pre-intervention) and up to 4 months post-intervention",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01058226",
    "endpoint": "measure - Occurrence of unsolicited AEs, description - , timeFrame - Day 0 through Day 56 post challenge",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01058226",
    "endpoint": "measure - Local and systemic solicited adverse events (AEs), description - , timeFrame - Day 5 through Day 28 post challenge",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01058226",
    "endpoint": "measure - Occurrence of serious AEs, description - , timeFrame - Day 0 through Day 56 post challenge",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01058226",
    "endpoint": "measure - Cell-mediated immune response to experimental malaria infection, description - , timeFrame - Day 0 through Day 56 post challenge",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01058226",
    "endpoint": "measure - Humoral immune responses to experimental malaria infection, description - , timeFrame - Day 0 through Day 56 post challenge",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04825782",
    "endpoint": "measure - Maternal Mortality, description - Maternal mortality up to 6 weeks post-delivery, timeFrame - Up to 6 weeks post-delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04825782",
    "endpoint": "measure - Neonatal mortality, description - Infant death by ≤28 days of birth, timeFrame - By 28 days post-delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04825782",
    "endpoint": "measure - Low birthweight, description - Birth weight&lt;2500gr, timeFrame - Within 48 hours of birth",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04825782",
    "endpoint": "measure - Prematurity, description - Delivery ≤37 completed weeks gestation, timeFrame - At delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03176719",
    "endpoint": "measure - Gametocyte PCR, description - Gametocyte PCR on EDTA whole blood stored in RNA protect, timeFrame - June 2017 - December 2017",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07261280",
    "endpoint": "measure - Timely full routine vaccination sequence (basic antigens) (Index children), description - Records of doses of routine vaccines (basic antigens) for the index child recorded in the individual child&#x27;s booklet (or self-reported by the mother if the booklet is not available).\nTaken within the appropriate time frame., timeFrame - Measured at endline, 24-26 months after baseline",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07261280",
    "endpoint": "measure - Timely full routine vaccination sequence (national schedule) (Index children), description - <p>Records of doses of routine vaccines (national schedule) for the index child recorded in the individual child&#x27;s booklet (or self-reported by the mother if the booklet is not available).</p><p>Full vaccination coverage based on the national schedule is defined as the index child having received all the following, taken within the appropriate time frame.</p>, timeFrame - Measured at endline, 24-26 months after baseline",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07261280",
    "endpoint": "measure - Early, Late or Very Late malaria vaccination (Index children), description - Record of 4 doses of malaria vaccines for the index child recorded by the individual child&#x27;s booklet (or self-reported by the mother if the booklet is not available).\nTaken outside the appropriate time frame., timeFrame - Measured at endline, 24-26 months after baseline",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07261280",
    "endpoint": "measure - Early, Late or Very Late full routine vaccination sequence (basic antigens) (Index children), description - Records of doses of routine vaccines (basic antigens) for the index child recorded in the individual child&#x27;s booklet (or self-reported by the mother if the booklet is not available).\nTaken outside the appropriate time frame, timeFrame - Measured at endline, 24-26 months after baseline",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07261280",
    "endpoint": "measure - Early, Late or Very Late full routine vaccination sequence (national schedule) (Index children), description - Records of doses of routine vaccines (national schedule) for the index child recorded in the individual child&#x27;s booklet (or self-reported by the mother if the booklet is not available).\nTaken outside the appropriate time frame., timeFrame - Measured at endline, 24-26 months after baseline",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07261280",
    "endpoint": "measure - Number of malaria vaccines taken (Index children), description - Number of recorded malaria vaccines taken (from 0 to 4) by the index child recorded by the individual child&#x27;s booklet (or self-reported by the mother if the booklet is not available)., timeFrame - Measured at endline, 24-26 months after baseline",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07261280",
    "endpoint": "measure - Number of routine vaccines taken (basic antigens) (Index children), description - Number of recorded basic antigens taken (0 to 9) by the index child recorded by the individual child&#x27;s booklet (or self-reported by the mother if the booklet is not available)., timeFrame - Measured at endline, 24-26 months after baseline",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07261280",
    "endpoint": "measure - Number of routine vaccines taken (full national schedule) (Index children), description - Number of recorded vaccinations taken (0 to 19) from the national schedule by the index child recorded by the individual child&#x27;s booklet (or self-reported by the mother if the booklet is not available), timeFrame - Measured at endline, 24-26 months after baseline",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07261280",
    "endpoint": "measure - Number of timely malaria vaccines taken (Index children), description - Number of recorded malaria vaccines taken (from 0 to 4) within the appropriate time frame by the index child recorded by the individual child&#x27;s booklet (or self-reported by the mother if the booklet is not available)., timeFrame - Measured at endline, 24-26 months after baseline",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07261280",
    "endpoint": "measure - Number of timely routine vaccines taken (basic antigens) (Index children), description - Number of recorded basic antigens taken (0 to 9) within the appropriate time frame by the index child recorded by the individual child&#x27;s booklet (or self-reported by the mother if the booklet is not available), timeFrame - Measured at endline, 24-26 months after baseline",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07261280",
    "endpoint": "measure - Number of timely routine vaccines taken (full national schedule) (Index children), description - Number of recorded vaccinations taken (0 to 19) from the national schedule within the appropriate time frame by the index child recorded by the individual child&#x27;s booklet (or self-reported by the mother if the booklet is not available), timeFrame - Measured at endline, 24-26 months after baseline",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07261280",
    "endpoint": "measure - Received each vaccine on time (full national schedule) (Index child), analyzed individually, description - Among each of the following, analyzed individually, index child received the vaccine within the appropriate time frame according to the national schedule (as recorded in the individual child&#x27;s booklet or as self-reported by the mother), timeFrame - Measured at endline, 24-26 months after baseline",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07261280",
    "endpoint": "measure - Up to date on malaria vaccine (children under 3 years old in study households), description - Record of having taken all doses of malaria vaccine as appropriate for child&#x27;s age as recorded by the children&#x27;s booklets (or self-reported by the mother if the booklet is not available), timeFrame - Measured at endline, 24-26 months after baseline",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07261280",
    "endpoint": "measure - Up to date on routine vaccines (basic antigens) (Children under 3 years old in study households), description - Record of having taken all doses of basic antigens as appropriate for child&#x27;s age as recorded by the children&#x27; s booklets (or self-reported by the mother if the booklet is not available), timeFrame - Measured at endline, 24-26 months after baseline",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07261280",
    "endpoint": "measure - Up to date on routine vaccines (full schedule) (Children under 3 years old in study households), description - Record of having taken all doses of national vaccine schedule as appropriate for child&#x27;s age as recorded by the children&#x27; s booklets (or self-reported by the mother if the booklet is not available), timeFrame - Measured at endline, 24-26 months after baseline",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07261280",
    "endpoint": "measure - Cumulative number of late days in receipt of malaria vaccination (index children), description - Among those who received at least a dose of the malaria vaccine, the number of days late the vaccine(s) were relative to what the national schedule considers &quot;on time&quot; for each dose.\nLate days are equal to zero for those who received the vaccine on time or early., timeFrame - Measured at endline, 24-26 months after baseline",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07261280",
    "endpoint": "measure - Cumulative number of late days in receipt of basic antigens (index children), description - Among those who received at least one dose of basic antigens, the number of days late the vaccine(s) were relative to what the national schedule considers &quot;on time&quot; for each dose.\nLate days are equal to zero for those who received the vaccine on time or early., timeFrame - Measured at endline, 24-26 months after baseline",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07261280",
    "endpoint": "measure - Cumulative number of late days in receipt of routine vaccines according to national schedule (index children), description - Among those who received at least one dose of routine vaccines according to the national schedule, the number of days late the vaccine(s) were relative to what the national schedule considers &quot;on time&quot; for each dose.\nLate days are equal to zero for those who received the vaccine on time or early., timeFrame - Measured at endline, 24-26 months after baseline",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07261280",
    "endpoint": "measure - Mother knows when to bring the child to the clinic for the first vaccination, description - Mother self-reports being sure or very sure about when to bring the child to the clinic for the first vaccination, timeFrame - Measured at endline, 24-26 months after baseline",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07261280",
    "endpoint": "measure - Facility Vaccine Data Accuracy, description - Discrepancy in the total number of children vaccinated based on paper-based records at the facility vs digital records in DHMIS 2. Measured as the vaccine &quot;verification factor&quot; for BCG, Penta 3 and MR-2 over a three month period, comparing the total number of children vaccinated with each of the three vaccines over this period reported in DHIMS 2 with the paper-based record., timeFrame - Measured around endline, 24-26 months after baseline",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01136850",
    "endpoint": "measure - Prevalence of P falciparum at delivery in peripheral, placental and cord blood films and on placental histology, description - , timeFrame - at delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01136850",
    "endpoint": "measure - Mean maternal hemoglobin concentration at delivery, and proportion of women anaemic (Hb &lt; 11 g&#x2F;dl)., description - , timeFrame - At delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01136850",
    "endpoint": "measure - Prevalence (at enrolment, second treatment, and delivery) and consequences (maternal haemoglobin, birth weight and placental pathology) of P. vivax infection in pregnancy, description - From enrolment at 14-26 weeks gestation, until delivery, timeFrame - up to 26 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01136850",
    "endpoint": "measure - Incidence of symptomatic malaria during pregnancy, description - From enrolment at 14-26 weeks until delivery, timeFrame - Up to 26 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01136850",
    "endpoint": "measure - Proportion of women carrying azithromycin-sensitive sexually transmitted infections at second treatment visit (28-34 weeks)., description - , timeFrame - 28-34 week gestation study visit",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01136850",
    "endpoint": "measure - Incidence of Adverse Events, including severe adverse events (SAEs), and AEs possibly or probably associated with study medications, description - From enrolment at 14-26 weeks gestation until delivery, timeFrame - 14-26 weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01136850",
    "endpoint": "measure - Prevalence of drug resistance markers in parasites infecting women in late pregnancy, particularly in the P falciparum and P vivax dihydrofolate reductase and dihydropteroate synthase enzymes, associated with SP resistance, description - , timeFrame - at delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01136850",
    "endpoint": "measure - Prevalence and antibiotic sensitivity patterns of S. pneumoniae in nasopharyngeal swabs collected at delivery, description - , timeFrame - at delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01136850",
    "endpoint": "measure - Maternal, perinatal and infant mortality rates, description - maternal mortality is during pregnancy and until 6 weeks post partum.\nPerinatal mortality is from 28 weeks gestation until 6 weeks postpartum.\nInfant mortality is from irth to 12 months of age, timeFrame - Mothers; up to 32 weeks, from enrolment at 14-26 weeks gestation, until delivery. Pernatal: 16 weeks, from 28 weeks gestation to 4 weeks of age. Infant: from live birth to 1 year of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01136850",
    "endpoint": "measure - Impact of IPTp on development of immunity to malaria in pregnancy, description - , timeFrame - at delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01136850",
    "endpoint": "measure - Characteristics of parasites infecting pregnant women, description - , timeFrame - Up to 26 weeks, from 14-26 weeks gestation until delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04529434",
    "endpoint": "measure - Mean number of female An. gambiae s.l., description - Mean number of female An.\ngambiae s.l.&#x2F;light trap&#x2F;night, timeFrame - Approximately 3 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04529434",
    "endpoint": "measure - Mean number of flies, description - Mean number of flies&#x2F;sticky trap&#x2F;week in kitchens of the houses, timeFrame - Approximately 3 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04529434",
    "endpoint": "measure - Entomological inoculation rate of malaria vectors., description - Compare entomological inoculation rate of mosquito inside novel and traditional rural houses., timeFrame - Approximately 3 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04529434",
    "endpoint": "measure - Children requiring hospital admission, description - Compare hospitalization rate of children under 13 years living inside novel and traditional rural houses., timeFrame - Approximately 3 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04529434",
    "endpoint": "measure - Major respiratory pathogens, description - From children requiring hospital admission, the most frequently detected respiratory tract pathogens will be assessed through blood culture., timeFrame - Approximately 3 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04529434",
    "endpoint": "measure - Major enteric pathogens, description - From children requiring hospital admission, the most frequently detected enteric pathogens will be assessed through rotavirus ELISA testing and bacterial culture of stool specimens., timeFrame - Approximately 3 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04529434",
    "endpoint": "measure - Prevalence of malaria parasitaemia among children living in novel design houses and traditional homes., description - Prevalence will be assessed from a cross-sectional surveys of children, based on dried blood smears will be collected for quantitative polymerase chain reaction once per quarter., timeFrame - Approximately 3 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04529434",
    "endpoint": "measure - Mean changes in weight, description - Weight in kilograms of children under 13 years of age recorded at baseline, annually and at end of the study., timeFrame - Approximately 3 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04529434",
    "endpoint": "measure - Mean changes in height, description - Height in meters of children under 13 years of age recorded at baseline, annually and at end of the study., timeFrame - Approximately 3 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04529434",
    "endpoint": "measure - Mean changes in body mass index (BMI), description - BMI in Kg&#x2F;m2 in meters of children under 13 years of age recorded at baseline, annually and at end of the study., timeFrame - Approximately 3 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04529434",
    "endpoint": "measure - Mean changes in mid-upper arm circumference, description - Mid-upper arm circumference in millimeters of children under 13 years of age recorded at baseline, annually and at end of the study., timeFrame - Approximately 3 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04529434",
    "endpoint": "measure - Disease severity, description - A subgroup analysis of children requiring hospital consultation and children requiring hospitalization., timeFrame - Approximately 3 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04529434",
    "endpoint": "measure - Indoor temperature, description - Temperature will be measured using data loggers., timeFrame - Approximately 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04529434",
    "endpoint": "measure - Humidity, description - Humidity will be measured using data loggers., timeFrame - Approximately 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04529434",
    "endpoint": "measure - Carbon dioxide (CO2), description - Carbon dioxide (CO2) will be measured using data loggers., timeFrame - Approximately 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04529434",
    "endpoint": "measure - Particulate matter 2.5 (PM2.5) particle pollution, description - PM2.5 particle pollution will be measured using data loggers., timeFrame - Approximately 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04529434",
    "endpoint": "measure - Acceptability of the novel design houses., description - The acceptability will be measured through a mixed method: 1) quantitative method i.e. closed ended questions with a pre-determined set of choices 2) qualitative method i.e. open ended questions through focused group discussions and in-depth interviews., timeFrame - Interviews at 6 months after moving in, 1 year and at the end of the study",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04529434",
    "endpoint": "measure - Bednet use, description - Assessed by asking residents and in children with less than 5 years old in traditional and novel design homes regarding the use of insecticide treated bednets., timeFrame - Annually (for three years)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04529434",
    "endpoint": "measure - Life-cycle analysis, description - This is the cost of illness averted by living in a novel-designed home against a background of complete coverage with insecticide-treated nets.\nThe analysis will include cost comparison (construction and maintenance of novel and control houses) and market analysis., timeFrame - Over 36 months period starting from moving in date.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04529434",
    "endpoint": "measure - Durability, description - Yearly inspections of houses (control and intervention).\nMaintenance of structural problems on demand., timeFrame - End of year 1, 2 and 3.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02991963",
    "endpoint": "measure - Proportion of malaria infections in Ubon Ratchathani Province, description - Proportion of malaria infections that are imported in Ubon Ratchathani Province, Thailand, timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02991963",
    "endpoint": "measure - Prevalence of clinical antimalarial drug resistance, description - Prevalence of clinical antimalarial drug resistance in cases of P. falciparum malaria in Ubon Ratchathani Province, Thailand, timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02991963",
    "endpoint": "measure - Human movement leading to spread of malaria and antimalarial drug resistance, description - 4. Estimates of the potential for spread of malaria and antimalarial drug resistance from Ubon Ratchathani Province, Thailand through human movement to other locations., timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02991963",
    "endpoint": "measure - Measure antimalarial drug in blood prior to participate in the study, description - List of antimalarials which patients have recently taken, if any, prior to presentation in order to estimate drug pressure on the parasite population., timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01156896",
    "endpoint": "measure - Erythrocyte 58Fe incorporation, description - Erythrocyte 58Fe incorporation will be measured using stable-isotope techniques., timeFrame - Determined 2 weeks after iron intervention",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01156896",
    "endpoint": "measure - Fractional 57Fe absorption, description - Fractional 57Fe absorption will be measured using stable-isotope techniques, timeFrame - Determined 2 weeks after iron intervention",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00167713",
    "endpoint": "measure - Parasite clearance time, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00167713",
    "endpoint": "measure - Adverse event during the entire study period, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01154803",
    "endpoint": "measure - Number of new events of a study disease, description - study disease: malaria, diarrhoea, and LRTI, timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05123378",
    "endpoint": "measure - Health care utilization, description - Determine effects of the NCHA program on health care utilization, timeFrame - Cross-sectional household surveys administered at baseline in 2018, midline 2019 and 2021, and endline in 2022",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05123378",
    "endpoint": "measure - Child illness prevalence, description - Determine effects of the NCHA program on child illness prevalence, timeFrame - Cross-sectional household surveys administered at baseline in 2018, midline 2019 and 2021, and endline in 2022",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05123378",
    "endpoint": "measure - Experiential quality and trust in the health care system, description - Determine effects of the NCHA program on experiential quality and trust in the health care system, timeFrame - Cross-sectional household surveys administered at baseline in 2018, midline 2019 and 2021, and endline in 2022",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02223871",
    "endpoint": "measure - Maximum Plasma Concentration (Cmax) of ACT-451840, description - Cmax was directly derived from the plasma concentrations-time curves of ACT-451840.\nBlood samples for pharmacokinetic characterization were drawn at pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 20, 24, 48, 72, 96, and 144 hours post-dose., timeFrame - From pre-dose to 144 hours after study drug adminsitration",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02223871",
    "endpoint": "measure - Time to Reach Maximum Plasma Concentration (Tmax) of ACT-451840, description - tmax was directly derived from the plasma concentration-time curves of ACT-451840.\nBlood samples for pharmacokinetic characterization were drawn at pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 20, 24, 48, 72, 96, and 144 hours post-dose., timeFrame - From pre-dose to144 hours after study drug administration",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02223871",
    "endpoint": "measure - Areas Under the Plasma Concentration-time Curve of ACT-451840, description - <p>Two AUCs were calculated using non-compartmental analysis: AUC(0-t) from pre-dose to last time-point of measure and AUC(0-inf) from pre-dose and extrapolated to infinity.</p><p>Blood samples for pharmacokinetic characterization were drawn at pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 20, 24, 48, 72, 96, and 144 hours post-dose</p>, timeFrame - From pre-dose to144 hours after study drug administration",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02223871",
    "endpoint": "measure - Terminal Half-life [t(1&#x2F;2)], description - Blood samples for pharmacokinetic characterization were drawn at pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 20, 24, 48, 72, 96, and 144 hours post-dose, timeFrame - From pre-dose to144 hours after study drug adminsitration",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02223871",
    "endpoint": "measure - Change From Baseline in Blood Pressure to End of Study (EOS), description - Vital signs, including diastolic and systolic blood pressure (DBP&#x2F;SBP), were measured at each outpatient visit up to 7 days after ACT-451840 administration, every day during confinement or when malaria symptoms were presented and at the end of study visit (EOS).\nOther measures were performed if required., timeFrame - Day 28 (EOS)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02223871",
    "endpoint": "measure - Change From Baseline in Body Temperature up to End of Study (EOS), description - Body temperature was measured orally, timeFrame - Day 28 (EOS)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02223871",
    "endpoint": "measure - Change From Baseline in Respiratory Rate to End of Study (EOS), description - , timeFrame - Day 28 (EOS)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06162078",
    "endpoint": "measure - Adverse birth outcomes, description - Prevalence of adverse birth outcomes (spontaneous abortion, stillbirth, low birth weight (&lt;2,500 g), preterm delivery (&lt;37 weeks)), timeFrame - 9 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06162078",
    "endpoint": "measure - Uptake IPTp-SP (Intermittent preventive treatment of malaria in pregnancy using sulfadoxine-pyrimethamine) during the pregnancy, description - Proportion of pregnant women receiving one, two, three and ≥ 3 doses of IPT-SP during the pregnancy, timeFrame - 9 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07094646",
    "endpoint": "measure - Frequency of Malaria Parasitemia, description - How common malaria parasitemia in children needing blood transfusions in Eastern Uganda., timeFrame - At enrollment.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07094646",
    "endpoint": "measure - Frequency of Iron Deficiency, description - How often people who get blood transfusions have low iron levels, and the iron levels in the blood that is donated and used for transfusions, timeFrame - At enrollment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07094646",
    "endpoint": "measure - Blood Group Markers, description - Checking to ensure safe blood matches from donated blood and people receiving blood transfusions., timeFrame - At enrollment.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01196520",
    "endpoint": "measure - Malaria, description - Positive diagnosis for parasitemia based on blood smear or antigenemia based on a rapid diagnostic test., timeFrame - At enrollment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00131235",
    "endpoint": "measure - Percentage of low birth weight babies, description - Birth weight &lt; 2500 g, timeFrame - Once, after delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00131235",
    "endpoint": "measure - Mean birth weight, description - Measured in grams, timeFrame - Once, after delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00131235",
    "endpoint": "measure - Mean duration of gestation, description - Measured in gestation weeks, expressed to one deciman,, timeFrame - Once, after delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00131235",
    "endpoint": "measure - Percentage of low head circumference at birth, description - Below 2 standard deviations of the mean of international reference population, timeFrame - Once, after delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00131235",
    "endpoint": "measure - Incidence of moderate underweight during infancy or childhood, description - weight for age Z-score &lt; -2, timeFrame - Cumulative during infancy and childhood",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00131235",
    "endpoint": "measure - Perinatal mortality, description - Stillbirths after 22 gestation weeks or within first 7 days of life &#x2F; 1000 live births, timeFrame - Cumulative until 7 days of post-natal life",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00131235",
    "endpoint": "measure - Neonatal mortality, description - Deaths within first 28 days of life &#x2F; 1000 live births, timeFrame - Cumulative until 28 days of post-natal life",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00131235",
    "endpoint": "measure - Infant mortality, description - Deaths within first 265 days of life &#x2F; 1000 live births, timeFrame - Cumulative until 365 days of post-natal life",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00131235",
    "endpoint": "measure - Mean maternal blood haemoglobin concentration at each antenatal visit and at 1, 3, and 6 months after delivery, description - Measured with hemocue meter, expressed as grams &#x2F; liter, timeFrame - Several antenatal and postnatal visits",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00131235",
    "endpoint": "measure - Percentage of women with mild, moderate or severe anaemia at every antenatal visit and at 1, 3, and 6 months after delivery, description - Cut-offs for mild, moderate and severa anaemia 110 g &#x2F; l - 80 g &#x2F; l - 50 g &#x2F; l, timeFrame - Several antenatal and postnatal visits",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00131235",
    "endpoint": "measure - Percentage of women with peripheral blood malaria parasitaemia at 32 gestational weeks and at delivery, description - Measured with microscopy from fresh blood slides and with real-time PCR from dried blood spots, timeFrame - At enrolment, every 4 weeks thereafter and at delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00131235",
    "endpoint": "measure - Maternal weight gain during pregnancy, description - grams &#x2F; gestation week, timeFrame - Cumulative during pregnancy",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00131235",
    "endpoint": "measure - Mean number of maternal illness days during pregnancy, description - Self reported illness symptoms, timeFrame - Cumulative during pregnancy",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00131235",
    "endpoint": "measure - Prevalence of maternal chlamydia trachomatis, neisseria gonorrhoea, and vaginal trichomoniasis infection at 4 weeks after delivery, description - Chlamydia and gonorhoea measured from urine samples with a PCR, vaginal trichomoniasis measures with a wet microscopy, timeFrame - At 4 weeks after delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00131235",
    "endpoint": "measure - Attained lenght &#x2F; height, description - Measured as length until 2 years of age, then height; expressed in cm (one decimal) and as length &#x2F; heigh for age Z-score, timeFrame - 1, 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 48, 60 months and 10-12 years of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00131235",
    "endpoint": "measure - Attained weight, description - Expressed in kg with two decimals and as weight for age Z-score, timeFrame - 1, 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 48, 60 months and 10-12 years of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00131235",
    "endpoint": "measure - Nutritional status, description - Mid-upper arm circumference, in mm (no decimals), timeFrame - 1, 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 48, 60 months and 10-12 years of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00131235",
    "endpoint": "measure - Attained head circumference, description - Head circumference, in mm, no decimals, timeFrame - 1, 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 48, 60 months and 10-12 years of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00131235",
    "endpoint": "measure - Childhood mortality, % of subjects who have died by the 10-12 year follow-up visit, description - Deaths, information obtained from parents or other adults who have lived in the same household with the child, timeFrame - Cumulative incidence by 10-12 years of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00131235",
    "endpoint": "measure - Motor development, Griffiths test, sub-score, description - Summary score from questions in the gross motor and fine motor domain questions, timeFrame - 5 years of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00131235",
    "endpoint": "measure - Social development, Griffiths test, sub-score, description - Summary score from questions in the social development domain questions, timeFrame - 5 years of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00131235",
    "endpoint": "measure - Cognitive development, Raven&#x27;s colour matrix, score, description - Summary score from 36 questions in the Raven&#x27;s colour matrix test, timeFrame - 10-12 years of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00131235",
    "endpoint": "measure - Reaction time, milliseconds, description - <p>This will be tested with an eye-tracking device (Tobii).\nParticipants are asked to look from the fixation point to different directions or fixate the gaze at one point.\nWe will measure the horizontal eye-movements (saccades) and calculate the reaction times, scoring the task correct&#x2F;incorrect (direction).</p><p>This eye-tracking system is based on a Pupil Centre Corneal Reflection (PCCR) technique, in which near infrared illumination is reflected on the cornea relative to the center of the pupil.\nThe eye-tracking cameras capture the light reflections and create a 3D model of the eye and head-position to track the participant&#x27;s point of gaze at high temporal and spatial accuracy (60 Hz&#x2F;0.4°).\nThe results will be stored automatically into a data base.</p>, timeFrame - 10-12 years of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00131235",
    "endpoint": "measure - Systolic blood pressure, mmHg, description - Will use oscillometric Mobil o Graph blood pressure monitoring system (accuracy +&#x2F;- 3 mmHg), when the child is first sitting, then standing and last lying down., timeFrame - 10-12 years of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00131235",
    "endpoint": "measure - Diastolic blood pressure, mmHg, description - Will use oscillometric Mobil o Graph blood pressure monitoring system (accuracy +&#x2F;- 3 mmHg), when the child is first sitting, then standing and last lying down., timeFrame - 10-12 years of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00131235",
    "endpoint": "measure - Central blood pressure, mmHg, description - Will use oscillometric Mobil o Graph blood pressure monitoring system (accuracy +&#x2F;- 3 mmHg), when the child is first sitting, then standing and last lying down., timeFrame - 10-12 years of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00131235",
    "endpoint": "measure - Pulse rate, beats &#x2F; minutes, description - Will use oscillometric Mobil o Graph blood pressure monitoring system.\nWe will measure pulse rate &#x2F; minutes, when the child is first sitting, then standing and last lying down., timeFrame - 10-12 years of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00131235",
    "endpoint": "measure - Vascular resistance, mmHg·min&#x2F;l, description - Will use oscillometric Mobil o Graph blood pressure monitoring system.\nWe will measure vascular resistance, when the child is first sitting, then standing and last lying down., timeFrame - 10-12 years of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00131235",
    "endpoint": "measure - Lean body mass, expressed in kg, with one decimal, description - Body composition measured with 8-polar biompedance method (Seca® mBCA 515 Medical Body Composition Analyser), validated with Deuterium Dilution Technique with Analysis of Saliva Samples by Fourier Transform Infrared Spectrometry (FTIR), timeFrame - 10-12 years of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00131235",
    "endpoint": "measure - Fat mass, expressed in kg, with one decimal, description - Body composition measured with 8-polar biompedance method (Seca® mBCA 515 Medical Body Composition Analyser), validated with Deuterium Dilution Technique with Analysis of Saliva Samples by Fourier Transform Infrared Spectrometry (FTIR), timeFrame - 10-12 years of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00131235",
    "endpoint": "measure - Fat percentage, expressed proportion of body weight (per cent, with one decimal), description - Body composition measured with 8-polar biompedance method (Seca® mBCA 515 Medical Body Composition Analyser), validated with Deuterium Dilution Technique with Analysis of Saliva Samples by Fourier Transform Infrared Spectrometry (FTIR), timeFrame - 10-12 years of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00131235",
    "endpoint": "measure - Self-rated well-being, score, description - Self-reported well-being will be measured with 11 question panel with rating from 1-5 expressed as smileys.\nThe questions consider about &quot;how happy you are about the things you own, school, house you live, food, clothes, other pupils, friends, the family, safety feeling, the way you look, with yourself&quot;.\nScore for self-reported well-being will be calculated as a sum of ratings for each item divided by the number of items with non-missing data.\nThere are two items related to the child&#x27;s school and they are not applicable if the child does not go to school.\nThe minimum score for self-reported well-being is 1 and the maximum is 5, and the score will be expressed with one decimal., timeFrame - 10-12 years of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04165590",
    "endpoint": "measure - Tumor marker level, description - The patient&#x27;s sensitive tumor markers will be reviewed periodically from the time they are enrolled into the study., timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04165590",
    "endpoint": "measure - Disease Control Rate, description - The proportion of patients who had a best response rating of complete response, partial response, or stable disease., timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04165590",
    "endpoint": "measure - Immunological index, description - Detection of absolute number of immune cells（such as CD3+CD4+、CD3+CD8+ and so on）in peripheral blood by flow cytometry., timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04165590",
    "endpoint": "measure - Quality of life score, description - Patients are regularly filled with QLQ-C30 (cancer patient quality of life scale) to assess the quality of life of the patients., timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04165590",
    "endpoint": "measure - Overall survival, description - The time starting from the treatment to death of whatever causes (when subjects have lost for follow-up before death, the last follow-up time will be calculated as the time of death)., timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04165590",
    "endpoint": "measure - 1 year of survival rate, description - The number of cancer cases remaining after 1 year of treatment &#x2F; the total number of cancer cases treated * 100%., timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04165590",
    "endpoint": "measure - 2 year of survival rate, description - The number of cancer cases remaining after 2 years of treatment &#x2F; the total number of cancer cases treated * 100%., timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04165590",
    "endpoint": "measure - time of tumor progression, description - TTP is the time between the beginning of treatment and the onset of tumor progression., timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04165590",
    "endpoint": "measure - Duration of disease control, description - Duration of disease control is the time from the first evaluation of the tumor as CR, PR or SD to the first evaluation as PD (progressive disease) or any cause of death., timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04165590",
    "endpoint": "measure - pain score, description - Patients are regularly evluated with pain assessment scale, timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02414399",
    "endpoint": "measure - Mean Change in Length for Age Z-score (LAZ) Between Baseline and Outcome Assessment, description - Mean change in length for age z-score (LAZ) between baseline and M3 or M6, timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02414399",
    "endpoint": "measure - The Number of Children With Diarrhea Re-hospitalizations Following Randomization, description - The number of children with diarrhea re-hospitalizations following randomization through follow-up, timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02414399",
    "endpoint": "measure - The Number of Children With Acute Respiratory Illness Re-hospitalizations Following Randomization, description - , timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02414399",
    "endpoint": "measure - The Number of Children With Malnutrition Re-hospitalizations Following Randomization, description - , timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02414399",
    "endpoint": "measure - The Number of Children With Malaria Re-hospitalizations Following Randomization, description - , timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02414399",
    "endpoint": "measure - Prevalence of Enteric Pathogen Carriage, description - Prevalence of enteric bacteria, viruses, and protozoa identified by qPCR at 3 months of follow-up, timeFrame - 3 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02414399",
    "endpoint": "measure - Prevalence of Streptococcus Pneumoniae Carriage, description - Prevalence of Streptococcus pneumoniae from nasopharyngeal swabs collected at M3 and M6 follow-up timepoints., timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02414399",
    "endpoint": "measure - Number of Participants With Escherichia Coli Isolates From Fecal Samples Resistant to Azithromycin, description - Among participants with E.coli isolated, # of participants with aizhtromycin resistance detected in E.coli form disc diffusion., timeFrame - 6 months (E.coli isolated at baseline, month 3, and month 6)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02414399",
    "endpoint": "measure - Proportion of Beta-lactam or Macrolide Resistance in Strep Pneumo in Children and Caregivers, description - , timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01459146",
    "endpoint": "measure - Number of participants with adverse events as a measure of safety and tolerability, description - Number of reported adverse events within twelve months of intervention per study arm, timeFrame - Day 365",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01459146",
    "endpoint": "measure - Number of schoolchildren with sustained attention and recall as a measure of efficacy, description - Change in sustained classroom attention and recall in 365 days of start of intervention from baseline, timeFrame - Day 365",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01459146",
    "endpoint": "measure - Proportion of schoolchildren with anemia as a measure of safety and tolerability, description - Proportion of schoolchildren having hemoglobin level less than 12.0g&#x2F;dl from baseline level in 365 days of start of intervention, timeFrame - Day 365",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01459146",
    "endpoint": "measure - Prevalence and intensity of urinary schistosomiasis as a measure of efficacy, description - Proportion of schoolchildren with urinary schistosomiasis by study arm compared to baseline, timeFrame - 365 days post first intervention",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01459146",
    "endpoint": "measure - Prevalence and density of malaria parasites by microscopy as a measure of efficacy, description - Proportion of schoolchildren with malaria parasitemia by study arm compared to baseline, timeFrame - 365 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01459146",
    "endpoint": "measure - Prevalence and intensity of intestinal schistosomiasis among schoolchildren as a measure of efficacy, description - Proportion of schoolchildren with intestinal schistosomiasis by study arm compared to baseline, timeFrame - 365 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03261401",
    "endpoint": "measure - Part A: Maximum Observed Plasma Concentration (Cmax) of M5717, description - Cmax was obtained directly from the concentration versus time curve., timeFrame - Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, 48, 72, 96, 120, 144, 192, 240, 384, 504, 768 and 1032 hours post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03261401",
    "endpoint": "measure - Part A: Time to Reach Maximum Observed Plasma Concentration (Tmax) of M5717, description - The time to reach the maximum observed plasma concentration (tmax) was obtained directly from the concentration versus time curve., timeFrame - Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, 48, 72, 96, 120, 144, 192, 240, 384, 504, 768 and 1032 hours post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03261401",
    "endpoint": "measure - Part A: Terminal Elimination Rate Constant (Lambda z) of M5717, description - Lambda z determined from the terminal slope of the log-transformed concentration curve using linear regression on terminal data points of the curve., timeFrame - Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, 48, 72, 96, 120, 144, 192, 240, 384, 504, 768 and 1032 hours post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03261401",
    "endpoint": "measure - Part A: Apparent Terminal Half Life (t1&#x2F;2) of M5717, description - T1&#x2F;2 was the time measured for the concentration to decrease by one half.\nT1&#x2F;2 was calculated as natural log2 divided by lambda z.\nLambda Z was terminal elimination rate constant determined from the terminal slope of the log-transformed plasma concentration curve., timeFrame - Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, 48, 72, 96, 120, 144, 192, 240, 384, 504, 768 and 1032 hours post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03261401",
    "endpoint": "measure - Part A: Area Under the Plasma Concentration Time Curve From Time Zero to Infinity (AUC0-inf) of M5717, description - The AUC from time zero (dosing time) extrapolated to infinity, based on the predicted value for the concentration at tlast, as estimated using the linear regression from the determination of the terminal first order (elimination) rate constant (lambda z).\nAUC0-inf = AUC0-t plus Clast pred&#x2F;lambda z.\nLambda Z was terminal elimination rate constant determined from the terminal slope of the log-transformed plasma concentration curve using linear regression on terminal data points of the curve.\nClastpred was the last predicted quantifiable concentration., timeFrame - Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, 48, 72, 96, 120, 144, 192, 240, 384, 504, 768 and 1032 hours post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03261401",
    "endpoint": "measure - Part A: Area Under the Plasma Concentration Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-t) of M5717, description - The AUC from time zero (= dosing time) to the last sampling time (tlast) at which the concentration is at or above the lower limit of quantification (LLOQ), calculated using the mixed log-linear trapezoidal rule (linear up, log down)., timeFrame - Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, 48, 72, 96, 120, 144, 192, 240, 384, 504, 768 and 1032 hours post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03261401",
    "endpoint": "measure - Part A: Area Under the Plasma Concentration-Time Curve From Time Zero to Time 144 Hours After Drug Administration (AUC0-144h) of M5717, description - The area under the plasma concentration-time curve from time zero to 144 hours after dosing was reported.\nIt is calculated using the mixed log-linear trapezoidal rule (linear up, log down)., timeFrame - Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, 48, 72, 96, 120, and 144 hours post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03261401",
    "endpoint": "measure - Part A: Extrapolated Area Under the Plasma Concentration Curve From Time of Last Quantifiable Sample to Infinity (AUCextra%) of M5717, description - AUCextra% was calculated as area under the curve from time tlast extrapolated to infinity given as percentage of AUC 0-infinity.\nHere, tlast is the last sampling time at which the concentration is at or above the lower limit of quantification., timeFrame - Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, 48, 72, 96, 120, 144, 192, 240, 384, 504, 768 and 1032 hours post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03261401",
    "endpoint": "measure - Part A: Apparent Total Clearance (CL&#x2F;f) of M5717, description - Apparent total body clearance of drug from plasma following extravascular administration, calculated as dose&#x2F;AUC0-infinity for M5717, whereas AUC0-infinity is area under the plasma concentration-time curve from time zero (dosing time) extrapolated to infinity of unchanged drug calculated as AUC0-t + AUCextra.\nAUCextra represents the extrapolated part of AUC0-infinity calculated by Clastpred&#x2F;lambda z, where Clastpred is the predicted plasma concentration at the last sampling time point, calculated from the log linear regression line for lambda z determination at which the measured plasma concentration is at or above lower limit of quantification., timeFrame - Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, 48, 72, 96, 120, 144, 192, 240, 384, 504, 768 and 1032 hours post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03261401",
    "endpoint": "measure - Part A: Apparent Volume of Distribution During Terminal Phase (VZ&#x2F;f) of M5717, description - Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.\nApparent volume of distribution during the terminal phase, calculated as Vz&#x2F;f = Dose&#x2F;(AUC0-infinity multiply by Lambda z) following single dose., timeFrame - Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, 48, 72, 96, 120, 144, 192, 240, 384, 504, 768 and 1032 hours post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03261401",
    "endpoint": "measure - Part A: Dose Normalized AUC0-inf [AUC(0-inf&#x2F;Dose)] of M5717, description - The AUC from time zero (dosing time) extrapolated to infinity, based on the predicted value for the concentration at tlast, as estimated using the linear regression from the determination of the terminal first order (elimination) rate constant (lambda z).\nAUC0-inf = AUC0-t plus Clast pred&#x2F;lambda z.\nLambda Z was terminal elimination rate constant determined from the terminal slope of the log-transformed plasma concentration curve using linear regression on terminal data points of the curve.\nClastpred was the last predicted quantifiable concentration.\nDose normalized was calculated using actual dose, using the formula AUC0-inf&#x2F;Dose., timeFrame - Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, 48, 72, 96, 120, 144, 192, 240, 384, 504, 768 and 1032 hours post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03261401",
    "endpoint": "measure - Part A: Dose Normalized AUC0-144h [AUC(0-144hour&#x2F;Dose)] of M5717, description - The area under the plasma concentration-time curve from time zero to 144 hours after dosing was reported.\nIt is calculated using the mixed log-linear trapezoidal rule (linear up, log down).\nDose normalized was calculated using actual dose, using the formula AUC0-144h&#x2F;Dose., timeFrame - Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, 48, 72, 96, 120, and 144 hours post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03261401",
    "endpoint": "measure - Part A: Dose Normalized AUC0-t [AUC( 0-t&#x2F;Dose)] of M5717, description - The AUC from time zero (= dosing time) to the last sampling time (tlast) at which the concentration is at or above the lower limit of quantification (LLOQ), calculated using the mixed log-linear trapezoidal rule (linear up, log down).\nDose normalized was calculated using actual dose, using the formula AUC0-t&#x2F;Dose., timeFrame - Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, 48, 72, 96, 120, 144, 192, 240, 384, 504, 768 and 1032 hours post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03261401",
    "endpoint": "measure - Part A: Dose Normalized Maximum Observed Plasma Concentration (Cmax&#x2F;Dose) of M5717, description - Cmax was obtained directly from the concentration versus time curve.\nDose normalized was calculated using actual dose, using the formula Cmax&#x2F;Dose., timeFrame - Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, 48, 72, 96, 120, 144, 192, 240, 384, 504, 768 and 1032 hours post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03261401",
    "endpoint": "measure - Part A: Time Above or Equal to the Predicted M5717 Minimum Inhibitory Concentration (MIC) of 3 ng&#x2F;mL (t =&gt;3 ng&#x2F;mL), description - Minimal inhibitory concentration (MIC), defined as the concentration at which the relative rate of change in parasitemia is equal to zero., timeFrame - Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, 48, 72, 96, 120, 144, 192, 240, 384, 504, 768 and 1032 hours post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03261401",
    "endpoint": "measure - Part A: Time Above or Equal to the Predicted M5717 Minimum Parasiticidal Concentration (MPC) of 10 ng&#x2F;mL (t=&gt;10 ng&#x2F;mL), description - Minimal parasiticidal concentration represents the lowest drug concentration value above which parasites decline at a maximal rate., timeFrame - Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, 48, 72, 96, 120, 144, 192, 240, 384, 504, 768 and 1032 hours post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03261401",
    "endpoint": "measure - Part C: Parasite Clearance Time, description - The parasite clearance time (PCT), defined as the time at which malaria parasite levels decline below detectable levels in blood after treatment, estimated as the time at which the linear portion of the optimal log parasitemia-versus-time relationship intersects the LLOQ concentration line., timeFrame - Day 1 up to Day 22",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03261401",
    "endpoint": "measure - Part C: Parasite Clearance Half-life (PCT 1&#x2F;2), description - The parasite clearance half-life (PCt1&#x2F;2), defined as the time needed for parasitemia to be reduced by half during the log-linear phase of parasite clearance, as derived using the slope of the optimal fit of the log-linear relationship of parasitemia decay.\nIt was observed that the decline of parasitemia had a biphasic profile, with the first phase, followed by a second phase (the main clearance phase)., timeFrame - Day 1 up to Day 22",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03261401",
    "endpoint": "measure - Part C: Number of Participants With Lag Phase, description - Lag phase is defined as an initial period after dosing that precedes a steady exponential decline in the parasite count.\nLag phase is categorized in lag of 4 hours, lag of 6 hours, lag of 12 hours and lag of 24 hours., timeFrame - Day 1 to Day 22",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03261401",
    "endpoint": "measure - Part C: Number of Participants With Recrudescence, description - Recrudescence is as defined as greater than and equal to 5000 blood stage parasites&#x2F;milliliter (mL) and a 2-fold parasitemia increase within 48 hours, or re-occurrence of malaria symptoms with a malaria clinical score &gt; 6.\nThe malaria clinical score consists of 14 signs&#x2F;symptoms frequently associated with malaria and graded using a 4-point scale with minimum score is 0 (no symptoms) and the maximum score is 42 (maximum symptoms)., timeFrame - Day 1 to Day 22",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03261401",
    "endpoint": "measure - Part C: Malarial Clinical Score, description - The malaria clinical score consists of 14 signs&#x2F;symptoms frequently associated with malaria and graded using a 4-point scale (absent: 0; mild: 1; moderate: 2; severe: 3) and summed to generate a total malaria clinical score (maximum score possible is 42): headache, myalgia (muscle ache), arthralgia (joint ache), fatigue&#x2F;lethargy, malaise (general discomfort&#x2F;uneasiness), chills&#x2F;shivering&#x2F;rigors, sweating&#x2F;hot spells, anorexia, nausea, vomiting, abdominal discomfort, fever, tachycardia and hypotension.\nTotal scores are reported here.\nThe minimum score is 0 (no symptoms) and the maximum score is 42 (maximum symptoms)., timeFrame - Day 1, 2, 3, 4, 5, 6, 7, 9, 11, 13, 15 and 22",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03261401",
    "endpoint": "measure - Part C: Minimum Inhibitory Concentration (MIC) and Minimum Parasiticidal Concentration at 90% (MPC90), description - MIC is defined as the minimum concentration of a drug at which parasite counts continue to decrease and is equivalent to equating the rate in the change of parasite to 0. Parasiticidal concentration required for 90% killing (MPC90) is defined as the concentration at which the parasite clearance effect is at 90% of the maximum.\nThe estimated MIC and MPC were derived from the final pharmacodynamics (PD) model and pharmacokinetic (PK)&#x2F;PD relationship., timeFrame - Day 1 up to Day 22",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03261401",
    "endpoint": "measure - Part C: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Discontinuation of Study Treatment, description - An adverse event (AE) was defined as any untoward medical occurrence in a participant administered with study drug which does not necessarily had a causal relationship with the treatment.\nAn AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, whether or not considered related to the medicinal product.\nA serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent&#x2F;significant disability&#x2F;incapacity; initial or prolonged inpatient hospitalization; congenital anomaly&#x2F;birth defect or was otherwise considered medically important.\nThe term TEAE is defined as AEs starting or worsening after the first intake of the study drug.\nTEAEs included both Serious TEAEs and non-serious TEAEs., timeFrame - Baseline up to Day 44",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03261401",
    "endpoint": "measure - Part C: Number of Participants With Clinically Significant Changes From Baseline in Laboratory Assessments, description - Laboratory assessments included hematology, biochemistry, urinalysis, and coagulation.\nNumber of participants with clinically significant change from baseline in laboratory parameters were reported.\nClinical significance was decided by the investigator., timeFrame - Baseline up to Day 44",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03261401",
    "endpoint": "measure - Part C: Number of Participants With Clinically Significant Changes From Baseline in 12-lead Electrocardiograms (ECGs) Findings, description - The 12-lead ECGs were recorded after the participants have rested for at least 5 minutes in supine position.\nNumber of participants with clinically significant change from baseline in ECG were reported.\nClinical significance was decided by the investigator., timeFrame - Baseline up to Day 44",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03261401",
    "endpoint": "measure - Part C: Number of Participants With Clinically Significant Changes From Baseline in Vital Signs, description - Vital signs included oral body temperature, systolic blood pressure, diastolic blood pressure, and pulse rate.\nNumber of participants with clinically significant change from baseline in vital signs were reported.\nClinical significance was decided by the investigator., timeFrame - Baseline up to Day 44",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03897673",
    "endpoint": "measure - ZPP, description - Prevalence of zinc protoporphyrin (ZPP) ≥ 80 umol&#x2F;mol heme in the early iron vs. delayed iron treatment groups, timeFrame - 12-months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03897673",
    "endpoint": "measure - Iron status: Hemoglobin, description - Concentrations of hemoglobin in the immediate vs. delayed groups, timeFrame - 6- and 12-months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03897673",
    "endpoint": "measure - Iron status: ferritin, description - Concentrations of ferritin in the early iron vs. delayed iron treatment groups, timeFrame - 6- and 12-months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03897673",
    "endpoint": "measure - Iron status: soluble transferrin receptor (sTFR), description - Concentrations of sTFR in the early iron vs. delayed iron treatment groups, timeFrame - 6- and 12-months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03897673",
    "endpoint": "measure - Iron status: hepcidin, description - Concentrations of hepcidin in the early iron vs. delayed iron treatment groups, timeFrame - 6- and 12-months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03897673",
    "endpoint": "measure - Iron status: C-reactive Protein (CRP), description - Concentrations of CRP in the early iron vs. delayed iron treatment groups, timeFrame - 6- and 12-months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03897673",
    "endpoint": "measure - All-cause infectious episodes, description - Incidence of all-cause infectious episodes and incidence of clinical malaria episodes during the 12-months follow-up period; incidence of all-cause and malaria-specific hospitalizations, timeFrame - 12-months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03897673",
    "endpoint": "measure - Proteobacteria, description - Change in relative fecal abundance of Proteobacteria, timeFrame - Baseline, 6-months, 12-months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03897673",
    "endpoint": "measure - Child Behavior Checklist (CBCL), description - CBCL scores at 12 months follow up.\nPreschool Child Behavioral Checklist (P-CBCL) is a parent-report checklist that assesses internalizing, externalizing, and total behavioral problems.\nHigher scores indicate more problematic behavior or diminished function., timeFrame - 12-months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03897673",
    "endpoint": "measure - Behaviors Related to Executive Function (BRIEF), description - BRIEF scores at 12 months follow up.\nBehavior Rating Inventory of Executive Functioning, Preschool edition (BRIEF-P) is a parent-report checklist that assesses global executive function.\nHigher scores indicate more problematic behavior or diminished function., timeFrame - 12-months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00509158",
    "endpoint": "measure - Phase I and IIa: Immunogenicity evaluation: antibody and cellular responses to vaccination with PfLSA-3-rec vaccine formulations., description - , timeFrame - 1 year from first immunization",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00509158",
    "endpoint": "measure - Phase IIa: The length of time (in hours) between parasite inoculation and detection of parasitemia, if any, up to 21 days., description - , timeFrame - 6 weeks from sporozoite challenge",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03474822",
    "endpoint": "measure - Progression free survival (PFS), description - Progression free survival (PFS): Starting from treatment until the disease progression is first found or the time of any cause of death (disease progression refers to tumor growth, or metastasis of primary tumor, or discovery of new lesions)., timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03474822",
    "endpoint": "measure - Overall survival, description - The time starting from the treatment to death of whatever causes (when subjects have lost for follow-up before death, the last follow-up time will be calculated as the time of death)., timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03474822",
    "endpoint": "measure - Tumor marker level, description - The patient&#x27;s sensitive tumor markers will be reviewed periodically from the time they are enrolled into the study., timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03474822",
    "endpoint": "measure - Objective response rate (ORR), description - The proportion of patients whose tumor is reduced to a certain amount and maintain a certain period of time., timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03474822",
    "endpoint": "measure - the Score of Quality of life, description - Patients are regularly filled with QLQ-C30 (cancer patient quality of life scale) to assess the quality of life of the patients., timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03474822",
    "endpoint": "measure - 1 year of survival rate, description - The number of cancer cases remaining after 1 year of treatment &#x2F; the total number of cancer cases treated * 100%., timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03474822",
    "endpoint": "measure - 2 year of survival rate, description - The number of cancer cases remaining after 2 years of treatment &#x2F; the total number of cancer cases treated * 100%., timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03474822",
    "endpoint": "measure - Immunological index, description - Detection of absolute number of immune cells（such as CD3+CD4+、CD3+CD8+ and so on）in peripheral blood by flow cytometry., timeFrame - 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00270530",
    "endpoint": "measure - • Prevalence of maternal peripheral parasitemia, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00270530",
    "endpoint": "measure - • Birth weight, including the proportion of LBW infants, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00270530",
    "endpoint": "measure - • Incidence of prematurity, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00270530",
    "endpoint": "measure - • Neonatal and fetal death and third trimester stillbirth, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00270530",
    "endpoint": "measure - • Incidence of neonatal jaundice, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00270530",
    "endpoint": "measure - • Third trimester anemia, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00270530",
    "endpoint": "measure - • Third trimester severe anemia, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00270530",
    "endpoint": "measure - • Proportion of mothers who develop symptomatic malaria during the course of pregnancy, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06408857",
    "endpoint": "measure - Percentage of participants with graded abnormal clinical hematology and chemistry laboratory results, description - , timeFrame - Up to 28 days post dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06408857",
    "endpoint": "measure - Maximal observed blood concentration of MAM01 following the first dose (Cmax1), description - Capillary blood samples will be collected for the analysis pharmacokinetic parameters.\nBlood concentrations of MAM01 will be measured using a validated immunoassay., timeFrame - Pre- and post-dose (IV dosing groups only) at Day 1, 4, 7, 14, 28, 56, 84, 112, 140, and 182",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06408857",
    "endpoint": "measure - Concentration at Day 182 (C182), description - , timeFrame - At Day 182 post first dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06408857",
    "endpoint": "measure - Total Area Under the Concentration Curve (AUC) Day 0 - Day 182, description - , timeFrame - From 0 to 182 days post dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06408857",
    "endpoint": "measure - Percentage of participants with antidrug antibodies (ADAs) to MAM01, description - , timeFrame - At Days 1, 28, 84, and 182",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01001871",
    "endpoint": "measure - changes in anemia status (blood levels of: haemoglobin(Hb) , ferritin (SF)), description - , timeFrame - 5 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01001871",
    "endpoint": "measure - severity of clinical malaria (blood parasite count), description - , timeFrame - 5 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01001871",
    "endpoint": "measure - cerebral malaria (defined by a parasite count &gt;5000&#x2F;μL blood and a concurrent score of &lt;2 on the Blantyre coma scale, with or without convulsions), description - , timeFrame - 5 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01001871",
    "endpoint": "measure - hospitalization (documentation of hospitalization for any reason), description - , timeFrame - 5 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01001871",
    "endpoint": "measure - death, description - , timeFrame - 5 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01001871",
    "endpoint": "measure - pneumonia (defined by the presence of a cough or breathing difficulties, tachypnea, lower chest wall indrawing, and the appearance of consolidation or pleural effusion on a chest X-ray), description - , timeFrame - 5 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01001871",
    "endpoint": "measure - diarrhea (defined by &gt;3 loose or watery stools in the previous 24 hours), description - , timeFrame - 5 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01001871",
    "endpoint": "measure - dehydration (defined by lethargy, sunken eyes, and decreased skin turgor [&gt;2 seconds for skin to return following a skin pinch]), description - , timeFrame - 5 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03637517",
    "endpoint": "measure - AUCinf, description - AUC from time 0 to infinity (AUCinf), timeFrame - 21 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04182126",
    "endpoint": "measure - Malaria infection prevalence, description - To compare infection prevalence rates among different intervention arms using microscopic, RDT and molecular diagnostic methods, timeFrame - Infection prevalence will be monitored for up to 60 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04182126",
    "endpoint": "measure - Malaria vector density, description - To compare malaria vector densities between different intervention arms, timeFrame - Vector density will be monitored for up to 60 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04182126",
    "endpoint": "measure - Malaria transmission intensity, description - To compare entomological inoculation rates between different intervention arms, timeFrame - Entomological inoculation rate will be examined for up to 60 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04250363",
    "endpoint": "measure - Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs and Treatment-related TEAEs, description - An adverse event (AE) was defined as any untoward medical occurrence in a participant administered with study drug which does not necessarily had a causal relationship with the treatment.\nAn AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, whether or not considered related to the medicinal product.\nA serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent&#x2F;significant disability&#x2F;incapacity; initial or prolonged inpatient hospitalization; congenital anomaly&#x2F;birth defect or was otherwise considered medically important.\nTEAE was defined as AEs starting or worsening after the first intake of the study drug.\nTEAEs included both serious TEAEs and non-serious TEAEs.\nTreatment-related TEAEs: reasonably related to study intervention., timeFrame - Early Liver Stage: From Day 1 up to Day 33; Late Liver Stage: From Day 1 up to Day 36",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04250363",
    "endpoint": "measure - Number of Participants With Treatment Emergent Adverse Events (TEAEs) Based on Severity, description - Severity of adverse events (AE) were assessed by the investigator per the Qualitative Toxicity Scale.\nGrade 1= Mild, Grade 2=Moderate, Grade 3=Severe.\nThe number of participants that experienced at least one solicited local TEAE were summarized by grade.\nThe term TEAE is defined as AEs starting or worsening after the first intake of the study drug.\nTEAEs include both Serious TEAEs and non-serious TEAEs.\nNumber of participants with Grade=1, Grade=2 and 3 were reported., timeFrame - Early Liver Stage: From Day 1 up to Day 33; Late Liver Stage: From Day 1 up to Day 36",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04250363",
    "endpoint": "measure - Number of Participants With Clinically Significant Change From Baseline in Laboratory Values, description - Laboratory assessments included hematology, biochemistry, urinalysis, and coagulation.\nNumber of participants with clinically significant changes from baseline in laboratory values which were deemed clinically significant by the investigator were reported., timeFrame - Early Liver Stage: From Day 1 up to Day 33; Late Liver Stage: From Day 1 up to Day 36",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04250363",
    "endpoint": "measure - Number of Participants With Clinically Significant Change From Baseline in Vital Signs, description - Vital signs included oral body temperature, height, weight, systolic blood pressure, diastolic blood pressure, and pulse rate.\nNumber of participants with clinically significant changes from baseline in Vital signs which were deemed clinically significant by the investigator were reported., timeFrame - Early Liver Stage: From Day 1 up to Day 33; Late Liver Stage: From Day 1 up to Day 36",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04250363",
    "endpoint": "measure - Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiogram (ECG) Findings, description - Single 12-lead ECG was obtained as outlined using an ECG machine that automatically calculates the heart rate and measures PR, QRS, and QT intervals.\nNumber of participants with clinically significant changes from baseline in ECG which were deemed clinically significant by the investigator were reported., timeFrame - Early Liver Stage: From Day 1 up to Day 33; Late Liver Stage: From Day 1 up to Day 36",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04250363",
    "endpoint": "measure - Area Under the Blood Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of M5717, description - AUC0-inf was calculated by combining AUC0-t and AUCextra.\nAUC extra represents an extrapolated value obtained by Clast&#x2F; λz, where Clast is the calculated blood concentration at the last sampling time point at which the measured blood concentration is at or above the Lower Limit of quantification (LLQ) and λz is the apparent terminal rate constant determined by log-linear regression analysis of the measured blood concentrations of the terminal log-linear phase., timeFrame - Pre-dose, 0.5, 1, 2, 3, 6, 12, 24, 120, 168, 192, 600, and 768 hours post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04250363",
    "endpoint": "measure - Area Under the Blood Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC 0-tlast) of M5717, description - Area under the blood concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLQ).\nAUC0-t was to be calculated according to the mixed log-linear trapezoidal rule., timeFrame - Pre-dose, 0.5, 1, 2, 3, 6, 12, 24, 120, 168, 192, 600, and 768 hours post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04250363",
    "endpoint": "measure - Area Under the Blood Concentration-Time Curve From Time Zero to 24 Hours Post-dose (AUC 0-24) of M5717, description - AUC from time zero to 24 hours post dose, calculated using the mixed log linear trapezoidal rule (linear up, log down) using the nominal dosing interval., timeFrame - Pre-dose, 0.5, 1, 2, 3, 6, 12 and 24 hours post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04250363",
    "endpoint": "measure - Area Under the Blood Concentration-Time Curve From Time Zero to 168 Hours Post-dose (AUC 0-168) of M5717, description - AUC from time zero to 168 hours post dose.\nCalculated using the mixed log linear trapezoidal rule (linear up, log down) using the nominal dosing interval., timeFrame - Pre-dose, 0.5, 1, 2, 3, 6, 12, 24, 120 and 168 hours post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04250363",
    "endpoint": "measure - Maximum Observed Blood Concentration (Cmax) of M5717, description - Cmax was obtained directly from the concentration versus time curve., timeFrame - Pre-dose, 0.5, 1, 2, 3, 6, 12, 24, 120, 168, 192, 600, and 768 hours post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04250363",
    "endpoint": "measure - Blood Concentration at 24 Hours (C24) of M5717, description - Blood samples for PK analysis of C24 of M5717 was reported., timeFrame - At 24 hours post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04250363",
    "endpoint": "measure - Blood Concentration at 168 Hours (C168) of M5717, description - C168 is the calculated blood concentration at 168 hours post-dose at which the measured blood concentration is at or above the Lower Limit of quantification (LLQ)., timeFrame - At 168 hours post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04250363",
    "endpoint": "measure - Time to Reach Maximum Blood Concentration (Tmax) of M5717, description - Time to reach the maximum blood concentration (Tmax) was obtained directly from the concentration versus time curve., timeFrame - Pre-dose, 0.5, 1, 2, 3, 6, 12, 24, 120, 168, 192, 600, and 768 hours post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04250363",
    "endpoint": "measure - Apparent Terminal Half-life (t1&#x2F;2) of M5717, description - Terminal half-life is the time measured for the concentration to decrease by one half.\nTerminal half-life calculated by natural log 2 divided by lambda z., timeFrame - Pre-dose, 0.5, 1, 2, 3, 6, 12, 24, 120, 168, 192, 600, and 768 hours post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04250363",
    "endpoint": "measure - Elimination Rate Constant (Lambda z) of M5717, description - Elimination rate constant determined from the terminal slope of the log-transformed concentration curve using linear regression on terminal data points of the curve., timeFrame - Pre-dose, 0.5, 1, 2, 3, 6, 12, 24, 120, 168, 192, 600, and 768 hours post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04250363",
    "endpoint": "measure - Apparent Total Body Clearance From Blood (CL&#x2F;f) of M5717, description - Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.\nApparent body clearance of the drug from blood, CL= Dose&#x2F;AUC0-inf, timeFrame - Pre-dose, 0.5, 1, 2, 3, 6, 12, 24, 120, 168, 192, 600, and 768 hours post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04250363",
    "endpoint": "measure - Apparent Volume of Distribution (Vz&#x2F;F) During the Terminal Phase of M5717, description - The Vz&#x2F;f was defined as the theoretical volume in which the total amount of required to uniformly distribute to produce the desired plasma concentration.\nApparent volume of distribution after oral dose (Vz&#x2F;F) was influenced by the fraction absorbed.\nThe Vz&#x2F;f was calculated by dividing the dose with area under the concentration time curve from time zero to infinity multiplied with terminal elimination rate constant Lambda(z).\nVz&#x2F;f=Dose&#x2F;AUC(0-inf) multiply Lambda(z)., timeFrame - Pre-dose, 0.5, 1, 2, 3, 6, 12, 24, 120, 168, 192, 600, and 768 hours post-dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00209781",
    "endpoint": "measure - To assess whether intermittent treatment with sulfadoxine-pyrimethamine provides any additional benefit to the protection afforded by ITNs on the:, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00209781",
    "endpoint": "measure - Maternal anaemia at and after delivery, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00209781",
    "endpoint": "measure - Parasite prevalence at and after delivery, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00209781",
    "endpoint": "measure - Placental malaria infection, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00209781",
    "endpoint": "measure - Infant mortality and morbidity, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00209781",
    "endpoint": "measure - Gestational age of the newborn, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00209781",
    "endpoint": "measure - Child parasitaemia and anaemia 12 months after delivery, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00209781",
    "endpoint": "measure - To identify the operational and socio-cultural issues involved in the delivery to and use of ITNs by pregnant women, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00209781",
    "endpoint": "measure - To evaluate the cost-effectiveness of the interventions, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00209781",
    "endpoint": "measure - To determine the duration of the efficacy of long-lasting insecticide-treated nets against Anopheles mosquitoes, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00209781",
    "endpoint": "measure - To assess the immunological protection against malaria in children during the first year of life regarding malaria preventive interventions in their mothers during pregnancy, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00209781",
    "endpoint": "measure - To asses the effect of IPT with SP in HIV positive pregnant women on the prevention of mother-to-child HIV transmission and on the viral load reduction in the mother, description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02488980",
    "endpoint": "measure - Protective Efficacy Based on Two Consecutive Positive Smears, description - Kaplan-Meier survival curves were produced for time to parasitaemia for both first positive smear and two consecutive positive smears.\nAnalysis was based on a calculation of protective efficacy (PE) of tefaenoquine, defined as (1-relative risk of developing parasitaemia tafenoquine: placebo) x100% and 95.5% confidence intervals were constructed for the relative risk using Koopman&#x27;s method., timeFrame - 24 Weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02488980",
    "endpoint": "measure - Time to a Single Positive Smear, description - Kaplan-Meier survival curves were produced for time to parasitaemia for both first positive smear and two consecutive positive smears.\n95.5% confidence intervals were constructed for the relative risk., timeFrame - 24 Weeks",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01829815",
    "endpoint": "measure - Mosquito net usage, description - A survey will be used to assess mosquito net usage by household members.\nItems will be analyzed separately to assess discrete behaviors (e.g., whether child him&#x2F;herself slept under the net; whether any adult(s) slept under the net), timeFrame - 1 month",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01784315",
    "endpoint": "measure - Genotyping of P.vivax strains in Bhutan., description - One time venous blood samples will be collected from patients infected with mixed or mono-infection of P.vivax malaria.\nAnd the genotyping will be conducted to study the strains of P.vivax malaria that exist in Bhutan., timeFrame - 12 months.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07060404",
    "endpoint": "measure - Safety: Change in haemoglobin over 28 days, description - Haemoglobin concentration will be measured on peripheral blood samples (HemoCue) at baseline (before drug administration) and on Days 3, 6, 8, 15, 20 and 28., timeFrame - Up to 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07060404",
    "endpoint": "measure - Safety: Change in haemotocrit over 28 days, description - Haematocrit will be measured at baseline (before drug administration), and on Days 3, 6, 8, 15, 20 and 28 using venous blood, that is drawn into a centrifuge tube and centrifuged to separate cellular components., timeFrame - Up to 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07060404",
    "endpoint": "measure - Safety: Change in methaemoglobin over 28 days, description - Methaemoglobin concentration will be measured by pulse oximetry (Masimo Rad-57 Pulse CO-Oximeter with SpMet functionality) at baseline (before drug administration), and on Days 1, 3, 6, 8, 15, 20 and 28., timeFrame - Up to 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07060404",
    "endpoint": "measure - Safety: Change in maternal and infant weight in kilograms over 28 days, description - Maternal and infant weight will be measured at all follow-up time-points (Baseline (Day 0), Days 1, 3, 6, 8, 15, 20, 28), using appropriate calibrated scales.\nAll measurements will be recorded to the closest kilogram., timeFrame - Up to 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07060404",
    "endpoint": "measure - Safety: Frequency of self-reported adverse events, description - , timeFrame - Up to 7 days after completion of treatment regimen",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07060404",
    "endpoint": "measure - Safety: Breastfeeding behaviour, description - At each follow-up time-point, mothers will be asked to report the estimated duration of breast feeding (minutes) during the previous 24 hours., timeFrame - Up to 14 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07060404",
    "endpoint": "measure - Change in alanine transaminase (ALT) over 28 days, description - Alanine transaminase (ALT) will be evaluated using point-of-care biochemistry analysis (Fuji Dri-Chem NX600).\nSamples will be evaluated at baseline (before drug administration), and on Days 3, 6, 8, 15, 20 and 28., timeFrame - Up to 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07060404",
    "endpoint": "measure - Change in total bilirubin (TBil) over 28 days, description - Total bilirubin (TBil) will be evaluated using point-of-care biochemistry analysis (Fuji Dri-Chem NX600).\nSamples will be evaluated at baseline (before drug administration) and on Days 3, 6, 8, 15, 20 and 28., timeFrame - Up to 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07060404",
    "endpoint": "measure - Change in creatinine (Cr) over 28 days, description - Creatinine (Cr) will be evaluated using point-of-care biochemistry analysis (Fuji Dri-Chem NX600).\nSamples will be evaluated at at baseline (before drug administration) and on Days 3, 6, 8, 15, 20 and 28., timeFrame - Up to 28 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05203744",
    "endpoint": "measure - Characterize the PK profiles of tafenoquine, description - A drug-free venous blood sample will be obtained from each participant at D0. PK blood sampling will be done to cover the absorption phase (Cabs, 1 to 4 hours after dosing), maximum concentration (Cmax, 22 to 24 hours after dosing), mid weekly or monthly concentration (Cmid) after dosing and the minimum concentration (Cmin) before the next dose of tafenoquine.\nPK parameters for each tafenoquine regimen will be calculated using a nonlinear mixed-effects modeling approach.\nThe population PK model will evaluate the impact of clinically appropriate covariates, such as body weight, BMI, age and dose.\nMedian (95% CI) Cmax and Cmin values of tafenoquine will also be estimated for the participants for each tafenoquine regimen., timeFrame - six months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05203744",
    "endpoint": "measure - Characterize the pharmacokinetic&#x2F;pharmacodynamic (PK&#x2F;PD) relationship, description - All collected PK samples will be analyzed using nonlinear mixed-effects modelling to describe the concentration-time profile of tafenoquine, and the association between drug exposure and potential adverse reactions.\nDifferent absorption and disposition models will be assessed to develop the structural PK model.\nClinical covariates will be evaluated with a traditional forward addition&#x2F;backward elimination approach, with particular focus on the influence of dose, body weight, BMI, and age.\nThe PK model will be summarized by population mean estimates for structural model parameters, as well as estimated precision and between-patient variability in the same parameters.\nSecondary PK parameters, such as maximum and minimum tafenoquine concentrations, will be derived for each dosing regimen in order to evaluate the prospect of reaching effective concentrations for participants within each of the three tafenoquine regimens., timeFrame - six months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05203744",
    "endpoint": "measure - Determine the association of tafenoquine and its metabolite 5,6, orthoquinone in red blood cells, description - <p>Because of the limited data on the association of tafenoquine in blood cells, venous blood and plasma samples will be measured in this study.\nBlood and plasma concentrations of tafenoquine and its metabolite, 5,6-orthoquinone will be quantified by liquid chromatography mass spectrometry (LCMS) in the selected reaction monitoring mode using heated electrospray ionization in positive ion mode.\nBlood and plasma samples (50 μL) will be precipitated with 200 μL of acetonitrile containing the internal standard.\nAfter centrifugation at 20,817 x g for 5 minutes at 4°C, an aliquot (10 μL) of the supernatant will be injected onto the analytical column.</p><p>orthoquinone in red blood cells, the site of action of the drug&#x27;s blood schizontocidal activity.</p>, timeFrame - six months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05203744",
    "endpoint": "measure - Determine the ex vivo antimalarial activity of tafenoquine in participants&#x27; plasma samples, description - Thirty participants will be invited to provide four additional 8 ml blood samples for assessing the ex vivo antimalarial activity of tafenoquine (TQ) and its metabolites.\nA blood sample will be collected before the 1st TQ dose to determine if their plasma can support the in vitro growth of P. falciparum isolates.\nAfter the collection of the pre-dose TQ blood sample, Cohort A participants will then provide additional blood samples after the 1st weekly 200 mg TQ dose and 1st monthly (600 mg and 800 mg) TQ doses.\nFor Cohort B participants they will provide additional blood samples after the 2nd weekly 200 mg TQ dose and 2nd monthly (600 mg and 800 mg) TQ doses.\nComparison of the inhibitory dilution of plasma samples on weekly and monthly TQ administration will be made to see which results in a 50% inhibition of uptake of [3H]-hypoxanthine (surrogate for parasite growth) compared to drugfree plasma samples (controls) against P. falciparum strains with different levels of drug., timeFrame - six months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04149119",
    "endpoint": "measure - Incidence of malaria per person times using molecular analysis tools, description - <p>PCR will be use to assess Incidence of malaria infection among cohort participants aged 5 to &lt;15 years.</p><p>2. Prevalence of malaria infection among a cross sectional sample 3. Incidence rate of passively reported clinical malaria among participants of all ages, defined as the number of malaria confirmed cases (by RDT or microscopy) per 1,000 population per year, 4. Vector age structure: survivorship will be monitored by ovarian dissection to examine ovarian dilatations.</p><p>5. Vector densities, Sporozoite rate by CS ELISA, Entomological inoculation rates (EIR), Biting profiles, Vector species composition.</p><p>6. Durability of the ATSB stations: 1) the effectiveness of the attractant; and 2) the effective toxicity of the ATSB.</p><p>7. Resistance to the ATSB toxicant: susceptibility to the ingestion toxicant (dinotefuran) will be evaluated on an annual basis.</p><p>a. Insecticide resistance: Physiological resistance phenotypes, Intensity of resistance, Behavioral resistance</p>, timeFrame - Through study completion (average 2 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04235816",
    "endpoint": "measure - The cause-specific mortality rate, description - Cause-specific mortality rate at 18 months of age, timeFrame - 18 months of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04235816",
    "endpoint": "measure - Malaria related mortality, description - Malaria related mortality at 18 months of age, timeFrame - 18 month of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04235816",
    "endpoint": "measure - Incidence of all-cause hospital admissions, description - Incidence of all-cause hospital admissions, timeFrame - Through study completion, 36 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04235816",
    "endpoint": "measure - Incidence of all-cause outpatient attendances, description - Incidence of all-cause outpatient attendances at the health facilities, timeFrame - Through study completion, 36 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04235816",
    "endpoint": "measure - Incidence of confirmed (RDT positive) malaria hospital admissions, description - Incidence of confirmed (RDT positive) malaria hospital admissions at all health facilities, timeFrame - Through study completion, 36 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04235816",
    "endpoint": "measure - Incidence of confirmed (blood smear positive&#x2F;RDT positive) malaria hospital admissions, description - Incidence of confirmed (blood smear positive&#x2F;RDT positive) malaria hospital admissions at all health facilities, timeFrame - Through study completion, 36 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04235816",
    "endpoint": "measure - Frequency and severity of drug adverse reactions, description - Frequency and severity of drug adverse reactions throughout the trial, timeFrame - Through study completion, 36 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04235816",
    "endpoint": "measure - Prevalence of macrolide resistance in nasopharyngeal isolates, description - Prevalence of macrolide resistance in nasopharyngeal isolates, timeFrame - Through study completion, 36 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04235816",
    "endpoint": "measure - Prevalence of macrolide resistance in the gut bacteria, description - Prevalence of macrolide resistance in the gut bacteria, timeFrame - Through study completion, 36 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04235816",
    "endpoint": "measure - Proportion of children with protective antibody responses to specific routine EPI immunizations (measles and yellow fever), description - Proportion of children with protective antibody responses to specific routine EPI, timeFrame - Through study completion, 36 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02198573",
    "endpoint": "measure - Prevalence of the drug resistance marker, description - By using the dried blood spots, drug resistance markers were detected by molecular method., timeFrame - up to day-3",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00931697",
    "endpoint": "measure - The comparative pharmacokinetics of AD 452 [(+)mefloquine] and racemic mefloquine, description - , timeFrame - Single dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03523182",
    "endpoint": "measure - Change from baseline in weight-for-age z-scores (WAZ) at 32 month follow up, description - Secondary outcome is changes in WAZ.\nWeight of the infants is transformed to standardized scores using the WHO Multicentre Growth Standards, timeFrame - Weight of the infants are measured at 0, 6, and 12 month by experienced field workers. Amendment: also measured at extension endline (October 2016), at 24 month follow up (April 2017) and at 32 month follow up (January 2018)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03523182",
    "endpoint": "measure - Change from baseline in pneumonia incidence at 32 month follow up, description - Secondary outcome is changes in pneumonia incidence.\nPneumonia was defined as cough accompanied by short and rapid breathing and difficulty in breathing, timeFrame - Data on pneumonia indicators were collected up to 12 months by trained local health workers. Amendment: also measured at extension endline (October 2016), at 24 month follow up (April 2017) and at 32 month follow up (January 2018)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03523182",
    "endpoint": "measure - Change from baseline in cough incidence at 32 month follow up, description - Secondary outcome is changes in cough incidence in the 4 weeks preceding the interview., timeFrame - Data on cough morbidity indicators are collected up to 12 months by trained local health workers. Amendment: also measured at extension endline (October 2016), at 24 month follow up (April 2017) and at 32 month follow up (January 2018)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03523182",
    "endpoint": "measure - Change from baseline in severe high fever incidence at 32 month follow up, description - Secondary outcome is changes in severe high fever incidence.\nSevere high fever was defined based on the following clinical signs: fever with rash on child&#x27;s body, fever with chills, shaking, nausea, or alternating high and low body temperature, timeFrame - Data are collected up to 12 months by trained local health workers. Amendment: also measured at extension endline (October 2016), at 24 month follow up (April 2017) and at 32 month follow up (January 2018)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03523182",
    "endpoint": "measure - Change from baseline in fever incidence at 32 month follow up, description - Secondary outcome is changes in fever incidence in the 4 weeks preceding the interview, timeFrame - Data are collected up to 12 months by trained local health workers. Amendment: also measured at extension endline (October 2016), at 24 month follow up (April 2017) and at 32 month follow up (January 2018)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03523182",
    "endpoint": "measure - Ability of the infant to walk independently., description - The ability of children to walk without assistance measured by the questionnaire., timeFrame - This indicator was evaluated at 0, 6 and 12 months by research assistants who visited the participants&#x27; homes",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03523182",
    "endpoint": "measure - Child development at 24 month follow up, description - Study children will be assessed at 24 month follow up (April 2017) using the Malawi Development Assessment Tool (MDAT) instrument.\nScores will be standardized within the study sample for analysis.\nScores of children in treatment group will be compared with children in comparison group to determine differences., timeFrame - At 24 month follow up survey (April 2017)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01650558",
    "endpoint": "measure - Number of Participants With at Least One Detectable HIV Viral Load, description - Number of participants who ever have a detectable viral load (&gt;400 copies&#x2F;ml)., timeFrame - Throughout study participation, measured every six months (2-5.5 years).",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01650558",
    "endpoint": "measure - CD4 Cell Count, description - Number of Participants with at Least One CD4 Count &lt;200, timeFrame - Every 6 months for 22-66 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01650558",
    "endpoint": "measure - WHO HIV Stage 2, 3, 4 Illness, description - Incidence of any WHO HIV stage 2, 3, or 4 illness, timeFrame - 32-66 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01650558",
    "endpoint": "measure - Bacterial Infections and Malaria, description - Incidence of bacterial infections and malaria, timeFrame - 32-66 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01650558",
    "endpoint": "measure - Adverse Events Greater Than or Equal to Grade 3 That Are Related to the Study Product, description - Occurrence of adverse events that are greater than or equal to Grade 3 that require discontinuation of TS or CQ prophylaxis, timeFrame - 32-66 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07052162",
    "endpoint": "measure - Safety: Change in haemoglobin over 28 days, description - <p>After admission, baseline demographic details (age, weight, height) and a detailed clinical history will be taken.\nAll participants will then undergo a full clinical assessment, documenting axillary temperature, heart and respiration rate, and methaemoglobin level (pulse oximetry; Rad57 pulse oximeter with SpMet% function).\nA blood sample will be drawn prior to drug administration via the cannula for baseline laboratory tests (safety analysis) and genotyping, including:</p><p>i) Haemoglobin and blood glucose ii) Dipstick urinalysis iii) Resting 12-lead electrocardiogram for rate-corrected QT interval iv) 250 μL blood sample for CYP2D6 genotyping v) Reticulocyte count vi) Hepatorenal function Safety testing, including collection of a 100 μL blood sample for hepatorenal function tests (ALT, total bilirubin and creatinine), haemoglobin, methaemoglobin, urine dipstick analysis (blood, protein and glucose), and an electrocardiogram trace, will be taken at 4, 12, 24 hrs, and on Days 3, 7 and 28.</p>, timeFrame - 28-days from drug administration",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07052162",
    "endpoint": "measure - Safety: Change in methaemoglobin over 28 days, description - , timeFrame - 28-days from drug administration",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07052162",
    "endpoint": "measure - Safety: Change in hepatorenal function over 7 days, description - , timeFrame - 7-days from drug administration",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07052162",
    "endpoint": "measure - Safety: Change in rate corrected QTc over 28 days, description - , timeFrame - 28-days from drug administration",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07052162",
    "endpoint": "measure - Tolerability: Taste and tolerability assessment, description - A standardized clinical taste evaluation&#x2F;tolerability survey will be conducted (child or parent response, dependent on age) 30 minutes after TQ dosing, which will be repeated on Day 1.\nThis survey will investigate the participant&#x27;s feelings towards the dosing experience (taste, tablet size, ease of swallowing) and any treatment related side effects (focussing on known complications including nausea, gastrointestinal disruption, vomiting)., timeFrame - 1-day following drug administration",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT07052162",
    "endpoint": "measure - Safety and tolerability: Number of participants with treatment-related adverse events as assessed by standardised questionnaire, description - Symptom questionnaires (used across all research conducted at this site) will be conducted at each follow-up time point from baseline (Day-0) until end of study (day 56).\nThe questionnaire will determine the frequency, duration and rating (mild, moderate, severe) of each adverse event experienced, from the perspective of the participant&#x2F;caregiver and clinic staff., timeFrame - 56-days after drug administration",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06816524",
    "endpoint": "measure - NANP-specific IgG, description - NANP-specific IgG, timeFrame - At 8 months age (1 month after the first R21&#x2F;Matrix-M dose)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06816524",
    "endpoint": "measure - NANP-specific IgG, description - NANP-specific IgG, timeFrame - At 9 months age (1 month after the second R21&#x2F;Matrix-M dose)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06816524",
    "endpoint": "measure - anti- full lengths CSP IgG, description - anti- full lengths circumsporozoite protein IgG, timeFrame - At 8 months age (1 month after the first R21&#x2F;Matrix-M dose)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06816524",
    "endpoint": "measure - anti- full lengths CSP IgG, description - anti- full lengths circumsporozoite protein IgG, timeFrame - At 9 months age (1 month after the second R21&#x2F;Matrix-M dose)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06816524",
    "endpoint": "measure - anti-CSP IgA, description - anti- circumsporozoite protein IgA titre, timeFrame - At 8 months age (1 month after the first R21&#x2F;Matrix-M dose)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06816524",
    "endpoint": "measure - anti-CSP IgA, description - anti-circumsporozoite protein IgA titre, timeFrame - At 9 months age (1 month after the second R21&#x2F;Matrix-M dose)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06816524",
    "endpoint": "measure - anti-CSP IgM, description - anti circumsporozoite protein IgM titre, timeFrame - At 8 months age (1 month after the first R21&#x2F;Matrix-M dose)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06816524",
    "endpoint": "measure - anti-CSP IgM, description - anti-circumsporozoite protein IgM titre, timeFrame - At 9 months age (1 month after the second R21&#x2F;Matrix-M dose)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06816524",
    "endpoint": "measure - Haemoglobin, description - Haemoglobin concentration (g&#x2F;dL), timeFrame - 6 months of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06816524",
    "endpoint": "measure - Haemoglobin, description - Haemoglobin concentration (g&#x2F;dL), timeFrame - 7 months of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06816524",
    "endpoint": "measure - Haemoglobin, description - Haemoglobin concentration (g&#x2F;dL), timeFrame - 8 months of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06816524",
    "endpoint": "measure - Haemoglobin, description - Haemoglobin concentration (g&#x2F;dL), timeFrame - 9 months of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06816524",
    "endpoint": "measure - Haemoglobin, description - Haemoglobin concentration (g&#x2F;dL), timeFrame - 10 months of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06816524",
    "endpoint": "measure - Plasma iron, description - Plasma iron concentration (μg&#x2F;mL), timeFrame - 6 months of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06816524",
    "endpoint": "measure - Plasma iron, description - Plasma iron concentration (μg&#x2F;mL), timeFrame - 7 months of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06816524",
    "endpoint": "measure - Plasma iron, description - Plasma iron concentration (μg&#x2F;mL), timeFrame - 8 months of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06816524",
    "endpoint": "measure - Plasma iron, description - Plasma iron concentration (μg&#x2F;mL), timeFrame - 9 months of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06816524",
    "endpoint": "measure - Plasma iron, description - Plasma iron concentration (μg&#x2F;mL), timeFrame - 10 months of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06816524",
    "endpoint": "measure - Total iron binding capacity, description - Total iron binding capacity (mcd&#x2F;dL), timeFrame - 6 months of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06816524",
    "endpoint": "measure - Total iron binding capacity, description - Total iron binding capacity (mcd&#x2F;dL), timeFrame - 7 months of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06816524",
    "endpoint": "measure - Total iron binding capacity, description - Total iron binding capacity (mcd&#x2F;dL), timeFrame - 8 months of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06816524",
    "endpoint": "measure - Total iron binding capacity, description - Total iron binding capacity (mcd&#x2F;dL), timeFrame - 9 months of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06816524",
    "endpoint": "measure - Total iron binding capacity, description - Total iron binding capacity (mcd&#x2F;dL), timeFrame - 10 months of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06816524",
    "endpoint": "measure - Transferrin saturation, description - Transferrin saturation (%), timeFrame - 6 months of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06816524",
    "endpoint": "measure - Transferrin saturation, description - Transferrin saturation (%), timeFrame - 7 months of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06816524",
    "endpoint": "measure - Transferrin saturation, description - Transferrin saturation (%), timeFrame - 8 months of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06816524",
    "endpoint": "measure - Transferrin saturation, description - Transferrin saturation (%), timeFrame - 9 months of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06816524",
    "endpoint": "measure - Transferrin saturation, description - Transferrin saturation (%), timeFrame - 10 months of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06816524",
    "endpoint": "measure - Plasma Ferritin, description - Plasma Ferritin concentration (μg&#x2F;mL), timeFrame - 6 months of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06816524",
    "endpoint": "measure - Plasma Ferritin, description - Plasma Ferritin concentration (μg&#x2F;mL), timeFrame - 7 months of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06816524",
    "endpoint": "measure - Plasma Ferritin, description - Plasma Ferritin concentration (μg&#x2F;mL), timeFrame - 8 months of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06816524",
    "endpoint": "measure - Plasma Ferritin, description - Plasma Ferritin concentration (μg&#x2F;mL), timeFrame - 9 months of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06816524",
    "endpoint": "measure - Plasma Ferritin, description - Plasma Ferritin concentration (μg&#x2F;mL), timeFrame - 10 months of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06816524",
    "endpoint": "measure - Soluble transferrin receptor, description - Soluble transferrin receptor concentration (μg&#x2F;mL), timeFrame - 6 months of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06816524",
    "endpoint": "measure - Soluble transferrin receptor, description - Soluble transferrin receptor concentration (μg&#x2F;mL), timeFrame - 7 months of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06816524",
    "endpoint": "measure - Soluble transferrin receptor, description - Soluble transferrin receptor concentration (μg&#x2F;mL), timeFrame - 8 months of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06816524",
    "endpoint": "measure - Soluble transferrin receptor, description - Soluble transferrin receptor concentration (μg&#x2F;mL), timeFrame - 9 months of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06816524",
    "endpoint": "measure - Soluble transferrin receptor, description - Soluble transferrin receptor concentration (μg&#x2F;mL), timeFrame - 10 months of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06816524",
    "endpoint": "measure - C-reactive protein, description - C-reactive protein concentration (mg&#x2F;L), timeFrame - 6 months of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06816524",
    "endpoint": "measure - C-reactive protein, description - C-reactive protein concentration (mg&#x2F;L), timeFrame - 7 months of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06816524",
    "endpoint": "measure - C-reactive protein, description - C-reactive protein concentration (mg&#x2F;L), timeFrame - 8 months of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06816524",
    "endpoint": "measure - C-reactive protein, description - C-reactive protein concentration (mg&#x2F;L), timeFrame - 9 months of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06816524",
    "endpoint": "measure - C-reactive protein, description - C-reactive protein concentration (mg&#x2F;L), timeFrame - 10 months of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06816524",
    "endpoint": "measure - Retinol-binding protein, description - Retinol-binding protein concentration (μmol&#x2F;L), timeFrame - 6 months of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06816524",
    "endpoint": "measure - Retinol-binding protein, description - Retinol-binding protein concentration (μmol&#x2F;L), timeFrame - 7 months of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06816524",
    "endpoint": "measure - Retinol-binding protein, description - Retinol-binding protein concentration (μmol&#x2F;L), timeFrame - 8 months of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06816524",
    "endpoint": "measure - Retinol-binding protein, description - Retinol-binding protein concentration (μmol&#x2F;L), timeFrame - 9 months of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06816524",
    "endpoint": "measure - Retinol-binding protein, description - Retinol-binding protein concentration (μmol&#x2F;L), timeFrame - 10 months of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06816524",
    "endpoint": "measure - Alpha-glycoprotein, description - Alpha-glycoprotein concentration (g&#x2F;L), timeFrame - 6 months of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06816524",
    "endpoint": "measure - Alpha-glycoprotein, description - Alpha-glycoprotein concentration (g&#x2F;L), timeFrame - 7 months of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06816524",
    "endpoint": "measure - Alpha-glycoprotein, description - Alpha-glycoprotein concentration (g&#x2F;L), timeFrame - 8 months of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06816524",
    "endpoint": "measure - Alpha-glycoprotein, description - Alpha-glycoprotein concentration (g&#x2F;L), timeFrame - 9 months of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06816524",
    "endpoint": "measure - Alpha-glycoprotein, description - Alpha-glycoprotein concentration (g&#x2F;L), timeFrame - 10 months of age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06816524",
    "endpoint": "measure - anti- C-terminal CSP IgG, description - anti- C-terminal circumsporozoite protein IgG, timeFrame - At 8 months age (1 month after the first R21&#x2F;Matrix-M dose)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06816524",
    "endpoint": "measure - anti- C-terminal CSP IgG, description - anti- C-terminal circumsporozoite protein IgG, timeFrame - At 9 months age (1 month after the second R21&#x2F;Matrix-M dose)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06816524",
    "endpoint": "measure - anti-CSP IgA, description - anti-circumsporozoite protein IgA titre, timeFrame - At 10 months age (1 month after the 3rd R21&#x2F;Matrix-M dose)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06816524",
    "endpoint": "measure - anti-CSP IgM, description - anti-circumsporozoite protein IgM titre, timeFrame - At 10 months age (1 month after the 3rd R21&#x2F;Matrix-M dose)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06816524",
    "endpoint": "measure - anti-measles IgG avidity, description - anti-measles IgG avidity, timeFrame - At 10 months age (1 month after the first MR dose)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01632891",
    "endpoint": "measure - Time to First Pf SCP Clearance, description - Time to clearance is defined by time to first measurement with PCR &lt; 10 parasites&#x2F;µL, and is evaluated as the point estimate and 95% CI for the day when 50% of participants cleared parasite., timeFrame - From study entry up to day 30",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01632891",
    "endpoint": "measure - Log10(Pf Parasite Density), description - Pf parasite density was determined by PCR.\nIf parasite density equals 0, the value is set to 0.01 before log10 transformation.\nThe value 0.01 was chosen based on the smallest observed parasite density value of 0.017., timeFrame - Entry, days 3, 6, 9, 12, 15, 20, 25, 30",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01632891",
    "endpoint": "measure - Change in log10(Pf Parasite Density) From Entry to Day 30, description - <p>Change is evaluated as log10(Pf parasite density) at day 30 minus log10(Pf parasite density) at entry.</p><p>Change is evaluated in four groups:</p><ul><li>Randomized to nNRTI-based ART with continued Pf SCP at day 15</li><li>Randomized to nNRTI-based ART with clearance of Pf SCP at day 15</li><li>Randomized to LPV&#x2F;r-based ART with continued Pf SCP at day 15</li><li>Randomized to LPV&#x2F;r-based ART with clearance of Pf SCP at day 15</li></ul>, timeFrame - Entry, Day 30",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01632891",
    "endpoint": "measure - Number of Participants With Uncomplicated Clinical Malaria, description - Uncomplicated clinical malaria is defined as the presence of non-severe fever&#x2F;symptoms and parasitemia without organ complication., timeFrame - From study entry to day 30",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01632891",
    "endpoint": "measure - Number of Participants With Detectable Pf Gametocyte Density, description - Number of participants with detectable Pf gametocyte density as determined by PCR.\nDue to the large number of undetectable results, this outcome was measured as dichotomous., timeFrame - Entry, days 3, 6, 9, 12, 15, 20, 25, 30",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01632891",
    "endpoint": "measure - Change in log10(Pf Gametocyte Density) From Entry to Day 30, description - <p>Change in log10(Pf gametocyte density) as evaluated using a Hodges-Lehmann estimate from entry to day 30 is evaluated in two groups:</p><ul><li>Randomized to nNRTI-based ART with continued Pf SCP at day 15</li><li>Randomized to LPV&#x2F;r-based ART with continued Pf SCP at day 15</li></ul><p>Analysis was not conducted in either group with clearance at day 15 due to the small sample size and high number of undetectable samples in both clearance groups at entry and day 30.</p>, timeFrame - Entry, Day 30",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04264130",
    "endpoint": "measure - Cure Rate (CR), description - CR of ACTs on Schistosoma haematobia, timeFrame - Day 28",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04264130",
    "endpoint": "measure - Cure Rate (CR), description - CR of ACTs on Schistosoma haematobia, timeFrame - Day 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05050825",
    "endpoint": "measure - Antibiotic prescription rate during 7 days of follow-up in the intervention arm compared to the control arm, description - This measure will further assess rational antibiotic prescribing using the CDSA strategy compared to routine practice., timeFrame - 4 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05050825",
    "endpoint": "measure - Diagnostic performance of the dengue rapid diagnostic test (RDT), description - The performance of the dengue RDT used in health facilities will be assessed against reference standards., timeFrame - 4 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05050825",
    "endpoint": "measure - Identification of risk factors associated with viral and bacterial infections, description - This measure aims to better characterize viral and bacterial infections in children and adolescents presenting with acute illness in these settings and improve the next version of the algorithm., timeFrame - 4 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05934318",
    "endpoint": "measure - Gestational hypertension, description - Assessed with systolic and diastolic blood pressure, timeFrame - 27 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05934318",
    "endpoint": "measure - Malaria infection during pregnancy, description - detected by microscopy and PCR (not for point of care) on peripheral blood, timeFrame - 27 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05934318",
    "endpoint": "measure - Placental malaria, description - detected by microscopy, by molecular methods, or by histology (past and active infection) on placental samples, timeFrame - 27 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05934318",
    "endpoint": "measure - Individual components of the placental malaria composite, description - detected by microscopy, by molecular methods, or by histology (past and active infection) on placental samples, timeFrame - 27 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05934318",
    "endpoint": "measure - Uncomplicated clinical malaria during pregnancy, description - RDTs will be used at the point of care for any patient presenting with fever, history of fever within 48h, or any other symptoms of clinical malaria infection.\nRDT-positivity is defined as either pLDH or HRP2 antigen positivity., timeFrame - 27 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05934318",
    "endpoint": "measure - SARS-CoV-2 infection during pregnancy, description - Plasma samples will also be assayed for SARS-CoV-2 antibodies using validated techniques available at the time of analysis.\nIf women are symptomatic a rapid SARS-COV-2 antigen test will also be conducted.\nIf the rapid SARS-COV-2 antigen test is negative a confirmatory PCR will be conducted., timeFrame - 27 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05934318",
    "endpoint": "measure - Maternal anaemia during pregnancy and delivery, description - Maternal anaemia is defined as haemoglobin concentration (Hb)&lt;11g&#x2F;dL; moderate maternal anaemia: Hb&lt;9g&#x2F;dL); severe anaemia: Hb&lt;7g&#x2F;dL); congenital anaemia: newborn Hb&lt;12.5 g&#x2F;dL., timeFrame - 27 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05934318",
    "endpoint": "measure - Individual components of the adverse pregnancy outcome composite, and sub-composites, description - Including fetal loss (spontaneous abortions and stillbirth) and adverse livebirth (SGA-LBW-PTB composite).\nGestational age will be assessed using ultrasound dating at enrolment.\nPreterm birth is defined as &lt;37 weeks&#x27; gestation.\nNewborns will be weighed within 24 hours of delivery using digital scales (± 10 g) with LBW defined as &lt;2,500g.\nSmall for gestational age (SGA) will be defined as birth weight below the tenth percentile for a given gestational age and sex using the new INTERGROWTH reference population.\nNeonatal length and stunting will be assessed within 24 hours of delivery.\nInfants will be defined as stunted if their height-for-age is more than two standard deviations below the WHO Child Growth Standards median., timeFrame - 27 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05934318",
    "endpoint": "measure - Fetal growth, description - estimated by validated ultrasound and maternal biomarkers, timeFrame - 27 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05934318",
    "endpoint": "measure - Birthweight-for-gestational age, description - Gestational age will be assessed using ultrasound dating at enrolment.\nSmall for gestational age (SGA) will be defined as birth weight below the tenth percentile for a given gestational age and sex using the new INTERGROWTH reference population., timeFrame - 27 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05934318",
    "endpoint": "measure - Neonatal length and stunting, description - Newborns will be measured for length within 24 hours of delivery.\nInfants will be defined as stunted if their height-for-age is more than two standard deviations below the WHO Child Growth Standards median., timeFrame - 27 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05934318",
    "endpoint": "measure - Congenital anaemia, description - congenital anaemia: newborn Hb&lt;12.5 g&#x2F;dL., timeFrame - 27 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05934318",
    "endpoint": "measure - Congenital malaria infection, description - detected by microscopy and PCR (not for point of care) on cord blood samples, timeFrame - 27 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05934318",
    "endpoint": "measure - Congenital SARS-CoV-2 infection, description - SARS-CoV-2 antibodies detected on cord blood samples, timeFrame - 27 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05934318",
    "endpoint": "measure - Neonatal death, description - vital status on discharge (alive&#x2F;dead), vital status at 7 days (alive&#x2F;dead) and 28 days (alive &#x2F;dead) post admission will be documented., timeFrame - 27 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05934318",
    "endpoint": "measure - Perinatal mortality, description - vital status on discharge (alive&#x2F;dead), vital status at 7 days (alive&#x2F;dead), timeFrame - 27 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05934318",
    "endpoint": "measure - Composite of fetal loss and neonatal mortality, description - miscarriage, still births or vital status on discharge (alive&#x2F;dead), vital status at 7 days (alive&#x2F;dead) and 28 days (alive &#x2F;dead) post admission will be documented., timeFrame - 27 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05934318",
    "endpoint": "measure - Neonatal sepsis, description - WHO Integrated Management of Childhood Illness criteria128, specifically any one of the following signs (i) not able to feed at all or not feeding well, (ii) convulsions, (iii) severe chest indrawing, (iv) high body temperature (380C or above), (iv) low body temperature (less than 35.50C), (v) movement only when stimulated or no movement at all (vi) in infants less than 7 days old, fast breathing (60 breaths per minute or more)., timeFrame - 27 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05934318",
    "endpoint": "measure - Early childhood neurocognitive development, description - Early childhood neurocognitive development will be assessed longitudinally over the first two years of life using a combination of questionnaires, direct assessments, and objective measures appropriate to the developmental periods within this time frame.\nThe Home Observation for Measurement of the Environment (HOME) is a 58-question assessment.\nThe WHO Motor Development Milestones checklist is a simple, WHO-validated assessment of six gross motor milestones in early childhood development.\nThe Mullen Scales of Early Learning (MSEL) is a comprehensive evaluation assessing early childhood development in five domains.\nThe MacArthur Bates Communication Developmental Inventory (MCAB-CDI)132 is an interview-style questionnaire that consists of 100 vocabulary items, 6 gesture items, and 5 grammatical items to assess communication&#x2F;language development., timeFrame - 27 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05934318",
    "endpoint": "measure - Allergic reaction, description - defined as anaphylaxis, hives&#x2F;rash after taking the supplement., timeFrame - 27 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05934318",
    "endpoint": "measure - Maternal mortality, description - Maternal mortality will be defined as the death of a woman while pregnant or within 42 days of termination of pregnancy, irrespective of the duration and site of the pregnancy, from any cause related to or aggravated by the pregnancy or its management but not from accidental or incidental causes.\nA verbal autopsy questionnaire will attempt to determine the cause of death., timeFrame - 27 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05934318",
    "endpoint": "measure - Congenital abnormalities, description - any abnormality detected in surface and clinical examination at birth and week 1 and 6-8, timeFrame - 27 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05934318",
    "endpoint": "measure - Vomiting study supplement, description - vomiting within 30 minutes of taking the supplement, timeFrame - 27 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05934318",
    "endpoint": "measure - Gastrointestinal complaints, description - including nausea, dyspepsia, diarrhea reported at scheduled and unscheduled visits and and through follow-up phone calls and home visits, timeFrame - 27 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05934318",
    "endpoint": "measure - Symptoms of dizziness or syncope or palpitations, description - Study staff will administer a questionnaire to assess for the occurrence of tolerability adverse events (including nausea, dyspepsia, diarrhoea, dizziness, palpitations) at scheduled and unscheduled visits, and and through follow-up phone calls and home visits, timeFrame - 27 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05934318",
    "endpoint": "measure - Markers of L-arginine bioavailability and nitric oxide biogenesis, description - L-arginine bioavailability will be assessed by plasma concentrations of L-arginine, ADMA and the L-arginine&#x2F;ADMA ratio.\nPlasma SDMA will also be quantified., timeFrame - 27 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05934318",
    "endpoint": "measure - Markers of endothelial function, placental function and inflammation, description - including plasma concentrations of Angiopoietin (Ang)-1, Ang-2, soluble Tyrosine kinase with immunoglobulin-like and EGF-like domains (sTIE)1, sTIE2, Vascular Endothelial Growth Factor (VEGF), soluble VEGF-receptor1, soluble Endoglin (sEng), Placental Growth Factor (PLGF), soluble Intercellular Adhesion Molecule (sICAM), soluble Tumour Necrosis Factor (sTNF) receptor 2 (sTNFR2), C5a, Chitinase-3-like protein 1 (CHI3L1), C-reactive protein (CRP), Interleukin (IL)-18 binding protein (IL-18BP), IL-6, Pregnancy-associated Protein A (PAPP-A), beta-human chorionic gonadotropin (β-hCG); and urine concentrations of protein and complement, timeFrame - 27 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05934318",
    "endpoint": "measure - Evidence of malaria or SARS-CoV-2 vertical transmission, description - Laboratory and nutritional outcomes, timeFrame - 27 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05934318",
    "endpoint": "measure - Evidence of SARS-CoV-2 infection, description - Laboratory and nutritional outcomes: (antigen, PCR, and&#x2F;or serology), timeFrame - 27 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05934318",
    "endpoint": "measure - Mediators of host immune function, description - Concentrations of circulating mediators of host immune function, response, endothelial function, and nutrition in the newborn at birth and six weeks of life, timeFrame - 27 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05934318",
    "endpoint": "measure - Microbial diversity, description - (N=132 maternal and N=132 newborn participants).\nShannon diversity and other measures of microbial diversity richness and abundance in maternal intestinal and vaginal microbiota at enrolment and the first post-treatment timepoint, across gestation and at six weeks post-partum, and in newborn intestinal microbiota at six weeks of life.\nNutritional and microbial composition of breast milk, timeFrame - 27 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00372632",
    "endpoint": "measure - LBW = birth weight &lt;2,500 grams, description - , timeFrame - at delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00372632",
    "endpoint": "measure - Premature delivery = delivery prior to 37 weeks gestation, description - , timeFrame - at delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00372632",
    "endpoint": "measure - Spontaneous miscarriage = any spontaneous abortion before the end of gestation, description - , timeFrame - at delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00372632",
    "endpoint": "measure - Stillbirth, description - , timeFrame - at delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00372632",
    "endpoint": "measure - Cord blood parasitaemia = presence of asexual stage parasites in thick smears, description - , timeFrame - at delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00372632",
    "endpoint": "measure - Neonatal death = infant death within the first 28 days of life, description - , timeFrame - 7days and 6 weeks after delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00372632",
    "endpoint": "measure - Maternal anemia = Hb &lt;11.0 g&#x2F;dL, description - , timeFrame - at monthly visits between 16 weeks of gestation and delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00372632",
    "endpoint": "measure - Maternal severe anemia = Hb &lt;6 g&#x2F;dL, description - , timeFrame - at monthly visits between 16 weeks of gestation and delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00372632",
    "endpoint": "measure - Symptomatic maternal malaria infection = axillary temperature 37.5°C and asexual parasitaemia, description - , timeFrame - at monthly visits between 16 weeks of gestation and delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00372632",
    "endpoint": "measure - Severe maternal adverse reactions to SP = severe cutaneous reactions (e.g., erythema multiform, Stevens-Johnson syndrome, or toxic epidermal necrolysis), description - , timeFrame - at monthly visits between 16 weeks of gestation and delivery plus at day 7 and week 6 after delivery",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02473796",
    "endpoint": "measure - prevalence of severe malnutrition, description - , timeFrame - 4 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04984759",
    "endpoint": "measure - To evaluate the pharmacokinetics (PK) of primaquine and tafenoquine in lactating women and their breastfed children at different time points following delivery., description - End point: AUC of tafenoquine and primaquine for mother and child (if measurable concentrations found in child plasma)., timeFrame - Days 1-14 for primaquine, Days 1-75 for tafenoquine",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04984759",
    "endpoint": "measure - To evaluate the pharmacokinetics (PK) of primaquine and tafenoquine in lactating women and their breastfed children at different time points following delivery., description - End point: Time to maximum concentration (Tmax) of tafenoquine and primaquine for mother and child (if measurable concentrations found in child plasma)., timeFrame - Days 1-14 for primaquine, Days 1-75 for tafenoquine",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04984759",
    "endpoint": "measure - To evaluate the pharmacokinetics (PK) of primaquine and tafenoquine in lactating women and their breastfed children at different time points following delivery., description - End point: Maximum concentration reached (Cmax) of tafenoquine and primaquine for mother and child (if measurable concentrations found in child plasma)., timeFrame - Days 1-14 for primaquine, Days 1-75 for tafenoquine",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04984759",
    "endpoint": "measure - To describe hematologic changes in mothers and breastfeed children during maternal ingestion of radical cure doses of 8-aminoquinolines., description - End points: Changes in hemoglobin (Hb), hematocrit (Hct) and methemoglobin (MetHb) in mothers and children over the period of drug exposure., timeFrame - Days 1-75",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04984759",
    "endpoint": "measure - To assess adverse events of maternal radical cure doses of 8-aminoquinolines in mothers and their breastfeeding children., description - End points: Number, severity and type of adverse events in mothers and children during the period of drug exposure., timeFrame - Days 1-75",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03394976",
    "endpoint": "measure - specificity of the HAT&#x2F;malaria combo test for gambiense HAT in passive screening in a population living in a setting where HAT is endemic, description - , timeFrame - Enrolment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03394976",
    "endpoint": "measure - specificity of the SD BIOLINE HAT 2.0 test for gambiense HAT in passive screening in a population living in a setting where HAT is endemic, description - , timeFrame - Enrolment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03394976",
    "endpoint": "measure - specificity of the HAT&#x2F;malaria combo test for gambiense HAT in passive screening in a population living in a setting where HAT and animal trypanosomiasis are not endemic, description - , timeFrame - Enrolment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT03394976",
    "endpoint": "measure - specificity of the SD BIOLINE HAT 2.0 test for gambiense HAT in passive screening in a population living in a setting where HAT and animal trypanosomiasis are not endemic, description - , timeFrame - Enrolment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05285657",
    "endpoint": "measure - Determine the proportion of participants who adhered to antimalarial and antibiotic prescription, description - Adherence to antimalarial and antibiotic prescription, timeFrame - 7 days follow-up",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05285657",
    "endpoint": "measure - Determine the accuracy of the algorithm for the diagnostic of malaria, description - Determine the specificity, sensitivity, positive and negative predictive value, timeFrame - Enrollment (Day 0)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00301054",
    "endpoint": "measure - Incidence of vaccine preventable diseases like measles whooping cough(pertussis), description - , timeFrame - ",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06651372",
    "endpoint": "measure - Distribution of the clinical symptoms and the biological findings, description - To estimate the prevalence of different clinical symptoms (patient medical records) in retrospectively identified cases of dengue, chikungunya and zika., timeFrame - 36 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01080989",
    "endpoint": "measure - Patients of confirmed malarial cases and those of cases suspicious of Flaviviral, Alpha-viral, Rickettsial,and Leptospiral infections., description - <ol><li>The confirmed malarial cases will be used for pathogen identification and drug resistance analysis.\nThe cases suspicious of Flaviviral (dengue virus, Japanese encephalitis virus), Alpha-viral(Chikungunya virus, Ross river virus), Rickettsial, and Leptospiral infections will be used for the following tests of either one, including ICT (immuno- chromatographic test) rapid test, ELISA, PCR, and the isolation and identification of pathogens.</li><li>Evaluate the incidence of above diseases after interventions(treatment, management and education capacity buildings).</li></ol>, timeFrame - one per year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01634945",
    "endpoint": "measure - Iron status indicators (SF, TfR), description - The study population will consist of 12 to 36-month-old infants in villages covered by the Taabo DSS site., timeFrame - 9 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01634945",
    "endpoint": "measure - Malaria prevalence, description - The study population will consist of 12 to 36-month-old infants in villages covered by the Taabo DSS site., timeFrame - 9 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01586923",
    "endpoint": "measure - Normalization of vital signs, description - , timeFrame - 24 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01586923",
    "endpoint": "measure - Correction of acidosis, description - , timeFrame - 24 hours",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01722539",
    "endpoint": "measure - Change in mean Hb concentration at month 4 and 8 of follow-up, description - , timeFrame - Month 0 - Month 4 - Month 8",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01722539",
    "endpoint": "measure - Prevalence of asymptomatic and clinical malaria at baseline &amp; one year after enrolment;, description - , timeFrame - Month 0 Month 12",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01722539",
    "endpoint": "measure - Prevalence of P. falciparum dihydrofolate reductase (dhfr) and dihydropteroate synthase (dhps) gene mutations at baseline and at month 12 follow-up, description - , timeFrame - Month 0 - Month 12",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01722539",
    "endpoint": "measure - Clinical (severe) malaria incidence and parasitaemia at month 4, 8, 12;, description - , timeFrame - Month 4, 8 12",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01722539",
    "endpoint": "measure - Percentages of acute and severe malnourished at month 0, 4, 8, 12 through z-scores, W&#x2F;H, H&#x2F;A, and skinfolds, description - , timeFrame - Month 0 - Month 12",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01722539",
    "endpoint": "measure - Educational achievement, at end of follow-up, and school attendance;, description - , timeFrame - Month 0 - Month 12",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01722539",
    "endpoint": "measure - Prevalence and risk of environmental and host-related predictors for malaria (re)infections;, description - , timeFrame - Month 0- Month 12",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01722539",
    "endpoint": "measure - adverse events, description - , timeFrame - Month 0- Months 12",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00628459",
    "endpoint": "measure - Growth, description - , timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06080243",
    "endpoint": "measure - Assessment of safety and tolerabilty, description - <ul><li>Occurrence of unsolicited adverse events 28 days follow-up following the vaccination.</li><li>Occurrence of serious adverse events for the whole study duration including in women who become pregnant.</li></ul>, timeFrame - Through study completion, an average of 26 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06080243",
    "endpoint": "measure - Anti-CSP antibody concentrations, description - Immunological assessment measuring the anti-CSP antibody concentrations in healthy Malian women of child bearing potential, timeFrame - Through study completion. Timepoints: baseline, days 70, 84, 140, 196, 434, 448, 504 and 560",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06080243",
    "endpoint": "measure - Rate of P.falciparum infection during pregnancy, description - P. falciparum blood stage infection defined as time to first positive blood smear during pregnancy, timeFrame - Over 9-months pregnancy",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06080243",
    "endpoint": "measure - Rate of P.falciparum infection, description - P. falciparum blood stage infection defined as time to first positive blood smear., timeFrame - Over 12-, 18- and 24-months post third vaccination",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06450379",
    "endpoint": "measure - The frequency of febrile illness and antibiotic use in children &lt;3 years after PCV13 schedule change or malaria vaccine introduction., description - aimed to understand how these interventions affect child health.\nThis involved gathering data on illness and antibiotic use against changes in schedules to analyze any changes.\nThe findings will inform public health strategies for improving child health outcomes., timeFrame - less than 3 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06450379",
    "endpoint": "measure - The stool carriage of ESBL E. coli or Klebsiella in children &lt;3 years after PCV13 schedule change or malaria vaccine introduction., description - This is significant for understanding the impact of these interventions on bacterial resistance patterns.\nHere, we examed stool samples from children on different vaccine schedule change or malaria vaccine introduction to determine if there were any changes in the prevalence of ESBL E. coli or Klebsiella.\nAnalyzing this data provided insights into how these interventions affect bacterial colonization in young children., timeFrame - less than 3 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06450379",
    "endpoint": "measure - The change in the upper respiratory tract resistome in children &lt;3 years after PCV13 schedule change or malaria vaccine introduction., description - Examined how the upper respiratory tract&#x27;s collection of antibiotic resistance genes, known as the resistome, changes in children under 3 years old following a shift in the PCV13 vaccine schedule or malaria vaccine introduction., timeFrame - less than 3 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04289688",
    "endpoint": "measure - Assess the association between the duration of the health itinerary and in hospital case fatality in hospital admitted children with suspected bloodstream infection, description - , timeFrame - 7 Months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04289688",
    "endpoint": "measure - Describe health itinerary based on the three delays model, description - <p>Stratification will be done according to the confirmed bloodstream infection:</p><ul><li>non-typhoidal Salmonella (NTS) bloodstream infection,</li><li>Plasmodium falciparum (Pf) malaria,</li><li>Pf malaria and bloodstream infection</li><li>Pf malaria and NTS bloodstream infection</li></ul>, timeFrame - 7 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04289688",
    "endpoint": "measure - Assess which factors influence the duration of the health itinerary, stratified per diagnostic category, description - <p>Stratification will be done according to the confirmed bloodstream infection:</p><ul><li>non-typhoidal Salmonella (NTS) bloodstream infection,</li><li>Plasmodium falciparum (Pf) malaria,</li><li>Pf malaria and bloodstream infection</li><li>Pf malaria and NTS bloodstream infection</li></ul>, timeFrame - 7 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04289688",
    "endpoint": "measure - Assess the association between the duration of the health itinerary and in hospital case fatality, description - <p>Stratification will be done according to the confirmed bloodstream infection:</p><ul><li>non-typhoidal Salmonella (NTS) bloodstream infection,</li><li>Plasmodium falciparum (Pf) malaria,</li><li>Pf malaria and bloodstream infection</li><li>Pf malaria and NTS bloodstream infection</li></ul>, timeFrame - 7 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04289688",
    "endpoint": "measure - Assess the diagnostic, therapeutic and referral practices at referring health centers in hospital admitted children with suspected bloodstream infection, description - , timeFrame - 7 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04289688",
    "endpoint": "measure - Assess the diagnostic and therapeutic practices before hospital admission per health care provider in hospital admitted children with suspected bloodstream infection, description - , timeFrame - 7 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04289688",
    "endpoint": "measure - Assess the coverage of blood cultures., description - , timeFrame - 7 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04672577",
    "endpoint": "measure - long-term sequelae of arboviral infections and malaria, description - The quality-of-life scores and health survey SF-12 version scores will be combined to determine the difference in quality of life due to the infections studied., timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04672577",
    "endpoint": "measure - change in epidemiology of travel-related infectious diseases, description - Change in incidence of travel related infectious diseases over time (incidence change&#x2F;time), timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01055002",
    "endpoint": "measure - Parasite growth rates by PCR, description - , timeFrame - 1-6 days after inoculation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00373048",
    "endpoint": "measure - Mean difference in log plasma viral load at different time points,, description - , timeFrame - during 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00373048",
    "endpoint": "measure - Rate of decline of humoral immunity between different time points., description - , timeFrame - during 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00373048",
    "endpoint": "measure - Proportion of patients with parasitaemia at the end of the intervention., description - , timeFrame - during 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00373048",
    "endpoint": "measure - All cause disease incidence and prevalence (including malaria, TB), description - , timeFrame - during 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00373048",
    "endpoint": "measure - Proportion of patients with Adverse event during monitoring, description - , timeFrame - during 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00373048",
    "endpoint": "measure - Prevalence of anaemia at different time points, description - , timeFrame - during 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00373048",
    "endpoint": "measure - Incidence of severe anaemia, description - , timeFrame - during 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01589289",
    "endpoint": "measure - Cure rate, description - Number of patients who positively respond to specific&#x2F;empirical therapies, as assessed as final patient outcomes (cure, referral, sequelae, death), timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01589289",
    "endpoint": "measure - Cost-effectiveness of the diagnostic tests, description - Unit costs of diagnostic tests for the diagnosis of HAT and other priority NTDs&#x2F;IDs in the setting, timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02900066",
    "endpoint": "measure - Clinical outcome of febrile illness during travel, description - Final clinical outcome per diagnosis (change of travel plans, repatriation, hospitalization as a result of illness during travel, death)., timeFrame - up to 6 months of follow-up per individual traveler",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02900066",
    "endpoint": "measure - incidence of etiological diagnoses of fever expressed as risk per person- year of travel per region traveled, description - , timeFrame - up to 6 months of follow-up per individual traveler",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02900066",
    "endpoint": "measure - Time from start of travel to development of fever by self-reporting, description - , timeFrame - up to 6 months of follow-up per individual traveler",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02900066",
    "endpoint": "measure - duration of symptoms by self-reporting in a structured study diary, description - , timeFrame - up to 6 months of follow-up per individual traveler",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02900066",
    "endpoint": "measure - Type of treatment per diagnosis reported in a structured study diary, description - symptomatic&#x2F; empiric&#x2F; targeted upon diagnosis abroad, timeFrame - up to 6 months of follow-up per individual traveler",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06973200",
    "endpoint": "measure - Cure rate (CR), description - The CR is defined as the proportion of egg-positive children at baseline, who become egg-negative after DP treatment in all collected stool or urine samples., timeFrame - 4 weeks and 6 weeks after starting DP treatment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06973200",
    "endpoint": "measure - Eggs reduction rate (ERR), description - The ERR (defined as the proportional reduction in the mean eggs per gram of faeces (S. mansoni) or per ml of urine (S. haematobium) post-treatment versus pre-treatment)), as assessed by microscopy., timeFrame - 4 weeks and 6 weeks after DP treatment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06973200",
    "endpoint": "measure - Drug-related adverse events, description - The number of participants with drug-related adverse events or serious adverse events, timeFrame - First 4 weeks after DP treatment",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06973200",
    "endpoint": "measure - Prevalence of malaria among schoolchildren, description - Proportion of children infected with malaria parasites as determined by microscopy and rapid diagnostic test, timeFrame - January 2025",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06973200",
    "endpoint": "measure - Risk factors of malaria among schoolchildren, description - Potential predictors of malaria including study participants&#x27; socio-demographic data and exposure to malaria will be collected using a structured questionnaire.\nThen predictors significantly associated with the prevalence of malaria will be explored using a multivariable logistic regression., timeFrame - January 2025",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06973200",
    "endpoint": "measure - Prevalence of anaemia among schoolchildren, description - Proportion of children with anaemia will determined and anaemia will be defined on the basis of haemoglobin concentration according to (WHO, 2011).\nHaemoglobin concentration will be measured using a Hemocue photometer from a venous blood sample., timeFrame - January 2025",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06973200",
    "endpoint": "measure - Risk factors of anaemia among schoolchildren, description - Key predictors of anaemia, including study participants&#x27; socio-demographic data, malaria infection, and helminth infection (i.e, schistosomiasis and STHs infection), will be collected using a structured questionnaire.\nThen predictors significantly associated with the prevalence of anaemia will be identified using a multivariable logistic regression., timeFrame - January 2025",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01088958",
    "endpoint": "measure - Prevalence of anemia, description - , timeFrame - Baseline and 12 and 24-month follow-up surveys",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01088958",
    "endpoint": "measure - Prevalence of iron deficiency, description - , timeFrame - Baseline and 12 and 24-month follow-up surveys",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01103063",
    "endpoint": "measure - Percentage of Participants With Sub-optimal Pregnancy Outcome in Efficacy Analyzable Per Protocol (PP) Population, description - Adverse pregnancy outcomes were defined as live-borne neonate (singleton) with LBW (&lt;2,500g), premature births (&lt;37 weeks as confirmed by the Ballard score), abortion (≤28 weeks), still birth (&gt;28 weeks), lost to follow-up prior to termination of pregnancy or delivery, or missing birth weight of the neonates., timeFrame - Approximately 40 weeks of gestational age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01103063",
    "endpoint": "measure - Percentage of Neonates With LBW (&lt;2500 g) in ITT Population, description - LBW was defined as live birth weight &lt;2500 g (up to and including 2499 g)., timeFrame - Approximately 40 weeks of gestational age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01103063",
    "endpoint": "measure - Percentage of Neonates With LBW (&lt;2500 g) in Efficacy Analyzable PP Population, description - LBW was defined as live birth weight &lt;2500 g (up to and including 2499 g)., timeFrame - Approximately 40 weeks of gestational age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01103063",
    "endpoint": "measure - Percentage of Participants With Severe Maternal Anemia (Hemoglobin [Hb] &lt;8 g&#x2F;dL) at 36-38 Weeks of Gestation, description - Severe maternal anemia was defined as Hb &lt;8 g&#x2F;dL., timeFrame - At 36-38 weeks of gestation.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01103063",
    "endpoint": "measure - Percentage of Participants With Maternal Anemia (Hb &lt;11 g&#x2F;dL) at 36-38 Weeks of Gestation, description - Anemia was defined as Hb &lt;11 g&#x2F;dL., timeFrame - At 36-38 weeks of gestation.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01103063",
    "endpoint": "measure - Percentage of Participants With Placental Parasitemia at Delivery, description - Participants with placental parasitemia at delivery were diagnosed using Placental blood smear at birth from participants who deliver at hospital., timeFrame - Approximately 40 weeks of gestational age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01103063",
    "endpoint": "measure - Percentage of Participants With Placental Malaria at Delivery Based on Histology, description - Participants positive for placental malaria at delivery were evaluated based on placental histology., timeFrame - Approximately 40 weeks of gestational age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01103063",
    "endpoint": "measure - Sexually Transmitted Infection (STI) Episodes Per Participant, description - Number of episodes of sexually transmitted infection episodes per participant were noted.\nThe STI&#x27;s including Treponema pallidum, Neisseria gonorrhoeae, Chlamydia trachomatis, from first dose to delivery (diagnosis was based on clinical presentation and lab results)., timeFrame - Approximately 40 weeks of gestational age .",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01103063",
    "endpoint": "measure - Percentage of Participants With Sub-optimal Pregnancy Outcome Including Neonatal Death and Congenital Malformation, description - Sub-optimal pregnancy outcome including neonatal deaths and congenital malformations, defined as any of the following: live-borne neonate (singleton) with low birth-weight (or LBW for short, defined as live birth weight &lt;2,500g), premature birth (&lt;37 weeks), abortion (≤28 weeks), still birth (&gt;28 weeks), neonatal death, congenital malformation, lost to follow-up prior to termination of pregnancy or delivery, or missing birth weight of the neonates., timeFrame - Approximately 40 weeks of gestational age.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01103063",
    "endpoint": "measure - Change From Baseline to 36-38 Weeks of Gestation in Hb Concentration., description - Change from Baseline to 36-38 weeks of gestation in Hb concentration was noted., timeFrame - Baseline, at 36-38 weeks of gestation.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01103063",
    "endpoint": "measure - Percentage of Neonates With Congenital Abnormalities at Birth, description - Neonates with congenital abnormalities at birth were noted., timeFrame - Approximately 40 weeks of gestational age.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01103063",
    "endpoint": "measure - Percentage of Perinatal or Neonatal Deaths, description - Percentage of perinatal or neonatal deaths were noted., timeFrame - Day 28 after delivery.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01103063",
    "endpoint": "measure - Birth Weight of Live Borne Neonate, description - Birth weight of live borne neonates were calculated in grams., timeFrame - Approximately 40 weeks of gestational age.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01103063",
    "endpoint": "measure - Number of Episodes of Symptomatic Malaria Per Participant From First Intermittent Preventive Treatment of Falciparum Dose to Delivery, description - This outcome measure determined if an episode of malaria started within the time period of first dose to delivery.\nClinical episode of malaria was determined if the participant presented with clinical symptoms of malaria (fever &gt;37.5°C, oral) and diagnosed (either by rapid diagnostic tests or microscopy) with malaria., timeFrame - Approximately 40 weeks of gestational age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01103063",
    "endpoint": "measure - Percentage of Participants Requiring Additional Treatment for Symptomatic Malaria From First Dose to Delivery, description - This outcome measure evaluated the participants requiring additional treatments for malaria during the study period following the first dose (diagnosed based on clinical presentation and&#x2F;or lab test results)., timeFrame - Approximately 40 weeks of gestational age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01103063",
    "endpoint": "measure - Percentage of Participants With Peripheral Parasitemia at 36-38 Weeks of Gestation, description - This outcome measure evaluated the percentage of participants positive for peripheral parasitemia at 36-38 weeks of gestation.\nA participant was positive for parasitemia if the number of asexual parasites per μL was &gt;0., timeFrame - At 36-38 weeks of gestation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01103063",
    "endpoint": "measure - Percentage of Participants With Peripheral Parasitemia at Delivery, description - This outcome measure evaluated the percentage of participants positive for peripheral parasitemia at delivery.\nA participant was positive for parasitemia if the number of asexual parasites per μL was &gt;0., timeFrame - Approximately 40 weeks of gestational age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01103063",
    "endpoint": "measure - Percentage of Participants With Cord Blood Parasitemia at Delivery, description - This outcome measure evaluated the percentage of participants positive for cord blood parasitemia at delivery.\nA participant was positive for parasitemia if the number of asexual parasites per μL was &gt;0., timeFrame - Approximately 40 weeks of gestational age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01103063",
    "endpoint": "measure - Percentage of Participants With Sexually Transmitted Infections From First Dose to 36-38 Weeks of Gestation, description - Sexual transmitted disease included Treponema pallidum, Neisseria gonorrhoeae, and Chlamydia trachomatis infections.\nThis was diagnosed based on clinical presentation prior to Week 36-38 and&#x2F;or lab test results between Week 36-38., timeFrame - Upto 36-38 weeks of gestation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01103063",
    "endpoint": "measure - Percentage of Participants With Chlamydia Trachomatis Infection at 36-38 Weeks of Gestation, description - Participants positive for Chlamydia trachomatis infection was diagnosed based on laboratory result at 36-38 weeks of gestation.\nA vaginal swab was collected and PCR assay was used for analysis., timeFrame - At 36-38 weeks of gestation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01103063",
    "endpoint": "measure - Percentage of Participants With Neisseria Gonorrhoeae Infection at 36-38 Weeks of Gestation, description - Participants positive for Neisseria gonorrhoeae infection was diagnosed based on laboratory result at 36-38 weeks of gestation.\nA vaginal swab was collected and PCR assay was used for analysis., timeFrame - At 36-38 weeks of gestation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01103063",
    "endpoint": "measure - Percentage of Participants With Treponema Pallidum Infection at 36-38 Weeks of Gestation, description - Participants positive for Treponema pallidum infection was diagnosed based on laboratory result at 36-38 weeks of gestation.\nTreponema Pallidum particle Agglutination Assay was used., timeFrame - At 36-38 weeks of gestation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01103063",
    "endpoint": "measure - Percentage of Participants With Trichomonas Vaginalis Infection at 36-38 Weeks of Gestation, description - Participants positive for Trichomonas vaginalis infection was diagnosed based on laboratory result at 36-38 weeks of gestation.\nA vaginal swab was collected for the laboratory test., timeFrame - At 36-38 weeks of gestation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01103063",
    "endpoint": "measure - Percentage of Participants With Bacterial Vaginosis Infection at 36-38 Weeks of Gestation., description - Bacterial vaginosis was diagnosed based on laboratory result at 36-38 weeks of gestation.\nA vaginal swab was collected for the Gram staining., timeFrame - At 36-38 weeks of gestation",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01103063",
    "endpoint": "measure - Percentage of Neonates With Ophthalmia Neonatorum at Birth Period, description - Ophthalmia neonatorum was diagnosed at birth.\nThe laboratory diagnosis was performed among neonates with purulent discharge., timeFrame - Approximately 40 weeks of gestational age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01103063",
    "endpoint": "measure - Percentage of Participants With Bacterial Infections Including Pneumonia and Other Lower Respiratory Tract Infections From First Dose to Delivery, description - Participants positive for bacterial infections including other lower respiratory tract infections were measured anytime from first dose administration to delivery., timeFrame - Up to approximately 40 weeks of gestational age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01103063",
    "endpoint": "measure - Percentage of Participants With Pre-eclampsia From Week 20 to Delivery, description - Pre-eclampsia was diagnosed as systolic blood pressure of at least 140 mmHg and&#x2F;or diastolic blood pressure of at least 90 mmHg on two separate readings taken at least 4 hours apart and proteinuria at least 300 mg protein in a 24 hour urine collection., timeFrame - From Week 20 to approximately 40 weeks of gestational age",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01103063",
    "endpoint": "measure - Nasopharyngeal Swabs Positive for Macrolide Resistant Streptococcus Pneumoniae, description - This outcome measure evaluated the Streptococcus pneumoniae sensitivity against macrolide antibiotics., timeFrame - Visits 6 and 7",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01103063",
    "endpoint": "measure - Nasopharyngeal Swabs Positive for Penicillin Resistant Streptococcus Pneumoniae, description - This outcome measure evaluated the Streptococcus pneumoniae sensitivity against penicillin antibiotics., timeFrame - Visits 6 and 7",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02118402",
    "endpoint": "measure - Iron status and systemic inflammation, description - We will assess serum ferritin, soluble transferrin receptor, erythrocyte zinc protoporphyrin and hemoglobin to define the iron status.\nC-reactive protein to assess systemic inflammatory status.\nThe changes in these measurements during the intervention will be compared among the three groups., timeFrame - Change from baseline to endpoint (16 weeks)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02118402",
    "endpoint": "measure - Anthropometry, description - Anthropometric data (weight, height, age and sex) will be recorded using standardized procedures to calculate the prevalence of child stunting.\nMeasurements will be conducted at the start of the intervention and after 4 months (end point).\nThe data analysis software WHO Anthro (WHO, Geneva Switzerland) will be used to calculate the prevalence of stunting among this infant population.\nThe changes in these measurements during the intervention will be compared among the three groups., timeFrame - Change from baseline to endpoint (16 weeks)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02118402",
    "endpoint": "measure - Child to -mother transmission of gut microbiota, description - We will measure key commensal and pathogenic members of the fecal gut microbiota of the mothers using qPCR and pyrosequencing.\nWe will measure fecal calprotectin and serum and fecal zonulin as markers of gut inflammation.\nThe changes in these measurements during the intervention will be compared among the three groups of mothers, and correlations will be done to assess associations of the variables within the mother-child pairs., timeFrame - Change from baseline to 3 weeks and endpoint (16 weeks)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02118402",
    "endpoint": "measure - Gut microbiota and gut inflammation during and after an oral antibiotic treatment, description - We will measure key commensal and pathogenic members of the fecal gut microbiota of the infants using qPCR and pyrosequencing.\nWe will measure fecal calprotectin and serum and fecal zonulin as markers of gut inflammation.\nThe changes in these measurements during and after an oral antibiotic treatment will be assessed and compared between the three groups., timeFrame - Change from baseline day 0 (prior to antibiotic administration) to day 5, 10, 20 and 40",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02118402",
    "endpoint": "measure - Morbidity, description - Morbidity data (fever, cough, diarrhea, bloody and mucous stool) will be assessed weekly with a questionnaire.\nThe frequency of these morbidities during the intervention will be compared among the three groups., timeFrame - Weekly assessment from baseline to endpoint (16 weeks)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02073149",
    "endpoint": "measure - Iron status, description - Iron status will be assessed by plasma concentrations of ferritin and soluble transferrin receptor, timeFrame - End of the 30-day fortification period",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02073149",
    "endpoint": "measure - Serum concentration of non-transferrin bound iron, description - , timeFrame - 3 hours after ingesting the first fortificant dose",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02073149",
    "endpoint": "measure - Faecal calprotectin concentration, description - Faecal calprotectin concentration is used as an indicator of intestinal inflammation, timeFrame - End of the 30-day fortification period",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02073149",
    "endpoint": "measure - P. falciparum infection, description - P. falciparum infection will be defined as the presence of either asexual parasites in blood smears or parasite antigens (either histidine-rich protein-2, or Plasmodium lactate dehydrogenase) in whole blood, timeFrame - End of the 30-day fortification period",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02073149",
    "endpoint": "measure - Adherence to intervention, description - Adherence will be defined for each individual as the number of days that the dispensing bottle has been opened during the 30-day intervention period, timeFrame - End of the 30-day fortification period",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01190540",
    "endpoint": "measure - Reduce Infection, Illness, and Mortality Rates, description - The population in the areas surrounding the proposed sites will benefit directly from lower infection, illness and mortality rates.\nThe improved ability of clinic staff to deliver quality prevention and care services will increase access to cost-effective interventions delivered according to national guidelines by 9% to 25% depending on the intervention., timeFrame - 3 years",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05218304",
    "endpoint": "measure - Health behaviors of the target population using the first step of the WHO STEPS survey method., description - To correlate health data and everyday behaviors of the target population in order to show a trend in causal effect, in order to have specific health indicators up to date, timeFrame - Within a year after recruiting the participant",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05218304",
    "endpoint": "measure - To calculate the cardiovascular risk of the New Caledonian population using the SCORE projet, description - To calculate the cardiovascular risk based on systolic blood pressure, sex, smoking status and cholesterol level., timeFrame - Within a year after recruiting the participant",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT05218304",
    "endpoint": "measure - Seroprevalence of infectious diseases, description - To Determine the seroprevalence of dengue, Zika, chikungunya and Ross River arboviruses in New Caledonia, the seroprevalence against the malaria agent as well as the seroprevalence of SARS-CoV-2., timeFrame - Within a year after recruiting the participant",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01998295",
    "endpoint": "measure - Time to recurrent infection, description - Time taken for parasites to reappear in the peripheral blood of the participant after initial treatment was assessed during the 42 days of follow up from blood samples taken on days 14, 21, 28 and 42., timeFrame - 42 days",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01497236",
    "endpoint": "measure - Number of new events of a study disease, description - study disease: malaria, diarrhoea, and LRTI, timeFrame - 6 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01636895",
    "endpoint": "measure - To determine the efficacy of SP-IPTp in preventing new infections in primi- and secundi-gravid women, description - PCR uncorrected parasitological clearance by day 42, timeFrame - 15 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01636895",
    "endpoint": "measure - To estimate the prevalence of molecular markers of SP resistance in primi- and secundi-gravid women, description - Prevalence of molecular markers of SP resistance at enrolment, timeFrame - 15 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06635733",
    "endpoint": "measure - Improvement in Metacognition (Conscious Competence), description - The degree of improvement in metacognition will be assessed using Howell&#x27;s metacognition categories, which include conscious competence, unconscious competence, conscious incompetence, and unconscious incompetence.\nProviders will be evaluated on their ability to accurately recognize their clinical skills and knowledge across these categories.\nThe focus will be on shifts from unconscious incompetence and conscious incompetence to conscious competence and unconscious competence as providers progress through the intervention., timeFrame - Assessed at baseline, 16 weeks(pilot only), and 32 weeks (repilot only) after intervention start.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06635733",
    "endpoint": "measure - Total ISP Score Improvement, description - The overall improvement in ISP (In-Person Skills Practice) performance scores.\nISP sessions will be evaluated using structured observation forms, and improvements will be tracked across multiple pediatric clinical skills, such as newborn resuscitation and management of severe pediatric conditions.\nScores will be based on specific skill proficiency and adherence to pediatric care protocols., timeFrame - Assessed after each ISP session and summarized at 16 (pilot) or 32 (repilot) weeks after intervention start.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06635733",
    "endpoint": "measure - Reduction in Common ISP Errors, description - The frequency and type of common errors observed during ISP sessions.\nClinical champions will document provider errors during ISP sessions, and the data will be analyzed to determine whether the intervention reduces the number of skill-based errors over time compared to the control group., timeFrame - Errors tracked throughout ISP sessions over the 16 or 32-week intervention period.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06635733",
    "endpoint": "measure - Proportion of Healthy Providers (HPs), description - The proportion of healthcare providers who achieve and maintain an Initial Learning Progress (ILP) of 95% or greater and participate in at least one ISP session per month.\nA &amp;#34;healthy provider&amp;#34; is defined as one who consistently meets these criteria over the course of the study., timeFrame - Assessed monthly and summarized at 16 or 32 weeks after intervention start.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00439595",
    "endpoint": "measure - Proportion of anaemic children and pregnant women treated for anaemia, description - , timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00439595",
    "endpoint": "measure - Prevalence of anaemia in study communities by age and season, description - , timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00439595",
    "endpoint": "measure - Proportion of clinic attenders referred to the district hospital with Hb&gt; and &lt;8g&#x2F;dl., description - , timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00439595",
    "endpoint": "measure - Effectiveness of current MOH anaemia treatment regimens., description - , timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00439595",
    "endpoint": "measure - Acceptability of HBCS and Hemocue and attitudes to anaemia diagnosis among caretakers and healthworkers, description - , timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT00439595",
    "endpoint": "measure - Cost effectiveness of HBC or Hemocue compared to current practice in increasing anaemia diagnosis., description - , timeFrame - 1 year",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01103713",
    "endpoint": "measure - Percentage of Participants With Parasitologic Response (PCR Corrected) at Days 7, 14, 21, 35, and 42 Post First Dose of Study Medication, description - The proportion of participants with parasitological response was estimated from the Kaplan Meier curve based on the time to the first occurrence of parasitological failure (PCR corrected).\nA participant will be a parasitological responder if she has a zero parasite count on the Day 7 visit without subsequent recurrence (PCR corrected) through the day of consideration, otherwise she is a parasitological failure., timeFrame - Days 7, 14, 21, 35, and 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01103713",
    "endpoint": "measure - Percentage of Participants With Parasitologic Response (PCR Corrected) at Days 7, 14, 21, 35, and 42 , Post First Dose of Study Medication, description - The proportion of participants with parasitological response was estimated from the Kaplan Meier curve based on the time to the first occurrence of parasitological failure (PCR corrected).\nA participant will be a parasitological responder if she has a zero parasite count on the Day 7 visit without subsequent recurrence (PCR corrected) through the day of consideration, otherwise she is a parasitological failure., timeFrame - Days 7, 14, 21, 35, and 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01103713",
    "endpoint": "measure - Percentage of Participants With Parasitologic Response (PCR Corrected) at Days 7, 14, 21, 28, 35, and 42 Post First Dose of Study Medication, description - The proportion of participants with parasitological response was estimated from the Kaplan Meier curve based on the time to the first occurrence of parasitological failure (PCR corrected).\nA participant will be a parasitological responder if she has a zero parasite count on the Day 7 visit without subsequent recurrence (PCR corrected) through the day of consideration, otherwise she is a parasitological failure., timeFrame - Days 7, 14, 21, 28, 35, and 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01103713",
    "endpoint": "measure - Percentage of Participants With Parasitologic Response (PCR Uncorrected) at Days 7, 14, 21, 28, 35, and 42 Post First Dose of Study Medication, description - The proportion of participants with parasitological response was estimated from the Kaplan Meier curve based on the time to the first occurrence of parasitological failure (PCR uncorrected).\nA participant will be a parasitological responder if she has a zero parasite count on the Day 7 visit without subsequent recurrence (PCR uncorrected) through the day of consideration, otherwise she is a parasitological failure., timeFrame - Days 7, 14, 21, 28, 35, and 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01103713",
    "endpoint": "measure - Number of Asexual P. Falciparum Per Microliter of Blood at Days 7, 14, 21, 28, 35, and 42 Post First Dose of Study Medication, description - Parasite counts (actual counts per microliter of blood) was measured at various time points., timeFrame - Days 7, 14, 21, 28, 35, and 42",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01766830",
    "endpoint": "measure - Cost-effectiveness of the diagnostic tests, description - Unit costs of diagnostic tests for the diagnosis of HAT and other priority NTDs&#x2F;IDs in the setting, timeFrame - 18 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06418256",
    "endpoint": "measure - Exploring splenic immunological mechanisms, description - Explore splenic immunological mechanisms including the maintenance of long-term memory against Plasmodium sp antigens.\nand other infectious agents: Bartonella sp., Babesia sp., smallpox virus, measles, hepatitis., timeFrame - Day 0",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06418256",
    "endpoint": "measure - Kinetics of splenic clearance of altered or modified circulating elements, description - Explore the spleen filter role during infections, illnesses or use of blood cells, including properties of cells retained in the spleen, possibily after modification in vitro., timeFrame - Day 0",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06418256",
    "endpoint": "measure - Exploring splenic clearance mechanisms, description - Clearance mechanisms: tissue and cellular topography and concentration of deposition of normal or altered or modified cells in the spleen (Histology, Imaging, Electron Microscopy, etc.)., timeFrame - Day 0",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06418256",
    "endpoint": "measure - Exploring the genetic control of spleen function, description - Genetic control of spleen function., timeFrame - Day 0",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT06418256",
    "endpoint": "measure - Explore the impact of preservation processes on organ and cell functions, as well as engraftment, description - Testing optimized freezing methods with evaluation of cell function in vitro and engraftment in a mouse model., timeFrame - Day 0",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04694898",
    "endpoint": "measure - Dietary diversity (%), description - Measured with a questionnaire using a qualitative food frequency questionnaire.\nUnit: Number of food group consumed and percentage of children having consumed 4 groups (upon 7) the previous three days., timeFrame - Baseline (2016) and after 4 years at endline (2020)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04694898",
    "endpoint": "measure - Food insecurity access prevalence (%), description - Measured with a questionnaire to calculate the Household Food Insecurity Access score., timeFrame - Baseline (2016) and after 4 years at endline (2020)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04694898",
    "endpoint": "measure - Women&#x27;s empowerment in agriculture (%), description - Measured by questionnaire, It measures the roles and extent of women&#x27;s engagement in the agriculture sector in five domains: (1) decisions about agricultural production, (2) access to and decision making power over productive resources, (3) control over use of income, (4) leadership in the community, and (5) time use.\nPercentage of women over a calculated score., timeFrame - After 4 years of intervention (endline, 2020)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04694898",
    "endpoint": "measure - Maternal knowledge of child care practices related to health&#x2F;diet&#x2F;WASH (%), description - Using questionnaire on knowledge.\nPercentage of women giving adequate answer., timeFrame - Baseline (2016) and after 4 years at endline (2020)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04694898",
    "endpoint": "measure - Maternal practices of child care related to health&#x2F;diet&#x2F;WASH (%), description - Using questionnaire on practices.\nPercentage of women giving adequate answer., timeFrame - Baseline (2016) and after 4 years at endline (2020)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04694898",
    "endpoint": "measure - Child weight (Z-score and %), description - Child weight (kg) and its Z-score, timeFrame - Measurements were made for children between the ages of 0 and 23 months of age at baseline and 4 years later, at endline, when the children are between the ages of 4 and 6 years.",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04694898",
    "endpoint": "measure - Agricultural production diversity, description - The production of different food groups by the household members that correspond to those groups used in the dietary diversity index., timeFrame - Baseline (2016) and after 4 years at endline (2020)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01425073",
    "endpoint": "measure - CD4 count increase, description - CD4 count increase, timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01425073",
    "endpoint": "measure - Rate of ART treatment failure, description - Rate of ART treatment failure, timeFrame - 12 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04073953",
    "endpoint": "measure - Primaquine Plasma Concentration, ng&#x2F;mL, description - Plasma concentrations of parent drug, timeFrame - Days 0, 3, 5",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04073953",
    "endpoint": "measure - Carboxy-Primaquine Plasma Contration, ng&#x2F;mL, description - Plasma concentrations of carboxy-primaquine metabolite, timeFrame - Days 0, 3, 5",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04073953",
    "endpoint": "measure - Primaquine N-carbamoyl-glucuronide Plasma contration, ng&#x2F;mL, description - Plasma concentrations of Primaquine N-carbamoyl-glucuronide metabolite, timeFrame - Days 0, 3, 5",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04073953",
    "endpoint": "measure - Primaquine Orthoquinone Plasma concentration, ng&#x2F;mL, description - Plasma concentrations of Primaquine Orthoquinone metabolite, timeFrame - Days 0, 3, 5",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04073953",
    "endpoint": "measure - Change in Hematocrit (%) compared to baseline, description - Change in Hematocrit (%) compared to baseline, timeFrame - Days 0, 3, 5",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04073953",
    "endpoint": "measure - Change in Hemoglobin (g&#x2F;dL) compared to baseline, description - Change in Hemoglobin (g&#x2F;dL) compared to baseline, timeFrame - Days 0, 3, 5",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04073953",
    "endpoint": "measure - Change is AST (U&#x2F;L) compared to baseline, description - Change is AST (U&#x2F;L) compared to baseline; used to monitor liver function, timeFrame - Days 0, 3, 5",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04073953",
    "endpoint": "measure - Change in ALT (U&#x2F;L) compared to baseline, description - Change in ALT (U&#x2F;L) compared to baseline; used to monitor liver function, timeFrame - Days 0, 3, 5",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT04073953",
    "endpoint": "measure - Change in total Bilirubin (mg&#x2F;dL) compared to baseline, description - Change in total Bilirubin (mg&#x2F;dL) compared to baseline; used to monitor liver function and red cell integrity, timeFrame - Days 0, 3, 5",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02341586",
    "endpoint": "measure - Change in ferritin concentration, description - Ferritin is a biomarker of iron status.\nFerritin will be corrected with measures using measures of alpha-1 acid glycoprotein and C-reactive protein., timeFrame - Baseline (t=0), midline (t=6 months), and endline (t=12 months)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02341586",
    "endpoint": "measure - Number of women in Preah Vihear, Cambodia with a genetic hemoglobin disorder, description - , timeFrame - Midline (t=6 months)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02341586",
    "endpoint": "measure - How the prevalence of malaria changes in women living in Preah Vihear Cambodia over one year, description - , timeFrame - Baseline (t=0), midline (t=6 months), and endline (t=12 months)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02341586",
    "endpoint": "measure - Change in soluble transferrin receptor (sTfR) concentration, description - sTfR is a biomarker of iron status, timeFrame - Baseline (t=0), midline (t=6 months), and endline (t=12 months)",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT01812785",
    "endpoint": "measure - Clinical and laboratory predictors of each disease, description - , timeFrame - December 2011",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02048007",
    "endpoint": "measure - Density of asexual stages and gametocytes, in children 1-60 months, description - MORDOR Malawi and Niger Please note: Each outcome will be analyzed separately in each of the two study sites., timeFrame - Each site will report outcomes at 24 months; Niger will also report outcomes at 48 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02048007",
    "endpoint": "measure - Hemoglobin concentration and presence of anemia (hemoglobin &lt;11 g&#x2F;dL) in children 1-60 months, description - MORDOR Malawi, Tanzania and Niger.\nPlease note: Each outcome will be analyzed separately for each study site., timeFrame - Each site will report outcomes at 24 months; Niger will also report outcomes at 48 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02048007",
    "endpoint": "measure - Genetic determinants of macrolide resistance in the nasopharynx (eg pneumococcal) in individuals 7-12 years of age, description - MORDOR Niger, timeFrame - 24 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02048007",
    "endpoint": "measure - Genetic determinants of macrolide resistance in the nasopharynx (eg pneumococcal) in individuals 1-60 month olds seen in local health clinics for a respiratory complaint, description - MORDOR Malawi, Tanzania and Niger.\nPlease note: Each outcome will be analyzed separately for each study site., timeFrame - 24 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02048007",
    "endpoint": "measure - Rates of acute respiratory illness among children 1-60 months., description - MORDOR Tanzania, timeFrame - 6-24 months after baseline",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02048007",
    "endpoint": "measure - Presence of the trachoma grades &quot;follicular trachoma&quot; (TF) and &quot;intense inflammatory trachoma&quot; (TI), as defined by the World Health Organization (WHO) simplified grading system, in children 1-60 months, description - MORDOR Malawi and Niger Please note: Each outcome will be analyzed separately for each study site., timeFrame - 24 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02048007",
    "endpoint": "measure - Rates of diarrhea among children (1-60 months), description - MORDOR Tanzania, timeFrame - 6-24 months after baseline",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02048007",
    "endpoint": "measure - Proportion of rectal&#x2F;stool isolates with evidence of resistance (in for example E.coli) to macrolides and other antibiotics commonly used to treat pediatric infections among children 1-60 months, description - MORDOR Malawi, Tanzania and Niger.\nPlease note: Each outcome will be analyzed separately for each study site., timeFrame - 6-24 months after baseline; Niger will also report outcomes at 48 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02048007",
    "endpoint": "measure - Proportions of E. coli isolates resistant to macrolides and to antibiotics commonly used to treat pediatric infections among children 1-60 months hospitalized for pneumonia and diarrhea., description - MORDOR Tanzania, timeFrame - 6-24 months after baseline",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02048007",
    "endpoint": "measure - Studies of intestinal permeability and inflammation, microbial translocation, and immune activation assessed through venous sampling of children 6 months, description - MORDOR Malawi, timeFrame - 5 x over 24 weeks after baseline",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02048007",
    "endpoint": "measure - Studies of intestinal permeability and inflammation, microbial translocation, and immune activation assessed through urine samples for L:M ratios of children 6 months, description - MORDOR Malawi, timeFrame - 5 x over 24 weeks after baseline",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02048007",
    "endpoint": "measure - Studies of intestinal permeability and inflammation, microbial translocation, and immune activation assessed through stool (fecal neopterin) of children 6 months, description - MORDOR Malawi, timeFrame - 5 x over 24 weeks after baseline",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02048007",
    "endpoint": "measure - Nasopharyngeal pneumococcal evidence of beta lactam and macrolide resistance in in children 1-60 months as measured by RNA-sequencing of the resistome, description - MORDOR Malawi, Tanzania and Niger.\nPlease note: Each outcome will be analyzed separately for each study site., timeFrame - Tanzania will report outcomes at 6-24 months. Each site will report outcomes at 24 months; Niger will also report outcomes at 36 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02048007",
    "endpoint": "measure - Nasopharyngeal pneumococcal macrolide resistance determinants (eg erythromycin ribosomal methylase B and mefA), serotype, and multilocus sequence type in children 1-60 months, description - MORDOR Niger, timeFrame - 24 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02048007",
    "endpoint": "measure - Microbiome in the stool, nasopharynx, nares, and conjunctiva in children aged 1-59 months, as measured using next generation sequencing. Arms will be compared using Euclidean distance and diversity compared using Simpson&#x27;s index., description - <p>Investigators will examine the effects of mass azithromycin (pre-treatment and post-treatment) on the human microbiome of African children by performing metagenomic experiments.</p><p>MORDOR Niger</p>, timeFrame - 24 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02048007",
    "endpoint": "measure - Microbial diversity in the intestinal microbiomes of children aged 1-60 months as measured by using next generation sequencing, description - <p>Investigators will examine the effects of mass azithromycin (pre-treatment and post-treatment) on the human microbiome of African children by performing metagenomic experiments.</p><p>MORDOR Malawi</p>, timeFrame - 24 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02048007",
    "endpoint": "measure - Serology for exposure to exotic pathogens of children aged 1-60 months as measured by lateral flow assays or Multiplex bead array, description - MORDOR Malawi, timeFrame - 24 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02048007",
    "endpoint": "measure - Head circumference over time in children aged 1-60 months, description - MORDOR Malawi, timeFrame - 24 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02048007",
    "endpoint": "measure - Knee-heel length over time in children aged 1-60 months, description - MORDOR Malawi, timeFrame - 24 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02048007",
    "endpoint": "measure - Resistance (in E.coli phenotypically or genetic determinants) in stool of children aged 1-60 months., description - MORDOR Malawi, Tanzania and Niger.\nPlease note: Each outcome will be analyzed separately for each study site., timeFrame - Each site will report outcomes at 24 months; Niger will also report outcomes at 48 months",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02048007",
    "endpoint": "measure - Prevalence of carriage of a panel of gastrointestinal parasites (Ancylostoma duodenale, Necator americanus, Ascaris lumbricoides, Trichuris trichiura, Giardia lamblia, Cryptosporidium hominis) of children aged 1-60 months, description - MORDOR Malawi, timeFrame - Baseline",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02048007",
    "endpoint": "measure - Prevalence of helicobacter pylori of children aged 1-60 months, description - MORDOR Malawi, timeFrame - Baseline",
    "type": "SECONDARY",
    "condition": "malaria"
  },
  {
    "nctId": "NCT02048007",
    "endpoint": "measure - Antibody response to enteric pathogens and malaria measured with a multiplex bead assay from dried blood spots collected from children 1 - 59 months, description - MORDOR Niger, timeFrame - Niger will report outcomes at 36, 48 and 60 months",
    "type": "SECONDARY",
    "condition": "malaria"
  }
]